Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)

RELATED APPLICATION

This application claims priority to and the benefit of Indian Provisional Patent Application No. 201941005395, filed on Feb. 11, 2019, the entire contents of which are incorporated herein by reference.

INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING

The contents of the text file named ZMTR-001_001US Seq_List_ST25 which was created on Apr. 21, 2020, and is 3.518 megabytes in size, are incorporated herein by reference in their entirety.

TECHNICAL FIELD

The present disclosure relates to immunology, especially immune-oncology. Particularly, this disclosure relates to novel antibody molecules against CLEC2D antigen. This disclosure also relates to multiple formats and amino acid compositions of the disclosed antibody molecules, variable regions of the heavy and light chains of the antibody molecules, and CDR composition and length distribution against CLEC2D antigen. The compositions of this disclosure can be used either as monotherapies or in combination with other antibody molecules or any other therapeutic agents that are relevant for the treatment or prevention of diseases, such as cancer.

BACKGROUND

Modulation of immune cell checkpoint receptors via antibody-based/directed therapeutic approaches has been gaining constant interest over the last decade. Many of these receptors are involved in T cell checkpoint modulation. However, B cell, natural killer (NK) cell, and myeloid cell checkpoint modulation is attracting attention.

NK cells are part of the innate immunity which recognize and induce cytotoxicity against a wide range of target cells, such as tumor cells or virus infected cells. In addition, NK cells participate in the initiation and progress of the adaptive immune response through the production of various cytokines. Usually, these responses are regulated by the interaction of a wide array of activating and inhibitory receptors with ligands on the surface of the target cells and immune cells.

The NK cell receptors are divided into two main structural classes: the immunoglobulin and C-type lectin-like (CTL) superfamilies. The NKR-P1 receptors (e.g., CD161) are a family of C-type lectin-like transmembrane molecules that are important immuno-regulatory genes and are expressed on various cell types, including spleen dendritic cells, subsets of T cells and granulocytes. The Lectin-Like Transcript 1 (LLT1) or C-Type Lectin Domain Family 2 Member D (CLEC2D) or osteoclast inhibitory lectin (OCIL) molecule is a ligand for the CD161 receptor and this interaction differentially regulates the NK cell and T cell function. There are six splice variants of CLEC2D, isoform 1 being the canonical sequence which is expressed on NK cells, T cells, monocytes/macrophages, activated B cells and dendritic cells, and functions as a human NK cell activating receptor. The polypeptide chain of CLEC2D can be divided into the N-terminal cytoplasmic part, trans-membrane and stalk regions and C-terminal CTL ectodomain with two predicted N-glycosylation sites.

CLEC2D and CD161 interaction leads to escape from the host defense in several disease scenarios, including various cancers. Such immune escape has been reported in human glioblastoma and other diseases. Moreover, CLEC2D expression on B cells is thought to regulate cross-talk between NK cells and antigen presenting cells (APC). Blocking CLEC2D-CD161 interaction therefore provides a new therapeutic option for the treatment of various cancers.

The downstream signaling of CLEC2D-CD161 interactions is poorly understood. The interaction of CLEC2D/CD161 inhibits NK cell functions and stimulates T cell proliferation and secretion of cytokines. Hence, the effects of CLEC2D/CD161 interaction could be reversed by using monoclonal antibodies specifically binding to CLEC2D, and disrupting the interaction between CLEC2D and its known receptor CD161 or other unknown cellular mechanisms.

SUMMARY

The disclosure provides an isolated antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence selected from the group consisting of: (a) a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 46, SEQ ID NO: 65, SEQ ID NO: 59, and SEQ ID NO: 99; (b) a sequence that is at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 57, SEQ ID NO: 91, SEQ ID NO: 98, SEQ ID NO: 84, SEQ ID NO: 58, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 47, SEQ ID NO: 17, and SEQ ID NO: 8; (c) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 93, SEQ ID NO: 53, SEQ ID NO: 95, SEQ ID NO: 23, SEQ ID NO: 103, and SEQ ID NO: 7; (d) a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 45, SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 44, SEQ ID NO: 73, SEQ ID NO: 36, SEQ ID NO: 77, SEQ ID NO: 50, and SEQ ID NO: 6; (e) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 97, SEQ ID NO: 16, SEQ ID NO: 76, SEQ ID NO: 9, SEQ ID NO: 89, SEQ ID NO: 107, SEQ ID NO: 68, SEQ ID NO: 29, SEQ ID NO: 67, SEQ ID NO: 74, SEQ ID NO: 32, SEQ ID NO: 81, SEQ ID NO: 106, SEQ ID NO: 31, SEQ ID NO: 62, SEQ ID NO: 48, SEQ ID NO: 75, SEQ ID NO: 12, SEQ ID NO: 102, SEQ ID NO: 54, SEQ ID NO: 80, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 92, SEQ ID NO: 108, and SEQ ID NO: 79; (f) a sequence that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 105, SEQ ID NO: 101, SEQ ID NO: 4, SEQ ID NO: 72, SEQ ID NO: 28, SEQ ID NO: 64, SEQ ID NO: 25, SEQ ID NO: 60, SEQ ID NO: 55, SEQ ID NO: 52, SEQ ID NO: 27, SEQ ID NO: 43, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 14, SEQ ID NO: 85, SEQ ID NO: 13, SEQ ID NO: 61, SEQ ID NO: 42, SEQ ID NO: 39, SEQ ID NO: 10, SEQ ID NO: 49, SEQ ID NO: 24, SEQ ID NO: 40, SEQ ID NO: 63, SEQ ID NO: 78, SEQ ID NO: 2, SEQ ID NO: 94, and SEQ ID NO: 5; (g) a sequence that is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 11, SEQ ID NO: 35, SEQ ID NO: 86, SEQ ID NO: 22, SEQ ID NO: 69, SEQ ID NO: 41, SEQ ID NO: 3, SEQ ID NO: 66, SEQ ID NO: 37, SEQ ID NO: 56, SEQ ID NO: 21, SEQ ID NO: 38, SEQ ID NO: 90, SEQ ID NO: 100, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 83, SEQ ID NO: 1, and SEQ ID NO: 19; and (h) a sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identical or 100% identical to a sequence selected from SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 87, SEQ ID NO: 82, and SEQ ID NO: 104, wherein the antibody or antigen-binding fragment thereof binds to C-Type Lectin Domain Family 2 Member D (CLEC2D).

The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the light chain comprises a sequence selected from the group consisting of: (a) sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 218, SEQ ID NO: 249, SEQ ID NO: 230, SEQ ID NO: 279, SEQ ID NO: 316, SEQ ID NO: 237, SEQ ID NO: 322, SEQ ID NO: 225, SEQ ID NO: 318, SEQ ID NO: 233, SEQ ID NO: 305, SEQ ID NO: 280, SEQ ID NO: 283, SEQ ID NO: 242, SEQ ID NO: 286, SEQ ID NO: 297, SEQ ID NO: 309, and SEQ ID NO: 246; (b) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 222, SEQ ID NO: 258, SEQ ID NO: 219, SEQ ID NO: 313, SEQ ID NO: 294, SEQ ID NO: 303, SEQ ID NO: 317, SEQ ID NO: 273, SEQ ID NO: 266, SEQ ID NO: 315, SEQ ID NO: 257, SEQ ID NO: 288, SEQ ID NO: 301, SEQ ID NO: 221, SEQ ID NO: 240, SEQ ID NO: 299, SEQ ID NO: 247, SEQ ID NO: 263, and SEQ ID NO: 274; (c) a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 231, SEQ ID NO: 250, SEQ ID NO: 260, SEQ ID NO: 226, SEQ ID NO: 271, SEQ ID NO: 256, SEQ ID NO: 272, SEQ ID NO: 278, SEQ ID NO: 302, SEQ ID NO: 320, SEQ ID NO: 295, SEQ ID NO: 292, SEQ ID NO: 229, SEQ ID NO: 264, SEQ ID NO: 252, SEQ ID NO: 267, SEQ ID NO: 304, SEQ ID NO: 300, SEQ ID NO: 311, and SEQ ID NO: 324; (d) a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 259, SEQ ID NO: 239, SEQ ID NO: 281, SEQ ID NO: 228, SEQ ID NO: 217, SEQ ID NO: 227, and SEQ ID NO: 251; (e) a sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 307, SEQ ID NO: 262, SEQ ID NO: 253, SEQ ID NO: 276, SEQ ID NO: 323, SEQ ID NO: 234, SEQ ID NO: 261, SEQ ID NO: 312, and SEQ ID NO: 290; (f) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 254, SEQ ID NO: 289, SEQ ID NO: 238, SEQ ID NO: 268, SEQ ID NO: 248, SEQ ID NO: 284, SEQ ID NO: 244, SEQ ID NO: 310, SEQ ID NO: 243, SEQ ID NO: 285, SEQ ID NO: 220, SEQ ID NO: 255, SEQ ID NO: 293, SEQ ID NO: 298, SEQ ID NO: 235, SEQ ID NO: 319, SEQ ID NO: 245, SEQ ID NO: 224, SEQ ID NO: 291, SEQ ID NO: 277, and SEQ ID NO: 232; and (g) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 282, SEQ ID NO: 308, SEQ ID NO: 287, SEQ ID NO: 321, SEQ ID NO: 236, SEQ ID NO: 265, SEQ ID NO: 270, SEQ ID NO: 275, SEQ ID NO: 306, SEQ ID NO: 296, SEQ ID NO: 241, SEQ ID NO: 314, and SEQ ID NO: 223; wherein the antibody or antigen-binding fragment thereof binds to CLEC2D.

The disclosure provides isolated antibodies or antigen-binding fragments thereof, comprising: (a) a heavy chain comprising a sequence selected from: (i) a sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 46, SEQ ID NO: 65, SEQ ID NO: 59, and SEQ ID NO: 99; (ii) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 57, SEQ ID NO: 91, SEQ ID NO: 98, SEQ ID NO: 84, SEQ ID NO: 58, SEQ ID NO: 88, SEQ ID NO: 96, SEQ ID NO: 47, SEQ ID NO: 17, and SEQ ID NO: 8; (iii) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 93, SEQ ID NO: 53, SEQ ID NO: 95, SEQ ID NO: 23, SEQ ID NO: 103, and SEQ ID NO: 7; (iv) a sequence that is at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 45, SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 44, SEQ ID NO: 73, SEQ ID NO: 36, SEQ ID NO: 77, SEQ ID NO: 50, and SEQ ID NO: 6; (v) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 97, SEQ ID NO: 16, SEQ ID NO: 76, SEQ ID NO: 9, SEQ ID NO: 89, SEQ ID NO: 107, SEQ ID NO: 68, SEQ ID NO: 29, SEQ ID NO: 67, SEQ ID NO: 74, SEQ ID NO: 32, SEQ ID NO: 81, SEQ ID NO: 106, SEQ ID NO: 31, SEQ ID NO: 62, SEQ ID NO: 48, SEQ ID NO: 75, SEQ ID NO: 12, SEQ ID NO: 102, SEQ ID NO: 54, SEQ ID NO: 80, SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 92, SEQ ID NO: 108, and SEQ ID NO: 79; (vi) a sequence that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 105, SEQ ID NO: 101, SEQ ID NO: 4, SEQ ID NO: 72, SEQ ID NO: 28, SEQ ID NO: 64, SEQ ID NO: 25, SEQ ID NO: 60, SEQ ID NO: 55, SEQ ID NO: 52, SEQ ID NO: 27, SEQ ID NO: 43, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 14, SEQ ID NO: 85, SEQ ID NO: 13, SEQ ID NO: 61, SEQ ID NO: 42, SEQ ID NO: 39, SEQ ID NO: 10, SEQ ID NO: 49, SEQ ID NO: 24, SEQ ID NO: 40, SEQ ID NO: 63, SEQ ID NO: 78, SEQ ID NO: 2, SEQ ID NO: 94, and SEQ ID NO: 5; (vii) a sequence that is at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 11, SEQ ID NO: 35, SEQ ID NO: 86, SEQ ID NO: 22, SEQ ID NO: 69, SEQ ID NO: 41, SEQ ID NO: 3, SEQ ID NO: 66, SEQ ID NO: 37, SEQ ID NO: 56, SEQ ID NO: 21, SEQ ID NO: 38, SEQ ID NO: 90, SEQ ID NO: 100, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 83, SEQ ID NO: 1, and SEQ ID NO: 19; and (viii) a sequence that is at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 87, SEQ ID NO: 82, and SEQ ID NO: 104; and (b) a light chain comprising a sequence selected from: (i) a sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 218, SEQ ID NO: 249, SEQ ID NO: 230, SEQ ID NO: 279, SEQ ID NO: 316, SEQ ID NO: 237, SEQ ID NO: 322, SEQ ID NO: 225, SEQ ID NO: 318, SEQ ID NO: 233, SEQ ID NO: 305, SEQ ID NO: 280, SEQ ID NO: 283, SEQ ID NO: 242, SEQ ID NO: 286, SEQ ID NO: 297, SEQ ID NO: 309, and SEQ ID NO: 246; (ii) a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 222, SEQ ID NO: 258, SEQ ID NO: 219, SEQ ID NO: 313, SEQ ID NO: 294, SEQ ID NO: 303, SEQ ID NO: 317, SEQ ID NO: 273, SEQ ID NO: 266, SEQ ID NO: 315, SEQ ID NO: 257, SEQ ID NO: 288, SEQ ID NO: 301, SEQ ID NO: 221, SEQ ID NO: 240, SEQ ID NO: 299, SEQ ID NO: 247, SEQ ID NO: 263, and SEQ ID NO: 274; (iii) a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 231, SEQ ID NO: 250, SEQ ID NO: 260, SEQ ID NO: 226, SEQ ID NO: 271, SEQ ID NO: 256, SEQ ID NO: 272, SEQ ID NO: 278, SEQ ID NO: 302, SEQ ID NO: 320, SEQ ID NO: 295, SEQ ID NO: 292, SEQ ID NO: 229, SEQ ID NO: 264, SEQ ID NO: 252, SEQ ID NO: 267, SEQ ID NO: 304, SEQ ID NO: 300, SEQ ID NO: 311, and SEQ ID NO: 324; (iv) a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 259, SEQ ID NO: 239, SEQ ID NO: 281, SEQ ID NO: 228, SEQ ID NO: 217, SEQ ID NO: 227, and SEQ ID NO: 251; (v) a sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 307, SEQ ID NO: 262, SEQ ID NO: 253, SEQ ID NO: 276, SEQ ID NO: 323, SEQ ID NO: 234, SEQ ID NO: 261, SEQ ID NO: 312, and SEQ ID NO: 290; (vi.) a sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 254, SEQ ID NO: 289, SEQ ID NO: 238, SEQ ID NO: 268, SEQ ID NO: 248, SEQ ID NO: 284, SEQ ID NO: 244, SEQ ID NO: 310, SEQ ID NO: 243, SEQ ID NO: 285, SEQ ID NO: 220, SEQ ID NO: 255, SEQ ID NO: 293, SEQ ID NO: 298, SEQ ID NO: 235, SEQ ID NO: 319, SEQ ID NO: 245, SEQ ID NO: 224, SEQ ID NO: 291, SEQ ID NO: 277, and SEQ ID NO: 232; and (vii) a sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, at least 99.9% or 100% identical to a sequence selected from SEQ ID NO: 282, SEQ ID NO: 308, SEQ ID NO: 287, SEQ ID NO: 321, SEQ ID NO: 236, SEQ ID NO: 265, SEQ ID NO: 270, SEQ ID NO: 275, SEQ ID NO: 306, SEQ ID NO: 296, SEQ ID NO: 241, SEQ ID NO: 314, and SEQ ID NO: 223; wherein the antibody or antigen-binding fragment thereof binds to CLEC2D.

The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises a sequence selected from any one of SEQ ID NOs: 1-108.

The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the heavy chain comprises: (i) a heavy chain (HC) CDR1 comprising a sequence selected from SEQ ID NOs: 433-485; (ii) an HC CDR2 comprising a sequence selected from SEQ ID NOs: 486-546; and (iii) an HC CDR3 comprising a sequence selected from SEQ ID NOs: 547-653, wherein the antibody or antigen-binding fragment thereof binds to CLEC2D.

The disclosure provides isolated antibodies or antigen-binding fragments thereof comprising a heavy chain and a light chain, wherein the light chain comprises: (i) a light chain (LC) CDR1 comprising a sequence selected from SEQ ID NOs: 654-726; (ii) an LC CDR2 comprising a sequence selected from SEQ ID NOs: 727-783; and (iii) an LC CDR3 comprising a sequence selected from SEQ ID NOs: 784-885; wherein the antibody or antigen-binding fragment thereof binds to CLEC2D.

The disclosure provides isolated antibodies or antigen-binding fragments thereof, comprising: a heavy chain comprising an HC CDR1 sequence selected from SEQ ID NOs: 433-485, an HC CDR2 sequence selected from SEQ ID NOs: 486-546, and an HC CDR3 sequence selected from SEQ ID NOs: 547-653; a light chain comprising a LC CDR1 sequence selected from SEQ ID NOs: 654-726, a LC CDR2 sequence selected from SEQ ID NOs: 727-783, and a LC CDR3 sequence selected from SEQ ID NOs: 784-885; or a combination thereof.

In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof binds to: a human CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 886-909; a human CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 930-1003; a cynomolgus CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 918-920; a mouse CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 911-915; a rat CLEC2D polypeptide comprising a sequence of SEQ ID NO: 910; and/or a dog CLEC2D polypeptide comprising a sequence selected from SEQ ID NOs: 916-917.

The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain complementarity determining region (CDRH) 1, CDRH2 and CDRH3 amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, and wherein the light chain comprises a light chain complementarity determining region (CDRL)1, CDRL2 and CDRL3 amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A.

The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable heavy chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, and wherein the light chain comprises a variable light chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A.

The disclosure provides an isolated antibody or antigen-binding fragment thereof, comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain frame work region sequence of a Germline family of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9B, as disclosed herein, and wherein the light chain comprises a frame work region sequence of a light chain Germline family of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9B, as disclosed herein.

In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof is a monoclonal antibody.

In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof blocks binding of CLEC2D to a receptor. In some embodiments, the receptor comprises a CD161 receptor, and the CD161 receptor comprises a sequence selected from SEQ ID NOs: 921-929.

In some embodiments of the antibodies or antigen binding fragments thereof of the disclosure, the antibody or antigen-binding fragment thereof is human, murine or chimeric. In some embodiments, the antigen-binding fragment is selected from the group consisting of Fv, Fav, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2, scFv-CH3, scFv-Fc, and diabody fragments. In some embodiments, the antibody or antigen-binding fragment thereof binds to human CLEC2D with an affinity (KD) of less than 100 nM.

The disclosure provides pharmaceutical compositions comprising peptides (e.g., antibodies or antigen-binding fragments thereof) or nucleic acids described in the disclosure.

The disclosure provides pharmaceutical compositions comprising antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides pharmaceutical compositions comprising nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

In some embodiments of the pharmaceutical compositions of the disclosure, the pharmaceutical composition further comprises at least one of a buffer, a pharmaceutically acceptable diluent, a carrier, a solubilizer, an emulsifier, and a preservative.

The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes an amino acid heavy chain sequence selected from SEQ ID NOs: 109-216.

The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes an amino acid light chain sequence selected from SEQ ID NOs: 325-432.

The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain comprising a CDRH1, CDRH2 and CDRH3 amino acid sequence according to the CDRH1, CDRH2 and CDRH3 amino acid sequence respectively, of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A, as disclosed herein.

The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a light chain comprising a CDRL1, CDRL2 and CDRL3 amino acid sequence according to the CDRL1, CDRL2 and CDRL3 amino acid sequence respectively, of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A, as disclosed herein.

The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain amino acid sequence according to variable heavy chain amino acid sequence of an anti-CLEC2D antibody antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A, as disclosed herein.

The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a light chain amino acid sequence according to variable light chain amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A, as disclosed herein.

The disclosure provides an isolated nucleic acid, comprising a polynucleotide sequence that encodes a heavy chain comprising a framework region amino acid sequence according to heavy chain framework region amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9B, as disclosed herein.

The disclosure provides an isolated nucleic acid comprising a polynucleotide sequence that encodes a light chain comprising a framework region amino acid sequence according to light chain framework region amino acid sequence of an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9B, as disclosed herein.

The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes a heavy chain amino acid sequence of an antibody or antigen binding fragment thereof of the disclosure.

The disclosure provides isolated nucleic acids comprising a polynucleotide sequence that encodes a light chain amino acid sequence of an antibody or antigen binding fragment thereof of the disclosure.

The disclosure provides compositions comprising a first nucleic acid that encodes a polypeptide selected from SEQ ID NOs: 109-216 and a second nucleic acid that encodes a polypeptide selected from SEQ ID NOs: 325-432.

The disclosure provides vectors comprising the nucleic acids of the disclosure.

The disclosure provides cells comprising the nucleic acids, nucleic acid compositions or vectors of the disclosure. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the mammalian cell is selected from the group consisting of a CHO cell, a 293 cell, an NSO cell, a PER.C6 cell, and a B cell. In some embodiments, the mammalian cell is a 293-6E cell or a DG44 cell. In some embodiments, the cells express the antibodies or antigen binding fragments thereof of the disclosure. In some embodiments, the cell is a germline cell.

The disclosure provides cells producing the antibodies or antigen-binding fragments thereof of the disclosure

The disclosure provides a method of treating a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides a composition for use in treating a disease in a subject in need thereof, comprising a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides a composition for use in the manufacture of a medicament for the prevention or treatment of a disease in a subject in need thereof, comprising a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

In some embodiments of the methods or compositions for use of the disclosure, the disease is rheumatoid arthritis. In some embodiments, the subject exhibits bone loss as a result of having rheumatoid arthritis. In some embodiments, administration of a therapeutically effective amount of the antibody or antigen-binding fragment thereof slows or reverses the bone loss in the subject.

In some embodiments of the methods or compositions for use of the disclosure, the disease is a cancer. In some embodiments, the cancer is selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma. In some embodiments, a cell of the cancer expresses CLEC2D on the cell surface. In some embodiments, administration of a therapeutically effective amount of the antibodies or antigen-binding fragments thereof results in an anti-tumor response in the subject.

In some embodiments of the methods or compositions for use of the disclosure, the antibodies or antigen-binding fragments thereof are administered as a monotherapy. In some embodiments, the antibodies or antigen-binding fragments thereof are administered in combination with at least one of a T cell targeted immunomodulatory agent, a second immunomodulatory agent, a cancer vaccine, an adoptive cell therapy, an oncolytic virus, a second antibody therapy, a radiotherapy, an antibody drug conjugate, a small interfering RNA, a chemotherapy, an immunotherapy, an immune checkpoint inhibitor, a mitotic inhibitor, or a combination thereof. In some embodiments, the adoptive cell therapy comprises a CAR-T therapy. In some embodiments, administration of a therapeutically effective amount of the antibody or antigen-binding fragment thereof alleviates a sign or a symptom of the disease.

In some embodiments of the antibody library of the disclosure, the CLEC2D antigen comprises an amino acid sequence selected from SEQ ID NOs: 886-920 and SEQ ID NOs: 930-1003. In some embodiments of the antibody library of the disclosure, the CLEC2D antigen comprises an amino acid sequence selected from SEQ ID NOs: 886-909 and SEQ ID NOs: 930-1003. In some embodiments, the CLEC2D antigen comprises a CLEC2D antigen expressed on a tumor cell surface, a variant of the CLEC2D antigen, or a homolog of the CLEC2D antigen. In some embodiments, the variant of the CLEC2D antigen comprises a fragment of the CLEC2D protein. In some embodiments, the homolog of the CLEC2D antigen comprises a human, a mouse, a dog, a rat or a cynomolgus CLEC2D.

The disclosure provides a method of modulating immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides a method of modulating (e.g., increasing) innate immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides a method of increasing the cytotoxicity of a natural killer cell in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments thereof of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides a method of modulating (e.g., increasing) adaptive immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibodies or antigen-binding fragments of the disclosure or the nucleic acids encoding the antibodies or antigen-binding fragments thereof of the disclosure.

The disclosure provides methods of screening a high diversity antibody gene library for antibodies that to a CLEC2D antibody comprising: (a) inserting a library of antibody genes into a phage protein gene and transforming a plurality of phages to produce a phage library, wherein the phages in the phage library display the library of antibody genes on the surface of the phage; (b) panning the phage library with a CLEC2D antigen for individual phages that bind to the CLEC2D antigen, thereby producing an enriched phage library that is enriched for antibody genes that encode antibodies that bind to the CLEC2D antigen; (c) repeating step (b) at least once or at least twice; (d) transferring the antibody genes from the enriched phage library to a yeast surface display library; (e) isolating individual yeast cells that bind to the CLEC2D antigen from the yeast surface display library; (f) culturing the isolated individual yeast cells that bind to the CLEC2D antigen to produce yeast surface display library clones; and (g) sequencing the yeast surface display library clones; thereby isolating antibody genes that bind to the CLEC2D antigen.

In some embodiments of the methods of screening of the disclosure, the panning step (b) comprises panning the phage library with CLEC2D coated magnetic beads. In some embodiments, the transferring step (d) comprises cloning the antibody genes into a yeast expression vector and transforming yeast cells. In some embodiments, the methods further comprise analyzing the surface expression of the antibody genes with a FLAG tag, a c-Myc tag, a polyhistidine tag or a V5 tag. In some embodiments, the testing step (e) comprises isolating yeast cells expressing antibody genes that bind to the CLEC2D antigen with flow cytometry. In some embodiments, the method further comprises repeating the flow cytometry isolation at least 1×, at least 2×, at least 3×, at least 4× or at least 5×. In some embodiments, the method further comprises cloning the antibody genes that bind to CLEC2D into a mammalian expression vector.

The disclosure provides methods of making a composition comprising anti-CLEC2D antibodies or antigen binding fragments thereof, comprising (a) transforming mammalian cells with a vector comprising a sequence encoding a promoter and a sequence encoding an anti-CLEC2D antibody or antibody fragment, wherein the sequence encoding the promoter and the anti-CLEC2D antibody or antibody fragment are operably linked; (b) culturing the mammalian cells under conditions suitable for the expression of the anti-CLEC2D antibody or antibody fragment; (c) centrifuging the cultured mammalian cells to produce a supernatant; (d) filtering the supernatant; and (e) purifying the filtered supernatant using liquid chromatography.

In some embodiments of the methods of the disclosure, the filtration step (d) comprises a 3 μm-30 μm filter. In some embodiments, the filtration step (d) further comprises a 0.22 μm filter. In some embodiments, the purifying step (e) comprises a Protein A column. In some embodiments, the protein A column is treated with a high salt wash buffer to remove host cell proteins. In some embodiments, the anti-CLEC2D antibody of fragment thereof is eluted using 30 mM Phosphate buffer at pH. 3.0-4.0. In some embodiments, the purifying step (e) further comprises an anion exchange chromatography (AEX) step. In some embodiments, the AEX step comprises a Q Sepharose column. In some embodiments, the Q Sepharose is pre-equilibrated in a pre-equilibration buffer comprising 10-100 mM Histidine. In some embodiments, the pre-equilibration buffer further comprises citrate, phosphate 2-(N-morpholino)ethanesulfonic acid (MES), acetate or a combination thereof. In some embodiments, the pre-equilibration buffer comprises a pH of 4.5-6.5. In some embodiments, the anti-CLEC2D antibody is eluted at step (e) with an elution buffer comprising 200-1000 mM NaCl, KCl or a combination thereof. In some embodiments, the elution buffer comprises a pH of 4.5-6.5.

In one aspect, this disclosure relates to the isolation of novel monoclonal antibodies that bind specifically to a CLEC2D antigen. The novel antibodies modulate (e.g., inhibit) the interaction of CD161 and CLEC2D to modify NK cell/immune cell mediated cytotoxicity and/or cytokine production.

In another aspect, this disclosure relates to cancer cells expressing CLEC2D are specifically recognized by these novel antibodies which may kill the tumor cells via ADCC (antibody dependent cellular cytotoxicity) and/or CDC (complement dependent cytotoxicity) and/or ADCP (antibody dependent cellular phagocytosis).

In a related aspect, this disclosure relates to methods of making an anti-CLEC2D antibody, comprising selecting from a high diversity antibody gene library an anti-CLEC2D antibody. In one embodiment, the high diversity antibody gene library is displayed through phage and/or yeast surface display. In one embodiment, the phage- and/or yeast-displayed high diversity antibody gene library is selected using purified CLEC2D antigen as a target. In one embodiment, the selected anti-CLEC2D antibody genes are expressed in a mammalian cell (e.g., Chinese hamster ovary (CHO) cell). In one embodiment, a single cell clone expressing an anti-CLEC2D antibody is expanded into a cell line and verified for anti-CLEC2D antibody expression. In one embodiment, overexpression of selected antibody clones is achieved through defined culture media, supplements, and specific bioreactor processes cumulatively described herein as upstream process development. In one embodiment, the anti-CLEC2D antibodies expressed from the cell line are purified to homogeneity, for example, through various filtration and chromatography, referred to herein as downstream purification processes.

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: determining a level of CLEC2D protein in the subject; and administering a therapeutically effective amount of an anti-CLEC2D antibody to the subject.

In some embodiments of the methods of the disclosure, the disease is a cancer. In some embodiments, the cancer comprises breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, pulmonary adenocarcinoma, adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, tubular cell carcinoma, ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, granulositic sarcoma, immunoblastic sarcoma, juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (leukemia), lymphatic sarcoma (lympho sarcoma), medullary sarcoma, myeloid sarcoma (granulocitic sarcoma), austiogenci sarcoma, periosteal sarcoma, reticulum cell sarcoma (histiocytic lymphoma), round cell sarcoma, spindle cell sarcoma, synovial sarcoma, telangiectatic audiogenic sarcoma, Burkitt's lymphoma, NPDL, NML, NH, diffuse lymphomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, acute myeloid lymphoma, chronic lymphocytic leukemia, chronic myeoloid leukemia, mantle cell lymphoma, and follicular lymphoma. In some embodiments, a cancer cell of the subject has an elevated level of CLEC2D protein when compared to a normal cell that does not have cancer. In some embodiments, an increased level of CLEC2D is associated with a poor prognostic outcome.

In some embodiments of the methods of the disclosure, the disease is an autoimmune or inflammatory disorder. In some embodiments, the autoimmune or inflammatory disorder is type I diabetes, rheumatoid arthritis, lupus, inflammatory bowel diseases, celiac disease, Crohn disease, ulcerative Colitis, psoriasis, or multiple Sclerosis.

In some embodiments of the methods of the disclosure, the disease is an autoimmune or inflammatory disorder. In some embodiments, the autoimmune disorder is type I diabetes, rheumatoid arthritis, lupus, inflammatory bowel diseases, celiac disease, Crohn disease, ulcerative Colitis, psoriasis, or multiple Sclerosis.

In some embodiments of the methods of the disclosure, the disease is infectious disease. In some embodiments, the disease is HIV infection, human Cytomegalovirus infection, Hepatitis B infection, Hepatitis C infection, Ebola virus infection, Dengue, Yellow fever, Listeriosis, Tuberculosis, Cholera, Malaria, Leishmaniasis, or Trypanosoma infection.

In another aspect, multiple in vitro and in vivo assays are used to characterize the novel antibodies produced from CHO cell lines which include, various biophysical parameters, antigen recognition, tumor cell surface binding, tumor cell death, production of cytokines, and analysis of downstream genes to define mode of action. These monoclonal antibodies are also tested for long term stability, various formulations relevant for therapeutic, prognostic and diagnostic uses in cancer, infectious diseases, autoimmune and chronic diseases. In another aspect, in vivo tumor suppression assays are carried out to establish anti-tumor activity of selected antibodies as monotherapy or in combination with other therapeutic products.

In one aspect, this disclosure further relates to the isolation of novel and unique monoclonal antibodies that bind specifically to CLEC2D antigen. In some aspect, the novel antibodies influence the interaction of CD161 and CLEC2D to modify immune cell (e.g., NK cell, B-cell, or T-cell) mediated cytotoxicity and/or cytokine production. In some aspects, various cancer cells, expressing CLEC2D, are recognized by these novel antibodies and have revealed cytotoxic effects through various means including, ADCC (antibody dependent cellular cytotoxicity) and/or CDC (Complement dependent cytotoxicity and/or ADCP (Antibody dependent cellular phagocytosis). In one aspect, the disclosure provides emphasis and postulates on the role of CLEC2D in cross-talk between lymphocytes and immune tolerance. In another aspect, in the realm of approved therapeutics or those in pre-clinical or clinical testing, the methods for identifying novel antibody molecules and related compositions provided herein comprise pharmaceutical features amenable to manufacturability/developability.

In one aspect, this disclosure relates to a method of treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof of, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A and B, as disclosed herein.

In one aspect, this disclosure relates to a method of modulating immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A and B, as disclosed herein.

In one aspect, this disclosure relates to a method of modulating (e.g., increasing) innate immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A and B, as disclosed herein.

In one aspect, this disclosure relates to a method of modulating (e.g., increasing) adaptive immunity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A and B, as disclosed herein.

In one aspect, this disclosure relates to a method of increasing the cytotoxicity of a natural killer cell in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment, wherein the antibody is an anti-CLEC2D antibody selected from the group consisting of: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, of Table 9A and B, as disclosed herein.

BRIEF DESCRIPTION OF THE FIGURES

The features of the present disclosure will become fully apparent from the following description taken in conjunction with the accompanying figures. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee. With the understanding that the figures depict only several embodiments in accordance with the disclosure and are not to be considered limiting its scope, the disclosure will be described further through use of the accompanying figures.

FIGS. 1A-1C illustrate present disclosure in a schematic format in: FIG. 1A, scenario wherein CLEC2D and CD161 interacts resulting in tumor cells escaping immune cells; FIG. 1B, scenario wherein interaction between CLEC2D and CD161 is blocked using an anti-CLEC2D antibody, resulting in lysis signal followed by killing of tumor cells; and FIG. 1C, scenario wherein ligation of CLEC2D antigen with anti-CLEC2D antibody resulting in activation of NK cell and in elevation of cytokine expression followed by enhanced target cell clearance either by direct killing or by involving other immune cells

FIGS. 2 A-2F illustrate expression and purification of CLEC2D antigen in mammalian cell in: FIG. 2A, generation of mammalian expression plasmids to express CLEC2D ecto-domain as soluble antigen. The construct was generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing; FIG. 2B, IMAC chromatography profile displaying purification of a soluble CLEC2D (Q72-V191), with inset showing elution profile of the CLEC2D antigen; FIG. 2C, SDS-PAGE profile of load, wash and final eluted CLEC2D protein, demonstrating that the purified CLEC2D protein was homogenous and pure, and suitable for further downstream experimentation; FIG. 2D, western blot of the purified CLEC2D protein, probed with a commercially available antibody against CLEC2D antigen; FIG. 2E, ELISA assay showing the binding specificity of a commercial antibody against different concentrations of the purified CLEC2D antigen; and FIG. 2F, SDS-PAGE analysis of the purified CLEC2D antigen incubated with PNGase enzyme under reducing conditions for 3 hrs or 6 hrs revealed deglycosylation of CLEC2D antigen.

FIG. 3 illustrates a schematic depiction of an antibody library screening strategy: the naïve antibody library screened against the target CLEC2D antigen using phage and yeast surface display systems.

FIGS. 4A-4E illustrate phage panning of antibody library with CLEC2D antigen coated on magnetic beads in: FIG. 4A, estimation of magnetic bead conjugation efficiency by flow cytometry; FIG. 4B, restriction enzyme digestion of independent heavy chain clones after panning of Fab library; FIG. 4C, restriction enzyme digestion of independent kappa light chain clones after panning of Fab library; FIG. 4D, restriction enzyme digestion of independent heavy chain clones after panning of ScFv library; and FIG. 4E, restriction enzyme digestion of independent kappa light chain clones after panning of ScFv library.

FIGS. 5A-5H illustrate screening of antibody against CLEC2D using yeast surface display in: FIG. 5A, plate images depicting yeast colony towards generation of ScFv antibody library through electroporation; FIG. 5B, plate images depicting generation of haploid heavy and light chain antibody libraries; FIG. 5C, plate images showing mating efficiency of haploid yeast strains containing heavy or light chain antibody libraries, wherein mating efficiency was estimated to be ˜29%; FIG. 5D, representative flow cytometric analysis of binding of antibody molecules expressed on the yeast cell surface with CLEC2D antigen, the ScFv libraries were sorted multiple times to enrich high affinity yeast clones; FIG. 5E, representative flow cytometric analysis of binding of antibody molecules expressed on the yeast cell surface with CLEC2D antigen, the Fab libraries were sorted multiple times to enrich high affinity yeast clones; FIG. 5F, representative data on enrichment of yeast clones after multiple rounds of sorting, both in terms of expression and antigen recognition; FIG. 5G, the individual yeast clones were separated and tested with CLEC2D antigen to identify yeast cell lines expressing high affinity antibody clones; and FIG. 5H, representative flow cytometry data to show the percentage binding of a soluble CLEC2D antigen with monoclonal antibody clones. At least about 80% of the clones detectably and specifically bound to the CLEC2D antigen.

FIGS. 6A-6D illustrate the peer group sequence analysis of clones screened through yeast display platform in: FIG. 6A, bar graph showing the CDRH3 length distribution of selected molecules; FIG. 6B, bar graph displaying relative amino acid frequency distribution for heavy chain CDRH3 (Kabat nomenclature); FIG. 6C, pie chart exhibiting heavy chain consensus family distribution; and FIG. 6D, pie chart exhibiting light chain consensus family distribution.

FIGS. 7A-7B illustrate the mammalian expression constructs used to generate full-length monoclonal antibody in: FIG. 7A, the vector designed to clone selected antibody variable heavy chain genes after screening through phage and yeast display platforms; and FIG. 7B, the vector designed to clone selected antibody variable light chain (kappa) genes after screening through phage and yeast display platforms. Constructs were generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing.

FIGS. 8A-8C illustrate mammalian expression system to express full-length CLEC2D on the cell surface, as shown in: FIG. 8A, CLEC2D gene expression construct was generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing; and FIG. 8B, flow cytometry with commercially available anti-CLEC2D antibody (4C7) showing expression of CLEC2D on transfected CHO cell surface (C4548); and FIG. 8C, the surface expression of CLEC2D as monitored with anti-CLEC2D (4C7) antibody on fixed and non-permeabilized cells by confocal microscopy (60×). Binding of anti-CLEC2D antibody was observed on C4548 cells whereas no binding was observed in un-transfected CHO cells. The nucleus was counterstained with DAPI (blue). Scale bar is 10 μm.

FIGS. 9A-9C illustrate anti-CLEC2D monoclonal antibody clones purified from transiently transfected CHO cell. Antibody was purified using protein A column chromatography, as shown in: FIG. 9A, SDS-PAGE profile of representative Anti-CLEC2D antibodies. The purified antibodies were subjected to SDS-PAGE analysis in both non-reducing and reducing conditions. Anti-CLEC2D Antibody clone purified from C3566 was shown in lane 9, upper panel of reducing and non-reducing gels. All clones from lower panels, except clone in lane 4 revealed good profiles in reducing and non-reducing gels. Clones showing degraded products were not considered for further studies. Similar criteria was employed for other clones as described in example section; FIG. 9B, the interaction of purified anti-CLEC2D antibody with CLEC2D antigen expressed on CHO cell surface through flow cytometry; Representative antibody clones, as exemplified by, C4577, C2907, C3566, C5582, C5397, were evaluated for CLEC2D binding on CHO cell lines either untransfected or transfected with full length CLEC2D construct. Shift in MFI towards right indicated binding of respective clones towards surface expressed CLEC2D antigen; and FIG. 9C, representative images of interaction of anti-CLEC2D antibodies with CLEC2D antigen expressed on PC3 tumor cells. As shown in Table 22 a qualitative rating of binding was carried out, “+” indicating low binding to “+++” indicating very high binding. As exemplified, surface binding was not detected with antibody C4252, whereas with antibody C0610, low binding was observed thereby rated as (+) while other clones have showed differential yet significant surface binding. The nucleus was counterstained with DAPI (violet). Scale bar is 10 μm.

FIGS. 10A-10E illustrate stable CHO cell line development expressing Anti-CLEC2D antibody, as shown in: FIG. 10A, the binding studies carried out with surface expressed CLEC2D as monitored using supernatant obtained from CHO mini-pool samples transfected with Anti-CLEC2D antibody expression plasmid, using flow cytometry. Histogram represents extent of binding against surface CLEC2D antigen expressed on C4548 cell, as observed for various clones. Fold change in MFI has been plotted against individual mini-pools binding. Higher fold change indicating higher binding of anti-CLEC2D antibody to CLEC2D antigen; FIG. 10B, single cell clone screening—Anti CLED2D antibody expressed from single cell clonal lines was purified and used for flow cytometry experiments. Higher fold change in fluorescence signal indicates stronger binding of anti-CLEC2D antibody binding to CLEC2D antigen; FIG. 10C, flow cytometric analysis of monoclonal antibody producing stable CHO cell lines—anti-CLED2D antibody expressed from single cell clonal lines was purified and used for flow cytometry experiments. Multiple monoclonal cell lines expressing the Anti-CLEC2D antibodies were (such as C4608, C5093, C5511, C6481, C6726, C7720, C9103, C5848 and C3452) were tested for binding to CHO cell surface expressed CLEC2D antigen by flow cytometry. Fold increase in median fluorescence intensity was estimated and was observed to be in the range of 3-10 fold for multiple stable clones; FIG. 10D, representative images of interaction of anti-CLED2D monoclonal antibodies produced from clonal CHO cell lines with the CLEC2D antigen expressed on PC3 tumor cell line. As depicted herein, various anti-CLEC2D antibodies showed differential yet significant surface binding to CLEC2D antigen on PC3 cell surface. The nucleus was counterstained with DAPI (violet). Scale bar is 10 μm; and FIG. 10E, quantitative RT PCR performed on of anti-CLEC2D antibody-stable cell clones C4608 and C5511 to confirm stable integration of antibody heavy chain and light chain genes. GAPDH house-keeping gene was used as internal normalizer. The study was carried out for 60 generations of CHO monoclonal lines expressing the Anti-CLEC2D antibodies.

FIGS. 11A-11F illustrate functional characterization of monoclonal anti-CLEC2D antibodies, as shown in: FIG. 11A, the binding of anti-CLEC2D antibodies, C4608, C5511, C6481, C2438, C3452, C0949 on surface expressed CLEC2D on prostate cancer cell line, PC3. Shift in MFI towards right indicated binding of antibody to surface expressed CLEC2D antigen on PC3 cell line; and FIG. 11B, representative flow cytometric analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells, at a ratio of 1:5 at a fixed concentration of 100 ug/mL of Anti-CLEC2D antibodies. Clones assessed for functionality herein were C5511, C4608 and C6481 with PBMC from Donor 1, while antibodies purified from clones C5392 and C3452 were tested with PBMC from Donor 2. The percentage of PC3 live cells is indicated by APC (eFluor 670) positive cells and dead cells indicates Sytox green-positive cells. Respective single cell clones have been labelled against each plot; FIG. 11C, representative flow cytometry analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells (1:5), with increasing concentrations of anti-CLEC2D antibody (C5511) from 10 μg/mL to 200 ug/mL revealed increased dose dependent tumor cell cytotoxicity; FIG. 11D, representative flow cytometric analysis of cytotoxicity assay performed on PC3 target cells using PBMC as effector cells at fixed concentration of anti-CLEC2D antibody C5511. The tumor to effector cell ratio (T:E) was increased from 1:5 to 1:10. The data revealed with increasing proportion of effector cells leads to higher levels of tumor cell cytotoxicity; and FIG. 11E, end point cytotoxicity assay revealed significant cytotoxicity of tumor cells at 10 μg/mL. The assay also determines optimum concentration of anti-CLEC2D antibody to kill target cells using confocal microscopy. Upper panel indicates all control treatments where no cytotoxicity was observed as expected, and lower panel indicates the enhanced PC3 tumour cell death when treated with increasing the concentration of anti-CLEC2D antibody (C6726) in presence of PBMC (T:E=1:5). The maximum cell death were observed at concentration of 50 ug/ml of Anti-CLEC2D antibody. PC3 tumor cells—Green; PBMC—red; Dead cells—Blue; and FIG. 11F, end point cytotoxicity assay using selected anti-CLEC2D antibody to kill target cells using confocal microscopy. No cytotoxicity observed in control treatments like PC3 tumor cell alone, PBMC alone, PBMC with isotype human IgG1 antibody. PC3 tumor cell cytotoxicity was observed when Anti-CLEC2D antibody (C6726, C5848, C4608, C5511 and C6481) clones were used. Size enhanced images revealed PC3 tumor cells were surrounded by effector cells inducing tumor cell death. PC3 tumor cells—Green; PBMC—red; Dead cells—Blue.

FIGS. 12A-12D illustrate NK cell mediated cytotoxicity of tumor cells with anti-CLEC2D antibody, a shown in: FIG. 12A, cytotoxicity of PC3 tumor cells when treated with purified NK cells and anti-CLEC2D antibodies (C6481 & C5511) at 100 ug/ml. The data revealed 86% NK cell mediated cytotoxicity of PC3 tumor cells at T:E of 1:1. The percentage of PC3 dead cells indicates Sytox green-positive cells; FIG. 12B, no target cell death was observed when incubated with either isotype control (human IgG1 antibody) or with only NK cells increasing T:E ratio starting from 1:0.5 to 1:10; Scale bar is 10 μm and FIG. 12C, anti-CLEC2D antibody alone cannot induce cytotoxicity of PC3 tumor cell; Scale bar is 10 μm and FIG. 12D anti-CLEC2D antibody C5511 (at 50 ug/mL) revealed increasing PC3 tumor cell death with increasing T:E ratio starting from 1:0.5, 1:5 and 1:10 C5511. Scale bar is 10 μm.

FIG. 13 illustrates cytotoxicity of PC3 tumor cells treated with isolated T cells and anti-CLEC2D antibodies (C5511 & C6481) at 100 ug/ml. The percentage of dead PC3 tumor cells indicated by Sytox green-positive cells.

FIGS. 14A-14B illustrate live cell imaging with Anti-CLEC2D antibody dependent cytotoxicity of PC3 tumor cells, a shown in: FIG. 14A, live cell imaging revealed cytotoxicity of PC3 tumor cells over a period of incubation with human PBMC cells and Anti-CLEC2D antibody at 200 μg/ml. The assay was carried out for 20 hrs in a humidifier maintained at 37° C. and 5% CO2 during the image acquisition. On the contrary, incubation with Control human IgG1 antibody (200 μg/ml) did not cause tumor cell cytotoxicity. Live PC3 tumor cells—Green; PBMC—Red; Dead cells—Blue; Scale bar is 20 μm and FIG. 14B, live cell imaging revealed cytotoxicity of PC3 tumor cells over a period of incubation with human NK cells and Anti-CLEC2D antibody at 200 μg/ml. The assay was carried out for 20 hrs in a humidifier maintained at 37° C. and 5% CO2 during the image acquisition. On the contrary, incubation with Control human IgG1 antibody (200 μg/ml) did not cause tumor cell cytotoxicity. Live PC3 tumor cells—Green; NK cells—Red; Dead cells—Blue. Scale bar is 20 μm.

FIGS. 15A-15G illustrate predictive models of anti-CLEC2D antibodies, as shown in: FIG. 15A, cartoon representation of epitope recognition (Chain A—Dark Blue, Chain B—Cyan) & CD161 (Chain C—Orange red, Chain D—Purple) complex PDB ID 5MGT; FIG. 15B, the red selections denote residues within 6 Å of NKR-P1's chains; FIG. 15C, ribbon representation of refined anti-CLEC2D antibody structures; respective clones for specific anti-CLEC2D monoclonal antibodies have been labelled appropriately. Variable light chain is depicted in darker shade while heavy chain variable region is shown in white; FIG. 15D, represents selected conformations following PIZSA scoring and conformation clustering principle, belonging to C4608, contributed to one of the clusters interacting against CLEC2D (darker shade); FIG. 15E, a visualization of the residues selected for mutation to determine if the G00001-G00004-G00007-G00010-G00015 cluster combination from C4608 contains the binding site towards CLEC2D antigen; FIG. 15F, represents selected conformations following PIZSA scoring and conformation clustering principle, belonging to C5511, contributed to one of the clusters interacting against CLEC2D (darker shade); and FIG. 15G, a visualization of the residues selected for mutation to determine if the G00001-G00005-G00011-G00019-G00020 cluster combination from C5511 contains the binding site towards CLEC2D antigen.

FIGS. 16A-16G illustrate on identified epitope patch on CLEC2D antigen against anti-CLEC2D antibody clones C4608 and C5511; FIG. 16A, surface representation of anti-CLEC2D antibody C4608 contact points on CLEC2D antigen; FIG. 16B, anti-CLEC2D antibody C4608 contact points on CLEC2D antigen that are overlapping with CD161 binding regions on CLEC2D; FIG. 16C, surface representation of anti-CLEC2D antibody C5511 contact points on CLEC2D antigen; FIG. 16D, anti-CLEC2D antibody C5511 contact points with CLEC2D antigen that are overlapping with CD161 binding regions on CLEC2D; In all depictions darker shade indicates the interacting residue locations on CLEC2D antigen; FIG. 16E, anti-CLEC2D antibody mediated disruption of CLEC2D and CD161 interaction-monitoring of CLEC2D antigen bead conjugation efficiency check; FIG. 16F, binding of CD161-FC to CLEC2D antigen was observed on magnetic beads in concentration depend manner; FIG. 16G, flow cytometric monitoring of CD161 binding in the absence and presence of Anti-CLEC2D antibody as compared with control, as a measure of disruption of CD161 and CLEC2D binding, as indicated by the solid black arrow.

FIGS. 17A-17B illustrate NK cell activation with anti-CLEC2D antibody, as shown in: FIG. 17A, anti-CLE2D antibody C5511 induces CD69 expression indicating NK cell activation towards becoming cytotoxic. Respective experimental conditions have been mentioned against each plot. IL2 treatment was carried out as positive control of CD69 overexpression; and FIG. 17B, anti-CLEC2D antibody mediated CD69 expression is higher compared to PC3 cell primed CD69 expression level on NK cells.

FIGS. 18A-18D illustrate effects of anti-CLEC2D antibody C5511 on cytokine expression by effector cells, as shown in: FIG. 18A, anti-CLEC2D antibody C5511 was used at concentrations of 10 μg/mL and 100 μg/mL to monitor elevation in IFNγ expression level; FIG. 18B, anti-CLEC2D antibody C5511 was used at concentration of 100 ug/mL in the presence or absence of PC3 cells (E:T=10:1). IFNγ expression was monitored in the CD3+ve gated population; FIG. 18C, anti-CLEC2D antibody C5511 was used at concentration of 100 ug/mL in the presence or absence of PC3 cells (E:T=10:1). IFNγ expression was monitored in the CD3-ve gated population; and FIG. 18D, anti-CLEC2D antibody C5511 was used as at concentrations of 100 μg/mL in the presence or absence of isolated NK cell. IFNγ overexpression was observed with anti-CLEC2D antibody C5511.

FIGS. 19A-19G illustrate mammalian expression constructs used to generate full-length monoclonal antibody. Constructs were generated through gene synthesis followed by confirmation through restriction digestion and Sanger sequencing, as shown in: FIG. 19A, vector designed to clone selected antibody variable heavy chain genes in IgG4 backbone; FIG. 19B, vector designed to clone selected antibody variable heavy chain genes in IgG1 N to A backbone; FIG. 19C, flow cytometric analysis of binding of Anti-CLEC2D antibody with IgG4 isotype backbone (C3256 and C3276) to CLEC2D antigen expressed on surface of CHO cells. Binding was compared with un-transfected CHO cells, as estimated from peak shift towards right; FIG. 19D, cytotoxicity of Anti-CLEC2D antibody using various antibody isotypes. IgG1 isotype (C3452 & C4608) and IgG4 isotype (C3256 & C3276) Anti-CLEC2D antibodies exhibited significant cytotoxicity when incubated with freshly isolated PBMC and PC3 tumor cells; FIG. 19E, anti-CLEC2D antibody produced as afucosylated monoclonal antibodies C0613, C1301, C6268, C1699, C2437, C9832, C8900 and C7749 revealed binding to CHO cell surface expressed CLEC2D antigen by flow cytometry; FIG. 19F, NK cell-mediated cytotoxicity of PC3 tumor cells with the afucosylated anti-CLEC2D antibody (C7749, C8800,C9832) used at 5X lesser concentration than C5511. The data revealed afucosylated Anti-CLEC2D antibodies achieved nearly equal cell death at 5 times less concentration, indicating afucosylated Anti-CLEC2D antibodies are more cytotoxic; and FIG. 19G, CDC mediated cytotoxicity was measured for anti-CLEC2D antibody C5511 using Ramos and PC3 tumor cell lines. Rituximab was used as positive control.

FIGS. 20A-20K illustrate anti-tumor effects in cancer xenograft mouse model. HuNOG-EXL mice were used for PC3 xenograft and the tumor bearing animals were randomized and used for injecting Anti-CLEC2D antibody product, as shown in: FIG. 20A, tumor volume vs. time plot demonstrating significant anti tumor effects observed with Anti-CLEC2D antibody alone or in combination with anti-PDL1 antibody; FIG. 20B, images displaying immune cell infiltration through staining of CD3+ T cells in the tumor micro environment; FIG. 20C, images of mice with the xenograft showing Alexa 647 labelled anti-CLEC2D antibody injected into the tumor over a 96-hour period; FIG. 20D, effect of test compounds on tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). **p<0.01 statistically significant (Day 36) when C5511 mAb group was compared with Vehicle control IgG1 group; FIG. 20E, effect of test compounds on tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). ***p<0.001 and *p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20F, effect of test compounds on delta tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). **p<0.01 statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; FIG. 20G, effect of test compounds on delta tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). ***p<0.001 and *p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20H, effect of test compounds on relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version 8.3.0). *p<0.05 statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; FIG. 20I, effect of test compounds on relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). ***p<0.001 and *p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group; FIG. 20J, effect of test compounds on delta relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 36). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). *p<0.05; and statistically significant (Day 36) when C5511 mAb group was compared to Vehicle control IgG1 group; and FIG. 20K, effect of test compounds on delta relative tumor volume in humanized (huNOG-EXL) mice bearing subcutaneous PC-3 tumor xenografts (up to day 24). Each treatment group consisted of 5 animals and named as C5511 mAb group, Vehicle control IgG1 group and C6481 mAb group. Values are expressed as mean of 2-5 animals in each group. Statistical analysis was carried out by Two-way ANOVA followed by Bonferroni post-tests using Graph Pad Prism (Version.8.3.0). ***p<0.001 and *p<0.05 statistically significant (Day 24) when C5511 mAb group and C6481 mAb group, respectively were compared to Vehicle control IgG1 group.

FIGS. 21A-21I illustrate characterization of purified Anti-CLEC2D antibody product, as shown in: FIG. 21A, SDS-PAGE analysis of purified C5511 antibody in non reducing and reducing conditions; FIG. 21B, TIC chromatogram from Intact Mass spectrometry analysis of Anti-CLEC2D antibody (3 replicates); FIG. 21C, WCX chromatogram analysis of Anti-CLEC2D antibody; FIG. 21D, Size Exclusion chromatogram of Anti-CLEC2D antibody; FIG. 21E, ELISA assay development of Anti-CLEC2D antibody against CLEC2D purified biotinylated antigen. The data was fit to one site binding model to calculate Kd of Anti-CLEC2D antibody; FIGS. 21E and 21F, CLEC2D antigen affinity based binding studies of representative Anti-CLEC2D antibody. FIG. G, Purified CLEC2D antigen ecto-domain was used as source of antigen in BIACORE studies; Response monitored has been plotted against time; FIG. 21H, affinity based binding studies of representative Anti-CLEC2D antibody molecules with FcRn at pH 5.9; and FIG. 21I, affinity based binding studies of representative Anti-CLEC2D antibody molecules with FcRn at at pH 7.4.

FIGS. 22A-22C illustrate that anti-CLEC2D antibody for plausible diagnostic and prognostic applications, as shown in: FIG. 22A, selection of Anti-CLEC2D antibody (C0949) based on binding characteristics. Four Anti-CLEC2D antibodies were evaluated (C2779, C2438, C0949 and C2543) for CLEC2D binding on PC3 target cells. C0949 showed excellent binding and peak median shift; FIG. 22B, anti-CLEC2D antibody C0949 recognizes CLEC2D antigen on multiple prostate cancer cell lines; and FIG. 22C, anti-CLEC2D antibody C0949 recognizes CLEC2D antigen on multiple tumor cell lines. Specific binding and fold change in mean fluorescence was calculated by ratio of mean FITC fluorescence between test and control.

FIGS. 23A-23D illustrate that anti-CLEC2D antibody recognize CLEC2D antigen on prostate cancer tumor cells, as shown in: FIG. 23A, expression level of CLEC2D antigen on prostate cancer disease stage after TCGA data analysis; FIG. 23B, expression level of CLEC2D antigen on prostate cancer cell lines PC3, DU145, 22RV1 and LnCap; FIG. 23C, expression level of CLEC2D antigen on prostate cancer cell lines PC3, LnCap, 22RV1, and DU145 with induction using LPS, Poly I:C, IFN-γ, PBMC supernatant, PBMC cells, NK cells and T cells. Upper panel with anti-CLEC2D antibody, lower panel representing the merged image; and FIG. 23D, human tissue microarray slides stained with anti-CLEC2D antibody C2685 showing staining of tumor cells in malignant prostate cancer tissue.

FIGS. 24A-24D illustrate that anti-CLEC2D antibody recognize CLEC2D antigen on various other tumor cells, as shown in: FIG. 24A, TCGA data analysis for CLEC2D antigen expression in various cancers; FIG. 24B, expression level of CLEC2D antigen on various tumor cell lines HepG2 (liver cancer), LN229 (Glioblastoma), SKOV3 (Ovary cancer), BT474 (Breast cancer), NCI-H929 (Myeloma), and Ramos (Lymphoma); FIG. 24C, expression level of CLEC2D antigen on BT474 (Breast cancer), SKOV3 (Ovary cancer), LN229 (Glioblastoma), Ramos (Lymphoma), NCI-H929 (Myeloma) and HepG2 (liver cancer), upon induction with LPS, Poly I:C, IFNγ; FIG. 24D, anti-CLEC2D antibody C5511 mediated cytotoxicity observed on SKOV3 (ovary cancer) at 100 μg/ml; and anti-CLEC2D antibodies C5511 and C6481 mediated cytotoxicity observed on HepG2 (liver cancer) cell lines at 100 m/ml. The percentage of dead cells indicated by Sytox green-positive cells.

FIGS. 25A-25E illustrate lymphocyte proliferation assay with anti-CLEC2D antibody using flow cytometry analysis, as shown in: FIG. 25A, Antibody wet-coating protocol; FIG. 25B, Air dried antibody coating protocol; FIG. 25C, High density pre-culture protocol; FIG. 25D, measurement of IFNγ cytokine secretion from effector cells when PBMC are incubated with Anti-CLEC2D antibodies (C5511, C4608, C6481) for extended period. Treatment with OKT3 antibody was used as a positive control; and FIG. 25E, measurement of IL2 cytokine secretion from effector cells when PBMC are incubated with Anti-CLEC2D antibodies (C5511, C4608, C6481) for extended period. Treatment with OKT3 antibody was used as a positive control. PBMCs were treated with anti CD3 antibody OKT3 (1 μg/ml), Anti-CLEC2D antibody C4608, C5511 and C6481 (1 μg/ml, 10 μg/ml, 50 μg/ml & 100 μg/ml) and incubated for four days. The fluorescent proliferation dye status was monitored using flow cytometer. Untreated PBMC was used as a control.

FIG. 26 illustrates histogram overlay showing binding of anti-CLEC2D antibodies (C3566 and C5511) against CLEC2D antigen homologs from Rat, Mouse and cynomolgus monkey, expressed on CHO cell surface, using flow cytometric analysis.

DETAILED DESCRIPTION

Modulation of immune cell checkpoint receptors via antibody-based/directed therapeutic approaches has been gaining constant interests over the past few years. The largest efforts have been centered on T cell checkpoint modulation. However, there is an increasing attention in B cell, NK cell, and myeloid cell checkpoint modulation as well. The innate immune system includes natural killer (NK) cells, which possess the ability to recognize and induce the cytotoxicity of a wide range of target cells, such as, tumor cells or virus infected cells. NK cells do not need any prior antigen sensitization. Apart from direct cytotoxicity, NK cells also participate in the initiation and progress of the adaptive immune response through the production and secretion of cytokines. Usually, these responses are regulated by adequate balance of signals induced by the interaction of a wide array of surface-activating and surface-inhibitory receptors with ligands on the surface of target cells. Modulation of NK cell numbers and/or its relevant function through a variety of agents such as monoclonal antibodies, cytokines may result in enhanced anti-tumor activity. These agents can be offered either alone or in combination as potential therapeutics. Therefore, anti-cancer activity of NK cell can be unleashed through harnessing surface receptors, both activating and/or inhibitory kinds.

Blocking these interactions may be a new therapeutic option for treatment of several cancers. However, the finding, understanding and designs need to be tuned and therapeutic treatment needs to be further tailored for specific receptor as targets against various cancers, which is still unmet.

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include the plural and plural terms shall include the singular as is considered appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for the sake of clarity. Generally, nomenclatures used in connection with, and techniques of biotechnology, immunology, molecular and cellular biology, recombinant DNA technology described herein are those well known and commonly used in the art. Certain references and other documents cited herein are expressly incorporated herein by reference. In case of conflict, the present specification, including definitions, will control. The materials, methods, figures and examples are illustrative only and not intended to be limiting.

Furthermore, the methods, preparation and use of the antibody naïve library disclosed employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, computational chemistry, cell culture, recombinant DNA technology, Polymerase Chain Reaction (PCR) and related fields. These techniques, their principles, and requirements are explained in the literature and known to a person skilled in the art.

Before the method of generating the antibody naïve library and the nucleic acids which encode the antibody naïve library and other embodiments of the present disclosure are disclosed and described, it is to be understood that the terminologies used herein are for the purpose of describing particular embodiments only and are not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

In one embodiment, the terms “library” and “libraries” are used interchangeably within this disclosure, which relate to the product of the disclosure. In one embodiment, it refers to a collection or pool of nucleic acid sequences. In one embodiment, it refers to a collection or pool of amino acid sequences. In some embodiments, it refers to a collection or pool of organisms that comprise a collection or pool of amino acid sequences or nucleic acid sequences. In some embodiments, the organisms are bacteriophages (phages) or yeast (e.g., Saccharomyces cerevisiae).

In one embodiment, the terms ‘pooling’, ‘pooled’, ‘pool’, and ‘pools’ in the context of the instant disclosure means combining the samples/nucleic acid sequences/nucleic acid fragments/gene clones/amplified product/antibodies obtained by employing the method of the instant disclosure from multiple donors i.e., more than one donor.

In one embodiment, the term “PBMC” refers to any peripheral blood cell having a round nucleus consisting of lymphocytes (T cells, B cells, NK cells) and monocytes, erythrocytes, platelet, and granulocytes (neutrophils, basophils, and eosinophils).

Antigens

As used herein, the terms “antigen” or “immunogen” refer to any foreign substance which induces an immune response in the body. In one embodiment, an antigen is a cellular protein. In one embodiment, an antigen is a cell surface protein.

The antigen may be isolated or derived from any species. Representative species include, but are not limited to Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus Macaca fascicularis. In some embodiments, the antigen is a fragment of a wild type protein isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris or Cynomolgus Macaca fascicularis. In some embodiments, the antigen is a mutant variant of a protein from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris or Cynomolgus Macaca fascicularis. In some embodiments, antigens can be mutated to increase the solubility and/or stability of the antigen. For example, a CLEC2D antigens can include a mutation at H176C to introduce an additional disulphide bridge with the Cys163 amino acid to increase the stability and homogeneity of the expressed protein.

In some embodiments, the antigen includes an epitope tag at either the N or C terminus of the polypeptide. Exemplary tags include, but are not limited to polyHistidine tags and FLAG tags. Any epitope tag known in the art is envisaged as within the scope of the disclosure.

C-type lectin domain family 2 member D (CLEC2D), also referred to as CLAX, Lectin Like Transcript-1 (LLT1) and OCIL, is a member of the natural killer cell receptor C-type lectin family. CLEC2D binds to Killer Cell Lectin Like Receptor B1 (KLRB1). KLRB1 is also known as CD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A and hNKR-P1A. All orthologs and isoforms of CLEC2D and CD161 are considered to be within the scope of the present disclosure.

In some embodiments, a C-type lectin domain family 2 member D (CLEC2D) protein or any of its aliases or homologs, known in the art, whether from humans or other species, represents a target antigen of an antibody produced by the methods described herein.

In some embodiments, the antigen is a CLEC2D antigen that has at least 85%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, at least 99% or 100% identity to a CLEC2D sequence isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus Macaca fascicularis.

In some embodiments, a CD161 protein or any of its aliases or homologs, known in the art, whether from humans or other species, represents a target antigen of an antibody produced by the methods described herein.

In some embodiments, the CD161 antigen has at least 85%, at least 90%, at least 95%, at least 96%, at least 97% at least 98%, at least 99% or 100% identity to a CD161 sequence isolated or derived from Homo sapiens, Mus musculus, Rattus norvegicus, Canis lupis familiaris and Cynomolgus Macaca fascicularis.

Exemplary antigens are shown in Table 1 below.

TABLE 1

Representative CLEC2D and CD161 Polypeptide Sequences

SEQ ID
Description
Amino Acid Sequence

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ

886

sapiens)
EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP

CLEC2D
SDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARHYTERKWICSKSDI

construct 1
HV

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

887

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARHYTERKWICSKSDIHVHHH

CLEC2D
HHHHH

construct 2

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

888

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHVHHH

CLEC2D
HHHHHG

construct 3

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVES

889

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARH

CLEC2D
YTERKWICSKSDIHVHHHHHHHH

construct 4

SEQ ID
Human (Homo
MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV

890

sapiens)
ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAR

CLEC2D
CYTERKWICSKSDIHVHHHHHHHHG

construct 5

SEQ ID
Human (Homo
MMSFVSLLLVGILFHATQAHHHHHHHHDDDDKQAACPESWIGFQRKCFYFSDDTKNWTSS

891

sapiens)
QRFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGA

CLEC2D
GECAYLNDKGASSARCYTERKWICSKSDIHV

construct 6

SEQ ID
Human (Homo
HHHHHHHHDDDDKQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQE

892

sapiens)
LNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSARCYTER

CLEC2D
KWICSKSDIHV

construct 7

SEQ ID
Human (Homo
MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV

893

sapiens)
ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAA

CLEC2D
CAAAAAWICSKSDIHVHHHHHHHH

construct 8

SEQ ID
Human (Homo
MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF

894

sapiens)
QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACA

CLEC2D
AAAAWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE

construct 9
LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV

F

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

895

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACAAAAAWICSKSDIHVEFE

CLEC2D
QKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYS

construct 10
LSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

896

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDKGASSAACAAAAAWICSKSDIHVHHH

CLEC2D
HHHHH

construct 11

SEQ ID
Human (Homo
MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV

897

sapiens)
ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSAR

CLEC2D
CYTERKWICSKSDIHVHHHHHHHH

construct 12

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

898

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCYTERKWICSKSDIHVHHH

CLEC2D
HHHHH

construct 13

SEQ ID
Human (Homo
MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF

899

sapiens)
QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCY

CLEC2D
TERKWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE

construct 14
LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV

F

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

900

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAALADKGASSARCYTERKWICSKSDIHVEFEQ

CLEC2D
KLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYSL

construct 15
STTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF

SEQ ID
Human (Homo
MMSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQV

901

sapiens)
ESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASA

CLEC2D
RCYTERKWICSKSDIHVHHHHHHHH

construct 16

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

902

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCYTERKWICSKSDIHVHHH

CLEC2D
HHHHH

construct 17

SEQ ID
Human (Homo
MQLLRCFSIFSVIASVLAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESF

903

sapiens)
QELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCY

CLEC2D
TERKWICSKSDIHVEFEQKLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQE

construct 18
LTTICEQIPSPTLESTPYSLSTTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYV

F

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGPSDHWI

904

sapiens)
GLSREQGQPWKWINGTEWTRQFPILGAGECAYLNDAGAASARCYTERKWICSKSDIHVEFEQ

CLEC2D
KLISEEDLDYKDDDDKENLYFQGLQASGGGGSGGGGSGGGGSQELTTICEQIPSPTLESTPYSL

construct 19
STTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPINTQYVF

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ

905

sapiens)
EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP

CLEC2D
SDHWIGLSREQGQPWKWINGTEWTRQLVMKEDGANLYVAKVSQVPRMNPRPVMVSYPG

construct 20
SRRVCLFE

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ

906

sapiens)
EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELNFLLRYKGP

CLEC2D
SDHWIGLSREQGQPWKWINGTEWTRQ

construct 21

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPGCLHSKEHSIKATLIWRLFFLIMFLTIIVCGMVAALSAIRANCHQ

907

sapiens)
EPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVESFQELVSYPGSRR

CLEC2D
VCLFE

construct 22

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPAIRANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSS

908

sapiens)
QRFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGA

CLEC2D
GECAYLNDKGASSARHYTERKWICSKSDIHV

construct 23

SEQ ID
Human (Homo
MHDSNNVEKDITPSELPANPAIRANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSS

909

sapiens)
QRFCDSQDADLAQVESFQELVSYPGSRRVCLFE

CLEC2D

construct 24

SEQ ID
Rat (Rattus
MPSSAHLQDPPPLLSRTLIQNEGQTSLRQSSSCGPSAASASESLSGSTESRIPHSKMLQGKLPR

910

norvegicus)
NIPLEYPAGLYCCYVVIIVLSVAVVALSVALSVKKTAQISTINTYAACPRNWIGVGNKCFYFNEIP

CLEC2D
SNWTLSQTLCKEQGAELARFDTEEELNFLRRYKGSSGYWFGLHRESSAHPWKWTDNTEYNN

construct 1
SVSIGGDEKHGFLSDNGFSSGRGYIVRKSICRKPNSYTSQCL

SEQ ID
Mouse (Mus
MCVTKASLPMLSPTGSPQEVEVGKILQGKRHGTISPESCAKLYCYYGVIMVLTVAVIALSVALS

911

Musculus)
ATKTEQIPVNKTYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELN

CLEC2D
FLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRIYSLRM

construct 1
WICSKLNSYSLHCQTPFFPS

SEQ ID
Mouse (Mus
MSFVSLLLVGILFHATQAYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFD

912

Musculus)
NQDELNFLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRI

CLEC2D
YSLRMWICSKLNSYSLHCQTPFFPSHHHHHHHH

construct 2

SEQ ID
Mouse (Mus
YAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELNFLMRYKANFDS

913

Musculus)
WIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRIYSLRMWICSKLNSYSLHC

CLEC2D
QTPFFPSHHHHHHHH

construct 3

SEQ ID
Mouse (Mus
MSFVSLLLVGILFHATQAYAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFD

914

Musculus)
NQDELNFLMRYKANFDSWIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTR

CLEC2D
CYSLRMWICSKLNSYSLHCQTPFFPSHHHHHHHH

construct 4

SEQ ID
Mouse (Mus
YAACPQNWIGVENKCFYFSEYPSNWTFAQAFCMAQEAQLARFDNQDELNFLMRYKANFDS

915

Musculus)
WIGLHRESSEHPWKWTDNTEYNNTIPIRGEERFAYLNNNGISSTRCYSLRMWICSKLNSYSLH

CLEC2D
CQTPFFPSHHHHHHHH

construct 5

SEQ ID
Dog (Canis
MSFVSLLLVGILFHATQAEAACPESWIGFQRKCFYFSDDIKNWTFSQRFCDSYGADLVQIETLL

916

lupus

ELNFLLRYKGPYDHWIGLSRDLGQPWKWVNGTEWTNCFPIRGGGECAYLNDKGASSARRYT

familiaris)
ERKWICSKPDIYAQIKRQNSIHHHHHHHH

CLEC2D

construct 1

SEQ ID
Dog (Canis
EAACPESWIGFQRKCFYFSDDIKNWTFSQRFCDSYGADLVQIETLLELNFLLRYKGPYDHWIGL

917

lupus

SRDLGQPWKWVNGTEWTNCFPIRGGGECAYLNDKGASSARRYTERKWICSKPDIYAQIKRQ

familiaris)
NSIHHHHHHHH

CLEC2D

construct 2

SEQ ID
Cynomolgus
MVTGSKMHDSNNVEKDIAPSELPANPGYRHSKQHSGKATLIWPLFFLIMFLTIIVCGMVVALS

918
(Macaca
AIRANCHQKPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVESFQEL

fascicularis)
NFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYYTERK

CLEC2D
WICSKPDTYVQMVQQSPN

construct 1

SEQ ID
Cynomolgus
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVES

919
(Macaca
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYY

fascicularis)
TERKWICSKPDTYVQMVQQSPNHHHHHHHH

CLEC2D

construct 2

SEQ ID
Cynomolgus
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDAALAQVESFQELNFLLRYKGPSDHWI

920
(Macaca
GLSREQGQPWKWINGTEWTRQFPILGAGEYAYLNDKGASSARYYTERKWICSKPDTYVQMV

fascicularis)
QQSPNHHHHHHHH

CLEC2D

construct 3

SEQ ID
Human (Homo
MDQQAIYAELNLPTDSGPESSSPSSLPRDVCQGSPWHQFALKLSCAGIILLVLVVTGLSVSVTSL

921

sapiens)
IQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLL

CD161
LIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDLEIRGDAKENSCISISQTS

construct 1
VYSEYCSTEIRWICQKELTPVRNKVYPDS

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVN

922

sapiens)
PWNNSLADCSTKESSLLLIRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNWKWINGSFLNSNDL

CD161
EIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSHHHHHHHH

construct 2

SEQ ID
Human (Homo
QKSSIEKCSVDIQQSRNKTTERPGLLNCPIYWQQLREKCLLFSHTVNPWNNSLADCSTKESSLLL

923

sapiens)
IRDKDELIHTQNLIRDKAILFWIGLNFSLSEKNW

CD161
KWINGSFLNSNDLEIRGDAKENSCISISQTSVYSEYCSTEIRWICQKELTPVRNKVYPDSHHHHH

construct 3
HHH

SEQ ID
Dog (Canis
MSFVSLLLVGILFHATQAQNSSIEECRVDVQVNGNETTEKPNLLQCPVHWHLLQEKCLFFSHA

924

lupus

SNTWKDSLTDCSAKESSLLLIQDQEELRLIRGLIYKKEILFWIGLNLTLSEKKWKWINGSFLNSNIL

familiaris)
QIAGYNKESSCVYISLTGIVSENCDAENQWICQKELKPDRNKICSKFHHHHHHHH

CD161

construct 1

SEQ ID
Dog (Canis
QNSSIEECRVDVQVNGNETTEKPNLLQCPVHWHLLQEKCLFFSHASNTWKDSLTDCSAKESSL

925

lupus

LLIQDQEELRLIRGLIYKKEILFWIGLNLTLSEKKWKWINGSFLNSNILQIAGYNKESSCVYISLTGI

familiaris)
VSENCDAENQWICQKELKPDRNKICSKFHHHHHHHH

CD161

construct 2

SEQ ID
Cynomolgus
MSFVSLLLVGILFHATQAQKPSIGKCSVDIQQNRTKTTERPDLLNCPIYWQQVQEKCLLFSHTV

926
(Macaca
NPWNNSLADCSTKESSLLLIQDKDELTRTQNLIHDKAISFWIGLNFSLSEKNWKWINGSFLSSN

fascicularis)
DLKITGDAKENSCVYISQTSVYSEYCSTEMKWICQKELTLVRNKVSPDSWLHHHHHHHH

CD161

construct 1

SEQ ID
Cynomolgus
QKPSIGKCSVDIQQNRTKTTERPDLLNCPIYWQQVQEKCLLFSHTVNPWNNSLADCSTKESSL

927
(Macaca
LLIQDKDELTRTQNLIHDKAISFWIGLNFSLSEKNWKWINGSFLSSNDLKITGDAKENSCVYISQ

fascicularis)
TSVYSEYCSTEMKWICQKELTLVRNKVSPDSWLHHHHHHHH

CD161

construct 2

SEQ ID
Mouse (Mus
MSFVSLLLVGILFHATQAQKPSREKCCVFIQENLNKTTDCSVNLECPQDWLLHRDKCFHVSQV

928

Musculus)
SNTWEEGQADCGRKGATLLLIQDQEELRFLLDSIKEKYNSFWIGLRFTLPDMNWKWINGTTF

CD161
NSDVLKITGVTENGSCASILGDKVTPESCASDNRWICQKELNHETPSNDSHHHHHHHH

construct 1

SEQ ID
Mouse (Mus
QKPSREKCCVFIQENLNKTTDCSVNLECPQDWLLHRDKCFHVSQVSNTWEEGQADCGRKGA

929

Musculus)
TLLLIQDQEELRFLLDSIKEKYNSFWIGLRFTLPDMNWKWINGTTFNSDVLKITGVTENGSCASI

CD161
LGDKVTPESCASDNRWICQKELNHETPSNDSHHHHHHHH

construct 2

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

930

sapiens)
DSQDADLAQVESFQELNFLLRYKGaSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 25
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

931

sapiens)
SFQELNFLLRYKGaSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 26

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

932

sapiens)
DSQDADLAQVESFQELNFLLRYKGPaDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 27
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

933

sapiens)
SFQELNFLLRYKGPaDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 28

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

934

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSaHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 29
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

935

sapiens)
SFQELNFLLRYKGPSaHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 30

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

936

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREaGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 31
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

937

sapiens)
SFQELNFLLRYKGPSDHWIGLSREaGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 32

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

938

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGaCAYLNDKGASSARCYTERKWICSKSDIH

construct 33
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

939

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGaCAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 34

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

940

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAaLNDKGASSARCYTERKWICSKSDIH

construct 35
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

941

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAaLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 36

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

942

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDaGASSARCYTERKWICSKSDIHV

construct 37
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

943

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDaGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 38

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

944

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASaARCYTERKWICSKSDIH

construct 39
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

945

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASaARCYTERKWICSKSDIHVHHHHHHHH

construct 40

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

946

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSAaCYTERKWICSKSDIHV

construct 41
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

947

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSAaCYTERKWICSKSDIHVHHHHHHHH

construct 42

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

948

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCaTERKWICSKSDIH

construct 43
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

949

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCaTERKWICSKSDIHVHHHHHHHH

construct 44

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

950

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYaERKWICSKSDIH

construct 45
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

951

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYaERKWICSKSDIHVHHHHHHHH

construct 46

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

952

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTaRKWICSKSDIH

construct 47
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

953

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTaRKWICSKSDIHVHHHHHHHH

construct 48

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

954

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTEaKWICSKSDIHV

construct 49
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

955

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTEaKWICSKSDIHVHHHHHHHH

construct 50

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

956

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERaWICSKSDIHV

construct 51
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

957

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERaWICSKSDIHVHHHHHHHH

construct 52

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

958

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAALADaGAaSARCYTERKWICSKSDIH

construct 53
VHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

959

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAALADaGAaSARCYTERKWICSKSDIHVHHHHHHH

construct 54

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

960

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAaLaDAGAASARCYTERKWICSKSDIH

construct 55
VHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

961

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAaLaDAGAASARCYTERKWICSKSDIHVHHHHHHH

construct 56

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQaFC

962

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 57
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQaFCDSQDADLAQVES

963

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 58

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

964

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 59
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

965

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGaPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 60

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

966

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV

construct 61
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

967

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTaQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 62

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

968

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKaDIH

construct 63
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

969

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKaDIHVHHHHHHHH

construct 64

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

970

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWIRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV

construct 65
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

971

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH

construct 66

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

972

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSAaCaTaRKWICSKSDIHV

construct 67
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

973

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSAaCaTaRKWICSKSDIHVHHHHHHHH

construct 68

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQaKCFYFSDDTKNWTSSQRFC

974

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWIRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV

construct 69
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQaKCFYFSDDTKNWTSSQRFCDSQDADLAQVES

975

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH

construct 70

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

976

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTaWaaaFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV

construct 71
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

977

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTaWaaaFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 72

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQaFC

978

sapiens)
DaQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 73
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQaFCDaQDADLAQVES

979

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 74

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

980

sapiens)
DSQaADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWIRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIaV

construct 75
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQaADLAQVES

981

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIaVHHHHHHHH

construct 76

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

982

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWKWI

CLEC2D
NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV

construct 77
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

983

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGaPWKWINGTEWTaQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 78

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDaaaNWTSSQRFC

984

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 79
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDaaaNWTSSQRFCDSQDADLAQVES

985

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 80

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

986

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGaPWaWIN

CLEC2D
GTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV

construct 81
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

987

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGaPWaWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 82

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

988

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSRaQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARaYTERKWICSKSDIHV

construct 83
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

989

sapiens)
SFQELNFLLRYKGPSDHWIGLSRaQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARaYTERKWICSKSDIHVHHHHHHHH

construct 84

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

990

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSRaaGaPWKWIN

CLEC2D
GTEWTRQFPILGAGECAYLNDKGASSAaCYTERKWICSKSDIHVH

construct 85
HHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

991

sapiens)
SFQELNFLLRYKGPSDHWIGLSRaaGaPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSAaCYTERKWICSKSDIHVHHHHHHHH

construct 86

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDaTKNWTSSQRFC

992

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCaTERaWICSKSDIHV

construct 87
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDaTKNWTSSQRFCDSQDADLAQVES

993

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCaTERaWICSKSDIHVHHHHHHHH

construct 88

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

994

sapiens)
DSQDADLAQVESaQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTaQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIHV

construct 89
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

995

sapiens)
SaQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTaQFPIL

CLEC2D
GAGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 90

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDaKaWTSSQRFC

996

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTERKWICSKSDIH

construct 91
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDaKaWTSSQRFCDSQDADLAQVES

997

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTERKWICSKSDIHVHHHHHHHH

construct 92

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDaKNWTSSQRFC

998

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCaTaRKWICSKSDIH

construct 93
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDaKNWTSSQRFCDSQDADLAQVE

999

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSARCaTaRKWICSKSDIHVHHHHHHHH

construct 94

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTaNWTSSQaFC

1000

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSARCYTaRKWICSKSDIH

construct 95
VHHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTaNWTSSQaFCDSQDADLAQVES

1001

sapiens)
FQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPILG

CLEC2D
AGECAYLNDKGASSARCYTaRKWICSKSDIHVHHHHHHHH

construct 96

SEQ ID
Human (Homo
MSFVSLLLVGILFHATQAQAACPESWIGFQRKCFYFSDDTKNWTSSQRFC

1002

sapiens)
DSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWI

CLEC2D
NGTEWTRQFPILGAGECAYLNDKGASSAaCaTEaKWICSKSDIHV

construct 97
HHHHHHHH

SEQ ID
Human (Homo
QAACPESWIGFQRKCFYFSDDTKNWTSSQRFCDSQDADLAQVE

1003

sapiens)
SFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTEWTRQFPIL

CLEC2D
GAGECAYLNDKGASSAaCaTEaKWICSKSDIHVHHHHHHHH

construct 98

Antibodies

In one embodiment, the term “antibody” refers to an immunoglobulin, which may be derived from natural sources or synthetically produced, in whole or in part. The terms “antibody” and “immunoglobulin” are used synonymously throughout the specification unless otherwise stated.

In one embodiment, the term “antibody” includes both polyclonal and monoclonal antibody preparations and also includes the following: chimeric antibody molecules, F(ab′)2 and F(ab) fragments, Fv molecules, single chain Fv molecules (ScFv), dimeric and trimeric antibody fragments, bispecific antibody, minibodies, humanized monoclonal antibody molecules, human antibodies, fusion proteins comprising Fc region of antibody and any functional fragments arising out of these molecules, where derivative molecules retain immunological functionality of the parent antibody molecule. The antibody according to this disclosure is a human antibody, humanized antibody, chimeric antibody, or further genetically engineered antibody as long as the characteristic properties according to this disclosure are retained.

“Native antibodies and immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains. Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light- and heavy-chain variable domains (Clothia et al., J. Mol. Biol. 186:651 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. U.S.A. 82:4592 (1985)).

The term “antigen-binding site,” or “binding portion” refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable (“V”) regions of the heavy (“H”) and light (“L”) chains. Three highly divergent stretches within the V regions of the heavy and light chains, referred to as “hypervariable regions,” are interposed between more conserved flanking stretches known as “framework regions,” or “FRs”. Thus, the term “FR” refers to amino acid sequences which are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as “complementarity-determining regions,” or “CDRs.”

The term “variable” refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

“Antibody fragments” comprise a portion of a full length antibody, preferably the variable domain thereof, or at least the antigen binding site thereof scFv antibodies are, e.g., described in Huston, J. S., Methods in Enzymol. 203 (1991) 46-88. In one embodiment, “antibody fragment” is a portion of a whole antibody which retains the ability to exhibit antigen binding activity. In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain binding to the respective antigen being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the properties of an antibody according to this disclosure.

Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab′)2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

“Fv” is the minimum antibody fragment which contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

A single chain Fv (“scFv”) polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed from a gene fusion including VH- and VL-encoding genes linked by a peptide-encoding linker. A number of methods have been described to discern chemical structures for converting the naturally aggregated, but chemically separated, light and heavy polypeptide chains from an antibody V region into an scFv molecule, which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, e.g., U.S. Pat. Nos. 5,091,513; 5,132,405; and 4,946,778.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab′ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab′-SH is the designation herein for Fab′ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab′)2 antibody fragments originally were produced as pairs of Fab′ fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The “light chains” of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (l), based on the amino acid sequences of their constant domains.

As used herein, the terms “immunological binding” and “immunological binding properties” refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (Kd) of the interaction, wherein a smaller Kd represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen-binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Thus, both the “on rate constant” (Kon) and the “off rate constant” (Koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. The ratio of Koff/Kon enables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant Kd. In some embodiments, an antibody of the present disclosure binds to CLEC2D at a Kd≤10 μM, preferably ≤1 μM, more preferably ≤100 nM, for example, ≤90 nM, ≤80 nM, ≤70 nM, ≤60 nM, ≤50 nM, ≤40 nM, ≤30 nM, ≤20 nM, ≤10 nM, ≤5 nM, or ≤1 nM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art. In some embodiment, the binding affinity of the antibody of this disclosure is within the range of 10⁻⁵M to 10⁻¹²M. For example, the binding affinity of the antibody of this disclosure is from 10⁻⁶M to 10⁻¹²M, from 10⁻⁷M to 10⁻¹²M, from 10⁻⁸M to 10⁻¹²M, from 10⁻⁹M to 10⁻¹²M, from 10⁻⁵M to 10⁻¹¹M, from 10⁻⁶M to 10⁻¹¹M, from 10⁻⁷M to 10⁻¹¹M, from 10⁻⁸M to 10⁻¹¹M, from 10⁻⁹M to 10⁻¹¹M, from 10⁻¹⁰M to 10⁻¹¹M, from 10⁻⁵M to 10⁻¹⁰M, from 10⁻⁶M to 10⁻¹⁰, from 10⁻⁷M to 10⁻¹⁰M, from 10⁻⁸M to 10⁻¹⁰, from 10⁻⁹M to 10⁻¹⁰M, from 10⁻⁵M to 10⁻⁹M, from 10⁻⁶M to 10⁻⁹M, from 10⁻⁷M to 10⁻⁹M, from 10⁻⁸M to 10⁻⁹M, from 10⁻⁵M to 10⁻⁸M, from 10⁻⁶M to 10⁻⁸M, from 10⁻⁷M to 10⁻⁸M, from 10⁻⁵M to 10⁻⁷M, from 10⁻⁶M to 10⁻⁷M or from 10⁻⁵M to 10⁻⁶M.

The present disclosure also features antibodies that have a specified percentage identity or similarity to the amino acid or nucleotide sequences of the CLEC2D antibodies described herein. For example, the antibodies may have at least 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Preferably, the antibodies may have at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. More preferably, the antibodies may have at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Even more preferably, the antibodies may have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the CLEC2D antibodies described herein. Sequence identity or similarity to the nucleic acids and proteins of the present disclosure can be determined by sequence comparison and/or alignment by methods known in the art. For example, sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual alignment or visual inspection can be utilized to determine percent sequence identity or similarity for the nucleic acids and proteins of the present disclosure.

As to amino acid sequences, one of skill in the art will readily recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, deletes, or substitutes a single amino acid or a small percentage of amino acids in the encoded sequence is collectively referred to herein as a “conservatively modified variant”. In some embodiments, the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called α, ∂, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

In one embodiment, a humanized antibody may be used in the compositions and methods provided herein. In some embodiments, the term “humanized antibody” or “humanized version of an antibody” refers to antibodies in which the framework or “complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin. In other embodiments, the CDRs of the VH and VL are grafted into the framework region of human antibody to prepare the “humanized antibody.” See e.g., Riechmann, L., et al, Nature 332 (1988) 323-327; and Neuberger, M. S., et al, Nature 314 (1985) 268-270. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences can be the sequences of naturally occurring human antibodies. Human heavy and light chain variable framework regions are listed e.g., in Lefranc, M.-P., Current Protocols in Immunology (2000)—Appendix IP A.1P.1-A.1P.37 and are accessible via IMGT, the international ImMunoGeneTics information System® (http://imgt.cines.fr) or via http://vbase.mrc-cpe.cam.ac.uk. Optionally the framework region can be modified by further mutations. Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric antibodies. The term “humanized antibody” as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to this disclosure, especially in regard to C1q binding and/or FcR binding, e.g., by “class switching” i.e., change or mutation of Fc parts (e.g., from IgG1 to IgG4 and/or IgG1/IgG4 mutation). The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germ line immunoglobulin sequences. Human antibodies are well-known in the state of the art (van Dijk, M. A., and van de Winkel, J. G., Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire or a selection of human antibodies in the absence of endogenous immunoglobulin production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A., et al, Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A., et al, Nature 362 (1993) 255-258; Brueggemann, M. D., et al., Year Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, H. R., and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, J. D., et al, J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole, A., et al. and Boerner, P., et al. are also available for the preparation of human monoclonal antibodies (Cole, A., et al., Monoclonal Antibodies and Cancer Therapy, Liss, A. L., p. 77 (1985); and Boerner, P., et al, J. Immunol. 147 (1991) 86-95). As already mentioned for humanized antibodies according to this disclosure the term “human antibody” as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to this disclosure.

In one embodiment, the term “monoclonal antibody” refers to an antibody composition having a homogeneous antibody population. The antibody is not limited to the species or source of the antibody or by the manner in which it is made. In another embodiment, the term encompasses whole immunoglobulins as well as fragments such as Fab, F(ab′)2, Fv, and other fragments, as well as chimeric and humanized homogeneous antibody populations that exhibit immunological binding properties of the parent monoclonal antibody molecule. In another embodiment, the terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of a single amino acid composition. In another embodiment, the terms Fab or ScFv are used as antibody fragments with specific mention.

In some embodiments, a chimeric antibody may be used in the compositions and methods provided herein. In one embodiment, the term “chimeric antibody” refers to a monoclonal antibody comprising a variable region, i.e., binding region, from one species (e.g., a mouse or rat) and at least a portion of a constant region derived from a different source or species (e.g., human), usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a mouse variable region and a human constant region are especially preferred. Such chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding immunoglobulin variable regions from one species and DNA segments encoding immunoglobulin constant regions for a different species. Other forms of “chimeric antibodies” encompassed by the present disclosure are those in which the class or subclass has been modified or changed from that of the original antibody. Such “chimeric” antibodies are also referred to as “class-switched antibodies.” Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S. L., et al, Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; U.S. Pat. Nos. 5,202,238 and 5,204,244.

In one embodiment, “antibody display library” refers to a platform(s) expressing antibodies on the surface of a cell or cell-free suited for a screening methodology against target antigens. Herein, phage display library and yeast display library are used with accurate specification unless indicated otherwise.

In one embodiment, the term “naïve library” refers to a collection of nucleic acid sequences encoding a naturally occurring VH repertoire from a non-immunized source.

In one embodiment, the term “VH” refers to the single heavy chain variable domain of antibody of the type that can be found in mammals which are naturally devoid of light chains or parts of the same; Naive VH can be understood accordingly.

In one embodiment, the term “VL” refers to single light chain variable domain of the antibody; they are found in two types based on the constant domain sequence. Vk (with kappa constant region) and V1 (lambda constant region) are understood accordingly.

In one embodiment, the term “CDR” refers to complementary determining region of the antibody structure.

In one embodiment, the term “repertoire,” means a collection, indicating genetic diversity.

In one embodiment, the term “framework region” is used herein to refer to the nucleic acid sequence regions of an antibody molecule that encode the structural elements of the molecule.

In another embodiment, the term “vector” refers to a DNA related to a cloning or expression system to accommodate antibody genes in specific designated restriction sites. Phagemid vectors (applicable to phage display systems) or yeast vectors (applicable to yeast display systems) are understood accordingly or mammalian expression vectors (applicable to mammalian expression systems).

The disclosure provides antibodies and antibody fragments that bind to a CLEC2D antigen of the disclosure.

The disclosure provides VH and VL domains of antibodies or antibody fragments that bind to a CLEC2D antigen or an epitope of CLEC2D as described in the disclosure.

The disclosure provides sequences of CDR1, CDR2 and CDR3 of the VH domain and CDR1, CDR2 and CD3 of the VL domain of antibodies that bind to a CLEC2D antigen or an epitope of CLEC2D as described in the disclosure.

Any combinations of VH and VL sequences of the disclosure are considered within the scope of this disclosure. Any combinations of the CDR1, CDR2 and CDR3 sequences of the VH domains, or the CDR1, CDR2 and CD3 sequences of the VL domains are considered within the scope of this disclosure.

Those skilled in the art will recognize that it is possible to determine, without undue experimentation, if a monoclonal antibody has the same specificity as a monoclonal antibody of the disclosure by ascertaining whether the former prevents the latter from binding to CLEC2D. If the monoclonal antibody being tested competes with the monoclonal antibody of the disclosure, as shown by a decrease in binding by the monoclonal antibody of the disclosure, then it is likely that the two monoclonal antibodies bind to the same, or to a closely related, epitope.

Another way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the disclosure is to pre-incubate the monoclonal antibody of the disclosure with the CLEC2D protein, with which it is normally reactive, and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind CLEC2D. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the disclosure. Screening of monoclonal antibodies of the disclosure can be also carried out by utilizing CLEC2D and determining whether the test monoclonal antibody is able to neutralize CLEC2D.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the disclosure, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).

Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. (See Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63)).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (MA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Moreover, in therapeutic applications of monoclonal antibodies, it is important to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the disclosure can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). In some embodiments, the hybridoma cells of the disclosure serve as a source of such DNA. In some embodiments, antibody gene sequences are isolated and cloned using the methods of the disclosure (e.g., phage and yeast library display), and serve as the source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (see U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the disclosure, or can be substituted for the variable domains of one antigen-combining site of an antibody of the disclosure to create a chimeric bivalent antibody.

All cell lines suitable for the expression and purification of antibodies or antibody fragments are considered to be within the scope of the disclosure. In some embodiments, the cell line is a mammalian cell line. Cell lines can be isolated or derived from any source, including human, mouse and hamster. Suitable cell lines include, but are not limited to, Chinese Hamster Ovary (CHO) cells, HEK 293 cells, HEK293T cells, BHK21 cells, NSO cells, PER.C6 cells, B cells, HEK 293-6E cells, Sp2/0-Ag14 cells and DG44 cells. In some embodiments, the cell line is a hybridoma cell line.

The antibody can be expressed by a vector containing a DNA segment encoding the single chain antibody described herein.

These can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, etc. Vectors include chemical conjugates such as described in WO 93/64701, which has targeting moiety (e.g., a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g., polylysine), viral vector (e.g., a DNA or RNA viral vector), fusion proteins such as described in PCT/US 95/02140 (WO 95/22618) which is a fusion protein containing a target moiety (e.g., an antibody specific for a target cell) and a nucleic acid binding moiety (e.g., a protamine), plasmids, phage, etc. The vectors can be chromosomal, non-chromosomal or synthetic.

Preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (see Geller, A. I. et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A. I. et al., Proc Natl. Acad. Sci.: U.S.A. 90:7603 (1993); Geller, A. I., et al., Proc Natl. Acad. Sci USA 87:1149 (1990), Adenovirus Vectors (see LeGal LaSalle et al., Science, 259:988 (1993); Davidson, et al., Nat. Genet 3:219 (1993); Yang, et al., J. Virol. 69:2004 (1995) and Adeno-associated Virus Vectors (see Kaplitt, M. G. et al., Nat. Genet. 8:148 (1994).

Pox viral vectors introduce the gene into the cells cytoplasm. Avipox virus vectors result in only a short term expression of the nucleic acid. Adenovirus vectors, adeno-associated virus vectors and herpes simplex virus (HSV) vectors are preferred for introducing the nucleic acid into neural cells. The adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The particular vector chosen will depend upon the target cell and the condition being treated. The introduction can be by standard techniques, e.g., infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g., naked DNA, CaPO4 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.

Exemplary VH amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 2 below. VH amino acid sequences having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100% identity to the sequences listed in Table 2 are considered within the scope of the disclosure.

TABLE 2

VH Amino Acid Sequences

SEQ ID
VH Amino Acid Sequence

SEQ ID 1
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI

TRDTSASTAYMELSSLRSEDTAVYYCARGSLSRSGWYAGLFDYWGQGTLVTVSS

SEQ ID 2
QITLKESGGGVVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLQWVAIISDDGSKSYYADSVQGRFTISRD

NSRNTVFLQMNSLRAEDTAMYYCARDRGTKWNQLNDVFDMWGQGTMVTVSS

SEQ ID 3
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMT

RDTSTSTVYMELSSLRSEDTAVYYCARGRGYSSSRLYYFDYWGQGTLVTVSS

SEQ ID 4
QVTLKESGGGLVRPGGSLRLSCEASGFTFSDPYMDWVRQAPGKGLEWVGRITNKRTGYATTYAASVKDRFTIS

RDDSRKSVYLQMNSLKTEDTAVYYCATDVSGSFAAYGGQGTLVTVSS

SEQ ID 5
EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI

TRDTSASTAYMELSSLRSEDTAVYYCAGEGGAVAGTVYWGQGTLVTVSS

SEQ ID 6
QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVKGRFT

ISRDDSKNTLYLQMNSLKTEDTAVYYCTIDEYFYWGQGTLVTVSS

SEQ ID 7
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARVNPGSYTREVSNFDYWGQGTLVTVSS

SEQ ID 8
QVQLQQSGPELVKPSQTLTLICGISGDSVSSNSVTWNWVRQSPSRGLEWLGRTYYRSQWYYNYAVSVKSRITI

SPDTSKNQFSLQLNSVTPEDTAVYYCATRGHNYGVDYWGPGTTVTVSS

SEQ ID 9
QVQLVQSGGGLVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVCRIKSKTDGETTDYAAPVKGRFTI

SRDDSKNTLYLQMNSLKTEDTAVYHCTTGVGWSPFQYWGQGTLVTVSS

SEQ ID 10
EVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTRDDKIAAAGFTYWYFDLWGRGTLVTVSS

SEQ ID 11
QVQLVQSGAEVKKPGASVKVSCKASGYTFAAYYLHWVRQAPGQGLEWMGRISPGNGVTSYAQKFQGRVTM

TGDTSINTVYMQLNNLISGDTAVYYCAREAADDPFDHWGQGALVTVSS

SEQ ID 12
EVQLVQSGGGVVQPGRSLTLSCAASGFTFSSHLMHWVRQAPGKGLEWVAVISYDGTSKYYGDSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAIYYCAKADYKYDWGQGTLVTVSS

SEQ ID 13
EVQLVQSGGGLVKPGGSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTTHRRPIYDILTGFDYWGQGTLVTVSS

SEQ ID 14
QLQLQESGGGLVQPGRSLRLSCTASGFTFGDYAMSWVRQAPGKGLEWVGFIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTREDTMVRGVIPWGQGTLVTVSS

SEQ ID 15
QLQLQESGSGLVKPSQTLSLTCAVSGGSISSGGYSWSWIRQPPGKGLEWIGYIYHSGSTYYNPSLKSRVTISVDRS

KNQFSLKLSSVTAADTAVYYCARDRRYYDSSGYYPAYYFDYWGQGTLVTVSS

SEQ ID 16
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSGSYTNYADSVKGRFTISRD

NAKNSLYLQINSLRAEDTAIYYCARDGGYDSSGFHFDYWGQGTLVTVSS

SEQ ID 17
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSNNRAAWNWIRQSPSRGLEWLGRTYYRSKWYNEYAVSVKSRITI

NPDTSKNQFSLQLNSMTPEDSAVYYCAILPSSGYLQDHHYYGMDVWGQGTTVTVSS

SEQ ID 18
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTM

TTDTSTSTAYMELSSLRSEDTAVYYCARAAVGDGYSYGRLDWGQGTLVTVSS

SEQ ID 19
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD

KSISTAYLQWSSLKASDTAMYYCARLPSYYYDSSGYFTWYFDLWGRGTLVTVSS

SEQ ID 20
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWIIPIFGIANYAQKFQGRVTITAD

KSTSTAYMELSSLRSEDTAVYYCARELYNYGSKDYFDYWGQGTLVTVSS

SEQ ID 21
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD

KSISTAYLQWSSLKASDTAMYYCARGGTWDTAMVTGFDYWGQGTLVTVSS

SEQ ID 22
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIAWVRQMPGKGLEWMGVIYPGDSDTRYSPSFQGQVTISAD

KSINTAYLQWSSLKASDTAMYYCARPHYDILTGSRAPFDYWGQGTLVTVSS

SEQ ID 23
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARARVESKDGYFDYWGQGTLVTVSS

SEQ ID 24
EVQLVESGGGVVQPGRSLRLSCAASGFTFTDAWMNWVRQAPGKGLEWIGRVKNKADGETTDYAAPVKGRIT

ISRDDAKNTLYVQMNSLKTEDTAVYYCTADLRLSTWDAYDFWGQGTMVTVSS

SEQ ID 25
QITLKESGGGLVQPGGSLRLSCTVSGFTFSNNWMTWVRQTPGKGLEWVANIKQDGTEKHYVDSVKGRFTISR

DNAENSLYLQMNSLRGEDTAVYYCARNSQRSFDYWGQGTLVTVSS

SEQ ID 26
QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCAKDLGDPRGGILNYWGQGTLVTVSS

SEQ ID 27
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCARSSPWGELSLYQGAFDIWGQGTMVTVSS

SEQ ID 28
QITLKESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKDNDFWSGKVFDYWGQGTLVTVSS

SEQ ID 29
EVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSTSSTIYYADSVKGRFTISRDN

SKNMLFLQMNSLRAEDTAVYYCAKEGGSGWRHYFDYWGQGTLVTVSS

SEQ ID 30
QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCARDYCSSTSCQNWFDPWGQGTLVTVSS

SEQ ID 31
QVQLVQSGGGLVQPGGSLRLSCAASGFTFSNYVMSWVRQAPGKGLEWVSAISGIGDTTYYADSVKGRFTISRD

NAKNTLYLQMNSLRAEDTAVYYCARGRVAGDAFDIWGQGTMVTVSS

SEQ ID 32
QLQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKDQGAAAGTLGYFDYWGQGTLVTVSS

SEQ ID 33
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVT

MTRNTSISTAYMELSSLRSEDTAVYYCTRGIYDSSGSSNPFDSWGQGTLVTVSS

SEQ ID 34
EVQLVQSGAEVKKPGASVKISCEASGYTFTDYAIHWVRQAPGQRLEWMGWINAGDGGTKSSREFQGRVTITR

DTSATTAYMEVSSLRSEDTAVYYCARGYCSGGSCPGTDFDYWGQGTLVTVSS

SEQ ID 35
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTM

TRDTSTSTVYMELSSLRSEDTAVYYCARDGVGGRDGYNFDYWGQGTLVTVSS

SEQ ID 36
EVQLVQSGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDN

SKNTLYLQMNSLRAEDTAVYYCARAPLAADGYFDYWGQGTLVTVSS

SEQ ID 37
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITAD

ESTSTAYMELSSLRSEDTAVYYCARARGLQYLIWYFDLWGRGTLVTVSS

SEQ ID 38
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTM

TRDTSTSTVYMELSSLRSEDTAVYYCASPGMVRGVITAPLDYWGQGTLVTVSS

SEQ ID 39
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYAISWVRQAPGQGLEWMGGIIPMYGTANYAQKFQGRVTITA

DESTSTAYMELSSLRSEDTALYYCAREAKWGMYYFDYWGQGTLVTVSS

SEQ ID 40
EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAIHWVRQAPGKGLEWVAIISDDGSKSYYADSVQGRFTISRDN

SRNTVYLQMNSLRAEDTAMYYCARDRGTKWNQLNDVFDMWGQGTMVTVSS

SEQ ID 41
QMQLVQSGAEVKKPGASVKVSCTASGYTFTSSDINWVRQATGQGLEWMGWMNPNSGNTGYAEKFQGRVT

MTSDSSISTAYMELRSLTTEDTAVYYCARGGGASYTDSWGQGTLVTVSS

SEQ ID 42
QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGEIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTAKGGYVGYSYGPFGGYWGQGTLVTVSS

SEQ ID 43
QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGEIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTRGGTMVRGFGFNYWGQGTLVTVSS

SEQ ID 44
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARARRAMIGPLPRLVGYFDLWGRGTLVTVSS

SEQ ID 45
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARGRPAPSWVKTRNWFDPWGQGTLVTVSS

SEQ ID 46
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI

NPDTSKNQFSLQLNSVTPEDTAVYYCAREASSGWNWGQGTLVTVSS

SEQ ID 47
QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNNAAWNWIRQSPSRGLEWLGRTFYRSKWYNDYAVSVKSRLTV

NPDTSKNQFSLRLNSVSPEDTAVYYCARGGRYTKGGYFDDWGQGTLVTVSS

SEQ ID 48
QVTLKESGPTLVKPTQTLTLICTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTS

KNQVVLTMTNMDPVDTATYYCAHRLDSSGRGGYFDYWGQGTLVTVSS

SEQ ID 49
EVQLVESGGGVVQPGRSLRLSCTASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKELVGTSSPYYYYYYGMDVWGQGTMVTVSS

SEQ ID 50
QLQLQESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDN

SKNTLYLQMNSLRAEDTAVYYCARDYYYGSGSSPWGQGTLVTVSS

SEQ ID 51
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARGRPYCSSTSCYPEWFDPWGQGTLVTVSS

SE ID 52Q
QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCAKLRGIDYYDSSGYQRGFDYWGQGTLVTVSS

SEQ ID 53
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYTGSTNYNPSLKSRVTISVDTSKN

QFSLKLSSVTTADTAVYYCARGGRGDGAAFDIWGQGTMVTVSS

SEQ ID 54
QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSSAMHWVRQAPGKGLEWVAMIWHDESKKYYADSVKGRFTIS

RDNSKNTLYLQMNSLRAEDTAVYYCARPPDGGNSGRWYFDLWGRGTLVTVSS

SEQ ID 55
QMQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCAKDKNVRKHDYGDHPYGGYFDYWGQGTLVTVSS

SEQ ID 56
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI

TRDTSASTAYMELSSLRSEDTAVYYCARVAGATSLWYWGQGTLVTVSS

SEQ ID 57
QVQLQQSGPGLVKPSQSLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIK

PDTSKNQFSLQLNSVTPEDTAVYYCTRLANSDGVDVWGQGTMVTVSS

SEQ ID 58
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSDSAVWTWIRQSPSRGLEWLGRTYYKSKWYNDYAASVKSRITIN

PDTSKNQFSLHLNSVTPEDTAVYYCARGVTRTFDYWGQGTTVTVSS

SEQ ID 59
QLQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIN

PDTSKNQFSLQLNSVTPEDTAVYYCAEGNGPFDPWGQGTLVTVSS

SEQ ID 60
QITLKESGGGVVQPGRSLRLSCVASGFTFSTYPMHWVRQAPGKGLEWVAVISYDGRNEYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCATRDTPLVGVSIYWGQGTLVTVSS

SEQ ID 61
QMQLVQSGGGLVKAGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYADSVKGRFTISRD

NSKNTLYLQMSSLRAEDTAVYYCVNRAGYGDYRHFQHWGQGTLVTVSS

SEQ ID 62
EVQLVQSGGGVVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFISYDGSNKYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCATTGDRFQEFDYWGQGTLVTVSS

SEQ ID 63
QMQLVQSGGVLLQPGRSLRLSCTASGFTFAAYNINWFRQGPGGGLEWVGEIRANADSGTTEYAASVKGRFFIS

RDDSRSTAYLQMTSLKTEDTAVYYCARDDRGRGDDFDYWGQGTLVTVSS

SEQ ID 64
QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYGMTWVRQAPGKGLEWVSTISGNGVGTYYPDSVKDRFTISR

DSSKNTVYLQMNSLRAEDTAVYYCVKHGRAGINWYFDLWGRGTLVTVSS

SEQ ID 65
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI

NPDTSKNQFSLQLNSVTPEDTAVYYCARGGGLWAFDIWGQGTTVTVSS

SEQ ID 66
EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVT

MTRDTSISTAYMELSRLRSDDTAVYYCARDKIGSCPYWGQGTLVTVSS

SEQ ID 67
QVTLKESGPTLVKPTQTLTLICTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTS

KNQVVLTMTNMDPVDTATYYCAHRPDSSSQCFDYWGQGTLVTVSS

SEQ ID 68
QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCARSSGWSLPEDYWGQGTLVTVSS

SEQ ID 69
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTM

TEDTSTDTAYMELSSLRSEDTAVYYCATDVNPELLGAGFDYWGQGTLVTVSS

SEQ ID 70
QVTLKESGGGLVQPGGSLRLSCAASGFTFSDQYMDWVRQAPGKGLEWVGRVRNKANSYTTEYAASVKGRFTI

SRDDSKNSLYLQMNSLNTEDTAMYFCASSLNSGGYRCFHHWGQGTLVTVSS

SEQ ID 71
QVQLVQSGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYADSVKGRFTISRD

NSKNTLYLQMSSLRAEDTAVYYCVKAPRGVVPAAMRGGYWGQGTLVTVSS

SEQ ID 72
QVQLQESGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVGEIRSKAYGGTTEYAASVKGRFTIS

RDDSKSIAYLQMNSLKTEDTAVYYCTRLVGNSGSYYPFGYWGQGTLVTVSS

SEQ ID 73
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARGRSLPYRGLAPRSEGGYYFDYWGQGTLVTVSS

SEQ ID 74
QVQLQESGGGLVRPGGSLRLSCGDSGFNFSGYEMNWVRQAPGKGLEWVSYVSTSGSTRYYADSVKGRFTISR

DNAKNTLYLQMNSLRVEDTAVYYCARGRTHWGPQDFDYWGQGTLVTVSS

SEQ ID 75
QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKGGMYYYGSGSSYFDYWGQGTLVTVSS

SEQ ID 76
QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTISR

DNSKNMLFLQMNSPRAEDTAVYYCAKKIAAAGKQPVDYWGQGTLVTVSS

SEQ ID 77
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARRKVYDYVWGSYRLPGSVSYYFDYWGQGTLVTVSS

SEQ ID 78
QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISAD

KSISTAYLQWSSLKASDTAMYYCARLPGRAARPDYWGQGTLVTVSS

SEQ ID 79
QVTLKESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCARGPGAVAGTKPKYYFDYWGQGTLVTVSS

SEQ ID 80
EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCARATYYYDSSGYRFDYWGQGTLVTVSS

SEQ ID 81
EVQLVQSGGGLVEPGGSLRLSCAASRFTFSDAWMSWVRQAPGKGLEWVGRIKSKISGGTTDYAAPVQGRFTI

SRDDSKNTLYLQMDSLKTEDTAVYYCANRNLGYWGQGTLVTVSS

SEQ ID 82
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVT

MTTDTSTSTAYMELRSLRSDDTAVYYCARARYYDSSGYIAPSGYFDYWGQGTLVTVSS

SEQ ID 83
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVT

ITRDTSASTAYMELSSLRSEDTAVYYCARDGPAVDGAEYFQHWGQGTLVTVSS

SEQ ID 84
QLQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSLKSRITIN

PDTSKNQFSLQLNSVTPEDTAVYYCASLASGSPPPGDYWGQGTLVTVSS

SEQ ID 85
QVTLKESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVALISYDGSKKYYANSVKGRFTISRD

NSKNTLYLQMKSLRAEDTAMYYCAKGPIVGATMDYWGQGALVTVSS

SEQ ID 86
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTM

TTDTSTSTAYMELRSLRSDDTAVYYCARWYGDYGLDYWGQGTLVTVSS

SEQ ID 87
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLAWMGWINAGNGNTKYSEKFEGRVTI

TRDTSASTAYMELSSLRSEDTAVYYCARVAKYYYESGGYRASNWFDPWGQGTLVTVSS

SEQ ID 88
QVQLQESGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITIN

PDTSKNQFSLQLNSVTPEDTAVYYCARAPPPTVGWYAPVFDYWGQGTLVTVSS

SEQ ID 89
QLQLQESGGGLVQPGGSLRLSCSASGISFRDYWMHWIRQTPGKGLVWVSRINPDGSSTSYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKVTGRRVGAHDYWGQGTLVTVSS

SEQ ID 90
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVT

MTRDTSISTAYMELSRLRSDDTAVYYCAFAQPGAETLNFDLWGRGTLVTVSS

SEQ ID 91
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSKSAAWNWIRQSPSRGLEWLGRTYYRSKWNNDYALSVKSRITI

NPDTSKNQFSLQLKSVTPEDTALYYCVRQVAGGMDVWGQGTTVTVSS

SEQ ID 92
QVQLVQSGGGLVQPGRSLRLSCTASGFTFGDYAMSWFRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISR

DNSKNTLYLQMNSLRAEDTAVYYCAKGSVYSGSYYMLIDYWGQGTLVTVSS

SEQ ID 93
QVQLQQSGPGLVRPSQTLSLTCVISGDSVSSGSAAWNWIRQSPSRGLEWLGRTYYRAKWYNEYAGSVKSRITIS

PDTSKNQFSLQLNSVTPEDTAVYFCTRQDKDNTRYSGLGVWGQGTTVTVSS

SEQ ID 94
EVQLVETGGGLVQPGGSLRLSCAASEFTLRNYGVSWVRQAPGKGLEWVSGMSGSGYSTYYADSVKGRFTISR

DSSKNTLFLQMDSLRAEDTAIYYCARGPRMWSSGIDAFDIWGHGTMVTVSS

SEQ ID 95
QVQLQQWGAGLLKPSETLSLTCAVYGGSVSGYYWSWIRQPPGKGLEWMGEIHHSGSTNYNPSLKSRVTISLDT

PKNQFSLKLSSVTAADTAVYYCARRDWAGKRVWGQGTLVTVSS

SEQ ID 96
QVQLQQSGPGLLKPSQTLSLTCAISGDSVSSNTATWNWIRQSPSRGLEWLGRTYYRSKWYKDNALSVKSRITIN

PDTSKNQFSLQLNSVTPEDTAVYYCAGGRAGIAAFDIWGQGTTVTVSS

SEQ ID 97
QVQLVQSGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSLIYSDGRTNYADSVKGRFTISRDN

SKNTLYLQMNSLRAEDTAVYYCAKGALQGEWRRFDYWGQGTLVTVSS

SEQ ID 98
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI

NPDTSKNQFSLQLNSVTPEDTAVYYCTRTNQGYGGNSGVFDYWGQGTLVTVSS

SEQ ID 99
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSGNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITI

NPDTSKNQFSLQLNSVTPEDTAVYYCARIVGGAVDCWGQGTLVTVSS

SEQ ID 100
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYAMHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTI

TRDTSASTAYMELSSLRSEDTAVYYCARVRVGATTVYDSWFDPWGQGTLVTVSS

SEQ ID 101
QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRD

NSKNTLYLQMNSLRAEDTAVYYCAKDGGSSPYYDSSGLLPWYFDLWGRGTLVTVSS

SEQ ID 102
QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEYVSAISSNGGSTYYANSVKGRFTISRD

NSKNTLYLQMGSLRAEDMAVYYCARAKFWTYYFDYWGQGTLVTVSS

SEQ ID 103
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTS

KNQFSLKLSSVTAADTAVYYCARGGGSGSYYKRFFDYWGQGTLVTVSS

SEQ ID 104
EVQLVQSGAEVRKPGASVKVSCKASGYTFTSYAISWVRQAPGQGLEWMGWISAYDGNTNYAQKLQGRVTM

TTDTSTSTAYMEVRSLRSDDTAVYYCARDGTVRRVVGATTPGNFDYRGQGTLVTVSS

SEQ ID 105
EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTIS

RDNSKNTLYLQMNSLRAEDTAVYYCARDLNRGYCSGGSCFGYWGQGTLVTVSS

SEQ ID 106
QVQLQESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYISSSGTTIYYADSVKGRFTVSRD

NAKNSLYLQMNSLRAEDTAVYYCARDYSSSGECFDYWGQGTLVTVSS

SEQ ID 107
EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTIS

RDNSKNTLYLQMNSLRAEDTAVYYCARDQAAMVGYFDYWGQGTLVTVSS

SEQ ID 108
QVTLKESGGGVVQPGRSLRLSCAASGFlFSNYAIHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDN

SKNTLYLQMNSLRAEDTAVYYCARTFAGYSSKLGYFDLWGRGTLVTVSS

A VH amino acid sequence of the disclosure may be encoded by a polynucleotide shown in Table 3 below.

TABLE 3

VH DNA Sequences

SEQ ID
VH DNA Sequence

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG

109
TTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGG

CCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAA

ATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAG

CCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGA

GGCTCCTTGTCCCGAAGTGGCTGGTACGCCGGACTCTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

110
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTATAGCATGAACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGCAGTGGGTGGCAATTATATCAGATGATGGAAGTAAGAGTTACT

ACGCAGACTCCGTGCAGGGCCGATTCACCATCTCCAGAGACAATTCGAGGAACACAGTA

TTTCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAGAGA

CAGGGGAACTAAATGGAACCAATTGAATGATGTTTTTGATATGTGGGGCCAAGGGACAA

TGGTCACCGTCTCTTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG

111
TTTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGG

CCCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGC

TACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAG

TCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA

GGCCGAGGGTATAGCAGCAGTCGGCTCTACTACTTTGACTACTGGGGCCAGGGAACCCT

GGTCACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCGGCCTGGAGGGTCCCTGAGACT

112
CTCCTGTGAAGCCTCTGGATTCACCTTCAGTGACCCCTACATGGACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTTGGCCGAATTACAAATAAGCGTACCGGTTACGCCA

CAACATATGCCGCGTCTGTGAAGGACAGATTCACCATCTCAAGAGATGATTCAAGGAAG

TCAGTATATCTGCAAATGAACAGCCTGAAGACCGAGGACACGGCCGTATATTATTGTGC

AACAGATGTCAGTGGGTCCTTCGCGGCCTACGGGGGCCAGGGCACCCTGGTCACCGTCT

CCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

113
CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGCTATGCATTGGGTGCGCCAGGC

CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA

TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGGGAG

AGGGCGGAGCAGTGGCTGGTACTGTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC

TCA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACT

114
CTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAACTGATGGTGGGACA

ACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA

CACGCTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTA

CCACAGACGAGTATTTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

115
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGTAA

ATCCGGGGAGTTATACGAGGGAGGTGAGCAACTTTGACTACTGGGGCCAGGGAACCCTG

GTGACCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGAATTGGTGAAGCCCTCGCAGACCCTCACACT

116
CACCTGTGGCATCTCCGGGGACAGTGTCTCTAGCAACAGTGTTACTTGGAACTGGGTCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACTTACTACCGGTCCCAGTGG

TATTATAATTATGCGGTGTCTGTGAAAAGTCGAATAACCATCAGCCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGTTGAATTCTGTGACTCCCGAGGACACGGCTGTCTATTACTG

TGCAACCAGGGGACATAACTACGGTGTAGATTACTGGGGCCCGGGGACCACGGTCACCG

TCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACT

117
CTCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTTGCCGTATTAAAAGCAAAACTGATGGTGAGACA

ACAGACTACGCTGCACCCGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA

CACGCTGTATCTGCAAATGAACAGCCTGAAAACTGAGGACACAGCCGTGTATCACTGTA

CCACAGGGGTGGGATGGTCGCCCTTCCAATACTGGGGCCAGGGCACCCTGGTCACCGTC

TCCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT

118
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC

ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC

TAGAGACGACAAAATAGCAGCAGCTGGATTCACATACTGGTACTTCGATCTCTGGGGCC

GTGGCACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

119
CTCCTGCAAGGCTTCTGGATACACCTTCGCCGCCTATTATTTACACTGGGTGCGACAGGC

CCCTGGACAAGGCCTTGAGTGGATGGGGCGGATCAGCCCTGGTAACGGTGTCACAAGTT

ATGCACAGAAATTTCAGGGCAGAGTCACCATGACCGGGGACACGTCCATTAACACAGTC

TACATGCAACTGAACAATTTGATTTCTGGCGACACGGCCGTATATTACTGTGCGAGAGA

GGCTGCCGACGACCCGTTTGACCATTGGGGCCAGGGAGCCCTGGTCACCGTCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGACACT

120
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTTCCCATCTTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAACTAGTAAATATT

ACGGAGACTCCGTGAAGGGCCGCTTCACCATCTCCAGAGACAATTCCAAGAACACGTTG

TATCTGCAAATGAACAGCCTGCGAGCTGAAGACACGGCTATATATTACTGTGCGAAAGC

AGATTATAAATATGACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACT

121
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC

ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC

TACTCATAGACGCCCAATTTACGATATTTTGACTGGTTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT

122
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC

ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC

TAGAGAGGATACTATGGTTCGGGGAGTTATTCCCTGGGGCCAGGGAACCCTGGTCACCG

TCTCCTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGCTCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCT

123
CACCTGCGCTGTCTCTGGTGGCTCCATCAGCAGTGGTGGTTACTCCTGGAGCTGGATCCG

GCAGCCACCAGGGAAGGGCCTGGAGTGGATTGGGTACATCTATCATAGTGGGAGCACCT

ACTACAACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACAGGTCCAAGAACCAG

TTCTCCCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGA

GATCGGCGTTACTATGATAGTAGTGGTTATTATCCCGCCTACTACTTTGACTACTGGGGC

CAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT

124
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTTACACAAACT

ACGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTG

TATCTGCAAATAAACAGCCTGAGAGCCGAGGACACGGCCATTTATTACTGTGCGAGAGA

CGGGGGCTATGATAGTAGTGGTTTTCACTTTGACTACTGGGGCCAGGGAACCCTGGTCA

CCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

125
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAACAACAGGGCTGCTTGGAACTGGATCA

GGCAGTCGCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGAATATGCAGTCTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTATGACTCCCGAGGACTCGGCTGTGTATTACTG

TGCAATTTTGCCTAGTAGTGGTTATCTACAGGACCACCACTACTACGGTATGGACGTCTG

GGGCCAAGGGACCACGGTCACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG

126
TCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTACGGTATCAGCTGGGTGCGACAGG

CCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAAC

TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG

CCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA

GCCGCGGTGGGGGATGGATACAGCTATGGTCGGCTCGATTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA

127
TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA

TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA

TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC

CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC

TCCCCTCGTATTACTATGATAGTAGTGGTTACTTTACCTGGTACTTCGATCTCTGGGGCCG

TGGCACCCTGGTGACCGTCTCTTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

128
CTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCATCCCTATCTTTGGTATAGCAAACT

ACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGCACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAG

AACTATACAACTATGGTTCAAAGGACTACTTTGACTACTGGGGCCAGGGAACCCTGGTC

ACCGTCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA

129
TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA

TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA

TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC

CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGGG

GCGGTACTTGGGATACAGCTATGGTTACGGGCTTTGACTACTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA

130
TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGCCTGGGTGCGCCAGA

TGCCCGGGAAAGGCCTGGAGTGGATGGGGGTCATCTATCCTGGTGACTCTGATACCAGA

TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAATACCGC

CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC

CCCATTACGATATTTTGACTGGTTCCCGGGCGCCCTTTGACTACTGGGGCCAGGGAACCC

TGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

131
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGCCC

GAGTGGAATCCAAGGATGGGTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC

TCCTCA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

132
CTCCTGTGCAGCCTCTGGATTCACTTTCACTGATGCCTGGATGAACTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGATTGGCCGTGTTAAAAACAAAGCTGATGGTGAGACA

ACGGACTACGCTGCACCCGTCAAAGGCAGAATCACCATCTCAAGAGATGATGCAAAGA

ACACTCTGTATGTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTATTGT

ACCGCTGACCTGCGACTTTCTACGTGGGATGCTTATGATTTCTGGGGCCAAGGGACAATG

GTCACCGTCTCTTCA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTAAGACT

133
CTCTTGTACAGTCTCAGGATTCACCTTTAGTAACAATTGGATGACCTGGGTCCGCCAGAC

TCCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAACTGAGAAACAC

TATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCGAGAACTCACT

GTATCTGCAGATGAACAGCCTGAGAGGTGAGGACACGGCCGTGTATTATTGTGCGAGAA

ACAGTCAACGTTCGTTTGACTACTGGGGCCAGGGCACCCTGGTGACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

134
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA

TTTAGGGGATCCCCGGGGTGGTATTTTGAACTACTGGGGCCAGGGCACCCTGGTCACCG

TCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

135
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCCCGGTC

GAGCCCCTGGGGGGAGTTATCGTTATACCAGGGGGCTTTTGATATCTGGGGCCAAGGGA

CAATGGTCACCGTCTCTTCA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACT

136
CTCCTGTGCAGCCTCTGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGGCAAGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA

TAACGATTTTTGGAGTGGGAAAGTCTTTGACTACTGGGGCCAGGGCACCCTGGTCACCG

TCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

137
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGTTATAGCATGAACTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATCAGTAGTACTAGTAGTACCATATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAATATGCTG

TTTCTACAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA

AGGGGGCAGTGGCTGGCGCCACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG

TCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

138
GTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGA

TTATTGTAGTAGTACCAGCTGCCAGAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGG

TCACCGTCTCCTCA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

139
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAACTATGTCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTATTGGTGATACTACATACT

ACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACACGCTG

TATCTGCAAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGG

GCGCGTGGCGGGGGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTGACCGTCTCTT

CA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

140
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA

TCAAGGGGCAGCAGCTGGTACCCTGGGGTACTTTGACTACTGGGGCCAGGGAACCCTGG

TGACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

141
CTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAACTGGGTGCGACAGGC

CACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACAGGCT

ATGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACAGCC

TACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTACGAGAGG

AATCTATGATAGTAGTGGTTCTTCCAATCCCTTTGACTCCTGGGGCCAGGGAACCCTGGT

GACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGA

142
TTTCCTGCGAGGCTTCTGGATACACCTTCACTGATTATGCTATACATTGGGTGCGCCAGG

CCCCCGGACAAAGACTTGAGTGGATGGGATGGATCAACGCTGGCGATGGTGGCACAAA

AAGTTCACGGGAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGACCACAG

CCTACATGGAGGTGAGCAGTCTGAGATCTGAAGACACGGCTGTCTATTACTGTGCGAGA

GGATATTGTAGTGGTGGTAGCTGCCCAGGAACGGATTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

143
TTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCT

ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGT

CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAG

ATGGTGTAGGAGGGAGAGATGGCTACAATTTTGACTACTGGGGCCAGGGAACCCTGGTC

ACCGTCTCCTCA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT

144
CTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACG

CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT

CTTCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGCCCC

CCTAGCAGCAGATGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC

A

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT

145
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGG

CCCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATCTTTGGTACAGCAAAC

TACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAG

CCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGA

GCCCGGGGGCTACAGTACCTAATCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTG

ACCGTCTCCTCA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

146
TTCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCT

ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGT

CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGCC

CGGGTATGGTTCGGGGAGTTATTACTGCCCCGCTTGACTACTGGGGCCAGGGCACCCTG

GTCACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACT

147
CTCCTGTGCAGCCTCTGGATTCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGAGGGATCATCCCTATGTATGGTACAGCAAACT

ACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAATCCACGAGCACAGC

CTACATGGAACTGAGCAGCCTGAGATCTGAGGACACGGCCCTCTATTACTGTGCGAGAG

AAGCTAAGTGGGGAATGTACTACTTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTC

TCCTCA

SEQ ID
GAGGTGCAGCTGGTGGAGTCCGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

148
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATACACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAATTATATCAGATGATGGAAGTAAGAGTTACT

ACGCAGACTCCGTGCAGGGCCGATTCACCATCTCCAGAGACAATTCGAGGAACACAGTA

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAGAGA

CAGGGGAACTAAATGGAACCAATTGAATGATGTTTTTGATATGTGGGGCCAAGGGACAA

TGGTCACCGTCTCTTCA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

149
CTCCTGCACGGCTTCTGGATACACCTTCACCAGTTCTGATATCAACTGGGTGCGACAGGC

CACTGGACAAGGGCTTGAGTGGATGGGATGGATGAACCCTAACAGTGGTAACACCGGCT

ATGCAGAGAAGTTCCAGGGCAGGGTCACCATGACCAGCGACTCCTCCATAAGCACCGCC

TACATGGAGTTGAGAAGCCTGACCACTGAGGACACGGCCGTATATTACTGTGCGAGAGG

TGGGGGTGCGAGCTATACTGACTCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT

150
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC

ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC

CGCTAAGGGGGGCTACGTCGGATACAGCTATGGACCTTTTGGGGGCTACTGGGGCCAGG

GAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT

151
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACAA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAGC

ATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTAC

TAGAGGGGGGACTATGGTTCGGGGTTTCGGATTTAACTACTGGGGCCAGGGAACCCTGG

TCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

152
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGCCC

GGCGGGCTATGATAGGGCCGCTTCCGCGACTTGTCGGGTACTTCGATCTCTGGGGCCGTG

GAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

153
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC

GCCCCGCCCCATCCTGGGTTAAAACCCGTAACTGGTTCGACCCCTGGGGCCAGGGAACC

CTGGTCACCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

154
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TGCAAGAGAGGCTAGCAGTGGCTGGAACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT

CA

SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

155
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAATGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATTCTACAGGTCCAAGTGG

TATAATGACTATGCAGTTTCTGTGAAAAGTCGACTAACCGTCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCGGTTGAACTCTGTGAGTCCCGAGGACACGGCTGTGTATTACTG

TGCAAGAGGGGGAAGATATACCAAGGGAGGGTACTTTGACGACTGGGGCCAGGGAACC

CTGGTGACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTCCTACGCTGGTGAAACCCACACAGACCCTCACGCT

156
GACCTGCACCTTCTCTGGGTTCTCACTCAGCACTAGTGGAGTGGGTGTGGGCTGGATCCG

TCAGCCCCCAGGAAAGGCCCTGGAGTGGCTTGCACTCATTTATTGGGATGATGATAAGC

GCTACAGCCCATCTCTGAAGAGCAGGCTCACCATCACCAAGGACACCTCCAAAAACCAG

GTGGTCCTTACAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTGTGCACA

CAGATTGGATAGCAGTGGCCGTGGTGGTTACTTTGACTACTGGGGCCAGGGCACCCTGG

TCACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

157
CTCCTGTACAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA

GTTGGTGGGTACCAGCTCTCCTTATTACTACTACTACTACGGTATGGACGTCTGGGGCCA

AGGGACAATGGTCACCGTCTCTTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT

158
CTCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACG

CAGACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT

CTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTA

TTACTATGGTTCGGGGAGTTCTCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

159
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC

GGCCATATTGTAGTAGTACCAGCTGCTACCCAGAGTGGTTCGACCCCTGGGGCCAGGGA

ACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

160
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAATT

AAGGGGTATAGATTACTATGATAGTAGTGGTTACCAACGGGGGTTTGACTACTGGGGCC

AGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCT

161
CACCTGCACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGGATCCGGCAGCC

CCCAGGGAAGGGACTGGAGTGGATTGGCTATATCTATTACACTGGGAGCACCAACTACA

ACCCCTCCCTCAAGAGCCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCC

CTGAAGCTGAGCTCTGTGACCACTGCGGACACGGCCGTGTATTACTGTGCGAGAGGTGG

GAGGGGGGATGGGGCCGCTTTTGACATCTGGGGCCAAGGGACAATGGTCACCGTCTCTT

CA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

162
CTCCTGTGCAGCGTCTGGATTCACCTTCAGCAGCTCTGCCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGACTGGAGTGGGTGGCAATGATTTGGCATGATGAGAGTAAGAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACTATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGACC

CCCCGACGGTGGTAACTCCGGTCGCTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGT

CACCGTCTCCTCA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

163
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA

CAAGAACGTCCGAAAACATGACTACGGTGACCACCCCTACGGGGGGTACTTTGACTACT

GGGGCCAGGGCACCCTGGTGACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

164
TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC

CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA

TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAG

TGGCGGGAGCTACTTCCCTATGGTACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGAGCCTCTCACT

165
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAGAGTCGAATAACCATCAAACCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TACAAGGCTAGCTAATTCCGACGGTGTGGACGTCTGGGGCCAAGGGACAATGGTCACCG

TCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

166
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCGACAGTGCTGTTTGGACCTGGATCAG

GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAAGTCGAAGTGGT

ATAATGATTATGCAGCATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAG

AACCAGTTCTCCCTGCACCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGT

GCAAGAGGTGTAACCCGGACCTTTGACTACTGGGGCCAGGGGACCACGGTCACCGTCTC

CTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

167
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TGCAGAAGGCAATGGGCCGTTCGACCCCTGGGGCCAGGGAACCCTGGTGACCGTCTCCT

CA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

168
CTCCTGTGTAGCCTCTGGATTCACCTTCAGTACCTATCCCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGACGTAATGAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAAAACACGCTG

TATCTGCAAATGAACAGTCTGCGAGCTGAAGACACGGCTGTCTATTATTGTGCGACTCG

GGATACACCTTTGGTTGGGGTTTCGATATACTGGGGCCAGGGCACCCTGGTCACCGTCTC

CTCA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGGGAGGCCTGGTCAAGGCTGGGGGGTCCCTGAGACT

169
CTCCTGTTCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATACT

ACGCAGACTCAGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTTCAAATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAATCG

GGCGGGTTACGGTGACTACAGACACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCG

TCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGGGGTCCCTGAGACT

170
CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCATTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGACAAC

AGGGGACCGCTTCCAAGAGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT

CA

SEQ ID
CAGATGCAGCTGGTGCAGTCTGGGGGAGTCTTGCTTCAGCCAGGGCGGTCCCTGAGACT

171
CTCCTGTACAGCTTCTGGATTCACCTTTGCTGCTTATAATATCAACTGGTTCCGCCAGGGT

CCTGGGGGGGGGCTGGAGTGGGTAGGTTTCATTAGAGCCAACGCTGATAGTGGGACAAC

AGAGTACGCCGCGTCTGTGAAAGGCAGATTCTTCATCTCAAGAGATGATTCCAGAAGCA

CCGCCTACCTGCAAATGACTAGCCTTAAAACCGAGGACACAGCCGTTTATTACTGTGCC

AGAGATGATCGGGGTCGGGGAGATGACTTTGACTACTGGGGCCAGGGCACCCTGGTCAC

CGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

172
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGGCATGACGTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAACTATTAGTGGTAATGGTGTTGGCACATACT

ACCCAGACTCCGTGAAGGACCGGTTCACCATCTCCAGAGACAGTTCCAAGAACACGGTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGTGAAACA

TGGTAGGGCCGGAATAAACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTGACCG

TCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

173
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TGCAAGAGGGGGAGGGCTTTGGGCTTTTGATATCTGGGGCCAAGGGACCACGGTCACCG

TCTCCTCA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

174
CTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACT

ATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCC

TACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGA

CAAGATCGGCAGCTGTCCTTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTCCTACGCTGGTGAAACCCACACAGACCCTCACGCT

175
GACCTGCACCTTCTCTGGGTTCTCACTCAGCACTAGTGGAGTGGGTGTGGGCTGGATCCG

TCAGCCCCCAGGAAAGGCCCTGGAGTGGCTTGCACTCATTTATTGGGATGATGATAAGC

GCTACAGCCCATCTCTGAAGAGCAGGCTCACCATCACCAAGGACACCTCCAAAAACCAG

GTGGTCCTTACAATGACCAACATGGACCCTGTGGACACAGCCACATATTACTGTGCACA

CAGACCGGATAGCAGCAGTCAATGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCG

TCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

176
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAAG

CAGTGGCTGGTCACTGCCTGAAGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCT

CA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

177
CTCCTGCAAGGTTTCCGGATACACCCTCACTGAATTATCCATGCACTGGGTGCGACAGGC

TCCTGGAAAAGGGCTTGAGTGGATGGGAGGTTTTGATCCTGAAGATGGTGAAACAATCT

ACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCGAGGACACATCTACAGACACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCAACGG

ATGTGAACCCGGAGCTACTGGGGGCGGGATTTGACTACTGGGGCCAGGGCACCCTGGTC

ACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGAGGGTCCCTGAGACT

178
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTGACCAGTACATGGACTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTGGCCGTGTTAGAAACAAAGCTAACAGTTACACCA

CAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCAAAGAAC

TCACTGTATCTGCAAATGAATAGTCTGAACACCGAGGACACGGCCATGTATTTCTGTGCT

AGTAGTCTCAATAGTGGGGGCTACCGATGCTTCCATCACTGGGGCCAGGGCACCCTGGT

GACCGTCTCCTCA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT

179
CTCCTGTTCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATACT

ACGCAGACTCAGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTTCAAATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGTGAAAGC

GCCGAGGGGTGTAGTACCAGCTGCTATGCGGGGGGGCTACTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGAC

180
TCTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGG

CTCCAGGGAAGGGGCTGGAGTGGGTAGGTTTCATTAGAAGCAAAGCTTATGGTGGGACA

ACAGAATACGCCGCGTCTGTGAAAGGCAGATTCACCATCTCAAGAGATGATTCCAAAAG

CATCGCCTATCTGCAAATGAACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTA

CTAGATTGGTGGGCAATAGTGGGAGCTACTATCCGTTTGGGTACTGGGGCCAGGGAACC

CTGGTGACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

181
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCGGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCC

GGTCCCTTCCCTACCGGGGGTTGGCTCCTAGATCTTTCGGAGGATACTACTTTGACTACT

GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACGGCCTGGAGGGTCCCTGAGACT

182
CTCCTGTGGAGACTCTGGATTCAACTTCAGTGGATATGAAATGAACTGGGTCCGCCAGG

CTCCAGGGAAGGGGCTGGAGTGGGTTTCATACGTCAGTACTAGTGGTAGTACCAGATAC

TACGCAGACTCTGTGAAGGGCCGATTTACCATCTCCAGAGACAACGCCAAGAACACCCT

GTATTTGCAAATGAACAGTCTGAGAGTCGAGGACACGGCTGTGTATTACTGTGCAAGAG

GACGGACTCACTGGGGCCCCCAGGACTTTGACTACTGGGGCCAGGGAACCCTGGTCACC

GTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

183
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGG

AGGAATGTATTACTATGGTTCGGGGAGCTCGTACTTTGACTACTGGGGCCAGGGAACCC

TGGTGACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

184
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAATGGGTCTCAGGTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACATGCTG

TTTCTGCAAATGAACAGCCCGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAGAA

AATAGCAGCAGCTGGTAAGCAACCTGTTGACTACTGGGGCCAGGGAACCCTGGTCACCG

TCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

185
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAAGGA

AGGTGTATGATTACGTTTGGGGGAGTTATCGCCTCCCCGGGTCGGTATCGTACTACTTTG

ACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGA

186
TCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGA

TGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGA

TACAGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGC

CTACCTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGAC

TCCCGGGGAGAGCAGCTCGTCCAGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCC

TCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

187
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGG

CCCCGGGGCAGTGGCTGGTACTAAGCCAAAGTACTACTTTGACTACTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

188
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGGC

CACGTATTACTATGATAGTAGTGGTTATAGGTTTGACTACTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGGGAGGCTTGGTAGAACCGGGGGGGTCCCTTAGACT

189
CTCCTGTGCAGCCTCTCGATTCACTTTCAGTGACGCCTGGATGAGCTGGGTCCGCCAGGC

TCCAGGTAAGGGGCTGGAGTGGGTTGGCCGTATTAAAAGCAAAATAAGTGGTGGGACA

ACAGACTACGCTGCACCCGTGCAAGGCAGATTCACCATCTCAAGAGATGATTCAAAAAA

CACGCTGTATCTGCAAATGGACAGCCTGAAAACCGAGGACACAGCCGTGTATTACTGTG

CGAACCGAAACTTAGGCTACTGGGGCCAGGGCACCCTGGTGACCGTCTCCTCA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

190
TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC

CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA

TATTCACAGAAGTTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAGC

CTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAG

CTCGTTACTATGATAGTAGTGGTTATATTGCCCCATCGGGTTACTTTGACTACTGGGGCC

AGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

191
TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC

CCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAA

TATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGAG

ATGGCCCCGCCGTTGATGGTGCTGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTC

ACCGTCTCCTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

192
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGCGAGGCCTTGAGTGGCTGGGAAGGACTTACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTCTGAAAAGTCGAATAACCATCAACCCGGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTATATTACTG

TGCAAGTTTGGCGAGTGGTTCCCCCCCTCCGGGGGACTACTGGGGCCAGGGAACCCTGG

TGACCGTCTCCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

193
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCACTTATATCATATGATGGAAGTAAAAAATACT

ATGCAAACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGTTG

TATCTGCAAATGAAAAGTCTGAGAGCTGAGGACACGGCTATGTATTACTGTGCGAAAGG

CCCTATAGTGGGAGCGACTATGGACTACTGGGGCCAGGGAGCCCTGGTCACCGTCTCCT

CA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT

194
CTCCTGCAAGGCTTCTGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGG

CCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCGCTTACAATGGTAACACAAAC

TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG

CCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGA

TGGTACGGTGACTACGGCCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC

A

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

195
TTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGGC

CCCCGGACAAAGGCTTGCGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAAAT

ATTCAGAGAAGTTCGAAGGCAGAGTCACCATCACCAGGGACACATCCGCGAGCACAGC

CTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGGG

TCGCCAAATATTATTACGAGAGTGGTGGTTATCGGGCCTCCAACTGGTTCGACCCCTGGG

GCCAGGGCACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

196
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TGCAAGAGCGCCCCCTCCGACTGTTGGCTGGTACGCCCCCGTCTTTGACTACTGGGGCCA

GGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGGGAGGCTTAGTTCAGCCGGGGGGGTCCCTGAGACT

197
CTCCTGCTCAGCCTCTGGAATCAGCTTCAGAGATTACTGGATGCACTGGATCCGCCAAAC

TCCAGGGAAGGGGCTGGTGTGGGTCTCACGTATTAATCCTGATGGGAGTAGCACAAGCT

ACGCGGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGT

TACGGGACGGAGAGTGGGAGCCCATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT

CCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGT

198
CTCCTGCAAGGCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGC

CCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACT

ATGCACAGAAGTTTCAGGGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACAGCC

TACATGGAGCTGAGCAGGCTGAGATCTGACGACACGGCCGTGTATTACTGTGCCTTTGC

CCAGCCGGGCGCTGAGACGTTGAACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCG

TCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

199
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAAAAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAATGG

AATAATGATTATGCATTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAAGTCTGTGACTCCCGAGGACACGGCTCTGTATTACTG

TGTAAGACAAGTCGCGGGCGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCT

CCTCA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGGGAGGCTTGGTACAGCCAGGGCGGTCCCTGAGACT

200
CTCCTGTACAGCTTCTGGATTCACCTTTGGTGATTATGCTATGAGCTGGTTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGG

ATCGGTATATAGTGGGAGCTACTATATGCTCATTGACTACTGGGGCCAGGGCACCCTGG

TCACCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAGGCCCTCGCAGACCCTCTCACT

201
CACCTGTGTCATCTCCGGGGACAGTGTCTCTAGCGGCAGTGCTGCTTGGAACTGGATCAG

GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTATAGGGCCAAGTGGT

ATAATGAATATGCAGGGTCTGTGAAAAGCCGAATAACCATCAGTCCGGACACATCCAAG

AACCAGTTCTCCCTGCAACTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTTCTGT

ACAAGACAAGACAAAGACAACACGAGATATTCCGGTTTGGGCGTCTGGGGCCAAGGGA

CCACGGTGACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGGAGACCGGGGGAGGCTTAGTTCAGCCTGGGGGGTCCCTGAGACT

202
CTCCTGTGCAGCCTCTGAATTCACCCTTAGGAACTATGGCGTGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATGAGTGGTAGTGGTTATAGTACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAGTTCCAAGAACACGCTG

TTTCTGCAAATGGACAGCCTGAGAGCCGAGGACACGGCCATATATTACTGTGCGAGAGG

GCCCCGAATGTGGAGCAGTGGCATTGATGCTTTTGATATCTGGGGCCACGGGACAATGG

TGACCGTCTCTTCA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

203
CACCTGCGCTGTCTATGGTGGGTCCGTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATGGGGGAAATCCATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCACTAGACACGCCCAAGAACCAGTTCTC

CCTGAAGCTAAGCTCTGTGACCGCCGCGGACACGGCTGTATATTACTGTGCGAGACGGG

ATTGGGCAGGAAAAAGGGTCTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTATTAAAGCCCTCGCAGACCCTCTCACT

204
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACACTGCTACTTGGAACTGGATCAG

GCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGGT

ATAAGGATAATGCACTGTCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAAG

AACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTGT

GCAGGAGGTCGGGCTGGTATTGCCGCTTTTGATATCTGGGGCCAAGGGACCACGGTCAC

CGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACT

205
CTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAATGGGTCTCACTTATTTATAGTGATGGTCGCACAAACTATG

CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT

CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAGGGGG

CCCTACAGGGCGAATGGCGGAGATTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTC

TCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

206
CACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATATTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGCTGAACTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TACAAGAACCAACCAGGGATACGGTGGTAACTCCGGGGTATTTGACTACTGGGGCCAGG

GAACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACT

207
CACCTGTGCCATCTCCGGGGACAGTGTCTCTGGCAACAGTGCTGCTTGGAACTGGATCA

GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGGAAGGACATACTACAGGTCCAAGTGG

TATAATGATTATGCAGTATCTGTGAAAAGTCGAATAACCATCAACCCAGACACATCCAA

GAACCAGTTCTCCCTGCAGTTGAATTCTGTGACTCCCGAGGACACGGCTGTGTATTACTG

TGCGAGGATAGTGGGAGGTGCCGTTGACTGCTGGGGCCAGGGAACCCTGGTGACCGTCT

CCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG

208
TTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATGCTATGCATTGGGTGCGCCAGG

CCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAACACAAA

ATATTCACAGAAGTTCCAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGCACAG

CCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCTGTGTATTACTGTGCGAGA

GTTAGAGTGGGAGCTACTACTGTTTACGACAGCTGGTTCGACCCCTGGGGCCAGGGAAC

CCTGGTGACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACT

209
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGCACATACT

ACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA

TGGGGGGTCCAGCCCATACTATGATAGTAGTGGTTTACTACCCTGGTACTTCGATCTCTG

GGGCCGTGGCACCCTGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT

210
CTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGC

TCCAGGGAAGGGACTGGAATATGTTTCAGCTATTAGTAGTAATGGGGGTAGCACATATT

ATGCAAACTCTGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTTCAAATGGGCAGCCTGAGAGCTGAGGACATGGCTGTGTATTACTGTGCGAGAGC

TAAGTTTTGGACATACTACTTTGACTACTGGGGCCAGGGAACCCTGGTGACCGTCTCCTC

A

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCT

211
CACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCC

CCCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTAC

AACCCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTC

CCTGAAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGGCG

GTGGTTCGGGGAGTTATTATAAGAGGTTCTTTGACTACTGGGGCCAGGGAACCCTGGTC

ACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAGGAAGCCTGGGGCCTCAGTGAAGG

212
TCTCCTGCAAGGCTTCTGGTTACACATTTACCAGTTATGCCATCAGCTGGGTGCGACAGG

CCCCTGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCTTACGACGGTAACACAAAC

TATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACATCCACGAGCACAG

CCTACATGGAGGTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGA

GATGGTACGGTCCGAAGGGTAGTGGGAGCTACTACCCCTGGAAACTTTGACTACAGGGG

CCAGGGAACCCTGGTCACCGTCTCCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

213
CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA

TCTGAATCGAGGATATTGTAGTGGTGGTAGCTGCTTTGGCTACTGGGGCCAGGGAACCC

TGGTCACCGTCTCCTCA

SEQ ID
CAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTACAGCCGGGGGGGTCCCTGAGACT

214
CTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGC

TCCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTACTACCATATACT

ACGCAGACTCTGTGAAGGGCCGATTCACCGTCTCCAGAGACAATGCCAAGAACTCACTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGGGA

TTATAGCAGCTCGGGGGAGTGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT

CCTCA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

215
CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACT

ATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA

TCAGGCAGCTATGGTAGGCTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT

CCTCA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT

216
CTCCTGTGCAGCCTCTGGATTCATCTTCAGTAACTATGCTATACACTGGGTCCGCCAGGC

TCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACT

ACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG

TATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGGAC

TTTTGCGGGGTATAGCAGCAAACTGGGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGT

CACCGTCTCCTCA

Exemplary VL amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 4 below. VL amino acid sequences having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100% identity to the sequences listed in Table 4 are considered within the scope of the disclosure.

TABLE 4

VL Amino Acid Sequences

SEQ

ID
VL Amino Acid Sequence

SEQ
ETTLTQSPATLSVSLGERATLSCRASQSIGSNLVWYQL

ID
KPGQGPRLVIYSATSRATGIPARFSGSGSGTEFILSIS

217
NLQSEDLAVYYCQQYGSSPPTTFGQGTRLEIKR

SEQ
EIVMTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGRAPRLLIYGASNRATGIPDRFSGSGSGTDFTLII

218
SRLEPEDFALYYCQQYGSSPGTFGQGTKVDIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

219
SLEPEDFAVYYCQQRSNWPRTFGQGTKLEIKR

SEQ
EIVLTQSPDSLAVSLGERATITCKSSRNILYSGNNKNF

ID
LAWYQHKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD

220
FTLTINSLEAEDAATYYCHQSSSLPHTFGPGTKVDIKR

SEQ
ETTLTQSPGTLSLSPGQRATLSCRASESVSKSYLLWYQ

ID
QKPGQAPRLLIYGASTRASGIPNRFSGSGSGTDFTLTI

221
SRLEPEDSAVYYCQHYGSSRTFGQGTRLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSISSTYLAWYQ

ID
QKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLSI

222
SRLEPEDFAVYYCQQYGNSPPGATFGQGTRLEIKR

SEQ
DIQLTQSPSSLSASVGERVTITCRSSQALRNVVGLGDD

ID
LAWYQHTPGSAPKILIYSTSTLQSGVSSRFSGGKSGRD

223
FTLTIDRLQPGDSATYYCLQHHDFPFTFGPGTKVEIKR

SEQ
DVVMTQSPLSLPVTPGEPASISCRSSQSLLNSNGYNYL

ID
EWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF

224
TLKISRVEADDAGVYYCMQSLQTPLTFGGGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

225
SRLEPEDFAVYYCQQYGSSPRITFGQGTRLEIKR

SEQ
DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

226
SLQSEDFAVYYCQQYNNWPPMYTFGQGTKLEIKR

SEQ
DVVMTQSPATLSVSPGERVTLSCRASQSVRDNVGWYKQ

ID
KPGQPPRLVIYGASTRATGIPARISGSGSGTEFTLTIS

227
SLQSEDFAVYYCQQFNNWPYTFGQGTKLEIKR

SEQ
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQ

ID
KPGKAPNLLIYAASSLHTGVPSRFSGSGSGTDFTLTIS

228
SLQPEDFATYYCQQSYSIPRTFGQGTKVEIKR

SEQ
DVVMTQSPATLSVTPGERATLSCRASQSVNSNVAWYQQ

ID
KPGQAPRLLIYDVSTRATDIPARFSGSGSGTDFTLTIS

229
RLDPEDFAVYYCQQCASSPPVTFGGGTKLEIKR

SEQ
EIVMTQSPATLSLSPGERATLSCGASQSVSSSYLAWYQ

ID
QKPGLAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTI

230
SRLEPEDFAVYYCQQYGSSPRVTFGGGTKVDIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSALAWFQ

ID
QKPGQAPRLLIYDSSSRATGIPDSFSGSGSGTEFTLTI

231
SSLQPEDFATYYCQQFNTYPNTFGQGTKLEIKR

SEQ
DIQMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYL

ID
DWFLQKPGQSPRLLIYMGSSRASGVPERFSGSGSGTDF

232
TLKISRVEAEDVGVYYCMQTLHTVTFGGGTKVEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

233
SRLEPEDFAVYYCQQYGSSLLFGQGTRLEIKR

SEQ
DIQLTQSPSFLSASVGDRVTITCRASQGISSSLAWYQQ

ID
KPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTFTIS

234
SLQPEDIATYYCQQYDNLPPLTFGGGTKVEIKR

SEQ
DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYL

ID
DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF

235
TVKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIKR

SEQ
EIVLTQSPLSLPVTLGQPASISCRSCQSLVYSDGNTYL

ID
NCFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDF

236
TLEISRVEAEDVGIYFCMQGLQTPFTFGPGTKVDIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

237
SRLEPEDFAVYYCQQYGSSPALTFGGGTKLEIKR

SEQ
EIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYL

ID
DWYLQKPGQSPQLLIYLGSTRASGVPDRFSGSGSGTDF

238
TLKISRAEAEDVGVYYCMQALHTPWTFGLGTKVDIKR

SEQ
DIQMTQSPATLSVSPGERATLFCRASEGLTTNLAWYQH

ID
KPGQAPRLLIYAASTRATGVPARFSGSGSGTDFTLTIS

239
SLQSEDSAVYYCQQYNHWPLYTFGQGTKVEIKR

SEQ
DIQLTQSPSTLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KSGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

240
SLEPEDFAVYYCQQGSNWPLTFGGGTKVEIKR

SEQ
DIVMTHTPLSSPVTLGQPASISCRSSQSLEHTDGNTYL

ID
SWLHQRPGQPPRLLIYKVSTRFSGVPDRFSGSGAGTDF

241
TLKISRVEAEDVGVYYCVQATHYPRTFGHGTKVEIKR

SEQ
EIVLTQSPGTLSLSPGERATLSCRASQSISGSYLAWYQ

ID
QKRGQAPRLLIYDASSRAEGIPDRFIGSGSGTDFTLTI

242
SRLEPEDFAMYYCQQYGSSPIFTFGPGTKVDIKR

SEQ
EIVLTQSPDSLPVTPGEPASISCRSSQSLLHSNGNNYL

ID
DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF

243
TLKLSRVEAEDVGVYYCMQGLQIPITFGPGTKVDIKR

SEQ
DIQMTQSPSSVSASVGDRVTITCRASQNIRHWLVWYQQ

ID
KLGQAPKLLIYAASNLQSGVPSRFSGSGSGTEFTLTIN

244
SLQAEDFATYYCLQHNSYPWTFGQGTKVEIKR

SEQ
EIVLTQSPDFQSVTPKQKVTITCRASQSIGGSLHWYQQ

ID
KPGQSPKLIIKYASQSFSGVPSRFSGSGSGTDFTLTID

245
SLEAEDAATYYCHQSISLPLTFGGGTKVDIKR

SEQ
ETTLTQSPGTLSLSPGEGATLSCRASQSVTSNYLAWYQ

ID
QKPGQAPRLLIYGASYRATGIPDRFSGSGSGTDFTLTI

246
SRLEPEDFAVYYCQQYASSVTFGQGTRLEIKR

SEQ
DVVMTQSPATLSVSPGERATLSCRASQSISSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

247
SLQSEDFAVYYCQQYNNWPRTFGQGTKLEIKR

SEQ
DIQLTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNY

ID
LAWYQQKPGQPPKLLIYWASARESGVPDRFSGSGSGTD

248
FTLTINSLQAEDVAVYYCQQFYSPPRTFGQGTKVEIKR

SEQ
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

249
SRLEPEDFAVYYCQQYGSSPPGTFGGGTKVDIKR

SEQ
EIVLTQSPGTLSLSPGERATLSCRASQSLSTNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIT

250
SLQSEDFAVYYCQQYHNWPPYTFGQGTKVEIKR

SEQ
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQ

ID
KPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTIS

251
SLQPDDFATYYCQQYNSYWTFGQGTKVEIKR

SEQ
ETTLTQSPGTLSLSPGEGATLSCRASHSVGANYIAWYQ

ID
QKPGQAPRLLIHTASKRATGVPERFSGSGSGTDFTLSI

252
SRLEPEDFAVYHCQQYAAAPITFGQGTRLEIKR

SEQ
EIVMTQSPSSLSASVGDRVIITCRASQGIANYLAWYQQ

ID
KPGKGPKLLIYASSTLQSGVPSRFSGSGSGTDFTLTIS

253
GLQPEDVATYYCQKYNSVPLTFGGGTKVDIKR

SEQ
DVVMTQSPVSLAVSLGERATINCKSSQSVLYRTNNKNY

ID
LAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD

254
FTLTISSLQPEDVAVYYCQQYYNLPRSFGQGTKLEIKR

SEQ
DIVMTHTPDSLAVSLGERATINCKSNRSVLYSPNNQNY

ID
LGWYQQKPGQPPKLLIYWASTRDSGAPDRFSGSGSGTD

255
FTLTINSLQAEDVAVYYCQQYASTPYTFGQGTKVEIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASESVNSNFLAWYQ

ID
QKPGQAPRLLIYAASTRATGIPARFSGSGSGTEFTLII

256
TSLQSEDFAVYYCQQYNNWPLTFGGGTKLEIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

257
SLEPEDFAVYYCQQRSNWSLTFGGGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTI

258
GRLEPEDFAVYYCQHYGPSRRITFGQGTRLEIKR

SEQ
ETTLTQSPDTLSVSPGGRATLSCRASQSIGSNLAWYQQ

ID
KPGQSPRLLIYDASTRATGIPARFSGSGSGTEFTLTIS

259
SLESEDFVLYYCQQHGEWPTFGQGTRLEIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVGNSLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIT

260
SLEPEDFAIYYCQQRGTWPPLTFGGGTKLEIKR

SEQ
DVVMTQSPSSLSASVGDTVTITCRASQSITNWLAWYQQ

ID
KPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTIS

261
SLQPEDFATYYCQQYTNYPRTFGQGTKLEIKR

SEQ
DIQMTQSPSTLSASVGDRVTITCRARQSISNRLAWYQQ

ID
KPGRAPNVLIYKASTLANGVPSRFSGSGSGTEFTLTIS

262
SLQPDDFATYYCQQYQSYWTFGPGTKVEIKR

SEQ
DIQLTQSPATLSLSPGERATLSCKASQSVSSYLAWYQQ

ID
KLGQAPRLLIYDASNRATGIPARFSASGSGTDFTLTIS

263
SLQPEDVATYYCQKYNSPPRTFGQGTKVEIKR

SEQ
ETTLTQSPGTLSLSPGERVSLSCRASQNVYSNFLAWYQ

ID
QRPGQAPSLLIYGASSRAAGVPDRFSGSGSGTDFALTI

264
SRVEPEDFAVYYCQQYGTSPITFGQGTRLEIKR

SEQ
EIVLTQSPRSSPVTLGQPASISCRSSQSLEHGDGNTYL

ID
SWLQQRPGQPPRLLIYKVSNRLSGVPDRFSGSGAGTDF

265
TLKISRVEAEDVGVYYCMQGIYWPRTFGQGTRLEIKR

SEQ
ETTLTQSPVTLSLSPGDRATLSCRASQSVSSTSLAWYQ

ID
HKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTI

266
NRLEPEDFAVYYCQHYGSSPPITFGQGTRLEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSVGSKLAWYQQ

ID
KPGQAPRLLIYGASTRATGVPVRFSGSGSGTEFTLTIS

267
SLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR

SEQ
EIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYL

ID
DWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDF

268
TLKISRVEAEDVGVYYCMQTLQTPLTFGGGTKVDIKR

SEQ
DVVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNY

ID
LAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD

269
FTLTISSLQAEDVAVYYCQQYYSSTPYTFGQGTKLEIK

R

SEQ
DIVMTHTPLSLSVTPGQPASISCKSSQSLLGGDGKTYL

ID
YWYLQKPGQPPQLLLYEVSNRFSGVPDRFSGSGAATDF

270
TLKISRVEAEDVGVYYCMQSTQFPWTFGQGTKVEIKR

SEQ
ETTLTQSPGTLSLSAGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYAASYRATGIPDRFSGRGSGTEFTLTI

271
SSLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR

SEQ
DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYDASTRATGIPARFSGSGSGTEFTLTIS

272
SLQSEDFAVYYCQHYNNWPHTFGQGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSNSLAWYQ

ID
QKPGQAPRLLIYGASSRASGIPDRFNGSGSGTDFTLTI

273
NRLEPEDFAVYYCQQYGNSQTFGQGTRLEIKR

SEQ
DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

274
SLQSEDFAVYYCQQYNNWPRTFGQGTKLEIKR

SEQ
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYL

ID
NWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDF

275
TLKISRVEAEDVGVYYCMQGTHWPRTFGGGTKLEIKR

SEQ
DIQMTQSPSTLSASVGDRVTITCRASQSISRWLAWYQQ

ID
KPGKAPKLLIYKASTIKSGVPSRFSASGSGTEFTLTIS

276
SLQPEDFATYYCQHYKSDSRTFGQGTKVEIKR

SEQ
DVVMTQSPSSLAASVGDRITITCRPSQDIGTYLNWYQQ

ID
KAGEAPKLLIYAASNLHSGVSSRFRGVGSGTQFTLTIS

277
SLQPEDFATYYCHQSYGPRTFGQGTKLEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

278
SLQSEDFAVYYCQQYNNWPPITFGQGTRLEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

279
SRLEPEDFAVYYCQQYGSSGYTFGQGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

280
SRLEPEDFAVYYCQQYGSSFGQGTRLEIKR

SEQ
EIVLTQSPSTLSASVGDRVTITCRASQSISSCLAWYQQ

ID
KPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTIS

281
TLQPEDFATYYCQQLNSYPQTFGQGTKVDIKR

SEQ
DIVMTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYL

ID
YWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDF

282
TLKISRVEAEDVGVYYCMQSIQLPLTFGGGTKVEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

283
SRLEPEDFAVYYCQQYNNWPLTFGGGTKLEIKR

SEQ
DIQLTQSPDSLAVSLGERATINCTSSQSVLYSSNNKNY

ID
IAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD

284
FTLTISSLQAEDVAVYYCQQYYYIPRTFGQGTKVEIKR

SEQ
DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYL

ID
DWYLQKPGQSPQLLIYLGSNRAPGVPDRFSGSGSGTDF

285
TLKISRVEAEDVGVYYCMQALQTRTFGQGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSLTSSYLAWYQ

ID
QKPGQAPRLLIYRASSRATGIPDRFSGSGSGTDFTLTI

286
SRLEPEDFAVYYCQQYGSSPNTFGQGTRLEIKR

SEQ
EIVLTQSPLSLPVTLGQPASISCRSSQSLVHSNGHTYL

ID
SWFQQRPGQSPRRLIYEVSNRDSGVPDRFSGSGSGTDF

287
TLRISRVEAEDVGVYYCLQGTHWPPLTVGGGTKVDIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVGSDLAWYQQ

ID
KPGQAPRLLIYRASTRAAGIPARFSGSGSGTDFTLTIS

288
RLEPEDFAVFYCQQYGRSPYTSGQGTKLEIKR

SEQ
DIVMTHTPDSLAVSLGERATINCKSSQSVLYSSNNKNY

ID
LAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTD

289
FTLTISSLQAEDVAVYYCQQYYSTPLTFGGGTKVEIKR

SEQ
EIVMTQSPLSLSVTPGEPASISCRSSQSLLHSSGYNYL

ID
DWYLQKPGQSPQLLIYLGSTRASGVPDRFSGSGSGTDF

290
TLKISRVEAEDVGVYYCMQGLQIPLTFGGGTKVDIKR

SEQ
DIVMTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYL

ID
YWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDF

291
TLKISRVEAEDVGVYYCMQSIQLPWTFGQGTKVEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

292
SLQSEDFAVYYCQQYNNWPRFGQGTRLEIKR

SEQ
DVVMTQSPSTLSASVGDRVTITCRASQTINSWLAWYQQ

ID
KPGKAPKLLISRASRLESGVPSRFSGSASGTEYILTIN

293
SLQPDDFAMYFCHQYNSYSPTFGQGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPARFSGSGSGTDFTLTI

294
SSLEPEDFAVYYCQQRYNWPITFGQGTRLEIKR

SEQ
EIVLTQSPATLSLSPGETATLSCRASQTIGPKSFGWYQ

ID
QRPGQAPRLLIYDSNRATGIPARFSGSGSGTDFTLTIS

295
SLEPEDFAVYYCQQRSRWPLTFGPGTKVDIKR

SEQ
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYL

ID
YWFQQRAGQSPRRLIYKVSKRDSGVPDRFSGSGSGTDF

296
TLKISRVEAEDVGIYYCVQGRHWPYTLGQGTKLEIKR

SEQ
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYDASNRATGIPARFSGSGSGTEFTLTI

297
SSLQPDDFATYYCQQYNSYSRTFGQGTKVDIKR

SEQ
DVVMTQSPSTLSASVGDRVTITCRASQSITTWLAWSQQ

ID
QPGKAPKLLIYKASSLTSGVPSRFSGSGSGTEFTLTIS

298
SLQPDDFASYYCHHYNGASRMFGQGTKLEIKR

SEQ
ETTLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

299
SLEPEDFAVYYCQQRSNWPFFGQGTRLEIKR

SEQ
ETTLTQSPATLTLSPGERVTLSCRASQSIGTYVAWYQQ

ID
KPGQAPRFLIYDSSNRATGIPARFSGSGSGTDFTLTIS

300
SLEPEDFAFYYCQQRAEWPLTFGQGTRLEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVNSGYLAWYQ

ID
QKPGQPPRLLISGVSTRATGIPDRFSGSGSGTDFTLTI

301
SRLEPEDFAVYYCQEYGNSAMYNFGQGTKLEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS

302
SLQSEDFAVYYCQQYNNWPPFTFGQGTRLEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLGWYQ

ID
QKSGQAPRLLIYGASSRATDIPDRFSGSGSGTDFTLTI

303
SKLEAEDSAVYYCQQYGISPLAFGQGTKLEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSISNNLAWYQQ

ID
KPGQAPRLLIYGTSTRATGIPARFSGSGSGTEFTLTIS

304
SLQSEDFAVYYCQQYNFWPSITFGQGTRLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVSSSSLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

305
SRLEPEDFAVYYCQQYGSSQTFGQGTRLEIKR

SEQ
DVVMTQSPLSLPVSLGQPASISCRSNQSLVYSDGGTYL

ID
NWFQQRAGQSPRRLVYKVSNRDSGVPDRFSGSGSGTDF

306
TLRISRVEAEDVGVYYCMQGTHWPYTFGQGTKLEIKR

SEQ
DIQLTQSPSSLSASVGDRVTVTCRASQSISSYLNWYQQ

ID
KPGKAPQLLIYDASNLETGVPSRFSGSGSGTDFTFTIS

307
SLQPEDFATYYCQQFDNVPVTFGGGTKVEIKR

SEQ
EIVLTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYL

ID
NWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDF

308
TLKISRVEAEDVGVYYCMQGTHWPRTFGQGTKLEIKR

SEQ
DVVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQ

ID
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTIN

309
RLEPEDFAVYYCQQYGSSSMYTFGQGTKLEIKR

SEQ
DVVMTQSPSSLSASVGDSVAITCRASQSISNYLNWYQQ

ID
RPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTIS

310
SLQPEDFATYSCQQSYITPWTFGQGTKLEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSTLLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPGRFSASGSGTDFSLTIS

311
SLETEDSAVYYCQHRYVWPFTFGGGTKLEIKR

SEQ
DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQ

ID
KPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTIR

312
SLQPEDFATYYCLQHNSYPRTFGQGTKVEIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

313
SLEPEDFAVYYCQQRSNWPWTFGQGTKLEIKR

SEQ
DVVMTQSPLSLPVTLGQAASISCRSSHSLTTTDGRTYV

ID
AWFQQRPGQSPRRLLYEVSKRDSGAPDRFSGSGSGTDF

314
TLKISRVEADDVGIYHCMQGTHGPHTFGQGTKLEIKR

SEQ
ETTLTQSPATLSVSPGERATLSCRASQSVTSNLAWYQQ

ID
KPGQAPRLLIYGASNRATGIPARFSVSGSGTDFTLTIS

315
RLEPEDFAVYYCQQYGSPPPTTFGQGTRLEIKR

SEQ
DVVMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQ

ID
QKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTI

316
SRLEPEDFAVYYCQQYGSSRRTFGQGTKLEIKR

SEQ
ETTLTQSPGTLSLSPGERATLSCRASQSVFNNYLAWYQ

ID
QRPGQAPRLLIYGASSRATGIPDRFSGGGSGTDFTLTI

317
SRLEPEDFAVYCCQQYGSSPITFGQGTRLEIKR

SEQ
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTIS

318
RLEPEDFAVYYCQQYGSSLRYTFGQGTKLEIKR

SEQ
EIVLTQSPDSLAVSLGERATINCKSSQSVLYDSNSKNY

ID
LSWYQQKPGQPPKLLISWASTRGSGVPDRFSGSGSGTD

319
FTLTISSLQAEDVAVYYCQQFYGIPHFGQGTRLEIKR

SEQ
DVVMTQSPATLSLSPGERATLSCRASQSVGTNLAWYQQ

ID
KPGQAPRLLIYDASNRATGIPARFSGSGSGTEFTLTIS

320
SLQSEDFAVYYCQQYNNWPPITFGGGTKLEIKR

SEQ
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYL

ID
SWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDF

321
TLKISRVEAEDVGVYYCMQGTQFPQTFGQGTKLEIKR

SEQ
EIVLTQSPGTLSLSPGERATLSCRASQSVISRYLAWYQ

ID
QKPGQAPRLLIHGASTRATGIPDRFSGSGSGTDFTLTI

322
SRLEPEDFAVYYCQQYGSSPPYTFGQGTKVEIKR

SEQ
DIQLTQSPSTLAASVGDRVTITCRASQSISSWLAWYQQ

ID
KPGKAPKVLIYKASSLESGVPSRFSGSGSGTEFTLTIS

323
SLQPDDFATYYCQQYNSYSGTFGQGTKVEIKR

SEQ
DVVMTQSPAILSVSPGERATLSCRASQSVSSSLAWYQQ

ID
KPGQPPRLLIYGASTRATAIPARFSGSGSGTEFTLTIS

324
SLQSEDFAVYYCQRYDNWPPLFGQGTKLEIKR

A VL amino acid sequence of the disclosure may be encoded by a polynucleotide shown in Table 5 below.

TABLE 5

VL DNA Sequences

SEQ

ID
VL DNA Sequence

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTATCTGTGTCTCTAGGAGAAAGAGCCACCC

ID
TTTCTTGCAGGGCCAGTCAGAGTATTGGCAGCAACTTAGTCTGGTACCAGCTGAAACCTGGC

325
CAGGGTCCCAGGCTCGTCATATATAGTGCAACCTCTAGGGCCACTGGAATCCCAGCCAGGT

TCAGCGGCAGTGGGTCTGGGACAGAGTTCATTCTCTCCATCAGCAACCTGCAGTCTGAAGAT

CTTGCAGTTTATTACTGTCAGCAGTATGGTAGTTCACCTCCGACCACCTTCGGCCAAGGGAC

ACGACTGGAGATTAAACGT

SEQ
GAAATTGTGATGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAAAAACCT

326
GGCCGGGCTCCCAGGCTCCTCATCTATGGCGCATCCAACAGGGCCACAGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCATCATCAGCAGACTGGAGCCTGA

AGATTTTGCCTTGTATTACTGTCAGCAGTATGGAAGCTCACCGGGAACGTTCGGCCAAGGG

ACCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC

327
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCGGACGTTCGGCCAAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CACCTGCAAGTCCAGCCGGAATATTTTATACAGCGGCAACAATAAAAACTTCTTGGCTTGGT

328
ATCAGCACAAACCAGGACAGCCTCCTAAGTTGCTCATTTACTGGGCATCTACCCGGGAATCC

GGGGTCCCTGACCGATTTAGTGGCAGCGGGTCTGGGACAGATTTCACCCTCACCATCAATA

GCCTGGAAGCTGAAGATGCTGCAACGTATTACTGTCATCAGAGTAGTAGTTTACCTCACACT

TTCGGCCCTGGGACCAAAGTGGATATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGCAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTGAGAGTGTTAGCAAGAGCTACTTACTCTGGTACCAGCAGAAACC

329
TGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCACCAGGGCCAGTGGCATCCCAAAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG

AAGATTCTGCAGTGTATTACTGTCAGCACTATGGCAGCTCTCGCACCTTCGGCCAAGGGACA

CGACTGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTATTAGCAGCACCTACTTAGCCTGGTACCAGCAGAAACC

330
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCAGCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACCTCCGGGAGCCACCTTCGGCC

AAGGGACACGACTGGAGATTAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCTTCCTCCCTGTCTGCATCTGTGGGAGAAAGAGTCACCAT

ID
CACTTGCCGGTCCAGCCAGGCCCTGCGAAATGTTGTCGGCCTTGGCGATGATTTAGCCTGGT

331
ATCAACACACGCCAGGCAGCGCCCCCAAGATCCTGATCTACTCTACATCGACTTTACAAAGT

GGAGTCTCATCAAGATTCAGCGGCGGAAAGTCTGGGAGAGACTTCACTCTCACGATCGATC

GTCTGCAGCCTGGAGATTCTGCAACTTATTACTGTCTCCAGCACCATGATTTCCCTTTCACTT

TCGGCCCTGGGACCAAGGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGAATAGTAATGGATACAACTATTTGGAGTGGTACC

332
TGCAGAAGCCGGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG

TGGAGGCTGACGATGCTGGTGTTTATTACTGCATGCAGTCTCTACAAACTCCTCTCACTTTC

GGCGGTGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC

333
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG

AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCCCGGATCACCTTCGGCCAA

GGGACACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC

334
CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCTATGTACACTTTTGGCCAGGG

GACCAAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGTCACACT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGAGACAACGTAGGTTGGTACAAGCAGAAACCTGGC

335
CAACCTCCCAGGCTCGTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGAT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGTTTAATAATTGGCCTTACACTTTTGGCCAGGGGACCAA

GCTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGG

336
AAAGCCCCTAACCTCCTGATCTATGCTGCATCCAGTTTGCACACTGGGGTCCCATCAAGGTT

CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATT

TTGCAACTTACTACTGTCAACAGAGTTACAGTATTCCTCGAACGTTCGGCCAAGGGACCAAG

GTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGGGAAAGGGCCACCCT

ID
CTCCTGCAGGGCCAGTCAAAGTGTTAACAGCAACGTAGCCTGGTACCAGCAGAAACCTGGC

337
CAGGCTCCCAGGCTCCTCATCTATGATGTATCCACCAGGGCCACTGATATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTTGACCCTGAAGAT

TTTGCAGTGTATTACTGTCAGCAGTGTGCTAGCTCACCTCCTGTCACTTTCGGCGGAGGGAC

CAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGATGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCGGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

338
GGCCTGGCGCCCAGGCTCCTCATCTATGATGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCGGGTCACTTTCGGCGGAG

GGACCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCGCCTTAGCCTGGTTCCAGCAGAAACCT

339
GGCCAGGCTCCCAGGCTCCTCATCTATGATTCATCCAGCAGGGCCACTGGCATCCCAGACA

GCTTCAGCGGCAGTGGATCTGGGACAGAATTCACACTCACAATCAGTAGCCTGCAGCCTGA

AGATTTTGCAACTTATTACTGTCAACAGTTTAATACCTACCCCAACACTTTTGGCCAGGGGA

CCAAGCTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTTCC

340
TGCAGAAGCCAGGGCAGTCTCCACGGCTCCTGATCTATATGGGTTCTAGTCGGGCCTCCGGG

GTCCCTGAGAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTCTATTACTGCATGCAAACTTTACACACTGTCACTTTCGGC

GGCGGGACCAAGGTGGAAATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC

341
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG

AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTCCTCTTCGGCCAAGGGACA

CGACTGGAGATTAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTTGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGGGCATTAGCAGTTCTTTGGCCTGGTATCAGCAAAAGCCAGGG

342
AAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTT

CAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGAT

ATTGCAACATATTACTGTCAACAGTATGATAATCTCCCTCCTCTCACTTTCGGCGGAGGGAC

CAAGGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC

343
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTCACAGTGAAAATCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCCGTACACTTTT

GGCCAGGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTTGTCAAAGCCTCGTATACAGTGATGGCAACACCTACTTGAATTGCTTTC

344
AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG

GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACAGATTTTACACTGGAAATCAGCAGA

GTGGAGGCTGAGGATGTTGGGATTTATTTCTGCATGCAAGGTCTACAAACTCCATTCACTTT

CGGCCCTGGGACCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

345
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTGCGCTCACTTTCGGCGGAG

GGACCAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGATGACGCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC

346
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTACTCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGACTTTACACTGAAAATCAGCAGAG

CGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACACACTCCGTGGACGTTC

GGCCTAGGGACCAAAGTGGATATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGGGCCACCC

ID
TCTTTTGCCGGGCCAGTGAAGGTCTTACCACCAACTTAGCCTGGTACCAGCACAAACCTGGC

347
CAGGCTCCCAGGCTCCTCATCTATGCTGCCTCCACCAGGGCCACTGGTGTCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TCCGCAGTTTATTACTGTCAGCAGTATAATCACTGGCCTCTCTACACTTTTGGCCAGGGGAC

CAAGGTGGAAATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCTTCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAATCTGGC

348
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGGGTAGCAACTGGCCGCTCACTTTCGGCGGAGGGACCAA

GGTGGAAATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCACTCTCCTCACCTGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGAACACACTGATGGAAACACCTACTTAAGTTGGCTTC

349
ACCAGAGGCCAGGCCAGCCCCCAAGACTGTTAATTTATAAGGTTTCTACCCGGTTCTCTGGG

GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGG

TGGAGGCTGAGGATGTCGGCGTTTATTACTGCGTGCAGGCTACACACTATCCTCGGACGTTC

GGCCATGGGACCAAGGTGGAGATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCCTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTATTAGCGGCAGTTACTTAGCCTGGTACCAGCAGAAACGT

350
GGCCAGGCTCCCAGGCTCCTCATCTATGATGCGTCCAGCAGGGCCGAAGGCATCCCAGACA

GGTTCATTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGACTTTGCTATGTATTACTGTCAGCAGTATGGTAGCTCACCAATATTCACTTTCGGCCCTG

GGACCAAAGTGGATATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGACTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGAAACAACTATTTGGATTGGTACC

351
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAACTCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTCTACAAATCCCTATCACTTTC

GGCCCTGGGACCAAAGTGGATATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCATCTTCTGTGTCTGCATCTGTGGGAGACAGAGTCACCAT

ID
CACTTGTCGGGCGAGTCAGAACATTCGCCACTGGTTAGTCTGGTATCAGCAAAAATTAGGG

352
CAAGCCCCTAAACTCCTGATCTATGCTGCGTCCAATTTGCAAAGTGGGGTCCCGTCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAACAGCCTGCAGGCTGAAGAT

TTTGCAACCTATTACTGTCTACAGCATAACAGTTACCCGTGGACGTTCGGCCAAGGGACCAA

GGTGGAAATCAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCAGACTTTCAGTCTGTGACTCCAAAGCAGAAAGTCACCAT

ID
CACCTGCCGGGCCAGTCAGAGCATTGGTGGTAGCTTACACTGGTACCAGCAGAAACCAGGT

353
CAGTCTCCAAAGCTCATCATCAAGTATGCTTCCCAGTCCTTCTCAGGGGTCCCCTCGAGGTT

CAGTGGCAGTGGATCTGGGACAGATTTCACCCTCACCATCGATAGCCTGGAGGCTGAAGAT

GCTGCAACGTACTATTGTCATCAGAGTATCAGTTTACCGCTCACTTTCGGCGGAGGGACCAA

AGTGGATATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAGGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTACCAGCAACTACTTAGCCTGGTACCAGCAGAAACC

354
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCTACAGGGCCACTGGCATCCCTGACA

GGTTCAGCGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGCTAGCTCAGTCACCTTCGGCCAAGGGACAC

GACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTATTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC

355
CAGGCTCCCAGGCTCCTCATCTATGGTGCCTCCACCAGGGCCACTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTAGAACGTTCGGCCAAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT

356
ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTGCCCGGGAATC

CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAAC

AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATTTTATAGTCCTCCTCGGAC

GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGT

SEQ
GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

357
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCCCCGGGCACTTTCGGCGGAG

GGACCAAAGTGGATATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTTTAAGTACCAACTTAGCCTGGTACCAGCAGAAACCTGGC

358
CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGCACAGAGTTCACTCTCACCATCACCAGCCTGCAGTCTGAAGATT

TTGCAGTTTATTACTGTCAGCAGTATCATAACTGGCCTCCGTACACTTTTGGCCAGGGGACC

AAGGTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGG

359
AAAGCCCCTAAGCTCCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAT

TTTGCAACTTATTACTGCCAACAGTATAATAGTTATTGGACGTTCGGCCAAGGGACCAAGGT

GGAAATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAGGCGCCACCC

ID
TCTCCTGCAGGGCCAGTCACAGTGTTGGCGCCAACTACATAGCCTGGTACCAGCAGAAACC

360
TGGCCAGGCTCCCAGGCTCCTTATCCATACTGCATCCAAAAGGGCCACTGGCGTCCCAGAG

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCAGTATCAGCAGACTGGAGCCTG

AAGACTTTGCCGTGTATCACTGTCAGCAGTATGCTGCCGCACCGATTACCTTCGGCCAAGGG

ACACGACTGGAGATTAAACGT

SEQ
GAAATTGTGATGACACAGTCTCCATCCTCCCTGTCTGCATCTGTGGGGGACAGAGTCATCAT

ID
CACTTGCCGGGCGAGTCAGGGCATTGCCAATTATTTAGCCTGGTATCAGCAGAAACCAGGG

361
AAAGGTCCTAAACTCCTGATCTATGCTTCATCTACTTTGCAATCAGGGGTCCCATCTCGGTT

CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGGCCTGCAGCCTGAAGAT

GTTGCAACTTATTACTGTCAGAAGTATAACAGTGTCCCTCTCACTTTCGGCGGAGGGACCAA

AGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGTCTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGAACCAACAATAAGAACTACTTGGCTTGG

362
TATCAGCAGAAACCAGGACAGCCTCCTAAGTTGCTCATTTACTGGGCATCTACCCGGGAATC

CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC

AGCCTGCAGCCTGAGGATGTGGCAGTGTACTACTGTCAGCAATATTACAATCTTCCTCGATC

TTTTGGCCAGGGGACCAAGCTGGAGATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAACCGGAGTGTTTTATACAGCCCCAACAATCAGAACTACTTAGGTTGGT

363
ACCAGCAGAAGCCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGACTC

CGGGGCCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAAC

AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATGCAAGTACTCCATACAC

TTTTGGCCAGGGGACCAAGGTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTGAGAGTGTTAATAGCAACTTCTTAGCCTGGTACCAGCAGAAACCT

364
GGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCACCAGGGCCACTGGTATCCCAGCCAG

GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCATCATCACCAGCCTGCAGTCTGAAG

ATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCGCTCACTTTCGGCGGAGGGACC

AAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC

365
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGTCGCTCACTTTCGGCGGAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAACAGAAACC

366
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCTTCCACCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACGGACTTCACTCTCACCATCGGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAACACTATGGTCCCTCACGTCGGATCACCTTCGGCCAAG

GGACACGACTGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGACACCCTGTCTGTGTCTCCAGGGGGAAGAGCCACCC

ID
TCTCCTGTAGGGCCAGTCAGAGCATTGGGAGCAATTTAGCCTGGTACCAACAGAAACCTGG

367
CCAGTCTCCCAGGCTCCTCATCTATGATGCATCCACCAGGGCCACGGGAATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGGAGTCTGAAGA

TTTTGTACTTTATTACTGTCAGCAGCATGGTGAATGGCCCACCTTCGGCCAAGGGACACGAC

TGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTCGGTAACTCCTTAGCCTGGTACCAGCAGAAGCCTGGC

368
CAGGCTCCCCGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCCGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCACCAGCCTAGAGCCTGAAGAT

TTTGCAATTTATTACTGTCAACAACGTGGCACCTGGCCTCCCCTCACTTTCGGCGGAGGGAC

CAAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACACAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATAACTAACTGGTTGGCCTGGTATCAGCAGAAACCAGGG

369
AAAGCCCCCAAGCGCCTGATCTATGGTGCGTCCAGTTTGCAGAGTGGGGTCCCATCAAGGT

TCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGA

TTTTGCAACTTATTACTGTCAACAGTATACTAATTACCCTCGTACGTTCGGCCAAGGGACCA

AGCTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGTCGGGCCAGGCAGAGCATCAGTAACCGGTTGGCCTGGTATCAGCAGAAACCAGGG

370
AGAGCCCCTAATGTCCTGATCTATAAGGCGTCTACTTTAGCAAATGGGGTCCCATCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAC

TTTGCAACTTATTACTGCCAACAGTATCAAAGTTACTGGACGTTCGGCCCAGGGACCAAGGT

GGAAATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAAGGCCAGTCAGAGTGTTAGTAGCTACTTAGCCTGGTACCAACAGAAACTTGGC

371
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGCCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGAT

GTTGCAACTTATTACTGTCAAAAGTATAACAGTCCCCCTCGGACGTTCGGCCAGGGGACCA

AGGTGGAAATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGGGTCAGCC

ID
TTTCCTGCAGGGCCAGTCAGAATGTTTACAGCAATTTCTTAGCCTGGTATCAACAGAGACCT

372
GGCCAGGCTCCCAGTCTCCTCATCTATGGTGCCTCCAGCAGGGCCGCTGGCGTCCCAGACAG

GTTCAGTGGCAGTGGGTCTGGGACAGACTTCGCTCTCACCATCAGCAGAGTGGAGCCTGAA

GATTTTGCAGTCTATTACTGTCAACAATATGGAACCTCACCGATCACCTTCGGCCAAGGGAC

ACGACTGGAGATTAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCACGCTCCTCACCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGTAGGTCTAGTCAAAGTCTCGAACACGGTGATGGAAACACGTACTTGAGTTGGCTTC

373
AGCAGAGGCCAGGCCAGCCTCCAAGACTCCTGATTTATAAGGTTTCTAACCGGTTGTCTGGG

GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACTGATTTCACACTGAAAATCAGCAGGG

TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAAGGTATATACTGGCCTCGAACCTTC

GGCCAAGGGACACGACTGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGTCACCCTGTCTTTGTCTCCAGGGGACAGAGCCACCCT

ID
CTCTTGCAGGGCCAGTCAGAGTGTTAGCAGCACCTCCTTAGCCTGGTACCAGCACAAACCTG

374
GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGGAGGGCCACTGGCATCCCAGACAG

GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAA

GATTTTGCAGTGTATTACTGTCAGCACTATGGTAGTTCACCTCCAATCACCTTCGGCCAAGG

GACACGACTGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTGGCAGCAAATTAGCCTGGTACCAGCAGAAACCTGG

375
CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTGTCCCAGTCCGGT

TCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCCGATCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC

376
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTGTATTACTGCATGCAAACTCTTCAAACTCCGCTCACTTTC

GGCGGAGGGACCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT

377
ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC

CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC

AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTAGTACTCCGTA

CACTTTTGGCCAGGGGACCAAGCTGGAGATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCCCTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT

ID
CTCCTGCAAGTCTAGTCAGAGCCTCCTGGGTGGTGATGGAAAGACCTATTTGTATTGGTACC

378
TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGCTCTATGAAGTTTCCAACCGATTCTCTGGA

GTGCCAGATAGGTTCAGTGGCAGCGGGGCAGCGACAGATTTCACACTGAAAATCAGCAGGG

TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAATCTACACAATTTCCGTGGACGTTC

GGCCAAGGGACCAAGGTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTGCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC

379
TGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCTACAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCCGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGA

AGATTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCCATCACCTTCGGCCAAG

GGACACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC

380
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCACTATAATAACTGGCCTCATACCTTCGGCCAAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTCCTTAGCCTGGTACCAGCAGAAACC

381
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCTCTGGCATCCCAGACA

GGTTCAATGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAATAGGCTGGAGCCTGA

AGACTTTGCAGTGTATTACTGTCAGCAGTATGGTAACTCACAGACCTTCGGCCAAGGGACA

CGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC

382
CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCCCGGACGTTCGGCCAAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAATTGGTTTC

383
AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG

GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG

GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACATTGGCCTCGGACTTT

CGGCGGAGGGACCAAGCTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATTAGTAGGTGGTTGGCCTGGTATCAGCAGAAGCCAGGG

384
AAAGCCCCTAAGCTCCTGATCTATAAGGCGTCTACTATAAAAAGTGGGGTCCCATCAAGAT

TCAGCGCCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGA

TTTTGCAACTTATTACTGCCAACACTATAAAAGTGATTCCCGGACGTTCGGCCAAGGGACCA

AGGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCATCCTCCCTCGCTGCATCTGTTGGAGACAGAATTACCAT

ID
CACTTGCCGGCCAAGTCAGGACATAGGCACTTATTTAAATTGGTATCAACAGAAGGCAGGG

385
GAAGCCCCTAAGCTCCTCATCTATGCTGCCTCCAATCTGCACAGTGGCGTCTCATCAAGGTT

CAGAGGCGTTGGGTCTGGGACACAATTCACTCTCACCATCAGCAGTCTGCAACCTGAGGAT

TTTGCAACTTACTACTGTCATCAGAGTTACGGTCCTCGGACATTCGGCCAAGGGACCAAGCT

GGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG

386
CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCGATCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

387
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCAGGGTACACTTTTGGCCAGGGGA

CCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC

388
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG

AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCGTTCGGCCAAGGGACACGACTG

GAGATTAAACGT

SEQ
GAAATTGTGTTGACACAGTCTCCTTCCACCCTGTCTGCATCTGTAGGGGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGCTTGGCCTGGTATCAGCAGAAACCAGGG

389
AAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGCACCCTGCAGCCTGAAGAT

TTTGCAACTTATTACTGTCAACAGCTTAATAGTTACCCTCAGACGTTCGGCCAAGGGACCAA

AGTGGATATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT

ID
CTCCTGCAAGTCTAGTCAGAGCCTCCTGCATAGTGATGGAAAGACCTATTTGTATTGGTACC

390
TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGATCTATGAAGTTTCCAACCGGTTCTCTGGA

GTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTTCACACTGAAAATCAGCCGGG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAAGTATACAGCTTCCGCTCACTTTC

GGCGGAGGGACCAAGGTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

391
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATAATAACTGGCCTCTCACTTTCGGCGGAGGGA

CCAAGCTGGAGATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCCGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCACGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACATAGCTTGGT

392
ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC

CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC

AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATTATATTCCTCGGAC

GTTCGGCCAAGGGACCAAGGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC

393
TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCCCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTCGGACATTCGGC

CAAGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTCTTACCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

394
GGCCAGGCTCCCAGACTCCTCATCTATCGTGCATCCAGCAGGGCCACTGGCATCCCAGACC

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTTTATTACTGTCAGCAGTATGGTAGTTCACCTAACACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GAAATTGTGTTGACACAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGTACACAGTAATGGACACACCTACTTGAGTTGGTTTC

395
AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTCATTTATGAGGTTTCTAACCGGGACTCTGG

TGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTAAGAATCAGCAGG

GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCTTGCAAGGAACACACTGGCCCCCCCTCAC

TGTCGGCGGAGGGACCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTGGCAGCGACTTAGCCTGGTACCAGCAGAAACCTGGC

396
CAGGCTCCCAGGCTCCTCATCTACCGTGCATCCACCAGGGCCGCTGGTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGAT

TTTGCAGTGTTTTACTGTCAGCAGTATGGTAGATCACCGTACACTTCTGGCCAGGGGACCAA

GCTGGAGATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT

397
ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC

CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGC

AGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATATTATAGTACTCCGCTCAC

TTTCGGCGGAGGGACCAAGGTGGAGATCAAACGT

SEQ
GAAATTGTGATGACGCAGTCTCCACTCTCCCTGTCCGTCACCCCTGGAGAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAGAGCCTCCTACATAGTAGTGGATACAACTATTTGGATTGGTACC

398
TGCAGAAGCCAGGCCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTACTCGGGCCTCCGGG

GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG

TGGAGGCTGAGGATGTTGGGGTTTATTATTGCATGCAAGGTCTACAAATTCCGCTCACTTTC

GGCGGAGGGACCAAAGTGGATATCAAACGT

SEQ
GATATTGTGATGACCCACACTCCACTCTCTCTGTCCGTCACCCCTGGACAGCCGGCCTCCAT

ID
CTCCTGCAAGTCTAGTCAGAGCCTCCTGCATAGTGATGGAAAGACCTATTTGTATTGGTACC

399
TGCAGAAGCCAGGCCAGCCTCCACAGCTCCTGATCTATGAAGTTTCCAACCGGTTCTCTGGA

GTGCCAGATAGGTTCAGTGGCAGCGGGTCAGGGACAGATTTCACACTGAAAATCAGCCGGG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAAGTATACAGCTTCCGTGGACGTTC

GGCCAAGGGACCAAGGTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG

400
CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGCATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCGGTTCGGCCAAGGGACACGAC

TGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGGGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGACTATTAATAGTTGGTTGGCCTGGTATCAGCAGAAACCAGGG

401
AAGGCCCCTAAGCTCCTCATCTCTAGGGCGTCTCGTTTAGAAAGTGGGGTCCCATCAAGGTT

CAGCGGCAGTGCATCTGGCACAGAATACATTCTCACCATCAACAGCCTGCAGCCTGATGAT

TTTGCAATGTACTTCTGCCATCAATATAATAGTTATTCTCCCACTTTTGGCCAGGGGACCAA

GCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACC

402
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGCCA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGA

AGATTTTGCAGTTTATTACTGTCAGCAGCGTTACAACTGGCCTATCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCGGGGGAAACAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGACTATTGGTCCCAAGTCCTTCGGCTGGTACCAACAGAGACCTG

403
GCCAGGCTCCCAGGCTCCTCATCTATGACTCCAACAGGGCCACTGGCATCCCAGCCAGGTTC

AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT

TTGCAGTTTATTACTGTCAGCAGCGTAGCAGGTGGCCTCTCACTTTCGGCCCTGGGACCAAA

GTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGTGTACAGTGATGGAAACACCTACTTGTATTGGTTTC

404
AGCAGAGGGCAGGCCAATCTCCAAGGCGCCTGATTTATAAGGTTTCTAAGCGGGACTCTGG

GGTCCCAGACAGGTTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG

GTGGAGGCTGAGGATGTTGGAATTTATTACTGCGTGCAAGGTAGACACTGGCCGTACACTC

TTGGCCAGGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

405
GGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCA

GGTTCAGTGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGA

TGATTTTGCAACTTATTACTGCCAACAGTATAATAGTTATTCAAGGACGTTCGGCCAGGGGA

CCAAAGTGGATATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCTTCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATTACTACCTGGTTGGCCTGGTCTCAGCAGCAACCAGGG

406
AAAGCCCCTAAGCTCCTCATCTATAAGGCCTCTAGTTTAACAAGTGGGGTCCCATCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGAT

TTTGCAAGTTATTACTGCCATCATTATAATGGTGCTTCTCGTATGTTCGGCCAAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGG

407
CCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTTTCTTCGGCCAAGGGACACGAC

TGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGACTTTGTCTCCAGGGGAAAGAGTCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTATTGGCACTTACGTCGCCTGGTATCAGCAGAAACCTGGC

408
CAGGCTCCCAGATTCCTCATCTATGATTCATCGAATAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGTAGTGGGTCTGGGACAGACTTCACTCTCACGATCAGCAGCCTGGAGCCTGAAGAT

TTTGCATTTTATTACTGTCAACAGCGTGCCGAGTGGCCTCTCACCTTCGGCCAAGGGACACG

ACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACTCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAATAGCGGCTACTTAGCCTGGTACCAGCAGAAACCT

409
GGCCAACCTCCCAGACTCCTCATCTCTGGTGTTTCCACCAGGGCCACTGGCATCCCAGACAG

GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAA

GATTTTGCAGTGTATTACTGTCAGGAGTATGGTAACTCAGCTATGTACAATTTTGGCCAGGG

GACCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG

410
CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCCTTCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGGCTGGTATCAGCAGAAATCC

411
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGACATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAAACTGGAGGCAGA

AGATTCTGCAGTGTATTACTGTCAGCAGTATGGTATCTCACCTCTCGCGTTCGGCCAAGGGA

CCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAGAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTATTAGCAACAACTTAGCCTGGTACCAGCAGAAACCTGG

412
CCAGGCTCCCAGGCTCCTCATCTATGGTACATCCACCAGGGCCACTGGTATCCCAGCCAGGT

TCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGTATAATTTCTGGCCTTCGATCACCTTCGGCCAAGGGAC

ACGACTGGAGATTAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTCCTTAGCCTGGTACCAGCAGAAACC

413
TGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTG

AAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACAGACCTTCGGCCAAGGGAC

ACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCTCCCTTGGACAGCCGGCCTCCATC

ID
TCCTGCAGGTCTAATCAAAGCCTCGTATACAGTGATGGAGGCACCTACTTGAATTGGTTTCA

414
GCAGAGGGCAGGCCAGTCTCCAAGGCGCCTAGTTTATAAGGTTTCTAACCGGGACTCTGGG

GTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAGAATCAGCAGGG

TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGGACACACTGGCCGTACACTTTT

GGCCAGGGGACCAAGCTGGAGATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCGT

ID
CACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGG

415
AAAGCCCCTCAACTCCTGATCTACGATGCATCCAATTTGGAAACAGGGGTCCCCTCAAGGTT

CAGTGGAAGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATT

TTGCAACATATTACTGTCAGCAGTTTGATAATGTCCCAGTCACTTTCGGCGGAGGGACCAAG

GTGGAAATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAATTGGTTTC

416
AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTAATTTATAAGGTTTCTAACCGGGACTCTGG

GGTCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACACTGAAAATCAGCAGG

GTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGGTACACACTGGCCTCGAACGT

TCGGCCAAGGGACCAAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC

417
CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAACAGACTGGAGCCTGAAGAT

TTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCATCCATGTACACTTTTGGCCAGGGGAC

CAAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGGGACAGCGTCGCCAT

ID
CACTTGCCGGGCAAGTCAGAGCATTAGCAACTATTTAAATTGGTATCAGCAGAGACCAGGG

418
AAAGCCCCTAAGCTCCTGATCTTTGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTT

CAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATT

TTGCAACTTACTCCTGTCAACAGAGTTACATTACCCCGTGGACGTTCGGCCAAGGGACCAAG

CTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCACCCTCTTAGCCTGGTACCAACAGAAACCTGGC

419
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGGCAGGTT

CAGTGCCAGTGGGTCTGGGACAGACTTCAGTCTCACCATCAGCAGCCTAGAGACTGAAGAT

TCTGCAGTTTATTACTGTCAGCACCGTTACGTGTGGCCGTTCACTTTCGGCGGAGGGACCAA

GCTGGAGATCAAACGT

SEQ
GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGG

420
AAAGCCCCTAAGCGTCTGATCTATGGTGCATCCAGTTTGCAAAGTGGAGTCCCATCAAGGTT

CAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCAGGAGCCTGCAGCCTGAAGAT

TTTGCAACTTATTATTGTCTACAGCATAATTCCTACCCTCGAACATTCGGCCAAGGGACCAA

GGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC

421
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCGTGGACGTTCGGCCAAGGGACCA

AGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCGCTCTCCCTGCCCGTCACCCTTGGACAGGCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCATAGCCTCACAACTACTGATGGACGTACTTACGTGGCTTGGTTTC

422
AGCAGAGGCCAGGCCAATCTCCAAGGCGCCTTCTTTATGAGGTTTCTAAGCGGGACTCTGG

GGCCCCAGACAGATTCAGCGGCAGTGGGTCAGGCACTGATTTCACTCTGAAAATCAGCAGG

GTGGAGGCTGACGATGTTGGAATTTATCATTGCATGCAAGGAACACATGGGCCTCACACGT

TCGGCCAAGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAAAGTGTTACCAGCAACTTAGCCTGGTACCAGCAGAAACCTGG

423
CCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAACAGGGCCACTGGTATCCCAGCCAGGT

TCAGTGTCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGA

TTTTGCAGTGTATTACTGTCAGCAGTATGGTAGTCCACCTCCGACCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCT

424
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACGTCGGACGTTCGGCCAAGGGA

CCAAGCTGGAGATCAAACGT

SEQ
GAAACGACACTCACGCAGTCTCCAGGCACCCTGTCCTTGTCTCCAGGGGAAAGAGCCACCC

ID
TCTCCTGCAGGGCCAGTCAGAGTGTTTTCAACAACTACTTAGCCTGGTACCAACAGAGACCT

425
GGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCGGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTCGCAGTGTATTGCTGTCAGCAGTATGGTAGTTCACCGATCACCTTCGGCCAAGGGA

CACGACTGGAGATTAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC

426
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGAT

TTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACTCAGGTACACTTTTGGCCAGGGGAC

CAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT

ID
CAACTGCAAGTCCAGCCAGAGTGTTTTATATGATTCCAACAGTAAGAACTACTTAAGTTGGT

427
ATCAGCAGAAACCAGGCCAGCCTCCTAAGTTGCTCATTTCCTGGGCGTCTACCCGGGGGTCC

GGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCA

GCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAATTTTATGGTATTCCCCACTTC

GGCCAAGGGACACGACTGGAGATTAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTGGTACCAATTTAGCCTGGTACCAGCAGAAACCTGGC

428
CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCAGTATAATAACTGGCCTCCGATAACTTTCGGCGGAGGGAC

CAAGCTGGAGATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCTTGGACAGCCGGCCTCCAT

ID
CTCCTGCAGGTCTAGTCAAAGCCTCGTATACAGTGATGGAAACACCTACTTGAGTTGGCTTC

429
AGCAGAGGCCAGGCCAGCCTCCAAGACTCCTAATTTATAAGATTTCTAACCGGTTCTCTGGG

GTCCCAGACAGATTCAGTGGCAGTGGGGCAGGGACAGATTTCACACTGAAAATCAGCAGGG

TGGAAGCTGAGGATGTCGGGGTTTATTACTGCATGCAAGGTACACAATTTCCTCAAACGTTC

GGCCAAGGGACCAAGCTGGAGATCAAACGT

SEQ
GAAATTGTGCTGACTCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTAATAAGCAGGTACTTAGCCTGGTATCAGCAGAAACCT

430
GGCCAGGCTCCCAGGCTCCTCATCCATGGTGCATCCACCAGGGCCACTGGCATCCCAGACA

GGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGACTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCCGTACACTTTTGGCCAGG

GGACCAAGGTGGAAATCAAACGT

SEQ
GACATCCAGTTGACCCAGTCTCCTTCCACCCTGGCTGCATCTGTAGGAGACAGAGTCACCAT

ID
CACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGG

431
AAAGCCCCTAAGGTCCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCAAGGT

TCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGA

TTTTGCAACTTATTACTGCCAACAGTATAATAGTTATTCGGGGACGTTCGGCCAAGGGACCA

AGGTGGAAATCAAACGT

SEQ
GATGTTGTGATGACTCAGTCTCCAGCCATCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT

ID
CTCCTGCAGGGCCAGTCAGAGTGTTAGTAGCAGCTTAGCCTGGTACCAGCAGAAACCTGGC

432
CAGCCTCCCAGGCTCCTCATCTATGGTGCCTCCACCAGGGCCACTGCTATCCCAGCCAGGTT

CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGAT

TTTGCAGTTTATTACTGTCAGCGCTATGATAACTGGCCTCCCCTTTTTGGCCAGGGGACCAA

GCTGGAGATCAAACGT

Exemplary CDR amino acid sequences of CLEC2D antibodies of the disclosure are shown in Table 6 below.

TABLE 6

CDR Amino Acid Sequences

VH
VL

SEQ

SEQ

SEQ

SEQ

SEQ

SEQ

ID
CDRH1
ID
CDRH2
ID
CDRH3
ID
CDRL1
ID
CDRL2
ID
CDRL3

SEQ
GYTFT
SEQ
WINAGNG
SEQ
GSLSRSGWY
SEQ
ASQSIGS
SEQ
SAT
SEQ
YGSS

ID
SYAM
ID
NTKYSQKF
ID
AGLFDY
ID
NLVW
ID
SRA
ID
PPTT

433
H
486
QG
547

654

727
TG
784
F

SEQ
GFTFS
SEQ
IISDDGSKS
SEQ
DRGTKWNQ
SEQ
ASQSVSS
SEQ
GAS
SEQ
YGSS

ID
SYSMN
ID
YYADSVQ
ID
LNDVFDM
ID
SYLAW
ID
NRA
ID
PGTF

434

487
G
548

655

728
TG
785

SEQ
GYTFT
SEQ
IINPSGGST
SEQ
GRGYSSSRL
SEQ
ASQSVSS
SEQ
DAS
SEQ
RSN

ID
SYYM
ID
SYAQKFQ
ID
YYFDY
ID
YLAW
ID
NRA
ID
WPRT

435
H
488
G
549

656

729
TG
786
F

SEQ
GFTFS
SEQ
RITNKRTG
SEQ
DVSGSFAAY
SEQ
SSRNILYS
SEQ
WAS
SEQ
SSSLP

ID
DPYM
ID
YATTYAA
ID

ID
GNNKNFL
ID
TRE
ID
HTF

436
D
489
SVKD
550

657
AW
730
SG
787

SEQ
GFTFS
SEQ
WINAGNG
SEQ
EGGAVAGTV
SEQ
ASESVSK
SEQ
GAS
SEQ
YGSS

ID
SYAM
ID
NTKYSQKF
ID
Y
ID
SYLLW
ID
TRA
ID
RTF

437
H
490
QG
551

658

731
SG
788

SEQ
GFTFS
SEQ
RIKSKTDG
SEQ
DEYFY
SEQ
ASQSISST
SEQ
GAS
SEQ
YGNS

ID
NAWM
ID
GTTDYAA
ID

ID
YLAW
ID
TRA
ID
PPGA

438
S
491
PVKG
552

659

732
TG
789
TF

SEQ
GGSFS
SEQ
EINHSGST
SEQ
VNPGSYTRE
SEQ
SSQALRN
SEQ
STS
SEQ
HHDF

ID
GYYW
ID
NYNPSLKS
ID
VSNFDY
ID
VVGLGD
ID
TLQ
ID
PFTF

439
S
492

553

660
DLAW
733
SG
790

SEQ
GDSVS
SEQ
RTYYRSQ
SEQ
RGHNYGVD
SEQ
SSQSLLN
SEQ
LGS
SEQ
SLQT

ID
SNSVT
ID
WYYNYAV
ID
Y
ID
SNGYNYL
ID
NRA
ID
PLTF

440
WN
493
SVKS
554

661
EW
734
SG
791

SEQ
GYTFA
SEQ
RIKSKTDG
SEQ
GVGWSPFQY
SEQ
ASQSVSS
SEQ
GAS
SEQ
YGSS

ID
AYYL
ID
ETTDYAAP
ID

ID
NLAW
ID
SRA
ID
PRITF

441
H
494
VKG
555

662

735
TG
792

SEQ
GFTFS
SEQ
FIRSKAYG
SEQ
DDKIAAAGF
SEQ
ASQSVRD
SEQ
AAS
SEQ
YNN

ID
SHLM
ID
GTTEYAAS
ID
TYWYFDL
ID
NVGW
ID
SM
ID
WPP

442
H
495
VKG
556

663

736
TG
793
MYTF

SEQ
GGSISS
SEQ
RISPGNGV
SEQ
EAADDPFDH
SEQ
ASQSISSY
SEQ
DVS
SEQ
FNN

ID
GGYS
ID
TSYAQKFQ
ID

ID
LNW
ID
TRA
ID
WPYT

443
WS
496
G
557

664

737
TD
794
F

SEQ
GDSVS
SEQ
VISYDGTS
SEQ
ADYKYD
SEQ
ASQSVNS
SEQ
DAS
SEQ
SYSIP

ID
NNRA
ID
KYYGDSV
ID

ID
NVAW
ID
SRA
ID
RTF

444
AWN
497
KG
558

665

738
TG
795

SEQ
GYTFT
SEQ
YIYHSGST
SEQ
HRRPIYDILT
SEQ
ASQSVSS
SEQ
DSS
SEQ
CASS

ID
SYGIS
ID
YYNPSLKS
ID
GFDY
ID
SALAW
ID
SRA
ID
PPVT

445

498

559

666

739
TG
796
F

SEQ
GYSFT
SEQ
YISSSGSYT
SEQ
EDTMVRGVI
SEQ
SSQSLLH
SEQ
MGS
SEQ
YGSS

ID
SWIG
ID
NYADSVK
ID
P
ID
SNGYNYL
ID
SRA
ID
PRVT

446

499
G
560

667
DW
740
SG
797
F

SEQ
GYSFT
SEQ
WISAYNG
SEQ
DRRYYDSSG
SEQ
ASQGISSS
SEQ
AAS
SEQ
FNTY

ID
SYWIA
ID
NTNYAQK
ID
YYPAYYFDY
ID
LAW
ID
TLQ
ID
PNTF

447

500
LQG
561

668

741

798

SEQ
GFTFT
SEQ
IIYPGDSDT
SEQ
DGGYDSSGF
SEQ
SCQSLVY
SEQ
KVS
SEQ
TLHT

ID
DAWM
ID
RYSPSFQG
ID
HFDY
ID
SDGNTYL
ID
NRD
ID
VTF

448
N
501

562

669
NC
742
SG
799

SEQ
GFTFS
SEQ
WIIPIFGIA
SEQ
LPSSGYLQD
SEQ
ASEGLTT
SEQ
LGS
SEQ
YGSS

ID
NNWM
ID
NYAQKFQ
ID
HHYYGMDV
ID
NLAW
ID
TRA
ID
LLF

449
T
502
G
563

670

743
SG
800

SEQ
GFTFS
SEQ
VIYPGDSD
SEQ
AAVGDGYSY
SEQ
SSQSLEH
SEQ
AAS
SEQ
YDNL

ID
SYGM
ID
TRYSPSFQ
ID
GRLD
ID
TDGNTYL
ID
TRA
ID
PPLT

450
H
503
G
564

671
SW
744
TG
801
F

SEQ
GFTFD
SEQ
RVKNKAD
SEQ
LPSYYYDSS
SEQ
ASQSISGS
SEQ
KVS
SEQ
ALQT

ID
DYAM
ID
GETTDYA
ID
GYFTWYFDL
ID
YLAW
ID
TRF
ID
PYTF

451
H
504
APVKG
565

672

745
SG
802

SEQ
GFTFS
SEQ
NIKQDGTE
SEQ
ELYNYGSKD
SEQ
SSQSLLH
SEQ
DAS
SEQ
GLQT

ID
NYVM
ID
KHYVDSV
ID
YFDY
ID
SNGNNYL
ID
SRA
ID
PFTF

452
S
505
KG
566

673
DW
746
FG
803

SEQ
GFTFS
SEQ
VISYDGSN
SEQ
GGTWDTAM
SEQ
ASQNIRH
SEQ
AAS
SEQ
YGSS

ID
SYAMS
ID
KYYADSV
ID
VTGFDY
ID
WLVW
ID
NLQ
ID
PALT

453

506
KG
567

674

747
SG
804
F

SEQ
GYTFT
SEQ
AISGSGGS
SEQ
PHYDILTGSR
SEQ
ASQSIGG
SEQ
YAS
SEQ
ALHT

ID
SYDIN
ID
TYYADSV
ID
APFDY
ID
SLHW
ID
QSF
ID
PWTF

454

507
KG
568

675

748
SG
805

SEQ
GYTFT
SEQ
YISSTSSTI
SEQ
ARVESKDGY
SEQ
ASQSVTS
SEQ
GAS
SEQ
YNH

ID
DYAIH
ID
YYADSVK
ID
FDY
ID
NYLAW
ID
YRA
ID
WNY

455

508
G
569

676

749
TG
806
TF

SEQ
GFTVS
SEQ
AISGIGDTT
SEQ
DLRLSTWDA
SEQ
ASQSISSN
SEQ
WAS
SEQ
GSN

ID
SNYMS
ID
YYADSVK
ID
YDF
ID
LAW
ID
ARE
ID
WPLT

456

509
G
570

677

750
SG
807
F

SEQ
GGTFS
SEQ
WMNPNSG
SEQ
NSQRSFDY
SEQ
SSQSVLY
SEQ
TAS
SEQ
ATHY

ID
SYAIS
ID
NTGYAQK
ID

ID
SSNNKNY
ID
KRA
ID
PRTF

457

510
FQG
571

678
LAW
751
TG
808

SEQ
GFTFS
SEQ
WINAGDG
SEQ
DLGDPRGGIL
SEQ
ASQSLST
SEQ
ASS
SEQ
YGSS

ID
SYAIS
ID
GTKSSREF
ID
NY
ID
NLAW
ID
TLQ
ID
PIFTF

458

511
QG
572

679

752
SG
809

SEQ
GFTFS
SEQ
VIYSGGST
SEQ
SSPWGELSL
SEQ
ASQSISS
SEQ
WAS
SEQ
GLQI

ID
SYAIH
ID
YYADSVK
ID
YQGAFDI
ID
WLAW
ID
TRD
ID
PITF

459

512
G
573

680

753
SG
810

SEQ
GYTFT
SEQ
GIIPIFGTA
SEQ
DNDFWSGKV
SEQ
ASHSVGA
SEQ
DAS
SEQ
HNSY

ID
SSDIN
ID
NYAQKFQ
ID
FDY
ID
NYIAW
ID
TRA
ID
PWTF

460

513
G
574

681

754
TG
811

SEQ
GDSVS
SEQ
GIIPMYGT
SEQ
EGGSGWRHY
SEQ
ASQGIAN
SEQ
GAS
SEQ
SISLP

ID
SNSAA
ID
ANYAQKF
ID
FDY
ID
YLAW
ID
SLQ
ID
LTF

461
WN
514
QG
575

682

755
SG
812

SEQ
GDSVS
SEQ
WMNPNSG
SEQ
DYCSSTSCQ
SEQ
SSQSVLY
SEQ
KAS
SEQ
YASS

ID
SNNAA
ID
NTGYAEK
ID
NWFDP
ID
RTNNKN
ID
TLA
ID
VTF

462
WN
515
FQG
576

683
YLAW
756
NG
813

SEQ
GFSLS
SEQ
RTYYRSK
SEQ
GRVAGDAFD
SEQ
SNRSVLY
SEQ
GAS
SEQ
YNN

ID
TSGVG
ID
WYNDYAV
ID
I
ID
SPNNQNY
ID
SRA
ID
WPRT

463
VG
516
SVKS
577

684
LGW
757
AG
814
F

SEQ
GGSISS
SEQ
RTFYRSK
SEQ
DQGAAAGTL
SEQ
ASESVNS
SEQ
KVS
SEQ
FYSP

ID
YYWS
ID
WYNDYAV
ID
GYFDY
ID
NFLAW
ID
NRL
ID
PRTF

464

517
SVKS
578

685

758
SG
815

SEQ
GFTFS
SEQ
LIYWDDD
SEQ
GIYDSSGSSN
SEQ
ASQSIGS
SEQ
GAS
SEQ
YGSS

ID
SSAMH
ID
KRYSPSLK
ID
PFDS
ID
NLAW
ID
RRA
ID
PPGT

465

518
S
579

686

759
TG
816
P

SEQ
GDSVS
SEQ
YIYYTGST
SEQ
GYCSGGSCP
SEQ
ASQSVGN
SEQ
EVS
SEQ
YHN

ID
SDSAV
ID
NYNPSLKS
ID
GTDFDY
ID
SLAW
ID
NRF
ID
WPPY

466
WT
519

580

687

760
SG
817
IF

SEQ
GFTFS
SEQ
MIWHDES
SEQ
DGVGGRDG
SEQ
ASQSITN
SEQ
AAS
SEQ
YNSY

ID
TYPM
ID
KKYYADS
ID
YNFDY
ID
WLAW
ID
YRA
ID
WTF

467
H
520
VKG
581

688

761
IG
818

SEQ
GFTFA
SEQ
RTYYKSK
SEQ
APLAADGYF
SEQ
ARQSISN
SEQ
GAS
SEQ
YAA

ID
AYNIN
ID
WYNDYAA
ID
DY
ID
RLAW
ID
SRA
ID
APITF

468

521
SVKS
582

689

762
SG
819

SEQ
GFTFS
SEQ
VISYDGRN
SEQ
ARGLQYLIW
SEQ
ASQNVYS
SEQ
KAS
SEQ
YNSV

ID
SYGM
ID
EYYADSV
ID
YFDL
ID
NFLAW
ID
TIKS
ID
PLTF

469
T
522
KG
583

690

763
G
820

SEQ
GYTFT
SEQ
FISYDGSN
SEQ
PGMVRGVIT
SEQ
SSQSLEH
SEQ
AAS
SEQ
YYNL

ID
GYYM
ID
KYYADSV
ID
APLDY
ID
GDGNTY
ID
NLH
ID
PRSF

470
H
523
KG
584

691
LSW
764
SG
821

SEQ
GYTLT
SEQ
FIRANADS
SEQ
EAKWGMYY
SEQ
ASQSVSS
SEQ
LGS
SEQ
YAST

ID
ELSMH
ID
GTTEYAAS
ID
FDY
ID
TSLAW
ID
NRA
ID
PYTF

471

524
VKG
585

692

765
PG
822

SEQ
GFTFS
SEQ
TISGNGVG
SEQ
GGGASYTDS
SEQ
ASQSVGS
SEQ
RAS
SEQ
YNN

ID
DQYM
ID
TYYPDSVK
ID

ID
KLAW
ID
SRA
ID
WFLT

472
D
525
D
586

693

766
IG
823
P

SEQ
GFTFG
SEQ
WINPNSGG
SEQ
KGGYVGYSY
SEQ
SSQSLLG
SEQ
EVS
SEQ
RSN

ID
DYAM
ID
TNYAQKF
ID
GPFGGY
ID
GDGKTY
ID
NRD
ID
WSLT

473
S
526
QG
587

694
LYW
767
SG
824
P

SEQ
GFNFS
SEQ
GFDPEDGE
SEQ
GGTMVRGFG
SEQ
ASQSVSS
SEQ
RAS
SEQ
YGPS

ID
GYEM
ID
TIYAQKFQ
ID
FNY
ID
NSLAW
ID
TRA
ID
RRITF

474
N
527
G
588

695

768
AG
825

SEQ
RFTFS
SEQ
RVRNKAN
SEQ
ARRAMIGPL
SEQ
SSQSLVY
SEQ
RAS
SEQ
HGE

ID
DAWM
ID
SYTTEYAA
ID
PRLVGYFDL
ID
SDGNTYL
ID
RLE
ID
WPTF

475
S
528
SVKG
589

696
NW
769
SG
826

SEQ
GFTFS
SEQ
AISSNGGS
SEQ
GRPAPSWVK
SEQ
ASQSISR
SEQ
DSN
SEQ
RGT

ID
TYGM
ID
TYYADSV
ID
TRNWFDP
ID
WLAW
ID
RAT
ID
WPPL

476
H
529
KG
590

697

770
G
827
IF

SEQ
GISFR
SEQ
YVSTSGST
SEQ
EASSGWN
SEQ
PSQDIGT
SEQ
KVS
SEQ
YTNY

ID
DYWM
ID
RYYADSV
ID

ID
YLNW
ID
KRD
ID
PRTF

477
H
530
KG
591

698

771
SG
828

SEQ
GDSVS
SEQ
GISGSGGS
SEQ
GGRYTKGGY
SEQ
ASQSISSC
SEQ
KAS
SEQ
YQSY

ID
SKSAA
ID
TYYADSV
ID
FDD
ID
LAW
ID
SLT
ID
WTF

478
WN
531
KG
592

699

772
SG
829

SEQ
GDSVS
SEQ
RIKSKISGG
SEQ
RLDSSGRGG
SEQ
SSQSLLH
SEQ
DSS
SEQ
YNSP

ID
SGSAA
ID
TTDYAAP
ID
YFDY
ID
SDGKTYL
ID
NRA
ID
PRTF

479
WN
532
VQG
593

700
YW
773
TG
830

SEQ
EFTLR
SEQ
RTYYRSK
SEQ
ELVGTSSPYY
SEQ
SSQSVLY
SEQ
GVS
SEQ
YGTS

ID
NYGVS
ID
WYNDYAV
ID
YYYYGMDV
ID
SSNNKNY
ID
TRA
ID
PITF

480

533
SLKS
594

701
IAW
774
TG
831

SEQ
GGSVS
SEQ
LISYDGSK
SEQ
DYYYGSGSS
SEQ
ASQSLTS
SEQ
GAS
SEQ
GIYW

ID
GYYW
ID
KYYANSV
ID
P
ID
SYLAW
ID
SRA
ID
PRTF

481
S
534
KG
595

702

775
TD
832

SEQ
GDSVS
SEQ
WINAGNG
SEQ
GRPYCSSTSC
SEQ
SSQSLVH
SEQ
GTS
SEQ
YGSS

ID
SNTAT
ID
NTKYSEKF
ID
YPEWFDP
ID
SNGHTYL
ID
TRA
ID
PPITF

482
WN
535
EG
596

703
SW
776
TG
833

SEQ
GDSVS
SEQ
RINPDGSS
SEQ
LRGIDYYDSS
SEQ
ASQSVGS
SEQ
DAS
SEQ
YNN

ID
GNSAA
ID
TSYADSVK
ID
GYQRGFDY
ID
DLAW
ID
NLE
ID
WPPI

483
WN
536
G
597

704

777
TG
834
TF

SEQ
GYTFT
SEQ
RTYYRSK
SEQ
GGRGDGAAF
SEQ
SSQSLLH
SEQ
AAS
SEQ
TLQT

ID
SYAIS
ID
WNNDYAL
ID
DI
ID
SSGYNYL
ID
SLQ
ID
PLTF

484

537
SVKS
598

705
DW
778
SG
835

SEQ
GFIFSN
SEQ
RTYYRAK
SEQ
PPDGGNSGR
SEQ
ASQTINS
SEQ
EVS
SEQ
YYSS

ID
YAIH
ID
WYNEYAG
ID
WYFDL
ID
WLAW
ID
KRD
ID
TPYT

485

538
SVKS
599

706

779
SG
836
F

SEQ
GMSGSGY
SEQ
DKNVRKHD
SEQ
ASQTIGP
SEQ
WAS
SEQ
STQF

ID
STYYADSV
ID
YGDHPYGGY
ID
KSFGW
ID
TRG
ID
PWTF

539
KG
600
FDY
707

780
SG
837

SEQ
EIHHSGST
SEQ
VAGATSLWY
SEQ
SSQSLVY
SEQ
KIS
SEQ
YNN

ID
NYNPSLKS
ID

ID
SDGNTYL
ID
NRF
ID
WPHT

540

601

708
YW
781
SG
838
F

SEQ
RTYYRSK
SEQ
LANSDGVDV
SEQ
ASQSITT
SEQ
KAS
SEQ
YGNS

ID
WYKDNAL
ID

ID
WLAW
ID
SLE
ID
QTF

541
SVKS
602

709

782
SG
839

SEQ
LIYSDGRT
SEQ
GVTRTFDY
SEQ
ASQSIGT
SEQ
GAS
SEQ
GTH

ID
NYADSVK
ID

ID
YVAW
ID
TRA
ID
WPRT

542
G
603

710

783
TA
840
F

SEQ
AISSNGGS
SEQ
GNGPFDP
SEQ
ASQSVNS

SEQ
YKSD

ID
TYYANSV
ID

ID
GYLAW

ID
SRTF

543
KG
604

711

841

SEQ
WISAYDG
SEQ
RDTPLVGVSI
SEQ
ASQSVSS

SEQ
SYGP

ID
NTNYAQK
ID
Y
ID
SYLGW

ID
RTF

544
LQG
605

712

842

SEQ
YISSSGTTI
SEQ
RAGYGDYRH
SEQ
ASQSISN

SEQ
YGSS

ID
YYADSVK
ID
FQH
ID
NLAW

ID
GYTF

545
G
606

713

843

SEQ
VIWYDGS
SEQ
TGDRFQEFD
SEQ
ASQSVSS

SEQ
YGSS

ID
NKYYADS
ID
Y
ID
SSLAW

ID
P

546
VKG
607

714

844

SEQ
DDRGRGDDF
SEQ
SNQSLVY

SEQ
LNSY

ID
DY
ID
SDGGTYL

ID
PQTF

608

715
NW

845

SEQ
HGRAGINWY
SEQ
ASQSISN

SEQ
SIQLP

ID
FDL
ID
YLNW

ID
LTF

609

716

846

SEQ
GGGLWAFDI
SEQ
ASQSVST

SEQ
YYYI

ID

ID
LLAW

ID
PRTF

610

717

847

SEQ
DKIGSCPY
SEQ
ASQGIRN

SEQ
ALQT

ID

ID
DLGW

ID
RTF

611

718

848

SEQ
RPDSSSQCFD
SEQ
SSHSLTT

SEQ
YGSS

ID
Y
ID
TDGRTYV

ID
PNTF

612

719
AW

849

SEQ
SSGWSLPED
SEQ
ASQSVTS

SEQ
GTH

ID
Y
ID
NLAW

ID
WPPL

613

720

850
TV

SEQ
DVNPELLGA
SEQ
ASQSVFN

SEQ
YGRS

ID
GFDY
ID
NYLAW

ID
PYTS

614

721

851

SEQ
SLNSGGYRC
SEQ
SSQSVLY

SEQ
YYST

ID
FHH
ID
DSNSKNY

ID
PLTF

615

722
LSW

852

SEQ
APRGVVPAA
SEQ
ASQSVGT

SEQ
GLQI

ID
MRGGY
ID
NLAW

ID
PLTF

616

723

853

SEQ
LVGNSGSYY
SEQ
SSQSLVY

SEQ
SIQLP

ID
PFGY
ID
SDGNTYL

ID
WTF

617

724
SW

854

SEQ
GRSLPYRGL
SEQ
ASQSVIS

SEQ
YNN

ID
APRSFGGYY
ID
RYLAW

ID
WPRF

618
FDY
725

855

SEQ
GRTHWGPQD
SEQ
ASQSVSS

SEQ
YNSY

ID
FDY
ID
SLAW

ID
SPTF

619

726

856

SEQ
GGMYYYGS

SEQ
RYN

ID
GSSYFDY

ID
WPIT

620

857
F

SEQ
KIAAAGKQP

SEQ
RSRW

ID
VDY

ID
PLTF

621

858

SEQ
RKVYDYVW

SEQ
GRH

ID
GSYRLPGSVS

ID
WPYT

622
YYFDY

859
L

SEQ
LPGRAARPD

SEQ
YNSY

ID
Y

ID
SRTF

623

860

SEQ
GPGAVAGTK

SEQ
YNG

ID
PKYYFDY

ID
ASRM

624

861
F

SEQ
ATYYYDSSG

SEQ
RSN

ID
YRFDY

ID
WPFF

625

862

SEQ
RNLGY

SEQ
RAE

ID

ID
WPLT

626

863
F

SEQ
ARYYDSSGY

SEQ
YGNS

ID
IAPSGYFDY

ID
AMY

627

864
NF

SEQ
DGPAVDGAE

SEQ
YNN

ID
YFQH

ID
WPPF

628

865
TF

SEQ
LASGSPPPGD

SEQ
YGIS

ID
Y

ID
PLAF

629

866

SEQ
GPIVGATMD

SEQ
YNF

ID
Y

ID
WPSI

630

867
TF

SEQ
WYGDYGLD

SEQ
YGSS

ID
Y

ID
QTF

631

868

SEQ
VAKYYYESG

SEQ
GTH

ID
GYRASNWFD

ID
WPYT

632
P

869
F

SEQ
APPPTVGWY

SEQ
FDNV

ID
APVFDY

ID
PVTF

633

870

SEQ
VTGRRVGAH

SEQ
YGSS

ID
DY

ID
SMYT

634

871
F

SEQ
AQPGAETLN

SEQ
SYITP

ID
FDL

ID
WTP

635

872

SEQ
QVAGGMDV

SEQ
RYV

ID

ID
WPFT

636

873
F

SEQ
GSVYSGSYY

SEQ
HNSY

ID
MLIDY

ID
PRTF

637

874

SEQ
QDKDNTRYS

SEQ
RSN

ID
GLGV

ID
WPW

638

875
TF

SEQ
GPRMWSSGI

SEQ
GTHG

ID
DAFDI

ID
PHTF

639

876

SEQ
RDWAGKRV

SEQ
YGSP

ID

ID
PPTT

640

877
F

SEQ
GRAGIAAFDI

SEQ
YGSS

ID

ID
RRTF

641

878

SEQ
GALQGEWRR

SEQ
YGSS

ID
FDY

ID
PITF

642

879

SEQ
TNQGYGGNS

SEQ
YGSS

ID
GVFDY

ID
LRYT

643

880
F

SEQ
IVGGAVDC

SEQ
FYGI

ID

ID
PHF

644

881

SEQ
VRVGATTVY

SEQ
GTQF

ID
DSWFDP

ID
PQTF

645

882

SEQ
DGGSSPYYD

SEQ
YGSS

ID
SSGLLPWYF

ID
PPYT

646
DL

883
F

SEQ
AKFWTYYFD

SEQ
YNSY

ID
Y

ID
SGTF

647

884

SEQ
GGGSGSYYK

SEQ
YDN

ID
RFFDY

ID
WPPL

648

885
F

SEQ
DGTVRRVVG

ID
ATTPGNFDY

649

SEQ
DLNRGYCSG

ID
GSCFGY

650

SEQ
DYSSSGECFD

ID
Y

651

SEQ
DQAAMVGY

ID
FDY

652

SEQ
TFAGYSSKL

ID
GYFDL

653

TABLE 7

Heavy Chain CDR DNA Sequences

SEQ ID
CDRH1 DNA Seq
SEQ ID
CDRH2 DNA Seq
SEQ ID
CDRH3 DNA Seq

SEQ ID 1004
GGGGACAGTGTCTCTAG
SEQ ID
AGGACATACTACAGGTCCAAG
SEQ ID
GCCCGGCGGGCTATGATAGGGCCGC

CAACACTGCTACTTGGA
1062
TGGTATAAGGATAATGCACTGT
1127
TTCCGCGACTTGTCGGGTACTTCGA

AC

CTGTGAAAAGT

TCTC

SEQ ID 1005
GGATTCACCTTCAGTTCC
SEQ ID
GTTATATCATATGATGGAACTA
SEQ ID
GGCCGCCCCGCCCCATCCTGGGTTA

CATCTTATGCAC
1063
GTAAATATTACGGAGACTCCGT
1128
AAACCCGTAACTGGTTCGACCCC

GAAGGGC

SEQ ID 1006
GGGGACAGTGTCTCTAG
SEQ ID
AGGACATATTATAGGGCCAAG
SEQ ID
GGAGGAATGTATTACTATGGTTCGG

CGGCAGTGCTGCTTGGA
1064
TGGTATAATGAATATGCAGGG
1129
GGAGCTCGTACTTTGACTAC

AC

TCTGTGAAAAGC

SEQ ID 1007
GGTTACACCTTTACCAGC
SEQ ID
TGGATCAGCGCTTACAATGGTA
SEQ ID
AGGAAGGTGTATGATTACGTTTGGG

TACGGTATCAGC
1065
ACACAAACTATGCACAGAAGC
1130
GGAGTTATCGCCTCCCCGGGTCGGT

TCCAGGGC

ATCGTACTACTTTGACTAC

SEQ ID 1008
GGATTCACCTTCAGTAG
SEQ ID
CTCATTTATTGGGATGATGATA
SEQ ID
AAGGGGGGCTACGTCGGATACAGCT

CTATGCTATACAC
1066
AGCGCTACAGCCCATCTCTGAA
1131
ATGGACCTTTTGGGGGCTAC

GAGC

SEQ ID 1009
GGGTTCTCACTCAGCACT
SEQ ID
TGGATGAACCCTAACAGTGGT
SEQ ID
GGTCGGGCTGGTATTGCCGCTTTTG

AGTGGAGTGGGTGTGGG
1067
AACACCGGCTATGCAGAGAAG
1132
ATATC

C

TTCCAGGGC

SEQ ID 1010
GGATACACCTTCACCAG
SEQ ID
GTTATATCATATGATGGAAGTA
SEQ ID
GCAGATTATAAATATGACT

TTCTGATATCAAC
1068
ATAAATACTACGCAGACTCCGT
1133

GAAGGGC

SEQ ID 1011
GGATTCACCTTCAGTAG
SEQ ID
ACTATTAGTGGTAATGGTGTTG
SEQ ID
AGCAGTGGCTGGTCACTGCCTGAAG

CTATGCTATGCAC
1069
GCACATACTACCCAGACTCCGT
1134
ACTAC

GAAGGAC

SEQ ID 1012
GGATTCACCTTTAGCAG
SEQ ID
GTTATATGGTATGATGGAAGTA
SEQ ID
CAAGACAAAGACAACACGAGATAT

CTATGGCATGACG
1070
ATAAATACTATGCAGACTCCGT
1135
TCCGGTTTGGGCGTC

GAAGGGC

SEQ ID 1013
GGATACACCTTCGCCGC
SEQ ID
CGGATCAGCCCTGGTAACGGT
SEQ ID
GCCGCGGTGGGGGATGGATACAGCT

CTATTATTTACAC
1071
GTCACAAGTTATGCACAGAAA
1136
ATGGTCGGCTCGATT

TTTCAGGGC

SEQ ID 1014
GGATACACCTTCACCGG
SEQ ID
TGGATCAACCCTAACAGTGGT
SEQ ID
GATCAGGCAGCTATGGTAGGCTACT

CTACTATATGCAC
1072
GGCACAAACTATGCACAGAAG
1137
TTGACTAC

TTTCAGGGC

SEQ ID 1015
GGATACACCTTCACCAG
SEQ ID
TGGATGAACCCTAACAGTGGT
SEQ ID
GGCCGGCCATATTGTAGTAGTACCA

TTATGATATCAAC
1073
AACACAGGCTATGCACAGAAG
1138
GCTGCTACCCAGAGTGGTTCGACCC

TTCCAGGGC

C

SEQ ID 1016
GGATTCATCTTCAGTAAC
SEQ ID
CGTGTTAAAAACAAAGCTGAT
SEQ ID
AGATTGGATAGCAGTGGCCGTGGTG

TATGCTATACAC
1074
GGTGAGACAACGGACTACGCT
1139
GTTACTTTGACTAC

GCACCCGTCAAAGGC

SEQ ID 1017
GGATTCACTTTCACTGAT
SEQ ID
GCTATTAGTGGTAGTGGTGGTA
SEQ ID
GACAAGAACGTCCGAAAACATGAC

GCCTGGATGAAC
1075
GCACATACTATGCAGACTCCGT
1140
TACGGTGACCACCCCTACGGGGGGT

GAAGGGC

ACTTTGACTAC

SEQ ID 1018
GGTGGGTCCGTCAGTGG
SEQ ID
GAAATCCATCATAGTGGAAGC
SEQ ID
GAGTTGGTGGGTACCAGCTCTCCTT

TTACTACTGGAGC
1076
ACCAACTACAACCCGTCCCTCA
1141
ATTACTACTACTACTACGGTATGGA

AGAGT

CGTC

SEQ ID 1019
GGATTCAACTTCAGTGG
SEQ ID
TACGTCAGTACTAGTGGTAGTA
SEQ ID
GGTGGGGGTGCGAGCTATACTGACT

ATATGAAATGAAC
1077
CCAGATACTACGCAGACTCTGT
1142
CC

GAAGGGC

SEQ ID 1020
GGGGACAGTGTCTCTAG
SEQ ID
AGGACTTACTACCGGTCCCAGT
SEQ ID
TCGAGCCCCTGGGGGGAGTTATCGT

CAACAGTGTTACTTGGA
1078
GGTATTATAATTATGCGGTGTC
1143
TATACCAGGGGGCTTTTGATATC

AC

TGTGAAAAGT

SEQ ID 1021
GGATTCACCTTCAGCAG
SEQ ID
CGTATTAATCCTGATGGGAGTA
SEQ ID
GTGGCGGGAGCTACTTCCCTATGGT

CTATGCTATGCAC
1079
GCACAAGCTACGCGGACTCCG
1144
AC

TGAAGGGC

SEQ ID 1022
GGAATCAGCTTCAGAGA
SEQ ID
TGGATCAACGCTGGCAATGGT
SEQ ID
CATGGTAGGGCCGGAATAAACTGGT

TTACTGGATGCAC
1080
AACACAAAATATTCACAGAAG
1145
ACTTCGATCTC

TTCCAGGGC

SEQ ID 1023
GGATACACCTTCACTAG
SEQ ID
CTTATTTATAGTGATGGTCGCA
SEQ ID
GCGCCCCCTCCGACTGTTGGCTGGT

CTATGCTATGCAT
1081
CAAACTATGCAGACTCCGTGA
1146
ACGCCCCCGTCTTTGACTAC

AGGGC

SEQ ID 1024
GGGTTCACCGTCAGTAG
SEQ ID
AACATAAAGCAAGATGGAACT
SEQ ID
GACTATTACTATGGTTCGGGGAGTT

CAACTACATGAGC
1082
GAGAAACACTATGTGGACTCT
1147
CTCCC

GTGAAGGGC

SEQ ID 1025
GGATTCACCTTTAGTAAC
SEQ ID
GGTATGAGTGGTAGTGGTTATA
SEQ ID
GATCTGAATCGAGGATATTGTAGTG

AATTGGATGACC
1083
GTACATACTACGCAGACTCCGT
1148
GTGGTAGCTGCTTTGGCTAC

GAAGGGC

SEQ ID 1026
GAATTCACCCTTAGGAA
SEQ ID
GCTATTAGTAGTAATGGGGGT
SEQ ID
GCCCAGCCGGGCGCTGAGACGTTGA

CTATGGCGTGAGC
1084
AGCACATACTACGCAGACTCA
1149
ACTTCGATCTC

GTGAAGGGC

SEQ ID 1027
GGTTACACATTTACCAGT
SEQ ID
TGGATCAGCGCTTACGACGGT
SEQ ID
CCGGGTATGGTTCGGGGAGTTATTA

TATGCCATCAGC
1085
AACACAAACTATGCACAGAAG
1150
CTGCCCCGCTTGACTAC

CTCCAGGGC

SEQ ID 1028
GGATTCACCTTCAGTACC
SEQ ID
GTTATATCATATGATGGACGTA
SEQ ID
GGGGGGACTATGGTTCGGGGTTTCG

TATCCCATGCAC
1086
ATGAATACTACGCAGACTCCGT
1151
GATTTAACTAC

GAAGGGC

SEQ ID 1029
GGATTCACCTTTGATGAT
SEQ ID
GCTATTAGTGGTAGTGGTGGTA
SEQ ID
GCCACGTATTACTATGATAGTAGTG

TATGCCATGCAC
1087
GCACATACTACGCAGACTCCGT
1152
GTTATAGGTTTGACTAC

GAAGGGC

SEQ ID 1030
GGGGACAGTGTCTCTAA
SEQ ID
AGGACATACTACAGGTCCAAG
SEQ ID
GAGGCTGCCGACGACCCGTTTGACC

CAACAGGGCTGCTTGGA
1088
TGGTATAATGAATATGCAGTCT
1153
AT

AC

CTGTGAAAAGT

SEQ ID 1031
GGATTCACCTTCAGTGA
SEQ ID
CGAATTACAAATAAGCGTACC
SEQ ID
GGCCCCGGGGCAGTGGCTGGTACTA

CCCCTACATGGAC
1089
GGTTACGCCACAACATATGCC
1154
AGCCAAAGTACTACTTTGACTAC

GCGTCTGTGAAGGAC

SEQ ID 1032
GGATTCACTTTCAGTAAC
SEQ ID
CGTATTAAAAGCAAAACTGAT
SEQ ID
GACAAGATCGGCAGCTGTCCTTAC

GCCTGGATGAGC
1090
GGTGGGACAACAGACTACGCT
1155

GCACCCGTGAAAGGC

SEQ ID 1033
GGGGACAGTGTCTCTAG
SEQ ID
AGGACATACTACAGGTCCAAG
SEQ ID
GGAATCTATGATAGTAGTGGTTCTT

CAACAGTGCTGCTTGGA
1091
TGGTATAATGATTATGCAGTAT
1156
CCAATCCCTTTGACTCC

AC

CTGTGAAAAGT

SEQ ID 1034
GGATTCACCTTCAGTAG
SEQ ID
TACATCTATCATAGTGGGAGCA
SEQ ID
ACTTTTGCGGGGTATAGCAGCAAAC

CTATGCTATGCAT
1092
CCTACTACAACCCGTCCCTCAA
1157
TGGGGTACTTCGATCTC

GAGT

SEQ ID 1035
GGTGGCTCCATCAGCAG
SEQ ID
AGGACTTACTACAGGTCCAAG
SEQ ID
GCCCGAGTGGAATCCAAGGATGGGT

TGGTGGTTACTCCTGGA
1093
TGGTATAATGATTATGCAGTAT
1158
ACTTTGACTAC

GC

CTCTGAAAAGT

SEQ ID 1036
GGGGACAGTGTCTCTGG
SEQ ID
TTCATTAGAGCCAACGCTGATA
SEQ ID
GACCTGCGACTTTCTACGTGGGATG

CAACAGTGCTGCTTGGA
1094
GTGGGACAACAGAGTACGCCG
1159
CTTATGATTTC

AC

CGTCTGTGAAAGGC

SEQ ID 1037
GGATTCACCTTTGCTGCT
SEQ ID
AGGACATACTACAGGTCCAAG
SEQ ID
GGATCGGTATATAGTGGGAGCTACT

TATAATATCAAC
1095
TGGTATAATGATTATGCAGTAT
1160
ATATGCTCATTGACTAC

CTGTGAAGAGT

SEQ ID 1038
GGGGACAGTGTCTCTAG
SEQ ID
AGGACATTCTACAGGTCCAAG
SEQ ID
CGGGATTGGGCAGGAAAAAGGGTC

CAACAATGCTGCTTGGA
1096
TGGTATAATGACTATGCAGTTT
1161

AC

CTGTGAAAAGT

SEQ ID 1039
GGTTACACCTTTACCAGC
SEQ ID
TGGATCATCCCTATCTTTGGTA
SEQ ID
GATGGGGGGTCCAGCCCATACTATG

TATGGTATCAGC
1097
TAGCAAACTACGCACAGAAGT
1162
ATAGTAGTGGTTTACTACCCTGGTA

TCCAGGGC

CTTCGATCTC

SEQ ID 1040
GGATTCACCTTTAGCAG
SEQ ID
TGGATCAACGCTGGCAATGGT
SEQ ID
GGCAATGGGCCGTTCGACCCC

CTATGCCATGAGC
1098
AACACAAAATATTCAGAGAAG
1163

TTCGAAGGC

SEQ ID 1041
GGATTCACCTTTAGCAA
SEQ ID
TACATCAGTAGTACTAGTAGTA
SEQ ID
GGACGGACTCACTGGGGCCCCCAGG

CTATGTCATGAGC
1099
CCATATACTACGCAGACTCCGT
1164
ACTTTGACTAC

GAAGGGC

SEQ ID 1042
GGATTCACCTTCAGCAG
SEQ ID
GCTATTAGTGGTATTGGTGATA
SEQ ID
AGGGGACATAACTACGGTGTAGATT

CTCTGCCATGCAC
1100
CTACATACTACGCGGACTCCGT
1165
AC

GAAGGGC

SEQ ID 1043
GGAGGCACCTTCAGCAG
SEQ ID
AGGACATATTACAGGTCCAAG
SEQ ID
GATTATTGTAGTAGTACCAGCTGCC

CTATGCTATCAGC
1101
TGGTATAATGATTATGCAGTAT
1166
AGAACTGGTTCGACCCC

CTGTGAAAAGT

SEQ ID 1044
GGATACAGCTTTACCAG
SEQ ID
ATGATTTGGCATGATGAGAGT
SEQ ID
TGGTACGGTGACTACGGCCTTGACT

CTACTGGATCGCC
1102
AAGAAATACTATGCAGACTCC
1167
AC

GTGAAGGGC

SEQ ID 1045
CGATTCACTTTCAGTGAC
SEQ ID
GGGATCATCCCTATCTTTGGTA
SEQ ID
GTTACGGGACGGAGAGTGGGAGCC

GCCTGGATGAGC
1103
CAGCAAACTACGCACAGAAGT
1168
CATGACTAC

TCCAGGGC

SEQ ID 1046
GGATTCACCTTCAGTACC
SEQ ID
GTCATCTATCCTGGTGACTCTG
SEQ ID
GGCTCCTTGTCCCGAAGTGGCTGGT

TATGGCATGCAC
1104
ATACCAGATACAGCCCGTCCTT
1169
ACGCCGGACTCTTTGACTAC

CCAAGGC

SEQ ID 1047
GGATTCACCGTCAGTAG
SEQ ID
CGTATTAAAAGCAAAATAAGT
SEQ ID
GGGGCCCTACAGGGCGAATGGCGG

CAACTACATGAGC
1105
GGTGGGACAACAGACTACGCT
1170
AGATTTGACTAC

GCACCCGTGCAAGGC

SEQ ID 1048
GGATTCACCTTCAGTAG
SEQ ID
GCTATTAGTAGTAATGGGGGT
SEQ ID
AACAGTCAACGTTCGTTTGACTAC

CTATAGCATGAAC
1106
AGCACATATTATGCAAACTCTG
1171

TGAAGGGC

SEQ ID 1049
GGGGACAGTGTCTCTAG
SEQ ID
GGTATTAGTGGTAGTGGTGGTA
SEQ ID
GGGCCCCGAATGTGGAGCAGTGGC

CGACAGTGCTGTTTGGA
1107
GCACATACTACGCAGACTCCGT
1172
ATTGATGCTTTTGATATC

CC

GAAGGGC

SEQ ID 1050
GGATTCACCTTTGGTGAT
SEQ ID
CTTATATCATATGATGGAAGTA
SEQ ID
CGGGCGGGTTACGGTGACTACAGAC

TATGCTATGAGC
1108
AAAAATACTATGCAAACTCCG
1173
ACTTCCAGCAC

TGAAGGGC

SEQ ID 1051
GGATTCACCTTCAGTAGT
SEQ ID
GTTATTTATAGCGGTGGTAGCA
SEQ ID
CATAGACGCCCAATTTACGATATTT

TATAGCATGAAC
1109
CATACTACGCAGACTCCGTGA
1174
TGACTGGTTTTGACTAC

AGGGC

SEQ ID 1052
GGATACACCTTCACTGA
SEQ ID
TACATTAGTAGTAGTGGTAGTT
SEQ ID
GATGGTACGGTCCGAAGGGTAGTGG

TTATGCTATACAT
1110
ACACAAACTACGCAGACTCTG
1175
GAGCTACTACCCCTGGAAACTTTGA

TGAAGGGC

CTAC

SEQ ID 1053
GGTGGCTCCATCAGTAG
SEQ ID
CGTATTAAAAGCAAAACTGAT
SEQ ID
CGGGATACACCTTTGGTTGGGGTTT

TTACTACTGGAGC
1111
GGTGAGACAACAGACTACGCT
1176
CGATATAC

GCACCCGTGAAAGGC

SEQ ID 1054
GGATTCACCTTCAGTAG
SEQ ID
AGGACATACTACAAGTCGAAG
SEQ ID
GATAACGATTTTTGGAGTGGGAAAG

CTATGGCATGCAC
1112
TGGTATAATGATTATGCAGCAT
1177
TCTTTGACTAC

CTGTGAAAAGT

SEQ ID 1055
GGATTCACCTTCAGTGA
SEQ ID
TTCATTAGAAGCAAAGCTTATG
SEQ ID
GGCCGGTCCCTTCCCTACCGGGGGT

CCAGTACATGGAC
1113
GTGGGACAACAGAATACGCCG
1178
TGGCTCCTAGATCTTTCGGAGGATA

CGTCTGTGAAAGGC

CTACTTTGACTAC

SEQ ID 1056
GGTGGGTCCTTCAGTGG
SEQ ID
TACATTAGTAGTAGTGGTACTA
SEQ ID
TTGCCTAGTAGTGGTTATCTACAGG

TTACTACTGGAGC
1114
CCATATACTACGCAGACTCTGT
1179
ACCACCACTACTACGGTATGGACGT

GAAGGGC

C

SEQ ID 1057
GGATTCACCTTCAGCAG
SEQ ID
ATTATATCAGATGATGGAAGT
SEQ ID
GATGTCAGTGGGTCCTTCGCGGCCT

CTATGCTATCAGC
1115
AAGAGTTACTACGCAGACTCC
1180
AC

GTGCAGGGC

SEQ ID 1058
GGATACACCTTCACCAG
SEQ ID
TGGATCAACGCTGGCGATGGT
SEQ ID
GACGAGTATTTCTAC

CTACTATATGCAC
1116
GGCACAAAAAGTTCACGGGAG
1181

TTCCAGGGC

SEQ ID 1059
GGGGACAGTGTCTCTAG
SEQ ID
TATATCTATTACACTGGGAGCA
SEQ ID
GAGGCTAGCAGTGGCTGGAAC

CAAAAGTGCTGCTTGGA
1117
CCAACTACAACCCCTCCCTCAA
1182

AC

GAGC

SEQ ID 1060
GGATACAGCTTTACCAG
SEQ ID
GTTATATCATATGATGGAAGTA
SEQ ID
GAGGGCGGAGCAGTGGCTGGTACT

CTACTGGATCGGC
1118
ATAAATACTATGCAGACTCCGT
1183
GTCTAC

GAAGGGC

SEQ ID 1061
GGATACACCCTCACTGA
SEQ ID
CGTGTTAGAAACAAAGCTAAC
SEQ ID
GATCGGCGTTACTATGATAGTAGTG

ATTATCCATGCAC
1119
AGTTACACCACAGAATACGCC
1184
GTTATTATCCCGCCTACTACTTTGAC

GCGTCTGTGAAAGGC

TAC

SEQ ID
GAAATCAATCATAGTGGAAGC
SEQ ID
GGCGGTACTTGGGATACAGCTATGG

1120
ACCAACTACAACCCGTCCCTCA
1185
TTACGGGCTTTGACTAC

AGAGT

SEQ ID
GGGATCATCCCTATGTATGGTA
SEQ ID
ATAGTGGGAGGTGCCGTTGACTGC

1121
CAGCAAACTACGCACAGAAGT
1186

TCCAGGGC

SEQ ID
ATAATCAACCCTAGTGGTGGTA
SEQ ID
GAGGATACTATGGTTCGGGGAGTTA

1122
GCACAAGCTACGCACAGAAGT
1187
TTCCC

TCCAGGGC

SEQ ID
AGGACATACTACAGGTCCAAA
SEQ ID
TTGGCGAGTGGTTCCCCCCCTCCGG

1123
TGGAATAATGATTATGCATTAT
1188
GGGACTAC

CTGTGAAAAGT

SEQ ID
ATCATCTATCCTGGTGACTCTG
SEQ ID
GTTAGAGTGGGAGCTACTACTGTTT

1124
ATACCAGATACAGCCCGTCCTT
1189
ACGACAGCTGGTTCGACCCC

CCAAGGC

SEQ ID
TTTATATCATATGATGGAAGTA
SEQ ID
GATGATCGGGGTCGGGGAGATGACT

1125
ATAAATACTACGCAGACTCCGT
1190
TTGACTAC

GAAGGGC

SEQ ID
GGTTTTGATCCTGAAGATGGTG
SEQ ID
CTAGCTAATTCCGACGGTGTGGACG

1126
AAACAATCTACGCACAGAAGT
1191
TC

TCCAGGGC

SEQ ID
GGCGGTGGTTCGGGGAGTTATTATA

1192
AGAGGTTCTTTGACTAC

SEQ ID
GGGGGAAGATATACCAAGGGAGGG

1193
TACTTTGACGAC

SEQ ID
GAACTATACAACTATGGTTCAAAGG

1194
ACTACTTTGACTAC

SEQ ID
GATGGCCCCGCCGTTGATGGTGCTG

1195
AATACTTCCAGCAC

SEQ ID
GTCGCCAAATATTATTACGAGAGTG

1196
GTGGTTATCGGGCCTCCAACTGGTT

CGACCCC

SEQ ID
GAAGGGGGCAGTGGCTGGCGCCAC

1197
TACTTTGACTAC

SEQ ID
GATCAAGGGGCAGCAGCTGGTACCC

1198
TGGGGTACTTTGACTAC

SEQ ID
GGGCGCGTGGCGGGGGATGCTTTTG

1199
ATATC

SEQ ID
ACCAACCAGGGATACGGTGGTAACT

1200
CCGGGGTATTTGACTAC

SEQ ID
CCCCCCGACGGTGGTAACTCCGGTC

1201
GCTGGTACTTCGATCTC

SEQ ID
GCCCGGGGGCTACAGTACCTAATCT

1202
GGTACTTCGATCTC

SEQ ID
GCTCGTTACTATGATAGTAGTGGTT

1203
ATATTGCCCCATCGGGTTACTTTGA

CTAC

SEQ ID
GATGGTGTAGGAGGGAGAGATGGC

1204
TACAATTTTGACTAC

SEQ ID
CCCCATTACGATATTTTGACTGGTTC

1205
CCGGGCGCCCTTTGACTAC

SEQ ID
CGAAACTTAGGCTAC

1206

SEQ ID
GCTAAGTTTTGGACATACTACTTTG

1207
ACTAC

SEQ ID
AAAATAGCAGCAGCTGGTAAGCAA

1208
CCTGTTGACTAC

SEQ ID
GGCCCTATAGTGGGAGCGACTATGG

1209
ACTAC

SEQ ID
AGACCGGATAGCAGCAGTCAATGTT

1210
TTGACTAC

SEQ ID
GCCCCCCTAGCAGCAGATGGCTACT

1211
TTGACTAC

SEQ ID
GACGGGGGCTATGATAGTAGTGGTT

1212
TTCACTTTGACTAC

SEQ ID
GGGGTGGGATGGTCGCCCTTCCAAT

1213
AC

SEQ ID
GGTGTAACCCGGACCTTTGACTAC

1214

SEQ ID
GACGACAAAATAGCAGCAGCTGGA

1215
TTCACATACTGGTACTTCGATCTC

SEQ ID
GATTATAGCAGCTCGGGGGAGTGCT

1216
TTGACTAC

SEQ ID
TTAAGGGGTATAGATTACTATGATA

1217
GTAGTGGTTACCAACGGGGGTTTGA

CTAC

SEQ ID
GCGCCGAGGGGTGTAGTACCAGCTG

1218
CTATGCGGGGGGGCTAC

SEQ ID
GACAGGGGAACTAAATGGAACCAA

1219
TTGAATGATGTTTTTGATATG

SEQ ID
GGATATTGTAGTGGTGGTAGCTGCC

1220
CAGGAACGGATTTTGACTAC

SEQ ID
GGTGGGAGGGGGGATGGGGCCGCT

1221
TTTGACATC

SEQ ID
GATTTAGGGGATCCCCGGGGTGGTA

1222
TTTTGAACTAC

SEQ ID
AGTCTCAATAGTGGGGGCTACCGAT

1223
GCTTCCATCAC

SEQ ID
GTAAATCCGGGGAGTTATACGAGGG

1224
AGGTGAGCAACTTTGACTAC

SEQ ID
CTCCCGGGGAGAGCAGCTCGTCCAG

1225
ACTAC

SEQ ID
GAAGCTAAGTGGGGAATGTACTACT

1226
TTGACTAC

SEQ ID
GGCCGAGGGTATAGCAGCAGTCGG

1227
CTCTACTACTTTGACTAC

SEQ ID
TTGGTGGGCAATAGTGGGAGCTACT

1228
ATCCGTTTGGGTAC

SEQ ID
CAAGTCGCGGGCGGTATGGACGTC

1229

SEQ ID
GGGGGAGGGCTTTGGGCTTTTGATA

1230
TC

SEQ ID
CTCCCCTCGTATTACTATGATAGTA

1231
GTGGTTACTTTACCTGGTACTTCGAT

CTC

SEQ ID
ACAGGGGACCGCTTCCAAGAGTTTG

1232
ACTAC

SEQ ID
GATGTGAACCCGGAGCTACTGGGGG

1233
CGGGATTTGACTAC

TABLE 8

Light Chain CDR DNA Sequences

SEQ ID
CDRL1 DNA Seq
SEQ ID
CDRL2 DNA Seq
SEQ ID
CDRL3DNASeq

SEQ ID
GCCAGTCAGAGTGTCGGTAACTCCTTA
SEQ ID 1308
GGTGCGTCCAGTTTGCAG
SEQ ID
CAACGTGGCACCTGGCCT

1234
GCCTGG

AGTGGG
1373
CCCCTCACTTTC

SEQ ID
GCCAGTCAGAGTATAACTAACTGGTTG
SEQ ID 1309
AGGGCGTCTCGTTTAGAA
SEQ ID
CAGTATACTAATTACCCTC

1235
GCCTGG

AGTGGG
1374
GTACGTTC

SEQ ID
GCCAGTCAGACTATTAATAGTTGGTTG
SEQ ID 1310
GGTGCTTCCACCAGGGCC
SEQ ID
CAAAGTATACAGCTTCCG

1236
GCCTGG

ACTGGC
1375
TGGACGTTC

SEQ ID
GCAAGTCAGGGCATTAGAAATGATTTA
SEQ ID 1311
GGTGCATCCAGTTTGCAA
SEQ ID
CAATATAATAGTTATTCTC

1237
GGCTGG

AGTGGA
1376
CCACTTTT

SEQ ID
GCAAGTCAGAGCATTAGCAGCTATTTA
SEQ ID 1312
GCTGCATCCAGTTTGCAC
SEQ ID
CACTATGGTCCCTCACGTC

1238
AATTGG

ACTGGG
1377
GGATCACCTTC

SEQ ID
TCCAGCCAGAGTGTTTTATACAGCTCC
SEQ ID 1313
GCTGCATCCACTTTGCAA
SEQ ID
CAGCATAATTCCTACCCTC

1239
AACAATAAGAACTACATAGCTTGG

AGTGGG
1378
GAACATTC

SEQ ID
GCCAGTCAGGGCATTAGCAGTTCTTTG
SEQ ID 1314
GCTGCATCCACCAGGGCC
SEQ ID
CAGAGTTACAGTATTCCTC

1240
GCCTGG

ACTGGT
1379
GAACGTTC

SEQ ID
GCCAGTGAGAGTGTTAATAGCAACTTC
SEQ ID 1315
GGTGCCTCCAGCAGGGCC
SEQ ID
CAATATTATTATATTCCTC

1241
TTAGCCTGG

GCTGGC
1380
GGACGTTC

SEQ ID
GCCAGTCAGAGTGTTGGCAGCAAATTA
SEQ ID 1316
GCTGCATCCTACAGGGCC
SEQ ID
CAGTATGGTAGCTCATCC

1242
GCCTGG

ACTGGC
1381
ATGTACACTTTT

SEQ ID
GCCAGTCAGAATGTTTACAGCAATTTC
SEQ ID 1317
AAGGTTTCTAACCGGTTG
SEQ ID
CAGTATGATAATCTCCCTC

1243
TTAGCCTGG

TCTGGG
1382
CTCTCACTTTC

SEQ ID
TCTAGTCAAAGTCTCGAACACGGTGAT
SEQ ID 1318
GATGCATCCACCAGGGCC
SEQ ID
CAGTATAATAACTGGCCG

1244
GGAAACACGTACTTGAGTTGG

ACTGGT
1383
CTCACTTTC

SEQ ID
TCTAGTCAGAGCCTCCTGCATAGTAAT
SEQ ID 1319
GGTACATCCACCAGGGCC
SEQ ID
CAGTATAATAGTTATTCGG

1245
GGAAACAACTATTTGGATTGG

ACTGGT
1384
GGACGTTC

SEQ ID
GCCAGTCAGAGTATTAGCAACAACTTA
SEQ ID 1320
GGTGCATCCAGGAGGGC
SEQ ID
CAGTATAATAACTGGCCC

1246
GCCTGG

CACTGGC
1385
CCGATCACCTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCACCTCC
SEQ ID 1321
AAGATTTCTAACCGGTTC
SEQ ID
CAATATGGAACCTCACCG

1247
TTAGCCTGG

TCTGGG
1386
ATCACCTTC

SEQ ID
TCTAGTCAAAGCCTCGTATACAGTGAT
SEQ ID 1322
GATGCATCCACCAGGGCC
SEQ ID
CAGTATAATAACTGGCCT

1248
GGAAACACCTACTTGAGTTGG

ACGGGA
1387
CCCATCACCTTC

SEQ ID
TCTAATCAAAGCCTCGTATACAGTGAT
SEQ ID 1323
AAGGTTTCTAAGCGGGAC
SEQ ID
CAAGGTATATACTGGCCT

1249
GGAGGCACCTACTTGAATTGG

TCTGGG
1388
CGAACCTTC

SEQ ID
TCCAGCCAGAGTGTTTTATACAGAACC
SEQ ID 1324
GACTCCAACAGGGCCACT
SEQ ID
CAGCGTAGCAACTGGTCG

1250
AACAATAAGAACTACTTGGCTTGG

GGC
1389
CTCACTTTC

SEQ ID
GCCAGTCAGAGCATTGGGAGCAATTTA
SEQ ID 1325
GAAGTTTCCAACCGGTTC
SEQ ID
CAAGGTCTACAAATCCCT

1251
GCCTGG

TCTGGA
1390
ATCACTTTC

SEQ ID
TCTAGTCAAAGCCTCGTGTACAGTGAT
SEQ ID 1326
GGTGCCTCCACCAGGGCC
SEQ ID
CACTATAATAACTGGCCTC

1252
GGAAACACCTACTTGTATTGG

ACTGCT
1391
ATACCTTC

SEQ ID
GCCAGTCAGAGTGTTAGAGACAACGTA
SEQ ID 1327
GCTGCCTCCACCAGGGCC
SEQ ID
CAGTATGGTAGCTCGTTC

1253
GGTTGG

ACTGGT
1392

SEQ ID
GCCAGTCAGACTATTGGTCCCAAGTCC
SEQ ID 1328
TTGGGTTCTAATCGGGCC
SEQ ID
CAGTATAATTTCTGGCCTT

1254
TTCGGCTGG

TCCGGG
1393
CGATCACCTTC

SEQ ID
TCTAGTCAGAGCCTCCTGCATAGTGAT
SEQ ID 1329
GGTGCATCCTACAGGGCC
SEQ ID
CACTATGGTAGTTCACCTC

1255
GGAAAGACCTATTTGTATTGG

ACTGGC
1394
CAATCACCTTC

SEQ ID
GCCAGTCAGAGTGTTAGTAGCAGCTTA
SEQ ID 1330
AGTGCAACCTCTAGGGCC
SEQ ID
CAAGGTACACAATTTCCTC

1256
GCCTGG

ACTGGA
1395
AAACGTTC

SEQ ID
GCCAGTGAAGGTCTTACCACCAACTTA
SEQ ID 1331
AAGGTTTCTACCCGGTTC
SEQ ID
CAAGGGACACACTGGCCG

1257
GCCTGG

TCTGGG
1396
TACACTTTT

SEQ ID
GCCAGTCAGAGTGTTAGCACCCTCTTA
SEQ ID 1332
GCTGCATCCAGTTTGCAA
SEQ ID
CAATATTACAATCTTCCTC

1258
GCCTGG

AGTGGG
1397
GATCTTTT

SEQ ID
GCCAGTCAGAGTGTTTTCAACAACTAC
SEQ ID 1333
GCTGCCTCCAATCTGCAC
SEQ ID
CAGCATGGTGAATGGCCC

1259
TTAGCCTGG

AGTGGC
1398
ACCTTC

SEQ ID
TCTAGTCAAAGCCTCGTATACAGTGAT
SEQ ID 1334
GATGTATCCACCAGGGCC
SEQ ID
CAAGGTAGACACTGGCCG

1260
GGAAACACCTACTTGAATTGG

ACTGAT
1399
TACACTCTT

SEQ ID
TCTAGTCAGAGCCTCCTACATAGTAGT
SEQ ID 1335
AAGGCGTCTACTATAAAA
SEQ ID
CAGTTTAATAATTGGCCTT

1261
GGATACAACTATTTGGATTGG

AGTGGG
1400
ACACTTTT

SEQ ID
TCTAGTCAGAGCCTCCTGAATAGTAAT
SEQ ID 1336
GCTGCGTCCAATTTGCAA
SEQ ID
CAGCGTAGCAGGTGGCCT

1262
GGATACAACTATTTGGAGTGG

AGTGGG
1401
CTCACTTTC

SEQ ID
GCCAGTCAGAGTGTTACCAGCAACTAC
SEQ ID 1337
TGGGCATCTACCCGGGAA
SEQ ID
CAAAGTATACAGCTTCCG

1263
TTAGCCTGG

TCCGGG
1402
CTCACTTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAGCTCC
SEQ ID 1338
GGTGCATCCACCAGGGCC
SEQ ID
CAGTATGGTAGCTCACCC

1264
TTAGCCTGG

ACTGGC
1403
CCGGGCACTTTC

SEQ ID
GCCAGTCAGAGTATTGGCAGCAACTTA
SEQ ID 1339
AAGGCGTCTACTTTAGCA
SEQ ID
CGCTATGATAACTGGCCTC

1265
GTCTGG

AATGGG
1404
CCCTTTTT

SEQ ID
TCTAGTCAAAGCCTCGAACACACTGAT
SEQ ID 1340
GGTGCATCCACCAGGGCC
SEQ ID
CAGTATAATCACTGGCCTC

1266
GGAAACACCTACTTAAGTTGG

AGTGGC
1405
TCTACACTTTT

SEQ ID
GCAAGTCAGAGCATTAGCAACTATTTA
SEQ ID 1341
GATTCATCCAGCAGGGCC
SEQ ID
CAGGGTAGCAACTGGCCG

1267
AATTGG

ACTGGC
1406
CTCACTTTC

SEQ ID
CCAAGTCAGGACATAGGCACTTATTTA
SEQ ID 1342
GGTGCATCCAACAGGGCC
SEQ ID
CAAGGTACACACTGGCCT

1268
AATTGG

ACTGGT
1407
CGAACGTTC

SEQ ID
GCCAGTCAAAGTGTTAACAGCAACGTA
SEQ ID 1343
GATGCATCCAGCAGGGCC
SEQ ID
CACCGTTACGTGTGGCCGT

1269
GCCTGG

ACTGGC
1408
TCACTTTC

SEQ ID
GCCAGTCAGAGTGTTGGTACCAATTTA
SEQ ID 1344
GATTCATCGAATAGGGCC
SEQ ID
CAGTATGGTAGTTCACCG

1270
GCCTGG

ACTGGC
1409
ATCACCTTC

SEQ ID
GCCAGTCAGAGTATTAGTAGGTGGTTG
SEQ ID 1345
GGTGCATCCAGCAGGGCC
SEQ ID
CAAGGTACACATTGGCCT

1271
GCCTGG

TCTGGC
1410
CGGACTTTC

SEQ ID
GCGAGTCAGAACATTCGCCACTGGTTA
SEQ ID 1346
TGGGCGTCTACCCGGGGG
SEQ ID
CAAGGTCTACAAATTCCG

1272
GTCTGG

TCCGGG
1411
CTCACTTTC

SEQ ID
TCCAGCCGGAATATTTTATACAGCGGC
SEQ ID 1347
AAGGTTTCTAACCGGGAC
SEQ ID
CAGTCTCTACAAACTCCTC

1273
AACAATAAAAACTTCTTGGCTTGG

TCTGGG
1412
TCACTTTC

SEQ ID
GCCAGTCAGAGTATTAGCAGCACCTAC
SEQ ID 1348
GGTGCATCCAGCAGGGCC
SEQ ID
CAGTATGCTAGCTCAGTC

1274
TTAGCCTGG

ACTGAC
1413
ACCTTC

SEQ ID
GCCAGGCAGAGCATCAGTAACCGGTTG
SEQ ID 1349
TATGCTTCCCAGTCCTTCT
SEQ ID
CAGTATAATAACTGGCCT

1275
GCCTGG

CAGGG
1414
CCCTTCACCTTC

SEQ ID
GCCAGTGAGAGTGTTAGCAAGAGCTAC
SEQ ID 1350
TGGGCATCTGCCCGGGAA
SEQ ID
CAGTATGGTAGCTCACAG

1276
TTACTCTGG

TCCGGG
1415
ACCTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAGCGCC
SEQ ID 1351
GGTGCCTCCACCAGGGCC
SEQ ID
CAGTATGGTAGTTCACCTC

1277
TTAGCCTGG

ACTGGT
1416
CGACCACCTTC

SEQ ID
GCCAGTCAAAGTGTTACCAGCAACTTA
SEQ ID 1352
GAGGTTTCTAAGCGGGAC
SEQ ID
CAGCGTAGCAACTGGCCG

1278
GCCTGG

TCTGGG
1417
TGGACGTTC

SEQ ID
GCCAGTCAGAGTATTGGCACTTACGTC
SEQ ID 1353
GAAGTTTCCAACCGATTC
SEQ ID
CAGGCTACACACTATCCTC

1279
GCCTGG

TCTGGA
1418
GGACGTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAACTCC
SEQ ID 1354
GCTTCATCTACTTTGCAA
SEQ ID
CAGAGTTACATTACCCCGT

1280
TTAGCCTGG

TCAGGG
1419
GGACGTTC

SEQ ID
TCCAGCCAGAGTGTTTTATATGATTCC
SEQ ID 1355
AAGGCCTCTAGTTTAACA
SEQ ID
CAGAGTTACGGTCCTCGG

1281
AACAGTAAGAACTACTTAAGTTGG

AGTGGG
1420
ACATTC

SEQ ID
GCCAGTCAGAGTGTTAGTAGCTACTTA
SEQ ID 1356
AAGGCGTCTAGTTTAGAA
SEQ ID
CAGTGTGCTAGCTCACCTC

1282
GCCTGG

AGTGGG
1421
CTGTCACTTTC

SEQ ID
TCTTGTCAAAGCCTCGTATACAGTGAT
SEQ ID 1357
TTGGGTTCTACTCGGGCC
SEQ ID
CAGTATAATAACTGGCCT

1283
GGCAACACCTACTTGAATTGC

TCCGGG
1422
CCGATAACTTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAGCTAC
SEQ ID 1358
GGTGTTTCCACCAGGGCC
SEQ ID
CACTATAAAAGTGATTCC

1284
TTAGGCTGG

ACTGGC
1423
CGGACGTTC

SEQ ID
GCCAGTCAGAGCATTGGTGGTAGCTTA
SEQ ID 1359
ACTGCATCCAAAAGGGCC
SEQ ID
CAGCATAACAGTTACCCG

1285
CACTGG

ACTGGC
1424
TGGACGTTC

SEQ ID
TCCAGCCAGAGTGTTTTATACAGCTCC
SEQ ID 1360
ATGGGTTCTAGTCGGGCC
SEQ ID
CAATATTATAGTACTCCGC

1286
AACAATAAGAACTACTTAGCTTGG

TCCGGG
1425
TCACTTTC

SEQ ID
GCCAGTCAGAGTATTAGCAGCAACTTA
SEQ ID 1361
GGTGCATCCAGCAGGGCC
SEQ ID
CAGTATGGTAGCTCACTCC

1287
GCCTGG

ACTGGC
1426
TCTTC

SEQ ID
TCTAGTCATAGCCTCACAACTACTGAT
SEQ ID 1362
GGTGCATCCACCAGGGCC
SEQ ID
CAGAGTAGTAGTTTACCTC

1288
GGACGTACTTACGTGGCTTGG

ACTGGT
1427
ACACTTTC

SEQ ID
TCTAGTCAGAGCCTCCTGGGTGGTGAT
SEQ ID 1363
GAGGTTTCTAACCGGGAC
SEQ ID
CAGTATGGTAACTCACCTC

1289
GGAAAGACCTATTTGTATTGG

TCTGGT
1428
CGGGAGCCACCTTC

SEQ ID
GCGAGTCAGGGCATTGCCAATTATTTA
SEQ ID 1364
GGCGCATCCAACAGGGC
SEQ ID
CAGTATCAAAGTTACTGG

1290
GCCTGG

CACAGGC
1429
ACGTTC

SEQ ID
GCCAGTCAGAGTATTACTACCTGGTTG
SEQ ID 1365
GATGCGTCCAGCAGGGCC
SEQ ID
CACTATGGCAGCTCTCGC

1291
GCCTGG

GAAGGC
1430
ACCTTC

SEQ ID
GCCAGTCAGAGTATTAGTAGCTGGTTG
SEQ ID 1366
CGTGCATCCAGCAGGGCC
SEQ ID
CAGTTTAATACCTACCCCA

1292
GCCTGG

ACTGGC
1431
ACACTTTT

SEQ ID
GCCAGTCAGAGTGTTAATAGCGGCTAC
SEQ ID 1367
TCTACATCGACTTTACAA
SEQ ID
CAGTATGGTAGCTCACCT

1293
TTAGCCTGG

AGTGGA
1432
GCGCTCACTTTC

SEQ ID
GCCAGTCACAGTGTTGGCGCCAACTAC
SEQ ID 1368
TGGGCATCTACCCGGGAC
SEQ ID
CAGTATGGTAGTCCACCTC

1294
ATAGCCTGG

TCCGGG
1433
CGACCACCTTC

SEQ ID
TCTAGTCAGAGCCTCCTGCATAGTAAT
SEQ ID 1369
GATGCATCCAACAGGGCC
SEQ ID
CAGTATGGTAGCTCACCTC

1295
GGATACAACTATTTGGATTGG

ACTGGC
1434
GGGTCACTTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAACTTA
SEQ ID 1370
CGTGCATCCACCAGGGCC
SEQ ID
CAGCGTGCCGAGTGGCCT

1296
GCCTGG

GCTGGT
1435
CTCACCTTC

SEQ ID
GCCAGTCAGAGTGTAATAAGCAGGTAC
SEQ ID 1371
GATGCATCCAATTTGGAA
SEQ ID
CAGTATGGTAGCTCACGT

1297
TTAGCCTGG

ACAGGG
1436
CGGACGTTC

SEQ ID
TCTAGTCAAAGCCTCGTACACAGTAAT
SEQ ID 1372
TTGGGTTCTAATCGGGCC
SEQ ID
CAGTATGGTAGCTCAGGG

1298
GGACACACCTACTTGAGTTGG

CCCGGG
1437
TACACTTTT

SEQ ID
GCCAGTCAGAGTGTTAGCAGCAGCTAC

SEQ ID
CAGTATGGTAACTCACAG

1299
TTAGCCTGG

1438
ACCTTC

SEQ ID
GCCAGTCAGAGTTTAAGTACCAACTTA

SEQ ID
CAATTTTATGGTATTCCCC

1300
GCCTGG

1439
ACTTC

SEQ ID
GCCAGTCAGAGTATTAGCGGCAGTTAC

SEQ ID
AAGTATAACAGTCCCCCT

1301
TTAGCCTGG

1440
CGGACGTTC

SEQ ID
GCCAGTCAGAGTCTTACCAGCAGCTAC

SEQ ID
CAAGGTCTACAAACTCCA

1302
TTAGCCTGG

1441
TTCACTTTC

SEQ ID
TCCAGCCAGGCCCTGCGAAATGTTGTC

SEQ ID
CAGCGTAGCAACTGGCCT

1303
GGCCTTGGCGATGATTTAGCCTGG

1442
TTCTTC

SEQ ID
TCCAACCGGAGTGTTTTATACAGCCCC

SEQ ID
CAGTATGGTATCTCACCTC

1304
AACAATCAGAACTACTTAGGTTGG

1443
TCGCGTTC

SEQ ID
GCCAGTCAGAGTGTTAGCAGCTACTTA

SEQ ID
CAGAGTATCAGTTTACCG

1305
GCCTGG

1444
CTCACTTTC

SEQ ID
GCCAGTCAGAGTGTTGGCAGCGACTTA

SEQ ID
CAATTTTATAGTCCTCCTC

1306
GCCTGG

1445
GGACGTTC

SEQ ID
GCCAGTCAGAGTATTAGTAGCTGCTTG

SEQ ID
CAGTATAATAACTGGCCT

1307
GCCTGG

1446
AGAACGTTC

SEQ ID
CAAGGAACACATGGGCCT

1447
CACACGTTC

SEQ ID
CAATCTACACAATTTCCGT

1448
GGACGTTC

SEQ ID
AAGTATAACAGTGTCCCT

1449
CTCACTTTC

SEQ ID
CATTATAATGGTGCTTCTC

1450
GTATGTTC

SEQ ID
CAGTATAATAGTTATTGG

1451
ACGTTC

SEQ ID
CAAGCTCTACACACTCCGT

1452
GGACGTTC

SEQ ID
CAGTATAATAGTTATTCAA

1453
GGACGTTC

SEQ ID
CAGTATGGTAGCTCACTC

1454
AGGTACACTTTT

SEQ ID
CAGTATAATAACTGGCCT

1455
CGGTTC

SEQ ID
GAGTATGGTAACTCAGCT

1456
ATGTACAATTTT

SEQ ID
CAGTATAATAACTGGCCT

1457
CTCACTTTC

SEQ ID
CAGTATGCTGCCGCACCG

1458
ATTACCTTC

SEQ ID
CAAACTTTACACACTGTCA

1459
CTTTC

SEQ ID
CAGTATGGTAGCTCACCC

1460
CGGATCACCTTC

SEQ ID
CAGTATAATAACTGGCCC

1461
CGGACGTTC

SEQ ID
CAGTATAATAACTGGCCT

1462
CCTATGTACACTTTT

SEQ ID
CAGTATGGTAGCTCACCTC

1463
CGTACACTTTT

SEQ ID
CAAACTCTTCAAACTCCGC

1464
TCACTTTC

SEQ ID
CAAGGAACACACTGGCCC

1465
CCCCTCACTGTC

SEQ ID
CAGTATGGAAGCTCACCG

1466
GGAACGTTC

SEQ ID
CAGTATCATAACTGGCCTC

1467
CGTACACTTTT

SEQ ID
CAATATTATAGTAGTACTC

1468
CGTACACTTTT

SEQ ID
CAGTATGGTAGCTCACCA

1469
ATATTCACTTTC

SEQ ID
CAGTATGGTAGTTCACCTA

1470
ACACCTTC

SEQ ID
CAGCACCATGATTTCCCTT

1471
TCACTTTC

SEQ ID
CAGCGTTACAACTGGCCT

1472
ATCACCTTC

SEQ ID
CAATATGCAAGTACTCCA

1473
TACACTTTT

SEQ ID
CAGCGTAGCAACTGGCCT

1474
CGGACGTTC

SEQ ID
CAGTATGGTAGATCACCG

1475
TACACTTCT

SEQ ID
CAGTTTGATAATGTCCCAG

1476
TCACTTTC

SEQ ID
CAGCTTAATAGTTACCCTC

1477
AGACGTTC

SEQ ID
CAAGCTCTACAAACTCCG

1478
TACACTTTT

SEQ ID
CAGTATAATAACTGGCCT

1479
CCGATCACCTTC

SEQ ID
CAAGCTCTACAAACTCGG

1480
ACATTC

In some embodiments, a nucleotide sequence encoding an antibody, antibody fragment, VH domain, VL domain or CDR of the disclosure is a wild type sequence. In some embodiments, the nucleotide sequence is codon optimized for expression in mammalian cells. In some embodiments, the nucleotide sequence is codon optimized for expression in human cells.

In some embodiments, the invention relates to an antibody that is capable of binding to CLEC2D and that blocks the interaction between CLEC2D and CD161 (FIG. 1). In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a monoclonal antibody. In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a polyclonal antibody.

In some embodiments, the invention relates to an antibody that is capable of binding to CLEC2D and that blocks the interaction between CLEC2D and CD161, which is capable of removing CLEC2D-expressing cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC) and/or by complement-dependent cytotoxicity (CDC). In some embodiments, the invention relates to an antibody that is capable of binding to CLEC2D and that blocks the interaction between CLEC2D and CD161, that is capable of stimulating the cytokine production and the cytotoxicity mediated by NK cells.

In some embodiments, the anti-CLEC2D antibody as disclosed herein, is a humanized antibody. In some embodiments, the anti-CLEC2D antibody as disclosed herein, is of human IgG1, IgG1 N296A, IgG2, IgG3 or IgG4 isotype. In some embodiments, the anti-CLEC2D antibody is a mouse IgG1, IgG2a, IgG2b or IgG3 isotype.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs. 217-324.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-108; and a variable light chain (VL) comprising an amino acid sequence having at least 50% identity, at least 55% identity, at least 60% identity, at least 65% identity, at least 70% identity, at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.8% identity, at least 99.9% identity or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 217-324.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 325-432.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 109-216; and a variable light chain (VL) comprising an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 325-432.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-108.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 217-324.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-108, and a variable light chain (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 217-324.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO 44 and a VL comprising an amino acid sequence according to SEQ ID NO: 260.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:45, and a VL comprising an amino acid sequence according to SEQ ID NO:261.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:42, and a VL comprising an amino acid sequence according to SEQ ID NO: 258.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:1, and a VL comprising an amino acid sequence according to SEQ ID NO: 217.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:73, and a VL comprising an amino acid sequence according to SEQ ID NO:289.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:21, and a VL comprising an amino acid sequence according to SEQ ID NO:237.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:35, and a VL comprising an amino acid sequence according to SEQ ID NO:251.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:58, and a VL comprising an amino acid sequence according to SEQ ID NO: 274.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH comprising an amino acid sequence according to SEQ ID NO:7, and a VL comprising an amino acid sequence according to SEQ ID NO:223.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 486-546.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 547-653.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 654-726.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 727-783.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable light chain (VL) complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 784-885.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable heavy chain (VH) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 433-485, a VH complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 486-546, and a VH complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 547-653.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a Variable Light chain (VL) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 654-726, a VL complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 727-783, and a VL complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 784-885.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain (VH) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 433-485, a VH complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 486-546, and a VH complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 547-653; and a variable light chain (VL) complementarity determining region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 654-726, a VL complementarity determining region 2 (CDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 727-783, and a VL complementarity determining region 3 (CDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 784-885.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID NO: 439, a VH CDR2 comprising an amino acid according to the SEQ ID NO:492, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID NOs: 589; and a VL CDR1 comprising an amino acid sequence according to SEQ ID NO: 687, a VL CDR2 comprising an amino acid sequence according to SEQ ID NOs: 729, and a VL CDR3 comprising an amino acid sequence according to SEQ ID NOs: 827.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID NO: 439, a VH CDR2 comprising an amino acid according to the SEQ ID NO: 492, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID NOs: 590; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 688, a VL CDR2 comprising an amino acid sequence according to SEQ ID 755, and a VL CDR3 comprising an amino acid sequence according to SEQ ID 828.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 473, a VH CDR2 comprising an amino acid according to the SEQ ID 495, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 587; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 655, a VL CDR2 comprising an amino acid sequence according to SEQ ID 732; and a VL CDR3 comprising an amino acid sequence according to SEQ ID 825.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 433, a VH CDR2 comprising an amino acid according to the SEQ ID 486, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 547; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 654, a VL CDR2 comprising an amino acid sequence according to SEQ ID 727, and a VL CDR3 comprising an amino acid sequence according to SEQ ID 784.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 439, a VH CDR2 comprising an amino acid according to the SEQ ID 492, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 618; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 678, a VL CDR2 comprising an amino acid sequence according to SEQ ID 730, and a VL CDR3 comprising an amino acid sequence according to SEQ ID 852.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 446, a VH CDR2 comprising an amino acid according to the SEQ ID 501, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 567; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 655, a VL CDR2 comprising an amino acid sequence according to SEQ ID 735, and a VL CDR3 comprising an amino acid sequence according to SEQ ID 804.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 435, a VH CDR2 comprising an amino acid according to the SEQ ID 488, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 581; and a VL CDR1 comprising an amino acid sequence according to SEQ ID 680, a VL CDR2 comprising an amino acid sequence according to SEQ ID 782, and a VL CDR3 comprising an amino acid sequence according to SEQ ID 818.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 466, a VH CDR2 comprising an amino acid according to SEQ ID 521, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 603; and a VL CDR1 comprising an amino acid sequence according to the SEQ ID 662, a VL CDR2 comprising an amino acid sequence according to the SEQ ID 732, and a VL CDR3 comprising an amino acid sequence according to the SEQ ID 814.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a VH CDR1 comprising an amino acid sequence according to the SEQ ID 439, a VH CDR2 comprising an amino acid according to the SEQ ID 492, and a VH CDR3 comprising an amino acid sequence according to the SEQ ID 553; and a VL CDR1 comprising an amino acid sequence according to the SEQ ID 660, a VL CDR2 comprising an amino acid sequence according to the SEQ ID 733, and a VL CDR3 comprising an amino acid sequence according to the SEQ ID 790.

The disclosure provides an antibody library comprising at least about 108 unique monoclonal antibody clones, wherein at least about 80% of the antibody clones detectably and specifically bind a CLEC2D antigen. Various anti-CLEC2D antibodies with specific combinations of heavy chain, light chain, heavy chain CDRs 1-3 (i.e., CDRH1, CDRH2, and CDRH3) and Light chain CDRs 1-3 (i.e., CDRL1, CDRL2, and CDRL3), are described in Table 9A.

TABLE 9A

Anti-

CLEC2D
SEQ ID

SEQ ID

antibody
code
SEQ ID
LC AA
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

No.
HC AA
HC DNA
SEQ ID
LC DNA
CDRH1
CDRH2
CDRH3
CDRL1
CDRL2
CDRL3

A1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

44
152
260
368
439
492
589
687
729
827

B1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

45
153
261
369
439
492
590
688
755
828

C1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

75
183
291
399
453
507
620
700
760
854

D1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

77
185
293
401
439
492
622
706
769
856

E1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

42
150
258
366
473
495
587
655
732
825

F1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

56
164
272
380
433
486
601
662
754
838

G1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

64
172
280
388
469
525
609
655
735
844

H1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

50
158
266
374
456
512
595
692
759
833

I1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

43
151
259
367
473
49S
588
686
754
826

J1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

80
188
296
404
437
506
625
708
771
859

K1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

33
141
249
357
454
510
579
655
735
816

L1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

23
131
239
347
439
492
569
670
744
806

M1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

24
132
240
348
448
504
570
656
729
807

N1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

59
167
275
383
461
516
604
696
742
840

O1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

74
182
290
398
474
530
619
705
743
853

P1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1
109
217
325
433
486
547
654
727
784

Q1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

25
133
241
349
449
505
571
671
745
808

R1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

61
169
277
385
437
529
606
698
764
842

S1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

60
168
276
384
467
522
605
697
763
841

T1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

28
136
244
352
451
507
574
674
747
811

U1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

73
181
289
397
439
492
618
678
730
852

V1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

4
112
220
328
436
489
550
657
730
787

W1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

6
114
222
330
438
491
552
659
732
789

X1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

46
154
262
370
461
516
591
689
756
829

Y1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

21
129
237
345
446
501
567
655
735
804

Z1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

63
171
279
387
468
524
608
655
735
843

A2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

57
165
273
381
461
516
602
695
762
839

B2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

47
155
263
371
462
517
592
656
729
830

C2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

83
191
299
407
433
486
628
656
729
862

D2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

29
137
245
353
434
508
575
675
748
812

E2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

35
143
251
359
435
488
581
680
782
818

F2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

81
189
297
405
475
532
626
655
729
860

G2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

76
184
292
400
453
531
621
662
732
855

H2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

36
144
252
360
456
512
582
681
751
819

I2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

58
166
274
382
466
521
603
662
732
814

J2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

52
160
268
376
450
506
597
667
734
835

K2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

71
179
287
395
437
529
616
703
767
850

L2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

7
115
223
331
439
492
553
660
733
790

M2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

72
180
288
396
473
495
617
704
768
851

N2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

62
170
278
386
450
523
607
662
732
834

TABLE 9B

Germline information of selected anti-CLEC2D

antibodies from Table 9A

Anti-CLEC2D
Variable
Variable

antibody
Heavy chain
Light chain

No* (Selected
Framework—
Framework—

Antibodies
Germline
Germline

from Table 9A)
Family Information
Family Information

A1
IGHV4; IGHD3; IGHJ2
IGKV3; IGKJ4

B1
IGHV4; IGHD3; IGHJ5
IGKV1; IGKJ1

E1
IGHV3; IGHD5; IGHJ4
IGKV3; IGKJ5

P1
IGHV1; IGHD6; IGHJ4
IGKV3; IGKJ5

U1
IGHV4; IGHD1; IGHJ4
IGKV4; IGKJ4

Y1
IGHV5; IGHD5; IGHJ4
IGKV3; IGKJ4

E2
IGHV1; IGHD5; IGHJ4
IGKV1; IGKJ1

I2
IGHV6; IGHD1; IGHJ4
IGKV3; IGKJ1

L2
IGHV4; IGHD3; IGHJ4
IGKV1; IGKJ3

TABLE 9C

Amino acid and DNA sequence information of anti-CLEC2D antibodies

formatted as IgGl, IgG4, IgG N2A and IgG2.

Anti-

CLEC2D

No. *

(Selected

Antibodies

IgG1
IgG1

IgG4

IgG

from Table
IgG1
IgG1
HC
LC
IgG4
HC
IgG
N2A

IgG2

9A and 9B)
HC
LC
DNA
DNA
HC
DNA
N2A
DNA
IgG2
DNA

A1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1524
1632
1740
1848
1956
2064
2172
2280
2388
2496

B1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1525
1633
1741
1849
1957
2065
2173
2281
2389
2497

E1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1522
1630
1738
1846
1954
2062
2170
2278
2386
2494

P1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1481
1589
1697
1805
1913
2021
2129
2237
2345
2453

U1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1553
1661
1769
1877
1985
2093
2201
2309
2417
2525

Y1
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1501
1609
1717
1825
1933
2041
2149
2257
2365
2473

E2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1515
1623
1731
1839
1947
2055
2163
2271
2379
2487

I2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1538
1646
1754
1862
1970
2078
2186
2294
2402
2510

L2
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID
SEQ ID

1487
1595
1703
1811
1919
2027
2135
2243
2351
2459

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of the anti-CLEC2D antibody No. A1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of the anti-CLEC2D antibody No. A1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. A1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV4, IGHD3 and IGHJ2. In some embodiments, the anti-CLEC2D antibody No. A1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV3 and IGKJ4.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. B1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. B1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. B1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV4, IGHD3 and IGHJ5. In some embodiments, the anti-CLEC2D antibody No. B1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV1 and IGKJ1.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. E1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. E1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. E1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV3, IGHD5 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. E1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV3 and IGKJ5.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. P1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. P1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. P1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV1, IGHD6 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. P1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV3 and IGKJ5.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. U1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. U1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. U1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV4, IGHD1 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. U1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV4 and IGKJ4.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. Y1, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. Y1, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. Y1, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV5, IGHD5 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. Y1, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV3 and IGKJ4.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. E2, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. E2, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. E2, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV1, IGHD5 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. E2, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV1 and IGKJ1.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. I2, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. I2, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. I2, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV6, IGHD1 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. I2, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV3 and IGKJ1.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3, according to the amino acid sequence of the heavy chain CDRs 1, 2 and 3, and light chain CDRs 1, 2 and 3 of anti-CLEC2D antibody No. L2, as disclosed in Table 9A. In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of anti-CLEC2D antibody No. L2, as disclosed in Table 9A. In some embodiments, the anti-CLEC2D antibody No. L2, as disclosed in Table 9B, comprises a variable heavy chain having a framework region sequence of the Germline gene families: IGHV4, IGHD3 and IGHJ4. In some embodiments, the anti-CLEC2D antibody No. L2, as disclosed in Table 9B, comprises a variable light chain having a framework region sequence of the Germline families: IGKV1 and IGKJ3.

In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B) comprise a human IgG1 Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B) comprise a human IgG4 Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B) comprise a human IgG1 N to A Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B) comprise a human IgG2 Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9) is afucosylated. In some embodiments, any one or all of the anti-CLEC2D antibodies disclosed herein (e.g., including any one or all of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9) comprises an afucosylated antibody region.

In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B, comprise a human IgG1 Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9C, comprise a human IgG4 Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A and B, comprise a human IgG1 N to A Fc region or backbone. In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9C, comprise a human IgG2 Fc region or backbone.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a combination of a heavy chain and a light chain, according to the amino acid sequence of the heavy chain and light chain of an IgG1 formatted anti-CLEC2D antibody No. A1, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a heavy chain, according to the amino acid sequence of the heavy chain of an IgG4 formatted anti-CLEC2D antibody No. A1, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises an IgG N2A sequence, according to the amino acid sequence of the heavy chain of an IgG4 formatted anti-CLEC2D antibody No. L2, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a heavy chain, according to the amino acid sequence of the heavy chain of an IgG2 formatted anti-CLEC2D antibody No. A1, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises an IgG N2A sequence, according to the amino acid sequence of the heavy chain of an IgG2 formatted anti-CLEC2D antibody No. L2, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises a heavy chain, according to the amino acid sequence of the heavy chain of an IgG N2A formatted anti-CLEC2D antibody No. A1, as disclosed in Table 9C.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein, comprises an IgG N2A sequence, according to the amino acid sequence of the heavy chain of an IgG N2A formatted anti-CLEC2D antibody No. L2, as disclosed in Table 9C.

In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, is afucosylated. In some embodiments, any one or all of the anti-CLEC2D antibodies selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises an afucosylated antibody region.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to conformational epitope of CLEC2D antigen, comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence, that inhibits or abrogates or competes with another antibody that recognizes and binds to conformational epitope of CLEC2D antigen, comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen comprising of any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence that inhibits or abrogates or competes for, the binding of another antibody to conformational epitope of CLEC2D antigen comprising of any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-920 and 930-1003, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-909 and 930-1003, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an anti-CLEC2D antibody selected from the group consisting of Antibody Nos: A1, B1, E1, P1, U1, Y1, E2, I2 and L2, as disclosed in Table 9A, 9B and 9C, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-890, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein is deglycosylated. In some embodiments, a deglycosylated anti-CLEC2D antibody, as disclosed herein exhibits increased cytotoxicity towards a host cell, as compared to a glycosylated form of the same anti-CLEC2D antibody. In some embodiments, an anti-CLEC2D antibody, as disclosed herein comprised an N-linked glycosylation.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein is afucosylated. In some embodiments, an afucosylated anti-CLEC2D antibody, as disclosed herein exhibits increased cytotoxicity towards a host cell, as compared to a fucosylated form of the same anti-CLEC2D antibody.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein is sialylated. In some embodiments, a sialylated anti-CLEC2D antibody, as disclosed herein exhibits increased cytotoxicity towards a host cell, as compared to an unsialylated form of the same anti-CLEC2D antibody.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein is hyper-galactosylated. In some embodiments, a hyper-galactosylated anti-CLEC2D antibody, as disclosed herein exhibits increased cytotoxicity towards a host cell, as compared to an un-galactosylated or low galactosylated form of the same anti-CLEC2D antibody.

In some embodiments, an anti-CLEC2D antibody, as disclosed herein is hyper-mannosylated. In some embodiments, a hyper-mannosylated anti-CLEC2D antibody, as disclosed herein exhibits increased cytotoxicity towards a host cell, as compared to a non-galactosylated or low mannosylated form of the same anti-CLEC2D antibody.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the heavy chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed herein. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the light chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed herein.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable heavy chain of any of the anti-CLEC2D antibodies, as disclosed herein. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the light chain of any of the anti-CLEC2D antibodies, as disclosed herein.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable heavy chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed in Table 9A. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable light chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed in Table 9A.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable heavy chain any of the anti-CLEC2D antibodies, as disclosed in Table 9A. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable light chain of any of the anti-CLEC2D antibodies, as disclosed in Table 9A.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable heavy chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed in Table 9A. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable heavy chain of any of the anti-CLEC2D antibodies, as disclosed in Table 9A.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable light chain CDRs 1, 2 and 3 of any of the anti-CLEC2D antibodies, as disclosed in Table 9A. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the variable light chain of any of the anti-CLEC2D antibodies, as disclosed in Table 9A.

In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the heavy chain of the anti-CLEC2D antibodies, as disclosed in Table 9A, having a framework region sequence of the Germline families as disclosed herein. In some embodiments, the invention as disclosed herein, relates to a nucleic acid sequence encoding the amino acid sequence of the light chain of the anti-CLEC2D antibodies, as disclosed in Table 9A, having a framework region sequence of the Germline families as disclosed herein.

In some embodiments, the anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, can comprise a framework region sequence that is derived from or is a human, a murine, a rodent, a lagomorph, an equine, a bovine, an avian, a caprine, a porcine, a piscean, a canine or a feline framework germline family. In some embodiments, the anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, can comprise a framework region sequence that is derived from or is a human framework germline family.

In some embodiments, the invention as disclosed herein, relates to a vector carrying the nucleic acid encoding the amino acid sequences of an anti-CLEC2D antibody, as disclosed herein. In some embodiments, the invention as disclosed herein, relates to a vector carrying any one or all of the nucleic acid sequences encoding the amino acid sequences of an anti-CLEC2D antibody, as disclosed in Table 9A.

In some embodiments, the invention as disclosed herein, relates to a host cell transfected with a vector carrying the nucleic acid encoding the amino acid sequences of an anti-CLEC2D antibody, as disclosed herein. In some embodiments, the invention as disclosed herein, relates to relates to a host cell transfected with a vector carrying the nucleic acid sequences encoding the amino acid sequences of an anti-CLEC2D antibody, as disclosed in Table 9A.

In some embodiments, the anti-CLEC2D antibodies or antibody fragments thereof, as disclosed herein, can be conjugated to an agent, a chemical or a small molecule. In some embodiments, the agent is a therapeutic agent. In some embodiments, the therapeutic agent is a chemotherapeutic drug. In some embodiments, the therapeutic agent is a cytotoxic agent or drug. In some embodiments, the therapeutic agent is a radioisotope. In some embodiments, the agent is a diagnostic agent. In some embodiments, the diagnostic agent includes but is not limited to a fluorescent, chemiluminescent or radioisotopic dye or agent.

Epitope Recognition

Generally, the term “epitope” refers to the area or region on an antigen to which an antibody specifically binds, i.e., it is the area or region in physical contact with the antibody. A protein epitope may comprise amino acid residues in the antigen that are directly involved in binding to an antibody (also called the immunodominant component of the epitope) and other amino acid residues, which are not directly involved in the binding. In some embodiments, the term epitope herein includes both types of binding sites of any particular region of CLEC2D that specifically binds to an anti-CLEC2D antibody, or another CLEC2D-specific agent according to this disclosure, unless otherwise stated (e.g., in some contexts this disclosure relates to antibodies that bind directly to particular amino acid residues). More detailed epitope mapping of specific anti-CLEC2D antibody could be determined through an alanine scan approach.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to a human CLEC2D protein of amino acid sequence according to at least one of SEQ ID NOs: 886 to 909. In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to a human CLEC2D protein of amino acid sequence according to at least one of SEQ ID NOs: 930 to 1003.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to conformational epitope of CLEC2D antigen, comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that inhibits or abrogates or competes with another antibody that recognizes and binds to conformational epitope of CLEC2D antigen, comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen comprising of any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that inhibits or abrogates or competes for, the binding of another antibody to conformational epitope of CLEC2D antigen comprising of any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-909 and 930-1003, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-890, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-909 and 930-1003, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-890, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-920 and 930-1003 binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-909 and 930-1003 binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-890 binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumour killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acid residues: THR178; ASN95; ARG137; GLU179; TYR177; SER98; GLU162; GLN139; ARG101; ALA160; TRP96; CYS176; GLU138; ARG175; GLY140; SER136; ASP104; ASP92; THR97; LYS94; GLU150; THR149; GLY148; GLN141; PRO142; LYS144; THR152; TRP151; ASN147; ARG153; TRP143; ILE157; CYS163; SER129; THR93; LYS181; ASP91; ARG180; SER187; LYS194; TYR165; ALA174; LEU110; ASN167; ASP168; ILE146; SER172; GLY161; SER173; LEU135; ASP130; GLN100; PHE155; GLY159; PRO156; LEU158; GLN117; SER115; GLU114; GLN154; ASN120; PHE116; PHE102; GLN106; SER105; ASP107; LYS186; ASP109; GLN112; VAL191; TRP145; LYS169; GLY127; PRO128; GLN83; LYS85; GLU77; GLY170; LEU119; LEU123; TRP182; SER90; ALA108; TYR88; HIS190; ILE189; ALA73; ARG84; SER78; TRP79; PRO76; PHE82; ALA171; ASP188; CYS75 within a human CLEC2D of amino acid sequence according to SEQ ID NOs: 886, 889, 894, 899, 903, 905, 906 or 907.

In some embodiments, an anti-CLEC2D antibody as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acid residues: ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, within a human CLEC2D of amino acid sequence according to SEQ ID NOs: 886, 889, 894, 899, 903, 905, 906 or 907.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence of SEQ ID 42 & SEQ ID 258, that recognizes and binds to a human CLEC2D protein of amino acid sequence according to at least one of SEQ ID NOs: 886 to 909. In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence of SEQ ID 42 & SEQ ID 258, that recognizes and binds to a human CLEC2D protein of amino acid sequence according to at least one of SEQ ID NOs: 921 to 909.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to conformational epitope of CLEC2D antigen, comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an anti-CLEC2D antibody or antibody fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that inhibits or abrogates or competes with another antibody that recognizes and binds to conformational epitope of CLEC2D antigen, and comprises of amino acids positions either overlapping and/or non-overlapping with CD161 receptor interacting amino acid residues.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that inhibits or abrogates or competes with, the binding of another antibody to conformational epitope of CLEC2D antigen comprising of any of the amino acid positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 or a combination thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-909 and 930-1003, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-890, constituting non-linear scaffolds for CD161 receptor interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-920 and 930-1003, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-909 and 930-1003, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that binds to conformational epitope of CLEC2D antigen, comprises at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95 of SEQ ID No: 886-890, constituting allosteric and non-linear scaffolds for CD161 receptor non-interacting amino acid residues, thereby blocking the interaction between CLEC2D and CD161 receptors.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-920 and 930-1003, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumor killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-909 and 930-1003, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumor killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that when bound to CLEC2D selected from SEQ ID Nos: 886-890, binds to at least one of the amino acids positions ARG175; TYR177; GLU179; ARG153; ARG84; HIS190; ARG101; GLU150; GLN154; THR152; GLN141; SER105; ASP107; ASP92; THR93; LYS94; LYS144; GLU138; CYS176; GLN139; ARG180; SER187; LYS181; PHE116; ASN95, either independently or in combination to induce tumor killing or cytotoxicity. In some embodiments, an antibody or antigen binding fragment thereof, as disclosed herein, induces cytotoxicity in at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%, of the total number of cells treated with the antibody or antigen binding fragment thereof.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 42 & SEQ ID 258, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acid ARG175-XAA176-TYR177-XAA178-GLU179; ARG153; ARG84; HIS190.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 44 & SEQ ID 260, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acid ARG101; GLU150-XAA151-THR152-ARG153-GLN154; ARG175-XAA176-TYR177-XAA178-GLU179.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 45 & SEQ ID 261, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acid GLN141; ARG101-XAA102-XAA-103-XAA104-SER105-XAA106-ASP107; HIS190.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 1 & SEQ ID 217, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acids GLN141; ARG153; ASP92-THR93-LYS94; HIS190.

In some embodiments, an anti-CLEC2D antibody SEQ ID 58 & SEQ ID 274, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acids GLU138-XAA139-XAA140-GLN141-XAA142-XAA143-LYS144; CYS176.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 35 & SEQ ID 251, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acids GLU138-GLN139-XAA140-GLN141; ARG175-XAA176-TYR177-XAA178-XAA179-ARG180; SER187.

In some embodiments, an anti-CLEC2D antibody SEQ ID 21 & SEQ ID 237, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence that recognizes and binds to the amino acids ASP92; TYR177-XAA179-XAA180-LYS181; THR152-ARG153-GLN154.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 7 & SEQ ID 223, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acids THR93-XAA94-ASN95; ARG101; GLN139; PHE116; ARG153.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 73 & SEQ ID 289, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to the amino acids THR93-LYS94; ARG101; GLN141; TYR177-XAA178-GLU179.

In some embodiments, an anti-CLEC2D antibody, SEQ ID 73 & SEQ ID 289, as disclosed herein, comprises a variable heavy chain sequence and a variable light chain sequence, that recognizes and binds to any one of the amino acids according to SEQ ID NOs: 2561-2567.

Library Screening

Without wishing to be bound by any particular technique, antibodies which bind to the antigens of the disclosure can be identified and characterized using the methods described below.

Provided herein is a naïve antibody library as a source of therapeutics for treatment of diseases comprising cancers, rheumatoid arthritis, neurological disorders, infectious diseases and metabolic disorders or any combination thereof. Antibodies identified using the methods of the disclosure can be used as diagnostic tools, as prognostic tools; for research purposes, for target discovery, for validation in functional genomics or any application where antibodies or derivatives of antibodies are employed.

In one embodiment, the term “panning” refers to an affinity selection technique which selects for binders against a specific target/antigen.

In some embodiments, methods of screening the naïve antibody gene expression library include sequentially exploring the expression profiles of a pool of gene clones by utilizing two separate scanning tools: 1) a phage display technology, and 2) a yeast display technology (FIG. 3). Use of yeast system for antibody gene expression is advantageous because of the eukaryotic protein translation, processing and proper folding of the antibody products on the cell surface. Further, yeast expression allows proper interaction with antigenic targets with high specificity.

In some embodiments, the methods disclosed herein preserve the diversity in the library that is capable of identifying unique molecules against varied antigenic targets.

In some embodiments of the methods of the disclosure, the methodology also involves a strategy wherein the diversity is translated between two platforms and explored as various engineered antibody formats including, but not limited to, chimeric antibody molecules, Fv, Fav, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2, scFv-CH3, scFv-Fc, ScFab, dimeric and trimeric antibody fragments, minibodies, humanized monoclonal antibody molecules, human antibodies, bispecific antibodies, fusion proteins comprising an Fc region of an antibody, and any functional fragments arising out of these molecules wherein the derivative molecules retain the immunological functionality of the parent antibody molecule, and all other antibody formats.

In some embodiments, the candidate antibody molecules obtained by the present method are further optimized through rational design guided by structure-function studies of antibody-antigen interactions. The prerequisite for success of manufacturability of monoclonal antibody drugs are dependent on a variety of biological and/or correlated properties such as solubility, aggregation, antigenicity, stability and so on. As exemplified, structure-based drug design, which is rational, evidence based and faster, has contributed tremendously to the field of cancer chemotherapy, drug resistant infections, neurological diseases, amongst others. The resulting outcome of these methods is employed in the instant disclosure to improve antibody library construction and manufacturability of selected molecules.

In some embodiments, the term “isolated” relates to novel and unique molecules comprising of two protein chains or fragments thereof which are not part of a biological membrane. In particular, the isolated molecule according to the current disclosure is soluble and is linked either directly or indirectly via linker molecules through covalent or non-covalent bonds. These molecules may comprise monoclonal or polyclonal antibodies, which can be easily obtained according to methods well-known to the man skilled in the art.

In some embodiments, an affinity tag may be included in an antigen or antibody disclosed herein for isolation or detection purposes. Affinity tags are well known in the art and are attached to a target and used to detect or isolate the target using a molecule that binds the affinity tag. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Exemplary affinity tags suitable for use include, but are not limited to, a monocytic adaptor protein (MONA) binding peptide, a T7 binding peptide, a v5 tag, a streptavidin binding peptide, a polyhistidine tract, protein A (Nilsson et al., EMBO J. 4:1075 (1985); Nilsson et al., Methods Enzymol. 198:3 (1991)), glutathione S transferase (Smith and Johnson, Gene 67:31 (1988)), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952 (1985)), substance P, FLAG peptide (Hopp et al., Biotechnology 6:1204 (1988)), or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2:95 (1991). In one embodiment, a His6 tag is used in the methods disclosed herein. In another embodiment, a FLAG tag is used in the methods disclosed herein. In another embodiment, a v5 tag is used in the methods and compositions disclosed herein. DNA molecules encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, N.J.).

Taken together, the methods of the present disclosure are centralized around identifying, validating, characterizing and developing novel monoclonal antibodies against CLEC2D antigenic target. These novel monoclonal antibodies are developed for use in therapeutics, diagnostics and prognostics products applicable in various diseases, including cancers.

In some embodiments, the antibody library, which can be a naïve antibody library, allows for isolation of unique antibody molecules with the desired functional properties for a specific therapeutic target. i.e., an antigen such as the CLEC2D protein or any fragments thereof disclosed herein.

The combination of a diverse library and an appropriate and compatible display platform enables the rapid selection and production of therapeutic antibodies with higher affinity and improved functionality against specific antigen molecule. Typical screening for targeted therapeutic antibody molecules comprises selecting molecules from a diverse and large antibody library against a target antigen through display platforms via smaller antibody fragments followed by constructing a full-length antibody molecule expressed in a mammalian cell line. Once expressed, the process of purification and several functional assays to validate the same are performed. Optimization of parameters such as identification of epitopes, formulation, stability studies and in vivo efficacy further strengthen the development of the selected lead antibodies.

In an exemplary embodiment of the present disclosure, the method of screening, isolation and development of monoclonal antibodies from the human naïve antibody library against CLEC2D antigen comprises the following description. Designing and generation of various CLEC2D antigen constructs, i.e., soluble ecto-domain of wild-type and mutants; full-length CLEC2D proteins, in appropriately optimized/customized vectors to express in mammalian system followed by purification through affinity chromatography methods to homogeneity.

In some embodiments, the screening of a library of molecules is performed by about 1 to 3 rounds of phage panning with a CLEC2D antigen. During each round, specific binders are selected out from the library by removing non-binders. Selected pools of molecules screened in the phage display platform are transferred, with or without randomization of selected diversity, to a yeast surface display platform. This avoids any PCR based method steps, thereby preserving the selected pool of molecules against the CLEC2D antigen. The yeast display platform comprises expressing a variety of antibody moieties in different formats. Displayed fragments are screened against specific antigenic targets and specific populations showing higher affinity to the target antigen are separated. These selected pools are further tested for antigen specificity. Finally, individual clones are separated and clonal populations are used for sequencing of individual antibody clones.

Methods of phage panning against antigens are known in the art. For example, magnetic beads can be used. Antigen coated on magnetic dynabeads can be prepared, and a phage antibody library panned against the antigen coated beads to separate phage particles expressing the desired antibody clones.

Purified DNA can then be digested and ligated into a suitable yeast expression vector to generate antibodies in the desired format, such as Fab or ScFv. Yeast cells can be transformed by standard methods and checked for antibody expression. The surface expression of antibodies can be analysed with multiple tags such as FLAG, c-Myc and (His)₆-tag and V5-tag for heavy chains and light chains, respectively and immunohistochemistry. Flow cytometry can be used to isolate yeast cells expressing antibody sequences showing specific antigen binding. Flow cytometry sorting of yeast cell populations can be repeated at least 1×, at least 2×, at least 3×, at least 4× or at least 5× to enrich for antibody clones with higher affinity towards labelled antigens.

Individual yeast clones are sequences using methods standard in the art, and the antibody sequences are further cloned into suitable mammalian gene expression vectors.

The disclosure provides methods of screening a high diversity antibody gene library for antibodies that bind to a CLEC2D antigen. In some embodiments, the methods comprise inserting a library of antibody genes into a phage protein gene in a vector, and transforming phages to produce a phage library comprising the high diversity antibody gene library. The phages in the phage library display the library of antibody genes on the surface of the phage. This phage library is then panned with a CLEC2D antigen for individual phages that bind to the CLEC2D antigen, thereby producing an enriched phage library that is enriched for antibody genes that encode antibodies that bind to the CLEC2D antigen. This panning can be accomplished, for example, by conjugating the antigen to magnetic beads, which can be used to isolated phages that bind to the antigen on the beads. The panning step can be repeated at least once, at least twice or more times to enrich for phages expressing antibodies or antibody fragments that bind to the antigen.

Antibody or antibody fragment genes from the enriched phage library are then transferred to a yeast surface display library. In some embodiments, this is accomplished by cloning the antibody or antibody fragment genes into a suitable yeast transformation vector, and transforming yeast cells with methods that are standard in the art. Yeast cells that express antibody or antibody fragments that bind that bind to the CLEC2D antigen are then isolated. In some embodiments, this isolation is accomplished using flow cytometry to sort the yeast cells. In some embodiments, the method further comprises repeating the flow cytometry isolation at least 1×, at least 2×, at least 3×, at least 4× or at least 5× or more times to enrich for yeast cells expressing antibodies or antibody fragments that bind the antigen. In some embodiments, the methods further comprise analyzing the surface expression of the antibody genes with a FLAG tag, a c-Myc tag, a polyhistidine tag or a V5 tag. In some embodiments, the method further comprises cloning the antibody genes that bind to CLEC2D into a mammalian expression vector.

Optimization and Purification

In some embodiments, the methods disclosed herein comprise the design, generation and optimization of vector constructs for smooth transfer of selected antibody gene sequences to mammalian cell lines such as Chinese hamster ovary (CHO) cell lines for expression, stable cell-line generation and subsequent purification of full-length monoclonal antibody. This allows the rapid and efficient establishment of stable cell lines expressing monoclonal antibodies with excellent homogeneity in terms of conformation and posttranslational modification that are seen in downstream processes.

In some embodiments, the CDR lengths and the amino acid composition of antibody clones is analyzed to understand the novelty of these clones. Additional careful analysis is performed to eliminate clones that have motifs with detrimental to physico-chemical properties that have a direct impact on purification strategy, stability, and charge variants present or within the antibodies.

In some embodiments, the scale up of lead antibody clones is achieved through defined culture media, supplements, and specific bioreactor processes which are known in the art and described herein.

Exemplary purification methods of the disclosure comprise multiple steps of chromatography techniques that utilize the exploiting physico-chemical nature of the amino acid composition in antibody molecules. In addition, higher purity can be attained by effectively removing the host cell protein/impurities, polymer (or aggregate), of the antibody and improving the antibody recovery rate. Purification of antibody molecules is concluded with appropriate formulation which will further improve the stability.

Therapeutic compositions comprise of conditions that are sterile and stable under the conditions of manufacture and storage.

Antibody purification processes will be known to those of skill in the art. Without wishing to be bound by any particular process, exemplary antibody purification processes comprise centrifugation of a primary cell culture expressing the antibody or antibody fragment to be purified, followed by further clarification using a filter such as a 3 μm-30 μm filter. Subsequently, collected filtrate can be further filtered, for example through 0.22 μm filters. This sample can be loaded onto a column for further purification by liquid chromatography. Exemplary columns include, but are not limited to, XK 16/20 Protein A Columns. Liquid chromatography can include treatment with a high salt wash buffer to remove loosely bound host cell proteins and other impurities. A low pH wash buffer can remove traces of impurities. Subsequently, bound protein can be eluted using 30 mM Phosphate buffer at pH.3.0-4.0. This sample can be diluted to reduce the conductivity, and then can be further purified using anion exchange (AEX) Chromatography in a flow through mode (i.e., using negative binding). An exemplary AEX column includes, but is not limited to, a Q Sepharose XK 16/20 column, which can be pre-equilibrated in 10-100 mM Histidine and/or citrate and/or phosphate and/or MES and/or acetate buffer (pH 4.5-6.5). Weakly interacting proteins can be removed using an elution buffer as a wash, and bound proteins such as the antibodies or antibody fragments of the disclosure are eluted, for example, in a single step using elution buffer containing 1 M NaCl and/or KCl. Flow through from AEX Chromatography can be loaded onto a pre-equilibrated apto SP ImpRes C10/20 column in 10-100 mM Histidine and/or citrate and/or phosphate and/or 2-(N-morpholino)ethanesulfonic acid (MES) and/or Acetate buffer (pH 4.5-6.5). Bound proteins such as antibodies or antibody fragments of the disclosure can be eluted through step elution followed by gradient elution using elution buffer (Equilibration buffer containing 200-1000 mM NaCl and/or KCl, pH 4.5-6.5). However, high salt buffer containing 1 to 1.5 M NaCl, pH 4.5-6.5, can be to remove strongly bound proteins, if present.

Taken together, antibodies and antibody fragments of the disclosure can be purified through multiple steps of chromatography techniques in order to achieve high purity, while effectively removing the host cell protein/impurities, polymer (or aggregate), of the antibody and improving the antibody recovery rate; Exemplary chromatography methods include the use of a mixed mode resin having both an ion exchange group and a hydrophobic functional group. Amino acids can be used as an additive.

Methods of Treatment

As used herein. “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of an antibody or pharmaceutical composition comprising same of the disclosure to alleviate one or more symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder. The term “treat” can also include treatment of a cell in vitro or an animal model.

An antibody of the present disclosure, or a pharmaceutical composition thereof, can also be used to prevent a disease, condition or disorder, or used to identify suitable candidates for such purposes. As used herein, “preventing” or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.

As used herein, the term “alleviate” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased. Importantly, a sign or symptom can be alleviated without being eliminated. In a preferred embodiment, the administration of pharmaceutical compositions of this disclosure leads to the elimination of a sign or symptom, however, elimination is not required. Effective dosages are expected to decrease the severity of a sign or symptom. For instance, a sign or symptom of a disorder such as cancer, which can occur in multiple locations, is alleviated if the severity of the cancer is decreased within at least one of multiple locations.

As used herein the term “symptom” is defined as an indication of disease, illness, injury, or that something is not right in the body. Symptoms are felt or noticed by the individual experiencing the symptom, but may not easily be noticed by others. Others are defined as non-health-care professionals.

As used herein the term “sign” is also defined as an indication that something is not right in the body. But signs are defined as things that can be seen by a doctor, nurse, or other health care professional.

A therapeutically effective amount of an antibody of the disclosure relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the disclosure may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. (See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)).

In a non-limiting embodiment of the disclosure, isolated monoclonal antibodies reveal differential expression of CLEC2D on various cell surfaces, including immune cells and tumor cells, in response to various inducing conditions. This indicates the use of anti-CLEC2D antibodies as therapeutic agents for multiple disease indications.

The disclosure provides methods of treating diseases by modulating or inhibiting the interaction of CLEC2D with its cognate receptor CD161 by administering the compositions, the antibodies or antigen binding fragments thereof, and/or nucleic acids encoding the antibodies or antigen binding fragments thereof of the disclosure to a subject in need thereof.

In some embodiments, the diseases treated by the compositions, antibodies or antigen binding fragments thereof, and/or nucleic acids encoding the antibodies or antigen binding fragments thereof of the disclosure is a cancer, an autoimmune disease, an inflammatory disease, an infectious disease, or other diseases in which CLEC2D plays a role (e.g., by inhibiting CD161) in the initiation and/or development of the disease.

Exemplary diseases include, but are not limited to seronegative spondyloarthropathies such as psoriatic arthritis, ankylosing spondylitis, reiters syndrome and spondyloarthropathy associated with inflammatory bowel disease.

Exemplary diseases include, but are not limited to prosthetic joint loosening.

Exemplary diseases include, but are not limited to connective tissue diseases such as juvenile rheumatoid arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and lupus nephritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease and polymyositis, dermatomyositis.

Exemplary diseases include, but are not limited to inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

Exemplary diseases include, but are not limited to Whipples disease and arthritis associated with granulomatous ileocolitis.

Exemplary diseases include, but are not limited to inflammatory skin conditions such as autoimmune bullous pemphigoid, autoimmune pemphigus vulgaris, eczema and dermatitis.

Exemplary diseases include, but are not limited to inflammatory lung diseases such as alveolitis, pulmonary fibrosis, sarcoidoisis, asthma, bronchitis and bronchiolitis obliterans.

Exemplary diseases include, but are not limited to inflammatory renal diseases such as glomerulonethritis, renal allograft rejection and renal tubular inflammation.

Exemplary diseases include, but are not limited to atherosclerosis.

Exemplary diseases include, but are not limited to systemic vasculitis such as temporal arteritis/giant cell arteritis, takayasu arteritis, polyarteritis nodosa, Kawasaki disease, Wegener's granulomatosis, churg strauss syndrome, microscopic polyangiitis, necrotising glomerulonephritis, henoch schonlein purpura, essential cryoglobulinaemic vasculitis, other small vessel vasculitis and Behcets disease

Exemplary diseases include, but are not limited to macrophage activation diseases such as macrophage activation syndrome (MAS), adult onset stills disease and haemophagocytic syndrome.

Exemplary diseases include, but are not limited to polymyalgia rheumatica, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Type 1 Diabetes Mellitus, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis (MS), Guillain-Barre syndrome, Addison's disease, and/or Raynaud's phenomenon and Goodpasture's syndrome.

Exemplary diseases include, but are not limited to diseases linked with cancers and cancers, which comprise breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, pulmonary adenocarcinoma, adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, tubular cell carcinoma, ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, granulositic sarcoma, immunoblastic sarcoma, juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (leukemia), lymphatic sarcoma (lympho sarcoma), medullary sarcoma, myeloid sarcoma (granulocitic sarcoma), austiogenci sarcoma, periosteal sarcoma, reticulum cell sarcoma (histiocytic lymphoma), round cell sarcoma, spindle cell sarcoma, synovial sarcoma, telangiectatic audiogenic sarcoma, Burkitt's lymphoma, NPDL, NML, NH, diffuse lymphomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, acute myeloid lymphoma, chronic lymphocytic leukemia, chronic myeoloid leukemia, mantle cell lymphoma, and follicular lymphoma.

Exemplary diseases include, but are not limited to Adrenocortical Carcinoma, Bladder Urothelial Carcinoma, Breast Invasive Carcinoma, Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma, Cholangiocarcinoma, Colon Adenocarcinoma, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma, Esophageal Carcinoma, Glioblastoma Multiforme, Head and Neck Squamous Cell Carcinoma, Kidney Chromophobe, Kidney Renal Clear Cell Carcinoma, Kidney Renal Papillary Cell Carcinoma, Acute Myeloid Leukemia, Brain Lower Grade Glioma, Liver Hepatocellular Carcinoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Mesothelioma, Ovarian Serous Cystadenocarcinoma, Pancreatic Adenocarcinoma, Pheochromocytoma and Paraganglioma, Prostate Adenocarcinoma, Rectum Adenocarcinoma, Sarcoma, Skin Cutaneous Melanoma, Stomach Adenocarcinoma, Testicular Germ Cell Tumors, Thyroid Carcinoma, Thymoma, Uterine Corpus Endometrial Carcinoma, Uterine Carcinosarcoma, and Uveal Melanoma.

According to a preferred embodiment, the compositions and methods of this disclosure are directed to the treatment of metastatic cancer to bone, wherein the metastatic cancer is breast, lung, renal, multiple myeloma, thyroid, prostate, adenocarcinoma, blood cell malignancies, including leukemia and lymphoma; head and neck cancers; gastrointestinal cancers, including esophageal cancer, stomach cancer, colon cancer, intestinal cancer, colorectal cancer, rectal cancer, pancreatic cancer, liver cancer, pharynx cancer, cancer of the bile duct or gall bladder; malignancies of the female genital tract, including ovarian carcinoma, uterine endometrial cancers, vaginal cancer, and cervical cancer; bladder cancer; brain cancer, including neuroblastoma; sarcoma, osteosarcoma; and skin cancer, including malignant melanoma or squamous cell cancer.

In some embodiments, the methods of treatment of a disease or disorder in a subject, as disclosed herein, relates to activation of an immune cell in the subject in need thereof. In some embodiments, the methods of treatment of a disease or disorder in a subject, as disclosed herein, relates to activation of an immune cell (e.g., NK cell, B-cell, or T-cell). In some embodiments, the methods of treatment of a disease or disorder in a subject, as disclosed herein, relates to treatment of a mammalian subject. In some embodiments, the methods of treatment of a disease or disorder in a subject, as disclosed herein, relates to treatment of a human subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used as a therapeutic agents for treatment of a disease or disorder associated with differential or aberrant expression of CLEC2D, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject. In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, used in a method of treating a disease or disorder associated with differential or aberrant expression of CLEC2D, in a subject in need thereof, modulate or inhibit the interaction of CLEC2D with its cognate receptor CD161.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including; but not limited to seronegative spondyloarthropathies such as psoriatic arthritis, ankylosing spondylitis, reiters syndrome and spondyloarthropathy associated with inflammatory bowel disease, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to connective tissue diseases such as juvenile rheumatoid arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and lupus nephritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease and polymyositis, dermatomyositis, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including; but not limited to connective tissue diseases such as juvenile rheumatoid arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and lupus nephritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease and polymyositis, dermatomyositis, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including; but not limited to connective tissue diseases such as inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC22) antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to connective tissue diseases such as Whipples disease and arthritis associated with granulomatous ileocolitis, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to inflammatory skin conditions such as autoimmune bullous pemphigoid, autoimmune pemphigus vulgaris, eczema and dermatitis, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to inflammatory lung diseases such as alveolitis, pulmonary fibrosis, sarcoidoisis, asthma, bronchitis and bronchiolitis obliterans, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to atherosclerosis and coronary vascular diseases in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to inflammatory renal diseases such as glomerulonethritis, renal allograft rejection and renal tubular inflammation, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to systemic vasculitis such as temporal arteritis/giant cell arteritis, takayasu arteritis, polyarteritis nodosa, Kawasaki disease, Wegener's granulomatosis, churg strauss syndrome, microscopic polyangiitis, necrotising glomerulonephritis, henoch schonlein purpura, essential cryoglobulinaemic vasculitis, other small vessel vasculitis and Behcets disease, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to macrophage activation diseases such as macrophage activation syndrome (MAS), adult onset stills disease and haemophagocytic syndrome, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to polymyalgia rheumatica, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Type 1 Diabetes Mellitus, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis (MS), Guillain-Barre syndrome, Addison's disease, and/or Raynaud's phenomenon and Goodpasture's syndrome, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to diseases linked with cancer and cancers, which comprise breast cancer, prostate cancer, endometrial cancer, uterine cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, glioma, glioblastoma, myeloma, pheochromocytoma, paraganglioma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, cervical cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, gastric cancer, intestinal cancer, testicular cancer, skin cancer, thyroid cancer, thymoma, head and neck cancer, liver cancer, pharynx cancer, adrenocortical cancer, cholangiocarcinoma, mesothelioma, sarcoma, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, pulmonary adenocarcinoma, adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, tubular cell carcinoma, ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, granulositic sarcoma, immunoblastic sarcoma, juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (leukemia), lymphatic sarcoma (lympho sarcoma), medullary sarcoma, myeloid sarcoma (granulocitic sarcoma), austiogenci sarcoma, periosteal sarcoma, reticulum cell sarcoma (histiocytic lymphoma), round cell sarcoma, spindle cell sarcoma, synovial sarcoma, telangiectatic audiogenic sarcoma, Burkitt's lymphoma, NPDL, NML, NH, diffuse lymphomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, acute myeloid lymphoma, chronic lymphocytic leukemia, chronic myeoloid leukemia, mantle cell lymphoma, and follicular lymphoma, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to diseases linked with a metastatic cancer or cancers, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to diseases linked with a metastatic cancer or cancers to bone, in a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder including but not limited to diseases linked with a metastatic cancer or cancers, wherein the metastatic cancer is breast, lung, renal, multiple myeloma, thyroid, prostate, adenocarcinoma, blood cell malignancies, including leukemia and lymphoma; head and neck cancers; gastrointestinal cancers, including esophageal cancer, stomach cancer, colon cancer, intestinal cancer, colorectal cancer, rectal cancer, pancreatic cancer, liver cancer, cancer of the bile duct or gall bladder; malignancies of the female genital tract, including ovarian carcinoma, uterine endometrial cancers, vaginal cancer, and cervical cancer; bladder cancer; brain cancer, including neuroblastoma; sarcoma, osteosarcoma; and skin cancer, including malignant melanoma or squamous cell cancerin a subject in need thereof, wherein the method comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies in an amount effective for treatment or alleviating the symptoms of the disease in the subject.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, are used in a method of treatment of a subject by organ transplant or adoptive immune cell transplant. In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, block CD161 and CLEC2D interaction and reduces Graft vs Host rejection, due to killing if recipient dendritic cells by alloreactive NK cells.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, are used in a method of treatment of an infectious disease in a subject caused by microorganisms including but not limited to bacteria, fungi, protozoa, parasites, and viruses. In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, is used in a method of treatment of a bacterial disease in a subject caused by any one or more of (or any combination of) Acinetobacter baumanii, Actinobacillus sp., Actinomycetes, Actinomyces sp. (such as Actinomyces israelii and Actinomyces naeslundii), Aeromonas sp. (such as Aeromonas hydrophila, Aeromonas veronii biovar sobria (Aeromonas sobria), and Aeromonas caviae), Anaplasma phagocytophilum, Anaplasma marginale Alcaligenes xylosoxidans, Acinetobacter baumanii, Actinobacillus actinomycetemcomitans, Bacillus sp. (such as Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacillus thuringiensis, and Bacillus stearothermophilus), Bacteroides sp. (such as Bacteroides fragilis), Bartonella sp. (such as Bartonella bacilliformis and Bartonella henselae, Bifidobacterium sp., Bordetella sp. (such as Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica), Borrelia sp. (such as Borrelia recurrentis,and Borrelia burgdorferi), Brucella sp. (such as Brucella abortus, Brucella canis, Brucella melintensis and Brucella suis), Burkholderia sp. (such as Burkholderia pseudomallei and Burkholderia cepacia), Campylobacter sp. (such as Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter fetus), Capnocytophaga sp., Cardiobacterium hominis, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, Citrobacter sp. Coxiella burnetii, Corynebacterium sp. (such as, Corynebacterium diphtheriae, Corynebacterium jeikeum and Corynebacterium), Clostridium sp. (such as Clostridium perfringens, Clostridium difficile, Clostridium botulinum and Clostridium tetani), Eikenella corrodens, Enterobacter sp. (such as Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae and Escherichia coli, including opportunistic Escherichia coli, such as enterotoxigenic E. coli, enteroinvasive E. coli, enteropathogenic E. coli, enterohemorrhagic E. coli, enteroaggregative E. coli and uropathogenic E. coli) Enterococcus sp. (such as Enterococcus faecalis and Enterococcus faecium), Ehrlichia sp. (such as Ehrlichia chafeensia and Ehrlichia canis), Epidermophyton floccosum, Erysipelothrix rhusiopathiae, Eubacterium sp., Francisella tularensis, Fusobacterium nucleatum, Gardnerella vaginalis, Gemella morbillorum, Haemophilus sp. (such as Haemophilus influenzae, Haemophilus ducreyi, Haemophilus aegyptius, Haemophilus parainfluenzae, Haemophilus haemolyticus and Haemophilus parahaemolyticus, Helicobacter sp. (such as Helicobacter pylori, Helicobacter cinaedi and Helicobacter fennelliae), Kingella kingii, Klebsiella sp. (such as Klebsiella pneumoniae, Klebsiella granulomatis and Klebsiella oxytoca), Lactobacillus sp., Listeria monocytogenes, Leptospira interrogans, Legionella pneumophila, Leptospira interrogans, Peptostreptococcus sp., Mannheimia hemolytica, Microsporum canis, Moraxella catarrhalis, Morganella sp., Mobiluncus sp., Micrococcus sp., Mycobacterium sp. (such as Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium paratuberculosis, Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium bovis, and Mycobacterium marinum), Mycoplasm sp. (such as Mycoplasma pneumoniae, Mycoplasma hominis, and Mycoplasma genitalium), Nocardia sp. (such as Nocardia asteroides, Nocardia cyriacigeorgica and Nocardia brasiliensis), Neisseria sp. (such as Neisseria gonorrhoeae and Neisseria meningitidis), Pasteurella multocida, Pityrosporum orbiculare (Malassezia furfur), Plesiomonas shigelloides. Prevotella sp., Porphyromonas sp., Prevotella melaninogenica, Proteus sp. (such as Proteus vulgaris and Proteus mirabilis), Providencia sp. (such as Providencia alcalifaciens, Providencia rettgeri and Providencia stuartii), Pseudomonas aeruginosa, Propionib acterium acnes, Rhodococcus equi, Rickettsia sp. (such as Rickettsia rickettsii, Rickettsia akari and Rickettsia prowazekii, Orientia tsutsugamushi (formerly: Rickettsia tsutsugamushi) and Rickettsia typhi), Rhodococcus sp., Serratia marcescens, Stenotrophomonas maltophilia, Salmonella sp. (such as Salmonella enterica, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Salmonella cholerasuis and Salmonella typhimurium), Serratia sp. (such as Serratia marcesans and Serratia liquifaciens), Shigella sp. (such as Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei), Staphylococcus sp. (such as Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hemolyticus, Staphylococcus saprophyticus), Streptococcus sp. (such as Streptococcus pneumoniae (for example chloramphenicol-resistant serotype 4 Streptococcus pneumoniae, spectinomycin-resistant serotype 6B Streptococcus pneumoniae, streptomycin-resistant serotype 9V Streptococcus pneumoniae, erythromycin-resistant serotype 14 Streptococcus pneumoniae, optochin-resistant serotype 14 Streptococcus pneumoniae, rifampicin-resistant serotype 18C Streptococcus pneumoniae, tetracycline-resistant serotype 19F Streptococcus pneumoniae, penicillin-resistant serotype 19F Streptococcus pneumoniae, and trimethoprim-resistant serotype 23F Streptococcus pneumoniae, chloramphenicol-resistant serotype 4 Streptococcus pneumoniae, spectinomycin-resistant serotype 6B Streptococcus pneumoniae, streptomycin-resistant serotype, 9V Streptococcus pneumoniae, optochin-resistant serotype 14 Streptococcus pneumoniae, rifampicin-resistant serotype 18C Streptococcus pneumoniae, penicillin-resistant serotype 19F, Streptococcus pneumoniae, or trimethoprim-resistant serotype 23F Streptococcus pneumoniae), Streptococcus agalactiae, Streptococcus mutans, Streptococcus pyogenes, Group A streptococci, Streptococcus pyogenes, Group B streptococci, Streptococcus agalactiae, Group C streptococci, Streptococcus anginosus, Streptococcus equismilis, Group D streptococci, Streptococcus bovis, Group F streptococci, and Streptococcus anginosus Group G streptococci), Spirillum minus, Streptobacillus moniliformi, Treponema sp. (such as Treponema carateum, Treponema petenue, Treponema pallidum and Treponema endemicum, Trichophyton rubrum, T. mentagrophytes, Tropheryma whippelii, Ureaplasma urealyticum, Veillonella sp., Vibrio sp. (such as Vibrio cholerae, Vibrio parahemolyticus, Vibrio vulnificus, Vibrio parahaemolyticus, Vibrio vulnificus, Vibrio alginolyticus, Vibrio mimicus, Vibrio hollisae, Vibrio fluvialis, Vibrio metchnikovii, Vibrio damsela and Vibrio furnisii), Yersinia sp. (such as Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis) and Xanthomonas maltophilia among others.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, is used in a method of treatment of a fungal disease in a subject caused by any one or more of (or any combination of) Aspergillus, Blastomyces, Candidiasis, Coccidiodomycosis, Cryptococcus neoformans, Cryptococcus gatti, sp. Histoplasma sp. (such as Histoplasma capsulatum), Pneumocystis sp. (such as Pneumocystis jirovecii), Stachybotrys (such as Stachybotrys chartarum), Mucroymcosis, Sporothrix, fungal eye infections ringworm, Exserohilum, Cladosporium.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, is used in a method of treatment of a protozoan disease in a subject caused by any one or more of (or any combination of) Euglenozoa, Heterolobosea, Diplomonadida, Amoebozoa, Blastocystic, and Apicomplexa. Example Euglenoza include, but are not limited to, Trypanosoma cruzi (Chagas disease), T. brucei gambiense, T. brucei rhodesiense, Leishmania braziliensis, L. infantum, L. mexicana, L. major, L. tropica, and L. donovani. Example Heterolobosea include, but are not limited to, Naegleria fowleri. Example Diplomonadids include, but are not limited to, Giardia intestinalis (G. lamblia, G. duodenalis). Example Amoebozoa include, but are not limited to, Acanthamoeba castellanii, Balamuthia madrillaris, Entamoeba histolytica. Example Blastocysts include, but are not limited to, Blastocystic hominis. Example Apicomplexa include, but are not limited to, Babesia microti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, is used in a method of treatment of a viral disease in a subject caused by any one or more of (or any combination of) Ebolavirus, measles virus, SARS, Chikungunya virus, hepatitis viruses, Marburg virus, yellow fever virus, MERS, Dengue virus, Lassa fever virus, influenza virus, rhabdovirus or HIV. A hepatitis virus may include hepatitis A, hepatitis B, or hepatitis C.

In some embodiments, the anti-CLEC2D antibody and compositions of the disclosure, is used in a method of treatment of a viral disease in a subject caused by any one or more of (or any combination of) a human respiratory syncytial virus, Sudan ebola virus, Bundibugyo virus, Tai Forest ebola virus, Reston ebola virus, Achimota, Aedes flavivirus, Aguacate virus, Akabane virus, Alethinophid reptarenavirus, Allpahuayo mammarenavirus, Amapari mmarenavirus, Andes virus, Apoi virus, Aravan virus, Aroa virus, Arumwot virus, Atlantic salmon paramyxovirus, Australian bat lyssavirus, Avian bornavirus, Avian metapneumovirus, Avian paramyxoviruses, penguin or Falkland Islandsvirus, BK polyomavirus, Bagaza virus, Banna virus, Bat herpesvirus, Bat sapovirus, Bear Canon mammarenavirus, Beilong virus, Betacoronavirus, Betapapillomavirus 1-6, Bhanja virus, Bokeloh bat lyssavirus, Borna disease virus, Bourbon virus, Bovine hepacivirus, Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Brazoran virus, Bunyamwera virus, Caliciviridae virus. California encephalitis virus, Candiru virus, Canine distemper virus, Canine pneumovirus, Cedar virus, Cell fusing agent virus, Cetacean morbillivirus, Chandipura virus, Chaoyang virus, Chapare mammarenavirus, Chikungunya virus, Colobus monkey papillomavirus, Colorado tick fever virus, Cowpox virus, Crimean-Congo hemorrhagic fever virus, Culex flavivirus, Cupixi mammarenavirus, Dengue virus, Dobrava-Belgrade virus, Donggang virus, Dugbe virus, Duvenhage virus, Eastern equine encephalitis virus, Entebbe bat virus, Enterovirus A-D, European bat lyssavirus 1-2, Eyach virus, Feline morbillivirus, Fer-de-Lance paramyxovirus, Fitzroy River virus, Flaviviridae virus, Flexal mammarenavirus, GB virus C, Gairo virus, Gemycircularvirus, Goose paramyxovirus SF02, Greatlsland virus, Guanarito mammarenavirus, Hantaan virus, Hantavirus Z10, Heartland virus, Hendra virus, Hepatitis A/B/C/E, Hepatitis delta virus, Human bocavirus, Human coronavirus, Human endogenous retrovirus K, Human enteric coronavirus, Human genital-associated circular DNA virus-1, Human herpesvirus 1-8, Human immunodeficiency virus 1/2, Human mastadenovirus AG, Human papillomavirus, Human parainfluenza virus 1-4, Human paraechovirus, Human picornavirus, Human smacovirus, Ikoma lyssavirus, Ilheus virus, Influenza A-C, Ippy mammarenavirus, Irkut virus, J-virus, JC polyomavirus, Japanese encephalitis virus, Junin mammarenavirus, KI polyomavirus, Kadipiro virus, Kamiti River virus, Kedougou virus, Khuj and virus, Kokobera virus, Kyasanur forest disease virus, Lagos bat virus, Langat virus, Lassa mammarenavirus, Latino mammarenavirus, Leopards Hill virus, Liao ning virus, Ljungan virus, Lloviu virus, Louping ill virus, Lujo mammarenavirus, Luna mammarenavirus, Lunk virus, Lymphocytic choriomeningitis mammarenavirus, Lyssavirus Ozernoe, MSSI2Y225 virus, Machupo mammarenavirus, Mamastrovirus 1, Manzanilla virus, Mapuera virus, Marburg virus, Mayaro virus, Measles virus, Menangle virus, Mercadeo virus, Merkel cell polyomavirus, Middle East respiratory syndrome coronavirus, Mobala mammarenavirus, Modoc virus, Moijang virus, Mokolo virus, Monkeypox virus, Montana myotis leukoenchalitis virus, Mopeia lassa virus reassortant 29, Mopeia mammarenavirus, Morogoro virus, Mossman virus, Mumps virus, Murine pneumonia virus, Murray Valley encephalitis virus, Nariva virus, Newcastle disease virus, Nipah virus, Norwalk virus, Norway rat hepacivirus, Ntaya virus, O'nyong-nyong virus, Oliveros mammarenavirus, Omsk hemorrhagic fever virus, Oropouche virus, Parainfluenza virus 5, Parana mammarenavirus, Parramatta River virus, Peste-des-petits-ruminants virus, Pichande mammarenavirus, Picornaviridae virus, Pirital mammarenavirus, Piscihepevirus A, Porcine parainfluenza virus 1, porcine rubulavirus, Powassan virus, Primate T-lymphotropic virus 1-2, Primate erythroparvovirus 1, Punta Toro virus, Puumala virus, Quang Binh virus, Rabies virus, Razdan virus, Reptile bornavirus 1, Rhinovirus A-B, Rift Valley fever virus, Rinderpest virus, Rio Bravo virus, Rodent Torque Teno virus, Rodent hepacivirus, Ross River virus, Rotavirus A-I, Royal Farm virus, Rubella virus, Sabia mammarenavirus, Salem virus, Sandfly fever Naples virus, Sandfly fever Sicilian virus, Sapporo virus, Sathuperi virus, Seal anellovirus, Semliki Forest virus, Sendai virus, Seoul virus, Sepik virus, Severe acute respiratory syndrome-related coronavirus, Severe fever with thrombocytopenia syndrome virus, Shamonda virus, Shimoni bat virus, Shuni virus, Simbu virus, Simian torque teno virus, Simian virus 40-41, Sin Nombre virus, Sindbis virus, Small anellovirus, Sosuga virus, Spanish goat encephalitis virus, Spondweni virus, St. Louisencephalitis virus, Sunshine virus, TTV-like mini virus, Tacaribe mammarenavirus, Taila virus, Tamana bat virus, Tamiami mammarenavirus, Tembusu virus, Thogoto virus, Thottapalayam virus, Tick-borne encephalitis virus, Tioman virus, Togaviridae virus, Torque teno canis virus, Torque teno douroucouli virus, Torque teno felis virus, Torque teno midi virus, Torque teno sus virus, Torque teno tamarin virus, Torque teno virus, Torque teno zalophus virus, Tuhoko virus, Tula virus, Tupaia paramyxovirus, Usutu virus, Uukuniemi virus, Vaccinia virus, Variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis Indiana virus, WU Polyomavirus, Wesselsbron virus, West Caucasian bat virus, West Nile virus, Western equine encephalitis virus, Whitewater Arroyo mammarenavirus, Yellow fever virus, Yokose virus, Yug Bogdanovac virus, Zaire ebolavirus, Zika virus, or Zygosaccharomyces bailii virus Z viral sequence. Examples of diseases caused by RNA viruses that may be treated include one or more of (or any combination of) Coronaviridae virus, a Picornaviridae virus, a Caliciviridae virus, a Flaviviridae virus, a Togaviridae virus, a Bornaviridae, a Filoviridae, a Paramyxoviridae, a Pneumoviridae, a Rhabdoviridae, an Arenaviridae, a Bunyaviridae, an Orthomyxoviridae, or a Deltavirus. In certain embodiments, the virus is Coronavirus, SARS, Poliovirus, Rhinovirus, Hepatitis A, Norwalk virus, Yellow fever virus, West Nile virus, Hepatitis C virus, Dengue fever virus, Zika virus, Rubella virus, Ross River virus, Sindbis virus, Chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, Measles virus, Mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, Human respiratory syncytial virus, Rabies virus, Lassa virus, Hantavirus, Crimean-Congo hemorrhagic fever virus, Influenza, or Hepatitis D virus. In certain embodiments, the virus is retrovirus, including but not limited to one or more of or any combination of viruses of the Genus Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, Epsilonretrovirus, Lentivirus, Spumavirus, or the Family Metaviridae, Pseudoviridae, and Retroviridae (including HIV), Hepadnaviridae (including Hepatitis B virus), and Caulimoviridae (including Cauliflower mosaic virus).

In some embodiments, the infectious diseases comprises a chronic viral infection, such as HIV. In some embodiments, the infectious disease comprises a chronic bacterial infection such as tuberculosis (TB). In some embodiments, the infectious disease comprises a chronic parasitic infection such as malaria.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure, are used in a method of treating a disease or disorder characterized by increased expression of CLEC2D on the surface of various cells of a subject in need thereof, comprising administering to a subject in need thereof one or more anti-CLEC2D antibodies of the disclosure as therapeutic agents in an amount sufficient to either: (i) block binding of the CLEC2D on the various cells to CD161 on the surface of an immune cell; (ii) reduce expression of CLEC2D on the various cells; (iii) reduce expression of one or more genes induced in an immune cell by binding of the CLEC2D to the CD161 on the immune cell (iv) binding to and/or activating one or more Fc receptors on the surface of the immune cell, (v) bind to CLEC2D on the surface of an immune cells and activate the immune cell, or any combination thereof.

In some embodiments, the invention relates to a method of assessing the efficacy of a therapeutic agent in a subject suffering from a cancer or tumor or both, comprising: a) detecting the number of viable and/or proliferating cancer cells in a sample from a subject; b) administering a therapeutically effective amount of one or more anti-CLEC2D antibodies of the disclosure to the subject; c) repeating step a) one or more times; and d) comparing the number of viable and/or proliferating cancer cells detected in steps a) to those detected in step c), wherein the anti-CLEC2D antibodies: (i) bind to CLEC2D on the surface of the cancer cells and inhibits the interaction between the CLEC2D on the tumor cells and CD161 on the surface of immune cells; (ii) bind to CLEC2D on the surface of the cancer cells and Fc receptors on the surface of immune cells to induce lysis of the cancer cell; (iii) bind to CLEC2D on the surface of immune cells and activate the immune cells; or a combination thereof, wherein the absence of, or decrease in number of viable and/or proliferating cancer cells detected in step c) as compared to the number of viable and/or proliferating cancer cells detected in step a) indicates that the agent is effective.

In some embodiments, the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D and bodies of the disclosure, may enhance the function of mucosal associated invariant T (MAIT) cells, NK cells or T cells.

In some embodiments, the invention relates to a method of treatment of a disease or disorder in a subject, wherein the method comprises administering to the subject in need thereof, a combination of a therapeutically effective amount of an anti-CLEC2D antibody of the disclosure and a therapeutically effective amount of at least a second therapeutic agent. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of a tumor cell or immune cell.

In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of a tumor cell, that induces apoptosis of the tumor cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of a tumor cell, that induces killing by the immune cell through antibody directed cellular cytotoxicity (ADCC) or complement directed cytotoxicity (CDC). In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that induces activation of the immune cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that induces cytokine production by the immune cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that induces chemokine production by the immune cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that induces production of inflammatory cytokines of the immune cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that activates the immune cells to recognize and induce cytotoxicity in a cancer cell. In some embodiments, the at least one second therapeutic agent as disclosed herein, comprises a therapeutic antibody against a protein or antigen expressed on the surface of an immune cell, that activates the immune cells to recognize and induce cytotoxicity in cell infected with a pathogen, wherein the pathogen includes but is not limited to a virus or a bacteria.

In some embodiments, the methods of treatment of a disease or disorder in a subject, as disclosed herein, comprises administering the anti-CLEC2D antibodies or a composition comprising the anti-CLEC2D antibodies of the disclosure and at least a second therapeutic agent, sequentially or simultaneously.

Treatment of Inflammatory Diseases

In some embodiments, the disease or disorder treated by the antibodies and pharmaceutical compositions comprising the same of the disclosure comprises an inflammatory or autoimmune disease or disorder.

As used herein, the term “inflammatory disorders” refers to pathological states resulting in inflammation, typically caused by neutrophil chemotaxis.

As used herein, autoimmune diseases or disorders are caused when the body's immune system, which normally defends the body against bacteria, viruses and other infective agents, attacks ‘self’ tissue, cells and organs. The mobilization of the immune system against such “self” targets is termed autoimmunity. Although some autoimmunity is present in every individual, rigid control systems suppress the self-recognizing cells of the immune system to an extent that the autoimmunity is normally asymptomatic. Disease states arise when there is some interruption in the control system, allowing the autoimmune cells to escape suppression, or when there is some change in a target tissue such that it is no longer recognized as self Autoimmune disorders can be characterized by inflammatory responses.

Exemplary, but non-limiting examples of inflammatory or autoimmune disorders include, but are not limited to seronegative spondyloarthropathies, connective tissue diseases, inflammatory bowel diseases, arthritis, inflammatory skin conditions, inflammatory lung diseases, inflammatory renal disease, systemic vasculitis, macrophage activation diseases, polymyalgia rheumatica, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Type 1 Diabetes Mellitus, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis (MS), Guillain-Barre syndrome, Addison's disease, Raynaud's phenomenon and Goodpasture's syndrome.

In some embodiments, a therapeutically effective amount of an antibody of pharmaceutical composition comprising same of the disclosure alleviates or prevents a sign or a symptom of an inflammatory or autoimmune disorder.

In some embodiments, a therapeutically effective amount of an antibody of pharmaceutical composition comprising same of the disclosure reduces an amount of inflammation in one or more tissues or organs of the subject.

In some embodiments, a therapeutically effective amount of an antibody of pharmaceutical composition comprising same of the disclosure transiently reduces or inhibits one or more aspects of the disease or of the immune response. Such a transient inhibition or reduction of one or more aspects of the disease or of the immune system can last for hours, days, weeks, or months. Preferably, the transient inhibition or reduction in one or more aspects of the disease or of the immune response last for a few hours (e.g., 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 14 hours, 16 hours, 18 hours, 24 hours, 36 hours, or 48 hours), a few days (e.g., 3 days, 4 days, 5 days, 6 days, 7 days, or 14 days), or a few weeks (e.g., 3 weeks, 4 weeks, 5 weeks or 6 weeks).

The prophylactic, therapeutic or immunomodulatory activity of an antibody or pharmaceutical composition comprising an antibody of the disclosure can be determined in vitro and/or in vivo by any technique well-known to one skilled in the art, including, e.g., by CTL assays, proliferation assays, and immunoassays (e.g., ELISAs) for the expression of particular proteins such as co-stimulatory molecules and cytokines.

Treatment of Cancer

As used herein, the term “severity” is meant to describe the potential of cancer to transform from a precancerous, or benign, state into a malignant state. Alternatively, or in addition, severity is meant to describe a cancer stage, for example, according to the TNM system (accepted by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC)) or by other art-recognized methods. Cancer stage refers to the extent or severity of the cancer, based on factors such as the location of the primary tumor, tumor size, number of tumors, and lymph node involvement (spread of cancer into lymph nodes). Alternatively, or in addition, severity is meant to describe the tumor grade by art-recognized methods (see, National Cancer Institute, www.cancer.gov). Tumor grade is a system used to classify cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread. Many factors are considered when determining tumor grade, including the structure and growth pattern of the cells. The specific factors used to determine tumor grade vary with each type of cancer. Severity also describes a histologic grade, also called differentiation, which refers to how much the tumor cells resemble normal cells of the same tissue type (see, National Cancer institute, www.cancer.gov). Furthermore, severity describes a nuclear grade, which refers to the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are dividing (see, National Cancer institute, www.cancer.gov).

In another aspect of this disclosure, severity describes the degree to which a tumor has secreted growth factors, degraded the extracellular matrix, become vascularized, lost adhesion to juxtaposed tissues, or metastasized. Moreover, severity describes the number of locations to which a primary tumor has metastasized. Finally, severity includes the difficulty of treating tumors of varying types and locations. For example, inoperable tumors, those cancers Which have greater access to multiple body systems (hematological and immunological tumors), and those which are the most resistant to traditional treatments are considered most severe. In these situations, prolonging the life expectancy of the subject and/or reducing pain, decreasing the proportion of cancerous cells or restricting cells to one system, and improving cancer stage/tumor grade/histological grade/nuclear grade are considered alleviating a sign or symptom of the cancer.

Cancer is a group of diseases that may cause almost any sign or symptom. The signs and symptoms will depend on where the cancer is, the size of the cancer, and how much it affects the nearby organs or structures. If a cancer spreads (metastasizes), then symptoms may appear in different parts of the body.

Treating cancer can result in a reduction in size of a tumor. A reduction in size of a tumor may also be referred to as “tumor regression”. Preferably, after treatment, tumor size is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor size is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Size of a tumor may be measured by any reproducible means of measurement. The size of a tumor may be measured as a diameter of the tumor.

Treating cancer can result in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Tumor volume may be measured by any reproducible means of measurement.

Treating cancer results in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. Number of tumors may be measured by any reproducible means of measurement. The number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2×, 3×, 4×, 5×, 10×, or 50×.

Treating cancer can result in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. The number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2×, 3×, 4×, 5×, 10×, or 50×.

Treating cancer can result in an increase in average survival time of a population of treated subjects in comparison to a population receiving earlier alone. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an antibody or pharmaceutical composition comprising same. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an antibody or pharmaceutical composition comprising same.

Treating cancer can result in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an antibody or pharmaceutical composition comprising same. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an antibody or pharmaceutical composition comprising same of the present disclosure.

Treating cancer can result in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not an antibody of the present disclosure. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an antibody or pharmaceutical composition comprising same of the present disclosure. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an antibody or pharmaceutical composition comprising same of the present disclosure.

Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not an antibody or a pharmaceutical composition comprising same of the present disclosure. Preferably, the mortality rate is decreased by more than 2%; more preferably, by more than 5%; more preferably, by more than 10%; and most preferably, by more than 25%. A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means. A decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an antibody. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an antibody.

Treating cancer can result in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Tumor growth rate may be measured by any reproducible means of measurement. Tumor growth rate can be measured according to a change in tumor diameter per unit time.

Treating cancer can result in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 30%; and most preferably, less than 75%. Tumor regrowth may be measured by any reproducible means of measurement. Tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. A decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.

Treating cancer can result in a reduction in the rate of cellular proliferation. Preferably, after treatment, the rate of cellular proliferation is reduced by at least 5%; inure preferably, by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. The rate of cellular proliferation may be measured by any reproducible means of measurement. The rate of cellular proliferation is measured, for example, by measuring the number of dividing cells in a tissue sample per unit time.

Treating cancer can result in a reduction in the proportion of proliferating cells. Preferably, after treatment, the proportion of proliferating cells is reduced by at least 5%; more preferably; by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%, even more preferably, by at least 50%; and most preferably, by at least 75%. The proportion of proliferating cells may be measured by any reproducible means of measurement. Preferably, the proportion of proliferating cells is measured, for example, by quantifying the number of dividing cells relative to the number of nondividing cells in a tissue sample. The proportion of proliferating cells can be equivalent to the mitotic index.

Treating cancer can result in a decrease in size of an area or zone of cellular proliferation. Preferably, after treatment, size of an area or zone of cellular proliferation is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Size of an area or zone of cellular proliferation may be measured by any reproducible means of measurement. The size of an area or zone of cellular proliferation may be measured as a diameter or width of an area or zone of cellular proliferation. Treating cancer can result in a decrease in the number or proportion of cells having an abnormal appearance or morphology. Preferably, after treatment, the number of cells having an abnormal morphology is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. An abnormal cellular appearance or morphology may be measured by any reproducible means of measurement. An abnormal cellular morphology can be measured by microscopy, e.g., using an inverted tissue culture microscope. An abnormal cellular morphology can take the form of nuclear pleiomorphism.

Treating cancer can result in cell death, and preferably, cell death results in a decrease of at least 10% in number of cells in a population. More preferably, cell death means a decrease of at least 20%; more preferably, a decrease of at least 30%; more preferably, a decrease of at least 40%; more preferably, a decrease of at least 50%; most preferably; a decrease of at least 75%. Number of cells in a population may be measured by any reproducible means. A number of cells in a population can be measured by fluorescence activated cell sorting (FACS), immunofluorescence microscopy and light microscopy. Methods of measuring cell death are as shown in Li et al., Proc Natl Acad Sci USA. 100(5): 2674-8, 2003. In an aspect; cell death occurs by apoptosis.

Monotherapies

In the some embodiments of the disclosure, the antibodies and compositions of the disclosure are administered as monotherapies for the treatment of a disease.

As used herein, “monotherapy” refers to the administration of a single active or therapeutic compound to a subject in need thereof. Preferably, monotherapy will involve administration of a therapeutically effective amount of an active compound. For example, cancer monotherapy with one of the antibodies of the present disclosure, or a pharmaceutical composition thereof, to a subject in need of treatment of cancer. Monotherapy may be contrasted with combination therapy, in which a combination of multiple active compounds is administered, preferably with each component of the combination present in a therapeutically effective amount. In one aspect, monotherapy with an antibody or pharmaceutical composition of the present disclosure is more effective than combination therapy in inducing a desired biological effect.

An antibody according to the disclosure can also be used as an agent for detecting the presence of CLEC2D (or a protein or a protein fragment thereof) in a sample. Preferably, the antibody contains a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab, scFv, or F_(ab)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the disclosure can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA includes Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and “Practice and Theory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

Antibodies directed against a CLEC2D protein (or a fragment thereof) may be used in methods known within the art relating to the localization and/or quantitation of a CLEC2D protein (e.g., for use in measuring levels of the CLEC2D protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a CLEC2D protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).

An antibody specific for a CLEC2D protein of the disclosure can be used to isolate a CLEC2D polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. Antibodies directed against a CLEC2D protein (or a fragment thereof) can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Combination Therapies

In the some embodiments of the disclosure, the antibodies and compositions of the disclosure are administered as part of a combination therapy for the treatment of a disease.

For example, anti-CLEC2D antibodies have been tested in xenograft studies alone and in combination with a check point monoclonal antibody (anti PDL1). The combinatorial treatment with anti-CLEC2D and anti-PDL1 had revealed significant tumor growth reduction. Therefore, Anti-CLEC2D antibody can be used in combination with other therapies for therapeutic purposes.

These therapies include, but are not restricted to, T cell targeted immunomodulatory mechanisms, other immunomodulatory mechanisms, cancer vaccines, adoptive cell therapies, oncolytic viruses, additional antibody therapies including bispecific and other combinations of antibody fragments, radiotherapy, antibody drug conjugates, small interfering RNAs, chemotherapy, immunotherapy, immune checkpoint inhibitors, mitotic inhibitors or a combination thereof.

Chemotherapies, small molecules and biologics that can be administered in combination with an anti-CLEC2D antibodies or compositions of the disclosure include, but are not restricted to hormonal therapies, PARP inhibitors, Androgen receptor inhibitors, tyrosine kinase inhibitors, Abiraterone acetate, Enzalutamide, Apalutamide, Darolutamide, Phosphoinositide 3 Kinase Beta-Selective Inhibitors, Radium 223 Dichloride and other variants, androgen receptor antagonist, CYP17A1 inhibitors, LHRH antagonist, LHRH analogs, Cyclophosphamide, cabazitaxel, Docetaxel, PULP vaccines like Sipuleucel-T, Prostvac, Provange, PSCA, whole cell vaccines and others, therapeutics against PULP surface antigens, Cisplatin, Bispecific antibody-CD3 and ADAM17, pTVG-HP Plasmid DNA Vaccine and other similar vaccines, Tisotumab Vedotin, DCVAC/PCa, GX301, GVAX-PCa and Denosumab.

Chemotherapeutic drugs and anti-cancer agents that can be administered in combination with an anti-CLEC2D antibodies or compositions of the disclosure include, but are not restricted to alkylating agents, antimetabolites, plant alkaloids, vinca alkaloids, mitotic inhibitors, antitumor antibiotics, platinum based anti-neoplastics, topoisomerase inhibitors and protein kinase inhibitors. Exemplary alkylating agents comprise busulfan, cyclophosphamide and temozolamide. Exemplary antimetabolites comprise 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), Capecitabine (Xeloda) and Gemcitabine. Exemplary anti tumor antibiotics comprise Dactinomycin, Bleomycin, Daunorubicin and Doxorubicin. Exemplary platinum based anti-neoplastics comprise Cisplatin and Carboplatin. Exemplary topoisomerase inhibitors comprise Etoposide, Irinotecan and Topotecan. Exemplary mitotic inhibitors comprise taxanes (e.g., Paclitaxel, Docetaxel), vinca alkaloids (Vinblastine, Vincristine, Vinorelbine) and colchicine. Additional chemotherapeutic agents comprise methotrexate.

Therapeutic agents that can be administered in combination with an anti-CLEC2D antibody or composition comprising the same of the disclosure include, but are not restricted to Orteronel, Geldanamycin, Cabozantinib, Alpharadin, 177Lu-J591, Mitoxantrone, Viamet, CFG920, Galeteron, Olaparib, ADXS-PSA, Taxotere, Gonax, Decapeptyl, Lupron, Vantas, Casodex, Zoladex, Eligard, Leuplin, Firmagon, mitoxantrone, Emcyt, lanreotide, Zaltrap, custirsen sodium and Sprycel.

The Anti-CLEC2D antibodies of the disclosure can be used in combination with monoclonal antibodies or fragments thereof, therapeutic biologics, small molecules or chemical agents that inhibit or modulate the following targets: Cluster of Differentiation 19 (CD19), Programmed cell death protein 1 (PD1), Programmed death-ligand 1 (PDL1), human epidermal growth factor receptor 2 (Her2), Signal transducer and activator of transcription 3 (STAT3), cluster of differentiation 152 (CTLA4), New York esophageal squamous cell carcinoma 1 (NYESO1), B-cell maturation antigen (BCMA), indoleamine 2,3-dioxygenase (IDO), Neo antigens, Colony Stimulating Factor 1 Receptor (CSF1R), B-lymphocyte surface antigen B1 (CD20), Wilms tumor protein (WT1), Cluster of Differentiation 47 (CD47), Mucin 1, cell surface associated (MUC1), TNF receptor superfamily member 9 (4-1BB), disialoganglioside GD2, Adenosine A2a Receptor (ADORA2A), nterferon-alpha/beta receptor alpha chain (IFNAR1), Toll-like receptor 7 (TLR7), Cluster of differentiation 40 (CD40), Mesothelin, epidermal growth factor receptor (EGFR), Histone deacetylase 1 (HDAC1), interleukin-2 receptor (IL2R), Telomerase reverse transcriptase (TERT), Toll-like receptor (TLR), Siglec-3 (CD33), Lymphocyte-activation gene 3 (LAG3), Tumor necrosis factor receptor superfamily, member 4 (OX40), C—X—C chemokine receptor type 4 (CXCR4), Histone deacetylase 6 (HDAC6), prostate-specific membrane antigen (PSMA), Epstein-Barr virus (EBV), granulocyte-macrophage colony-stimulating factor receptor (GMCSFR), Toll-like receptor 9 (TLR9), interleukin-3 receptor (CD123), Stimulator of interferon genes (STING), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), T-cell immunoglobulin and mucin-domain containing-3 (TIM3), Toll-like receptor 4 (TLR4), human papillomavirus gene E6 (HPV-E6), 5′-nucleotidase (CD73), Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (CEACAM5), Survivin, Cluster of differentiation 3 (CD3), cyclic ADP ribose hydrolase (CD38), glucocorticoid-induced TNFR-related protein (GITR), human papillomavirus E7 oncoprotein (HPVE7), Interleukin 21 Receptor (IL21R), CD137), cluster of differentiation-22 (CD22), tumor necrosis factor receptor superfamily member 8 (CD30), Glypican-3 (GPC3), Beta Catenin, fms-like tyrosine kinase 3 (FLT3), janus kinase 2 (JAK2), Epithelial cell adhesion molecule (EPCAM), Melanoma-Associated Antigen 3 (MAGE-A3), Toll-like receptor 3 (TLR3), human papillomavirus (HPV), K-ras (KRAS), Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), Ubiquitin Specific Peptidase 7 (USP7), Trophoblast glycoprotein (5T4), Interleukin-2 receptor alpha chain (CD25), Cytomegalovirus (CMV), C—X—C Motif Chemokine Ligand 12 (CXCL12), granulocyte colony-stimulating factor receptor (GCSFR), killer cell lectin like receptor K1 (NKG2D), premelanosome protein (PMEL), Preferentially Expressed Antigen In Melanoma (PRAME), V-domain Ig suppressor of T cell activation (VISTA), C-C Motif Chemokine Receptor 4 (CCR4), cluster of differentiation 46 (CD46), Macrophage Stimulating Protein Receptor (CDw136), cyclooxygenase-2 (COX2), SLAM family member 7 (CS1), C—X—C Motif Chemokine Receptor 1 (CXCR1), epidermal growth factor receptor variant III (EGFRvIII), p96, glucocorticoid receptor (GR), Inducible T-cell costimulator (ICOS), Insulin-like growth factor 1 (IGF1), interleukin-5 receptor (IL5R), janus kinase 1 (JAK1), prostate specific antigen (PSA), Signal transducer and activator of transcription 5 (STATS), Transforming Growth Factor Beta Receptor 2 (TGFBR2), Vascular endothelial growth factor (VEGF), Anaplastic lymphoma kinase (ALK), alpha-galactosidase A (Alpha-gal), Cluster of Differentiation 276 (B7-H3), C-C Motif Chemokine Receptor 1 (CCR1), C-C chemokine receptor type 2 (CCR2), CD27 molecule (CD27), ectonucleoside triphosphate diphosphohydrolase 1 (CD39), carcinoembryonic antigen (CEA), Gelactin-3, Interleukin 13 Receptor Subunit Alpha 2 (IL13RA2), Interleukin 6 (IL6), Interleukin 6 Receptor (IL6R), Interleukin 1 Receptor Associated Kinase 4 (IRAK4), MER Proto-Oncogene, Tyrosine Kinase (MERTK), Macrophage migration inhibitory factor (MIF), Protein melan-A (MLANA), Prostaglandin E Receptor 4 (PTGER4), distal-less homeobox 3 (TDO), transforming growth factor beta 1 (TGFB, TGFB1), toll like receptor 2 (TLR2), tumor necrosis factor (TNF), ADORA2B, alpha fetoprotein (AFP), angiopoietin 1 (ANG1), BTLA, prominin 1 (CD133), neural cell adhesion molecule 1 (CD56), CD70 molecule (CD70), carcinoembryonic antigen related cell adhesion molecule 6 (CEACAM6), C-type lectin domain family 12 member A (CLEC12A), C—X—C motif chemokine receptor 2 (CXCR2), fibroblast activation protein alpha (FAP), histone deacetylases (HDAC), interferon alpha and beta receptor subunit 1 (IFNAR), interferon gamma receptor 1 (IFNGR1), interleukin 17 receptor A (IL17R), Janus kinase (JAK), mucin 16, cell surface associated (MUC16), mitogen activated protein kinase (P38), tumor protein p53 (p53), DExD/H-box helicase 68 (RIG1), RAR related orphan receptor C (RORC), signal regulatory protein alpha (SIRPA), transforming growth factor beta receptor 1 (TGFBR1), dopachrome tautomerase (TRP2), adenosine A3 receptor (ADORA3), Brachyury, C-C motif chemokine receptor 7 (CCR7), syndecan 1 (CD138), L1 cell adhesion molecule (CD171), fucosyltransferase 3 (Lewis blood group) (CD174), Fc fragment of IgG receptor IIa (CD32), C-X3-C motif chemokine receptor 1 (CX3CR1), FPHA2, folate receptor 1 (FOLR1), beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) (GloboH), isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1), interleukin 2 receptor subunit beta (IL2rB), Janus kinase 3 (JAK3), prostate stem cell antigen (PSCA), RAS, transforming growth factor beta 2 (TGFB2), toll like receptor 8 (TLR8), acid phosphatase, prostate (ACPP), dipeptidyl peptidase 4 (ADABP), ADAM metallopeptidase domain 17 (ADAM17), androgen receptor (AR), ATRT, AXL receptor tyrosine kinase (AXL), V-set domain containing T cell activation inhibitor 1 (B7-H4), CA19-9, integrin subunit alpha M (CD11b), Fc fragment of IgG receptor Ma (CD16), CD16a, CD200 molecule (CD200), CD28 molecule (CD28), CD52 molecule (CD52), CD7 molecule (CD7), CD80 molecule (CD80), complement C5a receptor 1 (CD88), cadherin 3 (CDH3), CECAM1, cytochrome c oxidase subunit II (COX2), CCCTC-binding factor like (CTCFL), C—X—C motif chemokine receptor 5 (CXCR5), atypical chemokine receptor 3 (CXCR7), E1a, Gastrin, Graves disease, susceptibility to, X-linked (GD3), Gelactin-1, colony stimulating factor 2 (GMCSF), HBV, HLA-A2, HLA-DR, human papillomavirus (HPV) E6/7, HPV L2, interferon alpha and beta receptor subunit 2 (IFNAR2), insulin like growth factor 1 receptor (IGF1R), interleukin 12 (IL12), interleukin 1 beta (IL1B), interleukin 7 receptor (IL7R), C—X—C motif chemokine ligand 8 (IL8), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3), LXR, CD244 molecule (2B4), Mage family member A (MAGE-A), MAGE family member A1 (MAGE-A1), MAGE family member A4 (MAGE-A4), X-linked inhibitor of apoptosis (MiHA), killer cell lectin like receptor C1 (NKG2A), natural cytotoxicity triggering receptor 1 (NKp46), nuclear receptor subfamily 2 group F member 6 (NR2F6), PTTG1 interacting protein (PBF), sperm adhesion molecule 1 (SPAM1), signal transducer and activator of transcription 1 (STAT1), toll like receptor 5 (TLR5), peroxiredoxin 2 (TSA), tyrosine kinase 2 (TYK2), kinase insert domain receptor (VEGFR2), 5′ Nucleotidase, ATP binding cassette subfamily B member 5 (ABCB5), ADAM metallopeptidase domain 9 (ADAMS), Adenosine, ADP, metadherin (AEG1), absent in melanoma 2 (AIM2), Alpha-lactalbumin, anti-Mullerian hormone receptor type 2 (AMHR2), angiopoietin 2 (ANG2), Angiogenesis, aspartate beta-hydroxylase (ASPH), natural killer cell cytotoxicity receptor 3 ligand 1 (B7-H6), TNF receptor superfamily member 13C (BAFF-R), poly(ADP-ribose) polymerase family member 9 (Ball), BRCA1 associated RING domain 1 (BARD1), BCL2 apoptosis regulator (BCL2), POU class 2 associating factor 1 (BOB-1), BTE6-1X-8b, BTE6-X-15-7, KIT proto-oncogene, receptor tyrosine kinase (cKIT), carbonic anhydrase 9 (CA9), Carbohydrate antigens, cannabinoid receptor 2 (CB2), Cbl proto-oncogene B (CBLB), C-C motif chemokine ligand 20 (CCL20), C-C motif chemokine ligand 3 (CCL3), cyclin B1 (CCNB1), C-C motif chemokine receptor 9 (CCR9), alanyl aminopeptidase, membrane (CD13), interleukin 6 signal transducer (CD130), basigin (Ok blood group) (CD147), poliovirus receptor (CD155), CD160 molecule (CD160), selectin P ligand (CD162), CD200 receptor 1 (CD200R1), complement C3d receptor 2 (CD21), TNF receptor superfamily member 13B (CD267), integrin subunit beta 1 (CD29), CD3e molecule (CD3E), CD4 molecule (CD4), CD44 molecule (Indian blood group) (CD44), integrin subunit alpha V (CD51), intercellular adhesion molecule 1 (CD54), CD8a molecule (CD8), CGEN-XXXX, Claudin 18, Claudin 6, MET proto-oncogene, receptor tyrosine kinase (cMet), coproporphyrinogen oxidase (COX), prostaglandin-endoperoxide synthase 1 (COX-1), cytochrome c oxidase subunit I (COX-1), CPEG4, cereblon (CRBN), cytokine receptor like factor 2 (CRLF2), colony stimulating factor 1 (CSF1), phosphate cytidylyltransferase 1, choline, alpha (CTA), C—X—C motif chemokine ligand 1 (CXCL1), C—X—C motif chemokine receptor 3 (CXCR3), deoxycytidine kinase (DCK), dickkopf WNT signaling pathway inhibitor 1 (DKK1), delta like canonical Notch ligand 3 (DLL3), TNF receptor superfamily member 10b (DRS), EBNA3C, epidermal growth factor (EGF), C-type lectin domain containing 14A (EGFR5), eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), ELVAL4, EPH receptor A3 (EPHA3), epidermal growth factor receptor pathway substrate 8 (EPS8), ERG, Fc fragment of IgM receptor (FAIM-3), fibroblast growth factor 2 (FGF2), fms related tyrosine kinase 3 (FLT3), fibronectin 1 (FN1), folate receptor 1 (FOLR), forkhead box M1 (FOXM1), follicle stimulating hormone receptor (FSHR), Galectin 3, N-acetylgalactosaminyltransferase (GalNAc), leucine rich repeat containing 32 (GARP), GC vitamin D binding protein (GC), Gelactin 9, Gelactin1/3/9, GM2, gonadotropin releasing hormone receptor (GNRHR), glutamyl aminopeptidase (GP160), golgi membrane protein 1 (GP73), glycoprotein A33 (gpA33), H3.3K27M, DEAD-box helicase 43 (HAGE), histone deacetylase 2 (HDAC2), histone deacetylase 8 (HDAC8), Hemagglutinin, erb-b2 receptor tyrosine kinase 3 (HER3), hypoxia inducible lipid droplet associated (HILPDA), chondroitin sulfate proteoglycan 4 (HMWMAA), HP59, HPV16, HPV11, heat shock protein family H (Hsp110) member 1 (HSP105), heat shock protein family D (Hsp60) member 1 (HSP65), heat shock protein family A (Hsp70) member 4 (HSP70), TNF receptor superfamily member 14 (HVEM), Hyaluronan, indoleamine 2,3-dioxygenase 1 (IDO1), interferon gamma (IFNG), interferon gamma receptor 1 (IFNGR), interferon gamma receptor 2 (IFNGR2), insulin like growth factor 2 (IGF2), insulin like growth factor binding protein 2 (IGFBP2), IGK2, interleukin 10 (IL10), interleukin 10 receptor subunit alpha (IL10RA), interleukin 12 receptor subunit beta 1 (IL12RB1), interleukin (IL13), interleukin 13 receptor subunit alpha 2 (IL13R), interleukin 13 receptor subunit alpha 1 (IL13RA1), interleukin 15 (IL15), interleukin 15 receptor subunit alpha (IL15RA), interleukin 17A (IL17 IL17A), interleukin 17B (IL17B), interleukin 1 receptor type 1 (IL1R1), interleukin 1 receptor accessory protein (IL1R3), interleukin 21 receptor (IL21R), interleukin 27 receptor subunit alpha (IL27R), interleukin 2 receptor subunit alpha (IL2RA), IL35, interleukin 9 receptor (IL9R), Integrin beta 7, interleukin 1 receptor associated kinase 1 (IRAK1), integrin subunit beta 5 (ITGB5), Kappa Myeloma antigen, kinesin family member 20A (KIF20A), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2), Kynurenine, Lambda myeloma antigen, lysosomal associated membrane protein 3 (LAMP), LLO, nuclear receptor subfamily 1 group H member 3 (LXRA), nuclear receptor subfamily 1 group H member 2 (LXRB), MAGEA10 MAGE family member A10 (MAGE-A10), MAGEA6 MAGE family member A6 (MAGE-A6), MAGEC2 MAGE family member C2 (MAGE-C2), Mammaglobin A, mitogen-activated protein kinase (MAPK), Mas receptor, interferon induced with helicase C domain 1 (MDA5), MG7, major histocompatibility complex II (MHCII), MIC, MHC class I polypeptide-related sequence A (MICA), MHC class I polypeptide-related sequence (MICB), matrix metallopeptidase 11 (MMP-11), motile sperm domain containing 2 (MOSPD2), Multidrug resistance-associated protein-1 (MRP1), MRP3765, muGNTP01, major vault protein (MVP), MYB proto-oncogene, transcription factor (MYB), MYB proto-oncogene like 2 (MYBL2), Myeloblastin, MYCN proto-oncogene, bHLH transcription factor (N-myc), nuclear factor of activated T cells (NFAT), NLR family pyrin domain containing 3 (NLRP3), Oncofetal antigen, purinergic receptor P2X 5 (P2RX5), p38 map kinase, phosphoinositide-3-kinase regulatory subunit 3 (P55), PAM4, regenerating family member 3 alpha (PAP), PAS domain containing repressor 1 (PASD1), protocadherin 18 (PCDH18), programmed cell death 1 ligand 2 (PDL2), POTE ankyrin domain family member D (POTE), protein phosphatase 5 catalytic subunit (PPT), prostaglandin E receptor 2 (PTGER2), PVR related immunoglobulin domain containing (PVRIG), RBL001, ras homolog family member C (RhoC), receptor tyrosine kinase like orphan receptor 2 (ROR2), SEREX, SIM bHLH transcription factor 2 (SIM2), somatostatin receptor 2 (SSTR2), SSX family member 2 (SSX2), sterol O-acyltransferase 1 (STAT), eukaryotic translation elongation factor 1 alpha 2 (STn), mRNA cap guanine-N7 methyltransferase (TAG72), TAMA, TASTD2, TD02, transcription factor Dp family member 3 (TFDP3), Thymidylate synthase, DNA topoisomerase I (TOP1), T cell receptor beta constant 1 (TRBC1), T cell receptor beta constant 2 (TRBC2), Tryptophan, thyroid stimulating hormone receptor (TSHR), TNF superfamily member 12 (TWEAK), Tyrosine, lymphocyte antigen 6 family member K (URLC10), retroelement silencing factor 1 (UTA2-1), fms related tyrosine kinase 1 (VEGFR1), V-set and immunoglobulin domain containing 4 (VSIG-4), X antigen family, member 1 (XAGE1), zona pellucida glycoprotein 3 (ZP3), STEAP family member 1 (STEAP1), or TNF superfamily member 11 (RANKL).

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with an immune checkpoint inhibitor, include, but are not limited to CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, ICOS (CD278), PDL1, KIR, LAG3, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, LAIR1, SIGLEC7, SIGLEC9, CD244 (2B4), TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, VISTA, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, MT1, MT2, CD40, OX40, CD137, GITR, CD27, SHP-1, TIM-3, CEACAM-1, CEACAM-3, or CEACAM-5. In some embodiments, anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with an immune checkpoint inhibitor. Exemplary immune checkpoint genes and therapeutic targets include programmed cell death 1 (PD1), PD-L1, CLTA-4, T cell immunoglobulin and mucin 3 (TIM-3) and lymphocyte activating 3 (LAG-3). In some embodiments, the immune checkpoint inhibitor is a therapeutic antibody that binds to and inhibits PD1, PD-L1 (Programmed death-ligand 1), CLTA-4 or TIM3. Exemplary PD1 inhibitors comprise Pembrolizumab, Nivolumab and Cemiplimab. Exemplary PD-L1 inhibitors comprise Atezolizumab, Avelumab and Durvalumab. Exemplary CLTA-4 inhibitors comprise Ipilimumab.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a kinase inhibitor, wherein the kinase inhibitor inhibits BCR-Abl, B-raf, BTK, CDK family, c-Met, EGFR family, JAK family, MEK ½, PDGFR alpha/beta, RET, Src family, or VEGFR family kinases. In some embodiments, the kinase inhibitor as disclosed herein, is a small kinase molecule inhibitor. In some embodiments, the the kinase inhibitor as disclosed herein, is a therapeutic antibody or an antagonistic antibody. In some embodiments, the kinase inhibitor as disclosed herein, is a Crizotinib, Ceritinib, Alectinib, Brigatinib, Bosutinib, Dasatinib, Imatinib, Nilotinib, Ponatinib, Vemurafenib, Dabrafenib, Ibrutinib, Palbociclib, Sorafenib, Ribociclib, Crizotinib, Cabozantinib, Gefitinib, Erlotinib, Lapatinib, Vandetanib, Afatinib, Osimertinib, Ruxolitinib, Tofacitinib, Trametinib, Axitinib, Gefitinib, Imatinib, Lenvatinib, Nintedanib, Pazopanib, Regorafenib, Sorafenib, Sunitinib, Vandetanib, Bosutinib, Dasatinib, Ponatinib, Vandetanib, Axitinib, Lenvatinib, Nintedanib, Regorafenib, Pazopanib, Sorafenib, Sunitinib, or a combination thereof.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with an anti-CD20 antibody. In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with an anti-CD20 antibody, a TNF-receptor antagonist, an anti-TNF-α, or a combination thereof, e.g., for treatment of rheumatoid arthritis. In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with anti-CD11a, e.g., for treatment of psoriais, In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with IFN-γ, e.g., for treatment of multiple sclerosis. In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with TNF-α, e.g., for treatment of ulcerative colitis. In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with Infliximab or Natalizumab, e.g., for treatment of Crohn's disease.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a multispecific antibody directed against any combination of immune check points gene product and/or target antigens associated with cancer. In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a bispecific antibody directed against any combination of immune check points gene product and/or target antigens associated with cancer.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a bispecific antibody directed against an immune check point protein selected from the group consisting of include programmed cell death 1 (PD1), PD-L1, CLTA-4, T cell immunoglobulin and mucin 3 (TIM-3) and lymphocyte activating 3 (LAG-3). In some embodiments, the immune checkpoint inhibitor is a therapeutic antibody that binds to and inhibits PD1, PD-L1 (Programmed death-ligand 1), CLTA-4 or TIM3.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a bispecific antibody directed against a tumor antigen selected from the group consisting of: B cell maturation antigen (BCMA); PSA (prostate-specific antigen); prostatespecific membrane antigen (PSMA); PSCA (Prostate stem cell antigen); Tyrosine-protein kinase transmembrane receptor ROR1; fibroblast activation protein (FAP); Tumor-associated glycoprotein 72 (TAG72); Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); Mesothelin; Human Epidermal growth factor Receptor 2 (ERBB2 (Her2/neu)); Prostate; Prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); Insulin-like growth factor 1 receptor (IGF-1R); gplOO; BCR-ABL (breakpoint cluster region-Abelson); tyrosinase; New York esophageal squamous cell carcinoma 1 (NY-ESO-1); k-light chain, LAGE (L antigen); MAGE (melanoma antigen); Melanoma-associated antigen 1 (MAGE-A1); MAGE A3; MAGE A6; legumain; Human papillomavirus (HPV) E6; HPVE7; prostein; survivin; PCTA1 (Galectin 8); Melan-A/MART-1; Ras mutant; TRP-1 (tyrosinase related protein 1, or gp75); Tyrosinase-related Protein 2 (TRP2); TRP-2/INT2 (TRP-2/intron 2); RAGE (renal antigen); receptor for advanced glycation end products 1 (RAGED; Renal ubiquitous 1, 2 (RU1, RU2); intestinal carboxyl esterase (iCE); Heat shock protein 70-2 (HSP70-2) mutant; thyroid stimulating hormone receptor (TSHR); CD123; CD171; CD19; CD20; CD22; CD26; CD30; CD33; CD44v7/8 (cluster of differentiation 44, exons 7/8); CD53; CD92; CD100; CD148; CD150; CD200; CD261; CD262; CD362; CS-1 (CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(11)Cer); Tn antigen (Tn Ag); Fms-Like Tyrosine Kinase 3 (FLT3); CD38; CD138; CD44v6; B7H3 (CD276); KIT (CD1 17); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2); Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 2 1 (PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); Mucin 1, cell surface associated (MUC1); mucin 16 (MUC1 6); epidermal growth factor receptor (EGFR); epidermal growth factor receptor variant III (EGFRvIII); neural cell adhesion molecule (NCAM); carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); ephrin type-A receptor 2 (EphA2); Ephrin B2; Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(1-1)Cer); TGS5; high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor alpha; Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); G protein coupled receptor class C group 5, member D (GPRCSD); chromosome X open reading frame 6 1 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Poly sialic acid; placenta specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); CT (cancer/testis (antigen)); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53; p53 mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); NAcetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; Cyclin Dl; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS); Squamous Cell Carcinoma Antigen Recognized By T Cells-1 or 3 (SART1, SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint-1, -2, -3 or -4 (SSX1, SSX2, SSX3, SSX4); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); mouse double minute 2 homolog (MDM2); livin; alphafetoprotein (AFP); transmembrane activator and CAML Interactor (TACI); B-cell activating factor receptor (BAFF-R); V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS); immunoglobulin lambda-like polypeptide 1 (IGLL1); 707-AP (707 alanine proline); ART-4 (adenocarcinoma antigen recognized by T4 cells); BAGE (B antigen; b-catenin/m, bcatenin/mutated); CAMEL (CTL-recognized antigen on melanoma); CAP1 (carcinoembryonic antigen peptide 1); CASP-8 (caspase-8); CDC27m (cell-division cycle 27 mutated); CDK4/m (cycline-dependent kinase 4 mutated); Cyp-B (cyclophilin B); DAM (differentiation antigen melanoma); EGP-2 (epithelial glycoprotein 2); EGP-40 (epithelial glycoprotein 40); Erbb 2, 3, 4 (erythroblastic leukemia viral oncogene homolog-2, -3, 4); FBP (folate binding protein); fAchR (Fetal acetylcholine receptor); G250 (glycoprotein 250); GAGE (G antigen); GnT-V (Nacetylglucosaminyltransferase V); HAGE (helicose antigen); ULA-A (human leukocyte antigen-A); HST2 (human signet ring tumor 2); KIAA0205; KDR (kinase insert domain receptor); LDLR/FUT (low density lipid receptor/GDP L-fucose: b-D-galactosidase 2-a-L fucosyltransferase); LICAM (LI cell adhesion molecule); MC1R (melanocortin 1 receptor); Myosin/m (myosin mutated); MUM-1, -2, -3 (melanoma ubiquitous mutated 1, 2, 3); NA88-A (NA cDNA clone of patient M88); KG2D (Natural killer group 2, member D) ligands; oncofeta antigen (h5T4); pi 90 minor bcr-abl (protein of 190KD bcr-abl); Pml/RARa (promyelocytic leukaemia/retinoic acid receptor a); PRAME (preferentially expressed antigen of melanoma); SAGE (sarcoma antigen); TEL/AML1 (translocation Ets-family leukemia/acute myeloid leukemia 1); TPI/m (triosephosphate isomerase mutated); CD70; and any combination thereof.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a drug or therapeutic agent including but not limited to Mycophenolate, Azathioprine, Cyclophosphamide, Pirfenidone, Nintedanib, Lansoprazole (Prevacid 24HR Omeprazole (Prilosec OTC) and Pantoprazole (protonix), or a combination thereof.

In some embodiments, the anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with a cytokine or chemokine including but not limited to interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-8, vascular endothelial growth factor (VEGF), stromal cell-derived factor-1, and interferon gamma-inducible protein-10 (IP-10), chemokines (CCL1, CCL2, CCL3, CCL4, CCL5, and CXCL8) or a combination thereof.

In some embodiments, anti-CLEC2D antibodies or compositions of the disclosure are administered in combination with an adoptive cell therapy. In some embodiments, the adoptive cell therapy is autologous. In some embodiments, the adoptive cell therapy is allogenic. In some embodiments, the adoptive cell therapy comprises an immune cell such as a T cell or an NK cell. In some embodiments, the adoptive cell therapy comprises a chimeric antigen receptor T cell (CAR-T) or CAR-NK therapy.

In some embodiments, the CLEC2D antibodies or compositions of the disclosure are administered in combination with adoptive cell therapy comprising a chimeric antigen receptor T cell (CAR-T) directed against target antigens associated with cancer, including but not limited to acute lymphoblastic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, and others.

In some embodiments, the CLEC2D antibodies or compositions of the disclosure are administered in combination with adoptive cell therapy comprising a chimeric antigen receptor T cell (CAR-T) directed against a second antigen is a tumor antigen selected from the group consisting of: B cell maturation antigen (BCMA); PSA (prostate-specific antigen); prostatespecific membrane antigen (PSMA); PSCA (Prostate stem cell antigen); Tyrosine-protein kinase transmembrane receptor ROR1; fibroblast activation protein (FAP); Tumor-associated glycoprotein 72 (TAG72); Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); Mesothelin; Human Epidermal growth factor Receptor 2 (ERBB2 (Her2/neu)); Prostate; Prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); Insulin-like growth factor 1 receptor (IGF-1R); gp100; BCR-ABL (breakpoint cluster region-Abelson); tyrosinase; New York esophageal squamous cell carcinoma 1 (NY-ESO-1); k-light chain, LAGE (L antigen); MAGE (melanoma antigen); Melanoma-associated antigen 1 (MAGE-A1); MAGE A3; MAGE A6; legumain; Human papillomavirus (HPV) E6; HPVE7; prostein; survivin; PCTA1 (Galectin 8); Melan-A/MART-1; Ras mutant; TRP-1 (tyrosinase related protein 1, or gp75); Tyrosinase-related Protein 2 (TRP2); TRP-2/INT2 (TRP-2/intron 2); RAGE (renal antigen); receptor for advanced glycation end products 1 (RAGED; Renal ubiquitous 1, 2 (RU1, RU2); intestinal carboxyl esterase (iCE); Heat shock protein 70-2 (HSP70-2) mutant; thyroid stimulating hormone receptor (TSHR); CD123; CD171; CD19; CD20; CD22; CD26; CD30; CD33; CD44v7/8 (cluster of differentiation 44, exons 7/8); CD53; CD92; CD100; CD148; CD150; CD200; CD261; CD262; CD362; CS-1 (CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(11)Cer); Tn antigen (Tn Ag); Fms-Like Tyrosine Kinase 3 (FLT3); CD38; CD138; CD44v6; B7H3 (CD276); KIT (CD1 17); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2); Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 2 1 (PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); Mucin 1, cell surface associated (MUC1); mucin 16 (MUC1 6); epidermal growth factor receptor (EGFR); epidermal growth factor receptor variant III (EGFRvIII); neural cell adhesion molecule (NCAM); carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); ephrin type-A receptor 2 (EphA2); Ephrin B2; Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(1-1)Cer); TGS5; high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor alpha; Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); G protein coupled receptor class C group 5, member D (GPRCSD); chromosome X open reading frame 6 1 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Poly sialic acid; placenta specific1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); CT (cancer/testis (antigen)); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53; p53 mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); NAcetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; Cyclin Dl; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS); Squamous Cell Carcinoma Antigen Recognized By T Cells-1 or 3 (SART1, SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint-1, -2, -3 or -4 (SSX1, SSX2, SSX3, SSX4); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); mouse double minute 2 homolog (MDM2); livin; alphafetoprotein (AFP); transmembrane activator and CAML Interactor (TACI); B-cell activating factor receptor (BAFF-R); V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS); immunoglobulin lambda-like polypeptide 1 (IGLL1); 707-AP (707 alanine proline); ART-4 (adenocarcinoma antigen recognized by T4 cells); BAGE (B antigen; b-catenin/m, bcatenin/mutated); CAMEL (CTL-recognized antigen on melanoma); CAP1 (carcinoembryonic antigen peptide 1); CASP-8 (caspase-8); CDC27m (cell-division cycle 27 mutated); CDK4/m (cycline-dependent kinase 4 mutated); Cyp-B (cyclophilin B); DAM (differentiation antigen melanoma); EGP-2 (epithelial glycoprotein 2); EGP-40 (epithelial glycoprotein 40); Erbb 2, 3, 4 (erythroblastic leukemia viral oncogene homolog-2, -3, 4); FBP (folate binding protein); fAchR (Fetal acetylcholine receptor); G250 (glycoprotein 250); GAGE (G antigen); GnT-V (Nacetylglucosaminyltransferase V); HAGE (helicose antigen); ULA-A (human leukocyte antigen-A); HST2 (human signet ring tumor 2); KIAA0205; KDR (kinase insert domain receptor); LDLR/FUT (low density lipid receptor/GDP L-fucose: b-D-galactosidase 2-a-L fucosyltransferase); LICAM (LI cell adhesion molecule); MC1R (melanocortin 1 receptor); Myosin/m (myosin mutated); MUM-1, -2, -3 (melanoma ubiquitous mutated 1, 2, 3); NA88-A (NA cDNA clone of patient M88); KG2D (Natural killer group 2, member D) ligands; oncofeta antigen (h5T4); pi 90 minor bcr-abl (protein of 190KD bcr-abl); Pml/RARa (promyelocytic leukaemia/retinoic acid receptor a); PRAME (preferentially expressed antigen of melanoma); SAGE (sarcoma antigen); TEL/AML1 (translocation Ets-family leukemia/acute myeloid leukemia 1); TPI/m (triosephosphate isomerase mutated); CD70; and any combination thereof.

An anti-CLEC2D antibodies of the disclosure may be utilized to form a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an immune checkpoint inhibitor including but not limited to CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, ICOS (CD278), PDL1, KIR, LAG3, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, LAIR1, SIGLEC7, SIGLEC9, CD244 (2B4), TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, VISTA, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, MT1, MT2, CD40, OX40, CD137, GITR, CD27, SHP-1, TIM-3, CEACAM-1, CEACAM-3, or CEACAM-5. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an immune checkpoint gene and therapeutic target including but not limited to programmed cell death 1 (PD1), PD-L1, CLTA-4, T cell immunoglobulin and mucin 3 (TIM-3) and lymphocyte activating 3 (LAG-3). In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is associated with a cytokine or chemokine including but not limited to interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-8, vascular endothelial growth factor (VEGF), stromal cell-derived factor-1, and interferon gamma-inducible protein-10 (IP-10), chemokines (CCL1, CCL2, CCL3, CCL4, CCL5, and CXCL8) or a combination thereof

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen on the surface of a host cell. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody comprises a first pair of variable light chain and variable heavy chain that specifically binds CLEC2D and a second pair of variable light chain and variable heavy chain that specifically binds to a second antigen on the surface of a host cell. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen on the surface of a host cell, wherein the second antigen is an antigen associated with a cancer or tumor cell.

A bispecific antibody, as disclosed herein, may comprise constant regions representing specific isotypes e.g., human IgG1, IgG2, IgG3 and IgG4 or variants thereof, as described in this disclosure. A bispecific antibody, as disclosed herein, may comprise constant regions representing specific isotypes e.g., mouse IgG1, IgG2a, IgG2b or IgG3 or variants thereof, as described in this disclosure. A bispecific antibody, as disclosed herein, may having isotype backbones of IgG1, IgG1N297A and IgG4. A bispecific antibody, as disclosed herein, can be bispecific antibody formats using tri-functional antibody, chemically linked Fab, scFvs or disulfide bonded Fvs include tandem scFvs (often used as bispecific T cell engagers or ‘BiTEs’), tetravalent IgG-scFvs, diabodies, and many other formats. In some embodiments, a bispecific antibody, as disclosed herein, is produced as a diabody which are generated by combining sequences encoding two different scFvs into one construct in which heavy chains are expressed in a single polypeptide, and then joined with the corresponding light chains.

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen on the surface of a host cell, wherein the second antigen is an antigen associated with a cancer or tumor cell selected from the group consisting of breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen on the surface of a host cell, wherein the second antigen is a tumor antigen selected from the group consisting of: B cell maturation antigen (BCMA); PSA (prostate-specific antigen); prostatespecific membrane antigen (PSMA); PSCA (Prostate stem cell antigen); Tyrosine-protein kinase transmembrane receptor ROR1; fibroblast activation protein (FAP); Tumor-associated glycoprotein 72 (TAG72); Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); Mesothelin; Human Epidermal growth factor Receptor 2 (ERBB2 (Her2/neu)); Prostate; Prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); Insulin-like growth factor 1 receptor (IGF-1R); gp100; BCR-ABL (breakpoint cluster region-Abelson); tyrosinase; New York esophageal squamous cell carcinoma 1 (NY-ESO-1); k-light chain, LAGE (L antigen); MAGE (melanoma antigen); Melanoma-associated antigen 1 (MAGE-A1); MAGE A3; MAGE A6; legumain; Human papillomavirus (HPV) E6; HPVE7; prostein; survivin; PCTA1 (Galectin 8); Melan-A/MART-1; Ras mutant; TRP-1 (tyrosinase related protein 1, or gp75); Tyrosinase-related Protein 2 (TRP2); TRP-2/INT2 (TRP-2/intron 2); RAGE (renal antigen); receptor for advanced glycation end products 1 (RAGED; Renal ubiquitous 1, 2 (RU1, RU2); intestinal carboxyl esterase (iCE); Heat shock protein 70-2 (HSP70-2) mutant; thyroid stimulating hormone receptor (TSHR); CD123; CD171; CD19; CD20; CD22; CD26; CD30; CD33; CD44v7/8 (cluster of differentiation 44, exons 7/8); CD53; CD92; CD100; CD148; CD150; CD200; CD261; CD262; CD362; CS-1 (CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(11)Cer); Tn antigen (Tn Ag); Fms-Like Tyrosine Kinase 3 (FLT3); CD38; CD138; CD44v6; B7H3 (CD276); KIT (CD1 17); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2); Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 2 1 (PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); Mucin 1, cell surface associated (MUC1); mucin 16 (MUC1 6); epidermal growth factor receptor (EGFR); epidermal growth factor receptor variant III (EGFRvIII); neural cell adhesion molecule (NCAM); carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); ephrin type-A receptor 2 (EphA2); Ephrin B2; Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(1-1)Cer); TGS5; high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor alpha; Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); G protein coupled receptor class C group 5, member D (GPRCSD); chromosome X open reading frame 6 1 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Poly sialic acid; placenta specific1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); CT (cancer/testis (antigen)); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53; p53 mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); NAcetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; Cyclin Dl; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS); Squamous Cell Carcinoma Antigen Recognized By T Cells-1 or 3 (SART1, SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint-1, -2, -3 or -4 (SSX1, SSX2, SSX3, SSX4); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); mouse double minute 2 homolog (MDM2); livin; alphafetoprotein (AFP); transmembrane activator and CAML Interactor (TACI); B-cell activating factor receptor (BAFF-R); V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS); immunoglobulin lambda-like polypeptide 1 (IGLL1); 707-AP (707 alanine proline); ART-4 (adenocarcinoma antigen recognized by T4 cells); BAGE (B antigen; b-catenin/m, bcatenin/mutated); CAMEL (CTL-recognized antigen on melanoma); CAP1 (carcinoembryonic antigen peptide 1); CASP-8 (caspase-8); CDC27m (cell-division cycle 27 mutated); CDK4/m (cycline-dependent kinase 4 mutated); Cyp-B (cyclophilin B); DAM (differentiation antigen melanoma); EGP-2 (epithelial glycoprotein 2); EGP-40 (epithelial glycoprotein 40); Erbb 2, 3, 4 (erythroblastic leukemia viral oncogene homolog-2, -3, 4); FBP (folate binding protein); fAchR (Fetal acetylcholine receptor); G250 (glycoprotein 250); GAGE (G antigen); GnT-V (Nacetylglucosaminyltransferase V); HAGE (helicose antigen); ULA-A (human leukocyte antigen-A); HST2 (human signet ring tumor 2); KIAA0205; KDR (kinase insert domain receptor); LDLR/FUT (low density lipid receptor/GDP L-fucose: b-D-galactosidase 2-a-L fucosyltransferase); LICAM (LI cell adhesion molecule); MC1R (melanocortin 1 receptor); Myosin/m (myosin mutated); MUM-1, -2, -3 (melanoma ubiquitous mutated 1, 2, 3); NA88-A (NA cDNA clone of patient M88); KG2D (Natural killer group 2, member D) ligands; oncofeta antigen (h5T4); pi 90 minor bcr-abl (protein of 190KD bcr-abl); Pml/RARa (promyelocytic leukaemia/retinoic acid receptor a); PRAME (preferentially expressed antigen of melanoma); SAGE (sarcoma antigen); TEL/AML1 (translocation Ets-family leukemia/acute myeloid leukemia 1); TPI/m (triosephosphate isomerase mutated); CD70; or a combination thereof.

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with an infectious agent or pathogen. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with a microorganism. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with a microorganisms including but not limited to bacteria, fungi, protozoa, parasites, and viruses. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with a microorganisms including but not limited to a pathogenic bacteria, fungi, protozoa, parasites, and viruses. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with a microorganisms including but not limited to an intracellular bacteria. In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen that is specifically expressed on a host cell infected with a microorganisms including but not limited to a pathogenic bacteria, fungi, protozoa, parasites, and viruses.

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with inflammatory or autoimmune disorders including but not limited to seronegative spondyloarthropathies, connective tissue diseases, inflammatory bowel diseases, arthritis, inflammatory skin conditions, inflammatory lung diseases, inflammatory renal disease, systemic vasculitis, macrophage activation diseases, polymyalgia rheumatica, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Type 1 Diabetes Mellitus, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis (MS), Guillain-Barre syndrome, Addison's disease, Raynaud's phenomenon and Goodpasture's syndrome.

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with connective tissue diseases such as juvenile rheumatoid arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and lupus nephritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease and polymyositis, dermatomyositis.

In some embodiments, an anti-CLEC2D antibodies of the disclosure, is a bispecific antibody, wherein the bispecific antibody specifically binds to CLEC2D and a second antigen, wherein the second antigen is an antigen associated with Whipples disease and arthritis associated with granulomatous ileocolitis, inflammatory skin conditions such as autoimmune bullous pemphigoid, autoimmune pemphigus vulgaris, eczema and dermatitis, inflammatory lung diseases such as alveolitis, pulmonary fibrosis, sarcoidoisis, asthma, bronchitis and bronchiolitis obliterans, inflammatory renal diseases such as glomerulonethritis, renal allograft rejection and renal tubular inflammation, atherosclerosis, systemic vasculitis such as temporal arteritis/giant cell arteritis, takayasu arteritis, polyarteritis nodosa, Kawasaki disease, Wegener's granulomatosis, churg strauss syndrome, microscopic polyangiitis, necrotising glomerulonephritis, henoch schonlein purpura, essential cryoglobulinaemic vasculitis, other small vessel vasculitis and Behcets disease, macrophage activation diseases such as macrophage activation syndrome (MAS), adult onset stills disease, haemophagocytic syndrome, polymyalgia rheumatica, primary biliary sclerosis, sclerosing cholangitis, autoimmune hepatitis, Type 1 Diabetes Mellitus, Hashimoto's thyroiditis, Graves' disease, multiple sclerosis (MS), Guillain-Barre syndrome, Addison's disease, and/or Raynaud's phenomenon and Goodpasture's syndrome.

The bispecific antibodies of the invention are generated using any methods known in the art such as, by way of non-limiting example, the use of cross-linked fragments, quadromas, and/or any of a variety of recombinant formats such as, by way of non-limiting examples, linked antibody fragments, forced heterodimers, and or recombinant formats based on single domains. Examples of Bispecific formats include but are not limited to bispecific IgG based on Fab arm exchange (Gramer et al., 2013 MAbs. 5(6)); the CrossMab format (Klein C et al., 2012 MAbs 4(6)); multiple formats based on forced heterodimerization approaches such as SEED technology (Davis J H et al., 2010 Protein Eng Des Sel. 23(4):195-202), electrostatic steering (Gunasekaran K et al., J Biol Chem. 2010 285(25):19637-46.) or knob-into-hole (Ridgway J B et al., Protein Eng. 1996 9(7):617-21.) or other sets of mutations preventing homodimer formation (Von Kreudenstein T S et al., 2013 MAbs. 5(5):646-54.); fragment based bispecific formats such as tandem scFv (such asBiTEs) (Wolf E et al., 2005 Drug Discov. Today 10(18):1237-44.); bispecific tetravalent antibodies (Portner L M et al., 2012 Cancer Immunol Immunother. 61(10):1869-75.); dual affinity retargeting molecules (Moore P A et al., 2011 Blood. 117(17):4542-51), diabodies (Kontermann R E et al., Nat Biotechnol. 1997 15(7):629-31).

In some embodiments, the anti-CLEC2D antibodies and compositions and the additional therapeutic agent(s) act additively to treat a sign or a symptom of a disease.

In some embodiments, the anti-CLEC2D antibodies and compositions and the additional therapeutic agent(s) act synergistically to treat a sign or a symptom of a disease.

In some embodiments, the combination of anti-CLEC2D antibodies and compositions with an additional therapeutic agents leads to superior efficacy in the treatment of the disease or disorder, including increased reduction of one or more symptoms of the disease or disorder, the reduction in one or more side effects of the treatment, or a reduction in the therapeutically effective dose of the anti-CLEC2D antibodies or compositions or the additional therapeutic agent.

The antibodies or antigen-binding fragments thereof can be conjugated to another therapeutic modality. The conjugation may bring the antibodies or antigen-binding fragments thereof of the present disclosure into close proximity to the target, such as a target cell, improve the target specificity, increase the overall binding affinity of the conjugate to the target, and/or enhance the cytotoxicity of the NK cells towards the target, which increase the therapeutic efficacy and/or specificity of the antibodies or antigen-binding fragments thereof of the present disclosure. The another therapeutic modality can be any of the additional therapeutic agents described herein. Methods of making antibody conjugates are known in the art, for example, through protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Coupling may be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities. This linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation. The preferred binding is, however, covalent binding. Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines. This listing is not intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom, Jour. Immun. 133:1335-2549 (1984); Jansen et al., Immunological Reviews 62:185-216 (1982); and Vitetta et al., Science 238:1098 (1987).

The antibodies or antigen-binding fragments thereof of the present disclosure can also be used to make a bi-specific antibody. For example, the antibodies or antigen-binding fragments thereof of the present disclosure can be combined with the additional antibodies or antigen-binding fragments thereof described herein to form a bi-specific antibody. Methods of making bispecific antibodies are known in the art.

Dosage regimens are adjusted to provide the optimum desired response, e.g., therapeutic response or minimal adverse effects. For example, for administration of an anti-CLEC2D antibody, the dosage can range from about 0.0001 to about 1000 mg/kg. For example, dosages can be at least 0.1, at least 0.3, at least 1, at least 3, at least 5, at least 10, at least 15, at least 20 or at least 25 mg/kg body weight. The dosing schedule is typically designed to achieve exposures that result in sustained receptor occupancy based on typical pharmacokinetic properties of an antibody. An exemplary treatment regime entails administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every three to 6 months. The dosage and scheduling may change during a course of treatment. For example, dosing schedule may comprise administering the antibody: (i) every two weeks in 6-week cycles; (ii) every four weeks for six dosages, then every three months; (iii) every three weeks; (iv) with an initial high dose followed by a periodic lower maintenance dose. Intervals between single dosages can be, for example, weekly, every 2 weeks, every 3 weeks, monthly, every three months or yearly. Intervals can also be irregular as indicated by measuring blood levels of antibody to the target antigen in the patient. In some methods, dosage is adjusted to achieve a desired plasma a concentration of the antibody.

In some embodiments, the Ab can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the patient. In general, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is typically administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being unduly toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present disclosure employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts. A composition of the present disclosure can be administered via one or more routes of administration using one or more of a variety of methods well known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results.

Diagnosis and Prognosis

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: determining the level of CLEC2D protein in the subject; and administering a therapeutically effective amount of a CLEC2D antibody to the subject. In one embodiment, the level of CLEC2D protein is determined by measuring the level of CLEC2D expression in a cell from the subject. In one embodiment, the cell is a cancer cell (e.g., a cell from a cancer described herein).

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: obtaining a sample from the subject; determining the level of CLEC2D protein in the sample; if the level of CLEC2D protein in the sample is higher than the level of CLEC2D protein in a control sample, administering a therapeutically effective amount of a CLEC2D antibody to the subject. In one embodiment, the sample is a cell from the subject. In one embodiment, the cell is from a diseased tissue or organ. In one embodiment, the cell is a cancer cell (e.g., a cell from a cancer described herein). In one embodiment, the control sample is from a non-diseased tissue or organ of the subject. In one embodiment, the control sample is from a subject which does not have the disease.

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: obtaining a first sample from the subject; determining a first level of CLEC2D protein in the first sample; administering a therapeutically effective amount of a CLEC2D antibody to the subject; obtaining a second sample from the subject; determining a second level of CLEC2D protein in the second sample; comparing the second level with the first level; if the first level is greater than the second level, continuing administration of a therapeutically effective amount of the CLEC2D antibody to the subject. In one embodiment, the sample is a cell from the subject. In one embodiment, the cell is from a diseased tissue or organ. In one embodiment, the cell is a cancer cell (e.g., a cell from a cancer described herein). In one embodiment, the control sample is from a non-diseased tissue or organ of the subject. In one embodiment, the control sample is from a subject which does not have the disease.

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: obtaining a first sample from the subject; determining a first level of CLEC2D protein in the first sample; administering a first therapeutically effective amount of a CLEC2D antibody to the subject; obtaining a second sample from the subject; determining a second level of CLEC2D protein in the second sample; comparing the second level with the first level; if the first level is lower than the second level, administering a second therapeutically effective amount of the CLEC2D antibody to the subject, wherein the second therapeutically effective amount is greater than the first therapeutically effective amount. In one embodiment, the sample is a cell from the subject. In one embodiment, the cell is from a diseased tissue or organ. In one embodiment, the cell is a cancer cell (e.g., a cell from a cancer described herein). In one embodiment, the control sample is from a non-diseased tissue or organ of the subject. In one embodiment, the control sample is from a subject which does not have the disease.

The disclosure provides a method of treating a disease in a subject in need thereof, comprising: obtaining a first sample from the subject; determining a first level of CLEC2D protein in the first sample; administering a therapeutically effective amount of a CLEC2D antibody to the subject; obtaining a second sample from the subject; determining a second level of CLEC2D protein in the second sample; comparing the second level with the first level; if the first level is lower than the second level, terminating administration of the CLEC2D antibody to the subject. In one embodiment, the sample is a cell from the subject. In one embodiment, the cell is from a diseased tissue or organ. In one embodiment, the cell is a cancer cell (e.g., a cell from a cancer described herein). In one embodiment, the control sample is from a non-diseased tissue or organ of the subject. In one embodiment, the control sample is from a subject, which does not have the disease.

The isolated, novel antibody clones can be used to determine stage and aggressiveness of disease and to treat the disease appropriately.

The disclosure provides anti-CLEC2D antibodies and antibody fragments thereof, nucleic acids encoding the antibodies or antigen binding fragments thereof, or compositions comprising same, for use in the diagnosis and prognosis of diseases and disorders.

In some embodiments, isolated monoclonal antibodies reveal the differential expression of CLEC2D on various tumor cell surfaces, indicating that CLEC2D is a novel biomarker for the diagnosis of various disease conditions. Further CLEC2D antigen is significantly overexpressed on various tumors, indicating the usefulness of this target molecule as a novel molecular marker for disease diagnosis. Moreover, the expression level of CLEC2D significantly increases under the influence of various inducing agents. The differential expression of CLEC2D antigen on induced tumor cells is correlated with different stages of disease, disease progression, metastasis, and so on. Therefore CLEC2D has an enormous potential of prognostic biomarker. In some embodiments, an increase in CLEC2D protein expression, for example on a cancer cell in a subject, is associated with a poorer prognostic outcome than if CLEC2D protein expression is not elevated.

As detailed herein, isolated monoclonal antibodies are used to monitor CLEC2D surface expression on tumor cell lines.

Anti-CLEC2D antibodies can be used to diagnose and prognose diseases including, but not limited to breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, pulmonary adenocarcinoma, adenocarcinoma, acinic cell adenocarcinoma, adrenal cortical carcinomas, alveoli cell carcinoma, anaplastic carcinoma, basaloid carcinoma, basal cell carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, renaladinol carcinoma, embryonal carcinoma, anometroid carcinoma, fibrolamolar liver cell carcinoma, follicular carcinomas, giant cell carcinomas, hepatocellular carcinoma, intraepidermal carcinoma, intraepithelial carcinoma, leptomanigio carcinoma, medullary carcinoma, melanotic carcinoma, menigual carcinoma, mesometonephric carcinoma, oat cell carcinoma, squamal cell carcinoma, sweat gland carcinoma, transitional cell carcinoma, tubular cell carcinoma, ameloblastic sarcoma, angiolithic sarcoma, botryoid sarcoma, endometrial stroma sarcoma, ewing sarcoma, fascicular sarcoma, giant cell sarcoma, granulositic sarcoma, immunoblastic sarcoma, juxaccordial osteogenic sarcoma, coppices sarcoma, leukocytic sarcoma (leukemia), lymphatic sarcoma (lympho sarcoma), medullary sarcoma, myeloid sarcoma (granulocitic sarcoma), austiogenci sarcoma, periosteal sarcoma, reticulum cell sarcoma (histiocytic lymphoma), round cell sarcoma, spindle cell sarcoma, synovial sarcoma, telangiectatic audiogenic sarcoma, Burkitt's lymphoma, NPDL, NML, NH and diffuse lymphomas.

In spite of various treatment options currently available, multiple cancers, such as breast cancer, prostate cancer, endometrial cancer, bladder cancer, kidney cancer, esophageal cancer, squamous cell carcinoma, uveal melanoma, follicular lymphoma, renal cell carcinoma, cendcal cancer, ovarian cancer, lung cancer, colorectal cancer, brain cancer, pancreatic cancer, head and neck cancer, liver cancer, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, melanoma, astrocytoma, stomach cancer, and pulmonary adenocarcinoma, still remain as leading causes of death in people world-wide and lack unique therapeutic prospects. Diagnosis of these diseases at an early stage is one of the most important factors that determine survival. The present disclosure describes identification of CLEC2D as a biomarker target for these diseases and others, having profound therapeutic implications. The rapid advancement in overall antibody identification methods against CLEC2D, described in present disclosure, have made it possible to validate CLEC2D as novel biomarker against various disease indications mentioned above.

The present disclosure provides anti-CLEC2D antibodies and fragments thereof, and compositions comprising the same, as for use in the identification of CLEC2D expression as a predictive biomarker to stratify patients who are likely to have better response on certain treatments.

The present disclosure provides anti-CLEC2D antibodies and fragments thereof, nucleic acids encoding the antibodies or antigen binding fragments thereof, or compositions comprising the same, as for use in the identification of CLEC2D expression as a predictive biomarker and to pave the way to explore therapies aimed at enhancing NK cells cytolytic activity in metastatic cancer patients. In some embodiments, expression of these CLEC2D receptors on immune cells in the tumor microenvironment is associated with good prognosis. The expression of specific molecules on specific immune cells, such as NK cells and T cells, is involved in maintenance of particular immune function. The present disclosure describes the prognostic role of CLEC2D expression as NK receptor ligands, including in prostate cancer, and the association of CLEC2D expression with different prostate cancer disease stages, molecular subtypes and clinic-pathological features. Blocking CLEC2D expression on tumor cells with an anti-CLEC2D antibody signals in an NK cell mediated cytotoxic immune context and harnesses the positive prognostic value of infiltrating T cells. The human anti-CLEC2D monoclonal antibodies of the disclosure expand the opportunity/scope of these antibodies not only as therapeutic, also, as prognostic and diagnostics in various cancer types either alone or in association with other ligands, cytokines or other cellular factors.

Pharmaceutical Formulations

The disclosure provides a pharmaceutical composition of any of the anti-CLEC2D antibodies or antibody fragments thereof of the disclosure. Each of the anti-CLEC2D antibodies of the present disclosure can be formulated into a composition suitable for administration to the subject. In exemplary aspects, each of the anti-CLEC2D antibodies can be formulated with one or more agents which enhance the chemico-physico features of the anti-CLEC2D antibody, e.g., via stabilizing the anti-CLEC2D antibody at certain temperatures, e.g., room temperature, increasing shelf life, reducing degradation, e.g., oxidation protease mediated degradation, increasing half-life of the anti-CLEC2D antibody, etc. In exemplary aspects of the present disclosure, the anti-CLEC2D antibody may be formulated into a composition additionally comprising a pharmaceutically acceptable carrier, diluents, or excipient.

“Pharmaceutical compostions” and “pharmaceutical formulations” are used interchangeably herein unless the context clearly suggests otherwise.

The pharmaceutical compositions can be solid, semi-solid, or liquid. Generally the pharmaceutical composition is adapted for a particular route of administration. For example, the pharmaceutical composition can be adapted for oral administration, rectal administration, buccal administration, topical administration, etc. Preferably, the pharmaceutical composition is adapted for intravenous administration. In some embodiments the pharmaceutical composition comprising antibodies or antibody fragments of the disclosure is suitable for intravenous injection or infusion. In some embodiments, the aqueous stable monoclonal antibody formulation will be administered by parenteral routes preferably via intramuscular injection, sub-cutaneous injection, i.v. injection or, most preferably, i.v. infusion.

As used herein, a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). A pharmaceutical composition of this disclosure may include one or more pharmaceutically acceptable salts, anti-oxidant, aqueous and nonaqueous carriers; and/or adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. For example, a pharmaceutically acceptable carrier includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.

The pharmaceutical composition can comprise any pharmaceutically acceptable ingredients, including, for example, acidifying agents, additives, adsorbents, aerosol propellants, air displacement agents, alkalizing agents, anticaking agents, anticoagulants, antimicrobial preservatives, antioxidants, antiseptics, bases, binders, buffering agents, chelating agents, coating agents, coloring agents, desiccants, detergents, diluents, disinfectants, disintegrants, dispersing agents, dissolution enhancing agents, dyes, emollients, emulsifying agents, emulsion stabilizers, fillers, film forming agents, flavor enhancers, flavoring agents, flow enhancers, gelling agents, granulating agents, humectants, lubricants, mucoadhesives, ointment bases, ointments, oleaginous vehicles, organic bases, pastille bases, pigments, plasticizers, polishing agents, preservatives, sequestering agents, skin penetrants, solubilizing agents, solvents, stabilizing agents, suppository bases, surface active agents, surfactants, suspending agents, sweetening agents, therapeutic agents, thickening agents, tonicity agents, toxicity agents, viscosity-increasing agents, water-absorbing agents, watermiscible cosolvents, water softeners, or wetting agents. Other pharmaceutically acceptable excipients known in the art include diluents, carders, fillers, binders, lubricants, disintegrants, glidants, colorants, pigments, taste masking agents, sweeteners, plasticizers, and any acceptable auxiliary substances such as absorption enhancers, penetration enhancers, surfactants; co-surfactants, preservatives, anti-oxidants and specialized oils. Specific; to the field of biopharmaceutical proteins are excipients intended to stabilize proteins and cryo-protectants to provide protection during freeze-drying. Suitable excipient(s) are selected based in part on the dosage form, the intended mode of administration, the intended release rate, and manufacturing reliability. Non-limiting examples of commonly used excipients include polymers, waxes, calcium phosphates, sugars (e.g., trehalose, sucrose, or mannitol), buffers (such as phosphate, acetate, citrate, histidine, or glycine based buffers at pH between 5 and 7.5), salts (e.g., NaCl or NaEDTA), polysorbate 20, polysorbate 80; human albumin, dextran, and benzyl alcohol. See, e.g., the Handbook of Pharmaceutical Excipients, Third Edition, A. H. Kibbe (Pharmaceutical Press, London, U K, 2000), which is incorporated by reference in its entirety. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), which is incorporated by reference in its entirety.

In exemplary aspects, the pharmaceutical composition comprises formulation materials that are nontoxic to recipients at the dosages and concentrations employed. In specific embodiments, pharmaceutical compositions comprising an active agent and one or more pharmaceutically acceptable salts; polyols; surfactants; osmotic balancing agents; tonicity agents; anti-oxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; anti-foaming agents; chelating agents; preservatives; colorants; analgesics; or additional pharmaceutical agents.

In exemplary aspects, the pharmaceutical composition comprises one or more polyols and/or one or more surfactants, optionally, in addition to one or more excipients, including but not limited to, pharmaceutically acceptable salts; osmotic balancing agents (tonicity agents); anti-oxidants; antibiotics; antimycotics; bulking agents; lyoprotectants; antifoaming agents; chelating agents; preservatives; colorants; and analgesics.

In certain embodiments, the pharmaceutical composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. See, REMINGTON'S PHARMACEUTICAL CAR-TSCIENCES, 18″ Edition, (A. R. Genrmo, ed.), 1990, Mack Publishing Company.

The pharmaceutical compositions can be formulated to achieve a physiologically compatible pH. In some embodiments, the pH of the pharmaceutical composition can be for example between about 4 or about 5 and about 8.0, between about 4.5 and about 7.5, or between about 5.0 to about 7.5. In exemplary embodiments, the pH of the pharmaceutical composition is between 5.5 and 7.5.

Pharmaceutical compositions for administering the anti-CLEC2D antibodies via parenteral administration are typically liquid. Water is commonly used as a main excipient, although other pharmaceutically-acceptable liquids such as ethanol, glycerol, ethyl oleate, Myglyol benzyol oleate, castor oil, MCT, benzyl alcohol isopropyl myristate can be used alone or in combination with water or each other. Aqueous compositions that contain no other excipients are also contemplated, and can be prepared from lyophilized, amorphous, or crystalline compounds. Often the injectable composition, which can be for subcutaneous, IM, or IV injection, contains isotonizing agents. An injectable solution or suspension is typically sterile, as are all liquid pharmaceutical dosage forms.

Pharmaceutical compositions for administering anti-CLEC2D antibodies via topical administration include powders, creams, ointments, gels, lotions, solutions and suspensions (including mouth washes). The excipient earlier is often aqueous, oil, or polymer based, each optionally in the form of an emulsion or microemulsion. The term “topical administration” includes, for example, optical administration (e.g., via a cream/ointment) and administration to the skin (e.g., at an inflamed joint).

Pharmaceutical compositions for administering anti-CLEC2D antibodies via oral administration include solid oral dosage forms such as tablets, capsules, enteric coated forms thereof, lozenges, and films, as well as liquid dosage forms including solutions, suspensions, liquid filled capsules, and mouth washes. Tablets can be soluble tablets, dispersible tablets, effervescent tablets, chewable tablets, lyophilized tablets, coated tablets (e.g., sugar-coated or enteric-coated), and modified release tablets. Capsules include hard gelatin capsules that can be filled with powder, pellets, granules, small tablets, or mini-tablets, or solutions or emulsions or combinations and can be coated for enteric or modified release. Soft capsules are also contemplated and are more typically filled with liquids, gels or dispersions; but are not limited thereto. Granules can be effervescent granules, coated granules (e.g., sugar-coated or enteric-coated); and modified release granules. Although the anti-CLEC2D antibodies of the present disclosure can be administered orally, it should be understood that such administration may be considered to be a topical administration to the (ii tract. Likewise, a suppository or rectal injection may also be used to topically to the intestines. The use of an oral dosage form to treat gastrointestinal disease(s) using the anti-CLEC2D antibodies of the present disclosure is an aspect of the present disclosure.

An overview of dosage forms can be found in Ansel's Pharmaceutical Dosage forms and Drug Delivery Systems. 9^thed. L. V. Allan, N. G. Popovitch, H. C. Ansel; 2010 Lippincott, ISBN 978-0781779340; Formularium der Nederlandse Apothekers 2004 WINAp ISBN 90-70605-75-9; Recepteerkunde, G. K. Bolhuis, Bouwman-Boer, F. Kadir en J. Zuiderma, 2005 WINAp ISBN 90-70605-65-1; and Apothekenrezeptur und-defektur. Deutscher Apotheker Verlag Stuttgart 1986 ISBN 3-7692-1092-1. See also U.S. Pat. No. 7,147,854 for a description of topical preparations for delivering IL-S antibodies to treat skin inflammatory disease such as psoriasis.

The pharmaceutical composition generally contains about 0.01 to 1000 mg of the antibody per dose, depending in part upon the dosage form employed. The dose can be, for example, fixed or variable (e.g., based on body weight).

Development of a stable formulation is vital to successful clinical manufacturing of pharmaceutical compositions comprising the antibodies and antigen binding fragments of the disclosure.

In some embodiments, a stable formulation is prepared by screening various buffers, stabilizers at different pH with the help of additives and the final stable formulation should contain the physical, chemical stability and biological activity upon storage. The role of excipients in the stable formulation is to prevent and/or reduce the rate of degradation in order to provide an acceptable shelf life.

The current disclosure provides, in some embodiments, a stable liquid and/or lyophilized formulation of anti-CLEC2D monoclonal antibodies. In some embodiments, a formulation buffer contemplated for use in the present disclosure has a pH in the range from 4.0 to 8.0; preferably in the pH range from 4.5 to 7.5; most preferably in the pH range between 5.0 and 6.5.

In some embodiments, the present disclosure comprises buffering agents that can be any of the following and combinations thereof, sodium citrate, citric acid; sodium phosphate mono basic, sodium phosphate dibasic; potassium phosphate mono basic, potassium phosphate dibasic; acetic acid, sodium acetate; histidine, histidine HCl; succinic acid, sodium succinate; tartaric acid, sodium tartrate; maleic acid, maleate; succinate 2-(N-morpholino) ethane sulfonic acid (MES) and hydrochloric acid and sodium hydroxide to adjust the pH to desired range.

In some embodiments, the composition comprises other buffers such as Tris buffer, (3-(N-morpholino)propanesulfonic acid) (MOPS), MOPS-SDS (MEPS), N-cyclohexyl-2-hydroxyl-3-aminopropanesulfonic acid (CAPSO), piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) etc. some embodiments, the formulation comprises polyols, which are sugar alcohols. In some embodiments, the stabilizers in the formulation comprise any one of the following alone or in combination: a-trehalose, sucrose, mannitol, sorbitol. In other embodiments, the formulation comprises a second stabilizer that are any one of the following: methionine, lysine, arginine, glycine, glutamate etc.

In some embodiments, the present antibody formulations comprise hydrophobic salts namely sodium camphor sulphate, tri methyl ammonium iodide. In another embodiment, the present disclosure of anti-CLEC2D monoclonal antibody formulation comprises surfactants, as well. In some embodiments, any one of following surfactants are included in the formulations, as exemplified by Polysorbate 20, Polysorbate 40, Polysorbate 80, and Poloxamer 188. In some embodiments, the composition comprising an anti-CLEC2D monoclonal antibody comprises anti-oxidants, for example methionine and/or glutathione. In some embodiments, the composition comprises hydrochloric acid and sodium hydroxide to adjust the pH of formulation buffer.

In some embodiments, the present disclosure comprises other stabilizing and complexing agents such as disodium edetate (Na(2)EDTA) and diethylene triaminepentaacetic acid (DTPA). In some embodiments, all the excipients of the stable formulation are dissolved in water for injection (WFI).

In one embodiment, the final aqueous stable formulation is filtered suitably to remove particulate matter. In some embodiments, filtration is done through either polyethersulfone (PES) filters, Polyvinylidene Fluoride (PVDF) filters or regenerated cellulose (RC) filters, suitably filters sized at either 0.22 and/or 0.45 micron pore size.

In some embodiments, a drug delivery device is the second important aspect of the antibody formulation. In other embodiments, the drug delivery device is sterile. In other embodiments, the drug delivery device is a vial, ampoule, syringe, injection pen or an intravenous (i.v) bag.

In a non-limiting embodiment of the present disclosure, functional characterization comprises performing experiments to understand the kinetics and dynamics of binding of an anti-CLEC2D antibody using techniques that include, but are not limited to, ELISA, BIAcore, flow cytometry, western-blot and imaging, amongst other techniques that are well known in the art. Further CLEC2D-CD161 interaction sites are mapped, and then monitored and validated through flow cytometry based binding experiments.

In a non-limiting embodiment of the present disclosure, monoclonal antibodies function through various mechanisms to destroy tumor cells with an ultimate effect of priming either the innate or adaptive arm of the immune system. The effector functions include complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). One non-limiting approach employed in the methods disclosed herein is to enhance the efficacy of therapeutic antibodies by modifying the immunoglobulin constant region. An example of such an antibody includes an anti-CLEC2D antibody which consists of a variable region (novel heavy chain and light chain regions) and may consist constant regions representing specific isotypes e.g., IgG1, IgG2, IgG4 or variants thereof, as described in this disclosure. Similarly, the unique variable region sequences could be used to develop antibody molecules with enhanced ADCC function or modified thermal stability as well as developing bispecific antibodies, ScFv molecules or any other antibody formats, as further described herein.

In a non-limiting embodiment of the present disclosure, the phrase “cytokines” may include chemokines, interferons, interleukins, lymphokines and tumor necrosis factors, which may be produced as an effect of the treatment of isolated antibody used against any of the cell lines related to a mentioned disease and/or combination thereof

In a non-limiting embodiment of the present disclosure, the phrase an “inducer” is a molecule that regulates gene expression.

An embodiment of the present disclosure comprises using methods and tools to understand interaction of genes associated with pathways such as NK-cell signature, IFN-γ production etc., in relation to a mode of action of selected antibody molecules. To exemplify, techniques such as western blot, flow cytometry, imaging through confocal microscopy and RT PCR are employed together to decipher the mechanistic impact of selected anti-CLEC2D antibody molecules, wherein the effect of various inhibitors against major signaling pathways are assessed in multiple cancer cells. In one embodiment, an IFN-γ release assay, CD107a+ expression, and/or cytoxicity assays are used to estimate the effectiveness of an anti-CLEC2D antibody.

In a non-limiting embodiment of the present disclosure, anti-tumor activity is assessed in huNOG-EXL mice bearing subcutaneous PC3 tumor xenograft, wherein the effect of a selected anti-CLEC2D antibody is monitored either alone or in combination with monoclonal antibody against a checkpoint target. In another embodiment, antibody dosage regimens are adjusted to obtain an optimum and desired anti-tumor response. In some embodiments, the phrases “parenteral administration” or related terms as used herein means mode of administration other than enteral and topical administration, usually by injection and includes, but is not limited to the following administration means, intramuscular, intravenous, intrarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, subcutaneous, subcuticular, intraspinal, epidural, intraasternal injection and infusion.

The following examples are presented in order to more fully illustrate the preferred embodiments of this disclosure. They should in no way be construed, however, as limiting the broad scope of this disclosure.

EXAMPLES
Example 1: Expression of Soluble CLEC2D Antigen

The antigen construct comprising an ecto-domain of CLEC2D, either wild type or mutated, was expressed in Chinese hamster ovary (CHO) cell line and purified as a soluble antigen. The CLEC2D ectodomain contains 5 cysteines with 2 putative disulphide bonds. The mutation H176C was carried out to introduce an additional disulphide bridge with the Cys163 amino acid to increase the stability and homogeneity of the expressed protein. The construct was developed with a C-term Histidine tag to facilitate the antigen purification process.

The extracellular domain of the CLEC2D (Q72-V191, H176C) antigen was codon optimized for both human and CHO expression system and the construct was synthesized. A specific signal sequence was used for secretion of the CHO expressed antigen. The CLEC2D gene sequence and appropriate signal sequence was cloned into the pCDNA3.1 mammalian expression vector (FIG. 2A).

CHO suspension cells at more than 90% viability were used for transfection of the expression plasmid encoding the CLEC2D gene. Cells were centrifuged at 1000-1400 rpm for 4-5 minutes. The spent media was decanted and the cells were re-suspended in 250 ml of OptiMEM I media. The CLEC2D expression plasmid was transfected using Lipofectamine LTX with Plus™ reagent. 500 μg of DNA was used with 1:3 DNA to transfection reagent ratio and 500 μl Plus' reagent was used. DNA and Lipofectamine LTX complex was prepared in 250 ml OptiMEM I and incubated at 20-25° C. for 20 minutes for complex formation. The transfection mix was added slowly to the cell suspension. The cells were incubated for 5 hours at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. 500 ml of Power CHO2 CD growth media was added to the cells. The cells were incubated for 3 days at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. Day 3 post transfection 200 ml Power CHO2 CD growth media containing 2 mM Glutamax was added. The cells were incubated at 37° C. in a 5% CO2 shaker incubator at 100-120 RPM. Day 6 post transfection, cell culture supernatant was harvested by centrifugation at 1400-2000 rpm for 10-15 minutes.

The cell harvest was centrifuged and filtrated to remove cell debris. The clear supernatant was loaded onto pre-equilibrated Ni Sepharose FF C10 column. Subsequently the column was washed with 50 mM and 100 mM Imidazole solution sequentially followed by single-step elution of His-tagged CLEC2D protein with 500 mM imidazole. Multiple fractions were collected and buffer exchanged to 1× phosphate buffered saline (PBS) pH 7.4.

Purified CLEC2D antigen was analysed through SDS-PAGE. The human CLEC2D sequence has two putative N-glycosylation sites N95 and N147. The aberrant mobility in SDS-PAGE was speculated to be due to differential N-glycosylation pattern. Purified CLEC2D antigen was de-glycosylated using PNGase enzyme and appeared to be as single band on expected molecular weight as judged by SDS-PAGE analysis (FIGS. 2B-2F). Subsequently purified CLEC2D antigen was analysed by western blot experiments using a commercially available anti-CLEC2D antibody. The purified CLEC2D antigen was also confirmed through ELISA with a commercially available anti-CLEC2D antibody. The oligomeric status of the protein was found to be a dimer using size exclusion chromatography experiments. Finally, N-terminal sequencing was carried out by Edman degradation method to confirm the antigen sequence.

Example 2: Screening of Antibody Gene Library Using Phage and Yeast Display Platforms

Screening of antibody gene libraries was carried out with by combining phage display and yeast display of the antibody libraries. Phage and yeast display platforms expressing a human antibody repertoire were used sequentially to identify novel antibody clones with higher affinity and specificity against CLEC2D antigen (FIG. 3). For phage panning experiments against antigens, the magnetic bead based approach was adopted. Antigen coated on magnetic dynabeads were prepared and the efficiency of conjugation was >90%. Phage antibody library was panned against the antigen coated beads to separate phage particles expressing anti-CLEC2D antibody clones. The selected phage particles were used to generate replicative form containing the heavy and light chain repertoire. Purified DNA was digested and ligated into yeast expression vector in two different plasmid constructs to generate antibodies in Fab format and ScFv format.

For magnetic bead conjugation with purified CLEC2D antigen, at first, dyna beads were weighed at a quantity ranging from 0.5 mg to 1.5 mg corresponding to ˜0.5-1.0×10⁸beads and dissolved into 0.1 M sodium phosphate buffer, pH 7.4. This suspension was vortexed for 30-60 seconds followed by incubation at room temperature for 10-15 minutes with continuous rotation. The suspension was washed twice with 0.1 M sodium phosphate buffer and re-suspended again into 100 μL of 0.1 M sodium phosphate buffer. 5-10 μg of purified soluble CLEC2D antigen solution, (75-150 μL) was added to the bead suspension. Further, the suspension was mixed well before adding the 100 μL of 3 M ammonium sulfate solution. The mixture was incubated for 15-20 hours at 30-37° C. with slow tilt but continuous rotation. Post incubation the tube was placed on the magnet holder for 1 min for magnetic separation. The magnet holder (with the tube in place) was carefully turned upside-down twice to ensure no beads remain in the cap. The supernatant was removed and beads are washed four times with 1 mL 1×PBS containing BSA (0.05%). Finally, the beads are re-suspended in 100 μL of 1×PBS with BSA (0.05%) and are used in panning.

1 μL (˜10⁶number of beads) of bead alone and bead coated with CLEC2D antigen are mixed with commercial P4500/anti-CLEC2D antibody at amount of 0.1 μg followed by volume make up to 100 μL with 1×PBS containing 0.5% BSA. The mixture was incubated for 2 hrs on ice followed by a washing with 1×PBS containing 0.5% BSA. Anti-goat IgG conjugated with FITC at 1:400 dilution was added to the re-suspended beads in solution of 1×PBS containing 0.5% BSA to a volume of 100 μL before readings were taken. All the flow cytometry experiments were done using Accuri C6 flow cytometer while the analysis was done by using BD Accuri C6 software. Firstly, forward and side scatter data was seen to fix a gate followed by fluorescence reading through FLH1 filter. At least 5,000-10,000 data points are collected for each sample (FIG. 4A).

Phage panning experiment was started with inoculation of single colony from the freshly streaked TG1 bacterial plate into 3 ml LB medium followed by incubation at 37° C. until OD600≈0.9 and this was used for phage infection later. A phage naïve antibody library was thawed and the phage particles are precipitated with 250 μl (˜¼ of the phage suspension volume) PEG/NaCl solutions (20% PEG 8000 and 2.5 M NaCl) and incubated on ice for 30 minutes followed by centrifugation of the precipitated phage at 10,000×g for 10 minutes. The supernatant was discarded and the phage pellet was re-suspended in 200 μl PBS solution. Phage suspension (200 μl) was added to the bead conjugated with BSA and incubated on a rotator at room temperature for 2 hrs followed by adding the supernatant to bead conjugated with CLEC2D antigen and 10 μL of supernatant was kept aside for plaques assay later on. Phage suspension with conjugated bead with antigen was incubated on a rotator at room temperature for 2 hrs. The beads were washed two times with 1 ml 0.05% PBST (0.05% Tween-20 in PBS). Finally, magnetic beads bound with phage particle are re-suspended in 100 μl PBS. 10 μL of beads suspension was kept aside for plaques assay later on. The remaining 90 μl of the suspension was added to 2 ml of grown TG1 cells prepared earlier and the mixture was incubated at 37° C. for 1 h. Post incubation it was diluted into 10 ml LB medium containing ampicillin at a final concentration of 25 μg/ml. After two hours of incubation at 37° C. with constant shaking at 250 rpm, concentration of ampicillin was increased to a final concentration of 100 μg/ml. M13K07, helper phage, was mixed into the amplified TG1 cells with multiplicity of infection (MOI) of 10 and incubated at 37° C. for another 30 minutes. Helper phage-infected bacteria was spun down and the pellet was re-suspended into 10 ml of LB medium supplemented with 100 μg/ml ampicillin and 25 μg/ml kanamycin followed by incubation at 30° C. for 30 minutes to 100 minutes for phage amplification. The bacterial culture was pelleted down by centrifugation for 10 minutes at 10,000 g. The pellet was discarded and supernatant was used for precipitation of amplified phage molecules by adding PEG/NaCL solution to the supernatant (˜¼th volume of supernatant). The mixture was incubated for 30 min on ice, followed by spinning the precipitated phage at 10,000 g for 10 minutes. Supernatant was discarded and pellet was re-suspended in 1 ml of PBS. The Plaques assay was performed from the 10 μL of amplified phage suspension to estimate the amplified phage number while the remaining of the precipitated phage are stored with 50% glycerol at −80° C. freezer for long term storage.

Plaque assay was performed at every step to ensure the numbers of phage particles. A single colony from the TG1 bacterial plate was inoculated in bacteria in 3 ml LB medium and was grown at 37° C. until OD600≈0.9. 0.7% of agarose was prepared in purified water and stored at 50° C. in aliquots of 3 ml each in a 15 ml of falcon tubes. The phage supernatant and pellet were diluted at respective steps from 10⁻¹to 10⁻⁵. 100 μl of diluted phage and 100 μl TG1 cells were added in to each of agarose aliquots and mixed followed by immediately spreading on LB Agar plate. The plates were incubated in 37° C. in an incubator for overnight. The plaque formation was observed and counted next day. The number of panned molecules was calculated based on number of plaques observed (Table 10).

TABLE 10

Estimation of phage particle number at every step of panning

process against CLEC2D antigen.

Process Step
Pfu/mL

Panning with BSA conjugated beads
4 × 10⁸

Supernatant from BSA panning
1 × 10⁹

CLEC2D binders
4 × 10⁶

Single colony from the TG1 bacterial plate was inoculated into 20 ml LB medium at 37° C. until OD600 reaches ˜0.9. 200 μl of the precipitated panned phage suspension was inoculated into 2 ml TG1 cells (in 10 different tubes and each tube contains 2-5 ml of TG1 cells) followed by incubating the mixture at 37° C. with shaking for 1 hour. Volume in each tube was diluted into 10 ml LB medium containing 25 μg/ml Ampicillin. Following additional 2 hours of incubation at 37° C. with shaking at 220 rpm, ampicillin concentration was increased to a final concentration of 100 μg/ml and incubated further for 30 minutes to 100 min. Bacterial culture was spun down at 10,000 g for 10 minutes, and the pellet was used for DNA isolation through Qiagen midi prep as per manufacturer's protocol for further use.

Construction of heavy and light chain libraries in to yeast shuttle vectors in Fab format:

Isolated replicative form DNA of panned molecules along with the in-house yeast expression vector pZB003 (MTCC 25127) designated for light chain incorporation are digested with HindIII and AscI followed by ligation and transformation individually into TG1, highly competent cells. Likewise, heavy chain pool (sourced from isolated replicative form) and the respective vector pZB002 (MTCC 25126) are digested with NcoI and NotI followed by ligation and transformation into TG1, highly competent cells. Transformation efficiency obtained for both heavy and light chain panned library are >10⁷cfu. Obtained transformed colonies for both heavy and light chain libraries are checked for insert release using NcoI/NotI for heavy chain (FIG. 4B) and HindIII/AscI for light chain (FIG. 4C) before they are scraped for glycerol stock preparation. Insert release for both the chains confirmed the presence of panned variable heavy and light chain-kappa molecules. Glycerol stocks are stored at −80° C. for future use. Tables 10, 11 and 12 provide for components applicable in constructing libraries in yeast vectors.

Table 11

Components
Amount/Volume

DNA
20
ug

NcoI
4
uL

NotI
4
uL

CutSmart Buffer
10

Water
Respective Volume

Total
100
uL

TABLE 12

Components
Amount/Volume

DNA
20
ug

HindIII
4
uL

AscI
4
uL

CutSmart Buffer
10

Water
Respective Volume

Total
100
uL

TABLE 13

Components
Amount/Volume

Vector
100
ng

Insert
100
ng

T4 DNA ligase
0.5
uL

T4 DNA ligase Buffer
2
uL

Water
Respective Volume

Total
20
uL

Construction of Heavy and Light Chain Libraries in to Yeast Shuttle Vectors in ScFv Format:

ScFv format comprises of transfer of light chain (kappa repertoire originated from panned phage against CLEC2D antigen) into pZB004.4 vector between NdeI and AscI restriction sites followed by generation of a pool of light chain ScFv library. Subsequently the library was confirmed with restriction digestion confirmation followed by transfer of panned heavy chain pool into ScFv-light chain library between NcoI and NotI restriction enzymes. This final library was used as ScFv library of panned molecules which will be further transformed, sorted and screened in yeast expression system. Isolated replicative form DNA of panned molecules along with the in-house ScFv yeast expression vector are digested with NdeI and AscI followed by ligation and transformation individually into TG1, highly competent cells.

Obtained transformed colonies for light chain libraries are checked for insert release using NdeI/AscI before they are scraped for glycerol stock preparation. Insert release confirmed the presence of panned molecules. Glycerol stocks are stored at −80° C. for future use. Plasmid isolation was carried out using Qiagen midi prep kit which will be used for incorporation of heavy chain repertoire obtained from panning.

Likewise, heavy chain pool from isolated replicative form and the ScFv containing light chain library are digested with NcoI and NotI (FIG. 4D) followed by ligation and transformation into TG1, highly competent cells. Transformation efficiency obtained for both heavy and light chain panned library are >10⁷cfu. Colonies were confirmed with insert release for both heavy with NcoI/NotI and light chains with NdeI/AscI (FIG. 4E).

Tables 13, 14 and 15 provide for components applicable in constructing libraries in yeast expression vector.

TABLE 14

Components
Amount/Volume

DNA
20
ug

NdeI
4
uL

AscI
4
uL

CutSmart Buffer
10

Water
Respective Volume

Total
100
uL

TABLE 15

Components
Amount/Volume

DNA
20
ug

NcoI
4
uL

NotI
4
uL

CutSmart Buffer
10

Water
Respective Volume

Total
100
uL

TABLE 16

Components
Amount/Volume

Vector
100
ng

Insert
100
ng

T4 DNA ligase
0.5
uL

T4 DNA ligase Buffer
2
uL

Water
Respective Volume

Total
20
uL

DNA isolated in large scale was checked for restriction digestion, before transferred for yeast transformation. Post confirmation through restriction digestion at least 10 independent clones containing variable heavy and light-kappa chains for each of formats were sent for sequencing reactions. The sequencing results have been summarized in terms of productive heavy and light-kappa chains in the following Table 17.

TABLE 17

summarizes the percentage productivity

for variable heavy chain and light-kappa

chain as estimated from sequencing

reactions carried out from independent clones.

Antigen
Format
Chain Type
Productivity

CLEC2D
Fab
Variable heavy chain pool
81%

Variable Light chain Pool
80%

ScFv
Heavy and Light chain
85%

repertoire

As detailed above, phage antibody library was panned against the CLEC2D antigen coated beads in order to eliminate non-specific binders. The selected phage particles were used to generate replicative form containing the heavy and light chain repertoire. This method was devoid of any PCR based approached which might introduce unwanted biasness towards the panned pool of molecules. Purified replicative form of DNA was digested and ligated into yeast expression vector in two different plasmid constructs to generate antibody in Fab format and ScFv format, wherein the cloning efficiency was estimated to be >95% and the efficiency of TG1 cells transformation was more than 10⁷cfu. These parameters were essential to meet to ensure complete capturing of panned diversity.

Subsequently, yeast DNA libraries in both formats i.e., ScFv and Fab, were transformed into yeast cells. Transformed yeast cells were checked for heavy chain, light chain and Fab molecule expression. Surface expression of antibody genes were analysed with multiple tags such as FLAG, c-Myc and (His)₆-tag and V5-tag for heavy chains and light chains, respectively. Flow cytometry based sorting was carried out to isolate yeast cells expressing antibody sequences showing specific antigen binding ( )). Flow sorting of yeast cell populations were repeated 2-3 times to enrich antibody clones with higher affinity towards labelled CLEC2D antigen.

Generation of Yeast ScFv Library

EBY100 strain (S. cerevisiae cells) was grown for overnight in to 5 ml YPD media on a platform shaker at 220 rpm and 30° C. The next morning, an aliquot of the overnight culture was inoculated into 100 ml YPD media at OD600˜0.3. The inoculated cells continued to grow on a platform shaker at 30° C. and 220 rpm until OD600 reached to ˜1.6 (usually after 5 hours-6 hours). Yeast cells were collect by centrifugation at 3000 rpm for 3 minutes and the media was removed. The cell pellet was washed twice with 50 ml ice cold water and once by 50 ml of ice cold electroporation buffer (1 M Sorbitol/1 mM CaCl2). The yeast cells were condition by re-suspending the cell pellet in 20 ml (0.1 M LiAc/10 mM DTT) and shaking at 220 rpm in a culture flask for 30 minutes at 30° C. The conditioned cells were collected by centrifugation, washed once with 50 ml ice-cold electroporation buffer and re-suspended the cell pellet in 100 μl to 200 μl electroporation buffer to reach a final volume of 1 ml.

This corresponds to approximately 1.6×10⁹cells/ml and is sufficient for 2 electroporation reactions of 400 μl each. The cells were kept on ice until electroporation. 400 μl electro competent cells were gently mixed with required amount of plasmid DNA and transferred to a pre-chilled Bio-Rad GenePulser cuvette (0.2 cm electrode gap) and kept on ice for 5 min until electroporation. The cells were electroporated at 2.5 kV and 25 μF. Electroporated cells were transferred from each cuvette into 8 mL of 1:1 mix of 1 M sorbitol: YPD media, and incubated on a platform shaker at 220 rpm and 30° C. for 1 hour. Cells were collected by centrifugation and resuspended in SDCAA media. 10-fold serially diluted cells were prepare from the cell suspension and 100 μl of 10−3 and 10−4 diluted cells were plated onto selective plates (SDCAA plates) and incubated at 30° C. incubator for 3-4 days. Library size was determined from the colony counts after 3-4 days (FIG. 5A). After 3-4 days colonies were observed on SDCAA plate. Finally, 20% glycerol stock of the yeast ScFv antibody library was prepared by scrapping yeast cells and stored at −80° C.

Generation of Yeast Haploid Antibody Libraries for the Development of Fab Antibody Library

Transformation was performed according to manufacturer's (Zymo Research) protocol with minor modifications. Briefly, EBY100ura3Δ4.03 strain (S. cerevisiae cells) and YVH10 were grown for overnight in 5 ml YPD media on a platform shaker at 220 rpm and 30° C. The OD600 value of overnight culture was checked and the overnight culture was re-inoculated into 50 ml YPD medium with starting OD600 ˜0.4, until OD600 reached ˜1.0-1.2 at 30° C., in incubator shaker with 220 rpm. Yeast cells were collected by centrifugation at 3000 rpm for 3 minutes and the media was removed. Cell pellet was washed with 10 ml EZ1 solution followed by centrifugation at 3000 rpm for 10 min. Then, cell pellet was resuspended in to 600 μl of EZ2 solution and further incubated at RT for 5 min. 200 μl of EZ2 solution containing competent yeast cells was mixed with appropriate amount of plasmid DNA and 500 μl of EZ3 solution. Above mix of competent yeast cells and DNA was incubated at 30° C. for 1 hr and 30 min. The yeast cells were centrifuged at 2400 rpm for 5 min. 200 μl of the supernatant was discarded and the cell pellet resuspended in the remaining supernatant.

10-fold serially diluted cells from the cell suspension was prepared and 100 μl of 10 −3 diluted cells was plated on selective plates and incubated at 30° C. incubator for 3-4 days. EBY100ura3Δ4.03 transformed with heavy chain antibody library was selected on tryptophan drop out glucose medium. However, YVH10 strain with light chain antibody library was selected on uracil drop out medium. Library size was determined from the colony counts after three days and estimated to be ˜10⁵. (FIG. 5A) 20% glycerol stock of the haploid yeast antibody libraries was prepared and stored at −80° C.

Generation of Diploid Yeast Fab Library Through Yeast Mating

The two haploid yeast strains with heavy and light chain libraries having different mating types were scraped with amino acid drop out glucose media. OD600 of the both haploid cell cultures was checked. About 1 OD600 of each culture was taken in 1.5 ml microfuge tube and spun at 13000 rpm for 3-5 min. Discard the supernatant then added 100 μL of purified water in each pellet and mix them together. Plated mixed yeast cultures onto YPD plate and incubated for 5-6 hrs at 30° C. Yeast cells from the YPD plate after 5-6 hrs were scraped and OD600 of the scraped yeast cells was monitored. The scraped culture were inoculated into ura trp double drop out glucose media with starting OD600 of 0.1 and incubated for at least 24 hrs at 30° C., 220 rpm (for diploid enrichment).

OD600 of enriched diploid culture was monitored and dilutions were prepared from enriched culture containing approximately 500 and 1000 cells. The dilutions were plated onto single and double drop out amino acid glucose agar plates and incubated at 30° C. for 2-3 days. Diploid library was selected on ura trp double drop out glucose plate. 20% glycerol stock of the remaining enriched diploid culture was prepared and stored at −80° C. Percentage mating efficiency was calculated as the number of diploid colonies grown in the double drop out media plates divided by the number of total colonies grown in the single drop out plates. Yeast fab antibody library was generated through yeast mating (FIG. 5C).

Flow Sorting of Yeast Fab and ScFv Library

The yeast samples were inoculated into 3 ml of SDCAA media and incubated yeast cell for overnight at 30° C., 220 rpm. Next day, the OD600 value of the inoculated cultures was monitored by diluting of 1:10. 0.3 OD600 cells of the yeast samples was inoculated into 20 ml 2×SGCAA media and incubated for 48 hrs in incubator shaker at 20° C., at 220 rpm. The OD600 of the induced culture was monitored by diluting 1:10 after 48 hrs. About 0.1 OD600 cells was taken from grown yeast cultures into 1.5 ml tube and spun at 13,000 rpm for 2 minutes. The supernatant was discarded and the pellet was washed by adding 100 μl of 1×PBS and 241 pun at 13,000 rpm for 2 minutes. The supernatant was discarded again. 200 μl of primary antibody or biotinylated antigen with an appropriate concentration was added in yeast cell pellet and incubated for 45 min on rotation at RT. After incubation, the cells were spun at 13,000 rpm for 2 min and the supernatant was discarded. Cell pellet was washed twice by adding 200 μl of PBS containing 0.1% BSA and spun at 13,000 rpm for 2 minutes and the supernatant was discarded. 200 μl of secondary antibody with an appropriate concentration was added in to yeast cell pellet and incubated for 30 min on ice. After incubation, the cells were spun at 13,000 rpm for 2 minutes and the supernatant was discarded. The pellet was washed thrice by adding 200 μl of 1×PBS containing 0.1% BSA and spun at 13,000 rpm for 2 minutes. 300 μL of 1×PBS was added in yeast cell pellet and samples were analysed through flow sorter (FIGS. 5D and 5E). Concentrations for primary, secondary antibodies and biotinylated antigen are presented in Table 18.

TABLE 18

Format of

antibody
Primary antibody
Secondary antibody

library
(Concentration)
(Concentration)

Expression of library

ScFv
Myc Tag polyclonal
Goat anti-Chicken IgY

(5 μg/ml)
(H + L) Secondary

Antibody, Alexa Fluor

488 (5 μg/ml)

Fab
V5 Tag (5 μg/ml)
Goat anti-Chicken IgY

(H + L) Secondary

Antibody, Alexa Fluor

488 (5 μg/ml)

Binding of library

ScFv
Biotinylated CLEC2D
Streptavidin, Alexa Fluor ™

antigen (250 nM for
633 conjugate (5 μg/ml)

flow resort-1, 100 nM for

flow sort-1, 50 nM

for flow resort-2,)

Fab
Biotinylated CLEC2D

antigen (250 nM for

flow resort-1, 100 nM for

flow sort-1, 50 nM

for flow resort-2,)

Individual Clone Screening from Sorted/Resorted ScFv or Sorted/Resorted Fab Pool

Similar flow staining protocol was used as discussed during flow sorting for individual clone screening. About 1000 colonies were screened through flow cytometry for expression and antigen binding (FIGS. 5F, 5G, and 5H). These clones were selected on the basis of >2% and >5% positive for both binding and expression in case of Fab and ScFv clones respectively.

In addition selected pool of antibody genes as obtained from sorting against soluble CLEC2D antigen were subjected for next generation sequencing. This exercise was carried out for both ScFv and Fab format of antibody gene pools. As exemplified, Seq IDs SEQ ID 44; SEQ ID 45; SEQ ID 42; SEQ ID 1; SEQ ID 73; SEQ ID 21; SEQ ID 35; SEQ ID 58; SEQ ID 7; SEQ ID 260; SEQ ID 261; SEQ ID 258; SEQ ID 217; SEQ ID 289; SEQ ID 237; SEQ ID 251; SEQ ID 274; SEQ ID 223 were enriched at the final sorted round ranging from 2.5 fold to 7 fold, as applicable to clones screened in Fab format, while the clones screened in ScFv format were enriched to fold ranging from 2 fold to 106 fold, to an approximate. The fold enrichment estimation was carried out through number of gene copies seen at every round of sorting. This further supports the fact that antibodies against CLEC2D antigen were screened, isolated and identified via a robust platform comprising naïve antibody library screened phage and yeast display technologies.

Finally, individual yeast clones were identified using flow cytometry assays. Subsequently, peer group antibody gene sequencing was carried out and novel antibody sequences were taken for further cloning to mammalian gene expression vectors. Yeast plasmid DNA was isolated from selected yeast clones, existing in both Fab or ScFv formats, using Zymoprep Yeast Plasmid miniprep kit—The variable region of heavy and light chains in selected yeast clones with Fab format were amplified using vector specific primer followed by sequencing. While for clones in ScFv format, isolated plasmids from yeast colonies were subsequently transformed into NEB-alpha cells for larger production. The isolated plasmids from NEB-alpha cells were sent for sequencing confirmation. FIG. 5H summarizes percentage binding of monoclonal antibody clones with CLEC2D antigen, as determined by flow cytometry. The data suggest at least about 80% of the monoclonal antibody clones revealed detectably and specifically binding to CLEC2D antigen.

All sequence identifiers and relevant sequence identity analysis are described in Table 19, which lists antibody clones for variable heavy chains, and Table 20, which lists antibody clones for variable kappa light chains.

TABLE 19

SEQ ID NOs of VH Sequences of Anti-CLEC2D

% Sequence

Identity
Variable heavy chain Sequence ID NOs

35%-40%
SEQ ID NO: 33; SEQ ID NO: 34; SEQ ID NO: 87; SEQ ID NO: 82; SEQ ID

NO: 104

40%-45%
SEQ ID NO: 11; SEQ ID NO: 35; SEQ ID NO: 86; SEQ ID NO: 22; SEQ ID

NO: 69; SEQ ID NO: 41; SEQ ID NO: 3; SEQ ID NO: 66; SEQ ID NO: 37;

SEQ ID NO: 56; SEQ ID NO: 21; SEQ ID NO: 38; SEQ ID NO: 90; SEQ ID

NO: 100; SEQ ID NO: 18; SEQ ID NO: 20; SEQ ID NO: 83; SEQ ID NO: 1;

SEQ ID NO: 19

45%-50%
SEQ ID NO: 105; SEQ ID NO: 101; SEQ ID NO: 4; SEQ ID NO: 72; SEQ ID

NO: 28; SEQ ID NO: 64; SEQ ID NO: 25; SEQ ID NO: 60; SEQ ID NO: 55;

SEQ ID NO: 52; SEQ ID NO: 27; SEQ ID NO: 43; SEQ ID NO: 70; SEQ ID

NO: 71; SEQ ID NO: 14; SEQ ID NO: 85; SEQ ID NO: 13; SEQ ID NO: 61;

SEQ ID NO: 42; SEQ ID NO: 39; SEQ ID NO: 10; SEQ ID NO: 49; SEQ ID

NO: 24; SEQ ID NO: 40; SEQ ID NO: 63; SEQ ID NO: 78; SEQ ID NO: 2;

SEQ ID NO: 94; SEQ ID NO: 5

50%-55%
SEQ ID NO: 97; SEQ ID NO: 16; SEQ ID NO: 76; SEQ ID NO: 9; SEQ ID

NO: 89; SEQ ID NO: 107; SEQ ID NO: 68; SEQ ID NO: 29; SEQ ID NO: 67;

SEQ ID NO: 74; SEQ ID NO: 32; SEQ ID NO: 81; SEQ ID NO: 106; SEQ ID

NO: 31; SEQ ID NO: 62; SEQ ID NO: 48; SEQ ID NO: 75; SEQ ID NO: 12;

SEQ ID NO: 102; SEQ ID NO: 54; SEQ ID NO: 80; SEQ ID NO: 26; SEQ ID

NO: 30; SEQ ID NO: 92; SEQ ID NO: 108; SEQ ID NO: 79

55%-60%
SEQ ID NO: 45; SEQ ID NO: 15; SEQ ID NO: 51; SEQ ID NO: 44; SEQ ID

NO: 73; SEQ ID NO: 36; SEQ ID NO: 77; SEQ ID NO: 50; SEQ ID NO: 6

60%-80%
SEQ ID NO: 9; SEQ ID NO: 53; SEQ ID NO: 95; SEQ ID NO: 23; SEQ ID

NO: 103; SEQ ID NO: 7

80%-90%
SEQ ID NO: 57; SEQ ID NO: 91; SEQ ID NO: 98; SEQ ID NO: 84; SEQ ID

NO: 58; SEQ ID NO: 88; SEQ ID NO: 96; SEQ ID NO: 47; SEQ ID NO: 17;

SEQ ID NO: 8

90%-99%
SEQ ID NO: 46; SEQ ID NO: 65; SEQ ID NO: 59; SEQ ID NO: 99

TABLE 20

SEQ ID NOs of VL Sequences of Anti-CLEC2D

% Sequence

Identity
Variable kappa light chain Sequence IDs

50%-60%
SEQ ID NO: 282; SEQ ID NO: 308; SEQ ID NO: 287; SEQ ID NO: 321;

SEQ ID NO: 236; SEQ ID NO: 265; SEQ ID NO: 270; SEQ ID NO: 275;

SEQ ID NO: 306; SEQ ID NO: 296; SEQ ID NO: 241; SEQ ID NO: 314;

SEQ ID NO: 223

60%-65%
SEQ ID NO: 254; SEQ ID NO: 289; SEQ ID NO: 238; SEQ ID NO: 268;

SEQ ID NO: 248; SEQ ID NO: 284; SEQ ID NO: 244; SEQ ID NO: 310;

SEQ ID NO: 243; SEQ ID NO: 285; SEQ ID NO: 220; SEQ ID NO: 255;

SEQ ID NO: 293; SEQ ID NO: 298; SEQ ID NO: 235; SEQ ID NO: 319;

SEQ ID NO: 245; SEQ ID NO: 224; SEQ ID NO: 291; SEQ ID NO: 277;

SEQ ID NO: 232

65%-70%
SEQ ID NO: 307; SEQ ID NO: 262; SEQ ID NO: 253; SEQ ID NO: 276;

SEQ ID NO: 323; SEQ ID NO: 234; SEQ ID NO: 261; SEQ ID NO: 312;

SEQ ID NO: 290

70%-75%
SEQ ID NO: 259; SEQ ID NO: 239; SEQ ID NO: 281; SEQ ID NO: 228;

SEQ ID NO: 217; SEQ ID NO: 227; SEQ ID NO: 251

75%-80%
SEQ ID NO: 231; SEQ ID NO: 250; SEQ ID NO: 260; SEQ ID NO: 226;

SEQ ID NO: 271; SEQ ID NO: 256; SEQ ID NO: 272; SEQ ID NO: 278;

SEQ ID NO: 302; SEQ ID NO: 320; SEQ ID NO: 295; SEQ ID NO: 292;

SEQ ID NO: 229; SEQ ID NO: 264; SEQ ID NO: 252; SEQ ID NO: 267;

SEQ ID NO: 304; SEQ ID NO: 300; SEQ ID NO: 311; SEQ ID NO: 324

80%-85%
SEQ ID NO: 222; SEQ ID NO: 258; SEQ ID NO: 219; SEQ ID NO: 313;

SEQ ID NO: 294; SEQ ID NO: 303; SEQ ID NO: 317; SEQ ID NO: 273;

SEQ ID NO: 266; SEQ ID NO: 315; SEQ ID NO: 257; SEQ ID NO: 288;

SEQ ID NO: 301; SEQ ID NO: 221; SEQ ID NO: 240; SEQ ID NO: 299;

SEQ ID NO: 247; SEQ ID NO: 263; SEQ ID NO: 274

85%-99%
SEQ ID NO: 218; SEQ ID NO: 249; SEQ ID NO: 230; SEQ ID NO: 279;

SEQ ID NO: 316; SEQ ID NO: 237; SEQ ID NO: 322; SEQ ID NO: 225;

SEQ ID NO: 318; SEQ ID NO: 233; SEQ ID NO: 305; SEQ ID NO: 280;

SEQ ID NO: 283; SEQ ID NO: 242; SEQ ID NO: 286; SEQ ID NO: 297;

SEQ ID NO: 309; SEQ ID NO: 246

Example 3: Antibody Sequence Analysis to Identify Novel Antibody Clones

Variable regions of isolated antibodies for both heavy and light chains that specifically bind the CLEC2D antigen comprise of six hyper variable regions: 3 hyper variable regions from light chain (CDRL1, CDRL2, and CDRL3) and 3 hyper variable regions from heavy chain (CDRH1, CDRH2, and CDRH3). The length of the hypervariable regions may vary significantly, as shown for CDRH3, whose lengths have significant representation in the pool, ranging from 4-23 amino acids. The amino acid compositions were measured at every heavy chain CDRH3 length to understand the sequence variability of selected antibody genes against CLEC2D (FIGS. 6A, 6B, 6C, and 6D).The antibody sequences were analysed to determine uniqueness. Multiple sequence alignment tools were used to compare the antibody gene sequences with published antibody sequences in databases like IMGT, IgBLAST etc.

Further analysis of selected sequences identified antibody genes with de-amidation motifs, isomerization motifs, proteolytic cleavage motifs, N-linked glycosylation sites, plastic binding motifs, streptavidin binding motifs, human Fc binding motifs, mouse IgM binding motifs, bovine IgG motifs, proline rich motifs and cysteine rich motifs, etc. Such antibody genes were not deemed suitable for therapeutic monoclonal antibody development and therefore were not considered for further evaluation. Based on the extend of binding observed for antibody genes against soluble CLEC2D antigen at the level of individual yeast colony screening, top 40 binders, not limited to, were of further interest towards subsequent development. Only confirmed antibody gene sequences were taken for further cloning, expression and characterization.

Example 4: Cloning of Novel Antibody Genes

Error free antibody variable heavy and variable light chain regions were subsequently cloned into mammalian expression vectors, having various isotype backbones, either wildtype or mutants, originated from human, mouse and cynomolgus monkey species. Table 21 below summarizes relevants vectors developed towards cloning of identified anti-CLEC2D antibody genes and deposited to Microbial Type Culture Collection and Gene Bank (MTCC), India.

TABLE 21

Taxonomic
Identification
MTCC Number

S. No.
Designation
Reference
Assigned

1

E.coli

pZB005
MTCC 25356

2

E.coli

pZB006
MTCC 25357

3

E.coli

pZB007
MTCC 25358

4

E.coli

pZB008
MTCC 25359

5

E.coli

pZB009
MTCC 25360

6

E.coli

pZB010
MTCC 25361

7

E.coli

pZB011
MTCC 25362

8

E.coli

pZB012
MTCC 25363

9

E.coli

pZB013
MTCC 25364

10

E.coli

pZB014
MTCC 25365

As exemplified by, the mammalian expression vectors pZB007 (MTCC 25358) & pZB008 (MTCC 25359) were designated and used for variable heavy chain and light chain gene cloning, respectively (FIGS. 7A and 7B). The vectors were custom designed and synthesized for the expression of antibody genes under the control of suitable promoter sequences. The plasmids carry a kanamycinR/puromycinR cassette driven by strong promoter and high-copy-number ColE1/pMB1/pBR322/pUC origin of replication for propagation (FIGS. 7A and 7B).

Sequence confirmed selected plasmids, as screened through phage and yeast display platform, against soluble CLEC2D antigen, using human naïve antibody library, were used as template for subsequent PCR amplification. PCR reactions were performed using sequence specific primers to amplify the selected clones having variable heavy and light chain regions. PCR reactions was carried out on an Eppendorf™ Mastercycler™ pro PCR System in 50 μL mixture volume consisting of 0.2 μM of each primer (Eurofins, India), 200 units of Phusion polymerase (NEB). Following an initial denaturation at 94° C. for 3 min, 30 cycles of 30 seconds denaturation at 94° C., and 50 seconds annealing at 60° C., 10 seconds primer extension at 72° C., 10 minutes final extension at 72° C. were performed. The PCR amplified product was extracted using QIAquick Gel Extraction kit. The plasmid vector pZB007 was linearized through restriction enzyme digestion by AscI and XbaI and for pZB008 with EcoRI and AscI. The inserts fragment and linearized vector were gel extracted using QIAGEN kit (20021).These purified vector and insert were used for recombination using Infusion HD Cloning kit (Takara, USA). Transformation of infusion reaction mixture into bacterial cells were performed. 100 μL aliquot of competent E. coli cells (Stellar) were taken from −80° C. freezer, thawed on ice for 5 minutes. 50% of recombination sample were added to the competent cells and gently mixed, incubated on ice for 20 minutes. Heat shock was given at 42° C. for 50 seconds in a dry bath. The vials were quick chilled on ice for 2 minutes. 0.950 mL of LB broth pre-warmed at 37° C. was added and incubated at 37° C., 220 rpm for 1 hour, in shaker incubator. 100 μL of the resulting culture was plated on LB agar media with kanamycin and incubated for overnight at 37° C.

Transformants containing specific DNA plasmid were inoculated in 5 mL of LB broth with Kanamycin and were incubated at 220 rpm, at 37° C. for overnight. Plasmid DNA was isolated from overnight grown culture using QIAGEN kit. Isolated clones were screened through restriction enzyme analysis performed using SpeI and XhoI enzymes and confirmed through sequencing and found to be error free. Sequence confirmed plasmid DNA from confirmed clones were purified at large scale using QIAprep Spin Midiprep kit (Qiagen) and in order to be used for subsequent transfection experimentation.

Example 5: Preparation of Anti-CLEC2D Antibody and Selection of CHO Expressed Novel Monoclonal Antibodies

Strategy to Select Novel Monoclonal Antibody Clones

Owing to riveting design and properties of therapeutic antibody, it is required to be rational towards selecting a specific monoclonal antibody for further development. Moreover, generation, manufacturing and storage of antibodies are continuing to pose challenges as molecule properties such as pharmacokinetics, solubility, expression, viscosity and long-term stability are difficult to predict and understanding inter-parameter relationship is rather limited. Moreover considering the selected/identified diverse antibody genes which funnelled through antibody display platforms needed to be arranged through the ranking protocol. A comprehensive scoring function/methods was employed/developed based on existing sequencing data, exemplified by uniqueness, presence of certain motifs which could be not beneficial for further selection/development of clones; affinity towards CLEC2D antigen either in soluble form or as membrane bound format, and functionality; titre, yield, recovery, analytical profile, amongst others, either as independent or in combination, thereof.

The clones would go through multiple rounds of checks on salient parameters in due course of development having a dynamic selection system which will effectively be employed towards selection of final clones.

CHO Cell Transfection with Full Length CLEC2D Gene for Cell Surface Expression.

In order to estimate the binding propensity of novel antibody genes identified against CLEC2D protein expressed on cell surface, a full length CLEC2D construct was synthesized. Native signal sequence was used for efficient surface expression on CHO cells. The full length CLEC2D gene sequence was cloned into the pCDNA3.1 mammalian expression vector (FIG. 8A). Subsequently the construct was transformed into neb-alpha and isolated in large quantity using Qiagen midi prep kit. CHO suspension cells with >90% viability were transfected with a full-length CLEC2D gene expression plasmid. As exemplified, for 10 ml volume of transfection 1.25×10⁶cells/ml were taken, wherein CHO cells were centrifuged at 1000-1400 rpm for 4-5 minutes. The spent media was decanted, and the cells were re-suspended in 2.5 ml of OptiMEM I media. DNA constructs were transfected using Lipofectamine LTX with Plus' reagent. 5-10 of DNA was used with 1:3 to 1:6 DNA to transfection reagent ratio and 5-10 μl Plus™ reagent was used. DNA and Lipofectamine LTX complex was prepared in 2.5 ml OptiMEM I and incubated at 20-25° C. for 5 minutes for complex formation. The transfection mix was added slowly to the cell suspension. The cells were incubated for 4-6 hours at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. 5 ml of Power CHO2 CD growth media was added to the cells. The cells were incubated at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. 2-4 days post transfection 2 ml Power CHO2 CD growth media was added and Glutamax was added from 200 mM stock to achieve a final concentration of 2 mM. The cells were incubated at 37° C. in a 5% CO2 shaker incubator at 100-120 RPM. Cells were analyzed for surface antigen binding by flow-cytometry on day 3, day 4 and day 5 after transfection. Transfected CHO cells with full length constructs will be known here onwards as C4548, unless mentioned otherwise elsewhere.

C4548 cells, transiently expressing full-length membrane anchored CLEC2D antigen were validated through both flow cytometry and confocal microscopy by using commercial anti-CLEC2D antibody. Approximately, 50,000-100,000 cells were taken in a 96-well U bottom plate. 1-5 μg of commercial anti-CLEC2D Antibody (4C7) (Cat #H00029121-M01; Novus Biologicals) in 100 μl assay buffer was added to the both untransfected CHO and C4548 transfected with full length CLEC2D surface antigen construct and incubated for 1 hr at room temperature in DPBS with 1-2% BSA. After 1 hr incubation, the plate was centrifuged at 1000-1400 rpm for 3-5 minutes. The cells were further washed twice with 200 μl of 0.1% BSA solution. 1 in 100 dilution of secondary antibody i.e., anti-mouse Alexa 488 (Thermo Fisher Scientific) was added. Subsequently, the plates were incubated at room temperature for 30 minutes in dark. The wells were washed twice with 0.1% BSA solution and analyzed by flow cytometry. Cell surface binding of the monoclonal antibody was estimated by comparing increase in fluorescence signal between CLEC2D expressing CHO cells and un-transfected CHO cells. Surface expression of CLEC2D antigen was optimum on day 4 to day 5 on C4548 transfected CHO cells (FIG. 8B).

For confocal microscopy experimentation, 250 μl of 12 μg/ml Poly D Lysine was added per well and incubated overnight at 37° C. Chambers were washed twice with 500 μl of DPBS and stored in 2° C. to 8° C. Un-transfected and CLEC2D antigen expressing CHO cells, C4548, were used, wherein cell count and viability data was collected using vi-cell Beckman coulter. 50,000 cells were seeded in 500 μl growth media (Power CHO2 with 4 mM Glutamine+1% Penstrep) with 10% FBS per well. All the cells were incubated in humidified 5% CO2 incubator at 37° C. for 2 days prior to the experiment. Further, cells were washed with 1×PBS then fixed in 2% formaldehyde in PBS for 5 minutes at room temperature (RT). Cells were then rinsed twice with 1×PBS followed by blocking with 5% BSA for 1 hr at RT. After 1 hour incubated with diluted primary antibody i.e., anti-CLEC2D Antibody (4C7) (2 μg) for 1 hour at RT followed by washing for at least three times in PBS and then incubated with the anti-mouse Alexa 488 (Thermo Fisher Scientific), secondary antibody, (2 μg) for 1 hour at RT. Cell nuclei were stained using DAPI (1:1000 for 5 min at RT). Cells were then rinsed thrice in 1×PBS and remained submerged in PBS until imaging. Immunofluorescence microscopy was performed on Olympus FV3000-4 laser scanning confocal microscope with a 60× magnification with 1.35-NA objective. Cells were imaged at 16 hrs after treatment by using appropriate wavelengths (For DAPI, λex 405 nm and λem 430-470 nm; for Alexa 488, λex 488 nm and λem 510-530 nm. Images were analyzed with Fiji ImageJ software.

As confirmed by microscopy images, the surface expression of CLEC2D on C4548 cells, were observed as distributed on cell surface while untransfected CHO cells fails to provide any anti-CLEC2D antibody dependent signal under microscopy (FIG. 8C).

CHO Cell Transfection to Express Novel Anti-CLEC2D Monoclonal Antibody Clones

Antibody heavy chain and light chain genes were expressed using mammalian gene expression vectors with appropriate signal sequences for secretion of correctly folded monoclonal antibodies into culture media. CHO suspension cells at more than 90% viability were transfected for antibody gene expression. CHO cells, at 1.25×10⁶cells/ml, were centrifuged at 1000-1400 rpm for 4-5 minutes. The spent media was decanted. The cells were re-suspended in 25 ml of OptiMEM I media. Antibody heavy chain and light chain gene expressing plasmids were co-transfected at various stoichiometry (such as, 1:2, 1:3, 1:4, 2:3, 3:1, 4:1 etc.) using Lipofectamine LTX with Plus™ reagent. 50-100 pg of DNA was used with 1:3 to 1:6 DNA to transfection reagent ratio and 50-100 μl Plus™ reagent. DNA and Lipofectamine LTX complex was prepared in 25 ml OptiMEM I and incubated at 20-25° C. for 5 minutes for complex formation. The transfection mix was added slowly to the cell suspension. The cells were incubated for 4-6 hours at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. 50 ml of Power CHO2 CD growth media was added to the cells. The cells were incubated at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. 2-4 days post transfection 20 ml Power CHO2 CD growth media was added, and Glutamax was added from 200 mM stock to achieve final concentration of 2 mM. The cells were incubated at 37° C. in a 5% CO₂shaker incubator at 100-120 RPM. Day 6 post transfection, cell culture supernatant (50 mL) was harvested by centrifugation at 1400-2000 rpm for 10-15 minutes.

Screening of CHO expressed monoclonal antibodies using cell surface binding: transient

Subsequently, harvested culture supernatant of 50 mL containing secreted novel anti-CLEC2D antibody clones were subjected to purification by Protein A affinity chromatography using cellgravity columns containing Mabselect SuRe resin (GE Healthcare). The method starts with Protein A column sanitization step wherein 3 Column Volume (CV) of 0.5M Sodium Hydroxide (NaOH) solution was passed at RT for 5 minutes followed by 8 Column Volume of Purified water. Subsequently, Protein A column was equilibrated with 3 CV of Protein A equilibration buffer comprises of 30 mM Sodium phosphate, 120 mM NaCl pH 7.0±0.2. 50 mL culture supernatant was loaded on equilibrated Protein A column while flow through was reloaded. This procedure was repeated twice. 3 CV of Protein A equilibration buffer washing was carried out followed by 3 CV of Protein A high salt buffer (30 mM Sodium phosphate, 1M NaCl pH 7.0±0.2) wash.

Further 3 CV of Protein A equilibration buffer was passed through the column followed by 4 CV of Protein A low pH buffer (30 mM Sodium phosphate, 50 mM NaCl pH 6.0±0.2) wash. Next, 5 CV of Protein A elution buffer (30 mM Sodium phosphate, 50 mM NaCl pH 3.0±0.1) was employed in order to elute the bound monoclonal anti-CLEC2D antibody. Further, Protein-A elute, containing antibody, was neutralized to pH ˜7.0 by adding appropriate amount of 1M Tris solution.

Following neutralization, Protein-A elute was concentrated and buffer exchanged into 1×PBS using Amicon 30 kDa cut-off concentrator. Protein sample was recovered from concentrator and concentration was measured by A280 using Nanodrop Biophotometer. Proteins were analysed by SDS-PAGE as shown in FIG. 9A, under reducing and non-reducing condition. Subsequently, these protein samples were used for further experimentation.

As judged by quantitation, clones with product yield higher than 100 μg were shortlisted for the SDS-PAGE analysis to check the product quality under reducing and non-reducing conditions. Successively, clones with prominent bands in SDS-PAGE gels, as explained by, appearance of ˜150 kDa under non-reducing condition and ˜50 kDa (representing heavy chain) and ˜25 kDa (representing Light chain) under reducing condition were shortlisted for further analysis (FIG. 9A). In addition, purity was also judged through number of bands appeared along with the target protein and were also considered as criteria for selecting/shortlisting the clones. Proteins with more than 3 bands under non-reducing conditions similarly proteins with more than 1 band for heavy chain or light chain under reducing conditions were not taken into consideration.

Cell Surface Binding Assay: Through Flow Cytometry and Confocal Microscopy

CHO suspension cells transiently expressing full-length membrane anchored CLEC2D antigen were used to screen antibody samples (cell culture supernatant and/or purified protein). 50,000-100,000 cells were taken in a 96-well U bottom plate. 100 μl of cell culture supernatant or 0.03-3 μg of purified antibody in 100 μl assay buffer was added to the CLEC2D expressing cells and incubated for 1 hr at room temperature in DPBS with 1-2% BSA. After 1 hr incubation, the plate was centrifuged at 1000-1400 rpm for 3-5 minutes. The cells were further washed twice with 200 μl of 0.1% BSA solution. 1 in 100 dilution of secondary antibody—goat anti human IgG FITC was added. Subsequently, the plates were incubated at room temperature for 30 minutes in dark. The wells were washed twice with 0.1% BSA solution and analyzed by flow cytometry. Commercially available anti-CLEC2D monoclonal Ab (Novus Biologicals) was used as a positive control and anti-mouse Alexa 488 (Thermo Fisher Scientific) was used as the secondary antibody. Cell surface binding of the monoclonal antibody was estimated by comparing increase in fluorescence signal between CLEC2D expressing CHO cells and un-transfected CHO cells.

In order to screen identified novel anti-CLEC2D monoclonal antibody, validated C4548 cells and PC3 cells were subjected for monitoring CLEC2D antigen binding through both flow cytometry and confocal microscopy. Prior to experimentation, cell count was taken by Vi-cell XR automated cell counter. Method of sample preparation for flow cytometry was as described above while ˜1-5 μg of purified Anti-CLEC2D antibody clones and reference positive control, respectively, to estimate the membrane bound CLEC2D binding on Untransfected CHO cells and C4548 cells. Cells were centrifuged at 1400-1500 rpm for 4-5 minutes. The pellet was re-suspended in 1 ml DPBS. 50,000 cells were aliquoted in each well of a 96 well plate. Both test samples and reference control was added to each well and incubated for 30-60 minutes at room temperature (25° C.). The plate was centrifuged at 1400-1500 rpm for 4-5 minutes, the supernatant was aspirated and cells were washed with 0.1% BSA in DPBS. 2.5 ml of 2% BSA was diluted to 50 ml with DPBS. Goat anti human IgG FITC conjugate was used as secondary antibody. 1:100 dilution of secondary antibody was prepared in DPBS and 100 μl was added to each well. The plate was incubated for 30 minutes at room temperature (25° C.) in dark. The cells were washed with 0.1% BSA and re-suspended in 100 μl of 1% BSA. Samples were analyzed by flow-cytometry (FIG. 9B).

Binding of test sample supernatant on un-transfected CHO cells was estimated and used for calculation of specific binding on C4548 cell surface using following formula:

$Fold change in M F I = \frac{\begin{matrix} Median FITC - A of test sample on CHO cells \end{matrix}}{\begin{matrix} Median FITC - A of test sample on C 4548 cells \end{matrix}}$

For microscopy experimentation, PC3 cells were seeded, wherein, 250 μl of 12 μg/ml Poly D Lysine was added per well and incubated overnight at 37° C. Chambers were washed twice with 500 μl of DPBS and stored in 2° C. to 8° C. Adherent cell lines such as PC3, were trypsinized using 0.05% trypsin. Cell count and viability data was collected with hemocytometer using trypan blue staining. Cells were seeded at a density of 20000 cells/well with 500 μl growth media per well and incubated in humidified 5% CO2 incubator at 37° C. for 2 days prior to the experiment. Further, PC3 cells were washed with 1×PBS then fixed in 2% formaldehyde in PBS for 5 minutes at RT. Cells were then rinsed twice with 1×PBS followed by blocking with 5% BSA for 1 hour at RT.

After 1 hour incubated with diluted test antibody samples i.e., novel and unique anti-CLEC2D Antibody (at 2 μg) and commercial antibody as reference control, for 1 hr at RT followed by washing for at least three times in PBS and then incubated with the Alexa Fluor 488 goat anti-human IgG and anti-mouse Alexa 488 (Thermo Fisher Scientific), respectively as applicable, secondary antibody, (at 2 μg) for 1 hour at RT. Cell nuclei were stained using DAPI (1:1000 for 5 min at RT). Cells were then rinsed thrice in 1×PBS and remained submerged in PBS until imaging. Immunofluorescence microscopy was performed on Olympus FV3000-4 laser scanning confocal microscope with a 60× magnification with 1.35-NA objective. Cells were imaged at 16 hrs after treatment by using appropriate wavelengths (For DAPI, λex 405 nm and λem 430-470 nm; for Alexa 488, λex 488 nm and λem 510-530 nm. Images were analyzed with Fiji ImageJ software. Variation on CLEC2D antigen binding of mAbs tested and binding data is given as a rating of + (low binding) to +++ (high binding) (Table 19, and FIG. 9C). A variation on surface binding was observed and binding data is given as a rating of +(low binding) to +++ (high binding) on Table 22 As exemplified, surface binding was not detected with mAbC4252, whereas with antibodyC0610, low binding was observed thereby rated as (+) while other clones have showed differential yet significant surface binding.

TABLE 22

Cell surface

binding

(Flow

SI. No.
Codes
Titer data
cytometry)
Imaging

1
CO294
More than 100 μg
5.23
+++

2
C5397
More than 100 μg
4.88
+++

3
C5852
More than 100 μg
5.79
+++

4
C3566
More than 100 μg
10.21
+++

5
C7229
More than 100 μg
4.84
+

6
C2901
More than 100 μg
5.1
+++

7
C4252
More than 100 μg
5.91
Not detected

8
C4577
More than 100 μg
6.73
+++

9
C2685
More than 100 μg
9.78
+++

10
C5355
More than 100 μg
9.9
++

11
C0610
More than 100 μg
8.62
+

12
C8372
More than 100 μg
6.53
+

13
C0694
More than 100 μg
8.43
+++

14
C6525
More than 100 μg
3.27
+

15
C2771
More than 100 μg
7.94
++

16
C0672
More than 100 μg
6.74
+

17
C1063
More than 100 μg
1.96
Not done

18
C4899
More than 100 μg
1.46
Not done

19
C2302
More than 100 μg
7.72
+

20
C3651
10 μg-100 μg
4.73
Not done

21
C6803
More than 100 μg
6.17
Not done

22
C7997
More than 100 μg
4.62
+

23
C2060
More than 100 μg
3.91
+++

24
C0997
More than 100 μg
6.45
+++

25
C2119
More than 100 μg
2.64
++

26
C3482
More than 100 μg
4.17
Not done

27
C9652
More than 100 μg
2.17
Not done

28
C4148
More than 100 μg
6.34
+++

29
C0800
More than 100 μg
7.28
+++

30
CO225
More than 100 μg
5.14
+++

31
C9767
More than 100 μg
4.24
+

32
C9795
More than 100 μg
4.69
+++

33
C5870
More than 100 μg
2.6
+++

34
C7009
More than 100 μg
2.18
+++

35
C8637
10 μg-100 μg
Not done
Not done

36
C5749
10 μg-100 μg
Not done
Not done

37
C3558
10 μg-100 μg
Not done
Not done

38
C5327
10 μg-100 μg
Not done
Not done

39
C4137
10 μg-100 μg
Not done
++

40
C6616
10 μg-100 μg
Not done
+++

Based on all of above mentioned criteria and respective observed results covering biophysical and functional properties of isolated anti-CLEC2D antibodies, 9 unique anti-CLEC2D antibody sequences, C5397, C5852, C3566, C2901, C4577, C2685, C0694, C0997, C0800, not limited to, and were selected for stable cell line development.

Generation of Stable Cell Lines

Clinical effectiveness has driven the commercial success of monoclonal antibody (mAb) products. As known to others, mammalian cells are currently the preferred system for large-scale production as the mAbs produced are biochemically similar to human forms. The stable cell line generation process is tedious and time-consuming as clones with high productivity, stable long-term expression and good product quality are rare occurrences. mAb production in mammalian cells can be performed either in transient or stable transfections. As seen in previous section, transient transfections allow relatively fast generation of small amounts of product for use during early stages of drug discovery. However, stably transfected cell lines are more widely used in large scale industrial production. More importantly, stable cell lines used for manufacturing are from a single cell clone in order to obtain high amounts of consistent product.

Antibiotic Selection:

Antibiotic selection was initiated after transfection at 90% cell viability. Cell suspension was centrifuged at 1400 RPM for 4 mins. Pellet was re-suspended in complete Power CHO2 growth media and concentration of Puromycin Dihydrochloride was adjusted to 2 μg/1×10{circumflex over ( )}6 cells. Antibiotic selection was carried out on every 2nd or 3rd day. Refer table 5 for cell count and viability data.

TABLE 23

Total
Viable

Viability
cells/ml
cells/ml
Passage

Experiment
(%)
(×10⁶)
(×10⁶)
No

Transfection R1
95.8
5.42
5.19
35

Antibiotic selection 1 (AB 1)
90.4
3.73
3.37
36

Antibiotic selection 2 (AB 2)
78.7
4.3
3.4
37

Antibiotic selection 3 (AB 3)
82.3
4.4
3.6
38

Antibiotic selection 4 (AB 4)
80.9
4.8
3.9
39

Antibiotic selection 5 (AB 5)
81.8
4.0
3.2
40

Antibiotic selection 6 (AB 6)
77.5
3.9
3.1
41

Antibiotic selection 7 (AB 7)
76.9
4.2
3.2
42

Antibiotic selection 8 (AB 8)
84.5
2.0
1.7
43

Repeat Transfection of Stable Pool

Cell count was taken using Vi-cell XR (Refer Table 10). Cells were subcultured before the transfection. Two more sequential transfections were performed as mentioned previously. On completion of three rounds of transfection the pool was designated as R3 stable pool. See Table 24.

TABLE 24

Parameters
Transfection 1
Transfection 2
Transfection 3

Total volume of transfection
50
ml
21
ml
21
ml

Cell density
1.25 × 10{circumflex over ( )}6
cells/ml
1 × 10{circumflex over ( )}6
cells/ml
1 × 10{circumflex over ( )}6
cells/ml

OPTIMEM I
12.5
ml
1
ml
1
ml

Total DNA
25
μg
5
μg
5
μg

HC:LC
1:3
1:3
1:3

Amount of DNA:Lipofectamine
1:3
1:3
1:3

Amount of DNA:Plus reagent
1:1
1:1
1:1

Minipool Plating

TABLE 25

Viability
Total cells/ml
Viable cells/ml
Passage

Experiment
(%)
(×10⁶)
(×10⁶)
No

Minipool plating
97.1
2.5
2.4
50

Serial dilution of the cell suspension was carried out in complete Power CHO2 growth media at 1:10 ratio (refer Table 26). 0.52 ml cell suspension was taken from dilution D and added to 25 ml of cloning media. Cells were seeded at a density of 10 cells/well in a 96 well plate in 200 μl volume per well. These mini-pools were maintained at 37° C. temperature in a humidified 5% CO2 incubator.

TABLE 26

Cell count
Cell count

Dilution series
(cells/ml)
(cells/ml)

Culture flask
2400000
1370000

Dilution A
240000
137000

Dilution B
24000
13700

Dilution C
2400
1370

Dilution D
240
137

Screening of Mini-Pools and Amplification:

Total 117 mini-pools were screened by flow cytometry and binding to CHO cell surface expressed antigen was estimated. Minipools were ranked based on cell surface binding wherein the method of sample preparation for flow cytometry was as described above while ˜200 μl of cell culture supernatant expressing anti-CLEC2D antibody proteins and reference positive control, respectively, was used to estimate the membrane bound CLEC2D binding on untransfected CHO cells and C4548 cells (FIG. 10A). Minipools identified from flow cytometry screening, as selected through extend of binding as derived from observed fold change in median fluorescence intensity, were amplified from 96 well plate to 24 well plate and maintained at 37° C., humidified condition in a 5% CO₂incubator. These were further amplified from 24 well plate to one well of 6 well plate. After cell were confluent mini-pools were amplified from one well of 6 well plate to a bioreactor tube with 25 ml growth media and maintained at 37° C., humidified condition in a 5% CO₂incubator, 200 rpm.

Single Cell Cloning

Single cells were generated by serial dilution method. Continuously growing culture of mini-pool was subcultured at 1 million cells/ml in 30 ml complete Power CHO 2 growth media with 2 mM glutamax, 1 day before cloning. Cell count and viability data was collected using Vi-cell XR. Serial dilution of the cell suspension was carried out in complete power CHO2 growth media at 1:10 ratio (refer Table 26). Cells were seeded at a density of 0.5 cells/well in a 96 well plate and maintained at 37° C. temperature in a humidified 5% CO2 static incubator. Cells were aspirated from dilution D and seeded at density of 0.5 cells/200 μl cloning media per well in 96 well plates. The plates were incubated at 37° C., in a 5% CO2 incubator with 75% relative humidity. Plates were scanned by using CloneSelect Imager (Molecular Devices) for monoclonality report generation from day zero to day ten. The individual well images were collected on day 0, day 1, day 2, day 3, day 6, day 8 and day 10. The clonal population was confirmed from the day zero image of entire well and the monoclonality report generated by CloneSelect Imager. Passage number was P(x+0).The Single cell clones were amplified to 24 well plates after cells were confluent. Passage number was P(x+1).

Screening of Single Cell Clones and Clone Amplification:

Cell surface binding assay was performed to estimate antibody in cell culture supernatant and to rank the clones. Single cell clones showing higher binding on CHO cell surface expressed antigen were amplified from 24 to 6 well after 2 days. Passage number was (x+2). This was followed by amplification in 3 wells of 6 well plate. Passage number was (x+3). The clones were further amplified to tube bioreactors in 20 ml volume, passage number was (x+4). Following amplification RCB vials were prepared for the clones at passage number (x+5).

Stable cell culture supernatant was estimated for binding with CLEC2D surface protein on C4548 cells through flow cytometry, wherein the method of sample preparation and experimentation for flow cytometry was as described above while ˜200 μL of cell culture supernatant expressing anti-CLEC2D antibody proteins and reference positive control, respectively, was used to estimate the membrane bound CLEC2D binding on untransfected CHO cells and C4548 cells (FIG. 10B).

TABLE 27

Total
Viable

Viability
cells/ml
cells/ml
Passage

Experiment
(%)
(×10{circumflex over ( )}6)
(×10{circumflex over ( )}6)
No

Transfection R1
95.8
5.42
5.19
35

Antibiotic selection 1 (AB 1)
90.4
3.73
3.37
36

Antibiotic selection 2 (AB 2)
78.7
4.3
3.4
37

Antibiotic selection 3 (AB 3)
82.3
4.4
3.6
38

Antibiotic selection 4 (AB 4)
80.9
4.8
3.9
39

Antibiotic selection 5 (AB 5)
81.8
4.0
3.2
40

Antibiotic selection 6 (AB 6)
77.5
3.9
3.1
41

Antibiotic selection 7 (AB 7)
76.9
4.2
3.2
42

Antibiotic selection 8 (AB 8)
84.5
2.0
1.7
43

R1 Stable pool Subculture
96.7
2.6
2.5
44

R1 Stable pool Subculture
98.3
3.5
3.4
45

R1 Stable pool Subculture
98.3
3.5
3.4
46

Transfection R2
98.2
0.79
0.78
47

Transfection R3
93.0
1.3
1.2
48

Subculture
93.8
2.3
2.1
49

Minipool plating
97.1
2.5
2.4
50

Minipool screening and
NA
NA
NA
51-53

amplification

Mini-pool subculture and RCB
NA
NA
NA
54 to 59

Single cell cloning of Mini-pool
97.50%
1.41
1.37
60

Selection of Monoclonal Antibody Clones Expressed and Purified from Stable Cell Lines

Culture Harvest for Protein Purification:

Cells were seeded at a density of approximately 0.3×10⁶cells/ml in 30 ml Complete power CHO2 growth media and cultured for 6 days in 37° C., humidified condition in a 5% CO2 incubator with 120 RPM rotation. 20 ml media top-up was given with complete power CHO2 growth media on 4th day. Cells were harvested by centrifuging the entire cell suspension at 2000 RPM for 10 mins. The supernatant was collected and stored in −20° C. for further purification. Here onwards, all respective stable cell clones containing novel, unique anti-CLEC2D antibody genes will be referred as Cxxxx, wherein xxxx represents four digit numbers (Table 19). Each code represents a specific stable cell line containing specific antibody gene, otherwise mentioned elsewhere.

Subsequently, culture supernatants of ˜221 unique and confirmed stable cell clones were subjected to purification through Protein A followed through rational judgement on parameters as exemplified by yet not limited to, purity, titre. In addition, thermal stability estimation via thermal shift assay (TSA) was incorporated as an additional parameter towards selection/screening.

Higher melting temperature was considered as a characteristic of more stable protein while proteins with melting temperature less than 65° C. were decided to be not included for further development. TSA experimentation starts with appropriate dilution of protein sample to 0.5 mg/ml concentration in 1×PBS wherein SYPRO-ORANGE fluorescent dye (5000×) was added to the target protein to a final concentration of 5×. Further mixture was centrifuged at 500 RPM for 2 minutes and analyzed by CFX96 Real Time System. Thermal denaturation was carried out by increasing the temperature from 25° C. to 95° C. at a rate of 0.5° C. per minute. Fluorescence intensity was collected at 0.5° C. intervals and analyzed with CFX Maestro software and Tm value was calculated from melt curve.

Flow and/Imaging:

In addition, respective purified anti-CLEC2D proteins were also evaluated for Cell surface binding assay by flow-cytometry and confocal microscopy. The rationale behind inclusion of flow cytometry and confocal microscopy studies was to obtain comprehensive list of anti-CLEC2D clones through a combination ranking matrix.

The experimentation including the method of sample preparation for flow cytometry was as described above while ˜1-5 μg of purified anti-CLEC2D antibody proteins and reference positive control, respectively, was used to estimate binding of membrane expressed CLEC2D on untransfected CHO cells and C4548 cells (FIG. 10C).

The experimentation including the method of sample preparation for imaging acquisition through confocal microscopy was as described above while ˜2 μg of purified anti-CLEC2D antibody proteins, such as, C5848, C8408, C7832, C8800, C5595, C0694, not limited to, and reference positive control, respectively, was used to monitor the membrane bound CLEC2D antigen binding on PC3 cells. As observed through imaging studies for Anti-CLEC2D purified from stable cell clones, not limited to, C5848, C8408, C8800, C5595, C7832, exhibits uniform yet differential CLEC2D antigen binding on the surface of PC3 cells (FIG. 10D).

In order to assess/understand the stability of anti-CLEC2D antibody genes in stable cell clones, quantitative measurements through RT PCR was adopted wherein amplification of stably integrated anti-CLEC2D antibody genes into CHO cell genome would be monitored and estimated. CHO cell pellets were obtained from every passage as part of a continuous subculture of respective clones for 60 generations corresponding to P01 as first passage while P18 represents final 60^thgeneration. Herein, genomic DNA (gDNA) were isolated from cell pellets using the DNeasy® Blood & Tissue kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's protocol (protocol for cultured cells with proteinase K treatment). Concentration and purity of gDNA preparations were analyzed spectrophotometrically using Eppendorf BioPhotometer® D30 (Eppendorf AG, Germany). The isolated gDNA were diluted to a concentration of 100 ng/μL and passed through BD Ultra-Fine™ Needle Insulin Syringes (Becton, Dickinson and Company, NJ, USA) for qPCR. To quantify the Ct values qPCR was performed on a CFX96TMReal-Time system with 96-well, thin wall Hard-Shell PCR plates and Microseal® ‘B’ seal film sealer (all from Bio-Rad, Hercules, CA, USA) using the designed primers. Each qPCR run was performed with each sample in triplicates. GAPDH used as relative control and no template controls (NTC) were included in each qPCR run. Each reaction mix contained 12.5 μL of SYBR™ Green PCR Master Mix (appliedbiosystems by Thermo Fisher Scientific, Life technologies, Woolston Warrington, UK), 10 pmol of each primer (synthesised at Eurofins, Bangalore, India) and 100 ng lysed gDNA adjusted with Water, HPLC (HiMedia Laboratories, Mumbai, India) to a final volume of 25 μL. The qPCR run was performed as a 2-step protocol with an initial denaturation step at 95° C. for 10 min followed by 40 cycles of denaturation at 95° C. for 15 sec and annealing at 60° C. for 60 sec. Raw data were processed by the Bio-Rad CFX Manager™ software application version 3.1.1517.0823 (BioRad) using the settings baseline subtraction, to obtain the Cq (Cycle Quantification) values.

The described quantitative approach was employed for all clones, as exemplified by, for C5511, C4608. The data obtained from the study has been depicted in FIG. 10E. indicating non significant variation of <5% in Ct values for respective antibody chains across all passage numbers confirming the stable integration of anti-CLEC2D antibody genes into CHO cell genome and sustained for at least 60 generations.

Considering the combinatorial matrix, the number of stable cell line was selected to 11 clones, as exemplified by, C4608, C7720, C5093, C3452, C9136, C3641, C5372, C6481, C5511, C6726, C5392. Here onwards, understanding towards large scale production aspect and functionality feature, such as, anti-CLEC2D antibody driven cytotoxicity, was incorporated towards selection of final clones for further development.

For the process of clone selection, it was essential to have a method which is robust, repeatable and produces protein of consistent quality. Therefore, before clone screening was initiated, a platform process was developed to ensure efficient clone screening. A fed batch process was developed using ActiPro as basal media and cell boost 7a and cell boost 7b as the feeding. The interval and quantity of feeding was experimentally optimized and the optimized process was repeated to establish robustness. The fed process was further extended to clone screening to isolate the top performing clones. After the top performing clones were isolated, the clones were verified by culturing cells in a 10 L bioreactor using the optimized fed batch process. This step was carried out to ensure manufacturability of clones selected when transferred to a larger scale.

ActiPro media was chosen as the basal media for development of platform process, on the basis of historical data of comparison with different basal media. ActiPro was supplemented with 4 mM glutamine to ensure metabolic requirements of cell are met.

Multiple monoclonal cell lines were evaluated in order to understand, rank and select the better performers. Based on the results obtained on Viable Cell Density, Viability, Titer, C5511, C4608, C3452, C5392, C6481 were assessed to be best performers in terms of all the performance parameters.

Surface Antigen Expression on Various Prostate Cancer Cell Lines: PC3

Tumor cells expressing CLEC2D antigen were harvested by trypsinization. Cell count was taken by Vi-cell XR automated cell counter. Cells were centrifuged at 1400-1500 rpm for 4-5 minutes. The pellet was re-suspended in 1 ml DPBS. 50,000 cells were aliquoted in each well of a 96 well plate. 1 μg of test samples, as exemplified by C5511, control were added to each well and incubated for 30-60 minutes at room temperature (25° C.). The plate was centrifuged at 1400-1500 rpm for 4-5 minutes, the supernatant was aspirated and cells were washed with 0.1% BSA in DPBS. 2.5 ml of 2% BSA was diluted to 50 ml with DPBS. Goat anti human IgG FITC conjugate was used as secondary antibody. 1:100 dilution of secondary antibody was prepared in DPBS and 100 μl was added to each well. Goat anti human IgG FITC conjugate was used as control at dilution of 1:100. The plate was incubated for 30 minutes at room temperature (25° C.) in dark. The cells were washed with 0.1% BSA and re-suspended in 100 μl of 1% BSA. Samples were analyzed by flow-cytometry.

Binding of test samples were estimated and used for calculation of specific binding on tumor cell surface using following formula:

$Fold change in M F I = \frac{\begin{matrix} Median FITC - A of test sample \end{matrix}}{\begin{matrix} Median FITC - A of control \end{matrix}}$

Fold change in MFI of PC3 surface binding, as observed from flow cytometry experiments, as exemplified while not limited to, C5511, C4608, C6481, C2438, C3452, C0949antibody, was found to be increased by more than 2 folds when compared against control (FIG. 11A).

Further, surface binding was with various unique anti-CLEC2D antibody stable clones on the surface of PC3 through binding of antibody on the surface of PC3 cells through confocal microscopy, as described in Example 5, Section: Cell surface binding assay: through Flow Cytometry and Confocal Microscopy. As depicted in FIG. 11A, the binding of purified novel anti-CLEC2D on the surface of PC3 was observed with uniform distribution of CLEC2D antigen through novel antibody on PC3 cells.

Cytotoxicity Assay: Through Flow Cytometry and Imaging Methods

To assess the functional activity of anti-CLEC2D, cytotoxicity assay was performed employing both flow cytometry and confocal microscopy methods, with isolated PBMCs and incubated with target cell and anti-CLEC2D. Prior to this, optimization on mAb concentration and ideal T:E ratio was carried out.

Effector cells, PBMCs from healthy donors were isolated as per previous protocol (Jewett A, J Immunol 1996). Briefly, peripheral blood lymphocytes were obtained after Histopaque-1077 (Sigma) centrifugation. 1:2 diluted blood was layered on 15 mL Histopaque. All the reagents were maintained in room temperature. Tube containing histopaque and blood was centrifuged at 400 g for 30 minutes at room temperature with zero acceleration and brake. After centrifugation, upper layer was carefully aspirated to within 0.5 cm of the opaque interface containing mononuclear cells and the upper layer was discarded. Opaque interface was carefully transferred into a centrifuge tube. Cells were washed twice by adding 10-15 mL of 1×PBS at 250 g for 10 minutes. Pellet was resuspended in 2 mL of PBS and PBMCs count was done. Total 10 million PBMC was obtained from 10 mL of blood. Quality check of PBMC was done based on flow cytometry with CD45+ population 99%. NK cells were isolated via negative selection using NK isolation kit (Stem cells technologies, Vancouver, BC, Canada). The purity of NK cells was found to be >90% based on flow cytometry CD56+ population.

Target prostate cancer cell line, PC3 cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. After 24 hours, freshly isolated PBMCs were added in T:E of 1:5. Novel monoclonal anti-CLEC2D antibodies C5511, C6481, C5392, C3452 and C4608, not limited to, were added at ˜200 μg/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was collected from 24 well plate and adherent cells were trypsinized and collected in 1.5 ml tubes. Reaction mixture was incubated with sytox green (15 nM) for 20 min and fluorescence was detected in flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples.

Cytotoxicity was analysed by dual target cell staining by flow cytometry. FIG. 11B shows cytotoxicity of the 3 novel anti-CLEC2D monoclonal antibodies, C5511 (˜41%), C4608 (˜32%) and C6481 (˜37%) was observed compared with the control wherein percent cell death was measured from PBMC, isolated from donor 1, and target cell, incubated together at 1:5 ration without treatment. Following similar conditions, C5392 and C3452 clones were tested on donor 2 wherein cytotoxicity was found to be be ˜14% and ˜28%, respectively (FIG. 11B). More than 80% cytotoxicity of target cells was observed when anti-CLEC2D concentration was increased from 50 μg/ml to 200 μg/ml (FIG. 11C) and significant increase in tumour cell killing was also monitored when T:E ratio was increased from 1:5 to 1:10 (FIG. 11D).

For confocal microscopy experiments, PC3 cells were grown on 8-well slides (eppendorf) in complete media (20% FBS+DMEM-F12+1× Pen/Strep+1 mM sodium Pyruvate) to 70-80% of confluence. Freshly isolated PBMC cells were left overnight in culture media (RPMI1640 with 10% FBS) prior to be used in cytotoxicity as resting PBMC cells. PC3 cells were stained with cell tracker dye (100 nM) and PBMC cells were stained with cell proliferation dye EF670 (10 μM) separately. Different concentrations of novel antibodies along with stained PC3 and PBMC cells incubated for 6-7 hrs then images were acquired using Olympus FV3000-4 laser scanning confocal microscope with a 60× magnification, 1.35-NA objective. Laser light used for death dye sytox blue (at 5 μM), λex 405 nm and λem 450-500 nm; for cell tracker green, λex 488 nm and λem 510-530 nm; for cell proliferation dye EF670 λex 640 nm and λem 650-750 nm. Images were analyzed with Fiji ImageJ software.

In order to identify the optimal concentration of novel mAb for the cytotoxicity assay, target to effector cells ratio (1:5) and 3 different concentrations (i.e., 10 μg/ml, 20 μg/ml and 50 μg/ml) of novel anti-CLEC2D antibody (C6726) was used and incubated for 6-7 hrs in complete media. Cell death was monitored by disappearance of green fluorescence and appearance of violet fluorescence on PC3 cells. Maximum cytotoxicity observed at 50 μg/ml (FIG. 11E). Further end point cell death assay was continued using a concentration of 50 μg/ml for the same incubation timing for other antibody clones, not limited to, C6726, C4608, C5848, C5511, C6481, clones tested (FIG. 11F) indicating that the target cell death is observed in the presence of novel antibodies while no cell death was monitored when targets cells were not treated with novel antibodies.

Based on available data as described above, C4608, C5511, C6481, C5392 and C3452 clones were selected for final in vivo mouse efficacy experimentation.

During the development of therapeutic monoclonal antibodies (mAbs), a strategy for early identification of candidate antibodies with the greatest likelihood of success in the clinic is needed to avoid costly late-stage failures related to inadequate exposure, toxicity or lack of efficacy. Early screening and optimization of mAbs focus on characteristics such as affinity, potency and stability for selection of lead constructs, while confirmation on in vivo efficacy are typically required, although, characterized later in development and on a small number of lead mAb constructs. Herein, confirmed anti-CLEC2D clones, C4608, C5511, C6481, C5392 and C3452 were subjected to evaluate for in vivo efficacy against prostate cancer xenograft.

Example 6: Deciphering the Mechanism of Action of Novel Anti-CLEC2D Antibody Molecule

Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance and assist with immune response. In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body's immunological activity against tumors. Under normal circumstances, immune checkpoints allow the immune system to respond against infection and malignancy while protecting tissues from any harm that may derive from this action. However, the expression of some of these immune-checkpoint proteins by malignant cells dysregulates the antitumor immunity and favours the growth and expansion of cancer cells. Understanding the mechanism of action for immunotherapy, especially though monoclonal antibody based therapies, though multiple approaches would further reinvigorates on specific ways whether alone or in combination, that works in favour of tumour cell killing.

In present disclosure, mechanism of anti-CLEC2D antibody, as can be understood from in vitro experimentation, usually consists of events occurred at molecular interaction level, such as CLEC2D target dependence, interaction between CLEC2D/CD161, at cellular network level such as involvement of various effector cells, eg., natural killer (NK) cell, T cells on killing of tumour cells in presence or absence of anti-CLEC2D antibody, or specific mechanism that are driven by isotype of anti-CLEC2D antibody such as ADCC, CDC, ADCP and/or in combination, tumour cell death induced by elevation of cytokine/chemokine levels or various activating/inhibitory receptor's expression or in combination, and from in vivo experimentation, wherein, tumour regression occurred through lymphocyte infiltration.

Moreover, as the functions and target molecules of antibodies are more diverse, it becomes increasingly necessary to understand how the target molecule functions biologically and what will be the biological response to the modified functions induced by the antibody. Having mentioned this, understanding on mechanism of action will have immense emphasis on prostate cancer treatment, specifically on castration resistant prostate cancer, and will pave avenues for whole spectrum of multiple disease indications with novel immunotherapy strategies. Having mentioned this, a thorough employment of rational approach/stratification will ensure consistent incorporation of better-understood immunology in to cancer therapy and will dramatically impact on the development of overall therapeutic landscape.

The specific cell type involved in cytotoxicity was investigated through flow cytometry and confocal microscopy, wherein, in microscopy based approaches having both end point assay and live cell imaging methods.

NK Cell Mediated Cytotoxicity PC3 cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. After 24 hours, freshly isolated NK cell was added in T:E of 1:1. Novel monoclonal anti-CLEC2D antibody C5511 and C6481 were added at 100 μg/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was collected from 24 well plate and adherent cells were trypsinized and collected in 1.5 ml tubes. Reaction mixture was incubated with Sytox green (15 nM) for 20 min and fluorescence was detected in flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples. NK cell-mediated cytotoxicity (NKCC) was determined by using freshly isolated NK cells co-incubated with prelabelled target tumor cell line and anti-CLEC2D for 14 hours. Assay samples were incubated with dead cell dye sytox green and fluorescence was measured by flow cytometry. As estimated, Anti-CLEC2D antibody exhibited more than 80% cell death in the cytotoxicity assay (FIG. 12A).

Confocal microscopy based approach was employed further to understand the impact of NK cell mediated cytotoxicity through both fixed cell imaging and live cell imaging.

PC3 cells were grown on 8-well slides (eppendorf) in complete media (20% FBS+DMEM-F12+1× Pen/Strep+1 mM sodium Pyruvate) to 70-80% confluence. NK cells were isolated as described above. Freshly isolated NK cells were left overnight in in 10% RPMI media overnight prior to be used in cytotoxicity as resting NK cells. PC3 cells were stained with cell tracker dye and NK cells were stained with cell proliferation dye EF670 separately. Different ratio of NK:target cells (1:0.5, 1:5, 1:10) were used along with 50 μg/ml of novel antibodies, not limited to, C5511, C4608, C6481, and were incubated for 6-7 hrs before image acquisition using Olympus FV3000-4 laser scanning confocal microscope with a 60× magnification, 1.35-NA objective. Laser light used for death dye sytox blue, λex 405 nm and λem 450-500 nm; for cell tracker green, λex 488 nm and λem 510-530 nm; for cell proliferation dye EF670 λex 640 nm and λem 650-750 nm. Images were analyzed with Fiji ImageJ software.

To explore the role of NK cells on cytotoxicity, we have incubated PC3 with different ratio of NK cells along with the fixed concentration of novel antibodies for 6 to 7 hrs. We have observed an increase in cell death with increasing in ratio of E:T for all antibodies tested (C5511, C4608, C6481) wherein T:E ratio of 1:10 exhibited highest cell death as indicated in FIGS. 12B, 12C, and 12D).

T Cell Mediated Cytotoxicity

PC3 cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. Freshly isolated T cell was used in the cytotoxicity assay at T:E of 1:3 and antibody concentration of 100 ug/ml. Novel monoclonal anti-CLEC2D antibody C5511 and C6481 were added at 100 ug/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was collected from 24 well plate and adherent cells were trypsinized and collected in 1.5 ml tubes. Reaction mixture was incubated with sytox green (15 nM) for 20 min and fluorescence was detected in flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples.

FIG. 13 depicts T cell mediated killing as observed against PC3 cells wherein clone C5511 & C6481was incubated at a concentration of 100 μg/ml eliciting tumor cells cytotoxicity when compared with control having basal level of 6% dead cell. In experimental condition where T:E of 1:3 was used, upto 55% T cell mediated cytotoxicity was observed (FIG. 13).

To further define the process of cytotoxicity live-cell microscopy experiments were performed to track the target cell killing through effector cells for both PBMC and NK cells. For live cell imaging experimentation, PC3 cells were grown on 8-well slides (eppendorf) in complete media ((20% FBS+DMEM-F12+1× Pen/Strep+1 mM sodium Pyruvate)) to 70-80% confluence. PC3 cells were stained with cell tracker dye and PBMC/NK cells were stained with cell proliferation dye EF670 separately. 200 m/ml of novel antibodies along with stained PC3 and PBMC/NK cells. Target to effector ratio for both PBMC and NK cells were, 1:5 and 1:1, respectively. Cells were kept in a humidifier maintained at 37° C. and 5% CO2 during imaging. Live cell imaging was performed on the Zeiss LSM800 confocal microscope with a 63× magnification, 1.4-NA objective and images were captured at 8 min intervals for up to 20 hrs by using appropriate wavelengths (For sytox blue, λex 405 nm and λem 450-500 nm; for cell tracker green, λex 488 nm and λem 510-530 nm; for cell proliferation dye EF670 λex 630 nm and λem 650-750 nm. Images were analyzed with Zen lite Imaging software.

To further define the process of cytotoxicity, live-cell microscopy was performed to track the target cell killing through effector cells either PBMC or NK cells.

The purpose of live cell imaging was to understand and follow the anti-CLEC2D mediated tumour cell killing process in the presence of effector cells, such as PBMC or NK cell, in time dependent manner, under controlled experimental condition. Results obtained from live cell imaging prompted the fact that in the presence of isotype control, PBMC or NK cell made less direct contact with the PC3 target cells resulting in minor percentage of target cell death. On the contrary, addition of anti-CLEC2D (C5511) antibodies, on PBMC or NK cells and target cells causing an increase in extend of direct contacts between both PBMC or NK cells and PC3 target cells, resulting in significant target cell death. Interestingly, PC3 target cell killing mediated by anti-CLEC2D (C5511) antibody in presence of NK cells elicited more efficient clearance of tumor cells wherein most of the tumor cells lysis occurred within 10 hrs of incubation, while observed tumor cell death in presence of PBMC was found to be significantly lower within the said time point. This indicates that effective elimination of PC3 tumor cells via anti-CLEC2D antibody is predominantly NK cell mediated.

Molecular Interaction Between Anti-CLEC2D Antibody and CLEC2D Antigen: Through Epitope Mapping

In Silico Studies

The following protocol was developed to identify the binding site formed by the CLEC2D-Antibody complexes. Briefly the method involves using protein structures of both the antibody and CLEC2D in shape-complementarity based docking to generate CLEC2D-antibody conformations, followed by analysis of the conformation to shortlist mutations to verify the binding sites. (Germain et al, 2011, Rozbesky et al, 2015).

One of the central assumptions of this protocol is that the potential binding site should be more accommodating of a binding partner, i.e., a groove or channel—where an appropriate binding partner may be able to settle, somewhat illustrated by the lock-and-key model of enzymes and substrates, a specific lock (or binding site) would be receptive to a specific key (or binding partner) based on their structural compatibility. This concept was expanded upon to identify the binding site, as following shape-based docking, the largest concentrations of generated conformations were considered to be the possible binding sites.

The conformations were then clustered together on the basis of interacting pairs of residues, conformations that could not be incorporated into clusters were discarded after which the remaining conformations were energy minimized and screened for viability. For conformations found to be viable their interacting residue pairs were more closely scrutinized and mutations were suggested to test the association.

Killer cell lectin-like receptor subfamily B member 1 (NKR-P1) is an inhibitory receptor the regulates NK cell-mediated cytotoxicity. C-type lectin domain family 2 member D (CLEC2D) is a ligand of NKR-P1, the CLEC2D/CD161 interaction inhibits NK cell-mediated cytotoxicity, blocking the CLEC2D-NKR-P1 complex can enhance primary NK cell activity.

All unique anti-CLEC2D antibodies derived from novel library was found to prevent the CLEC2D-NKR-P1 association by binding with CLEC2D, however the exact location and nature of this inhibition was unknown. The following protocol was conceived to identify the likelihood of binding site through the use of modelling, docking and site-directed mutagenesis.

The procedure starts with identifying key interaction residues on CLEC2D wherein, the CLEC2D-antibody complex interactions can be understood by taking a closer look at the CLEC2D-NKR-P1 (CD161) complex and was done by studying the crystal structure of the complex, deposited in the PDB as 5MGT (FIG. 15A).

The 5MGT crystal structure describes the association between the CLEC2D and NKR-P1 complex. The residues involved in the association are of interest. If the inhibition mode of the antibody-CLEC2D complex is of a steric variety, the residues involved in both interactions, and their immediate neighbors, would likely overlap. Residues involved from the CLEC2D chains, henceforth called antigen interacting residues were identified by examining the 5MGT structure in Chimera (FIG. 15B) (Pettersen et al, 2004). Essentially all residues within contact distance (up to 6 Å) between the chains of CLEC2D and NKR-P1 (CD161) were identified (See Table 28).

TABLE 28

A list of the residues in CLEC2D Chains within

contact distances of NKR-P1(CD161).

Res No. &

Res No. &

Type
6 Å
5 Å
4 Å
Type
6 Å
5 Å
4 Å

91 ASP
✓
✓
X
161 GLY
✓
✓
X

92 ASP
✓
X
X
162 GLU
✓
✓
✓

93 THR
✓
✓
X

95 ASN
✓
X
X
165 TYR
✓
✓
✓

167 ASN
✓
✓
✓

124 ARG
✓
X
X
168 ASP
✓
✓
X

126 LYS
✓
✓
X
169 LYS
✓
✓
✓

127 GLY
✓
✓
X

128 PRO
✓
✓
✓
172 SER
✓
✓
X

129 SER
✓
✓
✓
173 SER
✓
✓
✓

130 ASP
✓
✓
✓
174 ALA
✓
✓
✓

131 HIS
✓
X
X
175 ARG
✓
✓
✓

177 TYR
✓
✓
✓

139 GLN
✓
✓
✓
178 THR
✓
✓
✓

179 GLU
✓
✓
✓

158 LEU
✓
✓
X
180 ARG
✓
✓
✓

159 GLY
✓
✓
X
181 LYS
✓
✓
✓

160 ALA
✓
✓
✓

These antigen-interacting residues were known to play crucial roles in the NKR-P1 (CD161)-CLEC2D complex and would therefore be considered as ‘significant’ residues in the following conformation analysis.

Building Antibody Structures

Models of the fourteen antibodies were generated through the use of homology modelling program MODELLER. The models generated were limited to the variable regions of the antibody, as that is the main area of interest. The PDB was parsed for structures of complete variable regions of antibodies. Each of the unique antibody variable region sequences were aligned against the available structures' sequences and the best match for each antibody sequence, was used as the template from which the antibody model was built. Multiple models were generated for each sequence and the most energy efficient structure was selected as the main model for the antibody (FIG. 15C).

Antibodies are very well conserved outside their hypervariable Complementarity Determining Regions (CDR) loops, and of the six CDR on the two chains of the antibody, three on each of the heavy and light chains, the CDR3 loop on the heavy chain is known to be the largest and most influential in the establishment of interactions, and this region along with the light chain CDR3, were run through several rounds of MODELLER's Loop Refinement to generate the most energy efficient structures, with respect to the CDR loops. Once again multiple variants of the main model were generated and the most energy efficient one was taken forward as the refined antibody model.

Docking the Antibody on the CLEC2D

The CLEC2D model was acquired from the PDB, deposited as 4QKI a dimer of CLEC2D chains. As the precise location of the interaction is not known, Molecular Docking was used to generate structures of the complex to explore the possible interaction modes. The program used was PatchDock, a shape complementarity docking program which permutes all possible interaction modes based on structural feasibility. (Schneidman-Duhovny et al, 2005)

Docking was carried out between the refined Antibody Variable region structures and the antigen CLEC2D (PDB: 4QKI), using PatchDock's High Accuracy Mode at a cluster distance of 4 Å (preventing conformations within 4 Å of existing conformations from being generated). Constraints were only provided for the antigen structure, wherein both CDR3 loops from the light and heavy chains were specified.

PatchDock generated several docking conformations against each of the provided antibodies. (See Table 29).

TABLE 29

The number of

output structures for

each Docking of

the unique anti-

CLEC2D

antibody refined

structures against

CLEC2D.

Refined
Conformations

Structure
Generated

1
6424

2
17370

3
7338

4
9245

5
17976

6
17170

7
20617

8
5750

9
18198

10
7604

11
10267

12
12699

13
15655

14
6219

Analysing Conformations

Following the generation of the docked conformations, their interacting residues were analysed.

In house scripts were used to query the complex structure and identify all residue pairs involving participants from different chains, at a maximum distance of 4Å from one another. These residue pairs were compiled into lists, Table 30 and 31 show such a few lines from such lists, which were then used to cluster the conformations.

TABLE 30

A selection of residue pairs from the contact list generated for C4608

complex 11712. Pairs denoted in single underline, double underline

and dashed underline denote pairs across the antigen- antibody chains.

The single underlined pairs are those between the antibody-antigen

chains that involve any of the previously identified significant

residues and CDR3 residues from either the antigen or the antibody.

The double underlined pairs involve significant residues on the

antigen and non-CDR3 residues on the antibody and dashed

underlined pairs involve significant residues from the antigen as

well as CDR3 residues on the antibody.

custom character

101:ARG:B 211:MET:D

custom character

182:TRP:B 93:THR:C

custom character

106:GLN:B 28:SER:C

94:LYS:B 95:PRO:C

78:SER:B 27:GLN:C

105:SER:B 214:PRO:D

102:PHE:B 28:SER:C

101:ARG:B 214:PRO:D

102:PHE:B 93:THR:C

105:SER:B 32:SER:C
106:GLN:B 32:SER:C

77:GLU:B 25:ALA:C
105:SER:B 30:GLY:C

77:GLU:B 26:SER:C
77:GLU:B 69:THR:C

106:GLN:B 29:VAL:C
79:TRP:B 28:SER:C

94:LYS:B 94:TRP:C
88:TYR:B 27:GLN:C

98:SER:B 93:THR:C
107:ASP:B 31:ASN:C

106:GLN:B 30:GLY:C
77:GLU:B 27:GLN:C

88:TYR:B 94:TRP:C
105:SER:B 29:VAL:C

94:LYS:B 93:THR:C
105:SER:B 31:ASN:C

TABLE 31

A selection of residue pairs from the contact list generated for C5511

complex 14228. Pairs denoted in single underline, double underline

and dashed underline denote pairs across the antigen-antibody chains.

The single underlined pairs are those between the antibody-antigen

chains that involve any of the previously identified significant

residues and CDR3 residues from either the antigen or the antibody.

The double underlined pairs involve significant residues on the

antigen and non-CDR3 residues on the antibody and dashed

underlined pairs involve significant residues from the antigen as

well as CDR3 residues on the antibody.

custom character

165:TYR:B 223:TRP:D

custom character

167:ASN:B 110:GLU:D

custom character

168:ASP:B 110:GLU:D

custom character

169:LYS:B 110:GLU:D

custom character

175:ARG:B 225:GLN:D

custom character

179:GLU:B 42:GLN:C

130:ASP:B 223:TRP:D

179:GLU:B 40:PRO:C

165:TYR:B 112:GLN:D

180:ARG:B 223:TRP:D

Clustering Conformations and Assessing Viability

Conformations were clustered on the basis of overlapping contacts, conformations were clustered together if at least 75% of the residue pairs were in common. Conformations that were not incorporated into a cluster were discarded.

Of the remaining structures, energy minimization was carried out on all the complexes before the next filtration step where the Protein Interaction Z Score Assessment (PIZ SA) tool was used to filter out non-binder conformations. PIZSA took in the protein complexes and identified all the likely residue interactions on the basis of a distance threshold applied to the residues' atoms. Following identification it evaluated every contact pair and scored the constituent associations, building up a cumulative score which was ultimately used to determine if the associations it has identified would lead to stable association, if the complex is viable, or not. (Roy et al, 2019) (This viability is based on the composition and combinations of the identified contact pairs.) Conformations identified as viable were the only ones retained. (See Table 32).

TABLE 32

The Total numbers and membership data of

clusters identified when clustering was carried

out for 75% identify of interactions. The final

column lists the number of conformations that

are recognised as PIZSA as being viable.

Total
Total
Viable

Antibody
Clusters
Conformations
Conformations

C2901
13
100
69

C4608
19
138
117

C3452
6
30
9

C5511
7
44
39

C0694
4
29
9

C0997
6
44
37

C5397
3
21
21

C5392
7
47
36

C0949
6
43
42

These reduced clusters were composed of several tightly grouped structures, all of which formed overlapping associations with the CLEC2D chain.

These cluster formations were taken as likely binding site positions and the validation of each site needed to be carried out (FIGS. 15D, 15E, 15F, and 15G).

Mutation Analysis

Following the short-listing of a smaller number of viable structures to explore, mutation analysis was carried out. PIZSA also had a feature whereby it takes identified contact pair and substitutes each participant residue with the other 19 natural amino acids and determined the impact on the overall score of the structure for that substitution. The impact value would be indicative of the loss of stability the complex would experience if a specific residue was swapped out for another. Residues that were important for the complex, which form strong associations would have high impact values, as mutating those positions could weaken or destabilise the complex. This information was used to identify which residue pairs mutations would be the most destabilizing to the overall complex. As the conformations were already clustered, an entire cluster could be evaluated by around identifying three to four high impact residue-pairs that were prevalent in all members of the clusters, for mutation. Herein significant considerations were made based on following parameters, such as, Same Cluster Count indicating the total number of times a specific residue was observed in an interaction within same cluster on the same antibody; Same_Cluster_Proportionate indicating proportionate number of times a specific residue was observed in an interaction within same cluster on the same antibody; Same antibody in Other Cluster occurrence count meaning the total number of times a specific residue was observed in an interaction among all clusters on the same antibody that can be seen multiple times in the same cluster; Same antibody Other Cluster count describes the total number of structures in which a specific residue was observed in an interaction among all clusters on the same antibody capturing multiple instances in the same cluster however only counted once; Other antibody Other Cluster occurrence count describes as the total number of times a specific residue was observed in an interaction among all clusters on the other antibodies; Other antibody other Cluster count indicating the total number of structures in which a specific residue was observed in an interaction among all clusters on other antibodies (multiple instances in the same cluster only counted once). Taking together, this approach in turn provided the epitope patch on CLEC2D antigen against respective anti-CLEC2D antibody. The similar method was justifiably adopted for all anti-CLEC2D antibodies as well.

TABLE 33

summarizes on significant residues on CLEC2D antigen contacting C4608 anti-CLEC2D antibody

Same Ab
Same
Other Ab
Other

Same
Other
Ab
Other
Ab

Same
Cluster
Cluster
Other
Cluster
Other

Clone
Cluster

Cluster
Propor-
occurrence
Cluster
occurrence
Cluster
CD161

No.
No.
Residue
Position
Count
tionate
count
count
count
count
overlap

C4608
G00001
ARG
101
10
100
26
4
100
22
No

G00001
SER
105
6
100
15
4
36
11
No

G00004
ASP
104
8
100
7
3
26
8
No

G00007
PHE
102
3
100
13
4
27
12
No

G00007
SER
98
1
100
10
5
37
19
No

G00007
SER
105
6
100
15
4
36
11
No

G00008
TYR
177
7
100
10
1
145
25
Yes

G00008
GLU
179
5
100
14
3
129
20
Yes

G00009
GLU
138
5
100
7
4
66
20
No

G00009
GLN
141
10
100
21
5
82
17
No

G00010
PHE
102
7
100
0
0
14
8
No

G00010
ARG
101
13
100
2
2
82
17
No

G00011
THR
152
3
100
10
2
67
21
No

G00011
ARG
153
12
100
12
2
159
25
No

G00011
GLN
154
5
100
9
2
72
16
No

G00011
PRO
156
3
100
1
1
53
16
No

G00011
GLN
117
4
100
4
2
44
13
No

G00012
THR
152
5
100
8
2
67
21
No

G00012
GLU
150
7
100
8
2
96
21
No

G00014
THR
152
5
100
8
2
67
21
No

G00014
GLU
150
3
100
12
2
96
21
No

G00014
ARG
153
4
100
20
2
159
25
No

G00015
PHE
102
3
100
13
4
27
12
No

G00016
TRP
151
1
100
4
3
18
10
No

G00016
GLU
150
6
100
24
5
59
13
No

G00016
THR
149
3
100
12
3
38
10
No

G00016
ARG
153
5
100
28
5
60
11
No

G00016
GLY
140
2
100
19
6
62
19
No

G00016
GLN
141
5
100
26
5
82
17
No

G00017
GLN
141
4
100
27
5
82
17
No

G00017
PRO
142
2
100
16
5
32
14
No

G00017
ARG
153
5
100
28
5
60
11
No

G00017
GLU
150
4
100
26
5
59
13
No

G00017
THR
152
4
100
16
4
34
10
No

G00018
PRO
156
4
100
2
1
14
6
No

G00018
LEU
158
3
100
0
0
14
8
No

G00018
ARG
153
7
100
26
5
60
11
No

G00018
PHE
155
2
100
3
2
11
5
No

G00018
LYS
169
4
100
4
1
6
5
Yes

G00020
ARG
137
1
100
6
5
26
16
No

G00020
TYR
177
6
100
27
4
158
24
Yes

G00020
GLU
162
3
100
6
2
49
18
Yes

G00020
ALA
160
2
100
10
4
44
19
Yes

G00020
ARG
175
4
100
18
3
90
21
Yes

G00020
GLN
139
5
100
15
7
77
21
Yes

G00020
TRP
96
1
100
1
1
9
8
No

G00020
GLU
138
4
100
8
4
66
20
No

G00020
ARG
101
1
100
14
2
82
17
No

G00020
SER
136
2
100
2
1
7
7
No

G00020
GLY
140
2
100
19
6
62
19
No

G00021
GLU
150
9
100
21
5
59
13
No

G00021
THR
149
4
100
11
3
38
10
No

G00022
THR
93
5
100
9
3
64
20
No

G00022
TYR
177
10
100
7
1
145
25
Yes

G00022
GLU
179
10
100
9
3
129
20
Yes

G00026
TRP
151
1
100
4
3
18
10
No

G00026
GLU
150
5
100
25
5
59
13
No

G00026
ARG
153
8
100
25
5
60
11
No

G00026
GLN
154
3
100
13
4
25
5
No

G00026
THR
152
6
100
14
4
34
10
No

G00031
THR
178
4
100
7
1
55
20
Yes

G00031
GLU
179
3
100
19
3
92
19
Yes

G00031
TYR
177
8
100
25
4
158
24
Yes

G00031
ARG
175
5
100
17
3
90
21
Yes

In order to identify which of the clusters describe the true binding sites, a series of mutations would be suggested to key residues. Due to the high number of clusters it was advantageous to identify mutations which were capable of testing multiple clusters concurrently. All the residues identified for all the clusters of a single antibody were analysed to achieve this. The idea was that multiple clusters would be put into combinations and residues that play a major role in all of their potential binding modes be suggested as mutations to concurrently test many conformations. These combinations were identified by inspecting the overlapping significantly involved residues (those occurring in the top 3 proportions of each cluster.) If clusters shared multiple significantly involved residues they were taken as possible combinations. As exemplified herein, mutations were suggested for C4608 and C5511. These antibodies had 21 and 7 clusters respectively, in order to cluster these, the represented residues from all these clusters were analysed. An inspection of the representative overlaps of significantly occurring residues suggested possible combinations of G00001-G00004-G00007-G00010-G00015, G00012-G00014-G00016-G00017-G00018-G00021-G00026, G00005-G00008-G00020-G00022-G00031 and G00011-G00012-G00014-G00018 for C4608 and possible combinations of G00001-G00005-G00011-G00019-G00020 with G00015 and G00017 by themselves for C5511. Strategy described above was adapted for all anti-CLEC2D antibodies.

To identify which residues played a role in combinations of clusters every possible combination of lengths varying from 2 to 13 cluster (depending on the total number of initial clusters available) were generated. For every combination, all the involved residues along with their impact values were identified. Residues that were involved in all or a majority (at most missing in two members) of the members of the combination were retained while the residues that only played a role in some of the clusters in the combination were removed from consideration, leaving only a list of highly occurring residues.

Once a preferable combination was identified based on the overlap of residues the residues that were highly occurring for that combination were scrutinized and residues that were observed to have a high impact value were put forward as mutation options (FIGS. 16E and 16G).

The picks made after all those considerations would possess all the following properties, (a) Be charged or polar residues (although if no such residues were observed other were selected based on their impact on the interaction.), (b) Be present in all or most of the clusters of a combination, (c) Have a significant on the potential binding mode, and (d) involve the antigen-interacting residues

As exemplified by C4608, wherein the above described strategy was adopted and following combinations of residues are believed to be involved in interaction with CLEC2D antigen. The similar method was justifiably adopted for all anti-CLEC2D antibodies as well.

TABLE 34

The final set of selections of the combinations identified for Antibody clone C4608

Present
Unique

Remaining
Residue
Average

on all
to

Clone Number
Clusters
Clusters
position
Impact
Impact
Clusters
clusters

C4608
G00001
G00005
101:ARG:A
−1092.6
yes
yes
no

G00004
G00008

G00007
G00011

G00010
G00012

G00015
G00014

G00016

G00017

G00018

G00020

G00021

G00022

G00026

G00031

G00012
G00005
150:GLU:A
−382.44
no
yes
no

G00014
G00008
154:GLN:A
−379.74
no
yes
no

G00016
G00011

G00017
G00020

G00018
G00022

G00021
G00031

G00026

G00005
G00011
175:ARG:A
−710.34
yes
yes
no

G00008

177:TYR:A
−1056.29
yes
yes
no

G00020

179:GLU:A
−612.15
yes
yes
no

G00011
—
150:GLU:A
−544.91
yes
yes
no

G00012

152:THR:A
−577.26
yes
yes
no

G00014

153:ARG:A
−649.57
yes
yes
no

G00018

154:GLN:A
−568.9
yes
yes
no

Construct Generation as Soluble CLEC2D Variants

Once the amino acids, which are in combination or independently, are either overlapping or non-overlapping with CD161 interaction points, were generated as CLEC2D antigen variants to map the epitope for novel anti-CLEC2D antibody clones. The constructs were generated either by site directed mutagenesis or by gene synthesis. All constructs were having C-term histidine tag, similar to soluble CLEC2D antigen used for screening, to facilitate the further purification. All possible positions were changed into amino acid alanine, as the observed in silico mutation impact was seen to be maximum for the said amino acid. Table 35 describes positions in CLEC2D soluble antigen wherein the mutations were introduced.

TABLE 35

Positions for mutation

P128A

S129A

D130A

Q139A

E162A

Y165A

K169A

S173A

R175A

Y177A

T178A

E179A

R180A

K181A

K169A & S172A

Y165A & N167A

R101A

Q141A

R153A

S187A

H190A

R175A, Y177A, E179A

R084A, H190A

E150A, T152A, R153A,

Q154A

R101A, S105A,

D107A, H190A

Q141A, R153A

D092A, T093A, K094A

Q141A, K144A

E138A, C176A

E138A, Q139A, Q141A,

R175A

D092A, Y177A, K181A

F116A, R153A,

T093A, N095A

T093A, Y177A, E179A

K094A, R101A, E179A

R175A, Y177A, R180A

As exemplified herein, site directed mutagenesis was performed using QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent by PCR using synthesizing two complimentary oligonucleotides containing the desired mutation, flanked by unmodified nucleotide sequence, which were synthesized at Eurofins. PCR was performed on an Eppendorf™ Mastercycler™ pro PCR System in 25-μL volumes consisting of 0.2 μM of each primer (Eurofins, India), 1.5 μL of Quick solution, 1 μL Quickchange XL dNTP mix, 10× quick change lightening buffer 2.5 μL. Also included were template DNA 15 ng. Following an initial denaturation at 95° C. for 2 min, 18 cycles of 20 seconds denaturation at 95° C., and 60 seconds annealing at 60° C., 3 minutes primer extension at 68° C., 5 minutes final extension at 68° C. were performed. After PCR 2 μL of Dpn I endonuclease was added which is specific for methylated and hemimethylated DNA and is used to digest the parental DNA template and to select for mutation-containing synthesized DNA (DNA isolated from almost all E. coli strains is dam methylated and therefore susceptible to Dpn I digestion.) The nicked vector DNA containing the desired mutations was then transformed into XL10-Gold ultracompetent cells and plated onto ampicillin-containing LB agar plates. Plasmid DNA from transformed colonies was purified by QIAprep Spin Miniprep kit (Qiagen) and sequenced at Eurofins.

Vector and the SDM construct having specific mutation were restriction endonuclease activity with HindIII and XhoI enzymes and product was extracted using QIAquick Gel Extraction kit, ligated using T4 DNA ligase (NEB) and 50% of mixture were transformed into NEB5α competent cells E. coli. Subsequently clone screening was carried out through restriction digestion and finally through sequencing reaction. Sequencing process confirmed the clones to contain desired mutation.

Anti-CLEC2D antibody mediated blocking of CLEC2D and CD161 interaction. Further probing into observations made from epitope mapping studies prompted to the fact that anti-CLEC2D antibody binding sites on CLEC2D antigen comprises of contact points having both unique/exclusive contact points established on CLEC2D antigen and binding sites overlapping with contact points established between CLEC2D-CD161 complex. As exemplified herein, epitope patches on CLEC2D antigen for C4608 (FIG. 16A and FIG. 16B) and C5511 (FIG. 16C and FIG. 16D), not limited to, has been represented wherein binding sites for both C4608 and C5511 anti-CLEC2D antibodies interacting with CLEC2D antigen overlaps significantly with contact points between CLEC2D antigen and CD161. Present disclosure explores the impact of identified anti-CLEC2D antibody on the interaction between CLEC2D and CD161 proteins. As tumour cell evades immune system through the said interaction between CLEC2D and CD161, therefore, experimental validation of CLEC2D binder i.e., anti-CLEC2D antibody disrupting the interaction has been further proved below. Experimental details starts with confirmation of CLEC2D and CD161 interaction followed by abrogating the same by the use of anti-CLEC2D antibody.

As exemplified herein, CLEC2D antigen was conjugated on magnetic beads wherein, 1 ml of 0.1 M phosphate buffer saline was added in to 0.5 mg Dynabeads and vortexed for 30 seconds followed by incubation at rotation, at RT for 10 minutes. After incubation, beads were washed twice with 1 ml of 0.1 M phosphate buffer saline with the help of Dynamag 2, then washed beads were resuspended in to 100 μl of 0.1 M PBS. To conjugate antigen on magnetic beads, 100 μl of washed beads and 100 μl PBS containing 1 μg of CLEC2D antigen were mixed thoroughly in the presence of 100 μl of 3 M ammonium sulphate then incubated at 37° C. for overnight. Overnight incubated mix was washed twice with PBS and blocked with 100 μl PBS containing 0.5% BSA for 2 hrs followed by separation of magnetic beads with Dynamag 2.

Finally conjugated antigen beads were resuspended in to 100 μl PBS. To check the identity of antigen, 1 μl of above conjugated antigen bead was resuspended in to 99 μl of 1×PBS and washed once with 0.1 M PBS and again resuspended in to 100 μl of 1×PBS. 0.5 μg of anti-CLEC2D monoclonal antibody, commercially available from Novus Biologicals was added in to 100 μl washed conjugated antigen beads then incubated on ice for 2 hrs with constant tapping. After incubation, conjugated antigen beads were washed twice with 100 μl of 1×PBS containing 0.25% BSA then 100 μl of 5 μg/ml Alexa Fluor 488 goat anti-mouse IgG (H+L) was added in to conjugated antigen beads and further incubated for 30 min on ice. After incubation, conjugated antigen beads were washed twice with 100 μl of 1×PBS containing 0.25% BSA and resuspended in to 200 μl of 1×PBS. Fluorescence of all samples including controls were read through CytoFLEX. Bead conjugation efficiency was found to be >95% as judged by flow cytometry analysis as depicted in (FIG. 16E).

To check the binding of CD161-Fc with CLEC2D antigen, 2 μl of above conjugated CLEC2D antigen beads was taken and different concentrations of CD161-FC (purchased from Biolegend) was added and incubated on ice for 2 hrs with constant tapping to avoid settling of beads. After incubation, the beads was washed twice with 100 μl of PBS with 1% BSA. 100 μl of 5 μg/ml of alexa fluor goat anti human IgG, was added and incubated on ice for 20 min on rotation. The beads was washed once with 100 μl of PBS with 1% BSA and resuspended with 100 μl of 1×PBS. Fluorescence of all samples including controls was read through CytoFLEX. As can be seen from FIG. 16F, CLEC2D antigen conjugated on magnetic beads interacts in a dose dependent manner to CD161 protein.

0.5 μg biotinylayted CD161-FC was added in to 2 μl of CLEC2D conjugated beads and incubated on ice for 2 hrs. After incubation the beads were washed twice with 100 μl of PBS containing 1% BSA and 200 ng of Streptavidin, Alexa Fluor™ 633 conjugate was added and further incubated on ice for 20 min. After incubation the beads were washed twice with 100 μl PBS containing 1% BSA and 2 μg of C5511 antibody was added for 2 hrs on ice. After 2 hrs incubation, 5 μg/ml of alexa fluor goat anti human IgG was added and further kept for 20 min on ice with rotation. Finally fluorescence of all samples including controls were read through CytoFLEX. Loss of signal CLEC2D-CD161 interaction at optimal concentration of anti-CLEC2D antibody as seen in FIG. 16G, indicates that anti-CLEC2D antibody can compete with CLEC2D-CD161 contact sites and disrupt the interaction.

Immune Cell Activation: Due to Binding of Anti-CLEC2D Antibody

The prevailing view of NK cell activation is their ability to distinguish healthy cells from sensitive target cells through a balance between signals from activating and inhibitory receptors. The net output of major positive and negative signalling events is viewed to determine the capacity of NK cells to kill target cells. However, the precise molecular check-points where inhibitory signals abrogate activating pathways are not well defined.

However, attempts towards delineating the contribution of individual receptors to NK cell activation, CD 69 surface receptor was considered as an early activation immune cells marker which gets rapidly induced in NK cells shortly after activation. CD69 promoter contains binding site for NF-κB, erythroblast transformation-specific related gene-1 (ERG-1) and AP-1. Its expression is upregulated upon activation in most leukocytes and use as a marker of activated lymphocytes and NK cells. In addition CD69 is also an important regulator of immune responses. CD69 is involved in NK-cells activation via Syk-Src-dependent manner. Whereas in T-cells CD69 is induced after TCR/CD3 engagement where it negatively regulates TH1/TH17 response and control inflammation in vivo also through TGF-B signaling. However in NK cells CD69 cross linking has been shown to induce cytotoxic activity and cytokines production of activated NK cells. Thereby, CD69 can be represented as a putative receptor for target cells in activated NK cells. Effector cells used in this study, PBMC and NK cells, as applicable, were isolated using protocol as described above.

In order to understand the impact of Anti-CLEC2D antibody on NK cell status, level of CD69 marker expression on NK cells were monitored in the presence and absence of Anti-CLEC2D antibody. For each reaction 0.1×10⁶of isolated NK cells were taken. IL-2 was used as positive control. 200 U of IL-2 (Acro biosystems) and anti-CLEC2D 100 μg/mL and 200 μg/mL was added to each well and incubated overnight. In order to understand the change in CD69 expression through PC3 priming, PC3 cells were added at 1:1 (T:E) ratio to NK cells with or without anti-CLEC2D antibody C5511. NK cells without any treatment or targets were kept as control. Post 12-16 hrs of incubation, CD markers not limited to, anti human CD3-FITC and anti human CD69-APC750 (Biolegend) staining was done 0.5 uL of respective antibodies were used against 0.1×10⁶cells. Cells were washed once with 1×PBS 0.2% BSA and reading was taken using CytoFLEX (Beckman Coulter). Data was acquired using default gain settings and 5000-10000 events were recorded per sample.

The results showed 40-50% upregulation of CD69 expression as observed in NK cells in presence of C5511 antibody (100 μg/mL and/or 200 μg/mL) when compared to NK control without treatment wherein the baseline expression was recorded to be 1-2% (FIG. 17A). IL-2 was used as positive control and showed 30-40% upregulation (FIG. 17A). In case of tumor (PC3) primed NK cells showed high expression close to 70-75% expression of CD69 while CD69 expression was upregulated to ˜85% in presence of both PC3 cell and antibody 100 μg/mL, (FIG. 17B).

Secretion/Intra-Cellular Expression of Cytokine/Chemokines

NK cells recognition of tumor cells/infected cells induces cytotoxicity and cytokines secretion. Signaling pathways which regulates the cytokines production and the contribution of NK cell activation receptor upon target cell recognition for the process is not well understood. In addition the condition/requirement of cytokines secretion on engagement of specific ligand in target cells is not known. Thereby, to understand the primary initiation of immune response upon target cell recognition by NK cells profile/screening of cytokines and chemokines are important. Here, the study was designed to detect cytokine secretion in presence of novel antibody C5511. IFN-γ and TNF-α are the two of the most prominent cytokines produced by NK cells and has been implicated in both cytotoxicity and proliferation of various immune cells. Thereby in this study experiments were conducted to detect IFN-γ secretion in PBMCs or isolated NK-cells by a well-established intracellular IFN-γ staining technique on flow based assay.

Cells Stimulation and IFN-γ Staining Protocol:

After overnight rest of PBMCs and NK cells at 37° C., the activation reagents and secretion inhibitor (Brefeldin A (10 μg/mL)/Monensin (6 μg/mL)) was added to the well. PBMCs and NK cells were left untreated or treated with novel antibody C5511 at 100 μg/mL. Cells were stimulated with anti human OKT-3 (1-2 μg/mL) as a positive control, as it is known to induce IFN-γ secretion. Target cells, at an effector to target ratio of 10:1 was used whenever required. Medium alone served as the negative control. Cells were incubated for 4 hours at 37° C., in CO2 incubator.

After incubation EDTA to a final concentration of 2 mM was added and incubated for 15 min at room temperature. Wash the cells with PBS at 1600 rpm, 8 min at room temperature. PBS wash was repeated at 1600 rpm, 8 min, room temperature and resuspend in 500 μl PBS. Anti-CD3 (Biolegend) cocktail for each sample (20 μl in final) was added. Compensation was done for appropriate amount of single antibodies for compensation controls. Cells were incubated for 30 min at room temperature in the dark. 2 ml of FACS buffer was added to each well tube. Cells were washed twice with FACS buffer at 1600 rpm, 8 min, room temperature. Cells are then re-suspended in 100 μl of flow buffer (0.1% BSA in DPBS) with or 250 μl/tube of BD cytofix/cytoperm, was incubated for 15 min at RT. Cells were then centrifuged at 2000 rpm for 8 min at 4° C. and supernatant was discarded.

Cells were washed twice in wash buffer. Supernatant was discarded and IFN-γ PE (Invitrogen) intracellular staining was done as per manufacturer's protocol. Cells were incubated for 30 min-60 min, on ice, in the dark. After the incubation cells were washed twice with 1 ml of FACS buffer. Supernatant was discarded and resuspend in a final volume of 150 μl FACS buffer for Flow.

As can be seen from FIG. 18A, release of IFN-γ in PBMCs when induced with C5511, anti-CLEC2D antibody, at a concentration of 100 μg/mL was found to be ˜2.97% as compared to uninduced control. Anti OKT-3 antibody, an anti CD3 antibody conjugated with FITC, was used as a positive control, showed 3-6% IFN-γ release when compared with uninduced PBMC (FIG. 18A). Subsequently PBMC cells were gated based on CD3+ive and −ive populations wherein CD3+ cells from total PBMC showed non-significant increase of IFN-γ release when treated with Anti-CLEC2D antibody, either alone or with target cells (at T:E ratio 1:10) (FIG. 18B). On the contrary, CD3−ive population exhibited significant increase of IFN-γ release upon treatment with Anti-CLEC2D antibody (FIG. 18C). It should be noted here that there was no or low increase in IFN-γ production in PC3 primed effector cells, either with whole PBMC or CD3+ cells or CD3− cells. Extending the observation to isolated NK cells, IFN-γ release experiments were performed wherein 1-2% of IFN-γ release, to an approximate, was monitored in the presence of Anti-CLEC2D antibody (FIG. 18D). Taken together, release of cytokine, such as IFN-γ, was elevated upon treatment of anti-CLEC2D antibody, as described in present disclosure. The said observation mediated through anti-CLEC2D antibody is subject to binding to CLEC2D antigen, expressed on effector cells, not limited to CD3-/NK cells, suggesting an independent pathway towards activation of other immune cells and essentially effective clearance of target cells.

Cytotoxicity Mechanism:

To understand the functional role of Anti-CLEC2D antibody in the cytotoxicity mechanism, anti-CLEC2D isotype variants were constructed and assessed in cytotoxicity assay.

Generation Relevant Isotype Constructs

As exemplified, mammalian expression vector pZB013 (accession #MTCC 25364) with IgG1, N→A mutation and pZB014 (accession #MTCC 25365) with IgG4 were generated, wherein selected anti-CLEC2D variable heavy chain region could be cloned. Subsequently said constructs with variable heavy chain and pZB008 (accession #MTCC 25359) with variable light chains, will be transfected, expressed and purified for subsequent experimentation. Both the mammalian constructs pZB013 with IgG1, N→A mutation and pZB014 with IgG4 were custom designed and synthesized (FIGS. 19A and 19B). The plasmid which carries a kanamycinR/puromycinR cassette driven by strong promoter and high-copy-number ColE1/pMB1/pBR322/pUC origin of replication for propagation. The variable heavy chain can be replaced using restriction enzyme AscI and XbaI. The variable light chain can be replaced by restriction enzyme EcoRI and AscI.

As exemplified herein, PCR was performed using sequence specific primers which were synthesized at Eurofins, and pZB014 and pZB008 vectors were restriction endonuclease activity with respective enzymes and the PCR amplified product was extracted using QIAquick Gel Extraction kit, infusion cloning was done using Infusion HD Cloning Plus CE from and 50% of mixture were transformed into Stellar competent cells E. coli and plated onto Kanamycin—containing LB agar plates. Plasmid DNA from transformed colonies was purified by QIAprep Spin Miniprep kit (Qiagen) and sequenced at Eurofins and large scale plasmid was isolated and used for transfection. Herein, Transformation of plasmid DNA into bacterial cell by heat shock method and Plasmid DNA Isolation from bacterial cells using QIAGEN kit and clone screening was similar to as described in section above. All clones were subsequently sequence verified and found to be error free. Respective anti CLEC2D clones in both IgG4 and/or IgG1 mutant formats, were isolated in large scale for transfection into mammalian expression system, CHO cells.

CHO Cell Transfection to Express Novel Anti-CLEC2D Monoclonal Antibody IgG4 Variants:

As exemplified, for transfection, cell count and viability data was collected using Vi-cell XR automated cell counter, Beckman coulter. Transfection was carried out as per manufacturer's protocol Lipofectamine® LTX Reagent with PLUS Reagent. Required volume of cell suspension was centrifuged at 1400-1500 RPM for 4-5 mins and re-suspended in specified volume of OPTIMEM I as per Table 36 in 125 ml shake flask. Transfection mix was prepared as per Table 3. Refer Table A for DNA details. 2-3 days post transfection 10 ml Power CHO2 CD growth media was added and Glutamax was added from 200 mM stock to achieve final concentration of 2 mM. Day 6 post transfection, cell culture supernatant was harvested by centrifugation at 1400-2000 rpm for 10-15 minutes. IgG4 antibody variants were purified from cell culture supernatant by Protein A affinity chromatography.

TABLE 36

Example of transfection with IgG4 constructs

Parameters
Details

Total volume of transfection
50 ml

Cell density
1.25 ×10{circumflex over ( )}6 cells/ml

OPTIMEM I
12.5 ml

Total DNA
25 μg

HC:LC
1:3

Amount of DNA: Lipofectamine
1:3

Amount of DNA: Plus reagent
1:1

As exemplified by, C4701, C3276, C3256 clones, not limited to, were transfected for further purification and evaluation in cytotoxicity assay.

TABLE 37

Anti-CLEC2D IgG1 antibody heavy chain and kappa light chain

amino acid sequence

SEQ ID
VH + CH AA_IgG1
SEQ ID
VK + CK AA

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1589
ETTLTQSPATLSVSLGERATLSC

1481
SCKASGYTFTSYAMHWVRQA

RASQSIGSNLVWYQLKPGQGPR

PGQRLEWMGWINAGNGNTK

LVIYSATSRATGIPARFSGSGSGT

YSQKFQGRVTITRDTSASTAY

EFILSISNLQSEDLAVYYCQQYGS

MELSSLRSEDTAVYYCARGSL

SPPTTFGQGTRLEIKRTVAAPSV

SRSGWYAGLFDYWGQGTLVT

FIFPPSDEQLKSGTASVVCLLNNF

VSSASTKGPSVFPLAPSSKST

YPREAKVQWKVDNALQSGNSQE

SGGTAALGCLVKDYFPEPVTV

SVTEQDSKDSTYSLSSTLTLSKA

SWNSGALTSGVHTFPAVLQS

DYEKHKVYACEVTHQGLSSPVTK

SGLYSLSSVVTVPSSSLGTQT

SFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QITLKESGGGVVQPGRSLRLS
SEQ ID 1590
EIVMTQSPATLSLSPGERATLSC

1482
CAASGFTFSSYSMNWVRQAP

RASQSVSSSYLAWYQQKPGRAP

GKGLQWVAIISDDGSKSYYAD

RLLIYGASNRATGIPDRFSGSGS

SVQGRFTISRDNSRNTVFLQM

GTDFTLIISRLEPEDFALYYCQQY

NSLRAEDTAMYYCARDRGTK

GSSPGTFGQGTKVDIKRTVAAPS

WNQLNDVFDMWGQGTMVTV

VFIFPPSDEQLKSGTASVVCLLNN

SSASTKGPSVFPLAPSSKSTS

FYPREAKVQWKVDNALQSGNSQ

GGTAALGCLVKDYFPEPVTVS

ESVTEQDSKDSTYSLSSTLTLSK

WNSGALTSGVHTFPAVLQSS

ADYEKHKVYACEVTHQGLSSPVT

GLYSLSSVVTVPSSSLGTQTYI

KSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1591
DVVMTQSPATLSLSPGERATLSC

1483
SCKASGYTFTSYYMHWVRQA

RASQSVSSYLAWYQQKPGQAPR

PGQGLEWMGIINPSGGSTSY

LLIYDASNRATGIPARFSGSGSGT

AQKFQGRVTMTRDTSTSTVY

DFTLTISSLEPEDFAVYYCQQRS

MELSSLRSEDTAVYYCARGR

NWPRTFGQGTKLEIKRTVAAPSV

GYSSSRLYYFDYWGQGTLVT

FIFPPSDEQLKSGTASVVCLLNNF

VSSASTKGPSVFPLAPSSKST

YPREAKVQWKVDNALQSGNSQE

SGGTAALGCLVKDYFPEPVTV

SVTEQDSKDSTYSLSSTLTLSKA

SWNSGALTSGVHTFPAVLQS

DYEKHKVYACEVTHQGLSSPVTK

SGLYSLSSVVTVPSSSLGTQT

SFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QVTLKESGGGLVRPGGSLRL
SEQ ID 1592
EIVLTQSPDSLAVSLGERATITCK

1484
SCEASGFTFSDPYMDWRQA

SSRNILYSGNNKNFLAWYQHKP

PGKGLEWVGRITNKRTGYATT

GQPPKLLIYWASTRESGVPDRFS

YAASVKDRFTISRDDSRKSVY

GSGSGTDFTLTINSLEAEDAATY

LQMNSLKTEDTAVYYCATDVS

YCHQSSSLPHTFGPGTKVDIKRT

GSFAAYGGQGTLVTVSSAST

VAAPSVFIFPPSDEQLKSGTASV

KGPSVFPLAPSSKSTSGGTAA

VCLLNNFYPREAKVQWKVDNAL

LGCLVKDYFPEPVTVSWNSG

QSGNSQESVTEQDSKDSTYSLS

ALTSGVHTFPAVLQSSGLYSL

STLTLSKADYEKHKVYACEVTHQ

SSVVTVPSSSLGTQTYICNVN

GLSSPVTKSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGVVQPGRSLRL
SEQ ID 1593
ETTLTQSPGTLSLSPGQRATLSC

1485
SCAASGFTFSSYAMHWVRQA

RASESVSKSYLLWYQQKPGQAP

PGQRLEWMGWINAGNGNTK

RLLIYGASTRASGIPNRFSGSGS

YSQKFQGRVTITRDTSASTAY

GTDFTLTISRLEPEDSAVYYCQH

MELSSLRSEDTAVYYCAGEG

YGSSRTFGQGTRLEIKRTVAAPS

GAVAGTVYWGQGTLVTVSSA

VFIFPPSDEQLKSGTASVVCLLNN

STKGPSVFPLAPSSKSTSGGT

FYPREAKVQWKVDNALQSGNSQ

AALGCLVKDYFPEPVTVSWN

ESVTEQDSKDSTYSLSSTLTLSK

SGALTSGVHTFPAVLQSSGLY

ADYEKHKVYACEVTHQGLSSPVT

SLSSVVTVPSSSLGTQTYICN

KSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVKPGGSLRL
SEQ ID 1594
ETTLTQSPGTLSLSPGERATLSC

1486
SCAASGFTFSNAWMSWVRQ

RASQSISSTYLAWYQQKPGQAP

APGKGLEWVGRIKSKTDGGT

RLLIYGASTRATGIPDRFSGSGS

TDYAAPVKGRFTISRDDSKNT

GTDFTLSISRLEPEDFAVYYCQQ

LYLQMNSLKTEDTAVYYCTTD

YGNSPPGATFGQGTRLEIKRTVA

EYFYWGQGTLVTVSSASTKG

APSVFIFPPSDEQLKSGTASVVCL

PSVFPLAPSSKSTSGGTAALG

LNNFYPREAKVQWKVDNALQSG

CLVKDYFPEPVTVSWNSGALT

NSQESVTEQDSKDSTYSLSSTLT

SGVHTFPAVLQSSGLYSLSSV

LSKADYEKHKVYACEVTHQGLSS

VTVPSSSLGTQTYICNVNHKP

PVTKSFNRGEC

SNTKVDKKVEPKSCDKTHTCP

PCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHE

DPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLH

QDWLNGKEYKCKVSNKALPA

PIEKTISKAKGQPREPQVYTLP

PSREEMTKNQVSLTCLVKGFY

PSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1595
DIQLTQSPSSLSASVGERVTITCR

1487
TCAVYGGSFSGYYWSWIRQP

SSQALRNVVGLGDDLAWYQHTP

PGKGLEWIGEINHSGSTNYNP

GSAPKILIYSTSTLQSGVSSRFSG

SLKSRVTISVDTSKNQFSLKLS

GKSGRDFTLTIDRLQPGDSATYY

SVTAADTAVYYCARVNPGSYT

CLQHHDFPFTFGPGTKVEIKRTV

REVSNFDYWGQGTLVTVSSA

AAPSVFIFPPSDEQLKSGTASVV

STKGPSVFPLAPSSKSTSGGT

CLLNNFYPREAKVQWKVDNALQ

AALGCLVKDYFPEPVTVSWN

SGNSQESVTEQDSKDSTYSLSST

SGALTSGVHTFPAVLQSSGLY

LTLSKADYEKHKVYACEVTHQGL

SLSSVVTVPSSSLGTQTYICN

SSPVTKSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPELVKPSQTLTLT
SEQ ID 1596
DVVMTQSPLSLPVTPGEPASISC

1488
CGISGDSVSSNSVTWNWVRQ

RSSQSLLNSNGYNYLEWYLQKP

SPSRGLEWLGRTYYRSQWYY

GQSPQLLIYLGSNRASGVPDRFS

NYAVSVKSRITISPDTSKNQFS

GSGSGTDFTLKISRVEADDAGVY

LQLNSVTPEDTAVYYCATRGH

YCMQSLQTPLTFGGGTKLEIKRT

NYGVDYWGPGTTVTVSSAST

VAAPSVFIFPPSDEQLKSGTASV

KGPSVFPLAPSSKSTSGGTAA

VCLLNNFYPREAKVQWKVDNAL

LGCLVKDYFPEPVTVSWNSG

QSGNSQESVTEQDSKDSTYSLS

ALTSGVHTFPAVLQSSGLYSL

STLTLSKADYEKHKVYACEVTHQ

SSVVTVPSSSLGTQTYICNVN

GLSSPVTKSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVKPGGSLRL
SEQ ID 1597
ETTLTQSPGTLSLSPGERATLSC

1489
SCAASGFTFSNAWMSWVRQ

RASQSVSSSYLAWYQQKPGQAP

APGKGLEWCRIKSKTDGETT

RLLIYGASSRATGIPDRFSGSGS

DYAAPVKGRFTISRDDSKNTL

GTDFTLTISRLEPEDFAVYYCQQ

YLQMNSLKTEDTAVYHCTTGV

YGSSPRITFGQGTRLEIKRTVAAP

GWSPFQYWGQGTLVTVSSAS

SVFIFPPSDEQLKSGTASVVCLLN

TKGPSVFPLAPSSKSTSGGTA

NFYPREAKVQWKVDNALQSGNS

ALGCLVKDYFPEPVTVSWNS

QESVTEQDSKDSTYSLSSTLTLS

GALTSGVHTFPAVLQSSGLYS

KADYEKHKVYACEVTHQGLSSP

LSSVVTVPSSSLGTQTYICNV

VTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGLVQPGRSLRL
SEQ ID 1598
DVVMTQSPATLSVSPGERATLSC

1490
SCTASGFTFGDYAMSWFRQA

RASQSVSSNLAWYQQKPGQAPR

PGKGLEWVGFIRSKAYGGTT

LLIYGASTRATGIPARFSGSGSGT

EYAASVKGRFTISRDDSKSIAY

EFTLTISSLQSEDFAVYYCQQYN

LQMNSLKTEDTAVYYCTRDD

NWPPMYTFGQGTKLEIKRTVAAP

KIAAAGFTYWYFDLWGRGTLV

SVFIFPPSDEQLKSGTASVVCLLN

TVSSASTKGPSVFPLAPSSKS

NFYPREAKVQWKVDNALQSGNS

TSGGTAALGCLVKDYFPEPVT

QESVTEQDSKDSTYSLSSTLTLS

VSWNSGALTSGVHTFPAVLQ

KADYEKHKVYACEVTHQGLSSP

SSGLYSLSSVVTVPSSSLGTQ

VTKSFNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1599
DVVMTQSPATLSVSPGERVTLSC

1491
SCKASGYTFAAYYLHWVRQA

RASQSVRDNVGWYKQKPGQPP

PGQGLEWMGRISPGNGVTSY

RLVIYGASTRATGIPARISGSGSG

AQKFQGRVTMTGDTSINTVY

TEFTLTISSLQSEDFAVYYCQQFN

MQLNNLISGDTAVYYCAREAA

NWPYTFGQGTKLEIKRTVAAPSV

DDPFDHWGQGALVTVSSAST

FIFPPSDEQLKSGTASVVCLLNNF

KGPSVFPLAPSSKSTSGGTAA

YPREAKVQWKVDNALQSGNSQE

LGCLVKDYFPEPVTVSWNSG

SVTEQDSKDSTYSLSSTLTLSKA

ALTSGVHTFPAVLQSSGLYSL

DYEKHKVYACEVTHQGLSSPVTK

SSVVTVPSSSLGTQTYICNVN

SFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGVVQPGRSLTL
SEQ ID 1600
DIQMTQSPSSLSASVGDRVTITC

1492
SCAASGFTFSSHLMHWVRQA

RASQSISSYLNWYQQKPGKAPN

PGKGLEWVAVISYDGTSKYY

LLIYAASSLHTGVPSRFSGSGSG

GDSVKGRFTISRDNSKNTLYL

TDFTLTISSLQPEDFATYYCQQSY

QMNSLRAEDTAIYYCAKADYK

SIPRTFGQGTKVEIKRTVAAPSVF

YDWGQGTLVTVSSASTKGPS

IFPPSDEQLKSGTASVVCLLNNFY

VFPLAPSSKSTSGGTAALGCL

PREAKVQWKVDNALQSGNSQES

VKDYFPEPVTVSWNSGALTS

VTEQDSKDSTYSLSSTLTLSKAD

GVHTFPAVLQSSGLYSLSSVV

YEKHKVYACEVTHQGLSSPVTKS

TVPSSSLGTQTYICNVNHKPS

FNRGEC

NTKVDKKVEPKSCDKTHTCPP

CPAPELLGGPSVFLFPPKPKD

TLMISRTPEVTCVVVDVSHED

PEVKFNWYVDGVEVHNAKTK

PREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPP

SREEMTKNQVSLTCLVKGFYP

SDIAVEWESNGQPENNYKTT

PPVLDSDGSFFLYSKLTVDKS

RWQQGNVFSCSVMHEALHN

HYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGLVKPGGSLRL
SEQ ID 1601
DVVMTQSPATLSVTPGERATLSC

1493
SCTASGFTFGDYAMSWVRQA

RASQSVNSNVAWYQQKPGQAP

PGKGLEWVGFIRSKAYGGTT

RLLIYDVSTRATDIPARFSGSGSG

EYAASVKGRFTISRDDSKSIAY

TDFTLTISRLDPEDFAVYYCQQC

LQMNSLKTEDTAVYYCTTHRR

ASSPPVTFGGGTKLEIKRTVAAP

PIYDILTGFDYWGQGTLVTVS

SVFIFPPSDEQLKSGTASVVCLLN

SASTKGPSVFPLAPSSKSTSG

NFYPREAKVQWKVDNALQSGNS

GTAALGCLVKDYFPEPVTVS

QESVTEQDSKDSTYSLSSTLTLS

WNSGALTSGVHTFPAVLQSS

KADYEKHKVYACEVTHQGLSSP

GLYSLSSVVTVPSSSLGTQTYI

VTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QLQLQESGGGLVQPGRSLRL
SEQ ID 1602
EIVMTQSPATLSLSPGERATLSC

1494
SCTASGFTFGDYAMSWvRQA

GASQSVSSSYLAWYQQKPGLAP

PGKGLEWVGFIRSKAYGGTT

RLLIYDASSRATGIPDRFSGSGS

EYAASVKGRFTISRDDSKSIAY

GTDFTLTISRLEPEDFAVYYCQQ

LQMNSLKTEDTAVYYCTREDT

YGSSPRVTFGGGTKVDIKRTVAA

MVRGVIPWGQGTLVTVSSAS

PSVFIFPPSDEQLKSGTASVVCLL

TKGPSVFPLAPSSKSTSGGTA

NNFYPREAKVQWKVDNALQSGN

ALGCLVKDYFPEPVTVSWNS

SQESVTEQDSKDSTYSLSSTLTL

GALTSGVHTFPAVLQSSGLYS

SKADYEKHKVYACEVTHQGLSS

LSSVVTVPSSSLGTQTYICNV

PVTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QLQLQESGSGLVKPSQTLSLT
SEQ ID 1603
DVVMTQSPGTLSLSPGERATLSC

1495
CAVSGGSISSGGYSWSWIRQ

RASQSVSSSALAWFQQKPGQAP

PPGKGLEWIGYIYHSGSTYYN

RLLIYDSSSRATGIPDSFSGSGSG

PSLKSRVTISVDRSKNQFSLKL

TEFTLTISSLQPEDFATYYCQQFN

SSVTAADTAVYYCARDRRYY

TYPNTFGQGTKLEIKRTVAAPSV

DSSGYYPAYYFDYWGQGTLV

FIFPPSDEQLKSGTASVVCLLNNF

TVSSASTKGPSVFPLAPSSKS

YPREAKVQWKVDNALQSGNSQE

TSGGTAALGCLVKDYFPEPVT

SVTEQDSKDSTYSLSSTLTLSKA

VSWNSGALTSGVHTFPAVLQ

DYEKHKVYACEVTHQGLSSPVTK

SSGLYSLSSVVTVPSSSLGTQ

SFNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
EVQLVQSGGGLVKPGGSLRL
SEQ ID 1604
DIQMTQSPLSLPVTPGEPASISCR

1496
SCAASGFTFSSYSMNWVRQA

SSQSLLHSNGYNYLDWFLQKPG

PGKGLEWVSYISSSGSYTNYA

QSPRLLIYMGSSRASGVPERFSG

DSVKGRFTISRDNAKNSLYLQI

SGSGTDFTLKISRVEAEDVGVYY

NSLRAEDTAIYYCARDGGYDS

CMQTLHTVTFGGGTKVEIKRTVA

SGFHFDYWGQGTLVTVSSAS

APSVFIFPPSDEQLKSGTASVVCL

TKGPSVFPLAPSSKSTSGGTA

LNNFYPREAKVQWKVDNALQSG

ALGCLVKDYFPEPVTVSWNS

NSQESVTEQDSKDSTYSLSSTLT

GALTSGVHTFPAVLQSSGLYS

LSKADYEKHKVYACEVTHQGLSS

LSSVVTVPSSSLGTQTYICNV

PVTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1605
ETTLTQSPGTLSLSPGERATLSC

1497
TCAISGDSVSNNRAAWNWIR

RASQSVSSSYLAWYQQKPGQAP

QSPSRGLEWLGRTYYRSKWY

RLLIYGASSRATGIPDRFSGSGS

NEYAVSVKSRITINPDTSKNQF

GTDFTLTISRLEPEDFAVYYCQQ

SLQLNSMTPEDSAVYYCAILP

YGSSLLFGQGTRLEIKRTVAAPS

SSGYLQDHHYYGMDVWGQG

VFIFPPSDEQLKSGTASVVCLLNN

TTVTVSSASTKGPSVFPLAPS

FYPREAKVQWKVDNALQSGNSQ

SKSTSGGTAALGCLVKDYFPE

ESVTEQDSKDSTYSLSSTLTLSK

PVTVSWNSGALTSGVHTFPA

ADYEKHKVYACEVTHQGLSSPVT

VLQSSGLYSLSSVVTVPSSSL

KSFNRGEC

GTQTYICNVNHKPSNTKVDKK

VEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRT

PEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1606
DIQLTQSPSFLSASVGDRVTITCR

1498
SCKASGYTFTSYGISWVRQAP

ASQGISSSLAWYQQKPGKAPKLL

GQGLEWMGWISAYNGNTNY

IYAASTLQSGVPSRFSGSGSGTD

AQKLQGRVTMTTDTSTSTAY

FTFTISSLQPEDIATYYCQQYDNL

MELSSLRSEDTAVYYCARAAV

PPLTFGGGTKVEIKRTVAAPSVFI

GDGYSYGRLDWGQGTLVTVS

FPPSDEQLKSGTASVVCLLNNFY

SASTKGPSVFPLAPSSKSTSG

PREAKVQWKVDNALQSGNSQES

GTAALGCLVKDYFPEPVTVS

VTEQDSKDSTYSLSSTLTLSKAD

WNSGALTSGVHTFPAVLQSS

YEKHKVYACEVTHQGLSSPVTKS

GLYSLSSWVTVPSSSLGTQTYI

FNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGESLKIS
SEQ ID 1607
DVVMTQSPLSLPVTPGEPASISC

1499
CKGSGYSFTSYWIGWVRQMP

RSSQSLLHSNGYNYLDWYLQKP

GKGLEWMGIIYPGDSDTRYSP

GQSPQLLIYLGSNRASGVPDRFS

SFQGQVTISADKSISTAYLQW

GSGSGTDFTVKISRVEAEDVGVY

SSLKASDTAMYYCARLPSYYY

YCMQALQTPYTFGQGTKLEIKRT

DSSGYFTWYFDLWGRGTLVT

VAAPSVFIFPPSDEQLKSGTASV

VSSASTKGPSVFPLAPSSKST

VCLLNNFYPREAKVQWKVDNAL

SGGTAALGCLVKDYFPEPVTV

QSGNSQESVTEQDSKDSTYSLS

SWNSGALTSGVHTFPAVLQS

STLTLSKADYEKHKVYACEVTHQ

SGLYSLSSVVTVPSSSLGTQT

GLSSPVTKSFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1608
EIVLTQSPLSLPVTLGQPASISCR

1500
SCKASGYTFTSYGISWVRQAP

SCQSLVYSDGNTYLNCFQQRPG

GQGLEWMGWIIPIFGIANYAQ

QSPRRLIYKVSNRDSGVPDRFSG

KFQGRVTITADKSTSTAYMEL

SGSGTDFTLEISRVEAEDVGIYFC

SSLRSEDTAVYYCARELYNYG

MQGLQTPFTFGPGTKVDIKRTVA

SKDYFDYWGQGTLVTVSSAS

APSVFIFPPSDEQLKSGTASVVCL

TKGPSVFPLAPSSKSTSGGTA

LNNFYPREAKVQWKVDNALQSG

ALGCLVKDYFPEPVTVSWNS

NSQESVTEQDSKDSTYSLSSTLT

GALTSGVHTFPAVLQSSGLYS

LSKADYEKHKVYACEVTHQGLSS

LSSVTVPSSSLGTQTYICNV

PVTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGESLKIS
SEQ ID 1609
DVVMTQSPGTLSLSPGERATLSC

1501
CKGSGYSFTSYWIGWVRQMP

RASQSVSSSYLAWYQQKPGQAP

GKGLEWMGIIYPGDSDTRYSP

RLLIYGASSRATGIPDRFSGSGS

SFQGQVTISADKSISTAYLQW

GTDFTLTISRLEPEDFAVYYCQQ

SSLKASDTAMYYCARGGTWD

YGSSPALTFGGGTKLEIKRTVAA

TAMVTGFDYWGQGTLVTVSS

PSVFIFPPSDEQLKSGTASVVCLL

ASTKGPSVFPLAPSSKSTSGG

NNFYPREAKVQWKVDNALQSGN

TAALGCLVKDYFPEPVTVSWN

SQESVTEQDSKDSTYSLSSTLTL

SGALTSGVHTFPAVLQSSGLY

SKADYEKHKVYACEVTHQGLSS

SLSSVVTVPSSSLGTQTYICN

PVTKSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGESLKIS
SEQ ID 1610
EIVMTQSPLSLPVTPGEPASISCR

1502
CKGSGYSFTSYWIAWVRQMP

SSQSLLHSNGYNYLDWYLQKPG

GKGLEWMGVIYPGDSDTRYS

QSPQLLIYLGSTRASGVPDRFSG

PSFQGQVTISADKSINTAYLQ

SGSGTDFTLKISRAEAEDVGVYY

WSSLKASDTAMYYCARPHYDI

CMQALHTPWTFGLGTKVDIKRTV

LTGSRAPFDYWGQGTLVTVS

AAPSVFIFPPSDEQLKSGTASVV

SASTKGPSVFPLAPSSKSTSG

CLLNNFYPREAKVQWKVDNALQ

GTAALGCLVKDYFPEPVTVS

SGNSQESVTEQDSKDSTYSLSST

WNSGALTSGVHTFPAVLQSS

LTLSKADYEKHKVYACEVTHQGL

GLYSLSSVVTVPSSSLGTQTYI

SSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1611
DIQMTQSPATLSVSPGERATLFC

1503
TCAVYGGSFSGYYWSWIRQP

RASEGLTTNLAWYQHKPGQAPR

PGKGLEWIGEINHSGSTNYNP

LLIYAASTRATGVPARFSGSGSG

SLKSRVTISVDTSKNQFSLKLS

TDFTLTISSLQSEDSAVYYCQQY

SVTAADTAVYYCARARVESKD

NHWPLYTFGQGTKVEIKRTVAAP

GYFDYWGQGTLVTVSSASTK

SVFIFPPSDEQLKSGTASVVCLLN

GPSVFPLAPSSKSTSGGTAAL

NFYPREAKVQWKVDNALQSGNS

GCLVKDYFPEPVTVSWNSGA

QESVTEQDSKDSTYSLSSTLTLS

LTSGVHTFPAVLQSSGLYSLS

KADYEKHKVYACEVTHQGLSSP

SVVTVPSSSLGTQTYICNVNH

VTKSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
EVQLVESGGGVVQPGRSLRL
SEQ ID 1612
DIQLTQSPSTLSLSPGERATLSCR

1504
SCAASGFTFTDAWMNWVRQ

ASQSVSSYLAWYQQKSGQAPRL

APGKGLEWIGRVKNKADGET

LIYDASNRATGIPARFSGSGSGT

TDYAAPVKGRITISRDDAKNTL

DFTLTISSLEPEDFAVYYCQQGS

YVQMNSLKTEDTAVYYCTADL

NWPLTFGGGTKVEIKRTVAAPSV

RLSTWDAYDFWGQGTMVTV

FIFPPSDEQLKSGTASVVCLLNNF

SSASTKGPSVFPLAPSSKSTS

YPREAKVQWKVDNALQSGNSQE

GGTAALGCLVKDYFPEPVTVS

SVTEQDSKDSTYSLSSTLTLSKA

WNSGALTSGVHTFPAVLQSS

DYEKHKVYACEVTHQGLSSPVTK

GLYSLSSVVTVPSSSLGTQTYI

SFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QITLKESGGGLVQPGGSLRLS
SEQ ID 1613
DIVMTHTPLSSPVTLGQPASISCR

1505
CTVSGFTFSNNWMTWVRQTP

SSQSLEHTDGNTYLSWLHQRPG

GKGLEWANIKQDGTEKHYV

QPPRLLIYKVSTRFSGVPDRFSG

DSVKGRFTISRDNAENSLYLQ

SGAGTDFTLKISRVEAEDVGVYY

MNSLRGEDTAVYYCARNSQR

CVQATHYPRTFGHGTKVEIKRTV

SFDYWGQGTLVTVSSASTKG

AAPSVFIFPPSDEQLKSGTASVV

PSVFPLAPSSKSTSGGTAALG

CLLNNFYPREAKVQWKVDNALQ

CLVKDYFPEPVTVSWNSGALT

SGNSQESVTEQDSKDSTYSLSST

SGVHTFPAVLQSSGLYSLSSV

LTLSKADYEKHKVYACEVTHQGL

VTVPSSSLGTQTYICNVNHKP

SSPVTKSFNRGEC

SNTKVDKKVEPKSCDKTHTCP

PCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHE

DPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLH

QDWLNGKEYKCKVSNKALPA

PIEKTISKAKGQPREPQVYTLP

PSREEMTKNQVSLTCLVKGFY

PSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1614
EIVLTQSPGTLSLSPGERATLSCR

1506
SCAASGFTFSSYAMHWVRQA

ASQSISGSYLAWYQQKRGQAPR

PGKGLEWVAVISYDGSNKYY

LLIYDASSRAEGIPDRFIGSGSGT

ADSVKGRFTISRDNSKNTLYL

DFTLTISRLEPEDFAMYYCQQYG

QMNSLRAEDTAVYYCAKDLG

SSPIFTFGPGTKVDIKRTVAAPSV

DPRGGILNYWGQGTLVTVSS

FIFPPSDEQLKSGTASVVCLLNNF

ASTKGPSVFPLAPSSKSTSGG

YPREAKVQWKVDNALQSGNSQE

TAALGCLVKDYFPEPVTVSWN

SVTEQDSKDSTYSLSSTLTLSKA

SGALTSGVHTFPAVLQSSGLY

DYEKHKVYACEVTHQGLSSPVTK

SLSSVVTVPSSSLGTQTYICN

SFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVESGGGVVQPGRSLRL
SEQ ID 1615
EIVLTQSPDSLPVTPGEPASISCR

1507
SCAASGFTFSSYAMHWVRQA

SSQSLLHSNGNNYLDWYLQKPG

PGKGLEWVAVISYDGSNKYY

QSPQLLIYLGSNRASGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGSGTDFTLKLSRVEAEDVGVYY

QMNSLRAEDTAVYYCARSSP

CMQGLQIPITFGPGTKVDIKRTVA

WGELSLYQGAFDIWGQGTMV

APSVFIFPPSDEQLKSGTASVVCL

TVSSASTKGPSVFPLAPSSKS

LNNFYPREAKVQWKVDNALQSG

TSGGTAALGCLVKDYFPEPVT

NSQESVTEQDSKDSTYSLSSTLT

VSWNSGALTSGVHTFPAVLQ

LSKADYEKHKVYACEVTHQGLSS

SSGLYSLSSVVTVPSSSLGTQ

PVTKSFNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
QITLKESGGGLVQPGRSLRLS
SEQ ID 1616
DIQMTQSPSSVSASVGDRVTITC

1508
CAASGFTFDDYAMHWVRQAP

RASQNIRHWLVWYQQKLGQAPK

GKGLEWVSAISGSGGSTYYA

LLIYAASNLQSGVPSRFSGSGSG

DSVKGRFTISRDNSKNTLYLQ

TEFTLTINSLQAEDFATYYCLQHN

MNSLRAEDTAVYYCAKDNDF

SYPWTFGQGTKVEIKRTVAAPSV

WSGKVFDYWGQGTLVTVSSA

FIFPPSDEQLKSGTASVVCLLNNF

STKGPSVFPLAPSSKSTSGGT

YPREAKVQWKVDNALQSGNSQE

AALGCLVKDYFPEPVTVSWN

SVTEQDSKDSTYSLSSTLTLSKA

SGALTSGVHTFPAVLQSSGLY

DYEKHKVYACEVTHQGLSSPVTK

SLSSVVTVPSSSLGTQTYICN

SFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGLVQPGGSLRL
SEQ ID 1617
EIVLTQSPDFQSVTPKQKVTITCR

1509
SCAASGFTFSSYSMNWVRQA

ASQSIGGSLHWYQQKPGQSPKLI

PGKGLEWSYISSTSSTIYYA

IKYASQSFSGVPSRFSGSGSGTD

DSVKGRFTISRDNSKNMLFLQ

FTLTIDSLEAEDAATYYCHQSISL

MNSLRAEDTAVYYCAKEGGS

PLTFGGGTKVDIKRTVAAPSVFIF

GWRHYFDYWGQGTLVTVSS

PPSDEQLKSGTASVVCLLNNFYP

ASTKGPSVFPLAPSSKSTSGG

REAKVQWKVDNALQSGNSQESV

TAALGCLVKDYFPEPVTVSWN

TEQDSKDSTYSLSSTLTLSKADY

SGALTSGVHTFPAVLQSSGLY

EKHKVYACEVTHQGLSSPVTKSF

SLSSVVTVPSSSLGTQTYICN

NRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1618
ETTLTQSPGTLSLSPGEGATLSC

1510
SCAASGFTFSSYAMHWVRQA

RASQSVTSNYLAWYQQKPGQAP

PGKGLEWAVISYDGSNKYY

RLLIYGASYRATGIPDRFSGSGS

ADSVKGRFTISRDNSKNTLYL

GTDFTLTISRLEPEDFAVYYCQQ

QMNSLRAEDTAVYYCARDYC

YASSVTFGQGTRLEIKRTVAAPS

SSTSCQNWFDPWGQGTLVTV

VFIFPPSDEQLKSGTASVVCLLNN

SSASTKGPSVFPLAPSSKSTS

FYPREAKVQWKVDNALQSGNSQ

GGTAALGCLVKDYFPEPVTVS

ESVTEQDSKDSTYSLSSTLTLSK

WNSGALTSGVHTFPAVLQSS

ADYEKHKVYACEVTHQGLSSPVT

GLYSLSSVVTVPSSSLGTQTYI

KSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVQPGGSLRL
SEQ ID 1619
DVVMTQSPATLSVSPGERATLSC

1511
SCAASGFTFSNYVMSWVRQA

RASQSISSNLAWYQQKPGQAPR

PGKGLEWSAISGIGDTTYYA

LLIYGASTRATGIPARFSGSGSGT

DSVKGRFTISRDNAKNTLYLQ

EFTLTISSLQSEDFAVYYCQQYN

MNSLRAEDTAVYYCARGRVA

NWPRTFGQGTKLEIKRTVAAPSV

GDAFDIWGQGTMVTVSSAST

FIFPPSDEQLKSGTASVVCLLNNF

KGPSVFPLAPSSKSTSGGTAA

YPREAKVQWKVDNALQSGNSQE

LGCLVKDYFPEPVTVSWNSG

SVTEQDSKDSTYSLSSTLTLSKA

ALTSGVHTFPAVLQSSGLYSL

DYEKHKVYACEVTHQGLSSPVTK

SSVVTVPSSSLGTQTYICNVN

SFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QLQLQESGGGLVQPGGSLRL
SEQ ID 1620
DIQLTQSPDSLAVSLGERATINCK

1512
SCAASGFTFSSYAMSWRQA

SSQSVLYSSNNKNYLAWYQQKP

PGKGLEWSAISGSGGSTYY

GQPPKLLIYWASARESGVPDRFS

ADSVKGRFTISRDNSKNTLYL

GSGSGTDFTLTINSLQAEDVAVY

QMNSLRAEDTAVYYCAKDQG

YCQQFYSPPRTFGQGTKVEIKRT

AAAGTLGYFDYWGQGTLVTV

VAAPSVFIFPPSDEQLKSGTASV

SSASTKGPSVFPLAPSSKSTS

VCLLNNFYPREAKVQWKVDNAL

GGTAALGCLVKDYFPEPVTVS

QSGNSQESVTEQDSKDSTYSLS

WNSGALTSGVHTFPAVLQSS

STLTLSKADYEKHKVYACEVTHQ

GLYSLSSVVTVPSSSLGTQTYI

GLSSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1621
EIVLTQSPGTLSLSPGERATLSCR

1513
SCKASGYTFTSYDINWRQAT

ASQSVSSSYLAWYQQKPGQAPR

GQGLEWMGWMNPNSGNTG

LLIYGASSRATGIPDRFSGSGSGT

YAQKFQGRVTMTRNTSISTAY

DFTLTISRLEPEDFAVYYCQQYG

MELSSLRSEDTAVYYCTRGIY

SSPPGTFGGGTKVDIKRTVAAPS

DSSGSSNPFDSWGQGTLVTV

VFIFPPSDEQLKSGTASVVCLLNN

SSASTKGPSVFPLAPSSKSTS

FYPREAKVQWKVDNALQSGNSQ

GGTAALGCLVKDYFPEPVTVS

ESVTEQDSKDSTYSLSSTLTLSK

WNSGALTSGVHTFPAVLQSS

ADYEKHKVYACEVTHQGLSSPVT

GLYSLSSVVTVPSSSLGTQTYI

KSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKIS
SEQ ID 1622
EIVLTQSPGTLSLSPGERATLSCR

1514
CEASGYTFTDYAIHWVRQAP

ASQSLSTNLAWYQQKPGQAPRL

GQRLEWMGWINAGDGGTKS

LIYGASTRATGIPARFSGSGSGTE

SREFQGRVTITRDTSATTAYM

FTLTITSLQSEDFAVYYCQQYHN

EVSSLRSEDTAVYYCARGYC

WPPYTFGQGTKVEIKRTVAAPSV

SGGSCPGTDFDYWGQGTLVT

FIFPPSDEQLKSGTASVVCLLNNF

VSSASTKGPSVFPLAPSSKST

YPREAKVQWKVDNALQSGNSQE

SGGTAALGCLVKDYFPEPVTV

SVTEQDSKDSTYSLSSTLTLSKA

SWNSGALTSGVHTFPAVLQS

DYEKHKVYACEVTHQGLSSPVTK

SGLYSLSSVVTVPSSSLGTQT

SFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1623
DIQMTQSPSTLSASVGDRVTITC

1515
SCKASGYTFTSYYMHWVRQA

RASQSISSWLAWYQQKPGKAPK

PGQGLEWMGIINPSGGSTSY

LLIYKASSLESGVPSRFSGSGSG

AQKFQGRVTMTRDTSTSTVY

TEFTLTISSLQPDDFATYYCQQY

MELSSLRSEDTAVYYCARDG

NSYWTFGQGTKVEIKRTVAAPSV

VGGRDGYNFDYWGQGTLVT

FIFPPSDEQLKSGTASVVCLLNNF

VSSASTKGPSVFPLAPSSKST

YPREAKVQWKVDNALQSGNSQE

SGGTAALGCLVKDYFPEPVTV

SVTEQDSKDSTYSLSSTLTLSKA

SWNSGALTSGVHTFPAVLQS

DYEKHKVYACEVTHQGLSSPVTK

SGLYSLSSVVTVPSSSLGTQT

SFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
EVQLVQSGGGLVQPGGSLRL
SEQ ID 1624
ETTLTQSPGTLSLSPGEGATLSC

1516
SCAASGFTVSSNYMSWVRQA

RASHSVGANYIAWYQQKPGQAP

PGKGLEWSVIYSGGSTYYA

RLLIHTASKRATGVPERFSGSGS

DSVKGRFTISRDNSKNTLYLQ

GTDFTLSISRLEPEDFAVYHCQQ

MNSLRAEDTAVYYCARAPLAA

YAAAPITFGQGTRLEIKRTVAAPS

DGYFDYWGQGTLVTVSSAST

VFIFPPSDEQLKSGTASVVCLLNN

KGPSVFPLAPSSKSTSGGTAA

FYPREAKVQWKVDNALQSGNSQ

LGCLVKDYFPEPVTVSWNSG

ESVTEQDSKDSTYSLSSTLTLSK

ALTSGVHTFPAVLQSSGLYSL

ADYEKHKVYACEVTHQGLSSPVT

SSVVTVPSSSLGTQTYICNVN

KSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGSSVKV
SEQ ID 1625
EIVMTQSPSSLSASVGDRVIITCR

1517
SCKASGGTFSSYAISWVRQA

ASQGIANYLAWYQQKPGKGPKL

PGQGLEWMGGIIPIFGTANYA

LIYASSTLQSGVPSRFSGSGSGT

QKFQGRVTITADESTSTAYME

DFTLTISGLQPEDVATYYCQKYN

LSSLRSEDTAVYYCARARGLQ

SVPLTFGGGTKVDIKRTVAAPSV

YLIWYFDLWGRGTLVTVSSAS

FIFPPSDEQLKSGTASVVCLLNNF

TKGPSVFPLAPSSKSTSGGTA

YPREAKVQWKVDNALQSGNSQE

ALGCLVKDYFPEPVTVSWNS

SVTEQDSKDSTYSLSSTLTLSKA

GALTSGVHTFPAVLQSSGLYS

DYEKHKVYACEVTHQGLSSPVTK

LSSVVTVPSSSLGTQTYICNV

SFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1626
DVVMTQSPVSLAVSLGERATINC

1518
SCKASGYTFTSYYMHWVRQA

KSSQSVLYRTNNKNYLAWYQQK

PGQGLEWMGIINPSGGSTSY

PGQPPKLLIYWASTRESGVPDRF

AQKFQGRVTMTRDTSTSTVY

SGSGSGTDFTLTISSLQPEDVAV

MELSSLRSEDTAVYYCASPG

YYCQQYYNLPRSFGQGTKLEIKR

MVRGVITAPLDYWGQGTLVT

TVAAPSVFIFPPSDEQLKSGTASV

VSSASTKGPSVFPLAPSSKST

VCLLNNFYPREAKVQWKVDNAL

SGGTAALGCLVKDYFPEPVTV

QSGNSQESVTEQDSKDSTYSLS

SWNSGALTSGVHTFPAVLQS

STLTLSKADYEKHKVYACEVTHQ

SGLYSLSSVVTVPSSSLGTQT

GLSSPVTKSFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
EVQLVQSGGGLVKPGGSLRL
SEQ ID 1627
DIVMTHTPDSLAVSLGERATINCK

1519
SCAASGFTFSSYAISWVRQAP

SNRSVLYSPNNQNYLGWYQQKP

GQGLEWMGGIIPMYGTANYA

GQPPKLLIYWASTRDSGAPDRFS

QKFQGRVTITADESTSTAYME

GSGSGTDFTLTINSLQAEDVAVY

LSSLRSEDTALYYCAREAKW

YCQQYASTPYTFGQGTKVEIKRT

GMYYFDYWGQGTLVTVSSAS

VAAPSVFIFPPSDEQLKSGTASV

TKGPSVFPLAPSSKSTSGGTA

VCLLNNFYPREAKVQWKVDNAL

ALGCLVKDYFPEPVTVSWNS

QSGNSQESVTEQDSKDSTYSLS

GALTSGVHTFPAVLQSSGLYS

STLTLSKADYEKHKVYACEVTHQ

LSSVVTVPSSSLGTQTYICNV

GLSSPVTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVESGGGWVQPGRSLRL
SEQ ID 1628
DVVMTQSPATLSLSPGERATLSC

1520
SCAASGFTFSSYAIHWVRQAP

RASESVNSNFLAWYQQKPGQAP

GKGLEWVAIISDDGSKSYYAD

RLLIYAASTRATGIPARFSGSGSG

SVQGRFTISRDNSRNTVYLQM

TEFTLIITSLQSEDFAVYYCQQYN

NSLRAEDTAMYYCARDRGTK

NWPLTFGGGTKLEIKRTVAAPSV

WNQLNDVFDMWGQGTMVTV

FIFPPSDEQLKSGTASVVCLLNNF

SSASTKGPSVFPLAPSSKSTS

YPREAKVQWKVDNALQSGNSQE

GGTAALGCLVKDYFPEPVTVS

SVTEQDSKDSTYSLSSTLTLSKA

WNSGALTSGVHTFPAVLQSS

DYEKHKVYACEVTHQGLSSPVTK

GLYSLSSVVTVPSSSLGTQTYI

SFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QMQLVQSGAEVKKPGASVKV
SEQ ID 1629
DVVMTQSPATLSLSPGERATLSC

1521
SCTASGYTFTSSDINWVRQAT

RASQSVSSYLAWYQQKPGQAPR

GQGLEWMGWMNPNSGNTG

LLIYDASNRATGIPARFSGSGSGT

YAEKFQGRVTMTSDSSISTAY

DFTLTISSLEPEDFAVYYCQQRS

MELRSLTTEDTAVYYCARGG

NWSLTFGGGTKLEIKRTVAAPSV

GASYTDSWGQGTLVTVSSAS

FIFPPSDEQLKSGTASVVCLLNNF

TKGPSVFPLAPSSKSTSGGTA

YPREAKVQWKVDNALQSGNSQE

ALGCLVKDYFPEPVTVSWNS

SVTEQDSKDSTYSLSSTLTLSKA

GALTSGVHTFPAVLQSSGLYS

DYEKHKVYACEVTHQGLSSPVTK

LSSVVTVPSSSLGTQTYICNV

SFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVQPGRSLRL
SEQ ID 1630
ETTLTQSPGTLSLSPGERATLSC

1522
SCTASGFTFGDYAMSWFRQA

RASQSVSSSYLAWYQQKPGQAP

PGKGLEWVGFIRSKAYGGTT

RLLIYGASTRATGIPDRFSGSGS

EYAASVKGRFTISRDDSKSIAY

GTDFTLTIGRLEPEDFAVYYCQH

LQMNSLKTEDTAVYYCTAKG

YGPSRRITFGQGTRLEIKRTVAAP

GYVGYSYGPFGGYWGQGTL

SVFIFPPSDEQLKSGTASVVCLLN

VTVSSASTKGPSVFPLAPSSK

NFYPREAKVQWKVDNALQSGNS

STSGGTAALGCLVKDYFPEPV

QESVTEQDSKDSTYSLSSTLTLS

TVSWNSGALTSGVHTFPAVL

KADYEKHKVYACEVTHQGLSSP

QSSGLYSLSSVVTVPSSSLGT

VTKSFNRGEC

QTYICNVNHKPSNTKVDKKVE

PKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEV

TCVVVDVSHEDPEVKFNWYV

DGVEVHNAKTKPREEQYNST

YRVVSVLTVLHQDWLNGKEY

KCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWE

SNGQPENNYKTTPPVLDSDG

SFFLYSKLTVDKSRWQQGNV

FSCSVMHEALHNHYTQKSLSL

SPGK

SEQ ID
QVQLVQSGGGLVQPGRSLRL
SEQ ID 1631
ETTLTQSPDTLSVSPGGRATLSC

1523
SCTASGFTFGDYAMSWFRQA

RASQSIGSNLAWYQQKPGQSPR

PGKGLEWVGFIRSKAYGGTT

LLIYDASTRATGIPARFSGSGSGT

EYAASVKGRFTISRDDSKSIAY

EFTLTISSLESEDFVLYYCQQHGE

LQMNSLKTEDTAVYYCTRGG

WPTFGQGTRLEIKRTVAAPSVFIF

TMVRGFGFNYWGQGTLVTVS

PPSDEQLKSGTASVVCLLNNFYP

SASTKGPSVFPLAPSSKSTSG

REAKVQWKVDNALQSGNSQESV

GTAALGCLVKDYFPEPVTVS

TEQDSKDSTYSLSSTLTLSKADY

WNSGALTSGVHTFPAVLQSS

EKHKVYACEVTHQGLSSPVTKSF

GLYSLSSVVTVPSSSLGTQTYI

NRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1632
DVVMTQSPATLSLSPGERATLSC

1524
TCAVYGGSFSGYYWSWIRQP

RASQSVGNSLAWYQQKPGQAP

PGKGLEWIGEINHSGSTNYNP

RLLIYDASNRATGIPARFSGSGS

SLKSRVTISVDTSKNQFSLKLS

GTDFTLTITSLEPEDFAIYYCQQR

SVTAADTAVYYCARARRAMIG

GTWPPLTFGGGTKLEIKRTVAAP

PLPRLVGYFDLWGRGTLVTVS

SVFIFPPSDEQLKSGTASVVCLLN

SASTKGPSVFPLAPSSKSTSG

NFYPREAKVQWKVDNALQSGNS

GTAALGCLVKDYFPEPVTVS

QESVTEQDSKDSTYSLSSTLTLS

WNSGALTSGVHTFPAVLQSS

KADYEKHKVYACEVTHQGLSSP

GLYSLSSVVTVPSSSLGTQTYI

VTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1633
DVVMTQSPSSLSASVGDTVTITC

1525
TCAVYGGSFSGYYWSWIRQP

RASQSITNWLAWYQQKPGKAPK

PGKGLEWIGEINHSGSTNYNP

RLIYGASSLQSGVPSRFSGSGSG

SLKSRVTISVDTSKNQFSLKLS

TEFTLTISSLQPEDFATYYCQQYT

SVTAADTAVYYCARGRPAPS

NYPRTFGQGTKLEIKRTVAAPSV

WVKTRNWFDPWGQGTLVTV

FIFPPSDEQLKSGTASVVCLLNNF

SSASTKGPSVFPLAPSSKSTS

YPREAKVQWKVDNALQSGNSQE

GGTAALGCLVKDYFPEPVTVS

SVTEQDSKDSTYSLSSTLTLSKA

WNSGALTSGVHTFPAVLQSS

DYEKHKVYACEVTHQGLSSPVTK

GLYSLSSVVTVPSSSLGTQTYI

SFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1634
DIQMTQSPSTLSASVGDRVTITC

1526
TCAISGDSVSSNSAAWNWIR

RARQSISNRLAWYQQKPGRAPN

QSPSRGLEWLGRTYYRSKWY

VLIYKASTLANGVPSRFSGSGSG

NDYAVSVKSRITINPDTSKNQF

TEFTLTISSLQPDDFATYYCQQY

SLQLNSVTPEDTAVYYCAREA

QSYWTFGPGTKVEIKRTVAAPSV

SSGWNWGQGTLVTVSSASTK

FIFPPSDEQLKSGTASVVCLLNNF

GPSVFPLAPSSKSTSGGTAAL

YPREAKVQWKVDNALQSGNSQE

GCLVKDYFPEPVTVSWNSGA

SVTEQDSKDSTYSLSSTLTLSKA

LTSGVHTFPAVLQSSGLYSLS

DYEKHKVYACEVTHQGLSSPVTK

SVVTVPSSSLGTQTYICNVNH

SFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QVQLQESGPGLVKPSQTLSLT
SEQ ID 1635
DIQLTQSPATLSLSPGERATLSCK

1527
CAISGDSVSSNNAAWNWIRQ

ASQSVSSYLAWYQQKLGQAPRL

SPSRGLEWLGRTFYRSKWYN

LIYDASNRATGIPARFSASGSGTD

DYAVSVKSRLTVNPDTSKNQF

FTLTISSLQPEDVATYYCQKYNSP

SLRLNSVSPEDTAVYYCARG

PRTFGQGTKVEIKRTVAAPSVFIF

GRYTKGGYFDDWGQGTLVTV

PPSDEQLKSGTASVVCLLNNFYP

SSASTKGPSVFPLAPSSKSTS

REAKVQWKVDNALQSGNSQESV

GGTAALGCLVKDYFPEPVTVS

TEQDSKDSTYSLSSTLTLSKADY

WNSGALTSGVHTFPAVLQSS

EKHKVYACEVTHQGLSSPVTKSF

GLYSLSSVVTVPSSSLGTQTYI

NRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGPTLVKPTQTLTLT
SEQ ID 1636
ETTLTQSPGTLSLSPGERVSLSC

1528
CTFSGFSLSTSGVGVGWIRQ

RASQNVYSNFLAWYQQRPGQAP

PPGKALEWLALIYWDDDKRYS

SLLIYGASSRAAGVPDRFSGSGS

PSLKSRLTITKDTSKNQVVLTM

GTDFALTISRVEPEDFAVYYCQQ

TNMDPVDTATYYCAHRLDSS

YGTSPITFGQGTRLEIKRTVAAPS

GRGGYFDYWGQGTLVTVSSA

VFIFPPSDEQLKSGTASVVCLLNN

STKGPSVFPLAPSSKSTSGGT

FYPREAKVQWKVDNALQSGNSQ

AALGCLVKDYFPEPVTVSWN

ESVTEQDSKDSTYSLSSTLTLSK

SGALTSGVHTFPAVLQSSGLY

ADYEKHKVYACEVTHQGLSSPVT

SLSSVVTVPSSSLGTQTYICN

KSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVESGGGVVQPGRSLRL
SEQ ID 1637
EIVLTQSPRSSPVTLGQPASISCR

1529
SCTASGFTFSSYGMHWRQA

SSQSLEHGDGNTYLSWLQQRPG

PGKGLEWVAVISYDGSNKYY

QPPRLLIYKVSNRLSGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGAGTDFTLKISRVEAEDVGVYY

QMNSLRAEDTAVYYCAKELV

CMQGIYWPRTFGQGTRLEIKRTV

GTSSPYYYYYYGMDVWGQG

AAPSVFIFPPSDEQLKSGTASVV

TMVTVSSASTKGPSVFPLAPS

CLLNNFYPREAKVQWKVDNALQ

SKSTSGGTAALGCLVKDYFPE

SGNSQESVTEQDSKDSTYSLSST

PVTVSWNSGALTSGVHTFPA

LTLSKADYEKHKVYACEVTHQGL

VLQSSGLYSLSSVVTVPSSSL

SSPVTKSFNRGEC

GTQTYICNVNHKPSNTKVDKK

VEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRT

PEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
QLQLQESGGGLVQPGGSLRL
SEQ ID 1638
ETTLTQSPVTLSLSPGDRATLSC

1530
SCAASGFTVSSNYMSWVRQA

RASQSVSSTSLAWYQHKPGQAP

PGKGLEWVSVIYSGGSTYYA

RLLIYGASRRATGIPDRFSGSGS

DSVKGRFTISRDNSKNTLYLQ

GTDFTLTINRLEPEDFAVYYCQH

MNSLRAEDTAVYYCARDYYY

YGSSPPITFGQGTRLEIKRTVAAP

GSGSSPWGQGTLVTVSSAST

SVFIFPPSDEQLKSGTASVVCLLN

KGPSVFPLAPSSKSTSGGTAA

NFYPREAKVQWKVDNALQSGNS

LGCLVKDYFPEPVTVSWNSG

QESVTEQDSKDSTYSLSSTLTLS

ALTSGVHTFPAVLQSSGLYSL

KADYEKHKVYACEVTHQGLSSP

SSVVTVPSSSLGTQTYICNVN

VTKSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1639
ETTLTQSPATLSVSPGERATLSC

1531
TCAVYGGSFSGYYWSWIRQP

RASQSVGSKLAWYQQKPGQAP

PGKGLEWIGEINHSGSTNYNP

RLLIYGASTRATGVPVRFSGSGS

SLKSRVTISVDTSKNQFSLKLS

GTEFTLTISSLQSEDFAVYYCQQ

SVTAADTAVYYCARGRPYCS

YNNWPPITFGQGTRLEIKRTVAA

STSCYPEWFDPWGQGTLVTV

PSVFIFPPSDEQLKSGTASVVCLL

SSASTKGPSVFPLAPSSKSTS

NNFYPREAKVQWKVDNALQSGN

GGTAALGCLVKDYFPEPVTVS

SQESVTEQDSKDSTYSLSSTLTL

WNSGALTSGVHTFPAVLQSS

SKADYEKHKVYACEVTHQGLSS

GLYSLSSVVTVPSSSLGTQTYI

PVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1640
EIVLTQSPLSLPVTPGEPASISCR

1532
SCAASGFTFSSYGMHWVRQA

SSQSLLHSNGYNYLDWYLQKPG

PGKGLEWVAVISYDGSNKYY

QSPQLLIYLGSNRASGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGSGTDFTLKISRVEAEDVGVYY

QMNSLRAEDTAVYYCAKLRGI

CMQTLQTPLTFGGGTKVDIKRTV

DYYDSSGYQRGFDYWGQGT

AAPSVFIFPPSDEQLKSGTASVV

LVTVSSASTKGPSVFPLAPSS

CLLNNFYPREAKVQWKVDNALQ

KSTSGGTAALGCLVKDYFPEP

SGNSQESVTEQDSKDSTYSLSST

VTVSWNSGALTSGVHTFPAVL

LTLSKADYEKHKVYACEVTHQGL

QSSGLYSLSSVVTVPSSSLGT

SSPVTKSFNRGEC

QTYICNVNHKPSNTKVDKKVE

PKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEV

TCVVVDVSHEDPEVKFNWYV

DGVEVHNAKTKPREEQYNST

YRVVSVLTVLHQDWLNGKEY

KCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWE

SNGQPENNYKTTPPVLDSDG

SFFLYSKLTVDKSRWQQGNV

FSCSVMHEALHNHYTQKSLSL

SPGK

SEQ ID
QVQLQESGPGLVKPSETLSLT
SEQ ID 1641
DVVMTQSPDSLAVSLGERATINC

1533
CTVSGGSISSYYWSWIRQPP

KSSQSVLYSSNNKNYLAWYQQK

GKGLEWIGYIYYTGSTNYNPS

PGQPPKLLIYWASTRESGVPDRF

LKSRVTISVDTSKNQFSLKLSS

SGSGSGTDFTLTISSLQAEDVAV

VTTADTAVYYCARGGRGDGA

YYCQQYYSSTPYTFGQGTKLEIK

AFDIWGQGTMVTVSSASTKG

RTVAAPSVFIFPPSDEQLKSGTA

PSVFPLAPSSKSTSGGTAALG

SVVCLLNNFYPREAKVQWKVDN

CLVKDYFPEPVTVSWNSGALT

ALQSGNSQESVTEQDSKDSTYS

SGVHTFPAVLQSSGLYSLSSV

LSSTLTLSKADYEKHKVYACEVT

VTVPSSSLGTQTYICNVNHKP

HQGLSSPVTKSFNRGEC

SNTKVDKKVEPKSCDKTHTCP

PCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHE

DPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLH

QDWLNGKEYKCKVSNKALPA

PIEKTISKAKGQPREPQVYTLP

PSREEMTKNQVSLTCLVKGFY

PSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGVVQPGRSLRL
SEQ ID 1642
DIVMTHTPLSLSVTPGQPASISCK

1534
SCAASGFTFSSSAMHWRQA

SSQSLLGGDGKTYLYWYLQKPG

PGKGLEWVAMIWHDESKKYY

QPPQLLLYEVSNRFSGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGAATDFTLKISRVEAEDVGVYY

QMNSLRAEDTAVYYCARPPD

CMQSTQFPWTFGQGTKVEIKRT

GGNSGRWYFDLWGRGTLVT

VAAPSVFIFPPSDEQLKSGTASV

VSSASTKGPSVFPLAPSSKST

VCLLNNFYPREAKVQWKVDNAL

SGGTAALGCLVKDYFPEPVTV

QSGNSQESVTEQDSKDSTYSLS

SWNSGALTSGVHTFPAVLQS

STLTLSKADYEKHKVYACEVTHQ

SGLYSLSSVVTVPSSSLGTQT

GLSSPVTKSFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QMQLVQSGGGLVQPGGSLRL
SEQ ID 1643
ETTLTQSPGTLSLSAGERATLSC

1535
SCAASGFTFSSYAMSWRQA

RASQSVSSSYLAWYQQKPGQAP

PGKGLEWSAISGSGGSTYY

RLLIYAASYRATGIPDRFSGRGS

ADSVKGRFTISRDNSKNTLYL

GTEFTLTISSLQSEDFAVYYCQQ

QMNSLRAEDTAVYYCAKDKN

YNNWPPITFGQGTRLEIKRTVAA

VRKHDYGDHPYGGYFDYWG

PSVFIFPPSDEQLKSGTASVVCLL

QGTLVTVSSASTKGPSVFPLA

NNFYPREAKVQWKVDNALQSGN

PSSKSTSGGTAALGCLVKDYF

SQESVTEQDSKDSTYSLSSTLTL

PEPVTVSWNSGALTSGVHTF

SKADYEKHKVYACEVTHQGLSS

PAVLQSSGLYSLSSVVTVPSS

PVTKSFNRGEC

SLGTQTYICNVNHKPSNTKVD

KKVEPKSCDKTHTCPPCPAPE

LLGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1644
DVVMTQSPATLSVSPGERATLSC

1536
SCKASGYTFTSYAMHWVRQA

RASQSVSSNLAWYQQKPGQAPR

PGQRLEWMGWINAGNGNTK

LLIYDASTRATGIPARFSGSGSGT

YSQKFQGRVTITRDTSASTAY

EFTLTISSLQSEDFAVYYCQHYN

MELSSLRSEDTAVYYCARVA

NWPHTFGQGTKLEIKRTVAAPSV

GATSLWYWGQGTLVTVSSAS

FIFPPSDEQLKSGTASVVCLLNNF

TKGPSVFPLAPSSKSTSGGTA

YPREAKVQWKVDNALQSGNSQE

ALGCLVKDYFPEPVTVSWNS

SVTEQDSKDSTYSLSSTLTLSKA

GALTSGVHTFPAVLQSSGLYS

DYEKHKVYACEVTHQGLSSPVTK

LSSVVTVPSSSLGTQTYICNV

SFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQSLSL
SEQ ID 1645
ETTLTQSPGTLSLSPGERATLSC

1537
TCAISGDSVSSNSAAWNWIR

RASQSVSSNSLAWYQQKPGQAP

QSPSRGLEWLGRTYYRSKWY

RLLIYGASSRASGIPDRENGSGS

NDYAVSVKSRITIKPDTSKNQF

GTDFTLTINRLEPEDFAVYYCQQ

SLQLNSVTPEDTAVYYCTRLA

YGNSQTFGQGTRLEIKRTVAAPS

NSDGVDVWGQGTMVTVSSA

VFIFPPSDEQLKSGTASVVCLLNN

STKGPSVFPLAPSSKSTSGGT

FYPREAKVQWKVDNALQSGNSQ

AALGCLVKDYFPEPVTVSWN

ESVTEQDSKDSTYSLSSTLTLSK

SGALTSGVHTFPAVLQSSGLY

ADYEKHKVYACEVTHQGLSSPVT

SLSSVVTVPSSSLGTQTYICN

KSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1646
DVVMTQSPATLSVSPGERATLSC

1538
TCAISGDSVSSDSAVWTWIRQ

RASQSVSSNLAWYQQKPGQAPR

SPSRGLEWLGRTYYKSKWYN

LLIYGASTRATGIPARFSGSGSGT

DYAASVKSRITINPDTSKNQFS

EFTLTISSLQSEDFAVYYCQQYN

LHLNSVTPEDTAVYYCARGVT

NWPRTFGQGTKLEIKRTVAAPSV

RTFDYWGQGTTVTVSSASTK

FIFPPSDEQLKSGTASVVCLLNNF

GPSVFPLAPSSKSTSGGTAAL

YPREAKVQWKVDNALQSGNSQE

GCLVKDYFPEPVTVSWNSGA

SVTEQDSKDSTYSLSSTLTLSKA

LTSGVHTFPAVLQSSGLYSLS

DYEKHKVYACEVTHQGLSSPVTK

SVVTVPSSSLGTQTYICNVNH

SFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QLQLQESGPGLVKPSQTLSLT
SEQ ID 1647
DVVMTQSPLSLPVTLGQPASISC

1539
CAISGDSVSSNSAAWNWIRQ

RSSQSLVYSDGNTYLNWFQQRP

SPSRGLEWLGRTYYRSKWYN

GQSPRRLIYKVSNRDSGVPDRFS

DYAVSVKSRITINPDTSKNQFS

GSGSGTDFTLKISRVEAEDVGVY

LQLNSVTPEDTAVYYCAEGN

YCMQGTHWPRTFGGGTKLEIKR

GPFDPWGQGTLVTVSSASTK

TVAAPSVFIFPPSDEQLKSGTASV

GPSVFPLAPSSKSTSGGTAAL

VCLLNNFYPREAKVQWKVDNAL

GCLVKDYFPEPVTVSWNSGA

QSGNSQESVTEQDSKDSTYSLS

LTSGVHTFPAVLQSSGLYSLS

STLTLSKADYEKHKVYACEVTHQ

SVTVPSSSLGTQTYICNVNH

GLSSPVTKSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QITLKESGGGVVQPGRSLRLS
SEQ ID 1648
DIQMTQSPSTLSASVGDRVTITC

1540
CVASGFTFSTYPMHWRQAP

RASQSISRWLAWYQQKPGKAPK

GKGLEWVAVISYDGRNEYYA

LLIYKASTIKSGVPSRFSASGSGT

DSVKGRFTISRDNSKNTLYLQ

EFTLTISSLQPEDFATYYCQHYKS

MNSLRAEDTAVYYCATRDTPL

DSRTFGQGTKVEIKRTVAAPSVFI

VGVSIYWGQGTLVTVSSASTK

FPPSDEQLKSGTASVVCLLNNFY

GPSVFPLAPSSKSTSGGTAAL

PREAKVQWKVDNALQSGNSQES

GCLVKDYFPEPVTVSWNSGA

VTEQDSKDSTYSLSSTLTLSKAD

LTSGVHTFPAVLQSSGLYSLS

YEKHKVYACEVTHQGLSSPVTKS

SVVTVPSSSLGTQTYICNVNH

FNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QMQLVQSGGGLVKAGGSLRL
SEQ ID 1649
DVVMTQSPSSLAASVGDRITITC

1541
SCSASGFTFSSYAMHWVRQA

RPSQDIGTYLNWYQQKAGEAPK

PGKGLEYVSAISSNGGSTYYA

LLIYAASNLHSGVSSRFRGVGSG

DSVKGRFTISRDNSKNTLYLQ

TQFTLTISSLQPEDFATYYCHQSY

MSSLRAEDTAVYYCVNRAGY

GPRTFGQGTKLEIKRTVAAPSVFI

GDYRHFQHWGQGTLVTVSSA

FPPSDEQLKSGTASVVCLLNNFY

STKGPSVFPLAPSSKSTSGGT

PREAKVQWKVDNALQSGNSQES

AALGCLVKDYFPEPVTVSWN

VTEQDSKDSTYSLSSTLTLSKAD

SGALTSGVHTFPAVLQSSGLY

YEKHKVYACEVTHQGLSSPVTKS

SLSSVVTVPSSSLGTQTYICN

FNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGVVQPGGSLRL
SEQ ID 1650
ETTLTQSPATLSVSPGERATLSC

1542
SCAASGFTFSSYGMHWRQA

RASQSVSSNLAWYQQKPGQAPR

PGKGLEWVAFISYDGSNKYYA

LLIYGASTRATGIPARFSGSGSGT

DSVKGRFTISRDNSKNTLYLQ

EFTLTISSLQSEDFAVYYCQQYN

MNSLRAEDTAVYYCATTGDR

NWPPITFGQGTRLEIKRTVAAPS

FQEFDYWGQGTLVTVSSAST

VFIFPPSDEQLKSGTASVVCLLNN

KGPSVFPLAPSSKSTSGGTAA

FYPREAKVQWKVDNALQSGNSQ

LGCLVKDYFPEPVTVSWNSG

ESVTEQDSKDSTYSLSSTLTLSK

ALTSGVHTFPAVLQSSGLYSL

ADYEKHKVYACEVTHQGLSSPVT

SSVVTVPSSSLGTQTYICNVN

KSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QMQLVQSGGVLLQPGRSLRL
SEQ ID 1651
DVVMTQSPGTLSLSPGERATLSC

1543
SCTASGFTFAAYNINWFRQGP

RASQSVSSSYLAWYQQKPGQAP

GGGLEWVGFIRANADSGTTE

RLLIYGASSRATGIPDRFSGSGS

YAASVKGRFFISRDDSRSTAY

GTDFTLTISRLEPEDFAVYYCQQ

LQMTSLKTEDTAVYYCARDD

YGSSGYTFGQGTKLEIKRTVAAP

RGRGDDFDYWGQGTLVTVSS

SVFIFPPSDEQLKSGTASVVCLLN

ASTKGPSVFPLAPSSKSTSGG

NFYPREAKVQWKVDNALQSGNS

TAALGCLVKDYFPEPVTVSWN

QESVTEQDSKDSTYSLSSTLTLS

SGALTSGVHTFPAVLQSSGLY

KADYEKHKVYACEVTHQGLSSP

SLSSVVTVPSSSLGTQTYICN

VTKSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVQPGGSLRL
SEQ ID 1652
ETTLTQSPGTLSLSPGERATLSC

1544
SCAASGFTFSSYGMTWVRQA

RASQSVSSSYLAWYQQKPGQAP

PGKGLEWSTISGNGVGTYY

RLLIYGASSRATGIPDRFSGSGS

PDSVKDRFTISRDSSKNTVYL

GTDFTLTISRLEPEDFAVYYCQQ

QMNSLRAEDTAVYYCVKHGR

YGSSFGQGTRLEIKRTVAAPSVFI

AGINWYFDLWGRGTLVTVSS

FPPSDEQLKSGTASVVCLLNNFY

ASTKGPSVFPLAPSSKSTSGG

PREAKVQWKVDNALQSGNSQES

TAALGCLVKDYFPEPVTVSWN

VTEQDSKDSTYSLSSTLTLSKAD

SGALTSGVHTFPAVLQSSGLY

YEKHKVYACEVTHQGLSSPVTKS

SLSSVVTVPSSSLGTQTYICN

FNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1653
EIVLTQSPSTLSASVGDRVTITCR

1545
TCAISGDSVSSNSAAWNWIR

ASQSISSCLAWYQQKPGKAPKLL

QSPSRGLEWLGRTYYRSKWY

IYAASTLQSGVPSRFSGSGSGTE

NDYAVSVKSRITINPDTSKNQF

FTLTISTLQPEDFATYYCQQLNSY

SLQLNSVTPEDTAVYYCARG

PQTFGQGTKVDIKRTVAAPSVFIF

GGLWAFDIWGQGTTVTVSSA

PPSDEQLKSGTASVVCLLNNFYP

STKGPSVFPLAPSSKSTSGGT

REAKVQWKVDNALQSGNSQESV

AALGCLVKDYFPEPVTVSWN

TEQDSKDSTYSLSSTLTLSKADY

SGALTSGVHTFPAVLQSSGLY

EKHKVYACEVTHQGLSSPVTKSF

SLSSVVTVPSSSLGTQTYICN

NRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1654
DIVMTHTPLSLSVTPGQPASISCK

1546
SCKASGYTFTGYYMHWVRQA

SSQSLLHSDGKTYLYWYLQKPG

PGQGLEWMGWINPNSGGTN

QPPQLLIYEVSNRFSGVPDRFSG

YAQKFQGRVTMTRDTSISTAY

SGSGTDFTLKISRVEAEDVGVYY

MELSRLRSDDTAVYYCARDKI

CMQSIQLPLTFGGGTKVEIKRTV

GSCPYWGQGTLVTVSSASTK

AAPSVFIFPPSDEQLKSGTASVV

GPSVFPLAPSSKSTSGGTAAL

CLLNNFYPREAKVQWKVDNALQ

GCLVKDYFPEPVTVSWNSGA

SGNSQESVTEQDSKDSTYSLSST

LTSGVHTFPAVLQSSGLYSLS

LTLSKADYEKHKVYACEVTHQGL

SWVTVPSSSLGTQTYICNVNH

SSPVTKSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGPTLVKPTQTLTLT
SEQ ID 1655
DVVMTQSPGTLSLSPGERATLSC

1547
CTFSGFSLSTSGVGVGWIRQ

RASQSVSSSYLAWYQQKPGQAP

PPGKALEWLALIYWDDDKRYS

RLLIYGASSRATGIPDRFSGSGS

PSLKSRLTITKDTSKNQVVLTM

GTDFTLTISRLEPEDFAVYYCQQ

TNMDPVDTATYYCAHRPDSS

YNNWPLTFGGGTKLEIKRTVAAP

SQCFDYWGQGTLVTVSSAST

SVFIFPPSDEQLKSGTASVVCLLN

KGPSVFPLAPSSKSTSGGTAA

NFYPREAKVQWKVDNALQSGNS

LGCLVKDYFPEPVTVSWNSG

QESVTEQDSKDSTYSLSSTLTLS

ALTSGVHTFPAVLQSSGLYSL

KADYEKHKVYACEVTHQGLSSP

SSVVTVPSSSLGTQTYICNVN

VTKSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1656
DIQLTQSPDSLAVSLGERATINCT

1548
SCAASGFTFSSYAMHWVRQA

SSQSVLYSSNNKNYIAWYQQKP

PGKGLEWVAVISYDGSNKYY

GQPPKLLIYWASTRESGVPDRFS

ADSVKGRFTISRDNSKNTLYL

GSGSGTDFTLTISSLQAEDVAVY

QMNSLRAEDTAVYYCARSSG

YCQQYYYIPRTFGQGTKVEIKRT

WSLPEDYWGQGTLVTVSSAS

VAAPSVFIFPPSDEQLKSGTASV

TKGPSVFPLAPSSKSTSGGTA

VCLLNNFYPREAKVQWKVDNAL

ALGCLVKDYFPEPVTVSWNS

QSGNSQESVTEQDSKDSTYSLS

GALTSGVHTFPAVLQSSGLYS

STLTLSKADYEKHKVYACEVTHQ

LSSVVTVPSSSLGTQTYICNV

GLSSPVTKSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1657
DVVMTQSPLSLPVTPGEPASISC

1549
SCKVSGYTLTELSMHWRQA

RSSQSLLHSNGYNYLDWYLQKP

PGKGLEWMGGFDPEDGETIY

GQSPQLLIYLGSNRAPGVPDRFS

AQKFQGRVTMTEDTSTDTAY

GSGSGTDFTLKISRVEAEDVGVY

MELSSLRSEDTAVYYCATDVN

YCMQALQTRTFGQGTKLEIKRTV

PELLGAGFDYWGQGTLVTVS

AAPSVFIFPPSDEQLKSGTASVV

SASTKGPSVFPLAPSSKSTSG

CLLNNFYPREAKVQWKVDNALQ

GTAALGCLVKDYFPEPVTVS

SGNSQESVTEQDSKDSTYSLSST

WNSGALTSGVHTFPAVLQSS

LTLSKADYEKHKVYACEVTHQGL

GLYSLSSVVTVPSSSLGTQTYI

SSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGLVQPGGSLRL
SEQ ID 1658
ETTLTQSPGTLSLSPGERATLSC

1550
SCAASGFTFSDQYMDWVRQA

RASQSLTSSYLAWYQQKPGQAP

PGKGLEWVGRVRNKANSYTT

RLLIYRASSRATGIPDRFSGSGS

EYAASVKGRFTISRDDSKNSL

GTDFTLTISRLEPEDFAVYYCQQ

YLQMNSLNTEDTAMYFCASSL

YGSSPNTFGQGTRLEIKRTVAAP

NSGGYRCFHHWGQGTLVTVS

SVFIFPPSDEQLKSGTASVVCLLN

SASTKGPSVFPLAPSSKSTSG

NFYPREAKVQWKVDNALQSGNS

GTAALGCLVKDYFPEPVTVS

QESVTEQDSKDSTYSLSSTLTLS

WNSGALTSGVHTFPAVLQSS

KADYEKHKVYACEVTHQGLSSP

GLYSLSSVVTVPSSSLGTQTYI

VTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVQPGGSLRL
SEQ ID 1659
EIVLTQSPLSLPVTLGQPASISCR

1551
SCSASGFTFSSYAMHWRQA

SSQSLVHSNGHTYLSWFQQRPG

PGKGLEYVSAISSNGGSTYYA

QSPRRLIYEVSNRDSGVPDRFSG

DSVKGRFTISRDNSKNTLYLQ

SGSGTDFTLRISRVEAEDVGVYY

MSSLRAEDTAVYYCVKAPRG

CLQGTHWPPLTVGGGTKVDIKRT

VVPAAMRGGYWGQGTLVTVS

VAAPSVFIFPPSDEQLKSGTASV

SASTKGPSVFPLAPSSKSTSG

VCLLNNFYPREAKVQWKVDNAL

GTAALGCLVKDYFPEPVTVS

QSGNSQESVTEQDSKDSTYSLS

WNSGALTSGVHTFPAVLQSS

STLTLSKADYEKHKVYACEVTHQ

GLYSLSSVVTVPSSSLGTQTYI

GLSSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQESGGGLVQPGRSLRL
SEQ ID 1660
DVVMTQSPATLSLSPGERATLSC

1552
SCTASGFTFGDYAMSWFRQA

RASQSVGSDLAWYQQKPGQAP

PGKGLEWVGFIRSKAYGGTT

RLLIYRASTRAAGIPARFSGSGSG

EYAASVKGRFTISRDDSKSIAY

TDFTLTISRLEPEDFAVFYCQQY

LQMNSLKTEDTAVYYCTRLVG

GRSPYTSGQGTKLEIKRTVAAPS

NSGSYYPFGYWGQGTLVTVS

VFIFPPSDEQLKSGTASVVCLLNN

SASTKGPSVFPLAPSSKSTSG

FYPREAKVQWKVDNALQSGNSQ

GTAALGCLVKDYFPEPVTVS

ESVTEQDSKDSTYSLSSTLTLSK

WNSGALTSGVHTFPAVLQSS

ADYEKHKVYACEVTHQGLSSPVT

GLYSLSSVVTVPSSSLGTQTYI

KSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1661
DIVMTHTPDSLAVSLGERATINCK

1553
TCAVYGGSFSGYYWSWIRQP

SSQSVLYSSNNKNYLAWYQQKP

PGKGLEWIGEINHSGSTNYNP

GQPPKLLIYWASTRESGVPDRFS

SLKSRVTISVDTSKNQFSLKLS

GSGSGTDFTLTISSLQAEDVAVY

SVTAADTAVYYCARGRSLPYR

YCQQYYSTPLTFGGGTKVEIKRT

GLAPRSFGGYYFDYWGQGTL

VAAPSVFIFPPSDEQLKSGTASV

VTVSSASTKGPSVFPLAPSSK

VCLLNNFYPREAKVQWKVDNAL

STSGGTAALGCLVKDYFPEPV

QSGNSQESVTEQDSKDSTYSLS

TVSWNSGALTSGVHTFPAVL

STLTLSKADYEKHKVYACEVTHQ

QSSGLYSLSSVVTVPSSSLGT

GLSSPVTKSFNRGEC

QTYICNVNHKPSNTKVDKKVE

PKSCDKTHTCPPCPAPELLGG

PSVFLFPPKPKDTLMISRTPEV

TCVVVDVSHEDPEVKFNWYV

DGVEVHNAKTKPREEQYNST

YRVVSVLTVLHQDWLNGKEY

KCKVSNKALPAPIEKTISKAKG

QPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWE

SNGQPENNYKTTPPVLDSDG

SFFLYSKLTVDKSRWQQGNV

FSCSVMHEALHNHYTQKSLSL

SPGK

SEQ ID
QVQLQESGGGLVRPGGSLRL
SEQ ID 1662
EIVMTQSPLSLSVTPGEPASISCR

1554
SCGDSGFNFSGYEMNWVRQ

SSQSLLHSSGYNYLDWYLQKPG

APGKGLEWVSYVSTSGSTRY

QSPQLLIYLGSTRASGVPDRFSG

YADSVKGRFTISRDNAKNTLY

SGSGTDFTLKISRVEAEDVGVYY

LQMNSLRVEDTAVYYCARGR

CMQGLQIPLTFGGGTKVDIKRTV

THWGPQDFDYWGQGTLVTV

AAPSVFIFPPSDEQLKSGTASVV

SSASTKGPSVFPLAPSSKSTS

CLLNNFYPREAKVQWKVDNALQ

GGTAALGCLVKDYFPEPVTVS

SGNSQESVTEQDSKDSTYSLSST

WNSGALTSGVHTFPAVLQSS

LTLSKADYEKHKVYACEVTHQGL

GLYSLSSVVTVPSSSLGTQTYI

SSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQESGGGLVQPGGSLRL
SEQ ID 1663
DIVMTHTPLSLSVTPGQPASISCK

1555
SCAASGFTFSSYAMSWVRQA

SSQSLLHSDGKTYLYWYLQKPG

PGKGLEWVSAISGSGGSTYY

QPPQLLIYEVSNRFSGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGSGTDFTLKISRVEAEDVGVYY

QMNSLRAEDTAVYYCAKGGM

CMQSIQLPWTFGQGTKVEIKRTV

YYYGSGSSYFDYWGQGTLVT

AAPSVFIFPPSDEQLKSGTASVV

VSSASTKGPSVFPLAPSSKST

CLLNNFYPREAKVQWKVDNALQ

SGGTAALGCLVKDYFPEPVTV

SGNSQESVTEQDSKDSTYSLSST

SWNSGALTSGVHTFPAVLQS

LTLSKADYEKHKVYACEVTHQGL

SGLYSLSSVVTVPSSSLGTQT

SSPVTKSFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QVQLVQSGGGLVQPGGSLRL
SEQ ID 1664
ETTLTQSPATLSVSPGERATLSC

1556
SCAASGFTFSSYAMSWRQA

RASQSVSSNLAWYQQKPGQAPR

PGKGLEWVSGISGSGGSTYY

LLIYGASTRATGIPARFSGSGSGT

ADSVKGRFTISRDNSKNMLFL

EFTLTISSLQSEDFAVYYCQQYN

QMNSPRAEDTAVYYCAKKIAA

NWPRFGQGTRLEIKRTVAAPSVF

AGKQPVDYWGQGTLVTVSSA

IFPPSDEQLKSGTASVVCLLNNFY

STKGPSVFPLAPSSKSTSGGT

PREAKVQWKVDNALQSGNSQES

AALGCLVKDYFPEPVTVSWN

VTEQDSKDSTYSLSSTLTLSKAD

SGALTSGVHTFPAVLQSSGLY

YEKHKVYACEVTHQGLSSPVTKS

SLSSVVTVPSSSLGTQTYICN

FNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1665
DVVMTQSPSTLSASVGDRVTITC

1557
TCAVYGGSFSGYYWSWIRQP

RASQTINSWLAWYQQKPGKAPK

PGKGLEWIGEINHSGSTNYNP

LLISRASRLESGVPSRFSGSASG

SLKSRVTISVDTSKNQFSLKLS

TEYILTINSLQPDDFAMYFCHQYN

SVTAADTAVYYCARRKVYDYV

SYSPTFGQGTKLEIKRTVAAPSV

WGSYRLPGSVSYYFDYWGQ

FIFPPSDEQLKSGTASVVCLLNNF

GTLVTVSSASTKGPSVFPLAP

YPREAKVQWKVDNALQSGNSQE

SSKSTSGGTAALGCLVKDYFP

SVTEQDSKDSTYSLSSTLTLSKA

EPVTVSWNSGALTSGVHTFP

DYEKHKVYACEVTHQGLSSPVTK

AVLQSSGLYSLSSVVTVPSSS

SFNRGEC

LGTQTYICNVNHKPSNTKVDK

KVEPKSCDKTHTCPPCPAPEL

LGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGESLKIS
SEQ ID 1666
ETTLTQSPGTLSLSPGERATLSC

1558
CKGSGYSFTSYWIGWVRQMP

RASQSVSSSYLAWYQQKPGQAP

GKGLEWMGIIYPGDSDTRYSP

RLLIYGASSRATGIPARFSGSGS

SFQGQVTISADKSISTAYLQW

GTDFTLTISSLEPEDFAVYYCQQ

SSLKASDTAMYYCARLPGRA

RYNWPITFGQGTRLEIKRTVAAP

ARPDYWGQGTLVTVSSASTK

SVFIFPPSDEQLKSGTASVVCLLN

GPSVFPLAPSSKSTSGGTAAL

NFYPREAKVQWKVDNALQSGNS

GCLVKDYFPEPVTVSWNSGA

QESVTEQDSKDSTYSLSSTLTLS

LTSGVHTFPAVLQSSGLYSLS

KADYEKHKVYACEVTHQGLSSP

SVVTVPSSSLGTQTYICNVNH

VTKSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1667
EIVLTQSPATLSLSPGETATLSCR

1559
SCAASGFTFSSYAMHWRQA

ASQTIGPKSFGWYQQRPGQAPR

PGKGLEWAVISYDGSNKYY

LLIYDSNRATGIPARFSGSGSGTD

ADSVKGRFTISRDNSKNTLYL

FTLTISSLEPEDFAVYYCQQRSR

QMNSLRAEDTAVYYCARGPG

WPLTFGPGTKVDIKRTVAAPSVFI

AVAGTKPKYYFDYWGQGTLV

FPPSDEQLKSGTASVVCLLNNFY

TVSSASTKGPSVFPLAPSSKS

PREAKVQWKVDNALQSGNSQES

TSGGTAALGCLVKDYFPEPVT

VTEQDSKDSTYSLSSTLTLSKAD

VSWNSGALTSGVHTFPAVLQ

YEKHKVYACEVTHQGLSSPVTKS

SSGLYSLSSVVTVPSSSLGTQ

FNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
EVQLVQSGGGVVQPGRSLRL
SEQ ID 1668
DVVMTQSPLSLPVTLGQPASISC

1560
SCAASGFTFSSYAMHWVRQA

RSSQSLVYSDGNTYLYWFQQRA

PGKGLEWVAVISYDGSNKYY

GQSPRRLIYKVSKRDSGVPDRFS

ADSVKGRFTISRDNSKNTLYL

GSGSGTDFTLKISRVEAEDVGIYY

QMNSLRAEDTAVYYCARATY

CVQGRHWPYTLGQGTKLEIKRT

YYDSSGYRFDYWGQGTLVTV

VAAPSVFIFPPSDEQLKSGTASV

SSASTKGPSVFPLAPSSKSTS

VCLLNNFYPREAKVQWKVDNAL

GGTAALGCLVKDYFPEPVTVS

QSGNSQESVTEQDSKDSTYSLS

WNSGALTSGVHTFPAVLQSS

STLTLSKADYEKHKVYACEVTHQ

GLYSLSSVVTVPSSSLGTQTYI

GLSSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGLVEPGGSLRL
SEQ ID 1669
EIVLTQSPGTLSLSPGERATLSCR

1561
SCAASRFTFSDAWMSWVRQ

ASQSVSSSYLAWYQQKPGQAPR

APGKGLEWVGRIKSKISGGTT

LLIYDASNRATGIPARFSGSGSGT

DYAAPVQGRFTISRDDSKNTL

EFTLTISSLQPDDFATYYCQQYN

YLQMDSLKTEDTAVYYCANR

SYSRTFGQGTKVDIKRTVAAPSV

NLGYWGQGTLVTVSSASTKG

FIFPPSDEQLKSGTASVVCLLNNF

PSVFPLAPSSKSTSGGTAALG

YPREAKVQWKVDNALQSGNSQE

CLVKDYFPEPVTVSWNSGALT

SVTEQDSKDSTYSLSSTLTLSKA

SGVHTFPAVLQSSGLYSLSSV

DYEKHKVYACEVTHQGLSSPVTK

VTVPSSSLGTQTYICNVNHKP

SFNRGEC

SNTKVDKKVEPKSCDKTHTCP

PCPAPELLGGPSVFLFPPKPK

DTLMISRTPEVTCVVVDVSHE

DPEVKFNWYVDGVEVHNAKT

KPREEQYNSTYRVVSVLTVLH

QDWLNGKEYKCKVSNKALPA

PIEKTISKAKGQPREPQVYTLP

PSREEMTKNQVSLTCLVKGFY

PSDIAVEWESNGQPENNYKT

TPPVLDSDGSFFLYSKLTVDK

SRWQQGNVFSCSVMHEALH

NHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1670
DVVMTQSPSTLSASVGDRVTITC

1562
SCKASGYTFTSYAMHWVRQA

RASQSITTWLAWSQQQPGKAPK

PGQRLEWMGWINAGNGNTK

LLIYKASSLTSGVPSRFSGSGSG

YSQKFQGRVTMTTDTSTSTA

TEFTLTISSLQPDDFASYYCHHYN

YMELRSLRSDDTAVYYCARA

GASRMFGQGTKLEIKRTVAAPSV

RYYDSSGYIAPSGYFDYWGQ

FIFPPSDEQLKSGTASVVCLLNNF

GTLVTVSSASTKGPSVFPLAP

YPREAKVQWKVDNALQSGNSQE

SSKSTSGGTAALGCLVKDYFP

SVTEQDSKDSTYSLSSTLTLSKA

EPVTVSWNSGALTSGVHTFP

DYEKHKVYACEVTHQGLSSPVTK

AVLQSSGLYSLSSVVTVPSSS

SFNRGEC

LGTQTYICNVNHKPSNTKVDK

KVEPKSCDKTHTCPPCPAPEL

LGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1671
ETTLTQSPATLSLSPGERATLSC

1563
SCKASGYTFTSYAMHWVRQA

RASQSVSSYLAWYQQKPGQAPR

PGQRLEWMGWINAGNGNTK

LLIYDASNRATGIPARFSGSGSGT

YSQKFQGRVTITRDTSASTAY

DFTLTISSLEPEDFAVYYCQQRS

MELSSLRSEDTAVYYCARDG

NWPFFGQGTRLEIKRTVAAPSVF

PAVDGAEYFQHWGQGTLVTV

IFPPSDEQLKSGTASVVCLLNNFY

SSASTKGPSVFPLAPSSKSTS

PREAKVQWKVDNALQSGNSQES

GGTAALGCLVKDYFPEPVTVS

VTEQDSKDSTYSLSSTLTLSKAD

WNSGALTSGVHTFPAVLQSS

YEKHKVYACEVTHQGLSSPVTKS

GLYSLSSVVTVPSSSLGTQTYI

FNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QLQLQESGPGLVKPSQTLSLT
SEQ ID 1672
ETTLTQSPATLTLSPGERVTLSC

1564
CAISGDSVSSNSAAWNWIRQ

RASQSIGTYVAWYQQKPGQAPR

SPSRGLEWLGRTYYRSKWYN

FLIYDSSNRATGIPARFSGSGSGT

DYAVSLKSRITINPDTSKNQFS

DFTLTISSLEPEDFAFYYCQQRAE

LQLNSVTPEDTAVYYCASLAS

WPLTFGQGTRLEIKRTVAAPSVFI

GSPPPGDYWGQGTLVTVSSA

FPPSDEQLKSGTASVVCLLNNFY

STKGPSVFPLAPSSKSTSGGT

PREAKVQWKVDNALQSGNSQES

AALGCLVKDYFPEPVTVSWN

VTEQDSKDSTYSLSSTLTLSKAD

SGALTSGVHTFPAVLQSSGLY

YEKHKVYACEVTHQGLSSPVTKS

SLSSVVTVPSSSLGTQTYICN

FNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1673
DVVMTQSPGTLSLSPGERATLSC

1565
SCAASGFTFSTYGMHWRQA

RASQSVNSGYLAWYQQKPGQP

PGKGLEWVALISYDGSKKYYA

PRLLISGVSTRATGIPDRFSGSGS

NSVKGRFTISRDNSKNTLYLQ

GTDFTLTISRLEPEDFAVYYCQEY

MKSLRAEDTAMYYCAKGPIVG

GNSAMYNFGQGTKLEIKRTVAAP

ATMDYWGQGALVTVSSASTK

SVFIFPPSDEQLKSGTASVVCLLN

GPSVFPLAPSSKSTSGGTAAL

NFYPREAKVQWKVDNALQSGNS

GCLVKDYFPEPVTVSWNSGA

QESVTEQDSKDSTYSLSSTLTLS

LTSGVHTFPAVLQSSGLYSLS

KADYEKHKVYACEVTHQGLSSP

SVVTVPSSSLGTQTYICNVNH

VTKSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGSSVKV
SEQ ID 1674
ETTLTQSPATLSVSPGERATLSC

1566
SCKASGGTFSSYAISWVRQA

RASQSVSSNLAWYQQKPGQAPR

PGQGLEWMGWISAYNGNTN

LLIYGASTRATGIPARFSGSGSGT

YAQKLQGRVTMTTDTSTSTAY

EFTLTISSLQSEDFAVYYCQQYN

MELRSLRSDDTAVYYCARWY

NWPPFTFGQGTRLEIKRTVAAPS

GDYGLDYWGQGTLVTVSSAS

VFIFPPSDEQLKSGTASVVCLLNN

TKGPSVFPLAPSSKSTSGGTA

FYPREAKVQWKVDNALQSGNSQ

ALGCLVKDYFPEPVTVSWNS

ESVTEQDSKDSTYSLSSTLTLSK

GALTSGVHTFPAVLQSSGLYS

ADYEKHKVYACEVTHQGLSSPVT

LSSVVTVPSSSLGTQTYICNV

KSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1675
DVVMTQSPGTLSLSPGERATLSC

1567
SCKASGYTFTSYAMHWVRQA

RASQSVSSSYLGWYQQKSGQAP

PGQRLAWMGWINAGNGNTK

RLLIYGASSRATDIPDRFSGSGS

YSEKFEGRVTITRDTSASTAY

GTDFTLTISKLEAEDSAVYYCQQ

MELSSLRSEDTAVYYCARVAK

YGISPLAFGQGTKLEIKRTVAAPS

YYYESGGYRASNWFDPWGQ

VFIFPPSDEQLKSGTASVVCLLNN

GTLVTVSSASTKGPSVFPLAP

FYPREAKVQWKVDNALQSGNSQ

SSKSTSGGTAALGCLVKDYFP

ESVTEQDSKDSTYSLSSTLTLSK

EPVTVSWNSGALTSGVHTFP

ADYEKHKVYACEVTHQGLSSPVT

AVLQSSGLYSLSSVVTVPSSS

KSFNRGEC

LGTQTYICNVNHKPSNTKVDK

KVEPKSCDKTHTCPPCPAPEL

LGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
QVQLQESGPGLVKPSQTLSLT
SEQ ID 1676
ETTLTQSPATLSVSPGERATLSC

1568
CAISGDSVSSNSAAWNWIRQ

RASQSISNNLAWYQQKPGQAPR

SPSRGLEWLGRTYYRSKWYN

LLIYGTSTRATGIPARFSGSGSGT

DYAVSVKSRITINPDTSKNQFS

EFTLTISSLQSEDFAVYYCQQYN

LQLNSVTPEDTAVYYCARAPP

FWPSITFGQGTRLEIKRTVAAPSV

PTVGWYAPVFDYWGQGTLVT

FIFPPSDEQLKSGTASVVCLLNNF

VSSASTKGPSVFPLAPSSKST

YPREAKVQWKVDNALQSGNSQE

SGGTAALGCLVKDYFPEPVTV

SVTEQDSKDSTYSLSSTLTLSKA

SWNSGALTSGVHTFPAVLQS

DYEKHKVYACEVTHQGLSSPVTK

SGLYSLSSVVTVPSSSLGTQT

SFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QLQLQESGGGLVQPGGSLRL
SEQ ID 1677
ETTLTQSPGTLSLSPGERATLSC

1569
SCSASGISFRDYWMHWIRQT

RASQSVSSSSLAWYQQKPGQAP

PGKGLVWVSRINPDGSSTSY

RLLIYGASSRATGIPDRFSGSGS

ADSVKGRFTISRDNSKNTLYL

GTDFTLTISRLEPEDFAVYYCQQ

QMNSLRAEDTAVYYCAKVTG

YGSSQTFGQGTRLEIKRTVAAPS

RRVGAHDYWGQGTLVTVSSA

VFIFPPSDEQLKSGTASVVCLLNN

STKGPSVFPLAPSSKSTSGGT

FYPREAKVQWKVDNALQSGNSQ

AALGCLVKDYFPEPVTVSWN

ESVTEQDSKDSTYSLSSTLTLSK

SGALTSGVHTFPAVLQSSGLY

ADYEKHKVYACEVTHQGLSSPVT

SLSSVVTVPSSSLGTQTYICN

KSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRWV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGAEVKKPGASVKV
SEQ ID 1678
DVVMTQSPLSLPVSLGQPASISC

1570
SCKASGYTFTGYYMHWVRQA

RSNQSLVYSDGGTYLNWFQQRA

PGQGLEWMGWINPNSGGTN

GQSPRRLVYKVSNRDSGVPDRF

YAQKFQGRVTMTRDTSISTAY

SGSGSGTDFTLRISRVEAEDVGV

MELSRLRSDDTAVYYCAFAQ

YYCMQGTHWPYTFGQGTKLEIK

PGAETLNFDLWGRGTLVTVS

RTVAAPSVFIFPPSDEQLKSGTA

SASTKGPSVFPLAPSSKSTSG

SVVCLLNNFYPREAKVQWKVDN

GTAALGCLVKDYFPEPVTVS

ALQSGNSQESVTEQDSKDSTYS

WNSGALTSGVHTFPAVLQSS

LSSTLTLSKADYEKHKVYACEVT

GLYSLSSVVTVPSSSLGTQTYI

HQGLSSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1679
DIQLTQSPSSLSASVGDRVTVTC

1571
TCAISGDSVSSKSAAWNWIRQ

RASQSISSYLNWYQQKPGKAPQ

SPSRGLEWLGRTYYRSKWNN

LLIYDASNLETGVPSRFSGSGSG

DYALSVKSRITINPDTSKNQFS

TDFTFTISSLQPEDFATYYCQQF

LQLKSVTPEDTALYYCVRQVA

DNVPVTFGGGTKVEIKRTVAAPS

GGMDVWGQGTTVTVSSASTK

VFIFPPSDEQLKSGTASVVCLLNN

GPSVFPLAPSSKSTSGGTAAL

FYPREAKVQWKVDNALQSGNSQ

GCLVKDYFPEPVTVSWNSGA

ESVTEQDSKDSTYSLSSTLTLSK

LTSGVHTFPAVLQSSGLYSLS

ADYEKHKVYACEVTHQGLSSPVT

SVVTVPSSSLGTQTYICNVNH

KSFNRGEC

KPSNTKVDKKVEPKSCDKTHT

CPPCPAPELLGGPSVFLFPPK

PKDTLMISRTPEVTCVVVDVS

HEDPEVKFNWYVDGVEVHNA

KTKPREEQYNSTYRVVSVLTV

LHQDWLNGKEYKCKVSNKAL

PAPIEKTISKAKGQPREPQVYT

LPPSREEMTKNQVSLTCLVKG

FYPSDIAVEWESNGQPENNY

KTTPPVLDSDGSFFLYSKLTV

DKSRWQQGNVFSCSVMHEA

LHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLVQPGRSLRL
SEQ ID 1680
EIVLTQSPLSLPVTLGQPASISCR

1572
SCTASGFTFGDYAMSWFRQA

SSQSLVYSDGNTYLNWFQQRPG

PGKGLEWVSAISGSGGSTYY

QSPRRLIYKVSNRDSGVPDRFSG

ADSVKGRFTISRDNSKNTLYL

SGSGTDFTLKISRVEAEDVGVYY

QMNSLRAEDTAVYYCAKGSV

CMQGTHWPRTFGQGTKLEIKRT

YSGSYYMLIDYWGQGTLVTV

VAAPSVFIFPPSDEQLKSGTASV

SSASTKGPSVFPLAPSSKSTS

VCLLNNFYPREAKVQWKVDNAL

GGTAALGCLVKDYFPEPVTVS

QSGNSQESVTEQDSKDSTYSLS

WNSGALTSGVHTFPAVLQSS

STLTLSKADYEKHKVYACEVTHQ

GLYSLSSVVTVPSSSLGTQTYI

GLSSPVTKSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVRPSQTLSL
SEQ ID 1681
DVVMTQSPATLSVSPGERATLSC

1573
TCVISGDSVSSGSAAWNWIR

RASQSVSSNLAWYQQKPGQAPR

QSPSRGLEWLGRTYYRAKWY

LLIYGASSRATGIPDRFSGSGSGT

NEYAGSVKSRITISPDTSKNQF

DFTLTINRLEPEDFAVYYCQQYG

SLQLNSVTPEDTAVYFCTRQD

SSSMYTFGQGTKLEIKRTVAAPS

KDNTRYSGLGVWGQGTTVTV

VFIFPPSDEQLKSGTASVVCLLNN

SSASTKGPSVFPLAPSSKSTS

FYPREAKVQWKVDNALQSGNSQ

GGTAALGCLVKDYFPEPVTVS

ESVTEQDSKDSTYSLSSTLTLSK

WNSGALTSGVHTFPAVLQSS

ADYEKHKVYACEVTHQGLSSPVT

GLYSLSSVVTVPSSSLGTQTYI

KSFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVETGGGLVQPGGSLRL
SEQ ID 1682
DVVMTQSPSSLSASVGDSVAITC

1574
SCAASEFTLRNYGVSWRQA

RASQSISNYLNWYQQRPGKAPK

PGKGLEWVSGMSGSGYSTYY

LLIFAASSLQSGVPSRFSGSGSG

ADSVKGRFTISRDSSKNTLFL

TDFTLTISSLQPEDFATYSCQQSY

QMDSLRAEDTAIYYCARGPR

ITPWTFGQGTKLEIKRTVAAPSVF

MWSSGIDAFDIWGHGTMVTV

IFPPSDEQLKSGTASVVCLLNNFY

SSASTKGPSVFPLAPSSKSTS

PREAKVQWKVDNALQSGNSQES

GGTAALGCLVKDYFPEPVTVS

VTEQDSKDSTYSLSSTLTLSKAD

WNSGALTSGVHTFPAVLQSS

YEKHKVYACEVTHQGLSSPVTKS

GLYSLSSVVTVPSSSLGTQTYI

FNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1683
DVVMTQSPGTLSLSPGERATLSC

1575
TCAVYGGSVSGYYWSWIRQP

RASQSVSTLLAWYQQKPGQAPR

PGKGLEWMGEIHHSGSTNYN

LLIYDASNRATGIPGRFSASGSGT

PSLKSRVTISLDTPKNQFSLKL

DFSLTISSLETEDSAVYYCQHRY

SSVTAADTAVYYCARRDWAG

VWPFTFGGGTKLEIKRTVAAPSV

KRVWGQGTLVTVSSASTKGP

FIFPPSDEQLKSGTASVVCLLNNF

SVFPLAPSSKSTSGGTAALGC

YPREAKVQWKVDNALQSGNSQE

LVKDYFPEPVTVSWNSGALTS

SVTEQDSKDSTYSLSSTLTLSKA

GVHTFPAVLQSSGLYSLSSVV

DYEKHKVYACEVTHQGLSSPVTK

TVPSSSLGTQTYICNVNHKPS

SFNRGEC

NTKVDKKVEPKSCDKTHTCPP

CPAPELLGGPSVFLFPPKPKD

TLMISRTPEVTCVVVDVSHED

PEVKFNWYVDGVEVHNAKTK

PREEQYNSTYRVVSVLTVLHQ

DWLNGKEYKCKVSNKALPAPI

EKTISKAKGQPREPQVYTLPP

SREEMTKNQVSLTCLVKGFYP

SDIAVEWESNGQPENNYKTT

PPVLDSDGSFFLYSKLTVDKS

RWQQGNVFSCSVMHEALHN

HYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLLKPSQTLSLT
SEQ ID 1684
DIQMTQSPSSLSASVGDRVTITC

1576
CAISGDSVSSNTATWNWIRQS

RASQGIRNDLGWYQQKPGKAPK

PSRGLEWLGRTYYRSKWYKD

RLIYGASSLQSGVPSRFSGSGSG

NALSVKSRITINPDTSKNQFSL

TEFTLTIRSLQPEDFATYYCLQHN

QLNSVTPEDTAVYYCAGGRA

SYPRTFGQGTKVEIKRTVAAPSV

GIAAFDIWGQGTTVTVSSAST

FIFPPSDEQLKSGTASVVCLLNNF

KGPSVFPLAPSSKSTSGGTAA

YPREAKVQWKVDNALQSGNSQE

LGCLVKDYFPEPVTVSWNSG

SVTEQDSKDSTYSLSSTLTLSKA

ALTSGVHTFPAVLQSSGLYSL

DYEKHKVYACEVTHQGLSSPVTK

SSVVTVPSSSLGTQTYICNVN

SFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLVQSGGGLIQPGGSLRL
SEQ ID 1685
DVVMTQSPATLSLSPGERATLSC

1577
SCAASGFTVSSNYMSWVRQA

RASQSVSSYLAWYQQKPGQAPR

PGKGLEWVSLIYSDGRTNYAD

LLIYDASNRATGIPARFSGSGSGT

SVKGRFTISRDNSKNTLYLQM

DFTLTISSLEPEDFAVYYCQQRS

NSLRAEDTAVYYCAKGALQG

NWPWTFGQGTKLEIKRTVAAPS

EWRRFDYWGQGTLVTVSSAS

VFIFPPSDEQLKSGTASVVCLLNN

TKGPSVFPLAPSSKSTSGGTA

FYPREAKVQWKVDNALQSGNSQ

ALGCLVKDYFPEPVTVSWNS

ESVTEQDSKDSTYSLSSTLTLSK

GALTSGVHTFPAVLQSSGLYS

ADYEKHKVYACEVTHQGLSSPVT

LSSVVTVPSSSLGTQTYICNV

KSFNRGEC

NHKPSNTKVDKKVEPKSCDK

THTCPPCPAPELLGGPSVFLF

PPKPKDTLMISRTPEVTCVVV

DVSHEDPEVKFNWYVDGVEV

HNAKTKPREEQYNSTYRVVS

VLTVLHQDWLNGKEYKCKVS

NKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTC

LVKGFYPSDIAVEWESNGQPE

NNYKTTPPVLDSDGSFFLYSK

LTVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1686
DVVMTQSPLSLPVTLGQAASISC

1578
TCAISGDSVSSNSAAWNWIR

RSSHSLTTTDGRTYVAWFQQRP

QSPSRGLEWLGRTYYRSKWY

GQSPRRLLYEVSKRDSGAPDRF

NDYAVSVKSRITINPDTSKNQF

SGSGSGTDFTLKISRVEADDVGI

SLQLNSVTPEDTAVYYCTRTN

YHCMQGTHGPHTFGQGTKLEIK

QGYGGNSGVFDYWGQGTLV

RTVAAPSVFIFPPSDEQLKSGTA

TVSSASTKGPSVFPLAPSSKS

SVVCLLNNFYPREAKVQWKVDN

TSGGTAALGCLVKDYFPEPVT

ALQSGNSQESVTEQDSKDSTYS

VSWNSGALTSGVHTFPAVLQ

LSSTLTLSKADYEKHKVYACEVT

SSGLYSLSSVVTVPSSSLGTQ

HQGLSSPVTKSFNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
QVQLQQSGPGLVKPSQTLSL
SEQ ID 1687
ETTLTQSPATLSVSPGERATLSC

1579
TCAISGDSVSGNSAAWNWIR

RASQSVTSNLAWYQQKPGQAPR

QSPSRGLEWLGRTYYRSKWY

LLIYGASNRATGIPARFSVSGSGT

NDYAVSVKSRITINPDTSKNQF

DFTLTISRLEPEDFAVYYCQQYG

SLQLNSVTPEDTAVYYCARIV

SPPPTTFGQGTRLEIKRTVAAPS

GGAVDCWGQGTLVTVSSAST

VFIFPPSDEQLKSGTASVVCLLNN

KGPSVFPLAPSSKSTSGGTAA

FYPREAKVQWKVDNALQSGNSQ

LGCLVKDYFPEPVTVSWNSG

ESVTEQDSKDSTYSLSSTLTLSK

ALTSGVHTFPAVLQSSGLYSL

ADYEKHKVYACEVTHQGLSSPVT

SSVVTVPSSSLGTQTYICNVN

KSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVKKPGASVKV
SEQ ID 1688
DVVMTQSPGTLSLSPGERATLSC

1580
SCKASGYTFTSYAMHWVRQA

RASQSVSSSYLAWYQQKPGQAP

PGQRLEWMGWINAGNGNTK

RLLIYGASSRATGIPDRFSGSGS

YSQKFQGRVTITRDTSASTAY

GTDFTLTISRLEPEDFAVYYCQQ

MELSSLRSEDTAVYYCARVRV

YGSSRRTFGQGTKLEIKRTVAAP

GATTVYDSWFDPWGQGTLVT

SVFIFPPSDEQLKSGTASVVCLLN

VSSASTKGPSVFPLAPSSKST

NFYPREAKVQWKVDNALQSGNS

SGGTAALGCLVKDYFPEPVTV

QESVTEQDSKDSTYSLSSTLTLS

SWNSGALTSGVHTFPAVLQS

KADYEKHKVYACEVTHQGLSSP

SGLYSLSSVVTVPSSSLGTQT

VTKSFNRGEC

YICNVNHKPSNTKVDKKVEPK

SCDKTHTCPPCPAPELLGGPS

VFLFPPKPKDTLMISRTPEVTC

VVVDVSHEDPEVKFNWYVDG

VEVHNAKTKPREEQYNSTYR

VVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQP

REPQVYTLPPSREEMTKNQV

SLTCLVKGFYPSDIAVEWESN

GQPENNYKTTPPVLDSDGSF

FLYSKLTVDKSRWQQGNVFS

CSVMHEALHNHYTQKSLSLSP

GK

SEQ ID
QVQLVQSGGGLVQPGGSLRL
SEQ ID 1689
ETTLTQSPGTLSLSPGERATLSC

1581
SCAASGFTFSSYAMSWVRQA

RASQSVFNNYLAWYQQRPGQAP

PGKGLEWVSAISGSGGSTYY

RLLIYGASSRATGIPDRFSGGGS

ADSVKGRFTISRDNSKNTLYL

GTDFTLTISRLEPEDFAVYCCQQ

QMNSLRAEDTAVYYCAKDGG

YGSSPITFGQGTRLEIKRTVAAPS

SSPYYDSSGLLPWYFDLWGR

VFIFPPSDEQLKSGTASVVCLLNN

GTLVTVSSASTKGPSVFPLAP

FYPREAKVQWKVDNALQSGNSQ

SSKSTSGGTAALGCLVKDYFP

ESVTEQDSKDSTYSLSSTLTLSK

EPVTVSWNSGALTSGVHTFP

ADYEKHKVYACEVTHQGLSSPVT

AVLQSSGLYSLSSVVTVPSSS

KSFNRGEC

LGTQTYICNVNHKPSNTKVDK

KVEPKSCDKTHTCPPCPAPEL

LGGPSVFLFPPKPKDTLMISR

TPEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
QVQLQESGGGLVQPGGSLRL
SEQ ID 1690
EIVLTQSPATLSLSPGERATLSCR

1582
SCAASGFTFSSYAMHWVRQA

ASQSVSSYLAWYQQKPGQAPRL

PGKGLEYVSAISSNGGSTYYA

LIYDASNRATGIPARFSGSGSGT

NSVKGRFTISRDNSKNTLYLQ

DFTLTISRLEPEDFAVYYCQQYG

MGSLRAEDMAVYYCARAKFW

SSLRYTFGQGTKLEIKRTVAAPS

TYYFDYWGQGTLVTVSSAST

VFIFPPSDEQLKSGTASVVCLLNN

KGPSVFPLAPSSKSTSGGTAA

FYPREAKVQWKVDNALQSGNSQ

LGCLVKDYFPEPVTVSWNSG

ESVTEQDSKDSTYSLSSTLTLSK

ALTSGVHTFPAVLQSSGLYSL

ADYEKHKVYACEVTHQGLSSPVT

SSVVTVPSSSLGTQTYICNVN

KSFNRGEC

HKPSNTKVDKKVEPKSCDKT

HTCPPCPAPELLGGPSVFLFP

PKPKDTLMISRTPEVTCVVVD

VSHEDPEVKFNWYVDGVEVH

NAKTKPREEQYNSTYRVVSVL

TVLHQDWLNGKEYKCKVSNK

ALPAPIEKTISKAKGQPREPQV

YTLPPSREEMTKNQVSLTCLV

KGFYPSDIAVEWESNGQPEN

NYKTTPPVLDSDGSFFLYSKL

TVDKSRWQQGNVFSCSVMH

EALHNHYTQKSLSLSPGK

SEQ ID
QVQLQQWGAGLLKPSETLSL
SEQ ID 1691
EIVLTQSPDSLAVSLGERATINCK

1583
TCAVYGGSFSGYYWSWIRQP

SSQSVLYDSNSKNYLSWYQQKP

PGKGLEWIGEINHSGSTNYNP

GQPPKLLISWASTRGSGVPDRFS

SLKSRVTISVDTSKNQFSLKLS

GSGSGTDFTLTISSLQAEDVAVY

SVTAADTAVYYCARGGGSGS

YCQQFYGIPHFGQGTRLEIKRTV

YYKRFFDYWGQGTLVTVSSA

AAPSVFIFPPSDEQLKSGTASVV

STKGPSVFPLAPSSKSTSGGT

CLLNNFYPREAKVQWKVDNALQ

AALGCLVKDYFPEPVTVSWN

SGNSQESVTEQDSKDSTYSLSST

SGALTSGVHTFPAVLQSSGLY

LTLSKADYEKHKVYACEVTHQGL

SLSSVVTVPSSSLGTQTYICN

SSPVTKSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGAEVRKPGASVKV
SEQ ID 1692
DVVMTQSPATLSLSPGERATLSC

1584
SCKASGYTFTSYAISWVRQAP

RASQSVGTNLAWYQQKPGQAP

GQGLEWMGWISAYDGNTNY

RLLIYDASNRATGIPARFSGSGS

AQKLQGRVTMTTDTSTSTAY

GTEFTLTISSLQSEDFAVYYCQQ

MEVRSLRSDDTAVYYCARDG

YNNWPPITFGGGTKLEIKRTVAA

TVRRVVGATTPGNFDYRGQG

PSVFIFPPSDEQLKSGTASVVCLL

TLVTVSSASTKGPSVFPLAPS

NNFYPREAKVQWKVDNALQSGN

SKSTSGGTAALGCLVKDYFPE

SQESVTEQDSKDSTYSLSSTLTL

PVTVSWNSGALTSGVHTFPA

SKADYEKHKVYACEVTHQGLSS

VLQSSGLYSLSSVVTVPSSSL

PVTKSFNRGEC

GTQTYICNVNHKPSNTKVDKK

VEPKSCDKTHTCPPCPAPELL

GGPSVFLFPPKPKDTLMISRT

PEVTCVVVDVSHEDPEVKFN

WYVDGVEVHNAKTKPREEQY

NSTYRVVSVLTVLHQDWLNG

KEYKCKVSNKALPAPIEKTISK

AKGQPREPQVYTLPPSREEM

TKNQVSLTCLVKGFYPSDIAV

EWESNGQPENNYKTTPPVLD

SDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQK

SLSLSPGK

SEQ ID
EVQLVQSGGGVVQPGRSLRL
SEQ ID 1693
DVVMTQSPLSLPVTLGQPASISC

1585
SCAASGFTFSSYGMHWRQA

RSSQSLVYSDGNTYLSWLQQRP

PGKGLEWVAVIWYDGSNKYY

GQPPRLLIYKISNRFSGVPDRFS

ADSVKGRFTISRDNSKNTLYL

GSGAGTDFTLKISRVEAEDVGVY

QMNSLRAEDTAVYYCARDLN

YCMQGTQFPQTFGQGTKLEIKRT

RGYCSGGSCFGYWGQGTLV

VAAPSVFIFPPSDEQLKSGTASV

TVSSASTKGPSVFPLAPSSKS

VCLLNNFYPREAKVQWKVDNAL

TSGGTAALGCLVKDYFPEPVT

QSGNSQESVTEQDSKDSTYSLS

VSWNSGALTSGVHTFPAVLQ

STLTLSKADYEKHKVYACEVTHQ

SSGLYSLSSVVTVPSSSLGTQ

GLSSPVTKSFNRGEC

TYICNVNHKPSNTKVDKKVEP

KSCDKTHTCPPCPAPELLGGP

SVFLFPPKPKDTLMISRTPEVT

CVVVDVSHEDPEVKFNWYVD

GVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYK

CKVSNKALPAPIEKTISKAKGQ

PREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWES

NGQPENNYKTTPPVLDSDGS

FFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLS

PGK

SEQ ID
QVQLQESGGGLVQPGGSLRL
SEQ ID 1694
EIVLTQSPGTLSLSPGERATLSCR

1586
SCAASGFTFSSYAMSWVRQA

ASQSVISRYLAWYQQKPGQAPR

PGKGLEWVSYISSSGTTIYYA

LLIHGASTRATGIPDRFSGSGSGT

DSVKGRFTVSRDNAKNSLYL

DFTLTISRLEPEDFAVYYCQQYG

QMNSLRAEDTAVYYCARDYS

SSPPYTFGQGTKVEIKRTVAAPS

SSGECFDYWGQGTLVTVSSA

VFIFPPSDEQLKSGTASVVCLLNN

STKGPSVFPLAPSSKSTSGGT

FYPREAKVQWKVDNALQSGNSQ

AALGCLVKDYFPEPVTVSWN

ESVTEQDSKDSTYSLSSTLTLSK

SGALTSGVHTFPAVLQSSGLY

ADYEKHKVYACEVTHQGLSSPVT

SLSSVVTVPSSSLGTQTYICN

KSFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
EVQLVQSGGGVVQPGRSLRL
SEQ ID 1695
DIQLTQSPSTLAASVGDRVTITCR

1587
SCAASGFTFSSYGMHWRQA

ASQSISSWLAWYQQKPGKAPKV

PGKGLEWVAVIWYDGSNKYY

LIYKASSLESGVPSRFSGSGSGT

ADSVKGRFTISRDNSKNTLYL

EFTLTISSLQPDDFATYYCQQYN

QMNSLRAEDTAVYYCARDQA

SYSGTFGQGTKVEIKRTVAAPSV

AMVGYFDYWGQGTLVTVSSA

FIFPPSDEQLKSGTASVVCLLNNF

STKGPSVFPLAPSSKSTSGGT

YPREAKVQWKVDNALQSGNSQE

AALGCLVKDYFPEPVTVSWN

SVTEQDSKDSTYSLSSTLTLSKA

SGALTSGVHTFPAVLQSSGLY

DYEKHKVYACEVTHQGLSSPVTK

SLSSVVTVPSSSLGTQTYICN

SFNRGEC

VNHKPSNTKVDKKVEPKSCD

KTHTCPPCPAPELLGGPSVFL

FPPKPKDTLMISRTPEVTCVV

VDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVV

SVLTVLHQDWLNGKEYKCKV

SNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLT

CLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

SEQ ID
QVTLKESGGGVVQPGRSLRL
SEQ ID 1696
DVVMTQSPAILSVSPGERATLSC

1588
SCAASGFIFSNYAIHWVRQAP

RASQSVSSSLAWYQQKPGQPPR

GKGLEWVAVISYDGSNKYYA

LLIYGASTRATAIPARFSGSGSGT

DSVKGRFTISRDNSKNTLYLQ

EFTLTISSLQSEDFAVYYCQRYD

MNSLRAEDTAVYYCARTFAG

NWPPLFGQGTKLEIKRTVAAPSV

YSSKLGYFDLWGRGTLVTVS

FIFPPSDEQLKSGTASVVCLLNNF

SASTKGPSVFPLAPSSKSTSG

YPREAKVQWKVDNALQSGNSQE

GTAALGCLVKDYFPEPVTVS

SVTEQDSKDSTYSLSSTLTLSKA

WNSGALTSGVHTFPAVLQSS

DYEKHKVYACEVTHQGLSSPVTK

GLYSLSSVVTVPSSSLGTQTYI

SFNRGEC

CNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSV

FLFPPKPKDTLMISRTPEVTCV

VVDVSHEDPEVKFNWYVDGV

EVHNAKTKPREEQYNSTYRV

VSVLTVLHQDWLNGKEYKCK

VSNKALPAPIEKTISKAKGQPR

EPQVYTLPPSREEMTKNQVSL

TCLVKGFYPSDIAVEWESNGQ

PENNYKTTPPVLDSDGSFFLY

SKLTVDKSRWQQGNVFSCSV

MHEALHNHYTQKSLSLSPGK

TABLE 38

Anti-CLEC2D IgG1 antibody Heavy and Kappa Light Chain

DNA sequence

SEQ ID
VH + CH DNA_IgG1
SEQ ID
VK + CK DNA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1697
CTGAGGTGAAGAAGCCTGGGGCCTC
1805
GCCACCCTATCTGTGTCTCTAGGAG

AGTGAAGGTTTCCTGCAAGGCTTCTG

AAAGAGCCACCCTTTCTTGCAGGG

GATACACCTTCACTAGCTATGCTATG

CCAGTCAGAGTATTGGCAGCAACT

CATTGGGTGCGCCAGGCCCCCGGAC

TAGTCTGGTACCAGCTGAAACCTG

AAAGGCTTGAGTGGATGGGATGGAT

GCCAGGGTCCCAGGCTCGTCATAT

CAACGCTGGCAATGGTAACACAAAA

ATAGTGCAACCTCTAGGGCCACTG

TATTCACAGAAGTTCCAGGGCAGAG

GAATCCCAGCCAGGTTCAGCGGCA

TCACCATTACCAGGGACACATCCGCG

GTGGGTCTGGGACAGAGTTCATTC

AGCACAGCCTACATGGAGCTGAGCA

TCTCCATCAGCAACCTGCAGTCTGA

GCCTGAGATCTGAAGACACGGCTGT

AGATCTTGCAGTTTATTACTGTCAG

GTATTACTGTGCGAGAGGCTCCTTGT

CAGTATGGTAGTTCACCTCCGACC

CCCGAAGTGGCTGGTACGCCGGACT

ACCTTCGGCCAAGGGACACGACTG

CTTTGACTACTGGGGCCAGGGAACCC

GAGATTAAACGTACTGTGGCTGCT

TGGTCACCGTCTCCTCAGCATCCACC

CCCTCCGTGTTCATTTTTCCTCCGT

AAGGGGCCTTCCGTGTTCCCCCTGGC

CGGACGAACAGCTGAAGTCCGGAA

CCCTTCATCCAAGTCGACCTCTGGTG

CCGCGTCCGTGGTCTGTCTCCTGAA

GAACCGCCGCACTCGGTTGCCTGGTC

CAACTTCTATCCGCGCGAGGCGAA

AAAGACTACTTCCCCGAGCCCGTGAC

AGTGCAGTGGAAGGTCGACAACGC

TGTCTCGTGGAACTCGGGCGCCCTCA

ACTGCAGTCGGGAAACTCCCAGGA

CATCCGGAGTGCATACCTTTCCCGCC

ATCGGTGACCGAGCAGGACTCGAA

GTGTTGCAGTCCAGCGGCCTGTACAG

GGACTCAACCTACTCATTGTCCTCC

CCTGAGCTCCGTCGTGACAGTGCCGT

ACCCTCACCCTGAGCAAGGCCGAT

CCTCCTCCCTTGGAACCCAGACCTAT

TACGAGAAGCATAAGGTCTACGCC

ATCTGCAACGTCAATCACAAGCCCTC

TGCGAAGTGACCCACCAGGGCCTG

CAACACCAAAGTGGACAAGAAGGTC

AGCAGCCCAGTGACGAAGTCCTTC

GAACCCAAGTCCTGCGACAAGACTC

AACCGGGGAGAATGC

ACACCTGTCCGCCTTGTCCAGCCCCT

GAGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGTC

GCACGAAGATCCCGAAGTGAAATTC

AATTGGTACGTGGATGGGGTCGAAG

TGCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTACAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAACA

AGGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAAC

CTAGGGAGCCCCAGGTCTATACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGCC

GGGAAAA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAATTGTGATGACACAGTCTCCA

1698
GAGGCGTGGTCCAGCCTGGGAGGTC
1806
GCCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGTTATAGCATG

CCAGTCAGAGTGTTAGCAGCAGCT

AACTGGGTCCGCCAGGCTCCAGGCA

ACTTAGCCTGGTACCAGCAAAAAC

AGGGGCTGCAGTGGGTGGCAATTAT

CTGGCCGGGCTCCCAGGCTCCTCAT

ATCAGATGATGGAAGTAAGAGTTAC

CTATGGCGCATCCAACAGGGCCAC

TACGCAGACTCCGTGCAGGGCCGATT

AGGCATCCCAGACAGGTTCAGTGG

CACCATCTCCAGAGACAATTCGAGG

CAGTGGGTCTGGGACAGACTTCAC

AACACAGTATTTCTGCAAATGAACA

TCTCATCATCAGCAGACTGGAGCC

GCCTGAGAGCTGAGGACACGGCTAT

TGAAGATTTTGCCTTGTATTACTGT

GTATTACTGTGCGAGAGACAGGGGA

CAGCAGTATGGAAGCTCACCGGGA

ACTAAATGGAACCAATTGAATGATG

ACGTTCGGCCAAGGGACCAAAGTG

TTTTTGATATGTGGGGCCAAGGGACA

GATATCAAACGTACTGTGGCTGCT

ATGGTCACCGTCTCTTCAGCATCCAC

CCCTCCGTGTTCATTTTTCCTCCGT

CAAGGGGCCTTCCGTGTTCCCCCTGG

CGGACGAACAGCTGAAGTCCGGAA

CCCCTTCATCCAAGTCGACCTCTGGT

CCGCGTCCGTGGTCTGTCTCCTGAA

GGAACCGCCGCACTCGGTTGCCTGGT

CAACTTCTATCCGCGCGAGGCGAA

CAAAGACTACTTCCCCGAGCCCGTGA

AGTGCAGTGGAAGGTCGACAACGC

CTGTCTCGTGGAACTCGGGCGCCCTC

ACTGCAGTCGGGAAACTCCCAGGA

ACATCCGGAGTGCATACCTTTCCCGC

ATCGGTGACCGAGCAGGACTCGAA

CGTGTTGCAGTCCAGCGGCCTGTACA

GGACTCAACCTACTCATTGTCCTCC

GCCTGAGCTCCGTCGTGACAGTGCCG

ACCCTCACCCTGAGCAAGGCCGAT

TCCTCCTCCCTTGGAACCCAGACCTA

TACGAGAAGCATAAGGTCTACGCC

TATCTGCAACGTCAATCACAAGCCCT

TGCGAAGTGACCCACCAGGGCCTG

CCAACACCAAAGTGGACAAGAAGGT

AGCAGCCCAGTGACGAAGTCCTTC

CGAACCCAAGTCCTGCGACAAGACT

AACCGGGGAGAATGC

CACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTGT

TCCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTGT

CGCACGAAGATCCCGAAGTGAAATT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTACAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAAA

GACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTATACTTT

GCCGCCTAGCCGGGAAGAAATGACT

AAGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1699
CTGAGGTGAAGAAGCCTGGGGCCTC
1807
CCACCCTGTCTTTGTCTCCAGGGGA

AGTGAAGGTTTCCTGCAAGGCATCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACACCTTCACCAGCTACTATATG

CAGTCAGAGTGTTAGCAGCTACTT

CACTGGGTGCGACAGGCCCCTGGAC

AGCCTGGTACCAACAGAAACCTGG

AAGGGCTTGAGTGGATGGGAATAAT

CCAGGCTCCCAGGCTCCTCATCTAT

CAACCCTAGTGGTGGTAGCACAAGC

GATGCATCCAACAGGGCCACTGGC

TACGCACAGAAGTTCCAGGGCAGAG

ATCCCAGCCAGGTTCAGTGGCAGT

TCACCATGACCAGGGACACGTCCAC

GGGTCTGGGACAGACTTCACTCTC

GAGCACAGTCTACATGGAGCTGAGC

ACCATCAGCAGCCTAGAGCCTGAA

AGCCTGAGATCTGAGGACACGGCCG

GATTTTGCAGTTTATTACTGTCAGC

TGTATTACTGTGCGAGAGGCCGAGG

AGCGTAGCAACTGGCCTCGGACGT

GTATAGCAGCAGTCGGCTCTACTACT

TCGGCCAAGGGACCAAGCTGGAGA

TTGACTACTGGGGCCAGGGAACCCT

TCAAACGTACTGTGGCTGCTCCCTC

GGTCACCGTCTCCTCAGCATCCACCA

CGTGTTCATTTTTCCTCCGTCGGAC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GAACAGCTGAAGTCCGGAACCGCG

CCTTCATCCAAGTCGACCTCTGGTGG

TCCGTGGTCTGTCTCCTGAACAACT

AACCGCCGCACTCGGTTGCCTGGTCA

TCTATCCGCGCGAGGCGAAAGTGC

AAGACTACTTCCCCGAGCCCGTGACT

AGTGGAAGGTCGACAACGCACTGC

GTCTCGTGGAACTCGGGCGCCCTCAC

AGTCGGGAAACTCCCAGGAATCGG

ATCCGGAGTGCATACCTTTCCCGCCG

TGACCGAGCAGGACTCGAAGGACT

TGTTGCAGTCCAGCGGCCTGTACAGC

CAACCTACTCATTGTCCTCCACCCT

CTGAGCTCCGTCGTGACAGTGCCGTC

CACCCTGAGCAAGGCCGATTACGA

CTCCTCCCTTGGAACCCAGACCTATA

GAAGCATAAGGTCTACGCCTGCGA

TCTGCAACGTCAATCACAAGCCCTCC

AGTGACCCACCAGGGCCTGAGCAG

AACACCAAAGTGGACAAGAAGGTCG

CCCAGTGACGAAGTCCTTCAACCG

AACCCAAGTCCTGCGACAAGACTCA

GGGAGAATGC

CACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1700
GAGGCTTGGTCCGGCCTGGAGGGTC
1808
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGAGACTCTCCTGTGAAGCCTCTG

AGAGGGCCACCATCACCTGCAAGT

GATTCACCTTCAGTGACCCCTACATG

CCAGCCGGAATATTTTATACAGCG

GACTGGGTCCGCCAGGCTCCAGGCA

GCAACAATAAAAACTTCTTGGCTT

AGGGGCTGGAGTGGGTTGGCCGAAT

GGTATCAGCACAAACCAGGACAGC

TACAAATAAGCGTACCGGTTACGCC

CTCCTAAGTTGCTCATTTACTGGGC

ACAACATATGCCGCGTCTGTGAAGG

ATCTACCCGGGAATCCGGGGTCCC

ACAGATTCACCATCTCAAGAGATGAT

TGACCGATTTAGTGGCAGCGGGTC

TCAAGGAAGTCAGTATATCTGCAAAT

TGGGACAGATTTCACCCTCACCATC

GAACAGCCTGAAGACCGAGGACACG

AATAGCCTGGAAGCTGAAGATGCT

GCCGTATATTATTGTGCAACAGATGT

GCAACGTATTACTGTCATCAGAGT

CAGTGGGTCCTTCGCGGCCTACGGGG

AGTAGTTTACCTCACACTTTCGGCC

GCCAGGGCACCCTGGTCACCGTCTCC

CTGGGACCAAAGTGGATATCAAAC

TCAGCATCCACCAAGGGGCCTTCCGT

GTACTGTGGCTGCTCCCTCCGTGTT

GTTCCCCCTGGCCCCTTCATCCAAGT

CATTTTTCCTCCGTCGGACGAACAG

CGACCTCTGGTGGAACCGCCGCACTC

CTGAAGTCCGGAACCGCGTCCGTG

GGTTGCCTGGTCAAAGACTACTTCCC

GTCTGTCTCCTGAACAACTTCTATC

CGAGCCCGTGACTGTCTCGTGGAACT

CGCGCGAGGCGAAAGTGCAGTGGA

CGGGCGCCCTCACATCCGGAGTGCAT

AGGTCGACAACGCACTGCAGTCGG

ACCTTTCCCGCCGTGTTGCAGTCCAG

GAAACTCCCAGGAATCGGTGACCG

CGGCCTGTACAGCCTGAGCTCCGTCG

AGCAGGACTCGAAGGACTCAACCT

TGACAGTGCCGTCCTCCTCCCTTGGA

ACTCATTGTCCTCCACCCTCACCCT

ACCCAGACCTATATCTGCAACGTCAA

GAGCAAGGCCGATTACGAGAAGCA

TCACAAGCCCTCCAACACCAAAGTG

TAAGGTCTACGCCTGCGAAGTGAC

GACAAGAAGGTCGAACCCAAGTCCT

CCACCAGGGCCTGAGCAGCCCAGT

GCGACAAGACTCACACCTGTCCGCCT

GACGAAGTCCTTCAACCGGGGAGA

TGTCCAGCCCCTGAGCTGCTGGGTGG

ATGC

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1701
GAGGCGTGGTCCAGCCTGGGAGGTC
1809
GGCACCCTGTCTTTGTCTCCAGGGC

CCTGAGACTCTCCTGTGCAGCGTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGCTATGCTATG

CCAGTGAGAGTGTTAGCAAGAGCT

CATTGGGTGCGCCAGGCCCCCGGAC

ACTTACTCTGGTACCAGCAGAAAC

AAAGGCTTGAGTGGATGGGATGGAT

CTGGCCAGGCTCCCAGACTCCTCAT

CAACGCTGGCAATGGTAACACAAAA

CTATGGTGCATCCACCAGGGCCAG

TATTCACAGAAGTTCCAGGGCAGAG

TGGCATCCCAAACAGGTTCAGTGG

TCACCATTACCAGGGACACATCCGCG

CAGTGGGTCTGGGACAGACTTCAC

AGCACAGCCTACATGGAGCTGAGCA

TCTCACCATCAGCAGACTGGAGCC

GCCTGAGATCTGAAGACACGGCTGT

TGAAGATTCTGCAGTGTATTACTGT

GTATTACTGTGCGGGAGAGGGCGGA

CAGCACTATGGCAGCTCTCGCACC

GCAGTGGCTGGTACTGTCTACTGGGG

TTCGGCCAAGGGACACGACTGGAG

CCAGGGAACCCTGGTCACCGTCTCCT

ATTAAACGTACTGTGGCTGCTCCCT

CAGCATCCACCAAGGGGCCTTCCGTG

CCGTGTTCATTTTTCCTCCGTCGGA

TTCCCCCTGGCCCCTTCATCCAAGTC

CGAACAGCTGAAGTCCGGAACCGC

GACCTCTGGTGGAACCGCCGCACTCG

GTCCGTGGTCTGTCTCCTGAACAAC

GTTGCCTGGTCAAAGACTACTTCCCC

TTCTATCCGCGCGAGGCGAAAGTG

GAGCCCGTGACTGTCTCGTGGAACTC

CAGTGGAAGGTCGACAACGCACTG

GGGCGCCCTCACATCCGGAGTGCAT

CAGTCGGGAAACTCCCAGGAATCG

ACCTTTCCCGCCGTGTTGCAGTCCAG

GTGACCGAGCAGGACTCGAAGGAC

CGGCCTGTACAGCCTGAGCTCCGTCG

TCAACCTACTCATTGTCCTCCACCC

TGACAGTGCCGTCCTCCTCCCTTGGA

TCACCCTGAGCAAGGCCGATTACG

ACCCAGACCTATATCTGCAACGTCAA

AGAAGCATAAGGTCTACGCCTGCG

TCACAAGCCCTCCAACACCAAAGTG

AAGTGACCCACCAGGGCCTGAGCA

GACAAGAAGGTCGAACCCAAGTCCT

GCCCAGTGACGAAGTCCTTCAACC

GCGACAAGACTCACACCTGTCCGCCT

GGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1702
GAGGCTTGGTAAAGCCTGGGGGGTC
1810
GGCACCCTGTCTTTGTCTCCAGGGG

CCTTAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACTTTCAGTAACGCCTGGATG

CCAGTCAGAGTATTAGCAGCACCT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTTGGCCGTAT

CTGGCCAGGCTCCCAGGCTCCTCAT

TAAAAGCAAAACTGATGGTGGGACA

CTATGGTGCATCCACCAGGGCCAC

ACAGACTACGCTGCACCCGTGAAAG

TGGCATCCCAGACAGGTTCAGTGG

GCAGATTCACCATCTCAAGAGATGAT

CAGTGGGTCTGGGACAGACTTCAC

TCAAAAAACACGCTGTATCTGCAAAT

TCTCAGCATCAGCAGACTGGAGCC

GAACAGCCTGAAAACCGAGGACACA

TGAAGATTTTGCAGTGTATTACTGT

GCCGTGTATTACTGTACCACAGACGA

CAGCAGTATGGTAACTCACCTCCG

GTATTTCTACTGGGGCCAGGGAACCC

GGAGCCACCTTCGGCCAAGGGACA

TGGTCACCGTCTCCTCAGCATCCACC

CGACTGGAGATTAAACGTACTGTG

AAGGGGCCTTCCGTGTTCCCCCTGGC

GCTGCTCCCTCCGTGTTCATTTTTC

CCCTTCATCCAAGTCGACCTCTGGTG

CTCCGTCGGACGAACAGCTGAAGT

GAACCGCCGCACTCGGTTGCCTGGTC

CCGGAACCGCGTCCGTGGTCTGTCT

AAAGACTACTTCCCCGAGCCCGTGAC

CCTGAACAACTTCTATCCGCGCGA

TGTCTCGTGGAACTCGGGCGCCCTCA

GGCGAAAGTGCAGTGGAAGGTCGA

CATCCGGAGTGCATACCTTTCCCGCC

CAACGCACTGCAGTCGGGAAACTC

GTGTTGCAGTCCAGCGGCCTGTACAG

CCAGGAATCGGTGACCGAGCAGGA

CCTGAGCTCCGTCGTGACAGTGCCGT

CTCGAAGGACTCAACCTACTCATT

CCTCCTCCCTTGGAACCCAGACCTAT

GTCCTCCACCCTCACCCTGAGCAA

ATCTGCAACGTCAATCACAAGCCCTC

GGCCGATTACGAGAAGCATAAGGT

CAACACCAAAGTGGACAAGAAGGTC

CTACGCCTGCGAAGTGACCCACCA

GAACCCAAGTCCTGCGACAAGACTC

GGGCCTGAGCAGCCCAGTGACGAA

ACACCTGTCCGCCTTGTCCAGCCCCT

GTCCTTCAACCGGGGAGAATGC

GAGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGTC

GCACGAAGATCCCGAAGTGAAATTC

AATTGGTACGTGGATGGGGTCGAAG

TGCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTACAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAACA

AGGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAAC

CTAGGGAGCCCCAGGTCTATACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGCC

GGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GACATCCAGTTGACCCAGTCTCCTT

1703
CAGGACTGTTGAAGCCTTCGGAGAC
1811
CCTCCCTGTCTGCATCTGTGGGAGA

CCTGTCCCTCACCTGCGCTGTCTATG

AAGAGTCACCATCACTTGCCGGTC

GTGGGTCCTTCAGTGGTTACTACTGG

CAGCCAGGCCCTGCGAAATGTTGT

AGCTGGATCCGCCAGCCCCCAGGGA

CGGCCTTGGCGATGATTTAGCCTG

AGGGGCTGGAGTGGATTGGGGAAAT

GTATCAACACACGCCAGGCAGCGC

CAATCATAGTGGAAGCACCAACTAC

CCCCAAGATCCTGATCTACTCTACA

AACCCGTCCCTCAAGAGTCGAGTCAC

TCGACTTTACAAAGTGGAGTCTCAT

CATATCAGTAGACACGTCCAAGAAC

CAAGATTCAGCGGCGGAAAGTCTG

CAGTTCTCCCTGAAGCTGAGCTCTGT

GGAGAGACTTCACTCTCACGATCG

GACCGCCGCGGACACGGCTGTGTATT

ATCGTCTGCAGCCTGGAGATTCTGC

ACTGTGCGAGAGTAAATCCGGGGAG

AACTTATTACTGTCTCCAGCACCAT

TTATACGAGGGAGGTGAGCAACTTT

GATTTCCCTTTCACTTTCGGCCCTG

GACTACTGGGGCCAGGGAACCCTGG

GGACCAAGGTGGAAATCAAACGTA

TGACCGTCTCCTCAGCATCCACCAAG

CTGTGGCTGCTCCCTCCGTGTTCAT

GGGCCTTCCGTGTTCCCCCTGGCCCC

TTTTCCTCCGTCGGACGAACAGCTG

TTCATCCAAGTCGACCTCTGGTGGAA

AAGTCCGGAACCGCGTCCGTGGTC

CCGCCGCACTCGGTTGCCTGGTCAAA

TGTCTCCTGAACAACTTCTATCCGC

GACTACTTCCCCGAGCCCGTGACTGT

GCGAGGCGAAAGTGCAGTGGAAG

CTCGTGGAACTCGGGCGCCCTCACAT

GTCGACAACGCACTGCAGTCGGGA

CCGGAGTGCATACCTTTCCCGCCGTG

AACTCCCAGGAATCGGTGACCGAG

TTGCAGTCCAGCGGCCTGTACAGCCT

CAGGACTCGAAGGACTCAACCTAC

GAGCTCCGTCGTGACAGTGCCGTCCT

TCATTGTCCTCCACCCTCACCCTGA

CCTCCCTTGGAACCCAGACCTATATC

GCAAGGCCGATTACGAGAAGCATA

TGCAACGTCAATCACAAGCCCTCCAA

AGGTCTACGCCTGCGAAGTGACCC

CACCAAAGTGGACAAGAAGGTCGAA

ACCAGGGCCTGAGCAGCCCAGTGA

CCCAAGTCCTGCGACAAGACTCACA

CGAAGTCCTTCAACCGGGGAGAAT

CCTGTCCGCCTTGTCCAGCCCCTGAG

GC

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1704
CAGAATTGGTGAAGCCCTCGCAGAC
1812
TCTCCCTGCCCGTCACCCCTGGAGA

CCTCACACTCACCTGTGGCATCTCCG

GCCGGCCTCCATCTCCTGCAGGTCT

GGGACAGTGTCTCTAGCAACAGTGTT

AGTCAGAGCCTCCTGAATAGTAAT

ACTTGGAACTGGGTCAGGCAGTCCCC

GGATACAACTATTTGGAGTGGTAC

ATCGAGAGGCCTTGAGTGGCTGGGA

CTGCAGAAGCCGGGGCAGTCTCCA

AGGACTTACTACCGGTCCCAGTGGTA

CAGCTCCTGATCTATTTGGGTTCTA

TTATAATTATGCGGTGTCTGTGAAAA

ATCGGGCCTCCGGGGTCCCTGACA

GTCGAATAACCATCAGCCCAGACAC

GGTTCAGTGGCAGTGGATCAGGCA

ATCCAAGAACCAGTTCTCCCTGCAGT

CAGATTTTACACTGAAAATCAGCA

TGAATTCTGTGACTCCCGAGGACACG

GAGTGGAGGCTGACGATGCTGGTG

GCTGTCTATTACTGTGCAACCAGGGG

TTTATTACTGCATGCAGTCTCTACA

ACATAACTACGGTGTAGATTACTGGG

AACTCCTCTCACTTTCGGCGGTGGG

GCCCGGGGACCACGGTCACCGTCTCC

ACCAAGCTGGAGATCAAACGTACT

TCAGCATCCACCAAGGGGCCTTCCGT

GTGGCTGCTCCCTCCGTGTTCATTT

GTTCCCCCTGGCCCCTTCATCCAAGT

TTCCTCCGTCGGACGAACAGCTGA

CGACCTCTGGTGGAACCGCCGCACTC

AGTCCGGAACCGCGTCCGTGGTCT

GGTTGCCTGGTCAAAGACTACTTCCC

GTCTCCTGAACAACTTCTATCCGCG

CGAGCCCGTGACTGTCTCGTGGAACT

CGAGGCGAAAGTGCAGTGGAAGGT

CGGGCGCCCTCACATCCGGAGTGCAT

CGACAACGCACTGCAGTCGGGAAA

ACCTTTCCCGCCGTGTTGCAGTCCAG

CTCCCAGGAATCGGTGACCGAGCA

CGGCCTGTACAGCCTGAGCTCCGTCG

GGACTCGAAGGACTCAACCTACTC

TGACAGTGCCGTCCTCCTCCCTTGGA

ATTGTCCTCCACCCTCACCCTGAGC

ACCCAGACCTATATCTGCAACGTCAA

AAGGCCGATTACGAGAAGCATAAG

TCACAAGCCCTCCAACACCAAAGTG

GTCTACGCCTGCGAAGTGACCCAC

GACAAGAAGGTCGAACCCAAGTCCT

CAGGGCCTGAGCAGCCCAGTGACG

GCGACAAGACTCACACCTGTCCGCCT

AAGTCCTTCAACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1705
GAGGCTTGGTAAAGCCTGGGGGGTC
1813
GGCACCCTGTCTTTGTCTCCAGGGG

CCTTAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACTTTCAGTAACGCCTGGATG

CCAGTCAGAGTGTTAGCAGCAGCT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTTTGCCGTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AAAAGCAAAACTGATGGTGAGACAA

CTATGGTGCATCCAGCAGGGCCAC

CAGACTACGCTGCACCCGTGAAAGG

TGGCATCCCAGACAGGTTCAGTGG

CAGATTCACCATCTCAAGAGATGATT

CAGTGGGTCTGGGACAGACTTCAC

CAAAAAACACGCTGTATCTGCAAAT

TCTCACCATCAGCAGACTGGAGCC

GAACAGCCTGAAAACTGAGGACACA

TGAAGATTTTGCAGTGTATTACTGT

GCCGTGTATCACTGTACCACAGGGGT

CAGCAGTATGGTAGCTCACCCCGG

GGGATGGTCGCCCTTCCAATACTGGG

ATCACCTTCGGCCAAGGGACACGA

GCCAGGGCACCCTGGTCACCGTCTCC

CTGGAGATTAAACGTACTGTGGCT

TCAGCATCCACCAAGGGGCCTTCCGT

GCTCCCTCCGTGTTCATTTTTCCTC

GTTCCCCCTGGCCCCTTCATCCAAGT

CGTCGGACGAACAGCTGAAGTCCG

CGACCTCTGGTGGAACCGCCGCACTC

GAACCGCGTCCGTGGTCTGTCTCCT

GGTTGCCTGGTCAAAGACTACTTCCC

GAACAACTTCTATCCGCGCGAGGC

CGAGCCCGTGACTGTCTCGTGGAACT

GAAAGTGCAGTGGAAGGTCGACAA

CGGGCGCCCTCACATCCGGAGTGCAT

CGCACTGCAGTCGGGAAACTCCCA

ACCTTTCCCGCCGTGTTGCAGTCCAG

GGAATCGGTGACCGAGCAGGACTC

CGGCCTGTACAGCCTGAGCTCCGTCG

GAAGGACTCAACCTACTCATTGTC

TGACAGTGCCGTCCTCCTCCCTTGGA

CTCCACCCTCACCCTGAGCAAGGC

ACCCAGACCTATATCTGCAACGTCAA

CGATTACGAGAAGCATAAGGTCTA

TCACAAGCCCTCCAACACCAAAGTG

CGCCTGCGAAGTGACCCACCAGGG

GACAAGAAGGTCGAACCCAAGTCCT

CCTGAGCAGCCCAGTGACGAAGTC

GCGACAAGACTCACACCTGTCCGCCT

CTTCAACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1706
GAGGCTTGGTACAGCCAGGGCGGTC
1814
CCACCCTGTCTGTGTCTCCAGGGGA

CCTGAGACTCTCCTGTACAGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCACCTTTGGTGATTATGCTATG

CAGTCAGAGTGTTAGCAGCAACTT

AGCTGGTTCCGCCAGGCTCCAGGGA

AGCCTGGTACCAGCAGAAACCTGG

AGGGGCTGGAGTGGGTAGGTTTCATT

CCAGGCTCCCAGGCTCCTCATCTAT

AGAAGCAAAGCTTATGGTGGGACAA

GGTGCATCCACCAGGGCCACTGGT

CAGAATACGCCGCGTCTGTGAAAGG

ATCCCAGCCAGGTTCAGTGGCAGT

CAGATTCACCATCTCAAGAGATGATT

GGGTCTGGGACAGAGTTCACTCTC

CCAAAAGCATCGCCTATCTGCAAATG

ACCATCAGCAGCCTGCAGTCTGAA

AACAGCCTGAAAACCGAGGACACAG

GATTTTGCAGTTTATTACTGTCAGC

CCGTGTATTACTGTACTAGAGACGAC

AGTATAATAACTGGCCTCCTATGTA

AAAATAGCAGCAGCTGGATTCACAT

CACTTTTGGCCAGGGGACCAAGCT

ACTGGTACTTCGATCTCTGGGGCCGT

GGAGATCAAACGTACTGTGGCTGC

GGCACCCTGGTCACCGTCTCCTCAGC

TCCCTCCGTGTTCATTTTTCCTCCGT

ATCCACCAAGGGGCCTTCCGTGTTCC

CGGACGAACAGCTGAAGTCCGGAA

CCCTGGCCCCTTCATCCAAGTCGACC

CCGCGTCCGTGGTCTGTCTCCTGAA

TCTGGTGGAACCGCCGCACTCGGTTG

CAACTTCTATCCGCGCGAGGCGAA

CCTGGTCAAAGACTACTTCCCCGAGC

AGTGCAGTGGAAGGTCGACAACGC

CCGTGACTGTCTCGTGGAACTCGGGC

ACTGCAGTCGGGAAACTCCCAGGA

GCCCTCACATCCGGAGTGCATACCTT

ATCGGTGACCGAGCAGGACTCGAA

TCCCGCCGTGTTGCAGTCCAGCGGCC

GGACTCAACCTACTCATTGTCCTCC

TGTACAGCCTGAGCTCCGTCGTGACA

ACCCTCACCCTGAGCAAGGCCGAT

GTGCCGTCCTCCTCCCTTGGAACCCA

TACGAGAAGCATAAGGTCTACGCC

GACCTATATCTGCAACGTCAATCACA

TGCGAAGTGACCCACCAGGGCCTG

AGCCCTCCAACACCAAAGTGGACAA

AGCAGCCCAGTGACGAAGTCCTTC

GAAGGTCGAACCCAAGTCCTGCGAC

AACCGGGGAGAATGC

AAGACTCACACCTGTCCGCCTTGTCC

AGCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1707
CTGAGGTGAAGAAGCCTGGGGCCTC
1815
CCACCCTGTCTGTGTCTCCAGGGGA

AGTGAAGGTCTCCTGCAAGGCTTCTG

AAGAGTCACACTCTCCTGCAGGGC

GATACACCTTCGCCGCCTATTATTTA

CAGTCAGAGTGTTAGAGACAACGT

CACTGGGTGCGACAGGCCCCTGGAC

AGGTTGGTACAAGCAGAAACCTGG

AAGGCCTTGAGTGGATGGGGCGGAT

CCAACCTCCCAGGCTCGTCATCTAT

CAGCCCTGGTAACGGTGTCACAAGTT

GGTGCATCCACCAGGGCCACTGGT

ATGCACAGAAATTTCAGGGCAGAGT

ATCCCAGCCAGGATCAGTGGCAGT

CACCATGACCGGGGACACGTCCATT

GGGTCTGGGACAGAGTTCACTCTC

AACACAGTCTACATGCAACTGAACA

ACCATCAGCAGCCTGCAGTCTGAA

ATTTGATTTCTGGCGACACGGCCGTA

GATTTTGCAGTTTATTACTGTCAGC

TATTACTGTGCGAGAGAGGCTGCCG

AGTTTAATAATTGGCCTTACACTTT

ACGACCCGTTTGACCATTGGGGCCAG

TGGCCAGGGGACCAAGCTGGAGAT

GGAGCCCTGGTCACCGTCTCCTCAGC

CAAACGTACTGTGGCTGCTCCCTCC

ATCCACCAAGGGGCCTTCCGTGTTCC

GTGTTCATTTTTCCTCCGTCGGACG

CCCTGGCCCCTTCATCCAAGTCGACC

AACAGCTGAAGTCCGGAACCGCGT

TCTGGTGGAACCGCCGCACTCGGTTG

CCGTGGTCTGTCTCCTGAACAACTT

CCTGGTCAAAGACTACTTCCCCGAGC

CTATCCGCGCGAGGCGAAAGTGCA

CCGTGACTGTCTCGTGGAACTCGGGC

GTGGAAGGTCGACAACGCACTGCA

GCCCTCACATCCGGAGTGCATACCTT

GTCGGGAAACTCCCAGGAATCGGT

TCCCGCCGTGTTGCAGTCCAGCGGCC

GACCGAGCAGGACTCGAAGGACTC

TGTACAGCCTGAGCTCCGTCGTGACA

AACCTACTCATTGTCCTCCACCCTC

GTGCCGTCCTCCTCCCTTGGAACCCA

ACCCTGAGCAAGGCCGATTACGAG

GACCTATATCTGCAACGTCAATCACA

AAGCATAAGGTCTACGCCTGCGAA

AGCCCTCCAACACCAAAGTGGACAA

GTGACCCACCAGGGCCTGAGCAGC

GAAGGTCGAACCCAAGTCCTGCGAC

CCAGTGACGAAGTCCTTCAACCGG

AAGACTCACACCTGTCCGCCTTGTCC

GGAGAATGC

AGCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GACATCCAGATGACCCAGTCTCCA

1708
GAGGCGTGGTCCAGCCTGGGAGGTC
1816
TCCTCCCTGTCTGCATCTGTAGGAG

CCTGACACTCTCCTGTGCAGCCTCTG

ACAGAGTCACCATCACTTGCCGGG

GATTCACCTTCAGTTCCCATCTTATG

CAAGTCAGAGCATTAGCAGCTATT

CACTGGGTCCGCCAGGCTCCAGGCA

TAAATTGGTATCAGCAGAAACCAG

AGGGGCTGGAGTGGGTGGCAGTTAT

GGAAAGCCCCTAACCTCCTGATCT

ATCATATGATGGAACTAGTAAATATT

ATGCTGCATCCAGTTTGCACACTGG

ACGGAGACTCCGTGAAGGGCCGCTT

GGTCCCATCAAGGTTCAGTGGCAG

CACCATCTCCAGAGACAATTCCAAG

TGGATCTGGGACAGATTTCACTCTC

AACACGTTGTATCTGCAAATGAACA

ACCATCAGCAGTCTGCAACCTGAA

GCCTGCGAGCTGAAGACACGGCTAT

GATTTTGCAACTTACTACTGTCAAC

ATATTACTGTGCGAAAGCAGATTATA

AGAGTTACAGTATTCCTCGAACGTT

AATATGACTGGGGCCAGGGAACCCT

CGGCCAAGGGACCAAGGTGGAAAT

GGTCACCGTCTCCTCAGCATCCACCA

CAAACGTACTGTGGCTGCTCCCTCC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GTGTTCATTTTTCCTCCGTCGGACG

CCTTCATCCAAGTCGACCTCTGGTGG

AACAGCTGAAGTCCGGAACCGCGT

AACCGCCGCACTCGGTTGCCTGGTCA

CCGTGGTCTGTCTCCTGAACAACTT

AAGACTACTTCCCCGAGCCCGTGACT

CTATCCGCGCGAGGCGAAAGTGCA

GTCTCGTGGAACTCGGGCGCCCTCAC

GTGGAAGGTCGACAACGCACTGCA

ATCCGGAGTGCATACCTTTCCCGCCG

GTCGGGAAACTCCCAGGAATCGGT

TGTTGCAGTCCAGCGGCCTGTACAGC

GACCGAGCAGGACTCGAAGGACTC

CTGAGCTCCGTCGTGACAGTGCCGTC

AACCTACTCATTGTCCTCCACCCTC

CTCCTCCCTTGGAACCCAGACCTATA

ACCCTGAGCAAGGCCGATTACGAG

TCTGCAACGTCAATCACAAGCCCTCC

AAGCATAAGGTCTACGCCTGCGAA

AACACCAAAGTGGACAAGAAGGTCG

GTGACCCACCAGGGCCTGAGCAGC

AACCCAAGTCCTGCGACAAGACTCA

CCAGTGACGAAGTCCTTCAACCGG

CACCTGTCCGCCTTGTCCAGCCCCTG

GGAGAATGC

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1709
GAGGCTTGGTCAAGCCTGGAGGGTC
1817
CCACCCTGTCTGTGACTCCAGGGG

CCTGAGACTCTCCTGTACAGCTTCTG

AAAGGGCCACCCTCTCCTGCAGGG

GATTCACCTTTGGTGATTATGCTATG

CCAGTCAAAGTGTTAACAGCAACG

AGCTGGGTCCGCCAGGCTCCAGGGA

TAGCCTGGTACCAGCAGAAACCTG

AGGGGCTGGAGTGGGTAGGTTTCATT

GCCAGGCTCCCAGGCTCCTCATCTA

AGAAGCAAAGCTTATGGTGGGACAA

TGATGTATCCACCAGGGCCACTGA

CAGAATACGCCGCGTCTGTGAAAGG

TATCCCAGCCAGGTTCAGTGGCAG

CAGATTCACCATCTCAAGAGATGATT

TGGGTCTGGGACAGACTTCACTCTC

CCAAAAGCATCGCCTATCTGCAAATG

ACCATCAGCAGACTTGACCCTGAA

AACAGCCTGAAAACCGAGGACACAG

GATTTTGCAGTGTATTACTGTCAGC

CCGTGTATTACTGTACTACTCATAGA

AGTGTGCTAGCTCACCTCCTGTCAC

CGCCCAATTTACGATATTTTGACTGG

TTTCGGCGGAGGGACCAAGCTGGA

TTTTGACTACTGGGGCCAGGGAACCC

GATCAAACGTACTGTGGCTGCTCC

TGGTCACCGTCTCCTCAGCATCCACC

CTCCGTGTTCATTTTTCCTCCGTCG

AAGGGGCCTTCCGTGTTCCCCCTGGC

GACGAACAGCTGAAGTCCGGAACC

CCCTTCATCCAAGTCGACCTCTGGTG

GCGTCCGTGGTCTGTCTCCTGAACA

GAACCGCCGCACTCGGTTGCCTGGTC

ACTTCTATCCGCGCGAGGCGAAAG

AAAGACTACTTCCCCGAGCCCGTGAC

TGCAGTGGAAGGTCGACAACGCAC

TGTCTCGTGGAACTCGGGCGCCCTCA

TGCAGTCGGGAAACTCCCAGGAAT

CATCCGGAGTGCATACCTTTCCCGCC

CGGTGACCGAGCAGGACTCGAAGG

GTGTTGCAGTCCAGCGGCCTGTACAG

ACTCAACCTACTCATTGTCCTCCAC

CCTGAGCTCCGTCGTGACAGTGCCGT

CCTCACCCTGAGCAAGGCCGATTA

CCTCCTCCCTTGGAACCCAGACCTAT

CGAGAAGCATAAGGTCTACGCCTG

ATCTGCAACGTCAATCACAAGCCCTC

CGAAGTGACCCACCAGGGCCTGAG

CAACACCAAAGTGGACAAGAAGGTC

CAGCCCAGTGACGAAGTCCTTCAA

GAACCCAAGTCCTGCGACAAGACTC

CCGGGGAGAATGC

ACACCTGTCCGCCTTGTCCAGCCCCT

GAGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGTC

GCACGAAGATCCCGAAGTGAAATTC

AATTGGTACGTGGATGGGGTCGAAG

TGCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTACAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAACA

AGGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAAC

CTAGGGAGCCCCAGGTCTATACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGCC

GGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG
SEQ ID
GAAATTGTGATGACGCAGTCTCCA

1710
GAGGCTTGGTACAGCCAGGGCGGTC
1818
GCCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTACAGCTTCTG

AAAGAGCCACCCTCTCCTGCGGGG

GATTCACCTTTGGTGATTATGCTATG

CCAGTCAGAGTGTTAGCAGCAGCT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTAGGTTTCATT

CTGGCCTGGCGCCCAGGCTCCTCAT

AGAAGCAAAGCTTATGGTGGGACAA

CTATGATGCATCCAGCAGGGCCAC

CAGAATACGCCGCGTCTGTGAAAGG

TGGCATCCCAGACAGGTTCAGTGG

CAGATTCACCATCTCAAGAGATGATT

CAGTGGGTCTGGGACAGACTTCAC

CCAAAAGCATCGCCTATCTGCAAATG

TCTCACCATCAGCAGACTGGAGCC

AACAGCCTGAAAACCGAGGACACAG

TGAAGATTTTGCAGTGTATTACTGT

CCGTGTATTACTGTACTAGAGAGGAT

CAGCAGTATGGTAGCTCACCTCGG

ACTATGGTTCGGGGAGTTATTCCCTG

GTCACTTTCGGCGGAGGGACCAAA

GGGCCAGGGAACCCTGGTCACCGTC

GTGGATATCAAACGTACTGTGGCT

TCCTCAGCATCCACCAAGGGGCCTTC

GCTCCCTCCGTGTTCATTTTTCCTC

CGTGTTCCCCCTGGCCCCTTCATCCA

CGTCGGACGAACAGCTGAAGTCCG

AGTCGACCTCTGGTGGAACCGCCGC

GAACCGCGTCCGTGGTCTGTCTCCT

ACTCGGTTGCCTGGTCAAAGACTACT

GAACAACTTCTATCCGCGCGAGGC

TCCCCGAGCCCGTGACTGTCTCGTGG

GAAAGTGCAGTGGAAGGTCGACAA

AACTCGGGCGCCCTCACATCCGGAGT

CGCACTGCAGTCGGGAAACTCCCA

GCATACCTTTCCCGCCGTGTTGCAGT

GGAATCGGTGACCGAGCAGGACTC

CCAGCGGCCTGTACAGCCTGAGCTCC

GAAGGACTCAACCTACTCATTGTC

GTCGTGACAGTGCCGTCCTCCTCCCT

CTCCACCCTCACCCTGAGCAAGGC

TGGAACCCAGACCTATATCTGCAACG

CGATTACGAGAAGCATAAGGTCTA

TCAATCACAAGCCCTCCAACACCAA

CGCCTGCGAAGTGACCCACCAGGG

AGTGGACAAGAAGGTCGAACCCAAG

CCTGAGCAGCCCAGTGACGAAGTC

TCCTGCGACAAGACTCACACCTGTCC

CTTCAACCGGGGAGAATGC

GCCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCACGAAG

ATCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAACG

CCAAGACCAAGCCTAGGGAAGAACA

GTACAACTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGCC

CCAGGTCTATACTTTGCCGCCTAGCC

GGGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGCT

TTTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAAG

TCAAGATGGCAGCAGGGAAACGTGT

TCTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAATC

ACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGCT
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1711
CAGGACTGGTGAAGCCTTCACAGAC
1819
GCACCCTGTCTTTGTCTCCAGGGGA

CCTGTCCCTCACCTGCGCTGTCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GTGGCTCCATCAGCAGTGGTGGTTAC

CAGTCAGAGTGTTAGCAGCAGCGC

TCCTGGAGCTGGATCCGGCAGCCACC

CTTAGCCTGGTTCCAGCAGAAACC

AGGGAAGGGCCTGGAGTGGATTGGG

TGGCCAGGCTCCCAGGCTCCTCATC

TACATCTATCATAGTGGGAGCACCTA

TATGATTCATCCAGCAGGGCCACT

CTACAACCCGTCCCTCAAGAGTCGAG

GGCATCCCAGACAGCTTCAGCGGC

TCACCATATCAGTAGACAGGTCCAA

AGTGGATCTGGGACAGAATTCACA

GAACCAGTTCTCCCTGAAGCTGAGCT

CTCACAATCAGTAGCCTGCAGCCT

CTGTGACCGCCGCGGACACGGCTGT

GAAGATTTTGCAACTTATTACTGTC

GTATTACTGTGCGAGAGATCGGCGTT

AACAGTTTAATACCTACCCCAACA

ACTATGATAGTAGTGGTTATTATCCC

CTTTTGGCCAGGGGACCAAGCTGG

GCCTACTACTTTGACTACTGGGGCCA

AGATCAAACGTACTGTGGCTGCTC

GGGAACCCTGGTCACCGTCTCCTCAG

CCTCCGTGTTCATTTTTCCTCCGTC

CATCCACCAAGGGGCCTTCCGTGTTC

GGACGAACAGCTGAAGTCCGGAAC

CCCCTGGCCCCTTCATCCAAGTCGAC

CGCGTCCGTGGTCTGTCTCCTGAAC

CTCTGGTGGAACCGCCGCACTCGGTT

AACTTCTATCCGCGCGAGGCGAAA

GCCTGGTCAAAGACTACTTCCCCGAG

GTGCAGTGGAAGGTCGACAACGCA

CCCGTGACTGTCTCGTGGAACTCGGG

CTGCAGTCGGGAAACTCCCAGGAA

CGCCCTCACATCCGGAGTGCATACCT

TCGGTGACCGAGCAGGACTCGAAG

TTCCCGCCGTGTTGCAGTCCAGCGGC

GACTCAACCTACTCATTGTCCTCCA

CTGTACAGCCTGAGCTCCGTCGTGAC

CCCTCACCCTGAGCAAGGCCGATT

AGTGCCGTCCTCCTCCCTTGGAACCC

ACGAGAAGCATAAGGTCTACGCCT

AGACCTATATCTGCAACGTCAATCAC

GCGAAGTGACCCACCAGGGCCTGA

AAGCCCTCCAACACCAAAGTGGACA

GCAGCCCAGTGACGAAGTCCTTCA

AGAAGGTCGAACCCAAGTCCTGCGA

ACCGGGGAGAATGC

CAAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GACATCCAGATGACCCAGTCTCCA

1712
GAGGCCTGGTCAAGCCTGGGGGGTC
1820
CTCTCCCTGCCCGTCACCCCTGGAG

CCTGAGACTCTCCTGTGCAGCCTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GATTCACCTTCAGTAGCTATAGCATG

TAGTCAGAGCCTCCTGCATAGTAA

AACTGGGTCCGCCAGGCTCCAGGGA

TGGATACAACTATTTGGATTGGTTC

AGGGGCTGGAGTGGGTTTCATACATT

CTGCAGAAGCCAGGGCAGTCTCCA

AGTAGTAGTGGTAGTTACACAAACT

CGGCTCCTGATCTATATGGGTTCTA

ACGCAGACTCTGTGAAGGGCCGATT

GTCGGGCCTCCGGGGTCCCTGAGA

CACCATCTCCAGAGACAACGCCAAG

GGTTCAGTGGCAGTGGATCAGGCA

AACTCACTGTATCTGCAAATAAACAG

CAGATTTTACACTGAAAATCAGCA

CCTGAGAGCCGAGGACACGGCCATT

GAGTGGAGGCTGAGGATGTTGGGG

TATTACTGTGCGAGAGACGGGGGCT

TCTATTACTGCATGCAAACTTTACA

ATGATAGTAGTGGTTTTCACTTTGAC

CACTGTCACTTTCGGCGGCGGGAC

TACTGGGGCCAGGGAACCCTGGTCA

CAAGGTGGAAATCAAACGTACTGT

CCGTCTCCTCAGCATCCACCAAGGGG

GGCTGCTCCCTCCGTGTTCATTTTT

CCTTCCGTGTTCCCCCTGGCCCCTTC

CCTCCGTCGGACGAACAGCTGAAG

ATCCAAGTCGACCTCTGGTGGAACCG

TCCGGAACCGCGTCCGTGGTCTGTC

CCGCACTCGGTTGCCTGGTCAAAGAC

TCCTGAACAACTTCTATCCGCGCGA

TACTTCCCCGAGCCCGTGACTGTCTC

GGCGAAAGTGCAGTGGAAGGTCGA

GTGGAACTCGGGCGCCCTCACATCCG

CAACGCACTGCAGTCGGGAAACTC

GAGTGCATACCTTTCCCGCCGTGTTG

CCAGGAATCGGTGACCGAGCAGGA

CAGTCCAGCGGCCTGTACAGCCTGA

CTCGAAGGACTCAACCTACTCATT

GCTCCGTCGTGACAGTGCCGTCCTCC

GTCCTCCACCCTCACCCTGAGCAA

TCCCTTGGAACCCAGACCTATATCTG

GGCCGATTACGAGAAGCATAAGGT

CAACGTCAATCACAAGCCCTCCAAC

CTACGCCTGCGAAGTGACCCACCA

ACCAAAGTGGACAAGAAGGTCGAAC

GGGCCTGAGCAGCCCAGTGACGAA

CCAAGTCCTGCGACAAGACTCACAC

GTCCTTCAACCGGGGAGAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1713
CAGGACTGGTGAAGCCCTCGCAGAC
1821
GGCACCCTGTCTTTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AAAGAGCCACCCTCTCCTGCAGGG

GGGACAGTGTCTCTAACAACAGGGC

CCAGTCAGAGTGTTAGCAGCAGCT

TGCTTGGAACTGGATCAGGCAGTCGC

ACTTAGCCTGGTACCAGCAGAAAC

CATCGAGAGGCCTTGAGTGGCTGGG

CTGGCCAGGCTCCCAGGCTCCTCAT

AAGGACATACTACAGGTCCAAGTGG

CTATGGTGCATCCAGCAGGGCCAC

TATAATGAATATGCAGTCTCTGTGAA

TGGCATCCCAGACAGGTTCAGTGG

AAGTCGAATAACCATCAACCCAGAC

CAGTGGGTCTGGGACAGACTTCAC

ACATCCAAGAACCAGTTCTCCCTGCA

TCTCACCATCAGCAGACTGGAGCC

GCTGAACTCTATGACTCCCGAGGACT

TGAAGATTTTGCAGTGTATTACTGT

CGGCTGTGTATTACTGTGCAATTTTG

CAGCAGTATGGTAGCTCACTCCTCT

CCTAGTAGTGGTTATCTACAGGACCA

TCGGCCAAGGGACACGACTGGAGA

CCACTACTACGGTATGGACGTCTGGG

TTAAACGTACTGTGGCTGCTCCCTC

GCCAAGGGACCACGGTCACCGTCTC

CGTGTTCATTTTTCCTCCGTCGGAC

CTCAGCATCCACCAAGGGGCCTTCCG

GAACAGCTGAAGTCCGGAACCGCG

TGTTCCCCCTGGCCCCTTCATCCAAG

TCCGTGGTCTGTCTCCTGAACAACT

TCGACCTCTGGTGGAACCGCCGCACT

TCTATCCGCGCGAGGCGAAAGTGC

CGGTTGCCTGGTCAAAGACTACTTCC

AGTGGAAGGTCGACAACGCACTGC

CCGAGCCCGTGACTGTCTCGTGGAAC

AGTCGGGAAACTCCCAGGAATCGG

TCGGGCGCCCTCACATCCGGAGTGCA

TGACCGAGCAGGACTCGAAGGACT

TACCTTTCCCGCCGTGTTGCAGTCCA

CAACCTACTCATTGTCCTCCACCCT

GCGGCCTGTACAGCCTGAGCTCCGTC

CACCCTGAGCAAGGCCGATTACGA

GTGACAGTGCCGTCCTCCTCCCTTGG

GAAGCATAAGGTCTACGCCTGCGA

AACCCAGACCTATATCTGCAACGTCA

AGTGACCCACCAGGGCCTGAGCAG

ATCACAAGCCCTCCAACACCAAAGT

CCCAGTGACGAAGTCCTTCAACCG

GGACAAGAAGGTCGAACCCAAGTCC

GGGAGAATGC

TGCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG
SEQ ID
GACATCCAGTTGACCCAGTCTCCAT

1714
CTGAGGTGAAGAAGCCTGGGGCCTC
1822
CCTTCCTGTCTGCATCTGTTGGAGA

AGTGAAGGTCTCCTGCAAGGCTTCTG

CAGAGTCACCATCACTTGCCGGGC

GTTACACCTTTACCAGCTACGGTATC

CAGTCAGGGCATTAGCAGTTCTTTG

AGCTGGGTGCGACAGGCCCCTGGAC

GCCTGGTATCAGCAAAAGCCAGGG

AAGGGCTTGAGTGGATGGGATGGAT

AAAGCCCCTAAGCTCCTGATCTAT

CAGCGCTTACAATGGTAACACAAAC

GCTGCATCCACTTTGCAAAGTGGG

TATGCACAGAAGCTCCAGGGCAGAG

GTCCCATCAAGGTTCAGTGGAAGT

TCACCATGACCACAGACACATCCAC

GGATCTGGGACAGATTTTACTTTCA

GAGCACAGCCTACATGGAGCTGAGC

CCATCAGCAGCCTGCAGCCTGAAG

AGCCTGAGATCTGAGGACACGGCCG

ATATTGCAACATATTACTGTCAACA

TGTATTACTGTGCGAGAGCCGCGGTG

GTATGATAATCTCCCTCCTCTCACT

GGGGATGGATACAGCTATGGTCGGC

TTCGGCGGAGGGACCAAGGTGGAA

TCGATTGGGGCCAGGGAACCCTGGT

ATCAAACGTACTGTGGCTGCTCCCT

CACCGTCTCCTCAGCATCCACCAAGG

CCGTGTTCATTTTTCCTCCGTCGGA

GGCCTTCCGTGTTCCCCCTGGCCCCT

CGAACAGCTGAAGTCCGGAACCGC

TCATCCAAGTCGACCTCTGGTGGAAC

GTCCGTGGTCTGTCTCCTGAACAAC

CGCCGCACTCGGTTGCCTGGTCAAAG

TTCTATCCGCGCGAGGCGAAAGTG

ACTACTTCCCCGAGCCCGTGACTGTC

CAGTGGAAGGTCGACAACGCACTG

TCGTGGAACTCGGGCGCCCTCACATC

CAGTCGGGAAACTCCCAGGAATCG

CGGAGTGCATACCTTTCCCGCCGTGT

GTGACCGAGCAGGACTCGAAGGAC

TGCAGTCCAGCGGCCTGTACAGCCTG

TCAACCTACTCATTGTCCTCCACCC

AGCTCCGTCGTGACAGTGCCGTCCTC

TCACCCTGAGCAAGGCCGATTACG

CTCCCTTGGAACCCAGACCTATATCT

AGAAGCATAAGGTCTACGCCTGCG

GCAACGTCAATCACAAGCCCTCCAA

AAGTGACCCACCAGGGCCTGAGCA

CACCAAAGTGGACAAGAAGGTCGAA

GCCCAGTGACGAAGTCCTTCAACC

CCCAAGTCCTGCGACAAGACTCACA

GGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1715
CAGAGGTGAAAAAGCCCGGGGAGTC
1823
TCTCCCTGCCCGTCACCCCTGGAGA

TCTGAAGATCTCCTGTAAGGGTTCTG

GCCGGCCTCCATCTCCTGCAGGTCT

GATACAGCTTTACCAGCTACTGGATC

AGTCAGAGCCTCCTGCATAGTAAT

GGCTGGGTGCGCCAGATGCCCGGGA

GGATACAACTATTTGGATTGGTAC

AAGGCCTGGAGTGGATGGGGATCAT

CTGCAGAAGCCAGGGCAGTCTCCA

CTATCCTGGTGACTCTGATACCAGAT

CAGCTCCTGATCTATTTGGGTTCTA

ACAGCCCGTCCTTCCAAGGCCAGGTC

ATCGGGCCTCCGGGGTCCCTGACA

ACCATCTCAGCCGACAAGTCCATCAG

GGTTCAGTGGCAGTGGATCAGGCA

CACCGCCTACCTGCAGTGGAGCAGC

CAGATTTCACAGTGAAAATCAGCA

CTGAAGGCCTCGGACACCGCCATGT

GAGTGGAGGCTGAGGATGTTGGGG

ATTACTGTGCGAGACTCCCCTCGTAT

TTTATTACTGCATGCAAGCTCTACA

TACTATGATAGTAGTGGTTACTTTAC

AACTCCGTACACTTTTGGCCAGGG

CTGGTACTTCGATCTCTGGGGCCGTG

GACCAAGCTGGAGATCAAACGTAC

GCACCCTGGTGACCGTCTCTTCAGCA

TGTGGCTGCTCCCTCCGTGTTCATT

TCCACCAAGGGGCCTTCCGTGTTCCC

TTTCCTCCGTCGGACGAACAGCTG

CCTGGCCCCTTCATCCAAGTCGACCT

AAGTCCGGAACCGCGTCCGTGGTC

CTGGTGGAACCGCCGCACTCGGTTGC

TGTCTCCTGAACAACTTCTATCCGC

CTGGTCAAAGACTACTTCCCCGAGCC

GCGAGGCGAAAGTGCAGTGGAAG

CGTGACTGTCTCGTGGAACTCGGGCG

GTCGACAACGCACTGCAGTCGGGA

CCCTCACATCCGGAGTGCATACCTTT

AACTCCCAGGAATCGGTGACCGAG

CCCGCCGTGTTGCAGTCCAGCGGCCT

CAGGACTCGAAGGACTCAACCTAC

GTACAGCCTGAGCTCCGTCGTGACAG

TCATTGTCCTCCACCCTCACCCTGA

TGCCGTCCTCCTCCCTTGGAACCCAG

GCAAGGCCGATTACGAGAAGCATA

ACCTATATCTGCAACGTCAATCACAA

AGGTCTACGCCTGCGAAGTGACCC

GCCCTCCAACACCAAAGTGGACAAG

ACCAGGGCCTGAGCAGCCCAGTGA

AAGGTCGAACCCAAGTCCTGCGACA

CGAAGTCCTTCAACCGGGGAGAAT

AGACTCACACCTGTCCGCCTTGTCCA

GC

GCCCCTGAGCTGCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACAACTCTA

CGTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGTC

AAACAAGGCTCTCCCTGCCCCTATCG

AAAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1716
CTGAGGTGAAGAAGCCTGGGGCCTC
1824
CTCTCCCTGCCCGTCACCCTTGGAC

AGTGAAGGTCTCCTGCAAGGCTTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GTTACACCTTTACCAGCTATGGTATC

TTGTCAAAGCCTCGTATACAGTGAT

AGCTGGGTGCGACAGGCCCCTGGAC

GGCAACACCTACTTGAATTGCTTTC

AAGGGCTTGAGTGGATGGGATGGAT

AGCAGAGGCCAGGCCAATCTCCAA

CATCCCTATCTTTGGTATAGCAAACT

GGCGCCTAATTTATAAGGTTTCTAA

ACGCACAGAAGTTCCAGGGCAGAGT

CCGGGACTCTGGGGTCCCAGACAG

CACGATTACCGCGGACAAATCCACG

ATTCAGCGGCAGTGGGTCAGGCAC

AGCACAGCCTACATGGAGCTGAGCA

AGATTTTACACTGGAAATCAGCAG

GCCTGAGATCTGAGGACACGGCCGT

AGTGGAGGCTGAGGATGTTGGGAT

GTATTACTGTGCGAGAGAACTATACA

TTATTTCTGCATGCAAGGTCTACAA

ACTATGGTTCAAAGGACTACTTTGAC

ACTCCATTCACTTTCGGCCCTGGGA

TACTGGGGCCAGGGAACCCTGGTCA

CCAAAGTGGATATCAAACGTACTG

CCGTCTCCTCAGCATCCACCAAGGGG

TGGCTGCTCCCTCCGTGTTCATTTT

CCTTCCGTGTTCCCCCTGGCCCCTTC

TCCTCCGTCGGACGAACAGCTGAA

ATCCAAGTCGACCTCTGGTGGAACCG

GTCCGGAACCGCGTCCGTGGTCTG

CCGCACTCGGTTGCCTGGTCAAAGAC

TCTCCTGAACAACTTCTATCCGCGC

TACTTCCCCGAGCCCGTGACTGTCTC

GAGGCGAAAGTGCAGTGGAAGGTC

GTGGAACTCGGGCGCCCTCACATCCG

GACAACGCACTGCAGTCGGGAAAC

GAGTGCATACCTTTCCCGCCGTGTTG

TCCCAGGAATCGGTGACCGAGCAG

CAGTCCAGCGGCCTGTACAGCCTGA

GACTCGAAGGACTCAACCTACTCA

GCTCCGTCGTGACAGTGCCGTCCTCC

TTGTCCTCCACCCTCACCCTGAGCA

TCCCTTGGAACCCAGACCTATATCTG

AGGCCGATTACGAGAAGCATAAGG

CAACGTCAATCACAAGCCCTCCAAC

TCTACGCCTGCGAAGTGACCCACC

ACCAAAGTGGACAAGAAGGTCGAAC

AGGGCCTGAGCAGCCCAGTGACGA

CCAAGTCCTGCGACAAGACTCACAC

AGTCCTTCAACCGGGGAGAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1717
CAGAGGTGAAAAAGCCCGGGGAGTC
1825
GCACCCTGTCTTTGTCTCCAGGGGA

TCTGAAGATCTCCTGTAAGGGTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACAGCTTTACCAGCTACTGGATC

CAGTCAGAGTGTTAGCAGCAGCTA

GGCTGGGTGCGCCAGATGCCCGGGA

CTTAGCCTGGTACCAGCAGAAACC

AAGGCCTGGAGTGGATGGGGATCAT

TGGCCAGGCTCCCAGGCTCCTCATC

CTATCCTGGTGACTCTGATACCAGAT

TATGGTGCATCCAGCAGGGCCACT

ACAGCCCGTCCTTCCAAGGCCAGGTC

GGCATCCCAGACAGGTTCAGTGGC

ACCATCTCAGCCGACAAGTCCATCAG

AGTGGGTCTGGGACAGACTTCACT

CACCGCCTACCTGCAGTGGAGCAGC

CTCACCATCAGCAGACTGGAGCCT

CTGAAGGCCTCGGACACCGCCATGT

GAAGATTTTGCAGTGTATTACTGTC

ATTACTGTGCGAGGGGCGGTACTTGG

AGCAGTATGGTAGCTCACCTGCGC

GATACAGCTATGGTTACGGGCTTTGA

TCACTTTCGGCGGAGGGACCAAGC

CTACTGGGGCCAGGGAACCCTGGTC

TGGAGATCAAACGTACTGTGGCTG

ACCGTCTCCTCAGCATCCACCAAGGG

CTCCCTCCGTGTTCATTTTTCCTCC

GCCTTCCGTGTTCCCCCTGGCCCCTT

GTCGGACGAACAGCTGAAGTCCGG

CATCCAAGTCGACCTCTGGTGGAACC

AACCGCGTCCGTGGTCTGTCTCCTG

GCCGCACTCGGTTGCCTGGTCAAAGA

AACAACTTCTATCCGCGCGAGGCG

CTACTTCCCCGAGCCCGTGACTGTCT

AAAGTGCAGTGGAAGGTCGACAAC

CGTGGAACTCGGGCGCCCTCACATCC

GCACTGCAGTCGGGAAACTCCCAG

GGAGTGCATACCTTTCCCGCCGTGTT

GAATCGGTGACCGAGCAGGACTCG

GCAGTCCAGCGGCCTGTACAGCCTG

AAGGACTCAACCTACTCATTGTCCT

AGCTCCGTCGTGACAGTGCCGTCCTC

CCACCCTCACCCTGAGCAAGGCCG

CTCCCTTGGAACCCAGACCTATATCT

ATTACGAGAAGCATAAGGTCTACG

GCAACGTCAATCACAAGCCCTCCAA

CCTGCGAAGTGACCCACCAGGGCC

CACCAAAGTGGACAAGAAGGTCGAA

TGAGCAGCCCAGTGACGAAGTCCT

CCCAAGTCCTGCGACAAGACTCACA

TCAACCGGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG
SEQ ID
GAAATTGTGATGACGCAGTCTCCA

1718
CAGAGGTGAAAAAGCCCGGGGAGTC
1826
CTCTCCCTGCCCGTCACCCCTGGAG

TCTGAAGATCTCCTGTAAGGGTTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GATACAGCTTTACCAGCTACTGGATC

TAGTCAGAGCCTCCTGCATAGTAA

GCCTGGGTGCGCCAGATGCCCGGGA

TGGATACAACTATTTGGATTGGTAC

AAGGCCTGGAGTGGATGGGGGTCAT

CTGCAGAAGCCAGGGCAGTCTCCA

CTATCCTGGTGACTCTGATACCAGAT

CAGCTCCTGATCTATTTGGGTTCTA

ACAGCCCGTCCTTCCAAGGCCAGGTC

CTCGGGCCTCCGGGGTCCCTGACA

ACCATCTCAGCCGACAAGTCCATCAA

GGTTCAGTGGCAGTGGATCAGGCA

TACCGCCTACCTGCAGTGGAGCAGCC

CAGACTTTACACTGAAAATCAGCA

TGAAGGCCTCGGACACCGCCATGTAT

GAGCGGAGGCTGAGGATGTTGGGG

TACTGTGCGAGACCCCATTACGATAT

TTTATTACTGCATGCAAGCTCTACA

TTTGACTGGTTCCCGGGCGCCCTTTG

CACTCCGTGGACGTTCGGCCTAGG

ACTACTGGGGCCAGGGAACCCTGGT

GACCAAAGTGGATATCAAACGTAC

CACCGTCTCCTCAGCATCCACCAAGG

TGTGGCTGCTCCCTCCGTGTTCATT

GGCCTTCCGTGTTCCCCCTGGCCCCT

TTTCCTCCGTCGGACGAACAGCTG

TCATCCAAGTCGACCTCTGGTGGAAC

AAGTCCGGAACCGCGTCCGTGGTC

CGCCGCACTCGGTTGCCTGGTCAAAG

TGTCTCCTGAACAACTTCTATCCGC

ACTACTTCCCCGAGCCCGTGACTGTC

GCGAGGCGAAAGTGCAGTGGAAG

TCGTGGAACTCGGGCGCCCTCACATC

GTCGACAACGCACTGCAGTCGGGA

CGGAGTGCATACCTTTCCCGCCGTGT

AACTCCCAGGAATCGGTGACCGAG

TGCAGTCCAGCGGCCTGTACAGCCTG

CAGGACTCGAAGGACTCAACCTAC

AGCTCCGTCGTGACAGTGCCGTCCTC

TCATTGTCCTCCACCCTCACCCTGA

CTCCCTTGGAACCCAGACCTATATCT

GCAAGGCCGATTACGAGAAGCATA

GCAACGTCAATCACAAGCCCTCCAA

AGGTCTACGCCTGCGAAGTGACCC

CACCAAAGTGGACAAGAAGGTCGAA

ACCAGGGCCTGAGCAGCCCAGTGA

CCCAAGTCCTGCGACAAGACTCACA

CGAAGTCCTTCAACCGGGGAGAAT

CCTGTCCGCCTTGTCCAGCCCCTGAG

GC

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GACATCCAGATGACCCAGTCTCCA

1719
CAGGACTGTTGAAGCCTTCGGAGAC
1827
GCCACCCTGTCTGTGTCTCCAGGGG

CCTGTCCCTCACCTGCGCTGTCTATG

AAAGGGCCACCCTCTTTTGCCGGG

GTGGGTCCTTCAGTGGTTACTACTGG

CCAGTGAAGGTCTTACCACCAACT

AGCTGGATCCGCCAGCCCCCAGGGA

TAGCCTGGTACCAGCACAAACCTG

AGGGGCTGGAGTGGATTGGGGAAAT

GCCAGGCTCCCAGGCTCCTCATCTA

CAATCATAGTGGAAGCACCAACTAC

TGCTGCCTCCACCAGGGCCACTGG

AACCCGTCCCTCAAGAGTCGAGTCAC

TGTCCCAGCCAGGTTCAGTGGCAG

CATATCAGTAGACACGTCCAAGAAC

TGGGTCTGGGACAGACTTCACTCTC

CAGTTCTCCCTGAAGCTGAGCTCTGT

ACCATCAGCAGCCTGCAGTCTGAA

GACCGCCGCGGACACGGCTGTGTATT

GATTCCGCAGTTTATTACTGTCAGC

ACTGTGCGAGAGCCCGAGTGGAATC

AGTATAATCACTGGCCTCTCTACAC

CAAGGATGGGTACTTTGACTACTGGG

TTTTGGCCAGGGGACCAAGGTGGA

GCCAGGGAACCCTGGTCACCGTCTCC

AATCAAACGTACTGTGGCTGCTCC

TCAGCATCCACCAAGGGGCCTTCCGT

CTCCGTGTTCATTTTTCCTCCGTCG

GTTCCCCCTGGCCCCTTCATCCAAGT

GACGAACAGCTGAAGTCCGGAACC

CGACCTCTGGTGGAACCGCCGCACTC

GCGTCCGTGGTCTGTCTCCTGAACA

GGTTGCCTGGTCAAAGACTACTTCCC

ACTTCTATCCGCGCGAGGCGAAAG

CGAGCCCGTGACTGTCTCGTGGAACT

TGCAGTGGAAGGTCGACAACGCAC

CGGGCGCCCTCACATCCGGAGTGCAT

TGCAGTCGGGAAACTCCCAGGAAT

ACCTTTCCCGCCGTGTTGCAGTCCAG

CGGTGACCGAGCAGGACTCGAAGG

CGGCCTGTACAGCCTGAGCTCCGTCG

ACTCAACCTACTCATTGTCCTCCAC

TGACAGTGCCGTCCTCCTCCCTTGGA

CCTCACCCTGAGCAAGGCCGATTA

ACCCAGACCTATATCTGCAACGTCAA

CGAGAAGCATAAGGTCTACGCCTG

TCACAAGCCCTCCAACACCAAAGTG

CGAAGTGACCCACCAGGGCCTGAG

GACAAGAAGGTCGAACCCAAGTCCT

CAGCCCAGTGACGAAGTCCTTCAA

GCGACAAGACTCACACCTGTCCGCCT

CCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG
SEQ ID
GACATCCAGTTGACCCAGTCTCCTT

1720
GAGGCGTGGTCCAGCCTGGGAGGTC
1828
CCACCCTGTCTTTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCACTTTCACTGATGCCTGGATG

CAGTCAGAGTGTTAGCAGCTACTT

AACTGGGTCCGCCAGGCTCCAGGGA

AGCCTGGTACCAACAGAAATCTGG

AGGGGCTGGAGTGGATTGGCCGTGT

CCAGGCTCCCAGGCTCCTCATCTAT

TAAAAACAAAGCTGATGGTGAGACA

GATGCATCCAACAGGGCCACTGGC

ACGGACTACGCTGCACCCGTCAAAG

ATCCCAGCCAGGTTCAGTGGCAGT

GCAGAATCACCATCTCAAGAGATGA

GGGTCTGGGACAGACTTCACTCTC

TGCAAAGAACACTCTGTATGTGCAA

ACCATCAGCAGCCTAGAGCCTGAA

ATGAACAGCCTGAAAACCGAGGACA

GATTTTGCAGTTTATTACTGTCAGC

CAGCCGTGTATTATTGTACCGCTGAC

AGGGTAGCAACTGGCCGCTCACTT

CTGCGACTTTCTACGTGGGATGCTTA

TCGGCGGAGGGACCAAGGTGGAAA

TGATTTCTGGGGCCAAGGGACAATG

TCAAACGTACTGTGGCTGCTCCCTC

GTCACCGTCTCTTCAGCATCCACCAA

CGTGTTCATTTTTCCTCCGTCGGAC

GGGGCCTTCCGTGTTCCCCCTGGCCC

GAACAGCTGAAGTCCGGAACCGCG

CTTCATCCAAGTCGACCTCTGGTGGA

TCCGTGGTCTGTCTCCTGAACAACT

ACCGCCGCACTCGGTTGCCTGGTCAA

TCTATCCGCGCGAGGCGAAAGTGC

AGACTACTTCCCCGAGCCCGTGACTG

AGTGGAAGGTCGACAACGCACTGC

TCTCGTGGAACTCGGGCGCCCTCACA

AGTCGGGAAACTCCCAGGAATCGG

TCCGGAGTGCATACCTTTCCCGCCGT

TGACCGAGCAGGACTCGAAGGACT

GTTGCAGTCCAGCGGCCTGTACAGCC

CAACCTACTCATTGTCCTCCACCCT

TGAGCTCCGTCGTGACAGTGCCGTCC

CACCCTGAGCAAGGCCGATTACGA

TCCTCCCTTGGAACCCAGACCTATAT

GAAGCATAAGGTCTACGCCTGCGA

CTGCAACGTCAATCACAAGCCCTCCA

AGTGACCCACCAGGGCCTGAGCAG

ACACCAAAGTGGACAAGAAGGTCGA

CCCAGTGACGAAGTCCTTCAACCG

ACCCAAGTCCTGCGACAAGACTCAC

GGGAGAATGC

ACCTGTCCGCCTTGTCCAGCCCCTGA

GCTGCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACACT

CTGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGGG

AAGAACAGTACAACTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTATACTTTGCC

GCCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGGG

AAACGTGTTCTCCTGCTCCGTGATGC

ACGAAGCGCTGCACAACCATTACAC

CCAGAAATCACTGTCACTTTCGCCGG

GAAAA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG
SEQ ID
GATATTGTGATGACCCACACTCCA

1721
GAGGCTTGGTCCAGCCTGGGGGGTC
1829
CTCTCCTCACCTGTCACCCTTGGAC

CCTAAGACTCTCTTGTACAGTCTCAG

AGCCGGCCTCCATCTCCTGCAGGTC

GATTCACCTTTAGTAACAATTGGATG

TAGTCAAAGCCTCGAACACACTGA

ACCTGGGTCCGCCAGACTCCAGGGA

TGGAAACACCTACTTAAGTTGGCTT

AGGGGCTGGAGTGGGTGGCCAACAT

CACCAGAGGCCAGGCCAGCCCCCA

AAAGCAAGATGGAACTGAGAAACAC

AGACTGTTAATTTATAAGGTTTCTA

TATGTGGACTCTGTGAAGGGCCGATT

CCCGGTTCTCTGGGGTCCCAGACA

CACCATCTCCAGAGACAACGCCGAG

GATTCAGTGGCAGTGGGGCAGGGA

AACTCACTGTATCTGCAGATGAACAG

CAGATTTCACACTGAAAATCAGCA

CCTGAGAGGTGAGGACACGGCCGTG

GGGTGGAGGCTGAGGATGTCGGCG

TATTATTGTGCGAGAAACAGTCAACG

TTTATTACTGCGTGCAGGCTACACA

TTCGTTTGACTACTGGGGCCAGGGCA

CTATCCTCGGACGTTCGGCCATGG

CCCTGGTGACCGTCTCCTCAGCATCC

GACCAAGGTGGAGATCAAACGTAC

ACCAAGGGGCCTTCCGTGTTCCCCCT

TGTGGCTGCTCCCTCCGTGTTCATT

GGCCCCTTCATCCAAGTCGACCTCTG

TTTCCTCCGTCGGACGAACAGCTG

GTGGAACCGCCGCACTCGGTTGCCTG

AAGTCCGGAACCGCGTCCGTGGTC

GTCAAAGACTACTTCCCCGAGCCCGT

TGTCTCCTGAACAACTTCTATCCGC

GACTGTCTCGTGGAACTCGGGCGCCC

GCGAGGCGAAAGTGCAGTGGAAG

TCACATCCGGAGTGCATACCTTTCCC

GTCGACAACGCACTGCAGTCGGGA

GCCGTGTTGCAGTCCAGCGGCCTGTA

AACTCCCAGGAATCGGTGACCGAG

CAGCCTGAGCTCCGTCGTGACAGTGC

CAGGACTCGAAGGACTCAACCTAC

CGTCCTCCTCCCTTGGAACCCAGACC

TCATTGTCCTCCACCCTCACCCTGA

TATATCTGCAACGTCAATCACAAGCC

GCAAGGCCGATTACGAGAAGCATA

CTCCAACACCAAAGTGGACAAGAAG

AGGTCTACGCCTGCGAAGTGACCC

GTCGAACCCAAGTCCTGCGACAAGA

ACCAGGGCCTGAGCAGCCCAGTGA

CTCACACCTGTCCGCCTTGTCCAGCC

CGAAGTCCTTCAACCGGGGAGAAT

CCTGAGCTGCTGGGTGGTCCGTCCGT

GC

GTTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCCG

GAAGTCACTTGCGTGGTCGTGGACGT

GTCGCACGAAGATCCCGAAGTGAAA

TTCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACAACTCTACGT

ACCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAAA

CAAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTATACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGCC

TTGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCAAGCTG

ACTGTGGACAAGTCAAGATGGCAGC

AGGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1722
GAGGCGTGGTCCAGCCTGGGAGGTC
1830
GGCACCCTGTCCTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGCTATGGCATG

CCAGTCAGAGTATTAGCGGCAGTT

CACTGGGTCCGCCAGGCTCCAGGCA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTGGCAGTTAT

GTGGCCAGGCTCCCAGGCTCCTCA

ATCATATGATGGAAGTAATAAATACT

TCTATGATGCGTCCAGCAGGGCCG

ATGCAGACTCCGTGAAGGGCCGATT

AAGGCATCCCAGACAGGTTCATTG

CACCATCTCCAGAGACAATTCCAAG

GCAGTGGGTCTGGGACAGACTTCA

AACACGCTGTATCTGCAAATGAACA

CTCTCACCATCAGCAGACTGGAGC

GCCTGAGAGCTGAGGACACGGCTGT

CTGAAGACTTTGCTATGTATTACTG

GTATTACTGTGCGAAAGATTTAGGGG

TCAGCAGTATGGTAGCTCACCAAT

ATCCCCGGGGTGGTATTTTGAACTAC

ATTCACTTTCGGCCCTGGGACCAA

TGGGGCCAGGGCACCCTGGTCACCG

AGTGGATATCAAACGTACTGTGGC

TCTCCTCAGCATCCACCAAGGGGCCT

TGCTCCCTCCGTGTTCATTTTTCCTC

TCCGTGTTCCCCCTGGCCCCTTCATC

CGTCGGACGAACAGCTGAAGTCCG

CAAGTCGACCTCTGGTGGAACCGCC

GAACCGCGTCCGTGGTCTGTCTCCT

GCACTCGGTTGCCTGGTCAAAGACTA

GAACAACTTCTATCCGCGCGAGGC

CTTCCCCGAGCCCGTGACTGTCTCGT

GAAAGTGCAGTGGAAGGTCGACAA

GGAACTCGGGCGCCCTCACATCCGG

CGCACTGCAGTCGGGAAACTCCCA

AGTGCATACCTTTCCCGCCGTGTTGC

GGAATCGGTGACCGAGCAGGACTC

AGTCCAGCGGCCTGTACAGCCTGAG

GAAGGACTCAACCTACTCATTGTC

CTCCGTCGTGACAGTGCCGTCCTCCT

CTCCACCCTCACCCTGAGCAAGGC

CCCTTGGAACCCAGACCTATATCTGC

CGATTACGAGAAGCATAAGGTCTA

AACGTCAATCACAAGCCCTCCAACA

CGCCTGCGAAGTGACCCACCAGGG

CCAAAGTGGACAAGAAGGTCGAACC

CCTGAGCAGCCCAGTGACGAAGTC

CAAGTCCTGCGACAAGACTCACACCT

CTTCAACCGGGGAGAATGC

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1723
GAGGCGTGGTCCAGCCTGGGAGGTC
1831
GACTCCCTGCCCGTCACCCCTGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

GAGCCGGCCTCCATCTCCTGCAGG

GATTCACCTTCAGTAGCTATGCTATG

TCTAGTCAGAGCCTCCTGCATAGTA

CACTGGGTCCGCCAGGCTCCAGGCA

ATGGAAACAACTATTTGGATTGGT

AGGGGCTGGAGTGGGTGGCAGTTAT

ACCTGCAGAAGCCAGGGCAGTCTC

ATCATATGATGGAAGTAATAAATACT

CACAGCTCCTGATCTATTTGGGTTC

ACGCAGACTCCGTGAAGGGCCGATT

TAATCGGGCCTCCGGGGTCCCTGA

CACCATCTCCAGAGACAATTCCAAG

CAGGTTCAGTGGCAGTGGATCAGG

AACACGCTGTATCTGCAAATGAACA

CACAGATTTTACACTGAAACTCAG

GCCTGAGAGCTGAGGACACGGCTGT

CAGAGTGGAGGCTGAGGATGTTGG

GTATTACTGTGCCCGGTCGAGCCCCT

GGTTTATTACTGCATGCAAGGTCTA

GGGGGGAGTTATCGTTATACCAGGG

CAAATCCCTATCACTTTCGGCCCTG

GGCTTTTGATATCTGGGGCCAAGGGA

GGACCAAAGTGGATATCAAACGTA

CAATGGTCACCGTCTCTTCAGCATCC

CTGTGGCTGCTCCCTCCGTGTTCAT

ACCAAGGGGCCTTCCGTGTTCCCCCT

TTTTCCTCCGTCGGACGAACAGCTG

GGCCCCTTCATCCAAGTCGACCTCTG

AAGTCCGGAACCGCGTCCGTGGTC

GTGGAACCGCCGCACTCGGTTGCCTG

TGTCTCCTGAACAACTTCTATCCGC

GTCAAAGACTACTTCCCCGAGCCCGT

GCGAGGCGAAAGTGCAGTGGAAG

GACTGTCTCGTGGAACTCGGGCGCCC

GTCGACAACGCACTGCAGTCGGGA

TCACATCCGGAGTGCATACCTTTCCC

AACTCCCAGGAATCGGTGACCGAG

GCCGTGTTGCAGTCCAGCGGCCTGTA

CAGGACTCGAAGGACTCAACCTAC

CAGCCTGAGCTCCGTCGTGACAGTGC

TCATTGTCCTCCACCCTCACCCTGA

CGTCCTCCTCCCTTGGAACCCAGACC

GCAAGGCCGATTACGAGAAGCATA

TATATCTGCAACGTCAATCACAAGCC

AGGTCTACGCCTGCGAAGTGACCC

CTCCAACACCAAAGTGGACAAGAAG

ACCAGGGCCTGAGCAGCCCAGTGA

GTCGAACCCAAGTCCTGCGACAAGA

CGAAGTCCTTCAACCGGGGAGAAT

CTCACACCTGTCCGCCTTGTCCAGCC

GC

CCTGAGCTGCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCCG

GAAGTCACTTGCGTGGTCGTGGACGT

GTCGCACGAAGATCCCGAAGTGAAA

TTCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACAACTCTACGT

ACCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAAA

CAAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTATACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGCC

TTGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCAAGCTG

ACTGTGGACAAGTCAAGATGGCAGC

AGGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG
SEQ ID
GACATCCAGATGACCCAGTCTCCA

1724
GAGGCTTGGTACAGCCTGGCAGGTC
1832
TCTTCTGTGTCTGCATCTGTGGGAG

CCTGAGACTCTCCTGTGCAGCCTCTG

ACAGAGTCACCATCACTTGTCGGG

GATTCACCTTTGATGATTATGCCATG

CGAGTCAGAACATTCGCCACTGGT

CACTGGGTCCGGCAAGCTCCAGGGA

TAGTCTGGTATCAGCAAAAATTAG

AGGGGCTGGAGTGGGTCTCAGCTATT

GGCAAGCCCCTAAACTCCTGATCT

AGTGGTAGTGGTGGTAGCACATACT

ATGCTGCGTCCAATTTGCAAAGTG

ACGCAGACTCCGTGAAGGGCCGGTT

GGGTCCCGTCAAGGTTCAGCGGCA

CACCATCTCCAGAGACAATTCCAAG

GTGGATCTGGGACAGAATTCACTC

AACACGCTGTATCTGCAAATGAACA

TCACAATCAACAGCCTGCAGGCTG

GCCTGAGAGCCGAGGACACGGCCGT

AAGATTTTGCAACCTATTACTGTCT

ATATTACTGTGCGAAAGATAACGATT

ACAGCATAACAGTTACCCGTGGAC

TTTGGAGTGGGAAAGTCTTTGACTAC

GTTCGGCCAAGGGACCAAGGTGGA

TGGGGCCAGGGCACCCTGGTCACCG

AATCAAACGTACTGTGGCTGCTCC

TCTCCTCAGCATCCACCAAGGGGCCT

CTCCGTGTTCATTTTTCCTCCGTCG

TCCGTGTTCCCCCTGGCCCCTTCATC

GACGAACAGCTGAAGTCCGGAACC

CAAGTCGACCTCTGGTGGAACCGCC

GCGTCCGTGGTCTGTCTCCTGAACA

GCACTCGGTTGCCTGGTCAAAGACTA

ACTTCTATCCGCGCGAGGCGAAAG

CTTCCCCGAGCCCGTGACTGTCTCGT

TGCAGTGGAAGGTCGACAACGCAC

GGAACTCGGGCGCCCTCACATCCGG

TGCAGTCGGGAAACTCCCAGGAAT

AGTGCATACCTTTCCCGCCGTGTTGC

CGGTGACCGAGCAGGACTCGAAGG

AGTCCAGCGGCCTGTACAGCCTGAG

ACTCAACCTACTCATTGTCCTCCAC

CTCCGTCGTGACAGTGCCGTCCTCCT

CCTCACCCTGAGCAAGGCCGATTA

CCCTTGGAACCCAGACCTATATCTGC

CGAGAAGCATAAGGTCTACGCCTG

AACGTCAATCACAAGCCCTCCAACA

CGAAGTGACCCACCAGGGCCTGAG

CCAAAGTGGACAAGAAGGTCGAACC

CAGCCCAGTGACGAAGTCCTTCAA

CAAGTCCTGCGACAAGACTCACACCT

CCGGGGAGAATGC

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1725
GAGGCTTGGTACAGCCTGGGGGGTC
1833
GACTTTCAGTCTGTGACTCCAAAGC

CCTGAGACTCTCCTGTGCAGCCTCTG

AGAAAGTCACCATCACCTGCCGGG

GATTCACCTTCAGTAGTTATAGCATG

CCAGTCAGAGCATTGGTGGTAGCT

AACTGGGTCCGCCAGGCTCCAGGGA

TACACTGGTACCAGCAGAAACCAG

AGGGGCTGGAGTGGGTTTCATACATC

GTCAGTCTCCAAAGCTCATCATCA

AGTAGTACTAGTAGTACCATATACTA

AGTATGCTTCCCAGTCCTTCTCAGG

CGCAGACTCCGTGAAGGGCCGATTC

GGTCCCCTCGAGGTTCAGTGGCAG

ACCATCTCCAGAGACAATTCCAAGA

TGGATCTGGGACAGATTTCACCCTC

ATATGCTGTTTCTACAAATGAACAGC

ACCATCGATAGCCTGGAGGCTGAA

CTGAGAGCTGAGGACACGGCTGTGT

GATGCTGCAACGTACTATTGTCATC

ATTACTGTGCGAAAGAAGGGGGCAG

AGAGTATCAGTTTACCGCTCACTTT

TGGCTGGCGCCACTACTTTGACTACT

CGGCGGAGGGACCAAAGTGGATAT

GGGGCCAGGGAACCCTGGTCACCGT

CAAACGTACTGTGGCTGCTCCCTCC

CTCCTCAGCATCCACCAAGGGGCCTT

GTGTTCATTTTTCCTCCGTCGGACG

CCGTGTTCCCCCTGGCCCCTTCATCC

AACAGCTGAAGTCCGGAACCGCGT

AAGTCGACCTCTGGTGGAACCGCCG

CCGTGGTCTGTCTCCTGAACAACTT

CACTCGGTTGCCTGGTCAAAGACTAC

CTATCCGCGCGAGGCGAAAGTGCA

TTCCCCGAGCCCGTGACTGTCTCGTG

GTGGAAGGTCGACAACGCACTGCA

GAACTCGGGCGCCCTCACATCCGGA

GTCGGGAAACTCCCAGGAATCGGT

GTGCATACCTTTCCCGCCGTGTTGCA

GACCGAGCAGGACTCGAAGGACTC

GTCCAGCGGCCTGTACAGCCTGAGCT

AACCTACTCATTGTCCTCCACCCTC

CCGTCGTGACAGTGCCGTCCTCCTCC

ACCCTGAGCAAGGCCGATTACGAG

CTTGGAACCCAGACCTATATCTGCAA

AAGCATAAGGTCTACGCCTGCGAA

CGTCAATCACAAGCCCTCCAACACCA

GTGACCCACCAGGGCCTGAGCAGC

AAGTGGACAAGAAGGTCGAACCCAA

CCAGTGACGAAGTCCTTCAACCGG

GTCCTGCGACAAGACTCACACCTGTC

GGAGAATGC

CGCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAAC

AGTACAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTATACTTTGCCGCCTAGC

CGGGAAGAAATGACTAAGAACCAAG

TGTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGGA

GTGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGTG

TTCTCCTGCTCCGTGATGCACGAAGC

GCTGCACAACCATTACACCCAGAAA

TCACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1726
GAGGCGTGGTCCAGCCTGGGAGGTC
1834
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTGTCCTGTGCAGCCTCTG

AAGGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGCAGCTATGCTATG

CCAGTCAGAGTGTTACCAGCAACT

CACTGGGTCCGCCAGGCTCCAGGCA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTGGCAGTTAT

CTGGCCAGGCTCCCAGGCTCCTCAT

ATCATATGATGGAAGTAATAAATACT

CTATGGTGCATCCTACAGGGCCAC

ACGCAGACTCCGTGAAGGGCCGATT

TGGCATCCCTGACAGGTTCAGCGG

CACCATCTCCAGAGACAATTCCAAG

CAGTGGGTCTGGGACAGACTTCAC

AACACGCTGTATCTGCAAATGAACA

TCTCACCATCAGCAGACTGGAGCC

GCCTGAGAGCTGAGGACACGGCTGT

TGAAGATTTTGCAGTGTATTACTGT

GTATTACTGTGCGAGAGATTATTGTA

CAGCAGTATGCTAGCTCAGTCACC

GTAGTACCAGCTGCCAGAACTGGTTC

TTCGGCCAAGGGACACGACTGGAG

GACCCCTGGGGCCAGGGCACCCTGG

ATTAAACGTACTGTGGCTGCTCCCT

TCACCGTCTCCTCAGCATCCACCAAG

CCGTGTTCATTTTTCCTCCGTCGGA

GGGCCTTCCGTGTTCCCCCTGGCCCC

CGAACAGCTGAAGTCCGGAACCGC

TTCATCCAAGTCGACCTCTGGTGGAA

GTCCGTGGTCTGTCTCCTGAACAAC

CCGCCGCACTCGGTTGCCTGGTCAAA

TTCTATCCGCGCGAGGCGAAAGTG

GACTACTTCCCCGAGCCCGTGACTGT

CAGTGGAAGGTCGACAACGCACTG

CTCGTGGAACTCGGGCGCCCTCACAT

CAGTCGGGAAACTCCCAGGAATCG

CCGGAGTGCATACCTTTCCCGCCGTG

GTGACCGAGCAGGACTCGAAGGAC

TTGCAGTCCAGCGGCCTGTACAGCCT

TCAACCTACTCATTGTCCTCCACCC

GAGCTCCGTCGTGACAGTGCCGTCCT

TCACCCTGAGCAAGGCCGATTACG

CCTCCCTTGGAACCCAGACCTATATC

AGAAGCATAAGGTCTACGCCTGCG

TGCAACGTCAATCACAAGCCCTCCAA

AAGTGACCCACCAGGGCCTGAGCA

CACCAAAGTGGACAAGAAGGTCGAA

GCCCAGTGACGAAGTCCTTCAACC

CCCAAGTCCTGCGACAAGACTCACA

GGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1727
GAGGCTTGGTACAGCCTGGGGGGTC
1835
CCACCCTGTCTGTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCACCTTTAGCAACTATGTCATG

CAGTCAGAGTATTAGCAGCAACTT

AGCTGGGTCCGCCAGGCTCCAGGGA

AGCCTGGTACCAGCAGAAACCTGG

AGGGGCTGGAGTGGGTCTCAGCTATT

CCAGGCTCCCAGGCTCCTCATCTAT

AGTGGTATTGGTGATACTACATACTA

GGTGCCTCCACCAGGGCCACTGGT

CGCGGACTCCGTGAAGGGCCGATTC

ATCCCAGCCAGGTTCAGTGGCAGT

ACCATCTCCAGAGACAACGCCAAGA

GGGTCTGGGACAGAGTTCACTCTC

ACACGCTGTATCTGCAAATGAACAGT

ACCATCAGCAGCCTGCAGTCTGAA

CTGAGAGCCGAGGACACGGCTGTGT

GATTTTGCAGTTTATTACTGTCAGC

ATTACTGTGCAAGAGGGCGCGTGGC

AGTATAATAACTGGCCTAGAACGT

GGGGGATGCTTTTGATATCTGGGGCC

TCGGCCAAGGGACCAAGCTGGAGA

AAGGGACAATGGTGACCGTCTCTTCA

TCAAACGTACTGTGGCTGCTCCCTC

GCATCCACCAAGGGGCCTTCCGTGTT

CGTGTTCATTTTTCCTCCGTCGGAC

CCCCCTGGCCCCTTCATCCAAGTCGA

GAACAGCTGAAGTCCGGAACCGCG

CCTCTGGTGGAACCGCCGCACTCGGT

TCCGTGGTCTGTCTCCTGAACAACT

TGCCTGGTCAAAGACTACTTCCCCGA

TCTATCCGCGCGAGGCGAAAGTGC

GCCCGTGACTGTCTCGTGGAACTCGG

AGTGGAAGGTCGACAACGCACTGC

GCGCCCTCACATCCGGAGTGCATACC

AGTCGGGAAACTCCCAGGAATCGG

TTTCCCGCCGTGTTGCAGTCCAGCGG

TGACCGAGCAGGACTCGAAGGACT

CCTGTACAGCCTGAGCTCCGTCGTGA

CAACCTACTCATTGTCCTCCACCCT

CAGTGCCGTCCTCCTCCCTTGGAACC

CACCCTGAGCAAGGCCGATTACGA

CAGACCTATATCTGCAACGTCAATCA

GAAGCATAAGGTCTACGCCTGCGA

CAAGCCCTCCAACACCAAAGTGGAC

AGTGACCCACCAGGGCCTGAGCAG

AAGAAGGTCGAACCCAAGTCCTGCG

CCCAGTGACGAAGTCCTTCAACCG

ACAAGACTCACACCTGTCCGCCTTGT

GGGAGAATGC

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GACATCCAGTTGACCCAGTCTCCA

1728
GAGGCTTGGTACAGCCTGGGGGGTC
1836
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGAGACTCTCCTGTGCAGCCTCTG

AGAGGGCCACCATCAACTGCAAGT

GATTCACCTTTAGCAGCTATGCCATG

CCAGCCAGAGTGTTTTATACAGCTC

AGCTGGGTCCGCCAGGCTCCAGGGA

CAACAATAAGAACTACTTAGCTTG

AGGGGCTGGAGTGGGTCTCAGCTATT

GTACCAGCAGAAACCAGGACAGCC

AGTGGTAGTGGTGGTAGCACATACT

TCCTAAGCTGCTCATTTACTGGGCA

ACGCAGACTCCGTGAAGGGCCGGTT

TCTGCCCGGGAATCCGGGGTCCCT

CACCATCTCCAGAGACAATTCCAAG

GACCGATTCAGTGGCAGCGGGTCT

AACACGCTGTATCTGCAAATGAACA

GGGACAGATTTCACTCTCACCATC

GCCTGAGAGCCGAGGACACGGCCGT

AACAGCCTGCAGGCTGAAGATGTG

ATATTACTGTGCGAAAGATCAAGGG

GCAGTTTATTACTGTCAGCAATTTT

GCAGCAGCTGGTACCCTGGGGTACTT

ATAGTCCTCCTCGGACGTTCGGCCA

TGACTACTGGGGCCAGGGAACCCTG

AGGGACCAAGGTGGAAATCAAACG

GTGACCGTCTCCTCAGCATCCACCAA

TACTGTGGCTGCTCCCTCCGTGTTC

GGGGCCTTCCGTGTTCCCCCTGGCCC

ATTTTTCCTCCGTCGGACGAACAGC

CTTCATCCAAGTCGACCTCTGGTGGA

TGAAGTCCGGAACCGCGTCCGTGG

ACCGCCGCACTCGGTTGCCTGGTCAA

TCTGTCTCCTGAACAACTTCTATCC

AGACTACTTCCCCGAGCCCGTGACTG

GCGCGAGGCGAAAGTGCAGTGGAA

TCTCGTGGAACTCGGGCGCCCTCACA

GGTCGACAACGCACTGCAGTCGGG

TCCGGAGTGCATACCTTTCCCGCCGT

AAACTCCCAGGAATCGGTGACCGA

GTTGCAGTCCAGCGGCCTGTACAGCC

GCAGGACTCGAAGGACTCAACCTA

TGAGCTCCGTCGTGACAGTGCCGTCC

CTCATTGTCCTCCACCCTCACCCTG

TCCTCCCTTGGAACCCAGACCTATAT

AGCAAGGCCGATTACGAGAAGCAT

CTGCAACGTCAATCACAAGCCCTCCA

AAGGTCTACGCCTGCGAAGTGACC

ACACCAAAGTGGACAAGAAGGTCGA

CACCAGGGCCTGAGCAGCCCAGTG

ACCCAAGTCCTGCGACAAGACTCAC

ACGAAGTCCTTCAACCGGGGAGAA

ACCTGTCCGCCTTGTCCAGCCCCTGA

TGC

GCTGCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACACT

CTGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGGG

AAGAACAGTACAACTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTATACTTTGCC

GCCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGGG

AAACGTGTTCTCCTGCTCCGTGATGC

ACGAAGCGCTGCACAACCATTACAC

CCAGAAATCACTGTCACTTTCGCCGG

GAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAATTGTGTTGACACAGTCTCCA

1729
CTGAGGTGAAGAAGCCTGGGGCCTC
1837
GGCACCCTGTCTTTGTCTCCAGGGG

AGTGAAGGTCTCCTGCAAGGCTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATACACCTTCACCAGTTATGATATC

CCAGTCAGAGTGTTAGCAGCAGCT

AACTGGGTGCGACAGGCCACTGGAC

ACTTAGCCTGGTACCAGCAGAAAC

AAGGGCTTGAGTGGATGGGATGGAT

CTGGCCAGGCTCCCAGGCTCCTCAT

GAACCCTAACAGTGGTAACACAGGC

CTATGGTGCATCCAGCAGGGCCAC

TATGCACAGAAGTTCCAGGGCAGAG

TGGCATCCCAGACAGGTTCAGTGG

TCACCATGACCAGGAACACCTCCATA

CAGTGGGTCTGGGACAGACTTCAC

AGCACAGCCTACATGGAGCTGAGCA

TCTCACCATCAGCAGACTGGAGCC

GCCTGAGATCTGAGGACACGGCCGT

TGAAGATTTTGCAGTGTATTACTGT

GTATTACTGTACGAGAGGAATCTATG

CAGCAGTATGGTAGCTCACCCCCG

ATAGTAGTGGTTCTTCCAATCCCTTT

GGCACTTTCGGCGGAGGGACCAAA

GACTCCTGGGGCCAGGGAACCCTGG

GTGGATATCAAACGTACTGTGGCT

TGACCGTCTCCTCAGCATCCACCAAG

GCTCCCTCCGTGTTCATTTTTCCTC

GGGCCTTCCGTGTTCCCCCTGGCCCC

CGTCGGACGAACAGCTGAAGTCCG

TTCATCCAAGTCGACCTCTGGTGGAA

GAACCGCGTCCGTGGTCTGTCTCCT

CCGCCGCACTCGGTTGCCTGGTCAAA

GAACAACTTCTATCCGCGCGAGGC

GACTACTTCCCCGAGCCCGTGACTGT

GAAAGTGCAGTGGAAGGTCGACAA

CTCGTGGAACTCGGGCGCCCTCACAT

CGCACTGCAGTCGGGAAACTCCCA

CCGGAGTGCATACCTTTCCCGCCGTG

GGAATCGGTGACCGAGCAGGACTC

TTGCAGTCCAGCGGCCTGTACAGCCT

GAAGGACTCAACCTACTCATTGTC

GAGCTCCGTCGTGACAGTGCCGTCCT

CTCCACCCTCACCCTGAGCAAGGC

CCTCCCTTGGAACCCAGACCTATATC

CGATTACGAGAAGCATAAGGTCTA

TGCAACGTCAATCACAAGCCCTCCAA

CGCCTGCGAAGTGACCCACCAGGG

CACCAAAGTGGACAAGAAGGTCGAA

CCTGAGCAGCCCAGTGACGAAGTC

CCCAAGTCCTGCGACAAGACTCACA

CTTCAACCGGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1730
CTGAGGTGAAGAAGCCTGGGGCCTC
1838
GGCACCCTGTCTTTGTCTCCAGGGG

AGTGAAGATTTCCTGCGAGGCTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATACACCTTCACTGATTATGCTATA

CCAGTCAGAGTTTAAGTACCAACT

CATTGGGTGCGCCAGGCCCCCGGAC

TAGCCTGGTACCAGCAGAAACCTG

AAAGACTTGAGTGGATGGGATGGAT

GCCAGGCTCCCAGGCTCCTCATCTA

CAACGCTGGCGATGGTGGCACAAAA

TGGTGCATCCACCAGGGCCACTGG

AGTTCACGGGAGTTCCAGGGCAGAG

TATCCCAGCCAGGTTCAGTGGCAG

TCACCATTACCAGGGACACATCCGCG

TGGGTCTGGCACAGAGTTCACTCTC

ACCACAGCCTACATGGAGGTGAGCA

ACCATCACCAGCCTGCAGTCTGAA

GTCTGAGATCTGAAGACACGGCTGTC

GATTTTGCAGTTTATTACTGTCAGC

TATTACTGTGCGAGAGGATATTGTAG

AGTATCATAACTGGCCTCCGTACA

TGGTGGTAGCTGCCCAGGAACGGAT

CTTTTGGCCAGGGGACCAAGGTGG

TTTGACTACTGGGGCCAGGGAACCCT

AGATCAAACGTACTGTGGCTGCTC

GGTCACCGTCTCCTCAGCATCCACCA

CCTCCGTGTTCATTTTTCCTCCGTC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GGACGAACAGCTGAAGTCCGGAAC

CCTTCATCCAAGTCGACCTCTGGTGG

CGCGTCCGTGGTCTGTCTCCTGAAC

AACCGCCGCACTCGGTTGCCTGGTCA

AACTTCTATCCGCGCGAGGCGAAA

AAGACTACTTCCCCGAGCCCGTGACT

GTGCAGTGGAAGGTCGACAACGCA

GTCTCGTGGAACTCGGGCGCCCTCAC

CTGCAGTCGGGAAACTCCCAGGAA

ATCCGGAGTGCATACCTTTCCCGCCG

TCGGTGACCGAGCAGGACTCGAAG

TGTTGCAGTCCAGCGGCCTGTACAGC

GACTCAACCTACTCATTGTCCTCCA

CTGAGCTCCGTCGTGACAGTGCCGTC

CCCTCACCCTGAGCAAGGCCGATT

CTCCTCCCTTGGAACCCAGACCTATA

ACGAGAAGCATAAGGTCTACGCCT

TCTGCAACGTCAATCACAAGCCCTCC

GCGAAGTGACCCACCAGGGCCTGA

AACACCAAAGTGGACAAGAAGGTCG

GCAGCCCAGTGACGAAGTCCTTCA

AACCCAAGTCCTGCGACAAGACTCA

ACCGGGGAGAATGC

CACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GACATCCAGATGACCCAGTCTCCTT

1731
CTGAGGTGAAGAAGCCTGGGGCCTC
1839
CCACCCTGTCTGCATCTGTAGGAG

AGTGAAGGTTTCCTGCAAGGCATCTG

ACAGAGTCACCATCACTTGCCGGG

GATACACCTTCACCAGCTACTATATG

CCAGTCAGAGTATTAGTAGCTGGT

CACTGGGTGCGACAGGCCCCTGGAC

TGGCCTGGTATCAGCAGAAACCAG

AAGGGCTTGAGTGGATGGGAATAAT

GGAAAGCCCCTAAGCTCCTGATCT

CAACCCTAGTGGTGGTAGCACAAGC

ATAAGGCGTCTAGTTTAGAAAGTG

TACGCACAGAAGTTCCAGGGCAGAG

GGGTCCCATCAAGGTTCAGCGGCA

TCACCATGACCAGGGACACGTCCAC

GTGGATCTGGGACAGAATTCACTC

GAGCACAGTCTACATGGAGCTGAGC

TCACCATCAGCAGCCTGCAGCCTG

AGCCTGAGATCTGAGGACACGGCCG

ATGATTTTGCAACTTATTACTGCCA

TGTATTACTGTGCGAGAGATGGTGTA

ACAGTATAATAGTTATTGGACGTTC

GGAGGGAGAGATGGCTACAATTTTG

GGCCAAGGGACCAAGGTGGAAATC

ACTACTGGGGCCAGGGAACCCTGGT

AAACGTACTGTGGCTGCTCCCTCCG

CACCGTCTCCTCAGCATCCACCAAGG

TGTTCATTTTTCCTCCGTCGGACGA

GGCCTTCCGTGTTCCCCCTGGCCCCT

ACAGCTGAAGTCCGGAACCGCGTC

TCATCCAAGTCGACCTCTGGTGGAAC

CGTGGTCTGTCTCCTGAACAACTTC

CGCCGCACTCGGTTGCCTGGTCAAAG

TATCCGCGCGAGGCGAAAGTGCAG

ACTACTTCCCCGAGCCCGTGACTGTC

TGGAAGGTCGACAACGCACTGCAG

TCGTGGAACTCGGGCGCCCTCACATC

TCGGGAAACTCCCAGGAATCGGTG

CGGAGTGCATACCTTTCCCGCCGTGT

ACCGAGCAGGACTCGAAGGACTCA

TGCAGTCCAGCGGCCTGTACAGCCTG

ACCTACTCATTGTCCTCCACCCTCA

AGCTCCGTCGTGACAGTGCCGTCCTC

CCCTGAGCAAGGCCGATTACGAGA

CTCCCTTGGAACCCAGACCTATATCT

AGCATAAGGTCTACGCCTGCGAAG

GCAACGTCAATCACAAGCCCTCCAA

TGACCCACCAGGGCCTGAGCAGCC

CACCAAAGTGGACAAGAAGGTCGAA

CAGTGACGAAGTCCTTCAACCGGG

CCCAAGTCCTGCGACAAGACTCACA

GAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1732
GAGGCTTGGTCCAGCCTGGGGGGTC
1840
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGGCGCCACCCTCTCCTGCAGGG

GATTCACCGTCAGTAGCAACTACATG

CCAGTCACAGTGTTGGCGCCAACT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACATAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTCTCAGTTATT

CTGGCCAGGCTCCCAGGCTCCTTAT

TATAGCGGTGGTAGCACATACTACGC

CCATACTGCATCCAAAAGGGCCAC

AGACTCCGTGAAGGGCCGATTCACC

TGGCGTCCCAGAGAGGTTCAGTGG

ATCTCCAGAGACAATTCCAAGAACA

CAGTGGGTCTGGGACAGACTTCAC

CGCTGTATCTTCAAATGAACAGCCTG

TCTCAGTATCAGCAGACTGGAGCC

AGAGCTGAGGACACGGCTGTGTATT

TGAAGACTTTGCCGTGTATCACTGT

ACTGTGCGAGAGCCCCCCTAGCAGC

CAGCAGTATGCTGCCGCACCGATT

AGATGGCTACTTTGACTACTGGGGCC

ACCTTCGGCCAAGGGACACGACTG

AGGGAACCCTGGTCACCGTCTCCTCA

GAGATTAAACGTACTGTGGCTGCT

GCATCCACCAAGGGGCCTTCCGTGTT

CCCTCCGTGTTCATTTTTCCTCCGT

CCCCCTGGCCCCTTCATCCAAGTCGA

CGGACGAACAGCTGAAGTCCGGAA

CCTCTGGTGGAACCGCCGCACTCGGT

CCGCGTCCGTGGTCTGTCTCCTGAA

TGCCTGGTCAAAGACTACTTCCCCGA

CAACTTCTATCCGCGCGAGGCGAA

GCCCGTGACTGTCTCGTGGAACTCGG

AGTGCAGTGGAAGGTCGACAACGC

GCGCCCTCACATCCGGAGTGCATACC

ACTGCAGTCGGGAAACTCCCAGGA

TTTCCCGCCGTGTTGCAGTCCAGCGG

ATCGGTGACCGAGCAGGACTCGAA

CCTGTACAGCCTGAGCTCCGTCGTGA

GGACTCAACCTACTCATTGTCCTCC

CAGTGCCGTCCTCCTCCCTTGGAACC

ACCCTCACCCTGAGCAAGGCCGAT

CAGACCTATATCTGCAACGTCAATCA

TACGAGAAGCATAAGGTCTACGCC

CAAGCCCTCCAACACCAAAGTGGAC

TGCGAAGTGACCCACCAGGGCCTG

AAGAAGGTCGAACCCAAGTCCTGCG

AGCAGCCCAGTGACGAAGTCCTTC

ACAAGACTCACACCTGTCCGCCTTGT

AACCGGGGAGAATGC

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAATTGTGATGACACAGTCTCCA

1733
CTGAGGTGAAGAAGCCTGGGTCCTC
1841
TCCTCCCTGTCTGCATCTGTGGGGG

GGTGAAGGTCTCCTGCAAGGCTTCTG

ACAGAGTCATCATCACTTGCCGGG

GAGGCACCTTCAGCAGCTATGCTATC

CGAGTCAGGGCATTGCCAATTATTT

AGCTGGGTGCGACAGGCCCCTGGAC

AGCCTGGTATCAGCAGAAACCAGG

AAGGGCTTGAGTGGATGGGAGGGAT

GAAAGGTCCTAAACTCCTGATCTA

CATCCCTATCTTTGGTACAGCAAACT

TGCTTCATCTACTTTGCAATCAGGG

ACGCACAGAAGTTCCAGGGCAGAGT

GTCCCATCTCGGTTCAGTGGCAGTG

CACGATTACCGCGGACGAATCCACG

GATCTGGGACAGATTTCACTCTCAC

AGCACAGCCTACATGGAGCTGAGCA

CATCAGCGGCCTGCAGCCTGAAGA

GCCTGAGATCTGAGGACACGGCCGT

TGTTGCAACTTATTACTGTCAGAAG

GTATTACTGTGCGAGAGCCCGGGGG

TATAACAGTGTCCCTCTCACTTTCG

CTACAGTACCTAATCTGGTACTTCGA

GCGGAGGGACCAAAGTGGATATCA

TCTCTGGGGCCGTGGCACCCTGGTGA

AACGTACTGTGGCTGCTCCCTCCGT

CCGTCTCCTCAGCATCCACCAAGGGG

GTTCATTTTTCCTCCGTCGGACGAA

CCTTCCGTGTTCCCCCTGGCCCCTTC

CAGCTGAAGTCCGGAACCGCGTCC

ATCCAAGTCGACCTCTGGTGGAACCG

GTGGTCTGTCTCCTGAACAACTTCT

CCGCACTCGGTTGCCTGGTCAAAGAC

ATCCGCGCGAGGCGAAAGTGCAGT

TACTTCCCCGAGCCCGTGACTGTCTC

GGAAGGTCGACAACGCACTGCAGT

GTGGAACTCGGGCGCCCTCACATCCG

CGGGAAACTCCCAGGAATCGGTGA

GAGTGCATACCTTTCCCGCCGTGTTG

CCGAGCAGGACTCGAAGGACTCAA

CAGTCCAGCGGCCTGTACAGCCTGA

CCTACTCATTGTCCTCCACCCTCAC

GCTCCGTCGTGACAGTGCCGTCCTCC

CCTGAGCAAGGCCGATTACGAGAA

TCCCTTGGAACCCAGACCTATATCTG

GCATAAGGTCTACGCCTGCGAAGT

CAACGTCAATCACAAGCCCTCCAAC

GACCCACCAGGGCCTGAGCAGCCC

ACCAAAGTGGACAAGAAGGTCGAAC

AGTGACGAAGTCCTTCAACCGGGG

CCAAGTCCTGCGACAAGACTCACAC

AGAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1734
CTGAGGTGAAGAAGCCTGGGGCCTC
1842
TCTCCCTGGCTGTGTCTCTGGGCGA

AGTGAAGGTTTCCTGCAAGGCATCTG

GAGGGCCACCATCAACTGCAAGTC

GATACACCTTCACCAGCTACTATATG

CAGCCAGAGTGTTTTATACAGAAC

CACTGGGTGCGACAGGCCCCTGGAC

CAACAATAAGAACTACTTGGCTTG

AAGGGCTTGAGTGGATGGGAATAAT

GTATCAGCAGAAACCAGGACAGCC

CAACCCTAGTGGTGGTAGCACAAGC

TCCTAAGTTGCTCATTTACTGGGCA

TACGCACAGAAGTTCCAGGGCAGAG

TCTACCCGGGAATCCGGGGTCCCT

TCACCATGACCAGGGACACGTCCAC

GACCGATTCAGTGGCAGCGGGTCT

GAGCACAGTCTACATGGAGCTGAGC

GGGACAGATTTCACTCTCACCATC

AGCCTGAGATCTGAGGACACGGCCG

AGCAGCCTGCAGCCTGAGGATGTG

TGTATTACTGTGCGAGCCCGGGTATG

GCAGTGTACTACTGTCAGCAATATT

GTTCGGGGAGTTATTACTGCCCCGCT

ACAATCTTCCTCGATCTTTTGGCCA

TGACTACTGGGGCCAGGGCACCCTG

GGGGACCAAGCTGGAGATCAAACG

GTCACCGTCTCCTCAGCATCCACCAA

TACTGTGGCTGCTCCCTCCGTGTTC

GGGGCCTTCCGTGTTCCCCCTGGCCC

ATTTTTCCTCCGTCGGACGAACAGC

CTTCATCCAAGTCGACCTCTGGTGGA

TGAAGTCCGGAACCGCGTCCGTGG

ACCGCCGCACTCGGTTGCCTGGTCAA

TCTGTCTCCTGAACAACTTCTATCC

AGACTACTTCCCCGAGCCCGTGACTG

GCGCGAGGCGAAAGTGCAGTGGAA

TCTCGTGGAACTCGGGCGCCCTCACA

GGTCGACAACGCACTGCAGTCGGG

TCCGGAGTGCATACCTTTCCCGCCGT

AAACTCCCAGGAATCGGTGACCGA

GTTGCAGTCCAGCGGCCTGTACAGCC

GCAGGACTCGAAGGACTCAACCTA

TGAGCTCCGTCGTGACAGTGCCGTCC

CTCATTGTCCTCCACCCTCACCCTG

TCCTCCCTTGGAACCCAGACCTATAT

AGCAAGGCCGATTACGAGAAGCAT

CTGCAACGTCAATCACAAGCCCTCCA

AAGGTCTACGCCTGCGAAGTGACC

ACACCAAAGTGGACAAGAAGGTCGA

CACCAGGGCCTGAGCAGCCCAGTG

ACCCAAGTCCTGCGACAAGACTCAC

ACGAAGTCCTTCAACCGGGGAGAA

ACCTGTCCGCCTTGTCCAGCCCCTGA

TGC

GCTGCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACACT

CTGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGGG

AAGAACAGTACAACTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTATACTTTGCC

GCCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGGG

AAACGTGTTCTCCTGCTCCGTGATGC

ACGAAGCGCTGCACAACCATTACAC

CCAGAAATCACTGTCACTTTCGCCGG

GAAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GATATTGTGATGACCCACACTCCA

1735
GAGGCCTGGTCAAGCCTGGGGGGTC
1843
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGAGACTCTCCTGTGCAGCCTCTG

AGAGGGCCACCATCAACTGCAAGT

GATTCACCTTCAGCAGCTATGCTATC

CCAACCGGAGTGTTTTATACAGCC

AGCTGGGTGCGACAGGCCCCTGGAC

CCAACAATCAGAACTACTTAGGTT

AAGGGCTTGAGTGGATGGGAGGGAT

GGTACCAGCAGAAGCCAGGACAGC

CATCCCTATGTATGGTACAGCAAACT

CTCCTAAGCTGCTCATTTACTGGGC

ACGCACAGAAGTTCCAGGGCAGAGT

ATCTACCCGGGACTCCGGGGCCCC

CACGATTACCGCGGACGAATCCACG

TGACCGATTCAGTGGCAGCGGGTC

AGCACAGCCTACATGGAACTGAGCA

TGGGACAGATTTCACTCTCACCATC

GCCTGAGATCTGAGGACACGGCCCT

AACAGCCTGCAGGCTGAAGATGTG

CTATTACTGTGCGAGAGAAGCTAAGT

GCAGTTTATTACTGTCAGCAATATG

GGGGAATGTACTACTTTGACTACTGG

CAAGTACTCCATACACTTTTGGCCA

GGCCAGGGCACCCTGGTCACCGTCTC

GGGGACCAAGGTGGAGATCAAACG

CTCAGCATCCACCAAGGGGCCTTCCG

TACTGTGGCTGCTCCCTCCGTGTTC

TGTTCCCCCTGGCCCCTTCATCCAAG

ATTTTTCCTCCGTCGGACGAACAGC

TCGACCTCTGGTGGAACCGCCGCACT

TGAAGTCCGGAACCGCGTCCGTGG

CGGTTGCCTGGTCAAAGACTACTTCC

TCTGTCTCCTGAACAACTTCTATCC

CCGAGCCCGTGACTGTCTCGTGGAAC

GCGCGAGGCGAAAGTGCAGTGGAA

TCGGGCGCCCTCACATCCGGAGTGCA

GGTCGACAACGCACTGCAGTCGGG

TACCTTTCCCGCCGTGTTGCAGTCCA

AAACTCCCAGGAATCGGTGACCGA

GCGGCCTGTACAGCCTGAGCTCCGTC

GCAGGACTCGAAGGACTCAACCTA

GTGACAGTGCCGTCCTCCTCCCTTGG

CTCATTGTCCTCCACCCTCACCCTG

AACCCAGACCTATATCTGCAACGTCA

AGCAAGGCCGATTACGAGAAGCAT

ATCACAAGCCCTCCAACACCAAAGT

AAGGTCTACGCCTGCGAAGTGACC

GGACAAGAAGGTCGAACCCAAGTCC

CACCAGGGCCTGAGCAGCCCAGTG

TGCGACAAGACTCACACCTGTCCGCC

ACGAAGTCCTTCAACCGGGGAGAA

TTGTCCAGCCCCTGAGCTGCTGGGTG

TGC

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGGAGTCCGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1736
GAGGCGTGGTCCAGCCTGGGAGGTC
1844
CCACCCTGTCTTTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCACCTTCAGTAGCTATGCTATA

CAGTGAGAGTGTTAATAGCAACTT

CACTGGGTCCGCCAGGCTCCAGGCA

CTTAGCCTGGTACCAGCAGAAACC

AGGGGCTGGAGTGGGTGGCAATTAT

TGGCCAGGCTCCCAGGCTCCTCATC

ATCAGATGATGGAAGTAAGAGTTAC

TATGCTGCATCCACCAGGGCCACT

TACGCAGACTCCGTGCAGGGCCGATT

GGTATCCCAGCCAGGTTCAGTGGC

CACCATCTCCAGAGACAATTCGAGG

AGTGGGTCTGGGACAGAGTTCACT

AACACAGTATATCTGCAAATGAACA

CTCATCATCACCAGCCTGCAGTCTG

GCCTGAGAGCTGAGGACACGGCTAT

AAGATTTTGCAGTTTATTACTGTCA

GTATTACTGTGCGAGAGACAGGGGA

GCAGTATAATAACTGGCCGCTCAC

ACTAAATGGAACCAATTGAATGATG

TTTCGGCGGAGGGACCAAGCTGGA

TTTTTGATATGTGGGGCCAAGGGACA

GATCAAACGTACTGTGGCTGCTCC

ATGGTCACCGTCTCTTCAGCATCCAC

CTCCGTGTTCATTTTTCCTCCGTCG

CAAGGGGCCTTCCGTGTTCCCCCTGG

GACGAACAGCTGAAGTCCGGAACC

CCCCTTCATCCAAGTCGACCTCTGGT

GCGTCCGTGGTCTGTCTCCTGAACA

GGAACCGCCGCACTCGGTTGCCTGGT

ACTTCTATCCGCGCGAGGCGAAAG

CAAAGACTACTTCCCCGAGCCCGTGA

TGCAGTGGAAGGTCGACAACGCAC

CTGTCTCGTGGAACTCGGGCGCCCTC

TGCAGTCGGGAAACTCCCAGGAAT

ACATCCGGAGTGCATACCTTTCCCGC

CGGTGACCGAGCAGGACTCGAAGG

CGTGTTGCAGTCCAGCGGCCTGTACA

ACTCAACCTACTCATTGTCCTCCAC

GCCTGAGCTCCGTCGTGACAGTGCCG

CCTCACCCTGAGCAAGGCCGATTA

TCCTCCTCCCTTGGAACCCAGACCTA

CGAGAAGCATAAGGTCTACGCCTG

TATCTGCAACGTCAATCACAAGCCCT

CGAAGTGACCCACCAGGGCCTGAG

CCAACACCAAAGTGGACAAGAAGGT

CAGCCCAGTGACGAAGTCCTTCAA

CGAACCCAAGTCCTGCGACAAGACT

CCGGGGAGAATGC

CACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTGT

TCCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTGT

CGCACGAAGATCCCGAAGTGAAATT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTACAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAAA

GACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTATACTTT

GCCGCCTAGCCGGGAAGAAATGACT

AAGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1737
CTGAGGTGAAGAAGCCTGGGGCCTC
1845
CCACCCTGTCTTTGTCTCCAGGGGA

AGTGAAGGTCTCCTGCACGGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACACCTTCACCAGTTCTGATATC

CAGTCAGAGTGTTAGCAGCTACTT

AACTGGGTGCGACAGGCCACTGGAC

AGCCTGGTACCAACAGAAACCTGG

AAGGGCTTGAGTGGATGGGATGGAT

CCAGGCTCCCAGGCTCCTCATCTAT

GAACCCTAACAGTGGTAACACCGGC

GATGCATCCAACAGGGCCACTGGC

TATGCAGAGAAGTTCCAGGGCAGGG

ATCCCAGCCAGGTTCAGTGGCAGT

TCACCATGACCAGCGACTCCTCCATA

GGGTCTGGGACAGACTTCACTCTC

AGCACCGCCTACATGGAGTTGAGAA

ACCATCAGCAGCCTAGAGCCTGAA

GCCTGACCACTGAGGACACGGCCGT

GATTTTGCAGTTTATTACTGTCAGC

ATATTACTGTGCGAGAGGTGGGGGT

AGCGTAGCAACTGGTCGCTCACTTT

GCGAGCTATACTGACTCCTGGGGCCA

CGGCGGAGGGACCAAGCTGGAGAT

GGGCACCCTGGTCACCGTCTCCTCAG

CAAACGTACTGTGGCTGCTCCCTCC

CATCCACCAAGGGGCCTTCCGTGTTC

GTGTTCATTTTTCCTCCGTCGGACG

CCCCTGGCCCCTTCATCCAAGTCGAC

AACAGCTGAAGTCCGGAACCGCGT

CTCTGGTGGAACCGCCGCACTCGGTT

CCGTGGTCTGTCTCCTGAACAACTT

GCCTGGTCAAAGACTACTTCCCCGAG

CTATCCGCGCGAGGCGAAAGTGCA

CCCGTGACTGTCTCGTGGAACTCGGG

GTGGAAGGTCGACAACGCACTGCA

CGCCCTCACATCCGGAGTGCATACCT

GTCGGGAAACTCCCAGGAATCGGT

TTCCCGCCGTGTTGCAGTCCAGCGGC

GACCGAGCAGGACTCGAAGGACTC

CTGTACAGCCTGAGCTCCGTCGTGAC

AACCTACTCATTGTCCTCCACCCTC

AGTGCCGTCCTCCTCCCTTGGAACCC

ACCCTGAGCAAGGCCGATTACGAG

AGACCTATATCTGCAACGTCAATCAC

AAGCATAAGGTCTACGCCTGCGAA

AAGCCCTCCAACACCAAAGTGGACA

GTGACCCACCAGGGCCTGAGCAGC

AGAAGGTCGAACCCAAGTCCTGCGA

CCAGTGACGAAGTCCTTCAACCGG

CAAGACTCACACCTGTCCGCCTTGTC

GGAGAATGC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1738
GAGGCTTGGTACAGCCAGGGCGGTC
1846
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTACAGCTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTGGTGATTATGCTATG

CCAGTCAGAGTGTTAGCAGCAGCT

AGCTGGTTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAACAGAAAC

AGGGGCTGGAGTGGGTAGGTTTCATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AGAAGCAAAGCTTATGGTGGGACAA

CTATGGTGCTTCCACCAGGGCCACT

CAGAATACGCCGCGTCTGTGAAAGG

GGCATCCCAGACAGGTTCAGTGGC

CAGATTCACCATCTCAAGAGATGATT

AGTGGGTCTGGGACGGACTTCACT

CCAAAAGCATCGCCTATCTGCAAATG

CTCACCATCGGCAGACTGGAGCCT

AACAGCCTGAAAACCGAGGACACAG

GAAGATTTTGCAGTGTATTACTGTC

CCGTGTATTACTGTACCGCTAAGGGG

AACACTATGGTCCCTCACGTCGGA

GGCTACGTCGGATACAGCTATGGAC

TCACCTTCGGCCAAGGGACACGAC

CTTTTGGGGGCTACTGGGGCCAGGG

TGGAGATTAAACGTACTGTGGCTG

AACCCTGGTCACCGTCTCCTCAGCAT

CTCCCTCCGTGTTCATTTTTCCTCC

CCACCAAGGGGCCTTCCGTGTTCCCC

GTCGGACGAACAGCTGAAGTCCGG

CTGGCCCCTTCATCCAAGTCGACCTC

AACCGCGTCCGTGGTCTGTCTCCTG

TGGTGGAACCGCCGCACTCGGTTGCC

AACAACTTCTATCCGCGCGAGGCG

TGGTCAAAGACTACTTCCCCGAGCCC

AAAGTGCAGTGGAAGGTCGACAAC

GTGACTGTCTCGTGGAACTCGGGCGC

GCACTGCAGTCGGGAAACTCCCAG

CCTCACATCCGGAGTGCATACCTTTC

GAATCGGTGACCGAGCAGGACTCG

CCGCCGTGTTGCAGTCCAGCGGCCTG

AAGGACTCAACCTACTCATTGTCCT

TACAGCCTGAGCTCCGTCGTGACAGT

CCACCCTCACCCTGAGCAAGGCCG

GCCGTCCTCCTCCCTTGGAACCCAGA

ATTACGAGAAGCATAAGGTCTACG

CCTATATCTGCAACGTCAATCACAAG

CCTGCGAAGTGACCCACCAGGGCC

CCCTCCAACACCAAAGTGGACAAGA

TGAGCAGCCCAGTGACGAAGTCCT

AGGTCGAACCCAAGTCCTGCGACAA

TCAACCGGGGAGAATGC

GACTCACACCTGTCCGCCTTGTCCAG

CCCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAGC

CTAGGGAAGAACAGTACAACTCTAC

GTACCGGGTGGTGTCCGTGCTGACCG

TGCTGCACCAGGACTGGCTGAACGG

AAAGGAGTACAAGTGCAAAGTGTCA

AACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1739
GAGGCTTGGTACAGCCAGGGCGGTC
1847
GACACCCTGTCTGTGTCTCCAGGG

CCTGAGACTCTCCTGTACAGCTTCTG

GGAAGAGCCACCCTCTCCTGTAGG

GATTCACCTTTGGTGATTATGCTATG

GCCAGTCAGAGCATTGGGAGCAAT

AGCTGGTTCCGCCAGGCTCCAGGGA

TTAGCCTGGTACCAACAGAAACCT

AGGGGCTGGAGTGGGTAGGTTTCATT

GGCCAGTCTCCCAGGCTCCTCATCT

AGAAGCAAAGCTTATGGTGGGACAA

ATGATGCATCCACCAGGGCCACGG

CAGAATACGCCGCGTCTGTGAAAGG

GAATCCCAGCCAGGTTCAGTGGCA

CAGATTCACCATCTCAAGAGATGATT

GTGGGTCTGGGACAGAATTCACTC

CCAAAAGCATCGCCTATCTGCAAATG

TCACCATCAGCAGCCTGGAGTCTG

AACAGCCTGAAAACCGAGGACACAG

AAGATTTTGTACTTTATTACTGTCA

CCGTGTATTACTGTACTAGAGGGGGG

GCAGCATGGTGAATGGCCCACCTT

ACTATGGTTCGGGGTTTCGGATTTAA

CGGCCAAGGGACACGACTGGAGAT

CTACTGGGGCCAGGGAACCCTGGTC

TAAACGTACTGTGGCTGCTCCCTCC

ACCGTCTCCTCAGCATCCACCAAGGG

GTGTTCATTTTTCCTCCGTCGGACG

GCCTTCCGTGTTCCCCCTGGCCCCTT

AACAGCTGAAGTCCGGAACCGCGT

CATCCAAGTCGACCTCTGGTGGAACC

CCGTGGTCTGTCTCCTGAACAACTT

GCCGCACTCGGTTGCCTGGTCAAAGA

CTATCCGCGCGAGGCGAAAGTGCA

CTACTTCCCCGAGCCCGTGACTGTCT

GTGGAAGGTCGACAACGCACTGCA

CGTGGAACTCGGGCGCCCTCACATCC

GTCGGGAAACTCCCAGGAATCGGT

GGAGTGCATACCTTTCCCGCCGTGTT

GACCGAGCAGGACTCGAAGGACTC

GCAGTCCAGCGGCCTGTACAGCCTG

AACCTACTCATTGTCCTCCACCCTC

AGCTCCGTCGTGACAGTGCCGTCCTC

ACCCTGAGCAAGGCCGATTACGAG

CTCCCTTGGAACCCAGACCTATATCT

AAGCATAAGGTCTACGCCTGCGAA

GCAACGTCAATCACAAGCCCTCCAA

GTGACCCACCAGGGCCTGAGCAGC

CACCAAAGTGGACAAGAAGGTCGAA

CCAGTGACGAAGTCCTTCAACCGG

CCCAAGTCCTGCGACAAGACTCACA

GGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1740
CAGGACTGTTGAAGCCTTCGGAGAC
1848
CCACCCTGTCTTTGTCTCCAGGGGA

CCTGTCCCTCACCTGCGCTGTCTATG

AAGAGCCACCCTCTCCTGCAGGGC

GTGGGTCCTTCAGTGGTTACTACTGG

CAGTCAGAGTGTCGGTAACTCCTT

AGCTGGATCCGCCAGCCCCCAGGGA

AGCCTGGTACCAGCAGAAGCCTGG

AGGGGCTGGAGTGGATTGGGGAAAT

CCAGGCTCCCCGGCTCCTCATCTAT

CAATCATAGTGGAAGCACCAACTAC

GATGCATCCAACAGGGCCACTGGC

AACCCGTCCCTCAAGAGTCGAGTCAC

ATCCCAGCCCGGTTCAGTGGCAGT

CATATCAGTAGACACGTCCAAGAAC

GGGTCTGGGACAGACTTCACTCTC

CAGTTCTCCCTGAAGCTGAGCTCTGT

ACCATCACCAGCCTAGAGCCTGAA

GACCGCCGCGGACACGGCTGTGTATT

GATTTTGCAATTTATTACTGTCAAC

ACTGTGCGAGAGCCCGGCGGGCTAT

AACGTGGCACCTGGCCTCCCCTCA

GATAGGGCCGCTTCCGCGACTTGTCG

CTTTCGGCGGAGGGACCAAGCTGG

GGTACTTCGATCTCTGGGGCCGTGGA

AGATCAAACGTACTGTGGCTGCTC

ACCCTGGTCACCGTCTCCTCAGCATC

CCTCCGTGTTCATTTTTCCTCCGTC

CACCAAGGGGCCTTCCGTGTTCCCCC

GGACGAACAGCTGAAGTCCGGAAC

TGGCCCCTTCATCCAAGTCGACCTCT

CGCGTCCGTGGTCTGTCTCCTGAAC

GGTGGAACCGCCGCACTCGGTTGCCT

AACTTCTATCCGCGCGAGGCGAAA

GGTCAAAGACTACTTCCCCGAGCCCG

GTGCAGTGGAAGGTCGACAACGCA

TGACTGTCTCGTGGAACTCGGGCGCC

CTGCAGTCGGGAAACTCCCAGGAA

CTCACATCCGGAGTGCATACCTTTCC

TCGGTGACCGAGCAGGACTCGAAG

CGCCGTGTTGCAGTCCAGCGGCCTGT

GACTCAACCTACTCATTGTCCTCCA

ACAGCCTGAGCTCCGTCGTGACAGTG

CCCTCACCCTGAGCAAGGCCGATT

CCGTCCTCCTCCCTTGGAACCCAGAC

ACGAGAAGCATAAGGTCTACGCCT

CTATATCTGCAACGTCAATCACAAGC

GCGAAGTGACCCACCAGGGCCTGA

CCTCCAACACCAAAGTGGACAAGAA

GCAGCCCAGTGACGAAGTCCTTCA

GGTCGAACCCAAGTCCTGCGACAAG

ACCGGGGAGAATGC

ACTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAGC

CTAGGGAAGAACAGTACAACTCTAC

GTACCGGGTGGTGTCCGTGCTGACCG

TGCTGCACCAGGACTGGCTGAACGG

AAAGGAGTACAAGTGCAAAGTGTCA

AACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAT

1741
CAGGACTGTTGAAGCCTTCGGAGAC
1849
CCTCCCTGTCTGCATCTGTAGGAGA

CCTGTCCCTCACCTGCGCTGTCTATG

CACAGTCACCATCACTTGCCGGGC

GTGGGTCCTTCAGTGGTTACTACTGG

CAGTCAGAGTATAACTAACTGGTT

AGCTGGATCCGCCAGCCCCCAGGGA

GGCCTGGTATCAGCAGAAACCAGG

AGGGGCTGGAGTGGATTGGGGAAAT

GAAAGCCCCCAAGCGCCTGATCTA

CAATCATAGTGGAAGCACCAACTAC

TGGTGCGTCCAGTTTGCAGAGTGG

AACCCGTCCCTCAAGAGTCGAGTCAC

GGTCCCATCAAGGTTCAGCGGCAG

CATATCAGTAGACACGTCCAAGAAC

TGGATCTGGGACAGAATTCACTCT

CAGTTCTCCCTGAAGCTGAGCTCTGT

CACAATCAGCAGCCTGCAGCCTGA

GACCGCCGCGGACACGGCTGTGTATT

AGATTTTGCAACTTATTACTGTCAA

ACTGTGCGAGAGGCCGCCCCGCCCC

CAGTATACTAATTACCCTCGTACGT

ATCCTGGGTTAAAACCCGTAACTGGT

TCGGCCAAGGGACCAAGCTGGAGA

TCGACCCCTGGGGCCAGGGAACCCT

TCAAACGTACTGTGGCTGCTCCCTC

GGTCACCGTCTCCTCAGCATCCACCA

CGTGTTCATTTTTCCTCCGTCGGAC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GAACAGCTGAAGTCCGGAACCGCG

CCTTCATCCAAGTCGACCTCTGGTGG

TCCGTGGTCTGTCTCCTGAACAACT

AACCGCCGCACTCGGTTGCCTGGTCA

TCTATCCGCGCGAGGCGAAAGTGC

AAGACTACTTCCCCGAGCCCGTGACT

AGTGGAAGGTCGACAACGCACTGC

GTCTCGTGGAACTCGGGCGCCCTCAC

AGTCGGGAAACTCCCAGGAATCGG

ATCCGGAGTGCATACCTTTCCCGCCG

TGACCGAGCAGGACTCGAAGGACT

TGTTGCAGTCCAGCGGCCTGTACAGC

CAACCTACTCATTGTCCTCCACCCT

CTGAGCTCCGTCGTGACAGTGCCGTC

CACCCTGAGCAAGGCCGATTACGA

CTCCTCCCTTGGAACCCAGACCTATA

GAAGCATAAGGTCTACGCCTGCGA

TCTGCAACGTCAATCACAAGCCCTCC

AGTGACCCACCAGGGCCTGAGCAG

AACACCAAAGTGGACAAGAAGGTCG

CCCAGTGACGAAGTCCTTCAACCG

AACCCAAGTCCTGCGACAAGACTCA

GGGAGAATGC

CACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GACATCCAGATGACCCAGTCTCCTT

1742
CAGGACTGGTGAAGCCCTCGCAGAC
1850
CCACCCTGTCTGCATCTGTAGGAG

CCTCTCACTCACCTGTGCCATCTCCG

ACAGAGTCACCATCACTTGTCGGG

GGGACAGTGTCTCTAGCAACAGTGCT

CCAGGCAGAGCATCAGTAACCGGT

GCTTGGAACTGGATCAGGCAGTCCCC

TGGCCTGGTATCAGCAGAAACCAG

ATCGAGAGGCCTTGAGTGGCTGGGA

GGAGAGCCCCTAATGTCCTGATCT

AGGACATACTACAGGTCCAAGTGGT

ATAAGGCGTCTACTTTAGCAAATG

ATAATGATTATGCAGTATCTGTGAAA

GGGTCCCATCAAGGTTCAGCGGCA

AGTCGAATAACCATCAACCCAGACA

GTGGATCTGGGACAGAATTCACTC

CATCCAAGAACCAGTTCTCCCTGCAG

TCACCATCAGCAGCCTGCAGCCTG

CTGAACTCTGTGACTCCCGAGGACAC

ATGACTTTGCAACTTATTACTGCCA

GGCTGTGTATTACTGTGCAAGAGAG

ACAGTATCAAAGTTACTGGACGTT

GCTAGCAGTGGCTGGAACTGGGGCC

CGGCCCAGGGACCAAGGTGGAAAT

AGGGAACCCTGGTCACCGTCTCCTCA

CAAACGTACTGTGGCTGCTCCCTCC

GCATCCACCAAGGGGCCTTCCGTGTT

GTGTTCATTTTTCCTCCGTCGGACG

CCCCCTGGCCCCTTCATCCAAGTCGA

AACAGCTGAAGTCCGGAACCGCGT

CCTCTGGTGGAACCGCCGCACTCGGT

CCGTGGTCTGTCTCCTGAACAACTT

TGCCTGGTCAAAGACTACTTCCCCGA

CTATCCGCGCGAGGCGAAAGTGCA

GCCCGTGACTGTCTCGTGGAACTCGG

GTGGAAGGTCGACAACGCACTGCA

GCGCCCTCACATCCGGAGTGCATACC

GTCGGGAAACTCCCAGGAATCGGT

TTTCCCGCCGTGTTGCAGTCCAGCGG

GACCGAGCAGGACTCGAAGGACTC

CCTGTACAGCCTGAGCTCCGTCGTGA

AACCTACTCATTGTCCTCCACCCTC

CAGTGCCGTCCTCCTCCCTTGGAACC

ACCCTGAGCAAGGCCGATTACGAG

CAGACCTATATCTGCAACGTCAATCA

AAGCATAAGGTCTACGCCTGCGAA

CAAGCCCTCCAACACCAAAGTGGAC

GTGACCCACCAGGGCCTGAGCAGC

AAGAAGGTCGAACCCAAGTCCTGCG

CCAGTGACGAAGTCCTTCAACCGG

ACAAGACTCACACCTGTCCGCCTTGT

GGAGAATGC

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGTC
SEQ ID
GACATCCAGTTGACCCAGTCTCCA

1743
CAGGACTGGTGAAGCCCTCGCAGAC
1851
GCCACCCTGTCTTTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AAAGAGCCACCCTCTCCTGCAAGG

GGGACAGTGTCTCTAGCAACAATGCT

CCAGTCAGAGTGTTAGTAGCTACTT

GCTTGGAACTGGATCAGGCAGTCCCC

AGCCTGGTACCAACAGAAACTTGG

ATCGAGAGGCCTTGAGTGGCTGGGA

CCAGGCTCCCAGGCTCCTCATCTAT

AGGACATTCTACAGGTCCAAGTGGT

GATGCATCCAACAGGGCCACTGGC

ATAATGACTATGCAGTTTCTGTGAAA

ATCCCAGCCAGGTTCAGTGCCAGT

AGTCGACTAACCGTCAACCCAGACA

GGGTCTGGGACAGACTTCACTCTC

CATCCAAGAACCAGTTCTCCCTGCGG

ACCATCAGCAGCCTGCAGCCTGAA

TTGAACTCTGTGAGTCCCGAGGACAC

GATGTTGCAACTTATTACTGTCAAA

GGCTGTGTATTACTGTGCAAGAGGG

AGTATAACAGTCCCCCTCGGACGT

GGAAGATATACCAAGGGAGGGTACT

TCGGCCAGGGGACCAAGGTGGAAA

TTGACGACTGGGGCCAGGGAACCCT

TCAAACGTACTGTGGCTGCTCCCTC

GGTGACCGTCTCCTCAGCATCCACCA

CGTGTTCATTTTTCCTCCGTCGGAC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GAACAGCTGAAGTCCGGAACCGCG

CCTTCATCCAAGTCGACCTCTGGTGG

TCCGTGGTCTGTCTCCTGAACAACT

AACCGCCGCACTCGGTTGCCTGGTCA

TCTATCCGCGCGAGGCGAAAGTGC

AAGACTACTTCCCCGAGCCCGTGACT

AGTGGAAGGTCGACAACGCACTGC

GTCTCGTGGAACTCGGGCGCCCTCAC

AGTCGGGAAACTCCCAGGAATCGG

ATCCGGAGTGCATACCTTTCCCGCCG

TGACCGAGCAGGACTCGAAGGACT

TGTTGCAGTCCAGCGGCCTGTACAGC

CAACCTACTCATTGTCCTCCACCCT

CTGAGCTCCGTCGTGACAGTGCCGTC

CACCCTGAGCAAGGCCGATTACGA

CTCCTCCCTTGGAACCCAGACCTATA

GAAGCATAAGGTCTACGCCTGCGA

TCTGCAACGTCAATCACAAGCCCTCC

AGTGACCCACCAGGGCCTGAGCAG

AACACCAAAGTGGACAAGAAGGTCG

CCCAGTGACGAAGTCCTTCAACCG

AACCCAAGTCCTGCGACAAGACTCA

GGGAGAATGC

CACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTCC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1744
TACGCTGGTGAAACCCACACAGACC
1852
GGCACCCTGTCTTTGTCTCCAGGGG

CTCACGCTGACCTGCACCTTCTCTGG

AAAGGGTCAGCCTTTCCTGCAGGG

GTTCTCACTCAGCACTAGTGGAGTGG

CCAGTCAGAATGTTTACAGCAATTT

GTGTGGGCTGGATCCGTCAGCCCCCA

CTTAGCCTGGTATCAACAGAGACC

GGAAAGGCCCTGGAGTGGCTTGCAC

TGGCCAGGCTCCCAGTCTCCTCATC

TCATTTATTGGGATGATGATAAGCGC

TATGGTGCCTCCAGCAGGGCCGCT

TACAGCCCATCTCTGAAGAGCAGGCT

GGCGTCCCAGACAGGTTCAGTGGC

CACCATCACCAAGGACACCTCCAAA

AGTGGGTCTGGGACAGACTTCGCT

AACCAGGTGGTCCTTACAATGACCA

CTCACCATCAGCAGAGTGGAGCCT

ACATGGACCCTGTGGACACAGCCAC

GAAGATTTTGCAGTCTATTACTGTC

ATATTACTGTGCACACAGATTGGATA

AACAATATGGAACCTCACCGATCA

GCAGTGGCCGTGGTGGTTACTTTGAC

CCTTCGGCCAAGGGACACGACTGG

TACTGGGGCCAGGGCACCCTGGTCA

AGATTAAACGTACTGTGGCTGCTC

CCGTCTCCTCAGCATCCACCAAGGGG

CCTCCGTGTTCATTTTTCCTCCGTC

CCTTCCGTGTTCCCCCTGGCCCCTTC

GGACGAACAGCTGAAGTCCGGAAC

ATCCAAGTCGACCTCTGGTGGAACCG

CGCGTCCGTGGTCTGTCTCCTGAAC

CCGCACTCGGTTGCCTGGTCAAAGAC

AACTTCTATCCGCGCGAGGCGAAA

TACTTCCCCGAGCCCGTGACTGTCTC

GTGCAGTGGAAGGTCGACAACGCA

GTGGAACTCGGGCGCCCTCACATCCG

CTGCAGTCGGGAAACTCCCAGGAA

GAGTGCATACCTTTCCCGCCGTGTTG

TCGGTGACCGAGCAGGACTCGAAG

CAGTCCAGCGGCCTGTACAGCCTGA

GACTCAACCTACTCATTGTCCTCCA

GCTCCGTCGTGACAGTGCCGTCCTCC

CCCTCACCCTGAGCAAGGCCGATT

TCCCTTGGAACCCAGACCTATATCTG

ACGAGAAGCATAAGGTCTACGCCT

CAACGTCAATCACAAGCCCTCCAAC

GCGAAGTGACCCACCAGGGCCTGA

ACCAAAGTGGACAAGAAGGTCGAAC

GCAGCCCAGTGACGAAGTCCTTCA

CCAAGTCCTGCGACAAGACTCACAC

ACCGGGGAGAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCAC

1745
GAGGCGTGGTCCAGCCTGGGAGGTC
1853
GCTCCTCACCCGTCACCCTTGGACA

CCTGAGACTCTCCTGTACAGCCTCTG

GCCGGCCTCCATCTCCTGTAGGTCT

GATTCACCTTCAGTAGCTATGGCATG

AGTCAAAGTCTCGAACACGGTGAT

CACTGGGTCCGCCAGGCTCCAGGCA

GGAAACACGTACTTGAGTTGGCTT

AGGGGCTGGAGTGGGTGGCAGTTAT

CAGCAGAGGCCAGGCCAGCCTCCA

ATCATATGATGGAAGTAATAAATACT

AGACTCCTGATTTATAAGGTTTCTA

ATGCAGACTCCGTGAAGGGCCGATT

ACCGGTTGTCTGGGGTCCCAGACA

CACCATCTCCAGAGACAATTCCAAG

GATTCAGTGGCAGTGGGGCAGGGA

AACACGCTGTATCTGCAAATGAACA

CTGATTTCACACTGAAAATCAGCA

GCCTGAGAGCTGAGGACACGGCTGT

GGGTGGAAGCTGAGGATGTCGGGG

GTATTACTGTGCGAAAGAGTTGGTGG

TTTATTACTGCATGCAAGGTATATA

GTACCAGCTCTCCTTATTACTACTAC

CTGGCCTCGAACCTTCGGCCAAGG

TACTACGGTATGGACGTCTGGGGCCA

GACACGACTGGAGATTAAACGTAC

AGGGACAATGGTCACCGTCTCTTCAG

TGTGGCTGCTCCCTCCGTGTTCATT

CATCCACCAAGGGGCCTTCCGTGTTC

TTTCCTCCGTCGGACGAACAGCTG

CCCCTGGCCCCTTCATCCAAGTCGAC

AAGTCCGGAACCGCGTCCGTGGTC

CTCTGGTGGAACCGCCGCACTCGGTT

TGTCTCCTGAACAACTTCTATCCGC

GCCTGGTCAAAGACTACTTCCCCGAG

GCGAGGCGAAAGTGCAGTGGAAG

CCCGTGACTGTCTCGTGGAACTCGGG

GTCGACAACGCACTGCAGTCGGGA

CGCCCTCACATCCGGAGTGCATACCT

AACTCCCAGGAATCGGTGACCGAG

TTCCCGCCGTGTTGCAGTCCAGCGGC

CAGGACTCGAAGGACTCAACCTAC

CTGTACAGCCTGAGCTCCGTCGTGAC

TCATTGTCCTCCACCCTCACCCTGA

AGTGCCGTCCTCCTCCCTTGGAACCC

GCAAGGCCGATTACGAGAAGCATA

AGACCTATATCTGCAACGTCAATCAC

AGGTCTACGCCTGCGAAGTGACCC

AAGCCCTCCAACACCAAAGTGGACA

ACCAGGGCCTGAGCAGCCCAGTGA

AGAAGGTCGAACCCAAGTCCTGCGA

CGAAGTCCTTCAACCGGGGAGAAT

CAAGACTCACACCTGTCCGCCTTGTC

GC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1746
GAGGCTTGGTCCAGCCTGGGGGGTC
1854
GTCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

ACAGAGCCACCCTCTCTTGCAGGG

GATTCACCGTCAGTAGCAACTACATG

CCAGTCAGAGTGTTAGCAGCACCT

AGCTGGGTCCGCCAGGCTCCAGGGA

CCTTAGCCTGGTACCAGCACAAAC

AGGGGCTGGAGTGGGTCTCAGTTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

TATAGCGGTGGTAGCACATACTACGC

CTATGGTGCATCCAGGAGGGCCAC

AGACTCCGTGAAGGGCAGATTCACC

TGGCATCCCAGACAGGTTCAGTGG

ATCTCCAGAGACAATTCCAAGAACA

CAGTGGGTCTGGGACAGACTTCAC

CGCTGTATCTTCAAATGAACAGCCTG

TCTCACCATCAACAGACTGGAGCC

AGAGCCGAGGACACGGCTGTGTATT

TGAAGATTTTGCAGTGTATTACTGT

ACTGTGCGAGAGACTATTACTATGGT

CAGCACTATGGTAGTTCACCTCCA

TCGGGGAGTTCTCCCTGGGGCCAGG

ATCACCTTCGGCCAAGGGACACGA

GAACCCTGGTCACCGTCTCCTCAGCA

CTGGAGATTAAACGTACTGTGGCT

TCCACCAAGGGGCCTTCCGTGTTCCC

GCTCCCTCCGTGTTCATTTTTCCTC

CCTGGCCCCTTCATCCAAGTCGACCT

CGTCGGACGAACAGCTGAAGTCCG

CTGGTGGAACCGCCGCACTCGGTTGC

GAACCGCGTCCGTGGTCTGTCTCCT

CTGGTCAAAGACTACTTCCCCGAGCC

GAACAACTTCTATCCGCGCGAGGC

CGTGACTGTCTCGTGGAACTCGGGCG

GAAAGTGCAGTGGAAGGTCGACAA

CCCTCACATCCGGAGTGCATACCTTT

CGCACTGCAGTCGGGAAACTCCCA

CCCGCCGTGTTGCAGTCCAGCGGCCT

GGAATCGGTGACCGAGCAGGACTC

GTACAGCCTGAGCTCCGTCGTGACAG

GAAGGACTCAACCTACTCATTGTC

TGCCGTCCTCCTCCCTTGGAACCCAG

CTCCACCCTCACCCTGAGCAAGGC

ACCTATATCTGCAACGTCAATCACAA

CGATTACGAGAAGCATAAGGTCTA

GCCCTCCAACACCAAAGTGGACAAG

CGCCTGCGAAGTGACCCACCAGGG

AAGGTCGAACCCAAGTCCTGCGACA

CCTGAGCAGCCCAGTGACGAAGTC

AGACTCACACCTGTCCGCCTTGTCCA

CTTCAACCGGGGAGAATGC

GCCCCTGAGCTGCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACAACTCTA

CGTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGTC

AAACAAGGCTCTCCCTGCCCCTATCG

AAAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1747
CAGGACTGTTGAAGCCTTCGGAGAC
1855
GCCACCCTGTCTGTGTCTCCAGGGG

CCTGTCCCTCACCTGCGCTGTCTATG

AAAGAGCCACCCTCTCCTGCAGGG

GTGGGTCCTTCAGTGGTTACTACTGG

CCAGTCAGAGTGTTGGCAGCAAAT

AGCTGGATCCGCCAGCCCCCAGGGA

TAGCCTGGTACCAGCAGAAACCTG

AGGGGCTGGAGTGGATTGGGGAAAT

GCCAGGCTCCCAGGCTCCTCATCTA

CAATCATAGTGGAAGCACCAACTAC

TGGTGCATCCACCAGGGCCACTGG

AACCCGTCCCTCAAGAGTCGAGTCAC

TGTCCCAGTCCGGTTCAGTGGCAGT

CATATCAGTAGACACGTCCAAGAAC

GGGTCTGGGACAGAATTCACTCTC

CAGTTCTCCCTGAAGCTGAGCTCTGT

ACCATCAGCAGCCTGCAGTCTGAA

GACCGCCGCGGACACGGCTGTGTATT

GATTTTGCAGTTTATTACTGTCAGC

ACTGTGCGAGAGGCCGGCCATATTGT

AGTATAATAACTGGCCCCCGATCA

AGTAGTACCAGCTGCTACCCAGAGT

CCTTCGGCCAAGGGACACGACTGG

GGTTCGACCCCTGGGGCCAGGGAAC

AGATTAAACGTACTGTGGCTGCTC

CCTGGTCACCGTCTCCTCAGCATCCA

CCTCCGTGTTCATTTTTCCTCCGTC

CCAAGGGGCCTTCCGTGTTCCCCCTG

GGACGAACAGCTGAAGTCCGGAAC

GCCCCTTCATCCAAGTCGACCTCTGG

CGCGTCCGTGGTCTGTCTCCTGAAC

TGGAACCGCCGCACTCGGTTGCCTGG

AACTTCTATCCGCGCGAGGCGAAA

TCAAAGACTACTTCCCCGAGCCCGTG

GTGCAGTGGAAGGTCGACAACGCA

ACTGTCTCGTGGAACTCGGGCGCCCT

CTGCAGTCGGGAAACTCCCAGGAA

CACATCCGGAGTGCATACCTTTCCCG

TCGGTGACCGAGCAGGACTCGAAG

CCGTGTTGCAGTCCAGCGGCCTGTAC

GACTCAACCTACTCATTGTCCTCCA

AGCCTGAGCTCCGTCGTGACAGTGCC

CCCTCACCCTGAGCAAGGCCGATT

GTCCTCCTCCCTTGGAACCCAGACCT

ACGAGAAGCATAAGGTCTACGCCT

ATATCTGCAACGTCAATCACAAGCCC

GCGAAGTGACCCACCAGGGCCTGA

TCCAACACCAAAGTGGACAAGAAGG

GCAGCCCAGTGACGAAGTCCTTCA

TCGAACCCAAGTCCTGCGACAAGAC

ACCGGGGAGAATGC

TCACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGGA

CACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGTG

TCGCACGAAGATCCCGAAGTGAAAT

TCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACAACTCTACGT

ACCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAAA

CAAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTATACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGCC

TTGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCAAGCTG

ACTGTGGACAAGTCAAGATGGCAGC

AGGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1748
GAGGCGTGGTCCAGCCTGGGAGGTC
1856
CTCTCCCTGCCCGTCACCCCTGGAG

CCTGAGACTCTCCTGTGCAGCCTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GATTCACCTTCAGTAGCTATGGCATG

TAGTCAGAGCCTCCTGCATAGTAA

CACTGGGTCCGCCAGGCTCCAGGCA

TGGATACAACTATTTGGATTGGTAC

AGGGGCTGGAGTGGGTGGCAGTTAT

CTGCAGAAGCCAGGGCAGTCTCCA

ATCATATGATGGAAGTAATAAATACT

CAGCTCCTGATCTATTTGGGTTCTA

ATGCAGACTCCGTGAAGGGCCGATT

ATCGGGCCTCCGGGGTCCCTGACA

CACCATCTCCAGAGACAATTCCAAG

GGTTCAGTGGCAGTGGATCAGGCA

AACACGCTGTATCTGCAAATGAACA

CAGATTTTACACTGAAAATCAGCA

GCCTGAGAGCTGAGGACACGGCTGT

GAGTGGAGGCTGAGGATGTTGGGG

GTATTACTGTGCGAAATTAAGGGGTA

TGTATTACTGCATGCAAACTCTTCA

TAGATTACTATGATAGTAGTGGTTAC

AACTCCGCTCACTTTCGGCGGAGG

CAACGGGGGTTTGACTACTGGGGCC

GACCAAAGTGGATATCAAACGTAC

AGGGAACCCTGGTCACCGTCTCCTCA

TGTGGCTGCTCCCTCCGTGTTCATT

GCATCCACCAAGGGGCCTTCCGTGTT

TTTCCTCCGTCGGACGAACAGCTG

CCCCCTGGCCCCTTCATCCAAGTCGA

AAGTCCGGAACCGCGTCCGTGGTC

CCTCTGGTGGAACCGCCGCACTCGGT

TGTCTCCTGAACAACTTCTATCCGC

TGCCTGGTCAAAGACTACTTCCCCGA

GCGAGGCGAAAGTGCAGTGGAAG

GCCCGTGACTGTCTCGTGGAACTCGG

GTCGACAACGCACTGCAGTCGGGA

GCGCCCTCACATCCGGAGTGCATACC

AACTCCCAGGAATCGGTGACCGAG

TTTCCCGCCGTGTTGCAGTCCAGCGG

CAGGACTCGAAGGACTCAACCTAC

CCTGTACAGCCTGAGCTCCGTCGTGA

TCATTGTCCTCCACCCTCACCCTGA

CAGTGCCGTCCTCCTCCCTTGGAACC

GCAAGGCCGATTACGAGAAGCATA

CAGACCTATATCTGCAACGTCAATCA

AGGTCTACGCCTGCGAAGTGACCC

CAAGCCCTCCAACACCAAAGTGGAC

ACCAGGGCCTGAGCAGCCCAGTGA

AAGAAGGTCGAACCCAAGTCCTGCG

CGAAGTCCTTCAACCGGGGAGAAT

ACAAGACTCACACCTGTCCGCCTTGT

GC

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGCC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1749
CAGGACTGGTGAAGCCTTCGGAGAC
1857
ACTCCCTGGCTGTGTCTCTGGGCGA

CCTGTCCCTCACCTGCACTGTCTCTG

GAGGGCCACCATCAACTGCAAGTC

GTGGCTCCATCAGTAGTTACTACTGG

CAGCCAGAGTGTTTTATACAGCTCC

AGCTGGATCCGGCAGCCCCCAGGGA

AACAATAAGAACTACTTAGCTTGG

AGGGACTGGAGTGGATTGGCTATAT

TACCAGCAGAAACCAGGACAGCCT

CTATTACACTGGGAGCACCAACTACA

CCTAAGCTGCTCATTTACTGGGCAT

ACCCCTCCCTCAAGAGCCGAGTCACC

CTACCCGGGAATCCGGGGTCCCTG

ATATCAGTAGACACGTCCAAGAACC

ACCGATTCAGTGGCAGCGGGTCTG

AGTTCTCCCTGAAGCTGAGCTCTGTG

GGACAGATTTCACTCTCACCATCA

ACCACTGCGGACACGGCCGTGTATTA

GCAGCCTGCAGGCTGAAGATGTGG

CTGTGCGAGAGGTGGGAGGGGGGAT

CAGTTTATTACTGTCAGCAATATTA

GGGGCCGCTTTTGACATCTGGGGCCA

TAGTAGTACTCCGTACACTTTTGGC

AGGGACAATGGTCACCGTCTCTTCAG

CAGGGGACCAAGCTGGAGATCAAA

CATCCACCAAGGGGCCTTCCGTGTTC

CGTACTGTGGCTGCTCCCTCCGTGT

CCCCTGGCCCCTTCATCCAAGTCGAC

TCATTTTTCCTCCGTCGGACGAACA

CTCTGGTGGAACCGCCGCACTCGGTT

GCTGAAGTCCGGAACCGCGTCCGT

GCCTGGTCAAAGACTACTTCCCCGAG

GGTCTGTCTCCTGAACAACTTCTAT

CCCGTGACTGTCTCGTGGAACTCGGG

CCGCGCGAGGCGAAAGTGCAGTGG

CGCCCTCACATCCGGAGTGCATACCT

AAGGTCGACAACGCACTGCAGTCG

TTCCCGCCGTGTTGCAGTCCAGCGGC

GGAAACTCCCAGGAATCGGTGACC

CTGTACAGCCTGAGCTCCGTCGTGAC

GAGCAGGACTCGAAGGACTCAACC

AGTGCCGTCCTCCTCCCTTGGAACCC

TACTCATTGTCCTCCACCCTCACCC

AGACCTATATCTGCAACGTCAATCAC

TGAGCAAGGCCGATTACGAGAAGC

AAGCCCTCCAACACCAAAGTGGACA

ATAAGGTCTACGCCTGCGAAGTGA

AGAAGGTCGAACCCAAGTCCTGCGA

CCCACCAGGGCCTGAGCAGCCCAG

CAAGACTCACACCTGTCCGCCTTGTC

TGACGAAGTCCTTCAACCGGGGAG

CAGCCCCTGAGCTGCTGGGTGGTCCG

AATGC

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG
SEQ ID
GATATTGTGATGACCCACACTCCCC

1750
GAGGCGTGGTCCAGCCTGGGAGGTC
1858
TCTCTCTGTCCGTCACCCCTGGACA

CCTGAGACTCTCCTGTGCAGCGTCTG

GCCGGCCTCCATCTCCTGCAAGTCT

GATTCACCTTCAGCAGCTCTGCCATG

AGTCAGAGCCTCCTGGGTGGTGAT

CACTGGGTCCGCCAGGCTCCAGGCA

GGAAAGACCTATTTGTATTGGTAC

AGGGACTGGAGTGGGTGGCAATGAT

CTGCAGAAGCCAGGCCAGCCTCCA

TTGGCATGATGAGAGTAAGAAATAC

CAGCTCCTGCTCTATGAAGTTTCCA

TATGCAGACTCCGTGAAGGGCCGATT

ACCGATTCTCTGGAGTGCCAGATA

CACTATCTCCAGAGACAATTCCAAGA

GGTTCAGTGGCAGCGGGGCAGCGA

ACACGCTGTATCTGCAAATGAACAG

CAGATTTCACACTGAAAATCAGCA

CCTGAGAGCTGAGGACACGGCTGTG

GGGTGGAAGCTGAGGATGTCGGGG

TATTACTGTGCGAGACCCCCCGACGG

TTTATTACTGCATGCAATCTACACA

TGGTAACTCCGGTCGCTGGTACTTCG

ATTTCCGTGGACGTTCGGCCAAGG

ATCTCTGGGGCCGTGGCACCCTGGTC

GACCAAGGTGGAGATCAAACGTAC

ACCGTCTCCTCAGCATCCACCAAGGG

TGTGGCTGCTCCCTCCGTGTTCATT

GCCTTCCGTGTTCCCCCTGGCCCCTT

TTTCCTCCGTCGGACGAACAGCTG

CATCCAAGTCGACCTCTGGTGGAACC

AAGTCCGGAACCGCGTCCGTGGTC

GCCGCACTCGGTTGCCTGGTCAAAGA

TGTCTCCTGAACAACTTCTATCCGC

CTACTTCCCCGAGCCCGTGACTGTCT

GCGAGGCGAAAGTGCAGTGGAAG

CGTGGAACTCGGGCGCCCTCACATCC

GTCGACAACGCACTGCAGTCGGGA

GGAGTGCATACCTTTCCCGCCGTGTT

AACTCCCAGGAATCGGTGACCGAG

GCAGTCCAGCGGCCTGTACAGCCTG

CAGGACTCGAAGGACTCAACCTAC

AGCTCCGTCGTGACAGTGCCGTCCTC

TCATTGTCCTCCACCCTCACCCTGA

CTCCCTTGGAACCCAGACCTATATCT

GCAAGGCCGATTACGAGAAGCATA

GCAACGTCAATCACAAGCCCTCCAA

AGGTCTACGCCTGCGAAGTGACCC

CACCAAAGTGGACAAGAAGGTCGAA

ACCAGGGCCTGAGCAGCCCAGTGA

CCCAAGTCCTGCGACAAGACTCACA

CGAAGTCCTTCAACCGGGGAGAAT

CCTGTCCGCCTTGTCCAGCCCCTGAG

GC

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1751
GAGGCTTGGTACAGCCTGGGGGGTC
1859
GGCACCCTGTCTTTGTCTGCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTAGCAGCTATGCCATG

CCAGTCAGAGTGTTAGCAGCAGCT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTCTCAGCTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AGTGGTAGTGGTGGTAGCACATACT

CTATGCTGCATCCTACAGGGCCACT

ACGCAGACTCCGTGAAGGGCCGGTT

GGCATCCCAGACAGGTTCAGTGGC

CACCATCTCCAGAGACAATTCCAAG

CGTGGGTCTGGGACAGAGTTCACT

AACACGCTGTATCTGCAAATGAACA

CTCACCATCAGCAGCCTGCAGTCT

GCCTGAGAGCCGAGGACACGGCCGT

GAAGATTTTGCAGTTTATTACTGTC

ATATTACTGTGCGAAAGACAAGAAC

AGCAGTATAATAACTGGCCTCCCA

GTCCGAAAACATGACTACGGTGACC

TCACCTTCGGCCAAGGGACACGAC

ACCCCTACGGGGGGTACTTTGACTAC

TGGAGATTAAACGTACTGTGGCTG

TGGGGCCAGGGCACCCTGGTGACCG

CTCCCTCCGTGTTCATTTTTCCTCC

TCTCCTCAGCATCCACCAAGGGGCCT

GTCGGACGAACAGCTGAAGTCCGG

TCCGTGTTCCCCCTGGCCCCTTCATC

AACCGCGTCCGTGGTCTGTCTCCTG

CAAGTCGACCTCTGGTGGAACCGCC

AACAACTTCTATCCGCGCGAGGCG

GCACTCGGTTGCCTGGTCAAAGACTA

AAAGTGCAGTGGAAGGTCGACAAC

CTTCCCCGAGCCCGTGACTGTCTCGT

GCACTGCAGTCGGGAAACTCCCAG

GGAACTCGGGCGCCCTCACATCCGG

GAATCGGTGACCGAGCAGGACTCG

AGTGCATACCTTTCCCGCCGTGTTGC

AAGGACTCAACCTACTCATTGTCCT

AGTCCAGCGGCCTGTACAGCCTGAG

CCACCCTCACCCTGAGCAAGGCCG

CTCCGTCGTGACAGTGCCGTCCTCCT

ATTACGAGAAGCATAAGGTCTACG

CCCTTGGAACCCAGACCTATATCTGC

CCTGCGAAGTGACCCACCAGGGCC

AACGTCAATCACAAGCCCTCCAACA

TGAGCAGCCCAGTGACGAAGTCCT

CCAAAGTGGACAAGAAGGTCGAACC

TCAACCGGGGAGAATGC

CAAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1752
CTGAGGTGAAGAAGCCTGGGGCCTC
1860
CCACCCTGTCTGTGTCTCCAGGGGA

AGTGAAGGTTTCCTGCAAGGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACACCTTCACTAGCTATGCTATG

CAGTCAGAGTGTTAGCAGCAACTT

CATTGGGTGCGCCAGGCCCCCGGAC

AGCCTGGTACCAGCAGAAACCTGG

AAAGGCTTGAGTGGATGGGATGGAT

CCAGGCTCCCAGGCTCCTCATCTAT

CAACGCTGGCAATGGTAACACAAAA

GATGCATCCACCAGGGCCACTGGT

TATTCACAGAAGTTCCAGGGCAGAG

ATCCCAGCCAGGTTCAGTGGCAGT

TCACCATTACCAGGGACACATCCGCG

GGGTCTGGGACAGAGTTCACTCTC

AGCACAGCCTACATGGAGCTGAGCA

ACCATCAGCAGCCTGCAGTCTGAA

GCCTGAGATCTGAAGACACGGCTGT

GATTTTGCAGTTTATTACTGTCAGC

GTATTACTGTGCGAGAGTGGCGGGA

ACTATAATAACTGGCCTCATACCTT

GCTACTTCCCTATGGTACTGGGGCCA

CGGCCAAGGGACCAAGCTGGAGAT

GGGCACCCTGGTCACCGTCTCCTCAG

CAAACGTACTGTGGCTGCTCCCTCC

CATCCACCAAGGGGCCTTCCGTGTTC

GTGTTCATTTTTCCTCCGTCGGACG

CCCCTGGCCCCTTCATCCAAGTCGAC

AACAGCTGAAGTCCGGAACCGCGT

CTCTGGTGGAACCGCCGCACTCGGTT

CCGTGGTCTGTCTCCTGAACAACTT

GCCTGGTCAAAGACTACTTCCCCGAG

CTATCCGCGCGAGGCGAAAGTGCA

CCCGTGACTGTCTCGTGGAACTCGGG

GTGGAAGGTCGACAACGCACTGCA

CGCCCTCACATCCGGAGTGCATACCT

GTCGGGAAACTCCCAGGAATCGGT

TTCCCGCCGTGTTGCAGTCCAGCGGC

GACCGAGCAGGACTCGAAGGACTC

CTGTACAGCCTGAGCTCCGTCGTGAC

AACCTACTCATTGTCCTCCACCCTC

AGTGCCGTCCTCCTCCCTTGGAACCC

ACCCTGAGCAAGGCCGATTACGAG

AGACCTATATCTGCAACGTCAATCAC

AAGCATAAGGTCTACGCCTGCGAA

AAGCCCTCCAACACCAAAGTGGACA

GTGACCCACCAGGGCCTGAGCAGC

AGAAGGTCGAACCCAAGTCCTGCGA

CCAGTGACGAAGTCCTTCAACCGG

CAAGACTCACACCTGTCCGCCTTGTC

GGAGAATGC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1753
CAGGACTGGTGAAGCCCTCGCAGAG
1861
GGCACCCTGTCTTTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AAAGAGCCACCCTCTCCTGCAGGG

GGGACAGTGTCTCTAGCAACAGTGCT

CCAGTCAGAGTGTTAGCAGCAACT

GCTTGGAACTGGATCAGGCAGTCCCC

CCTTAGCCTGGTACCAGCAGAAAC

ATCGAGAGGCCTTGAGTGGCTGGGA

CTGGCCAGGCTCCCAGGCTCCTCAT

AGGACATACTACAGGTCCAAGTGGT

CTATGGTGCATCCAGCAGGGCCTC

ATAATGATTATGCAGTATCTGTGAAG

TGGCATCCCAGACAGGTTCAATGG

AGTCGAATAACCATCAAACCAGACA

CAGTGGGTCTGGGACAGACTTCAC

CATCCAAGAACCAGTTCTCCCTGCAG

TCTCACCATCAATAGGCTGGAGCC

CTGAACTCTGTGACTCCCGAGGACAC

TGAAGACTTTGCAGTGTATTACTGT

GGCTGTGTATTACTGTACAAGGCTAG

CAGCAGTATGGTAACTCACAGACC

CTAATTCCGACGGTGTGGACGTCTGG

TTCGGCCAAGGGACACGACTGGAG

GGCCAAGGGACAATGGTCACCGTCT

ATTAAACGTACTGTGGCTGCTCCCT

CCTCAGCATCCACCAAGGGGCCTTCC

CCGTGTTCATTTTTCCTCCGTCGGA

GTGTTCCCCCTGGCCCCTTCATCCAA

CGAACAGCTGAAGTCCGGAACCGC

GTCGACCTCTGGTGGAACCGCCGCAC

GTCCGTGGTCTGTCTCCTGAACAAC

TCGGTTGCCTGGTCAAAGACTACTTC

TTCTATCCGCGCGAGGCGAAAGTG

CCCGAGCCCGTGACTGTCTCGTGGAA

CAGTGGAAGGTCGACAACGCACTG

CTCGGGCGCCCTCACATCCGGAGTGC

CAGTCGGGAAACTCCCAGGAATCG

ATACCTTTCCCGCCGTGTTGCAGTCC

GTGACCGAGCAGGACTCGAAGGAC

AGCGGCCTGTACAGCCTGAGCTCCGT

TCAACCTACTCATTGTCCTCCACCC

CGTGACAGTGCCGTCCTCCTCCCTTG

TCACCCTGAGCAAGGCCGATTACG

GAACCCAGACCTATATCTGCAACGTC

AGAAGCATAAGGTCTACGCCTGCG

AATCACAAGCCCTCCAACACCAAAG

AAGTGACCCACCAGGGCCTGAGCA

TGGACAAGAAGGTCGAACCCAAGTC

GCCCAGTGACGAAGTCCTTCAACC

CTGCGACAAGACTCACACCTGTCCGC

GGGGAGAATGC

CTTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATTT

CACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1754
CAGGACTGGTGAAGCCCTCGCAGAC
1862
CCACCCTGTCTGTGTCTCCAGGGGA

CCTCTCACTCACCTGTGCCATCTCCG

AAGAGCCACCCTCTCCTGCAGGGC

GGGACAGTGTCTCTAGCGACAGTGCT

CAGTCAGAGTGTTAGCAGCAACTT

GTTTGGACCTGGATCAGGCAGTCCCC

AGCCTGGTACCAGCAGAAACCTGG

ATCGAGAGGCCTTGAGTGGCTGGGA

CCAGGCTCCCAGGCTCCTCATCTAT

AGGACATACTACAAGTCGAAGTGGT

GGTGCATCCACCAGGGCCACTGGT

ATAATGATTATGCAGCATCTGTGAAA

ATCCCAGCCAGGTTCAGTGGCAGT

AGTCGAATAACCATCAACCCAGACA

GGGTCTGGGACAGAGTTCACTCTC

CATCCAAGAACCAGTTCTCCCTGCAC

ACCATCAGCAGCCTGCAGTCTGAA

CTGAACTCTGTGACTCCCGAGGACAC

GATTTTGCAGTTTATTACTGTCAGC

GGCTGTGTATTACTGTGCAAGAGGTG

AGTATAATAACTGGCCCCGGACGT

TAACCCGGACCTTTGACTACTGGGGC

TCGGCCAAGGGACCAAGCTGGAGA

CAGGGGACCACGGTCACCGTCTCCTC

TCAAACGTACTGTGGCTGCTCCCTC

AGCATCCACCAAGGGGCCTTCCGTGT

CGTGTTCATTTTTCCTCCGTCGGAC

TCCCCCTGGCCCCTTCATCCAAGTCG

GAACAGCTGAAGTCCGGAACCGCG

ACCTCTGGTGGAACCGCCGCACTCGG

TCCGTGGTCTGTCTCCTGAACAACT

TTGCCTGGTCAAAGACTACTTCCCCG

TCTATCCGCGCGAGGCGAAAGTGC

AGCCCGTGACTGTCTCGTGGAACTCG

AGTGGAAGGTCGACAACGCACTGC

GGCGCCCTCACATCCGGAGTGCATAC

AGTCGGGAAACTCCCAGGAATCGG

CTTTCCCGCCGTGTTGCAGTCCAGCG

TGACCGAGCAGGACTCGAAGGACT

GCCTGTACAGCCTGAGCTCCGTCGTG

CAACCTACTCATTGTCCTCCACCCT

ACAGTGCCGTCCTCCTCCCTTGGAAC

CACCCTGAGCAAGGCCGATTACGA

CCAGACCTATATCTGCAACGTCAATC

GAAGCATAAGGTCTACGCCTGCGA

ACAAGCCCTCCAACACCAAAGTGGA

AGTGACCCACCAGGGCCTGAGCAG

CAAGAAGGTCGAACCCAAGTCCTGC

CCCAGTGACGAAGTCCTTCAACCG

GACAAGACTCACACCTGTCCGCCTTG

GGGAGAATGC

TCCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACAAC

TCTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAAG

TGTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTATACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAAC

TACAAGACCACCCCACCGGTGCTCG

ATTCCGATGGCTCCTTCTTCCTGTACT

CCAAGCTGACTGTGGACAAGTCAAG

ATGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTGT

CACTTTCGCCGGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1755
CAGGACTGGTGAAGCCCTCGCAGAC
1863
TCTCCCTGCCCGTCACCCTTGGACA

CCTCTCACTCACCTGTGCCATCTCCG

GCCGGCCTCCATCTCCTGCAGGTCT

GGGACAGTGTCTCTAGCAACAGTGCT

AGTCAAAGCCTCGTATACAGTGAT

GCTTGGAACTGGATCAGGCAGTCCCC

GGAAACACCTACTTGAATTGGTTTC

ATCGAGAGGCCTTGAGTGGCTGGGA

AGCAGAGGCCAGGCCAATCTCCAA

AGGACATACTACAGGTCCAAGTGGT

GGCGCCTAATTTATAAGGTTTCTAA

ATAATGATTATGCAGTATCTGTGAAA

CCGGGACTCTGGGGTCCCAGACAG

AGTCGAATAACCATCAACCCAGACA

ATTCAGCGGCAGTGGGTCAGGCAC

CATCCAAGAACCAGTTCTCCCTGCAG

TGATTTCACACTGAAAATCAGCAG

CTGAACTCTGTGACTCCCGAGGACAC

GGTGGAGGCTGAGGATGTTGGGGT

GGCTGTGTATTACTGTGCAGAAGGCA

TTATTACTGCATGCAAGGTACACAT

ATGGGCCGTTCGACCCCTGGGGCCA

TGGCCTCGGACTTTCGGCGGAGGG

GGGAACCCTGGTGACCGTCTCCTCAG

ACCAAGCTGGAGATCAAACGTACT

CATCCACCAAGGGGCCTTCCGTGTTC

GTGGCTGCTCCCTCCGTGTTCATTT

CCCCTGGCCCCTTCATCCAAGTCGAC

TTCCTCCGTCGGACGAACAGCTGA

CTCTGGTGGAACCGCCGCACTCGGTT

AGTCCGGAACCGCGTCCGTGGTCT

GCCTGGTCAAAGACTACTTCCCCGAG

GTCTCCTGAACAACTTCTATCCGCG

CCCGTGACTGTCTCGTGGAACTCGGG

CGAGGCGAAAGTGCAGTGGAAGGT

CGCCCTCACATCCGGAGTGCATACCT

CGACAACGCACTGCAGTCGGGAAA

TTCCCGCCGTGTTGCAGTCCAGCGGC

CTCCCAGGAATCGGTGACCGAGCA

CTGTACAGCCTGAGCTCCGTCGTGAC

GGACTCGAAGGACTCAACCTACTC

AGTGCCGTCCTCCTCCCTTGGAACCC

ATTGTCCTCCACCCTCACCCTGAGC

AGACCTATATCTGCAACGTCAATCAC

AAGGCCGATTACGAGAAGCATAAG

AAGCCCTCCAACACCAAAGTGGACA

GTCTACGCCTGCGAAGTGACCCAC

AGAAGGTCGAACCCAAGTCCTGCGA

CAGGGCCTGAGCAGCCCAGTGACG

CAAGACTCACACCTGTCCGCCTTGTC

AAGTCCTTCAACCGGGGAGAATGC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG
SEQ ID
GACATCCAGATGACCCAGTCTCCTT

1756
GAGGCGTGGTCCAGCCTGGGAGGTC
1864
CCACCCTGTCTGCATCTGTAGGAG

CCTGAGACTCTCCTGTGTAGCCTCTG

ACAGAGTCACCATCACTTGCCGGG

GATTCACCTTCAGTACCTATCCCATG

CCAGTCAGAGTATTAGTAGGTGGT

CACTGGGTCCGCCAGGCTCCAGGCA

TGGCCTGGTATCAGCAGAAGCCAG

AGGGGCTGGAGTGGGTGGCAGTTAT

GGAAAGCCCCTAAGCTCCTGATCT

ATCATATGATGGACGTAATGAATACT

ATAAGGCGTCTACTATAAAAAGTG

ACGCAGACTCCGTGAAGGGCCGATT

GGGTCCCATCAAGATTCAGCGCCA

CACCATCTCCAGAGACAATTCCAAA

GTGGATCTGGGACAGAATTCACTC

AACACGCTGTATCTGCAAATGAACA

TCACCATCAGCAGCCTGCAGCCTG

GTCTGCGAGCTGAAGACACGGCTGT

AAGATTTTGCAACTTATTACTGCCA

CTATTATTGTGCGACTCGGGATACAC

ACACTATAAAAGTGATTCCCGGAC

CTTTGGTTGGGGTTTCGATATACTGG

GTTCGGCCAAGGGACCAAGGTGGA

GGCCAGGGCACCCTGGTCACCGTCTC

AATCAAACGTACTGTGGCTGCTCC

CTCAGCATCCACCAAGGGGCCTTCCG

CTCCGTGTTCATTTTTCCTCCGTCG

TGTTCCCCCTGGCCCCTTCATCCAAG

GACGAACAGCTGAAGTCCGGAACC

TCGACCTCTGGTGGAACCGCCGCACT

GCGTCCGTGGTCTGTCTCCTGAACA

CGGTTGCCTGGTCAAAGACTACTTCC

ACTTCTATCCGCGCGAGGCGAAAG

CCGAGCCCGTGACTGTCTCGTGGAAC

TGCAGTGGAAGGTCGACAACGCAC

TCGGGCGCCCTCACATCCGGAGTGCA

TGCAGTCGGGAAACTCCCAGGAAT

TACCTTTCCCGCCGTGTTGCAGTCCA

CGGTGACCGAGCAGGACTCGAAGG

GCGGCCTGTACAGCCTGAGCTCCGTC

ACTCAACCTACTCATTGTCCTCCAC

GTGACAGTGCCGTCCTCCTCCCTTGG

CCTCACCCTGAGCAAGGCCGATTA

AACCCAGACCTATATCTGCAACGTCA

CGAGAAGCATAAGGTCTACGCCTG

ATCACAAGCCCTCCAACACCAAAGT

CGAAGTGACCCACCAGGGCCTGAG

GGACAAGAAGGTCGAACCCAAGTCC

CAGCCCAGTGACGAAGTCCTTCAA

TGCGACAAGACTCACACCTGTCCGCC

CCGGGGAGAATGC

TTGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAT

1757
GAGGCCTGGTCAAGGCTGGGGGGTC
1865
CCTCCCTCGCTGCATCTGTTGGAGA

CCTGAGACTCTCCTGTTCAGCCTCTG

CAGAATTACCATCACTTGCCGGCC

GATTCACCTTCAGTAGCTATGCTATG

AAGTCAGGACATAGGCACTTATTT

CACTGGGTCCGCCAGGCTCCAGGGA

AAATTGGTATCAACAGAAGGCAGG

AGGGACTGGAATATGTTTCAGCTATT

GGAAGCCCCTAAGCTCCTCATCTAT

AGTAGTAATGGGGGTAGCACATACT

GCTGCCTCCAATCTGCACAGTGGC

ACGCAGACTCAGTGAAGGGCAGATT

GTCTCATCAAGGTTCAGAGGCGTT

CACCATCTCCAGAGACAATTCCAAG

GGGTCTGGGACACAATTCACTCTC

AACACGCTGTATCTTCAAATGAGCAG

ACCATCAGCAGTCTGCAACCTGAG

TCTGAGAGCTGAGGACACGGCTGTG

GATTTTGCAACTTACTACTGTCATC

TATTACTGTGTGAATCGGGCGGGTTA

AGAGTTACGGTCCTCGGACATTCG

CGGTGACTACAGACACTTCCAGCACT

GCCAAGGGACCAAGCTGGAGATCA

GGGGCCAGGGCACCCTGGTCACCGT

AACGTACTGTGGCTGCTCCCTCCGT

CTCCTCAGCATCCACCAAGGGGCCTT

GTTCATTTTTCCTCCGTCGGACGAA

CCGTGTTCCCCCTGGCCCCTTCATCC

CAGCTGAAGTCCGGAACCGCGTCC

AAGTCGACCTCTGGTGGAACCGCCG

GTGGTCTGTCTCCTGAACAACTTCT

CACTCGGTTGCCTGGTCAAAGACTAC

ATCCGCGCGAGGCGAAAGTGCAGT

TTCCCCGAGCCCGTGACTGTCTCGTG

GGAAGGTCGACAACGCACTGCAGT

GAACTCGGGCGCCCTCACATCCGGA

CGGGAAACTCCCAGGAATCGGTGA

GTGCATACCTTTCCCGCCGTGTTGCA

CCGAGCAGGACTCGAAGGACTCAA

GTCCAGCGGCCTGTACAGCCTGAGCT

CCTACTCATTGTCCTCCACCCTCAC

CCGTCGTGACAGTGCCGTCCTCCTCC

CCTGAGCAAGGCCGATTACGAGAA

CTTGGAACCCAGACCTATATCTGCAA

GCATAAGGTCTACGCCTGCGAAGT

CGTCAATCACAAGCCCTCCAACACCA

GACCCACCAGGGCCTGAGCAGCCC

AAGTGGACAAGAAGGTCGAACCCAA

AGTGACGAAGTCCTTCAACCGGGG

GTCCTGCGACAAGACTCACACCTGTC

AGAATGC

CGCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAAC

AGTACAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTATACTTTGCCGCCTAGC

CGGGAAGAAATGACTAAGAACCAAG

TGTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGGA

GTGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGTG

TTCTCCTGCTCCGTGATGCACGAAGC

GCTGCACAACCATTACACCCAGAAA

TCACTGTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1758
GAGGCGTGGTCCAGCCTGGGGGGTC
1866
GCCACCCTGTCTGTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCGTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGCTATGGCATG

CCAGTCAGAGTGTTAGCAGCAACT

CACTGGGTCCGCCAGGCTCCAGGCA

TAGCCTGGTACCAGCAGAAACCTG

AGGGGCTGGAGTGGGTGGCATTTAT

GCCAGGCTCCCAGGCTCCTCATCTA

ATCATATGATGGAAGTAATAAATACT

TGGTGCATCCACCAGGGCCACTGG

ACGCAGACTCCGTGAAGGGCCGATT

CATCCCAGCCAGGTTCAGTGGCAG

CACCATCTCCAGAGACAATTCCAAG

TGGGTCTGGGACAGAGTTCACTCT

AACACGCTGTATCTGCAAATGAACA

CACCATCAGCAGCCTGCAGTCTGA

GCCTGAGAGCCGAGGACACGGCCGT

AGATTTTGCAGTTTATTACTGTCAG

ATATTACTGTGCGACAACAGGGGAC

CAGTATAATAACTGGCCTCCGATC

CGCTTCCAAGAGTTTGACTACTGGGG

ACCTTCGGCCAAGGGACACGACTG

CCAGGGAACCCTGGTCACCGTCTCCT

GAGATTAAACGTACTGTGGCTGCT

CAGCATCCACCAAGGGGCCTTCCGTG

CCCTCCGTGTTCATTTTTCCTCCGT

TTCCCCCTGGCCCCTTCATCCAAGTC

CGGACGAACAGCTGAAGTCCGGAA

GACCTCTGGTGGAACCGCCGCACTCG

CCGCGTCCGTGGTCTGTCTCCTGAA

GTTGCCTGGTCAAAGACTACTTCCCC

CAACTTCTATCCGCGCGAGGCGAA

GAGCCCGTGACTGTCTCGTGGAACTC

AGTGCAGTGGAAGGTCGACAACGC

GGGCGCCCTCACATCCGGAGTGCAT

ACTGCAGTCGGGAAACTCCCAGGA

ACCTTTCCCGCCGTGTTGCAGTCCAG

ATCGGTGACCGAGCAGGACTCGAA

CGGCCTGTACAGCCTGAGCTCCGTCG

GGACTCAACCTACTCATTGTCCTCC

TGACAGTGCCGTCCTCCTCCCTTGGA

ACCCTCACCCTGAGCAAGGCCGAT

ACCCAGACCTATATCTGCAACGTCAA

TACGAGAAGCATAAGGTCTACGCC

TCACAAGCCCTCCAACACCAAAGTG

TGCGAAGTGACCCACCAGGGCCTG

GACAAGAAGGTCGAACCCAAGTCCT

AGCAGCCCAGTGACGAAGTCCTTC

GCGACAAGACTCACACCTGTCCGCCT

AACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGATGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1759
GAGTCTTGCTTCAGCCAGGGCGGTCC
1867
GCACCCTGTCTTTGTCTCCAGGGGA

CTGAGACTCTCCTGTACAGCTTCTGG

AAGAGCCACCCTCTCCTGCAGGGC

ATTCACCTTTGCTGCTTATAATATCA

CAGTCAGAGTGTTAGCAGCAGCTA

ACTGGTTCCGCCAGGGTCCTGGGGG

CTTAGCCTGGTACCAGCAGAAACC

GGGGCTGGAGTGGGTAGGTTTCATTA

TGGCCAGGCTCCCAGGCTCCTCATC

GAGCCAACGCTGATAGTGGGACAAC

TATGGTGCATCCAGCAGGGCCACT

AGAGTACGCCGCGTCTGTGAAAGGC

GGCATCCCAGACAGGTTCAGTGGC

AGATTCTTCATCTCAAGAGATGATTC

AGTGGGTCTGGGACAGACTTCACT

CAGAAGCACCGCCTACCTGCAAATG

CTCACCATCAGCAGACTGGAGCCT

ACTAGCCTTAAAACCGAGGACACAG

GAAGATTTTGCAGTGTATTACTGTC

CCGTTTATTACTGTGCCAGAGATGAT

AGCAGTATGGTAGCTCAGGGTACA

CGGGGTCGGGGAGATGACTTTGACT

CTTTTGGCCAGGGGACCAAGCTGG

ACTGGGGCCAGGGCACCCTGGTCAC

AGATCAAACGTACTGTGGCTGCTC

CGTCTCCTCAGCATCCACCAAGGGGC

CCTCCGTGTTCATTTTTCCTCCGTC

CTTCCGTGTTCCCCCTGGCCCCTTCAT

GGACGAACAGCTGAAGTCCGGAAC

CCAAGTCGACCTCTGGTGGAACCGCC

CGCGTCCGTGGTCTGTCTCCTGAAC

GCACTCGGTTGCCTGGTCAAAGACTA

AACTTCTATCCGCGCGAGGCGAAA

CTTCCCCGAGCCCGTGACTGTCTCGT

GTGCAGTGGAAGGTCGACAACGCA

GGAACTCGGGCGCCCTCACATCCGG

CTGCAGTCGGGAAACTCCCAGGAA

AGTGCATACCTTTCCCGCCGTGTTGC

TCGGTGACCGAGCAGGACTCGAAG

AGTCCAGCGGCCTGTACAGCCTGAG

GACTCAACCTACTCATTGTCCTCCA

CTCCGTCGTGACAGTGCCGTCCTCCT

CCCTCACCCTGAGCAAGGCCGATT

CCCTTGGAACCCAGACCTATATCTGC

ACGAGAAGCATAAGGTCTACGCCT

AACGTCAATCACAAGCCCTCCAACA

GCGAAGTGACCCACCAGGGCCTGA

CCAAAGTGGACAAGAAGGTCGAACC

GCAGCCCAGTGACGAAGTCCTTCA

CAAGTCCTGCGACAAGACTCACACCT

ACCGGGGAGAATGC

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1760
GAGGCTTGGTACAGCCTGGGGGGTC
1868
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTAGCAGCTATGGCATG

CCAGTCAGAGTGTTAGCAGCAGCT

ACGTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTCTCAACTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AGTGGTAATGGTGTTGGCACATACTA

CTATGGTGCATCCAGCAGGGCCAC

CCCAGACTCCGTGAAGGACCGGTTC

TGGCATCCCAGACAGGTTCAGTGG

ACCATCTCCAGAGACAGTTCCAAGA

CAGTGGGTCTGGGACAGACTTCAC

ACACGGTGTATCTGCAAATGAACAG

TCTCACCATCAGCAGACTGGAGCC

CCTGAGAGCCGAGGACACGGCCGTA

TGAAGATTTTGCAGTGTATTACTGT

TATTACTGTGTGAAACATGGTAGGGC

CAGCAGTATGGTAGCTCGTTCGGC

CGGAATAAACTGGTACTTCGATCTCT

CAAGGGACACGACTGGAGATTAAA

GGGGCCGTGGCACCCTGGTGACCGT

CGTACTGTGGCTGCTCCCTCCGTGT

CTCCTCAGCATCCACCAAGGGGCCTT

TCATTTTTCCTCCGTCGGACGAACA

CCGTGTTCCCCCTGGCCCCTTCATCC

GCTGAAGTCCGGAACCGCGTCCGT

AAGTCGACCTCTGGTGGAACCGCCG

GGTCTGTCTCCTGAACAACTTCTAT

CACTCGGTTGCCTGGTCAAAGACTAC

CCGCGCGAGGCGAAAGTGCAGTGG

TTCCCCGAGCCCGTGACTGTCTCGTG

AAGGTCGACAACGCACTGCAGTCG

GAACTCGGGCGCCCTCACATCCGGA

GGAAACTCCCAGGAATCGGTGACC

GTGCATACCTTTCCCGCCGTGTTGCA

GAGCAGGACTCGAAGGACTCAACC

GTCCAGCGGCCTGTACAGCCTGAGCT

TACTCATTGTCCTCCACCCTCACCC

CCGTCGTGACAGTGCCGTCCTCCTCC

TGAGCAAGGCCGATTACGAGAAGC

CTTGGAACCCAGACCTATATCTGCAA

ATAAGGTCTACGCCTGCGAAGTGA

CGTCAATCACAAGCCCTCCAACACCA

CCCACCAGGGCCTGAGCAGCCCAG

AAGTGGACAAGAAGGTCGAACCCAA

TGACGAAGTCCTTCAACCGGGGAG

GTCCTGCGACAAGACTCACACCTGTC

AATGC

CGCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAAC

AGTACAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTATACTTTGCCGCCTAGC

CGGGAAGAAATGACTAAGAACCAAG

TGTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGGA

GTGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGTG

TTCTCCTGCTCCGTGATGCACGAAGC

GCTGCACAACCATTACACCCAGAAA

TCACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GAAATTGTGTTGACACAGTCTCCTT

1761
CAGGACTGGTGAAGCCCTCGCAGAC
1869
CCACCCTGTCTGCATCTGTAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

ACAGAGTCACCATCACTTGCCGGG

GGGACAGTGTCTCTAGCAACAGTGCT

CCAGTCAGAGTATTAGTAGCTGCTT

GCTTGGAACTGGATCAGGCAGTCCCC

GGCCTGGTATCAGCAGAAACCAGG

ATCGAGAGGCCTTGAGTGGCTGGGA

GAAAGCCCCTAAGCTCCTGATCTA

AGGACATACTACAGGTCCAAGTGGT

TGCTGCATCCACTTTGCAAAGTGG

ATAATGATTATGCAGTATCTGTGAAA

GGTCCCATCAAGGTTCAGCGGCAG

AGTCGAATAACCATCAACCCAGACA

TGGATCTGGGACAGAATTCACTCT

CATCCAAGAACCAGTTCTCCCTGCAG

CACAATCAGCACCCTGCAGCCTGA

CTGAACTCTGTGACTCCCGAGGACAC

AGATTTTGCAACTTATTACTGTCAA

GGCTGTGTATTACTGTGCAAGAGGG

CAGCTTAATAGTTACCCTCAGACGT

GGAGGGCTTTGGGCTTTTGATATCTG

TCGGCCAAGGGACCAAAGTGGATA

GGGCCAAGGGACCACGGTCACCGTC

TCAAACGTACTGTGGCTGCTCCCTC

TCCTCAGCATCCACCAAGGGGCCTTC

CGTGTTCATTTTTCCTCCGTCGGAC

CGTGTTCCCCCTGGCCCCTTCATCCA

GAACAGCTGAAGTCCGGAACCGCG

AGTCGACCTCTGGTGGAACCGCCGC

TCCGTGGTCTGTCTCCTGAACAACT

ACTCGGTTGCCTGGTCAAAGACTACT

TCTATCCGCGCGAGGCGAAAGTGC

TCCCCGAGCCCGTGACTGTCTCGTGG

AGTGGAAGGTCGACAACGCACTGC

AACTCGGGCGCCCTCACATCCGGAGT

AGTCGGGAAACTCCCAGGAATCGG

GCATACCTTTCCCGCCGTGTTGCAGT

TGACCGAGCAGGACTCGAAGGACT

CCAGCGGCCTGTACAGCCTGAGCTCC

CAACCTACTCATTGTCCTCCACCCT

GTCGTGACAGTGCCGTCCTCCTCCCT

CACCCTGAGCAAGGCCGATTACGA

TGGAACCCAGACCTATATCTGCAACG

GAAGCATAAGGTCTACGCCTGCGA

TCAATCACAAGCCCTCCAACACCAA

AGTGACCCACCAGGGCCTGAGCAG

AGTGGACAAGAAGGTCGAACCCAAG

CCCAGTGACGAAGTCCTTCAACCG

TCCTGCGACAAGACTCACACCTGTCC

GGGAGAATGC

GCCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCACGAAG

ATCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAACG

CCAAGACCAAGCCTAGGGAAGAACA

GTACAACTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGCC

CCAGGTCTATACTTTGCCGCCTAGCC

GGGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGCT

TTTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAAG

TCAAGATGGCAGCAGGGAAACGTGT

TCTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAATC

ACTGTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GATATTGTGATGACCCACACTCCA

1762
CTGAGGTGAAGAAGCCTGGGGCCTC
1870
CTCTCTCTGTCCGTCACCCCTGGAC

AGTGAAGGTCTCCTGCAAGGCTTCTG

AGCCGGCCTCCATCTCCTGCAAGTC

GATACACCTTCACCGGCTACTATATG

TAGTCAGAGCCTCCTGCATAGTGA

CACTGGGTGCGACAGGCCCCTGGAC

TGGAAAGACCTATTTGTATTGGTAC

AAGGGCTTGAGTGGATGGGATGGAT

CTGCAGAAGCCAGGCCAGCCTCCA

CAACCCTAACAGTGGTGGCACAAAC

CAGCTCCTGATCTATGAAGTTTCCA

TATGCACAGAAGTTTCAGGGCAGGG

ACCGGTTCTCTGGAGTGCCAGATA

TCACCATGACCAGGGACACGTCCATC

GGTTCAGTGGCAGCGGGTCAGGGA

AGCACAGCCTACATGGAGCTGAGCA

CAGATTTCACACTGAAAATCAGCC

GGCTGAGATCTGACGACACGGCCGT

GGGTGGAGGCTGAGGATGTTGGGG

GTATTACTGTGCGAGAGACAAGATC

TTTATTACTGCATGCAAAGTATACA

GGCAGCTGTCCTTACTGGGGCCAGG

GCTTCCGCTCACTTTCGGCGGAGG

GAACCCTGGTCACCGTCTCCTCAGCA

GACCAAGGTGGAGATCAAACGTAC

TCCACCAAGGGGCCTTCCGTGTTCCC

TGTGGCTGCTCCCTCCGTGTTCATT

CCTGGCCCCTTCATCCAAGTCGACCT

TTTCCTCCGTCGGACGAACAGCTG

CTGGTGGAACCGCCGCACTCGGTTGC

AAGTCCGGAACCGCGTCCGTGGTC

CTGGTCAAAGACTACTTCCCCGAGCC

TGTCTCCTGAACAACTTCTATCCGC

CGTGACTGTCTCGTGGAACTCGGGCG

GCGAGGCGAAAGTGCAGTGGAAG

CCCTCACATCCGGAGTGCATACCTTT

GTCGACAACGCACTGCAGTCGGGA

CCCGCCGTGTTGCAGTCCAGCGGCCT

AACTCCCAGGAATCGGTGACCGAG

GTACAGCCTGAGCTCCGTCGTGACAG

CAGGACTCGAAGGACTCAACCTAC

TGCCGTCCTCCTCCCTTGGAACCCAG

TCATTGTCCTCCACCCTCACCCTGA

ACCTATATCTGCAACGTCAATCACAA

GCAAGGCCGATTACGAGAAGCATA

GCCCTCCAACACCAAAGTGGACAAG

AGGTCTACGCCTGCGAAGTGACCC

AAGGTCGAACCCAAGTCCTGCGACA

ACCAGGGCCTGAGCAGCCCAGTGA

AGACTCACACCTGTCCGCCTTGTCCA

CGAAGTCCTTCAACCGGGGAGAAT

GCCCCTGAGCTGCTGGGTGGTCCGTC

GC

CGTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACAACTCTA

CGTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGTC

AAACAAGGCTCTCCCTGCCCCTATCG

AAAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTCC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1763
TACGCTGGTGAAACCCACACAGACC
1871
GCACCCTGTCTTTGTCTCCAGGGGA

CTCACGCTGACCTGCACCTTCTCTGG

AAGAGCCACCCTCTCCTGCAGGGC

GTTCTCACTCAGCACTAGTGGAGTGG

CAGTCAGAGTGTTAGCAGCAGCTA

GTGTGGGCTGGATCCGTCAGCCCCCA

CTTAGCCTGGTACCAGCAGAAACC

GGAAAGGCCCTGGAGTGGCTTGCAC

TGGCCAGGCTCCCAGGCTCCTCATC

TCATTTATTGGGATGATGATAAGCGC

TATGGTGCATCCAGCAGGGCCACT

TACAGCCCATCTCTGAAGAGCAGGCT

GGCATCCCAGACAGGTTCAGTGGC

CACCATCACCAAGGACACCTCCAAA

AGTGGGTCTGGGACAGACTTCACT

AACCAGGTGGTCCTTACAATGACCA

CTCACCATCAGCAGACTGGAGCCT

ACATGGACCCTGTGGACACAGCCAC

GAAGATTTTGCAGTGTATTACTGTC

ATATTACTGTGCACACAGACCGGATA

AGCAGTATAATAACTGGCCTCTCA

GCAGCAGTCAATGTTTTGACTACTGG

CTTTCGGCGGAGGGACCAAGCTGG

GGCCAGGGAACCCTGGTCACCGTCTC

AGATCAAACGTACTGTGGCTGCTC

CTCAGCATCCACCAAGGGGCCTTCCG

CCTCCGTGTTCATTTTTCCTCCGTC

TGTTCCCCCTGGCCCCTTCATCCAAG

GGACGAACAGCTGAAGTCCGGAAC

TCGACCTCTGGTGGAACCGCCGCACT

CGCGTCCGTGGTCTGTCTCCTGAAC

CGGTTGCCTGGTCAAAGACTACTTCC

AACTTCTATCCGCGCGAGGCGAAA

CCGAGCCCGTGACTGTCTCGTGGAAC

GTGCAGTGGAAGGTCGACAACGCA

TCGGGCGCCCTCACATCCGGAGTGCA

CTGCAGTCGGGAAACTCCCAGGAA

TACCTTTCCCGCCGTGTTGCAGTCCA

TCGGTGACCGAGCAGGACTCGAAG

GCGGCCTGTACAGCCTGAGCTCCGTC

GACTCAACCTACTCATTGTCCTCCA

GTGACAGTGCCGTCCTCCTCCCTTGG

CCCTCACCCTGAGCAAGGCCGATT

AACCCAGACCTATATCTGCAACGTCA

ACGAGAAGCATAAGGTCTACGCCT

ATCACAAGCCCTCCAACACCAAAGT

GCGAAGTGACCCACCAGGGCCTGA

GGACAAGAAGGTCGAACCCAAGTCC

GCAGCCCAGTGACGAAGTCCTTCA

TGCGACAAGACTCACACCTGTCCGCC

ACCGGGGAGAATGC

TTGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GACATCCAGTTGACCCAGTCTCCC

1764
GAGGCGTGGTCCAGCCTGGGAGGTC
1872
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGAGACTCTCCTGTGCAGCCTCTG

AGAGGGCCACCATCAACTGCACGT

GATTCACCTTCAGTAGCTATGCTATG

CCAGCCAGAGTGTTTTATACAGCTC

CACTGGGTCCGCCAGGCTCCAGGCA

CAACAATAAGAACTACATAGCTTG

AGGGGCTGGAGTGGGTGGCAGTTAT

GTACCAGCAGAAACCAGGACAGCC

ATCATATGATGGAAGTAATAAATACT

TCCTAAGCTGCTCATTTACTGGGCA

ACGCAGACTCCGTGAAGGGCCGATT

TCTACCCGGGAATCCGGGGTCCCT

CACCATCTCCAGAGACAATTCCAAG

GACCGATTCAGTGGCAGCGGGTCT

AACACGCTGTATCTGCAAATGAACA

GGGACAGATTTCACTCTCACCATC

GCCTGAGAGCTGAGGACACGGCTGT

AGCAGCCTGCAGGCTGAAGATGTG

GTATTACTGTGCGAGAAGCAGTGGCT

GCAGTTTATTACTGTCAGCAATATT

GGTCACTGCCTGAAGACTACTGGGG

ATTATATTCCTCGGACGTTCGGCCA

CCAGGGAACCCTGGTCACCGTCTCCT

AGGGACCAAGGTGGAAATCAAACG

CAGCATCCACCAAGGGGCCTTCCGTG

TACTGTGGCTGCTCCCTCCGTGTTC

TTCCCCCTGGCCCCTTCATCCAAGTC

ATTTTTCCTCCGTCGGACGAACAGC

GACCTCTGGTGGAACCGCCGCACTCG

TGAAGTCCGGAACCGCGTCCGTGG

GTTGCCTGGTCAAAGACTACTTCCCC

TCTGTCTCCTGAACAACTTCTATCC

GAGCCCGTGACTGTCTCGTGGAACTC

GCGCGAGGCGAAAGTGCAGTGGAA

GGGCGCCCTCACATCCGGAGTGCAT

GGTCGACAACGCACTGCAGTCGGG

ACCTTTCCCGCCGTGTTGCAGTCCAG

AAACTCCCAGGAATCGGTGACCGA

CGGCCTGTACAGCCTGAGCTCCGTCG

GCAGGACTCGAAGGACTCAACCTA

TGACAGTGCCGTCCTCCTCCCTTGGA

CTCATTGTCCTCCACCCTCACCCTG

ACCCAGACCTATATCTGCAACGTCAA

AGCAAGGCCGATTACGAGAAGCAT

TCACAAGCCCTCCAACACCAAAGTG

AAGGTCTACGCCTGCGAAGTGACC

GACAAGAAGGTCGAACCCAAGTCCT

CACCAGGGCCTGAGCAGCCCAGTG

GCGACAAGACTCACACCTGTCCGCCT

ACGAAGTCCTTCAACCGGGGAGAA

TGTCCAGCCCCTGAGCTGCTGGGTGG

TGC

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1765
CTGAGGTGAAGAAGCCTGGGGCCTC
1873
TCTCCCTGCCCGTCACCCCTGGAGA

AGTGAAGGTCTCCTGCAAGGTTTCCG

GCCGGCCTCCATCTCCTGCAGGTCT

GATACACCCTCACTGAATTATCCATG

AGTCAGAGCCTCCTGCATAGTAAT

CACTGGGTGCGACAGGCTCCTGGAA

GGATACAACTATTTGGATTGGTAC

AAGGGCTTGAGTGGATGGGAGGTTT

CTGCAGAAGCCAGGGCAGTCTCCA

TGATCCTGAAGATGGTGAAACAATCT

CAGCTCCTGATCTATTTGGGTTCTA

ACGCACAGAAGTTCCAGGGCAGAGT

ATCGGGCCCCCGGGGTCCCTGACA

CACCATGACCGAGGACACATCTACA

GGTTCAGTGGCAGTGGATCAGGCA

GACACAGCCTACATGGAGCTGAGCA

CAGATTTTACACTGAAAATCAGCA

GCCTGAGATCTGAGGACACGGCCGT

GAGTGGAGGCTGAGGATGTTGGGG

GTATTACTGTGCAACGGATGTGAACC

TTTATTACTGCATGCAAGCTCTACA

CGGAGCTACTGGGGGCGGGATTTGA

AACTCGGACATTCGGCCAAGGGAC

CTACTGGGGCCAGGGCACCCTGGTC

CAAGCTGGAGATCAAACGTACTGT

ACCGTCTCCTCAGCATCCACCAAGGG

GGCTGCTCCCTCCGTGTTCATTTTT

GCCTTCCGTGTTCCCCCTGGCCCCTT

CCTCCGTCGGACGAACAGCTGAAG

CATCCAAGTCGACCTCTGGTGGAACC

TCCGGAACCGCGTCCGTGGTCTGTC

GCCGCACTCGGTTGCCTGGTCAAAGA

TCCTGAACAACTTCTATCCGCGCGA

CTACTTCCCCGAGCCCGTGACTGTCT

GGCGAAAGTGCAGTGGAAGGTCGA

CGTGGAACTCGGGCGCCCTCACATCC

CAACGCACTGCAGTCGGGAAACTC

GGAGTGCATACCTTTCCCGCCGTGTT

CCAGGAATCGGTGACCGAGCAGGA

GCAGTCCAGCGGCCTGTACAGCCTG

CTCGAAGGACTCAACCTACTCATT

AGCTCCGTCGTGACAGTGCCGTCCTC

GTCCTCCACCCTCACCCTGAGCAA

CTCCCTTGGAACCCAGACCTATATCT

GGCCGATTACGAGAAGCATAAGGT

GCAACGTCAATCACAAGCCCTCCAA

CTACGCCTGCGAAGTGACCCACCA

CACCAAAGTGGACAAGAAGGTCGAA

GGGCCTGAGCAGCCCAGTGACGAA

CCCAAGTCCTGCGACAAGACTCACA

GTCCTTCAACCGGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1766
GAGGCTTGGTCCAGCCTGGAGGGTC
1874
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTGACCAGTACATG

CCAGTCAGAGTCTTACCAGCAGCT

GACTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTTGGCCGTGT

CTGGCCAGGCTCCCAGACTCCTCAT

TAGAAACAAAGCTAACAGTTACACC

CTATCGTGCATCCAGCAGGGCCAC

ACAGAATACGCCGCGTCTGTGAAAG

TGGCATCCCAGACCGGTTCAGTGG

GCAGATTCACCATCTCAAGAGATGAT

CAGTGGGTCTGGGACAGACTTCAC

TCAAAGAACTCACTGTATCTGCAAAT

TCTCACCATCAGCAGACTGGAGCC

GAATAGTCTGAACACCGAGGACACG

TGAAGATTTTGCAGTTTATTACTGT

GCCATGTATTTCTGTGCTAGTAGTCT

CAGCAGTATGGTAGTTCACCTAAC

CAATAGTGGGGGCTACCGATGCTTCC

ACCTTCGGCCAAGGGACACGACTG

ATCACTGGGGCCAGGGCACCCTGGT

GAGATTAAACGTACTGTGGCTGCT

GACCGTCTCCTCAGCATCCACCAAGG

CCCTCCGTGTTCATTTTTCCTCCGT

GGCCTTCCGTGTTCCCCCTGGCCCCT

CGGACGAACAGCTGAAGTCCGGAA

TCATCCAAGTCGACCTCTGGTGGAAC

CCGCGTCCGTGGTCTGTCTCCTGAA

CGCCGCACTCGGTTGCCTGGTCAAAG

CAACTTCTATCCGCGCGAGGCGAA

ACTACTTCCCCGAGCCCGTGACTGTC

AGTGCAGTGGAAGGTCGACAACGC

TCGTGGAACTCGGGCGCCCTCACATC

ACTGCAGTCGGGAAACTCCCAGGA

CGGAGTGCATACCTTTCCCGCCGTGT

ATCGGTGACCGAGCAGGACTCGAA

TGCAGTCCAGCGGCCTGTACAGCCTG

GGACTCAACCTACTCATTGTCCTCC

AGCTCCGTCGTGACAGTGCCGTCCTC

ACCCTCACCCTGAGCAAGGCCGAT

CTCCCTTGGAACCCAGACCTATATCT

TACGAGAAGCATAAGGTCTACGCC

GCAACGTCAATCACAAGCCCTCCAA

TGCGAAGTGACCCACCAGGGCCTG

CACCAAAGTGGACAAGAAGGTCGAA

AGCAGCCCAGTGACGAAGTCCTTC

CCCAAGTCCTGCGACAAGACTCACA

AACCGGGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAATTGTGTTGACACAGTCTCCA

1767
GAGGCTTGGTCCAGCCTGGGGGGTC
1875
CTCTCCCTGCCCGTCACCCTTGGAC

CCTGAGACTCTCCTGTTCAGCCTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GATTCACCTTCAGTAGCTATGCTATG

TAGTCAAAGCCTCGTACACAGTAA

CACTGGGTCCGCCAGGCTCCAGGGA

TGGACACACCTACTTGAGTTGGTTT

AGGGACTGGAATATGTTTCAGCTATT

CAGCAGAGGCCAGGCCAATCTCCA

AGTAGTAATGGGGGTAGCACATACT

AGGCGCCTCATTTATGAGGTTTCTA

ACGCAGACTCAGTGAAGGGCAGATT

ACCGGGACTCTGGTGTCCCAGACA

CACCATCTCCAGAGACAATTCCAAG

GATTCAGCGGCAGTGGGTCAGGCA

AACACGCTGTATCTTCAAATGAGCAG

CTGATTTCACACTAAGAATCAGCA

TCTGAGAGCTGAGGACACGGCTGTG

GGGTGGAGGCTGAGGATGTTGGGG

TATTACTGTGTGAAAGCGCCGAGGG

TTTATTACTGCTTGCAAGGAACACA

GTGTAGTACCAGCTGCTATGCGGGG

CTGGCCCCCCCTCACTGTCGGCGG

GGGCTACTGGGGCCAGGGAACCCTG

AGGGACCAAAGTGGATATCAAACG

GTCACCGTCTCCTCAGCATCCACCAA

TACTGTGGCTGCTCCCTCCGTGTTC

GGGGCCTTCCGTGTTCCCCCTGGCCC

ATTTTTCCTCCGTCGGACGAACAGC

CTTCATCCAAGTCGACCTCTGGTGGA

TGAAGTCCGGAACCGCGTCCGTGG

ACCGCCGCACTCGGTTGCCTGGTCAA

TCTGTCTCCTGAACAACTTCTATCC

AGACTACTTCCCCGAGCCCGTGACTG

GCGCGAGGCGAAAGTGCAGTGGAA

TCTCGTGGAACTCGGGCGCCCTCACA

GGTCGACAACGCACTGCAGTCGGG

TCCGGAGTGCATACCTTTCCCGCCGT

AAACTCCCAGGAATCGGTGACCGA

GTTGCAGTCCAGCGGCCTGTACAGCC

GCAGGACTCGAAGGACTCAACCTA

TGAGCTCCGTCGTGACAGTGCCGTCC

CTCATTGTCCTCCACCCTCACCCTG

TCCTCCCTTGGAACCCAGACCTATAT

AGCAAGGCCGATTACGAGAAGCAT

CTGCAACGTCAATCACAAGCCCTCCA

AAGGTCTACGCCTGCGAAGTGACC

ACACCAAAGTGGACAAGAAGGTCGA

CACCAGGGCCTGAGCAGCCCAGTG

ACCCAAGTCCTGCGACAAGACTCAC

ACGAAGTCCTTCAACCGGGGAGAA

ACCTGTCCGCCTTGTCCAGCCCCTGA

TGC

GCTGCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACACT

CTGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGGG

AAGAACAGTACAACTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTATACTTTGCC

GCCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGGG

AAACGTGTTCTCCTGCTCCGTGATGC

ACGAAGCGCTGCACAACCATTACAC

CCAGAAATCACTGTCACTTTCGCCGG

GAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1768
GAGGCTTGGTACAGCCAGGGCGGTC
1876
CCACCCTGTCTTTGTCTCCAGGGGA

CCTGAGACTCTCCTGTACAGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCACCTTTGGTGATTATGCTATG

CAGTCAGAGTGTTGGCAGCGACTT

AGCTGGTTCCGCCAGGCTCCAGGGA

AGCCTGGTACCAGCAGAAACCTGG

AGGGGCTGGAGTGGGTAGGTTTCATT

CCAGGCTCCCAGGCTCCTCATCTAC

AGAAGCAAAGCTTATGGTGGGACAA

CGTGCATCCACCAGGGCCGCTGGT

CAGAATACGCCGCGTCTGTGAAAGG

ATCCCAGCCAGGTTCAGTGGCAGT

CAGATTCACCATCTCAAGAGATGATT

GGGTCTGGGACAGACTTCACTCTC

CCAAAAGCATCGCCTATCTGCAAATG

ACCATCAGCAGACTGGAGCCTGAA

AACAGCCTGAAAACCGAGGACACAG

GATTTTGCAGTGTTTTACTGTCAGC

CCGTGTATTACTGTACTAGATTGGTG

AGTATGGTAGATCACCGTACACTT

GGCAATAGTGGGAGCTACTATCCGTT

CTGGCCAGGGGACCAAGCTGGAGA

TGGGTACTGGGGCCAGGGAACCCTG

TCAAACGTACTGTGGCTGCTCCCTC

GTGACCGTCTCCTCAGCATCCACCAA

CGTGTTCATTTTTCCTCCGTCGGAC

GGGGCCTTCCGTGTTCCCCCTGGCCC

GAACAGCTGAAGTCCGGAACCGCG

CTTCATCCAAGTCGACCTCTGGTGGA

TCCGTGGTCTGTCTCCTGAACAACT

ACCGCCGCACTCGGTTGCCTGGTCAA

TCTATCCGCGCGAGGCGAAAGTGC

AGACTACTTCCCCGAGCCCGTGACTG

AGTGGAAGGTCGACAACGCACTGC

TCTCGTGGAACTCGGGCGCCCTCACA

AGTCGGGAAACTCCCAGGAATCGG

TCCGGAGTGCATACCTTTCCCGCCGT

TGACCGAGCAGGACTCGAAGGACT

GTTGCAGTCCAGCGGCCTGTACAGCC

CAACCTACTCATTGTCCTCCACCCT

TGAGCTCCGTCGTGACAGTGCCGTCC

CACCCTGAGCAAGGCCGATTACGA

TCCTCCCTTGGAACCCAGACCTATAT

GAAGCATAAGGTCTACGCCTGCGA

CTGCAACGTCAATCACAAGCCCTCCA

AGTGACCCACCAGGGCCTGAGCAG

ACACCAAAGTGGACAAGAAGGTCGA

CCCAGTGACGAAGTCCTTCAACCG

ACCCAAGTCCTGCGACAAGACTCAC

GGGAGAATGC

ACCTGTCCGCCTTGTCCAGCCCCTGA

GCTGCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACACT

CTGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGGG

AAGAACAGTACAACTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTATACTTTGCC

GCCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGGG

AAACGTGTTCTCCTGCTCCGTGATGC

ACGAAGCGCTGCACAACCATTACAC

CCAGAAATCACTGTCACTTTCGCCGG

GAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GATATTGTGATGACCCACACTCCA

1769
CAGGACTGTTGAAGCCTTCGGAGAC
1877
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGTCCCTCACCTGCGCTGTCTATG

AGAGGGCCACCATCAACTGCAAGT

GTGGGTCCTTCAGTGGTTACTACTGG

CCAGCCAGAGTGTTTTATACAGCTC

AGCTGGATCCGCCAGCCCCCAGGGA

CAACAATAAGAACTACTTAGCTTG

AGGGGCTGGAGTGGATTGGGGAAAT

GTACCAGCAGAAACCAGGACAGCC

CAATCATAGTGGAAGCACCAACTAC

TCCTAAGCTGCTCATTTACTGGGCA

AACCCGTCCCTCAAGAGTCGAGTCAC

TCTACCCGGGAATCCGGGGTCCCT

CATATCAGTAGACACGTCCAAGAAC

GACCGATTCAGTGGCAGCGGGTCT

CAGTTCTCCCTGAAGCTGAGCTCGGT

GGGACAGATTTCACTCTCACCATC

GACCGCCGCGGACACGGCTGTGTATT

AGCAGCCTGCAGGCTGAAGATGTG

ACTGTGCGAGAGGCCGGTCCCTTCCC

GCAGTTTATTACTGTCAGCAATATT

TACCGGGGGTTGGCTCCTAGATCTTT

ATAGTACTCCGCTCACTTTCGGCGG

CGGAGGATACTACTTTGACTACTGGG

AGGGACCAAGGTGGAGATCAAACG

GCCAGGGAACCCTGGTCACCGTCTCC

TACTGTGGCTGCTCCCTCCGTGTTC

TCAGCATCCACCAAGGGGCCTTCCGT

ATTTTTCCTCCGTCGGACGAACAGC

GTTCCCCCTGGCCCCTTCATCCAAGT

TGAAGTCCGGAACCGCGTCCGTGG

CGACCTCTGGTGGAACCGCCGCACTC

TCTGTCTCCTGAACAACTTCTATCC

GGTTGCCTGGTCAAAGACTACTTCCC

GCGCGAGGCGAAAGTGCAGTGGAA

CGAGCCCGTGACTGTCTCGTGGAACT

GGTCGACAACGCACTGCAGTCGGG

CGGGCGCCCTCACATCCGGAGTGCAT

AAACTCCCAGGAATCGGTGACCGA

ACCTTTCCCGCCGTGTTGCAGTCCAG

GCAGGACTCGAAGGACTCAACCTA

CGGCCTGTACAGCCTGAGCTCCGTCG

CTCATTGTCCTCCACCCTCACCCTG

TGACAGTGCCGTCCTCCTCCCTTGGA

AGCAAGGCCGATTACGAGAAGCAT

ACCCAGACCTATATCTGCAACGTCAA

AAGGTCTACGCCTGCGAAGTGACC

TCACAAGCCCTCCAACACCAAAGTG

CACCAGGGCCTGAGCAGCCCAGTG

GACAAGAAGGTCGAACCCAAGTCCT

ACGAAGTCCTTCAACCGGGGAGAA

GCGACAAGACTCACACCTGTCCGCCT

TGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GAAATTGTGATGACGCAGTCTCCA

1770
GAGGCTTGGTACGGCCTGGAGGGTC
1878
CTCTCCCTGTCCGTCACCCCTGGAG

CCTGAGACTCTCCTGTGGAGACTCTG

AGCCGGCCTCCATCTCCTGCAGGTC

GATTCAACTTCAGTGGATATGAAATG

TAGTCAGAGCCTCCTACATAGTAG

AACTGGGTCCGCCAGGCTCCAGGGA

TGGATACAACTATTTGGATTGGTAC

AGGGGCTGGAGTGGGTTTCATACGTC

CTGCAGAAGCCAGGCCAGTCTCCA

AGTACTAGTGGTAGTACCAGATACTA

CAGCTCCTGATCTATTTGGGTTCTA

CGCAGACTCTGTGAAGGGCCGATTTA

CTCGGGCCTCCGGGGTCCCTGACA

CCATCTCCAGAGACAACGCCAAGAA

GGTTCAGTGGCAGTGGATCAGGCA

CACCCTGTATTTGCAAATGAACAGTC

CAGATTTTACACTGAAAATCAGCA

TGAGAGTCGAGGACACGGCTGTGTA

GAGTGGAGGCTGAGGATGTTGGGG

TTACTGTGCAAGAGGACGGACTCACT

TTTATTATTGCATGCAAGGTCTACA

GGGGCCCCCAGGACTTTGACTACTGG

AATTCCGCTCACTTTCGGCGGAGG

GGCCAGGGAACCCTGGTCACCGTCTC

GACCAAAGTGGATATCAAACGTAC

CTCAGCATCCACCAAGGGGCCTTCCG

TGTGGCTGCTCCCTCCGTGTTCATT

TGTTCCCCCTGGCCCCTTCATCCAAG

TTTCCTCCGTCGGACGAACAGCTG

TCGACCTCTGGTGGAACCGCCGCACT

AAGTCCGGAACCGCGTCCGTGGTC

CGGTTGCCTGGTCAAAGACTACTTCC

TGTCTCCTGAACAACTTCTATCCGC

CCGAGCCCGTGACTGTCTCGTGGAAC

GCGAGGCGAAAGTGCAGTGGAAG

TCGGGCGCCCTCACATCCGGAGTGCA

GTCGACAACGCACTGCAGTCGGGA

TACCTTTCCCGCCGTGTTGCAGTCCA

AACTCCCAGGAATCGGTGACCGAG

GCGGCCTGTACAGCCTGAGCTCCGTC

CAGGACTCGAAGGACTCAACCTAC

GTGACAGTGCCGTCCTCCTCCCTTGG

TCATTGTCCTCCACCCTCACCCTGA

AACCCAGACCTATATCTGCAACGTCA

GCAAGGCCGATTACGAGAAGCATA

ATCACAAGCCCTCCAACACCAAAGT

AGGTCTACGCCTGCGAAGTGACCC

GGACAAGAAGGTCGAACCCAAGTCC

ACCAGGGCCTGAGCAGCCCAGTGA

TGCGACAAGACTCACACCTGTCCGCC

CGAAGTCCTTCAACCGGGGAGAAT

TTGTCCAGCCCCTGAGCTGCTGGGTG

GC

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GATATTGTGATGACCCACACTCCA

1771
GAGGCTTGGTACAGCCTGGGGGGTC
1879
CTCTCTCTGTCCGTCACCCCTGGAC

CCTGAGACTCTCCTGTGCAGCCTCTG

AGCCGGCCTCCATCTCCTGCAAGTC

GATTCACCTTTAGCAGCTATGCCATG

TAGTCAGAGCCTCCTGCATAGTGA

AGCTGGGTCCGCCAGGCTCCAGGGA

TGGAAAGACCTATTTGTATTGGTAC

AGGGGCTGGAGTGGGTCTCAGCTATT

CTGCAGAAGCCAGGCCAGCCTCCA

AGTGGTAGTGGTGGTAGCACATACT

CAGCTCCTGATCTATGAAGTTTCCA

ACGCAGACTCCGTGAAGGGCCGGTT

ACCGGTTCTCTGGAGTGCCAGATA

CACCATCTCCAGAGACAATTCCAAG

GGTTCAGTGGCAGCGGGTCAGGGA

AACACGCTGTATCTGCAAATGAACA

CAGATTTCACACTGAAAATCAGCC

GCCTGAGAGCCGAGGACACGGCCGT

GGGTGGAGGCTGAGGATGTTGGGG

ATATTACTGTGCGAAAGGAGGAATG

TTTATTACTGCATGCAAAGTATACA

TATTACTATGGTTCGGGGAGCTCGTA

GCTTCCGTGGACGTTCGGCCAAGG

CTTTGACTACTGGGGCCAGGGAACCC

GACCAAGGTGGAGATCAAACGTAC

TGGTGACCGTCTCCTCAGCATCCACC

TGTGGCTGCTCCCTCCGTGTTCATT

AAGGGGCCTTCCGTGTTCCCCCTGGC

TTTCCTCCGTCGGACGAACAGCTG

CCCTTCATCCAAGTCGACCTCTGGTG

AAGTCCGGAACCGCGTCCGTGGTC

GAACCGCCGCACTCGGTTGCCTGGTC

TGTCTCCTGAACAACTTCTATCCGC

AAAGACTACTTCCCCGAGCCCGTGAC

GCGAGGCGAAAGTGCAGTGGAAG

TGTCTCGTGGAACTCGGGCGCCCTCA

GTCGACAACGCACTGCAGTCGGGA

CATCCGGAGTGCATACCTTTCCCGCC

AACTCCCAGGAATCGGTGACCGAG

GTGTTGCAGTCCAGCGGCCTGTACAG

CAGGACTCGAAGGACTCAACCTAC

CCTGAGCTCCGTCGTGACAGTGCCGT

TCATTGTCCTCCACCCTCACCCTGA

CCTCCTCCCTTGGAACCCAGACCTAT

GCAAGGCCGATTACGAGAAGCATA

ATCTGCAACGTCAATCACAAGCCCTC

AGGTCTACGCCTGCGAAGTGACCC

CAACACCAAAGTGGACAAGAAGGTC

ACCAGGGCCTGAGCAGCCCAGTGA

GAACCCAAGTCCTGCGACAAGACTC

CGAAGTCCTTCAACCGGGGAGAAT

ACACCTGTCCGCCTTGTCCAGCCCCT

GC

GAGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGTC

GCACGAAGATCCCGAAGTGAAATTC

AATTGGTACGTGGATGGGGTCGAAG

TGCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTACAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAACA

AGGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAAC

CTAGGGAGCCCCAGGTCTATACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGCC

GGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1772
GAGGCTTGGTACAGCCTGGGGGGTC
1880
GCCACCCTGTCTGTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTAGCAGCTATGCCATG

CCAGTCAGAGTGTTAGCAGCAACT

AGCTGGGTCCGCCAGGCTCCAGGGA

TAGCCTGGTACCAGCAGAAACCTG

AGGGGCTGGAATGGGTCTCAGGTAT

GCCAGGCTCCCAGGCTCCTCATCTA

TAGTGGTAGTGGTGGTAGCACATACT

TGGTGCATCCACCAGGGCCACTGG

ACGCAGACTCCGTGAAGGGCCGGTT

CATCCCAGCCAGGTTCAGTGGCAG

CACCATCTCCAGAGACAATTCCAAG

TGGGTCTGGGACAGAGTTCACTCT

AACATGCTGTTTCTGCAAATGAACAG

CACCATCAGCAGCCTGCAGTCTGA

CCCGAGAGCCGAGGACACGGCCGTA

AGATTTTGCAGTTTATTACTGTCAG

TATTACTGTGCGAAGAAAATAGCAG

CAGTATAATAACTGGCCTCGGTTC

CAGCTGGTAAGCAACCTGTTGACTAC

GGCCAAGGGACACGACTGGAGATT

TGGGGCCAGGGAACCCTGGTCACCG

AAACGTACTGTGGCTGCTCCCTCCG

TCTCCTCAGCATCCACCAAGGGGCCT

TGTTCATTTTTCCTCCGTCGGACGA

TCCGTGTTCCCCCTGGCCCCTTCATC

ACAGCTGAAGTCCGGAACCGCGTC

CAAGTCGACCTCTGGTGGAACCGCC

CGTGGTCTGTCTCCTGAACAACTTC

GCACTCGGTTGCCTGGTCAAAGACTA

TATCCGCGCGAGGCGAAAGTGCAG

CTTCCCCGAGCCCGTGACTGTCTCGT

TGGAAGGTCGACAACGCACTGCAG

GGAACTCGGGCGCCCTCACATCCGG

TCGGGAAACTCCCAGGAATCGGTG

AGTGCATACCTTTCCCGCCGTGTTGC

ACCGAGCAGGACTCGAAGGACTCA

AGTCCAGCGGCCTGTACAGCCTGAG

ACCTACTCATTGTCCTCCACCCTCA

CTCCGTCGTGACAGTGCCGTCCTCCT

CCCTGAGCAAGGCCGATTACGAGA

CCCTTGGAACCCAGACCTATATCTGC

AGCATAAGGTCTACGCCTGCGAAG

AACGTCAATCACAAGCCCTCCAACA

TGACCCACCAGGGCCTGAGCAGCC

CCAAAGTGGACAAGAAGGTCGAACC

CAGTGACGAAGTCCTTCAACCGGG

CAAGTCCTGCGACAAGACTCACACCT

GAGAATGC

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GATGTTGTGATGACTCAGTCTCCTT

1773
CAGGACTGTTGAAGCCTTCGGAGAC
1881
CCACCCTGTCTGCATCTGTAGGGG

CCTGTCCCTCACCTGCGCTGTCTATG

ACAGAGTCACCATCACTTGCCGGG

GTGGGTCCTTCAGTGGTTACTACTGG

CCAGTCAGACTATTAATAGTTGGTT

AGCTGGATCCGCCAGCCCCCAGGGA

GGCCTGGTATCAGCAGAAACCAGG

AGGGGCTGGAGTGGATTGGGGAAAT

GAAGGCCCCTAAGCTCCTCATCTCT

CAATCATAGTGGAAGCACCAACTAC

AGGGCGTCTCGTTTAGAAAGTGGG

AACCCGTCCCTCAAGAGTCGAGTCAC

GTCCCATCAAGGTTCAGCGGCAGT

CATATCAGTAGACACGTCCAAGAAC

GCATCTGGCACAGAATACATTCTC

CAGTTCTCCCTGAAGCTGAGCTCTGT

ACCATCAACAGCCTGCAGCCTGAT

GACCGCCGCGGACACGGCTGTGTATT

GATTTTGCAATGTACTTCTGCCATC

ACTGTGCGAGAAGGAAGGTGTATGA

AATATAATAGTTATTCTCCCACTTT

TTACGTTTGGGGGAGTTATCGCCTCC

TGGCCAGGGGACCAAGCTGGAGAT

CCGGGTCGGTATCGTACTACTTTGAC

CAAACGTACTGTGGCTGCTCCCTCC

TACTGGGGCCAGGGAACCCTGGTCA

GTGTTCATTTTTCCTCCGTCGGACG

CCGTCTCCTCAGCATCCACCAAGGGG

AACAGCTGAAGTCCGGAACCGCGT

CCTTCCGTGTTCCCCCTGGCCCCTTC

CCGTGGTCTGTCTCCTGAACAACTT

ATCCAAGTCGACCTCTGGTGGAACCG

CTATCCGCGCGAGGCGAAAGTGCA

CCGCACTCGGTTGCCTGGTCAAAGAC

GTGGAAGGTCGACAACGCACTGCA

TACTTCCCCGAGCCCGTGACTGTCTC

GTCGGGAAACTCCCAGGAATCGGT

GTGGAACTCGGGCGCCCTCACATCCG

GACCGAGCAGGACTCGAAGGACTC

GAGTGCATACCTTTCCCGCCGTGTTG

AACCTACTCATTGTCCTCCACCCTC

CAGTCCAGCGGCCTGTACAGCCTGA

ACCCTGAGCAAGGCCGATTACGAG

GCTCCGTCGTGACAGTGCCGTCCTCC

AAGCATAAGGTCTACGCCTGCGAA

TCCCTTGGAACCCAGACCTATATCTG

GTGACCCACCAGGGCCTGAGCAGC

CAACGTCAATCACAAGCCCTCCAAC

CCAGTGACGAAGTCCTTCAACCGG

ACCAAAGTGGACAAGAAGGTCGAAC

GGAGAATGC

CCAAGTCCTGCGACAAGACTCACAC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
CAGGTCCAGCTGGTACAGTCTGGAG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1774
CAGAGGTGAAAAAGCCCGGGGAGTC
1882
GGCACCCTGTCTTTGTCTCCAGGGG

TCTGAAGATCTCCTGTAAGGGTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATACAGCTTTACCAGCTACTGGATC

CCAGTCAGAGTGTTAGCAGCAGCT

GGCTGGGTGCGCCAGATGCCCGGGA

ACTTAGCCTGGTACCAGCAGAAAC

AAGGCCTGGAGTGGATGGGGATCAT

CTGGCCAGGCTCCCAGGCTCCTCAT

CTATCCTGGTGACTCTGATACCAGAT

CTATGGTGCATCCAGCAGGGCCAC

ACAGCCCGTCCTTCCAAGGCCAGGTC

TGGCATCCCAGCCAGGTTCAGTGG

ACCATCTCAGCCGACAAGTCCATCAG

CAGTGGGTCTGGGACAGACTTCAC

CACCGCCTACCTGCAGTGGAGCAGC

TCTCACCATCAGCAGCCTAGAGCC

CTGAAGGCCTCGGACACCGCCATGT

TGAAGATTTTGCAGTTTATTACTGT

ATTACTGTGCGAGACTCCCGGGGAG

CAGCAGCGTTACAACTGGCCTATC

AGCAGCTCGTCCAGACTACTGGGGC

ACCTTCGGCCAAGGGACACGACTG

CAGGGCACCCTGGTCACCGTCTCCTC

GAGATTAAACGTACTGTGGCTGCT

AGCATCCACCAAGGGGCCTTCCGTGT

CCCTCCGTGTTCATTTTTCCTCCGT

TCCCCCTGGCCCCTTCATCCAAGTCG

CGGACGAACAGCTGAAGTCCGGAA

ACCTCTGGTGGAACCGCCGCACTCGG

CCGCGTCCGTGGTCTGTCTCCTGAA

TTGCCTGGTCAAAGACTACTTCCCCG

CAACTTCTATCCGCGCGAGGCGAA

AGCCCGTGACTGTCTCGTGGAACTCG

AGTGCAGTGGAAGGTCGACAACGC

GGCGCCCTCACATCCGGAGTGCATAC

ACTGCAGTCGGGAAACTCCCAGGA

CTTTCCCGCCGTGTTGCAGTCCAGCG

ATCGGTGACCGAGCAGGACTCGAA

GCCTGTACAGCCTGAGCTCCGTCGTG

GGACTCAACCTACTCATTGTCCTCC

ACAGTGCCGTCCTCCTCCCTTGGAAC

ACCCTCACCCTGAGCAAGGCCGAT

CCAGACCTATATCTGCAACGTCAATC

TACGAGAAGCATAAGGTCTACGCC

ACAAGCCCTCCAACACCAAAGTGGA

TGCGAAGTGACCCACCAGGGCCTG

CAAGAAGGTCGAACCCAAGTCCTGC

AGCAGCCCAGTGACGAAGTCCTTC

GACAAGACTCACACCTGTCCGCCTTG

AACCGGGGAGAATGC

TCCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACAAC

TCTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAAG

TGTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTATACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAAC

TACAAGACCACCCCACCGGTGCTCG

ATTCCGATGGCTCCTTCTTCCTGTACT

CCAAGCTGACTGTGGACAAGTCAAG

ATGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTGT

CACTTTCGCCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1775
GAGGCGTGGTCCAGCCTGGGAGGTC
1883
GCCACCCTGTCTTTGTCTCCGGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAACAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGCTATGCTATG

CCAGTCAGACTATTGGTCCCAAGT

CACTGGGTCCGCCAGGCTCCAGGCA

CCTTCGGCTGGTACCAACAGAGAC

AGGGGCTGGAGTGGGTGGCAGTTAT

CTGGCCAGGCTCCCAGGCTCCTCAT

ATCATATGATGGAAGTAATAAATACT

CTATGACTCCAACAGGGCCACTGG

ACGCAGACTCCGTGAAGGGCCGATT

CATCCCAGCCAGGTTCAGTGGCAG

CACCATCTCCAGAGACAATTCCAAG

TGGGTCTGGGACAGACTTCACTCTC

AACACGCTGTATCTGCAAATGAACA

ACCATCAGCAGCCTAGAGCCTGAA

GCCTGAGAGCTGAGGACACGGCTGT

GATTTTGCAGTTTATTACTGTCAGC

GTATTACTGTGCGAGAGGCCCCGGG

AGCGTAGCAGGTGGCCTCTCACTTT

GCAGTGGCTGGTACTAAGCCAAAGT

CGGCCCTGGGACCAAAGTGGATAT

ACTACTTTGACTACTGGGGCCAGGGA

CAAACGTACTGTGGCTGCTCCCTCC

ACCCTGGTCACCGTCTCCTCAGCATC

GTGTTCATTTTTCCTCCGTCGGACG

CACCAAGGGGCCTTCCGTGTTCCCCC

AACAGCTGAAGTCCGGAACCGCGT

TGGCCCCTTCATCCAAGTCGACCTCT

CCGTGGTCTGTCTCCTGAACAACTT

GGTGGAACCGCCGCACTCGGTTGCCT

CTATCCGCGCGAGGCGAAAGTGCA

GGTCAAAGACTACTTCCCCGAGCCCG

GTGGAAGGTCGACAACGCACTGCA

TGACTGTCTCGTGGAACTCGGGCGCC

GTCGGGAAACTCCCAGGAATCGGT

CTCACATCCGGAGTGCATACCTTTCC

GACCGAGCAGGACTCGAAGGACTC

CGCCGTGTTGCAGTCCAGCGGCCTGT

AACCTACTCATTGTCCTCCACCCTC

ACAGCCTGAGCTCCGTCGTGACAGTG

ACCCTGAGCAAGGCCGATTACGAG

CCGTCCTCCTCCCTTGGAACCCAGAC

AAGCATAAGGTCTACGCCTGCGAA

CTATATCTGCAACGTCAATCACAAGC

GTGACCCACCAGGGCCTGAGCAGC

CCTCCAACACCAAAGTGGACAAGAA

CCAGTGACGAAGTCCTTCAACCGG

GGTCGAACCCAAGTCCTGCGACAAG

GGAGAATGC

ACTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAGC

CTAGGGAAGAACAGTACAACTCTAC

GTACCGGGTGGTGTCCGTGCTGACCG

TGCTGCACCAGGACTGGCTGAACGG

AAAGGAGTACAAGTGCAAAGTGTCA

AACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1776
GAGGCGTGGTCCAGCCTGGGAGGTC
1884
TCTCCCTGCCCGTCACCCTTGGACA

CCTGAGACTCTCCTGTGCAGCCTCTG

GCCGGCCTCCATCTCCTGCAGGTCT

GATTCACCTTCAGTAGCTATGCTATG

AGTCAAAGCCTCGTGTACAGTGAT

CACTGGGTCCGCCAGGCTCCAGGCA

GGAAACACCTACTTGTATTGGTTTC

AGGGGCTGGAGTGGGTGGCAGTTAT

AGCAGAGGGCAGGCCAATCTCCAA

ATCATATGATGGAAGTAATAAATACT

GGCGCCTGATTTATAAGGTTTCTAA

ACGCAGACTCCGTGAAGGGCCGATT

GCGGGACTCTGGGGTCCCAGACAG

CACCATCTCCAGAGACAATTCCAAG

GTTCAGCGGCAGTGGGTCAGGCAC

AACACGCTGTATCTGCAAATGAACA

TGATTTCACACTGAAAATCAGCAG

GCCTGAGAGCTGAGGACACGGCTGT

GGTGGAGGCTGAGGATGTTGGAAT

GTATTACTGTGCGAGGGCCACGTATT

TTATTACTGCGTGCAAGGTAGACA

ACTATGATAGTAGTGGTTATAGGTTT

CTGGCCGTACACTCTTGGCCAGGG

GACTACTGGGGCCAGGGAACCCTGG

GACCAAGCTGGAGATCAAACGTAC

TCACCGTCTCCTCAGCATCCACCAAG

TGTGGCTGCTCCCTCCGTGTTCATT

GGGCCTTCCGTGTTCCCCCTGGCCCC

TTTCCTCCGTCGGACGAACAGCTG

TTCATCCAAGTCGACCTCTGGTGGAA

AAGTCCGGAACCGCGTCCGTGGTC

CCGCCGCACTCGGTTGCCTGGTCAAA

TGTCTCCTGAACAACTTCTATCCGC

GACTACTTCCCCGAGCCCGTGACTGT

GCGAGGCGAAAGTGCAGTGGAAG

CTCGTGGAACTCGGGCGCCCTCACAT

GTCGACAACGCACTGCAGTCGGGA

CCGGAGTGCATACCTTTCCCGCCGTG

AACTCCCAGGAATCGGTGACCGAG

TTGCAGTCCAGCGGCCTGTACAGCCT

CAGGACTCGAAGGACTCAACCTAC

GAGCTCCGTCGTGACAGTGCCGTCCT

TCATTGTCCTCCACCCTCACCCTGA

CCTCCCTTGGAACCCAGACCTATATC

GCAAGGCCGATTACGAGAAGCATA

TGCAACGTCAATCACAAGCCCTCCAA

AGGTCTACGCCTGCGAAGTGACCC

CACCAAAGTGGACAAGAAGGTCGAA

ACCAGGGCCTGAGCAGCCCAGTGA

CCCAAGTCCTGCGACAAGACTCACA

CGAAGTCCTTCAACCGGGGAGAAT

CCTGTCCGCCTTGTCCAGCCCCTGAG

GC

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG
SEQ ID
GAAATTGTGTTGACGCAGTCTCCA

1777
GAGGCTTGGTAGAACCGGGGGGGTC
1885
GGCACCCTGTCTTTGTCTCCAGGGG

CCTTAGACTCTCCTGTGCAGCCTCTC

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACTTTCAGTGACGCCTGGATG

CCAGTCAGAGTGTTAGCAGCAGCT

AGCTGGGTCCGCCAGGCTCCAGGTA

ACTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGAGTGGGTTGGCCGTAT

CTGGCCAGGCTCCCAGGCTCCTCAT

TAAAAGCAAAATAAGTGGTGGGACA

CTATGATGCATCCAACAGGGCCAC

ACAGACTACGCTGCACCCGTGCAAG

TGGCATCCCAGCCAGGTTCAGTGG

GCAGATTCACCATCTCAAGAGATGAT

CAGTGGATCTGGGACAGAATTCAC

TCAAAAAACACGCTGTATCTGCAAAT

TCTCACCATCAGCAGCCTGCAGCCT

GGACAGCCTGAAAACCGAGGACACA

GATGATTTTGCAACTTATTACTGCC

GCCGTGTATTACTGTGCGAACCGAAA

AACAGTATAATAGTTATTCAAGGA

CTTAGGCTACTGGGGCCAGGGCACC

CGTTCGGCCAGGGGACCAAAGTGG

CTGGTGACCGTCTCCTCAGCATCCAC

ATATCAAACGTACTGTGGCTGCTCC

CAAGGGGCCTTCCGTGTTCCCCCTGG

CTCCGTGTTCATTTTTCCTCCGTCG

CCCCTTCATCCAAGTCGACCTCTGGT

GACGAACAGCTGAAGTCCGGAACC

GGAACCGCCGCACTCGGTTGCCTGGT

GCGTCCGTGGTCTGTCTCCTGAACA

CAAAGACTACTTCCCCGAGCCCGTGA

ACTTCTATCCGCGCGAGGCGAAAG

CTGTCTCGTGGAACTCGGGCGCCCTC

TGCAGTGGAAGGTCGACAACGCAC

ACATCCGGAGTGCATACCTTTCCCGC

TGCAGTCGGGAAACTCCCAGGAAT

CGTGTTGCAGTCCAGCGGCCTGTACA

CGGTGACCGAGCAGGACTCGAAGG

GCCTGAGCTCCGTCGTGACAGTGCCG

ACTCAACCTACTCATTGTCCTCCAC

TCCTCCTCCCTTGGAACCCAGACCTA

CCTCACCCTGAGCAAGGCCGATTA

TATCTGCAACGTCAATCACAAGCCCT

CGAGAAGCATAAGGTCTACGCCTG

CCAACACCAAAGTGGACAAGAAGGT

CGAAGTGACCCACCAGGGCCTGAG

CGAACCCAAGTCCTGCGACAAGACT

CAGCCCAGTGACGAAGTCCTTCAA

CACACCTGTCCGCCTTGTCCAGCCCC

CCGGGGAGAATGC

TGAGCTGCTGGGTGGTCCGTCCGTGT

TCCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTGT

CGCACGAAGATCCCGAAGTGAAATT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTACAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAAA

GACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTATACTTT

GCCGCCTAGCCGGGAAGAAATGACT

AAGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCTT

1778
CTGAGGTGAAGAAGCCTGGGGCCTC
1886
CCACCCTGTCTGCATCTGTGGGAG

AGTGAAGGTTTCCTGCAAGGCTTCTG

ACAGAGTCACCATCACTTGCCGGG

GATACACCTTCACTAGCTATGCTATG

CCAGTCAGAGTATTACTACCTGGTT

CATTGGGTGCGCCAGGCCCCCGGAC

GGCCTGGTCTCAGCAGCAACCAGG

AAAGGCTTGAGTGGATGGGATGGAT

GAAAGCCCCTAAGCTCCTCATCTAT

CAACGCTGGCAATGGTAACACAAAA

AAGGCCTCTAGTTTAACAAGTGGG

TATTCACAGAAGTTCCAGGGCAGAG

GTCCCATCAAGGTTCAGCGGCAGT

TCACCATGACCACAGACACATCCAC

GGATCTGGGACAGAGTTCACTCTC

GAGCACAGCCTACATGGAGCTGAGG

ACCATCAGCAGCCTGCAGCCTGAT

AGCCTGAGATCTGACGACACGGCCG

GATTTTGCAAGTTATTACTGCCATC

TGTATTACTGTGCGAGAGCTCGTTAC

ATTATAATGGTGCTTCTCGTATGTT

TATGATAGTAGTGGTTATATTGCCCC

CGGCCAAGGGACCAAGCTGGAGAT

ATCGGGTTACTTTGACTACTGGGGCC

CAAACGTACTGTGGCTGCTCCCTCC

AGGGAACCCTGGTCACCGTCTCCTCA

GTGTTCATTTTTCCTCCGTCGGACG

GCATCCACCAAGGGGCCTTCCGTGTT

AACAGCTGAAGTCCGGAACCGCGT

CCCCCTGGCCCCTTCATCCAAGTCGA

CCGTGGTCTGTCTCCTGAACAACTT

CCTCTGGTGGAACCGCCGCACTCGGT

CTATCCGCGCGAGGCGAAAGTGCA

TGCCTGGTCAAAGACTACTTCCCCGA

GTGGAAGGTCGACAACGCACTGCA

GCCCGTGACTGTCTCGTGGAACTCGG

GTCGGGAAACTCCCAGGAATCGGT

GCGCCCTCACATCCGGAGTGCATACC

GACCGAGCAGGACTCGAAGGACTC

TTTCCCGCCGTGTTGCAGTCCAGCGG

AACCTACTCATTGTCCTCCACCCTC

CCTGTACAGCCTGAGCTCCGTCGTGA

ACCCTGAGCAAGGCCGATTACGAG

CAGTGCCGTCCTCCTCCCTTGGAACC

AAGCATAAGGTCTACGCCTGCGAA

CAGACCTATATCTGCAACGTCAATCA

GTGACCCACCAGGGCCTGAGCAGC

CAAGCCCTCCAACACCAAAGTGGAC

CCAGTGACGAAGTCCTTCAACCGG

AAGAAGGTCGAACCCAAGTCCTGCG

GGAGAATGC

ACAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1779
CTGAGGTGAAGAAGCCTGGGGCCTC
1887
GCCACCCTGTCTTTGTCTCCAGGGG

AGTGAAGGTTTCCTGCAAGGCTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATACACCTTCACTAGCTATGCTATG

CCAGTCAGAGTGTTAGCAGCTACT

CATTGGGTGCGCCAGGCCCCCGGAC

TAGCCTGGTACCAACAGAAACCTG

AAAGGCTTGAGTGGATGGGATGGAT

GCCAGGCTCCCAGGCTCCTCATCTA

CAACGCTGGCAATGGTAACACAAAA

TGATGCATCCAACAGGGCCACTGG

TATTCACAGAAGTTCCAGGGCAGAG

CATCCCAGCCAGGTTCAGTGGCAG

TCACCATTACCAGGGACACATCCGCG

TGGGTCTGGGACAGACTTCACTCTC

AGCACAGCCTACATGGAGCTGAGCA

ACCATCAGCAGCCTAGAGCCTGAA

GCCTGAGATCTGAAGACACGGCTGT

GATTTTGCAGTTTATTACTGTCAGC

GTATTACTGTGCGAGAGATGGCCCCG

AGCGTAGCAACTGGCCTTTCTTCGG

CCGTTGATGGTGCTGAATACTTCCAG

CCAAGGGACACGACTGGAGATTAA

CACTGGGGCCAGGGCACCCTGGTCA

ACGTACTGTGGCTGCTCCCTCCGTG

CCGTCTCCTCAGCATCCACCAAGGGG

TTCATTTTTCCTCCGTCGGACGAAC

CCTTCCGTGTTCCCCCTGGCCCCTTC

AGCTGAAGTCCGGAACCGCGTCCG

ATCCAAGTCGACCTCTGGTGGAACCG

TGGTCTGTCTCCTGAACAACTTCTA

CCGCACTCGGTTGCCTGGTCAAAGAC

TCCGCGCGAGGCGAAAGTGCAGTG

TACTTCCCCGAGCCCGTGACTGTCTC

GAAGGTCGACAACGCACTGCAGTC

GTGGAACTCGGGCGCCCTCACATCCG

GGGAAACTCCCAGGAATCGGTGAC

GAGTGCATACCTTTCCCGCCGTGTTG

CGAGCAGGACTCGAAGGACTCAAC

CAGTCCAGCGGCCTGTACAGCCTGA

CTACTCATTGTCCTCCACCCTCACC

GCTCCGTCGTGACAGTGCCGTCCTCC

CTGAGCAAGGCCGATTACGAGAAG

TCCCTTGGAACCCAGACCTATATCTG

CATAAGGTCTACGCCTGCGAAGTG

CAACGTCAATCACAAGCCCTCCAAC

ACCCACCAGGGCCTGAGCAGCCCA

ACCAAAGTGGACAAGAAGGTCGAAC

GTGACGAAGTCCTTCAACCGGGGA

CCAAGTCCTGCGACAAGACTCACAC

GAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1780
CAGGACTGGTGAAGCCCTCGCAGAC
1888
GCCACCCTGACTTTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AAAGAGTCACCCTCTCCTGCAGGG

GGGACAGTGTCTCTAGCAACAGTGCT

CCAGTCAGAGTATTGGCACTTACG

GCTTGGAACTGGATCAGGCAGTCCCC

TCGCCTGGTATCAGCAGAAACCTG

ATCGCGAGGCCTTGAGTGGCTGGGA

GCCAGGCTCCCAGATTCCTCATCTA

AGGACTTACTACAGGTCCAAGTGGT

TGATTCATCGAATAGGGCCACTGG

ATAATGATTATGCAGTATCTCTGAAA

CATCCCAGCCAGGTTCAGTGGTAG

AGTCGAATAACCATCAACCCGGACA

TGGGTCTGGGACAGACTTCACTCTC

CATCCAAGAACCAGTTCTCCCTGCAG

ACGATCAGCAGCCTGGAGCCTGAA

CTGAACTCTGTGACTCCCGAGGACAC

GATTTTGCATTTTATTACTGTCAAC

GGCTGTATATTACTGTGCAAGTTTGG

AGCGTGCCGAGTGGCCTCTCACCTT

CGAGTGGTTCCCCCCCTCCGGGGGAC

CGGCCAAGGGACACGACTGGAGAT

TACTGGGGCCAGGGAACCCTGGTGA

TAAACGTACTGTGGCTGCTCCCTCC

CCGTCTCCTCAGCATCCACCAAGGGG

GTGTTCATTTTTCCTCCGTCGGACG

CCTTCCGTGTTCCCCCTGGCCCCTTC

AACAGCTGAAGTCCGGAACCGCGT

ATCCAAGTCGACCTCTGGTGGAACCG

CCGTGGTCTGTCTCCTGAACAACTT

CCGCACTCGGTTGCCTGGTCAAAGAC

CTATCCGCGCGAGGCGAAAGTGCA

TACTTCCCCGAGCCCGTGACTGTCTC

GTGGAAGGTCGACAACGCACTGCA

GTGGAACTCGGGCGCCCTCACATCCG

GTCGGGAAACTCCCAGGAATCGGT

GAGTGCATACCTTTCCCGCCGTGTTG

GACCGAGCAGGACTCGAAGGACTC

CAGTCCAGCGGCCTGTACAGCCTGA

AACCTACTCATTGTCCTCCACCCTC

GCTCCGTCGTGACAGTGCCGTCCTCC

ACCCTGAGCAAGGCCGATTACGAG

TCCCTTGGAACCCAGACCTATATCTG

AAGCATAAGGTCTACGCCTGCGAA

CAACGTCAATCACAAGCCCTCCAAC

GTGACCCACCAGGGCCTGAGCAGC

ACCAAAGTGGACAAGAAGGTCGAAC

CCAGTGACGAAGTCCTTCAACCGG

CCAAGTCCTGCGACAAGACTCACAC

GGAGAATGC

CTGTCCGCCTTGTCCAGCCCCTGAGC

TGCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTCA

CTTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGAA

GAACAGTACAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGGC

TCTCCCTGCCCCTATCGAAAAGACCA

TCAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTATACTTTGCCGC

CTAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCCC

ACCGGTGCTCGATTCCGATGGCTCCT

TCTTCCTGTACTCCAAGCTGACTGTG

GACAAGTCAAGATGGCAGCAGGGAA

ACGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGGA

AAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1781
GAGGCGTGGTCCAGCCTGGGAGGTC
1889
GCACCCTGTCTTTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACTCTCTCCTGCAGGGC

GATTCACCTTCAGTACCTATGGCATG

CAGTCAGAGTGTTAATAGCGGCTA

CACTGGGTCCGCCAGGCTCCAGGCA

CTTAGCCTGGTACCAGCAGAAACC

AGGGGCTGGAGTGGGTGGCACTTAT

TGGCCAACCTCCCAGACTCCTCATC

ATCATATGATGGAAGTAAAAAATAC

TCTGGTGTTTCCACCAGGGCCACTG

TATGCAAACTCCGTGAAGGGCCGATT

GCATCCCAGACAGGTTCAGTGGCA

CACCATCTCCAGAGACAATTCCAAG

GTGGGTCTGGGACAGACTTCACTC

AACACGTTGTATCTGCAAATGAAAA

TCACCATCAGCAGACTGGAGCCTG

GTCTGAGAGCTGAGGACACGGCTAT

AAGATTTTGCAGTGTATTACTGTCA

GTATTACTGTGCGAAAGGCCCTATAG

GGAGTATGGTAACTCAGCTATGTA

TGGGAGCGACTATGGACTACTGGGG

CAATTTTGGCCAGGGGACCAAGCT

CCAGGGAGCCCTGGTCACCGTCTCCT

GGAGATCAAACGTACTGTGGCTGC

CAGCATCCACCAAGGGGCCTTCCGTG

TCCCTCCGTGTTCATTTTTCCTCCGT

TTCCCCCTGGCCCCTTCATCCAAGTC

CGGACGAACAGCTGAAGTCCGGAA

GACCTCTGGTGGAACCGCCGCACTCG

CCGCGTCCGTGGTCTGTCTCCTGAA

GTTGCCTGGTCAAAGACTACTTCCCC

CAACTTCTATCCGCGCGAGGCGAA

GAGCCCGTGACTGTCTCGTGGAACTC

AGTGCAGTGGAAGGTCGACAACGC

GGGCGCCCTCACATCCGGAGTGCAT

ACTGCAGTCGGGAAACTCCCAGGA

ACCTTTCCCGCCGTGTTGCAGTCCAG

ATCGGTGACCGAGCAGGACTCGAA

CGGCCTGTACAGCCTGAGCTCCGTCG

GGACTCAACCTACTCATTGTCCTCC

TGACAGTGCCGTCCTCCTCCCTTGGA

ACCCTCACCCTGAGCAAGGCCGAT

ACCCAGACCTATATCTGCAACGTCAA

TACGAGAAGCATAAGGTCTACGCC

TCACAAGCCCTCCAACACCAAAGTG

TGCGAAGTGACCCACCAGGGCCTG

GACAAGAAGGTCGAACCCAAGTCCT

AGCAGCCCAGTGACGAAGTCCTTC

GCGACAAGACTCACACCTGTCCGCCT

AACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1782
CTGAGGTGAAGAAGCCTGGGTCCTC
1890
GCCACCCTGTCTGTGTCTCCAGGGG

GGTGAAGGTCTCCTGCAAGGCTTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GAGGCACCTTCAGCAGCTATGCTATC

CCAGTCAGAGTGTTAGCAGCAACT

AGCTGGGTGCGACAGGCCCCTGGAC

TAGCCTGGTACCAGCAGAAACCTG

AAGGGCTTGAGTGGATGGGATGGAT

GCCAGGCTCCCAGGCTCCTCATCTA

CAGCGCTTACAATGGTAACACAAAC

TGGTGCATCCACCAGGGCCACTGG

TATGCACAGAAGCTCCAGGGCAGAG

TATCCCAGCCAGGTTCAGTGGCAG

TCACCATGACCACAGACACATCCAC

TGGGTCTGGGACAGAGTTCACTCT

GAGCACAGCCTACATGGAGCTGAGG

CACCATCAGCAGCCTGCAGTCTGA

AGCCTGAGATCTGACGACACGGCCG

AGATTTTGCAGTTTATTACTGTCAG

TGTATTACTGTGCGAGATGGTACGGT

CAGTATAATAACTGGCCTCCCTTCA

GACTACGGCCTTGACTACTGGGGCCA

CCTTCGGCCAAGGGACACGACTGG

GGGAACCCTGGTCACCGTCTCCTCAG

AGATTAAACGTACTGTGGCTGCTC

CATCCACCAAGGGGCCTTCCGTGTTC

CCTCCGTGTTCATTTTTCCTCCGTC

CCCCTGGCCCCTTCATCCAAGTCGAC

GGACGAACAGCTGAAGTCCGGAAC

CTCTGGTGGAACCGCCGCACTCGGTT

CGCGTCCGTGGTCTGTCTCCTGAAC

GCCTGGTCAAAGACTACTTCCCCGAG

AACTTCTATCCGCGCGAGGCGAAA

CCCGTGACTGTCTCGTGGAACTCGGG

GTGCAGTGGAAGGTCGACAACGCA

CGCCCTCACATCCGGAGTGCATACCT

CTGCAGTCGGGAAACTCCCAGGAA

TTCCCGCCGTGTTGCAGTCCAGCGGC

TCGGTGACCGAGCAGGACTCGAAG

CTGTACAGCCTGAGCTCCGTCGTGAC

GACTCAACCTACTCATTGTCCTCCA

AGTGCCGTCCTCCTCCCTTGGAACCC

CCCTCACCCTGAGCAAGGCCGATT

AGACCTATATCTGCAACGTCAATCAC

ACGAGAAGCATAAGGTCTACGCCT

AAGCCCTCCAACACCAAAGTGGACA

GCGAAGTGACCCACCAGGGCCTGA

AGAAGGTCGAACCCAAGTCCTGCGA

GCAGCCCAGTGACGAAGTCCTTCA

CAAGACTCACACCTGTCCGCCTTGTC

ACCGGGGAGAATGC

CAGCCCCTGAGCTGCTGGGTGGTCCG

TCCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACAACTC

TACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAAG

GGTCAACCTAGGGAGCCCCAGGTCT

ATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1783
CTGAGGTGAAGAAGCCTGGGGCCTC
1891
GCACCCTGTCTTTGTCTCCAGGGGA

AGTGAAGGTTTCCTGCAAGGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACACCTTCACTAGCTATGCTATG

CAGTCAGAGTGTTAGCAGCAGCTA

CATTGGGTGCGCCAGGCCCCCGGAC

CTTAGGCTGGTATCAGCAGAAATC

AAAGGCTTGCGTGGATGGGATGGAT

CGGCCAGGCTCCCAGGCTCCTCAT

CAACGCTGGCAATGGTAACACAAAA

CTATGGTGCATCCAGCAGGGCCAC

TATTCAGAGAAGTTCGAAGGCAGAG

TGACATCCCAGACAGGTTCAGTGG

TCACCATCACCAGGGACACATCCGC

CAGTGGGTCTGGGACAGACTTCAC

GAGCACAGCCTACATGGAGCTGAGC

TCTCACCATCAGCAAACTGGAGGC

AGCCTGAGATCTGAAGACACGGCTG

AGAAGATTCTGCAGTGTATTACTGT

TGTATTACTGTGCGAGGGTCGCCAAA

CAGCAGTATGGTATCTCACCTCTCG

TATTATTACGAGAGTGGTGGTTATCG

CGTTCGGCCAAGGGACCAAGCTGG

GGCCTCCAACTGGTTCGACCCCTGGG

AGATCAAACGTACTGTGGCTGCTC

GCCAGGGCACCCTGGTCACCGTCTCC

CCTCCGTGTTCATTTTTCCTCCGTC

TCAGCATCCACCAAGGGGCCTTCCGT

GGACGAACAGCTGAAGTCCGGAAC

GTTCCCCCTGGCCCCTTCATCCAAGT

CGCGTCCGTGGTCTGTCTCCTGAAC

CGACCTCTGGTGGAACCGCCGCACTC

AACTTCTATCCGCGCGAGGCGAAA

GGTTGCCTGGTCAAAGACTACTTCCC

GTGCAGTGGAAGGTCGACAACGCA

CGAGCCCGTGACTGTCTCGTGGAACT

CTGCAGTCGGGAAACTCCCAGGAA

CGGGCGCCCTCACATCCGGAGTGCAT

TCGGTGACCGAGCAGGACTCGAAG

ACCTTTCCCGCCGTGTTGCAGTCCAG

GACTCAACCTACTCATTGTCCTCCA

CGGCCTGTACAGCCTGAGCTCCGTCG

CCCTCACCCTGAGCAAGGCCGATT

TGACAGTGCCGTCCTCCTCCCTTGGA

ACGAGAAGCATAAGGTCTACGCCT

ACCCAGACCTATATCTGCAACGTCAA

GCGAAGTGACCCACCAGGGCCTGA

TCACAAGCCCTCCAACACCAAAGTG

GCAGCCCAGTGACGAAGTCCTTCA

GACAAGAAGGTCGAACCCAAGTCCT

ACCGGGGAGAATGC

GCGACAAGACTCACACCTGTCCGCCT

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCAGGTC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1784
CAGGACTGGTGAAGCCCTCGCAGAC
1892
GCCACCCTGTCTGTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AGAGAGCCACCCTCTCCTGCAGGG

GGGACAGTGTCTCTAGCAACAGTGCT

CCAGTCAGAGTATTAGCAACAACT

GCTTGGAACTGGATCAGGCAGTCCCC

TAGCCTGGTACCAGCAGAAACCTG

ATCGAGAGGCCTTGAGTGGCTGGGA

GCCAGGCTCCCAGGCTCCTCATCTA

AGGACATACTACAGGTCCAAGTGGT

TGGTACATCCACCAGGGCCACTGG

ATAATGATTATGCAGTATCTGTGAAA

TATCCCAGCCAGGTTCAGTGGCAG

AGTCGAATAACCATCAACCCAGACA

TGGGTCTGGGACAGAGTTCACTCT

CATCCAAGAACCAGTTCTCCCTGCAG

CACCATCAGCAGCCTGCAGTCTGA

CTGAACTCTGTGACTCCCGAGGACAC

AGATTTTGCAGTTTATTACTGTCAG

GGCTGTGTATTACTGTGCAAGAGCGC

CAGTATAATTTCTGGCCTTCGATCA

CCCCTCCGACTGTTGGCTGGTACGCC

CCTTCGGCCAAGGGACACGACTGG

CCCGTCTTTGACTACTGGGGCCAGGG

AGATTAAACGTACTGTGGCTGCTC

AACCCTGGTCACCGTCTCCTCAGCAT

CCTCCGTGTTCATTTTTCCTCCGTC

CCACCAAGGGGCCTTCCGTGTTCCCC

GGACGAACAGCTGAAGTCCGGAAC

CTGGCCCCTTCATCCAAGTCGACCTC

CGCGTCCGTGGTCTGTCTCCTGAAC

TGGTGGAACCGCCGCACTCGGTTGCC

AACTTCTATCCGCGCGAGGCGAAA

TGGTCAAAGACTACTTCCCCGAGCCC

GTGCAGTGGAAGGTCGACAACGCA

GTGACTGTCTCGTGGAACTCGGGCGC

CTGCAGTCGGGAAACTCCCAGGAA

CCTCACATCCGGAGTGCATACCTTTC

TCGGTGACCGAGCAGGACTCGAAG

CCGCCGTGTTGCAGTCCAGCGGCCTG

GACTCAACCTACTCATTGTCCTCCA

TACAGCCTGAGCTCCGTCGTGACAGT

CCCTCACCCTGAGCAAGGCCGATT

GCCGTCCTCCTCCCTTGGAACCCAGA

ACGAGAAGCATAAGGTCTACGCCT

CCTATATCTGCAACGTCAATCACAAG

GCGAAGTGACCCACCAGGGCCTGA

CCCTCCAACACCAAAGTGGACAAGA

GCAGCCCAGTGACGAAGTCCTTCA

AGGTCGAACCCAAGTCCTGCGACAA

ACCGGGGAGAATGC

GACTCACACCTGTCCGCCTTGTCCAG

CCCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAGC

CTAGGGAAGAACAGTACAACTCTAC

GTACCGGGTGGTGTCCGTGCTGACCG

TGCTGCACCAGGACTGGCTGAACGG

AAAGGAGTACAAGTGCAAAGTGTCA

AACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1785
GAGGCTTAGTTCAGCCGGGGGGGTC
1893
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGCTCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GAATCAGCTTCAGAGATTACTGGATG

CCAGTCAGAGTGTTAGCAGCAGCT

CACTGGATCCGCCAAACTCCAGGGA

CCTTAGCCTGGTACCAGCAGAAAC

AGGGGCTGGTGTGGGTCTCACGTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AATCCTGATGGGAGTAGCACAAGCT

CTATGGTGCATCCAGCAGGGCCAC

ACGCGGACTCCGTGAAGGGCCGATT

TGGCATCCCAGACAGGTTCAGTGG

CACCATCTCCAGAGACAATTCCAAG

CAGTGGGTCTGGGACAGACTTCAC

AACACGCTGTATCTGCAAATGAACA

TCTCACCATCAGCAGACTGGAGCC

GCCTGAGAGCTGAGGACACGGCTGT

TGAAGATTTTGCAGTGTATTACTGT

GTATTACTGTGCGAAAGTTACGGGAC

CAGCAGTATGGTAGCTCACAGACC

GGAGAGTGGGAGCCCATGACTACTG

TTCGGCCAAGGGACACGACTGGAG

GGGCCAGGGAACCCTGGTCACCGTC

ATTAAACGTACTGTGGCTGCTCCCT

TCCTCAGCATCCACCAAGGGGCCTTC

CCGTGTTCATTTTTCCTCCGTCGGA

CGTGTTCCCCCTGGCCCCTTCATCCA

CGAACAGCTGAAGTCCGGAACCGC

AGTCGACCTCTGGTGGAACCGCCGC

GTCCGTGGTCTGTCTCCTGAACAAC

ACTCGGTTGCCTGGTCAAAGACTACT

TTCTATCCGCGCGAGGCGAAAGTG

TCCCCGAGCCCGTGACTGTCTCGTGG

CAGTGGAAGGTCGACAACGCACTG

AACTCGGGCGCCCTCACATCCGGAGT

CAGTCGGGAAACTCCCAGGAATCG

GCATACCTTTCCCGCCGTGTTGCAGT

GTGACCGAGCAGGACTCGAAGGAC

CCAGCGGCCTGTACAGCCTGAGCTCC

TCAACCTACTCATTGTCCTCCACCC

GTCGTGACAGTGCCGTCCTCCTCCCT

TCACCCTGAGCAAGGCCGATTACG

TGGAACCCAGACCTATATCTGCAACG

AGAAGCATAAGGTCTACGCCTGCG

TCAATCACAAGCCCTCCAACACCAA

AAGTGACCCACCAGGGCCTGAGCA

AGTGGACAAGAAGGTCGAACCCAAG

GCCCAGTGACGAAGTCCTTCAACC

TCCTGCGACAAGACTCACACCTGTCC

GGGGAGAATGC

GCCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCACGAAG

ATCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAACG

CCAAGACCAAGCCTAGGGAAGAACA

GTACAACTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGCC

CCAGGTCTATACTTTGCCGCCTAGCC

GGGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGCT

TTTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAAG

TCAAGATGGCAGCAGGGAAACGTGT

TCTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAATC

ACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1786
CTGAGGTGAAGAAGCCTGGGGCCTC
1894
TCTCCCTGCCCGTCTCCCTTGGACA

AGTGAAGGTCTCCTGCAAGGCTTCTG

GCCGGCCTCCATCTCCTGCAGGTCT

GATACACCTTCACCGGCTACTATATG

AATCAAAGCCTCGTATACAGTGAT

CACTGGGTGCGACAGGCCCCTGGAC

GGAGGCACCTACTTGAATTGGTTTC

AAGGGCTTGAGTGGATGGGATGGAT

AGCAGAGGGCAGGCCAGTCTCCAA

CAACCCTAACAGTGGTGGCACAAAC

GGCGCCTAGTTTATAAGGTTTCTAA

TATGCACAGAAGTTTCAGGGCAGGG

CCGGGACTCTGGGGTCCCAGACAG

TCACCATGACCAGGGACACGTCCATC

ATTCAGCGGCAGTGGGTCAGGCAC

AGCACAGCCTACATGGAGCTGAGCA

TGATTTCACACTGAGAATCAGCAG

GGCTGAGATCTGACGACACGGCCGT

GGTGGAGGCTGAGGATGTTGGGGT

GTATTACTGTGCCTTTGCCCAGCCGG

TTATTACTGCATGCAAGGGACACA

GCGCTGAGACGTTGAACTTCGATCTC

CTGGCCGTACACTTTTGGCCAGGG

TGGGGCCGTGGCACCCTGGTCACCGT

GACCAAGCTGGAGATCAAACGTAC

CTCCTCAGCATCCACCAAGGGGCCTT

TGTGGCTGCTCCCTCCGTGTTCATT

CCGTGTTCCCCCTGGCCCCTTCATCC

TTTCCTCCGTCGGACGAACAGCTG

AAGTCGACCTCTGGTGGAACCGCCG

AAGTCCGGAACCGCGTCCGTGGTC

CACTCGGTTGCCTGGTCAAAGACTAC

TGTCTCCTGAACAACTTCTATCCGC

TTCCCCGAGCCCGTGACTGTCTCGTG

GCGAGGCGAAAGTGCAGTGGAAG

GAACTCGGGCGCCCTCACATCCGGA

GTCGACAACGCACTGCAGTCGGGA

GTGCATACCTTTCCCGCCGTGTTGCA

AACTCCCAGGAATCGGTGACCGAG

GTCCAGCGGCCTGTACAGCCTGAGCT

CAGGACTCGAAGGACTCAACCTAC

CCGTCGTGACAGTGCCGTCCTCCTCC

TCATTGTCCTCCACCCTCACCCTGA

CTTGGAACCCAGACCTATATCTGCAA

GCAAGGCCGATTACGAGAAGCATA

CGTCAATCACAAGCCCTCCAACACCA

AGGTCTACGCCTGCGAAGTGACCC

AAGTGGACAAGAAGGTCGAACCCAA

ACCAGGGCCTGAGCAGCCCAGTGA

GTCCTGCGACAAGACTCACACCTGTC

CGAAGTCCTTCAACCGGGGAGAAT

CGCCTTGTCCAGCCCCTGAGCTGCTG

GC

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAAC

AGTACAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTATACTTTGCCGCCTAGC

CGGGAAGAAATGACTAAGAACCAAG

TGTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGGA

GTGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGTG

TTCTCCTGCTCCGTGATGCACGAAGC

GCTGCACAACCATTACACCCAGAAA

TCACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GACATCCAGTTGACCCAGTCTCCAT

1787
CAGGACTGGTGAAGCCCTCGCAGAC
1895
CCTCCCTGTCTGCATCTGTAGGAGA

CCTCTCACTCACCTGTGCCATCTCCG

CAGAGTCACCGTCACTTGCCGGGC

GGGACAGTGTCTCTAGCAAAAGTGC

AAGTCAGAGCATTAGCAGCTATTT

TGCTTGGAACTGGATCAGGCAGTCCC

AAATTGGTATCAGCAGAAACCAGG

CATCGAGAGGCCTTGAGTGGCTGGG

GAAAGCCCCTCAACTCCTGATCTA

AAGGACATACTACAGGTCCAAATGG

CGATGCATCCAATTTGGAAACAGG

AATAATGATTATGCATTATCTGTGAA

GGTCCCCTCAAGGTTCAGTGGAAG

AAGTCGAATAACCATCAACCCAGAC

TGGATCTGGGACAGATTTTACTTTC

ACATCCAAGAACCAGTTCTCCCTGCA

ACCATCAGCAGCCTGCAGCCTGAA

GCTGAAGTCTGTGACTCCCGAGGAC

GATTTTGCAACATATTACTGTCAGC

ACGGCTCTGTATTACTGTGTAAGACA

AGTTTGATAATGTCCCAGTCACTTT

AGTCGCGGGCGGTATGGACGTCTGG

CGGCGGAGGGACCAAGGTGGAAAT

GGCCAAGGGACCACGGTCACCGTCT

CAAACGTACTGTGGCTGCTCCCTCC

CCTCAGCATCCACCAAGGGGCCTTCC

GTGTTCATTTTTCCTCCGTCGGACG

GTGTTCCCCCTGGCCCCTTCATCCAA

AACAGCTGAAGTCCGGAACCGCGT

GTCGACCTCTGGTGGAACCGCCGCAC

CCGTGGTCTGTCTCCTGAACAACTT

TCGGTTGCCTGGTCAAAGACTACTTC

CTATCCGCGCGAGGCGAAAGTGCA

CCCGAGCCCGTGACTGTCTCGTGGAA

GTGGAAGGTCGACAACGCACTGCA

CTCGGGCGCCCTCACATCCGGAGTGC

GTCGGGAAACTCCCAGGAATCGGT

ATACCTTTCCCGCCGTGTTGCAGTCC

GACCGAGCAGGACTCGAAGGACTC

AGCGGCCTGTACAGCCTGAGCTCCGT

AACCTACTCATTGTCCTCCACCCTC

CGTGACAGTGCCGTCCTCCTCCCTTG

ACCCTGAGCAAGGCCGATTACGAG

GAACCCAGACCTATATCTGCAACGTC

AAGCATAAGGTCTACGCCTGCGAA

AATCACAAGCCCTCCAACACCAAAG

GTGACCCACCAGGGCCTGAGCAGC

TGGACAAGAAGGTCGAACCCAAGTC

CCAGTGACGAAGTCCTTCAACCGG

CTGCGACAAGACTCACACCTGTCCGC

GGAGAATGC

CTTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATTT

CACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCAC

1788
GAGGCTTGGTACAGCCAGGGCGGTC
1896
TCTCCCTGCCCGTCACCCTTGGACA

CCTGAGACTCTCCTGTACAGCTTCTG

GCCGGCCTCCATCTCCTGCAGGTCT

GATTCACCTTTGGTGATTATGCTATG

AGTCAAAGCCTCGTATACAGTGAT

AGCTGGTTCCGCCAGGCTCCAGGGA

GGAAACACCTACTTGAATTGGTTTC

AGGGGCTGGAGTGGGTCTCAGCTATT

AGCAGAGGCCAGGCCAATCTCCAA

AGTGGTAGTGGTGGTAGCACATACT

GGCGCCTAATTTATAAGGTTTCTAA

ATGCAGACTCCGTGAAGGGCCGATT

CCGGGACTCTGGGGTCCCAGACAG

CACCATCTCCAGAGACAATTCCAAG

ATTCAGCGGCAGTGGGTCAGGCAC

AACACGCTGTATCTGCAAATGAACA

TGATTTCACACTGAAAATCAGCAG

GCCTGAGAGCTGAGGACACGGCTGT

GGTGGAGGCTGAGGATGTTGGGGT

GTATTACTGTGCGAAAGGATCGGTAT

TTATTACTGCATGCAAGGTACACA

ATAGTGGGAGCTACTATATGCTCATT

CTGGCCTCGAACGTTCGGCCAAGG

GACTACTGGGGCCAGGGCACCCTGG

GACCAAGCTGGAGATCAAACGTAC

TCACCGTCTCCTCAGCATCCACCAAG

TGTGGCTGCTCCCTCCGTGTTCATT

GGGCCTTCCGTGTTCCCCCTGGCCCC

TTTCCTCCGTCGGACGAACAGCTG

TTCATCCAAGTCGACCTCTGGTGGAA

AAGTCCGGAACCGCGTCCGTGGTC

CCGCCGCACTCGGTTGCCTGGTCAAA

TGTCTCCTGAACAACTTCTATCCGC

GACTACTTCCCCGAGCCCGTGACTGT

GCGAGGCGAAAGTGCAGTGGAAG

CTCGTGGAACTCGGGCGCCCTCACAT

GTCGACAACGCACTGCAGTCGGGA

CCGGAGTGCATACCTTTCCCGCCGTG

AACTCCCAGGAATCGGTGACCGAG

TTGCAGTCCAGCGGCCTGTACAGCCT

CAGGACTCGAAGGACTCAACCTAC

GAGCTCCGTCGTGACAGTGCCGTCCT

TCATTGTCCTCCACCCTCACCCTGA

CCTCCCTTGGAACCCAGACCTATATC

GCAAGGCCGATTACGAGAAGCATA

TGCAACGTCAATCACAAGCCCTCCAA

AGGTCTACGCCTGCGAAGTGACCC

CACCAAAGTGGACAAGAAGGTCGAA

ACCAGGGCCTGAGCAGCCCAGTGA

CCCAAGTCCTGCGACAAGACTCACA

CGAAGTCCTTCAACCGGGGAGAAT

CCTGTCCGCCTTGTCCAGCCCCTGAG

GC

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1789
CAGGACTGGTGAGGCCCTCGCAGAC
1897
CCACCCTGTCTGTGTCTCCAGGGGA

CCTCTCACTCACCTGTGTCATCTCCG

AAGAGCCACCCTCTCCTGCAGGGC

GGGACAGTGTCTCTAGCGGCAGTGCT

CAGTCAGAGTGTTAGCAGCAACTT

GCTTGGAACTGGATCAGGCAGTCCCC

AGCCTGGTACCAGCAGAAACCTGG

ATCGAGAGGCCTTGAGTGGCTGGGA

CCAGGCTCCCAGGCTCCTCATCTAT

AGGACATATTATAGGGCCAAGTGGT

GGTGCATCCAGCAGGGCCACTGGC

ATAATGAATATGCAGGGTCTGTGAA

ATCCCAGACAGGTTCAGTGGCAGT

AAGCCGAATAACCATCAGTCCGGAC

GGGTCTGGGACAGACTTCACTCTC

ACATCCAAGAACCAGTTCTCCCTGCA

ACCATCAACAGACTGGAGCCTGAA

ACTGAACTCTGTGACTCCCGAGGACA

GATTTTGCAGTGTATTACTGTCAGC

CGGCTGTGTATTTCTGTACAAGACAA

AGTATGGTAGCTCATCCATGTACA

GACAAAGACAACACGAGATATTCCG

CTTTTGGCCAGGGGACCAAGCTGG

GTTTGGGCGTCTGGGGCCAAGGGAC

AGATCAAACGTACTGTGGCTGCTC

CACGGTGACCGTCTCCTCAGCATCCA

CCTCCGTGTTCATTTTTCCTCCGTC

CCAAGGGGCCTTCCGTGTTCCCCCTG

GGACGAACAGCTGAAGTCCGGAAC

GCCCCTTCATCCAAGTCGACCTCTGG

CGCGTCCGTGGTCTGTCTCCTGAAC

TGGAACCGCCGCACTCGGTTGCCTGG

AACTTCTATCCGCGCGAGGCGAAA

TCAAAGACTACTTCCCCGAGCCCGTG

GTGCAGTGGAAGGTCGACAACGCA

ACTGTCTCGTGGAACTCGGGCGCCCT

CTGCAGTCGGGAAACTCCCAGGAA

CACATCCGGAGTGCATACCTTTCCCG

TCGGTGACCGAGCAGGACTCGAAG

CCGTGTTGCAGTCCAGCGGCCTGTAC

GACTCAACCTACTCATTGTCCTCCA

AGCCTGAGCTCCGTCGTGACAGTGCC

CCCTCACCCTGAGCAAGGCCGATT

GTCCTCCTCCCTTGGAACCCAGACCT

ACGAGAAGCATAAGGTCTACGCCT

ATATCTGCAACGTCAATCACAAGCCC

GCGAAGTGACCCACCAGGGCCTGA

TCCAACACCAAAGTGGACAAGAAGG

GCAGCCCAGTGACGAAGTCCTTCA

TCGAACCCAAGTCCTGCGACAAGAC

ACCGGGGAGAATGC

TCACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGGA

CACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGTG

TCGCACGAAGATCCCGAAGTGAAAT

TCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACAACTCTACGT

ACCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAAA

CAAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTATACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGCC

TTGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCAAGCTG

ACTGTGGACAAGTCAAGATGGCAGC

AGGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGGAGACCGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAT

1790
GAGGCTTAGTTCAGCCTGGGGGGTCC
1898
CCTCCCTGTCTGCATCTGTGGGGGA

CTGAGACTCTCCTGTGCAGCCTCTGA

CAGCGTCGCCATCACTTGCCGGGC

ATTCACCCTTAGGAACTATGGCGTGA

AAGTCAGAGCATTAGCAACTATTT

GCTGGGTCCGCCAGGCTCCAGGGAA

AAATTGGTATCAGCAGAGACCAGG

GGGGCTGGAGTGGGTCTCAGGTATG

GAAAGCCCCTAAGCTCCTGATCTTT

AGTGGTAGTGGTTATAGTACATACTA

GCTGCATCCAGTTTGCAAAGTGGG

CGCAGACTCCGTGAAGGGCCGGTTC

GTCCCATCAAGGTTCAGTGGCAGT

ACCATCTCCAGAGACAGTTCCAAGA

GGATCTGGGACAGATTTCACTCTC

ACACGCTGTTTCTGCAAATGGACAGC

ACCATCAGCAGTCTGCAACCTGAA

CTGAGAGCCGAGGACACGGCCATAT

GATTTTGCAACTTACTCCTGTCAAC

ATTACTGTGCGAGAGGGCCCCGAAT

AGAGTTACATTACCCCGTGGACGT

GTGGAGCAGTGGCATTGATGCTTTTG

TCGGCCAAGGGACCAAGCTGGAGA

ATATCTGGGGCCACGGGACAATGGT

TCAAACGTACTGTGGCTGCTCCCTC

GACCGTCTCTTCAGCATCCACCAAGG

CGTGTTCATTTTTCCTCCGTCGGAC

GGCCTTCCGTGTTCCCCCTGGCCCCT

GAACAGCTGAAGTCCGGAACCGCG

TCATCCAAGTCGACCTCTGGTGGAAC

TCCGTGGTCTGTCTCCTGAACAACT

CGCCGCACTCGGTTGCCTGGTCAAAG

TCTATCCGCGCGAGGCGAAAGTGC

ACTACTTCCCCGAGCCCGTGACTGTC

AGTGGAAGGTCGACAACGCACTGC

TCGTGGAACTCGGGCGCCCTCACATC

AGTCGGGAAACTCCCAGGAATCGG

CGGAGTGCATACCTTTCCCGCCGTGT

TGACCGAGCAGGACTCGAAGGACT

TGCAGTCCAGCGGCCTGTACAGCCTG

CAACCTACTCATTGTCCTCCACCCT

AGCTCCGTCGTGACAGTGCCGTCCTC

CACCCTGAGCAAGGCCGATTACGA

CTCCCTTGGAACCCAGACCTATATCT

GAAGCATAAGGTCTACGCCTGCGA

GCAACGTCAATCACAAGCCCTCCAA

AGTGACCCACCAGGGCCTGAGCAG

CACCAAAGTGGACAAGAAGGTCGAA

CCCAGTGACGAAGTCCTTCAACCG

CCCAAGTCCTGCGACAAGACTCACA

GGGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1791
CAGGACTGTTGAAGCCTTCGGAGAC
1899
GCACCCTGTCTTTGTCTCCAGGGGA

CCTGTCCCTCACCTGCGCTGTCTATG

AAGAGCCACCCTCTCCTGCAGGGC

GTGGGTCCGTCAGTGGTTACTACTGG

CAGTCAGAGTGTTAGCACCCTCTTA

AGCTGGATCCGCCAGCCCCCAGGGA

GCCTGGTACCAACAGAAACCTGGC

AGGGGCTGGAGTGGATGGGGGAAAT

CAGGCTCCCAGGCTCCTCATCTATG

CCATCATAGTGGAAGCACCAACTAC

ATGCATCCAACAGGGCCACTGGCA

AACCCGTCCCTCAAGAGTCGAGTCAC

TCCCAGGCAGGTTCAGTGCCAGTG

CATATCACTAGACACGCCCAAGAAC

GGTCTGGGACAGACTTCAGTCTCA

CAGTTCTCCCTGAAGCTAAGCTCTGT

CCATCAGCAGCCTAGAGACTGAAG

GACCGCCGCGGACACGGCTGTATATT

ATTCTGCAGTTTATTACTGTCAGCA

ACTGTGCGAGACGGGATTGGGCAGG

CCGTTACGTGTGGCCGTTCACTTTC

AAAAAGGGTCTGGGGCCAGGGAACC

GGCGGAGGGACCAAGCTGGAGATC

CTGGTCACCGTCTCCTCAGCATCCAC

AAACGTACTGTGGCTGCTCCCTCCG

CAAGGGGCCTTCCGTGTTCCCCCTGG

TGTTCATTTTTCCTCCGTCGGACGA

CCCCTTCATCCAAGTCGACCTCTGGT

ACAGCTGAAGTCCGGAACCGCGTC

GGAACCGCCGCACTCGGTTGCCTGGT

CGTGGTCTGTCTCCTGAACAACTTC

CAAAGACTACTTCCCCGAGCCCGTGA

TATCCGCGCGAGGCGAAAGTGCAG

CTGTCTCGTGGAACTCGGGCGCCCTC

TGGAAGGTCGACAACGCACTGCAG

ACATCCGGAGTGCATACCTTTCCCGC

TCGGGAAACTCCCAGGAATCGGTG

CGTGTTGCAGTCCAGCGGCCTGTACA

ACCGAGCAGGACTCGAAGGACTCA

GCCTGAGCTCCGTCGTGACAGTGCCG

ACCTACTCATTGTCCTCCACCCTCA

TCCTCCTCCCTTGGAACCCAGACCTA

CCCTGAGCAAGGCCGATTACGAGA

TATCTGCAACGTCAATCACAAGCCCT

AGCATAAGGTCTACGCCTGCGAAG

CCAACACCAAAGTGGACAAGAAGGT

TGACCCACCAGGGCCTGAGCAGCC

CGAACCCAAGTCCTGCGACAAGACT

CAGTGACGAAGTCCTTCAACCGGG

CACACCTGTCCGCCTTGTCCAGCCCC

GAGAATGC

TGAGCTGCTGGGTGGTCCGTCCGTGT

TCCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTGT

CGCACGAAGATCCCGAAGTGAAATT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTACAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAAA

GACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTATACTTT

GCCGCCTAGCCGGGAAGAAATGACT

AAGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC
SEQ ID
GACATCCAGATGACCCAGTCTCCA

1792
CAGGACTATTAAAGCCCTCGCAGAC
1900
TCCTCCCTGTCTGCATCTGTAGGAG

CCTCTCACTCACCTGTGCCATCTCCG

ACAGAGTCACCATCACTTGCCGGG

GGGACAGTGTCTCTAGCAACACTGCT

CAAGTCAGGGCATTAGAAATGATT

ACTTGGAACTGGATCAGGCAGTCCCC

TAGGCTGGTATCAGCAGAAACCAG

ATCGAGAGGCCTTGAGTGGCTGGGA

GGAAAGCCCCTAAGCGTCTGATCT

AGGACATACTACAGGTCCAAGTGGT

ATGGTGCATCCAGTTTGCAAAGTG

ATAAGGATAATGCACTGTCTGTGAA

GAGTCCCATCAAGGTTCAGCGGCA

AAGTCGAATAACCATCAACCCAGAC

GTGGATCTGGGACAGAATTCACTC

ACATCCAAGAACCAGTTCTCCCTGCA

TCACAATCAGGAGCCTGCAGCCTG

GCTGAACTCTGTGACTCCCGAGGACA

AAGATTTTGCAACTTATTATTGTCT

CGGCTGTGTATTACTGTGCAGGAGGT

ACAGCATAATTCCTACCCTCGAAC

CGGGCTGGTATTGCCGCTTTTGATAT

ATTCGGCCAAGGGACCAAGGTGGA

CTGGGGCCAAGGGACCACGGTCACC

AATCAAACGTACTGTGGCTGCTCC

GTCTCCTCAGCATCCACCAAGGGGCC

CTCCGTGTTCATTTTTCCTCCGTCG

TTCCGTGTTCCCCCTGGCCCCTTCATC

GACGAACAGCTGAAGTCCGGAACC

CAAGTCGACCTCTGGTGGAACCGCC

GCGTCCGTGGTCTGTCTCCTGAACA

GCACTCGGTTGCCTGGTCAAAGACTA

ACTTCTATCCGCGCGAGGCGAAAG

CTTCCCCGAGCCCGTGACTGTCTCGT

TGCAGTGGAAGGTCGACAACGCAC

GGAACTCGGGCGCCCTCACATCCGG

TGCAGTCGGGAAACTCCCAGGAAT

AGTGCATACCTTTCCCGCCGTGTTGC

CGGTGACCGAGCAGGACTCGAAGG

AGTCCAGCGGCCTGTACAGCCTGAG

ACTCAACCTACTCATTGTCCTCCAC

CTCCGTCGTGACAGTGCCGTCCTCCT

CCTCACCCTGAGCAAGGCCGATTA

CCCTTGGAACCCAGACCTATATCTGC

CGAGAAGCATAAGGTCTACGCCTG

AACGTCAATCACAAGCCCTCCAACA

CGAAGTGACCCACCAGGGCCTGAG

CCAAAGTGGACAAGAAGGTCGAACC

CAGCCCAGTGACGAAGTCCTTCAA

CAAGTCCTGCGACAAGACTCACACCT

CCGGGGAGAATGC

GTCCGCCTTGTCCAGCCCCTGAGCTG

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
CAGGTGCAGCTGGTGCAATCTGGAG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1793
GAGGCTTGATCCAGCCTGGGGGGTC
1901
CCACCCTGTCTTTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GGTTCACCGTCAGTAGCAACTACATG

CAGTCAGAGTGTTAGCAGCTACTT

AGCTGGGTCCGCCAGGCTCCAGGGA

AGCCTGGTACCAACAGAAACCTGG

AGGGGCTGGAATGGGTCTCACTTATT

CCAGGCTCCCAGGCTCCTCATCTAT

TATAGTGATGGTCGCACAAACTATGC

GATGCATCCAACAGGGCCACTGGC

AGACTCCGTGAAGGGCCGATTCACC

ATCCCAGCCAGGTTCAGTGGCAGT

ATCTCCAGAGACAATTCCAAGAACA

GGGTCTGGGACAGACTTCACTCTC

CGCTGTATCTGCAAATGAACAGCCTG

ACCATCAGCAGCCTAGAGCCTGAA

AGAGCCGAGGACACGGCCGTATATT

GATTTTGCAGTTTATTACTGTCAGC

ACTGTGCGAAGGGGGCCCTACAGGG

AGCGTAGCAACTGGCCGTGGACGT

CGAATGGCGGAGATTTGACTACTGG

TCGGCCAAGGGACCAAGCTGGAGA

GGCCAGGGCACCCTGGTCACCGTCTC

TCAAACGTACTGTGGCTGCTCCCTC

CTCAGCATCCACCAAGGGGCCTTCCG

CGTGTTCATTTTTCCTCCGTCGGAC

TGTTCCCCCTGGCCCCTTCATCCAAG

GAACAGCTGAAGTCCGGAACCGCG

TCGACCTCTGGTGGAACCGCCGCACT

TCCGTGGTCTGTCTCCTGAACAACT

CGGTTGCCTGGTCAAAGACTACTTCC

TCTATCCGCGCGAGGCGAAAGTGC

CCGAGCCCGTGACTGTCTCGTGGAAC

AGTGGAAGGTCGACAACGCACTGC

TCGGGCGCCCTCACATCCGGAGTGCA

AGTCGGGAAACTCCCAGGAATCGG

TACCTTTCCCGCCGTGTTGCAGTCCA

TGACCGAGCAGGACTCGAAGGACT

GCGGCCTGTACAGCCTGAGCTCCGTC

CAACCTACTCATTGTCCTCCACCCT

GTGACAGTGCCGTCCTCCTCCCTTGG

CACCCTGAGCAAGGCCGATTACGA

AACCCAGACCTATATCTGCAACGTCA

GAAGCATAAGGTCTACGCCTGCGA

ATCACAAGCCCTCCAACACCAAAGT

AGTGACCCACCAGGGCCTGAGCAG

GGACAAGAAGGTCGAACCCAAGTCC

CCCAGTGACGAAGTCCTTCAACCG

TGCGACAAGACTCACACCTGTCCGCC

GGGAGAATGC

TTGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCACGAAGATC

CCGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGTA

CAACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC
SEQ ID
GATGTTGTGATGACTCAGTCTCCGC

1794
CAGGACTGGTGAAGCCCTCGCAGAC
1902
TCTCCCTGCCCGTCACCCTTGGACA

CCTCTCACTCACCTGTGCCATCTCCG

GGCGGCCTCCATCTCCTGCAGGTCT

GGGACAGTGTCTCTAGCAACAGTGCT

AGTCATAGCCTCACAACTACTGAT

GCTTGGAACTGGATCAGGCAGTCCCC

GGACGTACTTACGTGGCTTGGTTTC

ATCGAGAGGCCTTGAGTGGCTGGGA

AGCAGAGGCCAGGCCAATCTCCAA

AGGACATATTACAGGTCCAAGTGGT

GGCGCCTTCTTTATGAGGTTTCTAA

ATAATGATTATGCAGTATCTGTGAAA

GCGGGACTCTGGGGCCCCAGACAG

AGTCGAATAACCATCAACCCAGACA

ATTCAGCGGCAGTGGGTCAGGCAC

CATCCAAGAACCAGTTCTCCCTGCAG

TGATTTCACTCTGAAAATCAGCAG

CTGAACTCTGTGACTCCCGAGGACAC

GGTGGAGGCTGACGATGTTGGAAT

GGCTGTGTATTACTGTACAAGAACCA

TTATCATTGCATGCAAGGAACACA

ACCAGGGATACGGTGGTAACTCCGG

TGGGCCTCACACGTTCGGCCAAGG

GGTATTTGACTACTGGGGCCAGGGA

GACCAAGCTGGAGATCAAACGTAC

ACCCTGGTCACCGTCTCCTCAGCATC

TGTGGCTGCTCCCTCCGTGTTCATT

CACCAAGGGGCCTTCCGTGTTCCCCC

TTTCCTCCGTCGGACGAACAGCTG

TGGCCCCTTCATCCAAGTCGACCTCT

AAGTCCGGAACCGCGTCCGTGGTC

GGTGGAACCGCCGCACTCGGTTGCCT

TGTCTCCTGAACAACTTCTATCCGC

GGTCAAAGACTACTTCCCCGAGCCCG

GCGAGGCGAAAGTGCAGTGGAAG

TGACTGTCTCGTGGAACTCGGGCGCC

GTCGACAACGCACTGCAGTCGGGA

CTCACATCCGGAGTGCATACCTTTCC

AACTCCCAGGAATCGGTGACCGAG

CGCCGTGTTGCAGTCCAGCGGCCTGT

CAGGACTCGAAGGACTCAACCTAC

ACAGCCTGAGCTCCGTCGTGACAGTG

TCATTGTCCTCCACCCTCACCCTGA

CCGTCCTCCTCCCTTGGAACCCAGAC

GCAAGGCCGATTACGAGAAGCATA

CTATATCTGCAACGTCAATCACAAGC

AGGTCTACGCCTGCGAAGTGACCC

CCTCCAACACCAAAGTGGACAAGAA

ACCAGGGCCTGAGCAGCCCAGTGA

GGTCGAACCCAAGTCCTGCGACAAG

CGAAGTCCTTCAACCGGGGAGAAT

ACTCACACCTGTCCGCCTTGTCCAGC

GC

CCCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAGC

CTAGGGAAGAACAGTACAACTCTAC

GTACCGGGTGGTGTCCGTGCTGACCG

TGCTGCACCAGGACTGGCTGAACGG

AAAGGAGTACAAGTGCAAAGTGTCA

AACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTATA

CTTTGCCGCCTAGCCGGGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCCG

ATGGCTCCTTCTTCCTGTACTCCAAG

CTGACTGTGGACAAGTCAAGATGGC

AGCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACTT

TCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1795
CAGGACTGGTGAAGCCCTCGCAGAC
1903
GCCACCCTGTCTGTGTCTCCAGGGG

CCTCTCACTCACCTGTGCCATCTCCG

AAAGAGCCACCCTCTCCTGCAGGG

GGGACAGTGTCTCTGGCAACAGTGCT

CCAGTCAAAGTGTTACCAGCAACT

GCTTGGAACTGGATCAGGCAGTCCCC

TAGCCTGGTACCAGCAGAAACCTG

ATCGAGAGGCCTTGAGTGGCTGGGA

GCCAGGCTCCCAGGCTCCTCATCTA

AGGACATACTACAGGTCCAAGTGGT

TGGTGCATCCAACAGGGCCACTGG

ATAATGATTATGCAGTATCTGTGAAA

TATCCCAGCCAGGTTCAGTGTCAGT

AGTCGAATAACCATCAACCCAGACA

GGGTCTGGGACAGACTTCACTCTC

CATCCAAGAACCAGTTCTCCCTGCAG

ACCATCAGCAGACTGGAGCCTGAA

TTGAATTCTGTGACTCCCGAGGACAC

GATTTTGCAGTGTATTACTGTCAGC

GGCTGTGTATTACTGTGCGAGGATAG

AGTATGGTAGTCCACCTCCGACCA

TGGGAGGTGCCGTTGACTGCTGGGG

CCTTCGGCCAAGGGACACGACTGG

CCAGGGAACCCTGGTGACCGTCTCCT

AGATTAAACGTACTGTGGCTGCTC

CAGCATCCACCAAGGGGCCTTCCGTG

CCTCCGTGTTCATTTTTCCTCCGTC

TTCCCCCTGGCCCCTTCATCCAAGTC

GGACGAACAGCTGAAGTCCGGAAC

GACCTCTGGTGGAACCGCCGCACTCG

CGCGTCCGTGGTCTGTCTCCTGAAC

GTTGCCTGGTCAAAGACTACTTCCCC

AACTTCTATCCGCGCGAGGCGAAA

GAGCCCGTGACTGTCTCGTGGAACTC

GTGCAGTGGAAGGTCGACAACGCA

GGGCGCCCTCACATCCGGAGTGCAT

CTGCAGTCGGGAAACTCCCAGGAA

ACCTTTCCCGCCGTGTTGCAGTCCAG

TCGGTGACCGAGCAGGACTCGAAG

CGGCCTGTACAGCCTGAGCTCCGTCG

GACTCAACCTACTCATTGTCCTCCA

TGACAGTGCCGTCCTCCTCCCTTGGA

CCCTCACCCTGAGCAAGGCCGATT

ACCCAGACCTATATCTGCAACGTCAA

ACGAGAAGCATAAGGTCTACGCCT

TCACAAGCCCTCCAACACCAAAGTG

GCGAAGTGACCCACCAGGGCCTGA

GACAAGAAGGTCGAACCCAAGTCCT

GCAGCCCAGTGACGAAGTCCTTCA

GCGACAAGACTCACACCTGTCCGCCT

ACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1796
CTGAGGTGAAGAAGCCTGGGGCCTC
1904
GCACCCTGTCTTTGTCTCCAGGGGA

AGTGAAGGTTTCCTGCAAGGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATACACCTTCACTAGCTATGCTATG

CAGTCAGAGTGTTAGCAGCAGCTA

CATTGGGTGCGCCAGGCCCCCGGAC

CTTAGCCTGGTACCAGCAGAAACC

AAAGGCTTGAGTGGATGGGATGGAT

TGGCCAGGCTCCCAGGCTCCTCATC

CAACGCTGGCAATGGTAACACAAAA

TATGGTGCATCCAGCAGGGCCACT

TATTCACAGAAGTTCCAGGGCAGAG

GGCATCCCAGACAGGTTCAGTGGC

TCACCATTACCAGGGACACATCCGCG

AGTGGGTCTGGGACAGACTTCACT

AGCACAGCCTACATGGAGCTGAGCA

CTCACCATCAGCAGACTGGAGCCT

GCCTGAGATCTGAAGACACGGCTGT

GAAGATTTTGCAGTGTATTACTGTC

GTATTACTGTGCGAGAGTTAGAGTGG

AGCAGTATGGTAGCTCACGTCGGA

GAGCTACTACTGTTTACGACAGCTGG

CGTTCGGCCAAGGGACCAAGCTGG

TTCGACCCCTGGGGCCAGGGAACCCT

AGATCAAACGTACTGTGGCTGCTC

GGTGACCGTCTCCTCAGCATCCACCA

CCTCCGTGTTCATTTTTCCTCCGTC

AGGGGCCTTCCGTGTTCCCCCTGGCC

GGACGAACAGCTGAAGTCCGGAAC

CCTTCATCCAAGTCGACCTCTGGTGG

CGCGTCCGTGGTCTGTCTCCTGAAC

AACCGCCGCACTCGGTTGCCTGGTCA

AACTTCTATCCGCGCGAGGCGAAA

AAGACTACTTCCCCGAGCCCGTGACT

GTGCAGTGGAAGGTCGACAACGCA

GTCTCGTGGAACTCGGGCGCCCTCAC

CTGCAGTCGGGAAACTCCCAGGAA

ATCCGGAGTGCATACCTTTCCCGCCG

TCGGTGACCGAGCAGGACTCGAAG

TGTTGCAGTCCAGCGGCCTGTACAGC

GACTCAACCTACTCATTGTCCTCCA

CTGAGCTCCGTCGTGACAGTGCCGTC

CCCTCACCCTGAGCAAGGCCGATT

CTCCTCCCTTGGAACCCAGACCTATA

ACGAGAAGCATAAGGTCTACGCCT

TCTGCAACGTCAATCACAAGCCCTCC

GCGAAGTGACCCACCAGGGCCTGA

AACACCAAAGTGGACAAGAAGGTCG

GCAGCCCAGTGACGAAGTCCTTCA

AACCCAAGTCCTGCGACAAGACTCA

ACCGGGGAGAATGC

CACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GAAACGACACTCACGCAGTCTCCA

1797
GAGGCTTGGTACAGCCTGGGGGGTC
1905
GGCACCCTGTCCTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTAGCAGCTATGCCATG

CCAGTCAGAGTGTTTTCAACAACT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTACCAACAGAGAC

AGGGGCTGGAGTGGGTCTCAGCTATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AGTGGTAGTGGTGGTAGCACATACT

CTATGGTGCATCCAGCAGGGCCAC

ACGCAGACTCCGTGAAGGGCCGGTT

TGGCATCCCAGACAGGTTCAGTGG

CACCATCTCCAGAGACAATTCCAAG

CGGTGGGTCTGGGACAGACTTCAC

AACACGCTGTATCTGCAAATGAACA

TCTCACCATCAGCAGACTGGAGCC

GCCTGAGAGCCGAGGACACGGCCGT

TGAAGATTTCGCAGTGTATTGCTGT

ATATTACTGTGCGAAAGATGGGGGG

CAGCAGTATGGTAGTTCACCGATC

TCCAGCCCATACTATGATAGTAGTGG

ACCTTCGGCCAAGGGACACGACTG

TTTACTACCCTGGTACTTCGATCTCT

GAGATTAAACGTACTGTGGCTGCT

GGGGCCGTGGCACCCTGGTCACCGTC

CCCTCCGTGTTCATTTTTCCTCCGT

TCCTCAGCATCCACCAAGGGGCCTTC

CGGACGAACAGCTGAAGTCCGGAA

CGTGTTCCCCCTGGCCCCTTCATCCA

CCGCGTCCGTGGTCTGTCTCCTGAA

AGTCGACCTCTGGTGGAACCGCCGC

CAACTTCTATCCGCGCGAGGCGAA

ACTCGGTTGCCTGGTCAAAGACTACT

AGTGCAGTGGAAGGTCGACAACGC

TCCCCGAGCCCGTGACTGTCTCGTGG

ACTGCAGTCGGGAAACTCCCAGGA

AACTCGGGCGCCCTCACATCCGGAGT

ATCGGTGACCGAGCAGGACTCGAA

GCATACCTTTCCCGCCGTGTTGCAGT

GGACTCAACCTACTCATTGTCCTCC

CCAGCGGCCTGTACAGCCTGAGCTCC

ACCCTCACCCTGAGCAAGGCCGAT

GTCGTGACAGTGCCGTCCTCCTCCCT

TACGAGAAGCATAAGGTCTACGCC

TGGAACCCAGACCTATATCTGCAACG

TGCGAAGTGACCCACCAGGGCCTG

TCAATCACAAGCCCTCCAACACCAA

AGCAGCCCAGTGACGAAGTCCTTC

AGTGGACAAGAAGGTCGAACCCAAG

AACCGGGGAGAATGC

TCCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCACGAAG

ATCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAACG

CCAAGACCAAGCCTAGGGAAGAACA

GTACAACTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGCC

CCAGGTCTATACTTTGCCGCCTAGCC

GGGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGCT

TTTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAAG

TCAAGATGGCAGCAGGGAAACGTGT

TCTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAATC

ACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1798
GAGGCTTGGTCCAGCCTGGGGGGTC
1906
GCCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTCAGTAGCTATGCTATG

CCAGTCAGAGTGTTAGCAGCTACT

CACTGGGTCCGCCAGGCTCCAGGGA

TAGCCTGGTACCAACAGAAACCTG

AGGGACTGGAATATGTTTCAGCTATT

GCCAGGCTCCCAGGCTCCTCATCTA

AGTAGTAATGGGGGTAGCACATATT

TGATGCATCCAACAGGGCCACTGG

ATGCAAACTCTGTGAAGGGCAGATT

CATCCCAGCCAGGTTCAGTGGCAG

CACCATCTCCAGAGACAATTCCAAG

TGGGTCTGGGACAGACTTCACTCTC

AACACGCTGTATCTTCAAATGGGCAG

ACCATCAGCAGACTGGAGCCTGAA

CCTGAGAGCTGAGGACATGGCTGTG

GATTTTGCAGTGTATTACTGTCAGC

TATTACTGTGCGAGAGCTAAGTTTTG

AGTATGGTAGCTCACTCAGGTACA

GACATACTACTTTGACTACTGGGGCC

CTTTTGGCCAGGGGACCAAGCTGG

AGGGAACCCTGGTGACCGTCTCCTCA

AGATCAAACGTACTGTGGCTGCTC

GCATCCACCAAGGGGCCTTCCGTGTT

CCTCCGTGTTCATTTTTCCTCCGTC

CCCCCTGGCCCCTTCATCCAAGTCGA

GGACGAACAGCTGAAGTCCGGAAC

CCTCTGGTGGAACCGCCGCACTCGGT

CGCGTCCGTGGTCTGTCTCCTGAAC

TGCCTGGTCAAAGACTACTTCCCCGA

AACTTCTATCCGCGCGAGGCGAAA

GCCCGTGACTGTCTCGTGGAACTCGG

GTGCAGTGGAAGGTCGACAACGCA

GCGCCCTCACATCCGGAGTGCATACC

CTGCAGTCGGGAAACTCCCAGGAA

TTTCCCGCCGTGTTGCAGTCCAGCGG

TCGGTGACCGAGCAGGACTCGAAG

CCTGTACAGCCTGAGCTCCGTCGTGA

GACTCAACCTACTCATTGTCCTCCA

CAGTGCCGTCCTCCTCCCTTGGAACC

CCCTCACCCTGAGCAAGGCCGATT

CAGACCTATATCTGCAACGTCAATCA

ACGAGAAGCATAAGGTCTACGCCT

CAAGCCCTCCAACACCAAAGTGGAC

GCGAAGTGACCCACCAGGGCCTGA

AAGAAGGTCGAACCCAAGTCCTGCG

GCAGCCCAGTGACGAAGTCCTTCA

ACAAGACTCACACCTGTCCGCCTTGT

ACCGGGGAGAATGC

CCAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACAACT

CTACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TATACTTTGCCGCCTAGCCGGGAAGA

AATGACTAAGAACCAAGTGTCCCTG

ACTTGCCTTGTCAAGGGCTTTTATCC

GTCCGACATCGCCGTGGAGTGGGAG

TCCAACGGACAACCGGAGAACAACT

ACAAGACCACCCCACCGGTGCTCGA

TTCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
CAGGTGCAGCTACAGCAGTGGGGCG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1799
CAGGACTGTTGAAGCCTTCGGAGAC
1907
GACTCCCTGGCTGTGTCTCTGGGCG

CCTGTCCCTCACCTGCGCTGTCTATG

AGAGGGCCACCATCAACTGCAAGT

GTGGGTCCTTCAGTGGTTACTACTGG

CCAGCCAGAGTGTTTTATATGATTC

AGCTGGATCCGCCAGCCCCCAGGGA

CAACAGTAAGAACTACTTAAGTTG

AGGGGCTGGAGTGGATTGGGGAAAT

GTATCAGCAGAAACCAGGCCAGCC

CAATCATAGTGGAAGCACCAACTAC

TCCTAAGTTGCTCATTTCCTGGGCG

AACCCGTCCCTCAAGAGTCGAGTCAC

TCTACCCGGGGGTCCGGGGTCCCT

CATATCAGTAGACACGTCCAAGAAC

GACCGATTCAGTGGCAGCGGGTCT

CAGTTCTCCCTGAAGCTGAGCTCTGT

GGGACAGATTTCACTCTCACCATC

GACCGCCGCGGACACGGCTGTGTATT

AGCAGCCTGCAGGCTGAAGATGTG

ACTGTGCGAGAGGCGGTGGTTCGGG

GCAGTTTATTACTGTCAGCAATTTT

GAGTTATTATAAGAGGTTCTTTGACT

ATGGTATTCCCCACTTCGGCCAAG

ACTGGGGCCAGGGAACCCTGGTCAC

GGACACGACTGGAGATTAAACGTA

CGTCTCCTCAGCATCCACCAAGGGGC

CTGTGGCTGCTCCCTCCGTGTTCAT

CTTCCGTGTTCCCCCTGGCCCCTTCAT

TTTTCCTCCGTCGGACGAACAGCTG

CCAAGTCGACCTCTGGTGGAACCGCC

AAGTCCGGAACCGCGTCCGTGGTC

GCACTCGGTTGCCTGGTCAAAGACTA

TGTCTCCTGAACAACTTCTATCCGC

CTTCCCCGAGCCCGTGACTGTCTCGT

GCGAGGCGAAAGTGCAGTGGAAG

GGAACTCGGGCGCCCTCACATCCGG

GTCGACAACGCACTGCAGTCGGGA

AGTGCATACCTTTCCCGCCGTGTTGC

AACTCCCAGGAATCGGTGACCGAG

AGTCCAGCGGCCTGTACAGCCTGAG

CAGGACTCGAAGGACTCAACCTAC

CTCCGTCGTGACAGTGCCGTCCTCCT

TCATTGTCCTCCACCCTCACCCTGA

CCCTTGGAACCCAGACCTATATCTGC

GCAAGGCCGATTACGAGAAGCATA

AACGTCAATCACAAGCCCTCCAACA

AGGTCTACGCCTGCGAAGTGACCC

CCAAAGTGGACAAGAAGGTCGAACC

ACCAGGGCCTGAGCAGCCCAGTGA

CAAGTCCTGCGACAAGACTCACACCT

CGAAGTCCTTCAACCGGGGAGAAT

GTCCGCCTTGTCCAGCCCCTGAGCTG

GC

CTGGGTGGTCCGTCCGTGTTCCTCTT

CCCGCCCAAGCCGAAGGACACTCTG

ATGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAAG

AACAGTACAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGCT

CTCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTATACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAACC

GGAGAACAACTACAAGACCACCCCA

CCGGTGCTCGATTCCGATGGCTCCTT

CTTCCTGTACTCCAAGCTGACTGTGG

ACAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCACG

AAGCGCTGCACAACCATTACACCCA

GAAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1800
CTGAGGTGAGGAAGCCTGGGGCCTC
1908
CCACCCTGTCTTTGTCTCCAGGGGA

AGTGAAGGTCTCCTGCAAGGCTTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GTTACACATTTACCAGTTATGCCATC

CAGTCAGAGTGTTGGTACCAATTT

AGCTGGGTGCGACAGGCCCCTGGAC

AGCCTGGTACCAGCAGAAACCTGG

AAGGGCTTGAGTGGATGGGGTGGAT

CCAGGCTCCCAGGCTCCTCATCTAT

CAGCGCTTACGACGGTAACACAAAC

GATGCATCCAACAGGGCCACTGGC

TATGCACAGAAGCTCCAGGGCAGAG

ATCCCAGCCAGGTTCAGTGGCAGT

TCACCATGACCACAGACACATCCAC

GGGTCTGGGACAGAGTTCACTCTC

GAGCACAGCCTACATGGAGGTGAGG

ACCATCAGCAGCCTGCAGTCTGAA

AGCCTGAGATCTGACGACACGGCCG

GATTTTGCAGTTTATTACTGTCAGC

TGTATTACTGTGCGAGAGATGGTACG

AGTATAATAACTGGCCTCCGATAA

GTCCGAAGGGTAGTGGGAGCTACTA

CTTTCGGCGGAGGGACCAAGCTGG

CCCCTGGAAACTTTGACTACAGGGGC

AGATCAAACGTACTGTGGCTGCTC

CAGGGAACCCTGGTCACCGTCTCCTC

CCTCCGTGTTCATTTTTCCTCCGTC

AGCATCCACCAAGGGGCCTTCCGTGT

GGACGAACAGCTGAAGTCCGGAAC

TCCCCCTGGCCCCTTCATCCAAGTCG

CGCGTCCGTGGTCTGTCTCCTGAAC

ACCTCTGGTGGAACCGCCGCACTCGG

AACTTCTATCCGCGCGAGGCGAAA

TTGCCTGGTCAAAGACTACTTCCCCG

GTGCAGTGGAAGGTCGACAACGCA

AGCCCGTGACTGTCTCGTGGAACTCG

CTGCAGTCGGGAAACTCCCAGGAA

GGCGCCCTCACATCCGGAGTGCATAC

TCGGTGACCGAGCAGGACTCGAAG

CTTTCCCGCCGTGTTGCAGTCCAGCG

GACTCAACCTACTCATTGTCCTCCA

GCCTGTACAGCCTGAGCTCCGTCGTG

CCCTCACCCTGAGCAAGGCCGATT

ACAGTGCCGTCCTCCTCCCTTGGAAC

ACGAGAAGCATAAGGTCTACGCCT

CCAGACCTATATCTGCAACGTCAATC

GCGAAGTGACCCACCAGGGCCTGA

ACAAGCCCTCCAACACCAAAGTGGA

GCAGCCCAGTGACGAAGTCCTTCA

CAAGAAGGTCGAACCCAAGTCCTGC

ACCGGGGAGAATGC

GACAAGACTCACACCTGTCCGCCTTG

TCCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACAAC

TCTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAAG

TGTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTATACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAAC

TACAAGACCACCCCACCGGTGCTCG

ATTCCGATGGCTCCTTCTTCCTGTACT

CCAAGCTGACTGTGGACAAGTCAAG

ATGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTGT

CACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAC

1801
GAGGCGTGGTCCAGCCTGGGAGGTC
1909
TCTCCCTGCCCGTCACCCTTGGACA

CCTGAGACTCTCCTGTGCAGCGTCTG

GCCGGCCTCCATCTCCTGCAGGTCT

GATTCACCTTCAGTAGCTATGGCATG

AGTCAAAGCCTCGTATACAGTGAT

CACTGGGTCCGCCAGGCTCCAGGCA

GGAAACACCTACTTGAGTTGGCTT

AGGGGCTGGAGTGGGTGGCAGTTAT

CAGCAGAGGCCAGGCCAGCCTCCA

ATGGTATGATGGAAGTAATAAATAC

AGACTCCTAATTTATAAGATTTCTA

TATGCAGACTCCGTGAAGGGCCGATT

ACCGGTTCTCTGGGGTCCCAGACA

CACCATCTCCAGAGACAATTCCAAG

GATTCAGTGGCAGTGGGGCAGGGA

AACACGCTGTATCTGCAAATGAACA

CAGATTTCACACTGAAAATCAGCA

GCCTGAGAGCCGAGGACACGGCTGT

GGGTGGAAGCTGAGGATGTCGGGG

GTATTACTGTGCGAGAGATCTGAATC

TTTATTACTGCATGCAAGGTACACA

GAGGATATTGTAGTGGTGGTAGCTGC

ATTTCCTCAAACGTTCGGCCAAGG

TTTGGCTACTGGGGCCAGGGAACCCT

GACCAAGCTGGAGATCAAACGTAC

GGTCACCGTCTCCTCAGCATCCACCA

TGTGGCTGCTCCCTCCGTGTTCATT

AGGGGCCTTCCGTGTTCCCCCTGGCC

TTTCCTCCGTCGGACGAACAGCTG

CCTTCATCCAAGTCGACCTCTGGTGG

AAGTCCGGAACCGCGTCCGTGGTC

AACCGCCGCACTCGGTTGCCTGGTCA

TGTCTCCTGAACAACTTCTATCCGC

AAGACTACTTCCCCGAGCCCGTGACT

GCGAGGCGAAAGTGCAGTGGAAG

GTCTCGTGGAACTCGGGCGCCCTCAC

GTCGACAACGCACTGCAGTCGGGA

ATCCGGAGTGCATACCTTTCCCGCCG

AACTCCCAGGAATCGGTGACCGAG

TGTTGCAGTCCAGCGGCCTGTACAGC

CAGGACTCGAAGGACTCAACCTAC

CTGAGCTCCGTCGTGACAGTGCCGTC

TCATTGTCCTCCACCCTCACCCTGA

CTCCTCCCTTGGAACCCAGACCTATA

GCAAGGCCGATTACGAGAAGCATA

TCTGCAACGTCAATCACAAGCCCTCC

AGGTCTACGCCTGCGAAGTGACCC

AACACCAAAGTGGACAAGAAGGTCG

ACCAGGGCCTGAGCAGCCCAGTGA

AACCCAAGTCCTGCGACAAGACTCA

CGAAGTCCTTCAACCGGGGAGAAT

CACCTGTCCGCCTTGTCCAGCCCCTG

GC

AGCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAAG

TCACTTGCGTGGTCGTGGACGTGTCG

CACGAAGATCCCGAAGTGAAATTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTATACTTTGC

CGCCTAGCCGGGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGATG

CACGAAGCGCTGCACAACCATTACA

CCCAGAAATCACTGTCACTTTCGCCG

GGAAAA

SEQ ID
CAGGTGCAGCTGCAGGAGTCTGGGG
SEQ ID
GAAATTGTGCTGACTCAGTCTCCA

1802
GAGGCTTGGTACAGCCGGGGGGGTC
1910
GGCACCCTGTCTTTGTCTCCAGGGG

CCTGAGACTCTCCTGTGCAGCCTCTG

AAAGAGCCACCCTCTCCTGCAGGG

GATTCACCTTTAGCAGCTATGCCATG

CCAGTCAGAGTGTAATAAGCAGGT

AGCTGGGTCCGCCAGGCTCCAGGGA

ACTTAGCCTGGTATCAGCAGAAAC

AGGGGCTGGAGTGGGTTTCATACATT

CTGGCCAGGCTCCCAGGCTCCTCAT

AGTAGTAGTGGTACTACCATATACTA

CCATGGTGCATCCACCAGGGCCAC

CGCAGACTCTGTGAAGGGCCGATTC

TGGCATCCCAGACAGGTTCAGTGG

ACCGTCTCCAGAGACAATGCCAAGA

CAGTGGGTCTGGGACAGACTTCAC

ACTCACTGTATCTGCAAATGAACAGC

TCTCACCATCAGCAGACTGGAGCC

CTGAGAGCCGAGGACACGGCCGTGT

TGAAGACTTTGCAGTGTATTACTGT

ATTACTGTGCGAGGGATTATAGCAGC

CAGCAGTATGGTAGCTCACCTCCG

TCGGGGGAGTGCTTTGACTACTGGGG

TACACTTTTGGCCAGGGGACCAAG

CCAGGGAACCCTGGTCACCGTCTCCT

GTGGAAATCAAACGTACTGTGGCT

CAGCATCCACCAAGGGGCCTTCCGTG

GCTCCCTCCGTGTTCATTTTTCCTC

TTCCCCCTGGCCCCTTCATCCAAGTC

CGTCGGACGAACAGCTGAAGTCCG

GACCTCTGGTGGAACCGCCGCACTCG

GAACCGCGTCCGTGGTCTGTCTCCT

GTTGCCTGGTCAAAGACTACTTCCCC

GAACAACTTCTATCCGCGCGAGGC

GAGCCCGTGACTGTCTCGTGGAACTC

GAAAGTGCAGTGGAAGGTCGACAA

GGGCGCCCTCACATCCGGAGTGCAT

CGCACTGCAGTCGGGAAACTCCCA

ACCTTTCCCGCCGTGTTGCAGTCCAG

GGAATCGGTGACCGAGCAGGACTC

CGGCCTGTACAGCCTGAGCTCCGTCG

GAAGGACTCAACCTACTCATTGTC

TGACAGTGCCGTCCTCCTCCCTTGGA

CTCCACCCTCACCCTGAGCAAGGC

ACCCAGACCTATATCTGCAACGTCAA

CGATTACGAGAAGCATAAGGTCTA

TCACAAGCCCTCCAACACCAAAGTG

CGCCTGCGAAGTGACCCACCAGGG

GACAAGAAGGTCGAACCCAAGTCCT

CCTGAGCAGCCCAGTGACGAAGTC

GCGACAAGACTCACACCTGTCCGCCT

CTTCAACCGGGGAGAATGC

TGTCCAGCCCCTGAGCTGCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTAC

AACTCTACGTACCGGGTGGTGTCCGT

GCTGACCGTGCTGCACCAGGACTGG

CTGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTATACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGTC

CCTGACTTGCCTTGTCAAGGGCTTTT

ATCCGTCCGACATCGCCGTGGAGTGG

GAGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCTG

CACAACCATTACACCCAGAAATCACT

GTCACTTTCGCCGGGAAAA

SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG
SEQ ID
GACATCCAGTTGACCCAGTCTCCTT

1803
GAGGCGTGGTCCAGCCTGGGAGGTC
1911
CCACCCTGGCTGCATCTGTAGGAG

CCTGAGACTCTCCTGTGCAGCGTCTG

ACAGAGTCACCATCACTTGCCGGG

GATTCACCTTCAGTAGCTATGGCATG

CCAGTCAGAGTATTAGTAGCTGGT

CACTGGGTCCGCCAGGCTCCAGGCA

TGGCCTGGTATCAGCAGAAACCAG

AGGGGCTGGAGTGGGTGGCAGTTAT

GGAAAGCCCCTAAGGTCCTGATCT

ATGGTATGATGGAAGTAATAAATAC

ATAAGGCGTCTAGTTTAGAAAGTG

TATGCAGACTCCGTGAAGGGCCGATT

GGGTCCCATCAAGGTTCAGCGGCA

CACCATCTCCAGAGACAATTCCAAG

GTGGATCTGGGACAGAATTCACTC

AACACGCTGTATCTGCAAATGAACA

TCACCATCAGCAGCCTGCAGCCTG

GCCTGAGAGCCGAGGACACGGCTGT

ATGATTTTGCAACTTATTACTGCCA

GTATTACTGTGCGAGAGATCAGGCA

ACAGTATAATAGTTATTCGGGGAC

GCTATGGTAGGCTACTTTGACTACTG

GTTCGGCCAAGGGACCAAGGTGGA

GGGCCAGGGAACCCTGGTCACCGTC

AATCAAACGTACTGTGGCTGCTCC

TCCTCAGCATCCACCAAGGGGCCTTC

CTCCGTGTTCATTTTTCCTCCGTCG

CGTGTTCCCCCTGGCCCCTTCATCCA

GACGAACAGCTGAAGTCCGGAACC

AGTCGACCTCTGGTGGAACCGCCGC

GCGTCCGTGGTCTGTCTCCTGAACA

ACTCGGTTGCCTGGTCAAAGACTACT

ACTTCTATCCGCGCGAGGCGAAAG

TCCCCGAGCCCGTGACTGTCTCGTGG

TGCAGTGGAAGGTCGACAACGCAC

AACTCGGGCGCCCTCACATCCGGAGT

TGCAGTCGGGAAACTCCCAGGAAT

GCATACCTTTCCCGCCGTGTTGCAGT

CGGTGACCGAGCAGGACTCGAAGG

CCAGCGGCCTGTACAGCCTGAGCTCC

ACTCAACCTACTCATTGTCCTCCAC

GTCGTGACAGTGCCGTCCTCCTCCCT

CCTCACCCTGAGCAAGGCCGATTA

TGGAACCCAGACCTATATCTGCAACG

CGAGAAGCATAAGGTCTACGCCTG

TCAATCACAAGCCCTCCAACACCAA

CGAAGTGACCCACCAGGGCCTGAG

AGTGGACAAGAAGGTCGAACCCAAG

CAGCCCAGTGACGAAGTCCTTCAA

TCCTGCGACAAGACTCACACCTGTCC

CCGGGGAGAATGC

GCCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCACGAAG

ATCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAACG

CCAAGACCAAGCCTAGGGAAGAACA

GTACAACTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGCC

CCAGGTCTATACTTTGCCGCCTAGCC

GGGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGCT

TTTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAAG

TCAAGATGGCAGCAGGGAAACGTGT

TCTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAATC

ACTGTCACTTTCGCCGGGAAAA

SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG
SEQ ID
GATGTTGTGATGACTCAGTCTCCAG

1804
GAGGCGTGGTCCAGCCTGGGAGGTC
1912
CCATCCTGTCTGTGTCTCCAGGGGA

CCTGAGACTCTCCTGTGCAGCCTCTG

AAGAGCCACCCTCTCCTGCAGGGC

GATTCATCTTCAGTAACTATGCTATA

CAGTCAGAGTGTTAGTAGCAGCTT

CACTGGGTCCGCCAGGCTCCAGGCA

AGCCTGGTACCAGCAGAAACCTGG

AGGGGCTGGAGTGGGTGGCAGTTAT

CCAGCCTCCCAGGCTCCTCATCTAT

ATCATATGATGGAAGTAATAAATACT

GGTGCCTCCACCAGGGCCACTGCT

ACGCAGACTCCGTGAAGGGCCGATT

ATCCCAGCCAGGTTCAGTGGCAGT

CACCATCTCCAGAGACAATTCCAAG

GGGTCTGGGACAGAGTTCACTCTC

AACACGCTGTATCTGCAAATGAACA

ACCATCAGCAGCCTGCAGTCTGAA

GCCTGAGAGCTGAGGACACGGCTGT

GATTTTGCAGTTTATTACTGTCAGC

GTATTACTGTGCGAGGACTTTTGCGG

GCTATGATAACTGGCCTCCCCTTTT

GGTATAGCAGCAAACTGGGGTACTT

TGGCCAGGGGACCAAGCTGGAGAT

CGATCTCTGGGGCCGTGGCACCCTGG

CAAACGTACTGTGGCTGCTCCCTCC

TCACCGTCTCCTCAGCATCCACCAAG

GTGTTCATTTTTCCTCCGTCGGACG

GGGCCTTCCGTGTTCCCCCTGGCCCC

AACAGCTGAAGTCCGGAACCGCGT

TTCATCCAAGTCGACCTCTGGTGGAA

CCGTGGTCTGTCTCCTGAACAACTT

CCGCCGCACTCGGTTGCCTGGTCAAA

CTATCCGCGCGAGGCGAAAGTGCA

GACTACTTCCCCGAGCCCGTGACTGT

GTGGAAGGTCGACAACGCACTGCA

CTCGTGGAACTCGGGCGCCCTCACAT

GTCGGGAAACTCCCAGGAATCGGT

CCGGAGTGCATACCTTTCCCGCCGTG

GACCGAGCAGGACTCGAAGGACTC

TTGCAGTCCAGCGGCCTGTACAGCCT

AACCTACTCATTGTCCTCCACCCTC

GAGCTCCGTCGTGACAGTGCCGTCCT

ACCCTGAGCAAGGCCGATTACGAG

CCTCCCTTGGAACCCAGACCTATATC

AAGCATAAGGTCTACGCCTGCGAA

TGCAACGTCAATCACAAGCCCTCCAA

GTGACCCACCAGGGCCTGAGCAGC

CACCAAAGTGGACAAGAAGGTCGAA

CCAGTGACGAAGTCCTTCAACCGG

CCCAAGTCCTGCGACAAGACTCACA

GGAGAATGC

CCTGTCCGCCTTGTCCAGCCCCTGAG

CTGCTGGGTGGTCCGTCCGTGTTCCT

CTTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGCA

CGAAGATCCCGAAGTGAAATTCAAT

TGGTACGTGGATGGGGTCGAAGTGC

ACAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTATACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTCC

TTCTTCCTGTACTCCAAGCTGACTGT

GGACAAGTCAAGATGGCAGCAGGGA

AACGTGTTCTCCTGCTCCGTGATGCA

CGAAGCGCTGCACAACCATTACACC

CAGAAATCACTGTCACTTTCGCCGGG

AAAA

TABLE 39

Anti-CLEC21D IgG4 antibody Variable Heavy and Light Chain

amino acid and DNA sequence

SEQ ID
VH + CH + AA_IgG4
SEQ ID
VH + CH + DNA_IgG4

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1913
YTFTSYAMHWVRQAPGQRLEWMGWI
2021
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARGSLSRSG

GGATACACCTTCACTAGCTATGCTA

WYAGLFDYWGQGTLVTVSSASTKGPS

TGCATTGGGTGCGCCAGGCCCCCGG

VFPLAPCSRSTSESTAALGCLVKDYFPE

ACAAAGGCTTGAGTGGATGGGATG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GATCAACGCTGGCAATGGTAACACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AAATATTCACAGAAGTTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATTACCAGGGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CGCGAGCACAGCCTACATGGAGCTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAAGACACG

KPREEQFNSTYRVVSVLTVLHQDWLN

GCTGTGTATTACTGTGCGAGAGGCT

GKEYKCKVSNKGLPSSIEKTISKAKGQ

CCTTGTCCCGAAGTGGCTGGTACGC

PREPQVYTLPPSQEEMTKNQVSLTCLV

CGGACTCTTTGACTACTGGGGCCAG

KGFYPSDIAVEWESNGQPENNYKTTPP

GGAACCCTGGTCACCGTCTCCTCAG

VLDSDGSFFLYSRLTVDKSRWQEGNV

CATCCACCAAGGGGCCTTCCGTGTT

FSCSVMHEALHNHYTQKSLSLSLGK

CCCCCTGGCCCCTTGCTCCCGCTCG

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QITLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

1914
TFSSYSMNWVRQAPGKGLQWVAIISD
2022
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSKSYYADSVQGRFTISRDNSRNTVF

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAMYYCARDRGTKWN

GGATTCACCTTCAGTAGTTATAGCA

QLNDVFDMWGQGTMVTVSSASTKGP

TGAACTGGGTCCGCCAGGCTCCAGG

SVFPLAPCSRSTSESTAALGCLVKDYFP

CAAGGGGCTGCAGTGGGTGGCAATT

EPVTVSWNSGALTSGVHTFPAVLQSSG

ATATCAGATGATGGAAGTAAGAGTT

LYSLSSVVTVPSSSLGTKTYTCNVDHK

ACTACGCAGACTCCGTGCAGGGCCG

PSNTKVDKRVESKYGPPCPPCPAPEFL

ATTCACCATCTCCAGAGACAATTCG

GGPSVFLFPPKPKDTLMISRTPEVTCVV

AGGAACACAGTATTTCTGCAAATGA

VDVSQEDPEVQFNWYVDGVEVHNAK

ACAGCCTGAGAGCTGAGGACACGG

TKPREEQFNSTYRVVSVLTVLHQDWL

CTATGTATTACTGTGCGAGAGACAG

NGKEYKCKVSNKGLPSSIEKTISKAKG

GGGAACTAAATGGAACCAATTGAAT

QPREPQVYTLPPSQEEMTKNQVSLTCL

GATGTTTTTGATATGTGGGGCCAAG

VKGFYPSDIAVEWESNGQPENNYKTTP

GGACAATGGTCACCGTCTCTTCAGC

PVLDSDGSFFLYSRLTVDKSRWQEGN

ATCCACCAAGGGGCCTTCCGTGTTC

VFSCSVMHEALHNHYTQKSLSLSLGK

CCCCTGGCCCCTTGCTCCCGCTCGA

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1915
YTFTSYYMHWVRQAPGQGLEWMGIIN
2023
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCARGRGYSSS

GGATACACCTTCACCAGCTACTATA

RLYYFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTGCGACAGGCCCCTGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGAAT

VTVSWNSGALTSGVHTFPAVLQSSGL

AATCAACCCTAGTGGTGGTAGCACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AGCTACGCACAGAAGTTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATGACCAGGGACACGTC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGTCTACATGGAGCTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQFNSTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCGAGAGGCC

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GAGGGTATAGCAGCAGTCGGCTCTA

PREPQVYTLPPSQEEMTKNQVSLTCLV

CTACTTTGACTACTGGGGCCAGGGA

KGFYPSDIAVEWESNGQPENNYKTTPP

ACCCTGGTCACCGTCTCCTCAGCAT

VLDSDGSFFLYSRLTVDKSRWQEGNV

CCACCAAGGGGCCTTCCGTGTTCCC

FSCSVMHEALHNHYTQKSLSLSLGK

CCTGGCCCCTTGCTCCCGCTCGACCT

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QVTLKESGGGLVRPGGSLRLSCEASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1916
TFSDPYMDWVRQAPGKGLEWVGRITN
2024
GAGGCTTGGTCCGGCCTGGAGGGTC

KRTGYATTYAASVKDRFTISRDDSRKS

CCTGAGACTCTCCTGTGAAGCCTCT

VYLQMNSLKTEDTAVYYCATDVSGSF

GGATTCACCTTCAGTGACCCCTACA

AAYGGQGTLVTVSSASTKGPSVFPLAP

TGGACTGGGTCCGCCAGGCTCCAGG

CSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTTGGCCG

WNSGALTSGVHTFPAVLQSSGLYSLSS

AATTACAAATAAGCGTACCGGTTAC

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GCCACAACATATGCCGCGTCTGTGA

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AGGACAGATTCACCATCTCAAGAGA

FPPKPKDTLMISRTPEVTCVVVDVSQE

TGATTCAAGGAAGTCAGTATATCTG

DPEVQFNWYVDGVEVHNAKTKPREE

CAAATGAACAGCCTGAAGACCGAG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GACACGGCCGTATATTATTGTGCAA

CKVSNKGLPSSIEKTISKAKGQPREPQV

CAGATGTCAGTGGGTCCTTCGCGGC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CTACGGGGGCCAGGGCACCCTGGTC

DIAVEWESNGQPENNYKTTPPVLDSD

ACCGTCTCCTCAGCATCCACCAAGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GGCCTTCCGTGTTCCCCCTGGCCCCT

MHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

1917
FTFSSYAMHWVRQAPGQRLEWMGWI
2025
GAGGCGTGGTCCAGCCTGGGAGGTC

NAGNGNTKYSQKFQGRVTITRDTSAST

CCTGAGACTCTCCTGTGCAGCGTCT

AYMELSSLRSEDTAVYYCAGEGGAVA

GGATTCACCTTCAGTAGCTATGCTA

GTVYWGQGTLVTVSSASTKGPSVFPL

TGCATTGGGTGCGCCAGGCCCCCGG

APCSRSTSESTAALGCLVKDYFPEPVT

ACAAAGGCTTGAGTGGATGGGATG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GATCAACGCTGGCAATGGTAACACA

SSVVTVPSSSLGTKTYTCNVDHKPSNT

AAATATTCACAGAAGTTCCAGGGCA

KVDKRVESKYGPPCPPCPAPEFLGGPS

GAGTCACCATTACCAGGGACACATC

VFLFPPKPKDTLMISRTPEVTCVVVDV

CGCGAGCACAGCCTACATGGAGCTG

SQEDPEVQFNWYVDGVEVHNAKTKP

AGCAGCCTGAGATCTGAAGACACG

REEQFNSTYRVVSVLTVLHQDWLNGK

GCTGTGTATTACTGTGCGGGAGAGG

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GCGGAGCAGTGGCTGGTACTGTCTA

PQVYTLPPSQEEMTKNQVSLTCLVKGF

CTGGGGCCAGGGAACCCTGGTCACC

YPSDIAVEWESNGQPENNYKTTPPVLD

GTCTCCTCAGCATCCACCAAGGGGC

SDGSFFLYSRLTVDKSRWQEGNVFSCS

CTTCCGTGTTCCCCCTGGCCCCTTGC

VMHEALHNHYTQKSLSLSLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

1918
FTFSNAWMSWVRQAPGKGLEWVGRI
2026
GAGGCTTGGTAAAGCCTGGGGGGTC

KSKTDGGTTDYAAPVKGRFTISRDDSK

CCTTAGACTCTCCTGTGCAGCCTCTG

NTLYLQMNSLKTEDTAVYYCTTDEYF

GATTCACTTTCAGTAACGCCTGGAT

YWGQGTLVTVSSASTKGPSVFPLAPCS

GAGCTGGGTCCGCCAGGCTCCAGGG

RSTSESTAALGCLVKDYFPEPVTVSWN

AAGGGGCTGGAGTGGGTTGGCCGTA

SGALTSGVHTFPAVLQSSGLYSLSSVV

TTAAAAGCAAAACTGATGGTGGGAC

TVPSSSLGTKTYTCNVDHKPSNTKVDK

AACAGACTACGCTGCACCCGTGAAA

RVESKYGPPCPPCPAPEFLGGPSVFLFP

GGCAGATTCACCATCTCAAGAGATG

PKPKDTLMISRTPEVTCVVVDVSQEDP

ATTCAAAAAACACGCTGTATCTGCA

EVQFNWYVDGVEVHNAKTKPREEQF

AATGAACAGCCTGAAAACCGAGGA

NSTYRVVSVLTVLHQDWLNGKEYKC

CACAGCCGTGTATTACTGTACCACA

KVSNKGLPSSIEKTISKAKGQPREPQVY

GACGAGTATTTCTACTGGGGCCAGG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GAACCCTGGTCACCGTCTCCTCAGC

IAVEWESNGQPENNYKTTPPVLDSDGS

ATCCACCAAGGGGCCTTCCGTGTTC

FFLYSRLTVDKSRWQEGNVFSCSVMH

CCCCTGGCCCCTTGCTCCCGCTCGA

EALHNHYTQKSLSLSLGK

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1919
GSFSGYYWSWIRQPPGKGLEWIGEINH
2027
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARVNPGSYTREV

GGTGGGTCCTTCAGTGGTTACTACT

SNFDYWGQGTLVTVSSASTKGPSVFPL

GGAGCTGGATCCGCCAGCCCCCAGG

APCSRSTSESTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGATTGGGGA

VSWNSGALTSGVHTFPAVLQSSGLYSL

AATCAATCATAGTGGAAGCACCAAC

SSVVTVPSSSLGTKTYTCNVDHKPSNT

TACAACCCGTCCCTCAAGAGTCGAG

KVDKRVESKYGPPCPPCPAPEFLGGPS

TCACCATATCAGTAGACACGTCCAA

VFLFPPKPKDTLMISRTPEVTCVVVDV

GAACCAGTTCTCCCTGAAGCTGAGC

SQEDPEVQFNWYVDGVEVHNAKTKP

TCTGTGACCGCCGCGGACACGGCTG

REEQFNSTYRVVSVLTVLHQDWLNGK

TGTATTACTGTGCGAGAGTAAATCC

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GGGGAGTTATACGAGGGAGGTGAG

PQVYTLPPSQEEMTKNQVSLTCLVKGF

CAACTTTGACTACTGGGGCCAGGGA

YPSDIAVEWESNGQPENNYKTTPPVLD

ACCCTGGTGACCGTCTCCTCAGCAT

SDGSFFLYSRLTVDKSRWQEGNVFSCS

CCACCAAGGGGCCTTCCGTGTTCCC

VMHEALHNHYTQKSLSLSLGK

CCTGGCCCCTTGCTCCCGCTCGACCT

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QVQLQQSGPELVKPSQTLTLTCGISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1920
SVSSNSVTWNWVRQSPSRGLEWLGRT
2028
CAGAATTGGTGAAGCCCTCGCAGAC

YYRSQWYYNYAVSVKSRITISPDTSKN

CCTCACACTCACCTGTGGCATCTCC

QFSLQLNSVTPEDTAVYYCATRGHNY

GGGGACAGTGTCTCTAGCAACAGTG

GVDYWGPGTTVTVSSASTKGPSVFPL

TTACTTGGAACTGGGTCAGGCAGTC

APCSRSTSESTAALGCLVKDYFPEPVT

CCCATCGAGAGGCCTTGAGTGGCTG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GGAAGGACTTACTACCGGTCCCAGT

SSVVTVPSSSLGTKTYTCNVDHKPSNT

GGTATTATAATTATGCGGTGTCTGT

KVDKRVESKYGPPCPPCPAPEFLGGPS

GAAAAGTCGAATAACCATCAGCCCA

VFLFPPKPKDTLMISRTPEVTCVVVDV

GACACATCCAAGAACCAGTTCTCCC

SQEDPEVQFNWYVDGVEVHNAKTKP

TGCAGTTGAATTCTGTGACTCCCGA

REEQFNSTYRVVSVLTVLHQDWLNGK

GGACACGGCTGTCTATTACTGTGCA

EYKCKVSNKGLPSSIEKTISKAKGQPRE

ACCAGGGGACATAACTACGGTGTAG

PQVYTLPPSQEEMTKNQVSLTCLVKGF

ATTACTGGGGCCCGGGGACCACGGT

YPSDIAVEWESNGQPENNYKTTPPVLD

CACCGTCTCCTCAGCATCCACCAAG

SDGSFFLYSRLTVDKSRWQEGNVFSCS

GGGCCTTCCGTGTTCCCCCTGGCCC

VMHEALHNHYTQKSLSLSLGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1921
FTFSNAWMSWVRQAPGKGLEWVCRI
2029
GAGGCTTGGTAAAGCCTGGGGGGTC

KSKTDGETTDYAAPVKGRFTISRDDSK

CCTTAGACTCTCCTGTGCAGCCTCTG

NTLYLQMNSLKTEDTAVYHCTTGVG

GATTCACTTTCAGTAACGCCTGGAT

WSPFQYWGQGTLVTVSSASTKGPSVF

GAGCTGGGTCCGCCAGGCTCCAGGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

AAGGGGCTGGAGTGGGTTTGCCGTA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAAAAGCAAAACTGATGGTGAGAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACAGACTACGCTGCACCCGTGAAA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GGCAGATTCACCATCTCAAGAGATG

SVFLFPPKPKDTLMISRTPEVTCVVVD

ATTCAAAAAACACGCTGTATCTGCA

VSQEDPEVQFNWYVDGVEVHNAKTK

AATGAACAGCCTGAAAACTGAGGA

PREEQFNSTYRVVSVLTVLHQDWLNG

CACAGCCGTGTATCACTGTACCACA

KEYKCKVSNKGLPSSIEKTISKAKGQP

GGGGTGGGATGGTCGCCCTTCCAAT

REPQVYTLPPSQEEMTKNQVSLTCLVK

ACTGGGGCCAGGGCACCCTGGTCAC

GFYPSDIAVEWESNGQPENNYKTTPPV

CGTCTCCTCAGCATCCACCAAGGGG

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCTTCCGTGTTCCCCCTGGCCCCTTG

CSVMHEALHNHYTQKSLSLSLGK

CTCCCGCTCGACCTCTGAATCCACC

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCAAGACCT

ATACCTGCAACGTCGACCACAAGCC

CTCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

1922
TFGDYAMSWFRQAPGKGLEWVGFIRS
2030
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRDDKIAA

GGATTCACCTTTGGTGATTATGCTAT

AGFTYWYFDLWGRGTLVTVSSASTKG

GAGCTGGTTCCGCCAGGCTCCAGGG

PSVFPLAPCSRSTSESTAALGCLVKDYF

AAGGGGCTGGAGTGGGTAGGTTTCA

PEPVTVSWNSGALTSGVHTFPAVLQSS

TTAGAAGCAAAGCTTATGGTGGGAC

GLYSLSSVVTVPSSSLGTKTYTCNVDH

AACAGAATACGCCGCGTCTGTGAAA

KPSNTKVDKRVESKYGPPCPPCPAPEF

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAAAAGCATCGCCTATCTGCA

VVDVSQEDPEVQFNWYVDGVEVHNA

AATGAACAGCCTGAAAACCGAGGA

KTKPREEQFNSTYRVVSVLTVLHQDW

CACAGCCGTGTATTACTGTACTAGA

LNGKEYKCKVSNKGLPSSIEKTISKAK

GACGACAAAATAGCAGCAGCTGGA

GQPREPQVYTLPPSQEEMTKNQVSLTC

TTCACATACTGGTACTTCGATCTCTG

LVKGFYPSDIAVEWESNGQPENNYKT

GGGCCGTGGCACCCTGGTCACCGTC

TPPVLDSDGSFFLYSRLTVDKSRWQEG

TCCTCAGCATCCACCAAGGGGCCTT

NVFSCSVMHEALHNHYTQKSLSLSLG

CCGTGTTCCCCCTGGCCCCTTGCTCC

K

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1923
YTFAAYYLHWVRQAPGQGLEWMGRI
2031
CTGAGGTGAAGAAGCCTGGGGCCTC

SPGNGVTSYAQKFQGRVTMTGDTSIN

AGTGAAGGTCTCCTGCAAGGCTTCT

TVYMQLNNLISGDTAVYYCAREAADD

GGATACACCTTCGCCGCCTATTATTT

PFDHWGQGALVTVSSASTKGPSVFPLA

ACACTGGGTGCGACAGGCCCCTGGA

PCSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGCCTTGAGTGGATGGGGCGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATCAGCCCTGGTAACGGTGTCACAA

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GTTATGCACAGAAATTTCAGGGCAG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AGTCACCATGACCGGGGACACGTCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

ATTAACACAGTCTACATGCAACTGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAATTTGATTTCTGGCGACACGGC

QFNSTYRVVSVLTVLHQDWLNGKEYK

CGTATATTACTGTGCGAGAGAGGCT

CKVSNKGLPSSIEKTISKAKGQPREPQV

GCCGACGACCCGTTTGACCATTGGG

YTLPPSQEEMTKNQVSLTCLVKGFYPS

GCCAGGGAGCCCTGGTCACCGTCTC

DIAVEWESNGQPENNYKTTPPVLDSD

CTCAGCATCCACCAAGGGGCCTTCC

GSFFLYSRLTVDKSRWQEGNVFSCSV

GTGTTCCCCCTGGCCCCTTGCTCCCG

MHEALHNHYTQKSLSLSLGK

CTCGACCTCTGAATCCACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCAAGACCTATACCT

GCAACGTCGACCACAAGCCCTCCAA

CACCAAAGTGGACAAGCGCGTCGA

ATCCAAGTACGGCCCCCCTTGTCCG

CCTTGTCCAGCCCCTGAGTTCCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCAGGAA

GATCCCGAAGTGCAGTTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTTCAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GGCCTCCCTTCATCCATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCAAGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCCGGC

TGACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLTLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1924
FTFSSHLMHWVRQAPGKGLEWVAVIS
2032
GAGGCGTGGTCCAGCCTGGGAGGTC

YDGTSKYYGDSVKGRFTISRDNSKNTL

CCTGACACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAIYYCAKADYKYD

GGATTCACCTTCAGTTCCCATCTTAT

WGQGTLVTVSSASTKGPSVFPLAPCSR

GCACTGGGTCCGCCAGGCTCCAGGC

STSESTAALGCLVKDYFPEPVTVSWNS

AAGGGGCTGGAGTGGGTGGCAGTT

GALTSGVHTFPAVLQSSGLYSLSSVVT

ATATCATATGATGGAACTAGTAAAT

VPSSSLGTKTYTCNVDHKPSNTKVDK

ATTACGGAGACTCCGTGAAGGGCCG

RVESKYGPPCPPCPAPEFLGGPSVFLFP

CTTCACCATCTCCAGAGACAATTCC

PKPKDTLMISRTPEVTCVVVDVSQEDP

AAGAACACGTTGTATCTGCAAATGA

EVQFNWYVDGVEVHNAKTKPREEQF

ACAGCCTGCGAGCTGAAGACACGG

NSTYRVVSVLTVLHQDWLNGKEYKC

CTATATATTACTGTGCGAAAGCAGA

KVSNKGLPSSIEKTISKAKGQPREPQVY

TTATAAATATGACTGGGGCCAGGGA

TLPPSQEEMTKNQVSLTCLVKGFYPSD

ACCCTGGTCACCGTCTCCTCAGCAT

IAVEWESNGQPENNYKTTPPVLDSDGS

CCACCAAGGGGCCTTCCGTGTTCCC

FFLYSRLTVDKSRWQEGNVFSCSVMH

CCTGGCCCCTTGCTCCCGCTCGACCT

EALHNHYTQKSLSLSLGK

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCTASGF
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

1925
TFGDYAMSWVRQAPGKGLEWVGFIRS
2033
GAGGCTTGGTCAAGCCTGGAGGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTTHRRPIY

GGATTCACCTTTGGTGATTATGCTAT

DILTGFDYWGQGTLVTVSSASTKGPSV

GAGCTGGGTCCGCCAGGCTCCAGGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

AAGGGGCTGGAGTGGGTAGGTTTCA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAAGCAAAGCTTATGGTGGGAC

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AACAGAATACGCCGCGTCTGTGAAA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GGCAGATTCACCATCTCAAGAGATG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ATTCCAAAAGCATCGCCTATCTGCA

DVSQEDPEVQFNWYVDGVEVHNAKT

AATGAACAGCCTGAAAACCGAGGA

KPREEQFNSTYRVVSVLTVLHQDWLN

CACAGCCGTGTATTACTGTACTACT

GKEYKCKVSNKGLPSSIEKTISKAKGQ

CATAGACGCCCAATTTACGATATTT

PREPQVYTLPPSQEEMTKNQVSLTCLV

TGACTGGTTTTGACTACTGGGGCCA

KGFYPSDIAVEWESNGQPENNYKTTPP

GGGAACCCTGGTCACCGTCTCCTCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

GCATCCACCAAGGGGCCTTCCGTGT

FSCSVMHEALHNHYTQKSLSLSLGK

TCCCCCTGGCCCCTTGCTCCCGCTCG

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QLQLQESGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG

1926
TFGDYAMSWVRQAPGKGLEWVGFIRS
2034
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTREDTMV

GGATTCACCTTTGGTGATTATGCTAT

RGVIPWGQGTLVTVSSASTKGPSVFPL

GAGCTGGGTCCGCCAGGCTCCAGGG

APCSRSTSESTAALGCLVKDYFPEPVT

AAGGGGCTGGAGTGGGTAGGTTTCA

VSWNSGALTSGVHTFPAVLQSSGLYSL

TTAGAAGCAAAGCTTATGGTGGGAC

SSVVTVPSSSLGTKTYTCNVDHKPSNT

AACAGAATACGCCGCGTCTGTGAAA

KVDKRVESKYGPPCPPCPAPEFLGGPS

GGCAGATTCACCATCTCAAGAGATG

VFLFPPKPKDTLMISRTPEVTCVVVDV

ATTCCAAAAGCATCGCCTATCTGCA

SQEDPEVQFNWYVDGVEVHNAKTKP

AATGAACAGCCTGAAAACCGAGGA

REEQFNSTYRVVSVLTVLHQDWLNGK

CACAGCCGTGTATTACTGTACTAGA

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GAGGATACTATGGTTCGGGGAGTTA

PQVYTLPPSQEEMTKNQVSLTCLVKGF

TTCCCTGGGGCCAGGGAACCCTGGT

YPSDIAVEWESNGQPENNYKTTPPVLD

CACCGTCTCCTCAGCATCCACCAAG

SDGSFFLYSRLTVDKSRWQEGNVFSCS

GGGCCTTCCGTGTTCCCCCTGGCCC

VMHEALHNHYTQKSLSLSLGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QLQLQESGSGLVKPSQTLSLTCAVSGG
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGCT

1927
SISSGGYSWSWIRQPPGKGLEWIGYIY
2035
CAGGACTGGTGAAGCCTTCACAGAC

HSGSTYYNPSLKSRVTISVDRSKNQFSL

CCTGTCCCTCACCTGCGCTGTCTCTG

KLSSVTAADTAVYYCARDRRYYDSSG

GTGGCTCCATCAGCAGTGGTGGTTA

YYPAYYFDYWGQGTLVTVSSASTKGP

CTCCTGGAGCTGGATCCGGCAGCCA

SVFPLAPCSRSTSESTAALGCLVKDYFP

CCAGGGAAGGGCCTGGAGTGGATT

EPVTVSWNSGALTSGVHTFPAVLQSSG

GGGTACATCTATCATAGTGGGAGCA

LYSLSSVVTVPSSSLGTKTYTCNVDHK

CCTACTACAACCCGTCCCTCAAGAG

PSNTKVDKRVESKYGPPCPPCPAPEFL

TCGAGTCACCATATCAGTAGACAGG

GGPSVFLFPPKPKDTLMISRTPEVTCVV

TCCAAGAACCAGTTCTCCCTGAAGC

VDVSQEDPEVQFNWYVDGVEVHNAK

TGAGCTCTGTGACCGCCGCGGACAC

TKPREEQFNSTYRVVSVLTVLHQDWL

GGCTGTGTATTACTGTGCGAGAGAT

NGKEYKCKVSNKGLPSSIEKTISKAKG

CGGCGTTACTATGATAGTAGTGGTT

QPREPQVYTLPPSQEEMTKNQVSLTCL

ATTATCCCGCCTACTACTTTGACTAC

VKGFYPSDIAVEWESNGQPENNYKTTP

TGGGGCCAGGGAACCCTGGTCACCG

PVLDSDGSFFLYSRLTVDKSRWQEGN

TCTCCTCAGCATCCACCAAGGGGCC

VFSCSVMHEALHNHYTQKSLSLSLGK

TTCCGTGTTCCCCCTGGCCCCTTGCT

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1928
FTFSSYSMNWVRQAPGKGLEWVSYIS
2036
GAGGCCTGGTCAAGCCTGGGGGGTC

SSGSYTNYADSVKGRFTISRDNAKNSL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQINSLRAEDTAIYYCARDGGYDSSG

GGATTCACCTTCAGTAGCTATAGCA

FHFDYWGQGTLVTVSSASTKGPSVFPL

TGAACTGGGTCCGCCAGGCTCCAGG

APCSRSTSESTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGGTTTCATAC

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTAGTAGTAGTGGTAGTTACACAA

SSVVTVPSSSLGTKTYTCNVDHKPSNT

ACTACGCAGACTCTGTGAAGGGCCG

KVDKRVESKYGPPCPPCPAPEFLGGPS

ATTCACCATCTCCAGAGACAACGCC

VFLFPPKPKDTLMISRTPEVTCVVVDV

AAGAACTCACTGTATCTGCAAATAA

SQEDPEVQFNWYVDGVEVHNAKTKP

ACAGCCTGAGAGCCGAGGACACGG

REEQFNSTYRVVSVLTVLHQDWLNGK

CCATTTATTACTGTGCGAGAGACGG

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GGGCTATGATAGTAGTGGTTTTCAC

PQVYTLPPSQEEMTKNQVSLTCLVKGF

TTTGACTACTGGGGCCAGGGAACCC

YPSDIAVEWESNGQPENNYKTTPPVLD

TGGTCACCGTCTCCTCAGCATCCAC

SDGSFFLYSRLTVDKSRWQEGNVFSCS

CAAGGGGCCTTCCGTGTTCCCCCTG

VMHEALHNHYTQKSLSLSLGK

GCCCCTTGCTCCCGCTCGACCTCTG

AATCCACCGCCGCACTCGGTTGCCT

GGTCAAAGACTACTTCCCCGAGCCC

GTGACTGTCTCGTGGAACTCGGGCG

CCCTCACATCCGGAGTGCATACCTT

TCCCGCCGTGTTGCAGTCCAGCGGC

CTGTACAGCCTGAGCTCCGTCGTGA

CAGTGCCGTCCTCCTCCCTTGGAAC

CAAGACCTATACCTGCAACGTCGAC

CACAAGCCCTCCAACACCAAAGTGG

ACAAGCGCGTCGAATCCAAGTACGG

CCCCCCTTGTCCGCCTTGTCCAGCCC

CTGAGTTCCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCAGGAAGATCCCGAAGTG

CAGTTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTTCAACTC

TACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAG

TGTCAAACAAGGGCCTCCCTTCATC

CATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1929
SVSNNRAAWNWIRQSPSRGLEWLGRT
2037
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNEYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSMTPEDSAVYYCAILPSSGY

GGGACAGTGTCTCTAACAACAGGGC

LQDHHYYGMDVWGQGTTVTVSSAST

TGCTTGGAACTGGATCAGGCAGTCG

KGPSVFPLAPCSRSTSESTAALGCLVK

CCATCGAGAGGCCTTGAGTGGCTGG

DYFPEPVTVSWNSGALTSGVHTFPAVL

GAAGGACATACTACAGGTCCAAGTG

QSSGLYSLSSVVTVPSSSLGTKTYTCN

GTATAATGAATATGCAGTCTCTGTG

VDHKPSNTKVDKRVESKYGPPCPPCPA

AAAAGTCGAATAACCATCAACCCAG

PEFLGGPSVFLFPPKPKDTLMISRTPEV

ACACATCCAAGAACCAGTTCTCCCT

TCVVVDVSQEDPEVQFNWYVDGVEV

GCAGCTGAACTCTATGACTCCCGAG

HNAKTKPREEQFNSTYRVVSVLTVLH

GACTCGGCTGTGTATTACTGTGCAA

QDWLNGKEYKCKVSNKGLPSSIEKTIS

TTTTGCCTAGTAGTGGTTATCTACAG

KAKGQPREPQVYTLPPSQEEMTKNQV

GACCACCACTACTACGGTATGGACG

SLTCLVKGFYPSDIAVEWESNGQPENN

TCTGGGGCCAAGGGACCACGGTCAC

YKTTPPVLDSDGSFFLYSRLTVDKSRW

CGTCTCCTCAGCATCCACCAAGGGG

QEGNVFSCSVMHEALHNHYTQKSLSL

CCTTCCGTGTTCCCCCTGGCCCCTTG

SLGK

CTCCCGCTCGACCTCTGAATCCACC

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCAAGACCT

ATACCTGCAACGTCGACCACAAGCC

CTCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG

1930
YTFTSYGISWVRQAPGQGLEWMGWIS
2038
CTGAGGTGAAGAAGCCTGGGGCCTC

AYNGNTNYAQKLQGRVTMTTDTSTST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARAAVGDG

GGTTACACCTTTACCAGCTACGGTA

YSYGRLDWGQGTLVTVSSASTKGPSV

TCAGCTGGGTGCGACAGGCCCCTGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGATG

VTVSWNSGALTSGVHTFPAVLQSSGL

GATCAGCGCTTACAATGGTAACACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AACTATGCACAGAAGCTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATGACCACAGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGCCTACATGGAGCTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQFNSTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCGAGAGCCG

GKEYKCKVSNKGLPSSIEKTISKAKGQ

CGGTGGGGGATGGATACAGCTATGG

PREPQVYTLPPSQEEMTKNQVSLTCLV

TCGGCTCGATTGGGGCCAGGGAACC

KGFYPSDIAVEWESNGQPENNYKTTPP

CTGGTCACCGTCTCCTCAGCATCCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

CCAAGGGGCCTTCCGTGTTCCCCCT

FSCSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG

1931
SFTSYWIGWVRQMPGKGLEWMGIIYP
2039
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARLPSYYYDSS

TGGATACAGCTTTACCAGCTACTGG

GYFTWYFDLWGRGTLVTVSSASTKGP

ATCGGCTGGGTGCGCCAGATGCCCG

SVFPLAPCSRSTSESTAALGCLVKDYFP

GGAAAGGCCTGGAGTGGATGGGGA

EPVTVSWNSGALTSGVHTFPAVLQSSG

TCATCTATCCTGGTGACTCTGATACC

LYSLSSVVTVPSSSLGTKTYTCNVDHK

AGATACAGCCCGTCCTTCCAAGGCC

PSNTKVDKRVESKYGPPCPPCPAPEFL

AGGTCACCATCTCAGCCGACAAGTC

GGPSVFLFPPKPKDTLMISRTPEVTCVV

CATCAGCACCGCCTACCTGCAGTGG

VDVSQEDPEVQFNWYVDGVEVHNAK

AGCAGCCTGAAGGCCTCGGACACCG

TKPREEQFNSTYRVVSVLTVLHQDWL

CCATGTATTACTGTGCGAGACTCCC

NGKEYKCKVSNKGLPSSIEKTISKAKG

CTCGTATTACTATGATAGTAGTGGT

QPREPQVYTLPPSQEEMTKNQVSLTCL

TACTTTACCTGGTACTTCGATCTCTG

VKGFYPSDIAVEWESNGQPENNYKTTP

GGGCCGTGGCACCCTGGTGACCGTC

PVLDSDGSFFLYSRLTVDKSRWQEGN

TCTTCAGCATCCACCAAGGGGCCTT

VFSCSVMHEALHNHYTQKSLSLSLGK

CCGTGTTCCCCCTGGCCCCTTGCTCC

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG

1932
YTFTSYGISWVRQAPGQGLEWMGWII
2040
CTGAGGTGAAGAAGCCTGGGGCCTC

PIFGIANYAQKFQGRVTITADKSTSTAY

AGTGAAGGTCTCCTGCAAGGCTTCT

MELSSLRSEDTAVYYCARELYNYGSK

GGTTACACCTTTACCAGCTATGGTA

DYFDYWGQGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGATG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATCTTTGGTATAGCA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACTACGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACGATTACCGCGGACAAATC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CACGAGCACAGCCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCGAGAGAAC

KEYKCKVSNKGLPSSIEKTISKAKGQP

TATACAACTATGGTTCAAAGGACTA

REPQVYTLPPSQEEMTKNQVSLTCLVK

CTTTGACTACTGGGGCCAGGGAACC

GFYPSDIAVEWESNGQPENNYKTTPPV

CTGGTCACCGTCTCCTCAGCATCCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCAAGGGGCCTTCCGTGTTCCCCCT

CSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG

1933
SFTSYWIGWVRQMPGKGLEWMGIIYP
2041
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARGGTWDTAM

TGGATACAGCTTTACCAGCTACTGG

VTGFDYWGQGTLVTVSSASTKGPSVF

ATCGGCTGGGTGCGCCAGATGCCCG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GGAAAGGCCTGGAGTGGATGGGGA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TCATCTATCCTGGTGACTCTGATACC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AGATACAGCCCGTCCTTCCAAGGCC

TKVDKRVESKYGPPCPPCPAPEFLGGP

AGGTCACCATCTCAGCCGACAAGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATCAGCACCGCCTACCTGCAGTGG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAAGGCCTCGGACACCG

PREEQFNSTYRVVSVLTVLHQDWLNG

CCATGTATTACTGTGCGAGGGGCGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

TACTTGGGATACAGCTATGGTTACG

REPQVYTLPPSQEEMTKNQVSLTCLVK

GGCTTTGACTACTGGGGCCAGGGAA

GFYPSDIAVEWESNGQPENNYKTTPPV

CCCTGGTCACCGTCTCCTCAGCATC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CACCAAGGGGCCTTCCGTGTTCCCC

CSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG

1934
SFTSYWIAWVRQMPGKGLEWMGVIYP
2042
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSINTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARPHYDILTGS

TGGATACAGCTTTACCAGCTACTGG

RAPFDYWGQGTLVTVSSASTKGPSVFP

ATCGCCTGGGTGCGCCAGATGCCCG

LAPCSRSTSESTAALGCLVKDYFPEPV

GGAAAGGCCTGGAGTGGATGGGGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

TCATCTATCCTGGTGACTCTGATACC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AGATACAGCCCGTCCTTCCAAGGCC

TKVDKRVESKYGPPCPPCPAPEFLGGP

AGGTCACCATCTCAGCCGACAAGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATCAATACCGCCTACCTGCAGTGG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAAGGCCTCGGACACCG

PREEQFNSTYRVVSVLTVLHQDWLNG

CCATGTATTACTGTGCGAGACCCCA

KEYKCKVSNKGLPSSIEKTISKAKGQP

TTACGATATTTTGACTGGTTCCCGG

REPQVYTLPPSQEEMTKNQVSLTCLVK

GCGCCCTTTGACTACTGGGGCCAGG

GFYPSDIAVEWESNGQPENNYKTTPPV

GAACCCTGGTCACCGTCTCCTCAGC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

ATCCACCAAGGGGCCTTCCGTGTTC

CSVMHEALHNHYTQKSLSLSLGK

CCCCTGGCCCCTTGCTCCCGCTCGA

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1935
GSFSGYYWSWIRQPPGKGLEWIGEINH
2043
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARARVESKDGYF

GGTGGGTCCTTCAGTGGTTACTACT

DYWGQGTLVTVSSASTKGPSVFPLAPC

GGAGCTGGATCCGCCAGCCCCCAGG

SRSTSESTAALGCLVKDYFPEPVTVSW

GAAGGGGCTGGAGTGGATTGGGGA

NSGALTSGVHTFPAVLQSSGLYSLSSV

AATCAATCATAGTGGAAGCACCAAC

VTVPSSSLGTKTYTCNVDHKPSNTKVD

TACAACCCGTCCCTCAAGAGTCGAG

KRVESKYGPPCPPCPAPEFLGGPSVFLF

TCACCATATCAGTAGACACGTCCAA

PPKPKDTLMISRTPEVTCVVVDVSQED

GAACCAGTTCTCCCTGAAGCTGAGC

PEVQFNWYVDGVEVHNAKTKPREEQF

TCTGTGACCGCCGCGGACACGGCTG

NSTYRVVSVLTVLHQDWLNGKEYKC

TGTATTACTGTGCGAGAGCCCGAGT

KVSNKGLPSSIEKTISKAKGQPREPQVY

GGAATCCAAGGATGGGTACTTTGAC

TLPPSQEEMTKNQVSLTCLVKGFYPSD

TACTGGGGCCAGGGAACCCTGGTCA

IAVEWESNGQPENNYKTTPPVLDSDGS

CCGTCTCCTCAGCATCCACCAAGGG

FFLYSRLTVDKSRWQEGNVFSCSVMH

GCCTTCCGTGTTCCCCCTGGCCCCTT

EALHNHYTQKSLSLSLGK

GCTCCCGCTCGACCTCTGAATCCAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCAAGACC

TATACCTGCAACGTCGACCACAAGC

CCTCCAACACCAAAGTGGACAAGCG

CGTCGAATCCAAGTACGGCCCCCCT

TGTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

1936
TFTDAWMNWVRQAPGKGLEWIGRVK
2044
GAGGCGTGGTCCAGCCTGGGAGGTC

NKADGETTDYAAPVKGRITISRDDAK

CCTGAGACTCTCCTGTGCAGCCTCT

NTLYVQMNSLKTEDTAVYYCTADLRL

GGATTCACTTTCACTGATGCCTGGA

STWDAYDFWGQGTMVTVSSASTKGPS

TGAACTGGGTCCGCCAGGCTCCAGG

VFPLAPCSRSTSESTAALGCLVKDYFPE

GAAGGGGCTGGAGTGGATTGGCCGT

PVTVSWNSGALTSGVHTFPAVLQSSGL

GTTAAAAACAAAGCTGATGGTGAG

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ACAACGGACTACGCTGCACCCGTCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

AAGGCAGAATCACCATCTCAAGAG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ATGATGCAAAGAACACTCTGTATGT

DVSQEDPEVQFNWYVDGVEVHNAKT

GCAAATGAACAGCCTGAAAACCGA

KPREEQFNSTYRVVSVLTVLHQDWLN

GGACACAGCCGTGTATTATTGTACC

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GCTGACCTGCGACTTTCTACGTGGG

PREPQVYTLPPSQEEMTKNQVSLTCLV

ATGCTTATGATTTCTGGGGCCAAGG

KGFYPSDIAVEWESNGQPENNYKTTPP

GACAATGGTCACCGTCTCTTCAGCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

TCCACCAAGGGGCCTTCCGTGTTCC

FSCSVMHEALHNHYTQKSLSLSLGK

CCCTGGCCCCTTGCTCCCGCTCGAC

CTCTGAATCCACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QITLKESGGGLVQPGGSLRLSCTVSGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

1937
TFSNNWMTWVRQTPGKGLEWVANIK
2045
GAGGCTTGGTCCAGCCTGGGGGGTC

QDGTEKHYVDSVKGRFTISRDNAENSL

CCTAAGACTCTCTTGTACAGTCTCA

YLQMNSLRGEDTAVYYCARNSQRSFD

GGATTCACCTTTAGTAACAATTGGA

YWGQGTLVTVSSASTKGPSVFPLAPCS

TGACCTGGGTCCGCCAGACTCCAGG

RSTSESTAALGCLVKDYFPEPVTVSWN

GAAGGGGCTGGAGTGGGTGGCCAA

SGALTSGVHTFPAVLQSSGLYSLSSVV

CATAAAGCAAGATGGAACTGAGAA

TVPSSSLGTKTYTCNVDHKPSNTKVDK

ACACTATGTGGACTCTGTGAAGGGC

RVESKYGPPCPPCPAPEFLGGPSVFLFP

CGATTCACCATCTCCAGAGACAACG

PKPKDTLMISRTPEVTCVVVDVSQEDP

CCGAGAACTCACTGTATCTGCAGAT

EVQFNWYVDGVEVHNAKTKPREEQF

GAACAGCCTGAGAGGTGAGGACAC

NSTYRVVSVLTVLHQDWLNGKEYKC

GGCCGTGTATTATTGTGCGAGAAAC

KVSNKGLPSSIEKTISKAKGQPREPQVY

AGTCAACGTTCGTTTGACTACTGGG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GCCAGGGCACCCTGGTGACCGTCTC

IAVEWESNGQPENNYKTTPPVLDSDGS

CTCAGCATCCACCAAGGGGCCTTCC

FFLYSRLTVDKSRWQEGNVFSCSVMH

GTGTTCCCCCTGGCCCCTTGCTCCCG

EALHNHYTQKSLSLSLGK

CTCGACCTCTGAATCCACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCAAGACCTATACCT

GCAACGTCGACCACAAGCCCTCCAA

CACCAAAGTGGACAAGCGCGTCGA

ATCCAAGTACGGCCCCCCTTGTCCG

CCTTGTCCAGCCCCTGAGTTCCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCAGGAA

GATCCCGAAGTGCAGTTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTTCAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GGCCTCCCTTCATCCATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCAAGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCCGGC

TGACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1938
TFSSYGMHWVRQAPGKGLEWVAVISY
2046
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDLGDPR

GGATTCACCTTCAGTAGCTATGGCA

GGILNYWGQGTLVTVSSASTKGPSVFP

TGCACTGGGTCCGCCAGGCTCCAGG

LAPCSRSTSESTAALGCLVKDYFPEPV

CAAGGGGCTGGAGTGGGTGGCAGTT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATATCATATGATGGAAGTAATAAAT

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ACTATGCAGACTCCGTGAAGGGCCG

TKVDKRVESKYGPPCPPCPAPEFLGGP

ATTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTGCAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCTGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CTGTGTATTACTGTGCGAAAGATTT

KEYKCKVSNKGLPSSIEKTISKAKGQP

AGGGGATCCCCGGGGTGGTATTTTG

REPQVYTLPPSQEEMTKNQVSLTCLVK

AACTACTGGGGCCAGGGCACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

1939
TFSSYAMHWVRQAPGKGLEWVAVISY
2047
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARSSPWGEL

GGATTCACCTTCAGTAGCTATGCTA

SLYQGAFDIWGQGTMVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPCSRSTSESTAALGCLVKDYFP

CAAGGGGCTGGAGTGGGTGGCAGTT

EPVTVSWNSGALTSGVHTFPAVLQSSG

ATATCATATGATGGAAGTAATAAAT

LYSLSSVVTVPSSSLGTKTYTCNVDHK

ACTACGCAGACTCCGTGAAGGGCCG

PSNTKVDKRVESKYGPPCPPCPAPEFL

ATTCACCATCTCCAGAGACAATTCC

GGPSVFLFPPKPKDTLMISRTPEVTCVV

AAGAACACGCTGTATCTGCAAATGA

VDVSQEDPEVQFNWYVDGVEVHNAK

ACAGCCTGAGAGCTGAGGACACGG

TKPREEQFNSTYRVVSVLTVLHQDWL

CTGTGTATTACTGTGCCCGGTCGAG

NGKEYKCKVSNKGLPSSIEKTISKAKG

CCCCTGGGGGGAGTTATCGTTATAC

QPREPQVYTLPPSQEEMTKNQVSLTCL

CAGGGGGCTTTTGATATCTGGGGCC

VKGFYPSDIAVEWESNGQPENNYKTTP

AAGGGACAATGGTCACCGTCTCTTC

PVLDSDGSFFLYSRLTVDKSRWQEGN

AGCATCCACCAAGGGGCCTTCCGTG

VFSCSVMHEALHNHYTQKSLSLSLGK

TTCCCCCTGGCCCCTTGCTCCCGCTC

GACCTCTGAATCCACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCAAGACCTATACCTGCAA

CGTCGACCACAAGCCCTCCAACACC

AAAGTGGACAAGCGCGTCGAATCC

AAGTACGGCCCCCCTTGTCCGCCTT

GTCCAGCCCCTGAGTTCCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCAGGAAGATC

CCGAAGTGCAGTTCAATTGGTACGT

GGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTTCAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGG

ACTGGCTGAACGGAAAGGAGTACA

AGTGCAAAGTGTCAAACAAGGGCCT

CCCTTCATCCATCGAAAAGACCATC

AGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTACACTTTGCCGC

CTAGCCAAGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCCGGCTG

ACTGTGGACAAGTCAAGATGGCAG

GAGGGAAACGTGTTCTCCTGCTCCG

TGATGCACGAAGCGCTGCACAACCA

TTACACCCAGAAATCACTGTCACTT

TCGCTGGGAAAA

SEQ ID
QITLKESGGGLVQPGRSLRLSCAASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

1940
TFDDYAMHWVRQAPGKGLEWVSAIS
2048
GAGGCTTGGTACAGCCTGGCAGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDNDFWS

GGATTCACCTTTGATGATTATGCCA

GKVFDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTCCGGCAAGCTCCAGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGGTCTCAGCT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATTAGTGGTAGTGGTGGTAGCACAT

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ACTACGCAGACTCCGTGAAGGGCCG

TKVDKRVESKYGPPCPPCPAPEFLGGP

GTTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTGCAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCCGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CCGTATATTACTGTGCGAAAGATAA

KEYKCKVSNKGLPSSIEKTISKAKGQP

CGATTTTTGGAGTGGGAAAGTCTTT

REPQVYTLPPSQEEMTKNQVSLTCLVK

GACTACTGGGGCCAGGGCACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1941
FTFSSYSMNWVRQAPGKGLEWVSYIS
2049
GAGGCTTGGTACAGCCTGGGGGGTC

STSSTIYYADSVKGRFTISRDNSKNMLF

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAVYYCAKEGGSGWR

GGATTCACCTTCAGTAGTTATAGCA

HYFDYWGQGTLVTVSSASTKGPSVFP

TGAACTGGGTCCGCCAGGCTCCAGG

LAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGGTTTCATAC

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATCAGTAGTACTAGTAGTACCATAT

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ACTACGCAGACTCCGTGAAGGGCCG

TKVDKRVESKYGPPCPPCPAPEFLGGP

ATTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAATATGCTGTTTCTACAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCTGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CTGTGTATTACTGTGCGAAAGAAGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

GGGCAGTGGCTGGCGCCACTACTTT

REPQVYTLPPSQEEMTKNQVSLTCLVK

GACTACTGGGGCCAGGGAACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1942
TFSSYAMHWVRQAPGKGLEWVAVISY
2050
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTGTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARDYCSSTS

GGATTCACCTTCAGCAGCTATGCTA

CQNWFDPWGQGTLVTVSSASTKGPSV

TGCACTGGGTCCGCCAGGCTCCAGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

CAAGGGGCTGGAGTGGGTGGCAGTT

VTVSWNSGALTSGVHTFPAVLQSSGL

ATATCATATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ACTACGCAGACTCCGTGAAGGGCCG

SNTKVDKRVESKYGPPCPPCPAPEFLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTGCAAATGA

DVSQEDPEVQFNWYVDGVEVHNAKT

ACAGCCTGAGAGCTGAGGACACGG

KPREEQFNSTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAGAGATTA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

TTGTAGTAGTACCAGCTGCCAGAAC

PREPQVYTLPPSQEEMTKNQVSLTCLV

TGGTTCGACCCCTGGGGCCAGGGCA

KGFYPSDIAVEWESNGQPENNYKTTPP

CCCTGGTCACCGTCTCCTCAGCATC

VLDSDGSFFLYSRLTVDKSRWQEGNV

CACCAAGGGGCCTTCCGTGTTCCCC

FSCSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

1943
FTFSNYVMSWVRQAPGKGLEWVSAIS
2051
GAGGCTTGGTACAGCCTGGGGGGTC

GIGDTTYYADSVKGRFTISRDNAKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARGRVAGD

GGATTCACCTTTAGCAACTATGTCA

AFDIWGQGTMVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

GAAGGGGCTGGAGTGGGTCTCAGCT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATTAGTGGTATTGGTGATACTACAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTACGCGGACTCCGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCATCTCCAGAGACAACGCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

AAGAACACGCTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAGTCTGAGAGCCGAGGACACGG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CTGTGTATTACTGTGCAAGAGGGCG

CKVSNKGLPSSIEKTISKAKGQPREPQV

CGTGGCGGGGGATGCTTTTGATATC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGGGGCCAAGGGACAATGGTGACC

DIAVEWESNGQPENNYKTTPPVLDSD

GTCTCTTCAGCATCCACCAAGGGGC

GSFFLYSRLTVDKSRWQEGNVFSCSV

CTTCCGTGTTCCCCCTGGCCCCTTGC

MHEALHNHYTQKSLSLSLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGG

1944
TFSSYAMSWVRQAPGKGLEWVSAISG
2052
GGAGGCTTGGTACAGCCTGGGGGGT

SGGSTYYADSVKGRFTISRDNSKNTLY

CCCTGAGACTCTCCTGTGCAGCCTC

LQMNSLRAEDTAVYYCAKDQGAAAG

TGGATTCACCTTTAGCAGCTATGCC

TLGYFDYWGQGTLVTVSSASTKGPSV

ATGAGCTGGGTCCGCCAGGCTCCAG

FPLAPCSRSTSESTAALGCLVKDYFPEP

GGAAGGGGCTGGAGTGGGTCTCAG

VTVSWNSGALTSGVHTFPAVLQSSGL

CTATTAGTGGTAGTGGTGGTAGCAC

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ATACTACGCAGACTCCGTGAAGGGC

SNTKVDKRVESKYGPPCPPCPAPEFLG

CGGTTCACCATCTCCAGAGACAATT

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CCAAGAACACGCTGTATCTGCAAAT

DVSQEDPEVQFNWYVDGVEVHNAKT

GAACAGCCTGAGAGCCGAGGACAC

KPREEQFNSTYRVVSVLTVLHQDWLN

GGCCGTATATTACTGTGCGAAAGAT

GKEYKCKVSNKGLPSSIEKTISKAKGQ

CAAGGGGCAGCAGCTGGTACCCTGG

PREPQVYTLPPSQEEMTKNQVSLTCLV

GGTACTTTGACTACTGGGGCCAGGG

KGFYPSDIAVEWESNGQPENNYKTTPP

AACCCTGGTGACCGTCTCCTCAGCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

TCCACCAAGGGGCCTTCCGTGTTCC

FSCSVMHEALHNHYTQKSLSLSLGK

CCCTGGCCCCTTGCTCCCGCTCGAC

CTCTGAATCCACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1945
YTFTSYDINWVRQATGQGLEWMGWM
2053
CTGAGGTGAAGAAGCCTGGGGCCTC

NPNSGNTGYAQKFQGRVTMTRNTSIST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCTRGIYDSSG

GGATACACCTTCACCAGTTATGATA

SSNPFDSWGQGTLVTVSSASTKGPSVF

TCAACTGGGTGCGACAGGCCACTGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGATG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATGAACCCTAACAGTGGTAACACA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

GGCTATGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACCATGACCAGGAACACCTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATAAGCACAGCCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTACGAGAGGAA

KEYKCKVSNKGLPSSIEKTISKAKGQP

TCTATGATAGTAGTGGTTCTTCCAAT

REPQVYTLPPSQEEMTKNQVSLTCLVK

CCCTTTGACTCCTGGGGCCAGGGAA

GFYPSDIAVEWESNGQPENNYKTTPPV

CCCTGGTGACCGTCTCCTCAGCATC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CACCAAGGGGCCTTCCGTGTTCCCC

CSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKISCEASGY
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

1946
TFTDYAIHWVRQAPGQRLEWMGWIN
2054
CTGAGGTGAAGAAGCCTGGGGCCTC

AGDGGTKSSREFQGRVTITRDTSATTA

AGTGAAGATTTCCTGCGAGGCTTCT

YMEVSSLRSEDTAVYYCARGYCSGGS

GGATACACCTTCACTGATTATGCTA

CPGTDFDYWGQGTLVTVSSASTKGPS

TACATTGGGTGCGCCAGGCCCCCGG

VFPLAPCSRSTSESTAALGCLVKDYFPE

ACAAAGACTTGAGTGGATGGGATG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GATCAACGCTGGCGATGGTGGCACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AAAAGTTCACGGGAGTTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATTACCAGGGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CGCGACCACAGCCTACATGGAGGTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGTCTGAGATCTGAAGACACGG

KPREEQFNSTYRVVSVLTVLHQDWLN

CTGTCTATTACTGTGCGAGAGGATA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

TTGTAGTGGTGGTAGCTGCCCAGGA

PREPQVYTLPPSQEEMTKNQVSLTCLV

ACGGATTTTGACTACTGGGGCCAGG

KGFYPSDIAVEWESNGQPENNYKTTPP

GAACCCTGGTCACCGTCTCCTCAGC

VLDSDGSFFLYSRLTVDKSRWQEGNV

ATCCACCAAGGGGCCTTCCGTGTTC

FSCSVMHEALHNHYTQKSLSLSLGK

CCCCTGGCCCCTTGCTCCCGCTCGA

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1947
YTFTSYYMHWVRQAPGQGLEWMGIIN
2055
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCARDGVGGRD

GGATACACCTTCACCAGCTACTATA

GYNFDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAAT

TVSWNSGALTSGVHTFPAVLQSSGLYS

AATCAACCCTAGTGGTGGTAGCACA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AGCTACGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACCATGACCAGGGACACGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CACGAGCACAGTCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCGAGAGATG

KEYKCKVSNKGLPSSIEKTISKAKGQP

GTGTAGGAGGGAGAGATGGCTACA

REPQVYTLPPSQEEMTKNQVSLTCLVK

ATTTTGACTACTGGGGCCAGGGAAC

GFYPSDIAVEWESNGQPENNYKTTPPV

CCTGGTCACCGTCTCCTCAGCATCC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

ACCAAGGGGCCTTCCGTGTTCCCCC

CSVMHEALHNHYTQKSLSLSLGK

TGGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
EVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

1948
FTVSSNYMSWVRQAPGKGLEWVSVIY
2056
GAGGCTTGGTCCAGCCTGGGGGGTC

SGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAVYYCARAPLAADG

GGATTCACCGTCAGTAGCAACTACA

YFDYWGQGTLVTVSSASTKGPSVFPL

TGAGCTGGGTCCGCCAGGCTCCAGG

APCSRSTSESTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGGTCTCAGTT

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTTATAGCGGTGGTAGCACATACT

SSVVTVPSSSLGTKTYTCNVDHKPSNT

ACGCAGACTCCGTGAAGGGCCGATT

KVDKRVESKYGPPCPPCPAPEFLGGPS

CACCATCTCCAGAGACAATTCCAAG

VFLFPPKPKDTLMISRTPEVTCVVVDV

AACACGCTGTATCTTCAAATGAACA

SQEDPEVQFNWYVDGVEVHNAKTKP

GCCTGAGAGCTGAGGACACGGCTGT

REEQFNSTYRVVSVLTVLHQDWLNGK

GTATTACTGTGCGAGAGCCCCCCTA

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GCAGCAGATGGCTACTTTGACTACT

PQVYTLPPSQEEMTKNQVSLTCLVKGF

GGGGCCAGGGAACCCTGGTCACCGT

YPSDIAVEWESNGQPENNYKTTPPVLD

CTCCTCAGCATCCACCAAGGGGCCT

SDGSFFLYSRLTVDKSRWQEGNVFSCS

TCCGTGTTCCCCCTGGCCCCTTGCTC

VMHEALHNHYTQKSLSLSLGK

CCGCTCGACCTCTGAATCCACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCAAGACCTATA

CCTGCAACGTCGACCACAAGCCCTC

CAACACCAAAGTGGACAAGCGCGT

CGAATCCAAGTACGGCCCCCCTTGT

CCGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGSSVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

1949
GTFSSYAISWVRQAPGQGLEWMGGIIP
2057
CTGAGGTGAAGAAGCCTGGGTCCTC

IFGTANYAQKFQGRVTITADESTSTAY

GGTGAAGGTCTCCTGCAAGGCTTCT

MELSSLRSEDTAVYYCARARGLQYLI

GGAGGCACCTTCAGCAGCTATGCTA

WYFDLWGRGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATCTTTGGTACAGCA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACTACGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACGATTACCGCGGACGAATC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CACGAGCACAGCCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCGAGAGCCC

KEYKCKVSNKGLPSSIEKTISKAKGQP

GGGGGCTACAGTACCTAATCTGGTA

REPQVYTLPPSQEEMTKNQVSLTCLVK

CTTCGATCTCTGGGGCCGTGGCACC

GFYPSDIAVEWESNGQPENNYKTTPPV

CTGGTGACCGTCTCCTCAGCATCCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCAAGGGGCCTTCCGTGTTCCCCCT

CSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG

1950
YTFTSYYMHWVRQAPGQGLEWMGIIN
2058
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCASPGMVRGV

GGATACACCTTCACCAGCTACTATA

ITAPLDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAAT

TVSWNSGALTSGVHTFPAVLQSSGLYS

AATCAACCCTAGTGGTGGTAGCACA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AGCTACGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACCATGACCAGGGACACGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CACGAGCACAGTCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCGAGCCCGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

GTATGGTTCGGGGAGTTATTACTGC

REPQVYTLPPSQEEMTKNQVSLTCLVK

CCCGCTTGACTACTGGGGCCAGGGC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCCTGGTCACCGTCTCCTCAGCAT

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCACCAAGGGGCCTTCCGTGTTCCC

CSVMHEALHNHYTQKSLSLSLGK

CCTGGCCCCTTGCTCCCGCTCGACCT

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

1951
FTFSSYAISWVRQAPGQGLEWMGGIIP
2059
GAGGCCTGGTCAAGCCTGGGGGGTC

MYGTANYAQKFQGRVTITADESTSTA

CCTGAGACTCTCCTGTGCAGCCTCT

YMELSSLRSEDTALYYCAREAKWGM

GGATTCACCTTCAGCAGCTATGCTA

YYFDYWGQGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATGTATGGTACAGCA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACTACGCACAGAAGTTCCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GAGTCACGATTACCGCGGACGAATC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CACGAGCACAGCCTACATGGAACTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCCTCTATTACTGTGCGAGAGAAG

KEYKCKVSNKGLPSSIEKTISKAKGQP

CTAAGTGGGGAATGTACTACTTTGA

REPQVYTLPPSQEEMTKNQVSLTCLVK

CTACTGGGGCCAGGGCACCCTGGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCGTCTCCTCAGCATCCACCAAGG

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGCCTTCCGTGTTCCCCCTGGCCCCT

CSVMHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVOLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCCGGG

1952
TFSSYAIHWVRQAPGKGLEWVAIISDD
2060
GGAGGCGTGGTCCAGCCTGGGAGGT

GSKSYYADSVQGRFTISRDNSRNTVYL

CCCTGAGACTCTCCTGTGCAGCCTC

QMNSLRAEDTAMYYCARDRGTKWNQ

TGGATTCACCTTCAGTAGCTATGCT

LNDVFDMWGQGTMVTVSSASTKGPS

ATACACTGGGTCCGCCAGGCTCCAG

VFPLAPCSRSTSESTAALGCLVKDYFPE

GCAAGGGGCTGGAGTGGGTGGCAA

PVTVSWNSGALTSGVHTFPAVLQSSGL

TTATATCAGATGATGGAAGTAAGAG

YSLSSVVTVPSSSLGTKTYTCNVDHKP

TTACTACGCAGACTCCGTGCAGGGC

SNTKVDKRVESKYGPPCPPCPAPEFLG

CGATTCACCATCTCCAGAGACAATT

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CGAGGAACACAGTATATCTGCAAAT

DVSQEDPEVQFNWYVDGVEVHNAKT

GAACAGCCTGAGAGCTGAGGACAC

KPREEQFNSTYRVVSVLTVLHQDWLN

GGCTATGTATTACTGTGCGAGAGAC

GKEYKCKVSNKGLPSSIEKTISKAKGQ

AGGGGAACTAAATGGAACCAATTG

PREPQVYTLPPSQEEMTKNQVSLTCLV

AATGATGTTTTTGATATGTGGGGCC

KGFYPSDIAVEWESNGQPENNYKTTPP

AAGGGACAATGGTCACCGTCTCTTC

VLDSDGSFFLYSRLTVDKSRWQEGNV

AGCATCCACCAAGGGGCCTTCCGTG

FSCSVMHEALHNHYTQKSLSLSLGK

TTCCCCCTGGCCCCTTGCTCCCGCTC

GACCTCTGAATCCACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCAAGACCTATACCTGCAA

CGTCGACCACAAGCCCTCCAACACC

AAAGTGGACAAGCGCGTCGAATCC

AAGTACGGCCCCCCTTGTCCGCCTT

GTCCAGCCCCTGAGTTCCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCAGGAAGATC

CCGAAGTGCAGTTCAATTGGTACGT

GGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTTCAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGG

ACTGGCTGAACGGAAAGGAGTACA

AGTGCAAAGTGTCAAACAAGGGCCT

CCCTTCATCCATCGAAAAGACCATC

AGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTACACTTTGCCGC

CTAGCCAAGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCCGGCTG

ACTGTGGACAAGTCAAGATGGCAG

GAGGGAAACGTGTTCTCCTGCTCCG

TGATGCACGAAGCGCTGCACAACCA

TTACACCCAGAAATCACTGTCACTT

TCGCTGGGAAAA

SEQ ID
QMQLVQSGAEVKKPGASVKVSCTASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

1953
YTFTSSDINWVRQATGQGLEWMGWM
2061
CTGAGGTGAAGAAGCCTGGGGCCTC

NPNSGNTGYAEKFQGRVTMTSDSSIST

AGTGAAGGTCTCCTGCACGGCTTCT

AYMELRSLTTEDTAVYYCARGGGASY

GGATACACCTTCACCAGTTCTGATA

TDSWGQGTLVTVSSASTKGPSVFPLAP

TCAACTGGGTGCGACAGGCCACTGG

CSRSTSESTAALGCLVKDYFPEPVTVS

ACAAGGGCTTGAGTGGATGGGATG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GATGAACCCTAACAGTGGTAACACC

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GGCTATGCAGAGAAGTTCCAGGGCA

DKRVESKYGPPCPPCPAPEFLGGPSVFL

GGGTCACCATGACCAGCGACTCCTC

FPPKPKDTLMISRTPEVTCVVVDVSQE

CATAAGCACCGCCTACATGGAGTTG

DPEVQFNWYVDGVEVHNAKTKPREE

AGAAGCCTGACCACTGAGGACACG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GCCGTATATTACTGTGCGAGAGGTG

CKVSNKGLPSSIEKTISKAKGQPREPQV

GGGGTGCGAGCTATACTGACTCCTG

YTLPPSQEEMTKNQVSLTCLVKGFYPS

GGGCCAGGGCACCCTGGTCACCGTC

DIAVEWESNGQPENNYKTTPPVLDSD

TCCTCAGCATCCACCAAGGGGCCTT

GSFFLYSRLTVDKSRWQEGNVFSCSV

CCGTGTTCCCCCTGGCCCCTTGCTCC

MHEALHNHYTQKSLSLSLGK

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

1954
TFGDYAMSWFRQAPGKGLEWVGFIRS
2062
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTAKGGYV

GGATTCACCTTTGGTGATTATGCTAT

GYSYGPFGGYWGQGTLVTVSSASTKG

GAGCTGGTTCCGCCAGGCTCCAGGG

PSVFPLAPCSRSTSESTAALGCLVKDYF

AAGGGGCTGGAGTGGGTAGGTTTCA

PEPVTVSWNSGALTSGVHTFPAVLQSS

TTAGAAGCAAAGCTTATGGTGGGAC

GLYSLSSVVTVPSSSLGTKTYTCNVDH

AACAGAATACGCCGCGTCTGTGAAA

KPSNTKVDKRVESKYGPPCPPCPAPEF

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAAAAGCATCGCCTATCTGCA

VVDVSQEDPEVQFNWYVDGVEVHNA

AATGAACAGCCTGAAAACCGAGGA

KTKPREEQFNSTYRVVSVLTVLHQDW

CACAGCCGTGTATTACTGTACCGCT

LNGKEYKCKVSNKGLPSSIEKTISKAK

AAGGGGGGCTACGTCGGATACAGCT

GQPREPQVYTLPPSQEEMTKNQVSLTC

ATGGACCTTTTGGGGGCTACTGGGG

LVKGFYPSDIAVEWESNGQPENNYKT

CCAGGGAACCCTGGTCACCGTCTCC

TPPVLDSDGSFFLYSRLTVDKSRWQEG

TCAGCATCCACCAAGGGGCCTTCCG

NVFSCSVMHEALHNHYTQKSLSLSLG

TGTTCCCCCTGGCCCCTTGCTCCCGC

K

TCGACCTCTGAATCCACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCAAGACCTATACCTG

CAACGTCGACCACAAGCCCTCCAAC

ACCAAAGTGGACAAGCGCGTCGAA

TCCAAGTACGGCCCCCCTTGTCCGC

CTTGTCCAGCCCCTGAGTTCCTGGG

TGGTCCGTCCGTGTTCCTCTTCCCGC

CCAAGCCGAAGGACACTCTGATGAT

TTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCAGGAAG

ATCCCGAAGTGCAGTTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTTCAACTCTACGTACCGGGTGG

TGTCCGTGCTGACCGTGCTGCACCA

GGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGG

CCTCCCTTCATCCATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTACACTTTGCC

GCCTAGCCAAGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCCGGCT

GACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1955
TFGDYAMSWFRQAPGKGLEWVGFIRS
2063
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRGGTMV

GGATTCACCTTTGGTGATTATGCTAT

RGFGFNYWGQGTLVTVSSASTKGPSV

GAGCTGGTTCCGCCAGGCTCCAGGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

AAGGGGCTGGAGTGGGTAGGTTTCA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAAGCAAAGCTTATGGTGGGAC

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AACAGAATACGCCGCGTCTGTGAAA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GGCAGATTCACCATCTCAAGAGATG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ATTCCAAAAGCATCGCCTATCTGCA

DVSQEDPEVQFNWYVDGVEVHNAKT

AATGAACAGCCTGAAAACCGAGGA

KPREEQFNSTYRVVSVLTVLHQDWLN

CACAGCCGTGTATTACTGTACTAGA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GGGGGGACTATGGTTCGGGGTTTCG

PREPQVYTLPPSQEEMTKNQVSLTCLV

GATTTAACTACTGGGGCCAGGGAAC

KGFYPSDIAVEWESNGQPENNYKTTPP

CCTGGTCACCGTCTCCTCAGCATCC

VLDSDGSFFLYSRLTVDKSRWQEGNV

ACCAAGGGGCCTTCCGTGTTCCCCC

FSCSVMHEALHNHYTQKSLSLSLGK

TGGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1956
GSFSGYYWSWIRQPPGKGLEWIGEINH
2064
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARARRAMIGPLP

GGTGGGTCCTTCAGTGGTTACTACT

RLVGYFDLWGRGTLVTVSSASTKGPS

GGAGCTGGATCCGCCAGCCCCCAGG

VFPLAPCSRSTSESTAALGCLVKDYFPE

GAAGGGGCTGGAGTGGATTGGGGA

PVTVSWNSGALTSGVHTFPAVLQSSGL

AATCAATCATAGTGGAAGCACCAAC

YSLSSVVTVPSSSLGTKTYTCNVDHKP

TACAACCCGTCCCTCAAGAGTCGAG

SNTKVDKRVESKYGPPCPPCPAPEFLG

TCACCATATCAGTAGACACGTCCAA

GPSVFLFPPKPKDTLMISRTPEVTCVVV

GAACCAGTTCTCCCTGAAGCTGAGC

DVSQEDPEVQFNWYVDGVEVHNAKT

TCTGTGACCGCCGCGGACACGGCTG

KPREEQFNSTYRVVSVLTVLHQDWLN

TGTATTACTGTGCGAGAGCCCGGCG

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GGCTATGATAGGGCCGCTTCCGCGA

PREPQVYTLPPSQEEMTKNQVSLTCLV

CTTGTCGGGTACTTCGATCTCTGGG

KGFYPSDIAVEWESNGQPENNYKTTPP

GCCGTGGAACCCTGGTCACCGTCTC

VLDSDGSFFLYSRLTVDKSRWQEGNV

CTCAGCATCCACCAAGGGGCCTTCC

FSCSVMHEALHNHYTQKSLSLSLGK

GTGTTCCCCCTGGCCCCTTGCTCCCG

CTCGACCTCTGAATCCACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCAAGACCTATACCT

GCAACGTCGACCACAAGCCCTCCAA

CACCAAAGTGGACAAGCGCGTCGA

ATCCAAGTACGGCCCCCCTTGTCCG

CCTTGTCCAGCCCCTGAGTTCCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCAGGAA

GATCCCGAAGTGCAGTTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTTCAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GGCCTCCCTTCATCCATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCAAGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCCGGC

TGACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1957
GSFSGYYWSWIRQPPGKGLEWIGEINH
2065
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRPAPSWVKT

GGTGGGTCCTTCAGTGGTTACTACT

RNWFDPWGQGTLVTVSSASTKGPSVF

GGAGCTGGATCCGCCAGCCCCCAGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGATTGGGGA

TVSWNSGALTSGVHTFPAVLQSSGLYS

AATCAATCATAGTGGAAGCACCAAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

TACAACCCGTCCCTCAAGAGTCGAG

TKVDKRVESKYGPPCPPCPAPEFLGGP

TCACCATATCAGTAGACACGTCCAA

SVFLFPPKPKDTLMISRTPEVTCVVVD

GAACCAGTTCTCCCTGAAGCTGAGC

VSQEDPEVQFNWYVDGVEVHNAKTK

TCTGTGACCGCCGCGGACACGGCTG

PREEQFNSTYRVVSVLTVLHQDWLNG

TGTATTACTGTGCGAGAGGCCGCCC

KEYKCKVSNKGLPSSIEKTISKAKGQP

CGCCCCATCCTGGGTTAAAACCCGT

REPQVYTLPPSQEEMTKNQVSLTCLVK

AACTGGTTCGACCCCTGGGGCCAGG

GFYPSDIAVEWESNGQPENNYKTTPPV

GAACCCTGGTCACCGTCTCCTCAGC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

ATCCACCAAGGGGCCTTCCGTGTTC

CSVMHEALHNHYTQKSLSLSLGK

CCCCTGGCCCCTTGCTCCCGCTCGA

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1958
SVSSNSAAWNWIRQSPSRGLEWLGRT
2066
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCAREASSG

GGGACAGTGTCTCTAGCAACAGTGC

WNWGQGTLVTVSSASTKGPSVFPLAP

TGCTTGGAACTGGATCAGGCAGTCC

CSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GTATAATGATTATGCAGTATCTGTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AAAAGTCGAATAACCATCAACCCAG

FPPKPKDTLMISRTPEVTCVVVDVSQE

ACACATCCAAGAACCAGTTCTCCCT

DPEVQFNWYVDGVEVHNAKTKPREE

GCAGCTGAACTCTGTGACTCCCGAG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GACACGGCTGTGTATTACTGTGCAA

CKVSNKGLPSSIEKTISKAKGQPREPQV

GAGAGGCTAGCAGTGGCTGGAACT

YTLPPSQEEMTKNQVSLTCLVKGFYPS

GGGGCCAGGGAACCCTGGTCACCGT

DIAVEWESNGQPENNYKTTPPVLDSD

CTCCTCAGCATCCACCAAGGGGCCT

GSFFLYSRLTVDKSRWQEGNVFSCSV

TCCGTGTTCCCCCTGGCCCCTTGCTC

MHEALHNHYTQKSLSLSLGK

CCGCTCGACCTCTGAATCCACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCAAGACCTATA

CCTGCAACGTCGACCACAAGCCCTC

CAACACCAAAGTGGACAAGCGCGT

CGAATCCAAGTACGGCCCCCCTTGT

CCGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLQESGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGTC

1959
SVSSNNAAWNWIRQSPSRGLEWLGRT
2067
CAGGACTGGTGAAGCCCTCGCAGAC

FYRSKWYNDYAVSVKSRLTVNPDTSK

CCTCTCACTCACCTGTGCCATCTCCG

NQFSLRLNSVSPEDTAVYYCARGGRY

GGGACAGTGTCTCTAGCAACAATGC

TKGGYFDDWGQGTLVTVSSASTKGPS

TGCTTGGAACTGGATCAGGCAGTCC

VFPLAPCSRSTSESTAALGCLVKDYFPE

CCATCGAGAGGCCTTGAGTGGCTGG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GAAGGACATTCTACAGGTCCAAGTG

YSLSSVVTVPSSSLGTKTYTCNVDHKP

GTATAATGACTATGCAGTTTCTGTG

SNTKVDKRVESKYGPPCPPCPAPEFLG

AAAAGTCGACTAACCGTCAACCCAG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ACACATCCAAGAACCAGTTCTCCCT

DVSQEDPEVQFNWYVDGVEVHNAKT

GCGGTTGAACTCTGTGAGTCCCGAG

KPREEQFNSTYRVVSVLTVLHQDWLN

GACACGGCTGTGTATTACTGTGCAA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GAGGGGGAAGATATACCAAGGGAG

PREPQVYTLPPSQEEMTKNQVSLTCLV

GGTACTTTGACGACTGGGGCCAGGG

KGFYPSDIAVEWESNGQPENNYKTTPP

AACCCTGGTGACCGTCTCCTCAGCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

TCCACCAAGGGGCCTTCCGTGTTCC

FSCSVMHEALHNHYTQKSLSLSLGK

CCCTGGCCCCTTGCTCCCGCTCGAC

CTCTGAATCCACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVTLKESGPTLVKPTQTLTLTCTFSGFS
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTC

1960
LSTSGVGVGWIRQPPGKALEWLALIY
2068
CTACGCTGGTGAAACCCACACAGAC

WDDDKRYSPSLKSRLTITKDTSKNQV

CCTCACGCTGACCTGCACCTTCTCTG

VLTMTNMDPVDTATYYCAHRLDSSGR

GGTTCTCACTCAGCACTAGTGGAGT

GGYFDYWGQGTLVTVSSASTKGPSVF

GGGTGTGGGCTGGATCCGTCAGCCC

PLAPCSRSTSESTAALGCLVKDYFPEPV

CCAGGAAAGGCCCTGGAGTGGCTTG

TVSWNSGALTSGVHTFPAVLQSSGLYS

CACTCATTTATTGGGATGATGATAA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

GCGCTACAGCCCATCTCTGAAGAGC

TKVDKRVESKYGPPCPPCPAPEFLGGP

AGGCTCACCATCACCAAGGACACCT

SVFLFPPKPKDTLMISRTPEVTCVVVD

CCAAAAACCAGGTGGTCCTTACAAT

VSQEDPEVQFNWYVDGVEVHNAKTK

GACCAACATGGACCCTGTGGACACA

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCACATATTACTGTGCACACAGAT

KEYKCKVSNKGLPSSIEKTISKAKGQP

TGGATAGCAGTGGCCGTGGTGGTTA

REPQVYTLPPSQEEMTKNQVSLTCLVK

CTTTGACTACTGGGGCCAGGGCACC

GFYPSDIAVEWESNGQPENNYKTTPPV

CTGGTCACCGTCTCCTCAGCATCCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCAAGGGGCCTTCCGTGTTCCCCCT

CSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
EVOLVESGGGVVQPGRSLRLSCTASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

1961
TFSSYGMHWVRQAPGKGLEWVAVISY
2069
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTACAGCCTCT

YLQMNSLRAEDTAVYYCAKELVGTSS

GGATTCACCTTCAGTAGCTATGGCA

PYYYYYYGMDVWGQGTMVTVSSAST

TGCACTGGGTCCGCCAGGCTCCAGG

KGPSVFPLAPCSRSTSESTAALGCLVK

CAAGGGGCTGGAGTGGGTGGCAGTT

DYFPEPVTVSWNSGALTSGVHTFPAVL

ATATCATATGATGGAAGTAATAAAT

QSSGLYSLSSVVTVPSSSLGTKTYTCN

ACTATGCAGACTCCGTGAAGGGCCG

VDHKPSNTKVDKRVESKYGPPCPPCPA

ATTCACCATCTCCAGAGACAATTCC

PEFLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSQEDPEVQFNWYVDGVEV

ACAGCCTGAGAGCTGAGGACACGG

HNAKTKPREEQFNSTYRVVSVLTVLH

CTGTGTATTACTGTGCGAAAGAGTT

QDWLNGKEYKCKVSNKGLPSSIEKTIS

GGTGGGTACCAGCTCTCCTTATTAC

KAKGQPREPQVYTLPPSQEEMTKNQV

TACTACTACTACGGTATGGACGTCT

SLTCLVKGFYPSDIAVEWESNGQPENN

GGGGCCAAGGGACAATGGTCACCG

YKTTPPVLDSDGSFFLYSRLTVDKSRW

TCTCTTCAGCATCCACCAAGGGGCC

QEGNVFSCSVMHEALHNHYTQKSLSL

TTCCGTGTTCCCCCTGGCCCCTTGCT

SLGK

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGG

1962
TVSSNYMSWVRQAPGKGLEWVSVIYS
2070
GGAGGCTTGGTCCAGCCTGGGGGGT

GGSTYYADSVKGRFTISRDNSKNTLYL

CCCTGAGACTCTCCTGTGCAGCCTC

QMNSLRAEDTAVYYCARDYYYGSGSS

TGGATTCACCGTCAGTAGCAACTAC

PWGQGTLVTVSSASTKGPSVFPLAPCS

ATGAGCTGGGTCCGCCAGGCTCCAG

RSTSESTAALGCLVKDYFPEPVTVSWN

GGAAGGGGCTGGAGTGGGTCTCAGT

SGALTSGVHTFPAVLQSSGLYSLSSVV

TATTTATAGCGGTGGTAGCACATAC

TVPSSSLGTKTYTCNVDHKPSNTKVDK

TACGCAGACTCCGTGAAGGGCAGAT

RVESKYGPPCPPCPAPEFLGGPSVFLFP

TCACCATCTCCAGAGACAATTCCAA

PKPKDTLMISRTPEVTCVVVDVSQEDP

GAACACGCTGTATCTTCAAATGAAC

EVQFNWYVDGVEVHNAKTKPREEQF

AGCCTGAGAGCCGAGGACACGGCT

NSTYRVVSVLTVLHQDWLNGKEYKC

GTGTATTACTGTGCGAGAGACTATT

KVSNKGLPSSIEKTISKAKGQPREPQVY

ACTATGGTTCGGGGAGTTCTCCCTG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GGGCCAGGGAACCCTGGTCACCGTC

IAVEWESNGQPENNYKTTPPVLDSDGS

TCCTCAGCATCCACCAAGGGGCCTT

FFLYSRLTVDKSRWQEGNVFSCSVMH

CCGTGTTCCCCCTGGCCCCTTGCTCC

EALHNHYTQKSLSLSLGK

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1963
GSFSGYYWSWIRQPPGKGLEWIGEINH
2071
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRPYCSSTSCY

GGTGGGTCCTTCAGTGGTTACTACT

PEWFDPWGQGTLVTVSSASTKGPSVFP

GGAGCTGGATCCGCCAGCCCCCAGG

LAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGATTGGGGA

TVSWNSGALTSGVHTFPAVLQSSGLYS

AATCAATCATAGTGGAAGCACCAAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

TACAACCCGTCCCTCAAGAGTCGAG

TKVDKRVESKYGPPCPPCPAPEFLGGP

TCACCATATCAGTAGACACGTCCAA

SVFLFPPKPKDTLMISRTPEVTCVVVD

GAACCAGTTCTCCCTGAAGCTGAGC

VSQEDPEVQFNWYVDGVEVHNAKTK

TCTGTGACCGCCGCGGACACGGCTG

PREEQFNSTYRVVSVLTVLHQDWLNG

TGTATTACTGTGCGAGAGGCCGGCC

KEYKCKVSNKGLPSSIEKTISKAKGQP

ATATTGTAGTAGTACCAGCTGCTAC

REPQVYTLPPSQEEMTKNQVSLTCLVK

CCAGAGTGGTTCGACCCCTGGGGCC

GFYPSDIAVEWESNGQPENNYKTTPPV

AGGGAACCCTGGTCACCGTCTCCTC

LDSDGSFFLYSRLTVDKSRWQEGNVFS

AGCATCCACCAAGGGGCCTTCCGTG

CSVMHEALHNHYTQKSLSLSLGK

TTCCCCCTGGCCCCTTGCTCCCGCTC

GACCTCTGAATCCACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCAAGACCTATACCTGCAA

CGTCGACCACAAGCCCTCCAACACC

AAAGTGGACAAGCGCGTCGAATCC

AAGTACGGCCCCCCTTGTCCGCCTT

GTCCAGCCCCTGAGTTCCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCAGGAAGATC

CCGAAGTGCAGTTCAATTGGTACGT

GGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTTCAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGG

ACTGGCTGAACGGAAAGGAGTACA

AGTGCAAAGTGTCAAACAAGGGCCT

CCCTTCATCCATCGAAAAGACCATC

AGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTACACTTTGCCGC

CTAGCCAAGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCCGGCTG

ACTGTGGACAAGTCAAGATGGCAG

GAGGGAAACGTGTTCTCCTGCTCCG

TGATGCACGAAGCGCTGCACAACCA

TTACACCCAGAAATCACTGTCACTT

TCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1964
TFSSYGMHWVRQAPGKGLEWVAVISY
2072
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKLRGIDYY

GGATTCACCTTCAGTAGCTATGGCA

DSSGYQRGFDYWGQGTLVTVSSASTK

TGCACTGGGTCCGCCAGGCTCCAGG

GPSVFPLAPCSRSTSESTAALGCLVKD

CAAGGGGCTGGAGTGGGTGGCAGTT

YFPEPVTVSWNSGALTSGVHTFPAVLQ

ATATCATATGATGGAAGTAATAAAT

SSGLYSLSSVVTVPSSSLGTKTYTCNV

ACTATGCAGACTCCGTGAAGGGCCG

DHKPSNTKVDKRVESKYGPPCPPCPAP

ATTCACCATCTCCAGAGACAATTCC

EFLGGPSVFLFPPKPKDTLMISRTPEVT

AAGAACACGCTGTATCTGCAAATGA

CVVVDVSQEDPEVQFNWYVDGVEVH

ACAGCCTGAGAGCTGAGGACACGG

NAKTKPREEQFNSTYRVVSVLTVLHQ

CTGTGTATTACTGTGCGAAATTAAG

DWLNGKEYKCKVSNKGLPSSIEKTISK

GGGTATAGATTACTATGATAGTAGT

AKGQPREPQVYTLPPSQEEMTKNQVS

GGTTACCAACGGGGGTTTGACTACT

LTCLVKGFYPSDIAVEWESNGQPENNY

GGGGCCAGGGAACCCTGGTCACCGT

KTTPPVLDSDGSFFLYSRLTVDKSRWQ

CTCCTCAGCATCCACCAAGGGGCCT

EGNVFSCSVMHEALHNHYTQKSLSLS

TCCGTGTTCCCCCTGGCCCCTTGCTC

LGK

CCGCTCGACCTCTGAATCCACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCAAGACCTATA

CCTGCAACGTCGACCACAAGCCCTC

CAACACCAAAGTGGACAAGCGCGT

CGAATCCAAGTACGGCCCCCCTTGT

CCGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLQESGPGLVKPSETLSLTCTVSGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGCC

1965
SISSYYWSWIRQPPGKGLEWIGYIYYT
2073
CAGGACTGGTGAAGCCTTCGGAGAC

GSTNYNPSLKSRVTISVDTSKNQFSLKL

CCTGTCCCTCACCTGCACTGTCTCTG

SSVTTADTAVYYCARGGRGDGAAFDI

GTGGCTCCATCAGTAGTTACTACTG

WGQGTMVTVSSASTKGPSVFPLAPCS

GAGCTGGATCCGGCAGCCCCCAGGG

RSTSESTAALGCLVKDYFPEPVTVSWN

AAGGGACTGGAGTGGATTGGCTATA

SGALTSGVHTFPAVLQSSGLYSLSSVV

TCTATTACACTGGGAGCACCAACTA

TVPSSSLGTKTYTCNVDHKPSNTKVDK

CAACCCCTCCCTCAAGAGCCGAGTC

RVESKYGPPCPPCPAPEFLGGPSVFLFP

ACCATATCAGTAGACACGTCCAAGA

PKPKDTLMISRTPEVTCVVVDVSQEDP

ACCAGTTCTCCCTGAAGCTGAGCTC

EVQFNWYVDGVEVHNAKTKPREEQF

TGTGACCACTGCGGACACGGCCGTG

NSTYRVVSVLTVLHQDWLNGKEYKC

TATTACTGTGCGAGAGGTGGGAGGG

KVSNKGLPSSIEKTISKAKGQPREPQVY

GGGATGGGGCCGCTTTTGACATCTG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GGGCCAAGGGACAATGGTCACCGTC

IAVEWESNGQPENNYKTTPPVLDSDGS

TCTTCAGCATCCACCAAGGGGCCTT

FFLYSRLTVDKSRWQEGNVFSCSVMH

CCGTGTTCCCCCTGGCCCCTTGCTCC

EALHNHYTQKSLSLSLGK

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

1966
FTFSSSAMHWVRQAPGKGLEWVAMI
2074
GAGGCGTGGTCCAGCCTGGGAGGTC

WHDESKKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARPPDGG

GGATTCACCTTCAGCAGCTCTGCCA

NSGRWYFDLWGRGTLVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPCSRSTSESTAALGCLVKDYFP

CAAGGGACTGGAGTGGGTGGCAAT

EPVTVSWNSGALTSGVHTFPAVLQSSG

GATTTGGCATGATGAGAGTAAGAAA

LYSLSSVVTVPSSSLGTKTYTCNVDHK

TACTATGCAGACTCCGTGAAGGGCC

PSNTKVDKRVESKYGPPCPPCPAPEFL

GATTCACTATCTCCAGAGACAATTC

GGPSVFLFPPKPKDTLMISRTPEVTCVV

CAAGAACACGCTGTATCTGCAAATG

VDVSQEDPEVQFNWYVDGVEVHNAK

AACAGCCTGAGAGCTGAGGACACG

TKPREEQFNSTYRVVSVLTVLHQDWL

GCTGTGTATTACTGTGCGAGACCCC

NGKEYKCKVSNKGLPSSIEKTISKAKG

CCGACGGTGGTAACTCCGGTCGCTG

QPREPQVYTLPPSQEEMTKNQVSLTCL

GTACTTCGATCTCTGGGGCCGTGGC

VKGFYPSDIAVEWESNGQPENNYKTTP

ACCCTGGTCACCGTCTCCTCAGCAT

PVLDSDGSFFLYSRLTVDKSRWQEGN

CCACCAAGGGGCCTTCCGTGTTCCC

VFSCSVMHEALHNHYTQKSLSLSLGK

CCTGGCCCCTTGCTCCCGCTCGACCT

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QMQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

1967
FTFSSYAMSWVRQAPGKGLEWVSAIS
2075
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDKNVRK

GGATTCACCTTTAGCAGCTATGCCA

HDYGDHPYGGYFDYWGQGTLVTVSS

TGAGCTGGGTCCGCCAGGCTCCAGG

ASTKGPSVFPLAPCSRSTSESTAALGCL

GAAGGGGCTGGAGTGGGTCTCAGCT

VKDYFPEPVTVSWNSGALTSGVHTFP

ATTAGTGGTAGTGGTGGTAGCACAT

AVLQSSGLYSLSSVVTVPSSSLGTKTY

ACTACGCAGACTCCGTGAAGGGCCG

TCNVDHKPSNTKVDKRVESKYGPPCP

GTTCACCATCTCCAGAGACAATTCC

PCPAPEFLGGPSVFLFPPKPKDTLMISR

AAGAACACGCTGTATCTGCAAATGA

TPEVTCVVVDVSQEDPEVQFNWYVDG

ACAGCCTGAGAGCCGAGGACACGG

VEVHNAKTKPREEQFNSTYRVVSVLT

CCGTATATTACTGTGCGAAAGACAA

VLHQDWLNGKEYKCKVSNKGLPSSIE

GAACGTCCGAAAACATGACTACGGT

KTISKAKGQPREPQVYTLPPSQEEMTK

GACCACCCCTACGGGGGGTACTTTG

NQVSLTCLVKGFYPSDIAVEWESNGQP

ACTACTGGGGCCAGGGCACCCTGGT

ENNYKTTPPVLDSDGSFFLYSRLTVDK

GACCGTCTCCTCAGCATCCACCAAG

SRWQEGNVFSCSVMHEALHNHYTQKS

GGGCCTTCCGTGTTCCCCCTGGCCC

LSLSLGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

1968
YTFTSYAMHWVRQAPGQRLEWMGWI
2076
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVAGATS

GGATACACCTTCACTAGCTATGCTA

LWYWGQGTLVTVSSASTKGPSVFPLA

TGCATTGGGTGCGCCAGGCCCCCGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

ACAAAGGCTTGAGTGGATGGGATG

WNSGALTSGVHTFPAVLQSSGLYSLSS

CGCGAGCACAGCCTACATGGAGCTG

GATCAACGCTGGCAATGGTAACACA

AGCAGCCTGAGATCTGAAGACACG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GCTGTGTATTACTGTGCGAGAGTGG

AAATATTCACAGAAGTTCCAGGGCA

CGGGAGCTACTTCCCTATGGTACTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

GGGCCAGGGCACCCTGGTCACCGTC

GAGTCACCATTACCAGGGACACATC

TCCTCAGCATCCACCAAGGGGCCTT

FPPKPKDTLMISRTPEVTCVVVDVSQE

CCGTGTTCCCCCTGGCCCCTTGCTCC

DPEVQFNWYVDGVEVHNAKTKPREE

CGCTCGACCTCTGAATCCACCGCCG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CACTCGGTTGCCTGGTCAAAGACTA

CKVSNKGLPSSIEKTISKAKGQPREPQV

CTTCCCCGAGCCCGTGACTGTCTCG

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGGAACTCGGGCGCCCTCACATCCG

DIAVEWESNGQPENNYKTTPPVLDSD

GAGTGCATACCTTTCCCGCCGTGTT

GSFFLYSRLTVDKSRWQEGNVFSCSV

GCAGTCCAGCGGCCTGTACAGCCTG

MHEALHNHYTQKSLSLSLGK

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQSLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1969
SVSSNSAAWNWIRQSPSRGLEWLGRT
2077
CAGGACTGGTGAAGCCCTCGCAGAG

YYRSKWYNDYAVSVKSRITIKPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCTRLANSDG

GGGACAGTGTCTCTAGCAACAGTGC

VDVWGQGTMVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GTATAATGATTATGCAGTATCTGTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AAGAGTCGAATAACCATCAAACCA

FPPKPKDTLMISRTPEVTCVVVDVSQE

GACACATCCAAGAACCAGTTCTCCC

DPEVQFNWYVDGVEVHNAKTKPREE

TGCAGCTGAACTCTGTGACTCCCGA

QFNSTYRVVSVLTVLHQDWLNGKEYK

GGACACGGCTGTGTATTACTGTACA

CKVSNKGLPSSIEKTISKAKGQPREPQV

AGGCTAGCTAATTCCGACGGTGTGG

YTLPPSQEEMTKNQVSLTCLVKGFYPS

ACGTCTGGGGCCAAGGGACAATGGT

DIAVEWESNGQPENNYKTTPPVLDSD

CACCGTCTCCTCAGCATCCACCAAG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GGGCCTTCCGTGTTCCCCCTGGCCC

MHEALHNHYTQKSLSLSLGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1970
SVSSDSAVWTWIRQSPSRGLEWLGRT
2078
CAGGACTGGTGAAGCCCTCGCAGAC

YYKSKWYNDYAASVKSRITINPDTSK

CCTCTCACTCACCTGTGCCATCTCCG

NQFSLHLNSVTPEDTAVYYCARGVTR

GGGACAGTGTCTCTAGCGACAGTGC

TFDYWGQGTTVTVSSASTKGPSVFPLA

TGTTTGGACCTGGATCAGGCAGTCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAAGTCGAAGT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GGTATAATGATTATGCAGCATCTGT

DKRVESKYGPPCPPCPAPEFLGGPSVFL

GAAAAGTCGAATAACCATCAACCCA

FPPKPKDTLMISRTPEVTCVVVDVSQE

GACACATCCAAGAACCAGTTCTCCC

DPEVQFNWYVDGVEVHNAKTKPREE

TGCACCTGAACTCTGTGACTCCCGA

QFNSTYRVVSVLTVLHQDWLNGKEYK

GGACACGGCTGTGTATTACTGTGCA

CKVSNKGLPSSIEKTISKAKGQPREPQV

AGAGGTGTAACCCGGACCTTTGACT

YTLPPSQEEMTKNQVSLTCLVKGFYPS

ACTGGGGCCAGGGGACCACGGTCA

DIAVEWESNGQPENNYKTTPPVLDSD

CCGTCTCCTCAGCATCCACCAAGGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GCCTTCCGTGTTCCCCCTGGCCCCTT

MHEALHNHYTQKSLSLSLGK

GCTCCCGCTCGACCTCTGAATCCAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCAAGACC

TATACCTGCAACGTCGACCACAAGC

CCTCCAACACCAAAGTGGACAAGCG

CGTCGAATCCAAGTACGGCCCCCCT

TGTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QLQLQESGPGLVKPSQTLSLTCAISGDS
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC

1971
VSSNSAAWNWIRQSPSRGLEWLGRTY
2079
CAGGACTGGTGAAGCCCTCGCAGAC

YRSKWYNDYAVSVKSRITINPDTSKNQ

CCTCTCACTCACCTGTGCCATCTCCG

FSLQLNSVTPEDTAVYYCAEGNGPFDP

GGGACAGTGTCTCTAGCAACAGTGC

WGQGTLVTVSSASTKGPSVFPLAPCSR

TGCTTGGAACTGGATCAGGCAGTCC

STSESTAALGCLVKDYFPEPVTVSWNS

CCATCGAGAGGCCTTGAGTGGCTGG

GALTSGVHTFPAVLQSSGLYSLSSVVT

GAAGGACATACTACAGGTCCAAGTG

VPSSSLGTKTYTCNVDHKPSNTKVDK

GTATAATGATTATGCAGTATCTGTG

RVESKYGPPCPPCPAPEFLGGPSVFLFP

AAAAGTCGAATAACCATCAACCCAG

PKPKDTLMISRTPEVTCVVVDVSQEDP

ACACATCCAAGAACCAGTTCTCCCT

EVQFNWYVDGVEVHNAKTKPREEQF

GCAGCTGAACTCTGTGACTCCCGAG

NSTYRVVSVLTVLHQDWLNGKEYKC

GACACGGCTGTGTATTACTGTGCAG

KVSNKGLPSSIEKTISKAKGQPREPQVY

AAGGCAATGGGCCGTTCGACCCCTG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GGGCCAGGGAACCCTGGTGACCGTC

IAVEWESNGQPENNYKTTPPVLDSDGS

TCCTCAGCATCCACCAAGGGGCCTT

FFLYSRLTVDKSRWQEGNVFSCSVMH

CCGTGTTCCCCCTGGCCCCTTGCTCC

EALHNHYTQKSLSLSLGK

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QITLKESGGGVVQPGRSLRLSCVASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

1972
TFSTYPMHWVRQAPGKGLEWVAVISY
2080
GAGGCGTGGTCCAGCCTGGGAGGTC

DGRNEYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGTAGCCTCT

YLQMNSLRAEDTAVYYCATRDTPLVG

GGATTCACCTTCAGTACCTATCCCA

VSIYWGQGTLVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTGGCAGTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATATCATATGATGGACGTAATGAAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTACGCAGACTCCGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCATCTCCAGAGACAATTCC

FPPKPKDTLMISRTPEVTCWVDVSQE

AAAAACACGCTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAGTCTGCGAGCTGAAGACACGGC

QFNSTYRVVSVLTVLHQDWLNGKEYK

TGTCTATTATTGTGCGACTCGGGAT

CKVSNKGLPSSIEKTISKAKGQPREPQV

ACACCTTTGGTTGGGGTTTCGATAT

YTLPPSQEEMTKNQVSLTCLVKGFYPS

ACTGGGGCCAGGGCACCCTGGTCAC

DIAVEWESNGQPENNYKTTPPVLDSD

CGTCTCCTCAGCATCCACCAAGGGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

CCTTCCGTGTTCCCCCTGGCCCCTTG

MHEALHNHYTQKSLSLSLGK

CTCCCGCTCGACCTCTGAATCCACC

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCAAGACCT

ATACCTGCAACGTCGACCACAAGCC

CTCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QMQLVQSGGGLVKAGGSLRLSCSASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

1973
FTFSSYAMHWVRQAPGKGLEYVSAISS
2081
GAGGCCTGGTCAAGGCTGGGGGGTC

NGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTTCAGCCTCTG

LQMSSLRAEDTAVYYCVNRAGYGDY

GATTCACCTTCAGTAGCTATGCTAT

RHFQHWGQGTLVTVSSASTKGPSVFPL

GCACTGGGTCCGCCAGGCTCCAGGG

APCSRSTSESTAALGCLVKDYFPEPVT

AAGGGACTGGAATATGTTTCAGCTA

VSWNSGALTSGVHTFPAVLQSSGLYSL

TTAGTAGTAATGGGGGTAGCACATA

SSVVTVPSSSLGTKTYTCNVDHKPSNT

CTACGCAGACTCAGTGAAGGGCAG

KVDKRVESKYGPPCPPCPAPEFLGGPS

ATTCACCATCTCCAGAGACAATTCC

VFLFPPKPKDTLMISRTPEVTCVVVDV

AAGAACACGCTGTATCTTCAAATGA

SQEDPEVQFNWYVDGVEVHNAKTKP

GCAGTCTGAGAGCTGAGGACACGG

REEQFNSTYRVVSVLTVLHQDWLNGK

CTGTGTATTACTGTGTGAATCGGGC

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GGGTTACGGTGACTACAGACACTTC

PQVYTLPPSQEEMTKNQVSLTCLVKGF

CAGCACTGGGGCCAGGGCACCCTGG

YPSDIAVEWESNGQPENNYKTTPPVLD

TCACCGTCTCCTCAGCATCCACCAA

SDGSFFLYSRLTVDKSRWQEGNVFSCS

GGGGCCTTCCGTGTTCCCCCTGGCC

VMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGGSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

1974
FTFSSYGMHWVRQAPGKGLEWVAFIS
2082
GAGGCGTGGTCCAGCCTGGGGGGTC

YDGSNKYYADSVKGRFTISRDNSKNT

CCTGAGACTCTCCTGTGCAGCGTCT

LYLQMNSLRAEDTAVYYCATTGDRFQ

GGATTCACCTTCAGTAGCTATGGCA

EFDYWGQGTLVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTGGCATTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATATCATATGATGGAAGTAATAAAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTACGCAGACTCCGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCATCTCCAGAGACAATTCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

AAGAACACGCTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAGCCTGAGAGCCGAGGACACGG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CCGTATATTACTGTGCGACAACAGG

CKVSNKGLPSSIEKTISKAKGQPREPQV

GGACCGCTTCCAAGAGTTTGACTAC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGGGGCCAGGGAACCCTGGTCACCG

DIAVEWESNGQPENNYKTTPPVLDSD

TCTCCTCAGCATCCACCAAGGGGCC

GSFFLYSRLTVDKSRWQEGNVFSCSV

TTCCGTGTTCCCCCTGGCCCCTTGCT

MHEALHNHYTQKSLSLSLGK

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QMQLVQSGGVLLQPGRSLRLSCTASG
SEQ ID
CAGATGCAGCTGGTGCAGTCTGGGG

1975
FTFAAYNINWFRQGPGGGLEWVGFIR
2083
GAGTCTTGCTTCAGCCAGGGCGGTC

ANADSGTTEYAASVKGRFFISRDDSRS

CCTGAGACTCTCCTGTACAGCTTCT

TAYLQMTSLKTEDTAVYYCARDDRGR

GGATTCACCTTTGCTGCTTATAATAT

GDDFDYWGQGTLVTVSSASTKGPSVF

CAACTGGTTCCGCCAGGGTCCTGGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GGGGGGCTGGAGTGGGTAGGTTTCA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAGAGCCAACGCTGATAGTGGGAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACAGAGTACGCCGCGTCTGTGAAA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GGCAGATTCTTCATCTCAAGAGATG

SVFLFPPKPKDTLMISRTPEVTCVVVD

ATTCCAGAAGCACCGCCTACCTGCA

VSQEDPEVQFNWYVDGVEVHNAKTK

AATGACTAGCCTTAAAACCGAGGAC

PREEQFNSTYRVVSVLTVLHQDWLNG

ACAGCCGTTTATTACTGTGCCAGAG

KEYKCKVSNKGLPSSIEKTISKAKGQP

ATGATCGGGGTCGGGGAGATGACTT

REPQVYTLPPSQEEMTKNQVSLTCLVK

TGACTACTGGGGCCAGGGCACCCTG

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCACCGTCTCCTCAGCATCCACCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

AGGGGCCTTCCGTGTTCCCCCTGGC

CSVMHEALHNHYTQKSLSLSLGK

CCCTTGCTCCCGCTCGACCTCTGAAT

CCACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCAA

GACCTATACCTGCAACGTCGACCAC

AAGCCCTCCAACACCAAAGTGGACA

AGCGCGTCGAATCCAAGTACGGCCC

CCCTTGTCCGCCTTGTCCAGCCCCTG

AGTTCCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCAGGAAGATCCCGAAGTGCA

GTTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTTCAACTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGGCCTCCCTTCATCCA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCAAGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCCGGCTGACTGTGGACAAGTC

AAGATGGCAGGAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

1976
FTFSSYGMTWVRQAPGKGLEWVSTIS
2084
GAGGCTTGGTACAGCCTGGGGGGTC

GNGVGTYYPDSVKDRFTISRDSSKNTV

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCVKHGRAGIN

GGATTCACCTTTAGCAGCTATGGCA

WYFDLWGRGTLVTVSSASTKGPSVFP

TGACGTGGGTCCGCCAGGCTCCAGG

LAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGGTCTCAACT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATTAGTGGTAATGGTGTTGGCACAT

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ACTACCCAGACTCCGTGAAGGACCG

TKVDKRVESKYGPPCPPCPAPEFLGGP

GTTCACCATCTCCAGAGACAGTTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGGTGTATCTGCAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCCGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CCGTATATTACTGTGTGAAACATGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

TAGGGCCGGAATAAACTGGTACTTC

REPQVYTLPPSQEEMTKNQVSLTCLVK

GATCTCTGGGGCCGTGGCACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TGACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

1977
SVSSNSAAWNWIRQSPSRGLEWLGRT
2085
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARGGGLW

GGGACAGTGTCTCTAGCAACAGTGC

AFDIWGQGTTVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GTATAATGATTATGCAGTATCTGTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AAAAGTCGAATAACCATCAACCCAG

FPPKPKDTLMISRTPEVTCVVVDVSQE

ACACATCCAAGAACCAGTTCTCCCT

DPEVQFNWYVDGVEVHNAKTKPREE

GCAGCTGAACTCTGTGACTCCCGAG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GACACGGCTGTGTATTACTGTGCAA

CKVSNKGLPSSIEKTISKAKGQPREPQV

GAGGGGGAGGGCTTTGGGCTTTTGA

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TATCTGGGGCCAAGGGACCACGGTC

DIAVEWESNGQPENNYKTTPPVLDSD

ACCGTCTCCTCAGCATCCACCAAGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GGCCTTCCGTGTTCCCCCTGGCCCCT

MHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

1978
YTFTGYYMHWVRQAPGQGLEWMGW
2086
CTGAGGTGAAGAAGCCTGGGGCCTC

INPNSGGTNYAQKFQGRVTMTRDTSIS

AGTGAAGGTCTCCTGCAAGGCTTCT

TAYMELSRLRSDDTAVYYCARDKIGS

GGATACACCTTCACCGGCTACTATA

CPYWGQGTLVTVSSASTKGPSVFPLAP

TGCACTGGGTGCGACAGGCCCCTGG

CSRSTSESTAALGCLVKDYFPEPVTVS

ACAAGGGCTTGAGTGGATGGGATG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GATCAACCCTAACAGTGGTGGCACA

VVTVPSSSLGTKTYTCNVDHKPSNTKV

AACTATGCACAGAAGTTTCAGGGCA

DKRVESKYGPPCPPCPAPEFLGGPSVFL

GGGTCACCATGACCAGGGACACGTC

FPPKPKDTLMISRTPEVTCVVVDVSQE

CATCAGCACAGCCTACATGGAGCTG

DPEVQFNWYVDGVEVHNAKTKPREE

AGCAGGCTGAGATCTGACGACACG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GCCGTGTATTACTGTGCGAGAGACA

CKVSNKGLPSSIEKTISKAKGQPREPQV

AGATCGGCAGCTGTCCTTACTGGGG

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CCAGGGAACCCTGGTCACCGTCTCC

DIAVEWESNGQPENNYKTTPPVLDSD

TCAGCATCCACCAAGGGGCCTTCCG

GSFFLYSRLTVDKSRWQEGNVFSCSV

TGTTCCCCCTGGCCCCTTGCTCCCGC

MHEALHNHYTQKSLSLSLGK

TCGACCTCTGAATCCACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCAAGACCTATACCTG

CAACGTCGACCACAAGCCCTCCAAC

ACCAAAGTGGACAAGCGCGTCGAA

TCCAAGTACGGCCCCCCTTGTCCGC

CTTGTCCAGCCCCTGAGTTCCTGGG

TGGTCCGTCCGTGTTCCTCTTCCCGC

CCAAGCCGAAGGACACTCTGATGAT

TTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCAGGAAG

ATCCCGAAGTGCAGTTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTTCAACTCTACGTACCGGGTGG

TGTCCGTGCTGACCGTGCTGCACCA

GGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGG

CCTCCCTTCATCCATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTACACTTTGCC

GCCTAGCCAAGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCCGGCT

GACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QVTLKESGPTLVKPTQTLTLTCTFSGFS
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTC

1979
LSTSGVGVGWIRQPPGKALEWLALIY
2087
CTACGCTGGTGAAACCCACACAGAC

WDDDKRYSPSLKSRLTITKDTSKNQV

CCTCACGCTGACCTGCACCTTCTCTG

VLTMTNMDPVDTATYYCAHRPDSSSQ

GGTTCTCACTCAGCACTAGTGGAGT

CFDYWGQGTLVTVSSASTKGPSVFPLA

GGGTGTGGGCTGGATCCGTCAGCCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCAGGAAAGGCCCTGGAGTGGCTTG

WNSGALTSGVHTFPAVLQSSGLYSLSS

CACTCATTTATTGGGATGATGATAA

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GCGCTACAGCCCATCTCTGAAGAGC

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AGGCTCACCATCACCAAGGACACCT

FPPKPKDTLMISRTPEVTCVVVDVSQE

CCAAAAACCAGGTGGTCCTTACAAT

DPEVQFNWYVDGVEVHNAKTKPREE

GACCAACATGGACCCTGTGGACACA

QFNSTYRVVSVLTVLHQDWLNGKEYK

GCCACATATTACTGTGCACACAGAC

CKVSNKGLPSSIEKTISKAKGQPREPQV

CGGATAGCAGCAGTCAATGTTTTGA

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CTACTGGGGCCAGGGAACCCTGGTC

DIAVEWESNGQPENNYKTTPPVLDSD

ACCGTCTCCTCAGCATCCACCAAGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GGCCTTCCGTGTTCCCCCTGGCCCCT

MHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1980
TFSSYAMHWVRQAPGKGLEWVAVISY
2088
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARSSGWSLP

GGATTCACCTTCAGTAGCTATGCTA

EDYWGQGTLVTVSSASTKGPSVFPLAP

TGCACTGGGTCCGCCAGGCTCCAGG

CSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTGGCAGTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATATCATATGATGGAAGTAATAAAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTACGCAGACTCCGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCATCTCCAGAGACAATTCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

AAGAACACGCTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAGCCTGAGAGCTGAGGACACGG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CTGTGTATTACTGTGCGAGAAGCAG

CKVSNKGLPSSIEKTISKAKGQPREPQV

TGGCTGGTCACTGCCTGAAGACTAC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGGGGCCAGGGAACCCTGGTCACCG

DIAVEWESNGQPENNYKTTPPVLDSD

TCTCCTCAGCATCCACCAAGGGGCC

GSFFLYSRLTVDKSRWQEGNVFSCSV

TTCCGTGTTCCCCCTGGCCCCTTGCT

MHEALHNHYTQKSLSLSLGK

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKVSG
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG

1981
YTLTELSMHWVRQAPGKGLEWMGGF
2089
CTGAGGTGAAGAAGCCTGGGGCCTC

DPEDGETIYAQKFQGRVTMTEDTSTDT

AGTGAAGGTCTCCTGCAAGGTTTCC

AYMELSSLRSEDTAVYYCATDVNPEL

GGATACACCCTCACTGAATTATCCA

LGAGFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTGCGACAGGCTCCTGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

AAAAGGGCTTGAGTGGATGGGAGG

VTVSWNSGALTSGVHTFPAVLQSSGL

TTTTGATCCTGAAGATGGTGAAACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ATCTACGCACAGAAGTTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATGACCGAGGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

TACAGACACAGCCTACATGGAGCTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQFNSTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCAACGGATG

GKEYKCKVSNKGLPSSIEKTISKAKGQ

TGAACCCGGAGCTACTGGGGGCGG

PREPQVYTLPPSQEEMTKNQVSLTCLV

GATTTGACTACTGGGGCCAGGGCAC

KGFYPSDIAVEWESNGQPENNYKTTPP

CCTGGTCACCGTCTCCTCAGCATCC

VLDSDGSFFLYSRLTVDKSRWQEGNV

ACCAAGGGGCCTTCCGTGTTCCCCC

FSCSVMHEALHNHYTQKSLSLSLGK

TGGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVTLKESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1982
TFSDQYMDWVRQAPGKGLEWVGRVR
2090
GAGGCTTGGTCCAGCCTGGAGGGTC

NKANSYTTEYAASVKGRFTISRDDSKN

CCTGAGACTCTCCTGTGCAGCCTCT

SLYLQMNSLNTEDTAMYFCASSLNSG

GGATTCACCTTCAGTGACCAGTACA

GYRCFHHWGQGTLVTVSSASTKGPSV

TGGACTGGGTCCGCCAGGCTCCAGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

GAAGGGGCTGGAGTGGGTTGGCCGT

VTVSWNSGALTSGVHTFPAVLQSSGL

GTTAGAAACAAAGCTAACAGTTACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

CCACAGAATACGCCGCGTCTGTGAA

SNTKVDKRVESKYGPPCPPCPAPEFLG

AGGCAGATTCACCATCTCAAGAGAT

GPSVFLFPPKPKDTLMISRTPEVTCVVV

GATTCAAAGAACTCACTGTATCTGC

DVSQEDPEVQFNWYVDGVEVHNAKT

AAATGAATAGTCTGAACACCGAGG

KPREEQFNSTYRVVSVLTVLHQDWLN

ACACGGCCATGTATTTCTGTGCTAG

GKEYKCKVSNKGLPSSIEKTISKAKGQ

TAGTCTCAATAGTGGGGGCTACCGA

PREPQVYTLPPSQEEMTKNQVSLTCLV

TGCTTCCATCACTGGGGCCAGGGCA

KGFYPSDIAVEWESNGQPENNYKTTPP

CCCTGGTGACCGTCTCCTCAGCATC

VLDSDGSFFLYSRLTVDKSRWQEGNV

CACCAAGGGGCCTTCCGTGTTCCCC

FSCSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCSASGF
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

1983
TFSSYAMHWVRQAPGKGLEYVSAISS
2091
GAGGCTTGGTCCAGCCTGGGGGGTC

NGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTTCAGCCTCTG

LQMSSLRAEDTAVYYCVKAPRGVVPA

GATTCACCTTCAGTAGCTATGCTAT

AMRGGYWGQGTLVTVSSASTKGPSVF

GCACTGGGTCCGCCAGGCTCCAGGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

AAGGGACTGGAATATGTTTCAGCTA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAGTAGTAATGGGGGTAGCACATA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

CTACGCAGACTCAGTGAAGGGCAG

TKVDKRVESKYGPPCPPCPAPEFLGGP

ATTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTTCAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

GCAGTCTGAGAGCTGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CTGTGTATTACTGTGTGAAAGCGCC

KEYKCKVSNKGLPSSIEKTISKAKGQP

GAGGGGTGTAGTACCAGCTGCTATG

REPQVYTLPPSQEEMTKNQVSLTCLVK

CGGGGGGGCTACTGGGGCCAGGGA

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCCTGGTCACCGTCTCCTCAGCAT

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCACCAAGGGGCCTTCCGTGTTCCC

CSVMHEALHNHYTQKSLSLSLGK

CCTGGCCCCTTGCTCCCGCTCGACCT

CTGAATCCACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCAAGACCTATACCTGCAACGTC

GACCACAAGCCCTCCAACACCAAAG

TGGACAAGCGCGTCGAATCCAAGTA

CGGCCCCCCTTGTCCGCCTTGTCCA

GCCCCTGAGTTCCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
QVQLQESGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

1984
TFGDYAMSWFRQAPGKGLEWVGFIRS
2092
GGAGGCTTGGTACAGCCAGGGCGGT

KAYGGTTEYAASVKGRFTISRDDSKSI

CCCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRLVGNSG

GGATTCACCTTTGGTGATTATGCTAT

SYYPFGYWGQGTLVTVSSASTKGPSVF

GAGCTGGTTCCGCCAGGCTCCAGGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

AAGGGGCTGGAGTGGGTAGGTTTCA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAGAAGCAAAGCTTATGGTGGGAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACAGAATACGCCGCGTCTGTGAAA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GGCAGATTCACCATCTCAAGAGATG

SVFLFPPKPKDTLMISRTPEVTCVVVD

ATTCCAAAAGCATCGCCTATCTGCA

VSQEDPEVQFNWYVDGVEVHNAKTK

AATGAACAGCCTGAAAACCGAGGA

PREEQFNSTYRVVSVLTVLHQDWLNG

CACAGCCGTGTATTACTGTACTAGA

KEYKCKVSNKGLPSSIEKTISKAKGQP

TTGGTGGGCAATAGTGGGAGCTACT

REPQVYTLPPSQEEMTKNQVSLTCLVK

ATCCGTTTGGGTACTGGGGCCAGGG

GFYPSDIAVEWESNGQPENNYKTTPPV

AACCCTGGTGACCGTCTCCTCAGCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

TCCACCAAGGGGCCTTCCGTGTTCC

CSVMHEALHNHYTQKSLSLSLGK

CCCTGGCCCCTTGCTCCCGCTCGAC

CTCTGAATCCACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1985
GSFSGYYWSWIRQPPGKGLEWIGEINH
2093
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRSLPYRGLA

GGTGGGTCCTTCAGTGGTTACTACT

PRSFGGYYFDYWGQGTLVTVSSASTK

GGAGCTGGATCCGCCAGCCCCCAGG

GPSVFPLAPCSRSTSESTAALGCLVKD

GAAGGGGCTGGAGTGGATTGGGGA

YFPEPVTVSWNSGALTSGVHTFPAVLQ

AATCAATCATAGTGGAAGCACCAAC

SSGLYSLSSVVTVPSSSLGTKTYTCNV

TACAACCCGTCCCTCAAGAGTCGAG

DHKPSNTKVDKRVESKYGPPCPPCPAP

TCACCATATCAGTAGACACGTCCAA

EFLGGPSVFLFPPKPKDTLMISRTPEVT

GAACCAGTTCTCCCTGAAGCTGAGC

CVVVDVSQEDPEVQFNWYVDGVEVH

TCGGTGACCGCCGCGGACACGGCTG

NAKTKPREEQFNSTYRVVSVLTVLHQ

TGTATTACTGTGCGAGAGGCCGGTC

DWLNGKEYKCKVSNKGLPSSIEKTISK

CCTTCCCTACCGGGGGTTGGCTCCT

AKGQPREPQVYTLPPSQEEMTKNQVS

AGATCTTTCGGAGGATACTACTTTG

LTCLVKGFYPSDIAVEWESNGQPENNY

ACTACTGGGGCCAGGGAACCCTGGT

KTTPPVLDSDGSFFLYSRLTVDKSRWQ

CACCGTCTCCTCAGCATCCACCAAG

EGNVFSCSVMHEALHNHYTQKSLSLS

GGGCCTTCCGTGTTCCCCCTGGCCC

LGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQESGGGLVRPGGSLRLSCGDSGF
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

1986
NFSGYEMNWVRQAPGKGLEWVSYVS
2094
GGAGGCTTGGTACGGCCTGGAGGGT

TSGSTRYYADSVKGRFTISRDNAKNTL

CCCTGAGACTCTCCTGTGGAGACTC

YLQMNSLRVEDTAVYYCARGRTHWG

TGGATTCAACTTCAGTGGATATGAA

PQDFDYWGQGTLVTVSSASTKGPSVFP

ATGAACTGGGTCCGCCAGGCTCCAG

LAPCSRSTSESTAALGCLVKDYFPEPV

GGAAGGGGCTGGAGTGGGTTTCATA

TVSWNSGALTSGVHTFPAVLQSSGLYS

CGTCAGTACTAGTGGTAGTACCAGA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

TACTACGCAGACTCTGTGAAGGGCC

TKVDKRVESKYGPPCPPCPAPEFLGGP

GATTTACCATCTCCAGAGACAACGC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CAAGAACACCCTGTATTTGCAAATG

VSQEDPEVQFNWYVDGVEVHNAKTK

AACAGTCTGAGAGTCGAGGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCTGTGTATTACTGTGCAAGAGGAC

KEYKCKVSNKGLPSSIEKTISKAKGQP

GGACTCACTGGGGCCCCCAGGACTT

REPQVYTLPPSQEEMTKNQVSLTCLVK

TGACTACTGGGGCCAGGGAACCCTG

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCACCGTCTCCTCAGCATCCACCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

AGGGGCCTTCCGTGTTCCCCCTGGC

CSVMHEALHNHYTQKSLSLSLGK

CCCTTGCTCCCGCTCGACCTCTGAAT

CCACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCAA

GACCTATACCTGCAACGTCGACCAC

AAGCCCTCCAACACCAAAGTGGACA

AGCGCGTCGAATCCAAGTACGGCCC

CCCTTGTCCGCCTTGTCCAGCCCCTG

AGTTCCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCAGGAAGATCCCGAAGTGCA

GTTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTTCAACTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGGCCTCCCTTCATCCA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCAAGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCCGGCTGACTGTGGACAAGTC

AAGATGGCAGGAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCTGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

1987
FTFSSYAMSWVRQAPGKGLEWVSAIS
2095
GGAGGCTTGGTACAGCCTGGGGGGT

GSGGSTYYADSVKGRFTISRDNSKNTL

CCCTGAGACTCTCCTGTGCAGCCTC

YLQMNSLRAEDTAVYYCAKGGMYYY

TGGATTCACCTTTAGCAGCTATGCC

GSGSSYFDYWGQGTLVTVSSASTKGPS

ATGAGCTGGGTCCGCCAGGCTCCAG

VFPLAPCSRSTSESTAALGCLVKDYFPE

GGAAGGGGCTGGAGTGGGTCTCAG

PVTVSWNSGALTSGVHTFPAVLQSSGL

CTATTAGTGGTAGTGGTGGTAGCAC

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ATACTACGCAGACTCCGTGAAGGGC

SNTKVDKRVESKYGPPCPPCPAPEFLG

CGGTTCACCATCTCCAGAGACAATT

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CCAAGAACACGCTGTATCTGCAAAT

DVSQEDPEVQFNWYVDGVEVHNAKT

GAACAGCCTGAGAGCCGAGGACAC

KPREEQFNSTYRVVSVLTVLHQDWLN

GGCCGTATATTACTGTGCGAAAGGA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GGAATGTATTACTATGGTTCGGGGA

PREPQVYTLPPSQEEMTKNQVSLTCLV

GCTCGTACTTTGACTACTGGGGCCA

KGFYPSDIAVEWESNGQPENNYKTTPP

GGGAACCCTGGTGACCGTCTCCTCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

GCATCCACCAAGGGGCCTTCCGTGT

FSCSVMHEALHNHYTQKSLSLSLGK

TCCCCCTGGCCCCTTGCTCCCGCTCG

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

1988
FTFSSYAMSWVRQAPGKGLEWVSGIS
2096
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNM

CCTGAGACTCTCCTGTGCAGCCTCT

LFLQMNSPRAEDTAVYYCAKKIAAAG

GGATTCACCTTTAGCAGCTATGCCA

KQPVDYWGQGTLVTVSSASTKGPSVF

TGAGCTGGGTCCGCCAGGCTCCAGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GAAGGGGCTGGAATGGGTCTCAGGT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATTAGTGGTAGTGGTGGTAGCACAT

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ACTACGCAGACTCCGTGAAGGGCCG

TKVDKRVESKYGPPCPPCPAPEFLGGP

GTTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACATGCTGTTTCTGCAAATGA

VSQEDPEVQFNWYVDGVEVHNAKTK

ACAGCCCGAGAGCCGAGGACACGG

PREEQFNSTYRVVSVLTVLHQDWLNG

CCGTATATTACTGTGCGAAGAAAAT

KEYKCKVSNKGLPSSIEKTISKAKGQP

AGCAGCAGCTGGTAAGCAACCTGTT

REPQVYTLPPSQEEMTKNQVSLTCLVK

GACTACTGGGGCCAGGGAACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

1989
GSFSGYYWSWIRQPPGKGLEWIGEINH
2097
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARRKVYDYVWG

GGTGGGTCCTTCAGTGGTTACTACT

SYRLPGSVSYYFDYWGQGTLVTVSSA

GGAGCTGGATCCGCCAGCCCCCAGG

STKGPSVFPLAPCSRSTSESTAALGCLV

GAAGGGGCTGGAGTGGATTGGGGA

KDYFPEPVTVSWNSGALTSGVHTFPA

AATCAATCATAGTGGAAGCACCAAC

VLQSSGLYSLSSVVTVPSSSLGTKTYTC

TACAACCCGTCCCTCAAGAGTCGAG

NVDHKPSNTKVDKRVESKYGPPCPPCP

TCACCATATCAGTAGACACGTCCAA

APEFLGGPSVFLFPPKPKDTLMISRTPE

GAACCAGTTCTCCCTGAAGCTGAGC

VTCVVVDVSQEDPEVQFNWYVDGVE

TCTGTGACCGCCGCGGACACGGCTG

VHNAKTKPREEQFNSTYRVVSVLTVL

TGTATTACTGTGCGAGAAGGAAGGT

HQDWLNGKEYKCKVSNKGLPSSIEKTI

GTATGATTACGTTTGGGGGAGTTAT

SKAKGQPREPQVYTLPPSQEEMTKNQ

CGCCTCCCCGGGTCGGTATCGTACT

VSLTCLVKGFYPSDIAVEWESNGQPEN

ACTTTGACTACTGGGGCCAGGGAAC

NYKTTPPVLDSDGSFFLYSRLTVDKSR

CCTGGTCACCGTCTCCTCAGCATCC

WQEGNVFSCSVMHEALHNHYTQKSLS

ACCAAGGGGCCTTCCGTGTTCCCCC

LSLGK

TGGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGAG

1990
SFTSYWIGWVRQMPGKGLEWMGIIYP
2098
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARLPGRAARPD

TGGATACAGCTTTACCAGCTACTGG

YWGQGTLVTVSSASTKGPSVFPLAPCS

ATCGGCTGGGTGCGCCAGATGCCCG

RSTSESTAALGCLVKDYFPEPVTVSWN

GGAAAGGCCTGGAGTGGATGGGGA

SGALTSGVHTFPAVLQSSGLYSLSSVV

TCATCTATCCTGGTGACTCTGATACC

TVPSSSLGTKTYTCNVDHKPSNTKVDK

AGATACAGCCCGTCCTTCCAAGGCC

RVESKYGPPCPPCPAPEFLGGPSVFLFP

AGGTCACCATCTCAGCCGACAAGTC

PKPKDTLMISRTPEVTCVVVDVSQEDP

CATCAGCACCGCCTACCTGCAGTGG

EVQFNWYVDGVEVHNAKTKPREEQF

AGCAGCCTGAAGGCCTCGGACACCG

NSTYRVVSVLTVLHQDWLNGKEYKC

CCATGTATTACTGTGCGAGACTCCC

KVSNKGLPSSIEKTISKAKGQPREPQVY

GGGGAGAGCAGCTCGTCCAGACTAC

TLPPSQEEMTKNQVSLTCLVKGFYPSD

TGGGGCCAGGGCACCCTGGTCACCG

IAVEWESNGQPENNYKTTPPVLDSDGS

TCTCCTCAGCATCCACCAAGGGGCC

FFLYSRLTVDKSRWQEGNVFSCSVMH

TTCCGTGTTCCCCCTGGCCCCTTGCT

EALHNHYTQKSLSLSLGK

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1991
TFSSYAMHWVRQAPGKGLEWVAVISY
2099
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARGPGAVA

GGATTCACCTTCAGTAGCTATGCTA

GTKPKYYFDYWGQGTLVTVSSASTKG

TGCACTGGGTCCGCCAGGCTCCAGG

PSVFPLAPCSRSTSESTAALGCLVKDYF

CAAGGGGCTGGAGTGGGTGGCAGTT

PEPVTVSWNSGALTSGVHTFPAVLQSS

ATATCATATGATGGAAGTAATAAAT

GLYSLSSVVTVPSSSLGTKTYTCNVDH

ACTACGCAGACTCCGTGAAGGGCCG

KPSNTKVDKRVESKYGPPCPPCPAPEF

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSQEDPEVQFNWYVDGVEVHNA

ACAGCCTGAGAGCTGAGGACACGG

KTKPREEQFNSTYRVVSVLTVLHQDW

CTGTGTATTACTGTGCGAGAGGCCC

LNGKEYKCKVSNKGLPSSIEKTISKAK

CGGGGCAGTGGCTGGTACTAAGCCA

GQPREPQVYTLPPSQEEMTKNQVSLTC

AAGTACTACTTTGACTACTGGGGCC

LVKGFYPSDIAVEWESNGQPENNYKT

AGGGAACCCTGGTCACCGTCTCCTC

TPPVLDSDGSFFLYSRLTVDKSRWQEG

AGCATCCACCAAGGGGCCTTCCGTG

NVFSCSVMHEALHNHYTQKSLSLSLG

TTCCCCCTGGCCCCTTGCTCCCGCTC

K

GACCTCTGAATCCACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCAAGACCTATACCTGCAA

CGTCGACCACAAGCCCTCCAACACC

AAAGTGGACAAGCGCGTCGAATCC

AAGTACGGCCCCCCTTGTCCGCCTT

GTCCAGCCCCTGAGTTCCTGGGTGG

TCCGTCCGTGTTCCTCTTCCCGCCCA

AGCCGAAGGACACTCTGATGATTTC

ACGCACCCCGGAAGTCACTTGCGTG

GTCGTGGACGTGTCGCAGGAAGATC

CCGAAGTGCAGTTCAATTGGTACGT

GGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTTCAACTCTACGTACCGGGTGGTG

TCCGTGCTGACCGTGCTGCACCAGG

ACTGGCTGAACGGAAAGGAGTACA

AGTGCAAAGTGTCAAACAAGGGCCT

CCCTTCATCCATCGAAAAGACCATC

AGCAAGGCCAAGGGTCAACCTAGG

GAGCCCCAGGTCTACACTTTGCCGC

CTAGCCAAGAAGAAATGACTAAGA

ACCAAGTGTCCCTGACTTGCCTTGT

CAAGGGCTTTTATCCGTCCGACATC

GCCGTGGAGTGGGAGTCCAACGGA

CAACCGGAGAACAACTACAAGACC

ACCCCACCGGTGCTCGATTCCGATG

GCTCCTTCTTCCTGTACTCCCGGCTG

ACTGTGGACAAGTCAAGATGGCAG

GAGGGAAACGTGTTCTCCTGCTCCG

TGATGCACGAAGCGCTGCACAACCA

TTACACCCAGAAATCACTGTCACTT

TCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

1992
FTFSSYAMHWVRQAPGKGLEWVAVIS
2100
GAGGCGTGGTCCAGCCTGGGAGGTC

YDGSNKYYADSVKGRFTISRDNSKNT

CCTGAGACTCTCCTGTGCAGCCTCT

LYLQMNSLRAEDTAVYYCARATYYY

GGATTCACCTTCAGTAGCTATGCTA

DSSGYRFDYWGQGTLVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPCSRSTSESTAALGCLVKDYFP

CAAGGGGCTGGAGTGGGTGGCAGTT

EPVTVSWNSGALTSGVHTFPAVLQSSG

ATATCATATGATGGAAGTAATAAAT

LYSLSSVVTVPSSSLGTKTYTCNVDHK

ACTACGCAGACTCCGTGAAGGGCCG

PSNTKVDKRVESKYGPPCPPCPAPEFL

ATTCACCATCTCCAGAGACAATTCC

GGPSVFLFPPKPKDTLMISRTPEVTCVV

AAGAACACGCTGTATCTGCAAATGA

VDVSQEDPEVQFNWYVDGVEVHNAK

ACAGCCTGAGAGCTGAGGACACGG

TKPREEQFNSTYRVVSVLTVLHQDWL

CTGTGTATTACTGTGCGAGGGCCAC

NGKEYKCKVSNKGLPSSIEKTISKAKG

GTATTACTATGATAGTAGTGGTTAT

QPREPQVYTLPPSQEEMTKNQVSLTCL

AGGTTTGACTACTGGGGCCAGGGAA

VKGFYPSDIAVEWESNGQPENNYKTTP

CCCTGGTCACCGTCTCCTCAGCATC

PVLDSDGSFFLYSRLTVDKSRWQEGN

CACCAAGGGGCCTTCCGTGTTCCCC

VFSCSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

SEQ ID
EVQLVQSGGGLVEPGGSLRLSCAASRF
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

1993
TFSDAWMSWVRQAPGKGLEWVGRIK
2101
GAGGCTTGGTAGAACCGGGGGGGT

SKISGGTTDYAAPVQGRFTISRDDSKN

CCCTTAGACTCTCCTGTGCAGCCTCT

TLYLQMDSLKTEDTAVYYCANRNLGY

CGATTCACTTTCAGTGACGCCTGGA

WGQGTLVTVSSASTKGPSVFPLAPCSR

TGAGCTGGGTCCGCCAGGCTCCAGG

STSESTAALGCLVKDYFPEPVTVSWNS

TAAGGGGCTGGAGTGGGTTGGCCGT

GALTSGVHTFPAVLQSSGLYSLSSVVT

ATTAAAAGCAAAATAAGTGGTGGG

VPSSSLGTKTYTCNVDHKPSNTKVDK

ACAACAGACTACGCTGCACCCGTGC

RVESKYGPPCPPCPAPEFLGGPSVFLFP

AAGGCAGATTCACCATCTCAAGAGA

PKPKDTLMISRTPEVTCVVVDVSQEDP

TGATTCAAAAAACACGCTGTATCTG

EVQFNWYVDGVEVHNAKTKPREEQF

CAAATGGACAGCCTGAAAACCGAG

NSTYRVVSVLTVLHQDWLNGKEYKC

GACACAGCCGTGTATTACTGTGCGA

KVSNKGLPSSIEKTISKAKGQPREPQVY

ACCGAAACTTAGGCTACTGGGGCCA

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GGGCACCCTGGTGACCGTCTCCTCA

IAVEWESNGQPENNYKTTPPVLDSDGS

GCATCCACCAAGGGGCCTTCCGTGT

FFLYSRLTVDKSRWQEGNVFSCSVMH

TCCCCCTGGCCCCTTGCTCCCGCTCG

EALHNHYTQKSLSLSLGK

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

1994
YTFTSYAMHWVRQAPGQRLEWMGWI
2102
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTMTTDTSTS

AGTGAAGGTTTCCTGCAAGGCTTCT

TAYMELRSLRSDDTAVYYCARARYYD

GGATACACCTTCACTAGCTATGCTA

SSGYIAPSGYFDYWGQGTLVTVSSAST

TGCATTGGGTGCGCCAGGCCCCCGG

KGPSVFPLAPCSRSTSESTAALGCLVK

ACAAAGGCTTGAGTGGATGGGATG

DYFPEPVTVSWNSGALTSGVHTFPAVL

GATCAACGCTGGCAATGGTAACACA

QSSGLYSLSSVVTVPSSSLGTKTYTCN

AAATATTCACAGAAGTTCCAGGGCA

VDHKPSNTKVDKRVESKYGPPCPPCPA

GAGTCACCATGACCACAGACACATC

PEFLGGPSVFLFPPKPKDTLMISRTPEV

CACGAGCACAGCCTACATGGAGCTG

TCVVVDVSQEDPEVQFNWYVDGVEV

AGGAGCCTGAGATCTGACGACACG

HNAKTKPREEQFNSTYRVVSVLTVLH

GCCGTGTATTACTGTGCGAGAGCTC

QDWLNGKEYKCKVSNKGLPSSIEKTIS

GTTACTATGATAGTAGTGGTTATAT

KAKGQPREPQVYTLPPSQEEMTKNQV

TGCCCCATCGGGTTACTTTGACTACT

SLTCLVKGFYPSDIAVEWESNGQPENN

GGGGCCAGGGAACCCTGGTCACCGT

YKTTPPVLDSDGSFFLYSRLTVDKSRW

CTCCTCAGCATCCACCAAGGGGCCT

QEGNVFSCSVMHEALHNHYTQKSLSL

TCCGTGTTCCCCCTGGCCCCTTGCTC

SLGK

CCGCTCGACCTCTGAATCCACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCAAGACCTATA

CCTGCAACGTCGACCACAAGCCCTC

CAACACCAAAGTGGACAAGCGCGT

CGAATCCAAGTACGGCCCCCCTTGT

CCGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

1995
YTFTSYAMHWVRQAPGQRLEWMGWI
2103
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARDGPAVD

GGATACACCTTCACTAGCTATGCTA

GAEYFQHWGQGTLVTVSSASTKGPSV

TGCATTGGGTGCGCCAGGCCCCCGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

ACAAAGGCTTGAGTGGATGGGATG

VTVSWNSGALTSGVHTFPAVLQSSGL

GATCAACGCTGGCAATGGTAACACA

YSLSSVVTVPSSSLGTKTYTCNVDHKP

AAATATTCACAGAAGTTCCAGGGCA

SNTKVDKRVESKYGPPCPPCPAPEFLG

GAGTCACCATTACCAGGGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CGCGAGCACAGCCTACATGGAGCTG

DVSQEDPEVQFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAAGACACG

KPREEQFNSTYRVVSVLTVLHQDWLN

GCTGTGTATTACTGTGCGAGAGATG

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GCCCCGCCGTTGATGGTGCTGAATA

PREPQVYTLPPSQEEMTKNQVSLTCLV

CTTCCAGCACTGGGGCCAGGGCACC

KGFYPSDIAVEWESNGQPENNYKTTPP

CTGGTCACCGTCTCCTCAGCATCCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

CCAAGGGGCCTTCCGTGTTCCCCCT

FSCSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QLQLQESGPGLVKPSQTLSLTCAISGDS
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC

1996
VSSNSAAWNWIRQSPSRGLEWLGRTY
2104
CAGGACTGGTGAAGCCCTCGCAGAC

YRSKWYNDYAVSLKSRITINPDTSKNQ

CCTCTCACTCACCTGTGCCATCTCCG

FSLQLNSVTPEDTAVYYCASLASGSPP

GGGACAGTGTCTCTAGCAACAGTGC

PGDYWGQGTLVTVSSASTKGPSVFPL

TGCTTGGAACTGGATCAGGCAGTCC

APCSRSTSESTAALGCLVKDYFPEPVT

CCATCGCGAGGCCTTGAGTGGCTGG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GAAGGACTTACTACAGGTCCAAGTG

SSVVTVPSSSLGTKTYTCNVDHKPSNT

GTATAATGATTATGCAGTATCTCTG

KVDKRVESKYGPPCPPCPAPEFLGGPS

AAAAGTCGAATAACCATCAACCCGG

VFLFPPKPKDTLMISRTPEVTCVVVDV

ACACATCCAAGAACCAGTTCTCCCT

SQEDPEVQFNWYVDGVEVHNAKTKP

GCAGCTGAACTCTGTGACTCCCGAG

REEQFNSTYRVVSVLTVLHQDWLNGK

GACACGGCTGTATATTACTGTGCAA

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GTTTGGCGAGTGGTTCCCCCCCTCC

PQVYTLPPSQEEMTKNQVSLTCLVKGF

GGGGGACTACTGGGGCCAGGGAAC

YPSDIAVEWESNGQPENNYKTTPPVLD

CCTGGTGACCGTCTCCTCAGCATCC

SDGSFFLYSRLTVDKSRWQEGNVFSCS

ACCAAGGGGCCTTCCGTGTTCCCCC

VMHEALHNHYTQKSLSLSLGK

TGGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

1997
TFSTYGMHWVRQAPGKGLEWVALISY
2105
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSKKYYANSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMKSLRAEDTAMYYCAKGPIVGAT

GGATTCACCTTCAGTACCTATGGCA

MDYWGQGALVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTGGCACTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATATCATATGATGGAAGTAAAAAAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTATGCAAACTCCGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCATCTCCAGAGACAATTCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

AAGAACACGTTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

AAAGTCTGAGAGCTGAGGACACGG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CTATGTATTACTGTGCGAAAGGCCC

CKVSNKGLPSSIEKTISKAKGQPREPQV

TATAGTGGGAGCGACTATGGACTAC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGGGGCCAGGGAGCCCTGGTCACCG

DIAVEWESNGQPENNYKTTPPVLDSD

TCTCCTCAGCATCCACCAAGGGGCC

GSFFLYSRLTVDKSRWQEGNVFSCSV

TTCCGTGTTCCCCCTGGCCCCTTGCT

MHEALHNHYTQKSLSLSLGK

CCCGCTCGACCTCTGAATCCACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCAAGACCTAT

ACCTGCAACGTCGACCACAAGCCCT

CCAACACCAAAGTGGACAAGCGCG

TCGAATCCAAGTACGGCCCCCCTTG

TCCGCCTTGTCCAGCCCCTGAGTTCC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAG

GAAGATCCCGAAGTGCAGTTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTTCAACTCTACGTACCGG

GTGGTGTCCGTGCTGACCGTGCTGC

ACCAGGACTGGCTGAACGGAAAGG

AGTACAAGTGCAAAGTGTCAAACA

AGGGCCTCCCTTCATCCATCGAAAA

GACCATCAGCAAGGCCAAGGGTCA

ACCTAGGGAGCCCCAGGTCTACACT

TTGCCGCCTAGCCAAGAAGAAATGA

CTAAGAACCAAGTGTCCCTGACTTG

CCTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGSSVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

1998
GTFSSYAISWVRQAPGQGLEWMGWIS
2106
CTGAGGTGAAGAAGCCTGGGTCCTC

AYNGNTNYAQKLQGRVTMTTDTSTST

GGTGAAGGTCTCCTGCAAGGCTTCT

AYMELRSLRSDDTAVYYCARWYGDY

GGAGGCACCTTCAGCAGCTATGCTA

GLDYWGQGTLVTVSSASTKGPSVFPL

TCAGCTGGGTGCGACAGGCCCCTGG

APCSRSTSESTAALGCLVKDYFPEPVT

ACAAGGGCTTGAGTGGATGGGATG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GATCAGCGCTTACAATGGTAACACA

SSVVTVPSSSLGTKTYTCNVDHKPSNT

AACTATGCACAGAAGCTCCAGGGCA

KVDKRVESKYGPPCPPCPAPEFLGGPS

GAGTCACCATGACCACAGACACATC

VFLFPPKPKDTLMISRTPEVTCVVVDV

CACGAGCACAGCCTACATGGAGCTG

SQEDPEVQFNWYVDGVEVHNAKTKP

AGGAGCCTGAGATCTGACGACACG

REEQFNSTYRVVSVLTVLHQDWLNGK

GCCGTGTATTACTGTGCGAGATGGT

EYKCKVSNKGLPSSIEKTISKAKGQPRE

ACGGTGACTACGGCCTTGACTACTG

PQVYTLPPSQEEMTKNQVSLTCLVKGF

GGGCCAGGGAACCCTGGTCACCGTC

YPSDIAVEWESNGQPENNYKTTPPVLD

TCCTCAGCATCCACCAAGGGGCCTT

SDGSFFLYSRLTVDKSRWQEGNVFSCS

CCGTGTTCCCCCTGGCCCCTTGCTCC

VMHEALHNHYTQKSLSLSLGK

CGCTCGACCTCTGAATCCACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCAAGACCTATAC

CTGCAACGTCGACCACAAGCCCTCC

AACACCAAAGTGGACAAGCGCGTC

GAATCCAAGTACGGCCCCCCTTGTC

CGCCTTGTCCAGCCCCTGAGTTCCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCAGG

AAGATCCCGAAGTGCAGTTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTTCAACTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGGCCTCCCTTCATCCATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCAAGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCCG

GCTGACTGTGGACAAGTCAAGATGG

CAGGAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

1999
YTFTSYAMHWVRQAPGQRLAWMGWI
2107
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSEKFEGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVAKYYY

GGATACACCTTCACTAGCTATGCTA

ESGGYRASNWFDPWGQGTLVTVSSAS

TGCATTGGGTGCGCCAGGCCCCCGG

TKGPSVFPLAPCSRSTSESTAALGCLVK

ACAAAGGCTTGCGTGGATGGGATGG

DYFPEPVTVSWNSGALTSGVHTFPAVL

ATCAACGCTGGCAATGGTAACACAA

QSSGLYSLSSVVTVPSSSLGTKTYTCN

AATATTCAGAGAAGTTCGAAGGCAG

VDHKPSNTKVDKRVESKYGPPCPPCPA

AGTCACCATCACCAGGGACACATCC

PEFLGGPSVFLFPPKPKDTLMISRTPEV

GCGAGCACAGCCTACATGGAGCTGA

TCVVVDVSQEDPEVQFNWYVDGVEV

GCAGCCTGAGATCTGAAGACACGGC

HNAKTKPREEQFNSTYRVVSVLTVLH

TGTGTATTACTGTGCGAGGGTCGCC

QDWLNGKEYKCKVSNKGLPSSIEKTIS

AAATATTATTACGAGAGTGGTGGTT

KAKGQPREPQVYTLPPSQEEMTKNQV

ATCGGGCCTCCAACTGGTTCGACCC

SLTCLVKGFYPSDIAVEWESNGQPENN

CTGGGGCCAGGGCACCCTGGTCACC

YKTTPPVLDSDGSFFLYSRLTVDKSRW

GTCTCCTCAGCATCCACCAAGGGGC

QEGNVFSCSVMHEALHNHYTQKSLSL

CTTCCGTGTTCCCCCTGGCCCCTTGC

SLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QVQLQESGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTGCAGGAGTCAGGTC

2000
SVSSNSAAWNWIRQSPSRGLEWLGRT
2108
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARAPPPTV

GGGACAGTGTCTCTAGCAACAGTGC

GWYAPVFDYWGQGTLVTVSSASTKGP

TGCTTGGAACTGGATCAGGCAGTCC

SVFPLAPCSRSTSESTAALGCLVKDYFP

CCATCGAGAGGCCTTGAGTGGCTGG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GAAGGACATACTACAGGTCCAAGTG

LYSLSSVVTVPSSSLGTKTYTCNVDHK

GTATAATGATTATGCAGTATCTGTG

PSNTKVDKRVESKYGPPCPPCPAPEFL

AAAAGTCGAATAACCATCAACCCAG

GGPSVFLFPPKPKDTLMISRTPEVTCVV

ACACATCCAAGAACCAGTTCTCCCT

VDVSQEDPEVQFNWYVDGVEVHNAK

GCAGCTGAACTCTGTGACTCCCGAG

TKPREEQFNSTYRVVSVLTVLHQDWL

GACACGGCTGTGTATTACTGTGCAA

NGKEYKCKVSNKGLPSSIEKTISKAKG

GAGCGCCCCCTCCGACTGTTGGCTG

QPREPQVYTLPPSQEEMTKNQVSLTCL

GTACGCCCCCGTCTTTGACTACTGG

VKGFYPSDIAVEWESNGQPENNYKTTP

GGCCAGGGAACCCTGGTCACCGTCT

PVLDSDGSFFLYSRLTVDKSRWQEGN

CCTCAGCATCCACCAAGGGGCCTTC

VFSCSVMHEALHNHYTQKSLSLSLGK

CGTGTTCCCCCTGGCCCCTTGCTCCC

GCTCGACCTCTGAATCCACCGCCGC

ACTCGGTTGCCTGGTCAAAGACTAC

TTCCCCGAGCCCGTGACTGTCTCGT

GGAACTCGGGCGCCCTCACATCCGG

AGTGCATACCTTTCCCGCCGTGTTG

CAGTCCAGCGGCCTGTACAGCCTGA

GCTCCGTCGTGACAGTGCCGTCCTC

CTCCCTTGGAACCAAGACCTATACC

TGCAACGTCGACCACAAGCCCTCCA

ACACCAAAGTGGACAAGCGCGTCG

AATCCAAGTACGGCCCCCCTTGTCC

GCCTTGTCCAGCCCCTGAGTTCCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCAGGA

AGATCCCGAAGTGCAGTTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTTCAACTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GGCCTCCCTTCATCCATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCAAGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCCGGC

TGACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCSASGI
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG

2001
SFRDYWMHWIRQTPGKGLVWVSRINP
2109
GAGGCTTAGTTCAGCCGGGGGGGTC

DGSSTSYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGCTCAGCCTCT

LQMNSLRAEDTAVYYCAKVTGRRVG

GGAATCAGCTTCAGAGATTACTGGA

AHDYWGQGTLVTVSSASTKGPSVFPL

TGCACTGGATCCGCCAAACTCCAGG

APCSRSTSESTAALGCLVKDYFPEPVT

GAAGGGGCTGGTGTGGGTCTCACGT

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTAATCCTGATGGGAGTAGCACAA

SSVVTVPSSSLGTKTYTCNVDHKPSNT

GCTACGCGGACTCCGTGAAGGGCCG

KVDKRVESKYGPPCPPCPAPEFLGGPS

ATTCACCATCTCCAGAGACAATTCC

VFLFPPKPKDTLMISRTPEVTCVVVDV

AAGAACACGCTGTATCTGCAAATGA

SQEDPEVQFNWYVDGVEVHNAKTKP

ACAGCCTGAGAGCTGAGGACACGG

REEQFNSTYRVVSVLTVLHQDWLNGK

CTGTGTATTACTGTGCGAAAGTTAC

EYKCKVSNKGLPSSIEKTISKAKGQPRE

GGGACGGAGAGTGGGAGCCCATGA

PQVYTLPPSQEEMTKNQVSLTCLVKGF

CTACTGGGGCCAGGGAACCCTGGTC

YPSDIAVEWESNGQPENNYKTTPPVLD

ACCGTCTCCTCAGCATCCACCAAGG

SDGSFFLYSRLTVDKSRWQEGNVFSCS

GGCCTTCCGTGTTCCCCCTGGCCCCT

VMHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2002
YTFTGYYMHWVRQAPGQGLEWMGW
2110
CTGAGGTGAAGAAGCCTGGGGCCTC

INPNSGGTNYAQKFQGRVTMTRDTSIS

AGTGAAGGTCTCCTGCAAGGCTTCT

TAYMELSRLRSDDTAVYYCAFAQPGA

GGATACACCTTCACCGGCTACTATA

ETLNFDLWGRGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPCSRSTSESTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGATG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCAACCCTAACAGTGGTGGCACA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

AACTATGCACAGAAGTTTCAGGGCA

TKVDKRVESKYGPPCPPCPAPEFLGGP

GGGTCACCATGACCAGGGACACGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATCAGCACAGCCTACATGGAGCTG

VSQEDPEVQFNWYVDGVEVHNAKTK

AGCAGGCTGAGATCTGACGACACG

PREEQFNSTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCCTTTGCCCA

KEYKCKVSNKGLPSSIEKTISKAKGQP

GCCGGGCGCTGAGACGTTGAACTTC

REPQVYTLPPSQEEMTKNQVSLTCLVK

GATCTCTGGGGCCGTGGCACCCTGG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCACCGTCTCCTCAGCATCCACCAA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

GGGGCCTTCCGTGTTCCCCCTGGCC

CSVMHEALHNHYTQKSLSLSLGK

CCTTGCTCCCGCTCGACCTCTGAATC

CACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCAAG

ACCTATACCTGCAACGTCGACCACA

AGCCCTCCAACACCAAAGTGGACAA

GCGCGTCGAATCCAAGTACGGCCCC

CCTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2003
SVSSKSAAWNWIRQSPSRGLEWLGRT
2111
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWNNDYALSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLKSVTPEDTALYYCVRQVAGG

GGGACAGTGTCTCTAGCAAAAGTGC

MDVWGQGTTVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAATG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GAATAATGATTATGCATTATCTGTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AAAAGTCGAATAACCATCAACCCAG

FPPKPKDTLMISRTPEVTCVVVDVSQE

ACACATCCAAGAACCAGTTCTCCCT

DPEVQFNWYVDGVEVHNAKTKPREE

GCAGCTGAAGTCTGTGACTCCCGAG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GACACGGCTCTGTATTACTGTGTAA

CKVSNKGLPSSIEKTISKAKGQPREPQV

GACAAGTCGCGGGCGGTATGGACGT

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CTGGGGCCAAGGGACCACGGTCACC

DIAVEWESNGQPENNYKTTPPVLDSD

GTCTCCTCAGCATCCACCAAGGGGC

GSFFLYSRLTVDKSRWQEGNVFSCSV

CTTCCGTGTTCCCCCTGGCCCCTTGC

MHEALHNHYTQKSLSLSLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

2004
TFGDYAMSWFRQAPGKGLEWVSAISG
2112
GAGGCTTGGTACAGCCAGGGCGGTC

SGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTACAGCTTCT

LQMNSLRAEDTAVYYCAKGSVYSGSY

GGATTCACCTTTGGTGATTATGCTAT

YMLIDYWGQGTLVTVSSASTKGPSVFP

GAGCTGGTTCCGCCAGGCTCCAGGG

LAPCSRSTSESTAALGCLVKDYFPEPV

AAGGGGCTGGAGTGGGTCTCAGCTA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAGTGGTAGTGGTGGTAGCACATA

LSSVVTVPSSSLGTKTYTCNVDHKPSN

CTATGCAGACTCCGTGAAGGGCCGA

TKVDKRVESKYGPPCPPCPAPEFLGGP

TTCACCATCTCCAGAGACAATTCCA

SVFLFPPKPKDTLMISRTPEVTCVVVD

AGAACACGCTGTATCTGCAAATGAA

VSQEDPEVQFNWYVDGVEVHNAKTK

CAGCCTGAGAGCTGAGGACACGGCT

PREEQFNSTYRVVSVLTVLHQDWLNG

GTGTATTACTGTGCGAAAGGATCGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

TATATAGTGGGAGCTACTATATGCT

REPQVYTLPPSQEEMTKNQVSLTCLVK

CATTGACTACTGGGGCCAGGGCACC

GFYPSDIAVEWESNGQPENNYKTTPPV

CTGGTCACCGTCTCCTCAGCATCCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

CCAAGGGGCCTTCCGTGTTCCCCCT

CSVMHEALHNHYTQKSLSLSLGK

GGCCCCTTGCTCCCGCTCGACCTCT

GAATCCACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCAAGACCTATACCTGCAACGTCGA

CCACAAGCCCTCCAACACCAAAGTG

GACAAGCGCGTCGAATCCAAGTACG

GCCCCCCTTGTCCGCCTTGTCCAGCC

CCTGAGTTCCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCAGGAAGATCCCGAAGT

GCAGTTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTTCAACT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGGCCTCCCTTCAT

CCATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
QVQLQQSGPGLVRPSQTLSLTCVISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2005
SVSSGSAAWNWIRQSPSRGLEWLGRT
2113
CAGGACTGGTGAGGCCCTCGCAGAC

YYRAKWYNEYAGSVKSRITISPDTSKN

CCTCTCACTCACCTGTGTCATCTCCG

QFSLQLNSVTPEDTAVYFCTRQDKDNT

GGGACAGTGTCTCTAGCGGCAGTGC

RYSGLGVWGQGTTVTVSSASTKGPSV

TGCTTGGAACTGGATCAGGCAGTCC

FPLAPCSRSTSESTAALGCLVKDYFPEP

CCATCGAGAGGCCTTGAGTGGCTGG

VTVSWNSGALTSGVHTFPAVLQSSGL

GAAGGACATATTATAGGGCCAAGTG

YSLSSVVTVPSSSLGTKTYTCNVDHKP

GTATAATGAATATGCAGGGTCTGTG

SNTKVDKRVESKYGPPCPPCPAPEFLG

AAAAGCCGAATAACCATCAGTCCGG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ACACATCCAAGAACCAGTTCTCCCT

DVSQEDPEVQFNWYVDGVEVHNAKT

GCAACTGAACTCTGTGACTCCCGAG

KPREEQFNSTYRVVSVLTVLHQDWLN

GACACGGCTGTGTATTTCTGTACAA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GACAAGACAAAGACAACACGAGAT

PREPQVYTLPPSQEEMTKNQVSLTCLV

ATTCCGGTTTGGGCGTCTGGGGCCA

KGFYPSDIAVEWESNGQPENNYKTTPP

AGGGACCACGGTGACCGTCTCCTCA

VLDSDGSFFLYSRLTVDKSRWQEGNV

GCATCCACCAAGGGGCCTTCCGTGT

FSCSVMHEALHNHYTQKSLSLSLGK

TCCCCCTGGCCCCTTGCTCCCGCTCG

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
EVQLVETGGGLVQPGGSLRLSCAASEF
SEQ ID
GAGGTGCAGCTGGTGGAGACCGGG

2006
TLRNYGVSWVRQAPGKGLEWVSGMS
2114
GGAGGCTTAGTTCAGCCTGGGGGGT

GSGYSTYYADSVKGRFTISRDSSKNTL

CCCTGAGACTCTCCTGTGCAGCCTC

FLQMDSLRAEDTAIYYCARGPRMWSS

TGAATTCACCCTTAGGAACTATGGC

GIDAFDIWGHGTMVTVSSASTKGPSVF

GTGAGCTGGGTCCGCCAGGCTCCAG

PLAPCSRSTSESTAALGCLVKDYFPEPV

GGAAGGGGCTGGAGTGGGTCTCAG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GTATGAGTGGTAGTGGTTATAGTAC

LSSVVTVPSSSLGTKTYTCNVDHKPSN

ATACTACGCAGACTCCGTGAAGGGC

TKVDKRVESKYGPPCPPCPAPEFLGGP

CGGTTCACCATCTCCAGAGACAGTT

SVFLFPPKPKDTLMISRTPEVTCVVVD

CCAAGAACACGCTGTTTCTGCAAAT

VSQEDPEVQFNWYVDGVEVHNAKTK

GGACAGCCTGAGAGCCGAGGACAC

PREEQFNSTYRVVSVLTVLHQDWLNG

GGCCATATATTACTGTGCGAGAGGG

KEYKCKVSNKGLPSSIEKTISKAKGQP

CCCCGAATGTGGAGCAGTGGCATTG

REPQVYTLPPSQEEMTKNQVSLTCLVK

ATGCTTTTGATATCTGGGGCCACGG

GFYPSDIAVEWESNGQPENNYKTTPPV

GACAATGGTGACCGTCTCTTCAGCA

LDSDGSFFLYSRLTVDKSRWQEGNVFS

TCCACCAAGGGGCCTTCCGTGTTCC

CSVMHEALHNHYTQKSLSLSLGK

CCCTGGCCCCTTGCTCCCGCTCGAC

CTCTGAATCCACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2007
GSVSGYYWSWIRQPPGKGLEWMGEIH
2115
GCAGGACTGTTGAAGCCTTCGGAGA

HSGSTNYNPSLKSRVTISLDTPKNQFSL

CCCTGTCCCTCACCTGCGCTGTCTAT

KLSSVTAADTAVYYCARRDWAGKRV

GGTGGGTCCGTCAGTGGTTACTACT

WGQGTLVTVSSASTKGPSVFPLAPCSR

GGAGCTGGATCCGCCAGCCCCCAGG

STSESTAALGCLVKDYFPEPVTVSWNS

GAAGGGGCTGGAGTGGATGGGGGA

GALTSGVHTFPAVLQSSGLYSLSSVVT

AATCCATCATAGTGGAAGCACCAAC

VPSSSLGTKTYTCNVDHKPSNTKVDK

TACAACCCGTCCCTCAAGAGTCGAG

RVESKYGPPCPPCPAPEFLGGPSVFLFP

TCACCATATCACTAGACACGCCCAA

PKPKDTLMISRTPEVTCVVVDVSQEDP

GAACCAGTTCTCCCTGAAGCTAAGC

EVQFNWYVDGVEVHNAKTKPREEQF

TCTGTGACCGCCGCGGACACGGCTG

NSTYRVVSVLTVLHQDWLNGKEYKC

TATATTACTGTGCGAGACGGGATTG

KVSNKGLPSSIEKTISKAKGQPREPQVY

GGCAGGAAAAAGGGTCTGGGGCCA

TLPPSQEEMTKNQVSLTCLVKGFYPSD

GGGAACCCTGGTCACCGTCTCCTCA

IAVEWESNGQPENNYKTTPPVLDSDGS

GCATCCACCAAGGGGCCTTCCGTGT

FFLYSRLTVDKSRWQEGNVFSCSVMH

TCCCCCTGGCCCCTTGCTCCCGCTCG

EALHNHYTQKSLSLSLGK

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQQSGPGLLKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2008
SVSSNTATWNWIRQSPSRGLEWLGRT
2116
CAGGACTATTAAAGCCCTCGCAGAC

YYRSKWYKDNALSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCAGGRAGIA

GGGACAGTGTCTCTAGCAACACTGC

AFDIWGQGTTVTVSSASTKGPSVFPLA

TACTTGGAACTGGATCAGGCAGTCC

PCSRSTSESTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTKTYTCNVDHKPSNTKV

GTATAAGGATAATGCACTGTCTGTG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

AAAAGTCGAATAACCATCAACCCAG

FPPKPKDTLMISRTPEVTCVVVDVSQE

ACACATCCAAGAACCAGTTCTCCCT

DPEVQFNWYVDGVEVHNAKTKPREE

GCAGCTGAACTCTGTGACTCCCGAG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GACACGGCTGTGTATTACTGTGCAG

CKVSNKGLPSSIEKTISKAKGQPREPQV

GAGGTCGGGCTGGTATTGCCGCTTT

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TGATATCTGGGGCCAAGGGACCACG

DIAVEWESNGQPENNYKTTPPVLDSD

GTCACCGTCTCCTCAGCATCCACCA

GSFFLYSRLTVDKSRWQEGNVFSCSV

AGGGGCCTTCCGTGTTCCCCCTGGC

MHEALHNHYTQKSLSLSLGK

CCCTTGCTCCCGCTCGACCTCTGAAT

CCACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCAA

GACCTATACCTGCAACGTCGACCAC

AAGCCCTCCAACACCAAAGTGGACA

AGCGCGTCGAATCCAAGTACGGCCC

CCCTTGTCCGCCTTGTCCAGCCCCTG

AGTTCCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCAGGAAGATCCCGAAGTGCA

GTTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTTCAACTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGGCCTCCCTTCATCCA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCAAGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCCGGCTGACTGTGGACAAGTC

AAGATGGCAGGAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCTGGGAAAA

SEQ ID
QVQLVQSGGGLIQPGGSLRLSCAASGF
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGAG

2009
TVSSNYMSWVRQAPGKGLEWVSLIYS
2117
GAGGCTTGATCCAGCCTGGGGGGTC

DGRTNYADSVKGRFTISRDNSKNTLYL

CCTGAGACTCTCCTGTGCAGCCTCT

QMNSLRAEDTAVYYCAKGALQGEWR

GGGTTCACCGTCAGTAGCAACTACA

RFDYWGQGTLVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

GAAGGGGCTGGAATGGGTCTCACTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATTTATAGTGATGGTCGCACAAACT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ATGCAGACTCCGTGAAGGGCCGATT

DKRVESKYGPPCPPCPAPEFLGGPSVFL

CACCATCTCCAGAGACAATTCCAAG

FPPKPKDTLMISRTPEVTCVVVDVSQE

AACACGCTGTATCTGCAAATGAACA

DPEVQFNWYVDGVEVHNAKTKPREE

GCCTGAGAGCCGAGGACACGGCCG

QFNSTYRVVSVLTVLHQDWLNGKEYK

TATATTACTGTGCGAAGGGGGCCCT

CKVSNKGLPSSIEKTISKAKGQPREPQV

ACAGGGCGAATGGCGGAGATTTGA

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CTACTGGGGCCAGGGCACCCTGGTC

DIAVEWESNGQPENNYKTTPPVLDSD

ACCGTCTCCTCAGCATCCACCAAGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GGCCTTCCGTGTTCCCCCTGGCCCCT

MHEALHNHYTQKSLSLSLGK

TGCTCCCGCTCGACCTCTGAATCCA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCAAGAC

CTATACCTGCAACGTCGACCACAAG

CCCTCCAACACCAAAGTGGACAAGC

GCGTCGAATCCAAGTACGGCCCCCC

TTGTCCGCCTTGTCCAGCCCCTGAGT

TCCTGGGTGGTCCGTCCGTGTTCCTC

TTCCCGCCCAAGCCGAAGGACACTC

TGATGATTTCACGCACCCCGGAAGT

CACTTGCGTGGTCGTGGACGTGTCG

CAGGAAGATCCCGAAGTGCAGTTCA

ATTGGTACGTGGATGGGGTCGAAGT

GCACAACGCCAAGACCAAGCCTAG

GGAAGAACAGTTCAACTCTACGTAC

CGGGTGGTGTCCGTGCTGACCGTGC

TGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC

2010
SVSSNSAAWNWIRQSPSRGLEWLGRT
2118
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCTRTNQGY

GGGACAGTGTCTCTAGCAACAGTGC

GGNSGVFDYWGQGTLVTVSSASTKGP

TGCTTGGAACTGGATCAGGCAGTCC

SVFPLAPCSRSTSESTAALGCLVKDYFP

CCATCGAGAGGCCTTGAGTGGCTGG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GAAGGACATATTACAGGTCCAAGTG

LYSLSSVVTVPSSSLGTKTYTCNVDHK

GTATAATGATTATGCAGTATCTGTG

PSNTKVDKRVESKYGPPCPPCPAPEFL

AAAAGTCGAATAACCATCAACCCAG

GGPSVFLFPPKPKDTLMISRTPEVTCVV

ACACATCCAAGAACCAGTTCTCCCT

VDVSQEDPEVQFNWYVDGVEVHNAK

GCAGCTGAACTCTGTGACTCCCGAG

TKPREEQFNSTYRVVSVLTVLHQDWL

GACACGGCTGTGTATTACTGTACAA

NGKEYKCKVSNKGLPSSIEKTISKAKG

GAACCAACCAGGGATACGGTGGTA

QPREPQVYTLPPSQEEMTKNQVSLTCL

ACTCCGGGGTATTTGACTACTGGGG

VKGFYPSDIAVEWESNGQPENNYKTTP

CCAGGGAACCCTGGTCACCGTCTCC

PVLDSDGSFFLYSRLTVDKSRWQEGN

TCAGCATCCACCAAGGGGCCTTCCG

VFSCSVMHEALHNHYTQKSLSLSLGK

TGTTCCCCCTGGCCCCTTGCTCCCGC

TCGACCTCTGAATCCACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCAAGACCTATACCTG

CAACGTCGACCACAAGCCCTCCAAC

ACCAAAGTGGACAAGCGCGTCGAA

TCCAAGTACGGCCCCCCTTGTCCGC

CTTGTCCAGCCCCTGAGTTCCTGGG

TGGTCCGTCCGTGTTCCTCTTCCCGC

CCAAGCCGAAGGACACTCTGATGAT

TTCACGCACCCCGGAAGTCACTTGC

GTGGTCGTGGACGTGTCGCAGGAAG

ATCCCGAAGTGCAGTTCAATTGGTA

CGTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTTCAACTCTACGTACCGGGTGG

TGTCCGTGCTGACCGTGCTGCACCA

GGACTGGCTGAACGGAAAGGAGTA

CAAGTGCAAAGTGTCAAACAAGGG

CCTCCCTTCATCCATCGAAAAGACC

ATCAGCAAGGCCAAGGGTCAACCTA

GGGAGCCCCAGGTCTACACTTTGCC

GCCTAGCCAAGAAGAAATGACTAA

GAACCAAGTGTCCCTGACTTGCCTT

GTCAAGGGCTTTTATCCGTCCGACA

TCGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCCGGCT

GACTGTGGACAAGTCAAGATGGCA

GGAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCTGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC

2011
SVSGNSAAWNWIRQSPSRGLEWLGRT
2119
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARIVGGAV

GGGACAGTGTCTCTGGCAACAGTGC

DCWGQGTLVTVSSASTKGPSVFPLAPC

TGCTTGGAACTGGATCAGGCAGTCC

SRSTSESTAALGCLVKDYFPEPVTVSW

CCATCGAGAGGCCTTGAGTGGCTGG

NSGALTSGVHTFPAVLQSSGLYSLSSV

GAAGGACATACTACAGGTCCAAGTG

VTVPSSSLGTKTYTCNVDHKPSNTKVD

GTATAATGATTATGCAGTATCTGTG

KRVESKYGPPCPPCPAPEFLGGPSVFLF

AAAAGTCGAATAACCATCAACCCAG

PPKPKDTLMISRTPEVTCVVVDVSQED

ACACATCCAAGAACCAGTTCTCCCT

PEVQFNWYVDGVEVHNAKTKPREEQF

GCAGTTGAATTCTGTGACTCCCGAG

NSTYRVVSVLTVLHQDWLNGKEYKC

GACACGGCTGTGTATTACTGTGCGA

KVSNKGLPSSIEKTISKAKGQPREPQVY

GGATAGTGGGAGGTGCCGTTGACTG

TLPPSQEEMTKNQVSLTCLVKGFYPSD

CTGGGGCCAGGGAACCCTGGTGACC

IAVEWESNGQPENNYKTTPPVLDSDGS

GTCTCCTCAGCATCCACCAAGGGGC

FFLYSRLTVDKSRWQEGNVFSCSVMH

CTTCCGTGTTCCCCCTGGCCCCTTGC

EALHNHYTQKSLSLSLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2012
YTFTSYAMHWVRQAPGQRLEWMGWI
2120
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVRVGAT

GGATACACCTTCACTAGCTATGCTA

TVYDSWFDPWGQGTLVTVSSASTKGP

TGCATTGGGTGCGCCAGGCCCCCGG

SVFPLAPCSRSTSESTAALGCLVKDYFP

ACAAAGGCTTGAGTGGATGGGATG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GATCAACGCTGGCAATGGTAACACA

LYSLSSVVTVPSSSLGTKTYTCNVDHK

AAATATTCACAGAAGTTCCAGGGCA

PSNTKVDKRVESKYGPPCPPCPAPEFL

GAGTCACCATTACCAGGGACACATC

GGPSVFLFPPKPKDTLMISRTPEVTCVV

CGCGAGCACAGCCTACATGGAGCTG

VDVSQEDPEVQFNWYVDGVEVHNAK

AGCAGCCTGAGATCTGAAGACACG

TKPREEQFNSTYRVVSVLTVLHQDWL

GCTGTGTATTACTGTGCGAGAGTTA

NGKEYKCKVSNKGLPSSIEKTISKAKG

GAGTGGGAGCTACTACTGTTTACGA

QPREPQVYTLPPSQEEMTKNQVSLTCL

CAGCTGGTTCGACCCCTGGGGCCAG

VKGFYPSDIAVEWESNGQPENNYKTTP

GGAACCCTGGTGACCGTCTCCTCAG

PVLDSDGSFFLYSRLTVDKSRWQEGN

CATCCACCAAGGGGCCTTCCGTGTT

VFSCSVMHEALHNHYTQKSLSLSLGK

CCCCCTGGCCCCTTGCTCCCGCTCG

ACCTCTGAATCCACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2013
FTFSSYAMSWVRQAPGKGLEWVSAIS
2121
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDGGSSPY

GGATTCACCTTTAGCAGCTATGCCA

YDSSGLLPWYFDLWGRGTLVTVSSAS

TGAGCTGGGTCCGCCAGGCTCCAGG

TKGPSVFPLAPCSRSTSESTAALGCLVK

GAAGGGGCTGGAGTGGGTCTCAGCT

DYFPEPVTVSWNSGALTSGVHTFPAVL

ATTAGTGGTAGTGGTGGTAGCACAT

QSSGLYSLSSVVTVPSSSLGTKTYTCN

ACTACGCAGACTCCGTGAAGGGCCG

VDHKPSNTKVDKRVESKYGPPCPPCPA

GTTCACCATCTCCAGAGACAATTCC

PEFLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSQEDPEVQFNWYVDGVEV

ACAGCCTGAGAGCCGAGGACACGG

HNAKTKPREEQFNSTYRVVSVLTVLH

CCGTATATTACTGTGCGAAAGATGG

QDWLNGKEYKCKVSNKGLPSSIEKTIS

GGGGTCCAGCCCATACTATGATAGT

KAKGQPREPQVYTLPPSQEEMTKNQV

AGTGGTTTACTACCCTGGTACTTCG

SLTCLVKGFYPSDIAVEWESNGQPENN

ATCTCTGGGGCCGTGGCACCCTGGT

YKTTPPVLDSDGSFFLYSRLTVDKSRW

CACCGTCTCCTCAGCATCCACCAAG

QEGNVFSCSVMHEALHNHYTQKSLSL

GGGCCTTCCGTGTTCCCCCTGGCCC

SLGK

CTTGCTCCCGCTCGACCTCTGAATCC

ACCGCCGCACTCGGTTGCCTGGTCA

AAGACTACTTCCCCGAGCCCGTGAC

TGTCTCGTGGAACTCGGGCGCCCTC

ACATCCGGAGTGCATACCTTTCCCG

CCGTGTTGCAGTCCAGCGGCCTGTA

CAGCCTGAGCTCCGTCGTGACAGTG

CCGTCCTCCTCCCTTGGAACCAAGA

CCTATACCTGCAACGTCGACCACAA

GCCCTCCAACACCAAAGTGGACAAG

CGCGTCGAATCCAAGTACGGCCCCC

CTTGTCCGCCTTGTCCAGCCCCTGA

GTTCCTGGGTGGTCCGTCCGTGTTCC

TCTTCCCGCCCAAGCCGAAGGACAC

TCTGATGATTTCACGCACCCCGGAA

GTCACTTGCGTGGTCGTGGACGTGT

CGCAGGAAGATCCCGAAGTGCAGTT

CAATTGGTACGTGGATGGGGTCGAA

GTGCACAACGCCAAGACCAAGCCTA

GGGAAGAACAGTTCAACTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGGCCTCCCTTCATCCATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCAAGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CCGGCTGACTGTGGACAAGTCAAGA

TGGCAGGAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCTGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

2014
FTFSSYAMHWVRQAPGKGLEYVSAISS
2122
GGAGGCTTGGTCCAGCCTGGGGGGT

NGGSTYYANSVKGRFTISRDNSKNTLY

CCCTGAGACTCTCCTGTGCAGCCTC

LQMGSLRAEDMAVYYCARAKFWTYY

TGGATTCACCTTCAGTAGCTATGCT

FDYWGQGTLVTVSSASTKGPSVFPLAP

ATGCACTGGGTCCGCCAGGCTCCAG

CSRSTSESTAALGCLVKDYFPEPVTVS

GGAAGGGACTGGAATATGTTTCAGC

WNSGALTSGVHTFPAVLQSSGLYSLSS

TATTAGTAGTAATGGGGGTAGCACA

VVTVPSSSLGTKTYTCNVDHKPSNTKV

TATTATGCAAACTCTGTGAAGGGCA

DKRVESKYGPPCPPCPAPEFLGGPSVFL

GATTCACCATCTCCAGAGACAATTC

FPPKPKDTLMISRTPEVTCVVVDVSQE

CAAGAACACGCTGTATCTTCAAATG

DPEVQFNWYVDGVEVHNAKTKPREE

GGCAGCCTGAGAGCTGAGGACATG

QFNSTYRVVSVLTVLHQDWLNGKEYK

GCTGTGTATTACTGTGCGAGAGCTA

CKVSNKGLPSSIEKTISKAKGQPREPQV

AGTTTTGGACATACTACTTTGACTA

YTLPPSQEEMTKNQVSLTCLVKGFYPS

CTGGGGCCAGGGAACCCTGGTGACC

DIAVEWESNGQPENNYKTTPPVLDSD

GTCTCCTCAGCATCCACCAAGGGGC

GSFFLYSRLTVDKSRWQEGNVFSCSV

CTTCCGTGTTCCCCCTGGCCCCTTGC

MHEALHNHYTQKSLSLSLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2015
GSFSGYYWSWIRQPPGKGLEWIGEINH
2123
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGGGSGSYYKR

GGTGGGTCCTTCAGTGGTTACTACT

FFDYWGQGTLVTVSSASTKGPSVFPLA

GGAGCTGGATCCGCCAGCCCCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

GAAGGGGCTGGAGTGGATTGGGGA

WNSGALTSGVHTFPAVLQSSGLYSLSS

AATCAATCATAGTGGAAGCACCAAC

VVTVPSSSLGTKTYTCNVDHKPSNTKV

TACAACCCGTCCCTCAAGAGTCGAG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

TCACCATATCAGTAGACACGTCCAA

FPPKPKDTLMISRTPEVTCVVVDVSQE

GAACCAGTTCTCCCTGAAGCTGAGC

DPEVQFNWYVDGVEVHNAKTKPREE

TCTGTGACCGCCGCGGACACGGCTG

QFNSTYRVVSVLTVLHQDWLNGKEYK

TGTATTACTGTGCGAGAGGCGGTGG

CKVSNKGLPSSIEKTISKAKGQPREPQV

TTCGGGGAGTTATTATAAGAGGTTC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TTTGACTACTGGGGCCAGGGAACCC

DIAVEWESNGQPENNYKTTPPVLDSD

TGGTCACCGTCTCCTCAGCATCCAC

GSFFLYSRLTVDKSRWQEGNVFSCSV

CAAGGGGCCTTCCGTGTTCCCCCTG

MHEALHNHYTQKSLSLSLGK

GCCCCTTGCTCCCGCTCGACCTCTG

AATCCACCGCCGCACTCGGTTGCCT

GGTCAAAGACTACTTCCCCGAGCCC

GTGACTGTCTCGTGGAACTCGGGCG

CCCTCACATCCGGAGTGCATACCTT

TCCCGCCGTGTTGCAGTCCAGCGGC

CTGTACAGCCTGAGCTCCGTCGTGA

CAGTGCCGTCCTCCTCCCTTGGAAC

CAAGACCTATACCTGCAACGTCGAC

CACAAGCCCTCCAACACCAAAGTGG

ACAAGCGCGTCGAATCCAAGTACGG

CCCCCCTTGTCCGCCTTGTCCAGCCC

CTGAGTTCCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCAGGAAGATCCCGAAGTG

CAGTTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTTCAACTC

TACGTACCGGGTGGTGTCCGTGCTG

ACCGTGCTGCACCAGGACTGGCTGA

ACGGAAAGGAGTACAAGTGCAAAG

TGTCAAACAAGGGCCTCCCTTCATC

CATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCAA

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCCGGCTGACTGTGGACA

AGTCAAGATGGCAGGAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCTGGGAA

AA

SEQ ID
EVQLVQSGAEVRKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG

2016
YTFTSYAISWVRQAPGQGLEWMGWIS
2124
CTGAGGTGAGGAAGCCTGGGGCCTC

AYDGNTNYAQKLQGRVTMTTDTSTST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMEVRSLRSDDTAVYYCARDGTVR

GGTTACACATTTACCAGTTATGCCA

RVVGATTPGNFDYRGQGTLVTVSSAS

TCAGCTGGGTGCGACAGGCCCCTGG

TKGPSVFPLAPCSRSTSESTAALGCLVK

ACAAGGGCTTGAGTGGATGGGGTG

DYFPEPVTVSWNSGALTSGVHTFPAVL

GATCAGCGCTTACGACGGTAACACA

QSSGLYSLSSVVTVPSSSLGTKTYTCN

AACTATGCACAGAAGCTCCAGGGCA

VDHKPSNTKVDKRVESKYGPPCPPCPA

GAGTCACCATGACCACAGACACATC

PEFLGGPSVFLFPPKPKDTLMISRTPEV

CACGAGCACAGCCTACATGGAGGTG

TCVVVDVSQEDPEVQFNWYVDGVEV

AGGAGCCTGAGATCTGACGACACG

HNAKTKPREEQFNSTYRVVSVLTVLH

GCCGTGTATTACTGTGCGAGAGATG

QDWLNGKEYKCKVSNKGLPSSIEKTIS

GTACGGTCCGAAGGGTAGTGGGAG

KAKGQPREPQVYTLPPSQEEMTKNQV

CTACTACCCCTGGAAACTTTGACTA

SLTCLVKGFYPSDIAVEWESNGQPENN

CAGGGGCCAGGGAACCCTGGTCACC

YKTTPPVLDSDGSFFLYSRLTVDKSRW

GTCTCCTCAGCATCCACCAAGGGGC

QEGNVFSCSVMHEALHNHYTQKSLSL

CTTCCGTGTTCCCCCTGGCCCCTTGC

SLGK

TCCCGCTCGACCTCTGAATCCACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCAAGACCTA

TACCTGCAACGTCGACCACAAGCCC

TCCAACACCAAAGTGGACAAGCGC

GTCGAATCCAAGTACGGCCCCCCTT

GTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2017
FTFSSYGMHWVRQAPGKGLEWVAVI
2125
GAGGCGTGGTCCAGCCTGGGAGGTC

WYDGSNKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARDLNRG

GGATTCACCTTCAGTAGCTATGGCA

YCSGGSCFGYWGQGTLVTVSSASTKG

TGCACTGGGTCCGCCAGGCTCCAGG

PSVFPLAPCSRSTSESTAALGCLVKDYF

CAAGGGGCTGGAGTGGGTGGCAGTT

PEPVTVSWNSGALTSGVHTFPAVLQSS

ATATGGTATGATGGAAGTAATAAAT

GLYSLSSVVTVPSSSLGTKTYTCNVDH

ACTATGCAGACTCCGTGAAGGGCCG

KPSNTKVDKRVESKYGPPCPPCPAPEF

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSQEDPEVQFNWYVDGVEVHNA

ACAGCCTGAGAGCCGAGGACACGG

KTKPREEQFNSTYRVVSVLTVLHQDW

CTGTGTATTACTGTGCGAGAGATCT

LNGKEYKCKVSNKGLPSSIEKTISKAK

GAATCGAGGATATTGTAGTGGTGGT

GQPREPQVYTLPPSQEEMTKNQVSLTC

AGCTGCTTTGGCTACTGGGGCCAGG

LVKGFYPSDIAVEWESNGQPENNYKT

GAACCCTGGTCACCGTCTCCTCAGC

TPPVLDSDGSFFLYSRLTVDKSRWQEG

ATCCACCAAGGGGCCTTCCGTGTTC

NVFSCSVMHEALHNHYTQKSLSLSLG

CCCCTGGCCCCTTGCTCCCGCTCGA

K

CCTCTGAATCCACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCAAGACCTATACCTGCAACG

TCGACCACAAGCCCTCCAACACCAA

AGTGGACAAGCGCGTCGAATCCAA

GTACGGCCCCCCTTGTCCGCCTTGTC

CAGCCCCTGAGTTCCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCAGGAAGATCCCG

AAGTGCAGTTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTT

CAACTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGGCCTCCC

TTCATCCATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCAAGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCCGGCTGACT

GTGGACAAGTCAAGATGGCAGGAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CTGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCTGGGG

2018
FTFSSYAMSWVRQAPGKGLEWVSYIS
2126
GAGGCTTGGTACAGCCGGGGGGGTC

SSGTTIYYADSVKGRFTVSRDNAKNSL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARDYSSSGE

GGATTCACCTTTAGCAGCTATGCCA

CFDYWGQGTLVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PCSRSTSESTAALGCLVKDYFPEPVTVS

GAAGGGGCTGGAGTGGGTTTCATAC

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATTAGTAGTAGTGGTACTACCATAT

VVTVPSSSLGTKTYTCNVDHKPSNTKV

ACTACGCAGACTCTGTGAAGGGCCG

DKRVESKYGPPCPPCPAPEFLGGPSVFL

ATTCACCGTCTCCAGAGACAATGCC

FPPKPKDTLMISRTPEVTCVVVDVSQE

AAGAACTCACTGTATCTGCAAATGA

DPEVQFNWYVDGVEVHNAKTKPREE

ACAGCCTGAGAGCCGAGGACACGG

QFNSTYRVVSVLTVLHQDWLNGKEYK

CCGTGTATTACTGTGCGAGGGATTA

CKVSNKGLPSSIEKTISKAKGQPREPQV

TAGCAGCTCGGGGGAGTGCTTTGAC

YTLPPSQEEMTKNQVSLTCLVKGFYPS

TACTGGGGCCAGGGAACCCTGGTCA

DIAVEWESNGQPENNYKTTPPVLDSD

CCGTCTCCTCAGCATCCACCAAGGG

GSFFLYSRLTVDKSRWQEGNVFSCSV

GCCTTCCGTGTTCCCCCTGGCCCCTT

MHEALHNHYTQKSLSLSLGK

GCTCCCGCTCGACCTCTGAATCCAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCAAGACC

TATACCTGCAACGTCGACCACAAGC

CCTCCAACACCAAAGTGGACAAGCG

CGTCGAATCCAAGTACGGCCCCCCT

TGTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2019
FTFSSYGMHWVRQAPGKGLEWVAVI
2127
GAGGCGTGGTCCAGCCTGGGAGGTC

WYDGSNKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARDQAA

GGATTCACCTTCAGTAGCTATGGCA

MVGYFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTCCGCCAGGCTCCAGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

CAAGGGGCTGGAGTGGGTGGCAGTT

VTVSWNSGALTSGVHTFPAVLQSSGL

ATATGGTATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ACTATGCAGACTCCGTGAAGGGCCG

SNTKVDKRVESKYGPPCPPCPAPEFLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTGCAAATGA

DVSQEDPEVQFNWYVDGVEVHNAKT

ACAGCCTGAGAGCCGAGGACACGG

KPREEQFNSTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAGAGATCA

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GGCAGCTATGGTAGGCTACTTTGAC

PREPQVYTLPPSQEEMTKNQVSLTCLV

TACTGGGGCCAGGGAACCCTGGTCA

KGFYPSDIAVEWESNGQPENNYKTTPP

CCGTCTCCTCAGCATCCACCAAGGG

VLDSDGSFFLYSRLTVDKSRWQEGNV

GCCTTCCGTGTTCCCCCTGGCCCCTT

FSCSVMHEALHNHYTQKSLSLSLGK

GCTCCCGCTCGACCTCTGAATCCAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCAAGACC

TATACCTGCAACGTCGACCACAAGC

CCTCCAACACCAAAGTGGACAAGCG

CGTCGAATCCAAGTACGGCCCCCCT

TGTCCGCCTTGTCCAGCCCCTGAGTT

CCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

AGGAAGATCCCGAAGTGCAGTTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTTCAACTCTACGTACC

GGGTGGTGTCCGTGCTGACCGTGCT

GCACCAGGACTGGCTGAACGGAAA

GGAGTACAAGTGCAAAGTGTCAAA

CAAGGGCCTCCCTTCATCCATCGAA

AAGACCATCAGCAAGGCCAAGGGT

CAACCTAGGGAGCCCCAGGTCTACA

CTTTGCCGCCTAGCCAAGAAGAAAT

GACTAAGAACCAAGTGTCCCTGACT

TGCCTTGTCAAGGGCTTTTATCCGTC

CGACATCGCCGTGGAGTGGGAGTCC

AACGGACAACCGGAGAACAACTAC

AAGACCACCCCACCGGTGCTCGATT

CCGATGGCTCCTTCTTCCTGTACTCC

CGGCTGACTGTGGACAAGTCAAGAT

GGCAGGAGGGAAACGTGTTCTCCTG

CTCCGTGATGCACGAAGCGCTGCAC

AACCATTACACCCAGAAATCACTGT

CACTTTCGCTGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2020
IFSNYAIHWVRQAPGKGLEWVAVISY
2128
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARTFAGYSS

GGATTCATCTTCAGTAACTATGCTA

KLGYFDLWGRGTLVTVSSASTKGPSV

TACACTGGGTCCGCCAGGCTCCAGG

FPLAPCSRSTSESTAALGCLVKDYFPEP

CAAGGGGCTGGAGTGGGTGGCAGTT

VTVSWNSGALTSGVHTFPAVLQSSGL

ATATCATATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTKTYTCNVDHKP

ACTACGCAGACTCCGTGAAGGGCCG

SNTKVDKRVESKYGPPCPPCPAPEFLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTGCAAATGA

DVSQEDPEVQFNWYVDGVEVHNAKT

ACAGCCTGAGAGCTGAGGACACGG

KPREEQFNSTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAGGACTTTT

GKEYKCKVSNKGLPSSIEKTISKAKGQ

GCGGGGTATAGCAGCAAACTGGGG

PREPQVYTLPPSQEEMTKNQVSLTCLV

TACTTCGATCTCTGGGGCCGTGGCA

KGFYPSDIAVEWESNGQPENNYKTTPP

CCCTGGTCACCGTCTCCTCAGCATC

VLDSDGSFFLYSRLTVDKSRWQEGNV

CACCAAGGGGCCTTCCGTGTTCCCC

FSCSVMHEALHNHYTQKSLSLSLGK

CTGGCCCCTTGCTCCCGCTCGACCTC

TGAATCCACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCAAGACCTATACCTGCAACGTCG

ACCACAAGCCCTCCAACACCAAAGT

GGACAAGCGCGTCGAATCCAAGTAC

GGCCCCCCTTGTCCGCCTTGTCCAG

CCCCTGAGTTCCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCAGGAAGATCCCGA

AGTGCAGTTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTTC

AACTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGGCCTCCCT

TCATCCATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCAAGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCCGGCTGACTG

TGGACAAGTCAAGATGGCAGGAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

TGGGAAAA

TABLE 40

Anti-CLEC2D antibody IgG1 N to A Heavy chain amino acid and DNA sequence

SEQ ID
VH + CH + AA_IgG1 N to A
SEQ ID
VH + CH + DNA_IgG1 N to A

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2129
YTFTSYAMHWVRQAPGQRLEWMGWI
2237
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARGSLSRSG

GGATACACCTTCACTAGCTATGCTA

WYAGLFDYWGQGTLVTVSSASTKGPS

TGCATTGGGTGCGCCAGGCCCCCGG

VFPLAPSSKSTSGGTAALGCLVKDYFP

ACAAAGGCTTGAGTGGATGGGATG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GATCAACGCTGGCAATGGTAACACA

LYSLSSVVTVPSSSLGTQTYICNVNHKP

AAATATTCACAGAAGTTCCAGGGCA

SNTKVDKKVEPKSCDKTHTCPPCPAPE

GAGTCACCATTACCAGGGACACATC

LLGGPSVFLFPPKPKDTLMISRTPEVTC

CGCGAGCACAGCCTACATGGAGCTG

VVVDVSHEDPEVKFNWYVDGVEVHN

AGCAGCCTGAGATCTGAAGACACG

AKTKPREEQYASTYRVVSVLTVLHQD

GCTGTGTATTACTGTGCGAGAGGCT

WLNGKEYKCKVSNKALPAPIEKTISKA

CCTTGTCCCGAAGTGGCTGGTACGC

KGQPREPQVYTLPPSREEMTKNQVSLT

CGGACTCTTTGACTACTGGGGCCAG

CLVKGFYPSDIAVEWESNGQPENNYK

GGAACCCTGGTCACCGTCTCCTCAG

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

CATCCACCAAGGGGCCTTCCGTGTT

GNVFSCSVMHEALHNHYTQKSLSLSP

CCCCCTGGCCCCTTCATCCAAGTCG

GK

ACCTCTGGTGGAACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QITLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

2130
TFSSYSMNWVRQAPGKGLQWVAIISD
2238
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSKSYYADSVQGRFTISRDNSRNTVF

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAMYYCARDRGTKWN

GGATTCACCTTCAGTAGTTATAGCA

QLNDVFDMWGQGTMVTVSSASTKGP

TGAACTGGGTCCGCCAGGCTCCAGG

SVFPLAPSSKSTSGGTAALGCLVKDYF

CAAGGGGCTGCAGTGGGTGGCAATT

PEPVTVSWNSGALTSGVHTFPAVLQSS

ATATCAGATGATGGAAGTAAGAGTT

GLYSLSSVVTVPSSSLGTQTYICNVNH

ACTACGCAGACTCCGTGCAGGGCCG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

ATTCACCATCTCCAGAGACAATTCG

PELLGGPSVFLFPPKPKDTLMISRTPEV

AGGAACACAGTATTTCTGCAAATGA

TCVVVDVSHEDPEVKFNWYVDGVEV

ACAGCCTGAGAGCTGAGGACACGG

HNAKTKPREEQYASTYRVVSVLTVLH

CTATGTATTACTGTGCGAGAGACAG

QDWLNGKEYKCKVSNKALPAPIEKTIS

GGGAACTAAATGGAACCAATTGAAT

KAKGQPREPQVYTLPPSREEMTKNQV

GATGTTTTTGATATGTGGGGCCAAG

SLTCLVKGFYPSDIAVEWESNGQPENN

GGACAATGGTCACCGTCTCTTCAGC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

ATCCACCAAGGGGCCTTCCGTGTTC

QQGNVFSCSVMHEALHNHYTQKSLSL

CCCCTGGCCCCTTCATCCAAGTCGA

SPGK

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2131
YTFTSYYMHWVRQAPGQGLEWMGIIN
2239
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCARGRGYSSS

GGATACACCTTCACCAGCTACTATA

RLYYFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTGCGACAGGCCCCTGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

ACAAGGGCTTGAGTGGATGGGAAT

PVTVSWNSGALTSGVHTFPAVLQSSGL

AATCAACCCTAGTGGTGGTAGCACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AGCTACGCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCAGGGACACGTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CACGAGCACAGTCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCGAGAGGCC

LNGKEYKCKVSNKALPAPIEKTISKAK

GAGGGTATAGCAGCAGTCGGCTCTA

GQPREPQVYTLPPSREEMTKNQVSLTC

CTACTTTGACTACTGGGGCCAGGGA

LVKGFYPSDIAVEWESNGQPENNYKT

ACCCTGGTCACCGTCTCCTCAGCAT

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCACCAAGGGGCCTTCCGTGTTCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTGGCCCCTTCATCCAAGTCGACC

K

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVTLKESGGGLVRPGGSLRLSCEASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2132
TFSDPYMDWVRQAPGKGLEWVGRITN
2240
GAGGCTTGGTCCGGCCTGGAGGGTC

KRTGYATTYAASVKDRFTISRDDSRKS

CCTGAGACTCTCCTGTGAAGCCTCT

VYLQMNSLKTEDTAVYYCATDVSGSF

GGATTCACCTTCAGTGACCCCTACA

AAYGGQGTLVTVSSASTKGPSVFPLAP

TGGACTGGGTCCGCCAGGCTCCAGG

SSKSTSGGTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTTGGCCG

WNSGALTSGVHTFPAVLQSSGLYSLSS

AATTACAAATAAGCGTACCGGTTAC

VVTVPSSSLGTQTYICNVNHKPSNTKV

GCCACAACATATGCCGCGTCTGTGA

DKKVEPKSCDKTHTCPPCPAPELLGGP

AGGACAGATTCACCATCTCAAGAGA

SVFLFPPKPKDTLMISRTPEVTCVVVD

TGATTCAAGGAAGTCAGTATATCTG

VSHEDPEVKFNWYVDGVEVHNAKTK

CAAATGAACAGCCTGAAGACCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCCGTATATTATTGTGCAA

KEYKCKVSNKALPAPIEKTISKAKGQP

CAGATGTCAGTGGGTCCTTCGCGGC

REPQVYTLPPSREEMTKNQVSLTCLVK

CTACGGGGGCCAGGGCACCCTGGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCGTCTCCTCAGCATCCACCAAGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GGCCTTCCGTGTTCCCCCTGGCCCCT

SCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

2133
FTFSSYAMHWVRQAPGQRLEWMGWI
2241
GAGGCGTGGTCCAGCCTGGGAGGTC

NAGNGNTKYSQKFQGRVTITRDTSAST

CCTGAGACTCTCCTGTGCAGCGTCT

AYMELSSLRSEDTAVYYCAGEGGAVA

GGATTCACCTTCAGTAGCTATGCTA

GTVYWGQGTLVTVSSASTKGPSVFPL

TGCATTGGGTGCGCCAGGCCCCCGG

APSSKSTSGGTAALGCLVKDYFPEPVT

ACAAAGGCTTGAGTGGATGGGATG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GATCAACGCTGGCAATGGTAACACA

SSVVTVPSSSLGTQTYICNVNHKPSNT

AAATATTCACAGAAGTTCCAGGGCA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAGTCACCATTACCAGGGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CGCGAGCACAGCCTACATGGAGCTG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAAGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCTGTGTATTACTGTGCGGGAGAGG

GKEYKCKVSNKALPAPIEKTISKAKGQ

GCGGAGCAGTGGCTGGTACTGTCTA

PREPQVYTLPPSREEMTKNQVSLTCLV

CTGGGGCCAGGGAACCCTGGTCACC

KGFYPSDIAVEWESNGQPENNYKTTPP

GTCTCCTCAGCATCCACCAAGGGGC

VLDSDGSFFLYSKLTVDKSRWQQGNV

CTTCCGTGTTCCCCCTGGCCCCTTCA

FSCSVMHEALHNHYTQKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

2134
FTFSNAWMSWVRQAPGKGLEWVGRI
2242
GAGGCTTGGTAAAGCCTGGGGGGTC

KSKTDGGTTDYAAPVKGRFTISRDDSK

CCTTAGACTCTCCTGTGCAGCCTCTG

NTLYLQMNSLKTEDTAVYYCTTDEYF

GATTCACTTTCAGTAACGCCTGGAT

YWGQGTLVTVSSASTKGPSVFPLAPSS

GAGCTGGGTCCGCCAGGCTCCAGGG

KSTSGGTAALGCLVKDYFPEPVTVSW

AAGGGGCTGGAGTGGGTTGGCCGTA

NSGALTSGVHTFPAVLQSSGLYSLSSV

TTAAAAGCAAAACTGATGGTGGGAC

VTVPSSSLGTQTYICNVNHKPSNTKVD

AACAGACTACGCTGCACCCGTGAAA

KKVEPKSCDKTHTCPPCPAPELLGGPS

GGCAGATTCACCATCTCAAGAGATG

VFLFPPKPKDTLMISRTPEVTCVVVDV

ATTCAAAAAACACGCTGTATCTGCA

SHEDPEVKFNWYVDGVEVHNAKTKP

AATGAACAGCCTGAAAACCGAGGA

REEQYASTYRVVSVLTVLHQDWLNGK

CACAGCCGTGTATTACTGTACCACA

EYKCKVSNKALPAPIEKTISKAKGQPR

GACGAGTATTTCTACTGGGGCCAGG

EPQVYTLPPSREEMTKNQVSLTCLVKG

GAACCCTGGTCACCGTCTCCTCAGC

FYPSDIAVEWESNGQPENNYKTTPPVL

ATCCACCAAGGGGCCTTCCGTGTTC

DSDGSFFLYSKLTVDKSRWQQGNVFS

CCCCTGGCCCCTTCATCCAAGTCGA

CSVMHEALHNHYTQKSLSLSPGK

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2135
GSFSGYYWSWIRQPPGKGLEWIGEINH
2243
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARVNPGSYTREV

GGTGGGTCCTTCAGTGGTTACTACT

SNFDYWGQGTLVTVSSASTKGPSVFPL

GGAGCTGGATCCGCCAGCCCCCAGG

APSSKSTSGGTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGATTGGGGA

VSWNSGALTSGVHTFPAVLQSSGLYSL

AATCAATCATAGTGGAAGCACCAAC

SSVVTVPSSSLGTQTYICNVNHKPSNT

TACAACCCGTCCCTCAAGAGTCGAG

KVDKKVEPKSCDKTHTCPPCPAPELLG

TCACCATATCAGTAGACACGTCCAA

GPSVFLFPPKPKDTLMISRTPEVTCVVV

GAACCAGTTCTCCCTGAAGCTGAGC

DVSHEDPEVKFNWYVDGVEVHNAKT

TCTGTGACCGCCGCGGACACGGCTG

KPREEQYASTYRVVSVLTVLHQDWLN

TGTATTACTGTGCGAGAGTAAATCC

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGGAGTTATACGAGGGAGGTGAG

PREPQVYTLPPSREEMTKNQVSLTCLV

CAACTTTGACTACTGGGGCCAGGGA

KGFYPSDIAVEWESNGQPENNYKTTPP

ACCCTGGTGACCGTCTCCTCAGCAT

VLDSDGSFFLYSKLTVDKSRWQQGNV

CCACCAAGGGGCCTTCCGTGTTCCC

FSCSVMHEALHNHYTQKSLSLSPGK

CCTGGCCCCTTCATCCAAGTCGACC

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLQQSGPELVKPSQTLTLTCGISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2136
SVSSNSVTWNWVRQSPSRGLEWLGRT
2244
CAGAATTGGTGAAGCCCTCGCAGAC

YYRSQWYYNYAVSVKSRITISPDTSKN

CCTCACACTCACCTGTGGCATCTCC

QFSLQLNSVTPEDTAVYYCATRGHNY

GGGGACAGTGTCTCTAGCAACAGTG

GVDYWGPGTTVTVSSASTKGPSVFPL

TTACTTGGAACTGGGTCAGGCAGTC

APSSKSTSGGTAALGCLVKDYFPEPVT

CCCATCGAGAGGCCTTGAGTGGCTG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GGAAGGACTTACTACCGGTCCCAGT

SSVVTVPSSSLGTQTYICNVNHKPSNT

GGTATTATAATTATGCGGTGTCTGT

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAAAAGTCGAATAACCATCAGCCCA

GPSVFLFPPKPKDTLMISRTPEVTCVVV

GACACATCCAAGAACCAGTTCTCCC

DVSHEDPEVKFNWYVDGVEVHNAKT

TGCAGTTGAATTCTGTGACTCCCGA

KPREEQYASTYRVVSVLTVLHQDWLN

GGACACGGCTGTCTATTACTGTGCA

GKEYKCKVSNKALPAPIEKTISKAKGQ

ACCAGGGGACATAACTACGGTGTAG

PREPQVYTLPPSREEMTKNQVSLTCLV

ATTACTGGGGCCCGGGGACCACGGT

KGFYPSDIAVEWESNGQPENNYKTTPP

CACCGTCTCCTCAGCATCCACCAAG

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGCCTTCCGTGTTCCCCCTGGCCC

FSCSVMHEALHNHYTQKSLSLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
QVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2137
FTFSNAWMSWVRQAPGKGLEWVCRI
2245
GAGGCTTGGTAAAGCCTGGGGGGTC

KSKTDGETTDYAAPVKGRFTISRDDSK

CCTTAGACTCTCCTGTGCAGCCTCTG

NTLYLQMNSLKTEDTAVYHCTTGVG

GATTCACTTTCAGTAACGCCTGGAT

WSPFQYWGQGTLVTVSSASTKGPSVF

GAGCTGGGTCCGCCAGGCTCCAGGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

AAGGGGCTGGAGTGGGTTTGCCGTA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAAAAGCAAAACTGATGGTGAGAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACAGACTACGCTGCACCCGTGAAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCAAAAAACACGCTGTATCTGCA

VVDVSHEDPEVKFNWYVDGVEVHNA

AATGAACAGCCTGAAAACTGAGGA

KTKPREEQYASTYRVVSVLTVLHQDW

CACAGCCGTGTATCACTGTACCACA

LNGKEYKCKVSNKALPAPIEKTISKAK

GGGGTGGGATGGTCGCCCTTCCAAT

GQPREPQVYTLPPSREEMTKNQVSLTC

ACTGGGGCCAGGGCACCCTGGTCAC

LVKGFYPSDIAVEWESNGQPENNYKT

CGTCTCCTCAGCATCCACCAAGGGG

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCTTCCGTGTTCCCCCTGGCCCCTTC

NVFSCSVMHEALHNHYTQKSLSLSPG

ATCCAAGTCGACCTCTGGTGGAACC

K

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCCAGACCT

ATATCTGCAACGTCAATCACAAGCC

CTCCAACACCAAAGTGGACAAGAA

GGTCGAACCCAAGTCCTGCGACAAG

ACTCACACCTGTCCGCCTTGTCCAG

CCCCTGAGCTGCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGA

CCAAGCCTAGGGAAGAACAGTACgc

cTCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

2138
TFGDYAMSWFRQAPGKGLEWVGFIRS
2246
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRDDKIAA

GGATTCACCTTTGGTGATTATGCTAT

AGFTYWYFDLWGRGTLVTVSSASTKG

GAGCTGGTTCCGCCAGGCTCCAGGG

PSVFPLAPSSKSTSGGTAALGCLVKDY

AAGGGGCTGGAGTGGGTAGGTTTCA

FPEPVTVSWNSGALTSGVHTFPAVLQS

TTAGAAGCAAAGCTTATGGTGGGAC

SGLYSLSSVVTVPSSSLGTQTYICNVNH

AACAGAATACGCCGCGTCTGTGAAA

KPSNTKVDKKVEPKSCDKTHTCPPCPA

GGCAGATTCACCATCTCAAGAGATG

PELLGGPSVFLFPPKPKDTLMISRTPEV

ATTCCAAAAGCATCGCCTATCTGCA

TCVVVDVSHEDPEVKFNWYVDGVEV

AATGAACAGCCTGAAAACCGAGGA

HNAKTKPREEQYASTYRVVSVLTVLH

CACAGCCGTGTATTACTGTACTAGA

QDWLNGKEYKCKVSNKALPAPIEKTIS

GACGACAAAATAGCAGCAGCTGGA

KAKGQPREPQVYTLPPSREEMTKNQV

TTCACATACTGGTACTTCGATCTCTG

SLTCLVKGFYPSDIAVEWESNGQPENN

GGGCCGTGGCACCCTGGTCACCGTC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

TCCTCAGCATCCACCAAGGGGCCTT

QQGNVFSCSVMHEALHNHYTQKSLSL

CCGTGTTCCCCCTGGCCCCTTCATCC

SPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2139
YTFAAYYLHWVRQAPGQGLEWMGRI
2247
CTGAGGTGAAGAAGCCTGGGGCCTC

SPGNGVTSYAQKFQGRVTMTGDTSIN

AGTGAAGGTCTCCTGCAAGGCTTCT

TVYMQLNNLISGDTAVYYCAREAADD

GGATACACCTTCGCCGCCTATTATTT

PFDHWGQGALVTVSSASTKGPSVFPLA

ACACTGGGTGCGACAGGCCCCTGGA

PSSKSTSGGTAALGCLVKDYFPEPVTV

CAAGGCCTTGAGTGGATGGGGCGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATCAGCCCTGGTAACGGTGTCACAA

SVVTVPSSSLGTQTYICNVNHKPSNTK

GTTATGCACAGAAATTTCAGGGCAG

VDKKVEPKSCDKTHTCPPCPAPELLGG

AGTCACCATGACCGGGGACACGTCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

ATTAACACAGTCTACATGCAACTGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAATTTGATTTCTGGCGACACGGC

PREEQYASTYRVVSVLTVLHQDWLNG

CGTATATTACTGTGCGAGAGAGGCT

KEYKCKVSNKALPAPIEKTISKAKGQP

GCCGACGACCCGTTTGACCATTGGG

REPQVYTLPPSREEMTKNQVSLTCLVK

GCCAGGGAGCCCTGGTCACCGTCTC

GFYPSDIA VEWESNGQPENNYKTTPPV

CTCAGCATCCACCAAGGGGCCTTCC

LDSDGSFFLYSKLTVDKSRWQQGNVF

GTGTTCCCCCTGGCCCCTTCATCCAA

SCSVMHEALHNHYTQKSLSLSPGK

GTCGACCTCTGGTGGAACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCCAGACCTATATCT

GCAACGTCAATCACAAGCCCTCCAA

CACCAAAGTGGACAAGAAGGTCGA

ACCCAAGTCCTGCGACAAGACTCAC

ACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCACGAAGATCCCGAAGTGAA

ATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACgccTCTAC

GTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGT

CAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TACACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAA

CTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCT

GCACAACCATTACACCCAGAAATCA

CTGTCACTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLTLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2140
FTFSSHLMHWVRQAPGKGLEWVAVIS
2248
GAGGCGTGGTCCAGCCTGGGAGGTC

YDGTSKYYGDSVKGRFTISRDNSKNTL

CCTGACACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAIYYCAKADYKYD

GGATTCACCTTCAGTTCCCATCTTAT

WGQGTLVTVSSASTKGPSVFPLAPSSK

GCACTGGGTCCGCCAGGCTCCAGGC

STSGGTAALGCLVKDYFPEPVTVSWN

AAGGGGCTGGAGTGGGTGGCAGTT

SGALTSGVHTFPAVLQSSGLYSLSSVV

ATATCATATGATGGAACTAGTAAAT

TVPSSSLGTQTYICNVNHKPSNTKVDK

ATTACGGAGACTCCGTGAAGGGCCG

KVEPKSCDKTHTCPPCPAPELLGGPSV

CTTCACCATCTCCAGAGACAATTCC

FLFPPKPKDTLMISRTPEVTCVVVDVS

AAGAACACGTTGTATCTGCAAATGA

HEDPEVKFNWYVDGVEVHNAKTKPR

ACAGCCTGCGAGCTGAAGACACGG

EEQYASTYRVVSVLTVLHQDWLNGKE

CTATATATTACTGTGCGAAAGCAGA

YKCKVSNKALPAPIEKTISKAKGQPRE

TTATAAATATGACTGGGGCCAGGGA

PQVYTLPPSREEMTKNQVSLTCLVKGF

ACCCTGGTCACCGTCTCCTCAGCAT

YPSDIAVEWESNGQPENNYKTTPPVLD

CCACCAAGGGGCCTTCCGTGTTCCC

SDGSFFLYSKLTVDKSRWQQGNVFSCS

CCTGGCCCCTTCATCCAAGTCGACC

VMHEALHNHYTQKSLSLSPGK

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCTASGF
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2141
TFGDYAMSWVRQAPGKGLEWVGFIRS
2249
GAGGCTTGGTCAAGCCTGGAGGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTTHRRPIY

GGATTCACCTTTGGTGATTATGCTAT

DILTGFDYWGQGTLVTVSSASTKGPSV

GAGCTGGGTCCGCCAGGCTCCAGGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

AAGGGGCTGGAGTGGGTAGGTTTCA

PVTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAAGCAAAGCTTATGGTGGGAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACAGAATACGCCGCGTCTGTGAAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAAAAGCATCGCCTATCTGCA

VVDVSHEDPEVKFNWYVDGVEVHNA

AATGAACAGCCTGAAAACCGAGGA

KTKPREEQYASTYRVVSVLTVLHQDW

CACAGCCGTGTATTACTGTACTACT

LNGKEYKCKVSNKALPAPIEKTISKAK

CATAGACGCCCAATTTACGATATTT

GQPREPQVYTLPPSREEMTKNQVSLTC

TGACTGGTTTTGACTACTGGGGCCA

LVKGFYPSDIAVEWESNGQPENNYKT

GGGAACCCTGGTCACCGTCTCCTCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GCATCCACCAAGGGGCCTTCCGTGT

NVFSCSVMHEALHNHYTQKSLSLSPG

TCCCCCTGGCCCCTTCATCCAAGTC

K

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QLQLQESGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG

2142
TFGDYAMSWVRQAPGKGLEWVGFIRS
2250
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTREDTMV

GGATTCACCTTTGGTGATTATGCTAT

RGVIPWGQGTLVTVSSASTKGPSVFPL

GAGCTGGGTCCGCCAGGCTCCAGGG

APSSKSTSGGTAALGCLVKDYFPEPVT

AAGGGGCTGGAGTGGGTAGGTTTCA

VSWNSGALTSGVHTFPAVLQSSGLYSL

TTAGAAGCAAAGCTTATGGTGGGAC

SSVVTVPSSSLGTQTYICNVNHKPSNT

AACAGAATACGCCGCGTCTGTGAAA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GGCAGATTCACCATCTCAAGAGATG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ATTCCAAAAGCATCGCCTATCTGCA

DVSHEDPEVKFNWYVDGVEVHNAKT

AATGAACAGCCTGAAAACCGAGGA

KPREEQYASTYRVVSVLTVLHQDWLN

CACAGCCGTGTATTACTGTACTAGA

GKEYKCKVSNKALPAPIEKTISKAKGQ

GAGGATACTATGGTTCGGGGAGTTA

PREPQVYTLPPSREEMTKNQVSLTCLV

TTCCCTGGGGCCAGGGAACCCTGGT

KGFYPSDIAVEWESNGQPENNYKTTPP

CACCGTCTCCTCAGCATCCACCAAG

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGCCTTCCGTGTTCCCCCTGGCCC

FSCSVMHEALHNHYTQKSLSLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
QLQLQESGSGLVKPSQTLSLTCAVSGG
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGCT

2143
SISSGGYSWSWIRQPPGKGLEWIGYIY
2251
CAGGACTGGTGAAGCCTTCACAGAC

HSGSTYYNPSLKSRVTISVDRSKNQFSL

CCTGTCCCTCACCTGCGCTGTCTCTG

KLSSVTAADTAVYYCARDRRYYDSSG

GTGGCTCCATCAGCAGTGGTGGTTA

YYPAYYFDYWGQGTLVTVSSASTKGP

CTCCTGGAGCTGGATCCGGCAGCCA

SVFPLAPSSKSTSGGTAALGCLVKDYF

CCAGGGAAGGGCCTGGAGTGGATT

PEPVTVSWNSGALTSGVHTFPAVLQSS

GGGTACATCTATCATAGTGGGAGCA

GLYSLSSVVTVPSSSLGTQTYICNVNH

CCTACTACAACCCGTCCCTCAAGAG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

TCGAGTCACCATATCAGTAGACAGG

PELLGGPSVFLFPPKPKDTLMISRTPEV

TCCAAGAACCAGTTCTCCCTGAAGC

TCVVVDVSHEDPEVKFNWYVDGVEV

TGAGCTCTGTGACCGCCGCGGACAC

HNAKTKPREEQYASTYRVVSVLTVLH

GGCTGTGTATTACTGTGCGAGAGAT

QDWLNGKEYKCKVSNKALPAPIEKTIS

CGGCGTTACTATGATAGTAGTGGTT

KAKGQPREPQVYTLPPSREEMTKNQV

ATTATCCCGCCTACTACTTTGACTAC

SLTCLVKGFYPSDIAVEWESNGQPENN

TGGGGCCAGGGAACCCTGGTCACCG

YKTTPPVLDSDGSFFLYSKLTVDKSRW

TCTCCTCAGCATCCACCAAGGGGCC

QQGNVFSCSVMHEALHNHYTQKSLSL

TTCCGTGTTCCCCCTGGCCCCTTCAT

SPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2144
FTFSSYSMNWVRQAPGKGLEWVSYIS
2252
GAGGCCTGGTCAAGCCTGGGGGGTC

SSGSYTNYADSVKGRFTISRDNAKNSL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQINSLRAEDTAIYYCARDGGYDSSG

GGATTCACCTTCAGTAGCTATAGCA

FHFDYWGQGTLVTVSSASTKGPSVFPL

TGAACTGGGTCCGCCAGGCTCCAGG

APSSKSTSGGTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGGTTTCATAC

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTAGTAGTAGTGGTAGTTACACAA

SSVVTVPSSSLGTQTYICNVNHKPSNT

ACTACGCAGACTCTGTGAAGGGCCG

KVDKKVEPKSCDKTHTCPPCPAPELLG

ATTCACCATCTCCAGAGACAACGCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACTCACTGTATCTGCAAATAA

DVSHEDPEVKFNWYVDGVEVHNAKT

ACAGCCTGAGAGCCGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CCATTTATTACTGTGCGAGAGACGG

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGCTATGATAGTAGTGGTTTTCAC

PREPQVYTLPPSREEMTKNQVSLTCLV

TTTGACTACTGGGGCCAGGGAACCC

KGFYPSDIAVEWESNGQPENNYKTTPP

TGGTCACCGTCTCCTCAGCATCCAC

VLDSDGSFFLYSKLTVDKSRWQQGNV

CAAGGGGCCTTCCGTGTTCCCCCTG

FSCSVMHEALHNHYTQKSLSLSPGK

GCCCCTTCATCCAAGTCGACCTCTG

GTGGAACCGCCGCACTCGGTTGCCT

GGTCAAAGACTACTTCCCCGAGCCC

GTGACTGTCTCGTGGAACTCGGGCG

CCCTCACATCCGGAGTGCATACCTT

TCCCGCCGTGTTGCAGTCCAGCGGC

CTGTACAGCCTGAGCTCCGTCGTGA

CAGTGCCGTCCTCCTCCCTTGGAAC

CCAGACCTATATCTGCAACGTCAAT

CACAAGCCCTCCAACACCAAAGTGG

ACAAGAAGGTCGAACCCAAGTCCTG

CGACAAGACTCACACCTGTCCGCCT

TGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTT

CACGCACCCCGGAAGTCACTTGCGT

GGTCGTGGACGTGTCGCACGAAGAT

CCCGAAGTGAAATTCAATTGGTACG

TGGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTACgccTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAA

GTGCAAAGTGTCAAACAAGGCTCTC

CCTGCCCCTATCGAAAAGACCATCA

GCAAGGCCAAGGGTCAACCTAGGG

AGCCCCAGGTCTACACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTC

GCCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2145
SVSNNRAAWNWIRQSPSRGLEWLGRT
2253
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNEYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSMTPEDSAVYYCAILPSSGY

GGGACAGTGTCTCTAACAACAGGGC

LQDHHYYGMDVWGQGTTVTVSSAST

TGCTTGGAACTGGATCAGGCAGTCG

KGPSVFPLAPSSKSTSGGTAALGCLVK

CCATCGAGAGGCCTTGAGTGGCTGG

DYFPEPVTVSWNSGALTSGVHTFPAVL

GAAGGACATACTACAGGTCCAAGTG

QSSGLYSLSSVVTVPSSSLGTQTYICNV

GTATAATGAATATGCAGTCTCTGTG

NHKPSNTKVDKKVEPKSCDKTHTCPP

AAAAGTCGAATAACCATCAACCCAG

CPAPELLGGPSVFLFPPKPKDTLMISRT

ACACATCCAAGAACCAGTTCTCCCT

PEVTCVVVDVSHEDPEVKFNWYVDG

GCAGCTGAACTCTATGACTCCCGAG

VEVHNAKTKPREEQYASTYRVVSVLT

GACTCGGCTGTGTATTACTGTGCAA

VLHQDWLNGKEYKCKVSNKALPAPIE

TTTTGCCTAGTAGTGGTTATCTACAG

KTISKAKGQPREPQVYTLPPSREEMTK

GACCACCACTACTACGGTATGGACG

NQVSLTCLVKGFYPSDIAVEWESNGQP

TCTGGGGCCAAGGGACCACGGTCAC

ENNYKTTPPVLDSDGSFFLYSKLTVDK

CGTCTCCTCAGCATCCACCAAGGGG

SRWQQGNVFSCSVMHEALHNHYTQK

CCTTCCGTGTTCCCCCTGGCCCCTTC

SLSLSPGK

ATCCAAGTCGACCTCTGGTGGAACC

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCCAGACCT

ATATCTGCAACGTCAATCACAAGCC

CTCCAACACCAAAGTGGACAAGAA

GGTCGAACCCAAGTCCTGCGACAAG

ACTCACACCTGTCCGCCTTGTCCAG

CCCCTGAGCTGCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGA

CCAAGCCTAGGGAAGAACAGTACgc

cTCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG

2146
YTFTSYGISWVRQAPGQGLEWMGWIS
2254
CTGAGGTGAAGAAGCCTGGGGCCTC

AYNGNTNYAQKLQGRVTMTTDTSTST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARAAVGDG

GGTTACACCTTTACCAGCTACGGTA

YSYGRLDWGQGTLVTVSSASTKGPSV

TCAGCTGGGTGCGACAGGCCCCTGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

ACAAGGGCTTGAGTGGATGGGATG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GATCAGCGCTTACAATGGTAACACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACTATGCACAGAAGCTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCACAGACACATC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CACGAGCACAGCCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCGAGAGCCG

LNGKEYKCKVSNKALPAPIEKTISKAK

CGGTGGGGGATGGATACAGCTATGG

GQPREPQVYTLPPSREEMTKNQVSLTC

TCGGCTCGATTGGGGCCAGGGAACC

LVKGFYPSDIAVEWESNGQPENNYKT

CTGGTCACCGTCTCCTCAGCATCCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCAAGGGGCCTTCCGTGTTCCCCCT

NVFSCSVMHEALHNHYTQKSLSLSPG

GGCCCCTTCATCCAAGTCGACCTCT

K

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG

2147
SFTSYWIGWVRQMPGKGLEWMGIIYP
2255
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARLPSYYYDSS

TGGATACAGCTTTACCAGCTACTGG

GYFTWYFDLWGRGTLVTVSSASTKGP

ATCGGCTGGGTGCGCCAGATGCCCG

SVFPLAPSSKSTSGGTAALGCLVKDYF

GGAAAGGCCTGGAGTGGATGGGGA

PEPVTVSWNSGALTSGVHTFPAVLQSS

TCATCTATCCTGGTGACTCTGATACC

GLYSLSSVVTVPSSSLGTQTYICNVNH

AGATACAGCCCGTCCTTCCAAGGCC

KPSNTKVDKKVEPKSCDKTHTCPPCPA

AGGTCACCATCTCAGCCGACAAGTC

PELLGGPSVFLFPPKPKDTLMISRTPEV

CATCAGCACCGCCTACCTGCAGTGG

TCVVVDVSHEDPEVKFNWYVDGVEV

AGCAGCCTGAAGGCCTCGGACACCG

HNAKTKPREEQYASTYRVVSVLTVLH

CCATGTATTACTGTGCGAGACTCCC

QDWLNGKEYKCKVSNKALPAPIEKTIS

CTCGTATTACTATGATAGTAGTGGT

KAKGQPREPQVYTLPPSREEMTKNQV

TACTTTACCTGGTACTTCGATCTCTG

SLTCLVKGFYPSDIAVEWESNGQPENN

GGGCCGTGGCACCCTGGTGACCGTC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

TCTTCAGCATCCACCAAGGGGCCTT

QQGNVFSCSVMHEALHNHYTQKSLSL

CCGTGTTCCCCCTGGCCCCTTCATCC

SPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGAG

2148
YTFTSYGISWVRQAPGQGLEWMGWII
2256
CTGAGGTGAAGAAGCCTGGGGCCTC

PIFGIANYAQKFQGRVTITADKSTSTAY

AGTGAAGGTCTCCTGCAAGGCTTCT

MELSSLRSEDTAVYYCARELYNYGSK

GGTTACACCTTTACCAGCTATGGTA

DYFDYWGQGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGATG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATCTTTGGTATAGCA

LSSVVTVPSSSLGTQTYICNVNHKPSNT

AACTACGCACAGAAGTTCCAGGGCA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAGTCACGATTACCGCGGACAAATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGCCTACATGGAGCTG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCGAGAGAAC

GKEYKCKVSNKALPAPIEKTISKAKGQ

TATACAACTATGGTTCAAAGGACTA

PREPQVYTLPPSREEMTKNQVSLTCLV

CTTTGACTACTGGGGCCAGGGAACC

KGFYPSDIAVEWESNGQPENNYKTTPP

CTGGTCACCGTCTCCTCAGCATCCA

VLDSDGSFFLYSKLTVDKSRWQQGNV

CCAAGGGGCCTTCCGTGTTCCCCCT

FSCSVMHEALHNHYTQKSLSLSPGK

GGCCCCTTCATCCAAGTCGACCTCT

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG

2149
SFTSYWIGWVRQMPGKGLEWMGIIYP
2257
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARGGTWDTAM

TGGATACAGCTTTACCAGCTACTGG

VTGFDYWGQGTLVTVSSASTKGPSVF

ATCGGCTGGGTGCGCCAGATGCCCG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GGAAAGGCCTGGAGTGGATGGGGA

VTVSWNSGALTSGVHTFPAVLQSSGL

TCATCTATCCTGGTGACTCTGATACC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AGATACAGCCCGTCCTTCCAAGGCC

NTKVDKKVEPKSCDKTHTCPPCPAPEL

AGGTCACCATCTCAGCCGACAAGTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CATCAGCACCGCCTACCTGCAGTGG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAAGGCCTCGGACACCG

KTKPREEQYASTYRVVSVLTVLHQDW

CCATGTATTACTGTGCGAGGGGCGG

LNGKEYKCKVSNKALPAPIEKTISKAK

TACTTGGGATACAGCTATGGTTACG

GQPREPQVYTLPPSREEMTKNQVSLTC

GGCTTTGACTACTGGGGCCAGGGAA

LVKGFYPSDIAVEWESNGQPENNYKT

CCCTGGTCACCGTCTCCTCAGCATC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CACCAAGGGGCCTTCCGTGTTCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CTGGCCCCTTCATCCAAGTCGACCT

K

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGAG

2150
SFTSYWIAWVRQMPGKGLEWMGVIYP
2258
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSINTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARPHYDILTGS

TGGATACAGCTTTACCAGCTACTGG

RAPFDYWGQGTLVTVSSASTKGPSVFP

ATCGCCTGGGTGCGCCAGATGCCCG

LAPSSKSTSGGTAALGCLVKDYFPEPV

GGAAAGGCCTGGAGTGGATGGGGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

TCATCTATCCTGGTGACTCTGATACC

LSSVVTVPSSSLGTQTYICNVNHKPSNT

AGATACAGCCCGTCCTTCCAAGGCC

KVDKKVEPKSCDKTHTCPPCPAPELLG

AGGTCACCATCTCAGCCGACAAGTC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CATCAATACCGCCTACCTGCAGTGG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGCAGCCTGAAGGCCTCGGACACCG

KPREEQYASTYRVVSVLTVLHQDWLN

CCATGTATTACTGTGCGAGACCCCA

GKEYKCKVSNKALPAPIEKTISKAKGQ

TTACGATATTTTGACTGGTTCCCGG

PREPQVYTLPPSREEMTKNQVSLTCLV

GCGCCCTTTGACTACTGGGGCCAGG

KGFYPSDIAVEWESNGQPENNYKTTPP

GAACCCTGGTCACCGTCTCCTCAGC

VLDSDGSFFLYSKLTVDKSRWQQGNV

ATCCACCAAGGGGCCTTCCGTGTTC

FSCSVMHEALHNHYTQKSLSLSPGK

CCCCTGGCCCCTTCATCCAAGTCGA

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2151
GSFSGYYWSWIRQPPGKGLEWIGEINH
2259
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARARVESKDGYF

GGTGGGTCCTTCAGTGGTTACTACT

DYWGQGTLVTVSSASTKGPSVFPLAPS

GGAGCTGGATCCGCCAGCCCCCAGG

SKSTSGGTAALGCLVKDYFPEPVTVS

GAAGGGGCTGGAGTGGATTGGGGA

WNSGALTSGVHTFPAVLQSSGLYSLSS

AATCAATCATAGTGGAAGCACCAAC

VVTVPSSSLGTQTYICNVNHKPSNTKV

TACAACCCGTCCCTCAAGAGTCGAG

DKKVEPKSCDKTHTCPPCPAPELLGGP

TCACCATATCAGTAGACACGTCCAA

SVFLFPPKPKDTLMISRTPEVTCVVVD

GAACCAGTTCTCCCTGAAGCTGAGC

VSHEDPEVKFNWYVDGVEVHNAKTK

TCTGTGACCGCCGCGGACACGGCTG

PREEQYASTYRVVSVLTVLHQDWLNG

TGTATTACTGTGCGAGAGCCCGAGT

KEYKCKVSNKALPAPIEKTISKAKGQP

GGAATCCAAGGATGGGTACTTTGAC

REPQVYTLPPSREEMTKNQVSLTCLVK

TACTGGGGCCAGGGAACCCTGGTCA

GFYPSDIAVEWESNGQPENNYKTTPPV

CCGTCTCCTCAGCATCCACCAAGGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GCCTTCCGTGTTCCCCCTGGCCCCTT

SCSVMHEALHNHYTQKSLSLSPGK

CATCCAAGTCGACCTCTGGTGGAAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCCAGACC

TATATCTGCAACGTCAATCACAAGC

CCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

2152
TFTDAWMNWVRQAPGKGLEWIGRVK
2260
GAGGCGTGGTCCAGCCTGGGAGGTC

NKADGETTDYAAPVKGRITISRDDAK

CCTGAGACTCTCCTGTGCAGCCTCT

NTLYVQMNSLKTEDTAVYYCTADLRL

GGATTCACTTTCACTGATGCCTGGA

STWDAYDFWGQGTMVTVSSASTKGPS

TGAACTGGGTCCGCCAGGCTCCAGG

VFPLAPSSKSTSGGTAALGCLVKDYFP

GAAGGGGCTGGAGTGGATTGGCCGT

EPVTVSWNSGALTSGVHTFPAVLQSSG

GTTAAAAACAAAGCTGATGGTGAG

LYSLSSVVTVPSSSLGTQTYICNVNHKP

ACAACGGACTACGCTGCACCCGTCA

SNTKVDKKVEPKSCDKTHTCPPCPAPE

AAGGCAGAATCACCATCTCAAGAG

LLGGPSVFLFPPKPKDTLMISRTPEVTC

ATGATGCAAAGAACACTCTGTATGT

VVVDVSHEDPEVKFNWYVDGVEVHN

GCAAATGAACAGCCTGAAAACCGA

AKTKPREEQYASTYRVVSVLTVLHQD

GGACACAGCCGTGTATTATTGTACC

WLNGKEYKCKVSNKALPAPIEKTISKA

GCTGACCTGCGACTTTCTACGTGGG

KGQPREPQVYTLPPSREEMTKNQVSLT

ATGCTTATGATTTCTGGGGCCAAGG

CLVKGFYPSDIAVEWESNGQPENNYK

GACAATGGTCACCGTCTCTTCAGCA

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

TCCACCAAGGGGCCTTCCGTGTTCC

GNVFSCSVMHEALHNHYTQKSLSLSP

CCCTGGCCCCTTCATCCAAGTCGAC

GK

CTCTGGTGGAACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QITLKESGGGLVQPGGSLRLSCTVSGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

2153
TFSNNWMTWVRQTPGKGLEWVANIK
2261
GAGGCTTGGTCCAGCCTGGGGGGTC

QDGTEKHYVDSVKGRFTISRDNAENSL

CCTAAGACTCTCTTGTACAGTCTCA

YLQMNSLRGEDTAVYYCARNSQRSFD

GGATTCACCTTTAGTAACAATTGGA

YWGQGTLVTVSSASTKGPSVFPLAPSS

TGACCTGGGTCCGCCAGACTCCAGG

KSTSGGTAALGCLVKDYFPEPVTVSW

GAAGGGGCTGGAGTGGGTGGCCAA

NSGALTSGVHTFPAVLQSSGLYSLSSV

CATAAAGCAAGATGGAACTGAGAA

VTVPSSSLGTQTYICNVNHKPSNTKVD

ACACTATGTGGACTCTGTGAAGGGC

KKVEPKSCDKTHTCPPCPAPELLGGPS

CGATTCACCATCTCCAGAGACAACG

VFLFPPKPKDTLMISRTPEVTCVVVDV

CCGAGAACTCACTGTATCTGCAGAT

SHEDPEVKFNWYVDGVEVHNAKTKP

GAACAGCCTGAGAGGTGAGGACAC

REEQYASTYRVVSVLTVLHQDWLNGK

GGCCGTGTATTATTGTGCGAGAAAC

EYKCKVSNKALPAPIEKTISKAKGQPR

AGTCAACGTTCGTTTGACTACTGGG

EPQVYTLPPSREEMTKNQVSLTCLVKG

GCCAGGGCACCCTGGTGACCGTCTC

FYPSDIAVEWESNGQPENNYKTTPPVL

CTCAGCATCCACCAAGGGGCCTTCC

DSDGSFFLYSKLTVDKSRWQQGNVFS

GTGTTCCCCCTGGCCCCTTCATCCAA

CSVMHEALHNHYTQKSLSLSPGK

GTCGACCTCTGGTGGAACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCCAGACCTATATCT

GCAACGTCAATCACAAGCCCTCCAA

CACCAAAGTGGACAAGAAGGTCGA

ACCCAAGTCCTGCGACAAGACTCAC

ACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCACGAAGATCCCGAAGTGAA

ATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACgccTCTAC

GTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGT

CAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TACACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAA

CTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCT

GCACAACCATTACACCCAGAAATCA

CTGTCACTTTCGCCGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2154
TFSSYGMHWVRQAPGKGLEWVAVISY
2262
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDLGDPR

GGATTCACCTTCAGTAGCTATGGCA

GGILNYWGQGTLVTVSSASTKGPSVFP

TGCACTGGGTCCGCCAGGCTCCAGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

CAAGGGGCTGGAGTGGGTGGCAGTT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATATCATATGATGGAAGTAATAAAT

LSSVVTVPSSSLGTQTYICNVNHKPSNT

ACTATGCAGACTCCGTGAAGGGCCG

KVDKKVEPKSCDKTHTCPPCPAPELLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTGCAAATGA

DVSHEDPEVKFNWYVDGVEVHNAKT

ACAGCCTGAGAGCTGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAAAGATTT

GKEYKCKVSNKALPAPIEKTISKAKGQ

AGGGGATCCCCGGGGTGGTATTTTG

PREPQVYTLPPSREEMTKNQVSLTCLV

AACTACTGGGGCCAGGGCACCCTGG

KGFYPSDIAVEWESNGQPENNYKTTPP

TCACCGTCTCCTCAGCATCCACCAA

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGGCCTTCCGTGTTCCCCCTGGCC

FSCSVMHEALHNHYTQKSLSLSPGK

CCTTCATCCAAGTCGACCTCTGGTG

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

2155
TFSSYAMHWVRQAPGKGLEWVAVISY
2263
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARSSPWGEL

GGATTCACCTTCAGTAGCTATGCTA

SLYQGAFDIWGQGTMVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPSSKSTSGGTAALGCLVKDYF

CAAGGGGCTGGAGTGGGTGGCAGTT

PEPVTVSWNSGALTSGVHTFPAVLQSS

ATATCATATGATGGAAGTAATAAAT

GLYSLSSVVTVPSSSLGTQTYICNVNH

ACTACGCAGACTCCGTGAAGGGCCG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

ATTCACCATCTCCAGAGACAATTCC

PELLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSHEDPEVKFNWYVDGVEV

ACAGCCTGAGAGCTGAGGACACGG

HNAKTKPREEQYASTYRVVSVLTVLH

CTGTGTATTACTGTGCCCGGTCGAG

QDWLNGKEYKCKVSNKALPAPIEKTIS

CCCCTGGGGGGAGTTATCGTTATAC

KAKGQPREPQVYTLPPSREEMTKNQV

CAGGGGGCTTTTGATATCTGGGGCC

SLTCLVKGFYPSDIAVEWESNGQPENN

AAGGGACAATGGTCACCGTCTCTTC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

AGCATCCACCAAGGGGCCTTCCGTG

QQGNVFSCSVMHEALHNHYTQKSLSL

TTCCCCCTGGCCCCTTCATCCAAGTC

SPGK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QITLKESGGGLVQPGRSLRLSCAASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

2156
TFDDYAMHWVRQAPGKGLEWVSAIS
2264
GAGGCTTGGTACAGCCTGGCAGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDNDFWS

GGATTCACCTTTGATGATTATGCCA

GKVFDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTCCGGCAAGCTCCAGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GAAGGGGCTGGAGTGGGTCTCAGCT

VTVSWNSGALTSGVHTFPAVLQSSGL

ATTAGTGGTAGTGGTGGTAGCACAT

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ACTACGCAGACTCCGTGAAGGGCCG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GTTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

ACAGCCTGAGAGCCGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CCGTATATTACTGTGCGAAAGATAA

LNGKEYKCKVSNKALPAPIEKTISKAK

CGATTTTTGGAGTGGGAAAGTCTTT

GQPREPQVYTLPPSREEMTKNQVSLTC

GACTACTGGGGCCAGGGCACCCTGG

LVKGFYPSDIAVEWESNGQPENNYKT

TCACCGTCTCCTCAGCATCCACCAA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GGGGCCTTCCGTGTTCCCCCTGGCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTTCATCCAAGTCGACCTCTGGTG

K

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
EVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2157
FTFSSYSMNWVRQAPGKGLEWVSYIS
2265
GAGGCTTGGTACAGCCTGGGGGGTC

STSSTIYYADSVKGRFTISRDNSKNMLF

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAVYYCAKEGGSGWR

GGATTCACCTTCAGTAGTTATAGCA

HYFDYWGQGTLVTVSSASTKGPSVFP

TGAACTGGGTCCGCCAGGCTCCAGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGGTTTCATAC

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATCAGTAGTACTAGTAGTACCATAT

LSSVVTVPSSSLGTQTYICNVNHKPSNT

ACTACGCAGACTCCGTGAAGGGCCG

KVDKKVEPKSCDKTHTCPPCPAPELLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAATATGCTGTTTCTACAAATGA

DVSHEDPEVKFNWYVDGVEVHNAKT

ACAGCCTGAGAGCTGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAAAGAAGG

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGCAGTGGCTGGCGCCACTACTTT

PREPQVYTLPPSREEMTKNQVSLTCLV

GACTACTGGGGCCAGGGAACCCTGG

KGFYPSDIAVEWESNGQPENNYKTTPP

TCACCGTCTCCTCAGCATCCACCAA

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGGCCTTCCGTGTTCCCCCTGGCC

FSCSVMHEALHNHYTQKSLSLSPGK

CCTTCATCCAAGTCGACCTCTGGTG

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2158
TFSSYAMHWVRQAPGKGLEWVAVISY
2266
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTGTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARDYCSSTS

GGATTCACCTTCAGCAGCTATGCTA

CQNWFDPWGQGTLVTVSSASTKGPSV

TGCACTGGGTCCGCCAGGCTCCAGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

CAAGGGGCTGGAGTGGGTGGCAGTT

PVTVSWNSGALTSGVHTFPAVLQSSGL

ATATCATATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ACTACGCAGACTCCGTGAAGGGCCG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

ACAGCCTGAGAGCTGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CTGTGTATTACTGTGCGAGAGATTA

LNGKEYKCKVSNKALPAPIEKTISKAK

TTGTAGTAGTACCAGCTGCCAGAAC

GQPREPQVYTLPPSREEMTKNQVSLTC

TGGTTCGACCCCTGGGGCCAGGGCA

LVKGFYPSDIAVEWESNGQPENNYKT

CCCTGGTCACCGTCTCCTCAGCATC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CACCAAGGGGCCTTCCGTGTTCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CTGGCCCCTTCATCCAAGTCGACCT

K

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

2159
FTFSNYVMSWVRQAPGKGLEWVSAIS
2267
GAGGCTTGGTACAGCCTGGGGGGTC

GIGDTTYYADSVKGRFTISRDNAKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARGRVAGD

GGATTCACCTTTAGCAACTATGTCA

AFDIWGQGTMVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

GAAGGGGCTGGAGTGGGTCTCAGCT

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATTAGTGGTATTGGTGATACTACAT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ACTACGCGGACTCCGTGAAGGGCCG

VDKKVEPKSCDKTHTCPPCPAPELLGG

ATTCACCATCTCCAGAGACAACGCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAGTCTGAGAGCCGAGGACACGG

PREEQYASTYRVVSVLTVLHQDWLNG

CTGTGTATTACTGTGCAAGAGGGCG

KEYKCKVSNKALPAPIEKTISKAKGQP

CGTGGCGGGGGATGCTTTTGATATC

REPQVYTLPPSREEMTKNQVSLTCLVK

TGGGGCCAAGGGACAATGGTGACC

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCTCTTCAGCATCCACCAAGGGGC

LDSDGSFFLYSKLTVDKSRWQQGNVF

CTTCCGTGTTCCCCCTGGCCCCTTCA

SCSVMHEALHNHYTQKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGG

2160
TFSSYAMSWVRQAPGKGLEWVSAISG
2268
GGAGGCTTGGTACAGCCTGGGGGGT

SGGSTYYADSVKGRFTISRDNSKNTLY

CCCTGAGACTCTCCTGTGCAGCCTC

LQMNSLRAEDTAVYYCAKDQGAAAG

TGGATTCACCTTTAGCAGCTATGCC

TLGYFDYWGQGTLVTVSSASTKGPSV

ATGAGCTGGGTCCGCCAGGCTCCAG

FPLAPSSKSTSGGTAALGCLVKDYFPE

GGAAGGGGCTGGAGTGGGTCTCAG

PVTVSWNSGALTSGVHTFPAVLQSSGL

CTATTAGTGGTAGTGGTGGTAGCAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ATACTACGCAGACTCCGTGAAGGGC

NTKVDKKVEPKSCDKTHTCPPCPAPEL

CGGTTCACCATCTCCAGAGACAATT

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CCAAGAACACGCTGTATCTGCAAAT

VVDVSHEDPEVKFNWYVDGVEVHNA

GAACAGCCTGAGAGCCGAGGACAC

KTKPREEQYASTYRVVSVLTVLHQDW

GGCCGTATATTACTGTGCGAAAGAT

LNGKEYKCKVSNKALPAPIEKTISKAK

CAAGGGGCAGCAGCTGGTACCCTGG

GQPREPQVYTLPPSREEMTKNQVSLTC

GGTACTTTGACTACTGGGGCCAGGG

LVKGFYPSDIAVEWESNGQPENNYKT

AACCCTGGTGACCGTCTCCTCAGCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

TCCACCAAGGGGCCTTCCGTGTTCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCCTGGCCCCTTCATCCAAGTCGAC

K

CTCTGGTGGAACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2161
YTFTSYDINWVRQATGQGLEWMGWM
2269
CTGAGGTGAAGAAGCCTGGGGCCTC

NPNSGNTGYAQKFQGRVTMTRNTSIST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCTRGIYDSSG

GGATACACCTTCACCAGTTATGATA

SSNPFDSWGQGTLVTVSSASTKGPSVF

TCAACTGGGTGCGACAGGCCACTGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGATG

VTVSWNSGALTSGVHTFPAVLQSSGL

GATGAACCCTAACAGTGGTAACACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

GGCTATGCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCAGGAACACCTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CATAAGCACAGCCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTACGAGAGGAA

LNGKEYKCKVSNKALPAPIEKTISKAK

TCTATGATAGTAGTGGTTCTTCCAAT

GQPREPQVYTLPPSREEMTKNQVSLTC

CCCTTTGACTCCTGGGGCCAGGGAA

LVKGFYPSDIAVEWESNGQPENNYKT

CCCTGGTGACCGTCTCCTCAGCATC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CACCAAGGGGCCTTCCGTGTTCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CTGGCCCCTTCATCCAAGTCGACCT

K

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKISCEASGY
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2162
TFTDYAIHWVRQAPGQRLEWMGWIN
2270
CTGAGGTGAAGAAGCCTGGGGCCTC

AGDGGTKSSREFQGRVTITRDTSATTA

AGTGAAGATTTCCTGCGAGGCTTCT

YMEVSSLRSEDTAVYYCARGYCSGGS

GGATACACCTTCACTGATTATGCTA

CPGTDFDYWGQGTLVTVSSASTKGPS

TACATTGGGTGCGCCAGGCCCCCGG

VFPLAPSSKSTSGGTAALGCLVKDYFP

ACAAAGACTTGAGTGGATGGGATG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GATCAACGCTGGCGATGGTGGCACA

LYSLSSVVTVPSSSLGTQTYICNVNHKP

AAAAGTTCACGGGAGTTCCAGGGCA

SNTKVDKKVEPKSCDKTHTCPPCPAPE

GAGTCACCATTACCAGGGACACATC

LLGGPSVFLFPPKPKDTLMISRTPEVTC

CGCGACCACAGCCTACATGGAGGTG

VVVDVSHEDPEVKFNWYVDGVEVHN

AGCAGTCTGAGATCTGAAGACACGG

AKTKPREEQYASTYRVVSVLTVLHQD

CTGTCTATTACTGTGCGAGAGGATA

WLNGKEYKCKVSNKALPAPIEKTISKA

TTGTAGTGGTGGTAGCTGCCCAGGA

KGQPREPQVYTLPPSREEMTKNQVSLT

ACGGATTTTGACTACTGGGGCCAGG

CLVKGFYPSDIAVEWESNGQPENNYK

GAACCCTGGTCACCGTCTCCTCAGC

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

ATCCACCAAGGGGCCTTCCGTGTTC

GNVFSCSVMHEALHNHYTQKSLSLSP

CCCCTGGCCCCTTCATCCAAGTCGA

GK

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2163
YTFTSYYMHWVRQAPGQGLEWMGIIN
2271
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCARDGVGGRD

GGATACACCTTCACCAGCTACTATA

GYNFDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGAAT

VTVSWNSGALTSGVHTFPAVLQSSGL

AATCAACCCTAGTGGTGGTAGCACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AGCTACGCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCAGGGACACGTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CACGAGCACAGTCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCGAGAGATG

LNGKEYKCKVSNKALPAPIEKTISKAK

GTGTAGGAGGGAGAGATGGCTACA

GQPREPQVYTLPPSREEMTKNQVSLTC

ATTTTGACTACTGGGGCCAGGGAAC

LVKGFYPSDIAVEWESNGQPENNYKT

CCTGGTCACCGTCTCCTCAGCATCC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

ACCAAGGGGCCTTCCGTGTTCCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

TGGCCCCTTCATCCAAGTCGACCTC

K

TGGTGGAACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCCAGACCTATATCTGCAACGTCA

ATCACAAGCCCTCCAACACCAAAGT

GGACAAGAAGGTCGAACCCAAGTC

CTGCGACAAGACTCACACCTGTCCG

CCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGGGG

2164
FTVSSNYMSWVRQAPGKGLEWVSVIY
2272
GAGGCTTGGTCCAGCCTGGGGGGTC

SGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTGCAGCCTCT

LQMNSLRAEDTAVYYCARAPLAADG

GGATTCACCGTCAGTAGCAACTACA

YFDYWGQGTLVTVSSASTKGPSVFPL

TGAGCTGGGTCCGCCAGGCTCCAGG

APSSKSTSGGTAALGCLVKDYFPEPVT

GAAGGGGCTGGAGTGGGTCTCAGTT

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTTATAGCGGTGGTAGCACATACT

SSVVTVPSSSLGTQTYICNVNHKPSNT

ACGCAGACTCCGTGAAGGGCCGATT

KVDKKVEPKSCDKTHTCPPCPAPELLG

CACCATCTCCAGAGACAATTCCAAG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AACACGCTGTATCTTCAAATGAACA

DVSHEDPEVKFNWYVDGVEVHNAKT

GCCTGAGAGCTGAGGACACGGCTGT

KPREEQYASTYRVVSVLTVLHQDWLN

GTATTACTGTGCGAGAGCCCCCCTA

GKEYKCKVSNKALPAPIEKTISKAKGQ

GCAGCAGATGGCTACTTTGACTACT

PREPQVYTLPPSREEMTKNQVSLTCLV

GGGGCCAGGGAACCCTGGTCACCGT

KGFYPSDIAVEWESNGQPENNYKTTPP

CTCCTCAGCATCCACCAAGGGGCCT

VLDSDGSFFLYSKLTVDKSRWQQGNV

TCCGTGTTCCCCCTGGCCCCTTCATC

FSCSVMHEALHNHYTQKSLSLSPGK

CAAGTCGACCTCTGGTGGAACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCCAGACCTATA

TCTGCAACGTCAATCACAAGCCCTC

CAACACCAAAGTGGACAAGAAGGT

CGAACCCAAGTCCTGCGACAAGACT

CACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACgccTCT

ACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCC

AAGGGTCAACCTAGGGAGCCCCAG

GTCTACACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGT

CCCTGACTTGCCTTGTCAAGGGCTTT

TATCCGTCCGACATCGCCGTGGAGT

GGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGT

GTTCTCCTGCTCCGTGATGCACGAA

GCGCTGCACAACCATTACACCCAGA

AATCACTGTCACTTTCGCCGGGAAA

A

SEQ ID
EVQLVQSGAEVKKPGSSVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

2165
GTFSSYAISWVRQAPGQGLEWMGGIIP
2273
CTGAGGTGAAGAAGCCTGGGTCCTC

IFGTANYAQKFQGRVTITADESTSTAY

GGTGAAGGTCTCCTGCAAGGCTTCT

MELSSLRSEDTAVYYCARARGLQYLI

GGAGGCACCTTCAGCAGCTATGCTA

WYFDLWGRGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATCTTTGGTACAGCA

LSSVVTVPSSSLGTQTYICNVNHKPSNT

AACTACGCACAGAAGTTCCAGGGCA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAGTCACGATTACCGCGGACGAATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGCCTACATGGAGCTG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCGAGAGCCC

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGGGCTACAGTACCTAATCTGGTA

PREPQVYTLPPSREEMTKNQVSLTCLV

CTTCGATCTCTGGGGCCGTGGCACC

KGFYPSDIAVEWESNGQPENNYKTTPP

CTGGTGACCGTCTCCTCAGCATCCA

VLDSDGSFFLYSKLTVDKSRWQQGNV

CCAAGGGGCCTTCCGTGTTCCCCCT

FSCSVMHEALHNHYTQKSLSLSPGK

GGCCCCTTCATCCAAGTCGACCTCT

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG

2166
YTFTSYYMHWVRQAPGQGLEWMGIIN
2274
CTGAGGTGAAGAAGCCTGGGGCCTC

PSGGSTSYAQKFQGRVTMTRDTSTSTV

AGTGAAGGTTTCCTGCAAGGCATCT

YMELSSLRSEDTAVYYCASPGMVRGV

GGATACACCTTCACCAGCTACTATA

ITAPLDYWGQGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGAAT

VTVSWNSGALTSGVHTFPAVLQSSGL

AATCAACCCTAGTGGTGGTAGCACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AGCTACGCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCAGGGACACGTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CACGAGCACAGTCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCGAGCCCGG

LNGKEYKCKVSNKALPAPIEKTISKAK

GTATGGTTCGGGGAGTTATTACTGC

GQPREPQVYTLPPSREEMTKNQVSLTC

CCCGCTTGACTACTGGGGCCAGGGC

LVKGFYPSDIAVEWESNGQPENNYKT

ACCCTGGTCACCGTCTCCTCAGCAT

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCACCAAGGGGCCTTCCGTGTTCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTGGCCCCTTCATCCAAGTCGACC

K

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGLVKPGGSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

2167
FTFSSYAISWVRQAPGQGLEWMGGIIP
2275
GAGGCCTGGTCAAGCCTGGGGGGTC

MYGTANYAQKFQGRVTITADESTSTA

CCTGAGACTCTCCTGTGCAGCCTCT

YMELSSLRSEDTALYYCAREAKWGM

GGATTCACCTTCAGCAGCTATGCTA

YYFDYWGQGTLVTVSSASTKGPSVFP

TCAGCTGGGTGCGACAGGCCCCTGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

ACAAGGGCTTGAGTGGATGGGAGG

TVSWNSGALTSGVHTFPAVLQSSGLYS

GATCATCCCTATGTATGGTACAGCA

LSSVVTVPSSSLGTQTYICNVNHKPSNT

AACTACGCACAGAAGTTCCAGGGCA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAGTCACGATTACCGCGGACGAATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGCCTACATGGAACTG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGCAGCCTGAGATCTGAGGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCCCTCTATTACTGTGCGAGAGAAG

GKEYKCKVSNKALPAPIEKTISKAKGQ

CTAAGTGGGGAATGTACTACTTTGA

PREPQVYTLPPSREEMTKNQVSLTCLV

CTACTGGGGCCAGGGCACCCTGGTC

KGFYPSDIAVEWESNGQPENNYKTTPP

ACCGTCTCCTCAGCATCCACCAAGG

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGCCTTCCGTGTTCCCCCTGGCCCCT

FSCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCAASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCCGGG

2168
TFSSYAIHWVRQAPGKGLEWVAIISDD
2276
GGAGGCGTGGTCCAGCCTGGGAGGT

GSKSYYADSVQGRFTISRDNSRNTVYL

CCCTGAGACTCTCCTGTGCAGCCTC

QMNSLRAEDTAMYYCARDRGTKWNQ

TGGATTCACCTTCAGTAGCTATGCT

LNDVFDMWGQGTMVTVSSASTKGPS

ATACACTGGGTCCGCCAGGCTCCAG

VFPLAPSSKSTSGGTAALGCLVKDYFP

GCAAGGGGCTGGAGTGGGTGGCAA

EPVTVSWNSGALTSGVHTFPAVLQSSG

TTATATCAGATGATGGAAGTAAGAG

LYSLSSVVTVPSSSLGTQTYICNVNHKP

TTACTACGCAGACTCCGTGCAGGGC

SNTKVDKKVEPKSCDKTHTCPPCPAPE

CGATTCACCATCTCCAGAGACAATT

LLGGPSVFLFPPKPKDTLMISRTPEVTC

CGAGGAACACAGTATATCTGCAAAT

VVVDVSHEDPEVKFNWYVDGVEVHN

GAACAGCCTGAGAGCTGAGGACAC

AKTKPREEQYASTYRVVSVLTVLHQD

GGCTATGTATTACTGTGCGAGAGAC

WLNGKEYKCKVSNKALPAPIEKTISKA

AGGGGAACTAAATGGAACCAATTG

KGQPREPQVYTLPPSREEMTKNQVSLT

AATGATGTTTTTGATATGTGGGGCC

CLVKGFYPSDIAVEWESNGQPENNYK

AAGGGACAATGGTCACCGTCTCTTC

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

AGCATCCACCAAGGGGCCTTCCGTG

GNVFSCSVMHEALHNHYTQKSLSLSP

TTCCCCCTGGCCCCTTCATCCAAGTC

GK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QMQLVQSGAEVKKPGASVKVSCTASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

2169
YTFTSSDINWVRQATGQGLEWMGWM
2277
CTGAGGTGAAGAAGCCTGGGGCCTC

NPNSGNTGYAEKFQGRVTMTSDSSIST

AGTGAAGGTCTCCTGCACGGCTTCT

AYMELRSLTTEDTAVYYCARGGGASY

GGATACACCTTCACCAGTTCTGATA

TDSWGQGTLVTVSSASTKGPSVFPLAP

TCAACTGGGTGCGACAGGCCACTGG

SSKSTSGGTAALGCLVKDYFPEPVTVS

ACAAGGGCTTGAGTGGATGGGATG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GATGAACCCTAACAGTGGTAACACC

VVTVPSSSLGTQTYICNVNHKPSNTKV

GGCTATGCAGAGAAGTTCCAGGGCA

DKKVEPKSCDKTHTCPPCPAPELLGGP

GGGTCACCATGACCAGCGACTCCTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATAAGCACCGCCTACATGGAGTTG

VSHEDPEVKFNWYVDGVEVHNAKTK

AGAAGCCTGACCACTGAGGACACG

PREEQYASTYRVVSVLTVLHQDWLNG

GCCGTATATTACTGTGCGAGAGGTG

KEYKCKVSNKALPAPIEKTISKAKGQP

GGGGTGCGAGCTATACTGACTCCTG

REPQVYTLPPSREEMTKNQVSLTCLVK

GGGCCAGGGCACCCTGGTCACCGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

TCCTCAGCATCCACCAAGGGGCCTT

LDSDGSFFLYSKLTVDKSRWQQGNVF

CCGTGTTCCCCCTGGCCCCTTCATCC

SCSVMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

2170
TFGDYAMSWFRQAPGKGLEWVGFIRS
2278
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTAKGGYV

GGATTCACCTTTGGTGATTATGCTAT

GYSYGPFGGYWGQGTLVTVSSASTKG

GAGCTGGTTCCGCCAGGCTCCAGGG

PSVFPLAPSSKSTSGGTAALGCLVKDY

AAGGGGCTGGAGTGGGTAGGTTTCA

FPEPVTVSWNSGALTSGVHTFPAVLQS

TTAGAAGCAAAGCTTATGGTGGGAC

SGLYSLSSVVTVPSSSLGTQTYICNVNH

AACAGAATACGCCGCGTCTGTGAAA

KPSNTKVDKKVEPKSCDKTHTCPPCPA

GGCAGATTCACCATCTCAAGAGATG

PELLGGPSVFLFPPKPKDTLMISRTPEV

ATTCCAAAAGCATCGCCTATCTGCA

TCVVVDVSHEDPEVKFNWYVDGVEV

AATGAACAGCCTGAAAACCGAGGA

HNAKTKPREEQYASTYRVVSVLTVLH

CACAGCCGTGTATTACTGTACCGCT

QDWLNGKEYKCKVSNKALPAPIEKTIS

AAGGGGGGCTACGTCGGATACAGCT

KAKGQPREPQVYTLPPSREEMTKNQV

ATGGACCTTTTGGGGGCTACTGGGG

SLTCLVKGFYPSDIAVEWESNGQPENN

CCAGGGAACCCTGGTCACCGTCTCC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

TCAGCATCCACCAAGGGGCCTTCCG

QQGNVFSCSVMHEALHNHYTQKSLSL

TGTTCCCCCTGGCCCCTTCATCCAAG

SPGK

TCGACCTCTGGTGGAACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCCAGACCTATATCTG

CAACGTCAATCACAAGCCCTCCAAC

ACCAAAGTGGACAAGAAGGTCGAA

CCCAAGTCCTGCGACAAGACTCACA

CCTGTCCGCCTTGTCCAGCCCCTGA

GCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTG

TCGCACGAAGATCCCGAAGTGAAAT

TCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACgccTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCGGGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2171
TFGDYAMSWFRQAPGKGLEWVGFIRS
2279
GAGGCTTGGTACAGCCAGGGCGGTC

KAYGGTTEYAASVKGRFTISRDDSKSI

CCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRGGTMV

GGATTCACCTTTGGTGATTATGCTAT

RGFGFNYWGQGTLVTVSSASTKGPSV

GAGCTGGTTCCGCCAGGCTCCAGGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

AAGGGGCTGGAGTGGGTAGGTTTCA

PVTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAAGCAAAGCTTATGGTGGGAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACAGAATACGCCGCGTCTGTGAAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAAAAGCATCGCCTATCTGCA

VVDVSHEDPEVKFNWYVDGVEVHNA

AATGAACAGCCTGAAAACCGAGGA

KTKPREEQYASTYRVVSVLTVLHQDW

CACAGCCGTGTATTACTGTACTAGA

LNGKEYKCKVSNKALPAPIEKTISKAK

GGGGGGACTATGGTTCGGGGTTTCG

GQPREPQVYTLPPSREEMTKNQVSLTC

GATTTAACTACTGGGGCCAGGGAAC

LVKGFYPSDIAVEWESNGQPENNYKT

CCTGGTCACCGTCTCCTCAGCATCC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

ACCAAGGGGCCTTCCGTGTTCCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

TGGCCCCTTCATCCAAGTCGACCTC

K

TGGTGGAACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCCAGACCTATATCTGCAACGTCA

ATCACAAGCCCTCCAACACCAAAGT

GGACAAGAAGGTCGAACCCAAGTC

CTGCGACAAGACTCACACCTGTCCG

CCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2172
GSFSGYYWSWIRQPPGKGLEWIGEINH
2280
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARARRAMIGPLP

GGTGGGTCCTTCAGTGGTTACTACT

RLVGYFDLWGRGTLVTVSSASTKGPS

GGAGCTGGATCCGCCAGCCCCCAGG

VFPLAPSSKSTSGGTAALGCLVKDYFP

GAAGGGGCTGGAGTGGATTGGGGA

EPVTVSWNSGALTSGVHTFPAVLQSSG

AATCAATCATAGTGGAAGCACCAAC

LYSLSSVVTVPSSSLGTQTYICNVNHKP

TACAACCCGTCCCTCAAGAGTCGAG

SNTKVDKKVEPKSCDKTHTCPPCPAPE

TCACCATATCAGTAGACACGTCCAA

LLGGPSVFLFPPKPKDTLMISRTPEVTC

GAACCAGTTCTCCCTGAAGCTGAGC

VVVDVSHEDPEVKFNWYVDGVEVHN

TCTGTGACCGCCGCGGACACGGCTG

AKTKPREEQYASTYRVVSVLTVLHQD

TGTATTACTGTGCGAGAGCCCGGCG

WLNGKEYKCKVSNKALPAPIEKTISKA

GGCTATGATAGGGCCGCTTCCGCGA

KGQPREPQVYTLPPSREEMTKNQVSLT

CTTGTCGGGTACTTCGATCTCTGGG

CLVKGFYPSDIAVEWESNGQPENNYK

GCCGTGGAACCCTGGTCACCGTCTC

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

CTCAGCATCCACCAAGGGGCCTTCC

GNVFSCSVMHEALHNHYTQKSLSLSP

GTGTTCCCCCTGGCCCCTTCATCCAA

GK

GTCGACCTCTGGTGGAACCGCCGCA

CTCGGTTGCCTGGTCAAAGACTACT

TCCCCGAGCCCGTGACTGTCTCGTG

GAACTCGGGCGCCCTCACATCCGGA

GTGCATACCTTTCCCGCCGTGTTGC

AGTCCAGCGGCCTGTACAGCCTGAG

CTCCGTCGTGACAGTGCCGTCCTCC

TCCCTTGGAACCCAGACCTATATCT

GCAACGTCAATCACAAGCCCTCCAA

CACCAAAGTGGACAAGAAGGTCGA

ACCCAAGTCCTGCGACAAGACTCAC

ACCTGTCCGCCTTGTCCAGCCCCTG

AGCTGCTGGGTGGTCCGTCCGTGTT

CCTCTTCCCGCCCAAGCCGAAGGAC

ACTCTGATGATTTCACGCACCCCGG

AAGTCACTTGCGTGGTCGTGGACGT

GTCGCACGAAGATCCCGAAGTGAA

ATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACgccTCTAC

GTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGT

CAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TACACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAA

CTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCT

GCACAACCATTACACCCAGAAATCA

CTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2173
GSFSGYYWSWIRQPPGKGLEWIGEINH
2281
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRPAPSWVKT

GGTGGGTCCTTCAGTGGTTACTACT

RNWFDPWGQGTLVTVSSASTKGPSVF

GGAGCTGGATCCGCCAGCCCCCAGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GAAGGGGCTGGAGTGGATTGGGGA

VTVSWNSGALTSGVHTFPAVLQSSGL

AATCAATCATAGTGGAAGCACCAAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

TACAACCCGTCCCTCAAGAGTCGAG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

TCACCATATCAGTAGACACGTCCAA

LGGPSVFLFPPKPKDTLMISRTPEVTCV

GAACCAGTTCTCCCTGAAGCTGAGC

VVDVSHEDPEVKFNWYVDGVEVHNA

TCTGTGACCGCCGCGGACACGGCTG

KTKPREEQYASTYRVVSVLTVLHQDW

TGTATTACTGTGCGAGAGGCCGCCC

LNGKEYKCKVSNKALPAPIEKTISKAK

CGCCCCATCCTGGGTTAAAACCCGT

GQPREPQVYTLPPSREEMTKNQVSLTC

AACTGGTTCGACCCCTGGGGCCAGG

LVKGFYPSDIAVEWESNGQPENNYKT

GAACCCTGGTCACCGTCTCCTCAGC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

ATCCACCAAGGGGCCTTCCGTGTTC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCCCTGGCCCCTTCATCCAAGTCGA

K

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2174
SVSSNSAAWNWIRQSPSRGLEWLGRT
2282
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCAREASSG

GGGACAGTGTCTCTAGCAACAGTGC

WNWGQGTLVTVSSASTKGPSVFPLAP

TGCTTGGAACTGGATCAGGCAGTCC

SSKSTSGGTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTQTYICNVNHKPSNTKV

GTATAATGATTATGCAGTATCTGTG

DKKVEPKSCDKTHTCPPCPAPELLGGP

AAAAGTCGAATAACCATCAACCCAG

SVFLFPPKPKDTLMISRTPEVTCVVVD

ACACATCCAAGAACCAGTTCTCCCT

VSHEDPEVKFNWYVDGVEVHNAKTK

GCAGCTGAACTCTGTGACTCCCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCTGTGTATTACTGTGCAA

KEYKCKVSNKALPAPIEKTISKAKGQP

GAGAGGCTAGCAGTGGCTGGAACT

REPQVYTLPPSREEMTKNQVSLTCLVK

GGGGCCAGGGAACCCTGGTCACCGT

GFYPSDIAVEWESNGQPENNYKTTPPV

CTCCTCAGCATCCACCAAGGGGCCT

LDSDGSFFLYSKLTVDKSRWQQGNVF

TCCGTGTTCCCCCTGGCCCCTTCATC

SCSVMHEALHNHYTQKSLSLSPGK

CAAGTCGACCTCTGGTGGAACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCCAGACCTATA

TCTGCAACGTCAATCACAAGCCCTC

CAACACCAAAGTGGACAAGAAGGT

CGAACCCAAGTCCTGCGACAAGACT

CACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACgccTCT

ACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCC

AAGGGTCAACCTAGGGAGCCCCAG

GTCTACACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGT

CCCTGACTTGCCTTGTCAAGGGCTTT

TATCCGTCCGACATCGCCGTGGAGT

GGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGT

GTTCTCCTGCTCCGTGATGCACGAA

GCGCTGCACAACCATTACACCCAGA

AATCACTGTCACTTTCGCCGGGAAA

A

SEQ ID
QVQLQESGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGTC

2175
SVSSNNAAWNWIRQSPSRGLEWLGRT
2283
CAGGACTGGTGAAGCCCTCGCAGAC

FYRSKWYNDYAVSVKSRLTVNPDTSK

CCTCTCACTCACCTGTGCCATCTCCG

NQFSLRLNSVSPEDTAVYYCARGGRY

GGGACAGTGTCTCTAGCAACAATGC

TKGGYFDDWGQGTLVTVSSASTKGPS

TGCTTGGAACTGGATCAGGCAGTCC

VFPLAPSSKSTSGGTAALGCLVKDYFP

CCATCGAGAGGCCTTGAGTGGCTGG

EPVTVSWNSGALTSGVHTFPAVLQSSG

GAAGGACATTCTACAGGTCCAAGTG

LYSLSSVVTVPSSSLGTQTYICNVNHKP

GTATAATGACTATGCAGTTTCTGTG

SNTKVDKKVEPKSCDKTHTCPPCPAPE

AAAAGTCGACTAACCGTCAACCCAG

LLGGPSVFLFPPKPKDTLMISRTPEVTC

ACACATCCAAGAACCAGTTCTCCCT

VVVDVSHEDPEVKFNWYVDGVEVHN

GCGGTTGAACTCTGTGAGTCCCGAG

AKTKPREEQYASTYRVVSVLTVLHQD

GACACGGCTGTGTATTACTGTGCAA

WLNGKEYKCKVSNKALPAPIEKTISKA

GAGGGGGAAGATATACCAAGGGAG

KGQPREPQVYTLPPSREEMTKNQVSLT

GGTACTTTGACGACTGGGGCCAGGG

CLVKGFYPSDIAVEWESNGQPENNYK

AACCCTGGTGACCGTCTCCTCAGCA

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

TCCACCAAGGGGCCTTCCGTGTTCC

GNVFSCSVMHEALHNHYTQKSLSLSP

CCCTGGCCCCTTCATCCAAGTCGAC

GK

CTCTGGTGGAACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVTLKESGPTLVKPTQTLTLTCTFSGFS
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTC

2176
LSTSGVGVGWIRQPPGKALEWLALIY
2284
CTACGCTGGTGAAACCCACACAGAC

WDDDKRYSPSLKSRLTITKDTSKNQV

CCTCACGCTGACCTGCACCTTCTCTG

VLTMTNMDPVDTATYYCAHRLDSSGR

GGTTCTCACTCAGCACTAGTGGAGT

GGYFDYWGQGTLVTVSSASTKGPSVF

GGGTGTGGGCTGGATCCGTCAGCCC

PLAPSSKSTSGGTAALGCLVKDYFPEP

CCAGGAAAGGCCCTGGAGTGGCTTG

VTVSWNSGALTSGVHTFPAVLQSSGL

CACTCATTTATTGGGATGATGATAA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

GCGCTACAGCCCATCTCTGAAGAGC

NTKVDKKVEPKSCDKTHTCPPCPAPEL

AGGCTCACCATCACCAAGGACACCT

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CCAAAAACCAGGTGGTCCTTACAAT

VVDVSHEDPEVKFNWYVDGVEVHNA

GACCAACATGGACCCTGTGGACACA

KTKPREEQYASTYRVVSVLTVLHQDW

GCCACATATTACTGTGCACACAGAT

LNGKEYKCKVSNKALPAPIEKTISKAK

TGGATAGCAGTGGCCGTGGTGGTTA

GQPREPQVYTLPPSREEMTKNQVSLTC

CTTTGACTACTGGGGCCAGGGCACC

LVKGFYPSDIAVEWESNGQPENNYKT

CTGGTCACCGTCTCCTCAGCATCCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCAAGGGGCCTTCCGTGTTCCCCCT

NVFSCSVMHEALHNHYTQKSLSLSPG

GGCCCCTTCATCCAAGTCGACCTCT

K

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVESGGGVVQPGRSLRLSCTASGF
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGGGG

2177
TFSSYGMHWVRQAPGKGLEWVAVISY
2285
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTACAGCCTCT

YLQMNSLRAEDTAVYYCAKELVGTSS

GGATTCACCTTCAGTAGCTATGGCA

PYYYYYYGMDVWGQGTMVTVSSAST

TGCACTGGGTCCGCCAGGCTCCAGG

KGPSVFPLAPSSKSTSGGTAALGCLVK

CAAGGGGCTGGAGTGGGTGGCAGTT

DYFPEPVTVSWNSGALTSGVHTFPAVL

ATATCATATGATGGAAGTAATAAAT

QSSGLYSLSSVVTVPSSSLGTQTYICNV

ACTATGCAGACTCCGTGAAGGGCCG

NHKPSNTKVDKKVEPKSCDKTHTCPP

ATTCACCATCTCCAGAGACAATTCC

CPAPELLGGPSVFLFPPKPKDTLMISRT

AAGAACACGCTGTATCTGCAAATGA

PEVTCVVVDVSHEDPEVKFNWYVDG

ACAGCCTGAGAGCTGAGGACACGG

VEVHNAKTKPREEQYASTYRVVSVLT

CTGTGTATTACTGTGCGAAAGAGTT

VLHQDWLNGKEYKCKVSNKALPAPIE

GGTGGGTACCAGCTCTCCTTATTAC

KTISKAKGQPREPQVYTLPPSREEMTK

TACTACTACTACGGTATGGACGTCT

NQVSLTCLVKGFYPSDIAVEWESNGQP

GGGGCCAAGGGACAATGGTCACCG

ENNYKTTPPVLDSDGSFFLYSKLTVDK

TCTCTTCAGCATCCACCAAGGGGCC

SRWQQGNVFSCSVMHEALHNHYTQK

TTCCGTGTTCCCCCTGGCCCCTTCAT

SLSLSPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGG

2178
TVSSNYMSWVRQAPGKGLEWVSVIYS
2286
GGAGGCTTGGTCCAGCCTGGGGGGT

GGSTYYADSVKGRFTISRDNSKNTLYL

CCCTGAGACTCTCCTGTGCAGCCTC

QMNSLRAEDTAVYYCARDYYYGSGSS

TGGATTCACCGTCAGTAGCAACTAC

PWGQGTLVTVSSASTKGPSVFPLAPSS

ATGAGCTGGGTCCGCCAGGCTCCAG

KSTSGGTAALGCLVKDYFPEPVTVSW

GGAAGGGGCTGGAGTGGGTCTCAGT

NSGALTSGVHTFPAVLQSSGLYSLSSV

TATTTATAGCGGTGGTAGCACATAC

VTVPSSSLGTQTYICNVNHKPSNTKVD

TACGCAGACTCCGTGAAGGGCAGAT

KKVEPKSCDKTHTCPPCPAPELLGGPS

TCACCATCTCCAGAGACAATTCCAA

VFLFPPKPKDTLMISRTPEVTCVVVDV

GAACACGCTGTATCTTCAAATGAAC

SHEDPEVKFNWYVDGVEVHNAKTKP

AGCCTGAGAGCCGAGGACACGGCT

REEQYASTYRVVSVLTVLHQDWLNGK

GTGTATTACTGTGCGAGAGACTATT

EYKCKVSNKALPAPIEKTISKAKGQPR

ACTATGGTTCGGGGAGTTCTCCCTG

EPQVYTLPPSREEMTKNQVSLTCLVKG

GGGCCAGGGAACCCTGGTCACCGTC

FYPSDIAVEWESNGQPENNYKTTPPVL

TCCTCAGCATCCACCAAGGGGCCTT

DSDGSFFLYSKLTVDKSRWQQGNVFS

CCGTGTTCCCCCTGGCCCCTTCATCC

CSVMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2179
GSFSGYYWSWIRQPPGKGLEWIGEINH
2287
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRPYCSSTSCY

GGTGGGTCCTTCAGTGGTTACTACT

PEWFDPWGQGTLVTVSSASTKGPSVFP

GGAGCTGGATCCGCCAGCCCCCAGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGATTGGGGA

TVSWNSGALTSGVHTFPAVLQSSGLYS

AATCAATCATAGTGGAAGCACCAAC

LSSVVTVPSSSLGTQTYICNVNHKPSNT

TACAACCCGTCCCTCAAGAGTCGAG

KVDKKVEPKSCDKTHTCPPCPAPELLG

TCACCATATCAGTAGACACGTCCAA

GPSVFLFPPKPKDTLMISRTPEVTCVVV

GAACCAGTTCTCCCTGAAGCTGAGC

DVSHEDPEVKFNWYVDGVEVHNAKT

TCTGTGACCGCCGCGGACACGGCTG

KPREEQYASTYRVVSVLTVLHQDWLN

TGTATTACTGTGCGAGAGGCCGGCC

GKEYKCKVSNKALPAPIEKTISKAKGQ

ATATTGTAGTAGTACCAGCTGCTAC

PREPQVYTLPPSREEMTKNQVSLTCLV

CCAGAGTGGTTCGACCCCTGGGGCC

KGFYPSDIA VEWESNGQPENNYKTTPP

AGGGAACCCTGGTCACCGTCTCCTC

VLDSDGSFFLYSKLTVDKSRWQQGNV

AGCATCCACCAAGGGGCCTTCCGTG

FSCSVMHEALHNHYTQKSLSLSPGK

TTCCCCCTGGCCCCTTCATCCAAGTC

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2180
TFSSYGMHWVRQAPGKGLEWVAVISY
2288
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKLRGIDYY

GGATTCACCTTCAGTAGCTATGGCA

DSSGYQRGFDYWGQGTLVTVSSASTK

TGCACTGGGTCCGCCAGGCTCCAGG

GPSVFPLAPSSKSTSGGTAALGCLVKD

CAAGGGGCTGGAGTGGGTGGCAGTT

YFPEPVTVSWNSGALTSGVHTFPAVLQ

ATATCATATGATGGAAGTAATAAAT

SSGLYSLSSVVTVPSSSLGTQTYICNVN

ACTATGCAGACTCCGTGAAGGGCCG

HKPSNTKVDKKVEPKSCDKTHTCPPCP

ATTCACCATCTCCAGAGACAATTCC

APELLGGPSVFLFPPKPKDTLMISRTPE

AAGAACACGCTGTATCTGCAAATGA

VTCVVVDVSHEDPEVKFNWYVDGVE

ACAGCCTGAGAGCTGAGGACACGG

VHNAKTKPREEQYASTYRVVSVLTVL

CTGTGTATTACTGTGCGAAATTAAG

HQDWLNGKEYKCKVSNKALPAPIEKT

GGGTATAGATTACTATGATAGTAGT

ISKAKGQPREPQVYTLPPSREEMTKNQ

GGTTACCAACGGGGGTTTGACTACT

VSLTCLVKGFYPSDIAVEWESNGQPEN

GGGGCCAGGGAACCCTGGTCACCGT

NYKTTPPVLDSDGSFFLYSKLTVDKSR

CTCCTCAGCATCCACCAAGGGGCCT

WQQGNVFSCSVMHEALHNHYTQKSL

TCCGTGTTCCCCCTGGCCCCTTCATC

SLSPGK

CAAGTCGACCTCTGGTGGAACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCCAGACCTATA

TCTGCAACGTCAATCACAAGCCCTC

CAACACCAAAGTGGACAAGAAGGT

CGAACCCAAGTCCTGCGACAAGACT

CACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACgccTCT

ACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCC

AAGGGTCAACCTAGGGAGCCCCAG

GTCTACACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGT

CCCTGACTTGCCTTGTCAAGGGCTTT

TATCCGTCCGACATCGCCGTGGAGT

GGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGT

GTTCTCCTGCTCCGTGATGCACGAA

GCGCTGCACAACCATTACACCCAGA

AATCACTGTCACTTTCGCCGGGAAA

A

SEQ ID
QVQLQESGPGLVKPSETLSLTCTVSGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGGCC

2181
SISSYYWSWIRQPPGKGLEWIGYIYYT
2289
CAGGACTGGTGAAGCCTTCGGAGAC

GSTNYNPSLKSRVTISVDTSKNQFSLKL

CCTGTCCCTCACCTGCACTGTCTCTG

SSVTTADTAVYYCARGGRGDGAAFDI

GTGGCTCCATCAGTAGTTACTACTG

WGQGTMVTVSSASTKGPSVFPLAPSSK

GAGCTGGATCCGGCAGCCCCCAGGG

STSGGTAALGCLVKDYFPEPVTVSWN

AAGGGACTGGAGTGGATTGGCTATA

SGALTSGVHTFPAVLQSSGLYSLSSVV

TCTATTACACTGGGAGCACCAACTA

TVPSSSLGTQTYICNVNHKPSNTKVDK

CAACCCCTCCCTCAAGAGCCGAGTC

KVEPKSCDKTHTCPPCPAPELLGGPSV

ACCATATCAGTAGACACGTCCAAGA

FLFPPKPKDTLMISRTPEVTCVVVDVS

ACCAGTTCTCCCTGAAGCTGAGCTC

HEDPEVKFNWYVDGVEVHNAKTKPR

TGTGACCACTGCGGACACGGCCGTG

EEQYASTYRVVSVLTVLHQDWLNGKE

TATTACTGTGCGAGAGGTGGGAGGG

YKCKVSNKALPAPIEKTISKAKGQPRE

GGGATGGGGCCGCTTTTGACATCTG

PQVYTLPPSREEMTKNQVSLTCLVKGF

GGGCCAAGGGACAATGGTCACCGTC

YPSDIAVEWESNGQPENNYKTTPPVLD

TCTTCAGCATCCACCAAGGGGCCTT

SDGSFFLYSKLTVDKSRWQQGNVFSCS

CCGTGTTCCCCCTGGCCCCTTCATCC

VMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

2182
FTFSSSAMHWVRQAPGKGLEWVAMI
2290
GAGGCGTGGTCCAGCCTGGGAGGTC

WHDESKKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARPPDGG

GGATTCACCTTCAGCAGCTCTGCCA

NSGRWYFDLWGRGTLVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPSSKSTSGGTAALGCLVKDYF

CAAGGGACTGGAGTGGGTGGCAAT

PEPVTVSWNSGALTSGVHTFPAVLQSS

GATTTGGCATGATGAGAGTAAGAAA

GLYSLSSVVTVPSSSLGTQTYICNVNH

TACTATGCAGACTCCGTGAAGGGCC

KPSNTKVDKKVEPKSCDKTHTCPPCPA

GATTCACTATCTCCAGAGACAATTC

PELLGGPSVFLFPPKPKDTLMISRTPEV

CAAGAACACGCTGTATCTGCAAATG

TCVVVDVSHEDPEVKFNWYVDGVEV

AACAGCCTGAGAGCTGAGGACACG

HNAKTKPREEQYASTYRVVSVLTVLH

GCTGTGTATTACTGTGCGAGACCCC

QDWLNGKEYKCKVSNKALPAPIEKTIS

CCGACGGTGGTAACTCCGGTCGCTG

KAKGQPREPQVYTLPPSREEMTKNQV

GTACTTCGATCTCTGGGGCCGTGGC

SLTCLVKGFYPSDIAVEWESNGQPENN

ACCCTGGTCACCGTCTCCTCAGCAT

YKTTPPVLDSDGSFFLYSKLTVDKSRW

CCACCAAGGGGCCTTCCGTGTTCCC

QQGNVFSCSVMHEALHNHYTQKSLSL

CCTGGCCCCTTCATCCAAGTCGACC

SPGK

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QMQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

2183
FTFSSYAMSWVRQAPGKGLEWVSAIS
2291
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDKNVRK

GGATTCACCTTTAGCAGCTATGCCA

HDYGDHPYGGYFDYWGQGTLVTVSS

TGAGCTGGGTCCGCCAGGCTCCAGG

ASTKGPSVFPLAPSSKSTSGGTAALGC

GAAGGGGCTGGAGTGGGTCTCAGCT

LVKDYFPEPVTVSWNSGALTSGVHTFP

ATTAGTGGTAGTGGTGGTAGCACAT

AVLQSSGLYSLSSVVTVPSSSLGTQTYI

ACTACGCAGACTCCGTGAAGGGCCG

CNVNHKPSNTKVDKKVEPKSCDKTHT

GTTCACCATCTCCAGAGACAATTCC

CPPCPAPELLGGPSVFLFPPKPKDTLMI

AAGAACACGCTGTATCTGCAAATGA

SRTPEVTCVVVDVSHEDPEVKFNWYV

ACAGCCTGAGAGCCGAGGACACGG

DGVEVHNAKTKPREEQYASTYRVVSV

CCGTATATTACTGTGCGAAAGACAA

LTVLHQDWLNGKEYKCKVSNKALPAP

GAACGTCCGAAAACATGACTACGGT

IEKTISKAKGQPREPQVYTLPPSREEMT

GACCACCCCTACGGGGGGTACTTTG

KNQVSLTCLVKGFYPSDIAVEWESNG

ACTACTGGGGCCAGGGCACCCTGGT

QPENNYKTTPPVLDSDGSFFLYSKLTV

GACCGTCTCCTCAGCATCCACCAAG

DKSRWQQGNVFSCSVMHEALHNHYT

GGGCCTTCCGTGTTCCCCCTGGCCC

QKSLSLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

2184
YTFTSYAMHWVRQAPGQRLEWMGWI
2292
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVAGATS

GGATACACCTTCACTAGCTATGCTA

LWYWGQGTLVTVSSASTKGPSVFPLA

TGCATTGGGTGCGCCAGGCCCCCGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

ACAAAGGCTTGAGTGGATGGGATG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GATCAACGCTGGCAATGGTAACACA

SVVTVPSSSLGTQTYICNVNHKPSNTK

AAATATTCACAGAAGTTCCAGGGCA

VDKKVEPKSCDKTHTCPPCPAPELLGG

GAGTCACCATTACCAGGGACACATC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

CGCGAGCACAGCCTACATGGAGCTG

VSHEDPEVKFNWYVDGVEVHNAKTK

AGCAGCCTGAGATCTGAAGACACG

PREEQYASTYRVVSVLTVLHQDWLNG

GCTGTGTATTACTGTGCGAGAGTGG

KEYKCKVSNKALPAPIEKTISKAKGQP

CGGGAGCTACTTCCCTATGGTACTG

REPQVYTLPPSREEMTKNQVSLTCLVK

GGGCCAGGGCACCCTGGTCACCGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

TCCTCAGCATCCACCAAGGGGCCTT

LDSDGSFFLYSKLTVDKSRWQQGNVF

CCGTGTTCCCCCTGGCCCCTTCATCC

SCSVMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQSLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2185
SVSSNSAAWNWIRQSPSRGLEWLGRT
2293
CAGGACTGGTGAAGCCCTCGCAGAG

YYRSKWYNDYAVSVKSRITIKPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCTRLANSDG

GGGACAGTGTCTCTAGCAACAGTGC

VDVWGQGTMVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCATCGAGAGGCCTTGAGTGGCTGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GAAGGACATACTACAGGTCCAAGTG

SVVTVPSSSLGTQTYICNVNHKPSNTK

GTATAATGATTATGCAGTATCTGTG

VDKKVEPKSCDKTHTCPPCPAPELLGG

AAGAGTCGAATAACCATCAAACCA

PSVFLFPPKPKDTLMISRTPEVTCVVVD

GACACATCCAAGAACCAGTTCTCCC

VSHEDPEVKFNWYVDGVEVHNAKTK

TGCAGCTGAACTCTGTGACTCCCGA

PREEQYASTYRVVSVLTVLHQDWLNG

GGACACGGCTGTGTATTACTGTACA

KEYKCKVSNKALPAPIEKTISKAKGQP

AGGCTAGCTAATTCCGACGGTGTGG

REPQVYTLPPSREEMTKNQVSLTCLVK

ACGTCTGGGGCCAAGGGACAATGGT

GFYPSDIAVEWESNGQPENNYKTTPPV

CACCGTCTCCTCAGCATCCACCAAG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GGGCCTTCCGTGTTCCCCCTGGCCC

SCSVMHEALHNHYTQKSLSLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2186
SVSSDSAVWTWIRQSPSRGLEWLGRT
2294
CAGGACTGGTGAAGCCCTCGCAGAC

YYKSKWYNDYAASVKSRITINPDTSK

CCTCTCACTCACCTGTGCCATCTCCG

NQFSLHLNSVTPEDTAVYYCARGVTR

GGGACAGTGTCTCTAGCGACAGTGC

TFDYWGQGTTVTVSSASTKGPSVFPLA

TGTTTGGACCTGGATCAGGCAGTCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCATCGAGAGGCCTTGAGTGGCTGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GAAGGACATACTACAAGTCGAAGT

SVVTVPSSSLGTQTYICNVNHKPSNTK

GGTATAATGATTATGCAGCATCTGT

VDKKVEPKSCDKTHTCPPCPAPELLGG

GAAAAGTCGAATAACCATCAACCCA

PSVFLFPPKPKDTLMISRTPEVTCVVVD

GACACATCCAAGAACCAGTTCTCCC

VSHEDPEVKFNWYVDGVEVHNAKTK

TGCACCTGAACTCTGTGACTCCCGA

PREEQYASTYRVVSVLTVLHQDWLNG

GGACACGGCTGTGTATTACTGTGCA

KEYKCKVSNKALPAPIEKTISKAKGQP

AGAGGTGTAACCCGGACCTTTGACT

REPQVYTLPPSREEMTKNQVSLTCLVK

ACTGGGGCCAGGGGACCACGGTCA

GFYPSDIAVEWESNGQPENNYKTTPPV

CCGTCTCCTCAGCATCCACCAAGGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GCCTTCCGTGTTCCCCCTGGCCCCTT

SCSVMHEALHNHYTQKSLSLSPGK

CATCCAAGTCGACCTCTGGTGGAAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCCAGACC

TATATCTGCAACGTCAATCACAAGC

CCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
QLQLQESGPGLVKPSQTLSLTCAISGDS
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC

2187
VSSNSAAWNWIRQSPSRGLEWLGRTY
2295
CAGGACTGGTGAAGCCCTCGCAGAC

YRSKWYNDYAVSVKSRITINPDTSKNQ

CCTCTCACTCACCTGTGCCATCTCCG

FSLQLNSVTPEDTAVYYCAEGNGPFDP

GGGACAGTGTCTCTAGCAACAGTGC

WGQGTLVTVSSASTKGPSVFPLAPSSK

TGCTTGGAACTGGATCAGGCAGTCC

STSGGTAALGCLVKDYFPEPVTVSWN

CCATCGAGAGGCCTTGAGTGGCTGG

SGALTSGVHTFPAVLQSSGLYSLSSVV

GAAGGACATACTACAGGTCCAAGTG

TVPSSSLGTQTYICNVNHKPSNTKVDK

GTATAATGATTATGCAGTATCTGTG

KVEPKSCDKTHTCPPCPAPELLGGPSV

AAAAGTCGAATAACCATCAACCCAG

FLFPPKPKDTLMISRTPEVTCVVVDVS

ACACATCCAAGAACCAGTTCTCCCT

HEDPEVKFNWYVDGVEVHNAKTKPR

GCAGCTGAACTCTGTGACTCCCGAG

EEQYASTYRVVSVLTVLHQDWLNGKE

GACACGGCTGTGTATTACTGTGCAG

YKCKVSNKALPAPIEKTISKAKGQPRE

AAGGCAATGGGCCGTTCGACCCCTG

PQVYTLPPSREEMTKNQVSLTCLVKGF

GGGCCAGGGAACCCTGGTGACCGTC

YPSDIAVEWESNGQPENNYKTTPPVLD

TCCTCAGCATCCACCAAGGGGCCTT

SDGSFFLYSKLTVDKSRWQQGNVFSCS

CCGTGTTCCCCCTGGCCCCTTCATCC

VMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
QITLKESGGGVVQPGRSLRLSCVASGF
SEQ ID
CAGATCACCTTGAAGGAGTCTGGGG

2188
TFSTYPMHWVRQAPGKGLEWVAVISY
2296
GAGGCGTGGTCCAGCCTGGGAGGTC

DGRNEYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGTAGCCTCT

YLQMNSLRAEDTAVYYCATRDTPLVG

GGATTCACCTTCAGTACCTATCCCA

VSIYWGQGTLVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

CAAGGGGCTGGAGTGGGTGGCAGTT

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATATCATATGATGGACGTAATGAAT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ACTACGCAGACTCCGTGAAGGGCCG

VDKKVEPKSCDKTHTCPPCPAPELLGG

ATTCACCATCTCCAGAGACAATTCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AAAAACACGCTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAGTCTGCGAGCTGAAGACACGGC

PREEQYASTYRVVSVLTVLHQDWLNG

TGTCTATTATTGTGCGACTCGGGAT

KEYKCKVSNKALPAPIEKTISKAKGQP

ACACCTTTGGTTGGGGTTTCGATAT

REPQVYTLPPSREEMTKNQVSLTCLVK

ACTGGGGCCAGGGCACCCTGGTCAC

GFYPSDIAVEWESNGQPENNYKTTPPV

CGTCTCCTCAGCATCCACCAAGGGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

CCTTCCGTGTTCCCCCTGGCCCCTTC

SCSVMHEALHNHYTQKSLSLSPGK

ATCCAAGTCGACCTCTGGTGGAACC

GCCGCACTCGGTTGCCTGGTCAAAG

ACTACTTCCCCGAGCCCGTGACTGT

CTCGTGGAACTCGGGCGCCCTCACA

TCCGGAGTGCATACCTTTCCCGCCG

TGTTGCAGTCCAGCGGCCTGTACAG

CCTGAGCTCCGTCGTGACAGTGCCG

TCCTCCTCCCTTGGAACCCAGACCT

ATATCTGCAACGTCAATCACAAGCC

CTCCAACACCAAAGTGGACAAGAA

GGTCGAACCCAAGTCCTGCGACAAG

ACTCACACCTGTCCGCCTTGTCCAG

CCCCTGAGCTGCTGGGTGGTCCGTC

CGTGTTCCTCTTCCCGCCCAAGCCG

AAGGACACTCTGATGATTTCACGCA

CCCCGGAAGTCACTTGCGTGGTCGT

GGACGTGTCGCACGAAGATCCCGAA

GTGAAATTCAATTGGTACGTGGATG

GGGTCGAAGTGCACAACGCCAAGA

CCAAGCCTAGGGAAGAACAGTACgc

cTCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QMQLVQSGGGLVKAGGSLRLSCSASG
SEQ ID
CAGATGCAGCTGGTGCAATCTGGGG

2189
FTFSSYAMHWVRQAPGKGLEYVSAISS
2297
GAGGCCTGGTCAAGGCTGGGGGGTC

NGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTTCAGCCTCTG

LQMSSLRAEDTAVYYCVNRAGYGDY

GATTCACCTTCAGTAGCTATGCTAT

RHFQHWGQGTLVTVSSASTKGPSVFPL

GCACTGGGTCCGCCAGGCTCCAGGG

APSSKSTSGGTAALGCLVKDYFPEPVT

AAGGGACTGGAATATGTTTCAGCTA

VSWNSGALTSGVHTFPAVLQSSGLYSL

TTAGTAGTAATGGGGGTAGCACATA

SSVVTVPSSSLGTQTYICNVNHKPSNT

CTACGCAGACTCAGTGAAGGGCAG

KVDKKVEPKSCDKTHTCPPCPAPELLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTTCAAATGA

DVSHEDPEVKFNWYVDGVEVHNAKT

GCAGTCTGAGAGCTGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGTGAATCGGGC

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGTTACGGTGACTACAGACACTTC

PREPQVYTLPPSREEMTKNQVSLTCLV

CAGCACTGGGGCCAGGGCACCCTGG

KGFYPSDIAVEWESNGQPENNYKTTPP

TCACCGTCTCCTCAGCATCCACCAA

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGGCCTTCCGTGTTCCCCCTGGCC

FSCSVMHEALHNHYTQKSLSLSPGK

CCTTCATCCAAGTCGACCTCTGGTG

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGGSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2190
FTFSSYGMHWVRQAPGKGLEWVAFIS
2298
GAGGCGTGGTCCAGCCTGGGGGGTC

YDGSNKYYADSVKGRFTISRDNSKNT

CCTGAGACTCTCCTGTGCAGCGTCT

LYLQMNSLRAEDTAVYYCATTGDRFQ

GGATTCACCTTCAGTAGCTATGGCA

EFDYWGQGTLVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

CAAGGGGCTGGAGTGGGTGGCATTT

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATATCATATGATGGAAGTAATAAAT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ACTACGCAGACTCCGTGAAGGGCCG

VDKKVEPKSCDKTHTCPPCPAPELLGG

ATTCACCATCTCCAGAGACAATTCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCCGAGGACACGG

PREEQYASTYRVVSVLTVLHQDWLNG

CCGTATATTACTGTGCGACAACAGG

KEYKCKVSNKALPAPIEKTISKAKGQP

GGACCGCTTCCAAGAGTTTGACTAC

REPQVYTLPPSREEMTKNQVSLTCLVK

TGGGGCCAGGGAACCCTGGTCACCG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCTCCTCAGCATCCACCAAGGGGCC

LDSDGSFFLYSKLTVDKSRWQQGNVF

TTCCGTGTTCCCCCTGGCCCCTTCAT

SCSVMHEALHNHYTQKSLSLSPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QMQLVQSGGVLLQPGRSLRLSCTASG
SEQ ID
CAGATGCAGCTGGTGCAGTCTGGGG

2191
FTFAAYNINWFRQGPGGGLEWVGFIR
2299
GAGTCTTGCTTCAGCCAGGGCGGTC

ANADSGTTEYAASVKGRFFISRDDSRS

CCTGAGACTCTCCTGTACAGCTTCT

TAYLQMTSLKTEDTAVYYCARDDRGR

GGATTCACCTTTGCTGCTTATAATAT

GDDFDYWGQGTLVTVSSASTKGPSVF

CAACTGGTTCCGCCAGGGTCCTGGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GGGGGGCTGGAGTGGGTAGGTTTCA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAGCCAACGCTGATAGTGGGAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACAGAGTACGCCGCGTCTGTGAAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGCAGATTCTTCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAGAAGCACCGCCTACCTGCA

VVDVSHEDPEVKFNWYVDGVEVHNA

AATGACTAGCCTTAAAACCGAGGAC

KTKPREEQYASTYRVVSVLTVLHQDW

ACAGCCGTTTATTACTGTGCCAGAG

LNGKEYKCKVSNKALPAPIEKTISKAK

ATGATCGGGGTCGGGGAGATGACTT

GQPREPQVYTLPPSREEMTKNQVSLTC

TGACTACTGGGGCCAGGGCACCCTG

LVKGFYPSDIAVEWESNGQPENNYKT

GTCACCGTCTCCTCAGCATCCACCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

AGGGGCCTTCCGTGTTCCCCCTGGC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCCTTCATCCAAGTCGACCTCTGGT

K

GGAACCGCCGCACTCGGTTGCCTGG

TCAAAGACTACTTCCCCGAGCCCGT

GACTGTCTCGTGGAACTCGGGCGCC

CTCACATCCGGAGTGCATACCTTTC

CCGCCGTGTTGCAGTCCAGCGGCCT

GTACAGCCTGAGCTCCGTCGTGACA

GTGCCGTCCTCCTCCCTTGGAACCC

AGACCTATATCTGCAACGTCAATCA

CAAGCCCTCCAACACCAAAGTGGAC

AAGAAGGTCGAACCCAAGTCCTGCG

ACAAGACTCACACCTGTCCGCCTTG

TCCAGCCCCTGAGCTGCTGGGTGGT

CCGTCCGTGTTCCTCTTCCCGCCCAA

GCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGG

TCGTGGACGTGTCGCACGAAGATCC

CGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCC

AAGACCAAGCCTAGGGAAGAACAG

TACgccTCTACGTACCGGGTGGTGTC

CGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCC

CTGCCCCTATCGAAAAGACCATCAG

CAAGGCCAAGGGTCAACCTAGGGA

GCCCCAGGTCTACACTTTGCCGCCT

AGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTC

GCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

2192
FTFSSYGMTWVRQAPGKGLEWVSTIS
2300
GAGGCTTGGTACAGCCTGGGGGGTC

GNGVGTYYPDSVKDRFTISRDSSKNTV

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCVKHGRAGIN

GGATTCACCTTTAGCAGCTATGGCA

WYFDLWGRGTLVTVSSASTKGPSVFP

TGACGTGGGTCCGCCAGGCTCCAGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

GAAGGGGCTGGAGTGGGTCTCAACT

TVSWNSGALTSGVHTFPAVLQSSGLYS

ATTAGTGGTAATGGTGTTGGCACAT

LSSVVTVPSSSLGTQTYICNVNHKPSNT

ACTACCCAGACTCCGTGAAGGACCG

KVDKKVEPKSCDKTHTCPPCPAPELLG

GTTCACCATCTCCAGAGACAGTTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGGTGTATCTGCAAATGA

DVSHEDPEVKFNWYVDGVEVHNAKT

ACAGCCTGAGAGCCGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CCGTATATTACTGTGTGAAACATGG

GKEYKCKVSNKALPAPIEKTISKAKGQ

TAGGGCCGGAATAAACTGGTACTTC

PREPQVYTLPPSREEMTKNQVSLTCLV

GATCTCTGGGGCCGTGGCACCCTGG

KGFYPSDIAVEWESNGQPENNYKTTPP

TGACCGTCTCCTCAGCATCCACCAA

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGGGCCTTCCGTGTTCCCCCTGGCC

FSCSVMHEALHNHYTQKSLSLSPGK

CCTTCATCCAAGTCGACCTCTGGTG

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2193
SVSSNSAAWNWIRQSPSRGLEWLGRT
2301
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARGGGLW

GGGACAGTGTCTCTAGCAACAGTGC

AFDIWGQGTTVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCATCGAGAGGCCTTGAGTGGCTGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GAAGGACATACTACAGGTCCAAGTG

SVVTVPSSSLGTQTYICNVNHKPSNTK

GTATAATGATTATGCAGTATCTGTG

VDKKVEPKSCDKTHTCPPCPAPELLGG

AAAAGTCGAATAACCATCAACCCAG

PSVFLFPPKPKDTLMISRTPEVTCVVVD

ACACATCCAAGAACCAGTTCTCCCT

VSHEDPEVKFNWYVDGVEVHNAKTK

GCAGCTGAACTCTGTGACTCCCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCTGTGTATTACTGTGCAA

KEYKCKVSNKALPAPIEKTISKAKGQP

GAGGGGGAGGGCTTTGGGCTTTTGA

REPQVYTLPPSREEMTKNQVSLTCLVK

TATCTGGGGCCAAGGGACCACGGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCGTCTCCTCAGCATCCACCAAGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GGCCTTCCGTGTTCCCCCTGGCCCCT

SCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

2194
YTFTGYYMHWVRQAPGQGLEWMGW
2302
CTGAGGTGAAGAAGCCTGGGGCCTC

INPNSGGTNYAQKFQGRVTMTRDTSIS

AGTGAAGGTCTCCTGCAAGGCTTCT

TAYMELSRLRSDDTAVYYCARDKIGS

GGATACACCTTCACCGGCTACTATA

CPYWGQGTLVTVSSASTKGPSVFPLAP

TGCACTGGGTGCGACAGGCCCCTGG

SSKSTSGGTAALGCLVKDYFPEPVTVS

ACAAGGGCTTGAGTGGATGGGATG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GATCAACCCTAACAGTGGTGGCACA

VVTVPSSSLGTQTYICNVNHKPSNTKV

AACTATGCACAGAAGTTTCAGGGCA

DKKVEPKSCDKTHTCPPCPAPELLGGP

GGGTCACCATGACCAGGGACACGTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CATCAGCACAGCCTACATGGAGCTG

VSHEDPEVKFNWYVDGVEVHNAKTK

AGCAGGCTGAGATCTGACGACACG

PREEQYASTYRVVSVLTVLHQDWLNG

GCCGTGTATTACTGTGCGAGAGACA

KEYKCKVSNKALPAPIEKTISKAKGQP

AGATCGGCAGCTGTCCTTACTGGGG

REPQVYTLPPSREEMTKNQVSLTCLVK

CCAGGGAACCCTGGTCACCGTCTCC

GFYPSDIAVEWESNGQPENNYKTTPPV

TCAGCATCCACCAAGGGGCCTTCCG

LDSDGSFFLYSKLTVDKSRWQQGNVF

TGTTCCCCCTGGCCCCTTCATCCAAG

SCSVMHEALHNHYTQKSLSLSPGK

TCGACCTCTGGTGGAACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCCAGACCTATATCTG

CAACGTCAATCACAAGCCCTCCAAC

ACCAAAGTGGACAAGAAGGTCGAA

CCCAAGTCCTGCGACAAGACTCACA

CCTGTCCGCCTTGTCCAGCCCCTGA

GCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTG

TCGCACGAAGATCCCGAAGTGAAAT

TCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACgccTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCGGGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCCGGGAAAA

SEQ ID
QVTLKESGPTLVKPTQTLTLTCTFSGFS
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGTC

2195
LSTSGVGVGWIRQPPGKALEWLALIY
2303
CTACGCTGGTGAAACCCACACAGAC

WDDDKRYSPSLKSRLTITKDTSKNQV

CCTCACGCTGACCTGCACCTTCTCTG

VLTMTNMDPVDTATYYCAHRPDSSSQ

GGTTCTCACTCAGCACTAGTGGAGT

CFDYWGQGTLVTVSSASTKGPSVFPLA

GGGTGTGGGCTGGATCCGTCAGCCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCAGGAAAGGCCCTGGAGTGGCTTG

SWNSGALTSGVHTFPAVLQSSGLYSLS

CACTCATTTATTGGGATGATGATAA

SVVTVPSSSLGTQTYICNVNHKPSNTK

GCGCTACAGCCCATCTCTGAAGAGC

VDKKVEPKSCDKTHTCPPCPAPELLGG

AGGCTCACCATCACCAAGGACACCT

PSVFLFPPKPKDTLMISRTPEVTCVVVD

CCAAAAACCAGGTGGTCCTTACAAT

VSHEDPEVKFNWYVDGVEVHNAKTK

GACCAACATGGACCCTGTGGACACA

PREEQYASTYRVVSVLTVLHQDWLNG

GCCACATATTACTGTGCACACAGAC

KEYKCKVSNKALPAPIEKTISKAKGQP

CGGATAGCAGCAGTCAATGTTTTGA

REPQVYTLPPSREEMTKNQVSLTCLVK

CTACTGGGGCCAGGGAACCCTGGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCGTCTCCTCAGCATCCACCAAGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GGCCTTCCGTGTTCCCCCTGGCCCCT

SCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2196
TFSSYAMHWVRQAPGKGLEWVAVISY
2304
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARSSGWSLP

GGATTCACCTTCAGTAGCTATGCTA

EDYWGQGTLVTVSSASTKGPSVFPLAP

TGCACTGGGTCCGCCAGGCTCCAGG

SSKSTSGGTAALGCLVKDYFPEPVTVS

CAAGGGGCTGGAGTGGGTGGCAGTT

WNSGALTSGVHTFPAVLQSSGLYSLSS

ATATCATATGATGGAAGTAATAAAT

VVTVPSSSLGTQTYICNVNHKPSNTKV

ACTACGCAGACTCCGTGAAGGGCCG

DKKVEPKSCDKTHTCPPCPAPELLGGP

ATTCACCATCTCCAGAGACAATTCC

SVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGCTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCTGAGGACACGG

PREEQYASTYRVVSVLTVLHQDWLNG

CTGTGTATTACTGTGCGAGAAGCAG

KEYKCKVSNKALPAPIEKTISKAKGQP

TGGCTGGTCACTGCCTGAAGACTAC

REPQVYTLPPSREEMTKNQVSLTCLVK

TGGGGCCAGGGAACCCTGGTCACCG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCTCCTCAGCATCCACCAAGGGGCC

LDSDGSFFLYSKLTVDKSRWQQGNVF

TTCCGTGTTCCCCCTGGCCCCTTCAT

SCSVMHEALHNHYTQKSLSLSPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKVSG
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGGG

2197
YTLTELSMHWVRQAPGKGLEWMGGF
2305
CTGAGGTGAAGAAGCCTGGGGCCTC

DPEDGETIYAQKFQGRVTMTEDTSTDT

AGTGAAGGTCTCCTGCAAGGTTTCC

AYMELSSLRSEDTAVYYCATDVNPEL

GGATACACCCTCACTGAATTATCCA

LGAGFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTGCGACAGGCTCCTGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

AAAAGGGCTTGAGTGGATGGGAGG

PVTVSWNSGALTSGVHTFPAVLQSSGL

TTTTGATCCTGAAGATGGTGAAACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ATCTACGCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATGACCGAGGACACATC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

TACAGACACAGCCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAGGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCAACGGATG

LNGKEYKCKVSNKALPAPIEKTISKAK

TGAACCCGGAGCTACTGGGGGCGG

GQPREPQVYTLPPSREEMTKNQVSLTC

GATTTGACTACTGGGGCCAGGGCAC

LVKGFYPSDIAVEWESNGQPENNYKT

CCTGGTCACCGTCTCCTCAGCATCC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

ACCAAGGGGCCTTCCGTGTTCCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

TGGCCCCTTCATCCAAGTCGACCTC

K

TGGTGGAACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCCAGACCTATATCTGCAACGTCA

ATCACAAGCCCTCCAACACCAAAGT

GGACAAGAAGGTCGAACCCAAGTC

CTGCGACAAGACTCACACCTGTCCG

CCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVTLKESGGGLVQPGGSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2198
TFSDQYMDWVRQAPGKGLEWVGRVR
2306
GAGGCTTGGTCCAGCCTGGAGGGTC

NKANSYTTEYAASVKGRFTISRDDSKN

CCTGAGACTCTCCTGTGCAGCCTCT

SLYLQMNSLNTEDTAMYFCASSLNSG

GGATTCACCTTCAGTGACCAGTACA

GYRCFHHWGQGTLVTVSSASTKGPSV

TGGACTGGGTCCGCCAGGCTCCAGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

GAAGGGGCTGGAGTGGGTTGGCCGT

PVTVSWNSGALTSGVHTFPAVLQSSGL

GTTAGAAACAAAGCTAACAGTTACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

CCACAGAATACGCCGCGTCTGTGAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

AGGCAGATTCACCATCTCAAGAGAT

LGGPSVFLFPPKPKDTLMISRTPEVTCV

GATTCAAAGAACTCACTGTATCTGC

VVDVSHEDPEVKFNWYVDGVEVHNA

AAATGAATAGTCTGAACACCGAGG

KTKPREEQYASTYRVVSVLTVLHQDW

ACACGGCCATGTATTTCTGTGCTAG

LNGKEYKCKVSNKALPAPIEKTISKAK

TAGTCTCAATAGTGGGGGCTACCGA

GQPREPQVYTLPPSREEMTKNQVSLTC

TGCTTCCATCACTGGGGCCAGGGCA

LVKGFYPSDIAVEWESNGQPENNYKT

CCCTGGTGACCGTCTCCTCAGCATC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CACCAAGGGGCCTTCCGTGTTCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CTGGCCCCTTCATCCAAGTCGACCT

K

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCSASGF
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGGGG

2199
TFSSYAMHWVRQAPGKGLEYVSAISS
2307
GAGGCTTGGTCCAGCCTGGGGGGTC

NGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTTCAGCCTCTG

LQMSSLRAEDTAVYYCVKAPRGVVPA

GATTCACCTTCAGTAGCTATGCTAT

AMRGGYWGQGTLVTVSSASTKGPSVF

GCACTGGGTCCGCCAGGCTCCAGGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

AAGGGACTGGAATATGTTTCAGCTA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAGTAGTAATGGGGGTAGCACATA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

CTACGCAGACTCAGTGAAGGGCAG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTTCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

GCAGTCTGAGAGCTGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CTGTGTATTACTGTGTGAAAGCGCC

LNGKEYKCKVSNKALPAPIEKTISKAK

GAGGGGTGTAGTACCAGCTGCTATG

GQPREPQVYTLPPSREEMTKNQVSLTC

CGGGGGGGCTACTGGGGCCAGGGA

LVKGFYPSDIAVEWESNGQPENNYKT

ACCCTGGTCACCGTCTCCTCAGCAT

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCACCAAGGGGCCTTCCGTGTTCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTGGCCCCTTCATCCAAGTCGACC

K

TCTGGTGGAACCGCCGCACTCGGTT

GCCTGGTCAAAGACTACTTCCCCGA

GCCCGTGACTGTCTCGTGGAACTCG

GGCGCCCTCACATCCGGAGTGCATA

CCTTTCCCGCCGTGTTGCAGTCCAG

CGGCCTGTACAGCCTGAGCTCCGTC

GTGACAGTGCCGTCCTCCTCCCTTG

GAACCCAGACCTATATCTGCAACGT

CAATCACAAGCCCTCCAACACCAAA

GTGGACAAGAAGGTCGAACCCAAG

TCCTGCGACAAGACTCACACCTGTC

CGCCTTGTCCAGCCCCTGAGCTGCT

GGGTGGTCCGTCCGTGTTCCTCTTCC

CGCCCAAGCCGAAGGACACTCTGAT

GATTTCACGCACCCCGGAAGTCACT

TGCGTGGTCGTGGACGTGTCGCACG

AAGATCCCGAAGTGAAATTCAATTG

GTACGTGGATGGGGTCGAAGTGCAC

AACGCCAAGACCAAGCCTAGGGAA

GAACAGTACgccTCTACGTACCGGGT

GGTGTCCGTGCTGACCGTGCTGCAC

CAGGACTGGCTGAACGGAAAGGAG

TACAAGTGCAAAGTGTCAAACAAG

GCTCTCCCTGCCCCTATCGAAAAGA

CCATCAGCAAGGCCAAGGGTCAACC

TAGGGAGCCCCAGGTCTACACTTTG

CCGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLQESGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

2200
TFGDYAMSWFRQAPGKGLEWVGFIRS
2308
GGAGGCTTGGTACAGCCAGGGCGGT

KAYGGTTEYAASVKGRFTISRDDSKSI

CCCTGAGACTCTCCTGTACAGCTTCT

AYLQMNSLKTEDTAVYYCTRLVGNSG

GGATTCACCTTTGGTGATTATGCTAT

SYYPFGYWGQGTLVTVSSASTKGPSVF

GAGCTGGTTCCGCCAGGCTCCAGGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

AAGGGGCTGGAGTGGGTAGGTTTCA

VTVSWNSGALTSGVHTFPAVLQSSGL

TTAGAAGCAAAGCTTATGGTGGGAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACAGAATACGCCGCGTCTGTGAAA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGCAGATTCACCATCTCAAGAGATG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ATTCCAAAAGCATCGCCTATCTGCA

VVDVSHEDPEVKFNWYVDGVEVHNA

AATGAACAGCCTGAAAACCGAGGA

KTKPREEQYASTYRVVSVLTVLHQDW

CACAGCCGTGTATTACTGTACTAGA

LNGKEYKCKVSNKALPAPIEKTISKAK

TTGGTGGGCAATAGTGGGAGCTACT

GQPREPQVYTLPPSREEMTKNQVSLTC

ATCCGTTTGGGTACTGGGGCCAGGG

LVKGFYPSDIAVEWESNGQPENNYKT

AACCCTGGTGACCGTCTCCTCAGCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

TCCACCAAGGGGCCTTCCGTGTTCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCCTGGCCCCTTCATCCAAGTCGAC

K

CTCTGGTGGAACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2201
GSFSGYYWSWIRQPPGKGLEWIGEINH
2309
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGRSLPYRGLA

GGTGGGTCCTTCAGTGGTTACTACT

PRSFGGYYFDYWGQGTLVTVSSASTK

GGAGCTGGATCCGCCAGCCCCCAGG

GPSVFPLAPSSKSTSGGTAALGCLVKD

GAAGGGGCTGGAGTGGATTGGGGA

YFPEPVTVSWNSGALTSGVHTFPAVLQ

AATCAATCATAGTGGAAGCACCAAC

SSGLYSLSSVVTVPSSSLGTQTYICNVN

TACAACCCGTCCCTCAAGAGTCGAG

HKPSNTKVDKKVEPKSCDKTHTCPPCP

TCACCATATCAGTAGACACGTCCAA

APELLGGPSVFLFPPKPKDTLMISRTPE

GAACCAGTTCTCCCTGAAGCTGAGC

VTCVVVDVSHEDPEVKFNWYVDGVE

TCGGTGACCGCCGCGGACACGGCTG

VHNAKTKPREEQYASTYRVVSVLTVL

TGTATTACTGTGCGAGAGGCCGGTC

HQDWLNGKEYKCKVSNKALPAPIEKT

CCTTCCCTACCGGGGGTTGGCTCCT

ISKAKGQPREPQVYTLPPSREEMTKNQ

AGATCTTTCGGAGGATACTACTTTG

VSLTCLVKGFYPSDIAVEWESNGQPEN

ACTACTGGGGCCAGGGAACCCTGGT

NYKTTPPVLDSDGSFFLYSKLTVDKSR

CACCGTCTCCTCAGCATCCACCAAG

WQQGNVFSCSVMHEALHNHYTQKSL

GGGCCTTCCGTGTTCCCCCTGGCCC

SLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
QVQLQESGGGLVRPGGSLRLSCGDSGF
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

2202
NFSGYEMNWVRQAPGKGLEWVSYVS
2310
GGAGGCTTGGTACGGCCTGGAGGGT

TSGSTRYYADSVKGRFTISRDNAKNTL

CCCTGAGACTCTCCTGTGGAGACTC

YLQMNSLRVEDTAVYYCARGRTHWG

TGGATTCAACTTCAGTGGATATGAA

PQDFDYWGQGTLVTVSSASTKGPSVFP

ATGAACTGGGTCCGCCAGGCTCCAG

LAPSSKSTSGGTAALGCLVKDYFPEPV

GGAAGGGGCTGGAGTGGGTTTCATA

TVSWNSGALTSGVHTFPAVLQSSGLYS

CGTCAGTACTAGTGGTAGTACCAGA

LSSVVTVPSSSLGTQTYICNVNHKPSNT

TACTACGCAGACTCTGTGAAGGGCC

KVDKKVEPKSCDKTHTCPPCPAPELLG

GATTTACCATCTCCAGAGACAACGC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CAAGAACACCCTGTATTTGCAAATG

DVSHEDPEVKFNWYVDGVEVHNAKT

AACAGTCTGAGAGTCGAGGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCTGTGTATTACTGTGCAAGAGGAC

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGACTCACTGGGGCCCCCAGGACTT

PREPQVYTLPPSREEMTKNQVSLTCLV

TGACTACTGGGGCCAGGGAACCCTG

KGFYPSDIAVEWESNGQPENNYKTTPP

GTCACCGTCTCCTCAGCATCCACCA

VLDSDGSFFLYSKLTVDKSRWQQGNV

AGGGGCCTTCCGTGTTCCCCCTGGC

FSCSVMHEALHNHYTQKSLSLSPGK

CCCTTCATCCAAGTCGACCTCTGGT

GGAACCGCCGCACTCGGTTGCCTGG

TCAAAGACTACTTCCCCGAGCCCGT

GACTGTCTCGTGGAACTCGGGCGCC

CTCACATCCGGAGTGCATACCTTTC

CCGCCGTGTTGCAGTCCAGCGGCCT

GTACAGCCTGAGCTCCGTCGTGACA

GTGCCGTCCTCCTCCCTTGGAACCC

AGACCTATATCTGCAACGTCAATCA

CAAGCCCTCCAACACCAAAGTGGAC

AAGAAGGTCGAACCCAAGTCCTGCG

ACAAGACTCACACCTGTCCGCCTTG

TCCAGCCCCTGAGCTGCTGGGTGGT

CCGTCCGTGTTCCTCTTCCCGCCCAA

GCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGG

TCGTGGACGTGTCGCACGAAGATCC

CGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCC

AAGACCAAGCCTAGGGAAGAACAG

TACgccTCTACGTACCGGGTGGTGTC

CGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCC

CTGCCCCTATCGAAAAGACCATCAG

CAAGGCCAAGGGTCAACCTAGGGA

GCCCCAGGTCTACACTTTGCCGCCT

AGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTC

GCCGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

2203
FTFSSYAMSWVRQAPGKGLEWVSAIS
2311
GGAGGCTTGGTACAGCCTGGGGGGT

GSGGSTYYADSVKGRFTISRDNSKNTL

CCCTGAGACTCTCCTGTGCAGCCTC

YLQMNSLRAEDTAVYYCAKGGMYYY

TGGATTCACCTTTAGCAGCTATGCC

GSGSSYFDYWGQGTLVTVSSASTKGPS

ATGAGCTGGGTCCGCCAGGCTCCAG

VFPLAPSSKSTSGGTAALGCLVKDYFP

GGAAGGGGCTGGAGTGGGTCTCAG

EPVTVSWNSGALTSGVHTFPAVLQSSG

CTATTAGTGGTAGTGGTGGTAGCAC

LYSLSSVVTVPSSSLGTQTYICNVNHKP

ATACTACGCAGACTCCGTGAAGGGC

SNTKVDKKVEPKSCDKTHTCPPCPAPE

CGGTTCACCATCTCCAGAGACAATT

LLGGPSVFLFPPKPKDTLMISRTPEVTC

CCAAGAACACGCTGTATCTGCAAAT

VVVDVSHEDPEVKFNWYVDGVEVHN

GAACAGCCTGAGAGCCGAGGACAC

AKTKPREEQYASTYRVVSVLTVLHQD

GGCCGTATATTACTGTGCGAAAGGA

WLNGKEYKCKVSNKALPAPIEKTISKA

GGAATGTATTACTATGGTTCGGGGA

KGQPREPQVYTLPPSREEMTKNQVSLT

GCTCGTACTTTGACTACTGGGGCCA

CLVKGFYPSDIAVEWESNGQPENNYK

GGGAACCCTGGTGACCGTCTCCTCA

TTPPVLDSDGSFFLYSKLTVDKSRWQQ

GCATCCACCAAGGGGCCTTCCGTGT

GNVFSCSVMHEALHNHYTQKSLSLSP

TCCCCCTGGCCCCTTCATCCAAGTC

GK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

2204
FTFSSYAMSWVRQAPGKGLEWVSGIS
2312
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNM

CCTGAGACTCTCCTGTGCAGCCTCT

LFLQMNSPRAEDTAVYYCAKKIAAAG

GGATTCACCTTTAGCAGCTATGCCA

KQPVDYWGQGTLVTVSSASTKGPSVF

TGAGCTGGGTCCGCCAGGCTCCAGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GAAGGGGCTGGAATGGGTCTCAGGT

VTVSWNSGALTSGVHTFPAVLQSSGL

ATTAGTGGTAGTGGTGGTAGCACAT

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ACTACGCAGACTCCGTGAAGGGCCG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GTTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACATGCTGTTTCTGCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

ACAGCCCGAGAGCCGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CCGTATATTACTGTGCGAAGAAAAT

LNGKEYKCKVSNKALPAPIEKTISKAK

AGCAGCAGCTGGTAAGCAACCTGTT

GQPREPQVYTLPPSREEMTKNQVSLTC

GACTACTGGGGCCAGGGAACCCTGG

LVKGFYPSDIAVEWESNGQPENNYKT

TCACCGTCTCCTCAGCATCCACCAA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GGGGCCTTCCGTGTTCCCCCTGGCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTTCATCCAAGTCGACCTCTGGTG

K

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2205
GSFSGYYWSWIRQPPGKGLEWIGEINH
2313
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARRKVYDYVWG

GGTGGGTCCTTCAGTGGTTACTACT

SYRLPGSVSYYFDYWGQGTLVTVSSA

GGAGCTGGATCCGCCAGCCCCCAGG

STKGPSVFPLAPSSKSTSGGTAALGCL

GAAGGGGCTGGAGTGGATTGGGGA

VKDYFPEPVTVSWNSGALTSGVHTFP

AATCAATCATAGTGGAAGCACCAAC

AVLQSSGLYSLSSVVTVPSSSLGTQTYI

TACAACCCGTCCCTCAAGAGTCGAG

CNVNHKPSNTKVDKKVEPKSCDKTHT

TCACCATATCAGTAGACACGTCCAA

CPPCPAPELLGGPSVFLFPPKPKDTLMI

GAACCAGTTCTCCCTGAAGCTGAGC

SRTPEVTCVVVDVSHEDPEVKFNWYV

TCTGTGACCGCCGCGGACACGGCTG

DGVEVHNAKTKPREEQYASTYRVVSV

TGTATTACTGTGCGAGAAGGAAGGT

LTVLHQDWLNGKEYKCKVSNKALPAP

GTATGATTACGTTTGGGGGAGTTAT

IEKTISKAKGQPREPQVYTLPPSREEMT

CGCCTCCCCGGGTCGGTATCGTACT

KNQVSLTCLVKGFYPSDIAVEWESNG

ACTTTGACTACTGGGGCCAGGGAAC

QPENNYKTTPPVLDSDGSFFLYSKLTV

CCTGGTCACCGTCTCCTCAGCATCC

DKSRWQQGNVFSCSVMHEALHNHYT

ACCAAGGGGCCTTCCGTGTTCCCCC

QKSLSLSPGK

TGGCCCCTTCATCCAAGTCGACCTC

TGGTGGAACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCCAGACCTATATCTGCAACGTCA

ATCACAAGCCCTCCAACACCAAAGT

GGACAAGAAGGTCGAACCCAAGTC

CTGCGACAAGACTCACACCTGTCCG

CCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLVQSGAEVKKPGESLKISCKGSGY
SEQ ID
CAGGTCCAGCTGGTACAGTCTGGAG

2206
SFTSYWIGWVRQMPGKGLEWMGIIYP
2314
CAGAGGTGAAAAAGCCCGGGGAGT

GDSDTRYSPSFQGQVTISADKSISTAYL

CTCTGAAGATCTCCTGTAAGGGTTC

QWSSLKASDTAMYYCARLPGRAARPD

TGGATACAGCTTTACCAGCTACTGG

YWGQGTLVTVSSASTKGPSVFPLAPSS

ATCGGCTGGGTGCGCCAGATGCCCG

KSTSGGTAALGCLVKDYFPEPVTVSW

GGAAAGGCCTGGAGTGGATGGGGA

NSGALTSGVHTFPAVLQSSGLYSLSSV

TCATCTATCCTGGTGACTCTGATACC

VTVPSSSLGTQTYICNVNHKPSNTKVD

AGATACAGCCCGTCCTTCCAAGGCC

KKVEPKSCDKTHTCPPCPAPELLGGPS

AGGTCACCATCTCAGCCGACAAGTC

VFLFPPKPKDTLMISRTPEVTCVVVDV

CATCAGCACCGCCTACCTGCAGTGG

SHEDPEVKFNWYVDGVEVHNAKTKP

AGCAGCCTGAAGGCCTCGGACACCG

REEQYASTYRVVSVLTVLHQDWLNGK

CCATGTATTACTGTGCGAGACTCCC

EYKCKVSNKALPAPIEKTISKAKGQPR

GGGGAGAGCAGCTCGTCCAGACTAC

EPQVYTLPPSREEMTKNQVSLTCLVKG

TGGGGCCAGGGCACCCTGGTCACCG

FYPSDIAVEWESNGQPENNYKTTPPVL

TCTCCTCAGCATCCACCAAGGGGCC

DSDGSFFLYSKLTVDKSRWQQGNVFS

TTCCGTGTTCCCCCTGGCCCCTTCAT

CSVMHEALHNHYTQKSLSLSPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2207
TFSSYAMHWVRQAPGKGLEWVAVISY
2315
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARGPGAVA

GGATTCACCTTCAGTAGCTATGCTA

GTKPKYYFDYWGQGTLVTVSSASTKG

TGCACTGGGTCCGCCAGGCTCCAGG

PSVFPLAPSSKSTSGGTAALGCLVKDY

CAAGGGGCTGGAGTGGGTGGCAGTT

FPEPVTVSWNSGALTSGVHTFPAVLQS

ATATCATATGATGGAAGTAATAAAT

SGLYSLSSVVTVPSSSLGTQTYICNVNH

ACTACGCAGACTCCGTGAAGGGCCG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

ATTCACCATCTCCAGAGACAATTCC

PELLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSHEDPEVKFNWYVDGVEV

ACAGCCTGAGAGCTGAGGACACGG

HNAKTKPREEQYASTYRVVSVLTVLH

CTGTGTATTACTGTGCGAGAGGCCC

QDWLNGKEYKCKVSNKALPAPIEKTIS

CGGGGCAGTGGCTGGTACTAAGCCA

KAKGQPREPQVYTLPPSREEMTKNQV

AAGTACTACTTTGACTACTGGGGCC

SLTCLVKGFYPSDIAVEWESNGQPENN

AGGGAACCCTGGTCACCGTCTCCTC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

AGCATCCACCAAGGGGCCTTCCGTG

QQGNVFSCSVMHEALHNHYTQKSLSL

TTCCCCCTGGCCCCTTCATCCAAGTC

SPGK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

2208
FTFSSYAMHWVRQAPGKGLEWVAVIS
2316
GAGGCGTGGTCCAGCCTGGGAGGTC

YDGSNKYYADSVKGRFTISRDNSKNT

CCTGAGACTCTCCTGTGCAGCCTCT

LYLQMNSLRAEDTAVYYCARATYYY

GGATTCACCTTCAGTAGCTATGCTA

DSSGYRFDYWGQGTLVTVSSASTKGP

TGCACTGGGTCCGCCAGGCTCCAGG

SVFPLAPSSKSTSGGTAALGCLVKDYF

CAAGGGGCTGGAGTGGGTGGCAGTT

PEPVTVSWNSGALTSGVHTFPAVLQSS

ATATCATATGATGGAAGTAATAAAT

GLYSLSSVVTVPSSSLGTQTYICNVNH

ACTACGCAGACTCCGTGAAGGGCCG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

ATTCACCATCTCCAGAGACAATTCC

PELLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSHEDPEVKFNWYVDGVEV

ACAGCCTGAGAGCTGAGGACACGG

HNAKTKPREEQYASTYRVVSVLTVLH

CTGTGTATTACTGTGCGAGGGCCAC

QDWLNGKEYKCKVSNKALPAPIEKTIS

GTATTACTATGATAGTAGTGGTTAT

KAKGQPREPQVYTLPPSREEMTKNQV

AGGTTTGACTACTGGGGCCAGGGAA

SLTCLVKGFYPSDIAVEWESNGQPENN

CCCTGGTCACCGTCTCCTCAGCATC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

CACCAAGGGGCCTTCCGTGTTCCCC

QQGNVFSCSVMHEALHNHYTQKSLSL

CTGGCCCCTTCATCCAAGTCGACCT

SPGK

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
EVQLVQSGGGLVEPGGSLRLSCAASRF
SEQ ID
GAGGTCCAGCTGGTACAGTCTGGGG

2209
TFSDAWMSWVRQAPGKGLEWVGRIK
2317
GAGGCTTGGTAGAACCGGGGGGGT

SKISGGTTDYAAPVQGRFTISRDDSKN

CCCTTAGACTCTCCTGTGCAGCCTCT

TLYLQMDSLKTEDTAVYYCANRNLGY

CGATTCACTTTCAGTGACGCCTGGA

WGQGTLVTVSSASTKGPSVFPLAPSSK

TGAGCTGGGTCCGCCAGGCTCCAGG

STSGGTAALGCLVKDYFPEPVTVSWN

TAAGGGGCTGGAGTGGGTTGGCCGT

SGALTSGVHTFPAVLQSSGLYSLSSVV

ATTAAAAGCAAAATAAGTGGTGGG

TVPSSSLGTQTYICNVNHKPSNTKVDK

ACAACAGACTACGCTGCACCCGTGC

KVEPKSCDKTHTCPPCPAPELLGGPSV

AAGGCAGATTCACCATCTCAAGAGA

FLFPPKPKDTLMISRTPEVTCVVVDVS

TGATTCAAAAAACACGCTGTATCTG

HEDPEVKFNWYVDGVEVHNAKTKPR

CAAATGGACAGCCTGAAAACCGAG

EEQYASTYRVVSVLTVLHQDWLNGKE

GACACAGCCGTGTATTACTGTGCGA

YKCKVSNKALPAPIEKTISKAKGQPRE

ACCGAAACTTAGGCTACTGGGGCCA

PQVYTLPPSREEMTKNQVSLTCLVKGF

GGGCACCCTGGTGACCGTCTCCTCA

YPSDIAVEWESNGQPENNYKTTPPVLD

GCATCCACCAAGGGGCCTTCCGTGT

SDGSFFLYSKLTVDKSRWQQGNVFSCS

TCCCCCTGGCCCCTTCATCCAAGTC

VMHEALHNHYTQKSLSLSPGK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

2210
YTFTSYAMHWVRQAPGQRLEWMGWI
2318
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTMTTDTSTS

AGTGAAGGTTTCCTGCAAGGCTTCT

TAYMELRSLRSDDTAVYYCARARYYD

GGATACACCTTCACTAGCTATGCTA

SSGYIAPSGYFDYWGQGTLVTVSSAST

TGCATTGGGTGCGCCAGGCCCCCGG

KGPSVFPLAPSSKSTSGGTAALGCLVK

ACAAAGGCTTGAGTGGATGGGATG

DYFPEPVTVSWNSGALTSGVHTFPAVL

GATCAACGCTGGCAATGGTAACACA

QSSGLYSLSSVVTVPSSSLGTQTYICNV

AAATATTCACAGAAGTTCCAGGGCA

NHKPSNTKVDKKVEPKSCDKTHTCPP

GAGTCACCATGACCACAGACACATC

CPAPELLGGPSVFLFPPKPKDTLMISRT

CACGAGCACAGCCTACATGGAGCTG

PEVTCVVVDVSHEDPEVKFNWYVDG

AGGAGCCTGAGATCTGACGACACG

VEVHNAKTKPREEQYASTYRVVSVLT

GCCGTGTATTACTGTGCGAGAGCTC

VLHQDWLNGKEYKCKVSNKALPAPIE

GTTACTATGATAGTAGTGGTTATAT

KTISKAKGQPREPQVYTLPPSREEMTK

TGCCCCATCGGGTTACTTTGACTACT

NQVSLTCLVKGFYPSDIAVEWESNGQP

GGGGCCAGGGAACCCTGGTCACCGT

ENNYKTTPPVLDSDGSFFLYSKLTVDK

CTCCTCAGCATCCACCAAGGGGCCT

SRWQQGNVFSCSVMHEALHNHYTQK

TCCGTGTTCCCCCTGGCCCCTTCATC

SLSLSPGK

CAAGTCGACCTCTGGTGGAACCGCC

GCACTCGGTTGCCTGGTCAAAGACT

ACTTCCCCGAGCCCGTGACTGTCTC

GTGGAACTCGGGCGCCCTCACATCC

GGAGTGCATACCTTTCCCGCCGTGT

TGCAGTCCAGCGGCCTGTACAGCCT

GAGCTCCGTCGTGACAGTGCCGTCC

TCCTCCCTTGGAACCCAGACCTATA

TCTGCAACGTCAATCACAAGCCCTC

CAACACCAAAGTGGACAAGAAGGT

CGAACCCAAGTCCTGCGACAAGACT

CACACCTGTCCGCCTTGTCCAGCCC

CTGAGCTGCTGGGTGGTCCGTCCGT

GTTCCTCTTCCCGCCCAAGCCGAAG

GACACTCTGATGATTTCACGCACCC

CGGAAGTCACTTGCGTGGTCGTGGA

CGTGTCGCACGAAGATCCCGAAGTG

AAATTCAATTGGTACGTGGATGGGG

TCGAAGTGCACAACGCCAAGACCA

AGCCTAGGGAAGAACAGTACgccTCT

ACGTACCGGGTGGTGTCCGTGCTGA

CCGTGCTGCACCAGGACTGGCTGAA

CGGAAAGGAGTACAAGTGCAAAGT

GTCAAACAAGGCTCTCCCTGCCCCT

ATCGAAAAGACCATCAGCAAGGCC

AAGGGTCAACCTAGGGAGCCCCAG

GTCTACACTTTGCCGCCTAGCCGGG

AAGAAATGACTAAGAACCAAGTGT

CCCTGACTTGCCTTGTCAAGGGCTTT

TATCCGTCCGACATCGCCGTGGAGT

GGGAGTCCAACGGACAACCGGAGA

ACAACTACAAGACCACCCCACCGGT

GCTCGATTCCGATGGCTCCTTCTTCC

TGTACTCCAAGCTGACTGTGGACAA

GTCAAGATGGCAGCAGGGAAACGT

GTTCTCCTGCTCCGTGATGCACGAA

GCGCTGCACAACCATTACACCCAGA

AATCACTGTCACTTTCGCCGGGAAA

A

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2211
YTFTSYAMHWVRQAPGQRLEWMGWI
2319
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARDGPAVD

GGATACACCTTCACTAGCTATGCTA

GAEYFQHWGQGTLVTVSSASTKGPSV

TGCATTGGGTGCGCCAGGCCCCCGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

ACAAAGGCTTGAGTGGATGGGATG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GATCAACGCTGGCAATGGTAACACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AAATATTCACAGAAGTTCCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GAGTCACCATTACCAGGGACACATC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CGCGAGCACAGCCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGCCTGAGATCTGAAGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCTGTGTATTACTGTGCGAGAGATG

LNGKEYKCKVSNKALPAPIEKTISKAK

GCCCCGCCGTTGATGGTGCTGAATA

GQPREPQVYTLPPSREEMTKNQVSLTC

CTTCCAGCACTGGGGCCAGGGCACC

LVKGFYPSDIAVEWESNGQPENNYKT

CTGGTCACCGTCTCCTCAGCATCCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CCAAGGGGCCTTCCGTGTTCCCCCT

NVFSCSVMHEALHNHYTQKSLSLSPG

GGCCCCTTCATCCAAGTCGACCTCT

K

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QLQLQESGPGLVKPSQTLSLTCAISGDS
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGGTC

2212
VSSNSAAWNWIRQSPSRGLEWLGRTY
2320
CAGGACTGGTGAAGCCCTCGCAGAC

YRSKWYNDYAVSLKSRITINPDTSKNQ

CCTCTCACTCACCTGTGCCATCTCCG

FSLQLNSVTPEDTAVYYCASLASGSPP

GGGACAGTGTCTCTAGCAACAGTGC

PGDYWGQGTLVTVSSASTKGPSVFPL

TGCTTGGAACTGGATCAGGCAGTCC

APSSKSTSGGTAALGCLVKDYFPEPVT

CCATCGCGAGGCCTTGAGTGGCTGG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GAAGGACTTACTACAGGTCCAAGTG

SSVVTVPSSSLGTQTYICNVNHKPSNT

GTATAATGATTATGCAGTATCTCTG

KVDKKVEPKSCDKTHTCPPCPAPELLG

AAAAGTCGAATAACCATCAACCCGG

GPSVFLFPPKPKDTLMISRTPEVTCVVV

ACACATCCAAGAACCAGTTCTCCCT

DVSHEDPEVKFNWYVDGVEVHNAKT

GCAGCTGAACTCTGTGACTCCCGAG

KPREEQYASTYRVVSVLTVLHQDWLN

GACACGGCTGTATATTACTGTGCAA

GKEYKCKVSNKALPAPIEKTISKAKGQ

GTTTGGCGAGTGGTTCCCCCCCTCC

PREPQVYTLPPSREEMTKNQVSLTCLV

GGGGGACTACTGGGGCCAGGGAAC

KGFYPSDIAVEWESNGQPENNYKTTPP

CCTGGTGACCGTCTCCTCAGCATCC

VLDSDGSFFLYSKLTVDKSRWQQGNV

ACCAAGGGGCCTTCCGTGTTCCCCC

FSCSVMHEALHNHYTQKSLSLSPGK

TGGCCCCTTCATCCAAGTCGACCTC

TGGTGGAACCGCCGCACTCGGTTGC

CTGGTCAAAGACTACTTCCCCGAGC

CCGTGACTGTCTCGTGGAACTCGGG

CGCCCTCACATCCGGAGTGCATACC

TTTCCCGCCGTGTTGCAGTCCAGCG

GCCTGTACAGCCTGAGCTCCGTCGT

GACAGTGCCGTCCTCCTCCCTTGGA

ACCCAGACCTATATCTGCAACGTCA

ATCACAAGCCCTCCAACACCAAAGT

GGACAAGAAGGTCGAACCCAAGTC

CTGCGACAAGACTCACACCTGTCCG

CCTTGTCCAGCCCCTGAGCTGCTGG

GTGGTCCGTCCGTGTTCCTCTTCCCG

CCCAAGCCGAAGGACACTCTGATGA

TTTCACGCACCCCGGAAGTCACTTG

CGTGGTCGTGGACGTGTCGCACGAA

GATCCCGAAGTGAAATTCAATTGGT

ACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2213
TFSTYGMHWVRQAPGKGLEWVALISY
2321
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSKKYYANSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMKSLRAEDTAMYYCAKGPIVGAT

GGATTCACCTTCAGTACCTATGGCA

MDYWGQGALVTVSSASTKGPSVFPLA

TGCACTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

CAAGGGGCTGGAGTGGGTGGCACTT

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATATCATATGATGGAAGTAAAAAAT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ACTATGCAAACTCCGTGAAGGGCCG

VDKKVEPKSCDKTHTCPPCPAPELLGG

ATTCACCATCTCCAGAGACAATTCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACACGTTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

AAAGTCTGAGAGCTGAGGACACGG

PREEQYASTYRVVSVLTVLHQDWLNG

CTATGTATTACTGTGCGAAAGGCCC

KEYKCKVSNKALPAPIEKTISKAKGQP

TATAGTGGGAGCGACTATGGACTAC

REPQVYTLPPSREEMTKNQVSLTCLVK

TGGGGCCAGGGAGCCCTGGTCACCG

GFYPSDIAVEWESNGQPENNYKTTPPV

TCTCCTCAGCATCCACCAAGGGGCC

LDSDGSFFLYSKLTVDKSRWQQGNVF

TTCCGTGTTCCCCCTGGCCCCTTCAT

SCSVMHEALHNHYTQKSLSLSPGK

CCAAGTCGACCTCTGGTGGAACCGC

CGCACTCGGTTGCCTGGTCAAAGAC

TACTTCCCCGAGCCCGTGACTGTCT

CGTGGAACTCGGGCGCCCTCACATC

CGGAGTGCATACCTTTCCCGCCGTG

TTGCAGTCCAGCGGCCTGTACAGCC

TGAGCTCCGTCGTGACAGTGCCGTC

CTCCTCCCTTGGAACCCAGACCTAT

ATCTGCAACGTCAATCACAAGCCCT

CCAACACCAAAGTGGACAAGAAGG

TCGAACCCAAGTCCTGCGACAAGAC

TCACACCTGTCCGCCTTGTCCAGCC

CCTGAGCTGCTGGGTGGTCCGTCCG

TGTTCCTCTTCCCGCCCAAGCCGAA

GGACACTCTGATGATTTCACGCACC

CCGGAAGTCACTTGCGTGGTCGTGG

ACGTGTCGCACGAAGATCCCGAAGT

GAAATTCAATTGGTACGTGGATGGG

GTCGAAGTGCACAACGCCAAGACC

AAGCCTAGGGAAGAACAGTACgccT

CTACGTACCGGGTGGTGTCCGTGCT

GACCGTGCTGCACCAGGACTGGCTG

AACGGAAAGGAGTACAAGTGCAAA

GTGTCAAACAAGGCTCTCCCTGCCC

CTATCGAAAAGACCATCAGCAAGGC

CAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGAEVKKPGSSVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2214
GTFSSYAISWVRQAPGQGLEWMGWIS
2322
CTGAGGTGAAGAAGCCTGGGTCCTC

AYNGNTNYAQKLQGRVTMTTDTSTST

GGTGAAGGTCTCCTGCAAGGCTTCT

AYMELRSLRSDDTAVYYCARWYGDY

GGAGGCACCTTCAGCAGCTATGCTA

GLDYWGQGTLVTVSSASTKGPSVFPL

TCAGCTGGGTGCGACAGGCCCCTGG

APSSKSTSGGTAALGCLVKDYFPEPVT

ACAAGGGCTTGAGTGGATGGGATG

VSWNSGALTSGVHTFPAVLQSSGLYSL

GATCAGCGCTTACAATGGTAACACA

SSVVTVPSSSLGTQTYICNVNHKPSNT

AACTATGCACAGAAGCTCCAGGGCA

KVDKKVEPKSCDKTHTCPPCPAPELLG

GAGTCACCATGACCACAGACACATC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

CACGAGCACAGCCTACATGGAGCTG

DVSHEDPEVKFNWYVDGVEVHNAKT

AGGAGCCTGAGATCTGACGACACG

KPREEQYASTYRVVSVLTVLHQDWLN

GCCGTGTATTACTGTGCGAGATGGT

GKEYKCKVSNKALPAPIEKTISKAKGQ

ACGGTGACTACGGCCTTGACTACTG

PREPQVYTLPPSREEMTKNQVSLTCLV

GGGCCAGGGAACCCTGGTCACCGTC

KGFYPSDIAVEWESNGQPENNYKTTPP

TCCTCAGCATCCACCAAGGGGCCTT

VLDSDGSFFLYSKLTVDKSRWQQGNV

CCGTGTTCCCCCTGGCCCCTTCATCC

FSCSVMHEALHNHYTQKSLSLSPGK

AAGTCGACCTCTGGTGGAACCGCCG

CACTCGGTTGCCTGGTCAAAGACTA

CTTCCCCGAGCCCGTGACTGTCTCG

TGGAACTCGGGCGCCCTCACATCCG

GAGTGCATACCTTTCCCGCCGTGTT

GCAGTCCAGCGGCCTGTACAGCCTG

AGCTCCGTCGTGACAGTGCCGTCCT

CCTCCCTTGGAACCCAGACCTATAT

CTGCAACGTCAATCACAAGCCCTCC

AACACCAAAGTGGACAAGAAGGTC

GAACCCAAGTCCTGCGACAAGACTC

ACACCTGTCCGCCTTGTCCAGCCCC

TGAGCTGCTGGGTGGTCCGTCCGTG

TTCCTCTTCCCGCCCAAGCCGAAGG

ACACTCTGATGATTTCACGCACCCC

GGAAGTCACTTGCGTGGTCGTGGAC

GTGTCGCACGAAGATCCCGAAGTGA

AATTCAATTGGTACGTGGATGGGGT

CGAAGTGCACAACGCCAAGACCAA

GCCTAGGGAAGAACAGTACgccTCTA

CGTACCGGGTGGTGTCCGTGCTGAC

CGTGCTGCACCAGGACTGGCTGAAC

GGAAAGGAGTACAAGTGCAAAGTG

TCAAACAAGGCTCTCCCTGCCCCTA

TCGAAAAGACCATCAGCAAGGCCA

AGGGTCAACCTAGGGAGCCCCAGGT

CTACACTTTGCCGCCTAGCCGGGAA

GAAATGACTAAGAACCAAGTGTCCC

TGACTTGCCTTGTCAAGGGCTTTTAT

CCGTCCGACATCGCCGTGGAGTGGG

AGTCCAACGGACAACCGGAGAACA

ACTACAAGACCACCCCACCGGTGCT

CGATTCCGATGGCTCCTTCTTCCTGT

ACTCCAAGCTGACTGTGGACAAGTC

AAGATGGCAGCAGGGAAACGTGTT

CTCCTGCTCCGTGATGCACGAAGCG

CTGCACAACCATTACACCCAGAAAT

CACTGTCACTTTCGCCGGGAAAA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGGGG

2215
YTFTSYAMHWVRQAPGQRLAWMGWI
2323
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSEKFEGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVAKYYY

GGATACACCTTCACTAGCTATGCTA

ESGGYRASNWFDPWGQGTLVTVSSAS

TGCATTGGGTGCGCCAGGCCCCCGG

TKGPSVFPLAPSSKSTSGGTAALGCLV

ACAAAGGCTTGCGTGGATGGGATGG

KDYFPEPVTVSWNSGALTSGVHTFPA

ATCAACGCTGGCAATGGTAACACAA

VLQSSGLYSLSSVVTVPSSSLGTQTYIC

AATATTCAGAGAAGTTCGAAGGCAG

NVNHKPSNTKVDKKVEPKSCDKTHTC

AGTCACCATCACCAGGGACACATCC

PPCPAPELLGGPSVFLFPPKPKDTLMIS

GCGAGCACAGCCTACATGGAGCTGA

RTPEVTCVVVDVSHEDPEVKFNWYVD

GCAGCCTGAGATCTGAAGACACGGC

GVEVHNAKTKPREEQYASTYRVVSVL

TGTGTATTACTGTGCGAGGGTCGCC

TVLHQDWLNGKEYKCKVSNKALPAPI

AAATATTATTACGAGAGTGGTGGTT

EKTISKAKGQPREPQVYTLPPSREEMT

ATCGGGCCTCCAACTGGTTCGACCC

KNQVSLTCLVKGFYPSDIAVEWESNG

CTGGGGCCAGGGCACCCTGGTCACC

QPENNYKTTPPVLDSDGSFFLYSKLTV

GTCTCCTCAGCATCCACCAAGGGGC

DKSRWQQGNVFSCSVMHEALHNHYT

CTTCCGTGTTCCCCCTGGCCCCTTCA

QKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVQLQESGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTGCAGGAGTCAGGTC

2216
SVSSNSAAWNWIRQSPSRGLEWLGRT
2324
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARAPPPTV

GGGACAGTGTCTCTAGCAACAGTGC

GWYAPVFDYWGQGTLVTVSSASTKGP

TGCTTGGAACTGGATCAGGCAGTCC

SVFPLAPSSKSTSGGTAALGCLVKDYF

CCATCGAGAGGCCTTGAGTGGCTGG

PEPVTVSWNSGALTSGVHTFPAVLQSS

GAAGGACATACTACAGGTCCAAGTG

GLYSLSSVVTVPSSSLGTQTYICNVNH

GTATAATGATTATGCAGTATCTGTG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

AAAAGTCGAATAACCATCAACCCAG

PELLGGPSVFLFPPKPKDTLMISRTPEV

ACACATCCAAGAACCAGTTCTCCCT

TCVVVDVSHEDPEVKFNWYVDGVEV

GCAGCTGAACTCTGTGACTCCCGAG

HNAKTKPREEQYASTYRVVSVLTVLH

GACACGGCTGTGTATTACTGTGCAA

QDWLNGKEYKCKVSNKALPAPIEKTIS

GAGCGCCCCCTCCGACTGTTGGCTG

KAKGQPREPQVYTLPPSREEMTKNQV

GTACGCCCCCGTCTTTGACTACTGG

SLTCLVKGFYPSDIAVEWESNGQPENN

GGCCAGGGAACCCTGGTCACCGTCT

YKTTPPVLDSDGSFFLYSKLTVDKSRW

CCTCAGCATCCACCAAGGGGCCTTC

QQGNVFSCSVMHEALHNHYTQKSLSL

CGTGTTCCCCCTGGCCCCTTCATCCA

SPGK

AGTCGACCTCTGGTGGAACCGCCGC

ACTCGGTTGCCTGGTCAAAGACTAC

TTCCCCGAGCCCGTGACTGTCTCGT

GGAACTCGGGCGCCCTCACATCCGG

AGTGCATACCTTTCCCGCCGTGTTG

CAGTCCAGCGGCCTGTACAGCCTGA

GCTCCGTCGTGACAGTGCCGTCCTC

CTCCCTTGGAACCCAGACCTATATC

TGCAACGTCAATCACAAGCCCTCCA

ACACCAAAGTGGACAAGAAGGTCG

AACCCAAGTCCTGCGACAAGACTCA

CACCTGTCCGCCTTGTCCAGCCCCT

GAGCTGCTGGGTGGTCCGTCCGTGT

TCCTCTTCCCGCCCAAGCCGAAGGA

CACTCTGATGATTTCACGCACCCCG

GAAGTCACTTGCGTGGTCGTGGACG

TGTCGCACGAAGATCCCGAAGTGAA

ATTCAATTGGTACGTGGATGGGGTC

GAAGTGCACAACGCCAAGACCAAG

CCTAGGGAAGAACAGTACgccTCTAC

GTACCGGGTGGTGTCCGTGCTGACC

GTGCTGCACCAGGACTGGCTGAACG

GAAAGGAGTACAAGTGCAAAGTGT

CAAACAAGGCTCTCCCTGCCCCTAT

CGAAAAGACCATCAGCAAGGCCAA

GGGTCAACCTAGGGAGCCCCAGGTC

TACACTTTGCCGCCTAGCCGGGAAG

AAATGACTAAGAACCAAGTGTCCCT

GACTTGCCTTGTCAAGGGCTTTTATC

CGTCCGACATCGCCGTGGAGTGGGA

GTCCAACGGACAACCGGAGAACAA

CTACAAGACCACCCCACCGGTGCTC

GATTCCGATGGCTCCTTCTTCCTGTA

CTCCAAGCTGACTGTGGACAAGTCA

AGATGGCAGCAGGGAAACGTGTTCT

CCTGCTCCGTGATGCACGAAGCGCT

GCACAACCATTACACCCAGAAATCA

CTGTCACTTTCGCCGGGAAAA

SEQ ID
QLQLQESGGGLVQPGGSLRLSCSASGI
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGGGG

2217
SFRDYWMHWIRQTPGKGLVWVSRINP
2325
GAGGCTTAGTTCAGCCGGGGGGGTC

DGSSTSYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGCTCAGCCTCT

LQMNSLRAEDTAVYYCAKVTGRRVG

GGAATCAGCTTCAGAGATTACTGGA

AHDYWGQGTLVTVSSASTKGPSVFPL

TGCACTGGATCCGCCAAACTCCAGG

APSSKSTSGGTAALGCLVKDYFPEPVT

GAAGGGGCTGGTGTGGGTCTCACGT

VSWNSGALTSGVHTFPAVLQSSGLYSL

ATTAATCCTGATGGGAGTAGCACAA

SSVVTVPSSSLGTQTYICNVNHKPSNT

GCTACGCGGACTCCGTGAAGGGCCG

KVDKKVEPKSCDKTHTCPPCPAPELLG

ATTCACCATCTCCAGAGACAATTCC

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AAGAACACGCTGTATCTGCAAATGA

DVSHEDPEVKFNWYVDGVEVHNAKT

ACAGCCTGAGAGCTGAGGACACGG

KPREEQYASTYRVVSVLTVLHQDWLN

CTGTGTATTACTGTGCGAAAGTTAC

GKEYKCKVSNKALPAPIEKTISKAKGQ

GGGACGGAGAGTGGGAGCCCATGA

PREPQVYTLPPSREEMTKNQVSLTCLV

CTACTGGGGCCAGGGAACCCTGGTC

KGFYPSDIAVEWESNGQPENNYKTTPP

ACCGTCTCCTCAGCATCCACCAAGG

VLDSDGSFFLYSKLTVDKSRWQQGNV

GGCCTTCCGTGTTCCCCCTGGCCCCT

FSCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
QVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2218
YTFTGYYMHWVRQAPGQGLEWMGW
2326
CTGAGGTGAAGAAGCCTGGGGCCTC

INPNSGGTNYAQKFQGRVTMTRDTSIS

AGTGAAGGTCTCCTGCAAGGCTTCT

TAYMELSRLRSDDTAVYYCAFAQPGA

GGATACACCTTCACCGGCTACTATA

ETLNFDLWGRGTLVTVSSASTKGPSVF

TGCACTGGGTGCGACAGGCCCCTGG

PLAPSSKSTSGGTAALGCLVKDYFPEP

ACAAGGGCTTGAGTGGATGGGATG

VTVSWNSGALTSGVHTFPAVLQSSGL

GATCAACCCTAACAGTGGTGGCACA

YSLSSVVTVPSSSLGTQTYICNVNHKPS

AACTATGCACAGAAGTTTCAGGGCA

NTKVDKKVEPKSCDKTHTCPPCPAPEL

GGGTCACCATGACCAGGGACACGTC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CATCAGCACAGCCTACATGGAGCTG

VVDVSHEDPEVKFNWYVDGVEVHNA

AGCAGGCTGAGATCTGACGACACG

KTKPREEQYASTYRVVSVLTVLHQDW

GCCGTGTATTACTGTGCCTTTGCCCA

LNGKEYKCKVSNKALPAPIEKTISKAK

GCCGGGCGCTGAGACGTTGAACTTC

GQPREPQVYTLPPSREEMTKNQVSLTC

GATCTCTGGGGCCGTGGCACCCTGG

LVKGFYPSDIAVEWESNGQPENNYKT

TCACCGTCTCCTCAGCATCCACCAA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GGGGCCTTCCGTGTTCCCCCTGGCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCTTCATCCAAGTCGACCTCTGGTG

K

GAACCGCCGCACTCGGTTGCCTGGT

CAAAGACTACTTCCCCGAGCCCGTG

ACTGTCTCGTGGAACTCGGGCGCCC

TCACATCCGGAGTGCATACCTTTCC

CGCCGTGTTGCAGTCCAGCGGCCTG

TACAGCCTGAGCTCCGTCGTGACAG

TGCCGTCCTCCTCCCTTGGAACCCA

GACCTATATCTGCAACGTCAATCAC

AAGCCCTCCAACACCAAAGTGGACA

AGAAGGTCGAACCCAAGTCCTGCGA

CAAGACTCACACCTGTCCGCCTTGT

CCAGCCCCTGAGCTGCTGGGTGGTC

CGTCCGTGTTCCTCTTCCCGCCCAAG

CCGAAGGACACTCTGATGATTTCAC

GCACCCCGGAAGTCACTTGCGTGGT

CGTGGACGTGTCGCACGAAGATCCC

GAAGTGAAATTCAATTGGTACGTGG

ATGGGGTCGAAGTGCACAACGCCA

AGACCAAGCCTAGGGAAGAACAGT

ACgccTCTACGTACCGGGTGGTGTCC

GTGCTGACCGTGCTGCACCAGGACT

GGCTGAACGGAAAGGAGTACAAGT

GCAAAGTGTCAAACAAGGCTCTCCC

TGCCCCTATCGAAAAGACCATCAGC

AAGGCCAAGGGTCAACCTAGGGAG

CCCCAGGTCTACACTTTGCCGCCTA

GCCGGGAAGAAATGACTAAGAACC

AAGTGTCCCTGACTTGCCTTGTCAA

GGGCTTTTATCCGTCCGACATCGCC

GTGGAGTGGGAGTCCAACGGACAA

CCGGAGAACAACTACAAGACCACC

CCACCGGTGCTCGATTCCGATGGCT

CCTTCTTCCTGTACTCCAAGCTGACT

GTGGACAAGTCAAGATGGCAGCAG

GGAAACGTGTTCTCCTGCTCCGTGA

TGCACGAAGCGCTGCACAACCATTA

CACCCAGAAATCACTGTCACTTTCG

CCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2219
SVSSKSAAWNWIRQSPSRGLEWLGRT
2327
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWNNDYALSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLKSVTPEDTALYYCVRQVAGG

GGGACAGTGTCTCTAGCAAAAGTGC

MDVWGQGTTVTVSSASTKGPSVFPLA

TGCTTGGAACTGGATCAGGCAGTCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCATCGAGAGGCCTTGAGTGGCTGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GAAGGACATACTACAGGTCCAAATG

SVVTVPSSSLGTQTYICNVNHKPSNTK

GAATAATGATTATGCATTATCTGTG

VDKKVEPKSCDKTHTCPPCPAPELLGG

AAAAGTCGAATAACCATCAACCCAG

PSVFLFPPKPKDTLMISRTPEVTCVVVD

ACACATCCAAGAACCAGTTCTCCCT

VSHEDPEVKFNWYVDGVEVHNAKTK

GCAGCTGAAGTCTGTGACTCCCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCTCTGTATTACTGTGTAA

KEYKCKVSNKALPAPIEKTISKAKGQP

GACAAGTCGCGGGCGGTATGGACGT

REPQVYTLPPSREEMTKNQVSLTCLVK

CTGGGGCCAAGGGACCACGGTCACC

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCTCCTCAGCATCCACCAAGGGGC

LDSDGSFFLYSKLTVDKSRWQQGNVF

CTTCCGTGTTCCCCCTGGCCCCTTCA

SCSVMHEALHNHYTQKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVQLVQSGGGLVQPGRSLRLSCTASGF
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGGG

2220
TFGDYAMSWFRQAPGKGLEWVSAISG
2328
GAGGCTTGGTACAGCCAGGGCGGTC

SGGSTYYADSVKGRFTISRDNSKNTLY

CCTGAGACTCTCCTGTACAGCTTCT

LQMNSLRAEDTAVYYCAKGSVYSGSY

GGATTCACCTTTGGTGATTATGCTAT

YMLIDYWGQGTLVTVSSASTKGPSVFP

GAGCTGGTTCCGCCAGGCTCCAGGG

LAPSSKSTSGGTAALGCLVKDYFPEPV

AAGGGGCTGGAGTGGGTCTCAGCTA

TVSWNSGALTSGVHTFPAVLQSSGLYS

TTAGTGGTAGTGGTGGTAGCACATA

LSSVVTVPSSSLGTQTYICNVNHKPSNT

CTATGCAGACTCCGTGAAGGGCCGA

KVDKKVEPKSCDKTHTCPPCPAPELLG

TTCACCATCTCCAGAGACAATTCCA

GPSVFLFPPKPKDTLMISRTPEVTCVVV

AGAACACGCTGTATCTGCAAATGAA

DVSHEDPEVKFNWYVDGVEVHNAKT

CAGCCTGAGAGCTGAGGACACGGCT

KPREEQYASTYRVVSVLTVLHQDWLN

GTGTATTACTGTGCGAAAGGATCGG

GKEYKCKVSNKALPAPIEKTISKAKGQ

TATATAGTGGGAGCTACTATATGCT

PREPQVYTLPPSREEMTKNQVSLTCLV

CATTGACTACTGGGGCCAGGGCACC

KGFYPSDIAVEWESNGQPENNYKTTPP

CTGGTCACCGTCTCCTCAGCATCCA

VLDSDGSFFLYSKLTVDKSRWQQGNV

CCAAGGGGCCTTCCGTGTTCCCCCT

FSCSVMHEALHNHYTQKSLSLSPGK

GGCCCCTTCATCCAAGTCGACCTCT

GGTGGAACCGCCGCACTCGGTTGCC

TGGTCAAAGACTACTTCCCCGAGCC

CGTGACTGTCTCGTGGAACTCGGGC

GCCCTCACATCCGGAGTGCATACCT

TTCCCGCCGTGTTGCAGTCCAGCGG

CCTGTACAGCCTGAGCTCCGTCGTG

ACAGTGCCGTCCTCCTCCCTTGGAA

CCCAGACCTATATCTGCAACGTCAA

TCACAAGCCCTCCAACACCAAAGTG

GACAAGAAGGTCGAACCCAAGTCCT

GCGACAAGACTCACACCTGTCCGCC

TTGTCCAGCCCCTGAGCTGCTGGGT

GGTCCGTCCGTGTTCCTCTTCCCGCC

CAAGCCGAAGGACACTCTGATGATT

TCACGCACCCCGGAAGTCACTTGCG

TGGTCGTGGACGTGTCGCACGAAGA

TCCCGAAGTGAAATTCAATTGGTAC

GTGGATGGGGTCGAAGTGCACAAC

GCCAAGACCAAGCCTAGGGAAGAA

CAGTACgccTCTACGTACCGGGTGGT

GTCCGTGCTGACCGTGCTGCACCAG

GACTGGCTGAACGGAAAGGAGTAC

AAGTGCAAAGTGTCAAACAAGGCTC

TCCCTGCCCCTATCGAAAAGACCAT

CAGCAAGGCCAAGGGTCAACCTAG

GGAGCCCCAGGTCTACACTTTGCCG

CCTAGCCGGGAAGAAATGACTAAG

AACCAAGTGTCCCTGACTTGCCTTG

TCAAGGGCTTTTATCCGTCCGACAT

CGCCGTGGAGTGGGAGTCCAACGG

ACAACCGGAGAACAACTACAAGAC

CACCCCACCGGTGCTCGATTCCGAT

GGCTCCTTCTTCCTGTACTCCAAGCT

GACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

SEQ ID
QVQLQQSGPGLVRPSQTLSLTCVISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2221
SVSSGSAAWNWIRQSPSRGLEWLGRT
2329
CAGGACTGGTGAGGCCCTCGCAGAC

YYRAKWYNEYAGSVKSRITISPDTSKN

CCTCTCACTCACCTGTGTCATCTCCG

QFSLQLNSVTPEDTAVYFCTRQDKDNT

GGGACAGTGTCTCTAGCGGCAGTGC

RYSGLGVWGQGTTVTVSSASTKGPSV

TGCTTGGAACTGGATCAGGCAGTCC

FPLAPSSKSTSGGTAALGCLVKDYFPE

CCATCGAGAGGCCTTGAGTGGCTGG

PVTVSWNSGALTSGVHTFPAVLQSSGL

GAAGGACATATTATAGGGCCAAGTG

YSLSSVVTVPSSSLGTQTYICNVNHKPS

GTATAATGAATATGCAGGGTCTGTG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

AAAAGCCGAATAACCATCAGTCCGG

LGGPSVFLFPPKPKDTLMISRTPEVTCV

ACACATCCAAGAACCAGTTCTCCCT

VVDVSHEDPEVKFNWYVDGVEVHNA

GCAACTGAACTCTGTGACTCCCGAG

KTKPREEQYASTYRVVSVLTVLHQDW

GACACGGCTGTGTATTTCTGTACAA

LNGKEYKCKVSNKALPAPIEKTISKAK

GACAAGACAAAGACAACACGAGAT

GQPREPQVYTLPPSREEMTKNQVSLTC

ATTCCGGTTTGGGCGTCTGGGGCCA

LVKGFYPSDIAVEWESNGQPENNYKT

AGGGACCACGGTGACCGTCTCCTCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GCATCCACCAAGGGGCCTTCCGTGT

NVFSCSVMHEALHNHYTQKSLSLSPG

TCCCCCTGGCCCCTTCATCCAAGTC

K

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
EVQLVETGGGLVQPGGSLRLSCAASEF
SEQ ID
GAGGTGCAGCTGGTGGAGACCGGG

2222
TLRNYGVSWVRQAPGKGLEWVSGMS
2330
GGAGGCTTAGTTCAGCCTGGGGGGT

GSGYSTYYADSVKGRFTISRDSSKNTL

CCCTGAGACTCTCCTGTGCAGCCTC

FLQMDSLRAEDTAIYYCARGPRMWSS

TGAATTCACCCTTAGGAACTATGGC

GIDAFDIWGHGTMVTVSSASTKGPSVF

GTGAGCTGGGTCCGCCAGGCTCCAG

PLAPSSKSTSGGTAALGCLVKDYFPEP

GGAAGGGGCTGGAGTGGGTCTCAG

VTVSWNSGALTSGVHTFPAVLQSSGL

GTATGAGTGGTAGTGGTTATAGTAC

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ATACTACGCAGACTCCGTGAAGGGC

NTKVDKKVEPKSCDKTHTCPPCPAPEL

CGGTTCACCATCTCCAGAGACAGTT

LGGPSVFLFPPKPKDTLMISRTPEVTCV

CCAAGAACACGCTGTTTCTGCAAAT

VVDVSHEDPEVKFNWYVDGVEVHNA

GGACAGCCTGAGAGCCGAGGACAC

KTKPREEQYASTYRVVSVLTVLHQDW

GGCCATATATTACTGTGCGAGAGGG

LNGKEYKCKVSNKALPAPIEKTISKAK

CCCCGAATGTGGAGCAGTGGCATTG

GQPREPQVYTLPPSREEMTKNQVSLTC

ATGCTTTTGATATCTGGGGCCACGG

LVKGFYPSDIAVEWESNGQPENNYKT

GACAATGGTGACCGTCTCTTCAGCA

TPPVLDSDGSFFLYSKLTVDKSRWQQG

TCCACCAAGGGGCCTTCCGTGTTCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CCCTGGCCCCTTCATCCAAGTCGAC

K

CTCTGGTGGAACCGCCGCACTCGGT

TGCCTGGTCAAAGACTACTTCCCCG

AGCCCGTGACTGTCTCGTGGAACTC

GGGCGCCCTCACATCCGGAGTGCAT

ACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2223
GSVSGYYWSWIRQPPGKGLEWMGEIH
2331
GCAGGACTGTTGAAGCCTTCGGAGA

HSGSTNYNPSLKSRVTISLDTPKNQFSL

CCCTGTCCCTCACCTGCGCTGTCTAT

KLSSVTAADTAVYYCARRDWAGKRV

GGTGGGTCCGTCAGTGGTTACTACT

WGQGTLVTVSSASTKGPSVFPLAPSSK

GGAGCTGGATCCGCCAGCCCCCAGG

STSGGTAALGCLVKDYFPEPVTVSWN

GAAGGGGCTGGAGTGGATGGGGGA

SGALTSGVHTFPAVLQSSGLYSLSSVV

AATCCATCATAGTGGAAGCACCAAC

TVPSSSLGTQTYICNVNHKPSNTKVDK

TACAACCCGTCCCTCAAGAGTCGAG

KVEPKSCDKTHTCPPCPAPELLGGPSV

TCACCATATCACTAGACACGCCCAA

FLFPPKPKDTLMISRTPEVTCVVVDVS

GAACCAGTTCTCCCTGAAGCTAAGC

HEDPEVKFNWYVDGVEVHNAKTKPR

TCTGTGACCGCCGCGGACACGGCTG

EEQYASTYRVVSVLTVLHQDWLNGKE

TATATTACTGTGCGAGACGGGATTG

YKCKVSNKALPAPIEKTISKAKGQPRE

GGCAGGAAAAAGGGTCTGGGGCCA

PQVYTLPPSREEMTKNQVSLTCLVKGF

GGGAACCCTGGTCACCGTCTCCTCA

YPSDIAVEWESNGQPENNYKTTPPVLD

GCATCCACCAAGGGGCCTTCCGTGT

SDGSFFLYSKLTVDKSRWQQGNVFSCS

TCCCCCTGGCCCCTTCATCCAAGTC

VMHEALHNHYTQKSLSLSPGK

GACCTCTGGTGGAACCGCCGCACTC

GGTTGCCTGGTCAAAGACTACTTCC

CCGAGCCCGTGACTGTCTCGTGGAA

CTCGGGCGCCCTCACATCCGGAGTG

CATACCTTTCCCGCCGTGTTGCAGTC

CAGCGGCCTGTACAGCCTGAGCTCC

GTCGTGACAGTGCCGTCCTCCTCCC

TTGGAACCCAGACCTATATCTGCAA

CGTCAATCACAAGCCCTCCAACACC

AAAGTGGACAAGAAGGTCGAACCC

AAGTCCTGCGACAAGACTCACACCT

GTCCGCCTTGTCCAGCCCCTGAGCT

GCTGGGTGGTCCGTCCGTGTTCCTCT

TCCCGCCCAAGCCGAAGGACACTCT

GATGATTTCACGCACCCCGGAAGTC

ACTTGCGTGGTCGTGGACGTGTCGC

ACGAAGATCCCGAAGTGAAATTCAA

TTGGTACGTGGATGGGGTCGAAGTG

CACAACGCCAAGACCAAGCCTAGG

GAAGAACAGTACgccTCTACGTACCG

GGTGGTGTCCGTGCTGACCGTGCTG

CACCAGGACTGGCTGAACGGAAAG

GAGTACAAGTGCAAAGTGTCAAAC

AAGGCTCTCCCTGCCCCTATCGAAA

AGACCATCAGCAAGGCCAAGGGTC

AACCTAGGGAGCCCCAGGTCTACAC

TTTGCCGCCTAGCCGGGAAGAAATG

ACTAAGAACCAAGTGTCCCTGACTT

GCCTTGTCAAGGGCTTTTATCCGTCC

GACATCGCCGTGGAGTGGGAGTCCA

ACGGACAACCGGAGAACAACTACA

AGACCACCCCACCGGTGCTCGATTC

CGATGGCTCCTTCTTCCTGTACTCCA

AGCTGACTGTGGACAAGTCAAGATG

GCAGCAGGGAAACGTGTTCTCCTGC

TCCGTGATGCACGAAGCGCTGCACA

ACCATTACACCCAGAAATCACTGTC

ACTTTCGCCGGGAAAA

SEQ ID
QVQLQQSGPGLLKPSQTLSLTCAISGD
SEQ ID
CAGGTACAGCTGCAGCAGTCAGGTC

2224
SVSSNTATWNWIRQSPSRGLEWLGRT
2332
CAGGACTATTAAAGCCCTCGCAGAC

YYRSKWYKDNALSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCAGGRAGIA

GGGACAGTGTCTCTAGCAACACTGC

AFDIWGQGTTVTVSSASTKGPSVFPLA

TACTTGGAACTGGATCAGGCAGTCC

PSSKSTSGGTAALGCLVKDYFPEPVTV

CCATCGAGAGGCCTTGAGTGGCTGG

SWNSGALTSGVHTFPAVLQSSGLYSLS

GAAGGACATACTACAGGTCCAAGTG

SVVTVPSSSLGTQTYICNVNHKPSNTK

GTATAAGGATAATGCACTGTCTGTG

VDKKVEPKSCDKTHTCPPCPAPELLGG

AAAAGTCGAATAACCATCAACCCAG

PSVFLFPPKPKDTLMISRTPEVTCVVVD

ACACATCCAAGAACCAGTTCTCCCT

VSHEDPEVKFNWYVDGVEVHNAKTK

GCAGCTGAACTCTGTGACTCCCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCTGTGTATTACTGTGCAG

KEYKCKVSNKALPAPIEKTISKAKGQP

GAGGTCGGGCTGGTATTGCCGCTTT

REPQVYTLPPSREEMTKNQVSLTCLVK

TGATATCTGGGGCCAAGGGACCACG

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCACCGTCTCCTCAGCATCCACCA

LDSDGSFFLYSKLTVDKSRWQQGNVF

AGGGGCCTTCCGTGTTCCCCCTGGC

SCSVMHEALHNHYTQKSLSLSPGK

CCCTTCATCCAAGTCGACCTCTGGT

GGAACCGCCGCACTCGGTTGCCTGG

TCAAAGACTACTTCCCCGAGCCCGT

GACTGTCTCGTGGAACTCGGGCGCC

CTCACATCCGGAGTGCATACCTTTC

CCGCCGTGTTGCAGTCCAGCGGCCT

GTACAGCCTGAGCTCCGTCGTGACA

GTGCCGTCCTCCTCCCTTGGAACCC

AGACCTATATCTGCAACGTCAATCA

CAAGCCCTCCAACACCAAAGTGGAC

AAGAAGGTCGAACCCAAGTCCTGCG

ACAAGACTCACACCTGTCCGCCTTG

TCCAGCCCCTGAGCTGCTGGGTGGT

CCGTCCGTGTTCCTCTTCCCGCCCAA

GCCGAAGGACACTCTGATGATTTCA

CGCACCCCGGAAGTCACTTGCGTGG

TCGTGGACGTGTCGCACGAAGATCC

CGAAGTGAAATTCAATTGGTACGTG

GATGGGGTCGAAGTGCACAACGCC

AAGACCAAGCCTAGGGAAGAACAG

TACgccTCTACGTACCGGGTGGTGTC

CGTGCTGACCGTGCTGCACCAGGAC

TGGCTGAACGGAAAGGAGTACAAG

TGCAAAGTGTCAAACAAGGCTCTCC

CTGCCCCTATCGAAAAGACCATCAG

CAAGGCCAAGGGTCAACCTAGGGA

GCCCCAGGTCTACACTTTGCCGCCT

AGCCGGGAAGAAATGACTAAGAAC

CAAGTGTCCCTGACTTGCCTTGTCA

AGGGCTTTTATCCGTCCGACATCGC

CGTGGAGTGGGAGTCCAACGGACA

ACCGGAGAACAACTACAAGACCAC

CCCACCGGTGCTCGATTCCGATGGC

TCCTTCTTCCTGTACTCCAAGCTGAC

TGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTC

GCCGGGAAAA

SEQ ID
QVQLVQSGGGLIQPGGSLRLSCAASGF
SEQ ID
CAGGTGCAGCTGGTGCAATCTGGAG

2225
TVSSNYMSWVRQAPGKGLEWVSLIYS
2333
GAGGCTTGATCCAGCCTGGGGGGTC

DGRTNYADSVKGRFTISRDNSKNTLYL

CCTGAGACTCTCCTGTGCAGCCTCT

QMNSLRAEDTAVYYCAKGALQGEWR

GGGTTCACCGTCAGTAGCAACTACA

RFDYWGQGTLVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

GAAGGGGCTGGAATGGGTCTCACTT

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATTTATAGTGATGGTCGCACAAACT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ATGCAGACTCCGTGAAGGGCCGATT

VDKKVEPKSCDKTHTCPPCPAPELLGG

CACCATCTCCAGAGACAATTCCAAG

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AACACGCTGTATCTGCAAATGAACA

VSHEDPEVKFNWYVDGVEVHNAKTK

GCCTGAGAGCCGAGGACACGGCCG

PREEQYASTYRVVSVLTVLHQDWLNG

TATATTACTGTGCGAAGGGGGCCCT

KEYKCKVSNKALPAPIEKTISKAKGQP

ACAGGGCGAATGGCGGAGATTTGA

REPQVYTLPPSREEMTKNQVSLTCLVK

CTACTGGGGCCAGGGCACCCTGGTC

GFYPSDIAVEWESNGQPENNYKTTPPV

ACCGTCTCCTCAGCATCCACCAAGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GGCCTTCCGTGTTCCCCCTGGCCCCT

SCSVMHEALHNHYTQKSLSLSPGK

TCATCCAAGTCGACCTCTGGTGGAA

CCGCCGCACTCGGTTGCCTGGTCAA

AGACTACTTCCCCGAGCCCGTGACT

GTCTCGTGGAACTCGGGCGCCCTCA

CATCCGGAGTGCATACCTTTCCCGC

CGTGTTGCAGTCCAGCGGCCTGTAC

AGCCTGAGCTCCGTCGTGACAGTGC

CGTCCTCCTCCCTTGGAACCCAGAC

CTATATCTGCAACGTCAATCACAAG

CCCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC

2226
SVSSNSAAWNWIRQSPSRGLEWLGRT
2334
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCTRTNQGY

GGGACAGTGTCTCTAGCAACAGTGC

GGNSGVFDYWGQGTLVTVSSASTKGP

TGCTTGGAACTGGATCAGGCAGTCC

SVFPLAPSSKSTSGGTAALGCLVKDYF

CCATCGAGAGGCCTTGAGTGGCTGG

PEPVTVSWNSGALTSGVHTFPAVLQSS

GAAGGACATATTACAGGTCCAAGTG

GLYSLSSVVTVPSSSLGTQTYICNVNH

GTATAATGATTATGCAGTATCTGTG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

AAAAGTCGAATAACCATCAACCCAG

PELLGGPSVFLFPPKPKDTLMISRTPEV

ACACATCCAAGAACCAGTTCTCCCT

TCVVVDVSHEDPEVKFNWYVDGVEV

GCAGCTGAACTCTGTGACTCCCGAG

HNAKTKPREEQYASTYRVVSVLTVLH

GACACGGCTGTGTATTACTGTACAA

QDWLNGKEYKCKVSNKALPAPIEKTIS

GAACCAACCAGGGATACGGTGGTA

KAKGQPREPQVYTLPPSREEMTKNQV

ACTCCGGGGTATTTGACTACTGGGG

SLTCLVKGFYPSDIAVEWESNGQPENN

CCAGGGAACCCTGGTCACCGTCTCC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

TCAGCATCCACCAAGGGGCCTTCCG

QQGNVFSCSVMHEALHNHYTQKSLSL

TGTTCCCCCTGGCCCCTTCATCCAAG

SPGK

TCGACCTCTGGTGGAACCGCCGCAC

TCGGTTGCCTGGTCAAAGACTACTT

CCCCGAGCCCGTGACTGTCTCGTGG

AACTCGGGCGCCCTCACATCCGGAG

TGCATACCTTTCCCGCCGTGTTGCA

GTCCAGCGGCCTGTACAGCCTGAGC

TCCGTCGTGACAGTGCCGTCCTCCT

CCCTTGGAACCCAGACCTATATCTG

CAACGTCAATCACAAGCCCTCCAAC

ACCAAAGTGGACAAGAAGGTCGAA

CCCAAGTCCTGCGACAAGACTCACA

CCTGTCCGCCTTGTCCAGCCCCTGA

GCTGCTGGGTGGTCCGTCCGTGTTC

CTCTTCCCGCCCAAGCCGAAGGACA

CTCTGATGATTTCACGCACCCCGGA

AGTCACTTGCGTGGTCGTGGACGTG

TCGCACGAAGATCCCGAAGTGAAAT

TCAATTGGTACGTGGATGGGGTCGA

AGTGCACAACGCCAAGACCAAGCCT

AGGGAAGAACAGTACgccTCTACGTA

CCGGGTGGTGTCCGTGCTGACCGTG

CTGCACCAGGACTGGCTGAACGGAA

AGGAGTACAAGTGCAAAGTGTCAA

ACAAGGCTCTCCCTGCCCCTATCGA

AAAGACCATCAGCAAGGCCAAGGG

TCAACCTAGGGAGCCCCAGGTCTAC

ACTTTGCCGCCTAGCCGGGAAGAAA

TGACTAAGAACCAAGTGTCCCTGAC

TTGCCTTGTCAAGGGCTTTTATCCGT

CCGACATCGCCGTGGAGTGGGAGTC

CAACGGACAACCGGAGAACAACTA

CAAGACCACCCCACCGGTGCTCGAT

TCCGATGGCTCCTTCTTCCTGTACTC

CAAGCTGACTGTGGACAAGTCAAGA

TGGCAGCAGGGAAACGTGTTCTCCT

GCTCCGTGATGCACGAAGCGCTGCA

CAACCATTACACCCAGAAATCACTG

TCACTTTCGCCGGGAAAA

SEQ ID
QVQLQQSGPGLVKPSQTLSLTCAISGD
SEQ ID
CAGGTGCAGCTACAGCAGTCAGGTC

2227
SVSGNSAAWNWIRQSPSRGLEWLGRT
2335
CAGGACTGGTGAAGCCCTCGCAGAC

YYRSKWYNDYAVSVKSRITINPDTSKN

CCTCTCACTCACCTGTGCCATCTCCG

QFSLQLNSVTPEDTAVYYCARIVGGAV

GGGACAGTGTCTCTGGCAACAGTGC

DCWGQGTLVTVSSASTKGPSVFPLAPS

TGCTTGGAACTGGATCAGGCAGTCC

SKSTSGGTAALGCLVKDYFPEPVTVS

CCATCGAGAGGCCTTGAGTGGCTGG

WNSGALTSGVHTFPAVLQSSGLYSLSS

GAAGGACATACTACAGGTCCAAGTG

VVTVPSSSLGTQTYICNVNHKPSNTKV

GTATAATGATTATGCAGTATCTGTG

DKKVEPKSCDKTHTCPPCPAPELLGGP

AAAAGTCGAATAACCATCAACCCAG

SVFLFPPKPKDTLMISRTPEVTCVVVD

ACACATCCAAGAACCAGTTCTCCCT

VSHEDPEVKFNWYVDGVEVHNAKTK

GCAGTTGAATTCTGTGACTCCCGAG

PREEQYASTYRVVSVLTVLHQDWLNG

GACACGGCTGTGTATTACTGTGCGA

KEYKCKVSNKALPAPIEKTISKAKGQP

GGATAGTGGGAGGTGCCGTTGACTG

REPQVYTLPPSREEMTKNQVSLTCLVK

CTGGGGCCAGGGAACCCTGGTGACC

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCTCCTCAGCATCCACCAAGGGGC

LDSDGSFFLYSKLTVDKSRWQQGNVF

CTTCCGTGTTCCCCCTGGCCCCTTCA

SCSVMHEALHNHYTQKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGAEVKKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2228
YTFTSYAMHWVRQAPGQRLEWMGWI
2336
CTGAGGTGAAGAAGCCTGGGGCCTC

NAGNGNTKYSQKFQGRVTITRDTSAST

AGTGAAGGTTTCCTGCAAGGCTTCT

AYMELSSLRSEDTAVYYCARVRVGAT

GGATACACCTTCACTAGCTATGCTA

TVYDSWFDPWGQGTLVTVSSASTKGP

TGCATTGGGTGCGCCAGGCCCCCGG

SVFPLAPSSKSTSGGTAALGCLVKDYF

ACAAAGGCTTGAGTGGATGGGATG

PEPVTVSWNSGALTSGVHTFPAVLQSS

GATCAACGCTGGCAATGGTAACACA

GLYSLSSVVTVPSSSLGTQTYICNVNH

AAATATTCACAGAAGTTCCAGGGCA

KPSNTKVDKKVEPKSCDKTHTCPPCPA

GAGTCACCATTACCAGGGACACATC

PELLGGPSVFLFPPKPKDTLMISRTPEV

CGCGAGCACAGCCTACATGGAGCTG

TCVVVDVSHEDPEVKFNWYVDGVEV

AGCAGCCTGAGATCTGAAGACACG

HNAKTKPREEQYASTYRVVSVLTVLH

GCTGTGTATTACTGTGCGAGAGTTA

QDWLNGKEYKCKVSNKALPAPIEKTIS

GAGTGGGAGCTACTACTGTTTACGA

KAKGQPREPQVYTLPPSREEMTKNQV

CAGCTGGTTCGACCCCTGGGGCCAG

SLTCLVKGFYPSDIAVEWESNGQPENN

GGAACCCTGGTGACCGTCTCCTCAG

YKTTPPVLDSDGSFFLYSKLTVDKSRW

CATCCACCAAGGGGCCTTCCGTGTT

QQGNVFSCSVMHEALHNHYTQKSLSL

CCCCCTGGCCCCTTCATCCAAGTCG

SPGK

ACCTCTGGTGGAACCGCCGCACTCG

GTTGCCTGGTCAAAGACTACTTCCC

CGAGCCCGTGACTGTCTCGTGGAAC

TCGGGCGCCCTCACATCCGGAGTGC

ATACCTTTCCCGCCGTGTTGCAGTCC

AGCGGCCTGTACAGCCTGAGCTCCG

TCGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLVQSGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGGGG

2229
FTFSSYAMSWVRQAPGKGLEWVSAIS
2337
GAGGCTTGGTACAGCCTGGGGGGTC

GSGGSTYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCAKDGGSSPY

GGATTCACCTTTAGCAGCTATGCCA

YDSSGLLPWYFDLWGRGTLVTVSSAS

TGAGCTGGGTCCGCCAGGCTCCAGG

TKGPSVFPLAPSSKSTSGGTAALGCLV

GAAGGGGCTGGAGTGGGTCTCAGCT

KDYFPEPVTVSWNSGALTSGVHTFPA

ATTAGTGGTAGTGGTGGTAGCACAT

VLQSSGLYSLSSVVTVPSSSLGTQTYIC

ACTACGCAGACTCCGTGAAGGGCCG

NVNHKPSNTKVDKKVEPKSCDKTHTC

GTTCACCATCTCCAGAGACAATTCC

PPCPAPELLGGPSVFLFPPKPKDTLMIS

AAGAACACGCTGTATCTGCAAATGA

RTPEVTCVVVDVSHEDPEVKFNWYVD

ACAGCCTGAGAGCCGAGGACACGG

GVEVHNAKTKPREEQYASTYRVVSVL

CCGTATATTACTGTGCGAAAGATGG

TVLHQDWLNGKEYKCKVSNKALPAPI

GGGGTCCAGCCCATACTATGATAGT

EKTISKAKGQPREPQVYTLPPSREEMT

AGTGGTTTACTACCCTGGTACTTCG

KNQVSLTCLVKGFYPSDIAVEWESNG

ATCTCTGGGGCCGTGGCACCCTGGT

QPENNYKTTPPVLDSDGSFFLYSKLTV

CACCGTCTCCTCAGCATCCACCAAG

DKSRWQQGNVFSCSVMHEALHNHYT

GGGCCTTCCGTGTTCCCCCTGGCCC

QKSLSLSPGK

CTTCATCCAAGTCGACCTCTGGTGG

AACCGCCGCACTCGGTTGCCTGGTC

AAAGACTACTTCCCCGAGCCCGTGA

CTGTCTCGTGGAACTCGGGCGCCCT

CACATCCGGAGTGCATACCTTTCCC

GCCGTGTTGCAGTCCAGCGGCCTGT

ACAGCCTGAGCTCCGTCGTGACAGT

GCCGTCCTCCTCCCTTGGAACCCAG

ACCTATATCTGCAACGTCAATCACA

AGCCCTCCAACACCAAAGTGGACAA

GAAGGTCGAACCCAAGTCCTGCGAC

AAGACTCACACCTGTCCGCCTTGTC

CAGCCCCTGAGCTGCTGGGTGGTCC

GTCCGTGTTCCTCTTCCCGCCCAAGC

CGAAGGACACTCTGATGATTTCACG

CACCCCGGAAGTCACTTGCGTGGTC

GTGGACGTGTCGCACGAAGATCCCG

AAGTGAAATTCAATTGGTACGTGGA

TGGGGTCGAAGTGCACAACGCCAA

GACCAAGCCTAGGGAAGAACAGTA

CgccTCTACGTACCGGGTGGTGTCCG

TGCTGACCGTGCTGCACCAGGACTG

GCTGAACGGAAAGGAGTACAAGTG

CAAAGTGTCAAACAAGGCTCTCCCT

GCCCCTATCGAAAAGACCATCAGCA

AGGCCAAGGGTCAACCTAGGGAGC

CCCAGGTCTACACTTTGCCGCCTAG

CCGGGAAGAAATGACTAAGAACCA

AGTGTCCCTGACTTGCCTTGTCAAG

GGCTTTTATCCGTCCGACATCGCCG

TGGAGTGGGAGTCCAACGGACAAC

CGGAGAACAACTACAAGACCACCC

CACCGGTGCTCGATTCCGATGGCTC

CTTCTTCCTGTACTCCAAGCTGACTG

TGGACAAGTCAAGATGGCAGCAGG

GAAACGTGTTCTCCTGCTCCGTGAT

GCACGAAGCGCTGCACAACCATTAC

ACCCAGAAATCACTGTCACTTTCGC

CGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGGG

2230
FTFSSYAMHWVRQAPGKGLEYVSAISS
2338
GGAGGCTTGGTCCAGCCTGGGGGGT

NGGSTYYANSVKGRFTISRDNSKNTLY

CCCTGAGACTCTCCTGTGCAGCCTC

LQMGSLRAEDMAVYYCARAKFWTYY

TGGATTCACCTTCAGTAGCTATGCT

FDYWGQGTLVTVSSASTKGPSVFPLAP

ATGCACTGGGTCCGCCAGGCTCCAG

SSKSTSGGTAALGCLVKDYFPEPVTVS

GGAAGGGACTGGAATATGTTTCAGC

WNSGALTSGVHTFPAVLQSSGLYSLSS

TATTAGTAGTAATGGGGGTAGCACA

VVTVPSSSLGTQTYICNVNHKPSNTKV

TATTATGCAAACTCTGTGAAGGGCA

DKKVEPKSCDKTHTCPPCPAPELLGGP

GATTCACCATCTCCAGAGACAATTC

SVFLFPPKPKDTLMISRTPEVTCVVVD

CAAGAACACGCTGTATCTTCAAATG

VSHEDPEVKFNWYVDGVEVHNAKTK

GGCAGCCTGAGAGCTGAGGACATG

PREEQYASTYRVVSVLTVLHQDWLNG

GCTGTGTATTACTGTGCGAGAGCTA

KEYKCKVSNKALPAPIEKTISKAKGQP

AGTTTTGGACATACTACTTTGACTA

REPQVYTLPPSREEMTKNQVSLTCLVK

CTGGGGCCAGGGAACCCTGGTGACC

GFYPSDIAVEWESNGQPENNYKTTPPV

GTCTCCTCAGCATCCACCAAGGGGC

LDSDGSFFLYSKLTVDKSRWQQGNVF

CTTCCGTGTTCCCCCTGGCCCCTTCA

SCSVMHEALHNHYTQKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
QVQLQQWGAGLLKPSETLSLTCAVYG
SEQ ID
CAGGTGCAGCTACAGCAGTGGGGC

2231
GSFSGYYWSWIRQPPGKGLEWIGEINH
2339
GCAGGACTGTTGAAGCCTTCGGAGA

SGSTNYNPSLKSRVTISVDTSKNQFSLK

CCCTGTCCCTCACCTGCGCTGTCTAT

LSSVTAADTAVYYCARGGGSGSYYKR

GGTGGGTCCTTCAGTGGTTACTACT

FFDYWGQGTLVTVSSASTKGPSVFPLA

GGAGCTGGATCCGCCAGCCCCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

GAAGGGGCTGGAGTGGATTGGGGA

SWNSGALTSGVHTFPAVLQSSGLYSLS

AATCAATCATAGTGGAAGCACCAAC

SVVTVPSSSLGTQTYICNVNHKPSNTK

TACAACCCGTCCCTCAAGAGTCGAG

VDKKVEPKSCDKTHTCPPCPAPELLGG

TCACCATATCAGTAGACACGTCCAA

PSVFLFPPKPKDTLMISRTPEVTCVVVD

GAACCAGTTCTCCCTGAAGCTGAGC

VSHEDPEVKFNWYVDGVEVHNAKTK

TCTGTGACCGCCGCGGACACGGCTG

PREEQYASTYRVVSVLTVLHQDWLNG

TGTATTACTGTGCGAGAGGCGGTGG

KEYKCKVSNKALPAPIEKTISKAKGQP

TTCGGGGAGTTATTATAAGAGGTTC

REPQVYTLPPSREEMTKNQVSLTCLVK

TTTGACTACTGGGGCCAGGGAACCC

GFYPSDIAVEWESNGQPENNYKTTPPV

TGGTCACCGTCTCCTCAGCATCCAC

LDSDGSFFLYSKLTVDKSRWQQGNVF

CAAGGGGCCTTCCGTGTTCCCCCTG

SCSVMHEALHNHYTQKSLSLSPGK

GCCCCTTCATCCAAGTCGACCTCTG

GTGGAACCGCCGCACTCGGTTGCCT

GGTCAAAGACTACTTCCCCGAGCCC

GTGACTGTCTCGTGGAACTCGGGCG

CCCTCACATCCGGAGTGCATACCTT

TCCCGCCGTGTTGCAGTCCAGCGGC

CTGTACAGCCTGAGCTCCGTCGTGA

CAGTGCCGTCCTCCTCCCTTGGAAC

CCAGACCTATATCTGCAACGTCAAT

CACAAGCCCTCCAACACCAAAGTGG

ACAAGAAGGTCGAACCCAAGTCCTG

CGACAAGACTCACACCTGTCCGCCT

TGTCCAGCCCCTGAGCTGCTGGGTG

GTCCGTCCGTGTTCCTCTTCCCGCCC

AAGCCGAAGGACACTCTGATGATTT

CACGCACCCCGGAAGTCACTTGCGT

GGTCGTGGACGTGTCGCACGAAGAT

CCCGAAGTGAAATTCAATTGGTACG

TGGATGGGGTCGAAGTGCACAACGC

CAAGACCAAGCCTAGGGAAGAACA

GTACgccTCTACGTACCGGGTGGTGT

CCGTGCTGACCGTGCTGCACCAGGA

CTGGCTGAACGGAAAGGAGTACAA

GTGCAAAGTGTCAAACAAGGCTCTC

CCTGCCCCTATCGAAAAGACCATCA

GCAAGGCCAAGGGTCAACCTAGGG

AGCCCCAGGTCTACACTTTGCCGCC

TAGCCGGGAAGAAATGACTAAGAA

CCAAGTGTCCCTGACTTGCCTTGTC

AAGGGCTTTTATCCGTCCGACATCG

CCGTGGAGTGGGAGTCCAACGGAC

AACCGGAGAACAACTACAAGACCA

CCCCACCGGTGCTCGATTCCGATGG

CTCCTTCTTCCTGTACTCCAAGCTGA

CTGTGGACAAGTCAAGATGGCAGCA

GGGAAACGTGTTCTCCTGCTCCGTG

ATGCACGAAGCGCTGCACAACCATT

ACACCCAGAAATCACTGTCACTTTC

GCCGGGAAAA

SEQ ID
EVQLVQSGAEVRKPGASVKVSCKASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGAG

2232
YTFTSYAISWVRQAPGQGLEWMGWIS
2340
CTGAGGTGAGGAAGCCTGGGGCCTC

AYDGNTNYAQKLQGRVTMTTDTSTST

AGTGAAGGTCTCCTGCAAGGCTTCT

AYMEVRSLRSDDTAVYYCARDGTVR

GGTTACACATTTACCAGTTATGCCA

RVVGATTPGNFDYRGQGTLVTVSSAS

TCAGCTGGGTGCGACAGGCCCCTGG

TKGPSVFPLAPSSKSTSGGTAALGCLV

ACAAGGGCTTGAGTGGATGGGGTG

KDYFPEPVTVSWNSGALTSGVHTFPA

GATCAGCGCTTACGACGGTAACACA

VLQSSGLYSLSSVVTVPSSSLGTQTYIC

AACTATGCACAGAAGCTCCAGGGCA

NVNHKPSNTKVDKKVEPKSCDKTHTC

GAGTCACCATGACCACAGACACATC

PPCPAPELLGGPSVFLFPPKPKDTLMIS

CACGAGCACAGCCTACATGGAGGTG

RTPEVTCVVVDVSHEDPEVKFNWYVD

AGGAGCCTGAGATCTGACGACACG

GVEVHNAKTKPREEQYASTYRVVSVL

GCCGTGTATTACTGTGCGAGAGATG

TVLHQDWLNGKEYKCKVSNKALPAPI

GTACGGTCCGAAGGGTAGTGGGAG

EKTISKAKGQPREPQVYTLPPSREEMT

CTACTACCCCTGGAAACTTTGACTA

KNQVSLTCLVKGFYPSDIAVEWESNG

CAGGGGCCAGGGAACCCTGGTCACC

QPENNYKTTPPVLDSDGSFFLYSKLTV

GTCTCCTCAGCATCCACCAAGGGGC

DKSRWQQGNVFSCSVMHEALHNHYT

CTTCCGTGTTCCCCCTGGCCCCTTCA

QKSLSLSPGK

TCCAAGTCGACCTCTGGTGGAACCG

CCGCACTCGGTTGCCTGGTCAAAGA

CTACTTCCCCGAGCCCGTGACTGTC

TCGTGGAACTCGGGCGCCCTCACAT

CCGGAGTGCATACCTTTCCCGCCGT

GTTGCAGTCCAGCGGCCTGTACAGC

CTGAGCTCCGTCGTGACAGTGCCGT

CCTCCTCCCTTGGAACCCAGACCTA

TATCTGCAACGTCAATCACAAGCCC

TCCAACACCAAAGTGGACAAGAAG

GTCGAACCCAAGTCCTGCGACAAGA

CTCACACCTGTCCGCCTTGTCCAGC

CCCTGAGCTGCTGGGTGGTCCGTCC

GTGTTCCTCTTCCCGCCCAAGCCGA

AGGACACTCTGATGATTTCACGCAC

CCCGGAAGTCACTTGCGTGGTCGTG

GACGTGTCGCACGAAGATCCCGAAG

TGAAATTCAATTGGTACGTGGATGG

GGTCGAAGTGCACAACGCCAAGAC

CAAGCCTAGGGAAGAACAGTACgcc

TCTACGTACCGGGTGGTGTCCGTGC

TGACCGTGCTGCACCAGGACTGGCT

GAACGGAAAGGAGTACAAGTGCAA

AGTGTCAAACAAGGCTCTCCCTGCC

CCTATCGAAAAGACCATCAGCAAGG

CCAAGGGTCAACCTAGGGAGCCCCA

GGTCTACACTTTGCCGCCTAGCCGG

GAAGAAATGACTAAGAACCAAGTG

TCCCTGACTTGCCTTGTCAAGGGCTT

TTATCCGTCCGACATCGCCGTGGAG

TGGGAGTCCAACGGACAACCGGAG

AACAACTACAAGACCACCCCACCGG

TGCTCGATTCCGATGGCTCCTTCTTC

CTGTACTCCAAGCTGACTGTGGACA

AGTCAAGATGGCAGCAGGGAAACG

TGTTCTCCTGCTCCGTGATGCACGA

AGCGCTGCACAACCATTACACCCAG

AAATCACTGTCACTTTCGCCGGGAA

AA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2233
FTFSSYGMHWVRQAPGKGLEWVAVI
2341
GAGGCGTGGTCCAGCCTGGGAGGTC

WYDGSNKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARDLNRG

GGATTCACCTTCAGTAGCTATGGCA

YCSGGSCFGYWGQGTLVTVSSASTKG

TGCACTGGGTCCGCCAGGCTCCAGG

PSVFPLAPSSKSTSGGTAALGCLVKDY

CAAGGGGCTGGAGTGGGTGGCAGTT

FPEPVTVSWNSGALTSGVHTFPAVLQS

ATATGGTATGATGGAAGTAATAAAT

SGLYSLSSVVTVPSSSLGTQTYICNVNH

ACTATGCAGACTCCGTGAAGGGCCG

KPSNTKVDKKVEPKSCDKTHTCPPCPA

ATTCACCATCTCCAGAGACAATTCC

PELLGGPSVFLFPPKPKDTLMISRTPEV

AAGAACACGCTGTATCTGCAAATGA

TCVVVDVSHEDPEVKFNWYVDGVEV

ACAGCCTGAGAGCCGAGGACACGG

HNAKTKPREEQYASTYRVVSVLTVLH

CTGTGTATTACTGTGCGAGAGATCT

QDWLNGKEYKCKVSNKALPAPIEKTIS

GAATCGAGGATATTGTAGTGGTGGT

KAKGQPREPQVYTLPPSREEMTKNQV

AGCTGCTTTGGCTACTGGGGCCAGG

SLTCLVKGFYPSDIAVEWESNGQPENN

GAACCCTGGTCACCGTCTCCTCAGC

YKTTPPVLDSDGSFFLYSKLTVDKSRW

ATCCACCAAGGGGCCTTCCGTGTTC

QQGNVFSCSVMHEALHNHYTQKSLSL

CCCCTGGCCCCTTCATCCAAGTCGA

SPGK

CCTCTGGTGGAACCGCCGCACTCGG

TTGCCTGGTCAAAGACTACTTCCCC

GAGCCCGTGACTGTCTCGTGGAACT

CGGGCGCCCTCACATCCGGAGTGCA

TACCTTTCCCGCCGTGTTGCAGTCCA

GCGGCCTGTACAGCCTGAGCTCCGT

CGTGACAGTGCCGTCCTCCTCCCTT

GGAACCCAGACCTATATCTGCAACG

TCAATCACAAGCCCTCCAACACCAA

AGTGGACAAGAAGGTCGAACCCAA

GTCCTGCGACAAGACTCACACCTGT

CCGCCTTGTCCAGCCCCTGAGCTGC

TGGGTGGTCCGTCCGTGTTCCTCTTC

CCGCCCAAGCCGAAGGACACTCTGA

TGATTTCACGCACCCCGGAAGTCAC

TTGCGTGGTCGTGGACGTGTCGCAC

GAAGATCCCGAAGTGAAATTCAATT

GGTACGTGGATGGGGTCGAAGTGCA

CAACGCCAAGACCAAGCCTAGGGA

AGAACAGTACgccTCTACGTACCGGG

TGGTGTCCGTGCTGACCGTGCTGCA

CCAGGACTGGCTGAACGGAAAGGA

GTACAAGTGCAAAGTGTCAAACAA

GGCTCTCCCTGCCCCTATCGAAAAG

ACCATCAGCAAGGCCAAGGGTCAA

CCTAGGGAGCCCCAGGTCTACACTT

TGCCGCCTAGCCGGGAAGAAATGAC

TAAGAACCAAGTGTCCCTGACTTGC

CTTGTCAAGGGCTTTTATCCGTCCG

ACATCGCCGTGGAGTGGGAGTCCAA

CGGACAACCGGAGAACAACTACAA

GACCACCCCACCGGTGCTCGATTCC

GATGGCTCCTTCTTCCTGTACTCCAA

GCTGACTGTGGACAAGTCAAGATGG

CAGCAGGGAAACGTGTTCTCCTGCT

CCGTGATGCACGAAGCGCTGCACAA

CCATTACACCCAGAAATCACTGTCA

CTTTCGCCGGGAAAA

SEQ ID
QVQLQESGGGLVQPGGSLRLSCAASG
SEQ ID
CAGGTGCAGCTGCAGGAGTCTGGGG

2234
FTFSSYAMSWVRQAPGKGLEWVSYIS
2342
GAGGCTTGGTACAGCCGGGGGGGTC

SSGTTIYYADSVKGRFTVSRDNAKNSL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARDYSSSGE

GGATTCACCTTTAGCAGCTATGCCA

CFDYWGQGTLVTVSSASTKGPSVFPLA

TGAGCTGGGTCCGCCAGGCTCCAGG

PSSKSTSGGTAALGCLVKDYFPEPVTV

GAAGGGGCTGGAGTGGGTTTCATAC

SWNSGALTSGVHTFPAVLQSSGLYSLS

ATTAGTAGTAGTGGTACTACCATAT

SVVTVPSSSLGTQTYICNVNHKPSNTK

ACTACGCAGACTCTGTGAAGGGCCG

VDKKVEPKSCDKTHTCPPCPAPELLGG

ATTCACCGTCTCCAGAGACAATGCC

PSVFLFPPKPKDTLMISRTPEVTCVVVD

AAGAACTCACTGTATCTGCAAATGA

VSHEDPEVKFNWYVDGVEVHNAKTK

ACAGCCTGAGAGCCGAGGACACGG

PREEQYASTYRVVSVLTVLHQDWLNG

CCGTGTATTACTGTGCGAGGGATTA

KEYKCKVSNKALPAPIEKTISKAKGQP

TAGCAGCTCGGGGGAGTGCTTTGAC

REPQVYTLPPSREEMTKNQVSLTCLVK

TACTGGGGCCAGGGAACCCTGGTCA

GFYPSDIAVEWESNGQPENNYKTTPPV

CCGTCTCCTCAGCATCCACCAAGGG

LDSDGSFFLYSKLTVDKSRWQQGNVF

GCCTTCCGTGTTCCCCCTGGCCCCTT

SCSVMHEALHNHYTQKSLSLSPGK

CATCCAAGTCGACCTCTGGTGGAAC

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCCAGACC

TATATCTGCAACGTCAATCACAAGC

CCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
EVQLVQSGGGVVQPGRSLRLSCAASG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGGGG

2235
FTFSSYGMHWVRQAPGKGLEWVAVI
2343
GAGGCGTGGTCCAGCCTGGGAGGTC

WYDGSNKYYADSVKGRFTISRDNSKN

CCTGAGACTCTCCTGTGCAGCGTCT

TLYLQMNSLRAEDTAVYYCARDQAA

GGATTCACCTTCAGTAGCTATGGCA

MVGYFDYWGQGTLVTVSSASTKGPSV

TGCACTGGGTCCGCCAGGCTCCAGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

CAAGGGGCTGGAGTGGGTGGCAGTT

PVTVSWNSGALTSGVHTFPAVLQSSGL

ATATGGTATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ACTATGCAGACTCCGTGAAGGGCCG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

ACAGCCTGAGAGCCGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CTGTGTATTACTGTGCGAGAGATCA

LNGKEYKCKVSNKALPAPIEKTISKAK

GGCAGCTATGGTAGGCTACTTTGAC

GQPREPQVYTLPPSREEMTKNQVSLTC

TACTGGGGCCAGGGAACCCTGGTCA

LVKGFYPSDIAVEWESNGQPENNYKT

CCGTCTCCTCAGCATCCACCAAGGG

TPPVLDSDGSFFLYSKLTVDKSRWQQG

GCCTTCCGTGTTCCCCCTGGCCCCTT

NVFSCSVMHEALHNHYTQKSLSLSPG

CATCCAAGTCGACCTCTGGTGGAAC

K

CGCCGCACTCGGTTGCCTGGTCAAA

GACTACTTCCCCGAGCCCGTGACTG

TCTCGTGGAACTCGGGCGCCCTCAC

ATCCGGAGTGCATACCTTTCCCGCC

GTGTTGCAGTCCAGCGGCCTGTACA

GCCTGAGCTCCGTCGTGACAGTGCC

GTCCTCCTCCCTTGGAACCCAGACC

TATATCTGCAACGTCAATCACAAGC

CCTCCAACACCAAAGTGGACAAGA

AGGTCGAACCCAAGTCCTGCGACAA

GACTCACACCTGTCCGCCTTGTCCA

GCCCCTGAGCTGCTGGGTGGTCCGT

CCGTGTTCCTCTTCCCGCCCAAGCC

GAAGGACACTCTGATGATTTCACGC

ACCCCGGAAGTCACTTGCGTGGTCG

TGGACGTGTCGCACGAAGATCCCGA

AGTGAAATTCAATTGGTACGTGGAT

GGGGTCGAAGTGCACAACGCCAAG

ACCAAGCCTAGGGAAGAACAGTACg

ccTCTACGTACCGGGTGGTGTCCGTG

CTGACCGTGCTGCACCAGGACTGGC

TGAACGGAAAGGAGTACAAGTGCA

AAGTGTCAAACAAGGCTCTCCCTGC

CCCTATCGAAAAGACCATCAGCAAG

GCCAAGGGTCAACCTAGGGAGCCCC

AGGTCTACACTTTGCCGCCTAGCCG

GGAAGAAATGACTAAGAACCAAGT

GTCCCTGACTTGCCTTGTCAAGGGC

TTTTATCCGTCCGACATCGCCGTGG

AGTGGGAGTCCAACGGACAACCGG

AGAACAACTACAAGACCACCCCACC

GGTGCTCGATTCCGATGGCTCCTTCT

TCCTGTACTCCAAGCTGACTGTGGA

CAAGTCAAGATGGCAGCAGGGAAA

CGTGTTCTCCTGCTCCGTGATGCAC

GAAGCGCTGCACAACCATTACACCC

AGAAATCACTGTCACTTTCGCCGGG

AAAA

SEQ ID
QVTLKESGGGVVQPGRSLRLSCAASGF
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGGG

2236
IFSNYAIHWVRQAPGKGLEWVAVISY
2344
GAGGCGTGGTCCAGCCTGGGAGGTC

DGSNKYYADSVKGRFTISRDNSKNTL

CCTGAGACTCTCCTGTGCAGCCTCT

YLQMNSLRAEDTAVYYCARTFAGYSS

GGATTCATCTTCAGTAACTATGCTA

KLGYFDLWGRGTLVTVSSASTKGPSV

TACACTGGGTCCGCCAGGCTCCAGG

FPLAPSSKSTSGGTAALGCLVKDYFPE

CAAGGGGCTGGAGTGGGTGGCAGTT

PVTVSWNSGALTSGVHTFPAVLQSSGL

ATATCATATGATGGAAGTAATAAAT

YSLSSVVTVPSSSLGTQTYICNVNHKPS

ACTACGCAGACTCCGTGAAGGGCCG

NTKVDKKVEPKSCDKTHTCPPCPAPEL

ATTCACCATCTCCAGAGACAATTCC

LGGPSVFLFPPKPKDTLMISRTPEVTCV

AAGAACACGCTGTATCTGCAAATGA

VVDVSHEDPEVKFNWYVDGVEVHNA

ACAGCCTGAGAGCTGAGGACACGG

KTKPREEQYASTYRVVSVLTVLHQDW

CTGTGTATTACTGTGCGAGGACTTTT

LNGKEYKCKVSNKALPAPIEKTISKAK

GCGGGGTATAGCAGCAAACTGGGG

GQPREPQVYTLPPSREEMTKNQVSLTC

TACTTCGATCTCTGGGGCCGTGGCA

LVKGFYPSDIAVEWESNGQPENNYKT

CCCTGGTCACCGTCTCCTCAGCATC

TPPVLDSDGSFFLYSKLTVDKSRWQQG

CACCAAGGGGCCTTCCGTGTTCCCC

NVFSCSVMHEALHNHYTQKSLSLSPG

CTGGCCCCTTCATCCAAGTCGACCT

K

CTGGTGGAACCGCCGCACTCGGTTG

CCTGGTCAAAGACTACTTCCCCGAG

CCCGTGACTGTCTCGTGGAACTCGG

GCGCCCTCACATCCGGAGTGCATAC

CTTTCCCGCCGTGTTGCAGTCCAGC

GGCCTGTACAGCCTGAGCTCCGTCG

TGACAGTGCCGTCCTCCTCCCTTGG

AACCCAGACCTATATCTGCAACGTC

AATCACAAGCCCTCCAACACCAAAG

TGGACAAGAAGGTCGAACCCAAGT

CCTGCGACAAGACTCACACCTGTCC

GCCTTGTCCAGCCCCTGAGCTGCTG

GGTGGTCCGTCCGTGTTCCTCTTCCC

GCCCAAGCCGAAGGACACTCTGATG

ATTTCACGCACCCCGGAAGTCACTT

GCGTGGTCGTGGACGTGTCGCACGA

AGATCCCGAAGTGAAATTCAATTGG

TACGTGGATGGGGTCGAAGTGCACA

ACGCCAAGACCAAGCCTAGGGAAG

AACAGTACgccTCTACGTACCGGGTG

GTGTCCGTGCTGACCGTGCTGCACC

AGGACTGGCTGAACGGAAAGGAGT

ACAAGTGCAAAGTGTCAAACAAGG

CTCTCCCTGCCCCTATCGAAAAGAC

CATCAGCAAGGCCAAGGGTCAACCT

AGGGAGCCCCAGGTCTACACTTTGC

CGCCTAGCCGGGAAGAAATGACTA

AGAACCAAGTGTCCCTGACTTGCCT

TGTCAAGGGCTTTTATCCGTCCGAC

ATCGCCGTGGAGTGGGAGTCCAACG

GACAACCGGAGAACAACTACAAGA

CCACCCCACCGGTGCTCGATTCCGA

TGGCTCCTTCTTCCTGTACTCCAAGC

TGACTGTGGACAAGTCAAGATGGCA

GCAGGGAAACGTGTTCTCCTGCTCC

GTGATGCACGAAGCGCTGCACAACC

ATTACACCCAGAAATCACTGTCACT

TTCGCCGGGAAAA

TABLE 41

Anti-CLEC2D IgG2 antibody amino acid and DNA sequence

SEQ ID
VH + CH IgG2 aa
SEQ ID
VH + IgG2 DNA

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2345
SVKVSCKASGYTFTSYA
2453
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQRLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSQKF

CTTCTGGATACACCTTCACTAGCT

QGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAR

GCCCCCGGACAAAGGCTTGAGTG

GSLSRSGWYAGLFDYW

GATGGGATGGATCAACGCTGGCA

GQGTLVTVSSASTKGPS

ATGGTAACACAAAATATTCACAGA

VFPLAPCSRSTSESTAA

AGTTCCAGGGCAGAGTCACCATTA

LGCLVKDYFPEPVTVSW

CCAGGGACACATCCGCGAGCACA

NSGALTSGVHTFPAVLQ

GCCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAAGACACGGCTGTGTA

FGTQTYTCNVDHKPSN

TTACTGTGCGAGAGGCTCCTTGTC

TKVDKTVERKCCVECPP

CCGAAGTGGCTGGTACGCCGGAC

CPAPPVAGPSVFLFPPK

TCTTTGACTACTGGGGCCAGGGAA

PKDTLMISRTPEVTCVV

CCCTGGTCACCGTCTCCTCAGCAA

VDVSHEDPEVQFNWYV

GCACAAAAGGTCCTTCAGTGTTCC

DGVEVHNAKTKPREEQ

CTCTGGCACCTTGCTCACGCAGCA

FNSTFRVVSVLTVVHQD

CCTCTGAGAGTACAGCCGCCCTG

WLNGKEYKCKVSNKGL

GGCTGCCTGGTAAAGGACTACTTT

PAPIEKTISKTKGQPREP

CCCGAACCAGTCACTGTGTCCTGG

QVYTLPPSREEMTKNQ

AATAGCGGGGCCTTGACCTCTGG

VSLTCLVKGFYPSDIAVE

AGTGCACACATTTCCAGCTGTACT

WESNGQPENNYKTTPP

GCAGTCATCTGGACTCTACAGCCT

MLDSDGSFFLYSKLTVD

GTCCAGTGTGGTCACCGTACCTTC

KSRWQQGNVFSCSVM

CTCCAACTTTGGCACTCAAACATA

HEALHNHYTQKSLSLSP

TACATGTAACGTGGATCATAAGCC

GK

CTCTAACACCAAAGTGGATAAAAC

TGTGGAGCGTAAGTGTTGTGTCGA

GTGTCCTCCTTGTCCTGCTCCTCC

TGTGGCAGGCCCATCTGTGTTTCT

CTTTCCCCCAAAGCCAAAGGACAC

TTTGATGATATCCCGGACCCCTGA

GGTGACTTGCGTCGTCGTAGATGT

TTCACACGAAGATCCAGAGGTGCA

GTTCAACTGGTACGTGGATGGCGT

GGAAGTGCATAATGCCAAGACAAA

GCCCCGCGAAGAGCAGTTTAATTC

CACCTTCCGCGTGGTGTCTGTGCT

GACCGTGGTACATCAGGATTGGCT

TAACGGTAAGGAGTACAAGTGCAA

GGTGAGTAACAAGGGGCTGCCCG

CCCCTATCGAGAAGACTATCAGTA

AAACCAAGGGCCAGCCAAGGGAG

CCACAGGTGTACACACTTCCACCA

TCTAGGGAGGAAATGACAAAGAAC

CAGGTGAGTTTGACCTGTCTCGTG

AAAGGCTTTTATCCCAGTGATATA

GCCGTGGAATGGGAAAGTAACGG

GCAGCCCGAGAACAACTATAAGAC

CACACCACCCATGCTGGACTCCGA

CGGTTCTTTCTTCCTTTATAGCAAG

CTGACAGTGGATAAATCCAGGTGG

CAGCAGGGTAACGTATTCAGTTGC

AGTGTCATGCACGAGGCACTCCAC

AACCACTATACTCAGAAAAGTCTTT

CCCTGAGTCCAGGCAAG

SEQ ID
QITLKESGGGVVQPGRS
SEQ ID
CAGATCACCTTGAAGGAGTCTGGG

2346
LRLSCAASGFTFSSYSM
2454
GGAGGCGTGGTCCAGCCTGGGAG

NWVRQAPGKGLQWVAI

GTCCCTGAGACTCTCCTGTGCAGC

ISDDGSKSYYADSVQGR

CTCTGGATTCACCTTCAGTAGTTAT

FTISRDNSRNTVFLQMN

AGCATGAACTGGGTCCGCCAGGC

SLRAEDTAMYYCARDR

TCCAGGCAAGGGGCTGCAGTGGG

GTKWNQLNDVFDMWG

TGGCAATTATATCAGATGATGGAA

QGTMVTVSSASTKGPS

GTAAGAGTTACTACGCAGACTCCG

VFPLAPCSRSTSESTAA

TGCAGGGCCGATTCACCATCTCCA

LGCLVKDYFPEPVTVSW

GAGACAATTCGAGGAACACAGTAT

NSGALTSGVHTFPAVLQ

TTCTGCAAATGAACAGCCTGAGAG

SSGLYSLSSVVTVPSSN

CTGAGGACACGGCTATGTATTACT

FGTQTYTCNVDHKPSN

GTGCGAGAGACAGGGGAACTAAA

TKVDKTVERKCCVECPP

TGGAACCAATTGAATGATGTTTTTG

CPAPPVAGPSVFLFPPK

ATATGTGGGGCCAAGGGACAATG

PKDTLMISRTPEVTCVV

GTCACCGTCTCTTCAGCAAGCACA

VDVSHEDPEVQFNWYV

AAAGGTCCTTCAGTGTTCCCTCTG

DGVEVHNAKTKPREEQ

GCACCTTGCTCACGCAGCACCTCT

FNSTFRVVSVLTVVHQD

GAGAGTACAGCCGCCCTGGGCTG

WLNGKEYKCKVSNKGL

CCTGGTAAAGGACTACTTTCCCGA

PAPIEKTISKTKGQPREP

ACCAGTCACTGTGTCCTGGAATAG

QVYTLPPSREEMTKNQ

CGGGGCCTTGACCTCTGGAGTGC

VSLTCLVKGFYPSDIAVE

ACACATTTCCAGCTGTACTGCAGT

WESNGQPENNYKTTPP

CATCTGGACTCTACAGCCTGTCCA

MLDSDGSFFLYSKLTVD

GTGTGGTCACCGTACCTTCCTCCA

KSRWQQGNVFSCSVM

ACTTTGGCACTCAAACATATACAT

HEALHNHYTQKSLSLSP

GTAACGTGGATCATAAGCCCTCTA

GK

ACACCAAAGTGGATAAAACTGTGG

AGCGTAAGTGTTGTGTCGAGTGTC

CTCCTTGTCCTGCTCCTCCTGTGG

CAGGCCCATCTGTGTTTCTCTTTC

CCCCAAAGCCAAAGGACACTTTGA

TGATATCCCGGACCCCTGAGGTGA

CTTGCGTCGTCGTAGATGTTTCAC

ACGAAGATCCAGAGGTGCAGTTCA

ACTGGTACGTGGATGGCGTGGAA

GTGCATAATGCCAAGACAAAGCCC

CGCGAAGAGCAGTTTAATTCCACC

TTCCGCGTGGTGTCTGTGCTGACC

GTGGTACATCAGGATTGGCTTAAC

GGTAAGGAGTACAAGTGCAAGGT

GAGTAACAAGGGGCTGCCCGCCC

CTATCGAGAAGACTATCAGTAAAA

CCAAGGGCCAGCCAAGGGAGCCA

CAGGTGTACACACTTCCACCATCT

AGGGAGGAAATGACAAAGAACCA

GGTGAGTTTGACCTGTCTCGTGAA

AGGCTTTTATCCCAGTGATATAGC

CGTGGAATGGGAAAGTAACGGGC

AGCCCGAGAACAACTATAAGACCA

CACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2347
SVKVSCKASGYTFTSYY
2455
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQGLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GIINPSGGSTSYAQKFQ

CATCTGGATACACCTTCACCAGCT

GRVTMTRDTSTSTVYM

ACTATATGCACTGGGTGCGACAGG

ELSSLRSEDTAVYYCAR

CCCCTGGACAAGGGCTTGAGTGG

GRGYSSSRLYYFDYWG

ATGGGAATAATCAACCCTAGTGGT

QGTLVTVSSASTKGPSV

GGTAGCACAAGCTACGCACAGAA

FPLAPCSRSTSESTAAL

GTTCCAGGGCAGAGTCACCATGA

GCLVKDYFPEPVTVSW

CCAGGGACACGTCCACGAGCACA

NSGALTSGVHTFPAVLQ

GTCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAGGACACGGCCGTGT

FGTQTYTCNVDHKPSN

ATTACTGTGCGAGAGGCCGAGGG

TKVDKTVERKCCVECPP

TATAGCAGCAGTCGGCTCTACTAC

CPAPPVAGPSVFLFPPK

TTTGACTACTGGGGCCAGGGAAC

PKDTLMISRTPEVTCVV

CCTGGTCACCGTCTCCTCAGCAAG

VDVSHEDPEVQFNWYV

CACAAAAGGTCCTTCAGTGTTCCC

DGVEVHNAKTKPREEQ

TCTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGGGLVRPGG
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2348
SLRLSCEASGFTFSDPY
2456
GGGAGGCTTGGTCCGGCCTGGAG

MDWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGAAG

GRITNKRTGYATTYAAS

CCTCTGGATTCACCTTCAGTGACC

VKDRFTISRDDSRKSVY

CCTACATGGACTGGGTCCGCCAG

LQMNSLKTEDTAVYYCA

GCTCCAGGCAAGGGGCTGGAGTG

TDVSGSFAAYGGQGTL

GGTTGGCCGAATTACAAATAAGCG

VTVSSASTKGPSVFPLA

TACCGGTTACGCCACAACATATGC

PCSRSTSESTAALGCLV

CGCGTCTGTGAAGGACAGATTCAC

KDYFPEPVTVSWNSGA

CATCTCAAGAGATGATTCAAGGAA

LTSGVHTFPAVLQSSGL

GTCAGTATATCTGCAAATGAACAG

YSLSSVVTVPSSNFGTQ

CCTGAAGACCGAGGACACGGCCG

TYTCNVDHKPSNTKVDK

TATATTATTGTGCAACAGATGTCAG

TVERKCCVECPPCPAP

TGGGTCCTTCGCGGCCTACGGGG

PVAGPSVFLFPPKPKDT

GCCAGGGCACCCTGGTCACCGTC

LMISRTPEVTCVVVDVS

TCCTCAGCAAGCACAAAAGGTCCT

HEDPEVQFNWYVDGVE

TCAGTGTTCCCTCTGGCACCTTGC

VHNAKTKPREEQFNSTF

TCACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
EVQLVQSGGGVVQPGR
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2349
SLRLSCAASGFTFSSYA
2457
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGQRLEWM

GGTCCCTGAGACTCTCCTGTGCAG

GWINAGNGNTKYSQKF

CGTCTGGATTCACCTTCAGTAGCT

QGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAG

GCCCCCGGACAAAGGCTTGAGTG

EGGAVAGTVYWGQGTL

GATGGGATGGATCAACGCTGGCA

VTVSSASTKGPSVFPLA

ATGGTAACACAAAATATTCACAGA

PCSRSTSESTAALGCLV

AGTTCCAGGGCAGAGTCACCATTA

KDYFPEPVTVSWNSGA

CCAGGGACACATCCGCGAGCACA

LTSGVHTFPAVLQSSGL

GCCTACATGGAGCTGAGCAGCCT

YSLSSVVTVPSSNFGTQ

GAGATCTGAAGACACGGCTGTGTA

TYTCNVDHKPSNTKVDK

TTACTGTGCGGGAGAGGGCGGAG

TVERKCCVECPPCPAP

CAGTGGCTGGTACTGTCTACTGGG

PVAGPSVFLFPPKPKDT

GCCAGGGAACCCTGGTCACCGTC

LMISRTPEVTCVVVDVS

TCCTCAGCAAGCACAAAAGGTCCT

HEDPEVQFNWYVDGVE

TCAGTGTTCCCTCTGGCACCTTGC

VHNAKTKPREEQFNSTF

TCACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVQLVQSGGGLVKPGG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGG

2350
SLRLSCAASGFTFSNAW
2458
GGGAGGCTTGGTAAAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTTAGACTCTCCTGTGCAG

GRIKSKTDGGTTDYAAP

CCTCTGGATTCACTTTCAGTAACG

VKGRFTISRDDSKNTLY

CCTGGATGAGCTGGGTCCGCCAG

LQMNSLKTEDTAVYYCT

GCTCCAGGGAAGGGGCTGGAGTG

TDEYFYWGQGTLVTVS

GGTTGGCCGTATTAAAAGCAAAAC

SASTKGPSVFPLAPCSR

TGATGGTGGGACAACAGACTACG

STSESTAALGCLVKDYF

CTGCACCCGTGAAAGGCAGATTCA

PEPVTVSWNSGALTSG

CCATCTCAAGAGATGATTCAAAAA

VHTFPAVLQSSGLYSLS

ACACGCTGTATCTGCAAATGAACA

SVVTVPSSNFGTQTYTC

GCCTGAAAACCGAGGACACAGCC

NVDHKPSNTKVDKTVE

GTGTATTACTGTACCACAGACGAG

RKCCVECPPCPAPPVA

TATTTCTACTGGGGCCAGGGAACC

GPSVFLFPPKPKDTLMI

CTGGTCACCGTCTCCTCAGCAAGC

SRTPEVTCVVVDVSHED

ACAAAAGGTCCTTCAGTGTTCCCT

PEVQFNWYVDGVEVHN

CTGGCACCTTGCTCACGCAGCAC

AKTKPREEQFNSTFRVV

CTCTGAGAGTACAGCCGCCCTGG

SVLTVVHQDWLNGKEY

GCTGCCTGGTAAAGGACTACTTTC

KCKVSNKGLPAPIEKTIS

CCGAACCAGTCACTGTGTCCTGGA

KTKGQPREPQVYTLPPS

ATAGCGGGGCCTTGACCTCTGGA

REEMTKNQVSLTCLVK

GTGCACACATTTCCAGCTGTACTG

GFYPSDIAVEWESNGQ

CAGTCATCTGGACTCTACAGCCTG

PENNYKTTPPMLDSDG

TCCAGTGTGGTCACCGTACCTTCC

SFFLYSKLTVDKSRWQ

TCCAACTTTGGCACTCAAACATATA

QGNVFSCSVMHEALHN

CATGTAACGTGGATCATAAGCCCT

HYTQKSLSLSPGK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2351
TLSLTCAVYGGSFSGYY
2459
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARVNP

CCCCCAGGGAAGGGGCTGGAGTG

GSYTREVSNFDYWGQG

GATTGGGGAAATCAATCATAGTGG

TLVTVSSASTKGPSVFP

AAGCACCAACTACAACCCGTCCCT

LAPCSRSTSESTAALGC

CAAGAGTCGAGTCACCATATCAGT

LVKDYFPEPVTVSWNS

AGACACGTCCAAGAACCAGTTCTC

GALTSGVHTFPAVLQSS

CCTGAAGCTGAGCTCTGTGACCG

GLYSLSSVVTVPSSNFG

CCGCGGACACGGCTGTGTATTACT

TQTYTCNVDHKPSNTKV

GTGCGAGAGTAAATCCGGGGAGT

DKTVERKCCVECPPCP

TATACGAGGGAGGTGAGCAACTTT

APPVAGPSVFLFPPKPK

GACTACTGGGGCCAGGGAACCCT

DTLMISRTPEVTCVVVD

GGTGACCGTCTCCTCAGCAAGCA

VSHEDPEVQFNWYVDG

CAAAAGGTCCTTCAGTGTTCCCTC

VEVHNAKTKPREEQFN

TGGCACCTTGCTCACGCAGCACCT

STFRVVSVLTVVHQDWL

CTGAGAGTACAGCCGCCCTGGGC

NGKEYKCKVSNKGLPA

TGCCTGGTAAAGGACTACTTTCCC

PIEKTISKTKGQPREPQV

GAACCAGTCACTGTGTCCTGGAAT

YTLPPSREEMTKNQVSL

AGCGGGGCCTTGACCTCTGGAGT

TCLVKGFYPSDIAVEWE

GCACACATTTCCAGCTGTACTGCA

SNGQPENNYKTTPPML

GTCATCTGGACTCTACAGCCTGTC

DSDGSFFLYSKLTVDKS

CAGTGTGGTCACCGTACCTTCCTC

RWQQGNVFSCSVMHE

CAACTTTGGCACTCAAACATATAC

ALHNHYTQKSLSLSPGK

ATGTAACGTGGATCATAAGCCCTC

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQSGPELVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2352
TLTLTCGISGDSVSSNS
2460
TCCAGAATTGGTGAAGCCCTCGCA

VTWNWVRQSPSRGLE

GACCCTCACACTCACCTGTGGCAT

WLGRTYYRSQWYYNYA

CTCCGGGGACAGTGTCTCTAGCAA

VSVKSRITISPDTSKNQF

CAGTGTTACTTGGAACTGGGTCAG

SLQLNSVTPEDTAVYYC

GCAGTCCCCATCGAGAGGCCTTG

ATRGHNYGVDYWGPGT

AGTGGCTGGGAAGGACTTACTACC

TVTVSSASTKGPSVFPL

GGTCCCAGTGGTATTATAATTATG

APCSRSTSESTAALGCL

CGGTGTCTGTGAAAAGTCGAATAA

VKDYFPEPVTVSWNSG

CCATCAGCCCAGACACATCCAAGA

ALTSGVHTFPAVLQSSG

ACCAGTTCTCCCTGCAGTTGAATT

LYSLSSVVTVPSSNFGT

CTGTGACTCCCGAGGACACGGCT

QTYTCNVDHKPSNTKV

GTCTATTACTGTGCAACCAGGGGA

DKTVERKCCVECPPCP

CATAACTACGGTGTAGATTACTGG

APPVAGPSVFLFPPKPK

GGCCCGGGGACCACGGTCACCGT

DTLMISRTPEVTCVVVD

CTCCTCAGCAAGCACAAAAGGTCC

VSHEDPEVQFNWYVDG

TTCAGTGTTCCCTCTGGCACCTTG

VEVHNAKTKPREEQFN

CTCACGCAGCACCTCTGAGAGTAC

STFRVVSVLTVVHQDWL

AGCCGCCCTGGGCTGCCTGGTAA

NGKEYKCKVSNKGLPA

AGGACTACTTTCCCGAACCAGTCA

PIEKTISKTKGQPREPQV

CTGTGTCCTGGAATAGCGGGGCC

YTLPPSREEMTKNQVSL

TTGACCTCTGGAGTGCACACATTT

TCLVKGFYPSDIAVEWE

CCAGCTGTACTGCAGTCATCTGGA

SNGQPENNYKTTPPML

CTCTACAGCCTGTCCAGTGTGGTC

DSDGSFFLYSKLTVDKS

ACCGTACCTTCCTCCAACTTTGGC

RWQQGNVFSCSVMHE

ACTCAAACATATACATGTAACGTG

ALHNHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
QVQLVQSGGGLVKPGG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2353
SLRLSCAASGFTFSNAW
2461
GGGAGGCTTGGTAAAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTTAGACTCTCCTGTGCAG

CRIKSKTDGETTDYAAP

CCTCTGGATTCACTTTCAGTAACG

VKGRFTISRDDSKNTLY

CCTGGATGAGCTGGGTCCGCCAG

LQMNSLKTEDTAVYHCT

GCTCCAGGGAAGGGGCTGGAGTG

TGVGWSPFQYWGQGT

GGTTTGCCGTATTAAAAGCAAAAC

LVTVSSASTKGPSVFPL

TGATGGTGAGACAACAGACTACGC

APCSRSTSESTAALGCL

TGCACCCGTGAAAGGCAGATTCAC

VKDYFPEPVTVSWNSG

CATCTCAAGAGATGATTCAAAAAA

ALTSGVHTFPAVLQSSG

CACGCTGTATCTGCAAATGAACAG

LYSLSSVVTVPSSNFGT

CCTGAAAACTGAGGACACAGCCGT

QTYTCNVDHKPSNTKV

GTATCACTGTACCACAGGGGTGG

DKTVERKCCVECPPCP

GATGGTCGCCCTTCCAATACTGGG

APPVAGPSVFLFPPKPK

GCCAGGGCACCCTGGTCACCGTC

DTLMISRTPEVTCVVVD

TCCTCAGCAAGCACAAAAGGTCCT

VSHEDPEVQFNWYVDG

TCAGTGTTCCCTCTGGCACCTTGC

VEVHNAKTKPREEQFN

TCACGCAGCACCTCTGAGAGTACA

STFRVVSVLTVVHQDWL

GCCGCCCTGGGCTGCCTGGTAAA

NGKEYKCKVSNKGLPA

GGACTACTTTCCCGAACCAGTCAC

PIEKTISKTKGQPREPQV

TGTGTCCTGGAATAGCGGGGCCTT

YTLPPSREEMTKNQVSL

GACCTCTGGAGTGCACACATTTCC

TCLVKGFYPSDIAVEWE

AGCTGTACTGCAGTCATCTGGACT

SNGQPENNYKTTPPML

CTACAGCCTGTCCAGTGTGGTCAC

DSDGSFFLYSKLTVDKS

CGTACCTTCCTCCAACTTTGGCAC

RWQQGNVFSCSVMHE

TCAAACATATACATGTAACGTGGA

ALHNHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
EVQLVQSGGGLVQPGR
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2354
SLRLSCTASGFTFGDYA
2462
GGGAGGCTTGGTACAGCCAGGGC

MSWFRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGTTCCGCCAGG

QMNSLKTEDTAVYYCT

CTCCAGGGAAGGGGCTGGAGTGG

RDDKIAAAGFTYWYFDL

GTAGGTTTCATTAGAAGCAAAGCT

WGRGTLVTVSSASTKG

TATGGTGGGACAACAGAATACGCC

PSVFPLAPCSRSTSEST

GCGTCTGTGAAAGGCAGATTCACC

AALGCLVKDYFPEPVTV

ATCTCAAGAGATGATTCCAAAAGC

SWNSGALTSGVHTFPA

ATCGCCTATCTGCAAATGAACAGC

VLQSSGLYSLSSVVTVP

CTGAAAACCGAGGACACAGCCGT

SSNFGTQTYTCNVDHK

GTATTACTGTACTAGAGACGACAA

PSNTKVDKTVERKCCVE

AATAGCAGCAGCTGGATTCACATA

CPPCPAPPVAGPSVFLF

CTGGTACTTCGATCTCTGGGGCCG

PPKPKDTLMISRTPEVT

TGGCACCCTGGTCACCGTCTCCTC

CVVVDVSHEDPEVQFN

AGCAAGCACAAAAGGTCCTTCAGT

WYVDGVEVHNAKTKPR

GTTCCCTCTGGCACCTTGCTCACG

EEQFNSTFRVVSVLTVV

CAGCACCTCTGAGAGTACAGCCG

HQDWLNGKEYKCKVSN

CCCTGGGCTGCCTGGTAAAGGAC

KGLPAPIEKTISKTKGQP

TACTTTCCCGAACCAGTCACTGTG

REPQVYTLPPSREEMTK

TCCTGGAATAGCGGGGCCTTGAC

NQVSLTCLVKGFYPSDI

CTCTGGAGTGCACACATTTCCAGC

AVEWESNGQPENNYKT

TGTACTGCAGTCATCTGGACTCTA

TPPMLDSDGSFFLYSKL

CAGCCTGTCCAGTGTGGTCACCGT

TVDKSRWQQGNVFSCS

ACCTTCCTCCAACTTTGGCACTCA

VMHEALHNHYTQKSLSL

AACATATACATGTAACGTGGATCA

SPGK

TAAGCCCTCTAACACCAAAGTGGA

TAAAACTGTGGAGCGTAAGTGTTG

TGTCGAGTGTCCTCCTTGTCCTGC

TCCTCCTGTGGCAGGCCCATCTGT

GTTTCTCTTTCCCCCAAAGCCAAA

GGACACTTTGATGATATCCCGGAC

CCCTGAGGTGACTTGCGTCGTCGT

AGATGTTTCACACGAAGATCCAGA

GGTGCAGTTCAACTGGTACGTGGA

TGGCGTGGAAGTGCATAATGCCAA

GACAAAGCCCCGCGAAGAGCAGT

TTAATTCCACCTTCCGCGTGGTGT

CTGTGCTGACCGTGGTACATCAGG

ATTGGCTTAACGGTAAGGAGTACA

AGTGCAAGGTGAGTAACAAGGGG

CTGCCCGCCCCTATCGAGAAGACT

ATCAGTAAAACCAAGGGCCAGCCA

AGGGAGCCACAGGTGTACACACTT

CCACCATCTAGGGAGGAAATGACA

AAGAACCAGGTGAGTTTGACCTGT

CTCGTGAAAGGCTTTTATCCCAGT

GATATAGCCGTGGAATGGGAAAGT

AACGGGCAGCCCGAGAACAACTA

TAAGACCACACCACCCATGCTGGA

CTCCGACGGTTCTTTCTTCCTTTAT

AGCAAGCTGACAGTGGATAAATCC

AGGTGGCAGCAGGGTAACGTATT

CAGTTGCAGTGTCATGCACGAGG

CACTCCACAACCACTATACTCAGA

AAAGTCTTTCCCTGAGTCCAGGCA

AG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2355
SVKVSCKASGYTFAAYY
2463
GGCTGAGGTGAAGAAGCCTGGGG

LHWVRQAPGQGLEWM

CCTCAGTGAAGGTCTCCTGCAAGG

GRISPGNGVTSYAQKFQ

CTTCTGGATACACCTTCGCCGCCT

GRVTMTGDTSINTVYM

ATTATTTACACTGGGTGCGACAGG

QLNNLISGDTAVYYCAR

CCCCTGGACAAGGCCTTGAGTGG

EAADDPFDHWGQGALV

ATGGGGCGGATCAGCCCTGGTAA

TVSSASTKGPSVFPLAP

CGGTGTCACAAGTTATGCACAGAA

CSRSTSESTAALGCLVK

ATTTCAGGGCAGAGTCACCATGAC

DYFPEPVTVSWNSGAL

CGGGGACACGTCCATTAACACAGT

TSGVHTFPAVLQSSGLY

CTACATGCAACTGAACAATTTGATT

SLSSVVTVPSSNFGTQT

TCTGGCGACACGGCCGTATATTAC

YTCNVDHKPSNTKVDKT

TGTGCGAGAGAGGCTGCCGACGA

VERKCCVECPPCPAPP

CCCGTTTGACCATTGGGGCCAGG

VAGPSVFLFPPKPKDTL

GAGCCCTGGTCACCGTCTCCTCA

MISRTPEVTCVVVDVSH

GCAAGCACAAAAGGTCCTTCAGTG

EDPEVQFNWYVDGVEV

TTCCCTCTGGCACCTTGCTCACGC

HNAKTKPREEQFNSTFR

AGCACCTCTGAGAGTACAGCCGC

VVSVLTVVHQDWLNGK

CCTGGGCTGCCTGGTAAAGGACT

EYKCKVSNKGLPAPIEK

ACTTTCCCGAACCAGTCACTGTGT

TISKTKGQPREPQVYTL

CCTGGAATAGCGGGGCCTTGACC

PPSREEMTKNQVSLTCL

TCTGGAGTGCACACATTTCCAGCT

VKGFYPSDIAVEWESNG

GTACTGCAGTCATCTGGACTCTAC

QPENNYKTTPPMLDSD

AGCCTGTCCAGTGTGGTCACCGTA

GSFFLYSKLTVDKSRW

CCTTCCTCCAACTTTGGCACTCAA

QQGNVFSCSVMHEALH

ACATATACATGTAACGTGGATCAT

NHYTQKSLSLSPGK

AAGCCCTCTAACACCAAAGTGGAT

AAAACTGTGGAGCGTAAGTGTTGT

GTCGAGTGTCCTCCTTGTCCTGCT

CCTCCTGTGGCAGGCCCATCTGT

GTTTCTCTTTCCCCCAAAGCCAAA

GGACACTTTGATGATATCCCGGAC

CCCTGAGGTGACTTGCGTCGTCGT

AGATGTTTCACACGAAGATCCAGA

GGTGCAGTTCAACTGGTACGTGGA

TGGCGTGGAAGTGCATAATGCCAA

GACAAAGCCCCGCGAAGAGCAGT

TTAATTCCACCTTCCGCGTGGTGT

CTGTGCTGACCGTGGTACATCAGG

ATTGGCTTAACGGTAAGGAGTACA

AGTGCAAGGTGAGTAACAAGGGG

CTGCCCGCCCCTATCGAGAAGACT

ATCAGTAAAACCAAGGGCCAGCCA

AGGGAGCCACAGGTGTACACACTT

CCACCATCTAGGGAGGAAATGACA

AAGAACCAGGTGAGTTTGACCTGT

CTCGTGAAAGGCTTTTATCCCAGT

GATATAGCCGTGGAATGGGAAAGT

AACGGGCAGCCCGAGAACAACTA

TAAGACCACACCACCCATGCTGGA

CTCCGACGGTTCTTTCTTCCTTTAT

AGCAAGCTGACAGTGGATAAATCC

AGGTGGCAGCAGGGTAACGTATT

CAGTTGCAGTGTCATGCACGAGG

CACTCCACAACCACTATACTCAGA

AAAGTCTTTCCCTGAGTCCAGGCA

AG

SEQ ID
EVQLVQSGGGVVQPGR
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2356
SLTLSCAASGFTFSSHL
2464
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGACACTCTCCTGTGCAG

AVISYDGTSKYYGDSVK

CCTCTGGATTCACCTTCAGTTCCC

GRFTISRDNSKNTLYLQ

ATCTTATGCACTGGGTCCGCCAGG

MNSLRAEDTAIYYCAKA

CTCCAGGCAAGGGGCTGGAGTGG

DYKYDWGQGTLVTVSS

GTGGCAGTTATATCATATGATGGA

ASTKGPSVFPLAPCSRS

ACTAGTAAATATTACGGAGACTCC

TSESTAALGCLVKDYFP

GTGAAGGGCCGCTTCACCATCTCC

EPVTVSWNSGALTSGV

AGAGACAATTCCAAGAACACGTTG

HTFPAVLQSSGLYSLSS

TATCTGCAAATGAACAGCCTGCGA

VVTVPSSNFGTQTYTCN

GCTGAAGACACGGCTATATATTAC

VDHKPSNTKVDKTVERK

TGTGCGAAAGCAGATTATAAATAT

CCVECPPCPAPPVAGP

GACTGGGGCCAGGGAACCCTGGT

SVFLFPPKPKDTLMISRT

CACCGTCTCCTCAGCAAGCACAAA

PEVTCVVVDVSHEDPEV

AGGTCCTTCAGTGTTCCCTCTGGC

QFNWYVDGVEVHNAKT

ACCTTGCTCACGCAGCACCTCTGA

KPREEQFNSTFRVVSVL

GAGTACAGCCGCCCTGGGCTGCC

TVVHQDWLNGKEYKCK

TGGTAAAGGACTACTTTCCCGAAC

VSNKGLPAPIEKTISKTK

CAGTCACTGTGTCCTGGAATAGCG

GQPREPQVYTLPPSRE

GGGCCTTGACCTCTGGAGTGCAC

EMTKNQVSLTCLVKGFY

ACATTTCCAGCTGTACTGCAGTCA

PSDIAVEWESNGQPEN

TCTGGACTCTACAGCCTGTCCAGT

NYKTTPPMLDSDGSFFL

GTGGTCACCGTACCTTCCTCCAAC

YSKLTVDKSRWQQGNV

TTTGGCACTCAAACATATACATGTA

FSCSVMHEALHNHYTQ

ACGTGGATCATAAGCCCTCTAACA

KSLSLSPGK

CCAAAGTGGATAAAACTGTGGAGC

GTAAGTGTTGTGTCGAGTGTCCTC

CTTGTCCTGCTCCTCCTGTGGCAG

GCCCATCTGTGTTTCTCTTTCCCC

CAAAGCCAAAGGACACTTTGATGA

TATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGLVKPGG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2357
SLRLSCTASGFTFGDYA
2465
GGGAGGCTTGGTCAAGCCTGGAG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGGTCCGCCAGG

QMNSLKTEDTAVYYCTT

CTCCAGGGAAGGGGCTGGAGTGG

HRRPIYDILTGFDYWGQ

GTAGGTTTCATTAGAAGCAAAGCT

GTLVTVSSASTKGPSVF

TATGGTGGGACAACAGAATACGCC

PLAPCSRSTSESTAALG

GCGTCTGTGAAAGGCAGATTCACC

CLVKDYFPEPVTVSWN

ATCTCAAGAGATGATTCCAAAAGC

SGALTSGVHTFPAVLQS

ATCGCCTATCTGCAAATGAACAGC

SGLYSLSSVVTVPSSNF

CTGAAAACCGAGGACACAGCCGT

GTQTYTCNVDHKPSNT

GTATTACTGTACTACTCATAGACG

KVDKTVERKCCVECPP

CCCAATTTACGATATTTTGACTGGT

CPAPPVAGPSVFLFPPK

TTTGACTACTGGGGCCAGGGAAC

PKDTLMISRTPEVTCVV

CCTGGTCACCGTCTCCTCAGCAAG

VDVSHEDPEVQFNWYV

CACAAAAGGTCCTTCAGTGTTCCC

DGVEVHNAKTKPREEQ

TCTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QLQLQESGGGLVQPGR
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGG

2358
SLRLSCTASGFTFGDYA
2466
GGGAGGCTTGGTACAGCCAGGGC

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGGTCCGCCAGG

QMNSLKTEDTAVYYCT

CTCCAGGGAAGGGGCTGGAGTGG

REDTMVRGVIPWGQGT

GTAGGTTTCATTAGAAGCAAAGCT

LVTVSSASTKGPSVFPL

TATGGTGGGACAACAGAATACGCC

APCSRSTSESTAALGCL

GCGTCTGTGAAAGGCAGATTCACC

VKDYFPEPVTVSWNSG

ATCTCAAGAGATGATTCCAAAAGC

ALTSGVHTFPAVLQSSG

ATCGCCTATCTGCAAATGAACAGC

LYSLSSVVTVPSSNFGT

CTGAAAACCGAGGACACAGCCGT

QTYTCNVDHKPSNTKV

GTATTACTGTACTAGAGAGGATAC

DKTVERKCCVECPPCP

TATGGTTCGGGGAGTTATTCCCTG

APPVAGPSVFLFPPKPK

GGGCCAGGGAACCCTGGTCACCG

DTLMISRTPEVTCVVVD

TCTCCTCAGCAAGCACAAAAGGTC

VSHEDPEVQFNWYVDG

CTTCAGTGTTCCCTCTGGCACCTT

VEVHNAKTKPREEQFN

GCTCACGCAGCACCTCTGAGAGTA

STFRVVSVLTVVHQDWL

CAGCCGCCCTGGGCTGCCTGGTA

NGKEYKCKVSNKGLPA

AAGGACTACTTTCCCGAACCAGTC

PIEKTISKTKGQPREPQV

ACTGTGTCCTGGAATAGCGGGGC

YTLPPSREEMTKNQVSL

CTTGACCTCTGGAGTGCACACATT

TCLVKGFYPSDIAVEWE

TCCAGCTGTACTGCAGTCATCTGG

SNGQPENNYKTTPPML

ACTCTACAGCCTGTCCAGTGTGGT

DSDGSFFLYSKLTVDKS

CACCGTACCTTCCTCCAACTTTGG

RWQQGNVFSCSVMHE

CACTCAAACATATACATGTAACGT

ALHNHYTQKSLSLSPGK

GGATCATAAGCCCTCTAACACCAA

AGTGGATAAAACTGTGGAGCGTAA

GTGTTGTGTCGAGTGTCCTCCTTG

TCCTGCTCCTCCTGTGGCAGGCC

CATCTGTGTTTCTCTTTCCCCCAAA

GCCAAAGGACACTTTGATGATATC

CCGGACCCCTGAGGTGACTTGCG

TCGTCGTAGATGTTTCACACGAAG

ATCCAGAGGTGCAGTTCAACTGGT

ACGTGGATGGCGTGGAAGTGCAT

AATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QLQLQESGSGLVKPSQ
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGG

2359
TLSLTCAVSGGSISSGG
2467
CTCAGGACTGGTGAAGCCTTCACA

YSWSWIRQPPGKGLEW

GACCCTGTCCCTCACCTGCGCTGT

IGYIYHSGSTYYNPSLKS

CTCTGGTGGCTCCATCAGCAGTG

RVTISVDRSKNQFSLKL

GTGGTTACTCCTGGAGCTGGATCC

SSVTAADTAVYYCARDR

GGCAGCCACCAGGGAAGGGCCTG

RYYDSSGYYPAYYFDY

GAGTGGATTGGGTACATCTATCAT

WGQGTLVTVSSASTKG

AGTGGGAGCACCTACTACAACCC

PSVFPLAPCSRSTSEST

GTCCCTCAAGAGTCGAGTCACCAT

AALGCLVKDYFPEPVTV

ATCAGTAGACAGGTCCAAGAACCA

SWNSGALTSGVHTFPA

GTTCTCCCTGAAGCTGAGCTCTGT

VLQSSGLYSLSSVVTVP

GACCGCCGCGGACACGGCTGTGT

SSNFGTQTYTCNVDHK

ATTACTGTGCGAGAGATCGGCGTT

PSNTKVDKTVERKCCVE

ACTATGATAGTAGTGGTTATTATCC

CPPCPAPPVAGPSVFLF

CGCCTACTACTTTGACTACTGGGG

PPKPKDTLMISRTPEVT

CCAGGGAACCCTGGTCACCGTCT

CVVVDVSHEDPEVQFN

CCTCAGCAAGCACAAAAGGTCCTT

WYVDGVEVHNAKTKPR

CAGTGTTCCCTCTGGCACCTTGCT

EEQFNSTFRVVSVLTVV

CACGCAGCACCTCTGAGAGTACA

HQDWLNGKEYKCKVSN

GCCGCCCTGGGCTGCCTGGTAAA

KGLPAPIEKTISKTKGQP

GGACTACTTTCCCGAACCAGTCAC

REPQVYTLPPSREEMTK

TGTGTCCTGGAATAGCGGGGCCTT

NQVSLTCLVKGFYPSDI

GACCTCTGGAGTGCACACATTTCC

AVEWESNGQPENNYKT

AGCTGTACTGCAGTCATCTGGACT

TPPMLDSDGSFFLYSKL

CTACAGCCTGTCCAGTGTGGTCAC

TVDKSRWQQGNVFSCS

CGTACCTTCCTCCAACTTTGGCAC

VMHEALHNHYTQKSLSL

TCAAACATATACATGTAACGTGGA

SPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
EVQLVQSGGGLVKPGG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2360
SLRLSCAASGFTFSSYS
2468
GGGAGGCCTGGTCAAGCCTGGGG

MNWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SYISSSGSYTNYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNAKNSLYLQI

ATAGCATGAACTGGGTCCGCCAG

NSLRAEDTAIYYCARDG

GCTCCAGGGAAGGGGCTGGAGTG

GYDSSGFHFDYWGQGT

GGTTTCATACATTAGTAGTAGTGG

LVTVSSASTKGPSVFPL

TAGTTACACAAACTACGCAGACTC

APCSRSTSESTAALGCL

TGTGAAGGGCCGATTCACCATCTC

VKDYFPEPVTVSWNSG

CAGAGACAACGCCAAGAACTCACT

ALTSGVHTFPAVLQSSG

GTATCTGCAAATAAACAGCCTGAG

LYSLSSVVTVPSSNFGT

AGCCGAGGACACGGCCATTTATTA

QTYTCNVDHKPSNTKV

CTGTGCGAGAGACGGGGGCTATG

DKTVERKCCVECPPCP

ATAGTAGTGGTTTTCACTTTGACTA

APPVAGPSVFLFPPKPK

CTGGGGCCAGGGAACCCTGGTCA

DTLMISRTPEVTCVVVD

CCGTCTCCTCAGCAAGCACAAAAG

VSHEDPEVQFNWYVDG

GTCCTTCAGTGTTCCCTCTGGCAC

VEVHNAKTKPREEQFN

CTTGCTCACGCAGCACCTCTGAGA

STFRVVSVLTVVHQDWL

GTACAGCCGCCCTGGGCTGCCTG

NGKEYKCKVSNKGLPA

GTAAAGGACTACTTTCCCGAACCA

PIEKTISKTKGQPREPQV

GTCACTGTGTCCTGGAATAGCGG

YTLPPSREEMTKNQVSL

GGCCTTGACCTCTGGAGTGCACA

TCLVKGFYPSDIAVEWE

CATTTCCAGCTGTACTGCAGTCAT

SNGQPENNYKTTPPML

CTGGACTCTACAGCCTGTCCAGTG

DSDGSFFLYSKLTVDKS

TGGTCACCGTACCTTCCTCCAACT

RWQQGNVFSCSVMHE

TTGGCACTCAAACATATACATGTAA

ALHNHYTQKSLSLSPGK

CGTGGATCATAAGCCCTCTAACAC

CAAAGTGGATAAAACTGTGGAGCG

TAAGTGTTGTGTCGAGTGTCCTCC

TTGTCCTGCTCCTCCTGTGGCAGG

CCCATCTGTGTTTCTCTTTCCCCC

AAAGCCAAAGGACACTTTGATGAT

ATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2361
TLSLTCAISGDSVSNNR
2469
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNEYAV

TCTCCGGGGACAGTGTCTCTAACA

SVKSRITINPDTSKNQFS

ACAGGGCTGCTTGGAACTGGATCA

LQLNSMTPEDSAVYYCA

GGCAGTCGCCATCGAGAGGCCTT

ILPSSGYLQDHHYYGMD

GAGTGGCTGGGAAGGACATACTA

VWGQGTTVTVSSASTK

CAGGTCCAAGTGGTATAATGAATA

GPSVFPLAPCSRSTSES

TGCAGTCTCTGTGAAAAGTCGAAT

TAALGCLVKDYFPEPVT

AACCATCAACCCAGACACATCCAA

VSWNSGALTSGVHTFP

GAACCAGTTCTCCCTGCAGCTGAA

AVLQSSGLYSLSSVVTV

CTCTATGACTCCCGAGGACTCGGC

PSSNFGTQTYTCNVDH

TGTGTATTACTGTGCAATTTTGCCT

KPSNTKVDKTVERKCCV

AGTAGTGGTTATCTACAGGACCAC

ECPPCPAPPVAGPSVFL

CACTACTACGGTATGGACGTCTGG

FPPKPKDTLMISRTPEV

GGCCAAGGGACCACGGTCACCGT

TCVVVDVSHEDPEVQF

CTCCTCAGCAAGCACAAAAGGTCC

NWYVDGVEVHNAKTKP

TTCAGTGTTCCCTCTGGCACCTTG

REEQFNSTFRVVSVLTV

CTCACGCAGCACCTCTGAGAGTAC

VHQDWLNGKEYKCKVS

AGCCGCCCTGGGCTGCCTGGTAA

NKGLPAPIEKTISKTKGQ

AGGACTACTTTCCCGAACCAGTCA

PREPQVYTLPPSREEMT

CTGTGTCCTGGAATAGCGGGGCC

KNQVSLTCLVKGFYPSD

TTGACCTCTGGAGTGCACACATTT

IAVEWESNGQPENNYK

CCAGCTGTACTGCAGTCATCTGGA

TTPPMLDSDGSFFLYSK

CTCTACAGCCTGTCCAGTGTGGTC

LTVDKSRWQQGNVFSC

ACCGTACCTTCCTCCAACTTTGGC

SVMHEALHNHYTQKSL

ACTCAAACATATACATGTAACGTG

SLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2362
SVKVSCKASGYTFTSYG
2470
AGCTGAGGTGAAGAAGCCTGGGG

ISWVRQAPGQGLEWMG

CCTCAGTGAAGGTCTCCTGCAAGG

WISAYNGNTNYAQKLQ

CTTCTGGTTACACCTTTACCAGCT

GRVTMTTDTSTSTAYM

ACGGTATCAGCTGGGTGCGACAG

ELSSLRSEDTAVYYCAR

GCCCCTGGACAAGGGCTTGAGTG

AAVGDGYSYGRLDWG

GATGGGATGGATCAGCGCTTACAA

QGTLVTVSSASTKGPSV

TGGTAACACAAACTATGCACAGAA

FPLAPCSRSTSESTAAL

GCTCCAGGGCAGAGTCACCATGA

GCLVKDYFPEPVTVSW

CCACAGACACATCCACGAGCACA

NSGALTSGVHTFPAVLQ

GCCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAGGACACGGCCGTGT

FGTQTYTCNVDHKPSN

ATTACTGTGCGAGAGCCGCGGTG

TKVDKTVERKCCVECPP

GGGGATGGATACAGCTATGGTCG

CPAPPVAGPSVFLFPPK

GCTCGATTGGGGCCAGGGAACCC

PKDTLMISRTPEVTCVV

TGGTCACCGTCTCCTCAGCAAGCA

VDVSHEDPEVQFNWYV

CAAAAGGTCCTTCAGTGTTCCCTC

DGVEVHNAKTKPREEQ

TGGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGE
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2363
SLKISCKGSGYSFTSYW
2471
AGCAGAGGTGAAAAAGCCCGGGG

IGWVRQMPGKGLEWM

AGTCTCTGAAGATCTCCTGTAAGG

GIIYPGDSDTRYSPSFQ

GTTCTGGATACAGCTTTACCAGCT

GQVTISADKSISTAYLQ

ACTGGATCGGCTGGGTGCGCCAG

WSSLKASDTAMYYCAR

ATGCCCGGGAAAGGCCTGGAGTG

LPSYYYDSSGYFTWYF

GATGGGGATCATCTATCCTGGTGA

DLWGRGTLVTVSSAST

CTCTGATACCAGATACAGCCCGTC

KGPSVFPLAPCSRSTSE

CTTCCAAGGCCAGGTCACCATCTC

STAALGCLVKDYFPEPV

AGCCGACAAGTCCATCAGCACCG

TVSWNSGALTSGVHTF

CCTACCTGCAGTGGAGCAGCCTG

PAVLQSSGLYSLSSVVT

AAGGCCTCGGACACCGCCATGTAT

VPSSNFGTQTYTCNVD

TACTGTGCGAGACTCCCCTCGTAT

HKPSNTKVDKTVERKC

TACTATGATAGTAGTGGTTACTTTA

CVECPPCPAPPVAGPS

CCTGGTACTTCGATCTCTGGGGCC

VFLFPPKPKDTLMISRTP

GTGGCACCCTGGTGACCGTCTCTT

EVTCVVVDVSHEDPEV

CAGCAAGCACAAAAGGTCCTTCAG

QFNWYVDGVEVHNAKT

TGTTCCCTCTGGCACCTTGCTCAC

KPREEQFNSTFRVVSVL

GCAGCACCTCTGAGAGTACAGCC

TVVHQDWLNGKEYKCK

GCCCTGGGCTGCCTGGTAAAGGA

VSNKGLPAPIEKTISKTK

CTACTTTCCCGAACCAGTCACTGT

GQPREPQVYTLPPSRE

GTCCTGGAATAGCGGGGCCTTGA

EMTKNQVSLTCLVKGFY

CCTCTGGAGTGCACACATTTCCAG

PSDIAVEWESNGQPEN

CTGTACTGCAGTCATCTGGACTCT

NYKTTPPMLDSDGSFFL

ACAGCCTGTCCAGTGTGGTCACC

YSKLTVDKSRWQQGNV

GTACCTTCCTCCAACTTTGGCACT

FSCSVMHEALHNHYTQ

CAAACATATACATGTAACGTGGAT

KSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2364
SVKVSCKASGYTFTSYG
2472
AGCTGAGGTGAAGAAGCCTGGGG

ISWVRQAPGQGLEWMG

CCTCAGTGAAGGTCTCCTGCAAGG

WIIPIFGIANYAQKFQGR

CTTCTGGTTACACCTTTACCAGCT

VTITADKSTSTAYMELSS

ATGGTATCAGCTGGGTGCGACAG

LRSEDTAVYYCARELYN

GCCCCTGGACAAGGGCTTGAGTG

YGSKDYFDYWGQGTLV

GATGGGATGGATCATCCCTATCTT

TVSSASTKGPSVFPLAP

TGGTATAGCAAACTACGCACAGAA

CSRSTSESTAALGCLVK

GTTCCAGGGCAGAGTCACGATTAC

DYFPEPVTVSWNSGAL

CGCGGACAAATCCACGAGCACAG

TSGVHTFPAVLQSSGLY

CCTACATGGAGCTGAGCAGCCTG

SLSSVVTVPSSNFGTQT

AGATCTGAGGACACGGCCGTGTAT

YTCNVDHKPSNTKVDKT

TACTGTGCGAGAGAACTATACAAC

VERKCCVECPPCPAPP

TATGGTTCAAAGGACTACTTTGAC

VAGPSVFLFPPKPKDTL

TACTGGGGCCAGGGAACCCTGGT

MISRTPEVTCVVVDVSH

CACCGTCTCCTCAGCAAGCACAAA

EDPEVQFNWYVDGVEV

AGGTCCTTCAGTGTTCCCTCTGGC

HNAKTKPREEQFNSTFR

ACCTTGCTCACGCAGCACCTCTGA

VVSVLTVVHQDWLNGK

GAGTACAGCCGCCCTGGGCTGCC

EYKCKVSNKGLPAPIEK

TGGTAAAGGACTACTTTCCCGAAC

TISKTKGQPREPQVYTL

CAGTCACTGTGTCCTGGAATAGCG

PPSREEMTKNQVSLTCL

GGGCCTTGACCTCTGGAGTGCAC

VKGFYPSDIAVEWESNG

ACATTTCCAGCTGTACTGCAGTCA

QPENNYKTTPPMLDSD

TCTGGACTCTACAGCCTGTCCAGT

GSFFLYSKLTVDKSRW

GTGGTCACCGTACCTTCCTCCAAC

QQGNVFSCSVMHEALH

TTTGGCACTCAAACATATACATGTA

NHYTQKSLSLSPGK

ACGTGGATCATAAGCCCTCTAACA

CCAAAGTGGATAAAACTGTGGAGC

GTAAGTGTTGTGTCGAGTGTCCTC

CTTGTCCTGCTCCTCCTGTGGCAG

GCCCATCTGTGTTTCTCTTTCCCC

CAAAGCCAAAGGACACTTTGATGA

TATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGE
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2365
SLKISCKGSGYSFTSYW
2473
AGCAGAGGTGAAAAAGCCCGGGG

IGWVRQMPGKGLEWM

AGTCTCTGAAGATCTCCTGTAAGG

GIIYPGDSDTRYSPSFQ

GTTCTGGATACAGCTTTACCAGCT

GQVTISADKSISTAYLQ

ACTGGATCGGCTGGGTGCGCCAG

WSSLKASDTAMYYCAR

ATGCCCGGGAAAGGCCTGGAGTG

GGTWDTAMVTGFDYW

GATGGGGATCATCTATCCTGGTGA

GQGTLVTVSSASTKGPS

CTCTGATACCAGATACAGCCCGTC

VFPLAPCSRSTSESTAA

CTTCCAAGGCCAGGTCACCATCTC

LGCLVKDYFPEPVTVSW

AGCCGACAAGTCCATCAGCACCG

NSGALTSGVHTFPAVLQ

CCTACCTGCAGTGGAGCAGCCTG

SSGLYSLSSVVTVPSSN

AAGGCCTCGGACACCGCCATGTAT

FGTQTYTCNVDHKPSN

TACTGTGCGAGGGGCGGTACTTG

TKVDKTVERKCCVECPP

GGATACAGCTATGGTTACGGGCTT

CPAPPVAGPSVFLFPPK

TGACTACTGGGGCCAGGGAACCC

PKDTLMISRTPEVTCVV

TGGTCACCGTCTCCTCAGCAAGCA

VDVSHEDPEVQFNWYV

CAAAAGGTCCTTCAGTGTTCCCTC

DGVEVHNAKTKPREEQ

TGGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGE
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2366
SLKISCKGSGYSFTSYW
2474
AGCAGAGGTGAAAAAGCCCGGGG

IAWVRQMPGKGLEWM

AGTCTCTGAAGATCTCCTGTAAGG

GVIYPGDSDTRYSPSFQ

GTTCTGGATACAGCTTTACCAGCT

GQVTISADKSINTAYLQ

ACTGGATCGCCTGGGTGCGCCAG

WSSLKASDTAMYYCAR

ATGCCCGGGAAAGGCCTGGAGTG

PHYDILTGSRAPFDYWG

GATGGGGGTCATCTATCCTGGTGA

QGTLVTVSSASTKGPSV

CTCTGATACCAGATACAGCCCGTC

FPLAPCSRSTSESTAAL

CTTCCAAGGCCAGGTCACCATCTC

GCLVKDYFPEPVTVSW

AGCCGACAAGTCCATCAATACCGC

NSGALTSGVHTFPAVLQ

CTACCTGCAGTGGAGCAGCCTGA

SSGLYSLSSVVTVPSSN

AGGCCTCGGACACCGCCATGTATT

FGTQTYTCNVDHKPSN

ACTGTGCGAGACCCCATTACGATA

TKVDKTVERKCCVECPP

TTTTGACTGGTTCCCGGGCGCCCT

CPAPPVAGPSVFLFPPK

TTGACTACTGGGGCCAGGGAACC

PKDTLMISRTPEVTCVV

CTGGTCACCGTCTCCTCAGCAAGC

VDVSHEDPEVQFNWYV

ACAAAAGGTCCTTCAGTGTTCCCT

DGVEVHNAKTKPREEQ

CTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2367
TLSLTCAVYGGSFSGYY
2475
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARARVE

CCCCCAGGGAAGGGGCTGGAGTG

SKDGYFDYWGQGTLVT

GATTGGGGAAATCAATCATAGTGG

VSSASTKGPSVFPLAPC

AAGCACCAACTACAACCCGTCCCT

SRSTSESTAALGCLVKD

CAAGAGTCGAGTCACCATATCAGT

YFPEPVTVSWNSGALTS

AGACACGTCCAAGAACCAGTTCTC

GVHTFPAVLQSSGLYSL

CCTGAAGCTGAGCTCTGTGACCG

SSVVTVPSSNFGTQTYT

CCGCGGACACGGCTGTGTATTACT

CNVDHKPSNTKVDKTV

GTGCGAGAGCCCGAGTGGAATCC

ERKCCVECPPCPAPPV

AAGGATGGGTACTTTGACTACTGG

AGPSVFLFPPKPKDTLM

GGCCAGGGAACCCTGGTCACCGT

ISRTPEVTCVVVDVSHE

CTCCTCAGCAAGCACAAAAGGTCC

DPEVQFNWYVDGVEVH

TTCAGTGTTCCCTCTGGCACCTTG

NAKTKPREEQFNSTFRV

CTCACGCAGCACCTCTGAGAGTAC

VSVLTVVHQDWLNGKE

AGCCGCCCTGGGCTGCCTGGTAA

YKCKVSNKGLPAPIEKTI

AGGACTACTTTCCCGAACCAGTCA

SKTKGQPREPQVYTLPP

CTGTGTCCTGGAATAGCGGGGCC

SREEMTKNQVSLTCLVK

TTGACCTCTGGAGTGCACACATTT

GFYPSDIAVEWESNGQ

CCAGCTGTACTGCAGTCATCTGGA

PENNYKTTPPMLDSDG

CTCTACAGCCTGTCCAGTGTGGTC

SFFLYSKLTVDKSRWQ

ACCGTACCTTCCTCCAACTTTGGC

QGNVFSCSVMHEALHN

ACTCAAACATATACATGTAACGTG

HYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVESGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGG

2368
SLRLSCAASGFTFTDAW
2476
GGGAGGCGTGGTCCAGCCTGGGA

MNWWRQAPGKGLEWIG

GGTCCCTGAGACTCTCCTGTGCAG

RVKNKADGETTDYAAP

CCTCTGGATTCACTTTCACTGATG

VKGRITISRDDAKNTLYV

CCTGGATGAACTGGGTCCGCCAG

QMNSLKTEDTAVYYCTA

GCTCCAGGGAAGGGGCTGGAGTG

DLRLSTWDAYDFWGQG

GATTGGCCGTGTTAAAAACAAAGC

TMVTVSSASTKGPSVFP

TGATGGTGAGACAACGGACTACG

LAPCSRSTSESTAALGC

CTGCACCCGTCAAAGGCAGAATCA

LVKDYFPEPVTVSWNS

CCATCTCAAGAGATGATGCAAAGA

GALTSGVHTFPAVLQSS

ACACTCTGTATGTGCAAATGAACA

GLYSLSSVVTVPSSNFG

GCCTGAAAACCGAGGACACAGCC

TQTYTCNVDHKPSNTKV

GTGTATTATTGTACCGCTGACCTG

DKTVERKCCVECPPCP

CGACTTTCTACGTGGGATGCTTAT

APPVAGPSVFLFPPKPK

GATTTCTGGGGCCAAGGGACAAT

DTLMISRTPEVTCVVVD

GGTCACCGTCTCTTCAGCAAGCAC

VSHEDPEVQFNWYVDG

AAAAGGTCCTTCAGTGTTCCCTCT

VEVHNAKTKPREEQFN

GGCACCTTGCTCACGCAGCACCT

STFRVVSVLTVVHQDWL

CTGAGAGTACAGCCGCCCTGGGC

NGKEYKCKVSNKGLPA

TGCCTGGTAAAGGACTACTTTCCC

PIEKTISKTKGQPREPQV

GAACCAGTCACTGTGTCCTGGAAT

YTLPPSREEMTKNQVSL

AGCGGGGCCTTGACCTCTGGAGT

TCLVKGFYPSDIAVEWE

GCACACATTTCCAGCTGTACTGCA

SNGQPENNYKTTPPML

GTCATCTGGACTCTACAGCCTGTC

DSDGSFFLYSKLTVDKS

CAGTGTGGTCACCGTACCTTCCTC

RWQQGNVFSCSVMHE

CAACTTTGGCACTCAAACATATAC

ALHNHYTQKSLSLSPGK

ATGTAACGTGGATCATAAGCCCTC

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QITLKESGGGLVQPGGS
SEQ ID
CAGATCACCTTGAAGGAGTCTGGG

2369
LRLSCTVSGFTFSNNW
2477
GGAGGCTTGGTCCAGCCTGGGGG

MTWVRQTPGKGLEWV

GTCCCTAAGACTCTCTTGTACAGT

ANIKQDGTEKHYVDSVK

CTCAGGATTCACCTTTAGTAACAAT

GRFTISRDNAENSLYLQ

TGGATGACCTGGGTCCGCCAGAC

MNSLRGEDTAVYYCAR

TCCAGGGAAGGGGCTGGAGTGGG

NSQRSFDYWGQGTLVT

TGGCCAACATAAAGCAAGATGGAA

VSSASTKGPSVFPLAPC

CTGAGAAACACTATGTGGACTCTG

SRSTSESTAALGCLVKD

TGAAGGGCCGATTCACCATCTCCA

YFPEPVTVSWNSGALTS

GAGACAACGCCGAGAACTCACTGT

GVHTFPAVLQSSGLYSL

ATCTGCAGATGAACAGCCTGAGAG

SSVVTVPSSNFGTQTYT

GTGAGGACACGGCCGTGTATTATT

CNVDHKPSNTKVDKTV

GTGCGAGAAACAGTCAACGTTCGT

ERKCCVECPPCPAPPV

TTGACTACTGGGGCCAGGGCACC

AGPSVFLFPPKPKDTLM

CTGGTGACCGTCTCCTCAGCAAGC

ISRTPEVTCVVVDVSHE

ACAAAAGGTCCTTCAGTGTTCCCT

DPEVQFNWYVDGVEVH

CTGGCACCTTGCTCACGCAGCAC

NAKTKPREEQFNSTFRV

CTCTGAGAGTACAGCCGCCCTGG

VSVLTVVHQDWLNGKE

GCTGCCTGGTAAAGGACTACTTTC

YKCKVSNKGLPAPIEKTI

CCGAACCAGTCACTGTGTCCTGGA

SKTKGQPREPQVYTLPP

ATAGCGGGGCCTTGACCTCTGGA

SREEMTKNQVSLTCLVK

GTGCACACATTTCCAGCTGTACTG

GFYPSDIAVEWESNGQ

CAGTCATCTGGACTCTACAGCCTG

PENNYKTTPPMLDSDG

TCCAGTGTGGTCACCGTACCTTCC

SFFLYSKLTVDKSRWQ

TCCAACTTTGGCACTCAAACATATA

QGNVFSCSVMHEALHN

CATGTAACGTGGATCATAAGCCCT

HYTQKSLSLSPGK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2370
SLRLSCAASGFTFSSYG
2478
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAK

GCTCCAGGCAAGGGGCTGGAGTG

DLGDPRGGILNYWGQG

GGTGGCAGTTATATCATATGATGG

TLVTVSSASTKGPSVFP

AAGTAATAAATACTATGCAGACTC

LAPCSRSTSESTAALGC

CGTGAAGGGCCGATTCACCATCTC

LVKDYFPEPVTVSWNS

CAGAGACAATTCCAAGAACACGCT

GALTSGVHTFPAVLQSS

GTATCTGCAAATGAACAGCCTGAG

GLYSLSSVVTVPSSNFG

AGCTGAGGACACGGCTGTGTATTA

TQTYTCNVDHKPSNTKV

CTGTGCGAAAGATTTAGGGGATCC

DKTVERKCCVECPPCP

CCGGGGTGGTATTTTGAACTACTG

APPVAGPSVFLFPPKPK

GGGCCAGGGCACCCTGGTCACCG

DTLMISRTPEVTCVVVD

TCTCCTCAGCAAGCACAAAAGGTC

VSHEDPEVQFNWYVDG

CTTCAGTGTTCCCTCTGGCACCTT

VEVHNAKTKPREEQFN

GCTCACGCAGCACCTCTGAGAGTA

STFRVVSVLTVVHQDWL

CAGCCGCCCTGGGCTGCCTGGTA

NGKEYKCKVSNKGLPA

AAGGACTACTTTCCCGAACCAGTC

PIEKTISKTKGQPREPQV

ACTGTGTCCTGGAATAGCGGGGC

YTLPPSREEMTKNQVSL

CTTGACCTCTGGAGTGCACACATT

TCLVKGFYPSDIAVEWE

TCCAGCTGTACTGCAGTCATCTGG

SNGQPENNYKTTPPML

ACTCTACAGCCTGTCCAGTGTGGT

DSDGSFFLYSKLTVDKS

CACCGTACCTTCCTCCAACTTTGG

RWQQGNVFSCSVMHE

CACTCAAACATATACATGTAACGT

ALHNHYTQKSLSLSPGK

GGATCATAAGCCCTCTAACACCAA

AGTGGATAAAACTGTGGAGCGTAA

GTGTTGTGTCGAGTGTCCTCCTTG

TCCTGCTCCTCCTGTGGCAGGCC

CATCTGTGTTTCTCTTTCCCCCAAA

GCCAAAGGACACTTTGATGATATC

CCGGACCCCTGAGGTGACTTGCG

TCGTCGTAGATGTTTCACACGAAG

ATCCAGAGGTGCAGTTCAACTGGT

ACGTGGATGGCGTGGAAGTGCAT

AATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVESGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGG

2371
SLRLSCAASGFTFSSYA
2479
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGCTATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

SSPWGELSLYQGAFDI

GGTGGCAGTTATATCATATGATGG

WGQGTMVTVSSASTKG

AAGTAATAAATACTACGCAGACTC

PSVFPLAPCSRSTSEST

CGTGAAGGGCCGATTCACCATCTC

AALGCLVKDYFPEPVTV

CAGAGACAATTCCAAGAACACGCT

SWNSGALTSGVHTFPA

GTATCTGCAAATGAACAGCCTGAG

VLQSSGLYSLSSVVTVP

AGCTGAGGACACGGCTGTGTATTA

SSNFGTQTYTCNVDHK

CTGTGCCCGGTCGAGCCCCTGGG

PSNTKVDKTVERKCCVE

GGGAGTTATCGTTATACCAGGGG

CPPCPAPPVAGPSVFLF

GCTTTTGATATCTGGGGCCAAGGG

PPKPKDTLMISRTPEVT

ACAATGGTCACCGTCTCTTCAGCA

CVVVDVSHEDPEVQFN

AGCACAAAAGGTCCTTCAGTGTTC

WYVDGVEVHNAKTKPR

CCTCTGGCACCTTGCTCACGCAGC

EEQFNSTFRVVSVLTVV

ACCTCTGAGAGTACAGCCGCCCT

HQDWLNGKEYKCKVSN

GGGCTGCCTGGTAAAGGACTACTT

KGLPAPIEKTISKTKGQP

TCCCGAACCAGTCACTGTGTCCTG

REPQVYTLPPSREEMTK

GAATAGCGGGGCCTTGACCTCTG

NQVSLTCLVKGFYPSDI

GAGTGCACACATTTCCAGCTGTAC

AVEWESNGQPENNYKT

TGCAGTCATCTGGACTCTACAGCC

TPPMLDSDGSFFLYSKL

TGTCCAGTGTGGTCACCGTACCTT

TVDKSRWQQGNVFSCS

CCTCCAACTTTGGCACTCAAACAT

VMHEALHNHYTQKSLSL

ATACATGTAACGTGGATCATAAGC

SPGK

CCTCTAACACCAAAGTGGATAAAA

CTGTGGAGCGTAAGTGTTGTGTCG

AGTGTCCTCCTTGTCCTGCTCCTC

CTGTGGCAGGCCCATCTGTGTTTC

TCTTTCCCCCAAAGCCAAAGGACA

CTTTGATGATATCCCGGACCCCTG

AGGTGACTTGCGTCGTCGTAGATG

TTTCACACGAAGATCCAGAGGTGC

AGTTCAACTGGTACGTGGATGGCG

TGGAAGTGCATAATGCCAAGACAA

AGCCCCGCGAAGAGCAGTTTAATT

CCACCTTCCGCGTGGTGTCTGTGC

TGACCGTGGTACATCAGGATTGGC

TTAACGGTAAGGAGTACAAGTGCA

AGGTGAGTAACAAGGGGCTGCCC

GCCCCTATCGAGAAGACTATCAGT

AAAACCAAGGGCCAGCCAAGGGA

GCCACAGGTGTACACACTTCCACC

ATCTAGGGAGGAAATGACAAAGAA

CCAGGTGAGTTTGACCTGTCTCGT

GAAAGGCTTTTATCCCAGTGATAT

AGCCGTGGAATGGGAAAGTAACG

GGCAGCCCGAGAACAACTATAAGA

CCACACCACCCATGCTGGACTCC

GACGGTTCTTTCTTCCTTTATAGCA

AGCTGACAGTGGATAAATCCAGGT

GGCAGCAGGGTAACGTATTCAGTT

GCAGTGTCATGCACGAGGCACTC

CACAACCACTATACTCAGAAAAGT

CTTTCCCTGAGTCCAGGCAAG

SEQ ID
QITLKESGGGLVQPGRS
SEQ ID
CAGATCACCTTGAAGGAGTCTGGG

2372
LRLSCAASGFTFDDYAM
2480
GGAGGCTTGGTACAGCCTGGCAG

HWVRQAPGKGLEWVS

GTCCCTGAGACTCTCCTGTGCAGC

AISGSGGSTYYADSVKG

CTCTGGATTCACCTTTGATGATTAT

RFTISRDNSKNTLYLQM

GCCATGCACTGGGTCCGGCAAGC

NSLRAEDTAVYYCAKDN

TCCAGGGAAGGGGCTGGAGTGGG

DFWSGKVFDYWGQGTL

TCTCAGCTATTAGTGGTAGTGGTG

VTVSSASTKGPSVFPLA

GTAGCACATACTACGCAGACTCCG

PCSRSTSESTAALGCLV

TGAAGGGCCGGTTCACCATCTCCA

KDYFPEPVTVSWNSGA

GAGACAATTCCAAGAACACGCTGT

LTSGVHTFPAVLQSSGL

ATCTGCAAATGAACAGCCTGAGAG

YSLSSVVTVPSSNFGTQ

CCGAGGACACGGCCGTATATTACT

TYTCNVDHKPSNTKVDK

GTGCGAAAGATAACGATTTTTGGA

TVERKCCVECPPCPAP

GTGGGAAAGTCTTTGACTACTGGG

PVAGPSVFLFPPKPKDT

GCCAGGGCACCCTGGTCACCGTC

LMISRTPEVTCVVVDVS

TCCTCAGCAAGCACAAAAGGTCCT

HEDPEVQFNWYVDGVE

TCAGTGTTCCCTCTGGCACCTTGC

VHNAKTKPREEQFNSTF

TCACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
EVQLVQSGGGLVQPGG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2373
SLRLSCAASGFTFSSYS
2481
GGGAGGCTTGGTACAGCCTGGGG

MNWRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SYISSTSSTIYYADSVKG

CCTCTGGATTCACCTTCAGTAGTT

RFTISRDNSKNMLFLQM

ATAGCATGAACTGGGTCCGCCAG

NSLRAEDTAVYYCAKEG

GCTCCAGGGAAGGGGCTGGAGTG

GSGWRHYFDYWGQGT

GGTTTCATACATCAGTAGTACTAG

LVTVSSASTKGPSVFPL

TAGTACCATATACTACGCAGACTC

APCSRSTSESTAALGCL

CGTGAAGGGCCGATTCACCATCTC

VKDYFPEPVTVSWNSG

CAGAGACAATTCCAAGAATATGCT

ALTSGVHTFPAVLQSSG

GTTTCTACAAATGAACAGCCTGAG

LYSLSSVVTVPSSNFGT

AGCTGAGGACACGGCTGTGTATTA

QTYTCNVDHKPSNTKV

CTGTGCGAAAGAAGGGGGCAGTG

DKTVERKCCVECPPCP

GCTGGCGCCACTACTTTGACTACT

APPVAGPSVFLFPPKPK

GGGGCCAGGGAACCCTGGTCACC

DTLMISRTPEVTCVVVD

GTCTCCTCAGCAAGCACAAAAGGT

VSHEDPEVQFNWYVDG

CCTTCAGTGTTCCCTCTGGCACCT

VEVHNAKTKPREEQFN

TGCTCACGCAGCACCTCTGAGAGT

STFRVVSVLTVVHQDWL

ACAGCCGCCCTGGGCTGCCTGGT

NGKEYKCKVSNKGLPA

AAAGGACTACTTTCCCGAACCAGT

PIEKTISKTKGQPREPQV

CACTGTGTCCTGGAATAGCGGGG

YTLPPSREEMTKNQVSL

CCTTGACCTCTGGAGTGCACACAT

TCLVKGFYPSDIAVEWE

TTCCAGCTGTACTGCAGTCATCTG

SNGQPENNYKTTPPML

GACTCTACAGCCTGTCCAGTGTGG

DSDGSFFLYSKLTVDKS

TCACCGTACCTTCCTCCAACTTTG

RWQQGNVFSCSVMHE

GCACTCAAACATATACATGTAACG

ALHNHYTQKSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2374
SLRLSCAASGFTFSSYA
2482
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTGTCCTGTGCA

AVISYDGSNKYYADSVK

GCCTCTGGATTCACCTTCAGCAGC

GRFTISRDNSKNTLYLQ

TATGCTATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

DYCSSTSCQNWFDPW

GGTGGCAGTTATATCATATGATGG

GQGTLVTVSSASTKGPS

AAGTAATAAATACTACGCAGACTC

VFPLAPCSRSTSESTAA

CGTGAAGGGCCGATTCACCATCTC

LGCLVKDYFPEPVTVSW

CAGAGACAATTCCAAGAACACGCT

NSGALTSGVHTFPAVLQ

GTATCTGCAAATGAACAGCCTGAG

SSGLYSLSSVVTVPSSN

AGCTGAGGACACGGCTGTGTATTA

FGTQTYTCNVDHKPSN

CTGTGCGAGAGATTATTGTAGTAG

TKVDKTVERKCCVECPP

TACCAGCTGCCAGAACTGGTTCGA

CPAPPVAGPSVFLFPPK

CCCCTGGGGCCAGGGCACCCTGG

PKDTLMISRTPEVTCVV

TCACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGG

2375
SLRLSCAASGFTFSNYV
2483
GGGAGGCTTGGTACAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SAISGIGDTTYYADSVK

CCTCTGGATTCACCTTTAGCAACT

GRFTISRDNAKNTLYLQ

ATGTCATGAGCTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGGAAGGGGCTGGAGTG

GRVAGDAFDIWGQGTM

GGTCTCAGCTATTAGTGGTATTGG

VTVSSASTKGPSVFPLA

TGATACTACATACTACGCGGACTC

PCSRSTSESTAALGCLV

CGTGAAGGGCCGATTCACCATCTC

KDYFPEPVTVSWNSGA

CAGAGACAACGCCAAGAACACGC

LTSGVHTFPAVLQSSGL

TGTATCTGCAAATGAACAGTCTGA

YSLSSVVTVPSSNFGTQ

GAGCCGAGGACACGGCTGTGTAT

TYTCNVDHKPSNTKVDK

TACTGTGCAAGAGGGCGCGTGGC

TVERKCCVECPPCPAP

GGGGGATGCTTTTGATATCTGGGG

PVAGPSVFLFPPKPKDT

CCAAGGGACAATGGTGACCGTCT

LMISRTPEVTCVVVDVS

CTTCAGCAAGCACAAAAGGTCCTT

HEDPEVQFNWYVDGVE

CAGTGTTCCCTCTGGCACCTTGCT

VHNAKTKPREEQFNSTF

CACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QLQLQESGGGLVQPGG
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGG

2376
SLRLSCAASGFTFSSYA
2484
GGGAGGCTTGGTACAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SAISGSGGSTYYADSVK

CCTCTGGATTCACCTTTAGCAGCT

GRFTISRDNSKNTLYLQ

ATGCCATGAGCTGGGTCCGCCAG

MNSLRAEDTAVYYCAK

GCTCCAGGGAAGGGGCTGGAGTG

DQGAAAGTLGYFDYWG

GGTCTCAGCTATTAGTGGTAGTGG

QGTLVTVSSASTKGPSV

TGGTAGCACATACTACGCAGACTC

FPLAPCSRSTSESTAAL

CGTGAAGGGCCGGTTCACCATCT

GCLVKDYFPEPVTVSW

CCAGAGACAATTCCAAGAACACGC

NSGALTSGVHTFPAVLQ

TGTATCTGCAAATGAACAGCCTGA

SSGLYSLSSVVTVPSSN

GAGCCGAGGACACGGCCGTATAT

FGTQTYTCNVDHKPSN

TACTGTGCGAAAGATCAAGGGGCA

TKVDKTVERKCCVECPP

GCAGCTGGTACCCTGGGGTACTTT

CPAPPVAGPSVFLFPPK

GACTACTGGGGCCAGGGAACCCT

PKDTLMISRTPEVTCVV

GGTGACCGTCTCCTCAGCAAGCA

VDVSHEDPEVQFNWYV

CAAAAGGTCCTTCAGTGTTCCCTC

DGVEVHNAKTKPREEQ

TGGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2377
SVKVSCKASGYTFTSYD
2485
GGCTGAGGTGAAGAAGCCTGGGG

INWRQATGQGLEWMG

CCTCAGTGAAGGTCTCCTGCAAGG

WMNPNSGNTGYAQKF

CTTCTGGATACACCTTCACCAGTT

QGRVTMTRNTSISTAYM

ATGATATCAACTGGGTGCGACAGG

ELSSLRSEDTAVYYCTR

CCACTGGACAAGGGCTTGAGTGG

GIYDSSGSSNPFDSWG

ATGGGATGGATGAACCCTAACAGT

QGTLVTVSSASTKGPSV

GGTAACACAGGCTATGCACAGAAG

FPLAPCSRSTSESTAAL

TTCCAGGGCAGAGTCACCATGACC

GCLVKDYFPEPVTVSW

AGGAACACCTCCATAAGCACAGCC

NSGALTSGVHTFPAVLQ

TACATGGAGCTGAGCAGCCTGAG

SSGLYSLSSVVTVPSSN

ATCTGAGGACACGGCCGTGTATTA

FGTQTYTCNVDHKPSN

CTGTACGAGAGGAATCTATGATAG

TKVDKTVERKCCVECPP

TAGTGGTTCTTCCAATCCCTTTGA

CPAPPVAGPSVFLFPPK

CTCCTGGGGCCAGGGAACCCTGG

PKDTLMISRTPEVTCVV

TGACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2378
SVKISCEASGYTFTDYAI
2486
GGCTGAGGTGAAGAAGCCTGGGG

HWVRQAPGQRLEWMG

CCTCAGTGAAGATTTCCTGCGAGG

WINAGDGGTKSSREFQ

CTTCTGGATACACCTTCACTGATTA

GRVTITRDTSATTAYME

TGCTATACATTGGGTGCGCCAGGC

VSSLRSEDTAVYYCARG

CCCCGGACAAAGACTTGAGTGGAT

YCSGGSCPGTDFDYWG

GGGATGGATCAACGCTGGCGATG

QGTLVTVSSASTKGPSV

GTGGCACAAAAAGTTCACGGGAGT

FPLAPCSRSTSESTAAL

TCCAGGGCAGAGTCACCATTACCA

GCLVKDYFPEPVTVSW

GGGACACATCCGCGACCACAGCC

NSGALTSGVHTFPAVLQ

TACATGGAGGTGAGCAGTCTGAGA

SSGLYSLSSVVTVPSSN

TCTGAAGACACGGCTGTCTATTAC

FGTQTYTCNVDHKPSN

TGTGCGAGAGGATATTGTAGTGGT

TKVDKTVERKCCVECPP

GGTAGCTGCCCAGGAACGGATTTT

CPAPPVAGPSVFLFPPK

GACTACTGGGGCCAGGGAACCCT

PKDTLMISRTPEVTCVV

GGTCACCGTCTCCTCAGCAAGCAC

VDVSHEDPEVQFNWYV

AAAAGGTCCTTCAGTGTTCCCTCT

DGVEVHNAKTKPREEQ

GGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2379
SVKVSCKASGYTFTSYY
2487
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQGLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GIINPSGGSTSYAQKFQ

CATCTGGATACACCTTCACCAGCT

GRVTMTRDTSTSTVYM

ACTATATGCACTGGGTGCGACAGG

ELSSLRSEDTAVYYCAR

CCCCTGGACAAGGGCTTGAGTGG

DGVGGRDGYNFDYWG

ATGGGAATAATCAACCCTAGTGGT

QGTLVTVSSASTKGPSV

GGTAGCACAAGCTACGCACAGAA

FPLAPCSRSTSESTAAL

GTTCCAGGGCAGAGTCACCATGA

GCLVKDYFPEPVTVSW

CCAGGGACACGTCCACGAGCACA

NSGALTSGVHTFPAVLQ

GTCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAGGACACGGCCGTGT

FGTQTYTCNVDHKPSN

ATTACTGTGCGAGAGATGGTGTAG

TKVDKTVERKCCVECPP

GAGGGAGAGATGGCTACAATTTTG

CPAPPVAGPSVFLFPPK

ACTACTGGGGCCAGGGAACCCTG

PKDTLMISRTPEVTCVV

GTCACCGTCTCCTCAGCAAGCACA

VDVSHEDPEVQFNWYV

AAAGGTCCTTCAGTGTTCCCTCTG

DGVEVHNAKTKPREEQ

GCACCTTGCTCACGCAGCACCTCT

FNSTFRVVSVLTVVHQD

GAGAGTACAGCCGCCCTGGGCTG

WLNGKEYKCKVSNKGL

CCTGGTAAAGGACTACTTTCCCGA

PAPIEKTISKTKGQPREP

ACCAGTCACTGTGTCCTGGAATAG

QVYTLPPSREEMTKNQ

CGGGGCCTTGACCTCTGGAGTGC

VSLTCLVKGFYPSDIAVE

ACACATTTCCAGCTGTACTGCAGT

WESNGQPENNYKTTPP

CATCTGGACTCTACAGCCTGTCCA

MLDSDGSFFLYSKLTVD

GTGTGGTCACCGTACCTTCCTCCA

KSRWQQGNVFSCSVM

ACTTTGGCACTCAAACATATACAT

HEALHNHYTQKSLSLSP

GTAACGTGGATCATAAGCCCTCTA

GK

ACACCAAAGTGGATAAAACTGTGG

AGCGTAAGTGTTGTGTCGAGTGTC

CTCCTTGTCCTGCTCCTCCTGTGG

CAGGCCCATCTGTGTTTCTCTTTC

CCCCAAAGCCAAAGGACACTTTGA

TGATATCCCGGACCCCTGAGGTGA

CTTGCGTCGTCGTAGATGTTTCAC

ACGAAGATCCAGAGGTGCAGTTCA

ACTGGTACGTGGATGGCGTGGAA

GTGCATAATGCCAAGACAAAGCCC

CGCGAAGAGCAGTTTAATTCCACC

TTCCGCGTGGTGTCTGTGCTGACC

GTGGTACATCAGGATTGGCTTAAC

GGTAAGGAGTACAAGTGCAAGGT

GAGTAACAAGGGGCTGCCCGCCC

CTATCGAGAAGACTATCAGTAAAA

CCAAGGGCCAGCCAAGGGAGCCA

CAGGTGTACACACTTCCACCATCT

AGGGAGGAAATGACAAAGAACCA

GGTGAGTTTGACCTGTCTCGTGAA

AGGCTTTTATCCCAGTGATATAGC

CGTGGAATGGGAAAGTAACGGGC

AGCCCGAGAACAACTATAAGACCA

CACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGLVQPGG
SEQ ID
GAAGTGCAGCTGGTGCAGTCTGG

2380
SLRLSCAASGFTVSSNY
2488
GGGAGGCTTGGTCCAGCCTGGGG

MSWRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SVIYSGGSTYYADSVKG

CCTCTGGATTCACCGTCAGTAGCA

RFTISRDNSKNTLYLQM

ACTACATGAGCTGGGTCCGCCAG

NSLRAEDTAVYYCARAP

GCTCCAGGGAAGGGGCTGGAGTG

LAADGYFDYWGQGTLV

GGTCTCAGTTATTTATAGCGGTGG

TVSSASTKGPSVFPLAP

TAGCACATACTACGCAGACTCCGT

CSRSTSESTAALGCLVK

GAAGGGCCGATTCACCATCTCCAG

DYFPEPVTVSWNSGAL

AGACAATTCCAAGAACACGCTGTA

TSGVHTFPAVLQSSGLY

TCTTCAAATGAACAGCCTGAGAGC

SLSSVVTVPSSNFGTQT

TGAGGACACGGCTGTGTATTACTG

YTCNVDHKPSNTKVDKT

TGCGAGAGCCCCCCTAGCAGCAG

VERKCCVECPPCPAPP

ATGGCTACTTTGACTACTGGGGCC

VAGPSVFLFPPKPKDTL

AGGGAACCCTGGTCACCGTCTCCT

MISRTPEVTCVVVDVSH

CAGCAAGCACAAAAGGTCCTTCAG

EDPEVQFNWYVDGVEV

TGTTCCCTCTGGCACCTTGCTCAC

HNAKTKPREEQFNSTFR

GCAGCACCTCTGAGAGTACAGCC

VVSVLTVVHQDWLNGK

GCCCTGGGCTGCCTGGTAAAGGA

EYKCKVSNKGLPAPIEK

CTACTTTCCCGAACCAGTCACTGT

TISKTKGQPREPQVYTL

GTCCTGGAATAGCGGGGCCTTGA

PPSREEMTKNQVSLTCL

CCTCTGGAGTGCACACATTTCCAG

VKGFYPSDIAVEWESNG

CTGTACTGCAGTCATCTGGACTCT

QPENNYKTTPPMLDSD

ACAGCCTGTCCAGTGTGGTCACC

GSFFLYSKLTVDKSRW

GTACCTTCCTCCAACTTTGGCACT

QQGNVFSCSVMHEALH

CAAACATATACATGTAACGTGGAT

NHYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
EVQLVQSGAEVKKPGS
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGG

2381
SVKVSCKASGGTFSSYA
2489
GGCTGAGGTGAAGAAGCCTGGGT

ISWVRQAPGQGLEWMG

CCTCGGTGAAGGTCTCCTGCAAG

GIIPIFGTANYAQKFQGR

GCTTCTGGAGGCACCTTCAGCAG

VTITADESTSTAYMELSS

CTATGCTATCAGCTGGGTGCGACA

LRSEDTAVYYCARARGL

GGCCCCTGGACAAGGGCTTGAGT

QYLIWYFDLWGRGTLVT

GGATGGGAGGGATCATCCCTATCT

VSSASTKGPSVFPLAPC

TTGGTACAGCAAACTACGCACAGA

SRSTSESTAALGCLVKD

AGTTCCAGGGCAGAGTCACGATTA

YFPEPVTVSWNSGALTS

CCGCGGACGAATCCACGAGCACA

GVHTFPAVLQSSGLYSL

GCCTACATGGAGCTGAGCAGCCT

SSVVTVPSSNFGTQTYT

GAGATCTGAGGACACGGCCGTGT

CNVDHKPSNTKVDKTV

ATTACTGTGCGAGAGCCCGGGGG

ERKCCVECPPCPAPPV

CTACAGTACCTAATCTGGTACTTC

AGPSVFLFPPKPKDTLM

GATCTCTGGGGCCGTGGCACCCT

ISRTPEVTCVVVDVSHE

GGTGACCGTCTCCTCAGCAAGCA

DPEVQFNWYVDGVEVH

CAAAAGGTCCTTCAGTGTTCCCTC

NAKTKPREEQFNSTFRV

TGGCACCTTGCTCACGCAGCACCT

VSVLTVVHQDWLNGKE

CTGAGAGTACAGCCGCCCTGGGC

YKCKVSNKGLPAPIEKTI

TGCCTGGTAAAGGACTACTTTCCC

SKTKGQPREPQVYTLPP

GAACCAGTCACTGTGTCCTGGAAT

SREEMTKNQVSLTCLVK

AGCGGGGCCTTGACCTCTGGAGT

GFYPSDIAVEWESNGQ

GCACACATTTCCAGCTGTACTGCA

PENNYKTTPPMLDSDG

GTCATCTGGACTCTACAGCCTGTC

SFFLYSKLTVDKSRWQ

CAGTGTGGTCACCGTACCTTCCTC

QGNVFSCSVMHEALHN

CAACTTTGGCACTCAAACATATAC

HYTQKSLSLSPGK

ATGTAACGTGGATCATAAGCCCTC

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTCCAGCTGGTACAGTCTGG

2382
SVKVSCKASGYTFTSYY
2490
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQGLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GIINPSGGSTSYAQKFQ

CATCTGGATACACCTTCACCAGCT

GRVTMTRDTSTSTVYM

ACTATATGCACTGGGTGCGACAGG

ELSSLRSEDTAVYYCAS

CCCCTGGACAAGGGCTTGAGTGG

PGMVRGVITAPLDYWG

ATGGGAATAATCAACCCTAGTGGT

QGTLVTVSSASTKGPSV

GGTAGCACAAGCTACGCACAGAA

FPLAPCSRSTSESTAAL

GTTCCAGGGCAGAGTCACCATGA

GCLVKDYFPEPVTVSW

CCAGGGACACGTCCACGAGCACA

NSGALTSGVHTFPAVLQ

GTCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAGGACACGGCCGTGT

FGTQTYTCNVDHKPSN

ATTACTGTGCGAGCCCGGGTATG

TKVDKTVERKCCVECPP

GTTCGGGGAGTTATTACTGCCCCG

CPAPPVAGPSVFLFPPK

CTTGACTACTGGGGCCAGGGCAC

PKDTLMISRTPEVTCVV

CCTGGTCACCGTCTCCTCAGCAAG

VDVSHEDPEVQFNWYV

CACAAAAGGTCCTTCAGTGTTCCC

DGVEVHNAKTKPREEQ

TCTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGLVKPGG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2383
SLRLSCAASGFTFSSYAI
2491
GGGAGGCCTGGTCAAGCCTGGGG

SWRQAPGQGLEWMG

GGTCCCTGAGACTCTCCTGTGCAG

GIIPMYGTANYAQKFQG

CCTCTGGATTCACCTTCAGCAGCT

RVTITADESTSTAYMEL

ATGCTATCAGCTGGGTGCGACAG

SSLRSEDTALYYCAREA

GCCCCTGGACAAGGGCTTGAGTG

KWGMYYFDYWGQGTL

GATGGGAGGGATCATCCCTATGTA

VTVSSASTKGPSVFPLA

TGGTACAGCAAACTACGCACAGAA

PCSRSTSESTAALGCLV

GTTCCAGGGCAGAGTCACGATTAC

KDYFPEPVTVSWNSGA

CGCGGACGAATCCACGAGCACAG

LTSGVHTFPAVLQSSGL

CCTACATGGAACTGAGCAGCCTGA

YSLSSVVTVPSSNFGTQ

GATCTGAGGACACGGCCCTCTATT

TYTCNVDHKPSNTKVDK

ACTGTGCGAGAGAAGCTAAGTGG

TVERKCCVECPPCPAP

GGAATGTACTACTTTGACTACTGG

PVAGPSVFLFPPKPKDT

GGCCAGGGCACCCTGGTCACCGT

LMISRTPEVTCVVVDVS

CTCCTCAGCAAGCACAAAAGGTCC

HEDPEVQFNWYVDGVE

TTCAGTGTTCCCTCTGGCACCTTG

VHNAKTKPREEQFNSTF

CTCACGCAGCACCTCTGAGAGTAC

RVVSVLTVVHQDWLNG

AGCCGCCCTGGGCTGCCTGGTAA

KEYKCKVSNKGLPAPIE

AGGACTACTTTCCCGAACCAGTCA

KTISKTKGQPREPQVYT

CTGTGTCCTGGAATAGCGGGGCC

LPPSREEMTKNQVSLTC

TTGACCTCTGGAGTGCACACATTT

LVKGFYPSDIAVEWESN

CCAGCTGTACTGCAGTCATCTGGA

GQPENNYKTTPPMLDS

CTCTACAGCCTGTCCAGTGTGGTC

DGSFFLYSKLTVDKSRW

ACCGTACCTTCCTCCAACTTTGGC

QQGNVFSCSVMHEALH

ACTCAAACATATACATGTAACGTG

NHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVESGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGGAGTCCGG

2384
SLRLSCAASGFTFSSYAI
2492
GGGAGGCGTGGTCCAGCCTGGGA

HWVRQAPGKGLEWVAII

GGTCCCTGAGACTCTCCTGTGCAG

SDDGSKSYYADSVQGR

CCTCTGGATTCACCTTCAGTAGCT

FTISRDNSRNTVYLQMN

ATGCTATACACTGGGTCCGCCAGG

SLRAEDTAMYYCARDR

CTCCAGGCAAGGGGCTGGAGTGG

GTKWNQLNDVFDMWG

GTGGCAATTATATCAGATGATGGA

QGTMVTVSSASTKGPS

AGTAAGAGTTACTACGCAGACTCC

VFPLAPCSRSTSESTAA

GTGCAGGGCCGATTCACCATCTCC

LGCLVKDYFPEPVTVSW

AGAGACAATTCGAGGAACACAGTA

NSGALTSGVHTFPAVLQ

TATCTGCAAATGAACAGCCTGAGA

SSGLYSLSSVVTVPSSN

GCTGAGGACACGGCTATGTATTAC

FGTQTYTCNVDHKPSN

TGTGCGAGAGACAGGGGAACTAA

TKVDKTVERKCCVECPP

ATGGAACCAATTGAATGATGTTTTT

CPAPPVAGPSVFLFPPK

GATATGTGGGGCCAAGGGACAAT

PKDTLMISRTPEVTCVV

GGTCACCGTCTCTTCAGCAAGCAC

VDVSHEDPEVQFNWYV

AAAAGGTCCTTCAGTGTTCCCTCT

DGVEVHNAKTKPREEQ

GGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QMQLVQSGAEVKKPGA
SEQ ID
CAGATGCAGCTGGTGCAATCTGG

2385
SVKVSCTASGYTFTSSD
2493
GGCTGAGGTGAAGAAGCCTGGGG

INWVRQATGQGLEWMG

CCTCAGTGAAGGTCTCCTGCACG

WMNPNSGNTGYAEKFQ

GCTTCTGGATACACCTTCACCAGT

GRVTMTSDSSISTAYME

TCTGATATCAACTGGGTGCGACAG

LRSLTTEDTAVYYCARG

GCCACTGGACAAGGGCTTGAGTG

GGASYTDSWGQGTLVT

GATGGGATGGATGAACCCTAACAG

VSSASTKGPSVFPLAPC

TGGTAACACCGGCTATGCAGAGAA

SRSTSESTAALGCLVKD

GTTCCAGGGCAGGGTCACCATGA

YFPEPVTVSWNSGALTS

CCAGCGACTCCTCCATAAGCACCG

GVHTFPAVLQSSGLYSL

CCTACATGGAGTTGAGAAGCCTGA

SSVVTVPSSNFGTQTYT

CCACTGAGGACACGGCCGTATATT

CNVDHKPSNTKVDKTV

ACTGTGCGAGAGGTGGGGGTGCG

ERKCCVECPPCPAPPV

AGCTATACTGACTCCTGGGGCCAG

AGPSVFLFPPKPKDTLM

GGCACCCTGGTCACCGTCTCCTCA

ISRTPEVTCVVVDVSHE

GCAAGCACAAAAGGTCCTTCAGTG

DPEVQFNWYVDGVEVH

TTCCCTCTGGCACCTTGCTCACGC

NAKTKPREEQFNSTFRV

AGCACCTCTGAGAGTACAGCCGC

VSVLTVVHQDWLNGKE

CCTGGGCTGCCTGGTAAAGGACT

YKCKVSNKGLPAPIEKTI

ACTTTCCCGAACCAGTCACTGTGT

SKTKGQPREPQVYTLPP

CCTGGAATAGCGGGGCCTTGACC

SREEMTKNQVSLTCLVK

TCTGGAGTGCACACATTTCCAGCT

GFYPSDIAVEWESNGQ

GTACTGCAGTCATCTGGACTCTAC

PENNYKTTPPMLDSDG

AGCCTGTCCAGTGTGGTCACCGTA

SFFLYSKLTVDKSRWQ

CCTTCCTCCAACTTTGGCACTCAA

QGNVFSCSVMHEALHN

ACATATACATGTAACGTGGATCAT

HYTQKSLSLSPGK

AAGCCCTCTAACACCAAAGTGGAT

AAAACTGTGGAGCGTAAGTGTTGT

GTCGAGTGTCCTCCTTGTCCTGCT

CCTCCTGTGGCAGGCCCATCTGT

GTTTCTCTTTCCCCCAAAGCCAAA

GGACACTTTGATGATATCCCGGAC

CCCTGAGGTGACTTGCGTCGTCGT

AGATGTTTCACACGAAGATCCAGA

GGTGCAGTTCAACTGGTACGTGGA

TGGCGTGGAAGTGCATAATGCCAA

GACAAAGCCCCGCGAAGAGCAGT

TTAATTCCACCTTCCGCGTGGTGT

CTGTGCTGACCGTGGTACATCAGG

ATTGGCTTAACGGTAAGGAGTACA

AGTGCAAGGTGAGTAACAAGGGG

CTGCCCGCCCCTATCGAGAAGACT

ATCAGTAAAACCAAGGGCCAGCCA

AGGGAGCCACAGGTGTACACACTT

CCACCATCTAGGGAGGAAATGACA

AAGAACCAGGTGAGTTTGACCTGT

CTCGTGAAAGGCTTTTATCCCAGT

GATATAGCCGTGGAATGGGAAAGT

AACGGGCAGCCCGAGAACAACTA

TAAGACCACACCACCCATGCTGGA

CTCCGACGGTTCTTTCTTCCTTTAT

AGCAAGCTGACAGTGGATAAATCC

AGGTGGCAGCAGGGTAACGTATT

CAGTTGCAGTGTCATGCACGAGG

CACTCCACAACCACTATACTCAGA

AAAGTCTTTCCCTGAGTCCAGGCA

AG

SEQ ID
QVQLVQSGGGLVQPGR
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGG

2386
SLRLSCTASGFTFGDYA
2494
GGGAGGCTTGGTACAGCCAGGGC

MSWFRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGTTCCGCCAGG

QMNSLKTEDTAVYYCTA

CTCCAGGGAAGGGGCTGGAGTGG

KGGYVGYSYGPFGGY

GTAGGTTTCATTAGAAGCAAAGCT

WGQGTLVTVSSASTKG

TATGGTGGGACAACAGAATACGCC

PSVFPLAPCSRSTSEST

GCGTCTGTGAAAGGCAGATTCACC

AALGCLVKDYFPEPVTV

ATCTCAAGAGATGATTCCAAAAGC

SWNSGALTSGVHTFPA

ATCGCCTATCTGCAAATGAACAGC

VLQSSGLYSLSSVVTVP

CTGAAAACCGAGGACACAGCCGT

SSNFGTQTYTCNVDHK

GTATTACTGTACCGCTAAGGGGGG

PSNTKVDKTVERKCCVE

CTACGTCGGATACAGCTATGGACC

CPPCPAPPVAGPSVFLF

TTTTGGGGGCTACTGGGGCCAGG

PPKPKDTLMISRTPEVT

GAACCCTGGTCACCGTCTCCTCAG

CVVVDVSHEDPEVQFN

CAAGCACAAAAGGTCCTTCAGTGT

WYVDGVEVHNAKTKPR

TCCCTCTGGCACCTTGCTCACGCA

EEQFNSTFRVVSVLTVV

GCACCTCTGAGAGTACAGCCGCC

HQDWLNGKEYKCKVSN

CTGGGCTGCCTGGTAAAGGACTA

KGLPAPIEKTISKTKGQP

CTTTCCCGAACCAGTCACTGTGTC

REPQVYTLPPSREEMTK

CTGGAATAGCGGGGCCTTGACCT

NQVSLTCLVKGFYPSDI

CTGGAGTGCACACATTTCCAGCTG

AVEWESNGQPENNYKT

TACTGCAGTCATCTGGACTCTACA

TPPMLDSDGSFFLYSKL

GCCTGTCCAGTGTGGTCACCGTAC

TVDKSRWQQGNVFSCS

CTTCCTCCAACTTTGGCACTCAAA

VMHEALHNHYTQKSLSL

CATATACATGTAACGTGGATCATA

SPGK

AGCCCTCTAACACCAAAGTGGATA

AAACTGTGGAGCGTAAGTGTTGTG

TCGAGTGTCCTCCTTGTCCTGCTC

CTCCTGTGGCAGGCCCATCTGTGT

TTCTCTTTCCCCCAAAGCCAAAGG

ACACTTTGATGATATCCCGGACCC

CTGAGGTGACTTGCGTCGTCGTAG

ATGTTTCACACGAAGATCCAGAGG

TGCAGTTCAACTGGTACGTGGATG

GCGTGGAAGTGCATAATGCCAAGA

CAAAGCCCCGCGAAGAGCAGTTTA

ATTCCACCTTCCGCGTGGTGTCTG

TGCTGACCGTGGTACATCAGGATT

GGCTTAACGGTAAGGAGTACAAGT

GCAAGGTGAGTAACAAGGGGCTG

CCCGCCCCTATCGAGAAGACTATC

AGTAAAACCAAGGGCCAGCCAAG

GGAGCCACAGGTGTACACACTTCC

ACCATCTAGGGAGGAAATGACAAA

GAACCAGGTGAGTTTGACCTGTCT

CGTGAAAGGCTTTTATCCCAGTGA

TATAGCCGTGGAATGGGAAAGTAA

CGGGCAGCCCGAGAACAACTATA

AGACCACACCACCCATGCTGGACT

CCGACGGTTCTTTCTTCCTTTATAG

CAAGCTGACAGTGGATAAATCCAG

GTGGCAGCAGGGTAACGTATTCA

GTTGCAGTGTCATGCACGAGGCA

CTCCACAACCACTATACTCAGAAA

AGTCTTTCCCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGR
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2387
SLRLSCTASGFTFGDYA
2495
GGGAGGCTTGGTACAGCCAGGGC

MSWFRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGTTCCGCCAGG

QMNSLKTEDTAVYYCT

CTCCAGGGAAGGGGCTGGAGTGG

RGGTMVRGFGFNYWG

GTAGGTTTCATTAGAAGCAAAGCT

QGTLVTVSSASTKGPSV

TATGGTGGGACAACAGAATACGCC

FPLAPCSRSTSESTAAL

GCGTCTGTGAAAGGCAGATTCACC

GCLVKDYFPEPVTVSW

ATCTCAAGAGATGATTCCAAAAGC

NSGALTSGVHTFPAVLQ

ATCGCCTATCTGCAAATGAACAGC

SSGLYSLSSVVTVPSSN

CTGAAAACCGAGGACACAGCCGT

FGTQTYTCNVDHKPSN

GTATTACTGTACTAGAGGGGGGAC

TKVDKTVERKCCVECPP

TATGGTTCGGGGTTTCGGATTTAA

CPAPPVAGPSVFLFPPK

CTACTGGGGCCAGGGAACCCTGG

PKDTLMISRTPEVTCVV

TCACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2388
TLSLTCAVYGGSFSGYY
2496
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARARRA

CCCCCAGGGAAGGGGCTGGAGTG

MIGPLPRLVGYFDLWGR

GATTGGGGAAATCAATCATAGTGG

GTLVTVSSASTKGPSVF

AAGCACCAACTACAACCCGTCCCT

PLAPCSRSTSESTAALG

CAAGAGTCGAGTCACCATATCAGT

CLVKDYFPEPVTVSWN

AGACACGTCCAAGAACCAGTTCTC

SGALTSGVHTFPAVLQS

CCTGAAGCTGAGCTCTGTGACCG

SGLYSLSSVVTVPSSNF

CCGCGGACACGGCTGTGTATTACT

GTQTYTCNVDHKPSNT

GTGCGAGAGCCCGGCGGGCTATG

KVDKTVERKCCVECPP

ATAGGGCCGCTTCCGCGACTTGTC

CPAPPVAGPSVFLFPPK

GGGTACTTCGATCTCTGGGGCCG

PKDTLMISRTPEVTCVV

TGGAACCCTGGTCACCGTCTCCTC

VDVSHEDPEVQFNWYV

AGCAAGCACAAAAGGTCCTTCAGT

DGVEVHNAKTKPREEQ

GTTCCCTCTGGCACCTTGCTCACG

FNSTFRVVSVLTVVHQD

CAGCACCTCTGAGAGTACAGCCG

WLNGKEYKCKVSNKGL

CCCTGGGCTGCCTGGTAAAGGAC

PAPIEKTISKTKGQPREP

TACTTTCCCGAACCAGTCACTGTG

QVYTLPPSREEMTKNQ

TCCTGGAATAGCGGGGCCTTGAC

VSLTCLVKGFYPSDIAVE

CTCTGGAGTGCACACATTTCCAGC

WESNGQPENNYKTTPP

TGTACTGCAGTCATCTGGACTCTA

MLDSDGSFFLYSKLTVD

CAGCCTGTCCAGTGTGGTCACCGT

KSRWQQGNVFSCSVM

ACCTTCCTCCAACTTTGGCACTCA

HEALHNHYTQKSLSLSP

AACATATACATGTAACGTGGATCA

GK

TAAGCCCTCTAACACCAAAGTGGA

TAAAACTGTGGAGCGTAAGTGTTG

TGTCGAGTGTCCTCCTTGTCCTGC

TCCTCCTGTGGCAGGCCCATCTGT

GTTTCTCTTTCCCCCAAAGCCAAA

GGACACTTTGATGATATCCCGGAC

CCCTGAGGTGACTTGCGTCGTCGT

AGATGTTTCACACGAAGATCCAGA

GGTGCAGTTCAACTGGTACGTGGA

TGGCGTGGAAGTGCATAATGCCAA

GACAAAGCCCCGCGAAGAGCAGT

TTAATTCCACCTTCCGCGTGGTGT

CTGTGCTGACCGTGGTACATCAGG

ATTGGCTTAACGGTAAGGAGTACA

AGTGCAAGGTGAGTAACAAGGGG

CTGCCCGCCCCTATCGAGAAGACT

ATCAGTAAAACCAAGGGCCAGCCA

AGGGAGCCACAGGTGTACACACTT

CCACCATCTAGGGAGGAAATGACA

AAGAACCAGGTGAGTTTGACCTGT

CTCGTGAAAGGCTTTTATCCCAGT

GATATAGCCGTGGAATGGGAAAGT

AACGGGCAGCCCGAGAACAACTA

TAAGACCACACCACCCATGCTGGA

CTCCGACGGTTCTTTCTTCCTTTAT

AGCAAGCTGACAGTGGATAAATCC

AGGTGGCAGCAGGGTAACGTATT

CAGTTGCAGTGTCATGCACGAGG

CACTCCACAACCACTATACTCAGA

AAAGTCTTTCCCTGAGTCCAGGCA

AG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2389
TLSLTCAVYGGSFSGYY
2497
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARGRP

CCCCCAGGGAAGGGGCTGGAGTG

APSWVKTRNWFDPWG

GATTGGGGAAATCAATCATAGTGG

QGTLVTVSSASTKGPSV

AAGCACCAACTACAACCCGTCCCT

FPLAPCSRSTSESTAAL

CAAGAGTCGAGTCACCATATCAGT

GCLVKDYFPEPVTVSW

AGACACGTCCAAGAACCAGTTCTC

NSGALTSGVHTFPAVLQ

CCTGAAGCTGAGCTCTGTGACCG

SSGLYSLSSVVTVPSSN

CCGCGGACACGGCTGTGTATTACT

FGTQTYTCNVDHKPSN

GTGCGAGAGGCCGCCCCGCCCCA

TKVDKTVERKCCVECPP

TCCTGGGTTAAAACCCGTAACTGG

CPAPPVAGPSVFLFPPK

TTCGACCCCTGGGGCCAGGGAAC

PKDTLMISRTPEVTCVV

CCTGGTCACCGTCTCCTCAGCAAG

VDVSHEDPEVQFNWYV

CACAAAAGGTCCTTCAGTGTTCCC

DGVEVHNAKTKPREEQ

TCTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2390
TLSLTCAISGDSVSSNS
2498
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCA

GGCAGTCCCCATCGAGAGGCCTT

REASSGWNWGQGTLV

GAGTGGCTGGGAAGGACATACTA

TVSSASTKGPSVFPLAP

CAGGTCCAAGTGGTATAATGATTA

CSRSTSESTAALGCLVK

TGCAGTATCTGTGAAAAGTCGAAT

DYFPEPVTVSWNSGAL

AACCATCAACCCAGACACATCCAA

TSGVHTFPAVLQSSGLY

GAACCAGTTCTCCCTGCAGCTGAA

SLSSVVTVPSSNFGTQT

CTCTGTGACTCCCGAGGACACGG

YTCNVDHKPSNTKVDKT

CTGTGTATTACTGTGCAAGAGAGG

VERKCCVECPPCPAPP

CTAGCAGTGGCTGGAACTGGGGC

VAGPSVFLFPPKPKDTL

CAGGGAACCCTGGTCACCGTCTC

MISRTPEVTCVVVDVSH

CTCAGCAAGCACAAAAGGTCCTTC

EDPEVQFNWYVDGVEV

AGTGTTCCCTCTGGCACCTTGCTC

HNAKTKPREEQFNSTFR

ACGCAGCACCTCTGAGAGTACAG

VVSVLTVVHQDWLNGK

CCGCCCTGGGCTGCCTGGTAAAG

EYKCKVSNKGLPAPIEK

GACTACTTTCCCGAACCAGTCACT

TISKTKGQPREPQVYTL

GTGTCCTGGAATAGCGGGGCCTT

PPSREEMTKNQVSLTCL

GACCTCTGGAGTGCACACATTTCC

VKGFYPSDIAVEWESNG

AGCTGTACTGCAGTCATCTGGACT

QPENNYKTTPPMLDSD

CTACAGCCTGTCCAGTGTGGTCAC

GSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVQLQESGPGLVKPSQ
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGG

2391
TLSLTCAISGDSVSSNN
2499
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTFYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRLTVNPDTSKNQF

ACAATGCTGCTTGGAACTGGATCA

SLRLNSVSPEDTAVYYC

GGCAGTCCCCATCGAGAGGCCTT

ARGGRYTKGGYFDDW

GAGTGGCTGGGAAGGACATTCTA

GQGTLVTVSSASTKGPS

CAGGTCCAAGTGGTATAATGACTA

VFPLAPCSRSTSESTAA

TGCAGTTTCTGTGAAAAGTCGACT

LGCLVKDYFPEPVTVSW

AACCGTCAACCCAGACACATCCAA

NSGALTSGVHTFPAVLQ

GAACCAGTTCTCCCTGCGGTTGAA

SSGLYSLSSVVTVPSSN

CTCTGTGAGTCCCGAGGACACGG

FGTQTYTCNVDHKPSN

CTGTGTATTACTGTGCAAGAGGGG

TKVDKTVERKCCVECPP

GAAGATATACCAAGGGAGGGTACT

CPAPPVAGPSVFLFPPK

TTGACGACTGGGGCCAGGGAACC

PKDTLMISRTPEVTCVV

CTGGTGACCGTCTCCTCAGCAAGC

VDVSHEDPEVQFNWYV

ACAAAAGGTCCTTCAGTGTTCCCT

DGVEVHNAKTKPREEQ

CTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGPTLVKPTQT
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGT

2392
LTLTCTFSGFSLSTSGV
2500
CCTACGCTGGTGAAACCCACACAG

GVGWIRQPPGKALEWL

ACCCTCACGCTGACCTGCACCTTC

ALIYWDDDKRYSPSLKS

TCTGGGTTCTCACTCAGCACTAGT

RLTITKDTSKNQVVLTM

GGAGTGGGTGTGGGCTGGATCCG

TNMDPVDTATYYCAHR

TCAGCCCCCAGGAAAGGCCCTGG

LDSSGRGGYFDYWGQ

AGTGGCTTGCACTCATTTATTGGG

GTLVTVSSASTKGPSVF

ATGATGATAAGCGCTACAGCCCAT

PLAPCSRSTSESTAALG

CTCTGAAGAGCAGGCTCACCATCA

CLVKDYFPEPVTVSWN

CCAAGGACACCTCCAAAAACCAGG

SGALTSGVHTFPAVLQS

TGGTCCTTACAATGACCAACATGG

SGLYSLSSVVTVPSSNF

ACCCTGTGGACACAGCCACATATT

GTQTYTCNVDHKPSNT

ACTGTGCACACAGATTGGATAGCA

KVDKTVERKCCVECPP

GTGGCCGTGGTGGTTACTTTGACT

CPAPPVAGPSVFLFPPK

ACTGGGGCCAGGGCACCCTGGTC

PKDTLMISRTPEVTCVV

ACCGTCTCCTCAGCAAGCACAAAA

VDVSHEDPEVQFNWYV

GGTCCTTCAGTGTTCCCTCTGGCA

DGVEVHNAKTKPREEQ

CCTTGCTCACGCAGCACCTCTGAG

FNSTFRVVSVLTVVHQD

AGTACAGCCGCCCTGGGCTGCCT

WLNGKEYKCKVSNKGL

GGTAAAGGACTACTTTCCCGAACC

PAPIEKTISKTKGQPREP

AGTCACTGTGTCCTGGAATAGCGG

QVYTLPPSREEMTKNQ

GGCCTTGACCTCTGGAGTGCACA

VSLTCLVKGFYPSDIAVE

CATTTCCAGCTGTACTGCAGTCAT

WESNGQPENNYKTTPP

CTGGACTCTACAGCCTGTCCAGTG

MLDSDGSFFLYSKLTVD

TGGTCACCGTACCTTCCTCCAACT

KSRWQQGNVFSCSVM

TTGGCACTCAAACATATACATGTAA

HEALHNHYTQKSLSLSP

CGTGGATCATAAGCCCTCTAACAC

GK

CAAAGTGGATAAAACTGTGGAGCG

TAAGTGTTGTGTCGAGTGTCCTCC

TTGTCCTGCTCCTCCTGTGGCAGG

CCCATCTGTGTTTCTCTTTCCCCC

AAAGCCAAAGGACACTTTGATGAT

ATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVESGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGGAGTCTGG

2393
SLRLSCTASGFTFSSYG
2501
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAK

GCTCCAGGCAAGGGGCTGGAGTG

ELVGTSSPYYYYYYGM

GGTGGCAGTTATATCATATGATGG

DVWGQGTMVTVSSAST

AAGTAATAAATACTATGCAGACTC

KGPSVFPLAPCSRSTSE

CGTGAAGGGCCGATTCACCATCTC

STAALGCLVKDYFPEPV

CAGAGACAATTCCAAGAACACGCT

TVSWNSGALTSGVHTF

GTATCTGCAAATGAACAGCCTGAG

PAVLQSSGLYSLSSVVT

AGCTGAGGACACGGCTGTGTATTA

VPSSNFGTQTYTCNVD

CTGTGCGAAAGAGTTGGTGGGTA

HKPSNTKVDKTVERKC

CCAGCTCTCCTTATTACTACTACTA

CVECPPCPAPPVAGPS

CTACGGTATGGACGTCTGGGGCC

VFLFPPKPKDTLMISRTP

AAGGGACAATGGTCACCGTCTCTT

EVTCVVVDVSHEDPEV

CAGCAAGCACAAAAGGTCCTTCAG

QFNWYVDGVEVHNAKT

TGTTCCCTCTGGCACCTTGCTCAC

KPREEQFNSTFRVVSVL

GCAGCACCTCTGAGAGTACAGCC

TVVHQDWLNGKEYKCK

GCCCTGGGCTGCCTGGTAAAGGA

VSNKGLPAPIEKTISKTK

CTACTTTCCCGAACCAGTCACTGT

GQPREPQVYTLPPSRE

GTCCTGGAATAGCGGGGCCTTGA

EMTKNQVSLTCLVKGFY

CCTCTGGAGTGCACACATTTCCAG

PSDIAVEWESNGQPEN

CTGTACTGCAGTCATCTGGACTCT

NYKTTPPMLDSDGSFFL

ACAGCCTGTCCAGTGTGGTCACC

YSKLTVDKSRWQQGNV

GTACCTTCCTCCAACTTTGGCACT

FSCSVMHEALHNHYTQ

CAAACATATACATGTAACGTGGAT

KSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QLQLQESGGGLVQPGG
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGG

2394
SLRLSCAASGFTVSSNY
2502
GGGAGGCTTGGTCCAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SVIYSGGSTYYADSVKG

CCTCTGGATTCACCGTCAGTAGCA

RFTISRDNSKNTLYLQM

ACTACATGAGCTGGGTCCGCCAG

NSLRAEDTAVYYCARDY

GCTCCAGGGAAGGGGCTGGAGTG

YYGSGSSPWGQGTLVT

GGTCTCAGTTATTTATAGCGGTGG

VSSASTKGPSVFPLAPC

TAGCACATACTACGCAGACTCCGT

SRSTSESTAALGCLVKD

GAAGGGCAGATTCACCATCTCCAG

YFPEPVTVSWNSGALTS

AGACAATTCCAAGAACACGCTGTA

GVHTFPAVLQSSGLYSL

TCTTCAAATGAACAGCCTGAGAGC

SSVVTVPSSNFGTQTYT

CGAGGACACGGCTGTGTATTACTG

CNVDHKPSNTKVDKTV

TGCGAGAGACTATTACTATGGTTC

ERKCCVECPPCPAPPV

GGGGAGTTCTCCCTGGGGCCAGG

AGPSVFLFPPKPKDTLM

GAACCCTGGTCACCGTCTCCTCAG

ISRTPEVTCVVVDVSHE

CAAGCACAAAAGGTCCTTCAGTGT

DPEVQFNWYVDGVEVH

TCCCTCTGGCACCTTGCTCACGCA

NAKTKPREEQFNSTFRV

GCACCTCTGAGAGTACAGCCGCC

VSVLTVVHQDWLNGKE

CTGGGCTGCCTGGTAAAGGACTA

YKCKVSNKGLPAPIEKTI

CTTTCCCGAACCAGTCACTGTGTC

SKTKGQPREPQVYTLPP

CTGGAATAGCGGGGCCTTGACCT

SREEMTKNQVSLTCLVK

CTGGAGTGCACACATTTCCAGCTG

GFYPSDIAVEWESNGQ

TACTGCAGTCATCTGGACTCTACA

PENNYKTTPPMLDSDG

GCCTGTCCAGTGTGGTCACCGTAC

SFFLYSKLTVDKSRWQ

CTTCCTCCAACTTTGGCACTCAAA

QGNVFSCSVMHEALHN

CATATACATGTAACGTGGATCATA

HYTQKSLSLSPGK

AGCCCTCTAACACCAAAGTGGATA

AAACTGTGGAGCGTAAGTGTTGTG

TCGAGTGTCCTCCTTGTCCTGCTC

CTCCTGTGGCAGGCCCATCTGTGT

TTCTCTTTCCCCCAAAGCCAAAGG

ACACTTTGATGATATCCCGGACCC

CTGAGGTGACTTGCGTCGTCGTAG

ATGTTTCACACGAAGATCCAGAGG

TGCAGTTCAACTGGTACGTGGATG

GCGTGGAAGTGCATAATGCCAAGA

CAAAGCCCCGCGAAGAGCAGTTTA

ATTCCACCTTCCGCGTGGTGTCTG

TGCTGACCGTGGTACATCAGGATT

GGCTTAACGGTAAGGAGTACAAGT

GCAAGGTGAGTAACAAGGGGCTG

CCCGCCCCTATCGAGAAGACTATC

AGTAAAACCAAGGGCCAGCCAAG

GGAGCCACAGGTGTACACACTTCC

ACCATCTAGGGAGGAAATGACAAA

GAACCAGGTGAGTTTGACCTGTCT

CGTGAAAGGCTTTTATCCCAGTGA

TATAGCCGTGGAATGGGAAAGTAA

CGGGCAGCCCGAGAACAACTATA

AGACCACACCACCCATGCTGGACT

CCGACGGTTCTTTCTTCCTTTATAG

CAAGCTGACAGTGGATAAATCCAG

GTGGCAGCAGGGTAACGTATTCA

GTTGCAGTGTCATGCACGAGGCA

CTCCACAACCACTATACTCAGAAA

AGTCTTTCCCTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2395
TLSLTCAVYGGSFSGYY
2503
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARGRP

CCCCCAGGGAAGGGGCTGGAGTG

YCSSTSCYPEWFDPWG

GATTGGGGAAATCAATCATAGTGG

QGTLVTVSSASTKGPSV

AAGCACCAACTACAACCCGTCCCT

FPLAPCSRSTSESTAAL

CAAGAGTCGAGTCACCATATCAGT

GCLVKDYFPEPVTVSW

AGACACGTCCAAGAACCAGTTCTC

NSGALTSGVHTFPAVLQ

CCTGAAGCTGAGCTCTGTGACCG

SSGLYSLSSVVTVPSSN

CCGCGGACACGGCTGTGTATTACT

FGTQTYTCNVDHKPSN

GTGCGAGAGGCCGGCCATATTGT

TKVDKTVERKCCVECPP

AGTAGTACCAGCTGCTACCCAGAG

CPAPPVAGPSVFLFPPK

TGGTTCGACCCCTGGGGCCAGGG

PKDTLMISRTPEVTCVV

AACCCTGGTCACCGTCTCCTCAGC

VDVSHEDPEVQFNWYV

AAGCACAAAAGGTCCTTCAGTGTT

DGVEVHNAKTKPREEQ

CCCTCTGGCACCTTGCTCACGCAG

FNSTFRVVSVLTVVHQD

CACCTCTGAGAGTACAGCCGCCCT

WLNGKEYKCKVSNKGL

GGGCTGCCTGGTAAAGGACTACTT

PAPIEKTISKTKGQPREP

TCCCGAACCAGTCACTGTGTCCTG

QVYTLPPSREEMTKNQ

GAATAGCGGGGCCTTGACCTCTG

VSLTCLVKGFYPSDIAVE

GAGTGCACACATTTCCAGCTGTAC

WESNGQPENNYKTTPP

TGCAGTCATCTGGACTCTACAGCC

MLDSDGSFFLYSKLTVD

TGTCCAGTGTGGTCACCGTACCTT

KSRWQQGNVFSCSVM

CCTCCAACTTTGGCACTCAAACAT

HEALHNHYTQKSLSLSP

ATACATGTAACGTGGATCATAAGC

GK

CCTCTAACACCAAAGTGGATAAAA

CTGTGGAGCGTAAGTGTTGTGTCG

AGTGTCCTCCTTGTCCTGCTCCTC

CTGTGGCAGGCCCATCTGTGTTTC

TCTTTCCCCCAAAGCCAAAGGACA

CTTTGATGATATCCCGGACCCCTG

AGGTGACTTGCGTCGTCGTAGATG

TTTCACACGAAGATCCAGAGGTGC

AGTTCAACTGGTACGTGGATGGCG

TGGAAGTGCATAATGCCAAGACAA

AGCCCCGCGAAGAGCAGTTTAATT

CCACCTTCCGCGTGGTGTCTGTGC

TGACCGTGGTACATCAGGATTGGC

TTAACGGTAAGGAGTACAAGTGCA

AGGTGAGTAACAAGGGGCTGCCC

GCCCCTATCGAGAAGACTATCAGT

AAAACCAAGGGCCAGCCAAGGGA

GCCACAGGTGTACACACTTCCACC

ATCTAGGGAGGAAATGACAAAGAA

CCAGGTGAGTTTGACCTGTCTCGT

GAAAGGCTTTTATCCCAGTGATAT

AGCCGTGGAATGGGAAAGTAACG

GGCAGCCCGAGAACAACTATAAGA

CCACACCACCCATGCTGGACTCC

GACGGTTCTTTCTTCCTTTATAGCA

AGCTGACAGTGGATAAATCCAGGT

GGCAGCAGGGTAACGTATTCAGTT

GCAGTGTCATGCACGAGGCACTC

CACAACCACTATACTCAGAAAAGT

CTTTCCCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2396
SLRLSCAASGFTFSSYG
2504
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAKL

GCTCCAGGCAAGGGGCTGGAGTG

RGIDYYDSSGYQRGFD

GGTGGCAGTTATATCATATGATGG

YWGQGTLVTVSSASTK

AAGTAATAAATACTATGCAGACTC

GPSVFPLAPCSRSTSES

CGTGAAGGGCCGATTCACCATCTC

TAALGCLVKDYFPEPVT

CAGAGACAATTCCAAGAACACGCT

VSWNSGALTSGVHTFP

GTATCTGCAAATGAACAGCCTGAG

AVLQSSGLYSLSSVVTV

AGCTGAGGACACGGCTGTGTATTA

PSSNFGTQTYTCNVDH

CTGTGCGAAATTAAGGGGTATAGA

KPSNTKVDKTVERKCCV

TTACTATGATAGTAGTGGTTACCAA

ECPPCPAPPVAGPSVFL

CGGGGGTTTGACTACTGGGGCCA

FPPKPKDTLMISRTPEV

GGGAACCCTGGTCACCGTCTCCT

TCVVVDVSHEDPEVQF

CAGCAAGCACAAAAGGTCCTTCAG

NWYVDGVEVHNAKTKP

TGTTCCCTCTGGCACCTTGCTCAC

REEQFNSTFRVVSVLTV

GCAGCACCTCTGAGAGTACAGCC

VHQDWLNGKEYKCKVS

GCCCTGGGCTGCCTGGTAAAGGA

NKGLPAPIEKTISKTKGQ

CTACTTTCCCGAACCAGTCACTGT

PREPQVYTLPPSREEMT

GTCCTGGAATAGCGGGGCCTTGA

KNQVSLTCLVKGFYPSD

CCTCTGGAGTGCACACATTTCCAG

IAVEWESNGQPENNYK

CTGTACTGCAGTCATCTGGACTCT

TTPPMLDSDGSFFLYSK

ACAGCCTGTCCAGTGTGGTCACC

LTVDKSRWQQGNVFSC

GTACCTTCCTCCAACTTTGGCACT

SVMHEALHNHYTQKSL

CAAACATATACATGTAACGTGGAT

SLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QVQLQESGPGLVKPSE
SEQ ID
CAGGTGCAGCTGCAGGAGTCCGG

2397
TLSLTCTVSGGSISSYY
2505
CCCAGGACTGGTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCACTG

YIYYTGSTNYNPSLKSR

TCTCTGGTGGCTCCATCAGTAGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGGCAG

VTTADTAVYYCARGGR

CCCCCAGGGAAGGGACTGGAGTG

GDGAAFDIWGQGTMVT

GATTGGCTATATCTATTACACTGG

VSSASTKGPSVFPLAPC

GAGCACCAACTACAACCCCTCCCT

SRSTSESTAALGCLVKD

CAAGAGCCGAGTCACCATATCAGT

YFPEPVTVSWNSGALTS

AGACACGTCCAAGAACCAGTTCTC

GVHTFPAVLQSSGLYSL

CCTGAAGCTGAGCTCTGTGACCAC

SSVVTVPSSNFGTQTYT

TGCGGACACGGCCGTGTATTACTG

CNVDHKPSNTKVDKTV

TGCGAGAGGTGGGAGGGGGGATG

ERKCCVECPPCPAPPV

GGGCCGCTTTTGACATCTGGGGC

AGPSVFLFPPKPKDTLM

CAAGGGACAATGGTCACCGTCTCT

ISRTPEVTCVVVDVSHE

TCAGCAAGCACAAAAGGTCCTTCA

DPEVQFNWYVDGVEVH

GTGTTCCCTCTGGCACCTTGCTCA

NAKTKPREEQFNSTFRV

CGCAGCACCTCTGAGAGTACAGC

VSVLTVVHQDWLNGKE

CGCCCTGGGCTGCCTGGTAAAGG

YKCKVSNKGLPAPIEKTI

ACTACTTTCCCGAACCAGTCACTG

SKTKGQPREPQVYTLPP

TGTCCTGGAATAGCGGGGCCTTG

SREEMTKNQVSLTCLVK

ACCTCTGGAGTGCACACATTTCCA

GFYPSDIAVEWESNGQ

GCTGTACTGCAGTCATCTGGACTC

PENNYKTTPPMLDSDG

TACAGCCTGTCCAGTGTGGTCACC

SFFLYSKLTVDKSRWQ

GTACCTTCCTCCAACTTTGGCACT

QGNVFSCSVMHEALHN

CAAACATATACATGTAACGTGGAT

HYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QVQLVQSGGGVVQPGR
SEQ ID
CAGGTGCAGCTGGTGCAATCTGG

2398
SLRLSCAASGFTFSSSA
2506
GGGAGGCGTGGTCCAGCCTGGGA

AMIWHDESKKYYADSV

GGTCCCTGAGACTCTCCTGTGCAG

KGRFTISRDNSKNTLYL

CGTCTGGATTCACCTTCAGCAGCT

QMNSLRAEDTAVYYCA

CTGCCATGCACTGGGTCCGCCAG

RPPDGGNSGRWYFDL

GCTCCAGGCAAGGGACTGGAGTG

WGRGTLVTVSSASTKG

GGTGGCAATGATTTGGCATGATGA

PSVFPLAPCSRSTSEST

GAGTAAGAAATACTATGCAGACTC

AALGCLVKDYFPEPVTV

CGTGAAGGGCCGATTCACTATCTC

SWNSGALTSGVHTFPA

CAGAGACAATTCCAAGAACACGCT

VLQSSGLYSLSSVVTVP

GTATCTGCAAATGAACAGCCTGAG

SSNFGTQTYTCNVDHK

AGCTGAGGACACGGCTGTGTATTA

PSNTKVDKTVERKCCVE

CTGTGCGAGACCCCCCGACGGTG

CPPCPAPPVAGPSVFLF

GTAACTCCGGTCGCTGGTACTTCG

PPKPKDTLMISRTPEVT

ATCTCTGGGGCCGTGGCACCCTG

CVVVDVSHEDPEVQFN

GTCACCGTCTCCTCAGCAAGCACA

WYVDGVEVHNAKTKPR

AAAGGTCCTTCAGTGTTCCCTCTG

EEQFNSTFRVVSVLTVV

GCACCTTGCTCACGCAGCACCTCT

HQDWLNGKEYKCKVSN

GAGAGTACAGCCGCCCTGGGCTG

KGLPAPIEKTISKTKGQP

CCTGGTAAAGGACTACTTTCCCGA

REPQVYTLPPSREEMTK

ACCAGTCACTGTGTCCTGGAATAG

NQVSLTCLVKGFYPSDI

CGGGGCCTTGACCTCTGGAGTGC

AVEWESNGQPENNYKT

ACACATTTCCAGCTGTACTGCAGT

TPPMLDSDGSFFLYSKL

CATCTGGACTCTACAGCCTGTCCA

TVDKSRWQQGNVFSCS

GTGTGGTCACCGTACCTTCCTCCA

VMHEALHNHYTQKSLSL

ACTTTGGCACTCAAACATATACAT

SPGK

GTAACGTGGATCATAAGCCCTCTA

ACACCAAAGTGGATAAAACTGTGG

AGCGTAAGTGTTGTGTCGAGTGTC

CTCCTTGTCCTGCTCCTCCTGTGG

CAGGCCCATCTGTGTTTCTCTTTC

CCCCAAAGCCAAAGGACACTTTGA

TGATATCCCGGACCCCTGAGGTGA

CTTGCGTCGTCGTAGATGTTTCAC

ACGAAGATCCAGAGGTGCAGTTCA

ACTGGTACGTGGATGGCGTGGAA

GTGCATAATGCCAAGACAAAGCCC

CGCGAAGAGCAGTTTAATTCCACC

TTCCGCGTGGTGTCTGTGCTGACC

GTGGTACATCAGGATTGGCTTAAC

GGTAAGGAGTACAAGTGCAAGGT

GAGTAACAAGGGGCTGCCCGCCC

CTATCGAGAAGACTATCAGTAAAA

CCAAGGGCCAGCCAAGGGAGCCA

CAGGTGTACACACTTCCACCATCT

AGGGAGGAAATGACAAAGAACCA

GGTGAGTTTGACCTGTCTCGTGAA

AGGCTTTTATCCCAGTGATATAGC

CGTGGAATGGGAAAGTAACGGGC

AGCCCGAGAACAACTATAAGACCA

CACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QMQLVQSGGGLVQPG
SEQ ID
CAGATGCAGCTGGTGCAATCTGG

2399
GSLRLSCAASGFTFSSY
2507
GGGAGGCTTGGTACAGCCTGGGG

AMSWVRQAPGKGLEW

GGTCCCTGAGACTCTCCTGTGCAG

VSAISGSGGSTYYADSV

CCTCTGGATTCACCTTTAGCAGCT

KGRFTISRDNSKNTLYL

ATGCCATGAGCTGGGTCCGCCAG

QMNSLRAEDTAVYYCA

GCTCCAGGGAAGGGGCTGGAGTG

KDKNVRKHDYGDHPYG

GGTCTCAGCTATTAGTGGTAGTGG

GYFDYWGQGTLVTVSS

TGGTAGCACATACTACGCAGACTC

ASTKGPSVFPLAPCSRS

CGTGAAGGGCCGGTTCACCATCT

TSESTAALGCLVKDYFP

CCAGAGACAATTCCAAGAACACGC

EPVTVSWNSGALTSGV

TGTATCTGCAAATGAACAGCCTGA

HTFPAVLQSSGLYSLSS

GAGCCGAGGACACGGCCGTATAT

VVTVPSSNFGTQTYTCN

TACTGTGCGAAAGACAAGAACGTC

VDHKPSNTKVDKTVERK

CGAAAACATGACTACGGTGACCAC

CCVECPPCPAPPVAGP

CCCTACGGGGGGTACTTTGACTAC

SVFLFPPKPKDTLMISRT

TGGGGCCAGGGCACCCTGGTGAC

PEVTCVVVDVSHEDPEV

CGTCTCCTCAGCAAGCACAAAAGG

QFNWYVDGVEVHNAKT

TCCTTCAGTGTTCCCTCTGGCACC

KPREEQFNSTFRVVSVL

TTGCTCACGCAGCACCTCTGAGAG

TVVHQDWLNGKEYKCK

TACAGCCGCCCTGGGCTGCCTGG

VSNKGLPAPIEKTISKTK

TAAAGGACTACTTTCCCGAACCAG

GQPREPQVYTLPPSRE

TCACTGTGTCCTGGAATAGCGGG

EMTKNQVSLTCLVKGFY

GCCTTGACCTCTGGAGTGCACACA

PSDIAVEWESNGQPEN

TTTCCAGCTGTACTGCAGTCATCT

NYKTTPPMLDSDGSFFL

GGACTCTACAGCCTGTCCAGTGTG

YSKLTVDKSRWQQGNV

GTCACCGTACCTTCCTCCAACTTT

FSCSVMHEALHNHYTQ

GGCACTCAAACATATACATGTAAC

KSLSLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2400
SVKVSCKASGYTFTSYA
2508
GGCTGAGGTGAAGAAGCCTGGGG

MHWRQAPGQRLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSQKF

CTTCTGGATACACCTTCACTAGCT

QGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAR

GCCCCCGGACAAAGGCTTGAGTG

VAGATSLWYWGQGTLV

GATGGGATGGATCAACGCTGGCA

TVSSASTKGPSVFPLAP

ATGGTAACACAAAATATTCACAGA

CSRSTSESTAALGCLVK

AGTTCCAGGGCAGAGTCACCATTA

DYFPEPVTVSWNSGAL

CCAGGGACACATCCGCGAGCACA

TSGVHTFPAVLQSSGLY

GCCTACATGGAGCTGAGCAGCCT

SLSSVVTVPSSNFGTQT

GAGATCTGAAGACACGGCTGTGTA

YTCNVDHKPSNTKVDKT

TTACTGTGCGAGAGTGGCGGGAG

VERKCCVECPPCPAPP

CTACTTCCCTATGGTACTGGGGCC

VAGPSVFLFPPKPKDTL

AGGGCACCCTGGTCACCGTCTCC

MISRTPEVTCVVVDVSH

TCAGCAAGCACAAAAGGTCCTTCA

EDPEVQFNWYVDGVEV

GTGTTCCCTCTGGCACCTTGCTCA

HNAKTKPREEQFNSTFR

CGCAGCACCTCTGAGAGTACAGC

VVSVLTVVHQDWLNGK

CGCCCTGGGCTGCCTGGTAAAGG

EYKCKVSNKGLPAPIEK

ACTACTTTCCCGAACCAGTCACTG

TISKTKGQPREPQVYTL

TGTCCTGGAATAGCGGGGCCTTG

PPSREEMTKNQVSLTCL

ACCTCTGGAGTGCACACATTTCCA

VKGFYPSDIAVEWESNG

GCTGTACTGCAGTCATCTGGACTC

QPENNYKTTPPMLDSD

TACAGCCTGTCCAGTGTGGTCACC

GSFFLYSKLTVDKSRW

GTACCTTCCTCCAACTTTGGCACT

QQGNVFSCSVMHEALH

CAAACATATACATGTAACGTGGAT

NHYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2401
SLSLTCAISGDSVSSNS
2509
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGAGCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITIKPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCT

GGCAGTCCCCATCGAGAGGCCTT

RLANSDGVDVWGQGT

GAGTGGCTGGGAAGGACATACTA

MVTVSSASTKGPSVFPL

CAGGTCCAAGTGGTATAATGATTA

APCSRSTSESTAALGCL

TGCAGTATCTGTGAAGAGTCGAAT

VKDYFPEPVTVSWNSG

AACCATCAAACCAGACACATCCAA

ALTSGVHTFPAVLQSSG

GAACCAGTTCTCCCTGCAGCTGAA

LYSLSSVVTVPSSNFGT

CTCTGTGACTCCCGAGGACACGG

QTYTCNVDHKPSNTKV

CTGTGTATTACTGTACAAGGCTAG

DKTVERKCCVECPPCP

CTAATTCCGACGGTGTGGACGTCT

APPVAGPSVFLFPPKPK

GGGGCCAAGGGACAATGGTCACC

DTLMISRTPEVTCVVVD

GTCTCCTCAGCAAGCACAAAAGGT

VSHEDPEVQFNWYVDG

CCTTCAGTGTTCCCTCTGGCACCT

VEVHNAKTKPREEQFN

TGCTCACGCAGCACCTCTGAGAGT

STFRVVSVLTVVHQDWL

ACAGCCGCCCTGGGCTGCCTGGT

NGKEYKCKVSNKGLPA

AAAGGACTACTTTCCCGAACCAGT

PIEKTISKTKGQPREPQV

CACTGTGTCCTGGAATAGCGGGG

YTLPPSREEMTKNQVSL

CCTTGACCTCTGGAGTGCACACAT

TCLVKGFYPSDIAVEWE

TTCCAGCTGTACTGCAGTCATCTG

SNGQPENNYKTTPPML

GACTCTACAGCCTGTCCAGTGTGG

DSDGSFFLYSKLTVDKS

TCACCGTACCTTCCTCCAACTTTG

RWQQGNVFSCSVMHE

GCACTCAAACATATACATGTAACG

ALHNHYTQKSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2402
TLSLTCAISGDSVSSDS
2510
TCCAGGACTGGTGAAGCCCTCGC

AVWTWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYKSKWYNDYAA

TCTCCGGGGACAGTGTCTCTAGC

SVKSRITINPDTSKNQFS

GACAGTGCTGTTTGGACCTGGATC

LHLNSVTPEDTAVYYCA

AGGCAGTCCCCATCGAGAGGCCT

RGVTRTFDYWGQGTTV

TGAGTGGCTGGGAAGGACATACTA

TVSSASTKGPSVFPLAP

CAAGTCGAAGTGGTATAATGATTA

CSRSTSESTAALGCLVK

TGCAGCATCTGTGAAAAGTCGAAT

DYFPEPVTVSWNSGAL

AACCATCAACCCAGACACATCCAA

TSGVHTFPAVLQSSGLY

GAACCAGTTCTCCCTGCACCTGAA

SLSSVVTVPSSNFGTQT

CTCTGTGACTCCCGAGGACACGG

YTCNVDHKPSNTKVDKT

CTGTGTATTACTGTGCAAGAGGTG

VERKCCVECPPCPAPP

TAACCCGGACCTTTGACTACTGGG

VAGPSVFLFPPKPKDTL

GCCAGGGGACCACGGTCACCGTC

MISRTPEVTCVVVDVSH

TCCTCAGCAAGCACAAAAGGTCCT

EDPEVQFNWYVDGVEV

TCAGTGTTCCCTCTGGCACCTTGC

HNAKTKPREEQFNSTFR

TCACGCAGCACCTCTGAGAGTACA

VVSVLTVVHQDWLNGK

GCCGCCCTGGGCTGCCTGGTAAA

EYKCKVSNKGLPAPIEK

GGACTACTTTCCCGAACCAGTCAC

TISKTKGQPREPQVYTL

TGTGTCCTGGAATAGCGGGGCCTT

PPSREEMTKNQVSLTCL

GACCTCTGGAGTGCACACATTTCC

VKGFYPSDIAVEWESNG

AGCTGTACTGCAGTCATCTGGACT

QPENNYKTTPPMLDSD

CTACAGCCTGTCCAGTGTGGTCAC

GSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QLQLQESGPGLVKPSQ
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGG

2403
TLSLTCAISGDSVSSNS
2511
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCA

GGCAGTCCCCATCGAGAGGCCTT

EGNGPFDPWGQGTLVT

GAGTGGCTGGGAAGGACATACTA

VSSASTKGPSVFPLAPC

CAGGTCCAAGTGGTATAATGATTA

SRSTSESTAALGCLVKD

TGCAGTATCTGTGAAAAGTCGAAT

YFPEPVTVSWNSGALTS

AACCATCAACCCAGACACATCCAA

GVHTFPAVLQSSGLYSL

GAACCAGTTCTCCCTGCAGCTGAA

SSVVTVPSSNFGTQTYT

CTCTGTGACTCCCGAGGACACGG

CNVDHKPSNTKVDKTV

CTGTGTATTACTGTGCAGAAGGCA

ERKCCVECPPCPAPPV

ATGGGCCGTTCGACCCCTGGGGC

AGPSVFLFPPKPKDTLM

CAGGGAACCCTGGTGACCGTCTC

ISRTPEVTCVVVDVSHE

CTCAGCAAGCACAAAAGGTCCTTC

DPEVQFNWYVDGVEVH

AGTGTTCCCTCTGGCACCTTGCTC

NAKTKPREEQFNSTFRV

ACGCAGCACCTCTGAGAGTACAG

VSVLTVVHQDWLNGKE

CCGCCCTGGGCTGCCTGGTAAAG

YKCKVSNKGLPAPIEKTI

GACTACTTTCCCGAACCAGTCACT

SKTKGQPREPQVYTLPP

GTGTCCTGGAATAGCGGGGCCTT

SREEMTKNQVSLTCLVK

GACCTCTGGAGTGCACACATTTCC

GFYPSDIAVEWESNGQ

AGCTGTACTGCAGTCATCTGGACT

PENNYKTTPPMLDSDG

CTACAGCCTGTCCAGTGTGGTCAC

SFFLYSKLTVDKSRWQ

CGTACCTTCCTCCAACTTTGGCAC

QGNVFSCSVMHEALHN

TCAAACATATACATGTAACGTGGA

HYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QITLKESGGGVVQPGRS
SEQ ID
CAGATCACCTTGAAGGAGTCTGGG

2404
LRLSCVASGFTFSTYPM
2512
GGAGGCGTGGTCCAGCCTGGGAG

HWVRQAPGKGLEWA

GTCCCTGAGACTCTCCTGTGTAGC

VISYDGRNEYYADSVKG

CTCTGGATTCACCTTCAGTACCTA

RFTISRDNSKNTLYLQM

TCCCATGCACTGGGTCCGCCAGG

NSLRAEDTAVYYCATRD

CTCCAGGCAAGGGGCTGGAGTGG

TPLVGVSIYWGQGTLVT

GTGGCAGTTATATCATATGATGGA

VSSASTKGPSVFPLAPC

CGTAATGAATACTACGCAGACTCC

SRSTSESTAALGCLVKD

GTGAAGGGCCGATTCACCATCTCC

YFPEPVTVSWNSGALTS

AGAGACAATTCCAAAAACACGCTG

GVHTFPAVLQSSGLYSL

TATCTGCAAATGAACAGTCTGCGA

SSVVTVPSSNFGTQTYT

GCTGAAGACACGGCTGTCTATTAT

CNVDHKPSNTKVDKTV

TGTGCGACTCGGGATACACCTTTG

ERKCCVECPPCPAPPV

GTTGGGGTTTCGATATACTGGGGC

AGPSVFLFPPKPKDTLM

CAGGGCACCCTGGTCACCGTCTC

ISRTPEVTCVVVDVSHE

CTCAGCAAGCACAAAAGGTCCTTC

DPEVQFNWYVDGVEVH

AGTGTTCCCTCTGGCACCTTGCTC

NAKTKPREEQFNSTFRV

ACGCAGCACCTCTGAGAGTACAG

VSVLTVVHQDWLNGKE

CCGCCCTGGGCTGCCTGGTAAAG

YKCKVSNKGLPAPIEKTI

GACTACTTTCCCGAACCAGTCACT

SKTKGQPREPQVYTLPP

GTGTCCTGGAATAGCGGGGCCTT

SREEMTKNQVSLTCLVK

GACCTCTGGAGTGCACACATTTCC

GFYPSDIAVEWESNGQ

AGCTGTACTGCAGTCATCTGGACT

PENNYKTTPPMLDSDG

CTACAGCCTGTCCAGTGTGGTCAC

SFFLYSKLTVDKSRWQ

CGTACCTTCCTCCAACTTTGGCAC

QGNVFSCSVMHEALHN

TCAAACATATACATGTAACGTGGA

HYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QMQLVQSGGGLVKAGG
SEQ ID
CAGATGCAGCTGGTGCAATCTGG

2405
SLRLSCSASGFTFSSYA
2513
GGGAGGCCTGGTCAAGGCTGGGG

MHWVRQAPGKGLEYVS

GGTCCCTGAGACTCTCCTGTTCAG

AISSNGGSTYYADSVKG

CCTCTGGATTCACCTTCAGTAGCT

RFTISRDNSKNTLYLQM

ATGCTATGCACTGGGTCCGCCAG

SSLRAEDTAVYYCVNRA

GCTCCAGGGAAGGGACTGGAATA

GYGDYRHFQHWGQGT

TGTTTCAGCTATTAGTAGTAATGG

LVTVSSASTKGPSVFPL

GGGTAGCACATACTACGCAGACTC

APCSRSTSESTAALGCL

AGTGAAGGGCAGATTCACCATCTC

VKDYFPEPVTVSWNSG

CAGAGACAATTCCAAGAACACGCT

ALTSGVHTFPAVLQSSG

GTATCTTCAAATGAGCAGTCTGAG

LYSLSSVVTVPSSNFGT

AGCTGAGGACACGGCTGTGTATTA

QTYTCNVDHKPSNTKV

CTGTGTGAATCGGGCGGGTTACG

DKTVERKCCVECPPCP

GTGACTACAGACACTTCCAGCACT

APPVAGPSVFLFPPKPK

GGGGCCAGGGCACCCTGGTCACC

DTLMISRTPEVTCVVVD

GTCTCCTCAGCAAGCACAAAAGGT

VSHEDPEVQFNWYVDG

CCTTCAGTGTTCCCTCTGGCACCT

VEVHNAKTKPREEQFN

TGCTCACGCAGCACCTCTGAGAGT

STFRVVSVLTVVHQDWL

ACAGCCGCCCTGGGCTGCCTGGT

NGKEYKCKVSNKGLPA

AAAGGACTACTTTCCCGAACCAGT

PIEKTISKTKGQPREPQV

CACTGTGTCCTGGAATAGCGGGG

YTLPPSREEMTKNQVSL

CCTTGACCTCTGGAGTGCACACAT

TCLVKGFYPSDIAVEWE

TTCCAGCTGTACTGCAGTCATCTG

SNGQPENNYKTTPPML

GACTCTACAGCCTGTCCAGTGTGG

DSDGSFFLYSKLTVDKS

TCACCGTACCTTCCTCCAACTTTG

RWQQGNVFSCSVMHE

GCACTCAAACATATACATGTAACG

ALHNHYTQKSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGWQPGG
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2406
SLRLSCAASGFTFSSYG
2514
GGGAGGCGTGGTCCAGCCTGGGG

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AFISYDGSNKYYADSVK

CGTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCATT

GCTCCAGGCAAGGGGCTGGAGTG

GDRFQEFDYWGQGTLV

GGTGGCATTTATATCATATGATGG

TVSSASTKGPSVFPLAP

AAGTAATAAATACTACGCAGACTC

CSRSTSESTAALGCLVK

CGTGAAGGGCCGATTCACCATCTC

DYFPEPVTVSWNSGAL

CAGAGACAATTCCAAGAACACGCT

TSGVHTFPAVLQSSGLY

GTATCTGCAAATGAACAGCCTGAG

SLSSVVTVPSSNFGTQT

AGCCGAGGACACGGCCGTATATTA

YTCNVDHKPSNTKVDKT

CTGTGCGACAACAGGGGACCGCT

VERKCCVECPPCPAPP

TCCAAGAGTTTGACTACTGGGGCC

VAGPSVFLFPPKPKDTL

AGGGAACCCTGGTCACCGTCTCCT

MISRTPEVTCVVVDVSH

CAGCAAGCACAAAAGGTCCTTCAG

EDPEVQFNWYVDGVEV

TGTTCCCTCTGGCACCTTGCTCAC

HNAKTKPREEQFNSTFR

GCAGCACCTCTGAGAGTACAGCC

VVSVLTVVHQDWLNGK

GCCCTGGGCTGCCTGGTAAAGGA

EYKCKVSNKGLPAPIEK

CTACTTTCCCGAACCAGTCACTGT

TISKTKGQPREPQVYTL

GTCCTGGAATAGCGGGGCCTTGA

PPSREEMTKNQVSLTCL

CCTCTGGAGTGCACACATTTCCAG

VKGFYPSDIAVEWESNG

CTGTACTGCAGTCATCTGGACTCT

QPENNYKTTPPMLDSD

ACAGCCTGTCCAGTGTGGTCACC

GSFFLYSKLTVDKSRW

GTACCTTCCTCCAACTTTGGCACT

QQGNVFSCSVMHEALH

CAAACATATACATGTAACGTGGAT

NHYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QMQLVQSGGVLLQPGR
SEQ ID
CAGATGCAGCTGGTGCAGTCTGG

2407
SLRLSCTASGFTFAAYNI
2515
GGGAGTCTTGCTTCAGCCAGGGC

NWFRQGPGGGLEWVG

GGTCCCTGAGACTCTCCTGTACAG

FIRANADSGTTEYAASV

CTTCTGGATTCACCTTTGCTGCTTA

KGRFFISRDDSRSTAYL

TAATATCAACTGGTTCCGCCAGGG

QMTSLKTEDTAVYYCAR

TCCTGGGGGGGGGCTGGAGTGG

DDRGRGDDFDYWGQG

GTAGGTTTCATTAGAGCCAACGCT

TLVTVSSASTKGPSVFP

GATAGTGGGACAACAGAGTACGC

LAPCSRSTSESTAALGC

CGCGTCTGTGAAAGGCAGATTCTT

LVKDYFPEPVTVSWNS

CATCTCAAGAGATGATTCCAGAAG

GALTSGVHTFPAVLQSS

CACCGCCTACCTGCAAATGACTAG

GLYSLSSVVTVPSSNFG

CCTTAAAACCGAGGACACAGCCGT

TQTYTCNVDHKPSNTKV

TTATTACTGTGCCAGAGATGATCG

DKTVERKCCVECPPCP

GGGTCGGGGAGATGACTTTGACT

APPVAGPSVFLFPPKPK

ACTGGGGCCAGGGCACCCTGGTC

DTLMISRTPEVTCVVVD

ACCGTCTCCTCAGCAAGCACAAAA

VSHEDPEVQFNWYVDG

GGTCCTTCAGTGTTCCCTCTGGCA

VEVHNAKTKPREEQFN

CCTTGCTCACGCAGCACCTCTGAG

STFRVVSVLTVVHQDWL

AGTACAGCCGCCCTGGGCTGCCT

NGKEYKCKVSNKGLPA

GGTAAAGGACTACTTTCCCGAACC

PIEKTISKTKGQPREPQV

AGTCACTGTGTCCTGGAATAGCGG

YTLPPSREEMTKNQVSL

GGCCTTGACCTCTGGAGTGCACA

TCLVKGFYPSDIAVEWE

CATTTCCAGCTGTACTGCAGTCAT

SNGQPENNYKTTPPML

CTGGACTCTACAGCCTGTCCAGTG

DSDGSFFLYSKLTVDKS

TGGTCACCGTACCTTCCTCCAACT

RWQQGNVFSCSVMHE

TTGGCACTCAAACATATACATGTAA

ALHNHYTQKSLSLSPGK

CGTGGATCATAAGCCCTCTAACAC

CAAAGTGGATAAAACTGTGGAGCG

TAAGTGTTGTGTCGAGTGTCCTCC

TTGTCCTGCTCCTCCTGTGGCAGG

CCCATCTGTGTTTCTCTTTCCCCC

AAAGCCAAAGGACACTTTGATGAT

ATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGG

2408
SLRLSCAASGFTFSSYG
2516
GGGAGGCTTGGTACAGCCTGGGG

MTWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

STISGNGVGTYYPDSVK

CCTCTGGATTCACCTTTAGCAGCT

DRFTISRDSSKNTVYLQ

ATGGCATGACGTGGGTCCGCCAG

MNSLRAEDTAVYYCVK

GCTCCAGGGAAGGGGCTGGAGTG

HGRAGINWYFDLWGRG

GGTCTCAACTATTAGTGGTAATGG

TLVTVSSASTKGPSVFP

TGTTGGCACATACTACCCAGACTC

LAPCSRSTSESTAALGC

CGTGAAGGACCGGTTCACCATCTC

LVKDYFPEPVTVSWNS

CAGAGACAGTTCCAAGAACACGGT

GALTSGVHTFPAVLQSS

GTATCTGCAAATGAACAGCCTGAG

GLYSLSSVVTVPSSNFG

AGCCGAGGACACGGCCGTATATTA

TQTYTCNVDHKPSNTKV

CTGTGTGAAACATGGTAGGGCCG

DKTVERKCCVECPPCP

GAATAAACTGGTACTTCGATCTCT

APPVAGPSVFLFPPKPK

GGGGCCGTGGCACCCTGGTGACC

DTLMISRTPEVTCVVVD

GTCTCCTCAGCAAGCACAAAAGGT

VSHEDPEVQFNWYVDG

CCTTCAGTGTTCCCTCTGGCACCT

VEVHNAKTKPREEQFN

TGCTCACGCAGCACCTCTGAGAGT

STFRVVSVLTVVHQDWL

ACAGCCGCCCTGGGCTGCCTGGT

NGKEYKCKVSNKGLPA

AAAGGACTACTTTCCCGAACCAGT

PIEKTISKTKGQPREPQV

CACTGTGTCCTGGAATAGCGGGG

YTLPPSREEMTKNQVSL

CCTTGACCTCTGGAGTGCACACAT

TCLVKGFYPSDIAVEWE

TTCCAGCTGTACTGCAGTCATCTG

SNGQPENNYKTTPPML

GACTCTACAGCCTGTCCAGTGTGG

DSDGSFFLYSKLTVDKS

TCACCGTACCTTCCTCCAACTTTG

RWQQGNVFSCSVMHE

GCACTCAAACATATACATGTAACG

ALHNHYTQKSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2409
TLSLTCAISGDSVSSNS
2517
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCA

GGCAGTCCCCATCGAGAGGCCTT

RGGGLWAFDIWGQGTT

GAGTGGCTGGGAAGGACATACTA

VTVSSASTKGPSVFPLA

CAGGTCCAAGTGGTATAATGATTA

PCSRSTSESTAALGCLV

TGCAGTATCTGTGAAAAGTCGAAT

KDYFPEPVTVSWNSGA

AACCATCAACCCAGACACATCCAA

LTSGVHTFPAVLQSSGL

GAACCAGTTCTCCCTGCAGCTGAA

YSLSSVVTVPSSNFGTQ

CTCTGTGACTCCCGAGGACACGG

TYTCNVDHKPSNTKVDK

CTGTGTATTACTGTGCAAGAGGGG

TVERKCCVECPPCPAP

GAGGGCTTTGGGCTTTTGATATCT

PVAGPSVFLFPPKPKDT

GGGGCCAAGGGACCACGGTCACC

LMISRTPEVTCVVVDVS

GTCTCCTCAGCAAGCACAAAAGGT

HEDPEVQFNWYVDGVE

CCTTCAGTGTTCCCTCTGGCACCT

VHNAKTKPREEQFNSTF

TGCTCACGCAGCACCTCTGAGAGT

RVVSVLTVVHQDWLNG

AAAGGACTACTTTCCCGAACCAGT

KEYKCKVSNKGLPAPIE

CACTGTGTCCTGGAATAGCGGGG

KTISKTKGQPREPQVYT

ACAGCCGCCCTGGGCTGCCTGGT

LPPSREEMTKNQVSLTC

CCTTGACCTCTGGAGTGCACACAT

LVKGFYPSDIAVEWESN

TTCCAGCTGTACTGCAGTCATCTG

GQPENNYKTTPPMLDS

GACTCTACAGCCTGTCCAGTGTGG

DGSFFLYSKLTVDKSRW

TCACCGTACCTTCCTCCAACTTTG

QQGNVFSCSVMHEALH

GCACTCAAACATATACATGTAACG

NHYTQKSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGG

2410
SVKVSCKASGYTFTGYY
2518
GGCTGAGGTGAAGAAGCCTGGGG

MHWRQAPGQGLEWM

CCTCAGTGAAGGTCTCCTGCAAGG

GWINPNSGGTNYAQKF

CTTCTGGATACACCTTCACCGGCT

QGRVTMTRDTSISTAYM

ACTATATGCACTGGGTGCGACAGG

ELSRLRSDDTAVYYCAR

CCCCTGGACAAGGGCTTGAGTGG

DKIGSCPYWGQGTLVT

ATGGGATGGATCAACCCTAACAGT

VSSASTKGPSVFPLAPC

GGTGGCACAAACTATGCACAGAAG

SRSTSESTAALGCLVKD

TTTCAGGGCAGGGTCACCATGACC

YFPEPVTVSWNSGALTS

AGGGACACGTCCATCAGCACAGC

GVHTFPAVLQSSGLYSL

CTACATGGAGCTGAGCAGGCTGA

SSVVTVPSSNFGTQTYT

GATCTGACGACACGGCCGTGTATT

CNVDHKPSNTKVDKTV

ACTGTGCGAGAGACAAGATCGGC

ERKCCVECPPCPAPPV

AGCTGTCCTTACTGGGGCCAGGG

AGPSVFLFPPKPKDTLM

AACCCTGGTCACCGTCTCCTCAGC

ISRTPEVTCVVVDVSHE

AAGCACAAAAGGTCCTTCAGTGTT

DPEVQFNWYVDGVEVH

CCCTCTGGCACCTTGCTCACGCAG

NAKTKPREEQFNSTFRV

CACCTCTGAGAGTACAGCCGCCCT

VSVLTVVHQDWLNGKE

GGGCTGCCTGGTAAAGGACTACTT

YKCKVSNKGLPAPIEKTI

TCCCGAACCAGTCACTGTGTCCTG

SKTKGQPREPQVYTLPP

GAATAGCGGGGCCTTGACCTCTG

SREEMTKNQVSLTCLVK

GAGTGCACACATTTCCAGCTGTAC

GFYPSDIAVEWESNGQ

TGCAGTCATCTGGACTCTACAGCC

PENNYKTTPPMLDSDG

TGTCCAGTGTGGTCACCGTACCTT

SFFLYSKLTVDKSRWQ

CCTCCAACTTTGGCACTCAAACAT

QGNVFSCSVMHEALHN

ATACATGTAACGTGGATCATAAGC

HYTQKSLSLSPGK

CCTCTAACACCAAAGTGGATAAAA

CTGTGGAGCGTAAGTGTTGTGTCG

AGTGTCCTCCTTGTCCTGCTCCTC

CTGTGGCAGGCCCATCTGTGTTTC

TCTTTCCCCCAAAGCCAAAGGACA

CTTTGATGATATCCCGGACCCCTG

AGGTGACTTGCGTCGTCGTAGATG

TTTCACACGAAGATCCAGAGGTGC

AGTTCAACTGGTACGTGGATGGCG

TGGAAGTGCATAATGCCAAGACAA

AGCCCCGCGAAGAGCAGTTTAATT

CCACCTTCCGCGTGGTGTCTGTGC

TGACCGTGGTACATCAGGATTGGC

TTAACGGTAAGGAGTACAAGTGCA

AGGTGAGTAACAAGGGGCTGCCC

GCCCCTATCGAGAAGACTATCAGT

AAAACCAAGGGCCAGCCAAGGGA

GCCACAGGTGTACACACTTCCACC

ATCTAGGGAGGAAATGACAAAGAA

CCAGGTGAGTTTGACCTGTCTCGT

GAAAGGCTTTTATCCCAGTGATAT

AGCCGTGGAATGGGAAAGTAACG

GGCAGCCCGAGAACAACTATAAGA

CCACACCACCCATGCTGGACTCC

GACGGTTCTTTCTTCCTTTATAGCA

AGCTGACAGTGGATAAATCCAGGT

GGCAGCAGGGTAACGTATTCAGTT

GCAGTGTCATGCACGAGGCACTC

CACAACCACTATACTCAGAAAAGT

CTTTCCCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGPTLVKPTQT
SEQ ID
CAGGTCACCTTGAAGGAGTCTGGT

2411
LTLTCTFSGFSLSTSGV
2519
CCTACGCTGGTGAAACCCACACAG

GVGWIRQPPGKALEWL

ACCCTCACGCTGACCTGCACCTTC

ALIYWDDDKRYSPSLKS

TCTGGGTTCTCACTCAGCACTAGT

RLTITKDTSKNQVVLTM

GGAGTGGGTGTGGGCTGGATCCG

TNMDPVDTATYYCAHR

TCAGCCCCCAGGAAAGGCCCTGG

PDSSSQCFDYWGQGTL

AGTGGCTTGCACTCATTTATTGGG

VTVSSASTKGPSVFPLA

ATGATGATAAGCGCTACAGCCCAT

PCSRSTSESTAALGCLV

CTCTGAAGAGCAGGCTCACCATCA

KDYFPEPVTVSWNSGA

CCAAGGACACCTCCAAAAACCAGG

LTSGVHTFPAVLQSSGL

TGGTCCTTACAATGACCAACATGG

YSLSSVVTVPSSNFGTQ

ACCCTGTGGACACAGCCACATATT

TYTCNVDHKPSNTKVDK

ACTGTGCACACAGACCGGATAGCA

TVERKCCVECPPCPAP

GCAGTCAATGTTTTGACTACTGGG

PVAGPSVFLFPPKPKDT

GCCAGGGAACCCTGGTCACCGTC

LMISRTPEVTCVVVDVS

TCCTCAGCAAGCACAAAAGGTCCT

HEDPEVQFNWYVDGVE

TCAGTGTTCCCTCTGGCACCTTGC

VHNAKTKPREEQFNSTF

TCACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2412
SLRLSCAASGFTFSSYA
2520
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGCTATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

SSGWSLPEDYWGQGTL

GGTGGCAGTTATATCATATGATGG

VTVSSASTKGPSVFPLA

AAGTAATAAATACTACGCAGACTC

PCSRSTSESTAALGCLV

CGTGAAGGGCCGATTCACCATCTC

KDYFPEPVTVSWNSGA

CAGAGACAATTCCAAGAACACGCT

LTSGVHTFPAVLQSSGL

GTATCTGCAAATGAACAGCCTGAG

YSLSSVVTVPSSNFGTQ

AGCTGAGGACACGGCTGTGTATTA

TYTCNVDHKPSNTKVDK

CTGTGCGAGAAGCAGTGGCTGGT

TVERKCCVECPPCPAP

CACTGCCTGAAGACTACTGGGGC

PVAGPSVFLFPPKPKDT

CAGGGAACCCTGGTCACCGTCTC

LMISRTPEVTCVVVDVS

CTCAGCAAGCACAAAAGGTCCTTC

HEDPEVQFNWYVDGVE

AGTGTTCCCTCTGGCACCTTGCTC

VHNAKTKPREEQFNSTF

ACGCAGCACCTCTGAGAGTACAG

RVVSVLTVVHQDWLNG

CCGCCCTGGGCTGCCTGGTAAAG

KEYKCKVSNKGLPAPIE

GACTACTTTCCCGAACCAGTCACT

KTISKTKGQPREPQVYT

GTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTCCAGCTGGTACAGTCTGG

2413
SVKVSCKVSGYTLTELS
2521
GGCTGAGGTGAAGAAGCCTGGGG

MHVWRQAPGKGLEWM

CCTCAGTGAAGGTCTCCTGCAAGG

GGFDPEDGETIYAQKFQ

TTTCCGGATACACCCTCACTGAAT

GRVTMTEDTSTDTAYM

TATCCATGCACTGGGTGCGACAG

ELSSLRSEDTAVYYCAT

GCTCCTGGAAAAGGGCTTGAGTG

DVNPELLGAGFDYWGQ

GATGGGAGGTTTTGATCCTGAAGA

GTLVTVSSASTKGPSVF

TGGTGAAACAATCTACGCACAGAA

PLAPCSRSTSESTAALG

GTTCCAGGGCAGAGTCACCATGA

CLVKDYFPEPVTVSWN

CCGAGGACACATCTACAGACACAG

SGALTSGVHTFPAVLQS

CCTACATGGAGCTGAGCAGCCTG

SGLYSLSSVVTVPSSNF

AGATCTGAGGACACGGCCGTGTAT

GTQTYTCNVDHKPSNT

TACTGTGCAACGGATGTGAACCCG

KVDKTVERKCCVECPP

GAGCTACTGGGGGCGGGATTTGA

CPAPPVAGPSVFLFPPK

CTACTGGGGCCAGGGCACCCTGG

PKDTLMISRTPEVTCVV

TCACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
QVTLKESGGGLVQPGG
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2414
SLRLSCAASGFTFSDQY
2522
GGGAGGCTTGGTCCAGCCTGGAG

MDWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

GRVRNKANSYTTEYAA

CCTCTGGATTCACCTTCAGTGACC

SVKGRFTISRDDSKNSL

AGTACATGGACTGGGTCCGCCAG

YLQMNSLNTEDTAMYF

GCTCCAGGGAAGGGGCTGGAGTG

CASSLNSGGYRCFHHW

GGTTGGCCGTGTTAGAAACAAAGC

GQGTLVTVSSASTKGPS

TAACAGTTACACCACAGAATACGC

VFPLAPCSRSTSESTAA

CGCGTCTGTGAAAGGCAGATTCAC

LGCLVKDYFPEPVTVSW

CATCTCAAGAGATGATTCAAAGAA

NSGALTSGVHTFPAVLQ

CTCACTGTATCTGCAAATGAATAG

SSGLYSLSSVVTVPSSN

TCTGAACACCGAGGACACGGCCA

FGTQTYTCNVDHKPSN

TGTATTTCTGTGCTAGTAGTCTCAA

TKVDKTVERKCCVECPP

TAGTGGGGGCTACCGATGCTTCCA

CPAPPVAGPSVFLFPPK

TCACTGGGGCCAGGGCACCCTGG

PKDTLMISRTPEVTCVV

TGACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGG
SEQ ID
CAGGTCCAGCTGGTGCAGTCTGG

2415
SLRLSCSASGFTFSSYA
2523
GGGAGGCTTGGTCCAGCCTGGGG

MHWVRQAPGKGLEYVS

GGTCCCTGAGACTCTCCTGTTCAG

AISSNGGSTYYADSVKG

CCTCTGGATTCACCTTCAGTAGCT

RFTISRDNSKNTLYLQM

ATGCTATGCACTGGGTCCGCCAG

SSLRAEDTAVYYCVKAP

GCTCCAGGGAAGGGACTGGAATA

RGVVPAAMRGGYWGQ

TGTTTCAGCTATTAGTAGTAATGG

GTLVTVSSASTKGPSVF

GGGTAGCACATACTACGCAGACTC

PLAPCSRSTSESTAALG

AGTGAAGGGCAGATTCACCATCTC

CLVKDYFPEPVTVSWN

CAGAGACAATTCCAAGAACACGCT

SGALTSGVHTFPAVLQS

GTATCTTCAAATGAGCAGTCTGAG

SGLYSLSSVVTVPSSNF

AGCTGAGGACACGGCTGTGTATTA

GTQTYTCNVDHKPSNT

CTGTGTGAAAGCGCCGAGGGGTG

KVDKTVERKCCVECPP

TAGTACCAGCTGCTATGCGGGGG

CPAPPVAGPSVFLFPPK

GGCTACTGGGGCCAGGGAACCCT

PKDTLMISRTPEVTCVV

GGTCACCGTCTCCTCAGCAAGCAC

VDVSHEDPEVQFNWYV

AAAAGGTCCTTCAGTGTTCCCTCT

DGVEVHNAKTKPREEQ

GGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQESGGGLVQPGR
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGG

2416
SLRLSCTASGFTFGDYA
2524
GGGAGGCTTGGTACAGCCAGGGC

MSWFRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

GFIRSKAYGGTTEYAAS

CTTCTGGATTCACCTTTGGTGATTA

VKGRFTISRDDSKSIAYL

TGCTATGAGCTGGTTCCGCCAGG

QMNSLKTEDTAVYYCT

CTCCAGGGAAGGGGCTGGAGTGG

RLVGNSGSYYPFGYWG

GTAGGTTTCATTAGAAGCAAAGCT

QGTLVTVSSASTKGPSV

TATGGTGGGACAACAGAATACGCC

FPLAPCSRSTSESTAAL

GCGTCTGTGAAAGGCAGATTCACC

GCLVKDYFPEPVTVSW

ATCTCAAGAGATGATTCCAAAAGC

NSGALTSGVHTFPAVLQ

ATCGCCTATCTGCAAATGAACAGC

SSGLYSLSSVVTVPSSN

CTGAAAACCGAGGACACAGCCGT

FGTQTYTCNVDHKPSN

GTATTACTGTACTAGATTGGTGGG

TKVDKTVERKCCVECPP

CAATAGTGGGAGCTACTATCCGTT

CPAPPVAGPSVFLFPPK

TGGGTACTGGGGCCAGGGAACCC

PKDTLMISRTPEVTCVV

TGGTGACCGTCTCCTCAGCAAGCA

VDVSHEDPEVQFNWYV

CAAAAGGTCCTTCAGTGTTCCCTC

DGVEVHNAKTKPREEQ

TGGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2417
TLSLTCAVYGGSFSGYY
2525
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARGRSL

CCCCCAGGGAAGGGGCTGGAGTG

PYRGLAPRSFGGYYFD

GATTGGGGAAATCAATCATAGTGG

YWGQGTLVTVSSASTK

AAGCACCAACTACAACCCGTCCCT

GPSVFPLAPCSRSTSES

CAAGAGTCGAGTCACCATATCAGT

TAALGCLVKDYFPEPVT

AGACACGTCCAAGAACCAGTTCTC

VSWNSGALTSGVHTFP

CCTGAAGCTGAGCTCGGTGACCG

AVLQSSGLYSLSSVVTV

CCGCGGACACGGCTGTGTATTACT

PSSNFGTQTYTCNVDH

GTGCGAGAGGCCGGTCCCTTCCC

KPSNTKVDKTVERKCCV

TACCGGGGGTTGGCTCCTAGATCT

ECPPCPAPPVAGPSVFL

TTCGGAGGATACTACTTTGACTAC

FPPKPKDTLMISRTPEV

TGGGGCCAGGGAACCCTGGTCAC

TCVVVDVSHEDPEVQF

CGTCTCCTCAGCAAGCACAAAAGG

NWYVDGVEVHNAKTKP

TCCTTCAGTGTTCCCTCTGGCACC

REEQFNSTFRVVSVLTV

TTGCTCACGCAGCACCTCTGAGAG

VHQDWLNGKEYKCKVS

TACAGCCGCCCTGGGCTGCCTGG

NKGLPAPIEKTISKTKGQ

TAAAGGACTACTTTCCCGAACCAG

PREPQVYTLPPSREEMT

TCACTGTGTCCTGGAATAGCGGG

KNQVSLTCLVKGFYPSD

GCCTTGACCTCTGGAGTGCACACA

IAVEWESNGQPENNYK

TTTCCAGCTGTACTGCAGTCATCT

TTPPMLDSDGSFFLYSK

GGACTCTACAGCCTGTCCAGTGTG

LTVDKSRWQQGNVFSC

GTCACCGTACCTTCCTCCAACTTT

SVMHEALHNHYTQKSL

GGCACTCAAACATATACATGTAAC

SLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQESGGGLVRPGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGG

2418
SLRLSCGDSGFNFSGY
2526
GGGAGGCTTGGTACGGCCTGGAG

EMNWVRQAPGKGLEW

GGTCCCTGAGACTCTCCTGTGGA

VSYVSTSGSTRYYADSV

GACTCTGGATTCAACTTCAGTGGA

KGRFTISRDNAKNTLYL

TATGAAATGAACTGGGTCCGCCAG

QMNSLRVEDTAVYYCA

GCTCCAGGGAAGGGGCTGGAGTG

RGRTHWGPQDFDYWG

GGTTTCATACGTCAGTACTAGTGG

QGTLVTVSSASTKGPSV

TAGTACCAGATACTACGCAGACTC

FPLAPCSRSTSESTAAL

TGTGAAGGGCCGATTTACCATCTC

GCLVKDYFPEPVTVSW

CAGAGACAACGCCAAGAACACCCT

NSGALTSGVHTFPAVLQ

GTATTTGCAAATGAACAGTCTGAG

SSGLYSLSSVVTVPSSN

AGTCGAGGACACGGCTGTGTATTA

FGTQTYTCNVDHKPSN

CTGTGCAAGAGGACGGACTCACT

TKVDKTVERKCCVECPP

GGGGCCCCCAGGACTTTGACTAC

CPAPPVAGPSVFLFPPK

TGGGGCCAGGGAACCCTGGTCAC

PKDTLMISRTPEVTCVV

CGTCTCCTCAGCAAGCACAAAAGG

VDVSHEDPEVQFNWYV

TCCTTCAGTGTTCCCTCTGGCACC

DGVEVHNAKTKPREEQ

TTGCTCACGCAGCACCTCTGAGAG

FNSTFRVVSVLTVVHQD

TACAGCCGCCCTGGGCTGCCTGG

WLNGKEYKCKVSNKGL

TAAAGGACTACTTTCCCGAACCAG

PAPIEKTISKTKGQPREP

TCACTGTGTCCTGGAATAGCGGG

QVYTLPPSREEMTKNQ

GCCTTGACCTCTGGAGTGCACACA

VSLTCLVKGFYPSDIAVE

TTTCCAGCTGTACTGCAGTCATCT

WESNGQPENNYKTTPP

GGACTCTACAGCCTGTCCAGTGTG

MLDSDGSFFLYSKLTVD

GTCACCGTACCTTCCTCCAACTTT

KSRWQQGNVFSCSVM

GGCACTCAAACATATACATGTAAC

HEALHNHYTQKSLSLSP

GTGGATCATAAGCCCTCTAACACC

GK

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQESGGGLVQPGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGG

2419
SLRLSCAASGFTFSSYA
2527
GGGAGGCTTGGTACAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SAISGSGGSTYYADSVK

CCTCTGGATTCACCTTTAGCAGCT

GRFTISRDNSKNTLYLQ

ATGCCATGAGCTGGGTCCGCCAG

MNSLRAEDTAVYYCAK

GCTCCAGGGAAGGGGCTGGAGTG

GGMYYYGSGSSYFDY

GGTCTCAGCTATTAGTGGTAGTGG

WGQGTLVTVSSASTKG

TGGTAGCACATACTACGCAGACTC

PSVFPLAPCSRSTSEST

CGTGAAGGGCCGGTTCACCATCT

AALGCLVKDYFPEPVTV

CCAGAGACAATTCCAAGAACACGC

SWNSGALTSGVHTFPA

TGTATCTGCAAATGAACAGCCTGA

VLQSSGLYSLSSVVTVP

GAGCCGAGGACACGGCCGTATAT

SSNFGTQTYTCNVDHK

TACTGTGCGAAAGGAGGAATGTAT

PSNTKVDKTVERKCCVE

TACTATGGTTCGGGGAGCTCGTAC

CPPCPAPPVAGPSVFLF

TTTGACTACTGGGGCCAGGGAAC

PPKPKDTLMISRTPEVT

CCTGGTGACCGTCTCCTCAGCAAG

CVVVDVSHEDPEVQFN

CACAAAAGGTCCTTCAGTGTTCCC

WYVDGVEVHNAKTKPR

TCTGGCACCTTGCTCACGCAGCAC

EEQFNSTFRVVSVLTVV

CTCTGAGAGTACAGCCGCCCTGG

HQDWLNGKEYKCKVSN

GCTGCCTGGTAAAGGACTACTTTC

KGLPAPIEKTISKTKGQP

CCGAACCAGTCACTGTGTCCTGGA

REPQVYTLPPSREEMTK

ATAGCGGGGCCTTGACCTCTGGA

NQVSLTCLVKGFYPSDI

GTGCACACATTTCCAGCTGTACTG

AVEWESNGQPENNYKT

CAGTCATCTGGACTCTACAGCCTG

TPPMLDSDGSFFLYSKL

TCCAGTGTGGTCACCGTACCTTCC

TVDKSRWQQGNVFSCS

TCCAACTTTGGCACTCAAACATATA

VMHEALHNHYTQKSLSL

CATGTAACGTGGATCATAAGCCCT

SPGK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGG

2420
SLRLSCAASGFTFSSYA
2528
GGGAGGCTTGGTACAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SGISGSGGSTYYADSVK

CCTCTGGATTCACCTTTAGCAGCT

GRFTISRDNSKNMLFLQ

ATGCCATGAGCTGGGTCCGCCAG

MNSPRAEDTAVYYCAK

GCTCCAGGGAAGGGGCTGGAATG

KIAAAGKQPVDYWGQG

GGTCTCAGGTATTAGTGGTAGTGG

TLVTVSSASTKGPSVFP

TGGTAGCACATACTACGCAGACTC

LAPCSRSTSESTAALGC

CGTGAAGGGCCGGTTCACCATCT

LVKDYFPEPVTVSWNS

CCAGAGACAATTCCAAGAACATGC

GALTSGVHTFPAVLQSS

TGTTTCTGCAAATGAACAGCCCGA

GLYSLSSVVTVPSSNFG

GAGCCGAGGACACGGCCGTATAT

TQTYTCNVDHKPSNTKV

TACTGTGCGAAGAAAATAGCAGCA

DKTVERKCCVECPPCP

GCTGGTAAGCAACCTGTTGACTAC

APPVAGPSVFLFPPKPK

TGGGGCCAGGGAACCCTGGTCAC

DTLMISRTPEVTCVVVD

CGTCTCCTCAGCAAGCACAAAAGG

VSHEDPEVQFNWYVDG

TCCTTCAGTGTTCCCTCTGGCACC

VEVHNAKTKPREEQFN

TTGCTCACGCAGCACCTCTGAGAG

STFRVVSVLTVVHQDWL

TACAGCCGCCCTGGGCTGCCTGG

NGKEYKCKVSNKGLPA

TAAAGGACTACTTTCCCGAACCAG

PIEKTISKTKGQPREPQV

TCACTGTGTCCTGGAATAGCGGG

YTLPPSREEMTKNQVSL

GCCTTGACCTCTGGAGTGCACACA

TCLVKGFYPSDIAVEWE

TTTCCAGCTGTACTGCAGTCATCT

SNGQPENNYKTTPPML

GGACTCTACAGCCTGTCCAGTGTG

DSDGSFFLYSKLTVDKS

GTCACCGTACCTTCCTCCAACTTT

RWQQGNVFSCSVMHE

GGCACTCAAACATATACATGTAAC

ALHNHYTQKSLSLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2421
TLSLTCAVYGGSFSGYY
2529
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARRKVY

CCCCCAGGGAAGGGGCTGGAGTG

DYVWGSYRLPGSVSYY

GATTGGGGAAATCAATCATAGTGG

FDYWGQGTLVTVSSAS

AAGCACCAACTACAACCCGTCCCT

TKGPSVFPLAPCSRSTS

CAAGAGTCGAGTCACCATATCAGT

ESTAALGCLVKDYFPEP

AGACACGTCCAAGAACCAGTTCTC

VTVSWNSGALTSGVHT

CCTGAAGCTGAGCTCTGTGACCG

FPAVLQSSGLYSLSSVV

CCGCGGACACGGCTGTGTATTACT

TVPSSNFGTQTYTCNVD

GTGCGAGAAGGAAGGTGTATGATT

HKPSNTKVDKTVERKC

ACGTTTGGGGGAGTTATCGCCTCC

CVECPPCPAPPVAGPS

CCGGGTCGGTATCGTACTACTTTG

VFLFPPKPKDTLMISRTP

ACTACTGGGGCCAGGGAACCCTG

EVTCVVVDVSHEDPEV

GTCACCGTCTCCTCAGCAAGCACA

QFNWYVDGVEVHNAKT

AAAGGTCCTTCAGTGTTCCCTCTG

KPREEQFNSTFRVVSVL

GCACCTTGCTCACGCAGCACCTCT

TVVHQDWLNGKEYKCK

GAGAGTACAGCCGCCCTGGGCTG

VSNKGLPAPIEKTISKTK

CCTGGTAAAGGACTACTTTCCCGA

GQPREPQVYTLPPSRE

ACCAGTCACTGTGTCCTGGAATAG

EMTKNQVSLTCLVKGFY

CGGGGCCTTGACCTCTGGAGTGC

PSDIAVEWESNGQPEN

ACACATTTCCAGCTGTACTGCAGT

NYKTTPPMLDSDGSFFL

CATCTGGACTCTACAGCCTGTCCA

YSKLTVDKSRWQQGNV

GTGTGGTCACCGTACCTTCCTCCA

FSCSVMHEALHNHYTQ

ACTTTGGCACTCAAACATATACAT

KSLSLSPGK

GTAACGTGGATCATAAGCCCTCTA

ACACCAAAGTGGATAAAACTGTGG

AGCGTAAGTGTTGTGTCGAGTGTC

CTCCTTGTCCTGCTCCTCCTGTGG

CAGGCCCATCTGTGTTTCTCTTTC

CCCCAAAGCCAAAGGACACTTTGA

TGATATCCCGGACCCCTGAGGTGA

CTTGCGTCGTCGTAGATGTTTCAC

ACGAAGATCCAGAGGTGCAGTTCA

ACTGGTACGTGGATGGCGTGGAA

GTGCATAATGCCAAGACAAAGCCC

CGCGAAGAGCAGTTTAATTCCACC

TTCCGCGTGGTGTCTGTGCTGACC

GTGGTACATCAGGATTGGCTTAAC

GGTAAGGAGTACAAGTGCAAGGT

GAGTAACAAGGGGCTGCCCGCCC

CTATCGAGAAGACTATCAGTAAAA

CCAAGGGCCAGCCAAGGGAGCCA

CAGGTGTACACACTTCCACCATCT

AGGGAGGAAATGACAAAGAACCA

GGTGAGTTTGACCTGTCTCGTGAA

AGGCTTTTATCCCAGTGATATAGC

CGTGGAATGGGAAAGTAACGGGC

AGCCCGAGAACAACTATAAGACCA

CACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGAEVKKPGE
SEQ ID
CAGGTCCAGCTGGTACAGTCTGG

2422
SLKISCKGSGYSFTSYW
2530
AGCAGAGGTGAAAAAGCCCGGGG

IGWVRQMPGKGLEWM

AGTCTCTGAAGATCTCCTGTAAGG

GIIYPGDSDTRYSPSFQ

GTTCTGGATACAGCTTTACCAGCT

GQVTISADKSISTAYLQ

ACTGGATCGGCTGGGTGCGCCAG

WSSLKASDTAMYYCAR

ATGCCCGGGAAAGGCCTGGAGTG

LPGRAARPDYWGQGTL

GATGGGGATCATCTATCCTGGTGA

VTVSSASTKGPSVFPLA

CTCTGATACCAGATACAGCCCGTC

PCSRSTSESTAALGCLV

CTTCCAAGGCCAGGTCACCATCTC

KDYFPEPVTVSWNSGA

AGCCGACAAGTCCATCAGCACCG

LTSGVHTFPAVLQSSGL

CCTACCTGCAGTGGAGCAGCCTG

YSLSSVVTVPSSNFGTQ

AAGGCCTCGGACACCGCCATGTAT

TYTCNVDHKPSNTKVDK

TACTGTGCGAGACTCCCGGGGAG

TVERKCCVECPPCPAP

AGCAGCTCGTCCAGACTACTGGG

PVAGPSVFLFPPKPKDT

GCCAGGGCACCCTGGTCACCGTC

LMISRTPEVTCVVVDVS

TCCTCAGCAAGCACAAAAGGTCCT

HEDPEVQFNWYVDGVE

TCAGTGTTCCCTCTGGCACCTTGC

VHNAKTKPREEQFNSTF

TCACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2423
SLRLSCAASGFTFSSYA
2531
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGCTATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

GPGAVAGTKPKYYFDY

GGTGGCAGTTATATCATATGATGG

WGQGTLVTVSSASTKG

AAGTAATAAATACTACGCAGACTC

PSVFPLAPCSRSTSEST

CGTGAAGGGCCGATTCACCATCTC

AALGCLVKDYFPEPVTV

CAGAGACAATTCCAAGAACACGCT

SWNSGALTSGVHTFPA

GTATCTGCAAATGAACAGCCTGAG

VLQSSGLYSLSSVVTVP

AGCTGAGGACACGGCTGTGTATTA

SSNFGTQTYTCNVDHK

CTGTGCGAGAGGCCCCGGGGCAG

PSNTKVDKTVERKCCVE

TGGCTGGTACTAAGCCAAAGTACT

CPPCPAPPVAGPSVFLF

ACTTTGACTACTGGGGCCAGGGAA

PPKPKDTLMISRTPEVT

CCCTGGTCACCGTCTCCTCAGCAA

CVVVDVSHEDPEVQFN

GCACAAAAGGTCCTTCAGTGTTCC

WYVDGVEVHNAKTKPR

CTCTGGCACCTTGCTCACGCAGCA

EEQFNSTFRVVSVLTVV

CCTCTGAGAGTACAGCCGCCCTG

HQDWLNGKEYKCKVSN

GGCTGCCTGGTAAAGGACTACTTT

KGLPAPIEKTISKTKGQP

CCCGAACCAGTCACTGTGTCCTGG

REPQVYTLPPSREEMTK

AATAGCGGGGCCTTGACCTCTGG

NQVSLTCLVKGFYPSDI

AGTGCACACATTTCCAGCTGTACT

AVEWESNGQPENNYKT

GCAGTCATCTGGACTCTACAGCCT

TPPMLDSDGSFFLYSKL

GTCCAGTGTGGTCACCGTACCTTC

TVDKSRWQQGNVFSCS

CTCCAACTTTGGCACTCAAACATA

VMHEALHNHYTQKSLSL

TACATGTAACGTGGATCATAAGCC

SPGK

CTCTAACACCAAAGTGGATAAAAC

TGTGGAGCGTAAGTGTTGTGTCGA

GTGTCCTCCTTGTCCTGCTCCTCC

TGTGGCAGGCCCATCTGTGTTTCT

CTTTCCCCCAAAGCCAAAGGACAC

TTTGATGATATCCCGGACCCCTGA

GGTGACTTGCGTCGTCGTAGATGT

TTCACACGAAGATCCAGAGGTGCA

GTTCAACTGGTACGTGGATGGCGT

GGAAGTGCATAATGCCAAGACAAA

GCCCCGCGAAGAGCAGTTTAATTC

CACCTTCCGCGTGGTGTCTGTGCT

GACCGTGGTACATCAGGATTGGCT

TAACGGTAAGGAGTACAAGTGCAA

GGTGAGTAACAAGGGGCTGCCCG

CCCCTATCGAGAAGACTATCAGTA

AAACCAAGGGCCAGCCAAGGGAG

CCACAGGTGTACACACTTCCACCA

TCTAGGGAGGAAATGACAAAGAAC

CAGGTGAGTTTGACCTGTCTCGTG

AAAGGCTTTTATCCCAGTGATATA

GCCGTGGAATGGGAAAGTAACGG

GCAGCCCGAGAACAACTATAAGAC

CACACCACCCATGCTGGACTCCGA

CGGTTCTTTCTTCCTTTATAGCAAG

CTGACAGTGGATAAATCCAGGTGG

CAGCAGGGTAACGTATTCAGTTGC

AGTGTCATGCACGAGGCACTCCAC

AACCACTATACTCAGAAAAGTCTTT

CCCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGVVQPGR
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGG

2424
SLRLSCAASGFTFSSYA
2532
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVISYDGSNKYYADSVK

CCTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGCTATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

ATYYYDSSGYRFDYWG

GGTGGCAGTTATATCATATGATGG

QGTLVTVSSASTKGPSV

AAGTAATAAATACTACGCAGACTC

FPLAPCSRSTSESTAAL

CGTGAAGGGCCGATTCACCATCTC

GCLVKDYFPEPVTVSW

CAGAGACAATTCCAAGAACACGCT

NSGALTSGVHTFPAVLQ

GTATCTGCAAATGAACAGCCTGAG

SSGLYSLSSVVTVPSSN

AGCTGAGGACACGGCTGTGTATTA

FGTQTYTCNVDHKPSN

CTGTGCGAGGGCCACGTATTACTA

TKVDKTVERKCCVECPP

TGATAGTAGTGGTTATAGGTTTGA

CPAPPVAGPSVFLFPPK

CTACTGGGGCCAGGGAACCCTGG

PKDTLMISRTPEVTCVV

TCACCGTCTCCTCAGCAAGCACAA

VDVSHEDPEVQFNWYV

AAGGTCCTTCAGTGTTCCCTCTGG

DGVEVHNAKTKPREEQ

CACCTTGCTCACGCAGCACCTCTG

FNSTFRVVSVLTVVHQD

AGAGTACAGCCGCCCTGGGCTGC

WLNGKEYKCKVSNKGL

CTGGTAAAGGACTACTTTCCCGAA

PAPIEKTISKTKGQPREP

CCAGTCACTGTGTCCTGGAATAGC

QVYTLPPSREEMTKNQ

GGGGCCTTGACCTCTGGAGTGCA

VSLTCLVKGFYPSDIAVE

CACATTTCCAGCTGTACTGCAGTC

WESNGQPENNYKTTPP

ATCTGGACTCTACAGCCTGTCCAG

MLDSDGSFFLYSKLTVD

TGTGGTCACCGTACCTTCCTCCAA

KSRWQQGNVFSCSVM

CTTTGGCACTCAAACATATACATGT

HEALHNHYTQKSLSLSP

AACGTGGATCATAAGCCCTCTAAC

GK

ACCAAAGTGGATAAAACTGTGGAG

CGTAAGTGTTGTGTCGAGTGTCCT

CCTTGTCCTGCTCCTCCTGTGGCA

GGCCCATCTGTGTTTCTCTTTCCC

CCAAAGCCAAAGGACACTTTGATG

ATATCCCGGACCCCTGAGGTGACT

TGCGTCGTCGTAGATGTTTCACAC

GAAGATCCAGAGGTGCAGTTCAAC

TGGTACGTGGATGGCGTGGAAGT

GCATAATGCCAAGACAAAGCCCCG

CGAAGAGCAGTTTAATTCCACCTT

CCGCGTGGTGTCTGTGCTGACCG

TGGTACATCAGGATTGGCTTAACG

GTAAGGAGTACAAGTGCAAGGTGA

GTAACAAGGGGCTGCCCGCCCCT

ATCGAGAAGACTATCAGTAAAACC

AAGGGCCAGCCAAGGGAGCCACA

GGTGTACACACTTCCACCATCTAG

GGAGGAAATGACAAAGAACCAGG

TGAGTTTGACCTGTCTCGTGAAAG

GCTTTTATCCCAGTGATATAGCCG

TGGAATGGGAAAGTAACGGGCAG

CCCGAGAACAACTATAAGACCACA

CCACCCATGCTGGACTCCGACGG

TTCTTTCTTCCTTTATAGCAAGCTG

ACAGTGGATAAATCCAGGTGGCAG

CAGGGTAACGTATTCAGTTGCAGT

GTCATGCACGAGGCACTCCACAAC

CACTATACTCAGAAAAGTCTTTCC

CTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGGGLVEPGG
SEQ ID
GAGGTCCAGCTGGTACAGTCTGG

2425
SLRLSCAASRFTFSDAW
2533
GGGAGGCTTGGTAGAACCGGGGG

MSWVRQAPGKGLEWV

GGTCCCTTAGACTCTCCTGTGCAG

GRIKSKISGGTTDYAAP

CCTCTCGATTCACTTTCAGTGACG

VQGRFTISRDDSKNTLY

CCTGGATGAGCTGGGTCCGCCAG

LQMDSLKTEDTAVYYCA

GCTCCAGGTAAGGGGCTGGAGTG

NRNLGYWGQGTLVTVS

GGTTGGCCGTATTAAAAGCAAAAT

SASTKGPSVFPLAPCSR

AAGTGGTGGGACAACAGACTACG

STSESTAALGCLVKDYF

CTGCACCCGTGCAAGGCAGATTCA

PEPVTVSWNSGALTSG

CCATCTCAAGAGATGATTCAAAAA

VHTFPAVLQSSGLYSLS

ACACGCTGTATCTGCAAATGGACA

SVVTVPSSNFGTQTYTC

GCCTGAAAACCGAGGACACAGCC

NVDHKPSNTKVDKTVE

GTGTATTACTGTGCGAACCGAAAC

RKCCVECPPCPAPPVA

TTAGGCTACTGGGGCCAGGGCAC

GPSVFLFPPKPKDTLMI

CCTGGTGACCGTCTCCTCAGCAAG

SRTPEVTCVVVDVSHED

CACAAAAGGTCCTTCAGTGTTCCC

PEVQFNWYVDGVEVHN

TCTGGCACCTTGCTCACGCAGCAC

AKTKPREEQFNSTFRVV

CTCTGAGAGTACAGCCGCCCTGG

SVLTVVHQDWLNGKEY

GCTGCCTGGTAAAGGACTACTTTC

KCKVSNKGLPAPIEKTIS

CCGAACCAGTCACTGTGTCCTGGA

KTKGQPREPQVYTLPPS

ATAGCGGGGCCTTGACCTCTGGA

REEMTKNQVSLTCLVK

GTGCACACATTTCCAGCTGTACTG

GFYPSDIAVEWESNGQ

CAGTCATCTGGACTCTACAGCCTG

PENNYKTTPPMLDSDG

TCCAGTGTGGTCACCGTACCTTCC

SFFLYSKLTVDKSRWQ

TCCAACTTTGGCACTCAAACATATA

QGNVFSCSVMHEALHN

CATGTAACGTGGATCATAAGCCCT

HYTQKSLSLSPGK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGG

2426
SVKVSCKASGYTFTSYA
2534
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQRLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSQKF

CTTCTGGATACACCTTCACTAGCT

QGRVTMTTDTSTSTAY

ATGCTATGCATTGGGTGCGCCAG

MELRSLRSDDTAVYYCA

GCCCCCGGACAAAGGCTTGAGTG

RARYYDSSGYIAPSGYF

GATGGGATGGATCAACGCTGGCA

DYWGQGTLVTVSSAST

ATGGTAACACAAAATATTCACAGA

KGPSVFPLAPCSRSTSE

AGTTCCAGGGCAGAGTCACCATGA

STAALGCLVKDYFPEPV

CCACAGACACATCCACGAGCACA

TVSWNSGALTSGVHTF

GCCTACATGGAGCTGAGGAGCCT

PAVLQSSGLYSLSSVVT

GAGATCTGACGACACGGCCGTGT

VPSSNFGTQTYTCNVD

ATTACTGTGCGAGAGCTCGTTACT

HKPSNTKVDKTVERKC

ATGATAGTAGTGGTTATATTGCCC

CVECPPCPAPPVAGPS

CATCGGGTTACTTTGACTACTGGG

VFLFPPKPKDTLMISRTP

GCCAGGGAACCCTGGTCACCGTC

EVTCVVVDVSHEDPEV

TCCTCAGCAAGCACAAAAGGTCCT

QFNWYVDGVEVHNAKT

TCAGTGTTCCCTCTGGCACCTTGC

KPREEQFNSTFRVVSVL

TCACGCAGCACCTCTGAGAGTACA

TVVHQDWLNGKEYKCK

GCCGCCCTGGGCTGCCTGGTAAA

VSNKGLPAPIEKTISKTK

GGACTACTTTCCCGAACCAGTCAC

GQPREPQVYTLPPSRE

TGTGTCCTGGAATAGCGGGGCCTT

EMTKNQVSLTCLVKGFY

GACCTCTGGAGTGCACACATTTCC

PSDIAVEWESNGQPEN

AGCTGTACTGCAGTCATCTGGACT

NYKTTPPMLDSDGSFFL

CTACAGCCTGTCCAGTGTGGTCAC

YSKLTVDKSRWQQGNV

CGTACCTTCCTCCAACTTTGGCAC

FSCSVMHEALHNHYTQ

TCAAACATATACATGTAACGTGGA

KSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2427
SVKVSCKASGYTFTSYA
2535
GGCTGAGGTGAAGAAGCCTGGGG

MHWRQAPGQRLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSQKF

CTTCTGGATACACCTTCACTAGCT

QGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAR

GCCCCCGGACAAAGGCTTGAGTG

DGPAVDGAEYFQHWG

GATGGGATGGATCAACGCTGGCA

QGTLVTVSSASTKGPSV

ATGGTAACACAAAATATTCACAGA

FPLAPCSRSTSESTAAL

AGTTCCAGGGCAGAGTCACCATTA

GCLVKDYFPEPVTVSW

CCAGGGACACATCCGCGAGCACA

NSGALTSGVHTFPAVLQ

GCCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAAGACACGGCTGTGTA

FGTQTYTCNVDHKPSN

TTACTGTGCGAGAGATGGCCCCG

TKVDKTVERKCCVECPP

CCGTTGATGGTGCTGAATACTTCC

CPAPPVAGPSVFLFPPK

AGCACTGGGGCCAGGGCACCCTG

PKDTLMISRTPEVTCVV

GTCACCGTCTCCTCAGCAAGCACA

VDVSHEDPEVQFNWYV

AAAGGTCCTTCAGTGTTCCCTCTG

DGVEVHNAKTKPREEQ

GCACCTTGCTCACGCAGCACCTCT

FNSTFRVVSVLTVVHQD

GAGAGTACAGCCGCCCTGGGCTG

WLNGKEYKCKVSNKGL

CCTGGTAAAGGACTACTTTCCCGA

PAPIEKTISKTKGQPREP

ACCAGTCACTGTGTCCTGGAATAG

QVYTLPPSREEMTKNQ

CGGGGCCTTGACCTCTGGAGTGC

VSLTCLVKGFYPSDIAVE

ACACATTTCCAGCTGTACTGCAGT

WESNGQPENNYKTTPP

CATCTGGACTCTACAGCCTGTCCA

MLDSDGSFFLYSKLTVD

GTGTGGTCACCGTACCTTCCTCCA

KSRWQQGNVFSCSVM

ACTTTGGCACTCAAACATATACAT

HEALHNHYTQKSLSLSP

GTAACGTGGATCATAAGCCCTCTA

GK

ACACCAAAGTGGATAAAACTGTGG

AGCGTAAGTGTTGTGTCGAGTGTC

CTCCTTGTCCTGCTCCTCCTGTGG

CAGGCCCATCTGTGTTTCTCTTTC

CCCCAAAGCCAAAGGACACTTTGA

TGATATCCCGGACCCCTGAGGTGA

CTTGCGTCGTCGTAGATGTTTCAC

ACGAAGATCCAGAGGTGCAGTTCA

ACTGGTACGTGGATGGCGTGGAA

GTGCATAATGCCAAGACAAAGCCC

CGCGAAGAGCAGTTTAATTCCACC

TTCCGCGTGGTGTCTGTGCTGACC

GTGGTACATCAGGATTGGCTTAAC

GGTAAGGAGTACAAGTGCAAGGT

GAGTAACAAGGGGCTGCCCGCCC

CTATCGAGAAGACTATCAGTAAAA

CCAAGGGCCAGCCAAGGGAGCCA

CAGGTGTACACACTTCCACCATCT

AGGGAGGAAATGACAAAGAACCA

GGTGAGTTTGACCTGTCTCGTGAA

AGGCTTTTATCCCAGTGATATAGC

CGTGGAATGGGAAAGTAACGGGC

AGCCCGAGAACAACTATAAGACCA

CACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QLQLQESGPGLVKPSQ
SEQ ID
CAGCTGCAGCTGCAGGAGTCGGG

2428
TLSLTCAISGDSVSSNS
2536
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SLKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCA

GGCAGTCCCCATCGCGAGGCCTT

SLASGSPPPGDYWGQG

GAGTGGCTGGGAAGGACTTACTA

TLVTVSSASTKGPSVFP

CAGGTCCAAGTGGTATAATGATTA

LAPCSRSTSESTAALGC

TGCAGTATCTCTGAAAAGTCGAAT

LVKDYFPEPVTVSWNS

AACCATCAACCCGGACACATCCAA

GALTSGVHTFPAVLQSS

GAACCAGTTCTCCCTGCAGCTGAA

GLYSLSSVVTVPSSNFG

CTCTGTGACTCCCGAGGACACGG

TQTYTCNVDHKPSNTKV

CTGTATATTACTGTGCAAGTTTGG

DKTVERKCCVECPPCP

CGAGTGGTTCCCCCCCTCCGGGG

APPVAGPSVFLFPPKPK

GACTACTGGGGCCAGGGAACCCT

DTLMISRTPEVTCVVVD

GGTGACCGTCTCCTCAGCAAGCA

VSHEDPEVQFNWYVDG

CAAAAGGTCCTTCAGTGTTCCCTC

VEVHNAKTKPREEQFN

TGGCACCTTGCTCACGCAGCACCT

STFRVVSVLTVVHQDWL

CTGAGAGTACAGCCGCCCTGGGC

NGKEYKCKVSNKGLPA

TGCCTGGTAAAGGACTACTTTCCC

PIEKTISKTKGQPREPQV

GAACCAGTCACTGTGTCCTGGAAT

YTLPPSREEMTKNQVSL

AGCGGGGCCTTGACCTCTGGAGT

TCLVKGFYPSDIAVEWE

GCACACATTTCCAGCTGTACTGCA

SNGQPENNYKTTPPML

GTCATCTGGACTCTACAGCCTGTC

DSDGSFFLYSKLTVDKS

CAGTGTGGTCACCGTACCTTCCTC

RWQQGNVFSCSVMHE

CAACTTTGGCACTCAAACATATAC

ALHNHYTQKSLSLSPGK

ATGTAACGTGGATCATAAGCCCTC

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2429
SLRLSCAASGFTFSTYG
2537
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

ALISYDGSKKYYANSVK

CCTCTGGATTCACCTTCAGTACCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MKSLRAEDTAMYYCAK

GCTCCAGGCAAGGGGCTGGAGTG

GPIVGATMDYWGQGAL

GGTGGCACTTATATCATATGATGG

VTVSSASTKGPSVFPLA

AAGTAAAAAATACTATGCAAACTCC

PCSRSTSESTAALGCLV

GTGAAGGGCCGATTCACCATCTCC

KDYFPEPVTVSWNSGA

AGAGACAATTCCAAGAACACGTTG

LTSGVHTFPAVLQSSGL

TATCTGCAAATGAAAAGTCTGAGA

YSLSSVVTVPSSNFGTQ

GCTGAGGACACGGCTATGTATTAC

TYTCNVDHKPSNTKVDK

TGTGCGAAAGGCCCTATAGTGGG

TVERKCCVECPPCPAP

AGCGACTATGGACTACTGGGGCC

PVAGPSVFLFPPKPKDT

AGGGAGCCCTGGTCACCGTCTCC

LMISRTPEVTCVVVDVS

TCAGCAAGCACAAAAGGTCCTTCA

HEDPEVQFNWYVDGVE

GTGTTCCCTCTGGCACCTTGCTCA

VHNAKTKPREEQFNSTF

CGCAGCACCTCTGAGAGTACAGC

RVVSVLTVVHQDWLNG

CGCCCTGGGCTGCCTGGTAAAGG

KEYKCKVSNKGLPAPIE

ACTACTTTCCCGAACCAGTCACTG

KTISKTKGQPREPQVYT

TGTCCTGGAATAGCGGGGCCTTG

LPPSREEMTKNQVSLTC

ACCTCTGGAGTGCACACATTTCCA

LVKGFYPSDIAVEWESN

GCTGTACTGCAGTCATCTGGACTC

GQPENNYKTTPPMLDS

TACAGCCTGTCCAGTGTGGTCACC

DGSFFLYSKLTVDKSRW

GTACCTTCCTCCAACTTTGGCACT

QQGNVFSCSVMHEALH

CAAACATATACATGTAACGTGGAT

NHYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
EVQLVQSGAEVKKPGS
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2430
SVKVSCKASGGTFSSYA
2538
GGCTGAGGTGAAGAAGCCTGGGT

ISWVRQAPGQGLEWMG

CCTCGGTGAAGGTCTCCTGCAAG

WISAYNGNTNYAQKLQ

GCTTCTGGAGGCACCTTCAGCAG

GRVTMTTDTSTSTAYM

CTATGCTATCAGCTGGGTGCGACA

ELRSLRSDDTAVYYCAR

GGCCCCTGGACAAGGGCTTGAGT

WYGDYGLDYWGQGTL

GGATGGGATGGATCAGCGCTTAC

VTVSSASTKGPSVFPLA

AATGGTAACACAAACTATGCACAG

PCSRSTSESTAALGCLV

AAGCTCCAGGGCAGAGTCACCAT

KDYFPEPVTVSWNSGA

GACCACAGACACATCCACGAGCA

LTSGVHTFPAVLQSSGL

CAGCCTACATGGAGCTGAGGAGC

YSLSSVVTVPSSNFGTQ

CTGAGATCTGACGACACGGCCGT

TYTCNVDHKPSNTKVDK

GTATTACTGTGCGAGATGGTACGG

TVERKCCVECPPCPAP

TGACTACGGCCTTGACTACTGGGG

PVAGPSVFLFPPKPKDT

CCAGGGAACCCTGGTCACCGTCT

LMISRTPEVTCVVVDVS

CCTCAGCAAGCACAAAAGGTCCTT

HEDPEVQFNWYVDGVE

CAGTGTTCCCTCTGGCACCTTGCT

VHNAKTKPREEQFNSTF

CACGCAGCACCTCTGAGAGTACA

RVVSVLTVVHQDWLNG

GCCGCCCTGGGCTGCCTGGTAAA

KEYKCKVSNKGLPAPIE

GGACTACTTTCCCGAACCAGTCAC

KTISKTKGQPREPQVYT

TGTGTCCTGGAATAGCGGGGCCTT

LPPSREEMTKNQVSLTC

GACCTCTGGAGTGCACACATTTCC

LVKGFYPSDIAVEWESN

AGCTGTACTGCAGTCATCTGGACT

GQPENNYKTTPPMLDS

CTACAGCCTGTCCAGTGTGGTCAC

DGSFFLYSKLTVDKSRW

CGTACCTTCCTCCAACTTTGGCAC

QQGNVFSCSVMHEALH

TCAAACATATACATGTAACGTGGA

NHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTCCAGCTGGTGCAGTCTGG

2431
SVKVSCKASGYTFTSYA
2539
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQRLAWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSEKF

CTTCTGGATACACCTTCACTAGCT

EGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAR

GCCCCCGGACAAAGGCTTGCGTG

VAKYYYESGGYRASNW

GATGGGATGGATCAACGCTGGCA

FDPWGQGTLVTVSSAS

ATGGTAACACAAAATATTCAGAGA

TKGPSVFPLAPCSRSTS

AGTTCGAAGGCAGAGTCACCATCA

ESTAALGCLVKDYFPEP

CCAGGGACACATCCGCGAGCACA

VTVSWNSGALTSGVHT

GCCTACATGGAGCTGAGCAGCCT

FPAVLQSSGLYSLSSVV

GAGATCTGAAGACACGGCTGTGTA

TVPSSNFGTQTYTCNVD

TTACTGTGCGAGGGTCGCCAAATA

HKPSNTKVDKTVERKC

TTATTACGAGAGTGGTGGTTATCG

CVECPPCPAPPVAGPS

GGCCTCCAACTGGTTCGACCCCT

VFLFPPKPKDTLMISRTP

GGGGCCAGGGCACCCTGGTCACC

EVTCVVVDVSHEDPEV

GTCTCCTCAGCAAGCACAAAAGGT

QFNWYVDGVEVHNAKT

CCTTCAGTGTTCCCTCTGGCACCT

KPREEQFNSTFRVVSVL

TGCTCACGCAGCACCTCTGAGAGT

TVVHQDWLNGKEYKCK

ACAGCCGCCCTGGGCTGCCTGGT

VSNKGLPAPIEKTISKTK

AAAGGACTACTTTCCCGAACCAGT

GQPREPQVYTLPPSRE

CACTGTGTCCTGGAATAGCGGGG

EMTKNQVSLTCLVKGFY

CCTTGACCTCTGGAGTGCACACAT

PSDIAVEWESNGQPEN

TTCCAGCTGTACTGCAGTCATCTG

NYKTTPPMLDSDGSFFL

GACTCTACAGCCTGTCCAGTGTGG

YSKLTVDKSRWQQGNV

TCACCGTACCTTCCTCCAACTTTG

FSCSVMHEALHNHYTQ

GCACTCAAACATATACATGTAACG

KSLSLSPGK

TGGATCATAAGCCCTCTAACACCA

AAGTGGATAAAACTGTGGAGCGTA

AGTGTTGTGTCGAGTGTCCTCCTT

GTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQESGPGLVKPSQ
SEQ ID
CAGGTGCAGCTGCAGGAGTCAGG

2432
TLSLTCAISGDSVSSNS
2540
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCA

GGCAGTCCCCATCGAGAGGCCTT

RAPPPTVGWYAPVFDY

GAGTGGCTGGGAAGGACATACTA

WGQGTLVTVSSASTKG

CAGGTCCAAGTGGTATAATGATTA

PSVFPLAPCSRSTSEST

TGCAGTATCTGTGAAAAGTCGAAT

AALGCLVKDYFPEPVTV

AACCATCAACCCAGACACATCCAA

SWNSGALTSGVHTFPA

GAACCAGTTCTCCCTGCAGCTGAA

VLQSSGLYSLSSVVTVP

CTCTGTGACTCCCGAGGACACGG

SSNFGTQTYTCNVDHK

CTGTGTATTACTGTGCAAGAGCGC

PSNTKVDKTVERKCCVE

CCCCTCCGACTGTTGGCTGGTAC

CPPCPAPPVAGPSVFLF

GCCCCCGTCTTTGACTACTGGGG

PPKPKDTLMISRTPEVT

CCAGGGAACCCTGGTCACCGTCT

CVVVDVSHEDPEVQFN

CCTCAGCAAGCACAAAAGGTCCTT

WYVDGVEVHNAKTKPR

CAGTGTTCCCTCTGGCACCTTGCT

EEQFNSTFRVVSVLTVV

CACGCAGCACCTCTGAGAGTACA

HQDWLNGKEYKCKVSN

GCCGCCCTGGGCTGCCTGGTAAA

KGLPAPIEKTISKTKGQP

GGACTACTTTCCCGAACCAGTCAC

REPQVYTLPPSREEMTK

TGTGTCCTGGAATAGCGGGGCCTT

NQVSLTCLVKGFYPSDI

GACCTCTGGAGTGCACACATTTCC

AVEWESNGQPENNYKT

AGCTGTACTGCAGTCATCTGGACT

TPPMLDSDGSFFLYSKL

CTACAGCCTGTCCAGTGTGGTCAC

TVDKSRWQQGNVFSCS

CGTACCTTCCTCCAACTTTGGCAC

VMHEALHNHYTQKSLSL

TCAAACATATACATGTAACGTGGA

SPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QLQLQESGGGLVQPGG
SEQ ID
CAGCTGCAGCTGCAGGAGTCCGG

2433
SLRLSCSASGISFRDYW
2541
GGGAGGCTTAGTTCAGCCGGGGG

MHWIRQTPGKGLVWVS

GGTCCCTGAGACTCTCCTGCTCAG

RINPDGSSTSYADSVKG

CCTCTGGAATCAGCTTCAGAGATT

RFTISRDNSKNTLYLQM

ACTGGATGCACTGGATCCGCCAAA

NSLRAEDTAVYYCAKVT

CTCCAGGGAAGGGGCTGGTGTGG

GRRVGAHDYWGQGTL

GTCTCACGTATTAATCCTGATGGG

VTVSSASTKGPSVFPLA

AGTAGCACAAGCTACGCGGACTC

PCSRSTSESTAALGCLV

CGTGAAGGGCCGATTCACCATCTC

KDYFPEPVTVSWNSGA

CAGAGACAATTCCAAGAACACGCT

LTSGVHTFPAVLQSSGL

GTATCTGCAAATGAACAGCCTGAG

YSLSSVVTVPSSNFGTQ

AGCTGAGGACACGGCTGTGTATTA

TYTCNVDHKPSNTKVDK

CTGTGCGAAAGTTACGGGACGGA

TVERKCCVECPPCPAP

GAGTGGGAGCCCATGACTACTGG

PVAGPSVFLFPPKPKDT

GGCCAGGGAACCCTGGTCACCGT

LMISRTPEVTCVVVDVS

CTCCTCAGCAAGCACAAAAGGTCC

HEDPEVQFNWYVDGVE

TTCAGTGTTCCCTCTGGCACCTTG

VHNAKTKPREEQFNSTF

CTCACGCAGCACCTCTGAGAGTAC

RVVSVLTVVHQDWLNG

AGCCGCCCTGGGCTGCCTGGTAA

KEYKCKVSNKGLPAPIE

AGGACTACTTTCCCGAACCAGTCA

KTISKTKGQPREPQVYT

CTGTGTCCTGGAATAGCGGGGCC

LPPSREEMTKNQVSLTC

TTGACCTCTGGAGTGCACACATTT

LVKGFYPSDIAVEWESN

CCAGCTGTACTGCAGTCATCTGGA

GQPENNYKTTPPMLDS

CTCTACAGCCTGTCCAGTGTGGTC

DGSFFLYSKLTVDKSRW

ACCGTACCTTCCTCCAACTTTGGC

QQGNVFSCSVMHEALH

ACTCAAACATATACATGTAACGTG

NHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
QVQLVQSGAEVKKPGA
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2434
SVKVSCKASGYTFTGYY
2542
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQGLEWM

CCTCAGTGAAGGTCTCCTGCAAGG

GWINPNSGGTNYAQKF

CTTCTGGATACACCTTCACCGGCT

QGRVTMTRDTSISTAYM

ACTATATGCACTGGGTGCGACAGG

ELSRLRSDDTAVYYCAF

CCCCTGGACAAGGGCTTGAGTGG

AQPGAETLNFDLWGRG

ATGGGATGGATCAACCCTAACAGT

TLVTVSSASTKGPSVFP

GGTGGCACAAACTATGCACAGAAG

LAPCSRSTSESTAALGC

TTTCAGGGCAGGGTCACCATGACC

LVKDYFPEPVTVSWNS

AGGGACACGTCCATCAGCACAGC

GALTSGVHTFPAVLQSS

CTACATGGAGCTGAGCAGGCTGA

GLYSLSSVVTVPSSNFG

GATCTGACGACACGGCCGTGTATT

TQTYTCNVDHKPSNTKV

ACTGTGCCTTTGCCCAGCCGGGC

DKTVERKCCVECPPCP

GCTGAGACGTTGAACTTCGATCTC

APPVAGPSVFLFPPKPK

TGGGGCCGTGGCACCCTGGTCAC

DTLMISRTPEVTCVVVD

CGTCTCCTCAGCAAGCACAAAAGG

VSHEDPEVQFNWYVDG

TCCTTCAGTGTTCCCTCTGGCACC

VEVHNAKTKPREEQFN

TTGCTCACGCAGCACCTCTGAGAG

STFRVVSVLTVVHQDWL

TACAGCCGCCCTGGGCTGCCTGG

NGKEYKCKVSNKGLPA

TAAAGGACTACTTTCCCGAACCAG

PIEKTISKTKGQPREPQV

TCACTGTGTCCTGGAATAGCGGG

YTLPPSREEMTKNQVSL

GCCTTGACCTCTGGAGTGCACACA

TCLVKGFYPSDIAVEWE

TTTCCAGCTGTACTGCAGTCATCT

SNGQPENNYKTTPPML

GGACTCTACAGCCTGTCCAGTGTG

DSDGSFFLYSKLTVDKS

GTCACCGTACCTTCCTCCAACTTT

RWQQGNVFSCSVMHE

GGCACTCAAACATATACATGTAAC

ALHNHYTQKSLSLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2435
TLSLTCAISGDSVSSKSA
2543
TCCAGGACTGGTGAAGCCCTCGC

AWNWIRQSPSRGLEWL

AGACCCTCTCACTCACCTGTGCCA

GRTYYRSKWNNDYALS

TCTCCGGGGACAGTGTCTCTAGCA

VKSRITINPDTSKNQFSL

AAAGTGCTGCTTGGAACTGGATCA

QLKSVTPEDTALYYCVR

GGCAGTCCCCATCGAGAGGCCTT

QVAGGMDVWGQGTTV

GAGTGGCTGGGAAGGACATACTA

TVSSASTKGPSVFPLAP

CAGGTCCAAATGGAATAATGATTA

CSRSTSESTAALGCLVK

TGCATTATCTGTGAAAAGTCGAAT

DYFPEPVTVSWNSGAL

AACCATCAACCCAGACACATCCAA

TSGVHTFPAVLQSSGLY

GAACCAGTTCTCCCTGCAGCTGAA

SLSSVVTVPSSNFGTQT

GTCTGTGACTCCCGAGGACACGG

YTCNVDHKPSNTKVDKT

CTCTGTATTACTGTGTAAGACAAG

VERKCCVECPPCPAPP

TCGCGGGCGGTATGGACGTCTGG

VAGPSVFLFPPKPKDTL

GGCCAAGGGACCACGGTCACCGT

MISRTPEVTCVVVDVSH

CTCCTCAGCAAGCACAAAAGGTCC

EDPEVQFNWYVDGVEV

TTCAGTGTTCCCTCTGGCACCTTG

HNAKTKPREEQFNSTFR

CTCACGCAGCACCTCTGAGAGTAC

VVSVLTVVHQDWLNGK

AGCCGCCCTGGGCTGCCTGGTAA

EYKCKVSNKGLPAPIEK

AGGACTACTTTCCCGAACCAGTCA

TISKTKGQPREPQVYTL

CTGTGTCCTGGAATAGCGGGGCC

PPSREEMTKNQVSLTCL

TTGACCTCTGGAGTGCACACATTT

VKGFYPSDIAVEWESNG

CCAGCTGTACTGCAGTCATCTGGA

QPENNYKTTPPMLDSD

CTCTACAGCCTGTCCAGTGTGGTC

GSFFLYSKLTVDKSRW

ACCGTACCTTCCTCCAACTTTGGC

QQGNVFSCSVMHEALH

ACTCAAACATATACATGTAACGTG

NHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGR
SEQ ID
CAGGTGCAGCTGGTGCAATCTGG

2436
SLRLSCTASGFTFGDYA
2544
GGGAGGCTTGGTACAGCCAGGGC

MSWFRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTACAG

SAISGSGGSTYYADSVK

CTTCTGGATTCACCTTTGGTGATTA

GRFTISRDNSKNTLYLQ

TGCTATGAGCTGGTTCCGCCAGG

MNSLRAEDTAVYYCAK

CTCCAGGGAAGGGGCTGGAGTGG

GSVYSGSYYMLIDYWG

GTCTCAGCTATTAGTGGTAGTGGT

QGTLVTVSSASTKGPSV

GGTAGCACATACTATGCAGACTCC

FPLAPCSRSTSESTAAL

GTGAAGGGCCGATTCACCATCTCC

GCLVKDYFPEPVTVSW

AGAGACAATTCCAAGAACACGCTG

NSGALTSGVHTFPAVLQ

TATCTGCAAATGAACAGCCTGAGA

SSGLYSLSSVVTVPSSN

GCTGAGGACACGGCTGTGTATTAC

FGTQTYTCNVDHKPSN

TGTGCGAAAGGATCGGTATATAGT

TKVDKTVERKCCVECPP

GGGAGCTACTATATGCTCATTGAC

CPAPPVAGPSVFLFPPK

TACTGGGGCCAGGGCACCCTGGT

PKDTLMISRTPEVTCVV

CACCGTCTCCTCAGCAAGCACAAA

VDVSHEDPEVQFNWYV

AGGTCCTTCAGTGTTCCCTCTGGC

DGVEVHNAKTKPREEQ

ACCTTGCTCACGCAGCACCTCTGA

FNSTFRVVSVLTVVHQD

GAGTACAGCCGCCCTGGGCTGCC

WLNGKEYKCKVSNKGL

TGGTAAAGGACTACTTTCCCGAAC

PAPIEKTISKTKGQPREP

CAGTCACTGTGTCCTGGAATAGCG

QVYTLPPSREEMTKNQ

GGGCCTTGACCTCTGGAGTGCAC

VSLTCLVKGFYPSDIAVE

ACATTTCCAGCTGTACTGCAGTCA

WESNGQPENNYKTTPP

TCTGGACTCTACAGCCTGTCCAGT

MLDSDGSFFLYSKLTVD

GTGGTCACCGTACCTTCCTCCAAC

KSRWQQGNVFSCSVM

TTTGGCACTCAAACATATACATGTA

HEALHNHYTQKSLSLSP

ACGTGGATCATAAGCCCTCTAACA

GK

CCAAAGTGGATAAAACTGTGGAGC

GTAAGTGTTGTGTCGAGTGTCCTC

CTTGTCCTGCTCCTCCTGTGGCAG

GCCCATCTGTGTTTCTCTTTCCCC

CAAAGCCAAAGGACACTTTGATGA

TATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLVRPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2437
TLSLTCVISGDSVSSGS
2545
TCCAGGACTGGTGAGGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGTCA

LGRTYYRAKWYNEYAG

TCTCCGGGGACAGTGTCTCTAGC

SVKSRITISPDTSKNQFS

GGCAGTGCTGCTTGGAACTGGAT

LQLNSVTPEDTAVYFCT

CAGGCAGTCCCCATCGAGAGGCC

RQDKDNTRYSGLGVWG

TTGAGTGGCTGGGAAGGACATATT

QGTTVTVSSASTKGPSV

ATAGGGCCAAGTGGTATAATGAAT

FPLAPCSRSTSESTAAL

ATGCAGGGTCTGTGAAAAGCCGAA

GCLVKDYFPEPVTVSW

TAACCATCAGTCCGGACACATCCA

NSGALTSGVHTFPAVLQ

AGAACCAGTTCTCCCTGCAACTGA

SSGLYSLSSVVTVPSSN

ACTCTGTGACTCCCGAGGACACG

FGTQTYTCNVDHKPSN

GCTGTGTATTTCTGTACAAGACAA

TKVDKTVERKCCVECPP

GACAAAGACAACACGAGATATTCC

CPAPPVAGPSVFLFPPK

GGTTTGGGCGTCTGGGGCCAAGG

PKDTLMISRTPEVTCVV

GACCACGGTGACCGTCTCCTCAG

VDVSHEDPEVQFNWYV

CAAGCACAAAAGGTCCTTCAGTGT

DGVEVHNAKTKPREEQ

TCCCTCTGGCACCTTGCTCACGCA

FNSTFRVVSVLTVVHQD

GCACCTCTGAGAGTACAGCCGCC

WLNGKEYKCKVSNKGL

CTGGGCTGCCTGGTAAAGGACTA

PAPIEKTISKTKGQPREP

CTTTCCCGAACCAGTCACTGTGTC

QVYTLPPSREEMTKNQ

CTGGAATAGCGGGGCCTTGACCT

VSLTCLVKGFYPSDIAVE

CTGGAGTGCACACATTTCCAGCTG

WESNGQPENNYKTTPP

TACTGCAGTCATCTGGACTCTACA

MLDSDGSFFLYSKLTVD

GCCTGTCCAGTGTGGTCACCGTAC

KSRWQQGNVFSCSVM

CTTCCTCCAACTTTGGCACTCAAA

HEALHNHYTQKSLSLSP

CATATACATGTAACGTGGATCATA

GK

AGCCCTCTAACACCAAAGTGGATA

AAACTGTGGAGCGTAAGTGTTGTG

TCGAGTGTCCTCCTTGTCCTGCTC

CTCCTGTGGCAGGCCCATCTGTGT

TTCTCTTTCCCCCAAAGCCAAAGG

ACACTTTGATGATATCCCGGACCC

CTGAGGTGACTTGCGTCGTCGTAG

ATGTTTCACACGAAGATCCAGAGG

TGCAGTTCAACTGGTACGTGGATG

GCGTGGAAGTGCATAATGCCAAGA

CAAAGCCCCGCGAAGAGCAGTTTA

ATTCCACCTTCCGCGTGGTGTCTG

TGCTGACCGTGGTACATCAGGATT

GGCTTAACGGTAAGGAGTACAAGT

GCAAGGTGAGTAACAAGGGGCTG

CCCGCCCCTATCGAGAAGACTATC

AGTAAAACCAAGGGCCAGCCAAG

GGAGCCACAGGTGTACACACTTCC

ACCATCTAGGGAGGAAATGACAAA

GAACCAGGTGAGTTTGACCTGTCT

CGTGAAAGGCTTTTATCCCAGTGA

TATAGCCGTGGAATGGGAAAGTAA

CGGGCAGCCCGAGAACAACTATA

AGACCACACCACCCATGCTGGACT

CCGACGGTTCTTTCTTCCTTTATAG

CAAGCTGACAGTGGATAAATCCAG

GTGGCAGCAGGGTAACGTATTCA

GTTGCAGTGTCATGCACGAGGCA

CTCCACAACCACTATACTCAGAAA

AGTCTTTCCCTGAGTCCAGGCAAG

SEQ ID
EVQLVETGGGLVQPGG
SEQ ID
GAGGTGCAGCTGGTGGAGACCGG

2438
SLRLSCAASEFTLRNYG
2546
GGGAGGCTTAGTTCAGCCTGGGG

VSWRQAPGKGLEWS

GGTCCCTGAGACTCTCCTGTGCAG

GMSGSGYSTYYADSVK

CCTCTGAATTCACCCTTAGGAACT

GRFTISRDSSKNTLFLQ

ATGGCGTGAGCTGGGTCCGCCAG

MDSLRAEDTAIYYCARG

GCTCCAGGGAAGGGGCTGGAGTG

PRMWSSGIDAFDIWGH

GGTCTCAGGTATGAGTGGTAGTG

GTMVTVSSASTKGPSVF

GTTATAGTACATACTACGCAGACT

PLAPCSRSTSESTAALG

CCGTGAAGGGCCGGTTCACCATC

CLVKDYFPEPVTVSWN

TCCAGAGACAGTTCCAAGAACACG

SGALTSGVHTFPAVLQS

CTGTTTCTGCAAATGGACAGCCTG

SGLYSLSSVVTVPSSNF

AGAGCCGAGGACACGGCCATATA

GTQTYTCNVDHKPSNT

TTACTGTGCGAGAGGGCCCCGAA

KVDKTVERKCCVECPP

TGTGGAGCAGTGGCATTGATGCTT

CPAPPVAGPSVFLFPPK

TTGATATCTGGGGCCACGGGACAA

PKDTLMISRTPEVTCVV

TGGTGACCGTCTCTTCAGCAAGCA

VDVSHEDPEVQFNWYV

CAAAAGGTCCTTCAGTGTTCCCTC

DGVEVHNAKTKPREEQ

TGGCACCTTGCTCACGCAGCACCT

FNSTFRVVSVLTVVHQD

CTGAGAGTACAGCCGCCCTGGGC

WLNGKEYKCKVSNKGL

TGCCTGGTAAAGGACTACTTTCCC

PAPIEKTISKTKGQPREP

GAACCAGTCACTGTGTCCTGGAAT

QVYTLPPSREEMTKNQ

AGCGGGGCCTTGACCTCTGGAGT

VSLTCLVKGFYPSDIAVE

GCACACATTTCCAGCTGTACTGCA

WESNGQPENNYKTTPP

GTCATCTGGACTCTACAGCCTGTC

MLDSDGSFFLYSKLTVD

CAGTGTGGTCACCGTACCTTCCTC

KSRWQQGNVFSCSVM

CAACTTTGGCACTCAAACATATAC

HEALHNHYTQKSLSLSP

ATGTAACGTGGATCATAAGCCCTC

GK

TAACACCAAAGTGGATAAAACTGT

GGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2439
TLSLTCAVYGGSVSGYY
2547
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWM

AGACCCTGTCCCTCACCTGCGCTG

GEIHHSGSTNYNPSLKS

TCTATGGTGGGTCCGTCAGTGGTT

RVTISLDTPKNQFSLKLS

ACTACTGGAGCTGGATCCGCCAG

SVTAADTAVYYCARRD

CCCCCAGGGAAGGGGCTGGAGTG

WAGKRVWGQGTLVTVS

GATGGGGGAAATCCATCATAGTGG

SASTKGPSVFPLAPCSR

AAGCACCAACTACAACCCGTCCCT

STSESTAALGCLVKDYF

CAAGAGTCGAGTCACCATATCACT

PEPVTVSWNSGALTSG

AGACACGCCCAAGAACCAGTTCTC

VHTFPAVLQSSGLYSLS

CCTGAAGCTAAGCTCTGTGACCGC

SVVTVPSSNFGTQTYTC

CGCGGACACGGCTGTATATTACTG

NVDHKPSNTKVDKTVE

TGCGAGACGGGATTGGGCAGGAA

RKCCVECPPCPAPPVA

AAAGGGTCTGGGGCCAGGGAACC

GPSVFLFPPKPKDTLMI

CTGGTCACCGTCTCCTCAGCAAGC

SRTPEVTCVVVDVSHED

ACAAAAGGTCCTTCAGTGTTCCCT

PEVQFNWYVDGVEVHN

CTGGCACCTTGCTCACGCAGCAC

AKTKPREEQFNSTFRVV

CTCTGAGAGTACAGCCGCCCTGG

SVLTVVHQDWLNGKEY

GCTGCCTGGTAAAGGACTACTTTC

KCKVSNKGLPAPIEKTIS

CCGAACCAGTCACTGTGTCCTGGA

KTKGQPREPQVYTLPPS

ATAGCGGGGCCTTGACCTCTGGA

REEMTKNQVSLTCLVK

GTGCACACATTTCCAGCTGTACTG

GFYPSDIAVEWESNGQ

CAGTCATCTGGACTCTACAGCCTG

PENNYKTTPPMLDSDG

TCCAGTGTGGTCACCGTACCTTCC

SFFLYSKLTVDKSRWQ

TCCAACTTTGGCACTCAAACATATA

QGNVFSCSVMHEALHN

CATGTAACGTGGATCATAAGCCCT

HYTQKSLSLSPGK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQQSGPGLLKPSQ
SEQ ID
CAGGTACAGCTGCAGCAGTCAGG

2440
TLSLTCAISGDSVSSNTA
2548
TCCAGGACTATTAAAGCCCTCGCA

TWNWIRQSPSRGLEWL

GACCCTCTCACTCACCTGTGCCAT

GRTYYRSKWYKDNALS

CTCCGGGGACAGTGTCTCTAGCAA

VKSRITINPDTSKNQFSL

CACTGCTACTTGGAACTGGATCAG

QLNSVTPEDTAVYYCAG

GCAGTCCCCATCGAGAGGCCTTG

GRAGIAAFDIWGQGTTV

AGTGGCTGGGAAGGACATACTACA

TVSSASTKGPSVFPLAP

GGTCCAAGTGGTATAAGGATAATG

CSRSTSESTAALGCLVK

CACTGTCTGTGAAAAGTCGAATAA

DYFPEPVTVSWNSGAL

CCATCAACCCAGACACATCCAAGA

TSGVHTFPAVLQSSGLY

ACCAGTTCTCCCTGCAGCTGAACT

SLSSVVTVPSSNFGTQT

CTGTGACTCCCGAGGACACGGCT

YTCNVDHKPSNTKVDKT

GTGTATTACTGTGCAGGAGGTCGG

VERKCCVECPPCPAPP

GCTGGTATTGCCGCTTTTGATATC

VAGPSVFLFPPKPKDTL

TGGGGCCAAGGGACCACGGTCAC

MISRTPEVTCVVVDVSH

CGTCTCCTCAGCAAGCACAAAAGG

EDPEVQFNWYVDGVEV

TCCTTCAGTGTTCCCTCTGGCACC

HNAKTKPREEQFNSTFR

TTGCTCACGCAGCACCTCTGAGAG

VVSVLTVVHQDWLNGK

TACAGCCGCCCTGGGCTGCCTGG

EYKCKVSNKGLPAPIEK

TAAAGGACTACTTTCCCGAACCAG

TISKTKGQPREPQVYTL

TCACTGTGTCCTGGAATAGCGGG

PPSREEMTKNQVSLTCL

GCCTTGACCTCTGGAGTGCACACA

VKGFYPSDIAVEWESNG

TTTCCAGCTGTACTGCAGTCATCT

QPENNYKTTPPMLDSD

GGACTCTACAGCCTGTCCAGTGTG

GSFFLYSKLTVDKSRW

GTCACCGTACCTTCCTCCAACTTT

QQGNVFSCSVMHEALH

GGCACTCAAACATATACATGTAAC

NHYTQKSLSLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLIQPGG
SEQ ID
CAGGTGCAGCTGGTGCAATCTGG

2441
SLRLSCAASGFTVSSNY
2549
AGGAGGCTTGATCCAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SLIYSDGRTNYADSVKG

CCTCTGGGTTCACCGTCAGTAGCA

RFTISRDNSKNTLYLQM

ACTACATGAGCTGGGTCCGCCAG

NSLRAEDTAVYYCAKGA

GCTCCAGGGAAGGGGCTGGAATG

LQGEWRRFDYWGQGT

GGTCTCACTTATTTATAGTGATGGT

LVTVSSASTKGPSVFPL

CGCACAAACTATGCAGACTCCGTG

APCSRSTSESTAALGCL

AAGGGCCGATTCACCATCTCCAGA

VKDYFPEPVTVSWNSG

GACAATTCCAAGAACACGCTGTAT

ALTSGVHTFPAVLQSSG

CTGCAAATGAACAGCCTGAGAGCC

LYSLSSVVTVPSSNFGT

GAGGACACGGCCGTATATTACTGT

QTYTCNVDHKPSNTKV

GCGAAGGGGGCCCTACAGGGCGA

DKTVERKCCVECPPCP

ATGGCGGAGATTTGACTACTGGG

APPVAGPSVFLFPPKPK

GCCAGGGCACCCTGGTCACCGTC

DTLMISRTPEVTCVVVD

TCCTCAGCAAGCACAAAAGGTCCT

VSHEDPEVQFNWYVDG

TCAGTGTTCCCTCTGGCACCTTGC

VEVHNAKTKPREEQFN

TCACGCAGCACCTCTGAGAGTACA

STFRVVSVLTVVHQDWL

GCCGCCCTGGGCTGCCTGGTAAA

NGKEYKCKVSNKGLPA

GGACTACTTTCCCGAACCAGTCAC

PIEKTISKTKGQPREPQV

TGTGTCCTGGAATAGCGGGGCCTT

YTLPPSREEMTKNQVSL

GACCTCTGGAGTGCACACATTTCC

TCLVKGFYPSDIAVEWE

AGCTGTACTGCAGTCATCTGGACT

SNGQPENNYKTTPPML

CTACAGCCTGTCCAGTGTGGTCAC

DSDGSFFLYSKLTVDKS

CGTACCTTCCTCCAACTTTGGCAC

RWQQGNVFSCSVMHE

TCAAACATATACATGTAACGTGGA

ALHNHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTGCAGCTACAGCAGTCAGG

2442
TLSLTCAISGDSVSSNS
2550
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTAGCA

SVKSRITINPDTSKNQFS

ACAGTGCTGCTTGGAACTGGATCA

LQLNSVTPEDTAVYYCT

GGCAGTCCCCATCGAGAGGCCTT

RTNQGYGGNSGVFDY

GAGTGGCTGGGAAGGACATATTAC

WGQGTLVTVSSASTKG

AGGTCCAAGTGGTATAATGATTAT

PSVFPLAPCSRSTSEST

GCAGTATCTGTGAAAAGTCGAATA

AALGCLVKDYFPEPVTV

ACCATCAACCCAGACACATCCAAG

SWNSGALTSGVHTFPA

AACCAGTTCTCCCTGCAGCTGAAC

VLQSSGLYSLSSVVTVP

TCTGTGACTCCCGAGGACACGGC

SSNFGTQTYTCNVDHK

TGTGTATTACTGTACAAGAACCAA

PSNTKVDKTVERKCCVE

CCAGGGATACGGTGGTAACTCCG

CPPCPAPPVAGPSVFLF

GGGTATTTGACTACTGGGGCCAG

PPKPKDTLMISRTPEVT

GGAACCCTGGTCACCGTCTCCTCA

CVVVDVSHEDPEVQFN

GCAAGCACAAAAGGTCCTTCAGTG

WYVDGVEVHNAKTKPR

TTCCCTCTGGCACCTTGCTCACGC

EEQFNSTFRVVSVLTVV

AGCACCTCTGAGAGTACAGCCGC

HQDWLNGKEYKCKVSN

CCTGGGCTGCCTGGTAAAGGACT

KGLPAPIEKTISKTKGQP

ACTTTCCCGAACCAGTCACTGTGT

REPQVYTLPPSREEMTK

CCTGGAATAGCGGGGCCTTGACC

NQVSLTCLVKGFYPSDI

TCTGGAGTGCACACATTTCCAGCT

AVEWESNGQPENNYKT

GTACTGCAGTCATCTGGACTCTAC

TPPMLDSDGSFFLYSKL

AGCCTGTCCAGTGTGGTCACCGTA

TVDKSRWQQGNVFSCS

CCTTCCTCCAACTTTGGCACTCAA

VMHEALHNHYTQKSLSL

ACATATACATGTAACGTGGATCAT

SPGK

AAGCCCTCTAACACCAAAGTGGAT

AAAACTGTGGAGCGTAAGTGTTGT

GTCGAGTGTCCTCCTTGTCCTGCT

CCTCCTGTGGCAGGCCCATCTGT

GTTTCTCTTTCCCCCAAAGCCAAA

GGACACTTTGATGATATCCCGGAC

CCCTGAGGTGACTTGCGTCGTCGT

AGATGTTTCACACGAAGATCCAGA

GGTGCAGTTCAACTGGTACGTGGA

TGGCGTGGAAGTGCATAATGCCAA

GACAAAGCCCCGCGAAGAGCAGT

TTAATTCCACCTTCCGCGTGGTGT

CTGTGCTGACCGTGGTACATCAGG

ATTGGCTTAACGGTAAGGAGTACA

AGTGCAAGGTGAGTAACAAGGGG

CTGCCCGCCCCTATCGAGAAGACT

ATCAGTAAAACCAAGGGCCAGCCA

AGGGAGCCACAGGTGTACACACTT

CCACCATCTAGGGAGGAAATGACA

AAGAACCAGGTGAGTTTGACCTGT

CTCGTGAAAGGCTTTTATCCCAGT

GATATAGCCGTGGAATGGGAAAGT

AACGGGCAGCCCGAGAACAACTA

TAAGACCACACCACCCATGCTGGA

CTCCGACGGTTCTTTCTTCCTTTAT

AGCAAGCTGACAGTGGATAAATCC

AGGTGGCAGCAGGGTAACGTATT

CAGTTGCAGTGTCATGCACGAGG

CACTCCACAACCACTATACTCAGA

AAAGTCTTTCCCTGAGTCCAGGCA

AG

SEQ ID
QVQLQQSGPGLVKPSQ
SEQ ID
CAGGTGCAGCTACAGCAGTCAGG

2443
TLSLTCAISGDSVSGNS
2551
TCCAGGACTGGTGAAGCCCTCGC

AAWNWIRQSPSRGLEW

AGACCCTCTCACTCACCTGTGCCA

LGRTYYRSKWYNDYAV

TCTCCGGGGACAGTGTCTCTGGC

SVKSRITINPDTSKNQFS

AACAGTGCTGCTTGGAACTGGATC

LQLNSVTPEDTAVYYCA

AGGCAGTCCCCATCGAGAGGCCT

RIVGGAVDCWGQGTLV

TGAGTGGCTGGGAAGGACATACTA

TVSSASTKGPSVFPLAP

CAGGTCCAAGTGGTATAATGATTA

CSRSTSESTAALGCLVK

TGCAGTATCTGTGAAAAGTCGAAT

DYFPEPVTVSWNSGAL

AACCATCAACCCAGACACATCCAA

TSGVHTFPAVLQSSGLY

GAACCAGTTCTCCCTGCAGTTGAA

SLSSWVTVPSSNFGTQT

TTCTGTGACTCCCGAGGACACGG

YTCNVDHKPSNTKVDKT

CTGTGTATTACTGTGCGAGGATAG

VERKCCVECPPCPAPP

TGGGAGGTGCCGTTGACTGCTGG

VAGPSVFLFPPKPKDTL

GGCCAGGGAACCCTGGTGACCGT

MISRTPEVTCVVVDVSH

CTCCTCAGCAAGCACAAAAGGTCC

EDPEVQFNWYVDGVEV

TTCAGTGTTCCCTCTGGCACCTTG

HNAKTKPREEQFNSTFR

CTCACGCAGCACCTCTGAGAGTAC

VVSVLTVVHQDWLNGK

AGCCGCCCTGGGCTGCCTGGTAA

EYKCKVSNKGLPAPIEK

AGGACTACTTTCCCGAACCAGTCA

TISKTKGQPREPQVYTL

CTGTGTCCTGGAATAGCGGGGCC

PPSREEMTKNQVSLTCL

TTGACCTCTGGAGTGCACACATTT

VKGFYPSDIAVEWESNG

CCAGCTGTACTGCAGTCATCTGGA

QPENNYKTTPPMLDSD

CTCTACAGCCTGTCCAGTGTGGTC

GSFFLYSKLTVDKSRW

ACCGTACCTTCCTCCAACTTTGGC

QQGNVFSCSVMHEALH

ACTCAAACATATACATGTAACGTG

NHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVQSGAEVKKPGA
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2444
SVKVSCKASGYTFTSYA
2552
GGCTGAGGTGAAGAAGCCTGGGG

MHWVRQAPGQRLEWM

CCTCAGTGAAGGTTTCCTGCAAGG

GWINAGNGNTKYSQKF

CTTCTGGATACACCTTCACTAGCT

QGRVTITRDTSASTAYM

ATGCTATGCATTGGGTGCGCCAG

ELSSLRSEDTAVYYCAR

GCCCCCGGACAAAGGCTTGAGTG

VRVGATTVYDSWFDPW

GATGGGATGGATCAACGCTGGCA

GQGTLVTVSSASTKGPS

ATGGTAACACAAAATATTCACAGA

VFPLAPCSRSTSESTAA

AGTTCCAGGGCAGAGTCACCATTA

LGCLVKDYFPEPVTVSW

CCAGGGACACATCCGCGAGCACA

NSGALTSGVHTFPAVLQ

GCCTACATGGAGCTGAGCAGCCT

SSGLYSLSSVVTVPSSN

GAGATCTGAAGACACGGCTGTGTA

FGTQTYTCNVDHKPSN

TTACTGTGCGAGAGTTAGAGTGGG

TKVDKTVERKCCVECPP

AGCTACTACTGTTTACGACAGCTG

CPAPPVAGPSVFLFPPK

GTTCGACCCCTGGGGCCAGGGAA

PKDTLMISRTPEVTCVV

CCCTGGTGACCGTCTCCTCAGCAA

VDVSHEDPEVQFNWYV

GCACAAAAGGTCCTTCAGTGTTCC

DGVEVHNAKTKPREEQ

CTCTGGCACCTTGCTCACGCAGCA

FNSTFRVVSVLTVVHQD

CCTCTGAGAGTACAGCCGCCCTG

WLNGKEYKCKVSNKGL

GGCTGCCTGGTAAAGGACTACTTT

PAPIEKTISKTKGQPREP

CCCGAACCAGTCACTGTGTCCTGG

QVYTLPPSREEMTKNQ

AATAGCGGGGCCTTGACCTCTGG

VSLTCLVKGFYPSDIAVE

AGTGCACACATTTCCAGCTGTACT

WESNGQPENNYKTTPP

GCAGTCATCTGGACTCTACAGCCT

MLDSDGSFFLYSKLTVD

GTCCAGTGTGGTCACCGTACCTTC

KSRWQQGNVFSCSVM

CTCCAACTTTGGCACTCAAACATA

HEALHNHYTQKSLSLSP

TACATGTAACGTGGATCATAAGCC

GK

CTCTAACACCAAAGTGGATAAAAC

TGTGGAGCGTAAGTGTTGTGTCGA

GTGTCCTCCTTGTCCTGCTCCTCC

TGTGGCAGGCCCATCTGTGTTTCT

CTTTCCCCCAAAGCCAAAGGACAC

TTTGATGATATCCCGGACCCCTGA

GGTGACTTGCGTCGTCGTAGATGT

TTCACACGAAGATCCAGAGGTGCA

GTTCAACTGGTACGTGGATGGCGT

GGAAGTGCATAATGCCAAGACAAA

GCCCCGCGAAGAGCAGTTTAATTC

CACCTTCCGCGTGGTGTCTGTGCT

GACCGTGGTACATCAGGATTGGCT

TAACGGTAAGGAGTACAAGTGCAA

GGTGAGTAACAAGGGGCTGCCCG

CCCCTATCGAGAAGACTATCAGTA

AAACCAAGGGCCAGCCAAGGGAG

CCACAGGTGTACACACTTCCACCA

TCTAGGGAGGAAATGACAAAGAAC

CAGGTGAGTTTGACCTGTCTCGTG

AAAGGCTTTTATCCCAGTGATATA

GCCGTGGAATGGGAAAGTAACGG

GCAGCCCGAGAACAACTATAAGAC

CACACCACCCATGCTGGACTCCGA

CGGTTCTTTCTTCCTTTATAGCAAG

CTGACAGTGGATAAATCCAGGTGG

CAGCAGGGTAACGTATTCAGTTGC

AGTGTCATGCACGAGGCACTCCAC

AACCACTATACTCAGAAAAGTCTTT

CCCTGAGTCCAGGCAAG

SEQ ID
QVQLVQSGGGLVQPGG
SEQ ID
CAGGTGCAGCTGGTGCAGTCTGG

2445
SLRLSCAASGFTFSSYA
2553
GGGAGGCTTGGTACAGCCTGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SAISGSGGSTYYADSVK

CCTCTGGATTCACCTTTAGCAGCT

GRFTISRDNSKNTLYLQ

ATGCCATGAGCTGGGTCCGCCAG

MNSLRAEDTAVYYCAK

GCTCCAGGGAAGGGGCTGGAGTG

DGGSSPYYDSSGLLPW

GGTCTCAGCTATTAGTGGTAGTGG

YFDLWGRGTLVTVSSA

TGGTAGCACATACTACGCAGACTC

STKGPSVFPLAPCSRST

CGTGAAGGGCCGGTTCACCATCT

SESTAALGCLVKDYFPE

CCAGAGACAATTCCAAGAACACGC

PVTVSWNSGALTSGVH

TGTATCTGCAAATGAACAGCCTGA

TFPAVLQSSGLYSLSSV

GAGCCGAGGACACGGCCGTATAT

VTVPSSNFGTQTYTCNV

TACTGTGCGAAAGATGGGGGGTC

DHKPSNTKVDKTVERK

CAGCCCATACTATGATAGTAGTGG

CCVECPPCPAPPVAGP

TTTACTACCCTGGTACTTCGATCTC

SVFLFPPKPKDTLMISRT

TGGGGCCGTGGCACCCTGGTCAC

PEVTCVVVDVSHEDPEV

CGTCTCCTCAGCAAGCACAAAAGG

QFNWYVDGVEVHNAKT

TCCTTCAGTGTTCCCTCTGGCACC

KPREEQFNSTFRVVSVL

TTGCTCACGCAGCACCTCTGAGAG

TVVHQDWLNGKEYKCK

TACAGCCGCCCTGGGCTGCCTGG

VSNKGLPAPIEKTISKTK

TAAAGGACTACTTTCCCGAACCAG

GQPREPQVYTLPPSRE

TCACTGTGTCCTGGAATAGCGGG

EMTKNQVSLTCLVKGFY

GCCTTGACCTCTGGAGTGCACACA

PSDIAVEWESNGQPEN

TTTCCAGCTGTACTGCAGTCATCT

NYKTTPPMLDSDGSFFL

GGACTCTACAGCCTGTCCAGTGTG

YSKLTVDKSRWQQGNV

GTCACCGTACCTTCCTCCAACTTT

FSCSVMHEALHNHYTQ

GGCACTCAAACATATACATGTAAC

KSLSLSPGK

GTGGATCATAAGCCCTCTAACACC

AAAGTGGATAAAACTGTGGAGCGT

AAGTGTTGTGTCGAGTGTCCTCCT

TGTCCTGCTCCTCCTGTGGCAGGC

CCATCTGTGTTTCTCTTTCCCCCAA

AGCCAAAGGACACTTTGATGATAT

CCCGGACCCCTGAGGTGACTTGC

GTCGTCGTAGATGTTTCACACGAA

GATCCAGAGGTGCAGTTCAACTGG

TACGTGGATGGCGTGGAAGTGCA

TAATGCCAAGACAAAGCCCCGCGA

AGAGCAGTTTAATTCCACCTTCCG

CGTGGTGTCTGTGCTGACCGTGG

TACATCAGGATTGGCTTAACGGTA

AGGAGTACAAGTGCAAGGTGAGTA

ACAAGGGGCTGCCCGCCCCTATC

GAGAAGACTATCAGTAAAACCAAG

GGCCAGCCAAGGGAGCCACAGGT

GTACACACTTCCACCATCTAGGGA

GGAAATGACAAAGAACCAGGTGA

GTTTGACCTGTCTCGTGAAAGGCT

TTTATCCCAGTGATATAGCCGTGG

AATGGGAAAGTAACGGGCAGCCC

GAGAACAACTATAAGACCACACCA

CCCATGCTGGACTCCGACGGTTCT

TTCTTCCTTTATAGCAAGCTGACA

GTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
QVQLQESGGGLVQPGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCGGG

2446
SLRLSCAASGFTFSSYA
2554
GGGAGGCTTGGTCCAGCCTGGGG

MHWVRQAPGKGLEYVS

GGTCCCTGAGACTCTCCTGTGCAG

AISSNGGSTYYANSVKG

CCTCTGGATTCACCTTCAGTAGCT

RFTISRDNSKNTLYLQM

ATGCTATGCACTGGGTCCGCCAG

GSLRAEDMAVYYCARA

GCTCCAGGGAAGGGACTGGAATA

KFWTYYFDYWGQGTLV

TGTTTCAGCTATTAGTAGTAATGG

TVSSASTKGPSVFPLAP

GGGTAGCACATATTATGCAAACTC

CSRSTSESTAALGCLVK

TGTGAAGGGCAGATTCACCATCTC

DYFPEPVTVSWNSGAL

CAGAGACAATTCCAAGAACACGCT

TSGVHTFPAVLQSSGLY

GTATCTTCAAATGGGCAGCCTGAG

SLSSVTVPSSNFGTQT

AGCTGAGGACATGGCTGTGTATTA

YTCNVDHKPSNTKVDKT

CTGTGCGAGAGCTAAGTTTTGGAC

VERKCCVECPPCPAPP

ATACTACTTTGACTACTGGGGCCA

VAGPSVFLFPPKPKDTL

GGGAACCCTGGTGACCGTCTCCT

MISRTPEVTCVVVDVSH

CAGCAAGCACAAAAGGTCCTTCAG

EDPEVQFNWYVDGVEV

TGTTCCCTCTGGCACCTTGCTCAC

HNAKTKPREEQFNSTFR

GCAGCACCTCTGAGAGTACAGCC

VVSVLTVVHQDWLNGK

GCCCTGGGCTGCCTGGTAAAGGA

EYKCKVSNKGLPAPIEK

CTACTTTCCCGAACCAGTCACTGT

TISKTKGQPREPQVYTL

GTCCTGGAATAGCGGGGCCTTGA

PPSREEMTKNQVSLTCL

CCTCTGGAGTGCACACATTTCCAG

VKGFYPSDIAVEWESNG

CTGTACTGCAGTCATCTGGACTCT

QPENNYKTTPPMLDSD

ACAGCCTGTCCAGTGTGGTCACC

GSFFLYSKLTVDKSRW

GTACCTTCCTCCAACTTTGGCACT

QQGNVFSCSVMHEALH

CAAACATATACATGTAACGTGGAT

NHYTQKSLSLSPGK

CATAAGCCCTCTAACACCAAAGTG

GATAAAACTGTGGAGCGTAAGTGT

TGTGTCGAGTGTCCTCCTTGTCCT

GCTCCTCCTGTGGCAGGCCCATCT

GTGTTTCTCTTTCCCCCAAAGCCA

AAGGACACTTTGATGATATCCCGG

ACCCCTGAGGTGACTTGCGTCGTC

GTAGATGTTTCACACGAAGATCCA

GAGGTGCAGTTCAACTGGTACGTG

GATGGCGTGGAAGTGCATAATGC

CAAGACAAAGCCCCGCGAAGAGC

AGTTTAATTCCACCTTCCGCGTGG

TGTCTGTGCTGACCGTGGTACATC

AGGATTGGCTTAACGGTAAGGAGT

ACAAGTGCAAGGTGAGTAACAAGG

GGCTGCCCGCCCCTATCGAGAAG

ACTATCAGTAAAACCAAGGGCCAG

CCAAGGGAGCCACAGGTGTACAC

ACTTCCACCATCTAGGGAGGAAAT

GACAAAGAACCAGGTGAGTTTGAC

CTGTCTCGTGAAAGGCTTTTATCC

CAGTGATATAGCCGTGGAATGGGA

AAGTAACGGGCAGCCCGAGAACA

ACTATAAGACCACACCACCCATGC

TGGACTCCGACGGTTCTTTCTTCC

TTTATAGCAAGCTGACAGTGGATA

AATCCAGGTGGCAGCAGGGTAAC

GTATTCAGTTGCAGTGTCATGCAC

GAGGCACTCCACAACCACTATACT

CAGAAAAGTCTTTCCCTGAGTCCA

GGCAAG

SEQ ID
QVQLQQWGAGLLKPSE
SEQ ID
CAGGTGCAGCTACAGCAGTGGGG

2447
TLSLTCAVYGGSFSGYY
2555
CGCAGGACTGTTGAAGCCTTCGG

WSWIRQPPGKGLEWIG

AGACCCTGTCCCTCACCTGCGCTG

EINHSGSTNYNPSLKSR

TCTATGGTGGGTCCTTCAGTGGTT

VTISVDTSKNQFSLKLSS

ACTACTGGAGCTGGATCCGCCAG

VTAADTAVYYCARGGG

CCCCCAGGGAAGGGGCTGGAGTG

SGSYYKRFFDYWGQGT

GATTGGGGAAATCAATCATAGTGG

LVTVSSASTKGPSVFPL

AAGCACCAACTACAACCCGTCCCT

APCSRSTSESTAALGCL

CAAGAGTCGAGTCACCATATCAGT

VKDYFPEPVTVSWNSG

AGACACGTCCAAGAACCAGTTCTC

ALTSGVHTFPAVLQSSG

CCTGAAGCTGAGCTCTGTGACCG

LYSLSSVVTVPSSNFGT

CCGCGGACACGGCTGTGTATTACT

QTYTCNVDHKPSNTKV

GTGCGAGAGGCGGTGGTTCGGGG

DKTVERKCCVECPPCP

AGTTATTATAAGAGGTTCTTTGACT

APPVAGPSVFLFPPKPK

ACTGGGGCCAGGGAACCCTGGTC

DTLMISRTPEVTCVVVD

ACCGTCTCCTCAGCAAGCACAAAA

VSHEDPEVQFNWYVDG

GGTCCTTCAGTGTTCCCTCTGGCA

VEVHNAKTKPREEQFN

CCTTGCTCACGCAGCACCTCTGAG

STFRVVSVLTVVHQDWL

AGTACAGCCGCCCTGGGCTGCCT

NGKEYKCKVSNKGLPA

GGTAAAGGACTACTTTCCCGAACC

PIEKTISKTKGQPREPQV

AGTCACTGTGTCCTGGAATAGCGG

YTLPPSREEMTKNQVSL

GGCCTTGACCTCTGGAGTGCACA

TCLVKGFYPSDIAVEWE

CATTTCCAGCTGTACTGCAGTCAT

SNGQPENNYKTTPPML

CTGGACTCTACAGCCTGTCCAGTG

DSDGSFFLYSKLTVDKS

TGGTCACCGTACCTTCCTCCAACT

RWQQGNVFSCSVMHE

TTGGCACTCAAACATATACATGTAA

ALHNHYTQKSLSLSPGK

CGTGGATCATAAGCCCTCTAACAC

CAAAGTGGATAAAACTGTGGAGCG

TAAGTGTTGTGTCGAGTGTCCTCC

TTGTCCTGCTCCTCCTGTGGCAGG

CCCATCTGTGTTTCTCTTTCCCCC

AAAGCCAAAGGACACTTTGATGAT

ATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

SEQ ID
EVQLVQSGAEVRKPGA
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2448
SVKVSCKASGYTFTSYA
2556
AGCTGAGGTGAGGAAGCCTGGGG

ISWVRQAPGQGLEWMG

CCTCAGTGAAGGTCTCCTGCAAGG

WISAYDGNTNYAQKLQ

CTTCTGGTTACACATTTACCAGTTA

GRVTMTTDTSTSTAYM

TGCCATCAGCTGGGTGCGACAGG

EVRSLRSDDTAVYYCAR

CCCCTGGACAAGGGCTTGAGTGG

DGTVRRVVGATTPGNF

ATGGGGTGGATCAGCGCTTACGA

DYRGQGTLVTVSSASTK

CGGTAACACAAACTATGCACAGAA

GPSVFPLAPCSRSTSES

GCTCCAGGGCAGAGTCACCATGA

TAALGCLVKDYFPEPVT

CCACAGACACATCCACGAGCACA

VSWNSGALTSGVHTFP

GCCTACATGGAGGTGAGGAGCCT

AVLQSSGLYSLSSVVTV

GAGATCTGACGACACGGCCGTGT

PSSNFGTQTYTCNVDH

ATTACTGTGCGAGAGATGGTACGG

KPSNTKVDKTVERKCCV

TCCGAAGGGTAGTGGGAGCTACT

ECPPCPAPPVAGPSVFL

ACCCCTGGAAACTTTGACTACAGG

FPPKPKDTLMISRTPEV

GGCCAGGGAACCCTGGTCACCGT

TCVVVDVSHEDPEVQF

CTCCTCAGCAAGCACAAAAGGTCC

NWYVDGVEVHNAKTKP

TTCAGTGTTCCCTCTGGCACCTTG

REEQFNSTFRVVSVLTV

CTCACGCAGCACCTCTGAGAGTAC

VHQDWLNGKEYKCKVS

AGCCGCCCTGGGCTGCCTGGTAA

NKGLPAPIEKTISKTKGQ

AGGACTACTTTCCCGAACCAGTCA

PREPQVYTLPPSREEMT

CTGTGTCCTGGAATAGCGGGGCC

KNQVSLTCLVKGFYPSD

TTGACCTCTGGAGTGCACACATTT

IAVEWESNGQPENNYK

CCAGCTGTACTGCAGTCATCTGGA

TTPPMLDSDGSFFLYSK

CTCTACAGCCTGTCCAGTGTGGTC

LTVDKSRWQQGNVFSC

ACCGTACCTTCCTCCAACTTTGGC

SVMHEALHNHYTQKSL

ACTCAAACATATACATGTAACGTG

SLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVQSGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2449
SLRLSCAASGFTFSSYG
2557
GGGAGGCGTGGTCCAGCCTGGGA

MHWRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVIWYDGSNKYYADSVK

CGTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

DLNRGYCSGGSCFGYW

GGTGGCAGTTATATGGTATGATGG

GQGTLVTVSSASTKGPS

AAGTAATAAATACTATGCAGACTC

VFPLAPCSRSTSESTAA

CGTGAAGGGCCGATTCACCATCTC

LGCLVKDYFPEPVTVSW

CAGAGACAATTCCAAGAACACGCT

NSGALTSGVHTFPAVLQ

GTATCTGCAAATGAACAGCCTGAG

SSGLYSLSSVVTVPSSN

AGCCGAGGACACGGCTGTGTATTA

FGTQTYTCNVDHKPSN

CTGTGCGAGAGATCTGAATCGAG

TKVDKTVERKCCVECPP

GATATTGTAGTGGTGGTAGCTGCT

CPAPPVAGPSVFLFPPK

TTGGCTACTGGGGCCAGGGAACC

PKDTLMISRTPEVTCVV

CTGGTCACCGTCTCCTCAGCAAGC

VDVSHEDPEVQFNWYV

ACAAAAGGTCCTTCAGTGTTCCCT

DGVEVHNAKTKPREEQ

CTGGCACCTTGCTCACGCAGCAC

FNSTFRVVSVLTVVHQD

CTCTGAGAGTACAGCCGCCCTGG

WLNGKEYKCKVSNKGL

GCTGCCTGGTAAAGGACTACTTTC

PAPIEKTISKTKGQPREP

CCGAACCAGTCACTGTGTCCTGGA

QVYTLPPSREEMTKNQ

ATAGCGGGGCCTTGACCTCTGGA

VSLTCLVKGFYPSDIAVE

GTGCACACATTTCCAGCTGTACTG

WESNGQPENNYKTTPP

CAGTCATCTGGACTCTACAGCCTG

MLDSDGSFFLYSKLTVD

TCCAGTGTGGTCACCGTACCTTCC

KSRWQQGNVFSCSVM

TCCAACTTTGGCACTCAAACATATA

HEALHNHYTQKSLSLSP

CATGTAACGTGGATCATAAGCCCT

GK

CTAACACCAAAGTGGATAAAACTG

TGGAGCGTAAGTGTTGTGTCGAGT

GTCCTCCTTGTCCTGCTCCTCCTG

TGGCAGGCCCATCTGTGTTTCTCT

TTCCCCCAAAGCCAAAGGACACTT

TGATGATATCCCGGACCCCTGAGG

TGACTTGCGTCGTCGTAGATGTTT

CACACGAAGATCCAGAGGTGCAG

TTCAACTGGTACGTGGATGGCGTG

GAAGTGCATAATGCCAAGACAAAG

CCCCGCGAAGAGCAGTTTAATTCC

ACCTTCCGCGTGGTGTCTGTGCTG

ACCGTGGTACATCAGGATTGGCTT

AACGGTAAGGAGTACAAGTGCAAG

GTGAGTAACAAGGGGCTGCCCGC

CCCTATCGAGAAGACTATCAGTAA

AACCAAGGGCCAGCCAAGGGAGC

CACAGGTGTACACACTTCCACCAT

CTAGGGAGGAAATGACAAAGAACC

AGGTGAGTTTGACCTGTCTCGTGA

AAGGCTTTTATCCCAGTGATATAG

CCGTGGAATGGGAAAGTAACGGG

CAGCCCGAGAACAACTATAAGACC

ACACCACCCATGCTGGACTCCGAC

GGTTCTTTCTTCCTTTATAGCAAGC

TGACAGTGGATAAATCCAGGTGGC

AGCAGGGTAACGTATTCAGTTGCA

GTGTCATGCACGAGGCACTCCACA

ACCACTATACTCAGAAAAGTCTTTC

CCTGAGTCCAGGCAAG

SEQ ID
QVQLQESGGGLVQPGG
SEQ ID
CAGGTGCAGCTGCAGGAGTCTGG

2450
SLRLSCAASGFTFSSYA
2558
GGGAGGCTTGGTACAGCCGGGGG

MSWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

SYISSSGTTIYYADSVKG

CCTCTGGATTCACCTTTAGCAGCT

RFTVSRDNAKNSLYLQ

ATGCCATGAGCTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGGAAGGGGCTGGAGTG

DYSSSGECFDYWGQGT

GGTTTCATACATTAGTAGTAGTGG

LVTVSSASTKGPSVFPL

TACTACCATATACTACGCAGACTC

APCSRSTSESTAALGCL

TGTGAAGGGCCGATTCACCGTCTC

VKDYFPEPVTVSWNSG

CAGAGACAATGCCAAGAACTCACT

ALTSGVHTFPAVLQSSG

GTATCTGCAAATGAACAGCCTGAG

LYSLSSVVTVPSSNFGT

AGCCGAGGACACGGCCGTGTATT

QTYTCNVDHKPSNTKV

ACTGTGCGAGGGATTATAGCAGCT

DKTVERKCCVECPPCP

CGGGGGAGTGCTTTGACTACTGG

APPVAGPSVFLFPPKPK

GGCCAGGGAACCCTGGTCACCGT

DTLMISRTPEVTCVVVD

TTCAGTGTTCCCTCTGGCACCTTG

VSHEDPEVQFNWYVDG

CTCACGCAGCACCTCTGAGAGTAC

VEVHNAKTKPREEQFN

AGCCGCCCTGGGCTGCCTGGTAA

STFRVVSVLTVVHQDWL

AGGACTACTTTCCCGAACCAGTCA

NGKEYKCKVSNKGLPA

CTGTGTCCTGGAATAGCGGGGCC

PIEKTISKTKGQPREPQV

CTCCTCAGCAAGCACAAAAGGTCC

YTLPPSREEMTKNQVSL

TTGACCTCTGGAGTGCACACATTT

TCLVKGFYPSDIAVEWE

CCAGCTGTACTGCAGTCATCTGGA

SNGQPENNYKTTPPML

CTCTACAGCCTGTCCAGTGTGGTC

DSDGSFFLYSKLTVDKS

ACCGTACCTTCCTCCAACTTTGGC

RWQQGNVFSCSVMHE

ACTCAAACATATACATGTAACGTG

ALHNHYTQKSLSLSPGK

GATCATAAGCCCTCTAACACCAAA

GTGGATAAAACTGTGGAGCGTAAG

TGTTGTGTCGAGTGTCCTCCTTGT

CCTGCTCCTCCTGTGGCAGGCCC

ATCTGTGTTTCTCTTTCCCCCAAAG

CCAAAGGACACTTTGATGATATCC

CGGACCCCTGAGGTGACTTGCGT

CGTCGTAGATGTTTCACACGAAGA

TCCAGAGGTGCAGTTCAACTGGTA

CGTGGATGGCGTGGAAGTGCATA

ATGCCAAGACAAAGCCCCGCGAA

GAGCAGTTTAATTCCACCTTCCGC

GTGGTGTCTGTGCTGACCGTGGTA

CATCAGGATTGGCTTAACGGTAAG

GAGTACAAGTGCAAGGTGAGTAAC

AAGGGGCTGCCCGCCCCTATCGA

GAAGACTATCAGTAAAACCAAGGG

CCAGCCAAGGGAGCCACAGGTGT

ACACACTTCCACCATCTAGGGAGG

AAATGACAAAGAACCAGGTGAGTT

TGACCTGTCTCGTGAAAGGCTTTT

ATCCCAGTGATATAGCCGTGGAAT

GGGAAAGTAACGGGCAGCCCGAG

AACAACTATAAGACCACACCACCC

ATGCTGGACTCCGACGGTTCTTTC

TTCCTTTATAGCAAGCTGACAGTG

GATAAATCCAGGTGGCAGCAGGG

TAACGTATTCAGTTGCAGTGTCAT

GCACGAGGCACTCCACAACCACTA

TACTCAGAAAAGTCTTTCCCTGAG

TCCAGGCAAG

SEQ ID
EVQLVQSGGGVVQPGR
SEQ ID
GAGGTGCAGCTGGTGCAGTCTGG

2451
SLRLSCAASGFTFSSYG
2559
GGGAGGCGTGGTCCAGCCTGGGA

MHWVRQAPGKGLEWV

GGTCCCTGAGACTCTCCTGTGCAG

AVIWYDGSNKYYADSVK

CGTCTGGATTCACCTTCAGTAGCT

GRFTISRDNSKNTLYLQ

ATGGCATGCACTGGGTCCGCCAG

MNSLRAEDTAVYYCAR

GCTCCAGGCAAGGGGCTGGAGTG

DQAAMVGYFDYWGQG

GGTGGCAGTTATATGGTATGATGG

TLVTVSSASTKGPSVFP

AAGTAATAAATACTATGCAGACTC

LAPCSRSTSESTAALGC

CGTGAAGGGCCGATTCACCATCTC

LVKDYFPEPVTVSWNS

CAGAGACAATTCCAAGAACACGCT

GALTSGVHTFPAVLQSS

GTATCTGCAAATGAACAGCCTGAG

GLYSLSSVVTVPSSNFG

AGCCGAGGACACGGCTGTGTATTA

TQTYTCNVDHKPSNTKV

CTGTGCGAGAGATCAGGCAGCTAT

DKTVERKCCVECPPCP

GGTAGGCTACTTTGACTACTGGGG

APPVAGPSVFLFPPKPK

CCAGGGAACCCTGGTCACCGTCT

DTLMISRTPEVTCVVVD

CCTCAGCAAGCACAAAAGGTCCTT

VSHEDPEVQFNWYVDG

CAGTGTTCCCTCTGGCACCTTGCT

VEVHNAKTKPREEQFN

CACGCAGCACCTCTGAGAGTACA

STFRVVSVLTVVHQDWL

GCCGCCCTGGGCTGCCTGGTAAA

NGKEYKCKVSNKGLPA

GGACTACTTTCCCGAACCAGTCAC

PIEKTISKTKGQPREPQV

TGTGTCCTGGAATAGCGGGGCCTT

YTLPPSREEMTKNQVSL

GACCTCTGGAGTGCACACATTTCC

TCLVKGFYPSDIAVEWE

AGCTGTACTGCAGTCATCTGGACT

SNGQPENNYKTTPPML

CTACAGCCTGTCCAGTGTGGTCAC

DSDGSFFLYSKLTVDKS

CGTACCTTCCTCCAACTTTGGCAC

RWQQGNVFSCSVMHE

TCAAACATATACATGTAACGTGGA

ALHNHYTQKSLSLSPGK

TCATAAGCCCTCTAACACCAAAGT

GGATAAAACTGTGGAGCGTAAGTG

TTGTGTCGAGTGTCCTCCTTGTCC

TGCTCCTCCTGTGGCAGGCCCATC

TGTGTTTCTCTTTCCCCCAAAGCC

AAAGGACACTTTGATGATATCCCG

GACCCCTGAGGTGACTTGCGTCG

TCGTAGATGTTTCACACGAAGATC

CAGAGGTGCAGTTCAACTGGTACG

TGGATGGCGTGGAAGTGCATAATG

CCAAGACAAAGCCCCGCGAAGAG

CAGTTTAATTCCACCTTCCGCGTG

GTGTCTGTGCTGACCGTGGTACAT

CAGGATTGGCTTAACGGTAAGGAG

TACAAGTGCAAGGTGAGTAACAAG

GGGCTGCCCGCCCCTATCGAGAA

GACTATCAGTAAAACCAAGGGCCA

GCCAAGGGAGCCACAGGTGTACA

CACTTCCACCATCTAGGGAGGAAA

TGACAAAGAACCAGGTGAGTTTGA

CCTGTCTCGTGAAAGGCTTTTATC

CCAGTGATATAGCCGTGGAATGG

GAAAGTAACGGGCAGCCCGAGAA

CAACTATAAGACCACACCACCCAT

GCTGGACTCCGACGGTTCTTTCTT

CCTTTATAGCAAGCTGACAGTGGA

TAAATCCAGGTGGCAGCAGGGTAA

CGTATTCAGTTGCAGTGTCATGCA

CGAGGCACTCCACAACCACTATAC

TCAGAAAAGTCTTTCCCTGAGTCC

AGGCAAG

SEQ ID
QVTLKESGGGVVQPGR
SEQ ID
CAGGTCACCTTGAAGGAGTCTGG

2452
SLRLSCAASGFIFSNYAI
2560
GGGAGGCGTGGTCCAGCCTGGGA

HWVRQAPGKGLEWVA

GGTCCCTGAGACTCTCCTGTGCAG

VISYDGSNKYYADSVKG

CCTCTGGATTCATCTTCAGTAACTA

RFTISRDNSKNTLYLQM

TGCTATACACTGGGTCCGCCAGG

NSLRAEDTAVYYCARTF

CTCCAGGCAAGGGGCTGGAGTGG

AGYSSKLGYFDLWGRG

GTGGCAGTTATATCATATGATGGA

TLVTVSSASTKGPSVFP

AGTAATAAATACTACGCAGACTCC

LAPCSRSTSESTAALGC

GTGAAGGGCCGATTCACCATCTCC

LVKDYFPEPVTVSWNS

AGAGACAATTCCAAGAACACGCTG

GALTSGVHTFPAVLQSS

TATCTGCAAATGAACAGCCTGAGA

GLYSLSSVVTVPSSNFG

GCTGAGGACACGGCTGTGTATTAC

TQTYTCNVDHKPSNTKV

TGTGCGAGGACTTTTGCGGGGTAT

DKTVERKCCVECPPCP

AGCAGCAAACTGGGGTACTTCGAT

APPVAGPSVFLFPPKPK

CTCTGGGGCCGTGGCACCCTGGT

DTLMISRTPEVTCVVVD

CACCGTCTCCTCAGCAAGCACAAA

VSHEDPEVQFNWYVDG

AGGTCCTTCAGTGTTCCCTCTGGC

VEVHNAKTKPREEQFN

ACCTTGCTCACGCAGCACCTCTGA

STFRVVSVLTVVHQDWL

GAGTACAGCCGCCCTGGGCTGCC

NGKEYKCKVSNKGLPA

TGGTAAAGGACTACTTTCCCGAAC

PIEKTISKTKGQPREPQV

CAGTCACTGTGTCCTGGAATAGCG

YTLPPSREEMTKNQVSL

GGGCCTTGACCTCTGGAGTGCAC

TCLVKGFYPSDIAVEWE

ACATTTCCAGCTGTACTGCAGTCA

SNGQPENNYKTTPPML

TCTGGACTCTACAGCCTGTCCAGT

DSDGSFFLYSKLTVDKS

GTGGTCACCGTACCTTCCTCCAAC

RWQQGNVFSCSVMHE

TTTGGCACTCAAACATATACATGTA

ALHNHYTQKSLSLSPGK

ACGTGGATCATAAGCCCTCTAACA

CCAAAGTGGATAAAACTGTGGAGC

GTAAGTGTTGTGTCGAGTGTCCTC

CTTGTCCTGCTCCTCCTGTGGCAG

GCCCATCTGTGTTTCTCTTTCCCC

CAAAGCCAAAGGACACTTTGATGA

TATCCCGGACCCCTGAGGTGACTT

GCGTCGTCGTAGATGTTTCACACG

AAGATCCAGAGGTGCAGTTCAACT

GGTACGTGGATGGCGTGGAAGTG

CATAATGCCAAGACAAAGCCCCGC

GAAGAGCAGTTTAATTCCACCTTC

CGCGTGGTGTCTGTGCTGACCGT

GGTACATCAGGATTGGCTTAACGG

TAAGGAGTACAAGTGCAAGGTGAG

TAACAAGGGGCTGCCCGCCCCTA

TCGAGAAGACTATCAGTAAAACCA

AGGGCCAGCCAAGGGAGCCACAG

GTGTACACACTTCCACCATCTAGG

GAGGAAATGACAAAGAACCAGGT

GAGTTTGACCTGTCTCGTGAAAGG

CTTTTATCCCAGTGATATAGCCGT

GGAATGGGAAAGTAACGGGCAGC

CCGAGAACAACTATAAGACCACAC

CACCCATGCTGGACTCCGACGGTT

CTTTCTTCCTTTATAGCAAGCTGAC

AGTGGATAAATCCAGGTGGCAGCA

GGGTAACGTATTCAGTTGCAGTGT

CATGCACGAGGCACTCCACAACCA

CTATACTCAGAAAAGTCTTTCCCT

GAGTCCAGGCAAG

Antibody Mediated Cytotoxicity

Post purification, anti-CLEC2D antibody clones were assessed for cell surface binding on C4548 cells using flow cytometry. As can be seen from FIG. 19C, both clones with IgG4 isotype, exhibited binding towards surface expressed CLEC2D antigen with ˜4-8 fold higher MFI when compared with control un-transfected CHO cell.

In order to evaluate functionality of isotype variants, PC3 cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. After 24 hours, freshly isolated PBMCs were added in T:E of 1:5 and novel monoclonal anti-CLEC2D antibodies C3276, C3256, C3452, and C4608 were added at 100 μg/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was collected from 24 well plate and adherent cells were trypsinized and collected in 1.5 ml tubes. Reaction mixture was incubated with sytox green (15 nM) for 20 min and fluorescence was detected in flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples.

As can be seen from FIG. 19D, for C3276, IgG4 variant and C4608 IgG1 variant exhibited similar percentage of cytotoxicity towards PC3 cells. Taken together, both IgG1 and IgG4 variants (treated at 100 μg/ml) showed anti-tumor activity towards PC3 cells signifying an engagement of both CD16 dependent target cell death and also killing of target cells via blocking of CLEC2D and CD161 interaction, in turn suggesting involvement of multiple pathways, probably functions independent of ADCC mechanism, to rapidly kill the tumour cells. In addition, different isotype format of the said antibody, could potentially pave new line of treatment for specific disease, not limiting to, prostate cancer.

Impact of Anti-CLEC2D Antibody with Modified Glycosylation on Cytotoxicity

The monoclonal antibody based biotherapeutics function through effective recognition of the antigenic epitopes on target cells as well as the antibody effector functions, as an outcome of formation of immune complexes. In recent times, antibody effector function has gained considerable interest towards improving efficacy of the said class of biotherapeutics. Antibody dependent Cellular Cytotoxicity (ADCC) improves clinical efficacy of therapeutic antibodies, the effect is more pronounced in case of anticancer antibodies as exemplified in studies involving allelic polymorphism of leucocyte receptors (FcγR) in patients. Recently, an elegant study with homogeneous IgG glycoforms developed through chemo-enzymatic methods revealed antibody sialylation negatively impacts ADCC in the context of core fucosylation but not in case of nonfucosylated antibody. Multiple studies reported that completely nonfucosylated monoclonal antibody has significantly increased Fc affinity to FcγRIII and thereby improving antibody ADCC function by many folds, in vitro and in vivo.

With the advent next generation monoclonal antibody drugs against immune oncology targets, where innate immune system is mobilized to tumor microenvironment, engaging NK cell effector functions becomes immensely important. Any such antibody with improved ADCC functionality recognizing epitopes on tumor cells has the potential to exert more inhibitory effects on tumor cell survival and hence tumor progression. In this context, controlling ADCC function of monoclonal antibody therapeutics helps balancing the optimal effector function to deleterious cytokine release.

Afucosylated Anti CLEC2D Antibody Expression:

Talen Fut8 gene knockout cell line was developed in GS negative CHO cell line. This cell line was sequence verified for FUT8 gene knock-out and was coded as C2899. C0694 (HC and LC vectors) and C2685 (HC and LC vectors) were transfected in this cell line. Antibiotic selection was performed, Minipools and single cell clones were developed from this cell line which expresses afucosylated anti-CLEC2D antibody. Afucosylated antibodies were tested for cell surface antigen binding on C4548 cells by flow-cytometry and on target cells by confocal imaging.

C2899 Cell Transfection to Express Novel Anti-CLEC2D Monoclonal Antibody Clones Transfection:

C2899 cells were transfected with C0694 and C2685 heavy chain and light chain vectors. Cell count and viability data was collected using Vi-cell XR automated cell counter, Beckman coulter. Transfection was carried out as per manufacturer's protocol Lipofectamine® LTX Reagent with PLUS Reagent. Required volume of cell suspension was centrifuged at 1400 RPM for 4 mins and re-suspended in specified volume of OPTIMEM I in 125 ml shake flask. Transfection mix was prepared as described before. C2899 cells transfected with C0694 HC and LC vectors were known as C3234 whereas C2899 cells transfected with C2685 HC and LC vectors were known as C4335.

Generation of Stable Cell Lines Expressing Afucosylated Anti-CLEC2D Antibody:

Antibiotic Selection:

Antibiotic selection was initiated after transfection at >80% cell viability. Cell suspension was centrifuged at 1400 RPM for 4-5 mins. Pellet was re-suspended in complete Power CHO2 growth media and concentration of Puromycin Dihydrochloride was adjusted to 2 μg/1×10{circumflex over ( )}6 cells. Antibiotic selection was carried out on every 2nd or 3rd day.

Repeat Transfection of Stable Pool:

Cell count was taken using Vi-cell XR. Cells were subcultured before the transfection. Two more sequential transfections were performed as mentioned previously. On completion of three rounds of transfection the pool was designated as R3 stable pool.

Minipool Plating:

Minipools were generated by serial dilution method. Continuously growing culture of cell line was subcultured at 0.5 million cells/ml in 30 ml complete PowerCHO 2 growth media with 2 mM glutamax, 1 to 2 days before plating. Cell count and viability data was collected using Vi-cell XR. Serial dilution of the cell suspension was carried out in complete PowerCHO2 growth media at 1:10 ratio. Cells were seeded at a density of 10 cells/well in a 96 well plate in 200 μl volume per well in cloning media. These mini-pools were maintained at 37° C. Temperature in a humidified 5% CO2 incubator.

Screening of Mini-Pools and Amplification:

Mini-pools were screened by flow cytometry wherein binding to C4548 cells was estimated. Minipools were ranked based on cell surface binding. Minipools selected from flow cytometry screening were amplified from 96 well plate to 24 well plate and maintained at 37° C., humidified condition in a 5% CO2 incubator. These were further amplified from 24 well plate to one well of 6 well plate. After cells were confluent mini-pools were amplified from one well of 6 well plate to a 50 ml bioreactor tube or 125 ml Erlenmeyer shake flask with 25-30 ml growth media and maintained at 37° C., humidified condition in a 5% CO2 incubator, 120-200RPM.

Single Cell Cloning

Single cells were generated by serial dilution method. Continuously growing culture of selected mini-pool was subcultured at 1 million cells/ml in 30 ml complete PowerCHO 2 growth media with 2 mM glutamax, 1-2 day before cloning. Cell count and viability data was collected using Vi-cell XR. Serial dilution of the cell suspension was carried out in complete powerCHO2 growth media at 1:10 ratio. Cells were seeded at a density of 0.5 cells/well in a 96 well plate and maintained at 37° C. Temperature in a humidified 5% CO2 static incubator. Plates were scanned by using CloneSelect Imager (Molecular Devices) for monoclonality report generation from day zero to day ten. The clonal population was confirmed from the day zero image of entire well and the monoclonality report generated by CloneSelect Imager. Passage number was P(x+0). Single cell clones were coded with four digit random numbers. The Single cell clones were amplified to 24 well plates after cells were confluent. Passage number was P(x+1).

Screening of Single Cell Clones and Clone Amplification:

Cell surface binding assay was performed to estimate antibody in cell culture supernatant and to rank the clones. Single cell clones showing higher binding on C4548 cell surface expressed CLEC2D antigen were amplified from 24 to 6 well. Passage number was (x+2). This was followed by amplification in 3 wells of 6 well plate. Passage number was (x+3). The clones were further amplified to bioreactor tubes or Erlenmeyer flasks. RCB vials were prepared for the clones.

Culture Harvest for Protein Purification:

Cells were seeded at a density of approximately 0.3×10{circumflex over ( )}6 cells/ml in 30-100 ml Complete power CHO2 growth media and cultured for 6 days in 37° C., humidified condition in a 5% CO2 incubator with 120 RPM rotation. 20% v/v media top-up was given with complete power CHO2 growth media on 3rd or 4th day. Supernatants were harvested by centrifuging the entire cell suspension at 1400-2000 RPM for 10 mins. The supernatants were collected and subjected to purification by protein-A affinity chromatography.

Cell Surface Binding Assay by Flow-Cytometry:

CHO cells were transiently transfected with CLEC2D surface expression vector. Surface expression was optimum on day 4 to day 5 on transfected cells. These cells were coded as C4548. Cell count was taken by Vi-cell XR automated cell counter. CHO and C4548 cells were centrifuged at 1000-1400 rpm for 4-5 minutes. The pellet was re-suspended in 1 ml DPBS. 50,000 cells were aliquoted in each well of a 96 well plate. 1-5 μg of purified antibody samples and reference control was added to each well and incubated for 40-60 minutes at room temperature (25° C.). The plate was centrifuged at 1000-1400 rpm for 4-5 minutes, the supernatant was aspirated and cells were washed with 0.1% BSA in DPBS. 2.5 ml of 2% BSA was diluted to 50 ml with DPBS. Goat anti human IgG FITC conjugate was used as secondary antibody. 1:100 dilution of secondary antibody was prepared in DPBS and 100 μl was added to each well. The plate was incubated for 30 minutes at room temperature (25° C.) in dark. The cells were washed with 0.1% BSA and re-suspended in 100 μl of 2% BSA. Samples were analyzed by flow-cytometry.

Binding of test sample supernatant on un-transfected CHO cells was estimated and used for calculation of specific binding on C4548 cell surface using following formula:

$Fold change in M F I = \frac{\begin{matrix} Median FITC - A of test sample on CHO cells \end{matrix}}{\begin{matrix} Median FITC - A of test sample on C 4548 cells \end{matrix}}$

Purified anti-CLEC2D antibody from stable cell clones were firstly assessed for cell surface binding on C4548 cells through flow cytometry, experimentation for flow cytometry based binding studies remains similar as described in Example 5, Section: Cell surface binding assay: through Flow Cytometry and Confocal Microscopy. As can be seen from FIG. 19E, all clones as exemplified by C0613, C1301, C6268, C1699, C2437, C9832, C8900 and C7749, exhibited differential binding towards surface expressed CLEC2D antigen with ˜2-10 fold higher MFI when compared with control, which is un-transfected CHO cell.

Cytotoxicity with Afucosylated Anti-CLEC2D Antibody

Confirmed afucosylated anti-CLEC2D mono clonal antibodies were used subsequently for cytotoxicity experiments and effect of glycosylation was compared with fucosylated anti-CLEC2D antibodies.

Herein, PC3 cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. After 24 hours, freshly isolated NK cell was added in T:E of 1:1. Novel monoclonal anti-CLEC2D antibody C5511 (100 μg/ml) and afucosylated mabs C7749, C8800 and C9832 were added at 20 μg/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was subsequently collected from 24 well plate followed by trypsinization of adherent cells. Reaction mixture was incubated with sytox green (15 nM) for 20 min and fluorescence signal was detected using flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples.

FIG. 19F depicts the impact of fucsylation on Anti-CLEC2D antibody mediated cytotoxicity as assessed through killing of PC3 cells. As mentioned before, afucosylated Anti-CLEC2D antibodies were used at a concentration that is 5 times lower than fucosylated antibody i.e., C5511. Observed cytotoxicity suggests that afucosylated anti-CLEC2D antibody is at least 5 times more effective when compared with the fucosylated anti-CLEC2D antibody. Thereby, the said and described version i.e., afucosylated anti-CLEC2D antibodies could be used as an efficient alternative treatment/therapy option to achieve increased clinical efficacy.

Taken together, functional efficiency of anti-CLEC2D monoclonal antibodies could be ADCC independent, as seen in functionality for said antibody in IgG4 isotype format, while afucosylated version of anti-CLEC2D antibody elicits an efficient ADCC mediated target killing, which in turn elaborates/expands about/on the functional and application related versatility in therapeutic space.

Complement Dependent Cytotoxicity

Complement-dependent cytotoxicity, or CDC, is a well-known mechanism through which antibodies lyse the unwanted target by activating a cascade of complement-related reactions. Usually IgG1 and IgG3, elicits CDC killing effects via binding its Fc region to serum complement components, particularly C1q. Following complicated enzyme activations and cleavage events, involving over 20 highly regulated elements, it will eventually lead to the formation of membrane attacking complex (MAC), thereby target cell destruction.

Specific example details on experimentation wherein 50 μL of target cell suspension (PC3 and Ramos) containing 5×10⁴cells were added to each well of the 96-well assay plate. 50 μL of different concentrations of C5511 antibody (200, 40, 0.4, 0.04 μg/mL) dilution was added to the plate to start the reaction. The plate was shaken for 30 seconds. Baby rabbit complement was then diluted (1:20) in cell medium, and 50 μL was added to the appropriate wells. Following shaking for 30 seconds, the plate was incubated at 37° C., 5% CO2 for 120 minutes. The plate was then removed from the 37° C. incubator and allowed to cool to room temperature (RT) for 15 minutes, and then add 25 μL of warm Risazurin solution and incubate overnight (16-20 hrs) at 37° C., 5% CO2 incubator. The plate was then removed from the 37° C. incubator and allowed to cool to room temperature (RT) for 15 minutes, and then read plate in fluorescence mode (excitation 530 and emission 590) using the Synergy HT BIOTEK micro plate reader.

The data obtained from both Ramos and PC3 cell line suggests that anti-CLEC2D antibody does not exhibits its cell killing mechanism through CDC pathway as shown in FIG. 19G.

Example 7: In Vivo Mouse Efficacy Studies with Anti-CLEC2D Monoclonal Antibody

In Vivo Mouse Efficacy Studies

During the development of therapeutic monoclonal antibodies (mAbs), a strategy for early identification of candidate mAbs with the greatest likelihood of success in the clinic is needed to avoid costly late-stage failures related to inadequate exposure, toxicity or lack of efficacy. Early screening and optimization of mAbs focus on characteristics such as affinity, potency and stability for selection of lead constructs, while confirmation on in vivo efficacy are typically required

The anticancer activity of anti-CLEC2D monoclonal antibody was evaluated in huNOG-EXL mice bearing subcutaneous PC3 tumor xenografts (FIGS. 20A and 20B). The procedure relies on super immune-deficient hGM-CSF/hIL3 transgenic-NOG mice, which upon engraftment with human hematopoietic stem cells, results in human-like immune system (lymphoid & myeloid lineage of human origin). This model enabled an efficacy study of the key innate mechanisms involved in the function of immune-therapy agents. The study was conducted for a period of 4-5 weeks with regular observation of tumor volume and body weight. The study was carried out in accordance with Institutional Animal Ethics Committee (IAEC).

All animals were kept for acclimatization for a period of about 5-7 days before initiation of the experiment. Animals were housed group wise (5 animals per cage) in IVCs and autoclaved corncob was used as the bedding material. Animals were maintained in a controlled environment with 22±3° C. temperature, 50±20% humidity, a light/dark cycle of 12 hours each and 15-20 fresh air changes per hour. The animals were fed, ad libitum, with certified Irradiated Laboratory Rodent Diet.

Species
Mus musculus

Strain
huNOGEXL

Source
Taconic Biosciences

Sex
Male

Age
5-6 weeks

Body weight
19-21 g

Cancer cell line
PC3 (Human prostate adenocarcinoma)

Cell inoculation density
5 × 10⁶cells/animal

Study initiation
Tumor volume (≈100 mm³)

Duration of the study
4-5 weeks

Test item
Anti-CLEC2D antibody clones, IgG1

control monoclonal antibody, Check

point monoclonal antibody

Dose & Dosing schedule
10 mg/kg, 4 intraperitoneal

dosing-once every 7 days

Route of dosing
Intraperitoneal

Tumor volume measurement
Once every three days

Body weight measurement
Once every three days

All procedures were performed in a laminar flow hood following sterile techniques. PC-3 (Human prostate adenocarcinoma) cells with a viability of >90% was chosen for the study. Around 5×10⁶cells were re-suspended in 200 μl of serum free media containing 50% of matrigel kept in ice. Male huNOG-EXL mice housed in Individually Ventilated Cages (IVCs) were used for the study. The PC-3 cell line was propagated into the animals by injecting the cells subcutaneously in the right flank region of the animals. The implanted area was monitored for growth of tumor. Once the tumor attained palpable stage and required volume (Mean tumor volume 115 mm³), animals were randomized and dosing was initiated with anti-CLEC2D monoclonal antibodies, the IgG1 control monoclonal antibody and check point monoclonal antibody. Antibodies were administered intraperitoneally. The dose of each individual animal was adjusted based on its body weight.

The primary objective of the study was to evaluate the antitumor activity of anti-CLEC2D monoclonal antibodies. In addition to the efficacy of the anti-CLEC2D antibody clones alone, experiments were carried out for combination treatment with a check point monoclonal antibody against PDL1 antigen. In huNOG-EXL mice bearing PC-3 tumor xenograft, animal body weight, clinical signs and tumor volume were recorded once every three days throughout the experimental period. The study was constituted with following arms as described in Table 42:

TABLE 42

Monoclonal

Frequency of

SI No
antibody
Dosage
treatment

Arm 1
Control human IgG1
10 mg/kg
Once a week

Arm 2
anti-CLEC2D mAb
10 mg/kg
Once a week

clone 1

Arm 3
anti-CLEC2D clone 2
10 mg/kg
Once a week

Arm 4
Anti PDL1 mAb
10 mg/kg
Once a week

Arm 5
anti-CLEC2D clone
5 mg/kg of anti-CLEC2D
Once a week

1 + Anti PDL1 mAb
clone 1 + 5 mg/kg of Anti

PDL1 mAb

Animals in “Arm 1” revealed progressive tumor growth during the study period. Tumor growth inhibition was observed in all other experimental arms. Individual body weight was measured once every three days during the study period. The percentage change in body weight of individual mouse was calculated and recorded. Animals were observed for visible clinical signs every day during the study period. The tumor volume was determined by two-dimensional measurement with a digital Vernier calliper on the day of randomization (Day 0) and then once every three days (i.e., on the same days when body weight was taken). Using a Vernier calliper the length (L) and width (W) of the tumor was measured. Tumor volume (TV) was calculated using the following formula:

TV=(L×W×W)/2; where L=Length (mm); W=Width (mm).

Mean, Standard Deviation (SD) or Standard Error of Mean (SEM) were calculated for individual groups. Antitumor activity was evaluated as maximum tumor volume inhibition versus the control IgG1 arm (Arm 1). Data evaluation was performed using statistical software Graph Pad Prism V 5.0. Tumor growth inhibition (TGI) was calculated using the following formula:

TGI=(1−T/C)×100%

where, T=(Mean Tumor volume (TV) of the test arm on Day X−Mean TV of the test arm on Day 0; C=(Mean TV of the control Human IgG (Arm 1) on Day X−Mean TV of the control Human IgG (Arm 1) on Day 0.

The relative tumor volume (RTV) and tumor growth inhibition were calculated. Mean±SEM was calculated for the RTV data and tumor growth inhibition was presented as a percentage. Two way ANOVA was utilized for statistical analysis and p value <0.05 between arms was considered significant. The results show significant tumor growth reduction with both monotherapy with anti-CLEC2D antibody and in combination with check point monoclonal antibody against PDL1.

Significant tumor growth inhibition was observed in Arm 2, Arm 3, Arm 4 and Arm 5 compared to Arm 1, representing Control human IgG1. It was unexpected that significant tumor growth inhibition over entire study period was observed in animals treated with anti-CLEC2D monoclonal antibody clones, and anti-PDL1 antibody. More interestingly, a completely novel finding where tumor sizes were reduced by half in animals treated with a combination of anti-CLEC2D monoclonal antibody clone and anti-PDL1 monoclonal antibody was observed. This observation is very significant as the combination treatment with anti-CLEC2D antibody and anti-PDL1 antibody achieved this high level of tumor growth inhibition at a reduced dosage of 5 mg/kg. The data indicates significant anti tumor activity when anti-CLEC2D antibody was used alone and when it was used in combination with anti PDL1 antibody, showing that the antibody clones against CLEC2D antigen have great therapeutic potential for various disease indications.

During the study period, monoclonal antibody dosages were well tolerated with mild body weight loss. Based on cage side observations there was no visible signs of abnormal behaviour or any adverse clinical symptoms in any of the groups during the experimental period. T cell infiltration to the tumor site was analysed using immunohistochemistry (IHC) of the excised tumor. The harvested tumor cells were subjected to different types of T cell markers to understand the infiltration. Histology processing was conducted for immunohistochemistry for FFPE tissue (Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens). Animals were euthanized and the tumors were harvested & fixed in 10% neutral buffer formalin for 24 hours. The tissues were subjected to tissue processing. Paraffin embedded tissue blocks were prepared after completion of tissue processing. Subsequently, sectioning blade holder angle was adjusted to the surface of tissue block in the microtome. Coarse trimming was carried out, and fine sections of 5 micron thickness were taken and transferred to the tissue water bath. Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens were processed for IHC staining with standard reagents.

Samples were washed in washing buffer (PBST-0.3% tritonX-100) for 10 min. Samples were incubated with blocking solution (10% Normal goat serum and 3% BSA in PBS) for 30-60 minutes in humidified environment. Primary antibodies were diluted in antibody dilution buffer (3% BSA in PBS). The tissues were incubated with primary antibody against CD3 antigen at 1:100 dilution and incubated overnight at 4° C. Subsequently slides were washed three times in washing buffer for 10-30 minutes/wash. This was followed by incubation with secondary antibody Goat Anti-Rabbit IgG H&L (HRP) at room temperature. Slides were washed three times in washing buffer for 15-30 minutes for each wash. The DAB Chromogen was applied to develop proper intensity of tissue staining. Counterstaining was carried out with hematoxylin.

The tumor samples were immunohistochemically stained with anti-CD3 antibody. CD3 cell (Pan T cell marker) infiltration was observed in the periphery of tumor tissues in human IgG control (Arm 1). However, in animals treated with anti-CLEC2D antibody, check point antibody alone, or a combination of anti-CLEC2D antibody with a check point antibody, the CD3 cell infiltration was observed heterogeneously in periphery and also around the tumor cells. CD3, a membranous immunohistochemical marker, revealed mild to moderate degree of staining of tumor samples harvested from animals treated with anti-CLEC2D antibody, check point antibody, and a combination of anti-CLEC2D antibody with check point antibody. The data provides clear insights into the mechanisms of tumor mediated immune suppression

Localization of Labelled Anti-CLEC2D Antibody

In a separate imaging experiment, anti-CLEC2D antibody labelled with Alexa 647 was administered at a single dose of 10 mg/kg intravenously. The fluorescently labelled antibody was administered to huNOG-EXL mice bearing subcutaneous PC-3 tumor (Mean Tumor volume ˜213 mm³). In-vivo imaging was carried out at 0 min, 5 min, 15 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr, 24 hr, 48 hr, 72 hr and 96 hr post administration of Alexa 647 labelled antibody (FIG. 20C). The monoclonal antibody against anti-CLEC2D antibody exhibited affinity (which was evident from tumor signal intensity) towards the target antigen of interest in huNOG-EXL mice bearing subcutaneous PC-3 tumor.

The signal intensity from the tumor appeared as early as 5 minutes post injection of the antibody and gradually increased with time. The peak signal intensity was observed at 3 hrs and the signal intensity from the tumor lasted until 96 hrs.

In Vivo Mouse Efficacy with Selected Monoclonal Antibody Products

In a separate follow up xenograft mouse study, the monoclonal antibody drug products were tested to evaluate tumor growth reduction upon monoclonal antibody treatment.

Origin of the animals: hGM-CSF/hIL3 NOG mice engrafted with human CD34+ hematopoietic stem cells (HSCs) stably develop extensive cell lineages as early as 6 to 8 weeks post-injection. Both myeloid and lymphoid lineage cells are present in peripheral blood, bone marrow, thymus and spleen and non-lymphoid tissue including lung and liver. For the current study huNOG-EXL mice with greater than 25% hCD45+ in peripheral blood were used

Rationale: The procedure relies on super immunodeficient the hGM-CSF/hIL3 transgenic-NOG mice which upon engraftment with human hematopoietic stem cells, results in a human-like immune system (lymphoid & myeloid lineage of human origin). This model enables to study the key innate mechanisms involved in the efficacy of immuno-therapy related agents and provide a suitable model for establishment of human xenografts.

Strain
huNOG-EXL

Sex
Male

Source
Taconic (USA)

Age at the start of experiment
13-14 weeks

Body Weight of animals
18-22 g

Animal Care

Animal Welfare

Animals were taken care as per the regulations of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines.

Housing and Feeding

Animals were housed in individually ventilated cages maintained in a controlled environment with 22+3° C. temperature, 50+20% humidity, 12 h light/dark cycle and 15-20 fresh air changes per hour. Animals were housed group-wise and autoclaved corncob (Sparconn Life Sciences, Bangalore, India) was used as a bedding material. The animals were fed (NIH-31), ad libitum, with certified irradiated laboratory rodent diet during the study period.

Drinking Water

Fresh, potable water, filtered through RO, was provided ad libitum after autoclaving to all animals via bottle fitted with nozzle.

Preparation of Animals

The animals were kept under acclimatization in the experimental room for a period of 10 days. A thorough observation was performed before selecting the animals and only animals that were apparently healthy were used for the study.

Animal Identification

Animals were individually numbered and the cage cards indicating the experiment, study number, date of randomization, mouse strain, gender and individual mouse numbers were displayed to corresponding cages. After randomization group identity, treatment code, dosage, schedule and route of administration were included in the cage cards.

Experimental Procedure

Preparation of Tumor Cells

Subcutaneous Injection of Cells

Male huNOG-EXL mice housed in Individually Ventilated Cages (IVCs) were used for the study. PC-3 cell line was propagated into the animals by injecting the cells subcutaneously in the right flank region of the animals. The implanted area was monitored for growth of tumor. Four days post injection of cells animals were randomized based on tumor volume (Mean tumor volume≈37 mm3) and dosing was initiated.

Route and Mode of Administration of the Test Substance:

Required quantity of test antibodies were prepared and stored at 2-80 C. The antibodies were administered intraperitoneally. The dose of individual animal was adjusted based on the body weight. For each antibody, unused new syringes and needles were used.

Experimental Design

- Monoclonal antibody products were used at 10 mg/kg dosage
  - a. C5511 mAb group;
  - b. C6481 mAb group.
- Vehicle control IgG1 group—Control IgG1 was used at 10 mg/kg dosage.
- 5 animals per treatment group.
- Antibody drug product was injected every 3 days for first 2 weeks and once weekly for remaining study period.
- Total study duration 36 days.
- Tumor volume measurement and animal body weight measurement was carried out every 3 days.

Dose and Route of Administration

Required quantity of test compounds (ready to use formulation) were used and it was stored at −200 C. Test compounds were administered intraperitoneally to their respective groups. The dose of each individual animal was adjusted based on the body weight determined just before dosing and dose volume was maintained at 10 mL/kg body weight. For each test compound, sterile new syringes and needles were used. The test compounds were freshly thawed on the day of drug administration.

Observations

Body weight—Individual body weight was measured once every three days during the study period. The % change in body weight of individual mouse was calculated and recorded.

Clinical sign—Animals were observed for visible clinical signs and recorded once in every third day during the treatment period.

Tumor volume measurement—The tumor volume was determined by two-dimensional measurement with a digital Vernier calliper on the day of randomization (Day 1). Second tumor volume measurement was on day 3, further every third day till the end of the experiment the tumor volume measurement was carried out (i.e. on the same days when body weight was taken). Using a Vernier calliper the length (L) and width (W) of the tumor was measured. Tumor volume (TV) was calculated using the following formula:

$Tumor volume (mm 3) = \frac{L \times W 2}{2}$

Where, L=Length (mm); W=Width (mm).

Mean, Standard Deviation (SD) or Standard Error of Mean (SEM) were calculated for individual groups.

Antitumor Activity

Antitumor activity was evaluated as maximum tumor volume inhibition versus the vehicle control group. Data evaluation was performed using statistical software Graph Pad Prism V 5.0.

- Tumor growth inhibition (TGI)
  
  TGI was calculated using the following formula:
  
  TGI=(1−T/C)×100
  
  Where, T=(Mean TV of the test group on Day X−Mean TV of the test group on Day 1) C=(Mean TV of the control group on Day X−Mean TV of the control group on Day 1)
- Relative tumor volume (RTV)
  
  Relative Tumor volume (RTV) was calculated using the following formula:

$R T V = \frac{Tx (absolute tumor volume of the respective tumor on day x)}{T 1 (absolute tumor volume of same tumor on day 1}$

Statistical Analysis

For the evaluation of the statistical significance of tumor inhibition, Two-way ANOVA followed by Bonferroni post hoc test was performed using Graph Pad Prism V 8.3.0. p values <0.05 indicate statistically significant differences between groups.

Necropsy

Tumor burden (TV>1500 mm3) and tumor necrosis/ulceration were observed due to progressive tumor growth. Hence, based on tumor end points & ethical reasons (Day 36), all animals in all experimental groups were humanely euthanized & gross pathological observations were recorded. Prior to euthanasia, blood sampling was carried out, serum was separated and stored at −80° C. All live animals & excised tumor tissues were photographed with scale and whole tumor tissues were formalin-fixed.

Results Obtained from the In Vivo Studies

Antitumor Activity

In this study, huNOG-EXL mice bearing PC-3 tumors were treated with test compounds at a dose of 10 mg/kg intraperitoneally (On day 1, 3, 6, 9, 12, 18, 24, 30 & 33). Under the present experimental condition, the vehicle control IgG1 group showed progressive tumor growth during the experimental period. Hence, other treatment groups were compared with this group for anticancer efficacy evaluation. Among the tested dose and regimen, two test arms revealed C5511 mAb group and C6481 mAb group showed significant tumor growth inhibition as p<0.001 and p<0.05 respectively when compared to vehicle control IgG1 on day 24. Whereas, on day 36 only C5511 mAb group exhibited significant tumor growth inhibition as p<0.05 when compared to vehicle control IgG1 group. The data is presented in Table 43.

TABLE 43

Effect of test compounds in humanized (huNOG-EXL) mice bearing

subcutaneous PC-3 tumor xenografts

Number of
% TGI
Statistical
% TGI
Statistical
Mean %

Test
animals/
(Day
Significance
(Day
Significance
BWC

Compound
group
24)
(Day 24)
36)
(Day 36)
(Day 36)

C5511 mAb
5
49
***(p < 0.001)
35
*(p < 0.05)
−14

group

(10 mg/kg, i.p;

On day 1, 3, 6,

9, 12, 18, 24,

30 & 33)

Vehicle
5
—
—
—
—
−21

Control IgG1

group

(10 mg/kg, i.p;

On day 1, 3, 6,

9, 12, 18, 24,

30 & 33)

C6481 mAb
5
25
*(p < 0.05)
8
ns
−15

group

(10 mg/kg,

i.p; On day 1,

3, 6, 9, 12, 18,

24, 30 & 33)

TGI—Tumor growth inhibition (TGI was calculated against vehicle control IgG1 group)

BWC—Body weight change

***p < 0.001, *p < 0.05 statistically significant when respective treatment groups were compared to vehicle control IgG1 group.

ns Statistically non-significant when respective treatment groups were compared to vehicle control IgG1 group.

Tumor Volume (TV) & Delta Tumor Volume (ΔTV) on Day 24 and Day 36

On day 24, the mean Tumor volume (mm3) for C5511 mAb group, Vehicle control IgG1 group, & C6481 mAb group were 241±31, 474±38, and 355±68, respectively. Further the mean delta tumor volume (ΔTV) on day 24 for C5511 mAb group, vehicle control IgG1 group, & C6481 mAb groups were 204±32, 437±38, and 318±68 mm3, respectively. The treatment groups, C5511 mAb group and C6481 mAb group showed significant decrease (p<0.001 & p<0.05) in the tumor volume and delta tumor volume when compared to Vehicle control IgG1 group on day 24. The mean tumor volume on day 36 for C5511 mAb group, vehicle control IgG1 group, and C6481 mAb group were 690±186, 1062±157, and 977±230 mm3 respectively. The mean delta tumor volume (ΔTV) on day 36 for C5511 mAb group, vehicle control IgG1 group, and C6481 mAb groups were 654±187, 1025±159, and 940±231 mm3 respectively. The treatment groups, C5511 mAb group showed significant decrease (p<0.05) in the tumor volume and delta tumor volume when compared to vehicle control IgG1 group. The results of tumor volume (TV) & Delta tumor volume (ΔTV) for all treatment groups are summarized in table 44 and 45, and FIGS. 20D, 20E, 20F and 20G.

TABLE 44

Effect of test compounds on mean tumor volume of (huNOG-EXL)

mice bearing subcutaneous PC-3 tumor xenograft

Mean Tumor volume (mm³)

Days

Groups

1
3
6
9
12
15
18
21
24
27
30
33
36

C5511
Mean
37
58
78
97
112
152
179
213
241
356
508
621
690

mAb
S.E.M
1
3
4
6
2
12
39
31
31
60
95
143
186

group

(10 mg/kg,

i.p; On

day 1, 3,

6, 9, 12,

18, 24, 30

& 33)

Vehicle
Mean
37
61
94
114
131
190
270
363
474
569
727
894
1062

control
S.E.M
1
2
4
7
11
12
25
32
38
38
69
83
157

IgG1

group (10

mg/kg, i.p;

On day 1,

3, 6, 9, 12,

18, 24, 30

& 33)

C6481
Mean
39
54
79
101
121
166
207
288
355
456
587
734
977

mAb
S.E.M
2
2
6
11
15
21
33
60
68
102
108
125
230

group

(10 mg/kg,

i.p; On

day 1, 3,

6, 9, 12,

18, 24, 30

& 33)

TABLE 45

Effect of test compounds on Δ (Delta) mean tumor volume of (huNOG-EXL) mice

bearing subcutaneous PC-3 tumor xenograft

Δ (Delta) Mean Tumor Volume (mm³)

Days

Groups

1
3
6
9
12
15
18
21
24
27
30
33
36

C5511 mAb group
Mean
0
20
41
60
75
115
142
176
204
320
473
585
654

(10 mg/kg, i.p; On
S.E.M
0
3
4
5
2
12
39
32
32
61
97
145
187

day 1, 3, 6, 9, 12,

18, 24, 30 & 33)

Vehicle control
Mean
0
24
56
77
94
153
233
326
437
531
689
856
1025

IgG1 group (10
S.E.M
0
2
4
7
11
13
25
33
38
39
70
83
159

mg/kg, i.p; On day

1, 3, 6, 9, 12, 18,

24, 30 & 33)

C6481 mAb group
Mean
0
15
42
64
83
129
170
250
318
419
550
697
940

(10 mg/kg, i.p; On
S.E.M
0
1
5
11
15
21
33
60
68
102
108
125
231

day 1, 3, 6, 9, 12,

18, 24, 30 & 33)

Percentage Tumor Growth Inhibition (% TGI) on Day 24 and Day 36

The % Tumor Growth Inhibition (% TGI) for C5511 mAb group showed maximum value of 49% followed by C6481 mAb group with % TGI value of 25%, on day 24. Whereas, the % TGI on day 36, values for C5511 mAb group, and C6481 mAb groups were 35%, and 8% respectively on day 36 against Vehicle control IgG1 group. The individual animal Tumor Growth Inhibition are summarized in Table 46.

TABLE 46

% Tumor growth inhibition (% TGI) of test compounds against

(huNOG-EXL) mice bearing PC-3 tumor xenograft

% Tumor growth inhibition (% TGI) by Delta

Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day

Groups
1
3
6
9
12
15
18
21
24
27
30
33
36

C5511 mAb group
0
6
17
15
14
20
34
41
49
37
30
31
35

(10 mg/kg, i.p; On day 1,

3, 6, 9, 12, 18, 24, 30 &

33)

Vehicle Control IgG1
−1
3
6
9
12
17
25
5
15
16
9
8
2

group

P3E (10 mg/kg, i.p; On

day 1, 3, 6, 9, 12, 18, 24,

30 & 33)

C6481 mAb group
−4
12
16
11
8
13
24
21
25
20
19
18
8

(10 mg/kg, i.p; On day 1,

3, 6, 9, 12, 18, 24, 30 &

33)

Relative Tumor Volume (RTV) & Delta Relative Tumor Volume (ΔRTV) on Day 24 and Day 36

On day 24, the mean relative tumor volume for C5511 mAb group vehicle control IgG1 group, and C6481 mAb group were 7±1, 13±1, and 10±2 respectively. The delta relative tumor volume (ΔRTV) for C5511 mAb group, vehicle control IgG1 group, and C6481 mAb group were 6±1, 12±1, and 9±2 respectively as shown in table 5. The treatment groups, C5511 mAb group showed significant decrease (p<0.001) in the relative tumor volume and delta relative tumor volume when compared to vehicle control IgG1 group FIGS. 20H and 20I. The mean relative tumor volume on day 36, 20±6 in C5511 mAb group, 29±5 in vehicle control IgG1 group, and 27±7 in C6481 mAb group. Whereas on day 36, the mean delta tumor volume (ΔRTV) for C5511 mAb group, vehicle control IgG1 group and C6481 mAb groups were 19±6, 28±5, and 26±7 respectively as shown in Table 47 and FIGS. 20J and 20K.

TABLE 47

Relative tumor volume (RTV) of test compounds against

(huNOG-EXL) mice bearing PC-3 tumor xenograft

Relative Tumor Volume (mm³)

Days

Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day

Groups

1
3
6
9
12
15
18
21
24
27
30
33
36

C5511 mAb group
Mean
1
2
2
3
3
4
5
6
7
10
15
18
20

(10 mg/kg, i.p; On
S.E.M
0
0
0
0
0
0
1
1
1
2
3
5
6

day 1, 3, 6, 9, 12,

18, 24, 30 & 33)

Vehicle control
Mean
1
2
3
3
4
5
7
10
13
15
20
24
29

IgG1 group
S.E.M
0
0
0
0
0
0
1
1
1
1
2
3
5

(10 mg/kg, i.p; On

day 1, 3, 6, 9, 12,

18, 24, 30 & 33)

C6481 mAb group
Mean
1
1
2
3
3
4
6
8
10
12
16
20
27

(10 mg/kg, i.p; On
S.E.M
0
0
0
0
0
1
1
2
2
3
3
4
7

day 1, 3, 6, 9, 12,

18, 24, 30 & 33)

TABLE 48

Delta relative tumor volume (ΔRTV) of test compounds against

(huNOG-EXL) mice bearing PC-3 tumor xenograft

Delta Relative Tumor Volume (mm³)

Days

Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day
Day

Groups

1
3
6
9
12
15
18
21
24
27
30
33
36

C5511 mAb group
Mean
0
1
1
2
2
3
4
5
6
9
14
17
19

(10 mg/kg, i.p; On
S.E.M
0
0
0
0
0
0
1
1
1
2
3
5
6

day 1, 3, 6, 9, 12, 18,

24, 30 & 33)

Vehicle control IgG1
Mean
0
1
2
2
3
4
6
9
12
14
19
23
28

group (10 mg/kg,
S.E.M
0
0
0
0
0
0
1
1
1
1
2
3
5

i.p; On day 1, 3, 6, 9,

12, 18, 24, 30 & 33)

C6481 mAb group
Mean
0
0
1
2
2
3
5
7
9
11
15
19
26

(10 mg/kg, i.p; On
S.E.M
0
0
0
0
0
1
1
2
2
3
3
4
7

day 1, 3, 6, 9, 12, 18,

24, 30 & 33)

The study revealed, under the test conditions, test compounds used in C5511 mAb group, vehicle control IgG1 group and C6481 mAb group at a dose of 10 mg/kg intraperitoneally (on day 1, 3, 6, 9, 12, 18, 24, 30 & 33) were tested to evaluate the anticancer efficacy against PC-3 tumor xenograft in huNOG-EXL mice. Efficacy evaluation was calculated against vehicle control IgG1 group. Among tested compounds, C5511 mAb group and C6481 mAb group exhibited significant anti-cancer efficacy when compared with vehicle control IgG1 group. Based on statistical analysis of tumor volume, tumor growth inhibition, relative tumor volume, treatment with C5511 mAb group showed better antitumor efficacy compared to test compound used in C6481 mAb group. Moderate body weight loss observed in all the treatment groups.

In this context, it should be noted that the monoclonal antibody products tested in current HuNOG study, were utilized under sub optimal assay condition. The monoclonal antibody products used in this study require human NK cells for optimal function and till date no animal model is available where human NK cells could mimic the in vivo condition. Considering these constrains, HuNOG model was used rationally, wherein the human immune cells (including human NK cells) are established in mouse. However, the abundance of NK cells are significantly low. Therefore HuNOG mice model is justifiably provides a suitable experimental condition to test these novel Anti-CLEC2D monoclonal antibody products. Moreover, it was observed that the overall number of human immune cells start to decline, as the animals become older, with progression of the study. These levels of tumor growth reduction in the HuNOG PC3 xenograft model is surprising, indicating highly superior efficacy of the novel Anti-CLEC2D monoclonal antibodies of the present disclosure.

Example 8: Characterization of Anti-CLEC2D Monoclonal Antibody

Purified anti-CLEC2D antibody was subjected various biophysical and biochemical characterization indicative of multiple inherent properties of antibody such as, mass, conformation, posttranslational modification, amongst others.

In order to identify the confirmation of isolated fragments, SDS PAGE was carried out

TABLE 49

intact mass analysis

Sr. No.
Mass (Da)
Intensity (Counts)
Intensity (%)

1
149301
252629056
100

2
149131
228375856
90.4

3
149302
227410624
90.02

4
149132
222516864
88.08

5
149300
217502800
86.1

6
149466
200116976
79.21

7
149465
198714320
78.66

8
149130
186866464
73.97

9
149133
183556800
72.66

10
149303
170258512
67.39

under non-reducing conditions, where a single major band corresponding to a molecular weight (MW) of 150 kDa was observed for all the samples indicating the intact anti-CLEC2D antibody. While under reducing conditions, two bands were evident at 25 kDa and 50 kDa which were associated with light chain and heavy chains of the anti-CLEC2D antibody. SDS PAGE data has been shown in FIG. 21A).

The intact mass experiment was carried out using methods based on ELISA, flow cytometry, Western blotting, BIACORE, Waters UPLC H-Class Bio with Xevo G2 XS QTOF with UNIFI. The Xevo G2 XS QTOF was run in positive sensitivity MS only mode. With no prior treatment, 1 μg sample was analyzed using the same chromatographic conditions (only gradient different from subunit mass analysis) and mass spectrometric conditions as subunit mass analysis as described above.

The most abundant masses are close to generic glycosylated IgG1 monoclonal antibody as shown in FIG. 21B), and Table 49, thus confirming the molecular weight of anti-CLEC2D monoclonal antibody.

Acidic, Basic and Main peak was resolved and the percentage of each variant along with main peak is tabulated in below shows the charge distribution determined by WCX-LC method in anti-CLEC2D antibody molecule. The relative abundance of acidic isoforms is generally attributed to oxidation, deamidation, and glycation process within the antibody. On the other hand, the presence of C-terminal Lysine and amidation are mainly responsible for forming basic isoforms in the antibody. The WCX chromatogram is shown in FIG. 21C).

Acidic Species: 10%

Main Species: 83%

Basic Species: 7%

It is known that protein aggregation can induce immunogenicity; although a small amount of aggregates is expected, this amount is likely to increase due to stress conditions that a antibody may undergo during its manufacture, purification, formulation, and shelf-life. Aggregation can also induce production of anti-drug antibodies (ADAs) which can result in the loss of activity or cause adverse effects upon administration. Anti-CLEC2D antibody sample was analyzed by size exclusion chromatography (SEC) and typical chromatograms were shown in below. As observed in attached chromatogram in FIG. 21D), 100% monomer was observed thus confirming that sample is free from any aggregates and/or degradant.

One of the important quality attribute for therapeutic monoclonal antibodies is their glycosylation profile. To check the glycan distributions of anti-CLEC2D antibody, the sample was analyzed by HILIC N-glycan profiling method. The major glycan such as G0F, G1F, G1F′ and G2F were identified and total percentage of Galactosylated glycan was found to be around 46.44%.

Binding Studies Against Soluble CLEC2D Antigen:

Binding studies were carried out using anti-CLEC2D antibody against purified soluble CLEC2D antigen while the measurements were made through both ELISA and SPR based methods.

Besides, SPR was also employed to understand the interaction between anti-CLEC2D antibody and FcRn, as Binding interactions with the neonatal Fc receptor (FcRn) are one determinant of pharmacokinetic properties of recombinant human monoclonal antibody therapeutics, and a conserved binding motif in the crystallizable fragment (Fc) region of IgG molecules interacts with FcRn.

ELISA:

Soluble CLEC2D antigen was produced and purified using CHO cell culture system and Anti-CLEC2D antibody C5511 were used for ELISA assay. The method was optimized using various ELISA formats, as exemplified by, direct ELISA, indirect ELISA and sandwich ELISA. Finally, the optimized ELISA assay was based on protein A coated plate wherein the antigen was labelled with biotin moiety. The Anti-CLEC2D antibody dilutions ranging from 0.01 μg/mL to 62.5 μg/mL were made in dilution buffer 0.5% BSA in (DPBS with 0.05% tween 20).

The protein A coated wells were washed thrice with 200 μL of wash buffer (DPBS with 0.1% Tween20). 100 μL of each antibody dilution was added to well, and the plate was incubated for 90 minutes at room temperature on orbital shaker. Each well was rinsed four times with 200 μL of wash buffer. 100 μL of different concentration of biotinylated antigen, labelling was carried out as described before, was added to each well and plate was incubated for 60 minutes at room temperature on orbital shaker. Each well was rinsed four times with 200 μL of wash buffer. 100 μL of 1:5000 diluted HRP-labelled streptavidin was added and plate was incubated for 60 minutes at room temperature on orbital shaker. Each well was rinsed five times with 200 μL of wash buffer. 100 μl 1×TMB was added and the plate was incubated for 30 min at RT in dark. After 30 minutes 100 μl of stop solution was added and the plate was read at 450 nm.

Further to appropriate subtraction of blank, absorbance values were plotted and fit into binding model based on sigmoidal association, using Graphpad PRISM 6.0. The KD value as obtained from the fit is found to be 10-17 nM for anti-CLEC2D antibody to purified CLEC2D antigen (FIG. 21F). The experiments were repeated at least 3 times independently in triplicates to achieve statistical confidence and variation was found to be less than 5%, while confidence interval resides within 95%.

BIAcore binding studies with anti-CLEC2D antibody against soluble CLEC2D antigen

CLEC2D antigen interaction with specific monoclonal antibody was monitored through surface plasmon resonance, using BIACORE. The kinetic parameters for the interaction of anti-CLEC2D antibodies with CLEC2D antigen were evaluated. This method was used to screen potential high affinity monoclonal antibodies against CLEC2D antigen. Different monoclonal antibodies revealed differential affinities towards the CLEC2D antigen. The experiment revealed affinity constants ranging from less than 100 nM (e.g., ≤90 nM, ≤80 nM, ≤70 nM, ≤60 nM, ≤50 nM, ≤40 nM, ≤30 nM, ≤20 nM, ≤10 nM, ≤5 nM, or ≤1 nM).

CLEC2D antigen binding kinetics and affinity studies between CLEC2D antigen and Anti-CLEC2D antibody binding studies were carried out using Anti-His Antibody binding capture chemistry on BIACORE 3000 instrument. His Capture Kit (GE healthcare) was immobilized onto CM5 chip surface at an RU of ˜1800. CLEC2D antigen was captured on Anti-His, coupled with CM5 chip, surface, at a concentration of ˜200 μg/mL, wherein the dilution of antigen was made through running buffer comprising HBS-EP+ buffer (GE healthcare). Subsequently anti-CLEC2D antibody C5511 was passed at concentrations ranging from 1 to 100 μg/mL, at association and dissociation time of 3 minutes and 25 minutes, respectively. Antibody dilutions were made in HBS-EP+ buffer (GE healthcare). Response curves (FIG. 21G) obtained were appropriately subtracted from reference flow cell signal and blanks, respectively and fit to a 1:1:1 Langmuir binding leading to estimated KD of ˜10⁹M−1.

FcRn Binding

Surface plasmon resonance (SPR) biosensor assays are often used to characterize interactions between FcRn and antibody therapeutics. Studies have shown that FcRn interacts with a binding motif in the crystallizable fragment (Fc) of IgG at the CH2-CH3 domain interface in a pH-dependent manner. 6.8 The pH dependency of this interaction is essential for maintaining the long serum half-life of IgG molecules. Specifically, in the endosomes of endothelial cells (˜pH 6.0), IgG internalized through pinocytosis binds to FcRn to form IgG-FcRn complexes; the IgG-FcRn complexes are then trafficked to the cell surface where IgG is released back into the circulation at physiological pH (˜7.4). This prevents lysosomal degradation of the IgG. For recombinant human monoclonal antibody (rhumAb) therapeutics, the FcRn-rhumAb binding interaction is a critical determinant of pharmacokinetic (PK) properties and targeted engineering of the FcRn binding motif may enable less frequent dosing of antibody therapeutics in patients. Multiple studies have suggested that there is a correlation between FcRn binding affinity and antibody half-life, although the absence of such a correlation has also been reported.

Binding kinetics and affinity studies between Human FcRn/FCGRT & B2M Heterodimer Protein and Anti-CLEC2D antibody binding studies were carried out using BIACORE 3000 instrument. Human FcRn/FCGRT & B2M Heterodimer Protein (Acro Biosystems) was immobilized onto CM5 chip surface at an RU of ˜300. Human FcRn/FCGRT & B2M Heterodimer Protein was captured on CM5 chip surface through amine coupling, at a concentration of ˜1 μg/mL, wherein the dilution of protein was made through running buffer comprising HBS-EP+ buffer (GE healthcare). Subsequently anti-CLEC2D antibody C5511 was passed at concentrations ranging from 0.0315 to 0.5 μM, at both pH 5.9 and pH 7.4. Antibody dilutions were made in HBS-EP+ buffer (GE healthcare). As can be seen from the response curve that there was no binding observed at pH 7.4 (FIG. 21H) while response was monitored at pH 5.9 (FIG. 21I). Response curves obtained were appropriately subtracted from reference flow cell signal and blanks, respectively and fit to a 1:1:1 Langmuir binding leading to estimated KD of ˜1.88×10⁶M−1. As can be concluded that no binding at neutral pH may increase the possibility of the anti-CLEC2D antibody to be released back into the blood stream.

Example 9: Anti-CLEC2D Monoclonal Antibody as a Diagnostic Tool/as Prognostic Marker Against Multiple Disease Indications

All high binding anti-CLEC2D antibodies were screened to pick the top binder as diagnostic antibody. Among the 4 high binding anti-CLEC2D antibody, one was selected through antigen binding assay with PC3 tumor cell line.

Tumor cells expressing CLEC2D antigen were harvested by trypsinization. Cell count was taken by Vi-cell XR automated cell counter. Cells were centrifuged at 1400-1500 rpm for 4-5 minutes. The pellet was re-suspended in 1 ml DPBS. 50,000 cells were aliquoted in each well of a 96 well plate. 1 μg of C2779, C2438, C0949, C2543 were added to each well and incubated for 30-60 minutes at room temperature (25° C.). The plate was centrifuged at 1400-1500 rpm for 4-5 minutes, the supernatant was aspirated and cells were washed with 0.1% BSA in DPBS. 2.5 ml of 2% BSA was diluted to 50 ml with DPBS. Goat anti human IgG FITC conjugate was used as secondary antibody. 1:100 dilution of secondary antibody was prepared in DPBS and 100 μl was added to each well. The secondary antibody, Goat anti human IgG FITC conjugate, was used as control at 1:100 dilution for all relevant experimentation. The plate was incubated for 30 minutes at room temperature (25° C.) in dark. The cells were washed with 0.1% BSA and re-suspended in 100 μl of 1% BSA. Samples were analyzed by flow-cytometry.

C0949 was selected as diagnostic antibody reagent due to maximum percentage of binding observed against surface expressed CLEC2D on PC3 when compared with other anti-CLEC2D clones (FIG. 22A) and purposed further to detect CLEC2D antigen on various tumour cell lines.

Among the prostate cancer cell lines, 22RV showed highest antigen expression with 5 fold increase as compared to secondary antibody control (FIG. 22B). Further, diagnostic anti-CLEC2D antibody, not limited to C0949, was used in antigen binding assay for multiple tumor cell lines of several disease indications shown in FIG. 22C.

Efficient and sensitive binding as observed in multiple cancer cell lines including prostate cancer cell lines, using various anti-CLEC2D antibody clones, strongly support the candidacy of the said molecules as diagnostic/prognostic reagent.

Clinical Prospect of Anti-CLEC2D Monoclonal Antibody

Disease relevance: prostate cancer

TCGA Analysis

The cancer genome atlas (TCGA) data was metastatic prostate cancer was analysed to improve on the current understanding of genes involved in the disease progression along with the expression level of CLEC2D in prostate cancer patients.

The PRAD project is the TCGA's prostate cancer project and it contains data for 500 Cancer cases. The relevant sources of data that were analysed were limited to Gene Expression Quantification, which included HTSeq Count Data, miRNA Expression Quantification and Isoform Expression Quantification. Table 50 shows a case-wise breakdown of the occurrences of the above specified files in the data that was accessible for download from the data categories of interest.

TABLE 50

A breakdown of the cases based

on the availability of different

data files, such as tumor and normal files

Description
Cases
Percentage

Transcriptome Profiling

No files
2
0.4

only miRNA + Isoform
3
0.6

only GEQ
4
0.8

all files, only Tumor
436
87.2

all files, Tumor + Normal
52
10.4

two different miRNA + Isoform Files
1
0.2

two different GEQ (tumor) files
2
0.4

TCGA Data—Transcriptome Profiling

The transcriptome profiling data category contains counts of gene, miRNA and isoform expression. Of the 500 cases deposited in the TCGA, 498 have data associated with Primary Tumor tissue, while 52 cases have expression data related to the Normal Tissue. The files are a list of 60483 genes and their variants, denoted by their Ensembl IDs and their counts within each case.

TCGA Data—Metastatic Cases Identification

The 500 TCGA PRAD Project cases were parsed to identify cases which displayed characteristics that would lead to them being identified as cases of metastatic prostate cancers. A total of 289 cases were identified to be metastatic, this identification was made on the basis of key parameters, in other TCGA documentation which lists among other parameters Gleason Scores and prescribed Drugs. Of the 289, only 18 had relevant Normal Tissue data, as this analysis is concerned with the change in expression levels for before and after the disease, it was necessary to establish baseline values, Normal data, for the other genes as well. This was achieved by looking at all 52 Normal Tissue data, these were used to create a baseline file, by taking into account all 52 values from each case for each gene, removing outlier values, and calculating an ‘normal baseline’ value for the gene. For cases lacking a Normal Tissue counts, the baseline file was used for the comparative analysis.

TCGA Data—Metastatic Cases Sub-Groupings

The same key parameters which served as the basis of the Metastatic case identification were also used to segregate the data into other sub-groupings such as stage of the cancer and current treatment regimen—this data was used to analyse the CLEC2D Expression levels among the sub-groups

Subsequently expression of CLEC2D gene was monitored wherein all the associated FPKM files from the projects were downloaded and specifically queried for CLEC2D expression. The FPKM files were made up of Tumor expression files and in some cases Normal Tissue Expression files. Both sets were separately used to calculate a range for CLEC2DCLEC2D Expression for each cancer among Normal and Tissue cases. Additionally outliers were omitted from the data by assuming a normal distribution of the Expression values and discarding values that were more than 2 standard deviations away from the mean.

In order to better understand the role of CLEC2D in cancers the relative expression levels of the gene in normal tissue samples and tumor tissue samples was analysed. This was done by collecting all the case data for specific cancers/conditions and retrieving the CLEC2D expression value from each file before analysing the sets of values. For each subset the ‘spread’ of the CLEC2D expression profile was plotted by looking at the minimum, maximum and interquartile values. As can be seen from FIG. 23A, CLEC2D appears to conform remarkable existence in terms of expression level seen in different subsets conditions, such as, metastasis, tumor stage and treatment received, amongst others.

Induction Driven Expression Increase

In order to determine the expression label of CLEC2D on the surface of different tumor cell lines, firstly surface expression of CLEC2D on the surface of CLEC2D transfected HDCHO, C4548, was looked at and distribution of same was observed on the transfected cells by using commercially available anti-CLEC2D (4C7) antibody. Assuming translation of CLEC2D could be heavily regulated upon various kind of inductions, various prostate cancer cell types were induced with multiple inducers such as effector cells (either whole PBMC or supernatant of PBMC) or activators of NK cells (e.g., LPS) on prostate tumor cell line (PC3) to monitor the impact on expression label of CLEC2D. Upon treatments with various inducers, an increased CLEC2D expression label was observed when compared to the untreated target cells.

Among the prostate tumor cell lines under no induction, castrate-resistant prostate cancer (CRPC) cell lines i.e. PC3 and DU145 have high CLEC2D surface expression compare to Non-CRPC cell lines i.e. LNCap and 22RV1 wherein the CLEC2D was probed by using Novel anti-CLEC2D antibody as exemplified by, not limited to, C2685 clone (FIG. 23B). Extending the observation obtained in uninduced condition, the therapeutic anti-CLEC2D antibody, such as C2685, not limited to, was used to understand the changes in expression level in the presence or absence of inducers. Next, in order to look into the changes in expression label of CLEC2D on all prostate tumor cell lines upon various treatments, prostate tumor cells were incubated with effector cells (either whole PBMC or supernatant of PBMC or isolated NK cells or isolated T cells) or with activators/inducers of NK cells (either LPS or Poly I:C or IFN gamma), and examined the expression label of CLEC2D by using C2685 anti-CLEC2D antibody. Upon treatment an increased expression label of CLEC2D was observed when compared with the untreated target cells (FIG. 23C). Among the prostate tumor cell lines, castrate-resistant prostate cancer (CRPC) cell lines i.e. PC3 and Non-CRPC cell line i.e., LNCap have shown further enhancement of CLEC2D surface expression upon treatment compare to DU145 and 22RV1 treated with said inducers (FIG. 23C).

Considering all and having specific focus on prostate cancer, cell lines such as, castrate-resistant prostate cancer (CRPC) cell lines (such as PC3 and DU145) and Non-CRPC cell lines (such as LNCap and 22RV1), revealed significant expression level of CLEC2D antigen on tumor cell surface, which was further increased with various treatments, including multiple TLR treatments. The choice of cell lines were strategic, as all prostate cancer cell lines used herein signifies certain stage or condition of prostate cancer disease and can be associated with CLEC2D expression level. As described and shown in the present disclosure, prostate cancer cell lines, LNCaP, DU145, 22RV1 and PC3 have low, moderate and high metastatic potential wherein PC3, with high cell surface CLEC2D expression, is effectively killed by NK cells when the inhibitory signal through CLEC2D-CD161 axis is blocked using identified anti-CLEC2D antibody, thereby, establishing CLEC2D as clinically relevant target for prostate cancer.

Example 10: Expression of CLEC2D Antigen in Cancer Tissue

CLEC2D has been described as a multi-functional protein, and to fully elucidate the functional consequences of its interactions with its receptor, CD161, a comprehensive characterisation of CLEC2D distribution is needed. CLEC2D has been observed to be activated in different tumor cell lines and present on various immune cells in humans. CLEC2D can be detected in several healthy human tissues, and can be remarkably prevalent in immune-privileged sites. This information will be used to emphasize and postulate on the role of CLEC2D in cross talk between lymphocytes and immune tolerance.

The tissue microarray (TMA) represents a high-throughput technology for the assessment of histology-based laboratory tests, including immunohistochemistry and fluorescent in-situ hybridization (FISH). For immune-fluorescent staining, anti-CLEC2D monoclonal antibody is used as primary antibody and either direct labelling or indirect labelling, with a labelled secondary Ab, is used for detection. Thus, the role of CLEC2D is determined in various cancers and in the context of various stages of cancer.

Additionally, 3D cell culture methodology is used to understand the interaction of tissue expressed CLEC2D antigen with human immune system to determine the cross-talk between CLEC2D antigen and interacting partners (including CD161) expressing on tumor cells, and immune cell types, such as B cells, T cells, monocytes and NK cells.

Having described embodiments of this disclosure with reference to the accompanying drawings, it is to be understood that this disclosure is not limited to the precise embodiments, and that various changes and modifications may be effected therein by those skilled in the art without departing from the scope or spirit of this disclosure as defined in the appended claims.

Human tissue microarray from US Biomax (cat number TP242d), top 4 types of cancer (colon, breast, lung and prostate) tissue array with normal tissue, including TNM and pathology grade, 24cases/24 cores were used to analyse reactivity of anti-CLEC2D antibody clones C0694 and C2685. The prostate cancer samples are as follows.

TABLE 51

Patient
Patient

Pathology

Age
sex
Cancer
Diagnosis
TNM
Grade
Stage
Type

71
M
Prostate
Adenocarcinoma
T2N0M0
1
I
Malignant

Gleason 2 (2 + 2)

73
M
Prostate
Adenocarcinoma
T3N0M0
2
III
Malignant

Gleason 4 (4 + 4)

60
M
Prostate
Adenocarcinoma
T3N1M0
2
IV
Malignant

Gleason 3 (3 + 3)

64
M
Prostate
Adenocarcinoma
T3N0M0
2
III
Malignant

Gleason 4 (4 + 3)

31
M
Prostate
Prostate tissue
—
—
—
Normal

35
M
Prostate
Prostate tissue
—
—
—
Normal

The IHC staining followed both CC1 and CC2 protocols at different concentrations of antibody from 1:10 dilution to 1:30 dilution. The data suggests C2685 revealed strong reactivity and less interference from negative regions. Results are described in FIG. 23D.

TCGA Data—all Cancers CLEC2D Expression

A pan-cancer analysis was carried out by studying all the TCGA cancer projects. All the associated FPKM files from the projects were downloaded and specifically queried for CLEC2D expression. The FPKM files were made up of Tumor expression files and in some cases Normal Tissue Expression files. Both sets were separately used to calculate a range for CLEC2D Expression for each cancer among Normal and Tissue cases. Additionally outliers were omitted from the data by assuming a normal distribution of the Expression values and discarding values that were more than 2 standard deviations away from the mean.

TABLE 52

A List of the Cancers analysed for CLEC2D Expression.

ACC
Adrenocortical Carcinoma

BLCA
Bladder Urothelial Carcinoma

BRCA
Breast Invasive Carcinoma

CESC
Cervical Squamous Cell Carcinoma and

Endocervical Adenocarcinoma

CHOL
Cholangiocarcinoma

COAD
Colon Adenocarcinoma

DLBC*
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma

ESCA
Esophageal Carcinoma

GBM
Glioblastoma Multiforme

HNSC
Head and Neck Squamous Cell Carcinoma

KICH
Kidney Chromophobe

KIRC
Kidney Renal Clear Cell Carcinoma

KIRP
Kidney Renal Papillary Cell Carcinoma

LAML
Acute Myeloid Leukemia

LGG
Brain Lower Grade Glioma

LIHC
Liver Hepatocellular Carcinoma

LUAD
Lung Adenocarcinoma

LUSC
Lung Squamous Cell Carcinoma

MESO
Mesothelioma

OV
Ovarian Serous Cystadenocarcinoma

PAAD*
Pancreatic Adenocarcinoma

PCPG
Pheochromocytoma and Paraganglioma

PRAD
Prostate Adenocarcinoma

READ
Rectum Adenocarcinoma

SARC
Sarcoma

SKCM
Skin Cutaneous Melanoma

STAD
Stomach Adenocarcinoma

TGCT*
Testicular Germ Cell Tumors

THCA
Thyroid Carcinoma

THYM*
Thymoma

UCEC
Uterine Corpus Endometrial Carcinoma

UCS
Uterine Carcinosarcoma

UVM
Uveal Melanoma

*denotes projects whose CLEC2D expression levels differed significantly from the rest.

For each subset the ‘spread’ of the CLEC2D expression profile was plotted by looking at the minimum, maximum and interquartile values. As can be seen from FIG. 24A CLEC2D appears to conform remarkable existence in terms of expression level seen in different cancer conditions as listed in above table, amongst others.

Binding Studies: Flow Cytometry and Imaging

As observed in prostate cancer cell lines, the observations were extended to other tumour cell lines as well, using identified anti-CLEC2D antibody clones, as exemplified by C2685, C5511, amongst others. The binding was also monitored through both flow cytometry and confocal microscopy, wherein respective experimental conditions are similar to the description above.

Using anti-CLEC2D antibody C5511, flow cytometric observation have been summarized in the following Table 53.

TABLE 53

Bispecific antibody

Binding fold

change against

Tumor

Control

cell line
Disease indication
(C5511)

HepG2
Liver cancer
1.5

SKBR3
Breast cancer
1.8

SKOV3
Ovary cancer
1.2

BT474
Breast cancer
2.0

Ramos
Lymphoma
2.2

FADu
Head & Neck
1.2

squamous cell carcinoma

LN229
Glioblastoma
7.5

SW620
Colon cancer
2.3

MDA-MB-361
Breast cancer
3

NCI-H1838
non-small cell lung cancer
2.3

Capan-1
Pancreatic cancer
1.8

As can be understood, the expression level of CLEC2D on various cancer cell lines was found to be either low or moderate to high.

Similarly, in order to determine the disease relevance for novel antibodies we have checked the expression label of CLEC2D on the surface of different tumor cell lines such as liver carcinoma cancer, Glioma, ovarian adenocarcinoma, lung carcinoma, myeloma, lymphoma and breast cancer tough confocal microscopy. There are varying labels of expression of CLEC2D observed across the cancer cell lines tested by using anti-CLEC2D antibody clone C2685 (FIG. 24B). Predominant expression of CLEC2D was observed on the surface of hepatocellular carcinoma (HepG2), breast cancer (BT474), and glioma (LN229) whereas a very low or no expression observed in ovarian adenocarcinoma (SkoV3), myeloma (NCI-H929) and lymphoma (Ramos) (FIG. 24B).

To check the regulation on the translation of CLEC2D in these cancer cell lines were induced with various inducers such as effector cells (either whole PBMC or soup of PBMC) or activator of NK cells (e.g. LPS), IFN-γ, poly I:C to all tumor cell lines (HepG2, BT474, LN229, SkoV3, NCI-H929 and Ramos) similar to prostate tumor cell line and monitored expression label of CLEC2D. Upon treatments, increased expression label of CLEC2D was observed when compared to the untreated target cells (FIG. 24C). Interestingly, on the SkoV3, NCI-H929 and Ramos cells have observed increased expression of CLEC2D upon treatment whereas on untreated cells have no/less expression (FIG. 24C). These finding indicates that CLEC2D is induced upon specific TLR stimulations on these cells and could be a potential target on these cancer conditions which can be targeted using anti-CLEC2D antibody.

Cytotoxicity

Tumour cell lines, as exemplified by SKOV3 (Ovarian cancer cell line), HepG2 (hepatocellular carcinoma) cells were labelled with Efluor as per the manufacturer's protocol and were seeded at a density of 0.04×10⁶in 20% DMEM in 24 well plates. After 24 hours, freshly isolated PBMCs were added in T:E of 1:5. Novel monoclonal anti-CLEC2D antibodies C5511 were added at 200 μg/ml in the assay reaction of 0.5 ml and incubated for 14 hours. Supernatant was collected from 24 well plate and adherent cells were trypsinized and collected in 1.5 ml tubes. Reaction mixture was incubated with sytox green (15 nM) for 20 min and fluorescence was detected in flow cytometer. Percent specific cell death was determined by subtracting the percent cell death of control from the test samples and showed significant cytotoxicity in ovarian (SKOv3) and liver (HepG2) (FIG. 24D) cancer cell lines indicating antitumor activity of anti-CLEC2D antibody against multiple diseases.

As can be understood, isolated anti-CLEC2D antibody that were used to monitor CLEC2D surface expression on several cell lines associated with diseases, such as breast cancer (BT474), lymphoma (ramos), liver cancer (HepG2), prostate cancer (PC3, DU145, LNCAP and 22RV1) glioma (LN229) ovarian adenocarcinoma (SkoV3), myeloma (NCI-H929), is first-in-class in the space. Moreover, cytotoxicity elicited by the said anti-CLEC2D antibody reflects the fact that these anti-CLEC2D antibody could be potentially used as therapeutic avenue against respective diseases. Taken together, this also signifies that CLEC2D antigen expression is linked with multiple cancer cell lines and could play an important role in cancer biology, as speculated the present disclosure.

Risk Mitigation Studies Done with Anti-CLEC2D Monoclonal Antibody

Immunogenicity to protein based biotherapeutics is a complex process involving numerous factors specific to products, including critical feature such as quality of drug, and patients. These critical quality attributes may include: variations in the primary sequence, host-cell specific post-translational modifications, the presence of host cell proteins, formulation changes, aggregation, chemical modifications (oxidation, deamidation, or glycation), and changes in protein structure. Some critical quality attributes of antibody drug products have been suggested to affect patient safety through enhancing the sequence based risk of immunogenicity, although the exact contribution of specific types of attributes is not known. T-cell dependent responses are the primary drivers of the long-term affinity matured immune response to biologics in the clinic. These include assay systems using: whole blood, peripheral blood mononuclear cells (PBMC), CD8+-depleted PBMC, immortalized cell lines, dendritic cells/monocytes/macrophages co-cultured with autologous CD4+ Tcells, and artificial lymph node systems, to name a few. Various biological outcomes can be measured at different stages of immune cell activation in these in vitro assays including, cytokine secretion, expression of cell surface markers of activation, identification of HLA-DR bound peptides, signal transduction events, phagocytosis by antigen presenting cells (APC), and proliferation. The application of the designated assay to the development of biopharmaceuticals can range from candidate selection at the early development phase to the late stage evaluation of specific attributes that may impact the risk of immunogenicity. Present disclosure details on attempts to evaluate anti-CLEC2D antibody associated risk towards immunogenicity or related attributes.

Lymphocyte Proliferation Studies

Proliferation of lymphocytes were tested by three independent experimental protocols such as, wet coating of antibodies, air dried coating of antibodies and high density PBMC pre-culture followed by induction with test antibodies, detailed as follows:

Wet Coating of Antibodies

Different concentrations of test antibodies, not limited to C5511, ranging from 1 μg/ml to 100 μg/ml and 1 μg/ml of the positive control—anti CD3 antibody, anti OKT3 antibody, were added to the wells of a 96 well flat bottom plate and incubated in a 37° C. incubator for 2-3 hours. After that the wells were washed three times with 200 μl of DPBS. PBMCs were labelled with Efluor 670 viable cell dye as per manufacturer's protocol. 30000 PBMC cells were seeded in each well in total 200 μl growth media (RPMI-1640 with 10% FBS). Day 0 samples were collected and analyzed by flow-cytometry. Cells were incubated at 37° C. in a 5% CO2 incubator for 4 days. On 4th day samples were collected, stained with anti CD4 antibody-FITC conjugate and analyzed by flow-cytometry.

Air Dried Coating of Antibodies

Different concentrations of test antibodies ranging from 1 μg/ml to 100 μg/ml and 1 μg/ml of the positive control anti CD3 antibody OKT3 were added to the wells of a 96 well flat bottom plate and air dried in biosafety cabinet. Volume of antibodies were restricted to less than 50 μl for optimum air drying. PBMCs were labelled with Efluor 670 viable cell dye as per manufacturer's protocol. Once the wells were dry, 30000 PBMC cells were seeded in each well in total 200 μl growth media (RPMI-1640 with 10% FBS). Day 0 samples were collected and analyzed by flow-cytometry. Cells were incubated at 37° C. in a 5% CO2 incubator for 4 days. On 4th day samples were collected, stained with anti CD4 antibody-FITC conjugate and analyzed by flow-cytometry.

High Density Pre-Culture of PBMC for TCR Priming Followed by Induction with Antibodies in Solution

PBMC cells were pre-cultured at 1×10{circumflex over ( )}6 cells/ml and 10×10{circumflex over ( )}6 cells/ml density for 48 hrs in growth media at 37° C. in a 5% CO2 incubator. After 48 hours PBMCs were labelled with Efluor 670 viable cell dye as per manufacturer's protocol. 1×10{circumflex over ( )}6 PBMC cells/ml were seeded in each well in total 200 μl growth media (RPMI-1640 with 10% FBS). Different concentrations of test antibodies ranging from 1 μg/ml to 100 μg/ml and 1 μg/ml of the positive control anti CD3 antibody OKT3 were added to the wells containing PBMCs. Day 0 samples were collected and analyzed by flow-cytometry. Cells were incubated at 37° C. in a 5% CO2 incubator for 4 days. On 4th day samples were collected, stained with anti CD4 antibody-FITC conjugate and analyzed by flow-cytometry.

Sample Processing for Flow-Cytometry

PBMC samples were centrifuged at 200 rpm for 5 minutes. Supernatants were discarded and the cells were re-suspended in 100 μl of DPBS with 0.5% BSA along with anti CD4 antibody-FITC conjugate (1:100 dilution in final reaction). Cells were incubated for 30 minutes in dark. After that cells were centrifuged at 200 rpm for 5 minutes, removed the supernatant and re-suspended in 100 μl of DPBS with 0.5% BSA.

As can be observed from FIGS. 25A, 25B and 25C, wherein anti-CLEC2D antibody treatment was used as positive control, PBMC treated with anti OKT3 antibody showed lymphocyte proliferation as observed by partitioning of Efluor viability dye into multiple daughter populations (showed by the arrows on the histogram). Appearance of single population after 4 days of culture was observed in untreated PBMC control and 1 μg/ml to 100 μg/ml anti-CLEC2D antibody treated test samples, shows that anti-CLEC2D antibodies did not induce any lymphocyte proliferation. This observation was consistent with three independent test protocols that are wet coating of antibodies (FIG. 25A), air dried coating of antibodies (FIG. 25B) and high density PBMC pre-culture (FIG. 25C) followed by induction with test antibodies. PBMC from multiple healthy donors were tested and the results obtained were consistent.

Measurement of Secreted Cytokines: IFN-γ and IL2

As described earlier in the current segment, apart from understanding lymphocyte proliferation assay, it is essential to confirm whether Anti-CLEC2D antibody induces any cytokines, such as IFN-γ, IL2, or not. Measurement of secreted cytokines such as IFN-γ, IL2, not limited to, were performed through ELISA based detection method wherein supernatant collected from various experimental set up/conditions as detailed above e.g., high density, wet coating, was used at 24 hrs interval for subsequent quantitation. In all experiments concentration of respective antibodies used are anti OKT3 antibody (1 ug/ml) and anti-CLEC2D antibody clones such as C5511 C6481 C4608 at 100 ug/ml. Subsequently, supernatant obtained from anti OKT3 antibody treated sample was diluted in the ratio of 1:4 wherein 50 ul of supernatant was diluted by adding 150 ul of 10% RPMI 1640, on the contrary, anti-CLEC2D antibody treated samples were used directly without any further dilution of supernatant. Simultaneously, samples to measure cytokine IL2 was prepared by wet coating method. Herein anti OKT3 antibody treated sample was diluted in the ratio of 1:10 while 25 ul was diluted by adding 225 ul of 10% RPMI 1640, while supernatant collected from anti-CLEC2D antibody treated samples were used directly. Supernatant obtained from PBMC without treatment was used as control against respective experimentation either for IFN-γ or IL2.

As can be seen from FIG. 25D, wherein PBMC treated with anti OKT3 antibody exhibited highest level of IFN gamma secretion in supernatant at a concentration of 1155 pg/mL while tested anti-CLEC2D antibodies did not elevate IFN gamma production beyond 30 pg/mL concentration, related to any anti-CLEC2D antibody clones (FIG. 25D). Similarly, for IL2 measurement anti OKT3 antibody induced elevation in secretion was found to be 121.50 pg/mL while anti-CLEC2D antibodies did not give rise to IL2 secretion more than 4.7 pg/mL (FIG. 25E). Taken together, identified therapeutic anti-CLEC2D antibody poses low possibility on immunogenicity reaction as judged by the lack of any T lymphocyte daughter population seen when treated with anti-CLEC2D antibody and also extremely low amount of cytokine secretion as observed with both IFN-γ and IL2.

Safety Study Performed with Anti-CLEC2D Monoclonal Antibody in Rat/Non-Human Primate

Toxicology studies with therapeutic monoclonal antibodies should be carried out in a species that are pharmacologically relevant, meaning one that both expresses the target antigen recognized by the monoclonal antibody and evokes a similar pharmacological response following antibody binding, similar to that expected in humans. It is required to demonstrate comparable effector function of monoclonal antibodies in animals that can be extended to humans, especially for antibodies with relatively strong effector function, such as, IgG1. Thereby, the most sensitive animal model available for predicting human safety is utilized. However, cross-reactivity, or lack in cross reactivity, can be predicted through a detailed in silico analysis of sequence and structural understanding between the human antigen protein or targeted epitopes and the equivalent proteins in conventional species used for toxicology studies. It is advisable that toxicology assessment should be performed in two relevant species if available, one rodent and one non-rodent, while non-human primates (NHP), such as, cynomolgus monkey, is celebrated as the most suitable species to ethically justify its use and strategies minimizing primate use.

In silico understanding of comparative sequence analysis of CLEC2D antigens homologs from Human Rat, Mouse and Cynomolgus monkey, indicated that human CLEC2D antigen shares highest sequence homology (>90%) with cynomolgus monkey CLEC2D homolog while sequence homology against Rat and mouse homologs being less than ˜70%. However, sequences were looked into in detail to identify the presence of the important residues which contacts antibody paratope sequence. The said exercise indicated that all species contain at least 70% of the contact points and interacting amino acid residues conserved and possibly available to interact with anti-CLEC2D antibody. Therefore efforts towards understanding the binding of anti-CLEC2D mono clonal antibodies was attempted through generating surface expressed CLEC2D antigen homologs from Rat, Mouse and cynomolgus monkey species. Flow cytometry based method was employed to assess the binding between antibody and CLEC2D antigen homologs.

As can be linked with SEQ IDs 886, 910, 911, 918, full length CLEC2D homologous sequences, from respective species were synthesized and cloned in pCDNA3.1, mammalian expression vector, which were transfected in CHO cells for binding studies through flow cytometry.

Transfection with Constructs of CLEC2D Antigen Variants for Homology Study

CHO suspension cells at more than 90% viability were used for expression of CLEC2D antigen variants. For 100 ml volume of transfection 1.25×10{circumflex over ( )}8 cells were taken. Cells were centrifuged at 1000-1400 rpm for 4-5 minutes, decanted the spent media and re-suspended in 25 ml of OptiMEM I media. DNA constructs were transfected using Lipofectamine LTX with Plus™ reagent. 50-100 μg of respective pCDNA 3.1, constructs, were used with 1:3 to 1:6 DNA to transfection reagent ratio and 50-100 μl Plus™ reagent was used. DNA and Lipofectamine LTX complex was prepared in 25 ml OptiMEM I and incubated at 20-25° C. for 5 minutes for complex formation. The transfection mix was added slowly to the cell suspension. The cells were incubated for 4-6 hours at 37° C. in a 5% CO2 shaker Incubator at 100-120 RPM. 50 ml of Power CHO2 CD growth media was added to the cells. The cells were incubated at 37° C. in a 5% CO2 shaker Incubator at 100-120 RPM. 2-3 days post transfection 200 ml Power CHO2 CD growth media was added and Glutamax was added from 200 mM stock to achieve final concentration of 2 mM. The cells were incubated at 37° C. in a 5% CO2 shaker Incubator at 100-120 RPM. Cells were analyzed for cell surface antigen binding by flow-cytometry on day 3 to day 6 after transfection.

As can be seen in FIG. 26, Anti-CLEC2D antibody clones C5511, C4608, not limited to, developed against human CLEC2D antigen, and exhibited similar binding ranging from 2-4 fold of MFI. This indicates a broad specificity of anti-CLEC2D antibodies towards CLEC2D homologs in both rodent and non-human primate species.

TABLE 54

Amino acid sequence recognized by anti-CLEC2D

antibody

SEQ ID
Amino acid sequence

NO
recognized by anti-CLEC2D antibody

2561
GLU150-XAA151-THR152-ARG153-GLN154

2562
ARG175-XAA176-TYR177-XAA178-GLU179

2563
ARG101-XAA102-XAA-103-XAA104-SER105-

XAA106-ASP107

2564
GLU138-XAA139-XAA140-GLN141-XAA142-XAA143-

LYS144

2565
GLU138-GLN139-XAA140-GLN141

2566
ARG175-XAA176-TYR177-XAA178-XAA179-ARG180

2567
TYR177-XAA179-XAA180-LYS181

Number	Name	Date	Kind
4816567	Cabilly et al.	Mar 1989	A
4946778	Ladner et al.	Aug 1990	A
5091513	Huston et al.	Feb 1992	A
5132405	Huston et al.	Jul 1992	A
5202238	Fell, Jr. et al.	Apr 1993	A
5204244	Fell et al.	Apr 1993	A
7147854	Ye	Dec 2006	B2

Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (7)

Foreign Referenced Citations (1)

Non-Patent Literature Citations (48)

Related Publications (1)